Drugs;Gene;Alleles;Genotype;Outcome;Effect_direction;Effect;Effect_subcat;Population_Affected;Entity_Affected;Therapeutic_Outcome
SITAGLIPTIN;DPP4;TT;rs2909451;EFFICACY;DECREASED;RESPONSE;;PEOPLE;OTHER:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*3;CYP2C9*1, CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
SITAGLIPTIN;KCNJ11;GG;rs2285676;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
SITAGLIPTIN;KCNQ1;GG;rs163184;EFFICACY;DECREASED;RESPONSE;;PEOPLE;OTHER:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;*1/*18;CYP2B6*1, CYP2B6*18;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
SITAGLIPTIN;DPP4;GG;rs4664443;EFFICACY;DECREASED;RESPONSE;;PEOPLE;OTHER:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_FAILURE
SITAGLIPTIN;CYP2C9;TT;rs1799853;EFFICACY;DECREASED;RESPONSE;;PEOPLE;OTHER:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_FAILURE
SITAGLIPTIN;GLP1R;AG;rs3765467;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
IVACAFTOR / LUMACAFTOR;CFTR;del/del;rs113993960;EFFICACY;;RESPONSE;;PEOPLE;DISEASE:CYSTIC_FIBROSIS;CAUTION_DOSE_ADJUST
FLUOXETINE;CYP2C19;;INTERMEDIATE_METABOLIZER;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
PAROXETINE;CYP2C19;;ULTRARAPID_METABOLIZER;EFFICACY;DECREASED;RESPONSE;;PEOPLE;OTHER:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
SITAGLIPTIN;GLP1R;AA;rs6923761;EFFICACY;DECREASED;RESPONSE;;PEOPLE;OTHER:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_FAILURE
EXENATIDE, LIRAGLUTIDE;GLP1R;GG;rs3765467;EFFICACY;INCREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
CITALOPRAM, FLUOXETINE, PAROXETINE, SERTRALINE;CYP2C19;;POOR_METABOLIZER;EFFICACY;DECREASED;RESPONSE;;PEOPLE;OTHER:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
ALBIGLUTIDE, DULAGLUTIDE, GLP-1 RECEPTOR AGONISTS;GLP1R;A;rs6923761;EFFICACY;DECREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_FAILURE
EXENATIDE;TCF7L2;CT + TT;rs7903146;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;METABOLISM/PK;DECREASED;EXPOSURE;;PEOPLE;OTHER:HISTORY_OF_GASTRIC_BYPASS_SURGERY;LIKELIHOOD_THERAPEUTIC_FAILURE
ALBIGLUTIDE, DULAGLUTIDE, GLP-1 RECEPTOR AGONISTS;ARRB1;A;rs140226575;EFFICACY;INCREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
PROPAFENONE;CYP2D6;*10/*10;CYP2D6*1, CYP2D6*10;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:CARDIAC_RHYTHM_DISEASE;CAUTION_DRUG_ACCUMULATION
PROPAFENONE;CYP2D6;*10/*10;CYP2D6*1, CYP2D6*10;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:CARDIAC_RHYTHM_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ALBIGLUTIDE, DULAGLUTIDE, GLP-1 RECEPTOR AGONISTS;ARRB1;A;rs78979036;EFFICACY;INCREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHADONE;CYP2D6;*1/*2xN + *2/*2xN;CYP2D6*1, CYP2D6*2, CYP2D6*2XN;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:OPIOID-RELATED_DISORDERS;LIKELIHOOD_THERAPEUTIC_SUCCESS
LURBINECTEDIN;CYP3A4;*1/*1;CYP3A4*1, CYP3A4*22;METABOLISM/PK;DECREASED;CONCENTRATIONS;;PEOPLE;OTHER:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;OTHER:LIVER_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
ALBIGLUTIDE, DULAGLUTIDE, GLP-1 RECEPTOR AGONISTS;ARRB1;T;rs78052828;EFFICACY;INCREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
PHENYTOIN;CYP2C9;*3;CYP2C9*1, CYP2C9*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;CAUTION_DRUG_ACCUMULATION
ALBIGLUTIDE, DULAGLUTIDE, GLP-1_RECEPTOR_AGONISTS;ARRB1;C;rs58428187;EFFICACY;INCREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
RALOXIFENE-6'-GLUCURONIDE, RALOXIFENE-4'-GLUCURONIDE;UGT1A1;*28/*28;UGT1A1*1, UGT1A1*28;METABOLISM/PK;INCREASED;CONCENTRATIONS;;WOMEN;DISEASE:OSTEOPOROSIS;CAUTION_DRUG_ACCUMULATION
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION, DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
DEXTROMETHORPHAN;CYP2D6;*41;CYP2D6*41;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
TRAMADOL;CYP2D6;*1/*4 + *1/*5 + *1/*9 + *1/*10 + *4/*10 + *5/*10 + *10/*10 + *10/*17;CYP2D6*1, CYP2D6*4, CYP2D6*5, CYP2D6*9, CYP2D6*10, CYP2D6*17;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
ARIPIPRAZOLE;CYP2D6;;INTERMEDIATE_METABOLIZER;METABOLISM/PK;INCREASED;CONCENTRATIONS;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
LURBINECTEDIN;CYP3A5;*1/*1;CYP3A5*1, CYP3A5*3;METABOLISM/PK;INCREASED;CLEARANCE;;PEOPLE;OTHER:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
LURBINECTEDIN;CYP3A5;*1/*1;CYP3A5*1, CYP3A5*3;METABOLISM/PK;DECREASED;CONCENTRATIONS;;PEOPLE;OTHER:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
LEFLUNOMIDE;PON1;GG;rs705379;EFFICACY;INCREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
TRAMADOL;CYP2D6;*4/*4 + *4/*6;CYP2D6*1, CYP2D6*4, CYP2D6*6;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
IRINOTECAN;UGT1A1;*1/*28 + *28/*28;UGT1A1*1, UGT1A1*28;DOSAGE;DECREASED;DOSE;;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_DOSE_ADJUST
DABIGATRAN;CYP3A5;*1/*1;CYP3A5*1, CYP3A5*3;METABOLISM/PK;DECREASED;EXPOSURE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
(S)-METHADONE;CYP2B6;*6/*6;CYP2B6*1, CYP2B6*5, CYP2B6*6, CYP2B6*7;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
ANTIEPILEPTICS;SCN1A;C;rs2298771;EFFICACY;INCREASED;RESISTANCE;;PEOPLE;OTHER:EPILEPSY;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIEPILEPTICS;SCN1A;T;rs10167228;EFFICACY;INCREASED;RESISTANCE;;PEOPLE;OTHER:EPILEPSY;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*1/*2;CYP2C9*1, CYP2C9*2;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*3;CYP2C9*1, CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*5;CYP2C9*1, CYP2C9*5;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*11;CYP2C9*1, CYP2C9*11;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
METHADONE;;;ACTIVITY;METABOLISM/PK;INCREASED;TROUGH_CONCENTRATION;;;;CAUTION_DRUG_ACCUMULATION
TELMISARTAN;UGT1A3;*2;UGT1A3*1, UGT1A3*2;METABOLISM/PK;DECREASED;CONCENTRATIONS;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
IRINOTECAN_SN-38;UGT1A1;*28/*28;UGT1A1*1, UGT1A1*28;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;OTHER:NEOPLASMS;CAUTION_DRUG_ACCUMULATION
BILIRUBIN;UGT1A1;*28/*28;UGT1A1*1, UGT1A1*28;OTHER;INCREASED;;;PEOPLE;DISEASE:NEOPLASMS;CAUTION_DOSE_ADJUST
IRINOTECAN_SN-38;UGT1A1;*1/*28 + *28/*28;UGT1A1*1, UGT1A1*28;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;OTHER:NEOPLASMS;CAUTION_DRUG_ACCUMULATION
CARVEDILOL;UGT1A1;*28;UGT1A1*1, UGT1A1*28;METABOLISM/PK;INCREASED;METABOLISM;;PEOPLE;OTHER:ANGINA_PECTORIS;LIKELIHOOD_THERAPEUTIC_FAILURE
LUMACAFTOR;CFTR;del/del;rs113993960;EFFICACY;;RESPONSE;;;;CAUTION_DOSE_ADJUST
OLANZAPINE;GSTM3;TCCTC/TCCTC;rs36120609;METABOLISM/PK;DECREASED;CONCENTRATIONS;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*3/*3 + *1/*3;CYP2C9*1, CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
OLANZAPINE;GSTM3;TCCTC/TCCTC;rs36120609;METABOLISM/PK;INCREASED;CLEARANCE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
DEXTROMETHORPHAN;CYP2D6;*17/*17 + *29/*29;CYP2D6*1, CYP2D6*2, CYP2D6*17, CYP2D6*29;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
LIRAGLUTIDE;CNR1;CT + TT;rs1049353;EFFICACY;INCREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:DIABETES_MELLITUS_T2, OTHER:OBESITY;LIKELIHOOD_THERAPEUTIC_SUCCESS
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;DECREASED;CONCENTRATIONS;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUVOXAMINE, PAROXETINE;SLC6A4;HTTLPR long form (L allele);SLC6A4 HTTLPR LONG FORM (L ALLELE), SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLONIDINE;ADRA2C;GGGGAGCTTTCCCAGAGACCC/del + del/del;rs11269124;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:LIVER_CIRRHOSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
DEXTROMETHORPHAN;CYP2D6;*10/*10 + *1/*10;CYP2D6*1, CYP2D6*10;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;*14;CYP2D6*1, CYP2D6*10, CYP2D6*14;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
SIMVASTATIN ACID;SLCO1B1;CC + CT;rs4149056;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;OTHER:CARDIOVASCULAR_DISEASE, OTHER:DYSLIPIDAEMIA;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;;POOR_METABOLIZER;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
SIMVASTATIN ACID;SLCO1B1;AG + GG;rs2306283;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;OTHER:CARDIOVASCULAR_DISEASE, OTHER:DYSLIPIDAEMIA;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;*3/*4 + *4/*4 + *4/*5;CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*9, CYP2D6*10, CYP2D6*17, CYP2D6*41;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
ASPIRIN;P2RY1;T;rs1371097;EFFICACY;DECREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:STROKE;LIKELIHOOD_THERAPEUTIC_FAILURE
ASPIRIN;ABCB1;GG;rs1045642;EFFICACY;INCREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:STROKE;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN_SN-38;UGT1A1;*28;UGT1A1*1, UGT1A1*28;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;OTHER:COLONIC_NEOPLASMS;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;;POOR_METABOLIZER;METABOLISM/PK;DECREASED;METABOLISM;;CHILDREN;;CAUTION_DRUG_ACCUMULATION
RIBAVIRIN, SOFOSBUVIR;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIFAMPIN;SLCO1B1;TT;rs4149032;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;OTHER:TUBERCULOSIS;CAUTION_DRUG_ACCUMULATION
MODAFINIL;COMT;GG;rs4680;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:METHAMPHETAMINE_DEPENDENCE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ISONIAZID;;AA;rs1495741;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;OTHER:TUBERCULOSIS;CAUTION_DRUG_ACCUMULATION
VALSARTAN;AGT;GG;rs699;EFFICACY;DECREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_FAILURE
MELOXICAM;CYP2C9;*1/*3;CYP2C9*1, CYP2C9*3;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
NALTREXONE;OPRM1;G;rs1799971;EFFICACY;INCREASED;CLINICAL_BENEFIT;;MEN;OTHER:ALCOHOL_ABUSE;LIKELIHOOD_THERAPEUTIC_SUCCESS
IVACAFTOR;CFTR;del;rs113993960;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IVACAFTOR;CFTR;del;rs113993960;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:CYSTIC_FIBROSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ELEXACAFTOR;CFTR;;DEFICIENCY;METABOLISM/PK;DECREASED;CONCENTRATIONS;;PEOPLE;OTHER:CYSTIC_FIBROSIS;LIKELIHOOD_THERAPEUTIC_FAILURE
ATORVASTATIN;SLCO1B1;*15;SLCO1B1*1, SLCO1B1*15;METABOLISM/PK;INCREASED;CONCENTRATIONS;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
REMIFENTANIL;ADRA2A;CG + GG;rs1800544;DOSAGE;INCREASED;DOSE;;WOMEN;OTHER:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
WARFARIN;UGT1A1;*1/*28 + *28/*28;UGT1A1*1, UGT1A1*28;DOSAGE;INCREASED;DOSE;;PEOPLE;OTHER:THROMBOEMBOLISM;CAUTION_DOSE_ADJUST
REMIFENTANIL;OPRM1;AG + GG;rs1799971;DOSAGE;INCREASED;DOSE;;WOMEN;OTHER:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;INCREASED;CLEARANCE;;PEOPLE;OTHER:LIVER_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
POSACONAZOLE, TACROLIMUS;ABCB1;GG;rs1045642;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*6;CYP3A5*1, CYP3A5*6;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
LACOSAMIDE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;OTHER:EPILEPSY;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*7;CYP3A5*1, CYP3A5*7;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;INCREASED;DOSE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
SERTRALINE;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3 + *3/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;OTHER:DEPRESSIVE_DISORDER;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*1/*1;CYP3A5*1, CYP3A5*3;DOSAGE;INCREASED;DOSE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
ESCITALOPRAM;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3 + *3/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;OTHER:DEPRESSIVE_DISORDER;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;DOSAGE;INCREASED;DOSE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;DOSAGE;DECREASED;DOSE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;INCREASED;DOSE;;CHILDREN;DISEASE:ORGAN_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;DOSAGE;DECREASED;DOSE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;DOSAGE;INCREASED;DOSE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3 + *1/*6 + *1/*7;CYP3A5*1, CYP3A5*3, CYP3A5*6, CYP3A5*7;DOSAGE;INCREASED;DOSE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1;CYP3A5*1, CYP3A5*3;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;DECREASED;CLEARANCE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;DECREASED;CLEARANCE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;DISEASE:ULCERATIVE_COLITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
COUMARIN;CYP2A6;*4/*4 + *4/*10;CYP2A6*1, CYP2A6*4, CYP2A6*10;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
NICOTINE;CYP2A6;*1/*2 + *2/*2;CYP2A6*1, CYP2A6*2;DOSAGE;DECREASED;DOSE;;PEOPLE;DISEASE:TOBACCO_USE_DISORDER;CAUTION_DOSE_ADJUST
MOXIFLOXACIN;UGT1A1;*1/*36;UGT1A1*1, UGT1A1*28, UGT1A1*36, UGT1A1*37;METABOLISM/PK;DECREASED;CLEARANCE;;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;;POOR_METABOLIZER;METABOLISM/PK;DECREASED;METABOLISM;;WOMEN;OTHER:BREAST_NEOPLASMS;CAUTION_DRUG_ACCUMULATION
NICOTINE;CYP2A6;*46/*46;CYP2A6*1, CYP2A6*46;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
BUPRENORPHINE;SLC39A10;C;rs149319538;EFFICACY;INCREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:OPIOID-RELATED_DISORDERS;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;*2;CYP2C9*1, CYP2C9*2;DOSAGE, METABOLISM/PK;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2/*2;CYP2C9*1, CYP2C9*2;DOSAGE, EFFICACY;DECREASED;DOSE;;CHILDREN;DISEASE:HEART_DISEASES;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*3;CYP2C9*1, CYP2C9*3;DOSAGE;DECREASED;DOSE;;PEOPLE;DISEASE:VENOUS_THROMBOEMBOLISM;CAUTION_DOSE_ADJUST
SIMVASTATIN, WARFARIN;CYP2C9;*3;CYP2C9*1, CYP2C9*3;DOSAGE, METABOLISM/PK;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
DEXTROMETHORPHAN;CYP2D6;*4/*4 + *6/*6 + *3/*4 + *3/*3;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*6, CYP2D6*7;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;*3;CYP2C9*1, CYP2C9*3;DOSAGE, METABOLISM/PK;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*3;CYP2C9*1, CYP2C9*3;DOSAGE;DECREASED;DOSE;;PEOPLE;DISEASE:ATRIAL_FIBRILLATION;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*3;CYP2C9*1, CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
DEXTROMETHORPHAN;CYP2D6;*4;CYP2D6*1, CYP2D6*4;METABOLISM/PK;DECREASED;METABOLISM;;WOMEN;;CAUTION_DRUG_ACCUMULATION
LETROZOLE;CYP2A6;*1/*1;CYP2A6*1, CYP2A6*2, CYP2A6*4, CYP2A6*9, CYP2A6*12;METABOLISM/PK;DECREASED;CONCENTRATIONS;;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
DEXTROMETHORPHAN;CYP2D6;*1/*2;CYP2D6*1, CYP2D6*2;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1, CYP2C9*2, CYP2C9*3;DOSAGE;DECREASED;DOSE;;PEOPLE;OTHER:HEART_VALVE_REPLACEMENT, OTHER:ATRIAL_FIBRILLATION,OTHER:STROKE, OTHER:PULMONARY_EMBOLISM, OTHER:VENOUS_THROMBOSIS;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED;DOSE;;PEOPLE;OTHER:HEART_VALVE_REPLACEMENT, OTHER:ATRIAL_FIBRILLATION,OTHER:STROKE, OTHER:PULMONARY_EMBOLISM, OTHER:VENOUS_THROMBOSIS;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1, CYP2C9*2, CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
RIVAROXABAN;ABCB1;CC;rs4148738;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;OTHER:ATRIAL_FIBRILLATION;CAUTION_DRUG_ACCUMULATION
RIVAROXABAN;ABCB1;AA;rs1128503;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;OTHER:ATRIAL_FIBRILLATION;CAUTION_DRUG_ACCUMULATION
DIAZEPAM;CYP2B6;;POOR_METABOLIZER;METABOLISM/PK;DECREASED;CLEARANCE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;TYMS;GG;rs2853542;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
MERCAPTOPURINE;TPMT;*1/*2 + *1/*3A;TPMT*1, TPMT*2, TPMT*3A;DOSAGE;DECREASED;DOSE;;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DOSE_ADJUST
MERCAPTOPURINE, THIOGUANINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TPMT*1, TPMT*2, TPMT*3A, TPMT*3C, TPMT*9, TPMT*21, TPMT*33, TPMT*34;DOSAGE;DECREASED;DOSE;;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DOSE_ADJUST
METHOTREXATE;ATIC;TT;rs4673993;EFFICACY;DECREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOXETINE;HTR1A;GG;rs6295;EFFICACY;INCREASED;RESPONSE;;PEOPLE;EFFICACY:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
RISPERIDONE;CYP2D6;*4/*4 + *4/*5 + *4/*3 + *5/*5 + *6/*6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*9, CYP2D6*10, CYP2D6*41;EFFICACY;INCREASED;DISCONTINUATION;;PEOPLE;OTHER:SCHIZOPHRENIA, OTHER:SCHIZOAFFECTIVE_DISORDER,OTHER:BIPOLAR_DISORDER, OTHER:DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
IRINOTECAN_SN-38;UGT1A1;*6/*60 + *6/*28;UGT1A1*1, UGT1A1*6, UGT1A1*28, UGT1A1*60;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:NEOPLASMS;CAUTION_DRUG_ACCUMULATION
DIHYDROPYRIDINE DERIVATIVES;NUMA1;AA + AG;rs10898815;OTHER;INCREASED;DISCONTINUATION;;;;CAUTION_SIDE_EFFECT
WARFARIN;CYP4F2;CC;rs2108622;DOSAGE;DECREASED;DOSE;;PEOPLE;OTHER:HEART_VALVE_REPLACEMENT;CAUTION_DOSE_ADJUST
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:GASTROESOPHAGEAL_REFLUX;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;INCREASED;METABOLISM;;PEOPLE;DISEASE:HEART_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
VORICONAZOLE;CYP2C19;*2/*2 + *2/*3 + *1/*2 + *1/*3 + *2/*17;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:FUNGAL_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
SULFONAMIDES, UREA DERIVATIVES;CYP2C19;*2/*2  + *2/*3 + *3/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
CORTICOSTEROIDS;NR3C1;GG;rs10482634;EFFICACY;INCREASED;RESISTANCE;;CHILDREN;OTHER:NEPHROTIC_SYNDROME;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*11 + *2 + *3 + *5 + *6;CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*5, CYP2C9*6, CYP2C9*10, CYP2C9*11;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;INCREASED;DOSE;;PEOPLE;DISEASE:HEART_TRANSPLANTATION;CAUTION_DOSE_ADJUST
VALPROIC ACID;UGT1A6;TT;rs6759892;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;OTHER:EPILEPSY;CAUTION_DRUG_ACCUMULATION
NICOTINE;CYP2A6;*46/*46;CYP2A6*1, CYP2A6*46;METABOLISM/PK;INCREASED;METABOLISM;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;DOSAGE;INCREASED;DOSE;;CHILDREN;DISEASE:LIVER_TRANSPLANTATION;CAUTION_DOSE_ADJUST
METHYLPHENIDATE;SYT1;AA + AG;rs2251214;EFFICACY;INCREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS
VORICONAZOLE;CYP2C19;*1/*17;CYP2C19*1, CYP2C19*17;METABOLISM/PK;INCREASED;METABOLISM;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;DOSAGE;INCREASED;DOSE;;CHILDREN;DISEASE:LIVER_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;DOSAGE;INCREASED;DOSE;;CHILDREN;DISEASE:LIVER_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;INCREASED;DOSE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
VORICONAZOLE;CYP2C19;*2/*2;CYP2C19*1, CYP2C19*2, CYP2C19*17;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;DECREASED;TROUGH_CONCENTRATION;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
CHOP, RITUXIMAB;CBR3;AA + AG;rs8133052;EFFICACY;DECREASED;RESPONSE;;PEOPLE;OTHER:NON-HODGKIN_LYMPHOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
CHOP, RITUXIMAB;ABCC2;AA + AG;rs8187710;EFFICACY;DECREASED;RESPONSE;;PEOPLE;OTHER:NON-HODGKIN_LYMPHOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*1/*11 + *2/*11;CYP2C9*1, CYP2C9*2, CYP2C9*11;METABOLISM/PK;DECREASED;CLEARANCE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
N-DESMETHYLTAMOXIFEN;SEPTIN3;AG;rs11914200;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
FENTANYL;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:NEOPLASMS, DISEASE:PAIN;CAUTION_DRUG_ACCUMULATION
CITALOPRAM;CYP2D6;*1/*10 + *10/*10;CYP2D6*1, CYP2D6*10;METABOLISM/PK;DECREASED;CLEARANCE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
N-DESMETHYLTAMOXIFEN;SREBF2;AC;rs133290;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
HYDROXYPHENYTOIN;CYP2C9;*1/*11 + *2/*11;CYP2C9*1, CYP2C9*2, CYP2C9*11;METABOLISM/PK;DECREASED;CONCENTRATIONS;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*2;CYP2C9*1, CYP2C9*2;DOSAGE;DECREASED;DOSE;;PEOPLE;DISEASE:VENOUS_THROMBOEMBOLISM;CAUTION_DOSE_ADJUST
N-DESMETHYLTAMOXIFEN;TCF20;GG;rs5751251;METABOLISM/PK;INCREASED;METABOLISM;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
N-DESMETHYLTAMOXIFEN;SREBF2;TT;rs2267439;METABOLISM/PK;INCREASED;METABOLISM;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
PIROXICAM;CYP2C9;*1/*3 + *3/*3;CYP2C9*1, CYP2C9*3;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
N-DESMETHYLTAMOXIFEN;SREBF2;TT;rs9607850;METABOLISM/PK;INCREASED;METABOLISM;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;DOSAGE, METABOLISM/PK;DECREASED;DOSE;;CHILDREN;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
N-DESMETHYLTAMOXIFEN;CENPM, SMIM45;AG;rs8140869;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
RIBAVIRIN, SOFOSBUVIR;IFNL4;GG;rs11322783;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_FAILURE
VARENICLINE;CYP2A6;;HIGH ACTIVITY;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:TOBACCO_USE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETOPOSIDE;;AA;rs446112;OTHER;INCREASED;RESISTANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
ROSUVASTATIN;ABCG2;GT + TT;rs2231142;METABOLISM/PK;INCREASED;EXPOSURE;;PEOPLE;OTHER:DIABETES_MELLITUS, OTHER:HYPERCHOLESTEROLEMIA;CAUTION_DRUG_ACCUMULATION
FLUVOXAMINE, PAROXETINE;SLC6A4;HTTLPR long form (L allele);SLC6A4 HTTLPR LONG FORM (L ALLELE), SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
MELOXICAM;CYP2C9;*1/*3 + *2/*2;CYP2C9*1, CYP2C9*2, CYP2C9*3;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
OPIOIDS;CYP2D6;;CYP2D6 POOR, ULTRARAPID METABOLIZER;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:PAIN;LIKELIHOOD_THERAPEUTIC_FAILURE
VORICONAZOLE;CYP2C19;*1/*17;CYP2C19*1, CYP2C19*2, CYP2C19*17;METABOLISM/PK;INCREASED;METABOLISM;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *3/*3 + *2/*3;CYP2C9*1, CYP2C9*2, CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
PAROXETINE;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR LONG FORM (L ALLELE), SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:PANIC_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
IVACAFTOR, LUMACAFTOR;CFTR;del;rs113993960;EFFICACY;;RESPONSE;;PEOPLE;DISEASE:CYSTIC_FIBROSIS;CAUTION_DOSE_ADJUST
PAROXETINE;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
AFATINIB;EGFR;GG;rs28929495;EFFICACY;DECREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
IVACAFTOR, LUMACAFTOR;CFTR;del/del;rs113993960;EFFICACY;;RESPONSE;;CHILDREN;DISEASE:CYSTIC_FIBROSIS;CAUTION_DOSE_ADJUST
3-AMINOISOBUTYRATE;DPYD;TT;rs3918290;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
HYDRALAZINE;NAT2;;RAPID_ACETYLATOR;DOSAGE, EFFICACY;INCREASED;DOSE;;PEOPLE;OTHER:HYPERTENSION;CAUTION_DOSE_ADJUST
MEXILETINE;CYP2D6;*41;CYP2D6*41;EFFICACY;DECREASED;RESPONSE;;PEOPLE;OTHER:MYOTONIC_DYSTROPHY, OTHER:NONDYSTROPHIC_MYOTONIA;LIKELIHOOD_THERAPEUTIC_FAILURE
3-AMINOISOBUTYRATE;UPB1;AA;rs143493067;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
3-AMINOISOBUTYRATE;AGXT2;TT;rs114286107;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
MELOXICAM;CYP2C9;*3 + *2;CYP2C9*1, CYP2C9*2, CYP2C9*3;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
MELOXICAM;CYP2C9;*1/*13;CYP2C9*1, CYP2C9*13;PD, METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
FENTANYL;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:POSTOPERATIVE_PAIN;CAUTION_DRUG_ACCUMULATION
URACIL;DPYD;TT;rs3918290;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
2-AMINOHEPTANOATE, 2-AMINOOCTANOIC ACID, 2-HYDROXYLAURATE;ACAD11;AA;rs41272317;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
CYSTEINE-S-SULFATE, L-ORNITHINE;NPC2;TT;rs140130028;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
5,6-DIHYDROTHYMINE;UPB1;AA;rs143493067;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
10-MONOHYDROXY OXCARBAZEPINE;ABCC2;G;rs2273697;METABOLISM/PK;INCREASED;CLEARANCE;;CHILDREN;OTHER:EPILEPSY;LIKELIHOOD_THERAPEUTIC_FAILURE
DEXTROMETHORPHAN;CYP2D6;*5/*10;CYP2D6*1, CYP2D6*5, CYP2D6*10;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;*1/*10;CYP2D6*1, CYP2D6*10;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;*2;CYP2C9*1, CYP2C9*2;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2B6;*6;CYP2B6*1, CYP2B6*6;METABOLISM/PK;DECREASED;CLEARANCE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;*10/*10;CYP2D6*1, CYP2D6*10;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
RIVAROXABAN;CYP3A5;TT;rs776746;TOXICITY;DECREASED;CONCENTRATIONS;;PEOPLE;OTHER:VENOUS_THROMBOEMBOLISM;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;AC;rs1057910;DOSAGE;DECREASED;DOSE;;PEOPLE;OTHER:HEART_VALVE_REPLACEMENT;CAUTION_DOSE_ADJUST
PRAZIQUANTEL;CYP1A2;*1/*30 + *30/*30;CYP1A2*1, CYP1A2*30;METABOLISM/PK;INCREASED;METABOLISM;;PEOPLE;OTHER:SCHISTOSOMIASIS;LIKELIHOOD_THERAPEUTIC_FAILURE
PRAZIQUANTEL;CYP2C9;*1/*9 + *9/*9;CYP2C9*1, CYP2C9*9;METABOLISM/PK;INCREASED;METABOLISM;;PEOPLE;OTHER:SCHISTOSOMIASIS;LIKELIHOOD_THERAPEUTIC_FAILURE
ARIPIPRAZOLE;CYP2D6;AA + AG;rs1065852;EFFICACY;INCREASED;CLINICAL_BENEFIT;;CHILDREN;OTHER:TIC_DISORDERS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ARIPIPRAZOLE;CYP2D6;CT + TT;rs1080989;EFFICACY;INCREASED;CLINICAL_BENEFIT;;CHILDREN;OTHER:TIC_DISORDERS;LIKELIHOOD_THERAPEUTIC_SUCCESS
QUINAPRIL;ACE;del/del;rs1799752;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ARIPIPRAZOLE;CYP2D6;CT + TT;rs1080989;EFFICACY;DECREASED;CLEARANCE;;CHILDREN;OTHER:TIC_DISORDERS;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOPHOSPHAMIDE;CYP3A4;CC + CT;rs2740574;EFFICACY;DECREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:CHRONIC_B-CELL_LYMPHOCITIC_LEUKEMIA,;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOPHOSPHAMIDE;CYP3A5;*3;CYP3A5*1, CYP3A5*3;EFFICACY;DECREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:CHRONIC_B-CELL_LYMPHOCITIC_LEUKEMIA,;LIKELIHOOD_THERAPEUTIC_FAILURE
ESOMEPRAZOLE, PANTOPRAZOLE;CYP2C19;*17/*17;CYP2C19*2, CYP2C19*3, CYP2C19*17;METABOLISM/PK;INCREASED;CLEARANCE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
AZATHIOPRINE, MERCAPTOPURINE, PURINE ANALOGUES;TPMT;*1/*3A + *1/*3C;TPMT*1, TPMT*3A, TPMT*3C;DOSAGE, EFFICACY, TOXICITY;DECREASED;DOSE;;PEOPLE;DISEASE:INFLAMMATORY_BOWEL_DISEASES;CAUTION_DOSE_ADJUST
VORICONAZOLE;CYP2C19;*2/*2;CYP2C19*1, CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
MELOXICAM;CYP2C9;*3/*3;CYP2C9*1, CYP2C9*3;METABOLISM/PK;DECREASED;CLEARANCE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;OTHER:LIVER_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;UGT1A4;TT;rs2011425;METABOLISM/PK;DECREASED;CONCENTRATIONS;;PEOPLE;OTHER:LIVER_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A4;GG;rs35599367;METABOLISM/PK;DECREASED;CONCENTRATIONS;;PEOPLE;OTHER:LIVER_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;*6/*6;CYP2B6*1, CYP2B6*6;METABOLISM/PK;INCREASED;CONCENTRATIONS;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
ROSUVASTATIN;SLCO1B1;CC + CT;rs4149056;METABOLISM/PK;INCREASED;EXPOSURE;;PEOPLE;OTHER:DIABETES_MELLITUS, OTHER:HYPERCHOLESTEROLEMIA;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;DECREASED;DOSE;;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*3;CYP2C9*1, CYP2C9*2, CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;*2/*3;CYP2C9*2, CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ALOGLIPTIN;PNPLA3;CG + GG;rs738409;EFFICACY;INCREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:DIABETES_MELLITUS_T2, OTHER:FATTY_LIVER_DISEASE,OTHER:BODY_WEIGHT_CHANGES;LIKELIHOOD_THERAPEUTIC_SUCCESS
AMLODIPINE;CYP3A4;*1/*22 + *22/*22;CYP3A4*1, CYP3A4*22;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;OTHER:HYPERTENSION;CAUTION_DRUG_ACCUMULATION
IVACAFTOR, LUMACAFTOR;CFTR;CTT/del;rs113993960;EFFICACY;;RESPONSE;;PEOPLE;DISEASE:CYSTIC_FIBROSIS;CAUTION_DOSE_ADJUST
SERTRALINE;DRD3;AG;rs167770;EFFICACY;INCREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:OBSESSIVE_COMPULSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
RABEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED;RESPONSE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
SERTRALINE;DRD3;AG;rs11721264;EFFICACY;INCREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:OBSESSIVE_COMPULSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
ILOPERIDONE, ILOPERIDONE METABOLITE P88;CYP2D6;AA;rs1065852;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;OTHER:SCHIZOPHRENIA;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
ASPIRIN, CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
IVACAFTOR, LUMACAFTOR;CFTR;del/del;rs113993960;EFFICACY;;RESPONSE;;PEOPLE;DISEASE:CYSTIC_FIBROSIS;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2B6;*1/*4;CYP2B6*1, CYP2B6*4;METABOLISM/PK;DECREASED;CONCENTRATIONS;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
IVACAFTOR, LUMACAFTOR;CFTR;del/del;rs113993960;EFFICACY;;RESPONSE;;CHILDREN;DISEASE:CYSTIC_FIBROSIS;CAUTION_DOSE_ADJUST
VALPROIC ACID;CACNA1H;T;rs3751664;EFFICACY;INCREASED;RESISTANCE;;PEOPLE;OTHER:EPILEPSY;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUVOXAMINE;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR LONG FORM (L ALLELE), SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
PENICILLIN G;IFNG;CC;rs1861494;EFFICACY;DECREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:SYPHILIS;LIKELIHOOD_THERAPEUTIC_FAILURE
ASPIRIN, CLOPIDOGREL;CYP2C19;*2;CYP2C19*1, CYP2C19*2;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1, CYP2C19*2;EFFICACY;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
PENICILLIN G;IFNG;TT;rs2430561;EFFICACY;DECREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:SYPHILIS;LIKELIHOOD_THERAPEUTIC_FAILURE
IVACAFTOR, LUMACAFTOR;CFTR;del/del;rs113993960;EFFICACY;;RESPONSE;;PEOPLE;DISEASE:CYSTIC_FIBROSIS;CAUTION_DOSE_ADJUST
IMIPRAMINE;CYP2D6;*1/*1xN + *1/*2xN;CYP2D6*1, CYP2D6*1XN, CYP2D6*2, CYP2D6*2XN;DOSAGE;INCREASED;DOSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DOSE_ADJUST
ISONIAZID;NAT2;*6/*6 + *6/*7 + *7/*7;NAT2*4, NAT2*5, NAT2*6, NAT2*7;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;OTHER:TUBERCULOSIS;CAUTION_DRUG_ACCUMULATION
SIMVASTATIN;CYP3A4;*1/*22;CYP3A4*1, CYP3A4*22;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:HYPERCHOLESTEROLEMIA;CAUTION_DRUG_ACCUMULATION
FLUVOXAMINE;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele) + HTTLPR long form (L allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR LONG FORM (L ALLELE), SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIVAROXABAN;ABCG2;GT + TT;rs2231142;METABOLISM/PK;INCREASED;EXPOSURE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;*2;CYP2C9*1, CYP2C9*2;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;DOSAGE, METABOLISM/PK;DECREASED;METABOLISM;;CHILDREN;DISEASE:LIVER_TRANSPLANTATION;CAUTION_DOSE_ADJUST
ATOMOXETINE;CYP2D6;*10/*10 + *1/*10;CYP2D6*1, CYP2D6*10;METABOLISM/PK;DECREASED;CLEARANCE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
IVACAFTOR, LUMACAFTOR;CFTR;del/del;rs113993960;EFFICACY;;RESPONSE;;MEN;DISEASE:CYSTIC_FIBROSIS;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1, CYP2C9*2, CYP2C9*3;METABOLISM/PK;DECREASED;CLEARANCE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
AVATROMBOPAG;CYP2C9;*1/*3;CYP2C9*1, CYP2C9*3;METABOLISM/PK;INCREASED;EXPOSURE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;*3 + *5 + *2 + *1;CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*5;DOSAGE;;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C9*1, CYP2C9*2, CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
AVATROMBOPAG;ABCB1;AA + AG;rs1128503;METABOLISM/PK;INCREASED;EXPOSURE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
VENETOCLAX;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;OTHER:ACUTE_MYELOID_LEUKEMIA;CAUTION_DRUG_ACCUMULATION
CLOZAPINE;NFIB;CT;rs28379954;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;OTHER:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_FAILURE
ATOMOXETINE;CYP2D6;*10/*10 + *1/*10;CYP2D6*1, CYP2D6*10;METABOLISM/PK;INCREASED;CONCENTRATIONS;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
PITAVASTATIN;SLCO1B1;*15;SLCO1B1*1, SLCO1B1*15;METABOLISM/PK;INCREASED;EXPOSURE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;*1/*3;CYP2C9*1, CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A4;TT;rs2740574;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;METABOLISM/PK;INCREASED;METABOLISM;;PEOPLE;DISEASE:GASTROESOPHAGEAL_REFLUX;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;METABOLISM/PK;INCREASED;METABOLISM;;PEOPLE;DISEASE:GASTROESOPHAGEAL_REFLUX;LIKELIHOOD_THERAPEUTIC_FAILURE
METHYLPHENIDATE;SLC6A2;GG;rs998424;EFFICACY;INCREASED;CLINICAL_BENEFIT;;CHILDREN;OTHER:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;*3;CYP2C9*1, CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
VORICONAZOLE;CYP2C19;*2/*2 + *2/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:LUPUS_NEPHRITIS;CAUTION_DRUG_ACCUMULATION
LITHIUM;;T;rs7405404;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:BIPOLAR_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
3,4-METHYLENEDIOXYMETHAMPHETAMINE;CYP2D6;*4/*4 + *3/*5;CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*9, CYP2D6*10, CYP2D6*41;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;C;rs28399499;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
FENTANYL;CYP2D6;*10/*10;CYP2D6*1, CYP2D6*10;DOSAGE;INCREASED;DOSE;;PEOPLE;OTHER:GASTROINTESTINAL_NEOPLASMS, OTHER:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
VARENICLINE;HYKK;CT + TT;rs7164594;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:TOBACCO_USE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
SIROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
4-HYDROXYTAMOXIFEN;CYP2D6;*10/*10;CYP2D6*1, CYP2D6*10;METABOLISM/PK;DECREASED;CONCENTRATIONS;;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
CAPTOPRIL;ACE;del/del;rs1799752;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_FAILURE
3,4-METHYLENEDIOXYMETHAMPHETAMINE;CYP2D6;*4/*4 + *3/*5;CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*9, CYP2D6*10, CYP2D6*41;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
MERCAPTOPURINE;NUDT15;*1/*1;NUDT15*1, NUDT15*2, NUDT15*3, NUDT15*5;METABOLISM/PK;INCREASED;METABOLISM;;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;T;rs3745274;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
ENALAPRIL, LOSARTAN;ACE;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;rs1799752;EFFICACY;INCREASED;RESPONSE;;MEN;DISEASE:CORONARY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;*1;CYP3A5*1, CYP3A5*3;METABOLISM/PK;INCREASED;CLEARANCE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
BENAZEPRIL;ACE;del/del;rs1799752;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:ESSENTIAL_HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
LANSOPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED;RESPONSE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
BUPROPION;CYP2B6;GG;rs8109525;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:TOBACCO_USE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;*1/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;INCREASED;METABOLISM;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED;RESPONSE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
MERCAPTOPURINE;NUDT15;*1/*1;NUDT15*1, NUDT15*2, NUDT15*3, NUDT15*4, NUDT15*5;DOSAGE;INCREASED;DOSE;;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*3 + *3/*3;CYP2C9*1, CYP2C9*3;DOSAGE;DECREASED;DOSE;;PEOPLE;DISEASE:HEART_VALVE_REPLACEMENT;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;DECREASED;CLEARANCE;;CHILDREN;DISEASE:NEPHROTIC_SYNDROME;CAUTION_DRUG_ACCUMULATION
ENDOXIFEN;CYP2D6;*10/*10 + *10/*41 + *1/*5 + *2/*5 + *5/*10;CYP2D6*1, CYP2D6*2, CYP2D6*5, CYP2D6*10, CYP2D6*41;METABOLISM/PK;DECREASED;CONCENTRATIONS;;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
ATOMOXETINE;CYP2D6;*10/*10;CYP2D6*1, CYP2D6*10;METABOLISM/PK;DECREASED;CLEARANCE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
MESALAZINE, THIOGUANINE;NAT1;*10;NAT1*3, NAT1*4, NAT1*10;METABOLISM/PK;DECREASED;CONCENTRATIONS;;CHILDREN;DISEASE:ULCERATIVE_COLITIS, DISEASE:CROHN_DISEASE,DISEASE:INFLAMMATORY_BOWEL_DISEASES;LIKELIHOOD_THERAPEUTIC_FAILURE
PIOGLITAZONE;CYP2C9;*1/*3;CYP2C9*1, CYP2C9*3;METABOLISM/PK;INCREASED;METABOLISM;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CC;rs776746;DOSAGE;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;DISEASE:ULCERATIVE_COLITIS;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;CHILDREN;DISEASE:ORGAN_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;DECREASED;TROUGH_CONCENTRATION;;CHILDREN;DISEASE:ORGAN_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;CYP2D6;*4/*5 + *4/*6 + *3/*4 + *4/*4;CYP2D6*1, CYP2D6*1XN, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
EXEMESTANE;CYP3A4;*1/*22;CYP3A4*1, CYP3A4*22;METABOLISM/PK;INCREASED;CONCENTRATIONS;;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP4F2;*3;CYP4F2*1, CYP4F2*3;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:HEART_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;CYP2D6;*4 + *5;CYP2D6*1, CYP2D6*4, CYP2D6*5;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;CYP2D6;*4 + *5 + *10 +*14;CYP2D6*1, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*14;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_DRUG_ACCUMULATION
METOPROLOL;CYP2D6;*4;CYP2D6*4;DOSAGE;DECREASED;DOSE;;PEOPLE;DISEASE:HEART_FAILURE;CAUTION_DOSE_ADJUST
CETUXIMAB;VEGFA;del/del;rs144854329;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN_SN-38;UGT1A1;*1/*28 + *28/*28;UGT1A1*1, UGT1A1*28;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;OTHER:NEOPLASMS;CAUTION_DRUG_ACCUMULATION
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:HELICOBACTER_INFECTIONS;LIKELIHOOD_THERAPEUTIC_FAILURE
IBUPROFEN;CYP2C9;*3;CYP2C9*1, CYP2C9*3;METABOLISM/PK;DECREASED;CLEARANCE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
LANSOPRAZOLE, OMEPRAZOLE, RABEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:HELICOBACTER_INFECTIONS;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE, OMEPRAZOLE, RABEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:HELICOBACTER_INFECTIONS;LIKELIHOOD_THERAPEUTIC_FAILURE
IBUPROFEN;CYP2C9;*2;CYP2C9*1, CYP2C9*2;METABOLISM/PK;DECREASED;CLEARANCE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;DOSAGE;INCREASED;DOSE;;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS, DISEASE:ULCERATIVE_COLITIS;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CC;rs776746;DOSAGE;INCREASED;TROUGH_CONCENTRATION;;PEOPLE;DISEASE:ULCERATIVE_COLITIS;CAUTION_DOSE_ADJUST
IRINOTECAN_SN-38;UGT1A1;*1/*28 + *28/*28;UGT1A1*1, UGT1A1*28;METABOLISM/PK;DECREASED;CLEARANCE;;PEOPLE;OTHER:NEOPLASMS;CAUTION_DRUG_ACCUMULATION
LORNOXICAM;CYP2C9;*1/*13;CYP2C9*1, CYP2C9*13;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
RABEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED;RESPONSE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
PILOCARPINE;CYP2A6;*4/*7 + *4/*9 + *4/*10 + *7/*9;CYP2A6*4, CYP2A6*7, CYP2A6*9, CYP2A6*10;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:HELICOBACTER_INFECTIONS;LIKELIHOOD_THERAPEUTIC_FAILURE
LORNOXICAM;CYP2C9;*1/*13;CYP2C9*1, CYP2C9*13;METABOLISM/PK;DECREASED;CLEARANCE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
LORNOXICAM;CYP2C9;*1/*3;CYP2C9*1, CYP2C9*3;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:HELICOBACTER_INFECTIONS;LIKELIHOOD_THERAPEUTIC_FAILURE
LORNOXICAM;CYP2C9;*1/*3;CYP2C9*1, CYP2C9*3;METABOLISM/PK;DECREASED;CLEARANCE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
ATENOLOL;ADRB1;C;rs1801253;EFFICACY;INCREASED;RESPONSE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;*1/*6;CYP2C9*1, CYP2C9*6;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*3 + *3/*3;CYP3A5*1, CYP3A5*3;DOSAGE;INCREASED;TROUGH_CONCENTRATION;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
VENLAFAXINE;CYP2D6;*3/*4 + *4/*4 + *4/*5;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
LETROZOLE;;C;rs7937;;INCREASED;CONCENTRATIONS;;WOMEN;OTHER:BREAST_NEOPLASMS;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;*3;CYP2C9*1, CYP2C9*3;DOSAGE;DECREASED;DOSE;;PEOPLE;OTHER:TOTAL_KNEE_OR_HIP_ARTHROPLASTY;CAUTION_DOSE_ADJUST
PROPOFOL;CYP2C9;*1/*1 + *1/*2;CYP2C9*1, CYP2C9*2;METABOLISM/PK;DECREASED;CONCENTRATIONS;;PEOPLE;;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*1/*3;CYP2C9*1, CYP2C9*3;METABOLISM/PK;;CLEARANCE;;PEOPLE;DISEASE:HEART_DISEASES;CAUTION_DOSE_ADJUST
LANSOPRAZOLE, OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HELICOBACTER_INFECTIONS;LIKELIHOOD_THERAPEUTIC_SUCCESS
NOROXYCODONE, OXYCODONE;CYP2D6;;CYP2D6 POOR_METABOLIZER, INTERMEDIATE_METABOLIZER;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
CITALOPRAM, ESCITALOPRAM, FLUOXETINE, FLUVOXAMINE, PAROXETINE, SERTRALINE;CYP2D6;*4/*4;CYP2D6*1, CYP2D6*4;DOSAGE, EFFICACY;DECREASED;DOSE;;PEOPLE;DISEASE:DEPRESSION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;DECREASED;TROUGH_CONCENTRATION;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
DISULFIRAM;SLC6A3;GGGGGCCCTGCATGCGTCCTGGGGTAGTACACGCTCCAGT/GGGGGCCCTGCATGCGTCCTGGGGTAGTACACGCTCCAGT;rs28363170;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:COCAINE_DEPENDENCE;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;*1/*2;CYP2C9*1, CYP2C9*2;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2;CYP2C9*1, CYP2C9*2;DOSAGE;DECREASED;DOSE;;PEOPLE;OTHER:TOTAL_KNEE_OR_HIP_ARTHROPLASTY;CAUTION_DOSE_ADJUST
BENAZEPRIL, PERINDOPRIL;ACE;del/del;rs1799752;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:DIABETES_MELLITUS;LIKELIHOOD_THERAPEUTIC_SUCCESS
RISPERIDONE;CYP2D6;*4/*4;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5;METABOLISM/PK;DECREASED;CLEARANCE;;PEOPLE;DISEASE:PSYCHOTIC_DISORDER;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;*1/*3;CYP2C9*1, CYP2C9*3;DOSAGE;DECREASED;DOSE;;CHILDREN;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*2;CYP2C9*1, CYP2C9*2;DOSAGE;DECREASED;DOSE;;CHILDREN;;CAUTION_DOSE_ADJUST
THIOGUANINE;TPMT;*1/*3A + *1/*3C;TPMT*1, TPMT*3A, TPMT*3C;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:CROHN_DISEASE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;CC;rs776746;DOSAGE;DECREASED;DOSE;;PEOPLE;DISEASE:ULCERATIVE_COLITIS;CAUTION_DOSE_ADJUST
PROGUANIL;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;METABOLISM/PK;DECREASED;METABOLISM;;CHILDREN;DISEASE:MALARIA;CAUTION_DRUG_ACCUMULATION
MERCAPTOPURINE;TPMT;*1/*3A + *1/*3C + *3A/*3A;TPMT*1, TPMT*3A, TPMT*3C;DOSAGE;DECREASED;DOSE;;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DOSE_ADJUST
ARTEMETHER;CYP2B6;*6/*6;CYP2B6*1, CYP2B6*6;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
FLUOXETINE;CYP2D6;;POOR_METABOLIZER;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
FLUOXETINE;CYP2D6;;POOR_METABOLIZER;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
N-DESMETHYLCLOZAPINE;CYP2C19;*17;CYP2C19*1, CYP2C19*17;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:SCHIZOAFFECTIVE_DISORDER, DISEASE:SCHIZOPHRENIA;CAUTION_DRUG_ACCUMULATION
CLOZAPINE;CYP2C19;*17/*17;CYP2C19*17;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:SCHIZOAFFECTIVE_DISORDER, DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;GG;rs36118214;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
CYCLOPHOSPHAMIDE;CYP2B6;*6;CYP2B6*1, CYP2B6*6;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:NON-HODGKIN_LYMPHOMA;CAUTION_DRUG_ACCUMULATION
CYCLOPHOSPHAMIDE;CYP2B6;*1/*30;CYP2B6*1, CYP2B6*30;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:NON-HODGKIN_LYMPHOMA;CAUTION_DRUG_ACCUMULATION
CYCLOPHOSPHAMIDE;CYP2B6;*1/*29;CYP2B6*1, CYP2B6*29;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:NON-HODGKIN_LYMPHOMA;CAUTION_DRUG_ACCUMULATION
LANSOPRAZOLE, OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:HELICOBACTER_INFECTIONS;LIKELIHOOD_THERAPEUTIC_FAILURE
ROSIGLITAZONE;CYP2C8;*3;CYP2C8*3;DOSAGE, METABOLISM/PK;INCREASED;METABOLISM;;HEALTHY;;CAUTION_DOSE_ADJUST
CYCLOPHOSPHAMIDE;CYP2C19;*1/*2 + *2/*2;CYP2C19*1, CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:NON-HODGKIN_LYMPHOMA;CAUTION_DRUG_ACCUMULATION
QUINAPRIL;ACE;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del + del/del;rs1799752;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE;CYP2C19;*1/*2 + *2/*2;CYP2C19*1, CYP2C19*2;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:NON-HODGKIN_LYMPHOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
ACENOCOUMAROL;CYP2C9;*2 + *3;CYP2C9*1, CYP2C9*2, CYP2C9*3;DOSAGE;DECREASED;DOSE;;PEOPLE;DISEASE:ATRIAL_FIBRILLATION, DISEASE:VENOUS_THROMBOEMBOLISM;CAUTION_DOSE_ADJUST
TESTOSTERONE;UGT1A4;*3a;UGT1A4*1A, UGT1A4*3A;EFFICACY, METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE;CYP3A5;*1/*3 + *3/*3;CYP3A5*1, CYP3A5*3;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:NON-HODGKIN_LYMPHOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
HYDRALAZINE;NAT2;;SLOW_ACETYLATOR;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;OTHER:HYPERTENSION;CAUTION_DRUG_ACCUMULATION
ACENOCOUMAROL;CYP2C9;*2 + *3;CYP2C9*2, CYP2C9*3;DOSAGE;;DOSE;;;;CAUTION_DOSE_ADJUST
LAMOTRIGINE;UGT1A4;*2 + *3a;UGT1A4*1A, UGT1A4*2, UGT1A4*3A;EFFICACY, METABOLISM/PK;DECREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
CURCUMIN, IVACAFTOR;CFTR;AA + AG;rs77010898;EFFICACY;;RESPONSE;;PEOPLE;DISEASE:CYSTIC_FIBROSIS;CAUTION_DOSE_ADJUST
AMITRIPTYLINE;CYP2C19;*1/*2;CYP2C19*1, CYP2C19*2;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:MENTAL_DISORDERS;CAUTION_DRUG_ACCUMULATION
3-HYDROXYCOTININE;CYP2A6;*1/*12;CYP2A6*1, CYP2A6*12;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
AMITRIPTYLINE;CYP2C19;*1/*2;CYP2C19*1, CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:MENTAL_DISORDERS;CAUTION_DRUG_ACCUMULATION
CAPTOPRIL;ACE;del/del;rs1799752;EFFICACY;DECREASED;RESPONSE;;MEN;DISEASE:CHRONIC_OBSTRUCTIVE_PULMONARY_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1;CYP3A5*1;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
VORICONAZOLE;CYP2C19;*2/*2;CYP2C19*1, CYP2C19*2;DOSAGE, METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;CHILDREN;DISEASE:NEOPLASMS;CAUTION_DOSE_ADJUST
DEXTROMETHORPHAN;CYP2D6;*10/*49 + *10/*52 + *49/*52 + *10/*41 + *10/*10 + *5/*5 + *41/*41 + *10/*21 + *10/*18;CYP2D6*1, CYP2D6*5, CYP2D6*10, CYP2D6*18, CYP2D6*21, CYP2D6*41, CYP2D6*49, CYP2D6*52;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;DOSAGE;INCREASED;DOSE;;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;CAUTION_DOSE_ADJUST
METOPROLOL;CYP2D6;*9 + *29 + *45 + *46 + *17 + *10;CYP2D6*1, CYP2D6*9, CYP2D6*10, CYP2D6*17, CYP2D6*29, CYP2D6*45, CYP2D6*46;TOXICITY, METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1, CYP2C19*2;EFFICACY;INCREASED;RESISTANCE;;PEOPLE;OTHER:CORONARY_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
ESCITALOPRAM;CYP2C19;*1/*2 + *1/*3 + *17/*2 + *17/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;METABOLISM/PK;DECREASED;CLEARANCE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*17/*17;CYP2C19*1, CYP2C19*17;DOSAGE, METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;CHILDREN;DISEASE:NEOPLASMS;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;INCREASED;CLEARANCE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;HLA-G;del/del;rs371194629;EFFICACY;INCREASED;RESPONSE;;PEOPLE;EFFICACY:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
METOPROLOL;CYP2D6;*4 + *3 + *5  + *6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6;TOXICITY, METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN_SN-38;UGT1A1;*28/*28;UGT1A1*1, UGT1A1*28;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:NEOPLASMS;CAUTION_DRUG_ACCUMULATION
ESOMEPRAZOLE;CYP2C19;*17;CYP2C19*1, CYP2C19*17;EFFICACY;DECREASED;RESPONSE;;CHILDREN;OTHER:EOSINOPHILIC_ESOPHAGITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1;CYP3A5*1, CYP3A5*3;METABOLISM/PK;INCREASED;CLEARANCE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
VORICONAZOLE;CYP2C19;*1/*2;CYP2C19*1, CYP2C19*2;DOSAGE, METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;CHILDREN;DISEASE:NEOPLASMS;CAUTION_DOSE_ADJUST
IRINOTECAN;UGT1A1;*6/*6 + *28/*28 + *6/*28;UGT1A1*1, UGT1A1*6, UGT1A1*28;DOSAGE;DECREASED;DOSE;;PEOPLE;DISEASE:NEOPLASMS;CAUTION_DOSE_ADJUST
CAPTOPRIL;ACE;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;rs1799752;EFFICACY;INCREASED;RESPONSE;;MEN;DISEASE:CHRONIC_OBSTRUCTIVE_PULMONARY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PHENPROCOUMON;CYP2C9;*2 + *3;CYP2C9*1, CYP2C9*2, CYP2C9*3;DOSAGE;DECREASED;DOSE;;CHILDREN;;CAUTION_DOSE_ADJUST
IVACAFTOR, TEZACAFTOR;CFTR;del/del;rs113993960;EFFICACY;;RESPONSE;;PEOPLE;DISEASE:CYSTIC_FIBROSIS;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;TT;rs9923231;DOSAGE;DECREASED;DOSE;;PEOPLE;OTHER:HEART_VALVE_REPLACEMENT;CAUTION_DOSE_ADJUST
TRAMADOL;CYP2D6;*1/*1xN;CYP2D6*1, CYP2D6*1XN;METABOLISM/PK;INCREASED;METABOLISM;;INFANTS;;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*1/*2;CYP2C9*1, CYP2C9*2;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
LOSARTAN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *2/*3;CYP2C9*1, CYP2C9*2, CYP2C9*3;EFFICACY;DECREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_FAILURE
CHIGLITAZAR;PPARA;CC + CT;rs1800234;EFFICACY;DECREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;*6/*6;CYP2B6*1, CYP2B6*6;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
LAMOTRIGINE;UGT1A4;*1b;UGT1A4*1A, UGT1A4*1B;METABOLISM/PK;DECREASED;CONCENTRATIONS;;PEOPLE;OTHER:EPILEPSY;LIKELIHOOD_THERAPEUTIC_FAILURE
HALOPERIDOL;CYP2D6;*5 + *10;CYP2D6*1, CYP2D6*5, CYP2D6*10;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_DRUG_ACCUMULATION
HALOPERIDOL;CYP2D6;*3 + *4;CYP2D6*1, CYP2D6*3, CYP2D6*4;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_DRUG_ACCUMULATION
ZUCLOPENTHIXOL;CYP2D6;*1/*4 + *3/*4;CYP2D6*1, CYP2D6*3, CYP2D6*4;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;OTHER:SCHIZOPHRENIA;CAUTION_DRUG_ACCUMULATION
AZATHIOPRINE, MERCAPTOPURINE;TPMT;;LOW ACTIVITY;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;CYP2D6;;POOR_METABOLIZER;METABOLISM/PK;DECREASED;CLEARANCE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
MERCAPTOPURINE;TPMT;;INTERMEDIATE ACTIVITY;EFFICACY;INCREASED;RESPONSE;;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
FENTANYL;CYP3A4;T/T;rs2242480;DOSAGE;DECREASED;DOSE;;WOMEN;DISEASE:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
SULFASALAZINE;NAT2;;SLOW_ACETYLATOR;OTHER;INCREASED;DISCONTINUATION;;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
FENTANYL;CYP3A4;T/T;rs2242480;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:POSTOPERATIVE_PAIN;CAUTION_DRUG_ACCUMULATION
ETHANOL;OPRM1;G;rs1799971;DOSAGE;INCREASED;DOSE;;CHILDREN;;CAUTION_DOSE_ADJUST
SUFENTANIL;CYP3A4;T/T;rs2242480;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:POSTOPERATIVE_PAIN;LIKELIHOOD_THERAPEUTIC_SUCCESS
SUFENTANIL;CYP3A4;T/T;rs2242480;DOSAGE;DECREASED;DOSE;;WOMEN;DISEASE:PAIN;CAUTION_DOSE_ADJUST
SUFENTANIL;CYP3A4;T/T;rs2242480;METABOLISM/PK;DECREASED;CONCENTRATIONS;;WOMEN;DISEASE:PAIN;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A4;C/C;rs2242480;OTHER, METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
FENTANYL;CYP3A4;T/T;rs2242480;DOSAGE;DECREASED;DOSE;;WOMEN;OTHER:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
SUFENTANIL;CYP3A4;T/T;rs2242480;DOSAGE;DECREASED;DOSE;;PEOPLE;OTHER:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
FENTANYL;CYP3A4;T/T;rs2242480;DOSAGE;DECREASED;DOSE;;PEOPLE;DISEASE:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
BETA BLOCKING AGENTS;GRK5;T;rs4752292;EFFICACY;DECREASED;RESPONSE;;PEOPLE;OTHER:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
INTERFERON BETA-1A;HLA-B;*15:01;HLA-B*15:01;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:MULTIPLE_SCLEROSIS;LIKELIHOOD_THERAPEUTIC_FAILURE
RUBELLA VACCINES;HLA-B;*35:03;HLA-B*35:03;EFFICACY;INCREASED;RESPONSE;;CHILDREN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;HLA-B;*38:01;HLA-B*38:01;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_FAILURE
HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART);OPRM1;GG;rs671531;EFFICACY;DECREASED;RESPONSE;;PEOPLE;OTHER:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A4;*1/*18;CYP3A4*1, CYP3A4*18;METABOLISM/PK;INCREASED;METABOLISM;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOSPORINE;CYP3A4;*18/*18;CYP3A4*1, CYP3A4*18;METABOLISM/PK;INCREASED;METABOLISM;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
USTEKINUMAB;HLA-C;*06:02;HLA-C*06:02;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:PSORIASIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;HLA-C;*06:02;HLA-C*06:02;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:PSORIASIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
FENTANYL;CYP3A4;*18/*18;CYP3A4*1, CYP3A4*18;DOSAGE, EFFICACY;DECREASED;DOSE;;PEOPLE;DISEASE:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
RUBELLA VACCINES;HLA-C;*15:02;HLA-C*15:02;EFFICACY;INCREASED;RESPONSE;;CHILDREN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B, RIBAVIRIN;HLA-C;*02:02 + *04:01 + *05:01 + *06:02 + *15:02 + *17:01;HLA-C*01:02, HLA-C*02:02, HLA-C*03:02, HLA-C*04:01, HLA-C*05:01, HLA-C*06:02, HLA-C*07:01, HLA-C*08:01, HLA-C*12:02, HLA-C*14:02, HLA-C*15:02, HLA-C*16:01, HLA-C*17:01;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_FAILURE
MEASLES VACCINES;HLA-DQA1;*01:04;HLA-DQA1*01:04;EFFICACY;INCREASED;RESPONSE;;CHILDREN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
MEASLES VACCINES;HLA-DRB1;*01:01;HLA-DRB1*01:01;EFFICACY;;RESPONSE;;CHILDREN;;CAUTION_DOSE_ADJUST
CYCLOSPORINE;CYP3A4;*1/*1;CYP3A4*1, CYP3A4*18;METABOLISM/PK;INCREASED;CONCENTRATIONS;;MEN;;CAUTION_DRUG_ACCUMULATION
INTERFERON BETA-1A;HLA-DRB1;*04:01;HLA-DRB1*04:01;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:MULTIPLE_SCLEROSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ADALIMUMAB, ETANERCEPT, INFLIXIMAB;HLA-DRB1;*04:01;HLA-DRB1*04:01;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
HEPATITIS VACCINES;HLA-DRB1;*07:01;HLA-DRB1*07:01;EFFICACY;DECREASED;RESPONSE;;CHILDREN;;LIKELIHOOD_THERAPEUTIC_FAILURE
INFLUENZA VACCINES;HLA-DRB1;*07:01;HLA-DRB1*07:01;EFFICACY;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
MEASLES VACCINES;HLA-DRB1;*08:01;HLA-DRB1*08:01;EFFICACY;;RESPONSE;;CHILDREN;;CAUTION_DOSE_ADJUST
INFLUENZA VACCINES;HLA-DRB1;*13:01;HLA-DRB1*13:01;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
MONTELUKAST;CYP2C8;*4;CYP2C8*1, CYP2C8*4;METABOLISM/PK;INCREASED;CONCENTRATIONS;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
MONTELUKAST;CYP2C8;*3;CYP2C8*1, CYP2C8*3;METABOLISM/PK;DECREASED;CONCENTRATIONS;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP2C8;*1/*3 + *3/*3;CYP2C8*1, CYP2C8*3;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;GGH;AA + AG;rs11545078;TOXICITY;INCREASED;DISCONTINUATION;;PEOPLE;SIDE_EFFECT:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
IBUPROFEN;CYP2C8;*1/*3;CYP2C8*1, CYP2C8*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ROSIGLITAZONE;CYP2C8;*1/*3;CYP2C8*1, CYP2C8*3;METABOLISM/PK;DECREASED;CONCENTRATIONS;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
IBUPROFEN;CYP2C8;*3;CYP2C8*1, CYP2C8*3;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
METHADONE;CYP2B6;*1/*6 + *1/*18 + *6/*6 + *6/*18;CYP2B6*1, CYP2B6*5, CYP2B6*6, CYP2B6*7, CYP2B6*18;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;OTHER:OPIOID-RELATED_DISORDERS;CAUTION_DRUG_ACCUMULATION
DISULFIRAM;SLC6A4;HTTLPR short form (S allele) / HTTLPR short form (S allele) + HTTLPR short form (S allele) / L allele-rs25531C + L allele-rs25531C / L allele-rs25531C;SLC6A4 HTTLPR SHORT FORM (S ALLELE), SLC6A4 L ALLELE-rs25531C, SLC6A4 L ALLELE-rs25531T;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:COCAINE_DEPENDENCE;LIKELIHOOD_THERAPEUTIC_SUCCESS
SERTRALINE;CYP2B6;*1/*4 + *4/*4;CYP2B6*1, CYP2B6*4;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
SERTRALINE;CYP2B6;*6 + *9;CYP2B6*1, CYP2B6*6, CYP2B6*9;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
SERTRALINE;CYP2C19;*1/*17 + *17/*17;CYP2C19*1, CYP2C19*17;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
SERTRALINE;CYP2C19;*2 + *3 + *4;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*4;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
SERTRALINE;CYP2B6;*9/*9;CYP2B6*1, CYP2B6*9;METABOLISM/PK;INCREASED;HALF-LIFE_TIME;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
ATORVASTATIN;CYP3A5;*1/*3 + *3/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;DECREASED;CONCENTRATIONS;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
ATORVASTATIN;SLCO1B1;*1/*5 + *5/*5;SLCO1B1*1, SLCO1B1*5;METABOLISM/PK;INCREASED;CONCENTRATIONS;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
PRAVASTATIN;SLCO1B1;*1/*15;SLCO1B1*1, SLCO1B1*15;EFFICACY;DECREASED;RESPONSE;;PEOPLE;OTHER:HYPERCHOLESTEROLEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
RIFAMPIN, WARFARIN;CYP2C9;*2 + *3 + *11;CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*11;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:TUBERCULOSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
PRAVASTATIN;SLCO1B1;*15;SLCO1B1*1, SLCO1B1*15;METABOLISM/PK;INCREASED;CONCENTRATIONS;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
PITAVASTATIN, PRAVASTATIN;SLCO1B1;*15/*15;SLCO1B1*1, SLCO1B1*15;METABOLISM/PK;INCREASED;CONCENTRATIONS;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
ACYCLOVIR;NUDT15;*2/*2 +*2/*3 +*3/*3 + *5/*5;NUDT15*1, NUDT15*2, NUDT15*3, NUDT15*5;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;ABCB1;GG;rs1045642;METABOLISM/PK;INCREASED;METABOLISM;;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
ACENOCOUMAROL;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;CHILDREN;;CAUTION_DOSE_ADJUST
FLUVASTATIN;SLCO1B1;*14;SLCO1B1*1, SLCO1B1*14;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HYPERCHOLESTEROLEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACENOCOUMAROL;CYP2C9;*2;CYP2C9*2;DOSAGE;DECREASED;DOSE;;CHILDREN;;CAUTION_DOSE_ADJUST
METHOTREXATE;SLCO1B1;*31;SLCO1B1*1, SLCO1B1*31, SLCO1B1*37;METABOLISM/PK;DECREASED;CLEARANCE;;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;SLCO1B1;*20;SLCO1B1*1, SLCO1B1*20, SLCO1B1*37;METABOLISM/PK;INCREASED;CLEARANCE;;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
CONJUGATED ESTROGENS;SLCO1B1;TT;rs4149056;METABOLISM/PK;DECREASED;CONCENTRATIONS;;WOMEN;DISEASE:MENOPAUSE;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;SLCO1B1;*23;SLCO1B1*1, SLCO1B1*23, SLCO1B1*37;METABOLISM/PK;DECREASED;CLEARANCE;;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DRUG_ACCUMULATION
ACENOCOUMAROL;CYP2C18;GG;rs1998591;DOSAGE;INCREASED;DOSE;;CHILDREN;;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;VKORC1;AA;rs9934438;DOSAGE;DECREASED;DOSE;;CHILDREN;;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;INCREASED;RESISTANCE;;PEOPLE;OTHER:STROKE;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;SLCO1B1;*15;SLCO1B1*1, SLCO1B1*15, SLCO1B1*37;METABOLISM/PK;DECREASED;CLEARANCE;;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DRUG_ACCUMULATION
ROSUVASTATIN;SLCO1B1;*15/*15;SLCO1B1*15, SLCO1B1*37;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
ESCITALOPRAM;CYP2C19;*2/*2 +*3/*3 + *2/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;METABOLISM/PK;INCREASED;EXPOSURE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
ATORVASTATIN;SLCO1B1;*15/*15;SLCO1B1*1, SLCO1B1*15;METABOLISM/PK;INCREASED;CONCENTRATIONS;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
ATORVASTATIN;SLCO1B1;*15;SLCO1B1*1, SLCO1B1*15, SLCO1B1*37;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;OTHER:HYPERCHOLESTEROLEMIA;CAUTION_DRUG_ACCUMULATION
ATRASENTAN;SLCO1B1;*15/*15 + *1/*15 + *15/*37 + *14/*37;SLCO1B1*1, SLCO1B1*14, SLCO1B1*15, SLCO1B1*37;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
ESCITALOPRAM;CYP2C19;*1/*17 + *17/*17;CYP2C19*1, CYP2C19*17;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;DECREASED;STEADY-STATE_CONCENTRATION;;PEOPLE;OTHER:TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
3,4-DEHYDROCILOSTAZOL;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;DECREASED;CONCENTRATIONS;;PEOPLE;OTHER:CEREBRAL_INFARCTION;LIKELIHOOD_THERAPEUTIC_FAILURE
BETA BLOCKING AGENTS;ADRA2C;del;rs61767072;EFFICACY;INCREASED;RESPONSE;;CHILDREN;OTHER:CARDIOMYOPATHY, DILATED;LIKELIHOOD_THERAPEUTIC_SUCCESS
HYDROXYBUPROPION;CYP2B6;*6;CYP2B6*6;METABOLISM/PK;DECREASED;EXPOSURE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
ARIPIPRAZOLE;CYP2D6;*3 + *4 + *4xN + *5 + *6 + *10 + *41;CYP2D6*1, CYP2D6*1XN, CYP2D6*3, CYP2D6*4, CYP2D6*4XN, CYP2D6*5, CYP2D6*6, CYP2D6*10, CYP2D6*41;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
ATOMOXETINE;CYP2D6;;CYP2D6 POOR_METABOLIZER, INTERMEDIATE_METABOLIZER;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;OTHER:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY;CAUTION_DRUG_ACCUMULATION
DOCETAXEL, THALIDOMIDE;SULT1C4;G;rs1402467;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:PROSTATIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATOMOXETINE;CYP2D6;;CYP2D6 POOR_METABOLIZER, INTERMEDIATE_METABOLIZER;DOSAGE;DECREASED;DOSE;;PEOPLE;OTHER:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY;CAUTION_DOSE_ADJUST
ATOMOXETINE;CYP2C19;*2;CYP2C19*1, CYP2C19*2;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;OTHER:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY;CAUTION_DRUG_ACCUMULATION
ENDOXIFEN;CYP2D6;*17;CYP2D6*1, CYP2D6*2, CYP2D6*17;METABOLISM/PK;INCREASED;EXPOSURE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
AMITRIPTYLINE, CLOMIPRAMINE;CYP2C19;*17/*17;CYP2C19*1, CYP2C19*17;OTHER;INCREASED;DISCONTINUATION;;PEOPLE;OTHER:BIPOLAR_DISORDER;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;NUDT15;*1/*2 + *1/*3 + *1/*5 + *1/*6;NUDT15*1, NUDT15*2, NUDT15*3, NUDT15*5, NUDT15*6;DOSAGE;DECREASED;DOSE;;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1;CYP3A5*1, CYP3A5*3, CYP3A5*6, CYP3A5*7;DOSAGE;INCREASED;DOSE;;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
BREXPIPRAZOLE;CYP2D6;*2;CYP2D6*1, CYP2D6*2;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
BREXPIPRAZOLE;CYP2D6;*9 +*10 + *14 + *17 + *29 + *41;CYP2D6*1, CYP2D6*9, CYP2D6*10, CYP2D6*14, CYP2D6*17, CYP2D6*29, CYP2D6*41;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;DOSAGE;INCREASED;DOSE;;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
N-DESMETHYLTRAMADOL;CYP2D6;*1/*5 + *1/*10 + *2/*5 + *2/*10 + *5/*10 + *10/*10;CYP2D6*1, CYP2D6*2, CYP2D6*5, CYP2D6*10;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;OTHER:HEAD_AND_NECK_NEOPLASMS;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;C;rs1057910;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
VENLAFAXINE;SLC6A4;HTTLPR long form (L allele);SLC6A4 HTTLPR LONG FORM (L ALLELE), SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
VENLAFAXINE;SLC6A4;L allele-rs25531T/L allele-rs25531T;SLC6A4 L ALLELE-rs25531T;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:ANXIETY_DISORDERS;LIKELIHOOD_THERAPEUTIC_SUCCESS
VENLAFAXINE;SLC6A4;L allele-rs25531T/L allele-rs25531T;SLC6A4 L ALLELE-rs25531T;EFFICACY;DECREASED;RESPONSE;;PEOPLE;OTHER:DEPRESSION;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;ABCC2;CT + TT;rs717620;TOXICITY;DECREASED;DISCONTINUATION;;PEOPLE;SIDE_EFFECT:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
KETOROLAC;CYP2C9;*2 + *3;CYP2C9*1, CYP2C9*2, CYP2C9*3;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:POSTOPERATIVE_PAIN;LIKELIHOOD_THERAPEUTIC_SUCCESS
TRAMADOL;CYP2D6;*4;CYP2D6*1, CYP2D6*4;EFFICACY;DECREASED;RESPONSE;;PEOPLE;OTHER:POSTOPERATIVE_PAIN;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;ERCC1;C;rs3212948;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
SERTRALINE;SLC6A4;HTTLPR short form (S allele);SLC6A4 HTTLPR LONG FORM (L ALLELE), SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;DECREASED;RESPONSE;;PEOPLE;OTHER:PANIC_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP3A4;*22/*22;CYP3A4*1, CYP3A4*22;METABOLISM/PK;DECREASED;CONCENTRATIONS;;PEOPLE;OTHER:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
MIDAZOLAM;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;DECREASED;CLEARANCE;;PEOPLE;OTHER:NEOPLASMS;CAUTION_DRUG_ACCUMULATION
ENDOXIFEN;CYP2D6;*17/*29 + *17/*17;CYP2D6*1, CYP2D6*2, CYP2D6*17, CYP2D6*29;METABOLISM/PK;DECREASED;CONCENTRATIONS;;WOMEN;OTHER:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
LIRAGLUTIDE;GLP1R;TT;rs10305420;EFFICACY;INCREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;CHILDREN;OTHER:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
OXYCODONE;CYP2C19;;CYP2C19 POOR METABOLIZER, INTERMEDIATE METABOLIZER;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
OXYCODONE;CYP2D6;;CYP2D6 POOR METABOLIZER, INTERMEDIATE METABOLIZER;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
OXYCODONE;CYP3A4;*22;CYP3A4*1, CYP3A4*22;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;INCREASED;CLEARANCE;;PEOPLE;OTHER:LUNG_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
GLICLAZIDE;CYP2C19;;CYP2C19 POOR METABOLIZER, INTERMEDIATE METABOLIZER;METABOLISM/PK;DECREASED;CLEARANCE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
FLUVASTATIN;CYP2C9;*1/*3;CYP2C9*1, CYP2C9*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
BEVACIZUMAB, CYCLOPHOSPHAMIDE;CXCL8;AA + AT;rs4073;EFFICACY;DECREASED;RESPONSE;;WOMEN;DISEASE:OVARIAN_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
NICOTINE;CYP2A6;*4/*4;CYP2A6*1, CYP2A6*4;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
N-DESMETHYLCLOZAPINE;CYP3A4;;LOW ACTIVITY;METABOLISM/PK;DECREASED;CONCENTRATIONS;;PEOPLE;OTHER:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_FAILURE
DIHYDROPYRIDINE DERIVATIVES;CYP3A5;TT;rs776746;OTHER;INCREASED;DISCONTINUATION;;;;CAUTION_SIDE_EFFECT
N-DESMETHYLCLOZAPINE;CYP1A2;;LOW ACTIVITY;METABOLISM/PK;DECREASED;CONCENTRATIONS;;PEOPLE;OTHER:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_FAILURE
NICOTINE;CYP2A6;*1/*35 + *9/*35 + *17/*35;CYP2A6*1, CYP2A6*9, CYP2A6*17, CYP2A6*35;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
NICOTINE;CYP2A6;*1/*2 + *1/*4 + *1/*9 + *1/*12 + *4/*9 + *9/*9 + *9/*12;CYP2A6*1, CYP2A6*2, CYP2A6*4, CYP2A6*9, CYP2A6*12;METABOLISM/PK;DECREASED;CLEARANCE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
DISULFIRAM;ALDH2;;DEFICIENCY;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:ALCOHOL_ABUSE;LIKELIHOOD_THERAPEUTIC_SUCCESS
COUMARIN, NICOTINE;CYP2A6;*1/*4 + *1/*7 + *1/*9 + *1/*10 + *4/*4 + *7/*7 + *9/*9;CYP2A6*1, CYP2A6*4, CYP2A6*7, CYP2A6*9, CYP2A6*10;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
NICOTINE;CYP2A6;*1/*46 + *46/*46;CYP2A6*1, CYP2A6*46;METABOLISM/PK;INCREASED;METABOLISM;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
NICOTINE;CYP2A6;*1/*2 + *1/*4 + *1/*17 + *1/*20 + *1/*23 + *1/*24 + *1/*25 + *1/*26 + *1/*27  + *1/*28 + *1/*35 + *9/*9 + *17/*17 + *20/*20 + *35/*35;CYP2A6*1, CYP2A6*2, CYP2A6*4, CYP2A6*9, CYP2A6*12, CYP2A6*17, CYP2A6*20, CYP2A6*23, CYP2A6*24, CYP2A6*25, CYP2A6*26, CYP2A6*27, CYP2A6*28, CYP2A6*35;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
ROSUVASTATIN;SLCO1B1;*15/*15;SLCO1B1*1, SLCO1B1*15;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
FLUVASTATIN;CYP2C9;*1/*3;CYP2C9*1, CYP2C9*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
PITAVASTATIN;SLCO1B1;*15/*15 + *15/*37;SLCO1B1*15, SLCO1B1*37;METABOLISM/PK;INCREASED;CONCENTRATIONS;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;C;rs11150606;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
PITAVASTATIN;CYP2C9;*1/*3;CYP2C9*1, CYP2C9*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
NICOTINE;CYP2A6;*1 + *46 + *9 + *14 + *38;CYP2A6*1, CYP2A6*2, CYP2A6*4, CYP2A6*9, CYP2A6*14, CYP2A6*38, CYP2A6*46;METABOLISM/PK;INCREASED;METABOLISM;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
NICOTINE;CYP2A6;*1 + *9 + *12 + *38;CYP2A6*1, CYP2A6*9, CYP2A6*12, CYP2A6*38, CYP2A6*46;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;C;rs1057910;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
OXALIPLATIN;MTHFR;GG + GT;rs1801131;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ALPRAZOLAM;CYP3A4;;LOW ACTIVITY;EFFICACY;INCREASED;RESPONSE;;MEN;OTHER:ALCOHOL_ABUSE, OTHER:ANXIETY_DISORDERS;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A4;C/C;rs2242480;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A4;C/C;rs2242480;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A4;C/T + T/T;rs2242480;METABOLISM/PK;INCREASED;CLEARANCE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A4;C/C;rs2242480;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
FENTANYL;CYP3A4;T/T;rs2242480;DOSAGE;DECREASED;DOSE;;WOMEN;DISEASE:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
ENDOXIFEN;CYP2D6;;INTERMEDIATE_METABOLIZER;METABOLISM/PK;DECREASED;CONCENTRATIONS;;PEOPLE;OTHER:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;;CYP3A5 INTERMEDIATE_METABOLIZER, NORMAL_METABOLIZER;DOSAGE;INCREASED;DOSE;;CHILDREN;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
DICLOFENAC;CYP2C9;*1/*3 + *1/*8;CYP2C9*1, CYP2C9*3, CYP2C9*8;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
CLOZAPINE;ABCG2;GT + TT;rs2231142;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_DRUG_ACCUMULATION
DOLUTEGRAVIR;UGT1A1;*28/*28 + *6/*6;UGT1A1*1, UGT1A1*6, UGT1A1*28;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;OTHER:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
ASPIRIN, CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;EFFICACY;DECREASED;RESPONSE;;PEOPLE;OTHER:PERCUTANEOUS_CORONARY_INTERVENTIONS_AND_DRUG-ELUTING_STENTS;LIKELIHOOD_THERAPEUTIC_FAILURE
(S)-METHADONE;CYP2B6;*6 + *7 + *9 + *18;CYP2B6*1, CYP2B6*6, CYP2B6*7, CYP2B6*9, CYP2B6*18;METABOLISM/PK;DECREASED;CLEARANCE;;CHILDREN;OTHER:SCOLIOSIS;CAUTION_DRUG_ACCUMULATION
MERCAPTOPURINE, THIOGUANINE;TPMT;*1/*3C;TPMT*1, TPMT*3C;DOSAGE;DECREASED;DOSE;;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DOSE_ADJUST
MERCAPTOPURINE, THIOGUANINE;TPMT;*1/*3A;TPMT*1, TPMT*3A;DOSAGE;DECREASED;DOSE;;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DOSE_ADJUST
NICOTINE;CYP2A6;*4/*4 + *4/*7;CYP2A6*1, CYP2A6*4, CYP2A6*7;OTHER, METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
HYDRALAZINE;NAT2;;RAPID_ACETYLATOR;DOSAGE, EFFICACY;INCREASED;DOSE;;PEOPLE;OTHER:HYPERTENSION;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*13;CYP2C9*1, CYP2C9*13;DOSAGE;DECREASED;DOSE;;PEOPLE;OTHER:ATRIAL_FIBRILLATION;CAUTION_DOSE_ADJUST
VORICONAZOLE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA_OTHER:LYMPHOMA,OTHER:ACUTE_MYELOID_LEUKEMIA;CAUTION_DRUG_ACCUMULATION
ROSUVASTATIN;SLCO1B1;A;rs11045854;METABOLISM/PK;DECREASED;EXPOSURE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
HYDRALAZINE;NAT2;;SLOW_ACETYLATOR;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;OTHER:HYPERTENSION;CAUTION_DRUG_ACCUMULATION
VENLAFAXINE;CYP2D6;;INTERMEDIATE_METABOLIZER;METABOLISM/PK;DECREASED;METABOLISM;;;OTHER:ELDERLY_ADULT;CAUTION_DRUG_ACCUMULATION
ESCITALOPRAM;CYP2C19;;INTERMEDIATE_METABOLIZER;METABOLISM/PK;DECREASED;METABOLISM;;;OTHER:ELDERLY_ADULT;CAUTION_DRUG_ACCUMULATION
SOMATROPIN RECOMBINANT;COL1A1;AA;rs1800012;DOSAGE;DECREASED;DOSE;;PEOPLE;OTHER:GROWTH_HORMONE_DEFICIENCY;CAUTION_DOSE_ADJUST
LETROZOLE;CYP2A6;*1/*17 + *20/*23 + *9/*9 + *1/*4 + *1/*2 + *17/*17 + *17/*35 + *2/*9 + *9/*12 + *1/*9 + *1/*12;CYP2A6*1, CYP2A6*2, CYP2A6*4, CYP2A6*9, CYP2A6*12, CYP2A6*17, CYP2A6*20, CYP2A6*23, CYP2A6*35;METABOLISM/PK;DECREASED;CLEARANCE;;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_DRUG_ACCUMULATION
NICOTINE;CYP2A6;*1/*46;CYP2A6*1, CYP2A6*46;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
NICOTINE;CYP2A6;*1/*2 + *1/*4 + *1/*9 + *1/*12 + *1/*17 + *1/*20 + *1/*23 + *1/*24 + *1/*25 + *1/*26 + *1/*27  + *1/*28 + *1/*35 + *9/*9 + *17/*17 + *20/*20 + *35/*35;CYP2A6*1, CYP2A6*2, CYP2A6*4, CYP2A6*9, CYP2A6*12, CYP2A6*17, CYP2A6*20, CYP2A6*23, CYP2A6*24, CYP2A6*25, CYP2A6*26, CYP2A6*27, CYP2A6*28, CYP2A6*35, CYP2A6*46;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
VITAMIN B-COMPLEX, INCL. COMBINATIONS;MTHFR;A;rs1801133;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
ROSUVASTATIN;SLCO1B1;GG;rs2306283;METABOLISM/PK;INCREASED;CONCENTRATIONS;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;A;rs2359612;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
VITAMIN B-COMPLEX, INCL. COMBINATIONS;MTHFR;G;rs1801131;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATOMOXETINE;SLC6A2;A;rs12708954;EFFICACY;INCREASED;RESPONSE;;CHILDREN;DISEASE:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOSPORINE, TACROLIMUS;CYP3A4;C;rs2740574;METABOLISM/PK;DECREASED;CONCENTRATIONS;;PEOPLE;SIDE_EFFECT:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
ROSUVASTATIN;SLCO1B1;CC;rs4149056;METABOLISM/PK;INCREASED;CONCENTRATIONS;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;AC;rs1057910;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
RIZATRIPTAN;DRD2;AA + AG;rs6275;EFFICACY;DECREASED;RESPONSE;;PEOPLE;OTHER:MIGRAINE_WITHOUT_AURA;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;TT;rs3745274;METABOLISM/PK;DECREASED;CLEARANCE;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;G;rs61162043;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
SULFONAMIDES, UREA DERIVATIVES;CYP2C9;CC;rs1057910;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;OPRM1;AG + GG;rs1799971;EFFICACY;DECREASED;RESPONSE;;WOMEN;OTHER:TOBACCO_USE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;DRD3;CC + CT;rs6280;EFFICACY;INCREASED;RESPONSE;;CHILDREN;DISEASE:AUTISM;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACENOCOUMAROL;VKORC1;TT;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ROSUVASTATIN;FOXA3;T;rs16980091;METABOLISM/PK;INCREASED;EXPOSURE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;C;rs1057910;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ROSUVASTATIN;SLCO1B1;C;rs34671512;METABOLISM/PK;DECREASED;EXPOSURE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
SIROLIMUS;CYP3A5;*1/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*2/*3;CYP2C9*1, CYP2C9*2, CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
CYSTEAMINE;CFTR;CTT/del + del/del;rs113993960;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:CYSTIC_FIBROSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESCITALOPRAM;CYP2C19;*2/*2 + *2/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:PANIC_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
DEXTROPROPOXYPHENE;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;INCREASED;EXPOSURE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
FELODIPINE;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;INCREASED;EXPOSURE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;*3/*3;CYP2C9*1, CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*3;CYP2C9*1, CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2/*2;CYP2C9*1, CYP2C9*2;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
HYDRALAZINE;NAT2;;SLOW_ACETYLATOR;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;OTHER:HYPERTENSION;CAUTION_DRUG_ACCUMULATION
AZATHIOPRINE;TPMT;*1/*3A + *1/*3C;TPMT*1, TPMT*3A, TPMT*3C;DOSAGE;DECREASED;DOSE;;PEOPLE;DISEASE:TRANSPLANTATION;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2B6;*6;CYP2B6*1, CYP2B6*6;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:MYOCARDIAL_INFARCTION;LIKELIHOOD_THERAPEUTIC_FAILURE
CODEINE;CYP2D6;*17;CYP2D6*17;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:SICKLE_CELL_ANEMIA;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
RABEPRAZOLE;CYP2C19;*2/*2 + *3/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;METABOLISM/PK;DECREASED;CLEARANCE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*1/*1;CYP3A5*1, CYP3A5*3;DOSAGE;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
PANTOPRAZOLE;CYP2C19;*1/*2;CYP2C19*1, CYP2C19*2;EFFICACY;INCREASED;RESPONSE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_SUCCESS
VORICONAZOLE;CYP2C19;*1/*17 + *1/*2 + *17/*17;CYP2C19*1, CYP2C19*2, CYP2C19*17;DOSAGE;;DOSE;;PEOPLE;DISEASE:CYSTIC_FIBROSIS, DISEASE:LUNG_TRANSPLANTATION;CAUTION_DOSE_ADJUST
LANSOPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;METABOLISM/PK;INCREASED;CLEARANCE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
PANTOPRAZOLE;CYP2C19;*2/*2;CYP2C19*1, CYP2C19*2;METABOLISM/PK;DECREASED;CLEARANCE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
PANTOPRAZOLE;CYP2C19;*17;CYP2C19*1, CYP2C19*17;METABOLISM/PK;INCREASED;CLEARANCE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;METABOLISM/PK;INCREASED;CLEARANCE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1;CYP3A5*1, CYP3A5*3;METABOLISM/PK;DECREASED;TROUGH_CONCENTRATION;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*1/*3 + *3/*3;CYP2C9*1, CYP2C9*3;DOSAGE, EFFICACY;DECREASED;DOSE;;MEN;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
ARIPIPRAZOLE;CYP2D6;*4 + *5 + *6;CYP2D6*1, CYP2D6*4, CYP2D6*5, CYP2D6*6;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
RABEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:HELICOBACTER_INFECTIONS;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE, OMEPRAZOLE;CYP2C19;*1/*1 + *1/*17;CYP2C19*1, CYP2C19*2, CYP2C19*17;EFFICACY;DECREASED;RESPONSE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:GASTROESOPHAGEAL_REFLUX;LIKELIHOOD_THERAPEUTIC_SUCCESS
VORICONAZOLE;CYP2C19;*1/*17 + *17/*17 + *1/*2;CYP2C19*1, CYP2C19*2, CYP2C19*17;DOSAGE;;DOSE;;PEOPLE;DISEASE:CYSTIC_FIBROSIS, DISEASE:LUNG_TRANSPLANTATION;CAUTION_DOSE_ADJUST
PANTOPRAZOLE;CYP2C19;*1/*1 + *1/*17;CYP2C19*1, CYP2C19*2, CYP2C19*17;METABOLISM/PK;INCREASED;METABOLISM;;CHILDREN;;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*1/*3 + *2/*3;CYP2C9*1, CYP2C9*2, CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ANTHRACYCLINES AND RELATED SUBSTANCES, CAPECITABINE, CYCLOPHOSPHAMIDE, FLUOROURACIL, TAXANES;GSTM1;;GSTM1 NON-NULL, GSTM1 NULL;EFFICACY;DECREASED;RESPONSE;;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*2/*2 + *2/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:GASTROESOPHAGEAL_REFLUX;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;DECREASED;TROUGH_CONCENTRATION;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;INCREASED;METABOLISM;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;DOSAGE;INCREASED;DOSE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TOLPERISONE;CYP2D6;*4 + *5;CYP2D6*1, CYP2D6*4, CYP2D6*5;METABOLISM/PK;INCREASED;EXPOSURE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C9*1, CYP2C9*2, CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
LANSOPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;METABOLISM/PK;INCREASED;METABOLISM;;PEOPLE;DISEASE:GASTROESOPHAGEAL_REFLUX;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*3;CYP2C9*1, CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;INCREASED;METABOLISM;;CHILDREN;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*3;CYP3A5*1, CYP3A5*3;DOSAGE;INCREASED;DOSE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;METABOLISM/PK;INCREASED;METABOLISM;;PEOPLE;DISEASE:GASTROESOPHAGEAL_REFLUX;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C9*1, CYP2C9*2, CYP2C9*3;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*1/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;INCREASED;CLEARANCE;;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
BUPROPION;CYP2B6;*6;CYP2B6*1, CYP2B6*6;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
MIANSERIN;CYP2D6;*1/*10 + *5/*10;CYP2D6*1, CYP2D6*5, CYP2D6*10;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:DEPRESSION;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*1/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
SALVIANOLIC ACID B;ACE;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;rs1799752;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:CORONARY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
MEPHENYTOIN;CYP2C19;*1/*2 + *2/*2;CYP2C19*1, CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;DOSAGE;INCREASED;DOSE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
VALPROIC ACID;UGT1A6;*1a;UGT1A6*1A, UGT1A6*2A, UGT1A6*3A, UGT1A6*4A, UGT1A6*8;METABOLISM/PK;;METABOLISM;;CHILDREN;DISEASE:EPILEPSY;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*3 + *3/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;DISEASE:MYASTHENIA_GRAVIS;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;*1/*2;CYP2C19*1, CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
VALPROIC ACID;UGT1A6;*1a;UGT1A6*1A, UGT1A6*2A, UGT1A6*3A, UGT1A6*4A, UGT1A6*8;DOSAGE;DECREASED;DOSE;;CHILDREN;DISEASE:EPILEPSY;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*8/*8;CYP2C9*1, CYP2C9*8;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1;CYP3A5*1, CYP3A5*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
CYCLOSPORINE;CYP3A4;*1/*1;CYP3A4*1, CYP3A4*22;METABOLISM/PK;INCREASED;CLEARANCE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1;CYP3A5*1, CYP3A5*3;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
SIROLIMUS, TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;DOSAGE;INCREASED;DOSE;;CHILDREN;DISEASE:LIVER_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;DOSAGE;INCREASED;DOSE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
VORICONAZOLE;CYP2C19;*2/*2 + *2/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;CYP2D6;*4/*4;CYP2D6*1, CYP2D6*4;DOSAGE;DECREASED;DOSE;;PEOPLE;DISEASE:DEPRESSION;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A4;*18;CYP3A4*1, CYP3A4*18;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
TRAMADOL;CYP2D6;*10/*10;CYP2D6*1, CYP2D6*10;DOSAGE, EFFICACY;INCREASED;DOSE;;PEOPLE;OTHER:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;DOSAGE;DECREASED;DOSE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
TRAMADOL;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *3/*3 + *4/*4 + *4/*5 + *4/*10 + *4/*41 + *5/*41;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*10, CYP2D6*41;METABOLISM/PK;DECREASED;METABOLISM;;INFANTS;;CAUTION_DRUG_ACCUMULATION
ENDOXIFEN;CYP2D6;;NORMAL_METABOLIZER, ULTRARAPID_METABOLIZER;METABOLISM/PK;INCREASED;CONCENTRATIONS;;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_DRUG_ACCUMULATION
IMIPRAMINE;CYP2C19;*2;CYP2C19*1, CYP2C19*2;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DRUG_ACCUMULATION
O-DESMETHYLTRAMADOL;CYP2D6;;POOR_METABOLIZER;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:LOW_BACK_PAIN, DISEASE:OSTEOARTHRITIS;CAUTION_DRUG_ACCUMULATION
RASAGILINE;ABCB1;AA + AG;rs1045642;METABOLISM/PK;DECREASED;CLEARANCE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
ANTIDEPRESSANTS;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR LONG FORM (L ALLELE), SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;DECREASED;RESPONSE;;WOMEN;DISEASE:DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
ISONIAZID;NAT2;;SLOW_ACETYLATOR;METABOLISM/PK;DECREASED;CONCENTRATIONS;;PEOPLE;DISEASE:TUBERCULOSIS;LIKELIHOOD_THERAPEUTIC_FAILURE
ESCITALOPRAM;SLC6A4;HTTLPR long form (L allele);SLC6A4 HTTLPR LONG FORM (L ALLELE), SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;RESPONSE;;MEN;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
VORICONAZOLE;CYP2C19;*1/*2;CYP2C19*1, CYP2C19*2, CYP2C19*17;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:FUNGAL_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;*3;CYP2C9*1, CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
OMEPRAZOLE, PANTOPRAZOLE, RABEPRAZOLE;CYP2C19;*1/*2;CYP2C19*1, CYP2C19*2, CYP2C19*17;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
CORTICOSTEROIDS;NR1I2;del/del;rs3842689;EFFICACY;INCREASED;RESISTANCE;;CHILDREN;;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL4;GG;rs11322783;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*1/*3 + *3/*3;CYP2C9*1, CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;DOSAGE;DECREASED;DOSE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
VORICONAZOLE;CYP2C19;;CYP2C19 POOR METABOLIZER, INTERMEDIATE METABOLIZER;METABOLISM/PK;INCREASED;TROUGH_CONCENTRATION;;PEOPLE;DISEASE:FUNGAL_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;*26;CYP2C19*1, CYP2C19*26;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
IRBESARTAN;ACE;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;rs1799752;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
TRIMIPRAMINE;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
ESCITALOPRAM;CYP2C19;*1/*17 + *17/*17;CYP2C19*1, CYP2C19*17;METABOLISM/PK;DECREASED;EXPOSURE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
ESCITALOPRAM;CYP2C19;*2 + *3 + *4;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*4;METABOLISM/PK;INCREASED;EXPOSURE;;;;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;CHILDREN;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1, CYP2C9*2, CYP2C9*3;DOSAGE;DECREASED;DOSE;;PEOPLE;DISEASE:CARDIOVASCULAR_DISEASE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;DOSAGE;DECREASED;DOSE;;CHILDREN;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;INCREASED;CLEARANCE;;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
SIPOGLITAZAR;UGT2B15;*2/*2;UGT2B15*1, UGT2B15*2;EFFICACY, METABOLISM/PK;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1, CYP2C9*2, CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
PAROXETINE;SLC6A4;HTTLPR long form (L allele);SLC6A4 HTTLPR LONG FORM (L ALLELE), SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
NORTRIPTYLINE;CYP2C19;*2/*2 + *2/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;METABOLISM/PK;DECREASED;CONCENTRATIONS;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
SERTRALINE;CYP2B6;*6/*9 + *1/*6 + *6/*6;CYP2B6*1, CYP2B6*6, CYP2B6*9;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DRUG_ACCUMULATION
METFORMIN;SLC22A1;del/del;rs72552763;METABOLISM/PK;DECREASED;EXPOSURE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
VENLAFAXINE;CYP2D6;*10/*10;CYP2D6*1, CYP2D6*2, CYP2D6*10;METABOLISM/PK;INCREASED;CONCENTRATIONS;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1, CYP2C19*2;EFFICACY;INCREASED;RESISTANCE;;PEOPLE;DISEASE:STROKE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A4;*1/*22;CYP3A4*1, CYP3A4*22;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
ACENOCOUMAROL;CYP2C9;*2;CYP2C9*1, CYP2C9*2;DOSAGE;DECREASED;DOSE;;PEOPLE;DISEASE:CEREBRAL_SINOVENOUS_THROMBOSIS;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;CYP2C9;*3;CYP2C9*1, CYP2C9*3;DOSAGE;DECREASED;DOSE;;PEOPLE;DISEASE:CEREBRAL_SINOVENOUS_THROMBOSIS;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1;CYP3A5*1;METABOLISM/PK;DECREASED;TROUGH_CONCENTRATION;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;DOSAGE;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;CHILDREN;DISEASE:LIVER_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
SERTRALINE;CYP2C19;*2/*2 + *2/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
SERTRALINE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*2;CYP2C19*1, CYP2C19*2;EFFICACY;INCREASED;RESISTANCE;;PEOPLE;DISEASE:STROKE;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;*3/*4 + *4/*4;CYP2D6*1, CYP2D6*1XN, CYP2D6*2, CYP2D6*2XN, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*9, CYP2D6*10, CYP2D6*41;METABOLISM/PK;DECREASED;CONCENTRATIONS;;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*17 + *2/*2;CYP2C19*1, CYP2C19*2, CYP2C19*17;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
ENDOXIFEN;CYP2D6;*4/*4 + *3/*4 + *4/*5 + *4/*6;CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6;METABOLISM/PK;DECREASED;CONCENTRATIONS;;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
MORPHINE;SLC22A1;GAT/del + del/del;rs72552763;METABOLISM/PK;DECREASED;CLEARANCE;;CHILDREN;;CAUTION_DRUG_ACCUMULATION
ENDOXIFEN;CYP2D6;*4/*41 + *4/*10 + *4/*17 + *5/*41;CYP2D6*1, CYP2D6*2, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*17, CYP2D6*41;METABOLISM/PK;DECREASED;CONCENTRATIONS;;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;*1/*4 + *2/*4 + *1/*5 + *1/*3 + *2/*5 + *1/*6 + *2/*3 + *2/*6;CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6;METABOLISM/PK;DECREASED;CONCENTRATIONS;;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
IMATINIB;GSTT1;null/null;GSTT1 NON-NULL, GSTT1 NULL;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;LIKELIHOOD_THERAPEUTIC_FAILURE
GLUCOCORTICOIDS;HSD3B1;AA + AC;rs1047303;EFFICACY;INCREASED;RESISTANCE;;PEOPLE;OTHER:ASTHMA;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*2/*2;CYP2C19*1, CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;;CHILDREN;;CAUTION_DRUG_ACCUMULATION
ESOMEPRAZOLE, LANSOPRAZOLE, OMEPRAZOLE, PANTOPRAZOLE, RABEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:HELICOBACTER_INFECTIONS;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*17/*17;CYP2C19*1, CYP2C19*17;METABOLISM/PK;INCREASED;METABOLISM;;CHILDREN;;LIKELIHOOD_THERAPEUTIC_FAILURE
VORICONAZOLE;CYP2C19;*17/*17;CYP2C19*1, CYP2C19*2, CYP2C19*17;METABOLISM/PK;DECREASED;CONCENTRATIONS;;PEOPLE;DISEASE:FUNGAL_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
ACENOCOUMAROL;CYP2C9;*3;CYP2C9*1, CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;CYP2C9;*2;CYP2C9*1, CYP2C9*2;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ENDOXIFEN;CYP2D6;*3/*9 + *4/*4 + *4/*5 + *4/*10 + *4/*41 + *5/*17 + *5/*41 + *41/*41;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*9, CYP2D6*10, CYP2D6*17, CYP2D6*41;METABOLISM/PK;DECREASED;CONCENTRATIONS;;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
SIMVASTATIN;CYP3A4;*1/*22 + *22/*22;CYP3A4*1, CYP3A4*22;METABOLISM/PK;;CONCENTRATIONS;;;;CAUTION_DOSE_ADJUST
MORPHINE;SLC22A1;del/del;rs72552763;METABOLISM/PK;DECREASED;CLEARANCE;;CHILDREN;OTHER:ADENOTONSILLECTOMY;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;SLCO1B1;*5;SLCO1B1*1, SLCO1B1*5, SLCO1B1*37;METABOLISM/PK;DECREASED;CLEARANCE;;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DRUG_ACCUMULATION
NORTRIPTYLINE;CYP2D6;*10/*10;CYP2D6*1, CYP2D6*10;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*2;CYP2C19*1, CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;CAUTION_DRUG_ACCUMULATION
FLUVOXAMINE, PAROXETINE;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR LONG FORM (L ALLELE), SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:MOOD_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*2;CYP2C19*1, CYP2C19*2;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;LIKELIHOOD_THERAPEUTIC_FAILURE
SILDENAFIL;CYP3A4;*1/*22;CYP3A4*1, CYP3A4*22;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:HEART_FAILURE;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;*6/*6;CYP2B6*6;METABOLISM/PK;DECREASED;CLEARANCE;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
MERCAPTOPURINE;TPMT;*1/*3A;TPMT*1, TPMT*3A;DOSAGE;DECREASED;DOSE;;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DOSE_ADJUST
IRINOTECAN_SN-38;UGT1A1;*28/*28 + *1/*28;UGT1A1*1, UGT1A1*28;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:NEOPLASMS;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;*6;CYP2B6*6;METABOLISM/PK;;METABOLISM;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DOSE_ADJUST
FLUOROURACIL;TYMS;(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2 + (CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/3;rs45445694;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:RECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
BILIRUBIN;UGT1A1;*1/*6 + *6/*6;UGT1A1*1, UGT1A1*6;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:NEOPLASMS;CAUTION_DRUG_ACCUMULATION
METHADONE;CYP2C9;*1/*2 + *1/*3;CYP2C9*1, CYP2C9*2, CYP2C9*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
BILIRUBIN;UGT1A1;*1/*28 + *28/*28;UGT1A1*1, UGT1A1*28;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:NEOPLASMS;CAUTION_DRUG_ACCUMULATION
METHADONE;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
METHADONE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
LOSARTAN;CYP2C9;*1/*3;CYP2C9*1, CYP2C9*3;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;SLCO1B1;*14;SLCO1B1*1, SLCO1B1*14, SLCO1B1*37;METABOLISM/PK;INCREASED;CLEARANCE;;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*1/*1;CYP2C9*1;DOSAGE, METABOLISM/PK;INCREASED;DOSE;;CHILDREN;;CAUTION_DOSE_ADJUST
IRINOTECAN_SN-38;UGT1A1;*6/*6 + *1/*6;UGT1A1*1, UGT1A1*6;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:NEOPLASMS;CAUTION_DRUG_ACCUMULATION
ROSUVASTATIN;RXRA;A;rs1805343;METABOLISM/PK;INCREASED;EXPOSURE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
VENLAFAXINE;CYP2D6;*3/*9 + *4/*17 +  *4/*41 + *4/*10;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*9, CYP2D6*10, CYP2D6*17, CYP2D6*41;DOSAGE;DECREASED;DOSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DOSE_ADJUST
PACLITAXEL;CYP2C8;*3;CYP2C8*3;METABOLISM/PK;DECREASED;EXPOSURE;;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOBAZAM;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;METABOLISM/PK;;METABOLISM;;CHILDREN;;CAUTION_DOSE_ADJUST
BUPROPION;CYP2B6;*4;CYP2B6*4;OTHER, METABOLISM/PK;INCREASED;CLEARANCE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1, CYP2C9*2, CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
ACENOCOUMAROL;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
GLATIRAMER ACETATE;CCR5;del;rs333;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:MULTIPLE_SCLEROSIS;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*1/*13 + *1/*16 + *1/*60;CYP2C9*1, CYP2C9*3, CYP2C9*13, CYP2C9*16, CYP2C9*60;DOSAGE;DECREASED;DOSE;;PEOPLE;OTHER:ATRIAL_FIBRILLATION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;DECREASED;TROUGH_CONCENTRATION;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
SERTRALINE;CYP2C19;*2/*2 + *2/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;METABOLISM/PK;DECREASED;CLEARANCE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A4;*1/*1;CYP3A4*1, CYP3A4*22;METABOLISM/PK;;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;CAUTION_DOSE_ADJUST
LANSOPRAZOLE;CYP2C19;*2 + *3 + *8 + *9;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*8, CYP2C19*9;METABOLISM/PK;DECREASED;METABOLISM;;CHILDREN;DISEASE:ASTHMA;CAUTION_DRUG_ACCUMULATION
GLIPIZIDE;TCF7L2;T;rs7903146;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;INCREASED;CLEARANCE;;CHILDREN;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1, CYP2C19*2;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:CAROTID_ARTERY_DISEASES;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;SLC14A2;T;rs12456693;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HEPATITIS_B_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;*1/*3;CYP2C9*1, CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
CISPLATIN, FLUOROURACIL;TPMT;*3C;TPMT*3C;EFFICACY;DECREASED;RESPONSE;;MEN;DISEASE:HEAD_AND_NECK_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*3;CYP3A5*1, CYP3A5*3;DOSAGE;INCREASED;DOSE;;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
CAVOSONSTAT;CFTR;del/del;rs113993960;EFFICACY;;RESPONSE;;PEOPLE;DISEASE:CYSTIC_FIBROSIS;CAUTION_DOSE_ADJUST
BUPROPION;CYP2B6;*6;CYP2B6*6;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*2;CYP2C19*1, CYP2C19*2, CYP2C19*17;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;CYP2D6;*10 + *5;CYP2D6*5, CYP2D6*10;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*2 + *3;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;METABOLISM/PK;INCREASED;TROUGH_CONCENTRATION;;CHILDREN;;CAUTION_DRUG_ACCUMULATION
ZUCLOPENTHIXOL;CYP2D6;*4;CYP2D6*1, CYP2D6*4;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_DRUG_ACCUMULATION
NEVIRAPINE;NR1I2;GAGAAG/del + del/del;rs3842689;DOSAGE, METABOLISM/PK;INCREASED;CLEARANCE;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DOSE_ADJUST
GEFITINIB;CYP2D6;*4/*4 + *4/*5 + *3/*4 + *4/*6 + *3/*5 + *4/*4xN;CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*4XN, CYP2D6*5, CYP2D6*6, CYP2D6*41;METABOLISM/PK;INCREASED;CONCENTRATIONS;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
TRAMADOL;CYP2D6;*10/*10;CYP2D6*1, CYP2D6*2, CYP2D6*10;METABOLISM/PK;INCREASED;EXPOSURE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
VORICONAZOLE;ABCB1;AA;rs1045642;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
IVACAFTOR / LUMACAFTOR;CFTR;del/del;rs113993960;EFFICACY;;RESPONSE;;PEOPLE;DISEASE:CYSTIC_FIBROSIS;CAUTION_DOSE_ADJUST
VORICONAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;METABOLISM/PK;DECREASED;TROUGH_CONCENTRATION;;PEOPLE;DISEASE:FUNGAL_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
MIDAZOLAM;CYP3A4;*1/*22;CYP3A4*1, CYP3A4*22;METABOLISM/PK;DECREASED;CLEARANCE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
IRINOTECAN_SN-38;UGT1A1;*6 + *28;UGT1A1*1, UGT1A1*6, UGT1A1*28;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;DOSAGE;INCREASED;DOSE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TELMISARTAN;UGT1A3;*3;UGT1A3*1, UGT1A3*3;METABOLISM/PK;DECREASED;CONCENTRATIONS;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A4;*1/*22;CYP3A4*1, CYP3A4*22;DOSAGE;DECREASED;DOSE;;CHILDREN;DISEASE:TRANSPLANTATION;CAUTION_DOSE_ADJUST
IVACAFTOR / LUMACAFTOR;CFTR;del/del;rs113993960;EFFICACY;;RESPONSE;;PEOPLE;DISEASE:CYSTIC_FIBROSIS;CAUTION_DOSE_ADJUST
HALOPERIDOL;CYP2D6;*5;CYP2D6*1, CYP2D6*5;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;INCREASED;METABOLISM;;PEOPLE;DISEASE:ULCERATIVE_COLITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*8 + *2/*2 + *2/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*8, CYP2C19*17;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;CAUTION_DRUG_ACCUMULATION
MEASLES VACCINES;HLA-B;*51:01;HLA-B*51:01;EFFICACY;DECREASED;RESPONSE;;CHILDREN;;LIKELIHOOD_THERAPEUTIC_FAILURE
BUCINDOLOL;ADRA2C;GGGGCGGGGCCG/GGGGCGGGGCCG;rs61767072;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HEART_FAILURE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;DECREASED;METABOLISM;;CHILDREN;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;CYP2D6;;CYP2D6 POOR_METABOLIZER, INTERMEDIATE_METABOLIZER;DOSAGE;DECREASED;DOSE;;PEOPLE;DISEASE:PSYCHOTIC_DISORDER;CAUTION_DOSE_ADJUST
MEASLES VACCINES;HLA-B;*07:02;HLA-B*07:02;EFFICACY;INCREASED;RESPONSE;;CHILDREN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
MEASLES VACCINES;HLA-B;*13:01;HLA-B*13:01;EFFICACY;DECREASED;RESPONSE;;CHILDREN;;LIKELIHOOD_THERAPEUTIC_FAILURE
MEASLES VACCINES;HLA-B;*08:01;HLA-B*08:01;EFFICACY;DECREASED;RESPONSE;;CHILDREN;;LIKELIHOOD_THERAPEUTIC_FAILURE
ROSUVASTATIN;ABCB11;G;rs7579275;METABOLISM/PK;INCREASED;EXPOSURE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*3;CYP2C9*1, CYP2C9*2, CYP2C9*3;DOSAGE;DECREASED;DOSE;;CHILDREN;;CAUTION_DOSE_ADJUST
INFLUENZA VACCINES;HLA-DQB1;*03:03;HLA-DQB1*03:03;EFFICACY;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*1 + *1/*2 + *1/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:HELICOBACTER_INFECTIONS;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE, RABEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:HELICOBACTER_INFECTIONS;LIKELIHOOD_THERAPEUTIC_FAILURE
MEASLES VACCINES;HLA-DQA1;*02:01;HLA-DQA1*02:01;EFFICACY;DECREASED;RESPONSE;;CHILDREN;;LIKELIHOOD_THERAPEUTIC_FAILURE
MEASLES VACCINES;HLA-DRB1;*03:01;HLA-DRB1*03:01;EFFICACY;DECREASED;RESPONSE;;CHILDREN;;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A4;*1/*20;CYP3A4*1, CYP3A4*20;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;INCREASED;METABOLISM;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A4;*1/*22 + *22/*22;CYP3A4*1, CYP3A4*22;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:HELICOBACTER_INFECTIONS;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL;DPYD;;POOR_METABOLIZER;DOSAGE;DECREASED;DOSE;;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS, DISEASE:GASTROINTESTINAL_NEOPLASMS,DISEASE:RECTAL_NEOPLASMS;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2B6;*6;CYP2B6*1, CYP2B6*6;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
ESOMEPRAZOLE, LANSOPRAZOLE, OMEPRAZOLE, RABEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:HELICOBACTER_INFECTIONS;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*3 + *3/*3;CYP3A5*1, CYP3A5*3;DOSAGE;DECREASED;DOSE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
ESOMEPRAZOLE, LANSOPRAZOLE, OMEPRAZOLE, RABEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:HELICOBACTER_INFECTIONS;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*3;CYP3A5*1, CYP3A5*3;DOSAGE;INCREASED;DOSE;;PEOPLE;OTHER:HEART_TRANSPLANTATION;CAUTION_DOSE_ADJUST
CISPLATIN, FLUOROURACIL;TPMT;*3B;TPMT*3B;EFFICACY;DECREASED;RESPONSE;;MEN;DISEASE:HEAD_AND_NECK_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
ESOMEPRAZOLE, LANSOPRAZOLE, OMEPRAZOLE, RABEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:HELICOBACTER_INFECTIONS;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*3;CYP2C19*1, CYP2C19*3;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1, CYP2C19*2;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;DOSAGE;INCREASED;DOSE;;CHILDREN;OTHER:HEART_TRANSPLANTATION;CAUTION_DOSE_ADJUST
ROSUVASTATIN;ABCB11;G;rs2287622;METABOLISM/PK;INCREASED;EXPOSURE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:HELICOBACTER_INFECTIONS;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:HELICOBACTER_INFECTIONS;LIKELIHOOD_THERAPEUTIC_FAILURE
PHENPROCOUMON;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *3/*3 + *2/*3;CYP2C9*1, CYP2C9*2, CYP2C9*3;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;INCREASED;METABOLISM;;PEOPLE;DISEASE:ULCERATIVE_COLITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*3;CYP3A5*1, CYP3A5*3;DOSAGE;INCREASED;DOSE;;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;CAUTION_DOSE_ADJUST
AMITRIPTYLINE;CYP2D6;*4/*5 + *4/*4;CYP2D6*1, CYP2D6*2, CYP2D6*4, CYP2D6*5, CYP2D6*9, CYP2D6*10;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
SIROLIMUS, TEMSIROLIMUS;ABCB1;GG;rs1128503;METABOLISM/PK;DECREASED;EXPOSURE;;PEOPLE;DISEASE:URINARY_BLADDER_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*1 + *1/*2 + *1/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:HELICOBACTER_INFECTIONS;LIKELIHOOD_THERAPEUTIC_FAILURE
METHADONE;CYP2B6;*6/*6;CYP2B6*1, CYP2B6*6;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
ACENOCOUMAROL;CYP2C9;*1/*3 + *3/*3 + *2/*3;CYP2C9*1, CYP2C9*2, CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
GRANISETRON;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
CODEINE;CYP2D6;*40;CYP2D6*1, CYP2D6*40;EFFICACY;DECREASED;RESPONSE;;CHILDREN;DISEASE:SICKLE_CELL_ANEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
CODEINE;CYP2D6;*17;CYP2D6*1, CYP2D6*17;EFFICACY;DECREASED;RESPONSE;;CHILDREN;DISEASE:SICKLE_CELL_ANEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1;CYP3A5*1, CYP3A5*3;OTHER;INCREASED;DISCONTINUATION;;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
CODEINE;CYP2D6;*6;CYP2D6*1, CYP2D6*6;EFFICACY;DECREASED;RESPONSE;;CHILDREN;DISEASE:SICKLE_CELL_ANEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
CODEINE;CYP2D6;*4;CYP2D6*1, CYP2D6*4;EFFICACY;DECREASED;RESPONSE;;CHILDREN;DISEASE:SICKLE_CELL_ANEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
ASPIRIN, CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *3/*17 + *2/*2 + *2/*3 + *3/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:STROKE;LIKELIHOOD_THERAPEUTIC_FAILURE
CODEINE;CYP2D6;*5;CYP2D6*1, CYP2D6*5;EFFICACY;DECREASED;RESPONSE;;CHILDREN;DISEASE:SICKLE_CELL_ANEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
GRANISETRON;CYP1A1;*2A;CYP1A1*1, CYP1A1*2A;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_DRUG_ACCUMULATION
CLOMIPRAMINE;CYP2C19;*2/*2;CYP2C19*1, CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:MENTAL_DISORDERS;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*1/*3 + *3/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
HMG_COA_REDUCTASE_INHIBITORS;UGT1A1;*28;UGT1A1*28;TOXICITY;DECREASED;DISCONTINUATION;;PEOPLE;DISEASE:HYPERLIPIDEMIAS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ROCURONIUM;SLCO1A2;CC;rs7967354;DOSAGE;DECREASED;DOSE;;WOMEN;;CAUTION_DOSE_ADJUST
PHENPROCOUMON;CYP2C9;*1/*2 + *2/*2 + *1/*3 + *2/*3;CYP2C9*1, CYP2C9*2, CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ROSUVASTATIN;ABCC2;A;rs8187692;METABOLISM/PK;INCREASED;EXPOSURE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
NORTRIPTYLINE;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:MENTAL_DISORDERS;CAUTION_DRUG_ACCUMULATION
AMITRIPTYLINE;CYP2C19;*2/*2;CYP2C19*1, CYP2C19*2;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:MENTAL_DISORDERS;CAUTION_DRUG_ACCUMULATION
CAPECITABINE, FLUOROURACIL;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/CCGCGC(CACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:RECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
AMITRIPTYLINE;CYP2C19;*2;CYP2C19*1, CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:MENTAL_DISORDERS;CAUTION_DRUG_ACCUMULATION
LANSOPRAZOLE, OMEPRAZOLE, RABEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:HELICOBACTER_INFECTIONS;LIKELIHOOD_THERAPEUTIC_FAILURE
FENTANYL;CYP3A4;*1/*22;CYP3A4*1, CYP3A4*22;METABOLISM/PK;INCREASED;EXPOSURE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED;RESPONSE;;MEN;DISEASE:HELICOBACTER_INFECTIONS;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED;RESPONSE;;MEN;DISEASE:HELICOBACTER_INFECTIONS;LIKELIHOOD_THERAPEUTIC_FAILURE
CARVEDILOL;CYP2D6;*3/*10 + *4/*4;CYP2D6*3, CYP2D6*4, CYP2D6*10;DOSAGE;INCREASED;DOSE;;PEOPLE;DISEASE:HEART_FAILURE;CAUTION_DOSE_ADJUST
LANSOPRAZOLE, OMEPRAZOLE, RABEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HELICOBACTER_INFECTIONS;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;*3/*3 + *1/*3;CYP2C9*1, CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;CYP2C9;*1/*3 + *3/*3 + *2/*3;CYP2C9*1, CYP2C9*2, CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
LANSOPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HELICOBACTER_INFECTIONS;LIKELIHOOD_THERAPEUTIC_SUCCESS
LANSOPRAZOLE, OMEPRAZOLE, RABEPRAZOLE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HELICOBACTER_INFECTIONS;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
LANSOPRAZOLE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HELICOBACTER_INFECTIONS;LIKELIHOOD_THERAPEUTIC_SUCCESS
VORICONAZOLE;CYP3A4;*22;CYP3A4*1, CYP3A4*22;METABOLISM/PK;INCREASED;EXPOSURE;;;;CAUTION_DRUG_ACCUMULATION
HALOPERIDOL;CYP2D6;*4/*4;CYP2D6*1, CYP2D6*4;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
ROSUVASTATIN;SLC10A1;T;rs56903885;METABOLISM/PK;DECREASED;EXPOSURE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
VITAMIN K1;CYP4F2;*1/*3 + *3/*3;CYP4F2*1, CYP4F2*3;METABOLISM/PK;INCREASED;EXPOSURE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
TROPISETRON;CYP2D6;*10/*10 + *5/*10;CYP2D6*1, CYP2D6*5, CYP2D6*10;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
BUMETANIDE, FUROSEMIDE, TORASEMIDE;ACE;del/del;rs1799752;EFFICACY;INCREASED;RESPONSE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_SUCCESS
VORICONAZOLE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:ULCERATIVE_COLITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
VORICONAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
TROPISETRON;CYP2D6;*1/*10;CYP2D6*1, CYP2D6*10;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
AMITRIPTYLINE;CYP2C19;*2;CYP2C19*1, CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:MENTAL_DISORDERS;CAUTION_DRUG_ACCUMULATION
IMIPRAMINE;CYP2C19;*2/*2 + *2/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;*1/*3 + *2/*3 + *3/*3;CYP2C9*1, CYP2C9*2, CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;CYP2C9;*1/*3 + *2/*3 + *2/*2;CYP2C9*1, CYP2C9*2, CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
MORPHINE;SLC22A1;;LOW ACTIVITY;METABOLISM/PK;INCREASED;CONCENTRATIONS;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
VARENICLINE;CYP2A6;;NORMAL_METABOLIZER;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:TOBACCO_USE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
AZATHIOPRINE;GSTM1;;GSTM1 NON-NULL, GSTM1 NULL;METABOLISM/PK;INCREASED;DOSE;;PEOPLE;DISEASE:INFLAMMATORY_BOWEL_DISEASES;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;CYP2C9;*1/*2 + *2/*2 + *1/*3 + *3/*3 + *2/*3;CYP2C9*1, CYP2C9*2, CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
RALOXIFENE;UGT1A8;*1a/*3;UGT1A8*1A, UGT1A8*2, UGT1A8*3;METABOLISM/PK;INCREASED;METABOLISM;;WOMEN;;LIKELIHOOD_THERAPEUTIC_FAILURE
PHENAZEPAM;CYP2C19;*17;CYP2C19*1, CYP2C19*17;EFFICACY;DECREASED;CLINICAL_BENEFIT;;MEN;OTHER:ALCOHOL_ABUSE, OTHER:ANXIETY_DISORDERS;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*5 + *6 + *11;CYP2C9*1, CYP2C9*5, CYP2C9*6, CYP2C9*11;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ROSUVASTATIN;NR1I2;T;rs12721616;METABOLISM/PK;DECREASED;EXPOSURE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*3;CYP2C9*1, CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
DIMETHYL FUMARATE;GSTP1;GG;rs1695;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:PSORIASIS;LIKELIHOOD_THERAPEUTIC_FAILURE
CELECOXIB;CYP2C9;*3/*3;CYP2C9*1, CYP2C9*3;METABOLISM/PK;DECREASED;CLEARANCE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
VENLAFAXINE;CYP2D6;*1/*3 + *1/*4 + *1/*5;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DRUG_ACCUMULATION
ROSUVASTATIN;SLCO1B1;C;rs11045874;METABOLISM/PK;DECREASED;EXPOSURE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:ULCERATIVE_COLITIS;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1, CYP2C9*2, CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
CELECOXIB;CYP2C9;*3/*3;CYP2C9*1, CYP2C9*3;METABOLISM/PK;DECREASED;CLEARANCE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
CELECOXIB;CYP2C9;*1/*3;CYP2C9*1, CYP2C9*3;METABOLISM/PK;DECREASED;CLEARANCE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
ESCITALOPRAM;SLC6A4;HTTLPR long form (L allele);SLC6A4 HTTLPR LONG FORM (L ALLELE), SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
MERCAPTOPURINE;TPMT;*1/*3A + *1/*3C + *3A/*3A;TPMT*1, TPMT*3A, TPMT*3C;OTHER;INCREASED;DISCONTINUATION;;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*2 + *3 + *5 + *8 + *11;CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*5, CYP2C9*8, CYP2C9*11;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
O-DESMETHYLTRAMADOL;CYP2D6;;ULTRARAPID_METABOLIZER;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:LOW_BACK_PAIN, DISEASE:OSTEOARTHRITIS;CAUTION_DRUG_ACCUMULATION
PRIMAQUINE;CYP2D6;*4/*41 + *5/*6;CYP2D6*1, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*10, CYP2D6*41;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:MALARIA;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP3A5;*1/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;;METABOLISM;;HEALTHY;;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1, CYP2C19*2;EFFICACY;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*3;CYP2C19*1, CYP2C19*3;EFFICACY;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2C19;*2;CYP2C19*1, CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;DECREASED;CLEARANCE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
ACENOCOUMAROL;CYP2C9;*3;CYP2C9*3;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOXEPIN;CYP2D6;*4/*4 + *3/*5 + *4/*5;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
MEPHEDRONE;CYP2D6;*1/*9 + *1/*4 + *1/*41 + *2/*4 + *1/*5 + *2/*10 + *1/*41 + *1/*3 + *2/*4 + *1/*4;CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*9, CYP2D6*10, CYP2D6*41;METABOLISM/PK;INCREASED;CONCENTRATIONS;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
DOXEPIN;CYP2D6;*1xN/*9 + *1xN/*10 + *1xN/*41 + *2xN/*41 + *1xN/*1 + *2xN/*1 + *1xN/*35 + *2xN/*35 + *35xN/*1;CYP2D6*1, CYP2D6*1XN, CYP2D6*2, CYP2D6*2XN, CYP2D6*9, CYP2D6*10, CYP2D6*35, CYP2D6*35XN, CYP2D6*41;METABOLISM/PK;INCREASED;METABOLISM;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1, CYP2C19*2;OTHER;INCREASED;RESISTANCE;;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
CAPECITABINE, FLUOROURACIL;TYMP;AA + AG;rs11479;DOSAGE;;DOSE;;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_DOSE_ADJUST
USTEKINUMAB;HLA-C;*06:02;HLA-C*06:02;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:PSORIASIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
PHENYTOIN;CYP2C19;*2 + *3;CYP2C19*2, CYP2C19*3;DOSAGE;;DOSE;;CHILDREN;DISEASE:EPILEPSY;CAUTION_DOSE_ADJUST
CLOZAPINE;SLC6A4;HTTLPR short form (S allele)/L allele-rs25531C;SLC6A4 HTTLPR SHORT FORM (S ALLELE), SLC6A4 L ALLELE-rs25531C, SLC6A4 L ALLELE-rs25531T;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_FAILURE
PHENYTOIN;CYP2C9;*3;CYP2C9*3;DOSAGE;;DOSE;;CHILDREN;DISEASE:EPILEPSY;CAUTION_DOSE_ADJUST
ANTIPSYCHOTICS, HALOPERIDOL, OLANZAPINE, RISPERIDONE;SLC6A4;HTTLPR long form (L allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR LONG FORM (L ALLELE), SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*2;CYP2C19*1, CYP2C19*2;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;LIKELIHOOD_THERAPEUTIC_FAILURE
FOLIC ACID, HYDROXYCHLOROQUINE, METHOTREXATE, SULFASALAZINE;C18orf56, TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
TICAGRELOR;CYP3A4;*1/*22;CYP3A4*1, CYP3A4*22;METABOLISM/PK;INCREASED;CONCENTRATIONS;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
FLUVASTATIN;ACE;del/del;rs1799752;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ONDANSETRON;CYP2D6;*1/*1xN;CYP2D6*1, CYP2D6*1XN;METABOLISM/PK;INCREASED;METABOLISM;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
"""INTERFERON ALFA-2A, RECOMBINANT"", ""RIBAVIRIN""";HLA-B;*44:02;HLA-B*44:02;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ONDANSETRON, TROPISETRON;CYP2D6;*1/*1xN;CYP2D6*1, CYP2D6*1XN;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOSPORINE, TACROLIMUS;CYP3A5;*1;CYP3A5*1, CYP3A5*3;METABOLISM/PK;DECREASED;CONCENTRATIONS;;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
PRAVASTATIN;ACE;del/del;rs1799752;EFFICACY;;RESPONSE;;PEOPLE;OTHER:NON-HYPERCHOLESTEROLAEMIC_PATIENTS_SCHEDULED_FOR_ANGIOPLASTY;CAUTION_DOSE_ADJUST
MERCAPTOPURINE;NUDT15;*1/*2 + *1/*3 + *1/*4 + *1/*6;NUDT15*1, NUDT15*2, NUDT15*3, NUDT15*4, NUDT15*6;DOSAGE;DECREASED;DOSE;;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2B6;*6/*6;CYP2B6*6;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;*1/*18;CYP2B6*1, CYP2B6*18;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;*1/*9;CYP2B6*1, CYP2B6*9;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
FLUOXETINE, SERTRALINE;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR LONG FORM (L ALLELE), SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE, FLUOROURACIL;DPYD;CT;rs3918290;DOSAGE;;DOSE;;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3 + *3/*3 + *1/*2 + *1/*3 + *2/*17;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;EFFICACY;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
ROSUVASTATIN;SLCO1B1;A;rs12305884;METABOLISM/PK;DECREASED;EXPOSURE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
4-HYDROXYTAMOXIFEN, ENDOXIFEN;CYP2D6;*10;CYP2D6*1, CYP2D6*10;METABOLISM/PK;DECREASED;CONCENTRATIONS;;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
(S)-METHADONE;CYP2B6;*6/*6;CYP2B6*1, CYP2B6*6;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:OPIOID-RELATED_DISORDERS;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;DOSAGE;INCREASED;DOSE;;CHILDREN;DISEASE:LIVER_TRANSPLANTATION;CAUTION_DOSE_ADJUST
METOPROLOL;ADRA2C;del;rs61767072;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HEART_FAILURE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ENDOXIFEN;CYP3A4;*1/*22 + *22/*22;CYP3A4*1, CYP3A4*22;METABOLISM/PK;INCREASED;CONCENTRATIONS;;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_DRUG_ACCUMULATION
IMATINIB;ABCG2;GT + TT;rs2231142;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;OTHER:GASTROINTESTINAL_STROMAL_TUMORS;CAUTION_DRUG_ACCUMULATION
OMEPRAZOLE;CYP2C19;*2/*2;CYP2C19*1, CYP2C19*2, CYP2C19*3;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A4;*1/*22;CYP3A4*1, CYP3A4*22;DOSAGE;DECREASED;DOSE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
CAPECITABINE, FLUOROURACIL;DPYD;AT;rs67376798;DOSAGE;;DOSE;;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A4;*1/*22;CYP3A4*1, CYP3A4*22;METABOLISM/PK;DECREASED;CLEARANCE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;METABOLISM/PK;INCREASED;METABOLISM;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*2/*2 + *2/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1, CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A4;*1/*22;CYP3A4*1, CYP3A4*22;METABOLISM/PK;DECREASED;CONCENTRATIONS;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*3/*3 + *6/*6 + *7/*7 + *3/*6 + *3/*7 + *6/*7;CYP3A5*1, CYP3A5*3, CYP3A5*6, CYP3A5*7;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;OTHER:LUNG_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A4;*1/*22;CYP3A4*1, CYP3A4*22;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
VINCRISTINE;CYP3A5;*1/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;INCREASED;METABOLISM;;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;*9/*4;CYP2D6*4, CYP2D6*9, CYP2D6*10, CYP2D6*41;METABOLISM/PK;INCREASED;CONCENTRATIONS;;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_DRUG_ACCUMULATION
ENDOXIFEN;CYP2D6;*1/*4 + *1/*5 + *1/*6;CYP2D6*1, CYP2D6*4, CYP2D6*5, CYP2D6*6;METABOLISM/PK;DECREASED;CONCENTRATIONS;;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;*9/*41 + *10/*10 + *41/*41;CYP2D6*1, CYP2D6*9, CYP2D6*10, CYP2D6*41;METABOLISM/PK;DECREASED;CONCENTRATIONS;;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
PHENPROCOUMON;CYP2C9;*2 + *3;CYP2C9*1, CYP2C9*2, CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;*1/*9 + *1/*10 + *1/*41;CYP2D6*1, CYP2D6*9, CYP2D6*10, CYP2D6*41;METABOLISM/PK;DECREASED;CONCENTRATIONS;;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
MERCAPTOPURINE;TPMT;*1/*3A;TPMT*1, TPMT*3A;DOSAGE;DECREASED;DOSE;;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DOSE_ADJUST
CAPECITABINE, FLUOROURACIL;DPYD;CG;rs75017182;DOSAGE;;DOSE;;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_DOSE_ADJUST
SIROLIMUS, TEMSIROLIMUS;NR1I2;GG;rs6785049;METABOLISM/PK;INCREASED;EXPOSURE;;PEOPLE;DISEASE:URINARY_BLADDER_NEOPLASMS;CAUTION_DRUG_ACCUMULATION
FLUVASTATIN;CYP2C9;*3;CYP2C9*1, CYP2C9*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
NORTRIPTYLINE;CYP2D6;*4/*4 + *1/*4 + *1/*5;CYP2D6*1, CYP2D6*2XN, CYP2D6*4, CYP2D6*5;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
ROSUVASTATIN;SLCO1B1;A;rs11045873;METABOLISM/PK;DECREASED;EXPOSURE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;INCREASED;CLEARANCE;;PEOPLE;DISEASE:LAPAROSCOPIC_SLEEVE_GASTRECTOMY;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;;G;rs4646458;DOSAGE;;DOSE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
NORTRIPTYLINE;CYP2D6;*2/*2 + *2/*10 + *1/*3 + *1/*4 + *2/*4 + *5/*10 + *4/*4 + *3/*4;CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*10;DOSAGE;DECREASED;DOSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DOSE_ADJUST
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;METABOLISM/PK;INCREASED;METABOLISM;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
ROCURONIUM;IAPP, SLCO1A2;CC;rs11045995;DOSAGE;DECREASED;DOSE;;WOMEN;;CAUTION_DOSE_ADJUST
MEASLES VACCINES;HLA-B;*44:02;HLA-B*44:02;EFFICACY;;RESPONSE;;CHILDREN;;CAUTION_DOSE_ADJUST
ENDOXIFEN;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6;METABOLISM/PK;DECREASED;CONCENTRATIONS;;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;DECREASED;CONCENTRATIONS;;PEOPLE;DISEASE:LAPAROSCOPIC_SLEEVE_GASTRECTOMY;LIKELIHOOD_THERAPEUTIC_FAILURE
METOPROLOL;CYP2D6;del/del;rs5030655;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
AMOXICILLIN, OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:HELICOBACTER_INFECTIONS;LIKELIHOOD_THERAPEUTIC_FAILURE
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;;RESPONSE;;;;CAUTION_DOSE_ADJUST
AMOXICILLIN, OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:HELICOBACTER_INFECTIONS;LIKELIHOOD_THERAPEUTIC_FAILURE
MERCAPTOPURINE;NUDT15;*2/*3;NUDT15*1, NUDT15*2, NUDT15*3;TOXICITY;DECREASED;DOSE;;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
MERCAPTOPURINE;NUDT15;*1/*2 + *1/*3 + *1/*5;NUDT15*1, NUDT15*2, NUDT15*3, NUDT15*5;TOXICITY;DECREASED;DOSE;;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;DECREASED;DOSE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
ESTRONE SULFATE;SLCO1B1;*5;SLCO1B1*1, SLCO1B1*5;METABOLISM/PK;INCREASED;;;WOMEN;OTHER:BREAST_NEOPLASMS;CAUTION_DOSE_ADJUST
HMG_COA_REDUCTASE_INHIBITORS;CXCL5;CC;rs352046;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;LIKELIHOOD_THERAPEUTIC_SUCCESS
PAROXETINE;CYP2D6;*10/*10;CYP2D6*1, CYP2D6*2, CYP2D6*10;METABOLISM/PK;DECREASED;CLEARANCE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
AMOXICILLIN, OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:HELICOBACTER_INFECTIONS;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*1/*3;CYP3A5*1, CYP3A5*3;DOSAGE, METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1, CYP2C9*2, CYP2C9*3;DOSAGE;DECREASED;DOSE;;PEOPLE;DISEASE:VENOUS_THROMBOEMBOLISM;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *2/*3;CYP2C9*1, CYP2C9*2, CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ATAZANAVIR / RITONAVIR;UGT1A1;*28/*28;UGT1A1*1, UGT1A1*28, UGT1A1*36;TOXICITY;INCREASED;DISCONTINUATION;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*1/*3;CYP2C9*1, CYP2C9*3;DOSAGE;DECREASED;DOSE;;PEOPLE;DISEASE:ATRIAL_FIBRILLATION;CAUTION_DOSE_ADJUST
CELECOXIB;CYP2C9;*1/*3 + *1/*13 + *3/*3;CYP2C9*1, CYP2C9*3, CYP2C9*13;METABOLISM/PK;DECREASED;CLEARANCE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN, DEXTRORPHAN;TCF20;C;rs5758651;METABOLISM/PK;INCREASED;CONCENTRATIONS;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;*2 + *6 + *5 + *11;CYP2C9*1, CYP2C9*2, CYP2C9*5, CYP2C9*6, CYP2C9*11;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2 + *6 + *5 + *11;CYP2C9*1, CYP2C9*2, CYP2C9*5, CYP2C9*6, CYP2C9*8, CYP2C9*9, CYP2C9*11;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;*2;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOSPORINE;CYP3A5;*1/*1;CYP3A5*1, CYP3A5*3;METABOLISM/PK;DECREASED;CONCENTRATIONS;;WOMEN;;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;*1/*3;CYP2C9*1, CYP2C9*3;DOSAGE;;DOSE;;;;CAUTION_DOSE_ADJUST
ENDOXIFEN;CYP2D6;*4 + *6 + *8;CYP2D6*1, CYP2D6*4, CYP2D6*6, CYP2D6*8;METABOLISM/PK;DECREASED;CONCENTRATIONS;;WOMEN;;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIR;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
METFORMIN;CSMD1;CT + TT;rs2954625;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:DIABETES_MELLITUS;LIKELIHOOD_THERAPEUTIC_FAILURE
ATAZANAVIR / RITONAVIR;UGT1A1;*28/*28;UGT1A1*1, UGT1A1*28;TOXICITY;INCREASED;DISCONTINUATION;;PEOPLE;OTHER:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
ESTRONE;SLCO1B1;*5/*5;SLCO1B1*1, SLCO1B1*5;EFFICACY;INCREASED;CONCENTRATIONS;;WOMEN;OTHER:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
VORICONAZOLE;ABCB1;AA;rs1045642;METABOLISM/PK;DECREASED;TROUGH_CONCENTRATION;;CHILDREN;;LIKELIHOOD_THERAPEUTIC_FAILURE
MERCAPTOPURINE;NT5C2;AA + AG;rs72846714;METABOLISM/PK;DECREASED;METABOLISM;;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DRUG_ACCUMULATION
BUPROPION;CYP2C19;*2;CYP2C19*1, CYP2C19*2;METABOLISM/PK;INCREASED;EXPOSURE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
BUPROPION;CYP2B6;*1/*6 + *6/*6;CYP2B6*1, CYP2B6*6;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
HALOPERIDOL;CYP2D6;*2/*2;CYP2D6*1, CYP2D6*2;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_DRUG_ACCUMULATION
CYCLOSPORINE;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;;CHILDREN;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
IRINOTECAN, OXALIPLATIN, TEGAFUR / GIMERACIL / OTERACIL;UGT1A1;*60;UGT1A1*60;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*1/*8 + *8/*8;CYP2C9*1, CYP2C9*8;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
ENDOXIFEN;CYP2D6;*4/*4 + *41/*4 + *41/*3 + *10/*4 + *9/*41 + *17/*41 + *41/*41 + *9/*5 + *1/*29 + *2xN/*4;CYP2D6*1, CYP2D6*2, CYP2D6*2XN, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*9, CYP2D6*10, CYP2D6*17, CYP2D6*29, CYP2D6*35, CYP2D6*41;METABOLISM/PK;DECREASED;CONCENTRATIONS;;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
SERTRALINE;CYP2C18;GG;rs11188059;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
SIMVASTATIN;CYP2D6;*14;CYP2D6*1, CYP2D6*14;METABOLISM/PK;INCREASED;CONCENTRATIONS;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
IRINOTECAN, OXALIPLATIN, TEGAFUR / GIMERACIL / OTERACIL;CYP2A6;*4 + *7 + *9;CYP2A6*1, CYP2A6*4, CYP2A6*7, CYP2A6*9;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
DONEPEZIL;CYP2D6;*4/*4 + *4/*5;CYP2D6*4, CYP2D6*5;METABOLISM/PK;DECREASED;CLEARANCE;;PEOPLE;DISEASE:ALZHEIMER_DISEASE;CAUTION_DRUG_ACCUMULATION
NICOTINE;CYP2A6;;HIGH ACTIVITY;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:TOBACCO_USE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
AZATHIOPRINE, MERCAPTOPURINE, PURINE ANALOGUES;TPMT;*1/*2 + *1/*3A;TPMT*1, TPMT*2, TPMT*3A;DOSAGE;DECREASED;DOSE;;CHILDREN;DISEASE:INFLAMMATORY_BOWEL_DISEASES;CAUTION_DOSE_ADJUST
FENTANYL;CYP2D6;*29;CYP2D6*1, CYP2D6*29;METABOLISM/PK;DECREASED;CLEARANCE;;PEOPLE;OTHER:BURNS;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;*10/*10 + *10/*10x2;CYP2D6*1, CYP2D6*2, CYP2D6*10, CYP2D6*10X2;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
ENDOXIFEN;CYP2D6;*1/*4 + *1/*5 + *2/*4 + *1/*3 + *35/*4 + *1/*6 + *35/*5 + *9/*5 + *2/*41 + *1/*41 + *35/*41 + *1/*10 + *2/*10 + *35/*10;CYP2D6*1, CYP2D6*1XN, CYP2D6*2, CYP2D6*2XN, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*9, CYP2D6*10, CYP2D6*35, CYP2D6*41;METABOLISM/PK;DECREASED;CONCENTRATIONS;;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
LEVONORGESTREL;CYP2B6;GT + TT;rs3745274;METABOLISM/PK;DECREASED;CONCENTRATIONS;;WOMEN;DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
ADALIMUMAB;;T;rs9828223;EFFICACY;DECREASED;RESPONSE;;PEOPLE;OTHER:CROHN_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
DEXTROMETHORPHAN, DEXTRORPHAN;IP6K2;AG;rs61740999;METABOLISM/PK;INCREASED;CONCENTRATIONS;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;rs45445694;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
DEBRISOQUINE;CYP2D6;*29/*29;CYP2D6*1, CYP2D6*29;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
DEBRISOQUINE;CYP2D6;*17/*29;CYP2D6*1, CYP2D6*17, CYP2D6*29;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
ESCITALOPRAM;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);SLC6A4 HTTLPR LONG FORM (L ALLELE), SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
PROGESTERONE;CYP2C19;*1/*2 + *2/*17;CYP2C19*1, CYP2C19*2, CYP2C19*17;METABOLISM/PK;INCREASED;EXPOSURE;;WOMEN;;CAUTION_DRUG_ACCUMULATION
DEBRISOQUINE, METOPROLOL;CYP2D6;*17/*17;CYP2D6*1, CYP2D6*2, CYP2D6*17;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
DONEPEZIL;CYP2D6;*1/*1xN + *1xN/*1xN;CYP2D6*1, CYP2D6*1XN;METABOLISM/PK;INCREASED;CLEARANCE;;PEOPLE;DISEASE:ALZHEIMER_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOPHOSPHAMIDE, FLUDARABINE;CYP2B6;*1/*6 + *6/*6;CYP2B6*1, CYP2B6*6;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_B-CELL_LYMPHOCITIC_LEUKEMIA,;LIKELIHOOD_THERAPEUTIC_FAILURE
LEVONORGESTREL;CYP2B6;CT;rs4803419;METABOLISM/PK;DECREASED;CONCENTRATIONS;;WOMEN;DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
ATORVASTATIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;DECREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1, CYP2C19*2;METABOLISM/PK;INCREASED;DOSE;;HEALTHY;;CAUTION_DOSE_ADJUST
CILOSTAZOL;CYP2C19;*2 + *3;CYP2C19*1, CYP2C19*2, CYP2C19*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
CODEINE, DEBRISOQUINE, DEXTROMETHORPHAN, METOPROLOL;CYP2D6;*5/*17;CYP2D6*1, CYP2D6*5, CYP2D6*17;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*1, CYP2C19*2, CYP2C19*3;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
SORAFENIB;UGT1A1;*1/*28 + *28/*28;UGT1A1*1, UGT1A1*28;METABOLISM/PK;INCREASED;EXPOSURE;;PEOPLE;DISEASE:NEOPLASMS;CAUTION_DRUG_ACCUMULATION
METOPROLOL;CYP2D6;*29/*29;CYP2D6*1, CYP2D6*2, CYP2D6*29;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;*1/*3;CYP2C9*1, CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
FLUOXETINE;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);SLC6A4 HTTLPR LONG FORM (L ALLELE), SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOBAZAM;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;METABOLISM/PK;DECREASED;DOSE;;PEOPLE;DISEASE:EPILEPSY;CAUTION_DOSE_ADJUST
DEXTROMETHORPHAN;CYP2D6;*17;CYP2D6*1, CYP2D6*17;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
CLOBAZAM;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;METABOLISM/PK;;METABOLISM;;PEOPLE;DISEASE:EPILEPSY;CAUTION_DOSE_ADJUST
OMEPRAZOLE;CYP2C19;*2;CYP2C19*1, CYP2C19*2, CYP2C19*17;METABOLISM/PK;DECREASED;CLEARANCE;;INFANTS;DISEASE:GASTROESOPHAGEAL_REFLUX;CAUTION_DRUG_ACCUMULATION
ATENOLOL, ENALAPRIL;ACE;del/del;rs1799752;EFFICACY;INCREASED;RESISTANCE;;PEOPLE;DISEASE:KIDNEY_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
MERCAPTOPURINE;TPMT;*1/*3C + *1/*2 + *1/*3A;TPMT*1, TPMT*2, TPMT*3A, TPMT*3C;DOSAGE;DECREASED;DOSE;;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DOSE_ADJUST
CLOBAZAM;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;METABOLISM/PK;;METABOLISM;;PEOPLE;DISEASE:EPILEPSY;CAUTION_DOSE_ADJUST
CLOBAZAM;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED;RESISTANCE;;PEOPLE;DISEASE:EPILEPSY;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;GT + TT;rs3745274;METABOLISM/PK;INCREASED;CONCENTRATIONS;;WOMEN;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
LOPINAVIR;CYP3A4;*22/*22;CYP3A4*1, CYP3A4*22;METABOLISM/PK;DECREASED;CLEARANCE;;PEOPLE;OTHER:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
CLOBAZAM;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;METABOLISM/PK;;METABOLISM;;PEOPLE;DISEASE:EPILEPSY;CAUTION_DOSE_ADJUST
CLOBAZAM;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:EPILEPSY;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;CYP2A6;*4/*9 + *9/*9;CYP2A6*1, CYP2A6*4, CYP2A6*9;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2;METABOLISM/PK;INCREASED;METABOLISM;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C9*1, CYP2C9*2, CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
EFAVIRENZ;ABCB1;C;rs3842;METABOLISM/PK;;METABOLISM;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DOSE_ADJUST
CLOBAZAM;CYP2C19;*1/*2;CYP2C19*1, CYP2C19*2;METABOLISM/PK;;METABOLISM;;PEOPLE;DISEASE:EPILEPSY;CAUTION_DOSE_ADJUST
CAPTOPRIL;ACE;del/del;rs1799752;EFFICACY;DECREASED;RESPONSE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
CITALOPRAM, FLUOXETINE;SERPINE1;G;rs2227631;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
PHENYTOIN;CYP2C9;GT/del + del/del;rs71486745;DOSAGE, METABOLISM/PK;DECREASED;DOSE;;PEOPLE;DISEASE:EPILEPSY;CAUTION_DOSE_ADJUST
ATENOLOL, HYDROCHLOROTHIAZIDE, METOPROLOL;SLC25A31;TTA/del;rs201279313;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
VORICONAZOLE;CYP2C19;*1/*17;CYP2C19*1, CYP2C19*2, CYP2C19*17;METABOLISM/PK;INCREASED;METABOLISM;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CC;rs776746;DOSAGE, METABOLISM/PK;DECREASED;DOSE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
CAPTOPRIL;ACE;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;rs1799752;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:DIABETES_MELLITUS;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;rs45445694;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3 + *1/*6 + *1/*7;CYP3A5*1, CYP3A5*3, CYP3A5*6, CYP3A5*7;DOSAGE;INCREASED;DOSE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TAMOXIFEN;CYP2C19;*17;CYP2C19*1, CYP2C19*17;EFFICACY, METABOLISM/PK;DECREASED;RESPONSE;;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*1/*1;CYP2C9*1, CYP2C9*2, CYP2C9*3;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
TAMOXIFEN;CYP2C19;*2;CYP2C19*1, CYP2C19*2;EFFICACY, METABOLISM/PK;INCREASED;RESPONSE;;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPTOPRIL;ACE;del/del;rs1799752;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:HEART_FAILURE;LIKELIHOOD_THERAPEUTIC_FAILURE
MERCAPTOPURINE;CNNM2;CC + CT;rs58700372;METABOLISM/PK;DECREASED;METABOLISM;;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DRUG_ACCUMULATION
OXYCODONE;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;DOSAGE;INCREASED;DOSE;;PEOPLE;DISEASE:NEOPLASMS;CAUTION_DOSE_ADJUST
VORICONAZOLE;CYP2C19;*1/*1 + *1/*17;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;METABOLISM/PK;DECREASED;TROUGH_CONCENTRATION;;PEOPLE;DISEASE:HEMATOLOGIC_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
MONTELUKAST;UGT1A3;*2;UGT1A3*1, UGT1A3*2;METABOLISM/PK;DECREASED;CONCENTRATIONS;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
PHENYTOIN;CYP2C9;*1/*2;CYP2C9*1, CYP2C9*2;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;TYMS;TTAAAGTTA/del;rs11280056;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;INCREASED;METABOLISM;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
PRIMAQUINE;CYP2D6;*4/*41 + *1/*4 + *10/*10 + *10/*41 + *2/*4 + *41/*41;CYP2D6*1, CYP2D6*2, CYP2D6*4, CYP2D6*9, CYP2D6*10, CYP2D6*41;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:MALARIA;LIKELIHOOD_THERAPEUTIC_FAILURE
PHENYTOIN;CYP2C9;*1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C9*1, CYP2C9*2, CYP2C9*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
SERTRALINE;ACE;del/del;rs1799752;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
ROSUVASTATIN;ABCC2;C;rs17216177;METABOLISM/PK;DECREASED;EXPOSURE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
PHENYTOIN;CYP2C9;*1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C9*1, CYP2C9*2, CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
PRIMAQUINE;CYP2D6;*4/*41 + *5/*6;CYP2D6*1, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*10, CYP2D6*41;METABOLISM/PK;DECREASED;CLEARANCE;;PEOPLE;DISEASE:MALARIA;CAUTION_DRUG_ACCUMULATION
CILOSTAZOL;CYP3A5;*1/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;DECREASED;CONCENTRATIONS;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;*10/*10 + *5/*10;CYP2D6*1, CYP2D6*5, CYP2D6*10;METABOLISM/PK;DECREASED;CONCENTRATIONS;;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
RASAGILINE;SLC22A1;CT;rs12208357;METABOLISM/PK;DECREASED;CLEARANCE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;;CHILDREN;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
ESOMEPRAZOLE, PANTOPRAZOLE;CYP2C19;*2/*2 + *2/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HELICOBACTER_INFECTIONS;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A7;*1A/*1A;CYP3A7*1A, CYP3A7*1C;METABOLISM/PK;DECREASED;CONCENTRATIONS;;CHILDREN;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1, CYP2C9*2, CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
COTININE, NICOTINE;CYP2A6;*2 + *4 + *9 + *12;CYP2A6*1, CYP2A6*2, CYP2A6*4, CYP2A6*9, CYP2A6*12;METABOLISM/PK;DECREASED;CLEARANCE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
KETAMINE;CYP2B6;*6;CYP2B6*1, CYP2B6*6;METABOLISM/PK;DECREASED;CLEARANCE;;PEOPLE;DISEASE:NEOPLASMS, DISEASE:PAIN;CAUTION_DRUG_ACCUMULATION
DEBRISOQUINE;CYP2D6;*10/*10;CYP2D6*1, CYP2D6*10;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
ESOMEPRAZOLE, PANTOPRAZOLE;CYP2C19;*2/*2 + *2/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HELICOBACTER_INFECTIONS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ROSUVASTATIN;ABCC2;T;rs7899457;METABOLISM/PK;DECREASED;EXPOSURE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
ESOMEPRAZOLE, LANSOPRAZOLE, OMEPRAZOLE, PANTOPRAZOLE, RABEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:HELICOBACTER_INFECTIONS;LIKELIHOOD_THERAPEUTIC_FAILURE
ESOMEPRAZOLE, LANSOPRAZOLE, OMEPRAZOLE, PANTOPRAZOLE, RABEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:HELICOBACTER_INFECTIONS;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;VKORC1;AA + AG;rs9934438;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:HELICOBACTER_INFECTIONS;LIKELIHOOD_THERAPEUTIC_FAILURE
ROSUVASTATIN;ABCC2;A;rs8187706;METABOLISM/PK;DECREASED;EXPOSURE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
FLURBIPROFEN;CYP2C9;*1/*1;CYP2C9*1, CYP2C9*3;METABOLISM/PK;INCREASED;CLEARANCE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:HELICOBACTER_INFECTIONS;LIKELIHOOD_THERAPEUTIC_FAILURE
PITAVASTATIN;ABCC2;T;rs717620;METABOLISM/PK;DECREASED;EXPOSURE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
ETHANOL;SLC6A3;del;rs28363170;OTHER;INCREASED;RESPONSE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHANOL;DRD2;A;rs1800497;DOSAGE;INCREASED;DOSE;;CHILDREN;;CAUTION_DOSE_ADJUST
VARDENAFIL;CYP3A5;TT;rs776746;OTHER, METABOLISM/PK;INCREASED;CLEARANCE;;MEN;;LIKELIHOOD_THERAPEUTIC_FAILURE
SIPOGLITAZAR;UGT2B15;*2;UGT2B15*1, UGT2B15*2;METABOLISM/PK;DECREASED;CLEARANCE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
ETHANOL;SLC6A3;del;rs28363170;TOXICITY;INCREASED;EXPOSURE;;HEALTHY;;CAUTION_SIDE_EFFECT
ETHANOL;OPRM1;G;rs1799971;DOSAGE;INCREASED;DOSE;;CHILDREN;;CAUTION_DOSE_ADJUST
IMATINIB;SLC22A1;CC;rs683369;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;OTHER:GASTROINTESTINAL_STROMAL_TUMORS;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;INCREASED;RESISTANCE;;PEOPLE;DISEASE:GASTROESOPHAGEAL_REFLUX;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED;RESISTANCE;;PEOPLE;DISEASE:GASTROESOPHAGEAL_REFLUX;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACETAMINOPHEN;UGT1A6;*2a;UGT1A6*1A, UGT1A6*2A;METABOLISM/PK;INCREASED;CLEARANCE;;PEOPLE;DISEASE:BETA-THALASSEMIA_AND_RELATED_DISEASES;LIKELIHOOD_THERAPEUTIC_FAILURE
ACENOCOUMAROL;CYP2C9;*3;CYP2C9*1, CYP2C9*3;DOSAGE;DECREASED;DOSE;;PEOPLE;DISEASE:ATRIAL_FIBRILLATION, DISEASE:ATRIAL_FLUTTER,DISEASE:VENOUS_THROMBOSIS;CAUTION_DOSE_ADJUST
ACETAMINOPHEN;UGT1A6;*2a/*2a + *1a/*2a;UGT1A6*1A, UGT1A6*2A;METABOLISM/PK;INCREASED;METABOLISM;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;DOSAGE;INCREASED;DOSE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
ACETAMINOPHEN;UGT2B15;*2;UGT2B15*1, UGT2B15*2;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
HALOPERIDOL;CYP2D6;*10;CYP2D6*1, CYP2D6*10;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_DRUG_ACCUMULATION
METHADONE;OPRK1;TT;rs3802281;DOSAGE;DECREASED;DOSE;;PEOPLE;OTHER:HEROIN_DEPENDENCE;CAUTION_DOSE_ADJUST
DEBRISOQUINE;CYP2D6;*1/*17;CYP2D6*1, CYP2D6*2, CYP2D6*17;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
DEBRISOQUINE;CYP2D6;*17/*17;CYP2D6*1, CYP2D6*2, CYP2D6*17;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
AZATHIOPRINE;TPMT;CT;rs1142345;DOSAGE;DECREASED;DOSE;;CHILDREN;OTHER:ULCERATIVE_COLITIS, OTHER:CROHN_DISEASE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;INCREASED;METABOLISM;;CHILDREN;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
TOLTERODINE;CYP2D6;*3 + *4;CYP2D6*1, CYP2D6*3, CYP2D6*4;METABOLISM/PK;DECREASED;METABOLISM;;WOMEN;;CAUTION_DRUG_ACCUMULATION
CITALOPRAM, MIANSERIN, MIRTAZAPINE, NORTRIPTYLINE, PAROXETINE, VENLAFAXINE;CYP2D6;*1xN + *2xN;CYP2D6*1XN, CYP2D6*2XN;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:MOOD_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;DECREASED;CONCENTRATIONS;;PEOPLE;DISEASE:AUTOIMMUNE_DISEASES;LIKELIHOOD_THERAPEUTIC_FAILURE
HYDROXYUREA;SIN3A;GG;rs7166737;EFFICACY;DECREASED;RESPONSE;;PEOPLE;OTHER:BETA-THALASSEMIA_AND_RELATED_DISEASES;LIKELIHOOD_THERAPEUTIC_FAILURE
RABEPRAZOLE;CYP2C19;*2/*2 + *2/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;METABOLISM/PK;DECREASED;CLEARANCE;;PEOPLE;DISEASE:HELICOBACTER_INFECTIONS;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
FLUOXETINE;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);SLC6A4 HTTLPR LONG FORM (L ALLELE), SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
HYDRALAZINE;NAT2;;SLOW_ACETYLATOR;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;OTHER:HYPERTENSION;CAUTION_DRUG_ACCUMULATION
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;TT;rs1799964;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:ANKYLOSING_SPONDYLITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;*1/*3;CYP2C9*1, CYP2C9*3;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PROPAFENONE;CYP2D6;*10/*10;CYP2D6*1, CYP2D6*10;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
VENLAFAXINE;CYP2D6;;POOR_METABOLIZER;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*1/*1 + *1/*6;CYP3A5*1, CYP3A5*6;METABOLISM/PK;INCREASED;CLEARANCE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
CAPECITABINE, RALTITREXED;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1 + *1/*7;CYP3A5*1, CYP3A5*7;METABOLISM/PK;INCREASED;CLEARANCE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*1/*1;CYP2C9*1, CYP2C9*3;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;LIKELIHOOD_THERAPEUTIC_FAILURE
VENLAFAXINE;CYP2D6;;POOR_METABOLIZER;METABOLISM/PK;DECREASED;METABOLISM;;;OTHER:ELDERLY_ADULT;CAUTION_DRUG_ACCUMULATION
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL4;G/TT + TT/TT;rs11322783;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
VENLAFAXINE;CYP2D6;;NORMAL_METABOLIZER;METABOLISM/PK;DECREASED;METABOLISM;;;OTHER:ELDERLY_ADULT;CAUTION_DRUG_ACCUMULATION
RASAGILINE;SLC22A1;AG;rs34059508;METABOLISM/PK;INCREASED;CLEARANCE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
ESCITALOPRAM;CYP2C19;;NORMAL_METABOLIZER;METABOLISM/PK;DECREASED;METABOLISM;;;OTHER:ELDERLY_ADULT;CAUTION_DRUG_ACCUMULATION
PHENYTOIN;CYP2C9;*1/*3;CYP2C9*1, CYP2C9*3;TOXICITY;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:EPILEPSY;CAUTION_SIDE_EFFECT
LOVASTATIN ACID;SLCO1B1;*5/*15 + *15/*15;SLCO1B1*1, SLCO1B1*5, SLCO1B1*15;METABOLISM/PK;INCREASED;EXPOSURE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
PHENYTOIN;CYP2C9;*1/*3 + *2/*3;CYP2C9*1, CYP2C9*2, CYP2C9*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;;CHILDREN;;CAUTION_DRUG_ACCUMULATION
FLURBIPROFEN;CYP2C9;*1/*3;CYP2C9*1, CYP2C9*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
AMBRISENTAN;CYP2C19;*2 + *3 + *4;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*4, CYP2C19*17;METABOLISM/PK;DECREASED;CLEARANCE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;*6/*6;CYP2B6*1, CYP2B6*6;METABOLISM/PK;DECREASED;CLEARANCE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
CYCLOPHOSPHAMIDE;CYP2B6;*6;CYP2B6*1, CYP2B6*6;METABOLISM/PK;DECREASED;CLEARANCE;;CHILDREN;DISEASE:B-CELL_LYMPHOMA;CAUTION_DRUG_ACCUMULATION
SERTRALINE;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);SLC6A4 HTTLPR LONG FORM (L ALLELE), SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:POSTTRAUMATIC_STRESS_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
RASAGILINE;ABCC2;AA;rs2273697;METABOLISM/PK;DECREASED;CLEARANCE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
BUPROPION;HTR2A;CC;rs2770296;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE, FLUOROURACIL;HLA-G;ATTTGTTCATGCCT/ATTTGTTCATGCCT + ATTTGTTCATGCCT/del;rs371194629;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
VORICONAZOLE;CYP2C19;*2/*2 + *2/*3;POOR_METABOLIZER;METABOLISM/PK;INCREASED;TROUGH_CONCENTRATION;;PEOPLE;DISEASE:FUNGAL_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
PRAVASTATIN;KIF6;AG + GG;rs20455;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:MYOCARDIAL_INFARCTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUVOXAMINE;SLC6A4;HTTLPR short form (S allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;*1/*3;CYP3A5*1, CYP3A5*3;DOSAGE;INCREASED;DOSE;;CHILDREN;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
VORICONAZOLE;CYP2C19;*2/*2;CYP2C19*1, CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;*2/*3 + *3/*3;CYP2C9*1, CYP2C9*2, CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*3;CYP2C9*1, CYP2C9*3;DOSAGE;DECREASED;DOSE;;CHILDREN;;CAUTION_DOSE_ADJUST
DONEPEZIL;CYP2D6;;POOR_METABOLIZER;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:ALZHEIMER_DISEASE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*1/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;CHILDREN;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;CYP2D6;*10/*10;CYP2D6*1, CYP2D6*10;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;CYP2D6;*4/*4 + *4/*5 + *4/*6;CYP2D6*1, CYP2D6*4, CYP2D6*5, CYP2D6*6;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
FLUOXETINE;ABCB1;A;rs2032582;EFFICACY;INCREASED;RESPONSE;;CHILDREN;DISEASE:DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
4-HYDROXYTAMOXIFEN, ENDOXIFEN;CYP2D6;*4/*4 + *4/*5;CYP2D6*1, CYP2D6*4, CYP2D6*5;METABOLISM/PK;DECREASED;CONCENTRATIONS;;WOMEN;;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;DECREASED;EXPOSURE;;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
DEXTROMETHORPHAN;CYP2D6;*10/*10 + *1/*10;CYP2D6*1, CYP2D6*10;METABOLISM/PK;INCREASED;EXPOSURE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
BUPROPION;CYP2B6;*1/*6 + *6/*6;CYP2B6*1, CYP2B6*6;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:TOBACCO_USE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
RABEPRAZOLE;CYP2C19;*2/*2;CYP2C19*1, CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
DIPYRONE;CYP2C19;*2;CYP2C19*1, CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
FLUOXETINE, SERTRALINE;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR LONG FORM (L ALLELE), SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
TEGAFUR;CYP2A6;*1/*4 + *4/*4 + *4/*7 + *4/*9;CYP2A6*1, CYP2A6*4, CYP2A6*7, CYP2A6*9;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_DRUG_ACCUMULATION
ESCITALOPRAM;SLC6A4;HTTLPR short form (S allele);SLC6A4 HTTLPR LONG FORM (L ALLELE), SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
AZATHIOPRINE;GSTM1;;GSTM1 NON-NULL, GSTM1 NULL;EFFICACY;DECREASED;CLINICAL_BENEFIT;;CHILDREN;OTHER:ULCERATIVE_COLITIS, OTHER:CROHN_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;CYP2D6;*4/*10 + *5/*10;CYP2D6*1, CYP2D6*2, CYP2D6*4, CYP2D6*5, CYP2D6*10;METABOLISM/PK;DECREASED;METABOLISM;;CHILDREN;;CAUTION_DRUG_ACCUMULATION
NILOTINIB;UGT1A1;*6/*6 + *6/*28;UGT1A1*1, UGT1A1*6, UGT1A1*27, UGT1A1*28;DOSAGE;DECREASED;DOSE;;PEOPLE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;CAUTION_DOSE_ADJUST
COTININE, NICOTINE;CYP2B6;*1/*6;CYP2B6*1, CYP2B6*6;METABOLISM/PK;INCREASED;CLEARANCE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*3 + *2/*2 + *1/*5 + *2/*5;CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*5;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
METHADONE;CYP2B6;*6;CYP2B6*1, CYP2B6*6;METABOLISM/PK;DECREASED;CLEARANCE;;PEOPLE;DISEASE:OPIOID-RELATED_DISORDERS;CAUTION_DRUG_ACCUMULATION
BUPROPION;DBH;CC;rs2873804;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS, DISEASE:SYSTEMIC_LUPUS_ERYTHEMATOSUS;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;rs45445694;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:NEOPLASM_OF_ESOPHAGUS, DISEASE:STOMACH_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
HYDRALAZINE;NAT2;;SLOW_ACETYLATOR;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;OTHER:HYPERTENSION;CAUTION_DRUG_ACCUMULATION
PACLITAXEL, PLATINUM COMPOUNDS;GSTM1;non-null;GSTM1 NON-NULL, GSTM1 NULL;EFFICACY;DECREASED;RESPONSE;;WOMEN;DISEASE:OVARIAN_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
BLEOMYCIN, DACARBAZINE, DOXORUBICIN, VINBLASTINE;GSTM1;non-null/non-null;GSTM1 NON-NULL, GSTM1 NULL;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HODGKIN_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CITALOPRAM;CYP2C19;*2;CYP2C19*1, CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DRUG_ACCUMULATION
ENALAPRIL, LISINOPRIL;ACE;del/del;rs1799752;EFFICACY;INCREASED;CLINICAL_BENEFIT;;MEN;OTHER:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;*1/*3 + *3/*3;CYP3A5*1, CYP3A5*3;DOSAGE;DECREASED;DOSE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TRIMIPRAMINE;CYP2C9;*3/*3;CYP2C9*3;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
BUPROPION;SLC18A2;CC;rs363225;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
TRIMIPRAMINE;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6;METABOLISM/PK;DECREASED;CLEARANCE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
METHADONE;CYP2B6;*1/*4 + *4/*6;CYP2B6*1, CYP2B6*4, CYP2B6*6;METABOLISM/PK;INCREASED;CLEARANCE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;INCREASED;RESPONSE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OMEPRAZOLE;CYP2C19;*2/*2 + *2/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;INCREASED;RESPONSE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RALTEGRAVIR;UGT1A9;*3a;UGT1A9*3A;METABOLISM/PK;INCREASED;EXPOSURE;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
OMEPRAZOLE;CYP2C19;*2/*2 + *2/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;INCREASED;RESPONSE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUVOXAMINE;CYP2D6;;POOR_METABOLIZER;METABOLISM/PK;DECREASED;CLEARANCE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
METHADONE;CYP2B6;*1/*6 + *6/*6;CYP2B6*1, CYP2B6*6;METABOLISM/PK;DECREASED;CLEARANCE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
FLUVOXAMINE;CYP2D6;;POOR_METABOLIZER;METABOLISM/PK;DECREASED;CLEARANCE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
SERTRALINE;CYP2C18;TT;rs2860840;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
ACENOCOUMAROL;CYP2C9;*2 + *3;CYP2C9*1, CYP2C9*2, CYP2C9*3;DOSAGE;DECREASED;DOSE;;PEOPLE;DISEASE:RHEUMATIC_HEART_DISEASE;CAUTION_DOSE_ADJUST
ARIPIPRAZOLE;CYP2D6;;POOR_METABOLIZER;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:SCHIZOAFFECTIVE_DISORDER, DISEASE:SCHIZOPHRENIA;CAUTION_DRUG_ACCUMULATION
4-HYDROXYTAMOXIFEN;CYP3A4;*22;CYP3A4*1, CYP3A4*22;METABOLISM/PK;INCREASED;CONCENTRATIONS;;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_DRUG_ACCUMULATION
TAMOXIFEN;CYP3A4;*22;CYP3A4*1, CYP3A4*22;METABOLISM/PK;INCREASED;CONCENTRATIONS;;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_DRUG_ACCUMULATION
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;METABOLISM/PK;INCREASED;METABOLISM;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:RECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
VORICONAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;METABOLISM/PK;DECREASED;TROUGH_CONCENTRATION;;PEOPLE;DISEASE:FUNGAL_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;CC;rs1799724;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:ANKYLOSING_SPONDYLITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
HYDROXYAMITRIPTYLINE;CYP2D6;*10/*10;CYP2D6*1, CYP2D6*10;METABOLISM/PK;DECREASED;CONCENTRATIONS;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
AMITRIPTYLINE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;METABOLISM/PK;INCREASED;EXPOSURE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
ACETYLCYSTEINE;EPHX1;;POOR_METABOLIZER;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_OBSTRUCTIVE_PULMONARY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUPROPION;SLC18A2;GG;rs363226;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;*2;CYP2C9*1, CYP2C9*2;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
METHOTREXATE;C18orf56, TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;rs45445694;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
OLANZAPINE;GSTM3;CCT/CCT;rs1799735;METABOLISM/PK;INCREASED;CLEARANCE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
LEVODOPA, METHYLPHENIDATE;SLC6A3;ACATACACACTCAGACACACATACCATGCA/ACATACACACTCAGACACACATACCATGCA;rs3836790;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:PARKINSON_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATOMOXETINE;CYP2D6;*4/*4xN + *4/*4;CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*4XN, CYP2D6*5, CYP2D6*9, CYP2D6*10, CYP2D6*29, CYP2D6*41;METABOLISM/PK;DECREASED;CLEARANCE;;CHILDREN;DISEASE:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;*3/*3;CYP2C9*1, CYP2C9*3;DOSAGE, EFFICACY;DECREASED;DOSE;;CHILDREN;DISEASE:HEART_DISEASES;CAUTION_DOSE_ADJUST
LEVODOPA;SLC6A3;ACATACACACTCAGACACACATACCATGCA/ACATACACACTCAGACACACATACCATGCA;rs3836790;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:PARKINSON_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;DPYD;;DEFICIENCY;METABOLISM/PK;;CLEARANCE;;PEOPLE;DISEASE:HEAD_AND_NECK_NEOPLASMS;CAUTION_DOSE_ADJUST
ATOMOXETINE;CYP2D6;*4/*4xN + *4/*4;CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*4XN, CYP2D6*5, CYP2D6*9, CYP2D6*10, CYP2D6*17, CYP2D6*29, CYP2D6*41;METABOLISM/PK;INCREASED;CONCENTRATIONS;;CHILDREN;DISEASE:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY;CAUTION_DRUG_ACCUMULATION
BUPROPION;FKBP5;TT;rs17614642;EFFICACY;DECREASED;RESPONSE;;PEOPLE;OTHER:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
ATAZANAVIR;CYP3A5;*3 + *6 + *7;CYP3A5*1, CYP3A5*3, CYP3A5*6, CYP3A5*7;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;*1/*3;CYP2C9*1, CYP2C9*3;DOSAGE, EFFICACY;DECREASED;DOSE;;CHILDREN;DISEASE:HEART_DISEASES;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*2;CYP2C9*1, CYP2C9*2;DOSAGE, EFFICACY;DECREASED;DOSE;;CHILDREN;DISEASE:HEART_DISEASES;CAUTION_DOSE_ADJUST
INTERFERON BETA-1A;ACE;del/del;rs1799752;EFFICACY;DECREASED;RESPONSE;;MEN;DISEASE:MULTIPLE_SCLEROSIS;LIKELIHOOD_THERAPEUTIC_FAILURE
ETHANOL;OPRM1;AG;rs1799971;EFFICACY;INCREASED;RESPONSE;;MEN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RABEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2;METABOLISM/PK;INCREASED;METABOLISM;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*2/*2;CYP2C19*1, CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
ACENOCOUMAROL;CYP2C9;*2 + *3;CYP2C9*1, CYP2C9*2, CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;EPHX1;CG;rs2260863;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;DISEASE:LUNG_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
PANTOPRAZOLE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED;RESPONSE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
CAPTOPRIL;ACE;del/del;rs1799752;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:ESOPHAGITIS, DISEASE:GASTROESOPHAGEAL_REFLUX;LIKELIHOOD_THERAPEUTIC_SUCCESS
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED;RESPONSE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
LOSARTAN;ACE;del/del;rs1799752;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A4;GG;rs35599367;METABOLISM/PK;INCREASED;METABOLISM;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
THALIDOMIDE;CYP2C19;*2;CYP2C19*1, CYP2C19*2;DOSAGE;INCREASED;DOSE;;PEOPLE;DISEASE:ERYTHEMA_NODOSUM, DISEASE:LEPROSY;CAUTION_DOSE_ADJUST
CARVEDILOL;CYP2D6;*10;CYP2D6*10;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:ANGINA_PECTORIS;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;*1/*1;CYP2B6*1;METABOLISM/PK;INCREASED;CLEARANCE;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*3;CYP2C9*1, CYP2C9*3;DOSAGE;DECREASED;DOSE;;PEOPLE;OTHER:ATRIAL_FIBRILLATION, OTHER:PULMONARY_EMBOLISM,OTHER:VENOUS_THROMBOSIS;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;METABOLISM;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;INCREASED;CLEARANCE;;CHILDREN;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
VORICONAZOLE;CYP2C19;*1/*17 + *17/*17;CYP2C19*1, CYP2C19*17;METABOLISM/PK;INCREASED;METABOLISM;;PEOPLE;DISEASE:FUNGAL_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C9*1, CYP2C9*2, CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3 + *1/*6;CYP3A5*1, CYP3A5*3, CYP3A5*6;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
NICOTINE;CYP2A6;;LOW ACTIVITY;DOSAGE;DECREASED;DOSE;;PEOPLE;DISEASE:TOBACCO_USE_DISORDER;CAUTION_DOSE_ADJUST
VORICONAZOLE;CYP2C19;*1/*2;CYP2C19*1, CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:FUNGAL_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;*1/*3 + *2/*3;CYP2C9*1, CYP2C9*2, CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
VORICONAZOLE;CYP2C19;*1/*17 + *17/*17;CYP2C19*1, CYP2C19*17;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;DISEASE:FUNGAL_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*2;CYP2C9*1, CYP2C9*2;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
IMATINIB;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;TROUGH_CONCENTRATION;;PEOPLE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;CAUTION_DRUG_ACCUMULATION
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:HELICOBACTER_INFECTIONS;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:GASTROESOPHAGEAL_REFLUX;LIKELIHOOD_THERAPEUTIC_FAILURE
PACLITAXEL;SLCO1B1;*5 + *15;SLCO1B1*5, SLCO1B1*15;METABOLISM/PK;INCREASED;EXPOSURE;;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_DRUG_ACCUMULATION
IMIPRAMINE;CYP2C19;*2/*3 + *2/*2;CYP2C19*1, CYP2C19*2, CYP2C19*3;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DRUG_ACCUMULATION
RABEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;METABOLISM/PK;INCREASED;METABOLISM;;PEOPLE;DISEASE:GASTROESOPHAGEAL_REFLUX;LIKELIHOOD_THERAPEUTIC_FAILURE
LAMOTRIGINE;UGT2B7;CC;rs7668258;DOSAGE, METABOLISM/PK;INCREASED;CLEARANCE;;;;CAUTION_DOSE_ADJUST
RABEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;METABOLISM/PK;INCREASED;METABOLISM;;PEOPLE;DISEASE:GASTROESOPHAGEAL_REFLUX;LIKELIHOOD_THERAPEUTIC_FAILURE
BUPRENORPHINE;UGT2B7;*2;UGT2B7;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:PAIN;LIKELIHOOD_THERAPEUTIC_FAILURE
VORICONAZOLE;CYP2C19;*1/*17 + *17/*17;CYP2C19*1, CYP2C19*17;DOSAGE;INCREASED;DOSE;;PEOPLE;DISEASE:FUNGAL_INFECTIOUS_DISEASE;CAUTION_DOSE_ADJUST
VORICONAZOLE;CYP2C19;*1/*2 + *2/*2;CYP2C19*1, CYP2C19*2;METABOLISM/PK;INCREASED;TROUGH_CONCENTRATION;;PEOPLE;DISEASE:FUNGAL_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
IMATINIB;ABCB1;AG;rs1045642;METABOLISM/PK;DECREASED;TROUGH_CONCENTRATION;;PEOPLE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;LIKELIHOOD_THERAPEUTIC_FAILURE
VORICONAZOLE;CYP2C19;*1/*17 + *17/*17;CYP2C19*1, CYP2C19*17;METABOLISM/PK;DECREASED;TROUGH_CONCENTRATION;;PEOPLE;DISEASE:FUNGAL_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
TOLBUTAMIDE;CYP2C9;*1/*3 + *2/*3 + *3/*3;CYP2C9*1, CYP2C9*2, CYP2C9*3;METABOLISM/PK;DECREASED;CLEARANCE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
BUPROPION;CYP2B6;*6/*6;CYP2B6*1, CYP2B6*6;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
BUPROPION;CYP2B6;*1/*4 + *4/*6;CYP2B6*1, CYP2B6*4, CYP2B6*6;METABOLISM/PK;INCREASED;METABOLISM;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;;CYP2D6 POOR_METABOLIZER, INTERMEDIATE_METABOLIZER;METABOLISM/PK;;CONCENTRATIONS;;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_DOSE_ADJUST
ZAFIRLUKAST;CYP2C9;*1/*3 + *1/*13;CYP2C9*1, CYP2C9*3, CYP2C9*13;METABOLISM/PK;INCREASED;EXPOSURE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
DEXLANSOPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
ZAFIRLUKAST;CYP2C9;*1/*3 + *1/*13;CYP2C9*1, CYP2C9*3, CYP2C9*13;METABOLISM/PK;DECREASED;CLEARANCE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
NELFINAVIR;CYP2C19;*1/*2;CYP2C19*1, CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;;CAUTION_DRUG_ACCUMULATION
HYDROXYBUPROPION;CYP2B6;*6/*6;CYP2B6*1, CYP2B6*6;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
NELFINAVIR;CYP2C19;*1/*2;CYP2C19*1, CYP2C19*2;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:PANCREATIC_NEOPLASMS;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1, CYP2C9*2, CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*3;CYP2C9*1, CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
BUPROPION;CYP2B6;*1/*6 + *1/*18;CYP2B6*1, CYP2B6*4, CYP2B6*5, CYP2B6*6, CYP2B6*18, CYP2B6*22;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:TOBACCO_USE_DISORDER;CAUTION_DRUG_ACCUMULATION
IVACAFTOR, TEZACAFTOR;CFTR;del/del;rs113993960;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:CYSTIC_FIBROSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIR;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUPROPION;CYP2B6;*6/*6 + *6/*18;CYP2B6*1, CYP2B6*4, CYP2B6*5, CYP2B6*6, CYP2B6*18, CYP2B6*22;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:TOBACCO_USE_DISORDER;CAUTION_DRUG_ACCUMULATION
IVACAFTOR, TEZACAFTOR;CFTR;CTT/del;rs113993960;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:CYSTIC_FIBROSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C19;*1/*2 + *1/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;DOSAGE;INCREASED;DOSE;;PEOPLE;DISEASE:ATRIAL_FIBRILLATION;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;DOSAGE;INCREASED;DOSE;;PEOPLE;DISEASE:ATRIAL_FIBRILLATION;CAUTION_DOSE_ADJUST
ATOMOXETINE;CYP2D6;*10/*10;CYP2D6*1, CYP2D6*2, CYP2D6*10;METABOLISM/PK;DECREASED;CLEARANCE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*1/*1 + *1/*3 + *1/*6;CYP3A5*1, CYP3A5*3, CYP3A5*6;DOSAGE;INCREASED;DOSE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
ATOMOXETINE;CYP2D6;;POOR_METABOLIZER;DOSAGE;DECREASED;DOSE;;CHILDREN;DISEASE:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY;CAUTION_DOSE_ADJUST
LANSOPRAZOLE;CYP2C19;*1/*1 + *1/*2 + *1/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;METABOLISM/PK;INCREASED;METABOLISM;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*1 + *1/*2 + *1/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;METABOLISM/PK;INCREASED;METABOLISM;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
GEMCITABINE;CDA;A;rs60369023;OTHER, METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:NEOPLASMS;CAUTION_DRUG_ACCUMULATION
APIXABAN, DABIGATRAN, EDOXABAN, RIVAROXABAN;ABCB1;GG;rs1045642;METABOLISM/PK;DECREASED;CONCENTRATIONS;;PEOPLE;OTHER:THROMBOEMBOLISM;LIKELIHOOD_THERAPEUTIC_FAILURE
ATAZANAVIR;NR1I2;TT;rs2472677;METABOLISM/PK;DECREASED;CONCENTRATIONS;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
IMATINIB;ABCB1;A;rs2032582;EFFICACY;INCREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIDEPRESSANTS;FKBP5;CC;rs1360780;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
IMATINIB;ABCB1;A;rs1128503;EFFICACY;INCREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;TT;rs776746;METABOLISM/PK;INCREASED;METABOLISM;;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIDEPRESSANTS;GNB3;CC + CT;rs5443;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
IMATINIB;ABCB1;A;rs1045642;EFFICACY;INCREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIDEPRESSANTS;FKBP5;AC + CC;rs3800373;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;*2;CYP2C9*1, CYP2C9*2;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
METHADONE;OPRK1;CC;rs963549;DOSAGE;DECREASED;DOSE;;PEOPLE;OTHER:HEROIN_DEPENDENCE;CAUTION_DOSE_ADJUST
ANTIPSYCHOTICS;ABCB1;AA;rs1128503;DOSAGE, METABOLISM/PK;INCREASED;DOSE;;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_DOSE_ADJUST
IMATINIB;ABCG2;T;rs2231142;EFFICACY;INCREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;GT + TT;rs3745274;EFFICACY;DECREASED;RESISTANCE;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;PPARA;G;rs4823613;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
INFLIXIMAB;SLCO1C1;G;rs3794271;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
ACENOCOUMAROL;CYP2C9;*3;CYP2C9*1, CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
TACROLIMUS;POR;T;rs1057868;METABOLISM/PK;INCREASED;METABOLISM;;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
DALCETRAPIB;ADCY9;AA;rs1967309;EFFICACY;INCREASED;RESPONSE;;PEOPLE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIDEPRESSANTS;BDNF;CT;rs6265;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
BETA BLOCKING AGENTS, FLECAINIDE;ADRB1;G;rs1801253;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:TACHYCARDIA;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;ABCC2;T;rs717620;METABOLISM/PK;DECREASED;CLEARANCE;;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DRUG_ACCUMULATION
RITUXIMAB;FCGR3A;AA;rs396991;EFFICACY;INCREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:NEUROMYELITIS_OPTICA;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;*18;CYP2B6*1, CYP2B6*18;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
DRUGS USED IN ALCOHOL DEPENDENCE;GATA4;CC;rs13273672;EFFICACY;DECREASED;CLINICAL_BENEFIT;;PEOPLE;DISEASE:ALCOHOL_ABUSE;LIKELIHOOD_THERAPEUTIC_FAILURE
CHORIONIC GONADOTROPIN;FSHR;CC;rs6166;DOSAGE;INCREASED;DOSE;;WOMEN;;CAUTION_DOSE_ADJUST
BEPRIDIL;CYP2D6;*10;CYP2D6*10;METABOLISM/PK;INCREASED;CLEARANCE;;PEOPLE;DISEASE:CARDIAC_RHYTHM_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A4;GG;rs35599367;DOSAGE;INCREASED;DOSE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
NICARDIPINE, NIMODIPINE;CACNA1B;AG + GG;rs2739260;EFFICACY;INCREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:BIPOLAR_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
CITALOPRAM, ESCITALOPRAM;GLDC;G;rs10975641;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
CORTISONE ACETATE;CYP3A7;*1C;CYP3A7*1A, CYP3A7*1C;DOSAGE;DECREASED;DOSE;;CHILDREN;DISEASE:ADRENAL_HYPERPLASIA, CONGENITAL;CAUTION_DOSE_ADJUST
DAUNORUBICIN;G6PD;A-202A_376G;G6PD A- 202A_376G;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
TEGAFUR;CYP2A6;*4/*4 + *4/*7 + *7/*7;CYP2A6*1, CYP2A6*4, CYP2A6*7;METABOLISM/PK;DECREASED;CLEARANCE;;PEOPLE;DISEASE:NEOPLASMS;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2A6;*2;CYP2A6*2;OTHER, METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;*1/*3 + *3/*3;CYP2C9*1, CYP2C9*3;DOSAGE, EFFICACY;DECREASED;DOSE;;PEOPLE;OTHER:MECHANICAL_HEART_VALVE_REPLACEMENT;CAUTION_DOSE_ADJUST
METFORMIN;HNF1B;AA + AG;rs11868513;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACENOCOUMAROL;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
IBUPROFEN;CYP2C9;*3;CYP2C9*3;METABOLISM/PK;DECREASED;CLEARANCE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
ACENOCOUMAROL;CYP2C9;*3;CYP2C9*1, CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ATORVASTATIN;CYP3A4;C/C;rs2242480;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:HYPERLIPIDEMIAS;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED;RESPONSE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
ACENOCOUMAROL;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
GLATIRAMER ACETATE;HLA-DRB1;*15:01;HLA-DRB1*15:01;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:MULTIPLE_SCLEROSIS;LIKELIHOOD_THERAPEUTIC_FAILURE
ACENOCOUMAROL;CYP2C9;*2 + *3;CYP2C9*1, CYP2C9*2, CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*3;CYP2C9*1, CYP2C9*3;DOSAGE, METABOLISM/PK;DECREASED;CLEARANCE;;PEOPLE;DISEASE:CARDIOVASCULAR_DISEASE;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*3;CYP2C9*3;METABOLISM/PK;DECREASED;DOSE;;PEOPLE;DISEASE:CARDIOVASCULAR_DISEASE;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;*1/*1 + *1/*17 + *2/*17 + *3/*17;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:ANGINA_PECTORIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACENOCOUMAROL;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
CAFFEINE;NAT2;*4;NAT2*4;METABOLISM/PK;INCREASED;METABOLISM;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
ATORVASTATIN;CYP3A4;C/C;rs2242480;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:HYPERLIPIDEMIAS;LIKELIHOOD_THERAPEUTIC_FAILURE
DIAZEPAM;CYP2C19;*2 + *3;CYP2C19*1, CYP2C19*2, CYP2C19*3;OTHER, METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
"""INTERFERON ALFA-2A, RECOMBINANT"", ""INTERFERON ALFA-2B, RECOMBINANT"", ""INTERFERONS"", ""PEGINTERFERON ALFA-2A"", ""PEGINTERFERON ALFA-2B"", ""RIBAVIRIN""";IL18;T;rs1946518;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOXETINE, PAROXETINE;SLC6A4;(CCCACCCGA)12/(CCCACCCGA)12;rs57098334;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:DEPRESSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
IBUPROFEN;CYP2C9;*3;CYP2C9*3;METABOLISM/PK;DECREASED;CLEARANCE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
VENLAFAXINE;CYP2D6;*4/*4;CYP2D6*4;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;POR;CC;rs1057868;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
ACENOCOUMAROL;CYP2C9;*2;CYP2C9*2;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
THIOGUANOSINE DIPHOSPHATE, THIOGUANOSINE MONOPHOSPHATE, THIOGUANOSINE TRIPHOSPHATE;TPMT;;POOR_METABOLIZER;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:INFLAMMATORY_BOWEL_DISEASES;CAUTION_DRUG_ACCUMULATION
VALPROIC ACID;CYP2A6;*4;CYP2A6*1, CYP2A6*4;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:EPILEPSY;CAUTION_DRUG_ACCUMULATION
TEGAFUR;CYP2A6;*4;CYP2A6*1, CYP2A6*4;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
NICOTINE;CYP2A6;*1/*7;CYP2A6*1, CYP2A6*7;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;*3/*3;CYP2C9*1, CYP2C9*3;DOSAGE;DECREASED;DOSE;;PEOPLE;OTHER:A_STABLE_INTERNATIONAL_NORMALIZED_RATIO_OF_BETWEEN_TWO_AND_THREE;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2/*2;CYP2C9*1, CYP2C9*2;DOSAGE;DECREASED;DOSE;;PEOPLE;OTHER:A_STABLE_INTERNATIONAL_NORMALIZED_RATIO_OF_BETWEEN_TWO_AND_THREE;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP4F2;*3/*3;CYP4F2*1, CYP4F2*3;DOSAGE;INCREASED;DOSE;;PEOPLE;OTHER:A_STABLE_INTERNATIONAL_NORMALIZED_RATIO_OF_BETWEEN_TWO_AND_THREE;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2/*3;CYP2C9*1, CYP2C9*2, CYP2C9*3;DOSAGE;DECREASED;DOSE;;PEOPLE;OTHER:A_STABLE_INTERNATIONAL_NORMALIZED_RATIO_OF_BETWEEN_TWO_AND_THREE;CAUTION_DOSE_ADJUST
PACLITAXEL;CYP2C8;*1/*3 + *3/*3;CYP2C8*1, CYP2C8*3;EFFICACY;INCREASED;RESPONSE;;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAFFEINE;CYP2A6;*1/*4 + *1/*9 + *4/*4 + *4/*9;CYP2A6*1, CYP2A6*4, CYP2A6*9;OTHER, METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;*1/*3;CYP2C9*1, CYP2C9*3;DOSAGE, METABOLISM/PK;DECREASED;DOSE;;PEOPLE;DISEASE:THROMBOEMBOLISM;CAUTION_DOSE_ADJUST
TOCILIZUMAB;IL6R;CT + TT;rs4845625;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACENOCOUMAROL;CYP2C9;*3;CYP2C9*3;EFFICACY;INCREASED;RESPONSE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ROSUVASTATIN;ABCC2;T;rs17216198;METABOLISM/PK;DECREASED;EXPOSURE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
ATORVASTATIN;CYP3A4;T/T;rs2242480;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HYPERLIPIDEMIAS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:CARDIOVASCULAR_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUVASTATIN;CYP2C9;*2;CYP2C9*1, CYP2C9*2;METABOLISM/PK;INCREASED;CONCENTRATIONS;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
MIRTAZAPINE;CYP2B6;*6/*6;CYP2B6*6;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:DEPRESSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
SULFAPYRIDINE;NAT2;*7/*7;NAT2*7;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;SLC19A1;CT;rs1051266;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*2;CYP2C9*1, CYP2C9*2;DOSAGE, METABOLISM/PK;DECREASED;CLEARANCE;;PEOPLE;DISEASE:CARDIOVASCULAR_DISEASE;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2;CYP2C9*2;METABOLISM/PK;DECREASED;DOSE;;PEOPLE;DISEASE:CARDIOVASCULAR_DISEASE;CAUTION_DOSE_ADJUST
ISONIAZID;NAT2;*4;NAT2*4;METABOLISM/PK;INCREASED;METABOLISM;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
"""INTERFERON ALFA-2A, RECOMBINANT"", ""INTERFERON ALFA-2B, RECOMBINANT"", ""INTERFERONS"", ""PEGINTERFERON ALFA-2A"", ""PEGINTERFERON ALFA-2B"", ""RIBAVIRIN""";IL18;C;rs187238;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;*6;CYP2B6*1, CYP2B6*6;METABOLISM/PK;DECREASED;METABOLISM;;;OTHER:HUMAN_LIVER_MICROSOMES;CAUTION_DRUG_ACCUMULATION
ACENOCOUMAROL;CYP2C9;*1/*1;CYP2C9*1;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ISONIAZID;NAT2;*4/*4;NAT2*4;METABOLISM/PK;INCREASED;METABOLISM;;PEOPLE;DISEASE:TUBERCULOSIS;LIKELIHOOD_THERAPEUTIC_FAILURE
ISONIAZID;NAT2;*4/*4;NAT2*4;METABOLISM/PK;INCREASED;METABOLISM;;PEOPLE;DISEASE:TUBERCULOSIS;LIKELIHOOD_THERAPEUTIC_FAILURE
ACENOCOUMAROL;CYP2C9;*2;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
IBUPROFEN;CYP2C8;*3;CYP2C8*3;METABOLISM/PK;DECREASED;CLEARANCE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
ACENOCOUMAROL;CYP2C9;*2;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;CYP2C9;*1/*1;CYP2C9*1;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;CYP2C9;*2;CYP2C9*2;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
LOSARTAN;CYP2C9;*1/*3;CYP2C9*1, CYP2C9*2, CYP2C9*3;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:KIDNEY_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
LOSARTAN;CYP2C9;*1/*3;CYP2C9*1, CYP2C9*3;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
TROPISETRON;CYP2D6;*3/*3;CYP2D6*3;EFFICACY;DECREASED;METABOLISM;;PEOPLE;DISEASE:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
METOPROLOL;CYP2D6;*10;CYP2D6*10;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
LOSARTAN;CYP2C9;*1/*2;CYP2C9*1, CYP2C9*2, CYP2C9*3;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:KIDNEY_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
PHENPROCOUMON;CYP2C9;*2 + *3;CYP2C9*1, CYP2C9*2, CYP2C9*3;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
CLOPIDOGREL;CYP2C19;*2;CYP2C19*2;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:MYOCARDIAL_ISCHEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
OLMESARTAN;SLCO1B1;*15;SLCO1B1*15, SLCO1B1*37;METABOLISM/PK;DECREASED;CLEARANCE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP2C19;*2/*2;CYP2C19*1, CYP2C19*2;DOSAGE;DECREASED;DOSE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
METOPROLOL;CYP2D6;*10;CYP2D6*10;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
ROSUVASTATIN;SLCO1B1;*15/*15;SLCO1B1*15, SLCO1B1*37;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
SIMVASTATIN;CYP3A4;*1/*4;CYP3A4*1, CYP3A4*4;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HYPERLIPIDEMIAS;LIKELIHOOD_THERAPEUTIC_SUCCESS
LOSARTAN;CYP2C9;*1/*13;CYP2C9*1, CYP2C9*13;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
PHENPROCOUMON;CYP2C9;*2 + *3;CYP2C9*1, CYP2C9*2, CYP2C9*3;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
ONDANSETRON;CYP2D6;*1xN + *2xN;CYP2D6*1, CYP2D6*1XN, CYP2D6*2XN;EFFICACY;DECREASED;RESPONSE;;WOMEN;;LIKELIHOOD_THERAPEUTIC_FAILURE
NATEGLINIDE;CYP2C9;*1/*3;CYP2C9*1, CYP2C9*3;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
PHENPROCOUMON;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
PHENPROCOUMON;CYP2C9;*2 + *3;CYP2C9*1, CYP2C9*2, CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
RISPERIDONE;CYP2D6;*10;CYP2D6*1, CYP2D6*10;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_DRUG_ACCUMULATION
HALOPERIDOL;CYP2D6;*10;CYP2D6*1, CYP2D6*10;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_DRUG_ACCUMULATION
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED;RESPONSE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
CARVEDILOL;CYP2D6;*1/*4;CYP2D6*1, CYP2D6*4;METABOLISM/PK;DECREASED;CLEARANCE;;PEOPLE;DISEASE:HEART_DISEASES;CAUTION_DRUG_ACCUMULATION
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:HELICOBACTER_INFECTIONS;LIKELIHOOD_THERAPEUTIC_FAILURE
ROSUVASTATIN;ABCC2;T;rs3740066;METABOLISM/PK;DECREASED;EXPOSURE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
PANTOPRAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*17;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:HELICOBACTER_INFECTIONS;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:GASTROESOPHAGEAL_REFLUX;LIKELIHOOD_THERAPEUTIC_FAILURE
CARVEDILOL;CYP2D6;*4/*5 + *4/*6;CYP2D6*4, CYP2D6*5, CYP2D6*6;DOSAGE;INCREASED;DOSE;;PEOPLE;DISEASE:HEART_FAILURE;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
OMEPRAZOLE, PANTOPRAZOLE;CYP2C19;*1/*2;CYP2C19*1, CYP2C19*2;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HELICOBACTER_INFECTIONS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARVEDILOL;CYP2D6;*10/*10;CYP2D6*10;METABOLISM/PK;DECREASED;CLEARANCE;;PEOPLE;DISEASE:HEART_DISEASES;CAUTION_DRUG_ACCUMULATION
CARVEDILOL;CYP2D6;*1/*5;CYP2D6*1, CYP2D6*5;METABOLISM/PK;DECREASED;CLEARANCE;;PEOPLE;DISEASE:HEART_DISEASES;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;*1/*3;CYP2C9*1, CYP2C9*3;DOSAGE;DECREASED;DOSE;;CHILDREN;;CAUTION_DOSE_ADJUST
RABEPRAZOLE;CYP2C19;*2/*2 + *3/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;INCREASED;RESPONSE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARVEDILOL;CYP2D6;*10/*10;CYP2D6*1, CYP2D6*2, CYP2D6*10;METABOLISM/PK;DECREASED;CLEARANCE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
ZUCLOPENTHIXOL;CYP2D6;*3;CYP2D6*1, CYP2D6*3;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;CYP2D6;*4/*4;CYP2D6*1, CYP2D6*4;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOXETINE;CYP2D6;CC;rs3892097;EFFICACY;INCREASED;RESPONSE;;MEN;EFFICACY:ALCOHOL_ABUSE, EFFICACY:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
AMITRIPTYLINE, CLOMIPRAMINE, DOXEPIN, IMIPRAMINE, MAPROTILINE, NORTRIPTYLINE, OPIPRAMOL;CYP2D6;*4/*4;CYP2D6*1, CYP2D6*4;DOSAGE, EFFICACY;DECREASED;DOSE;;PEOPLE;DISEASE:DEPRESSION;CAUTION_DOSE_ADJUST
SUFENTANIL;CYP3A5;*1/*3 + *3/*3;CYP3A5*1, CYP3A5*3;DOSAGE;INCREASED;DOSE;;PEOPLE;OTHER:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
METFORMIN;;CG;rs6719578;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RISPERIDONE;CYP2D6;*10;CYP2D6*1, CYP2D6*10;EFFICACY, METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;*6/*6;CYP2B6*1, CYP2B6*6;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;*2/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
HALOPERIDOL;CYP2D6;*10;CYP2D6*1, CYP2D6*10;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;CYP2D6;*4;CYP2D6*1, CYP2D6*4;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;ATIC;CC;rs4673993;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
LORNOXICAM;CYP2C9;*1/*3;CYP2C9*1, CYP2C9*3;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:ULCER;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:HELICOBACTER_INFECTIONS;LIKELIHOOD_THERAPEUTIC_FAILURE
RABEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2;EFFICACY;DECREASED;RESPONSE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
ESOMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2;EFFICACY;DECREASED;RESPONSE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
TRAMADOL;CYP2D6;*4/*4;CYP2D6*1, CYP2D6*3, CYP2D6*4;METABOLISM/PK;DECREASED;CLEARANCE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:CARDIOVASCULAR_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*1/*2;CYP2C19*1, CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;;CHILDREN;;CAUTION_DRUG_ACCUMULATION
DEXLANSOPRAZOLE;CYP2C19;*2/*2;CYP2C19*1, CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:HELICOBACTER_INFECTIONS;LIKELIHOOD_THERAPEUTIC_FAILURE
LOVASTATIN;CYP2D6;*10 + *5;CYP2D6*1, CYP2D6*5, CYP2D6*10;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
BENZBROMARONE;CYP2C9;*1/*3;CYP2C9*1, CYP2C9*3;METABOLISM/PK;DECREASED;CLEARANCE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
LABETALOL;CYP2C19;*2/*2;CYP2C19*1, CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
CELECOXIB;CYP2C9;*1/*2;CYP2C9*1, CYP2C9*2;METABOLISM/PK;INCREASED;METABOLISM;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP4F2;CT + TT;rs2108622;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2;CYP2C9*1, CYP2C9*2;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*2 + *2/*2 + *2/*3;CYP2C9*1, CYP2C9*2, CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*3 + *2/*3 + *3/*3;CYP2C9*1, CYP2C9*2, CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:HELICOBACTER_INFECTIONS;LIKELIHOOD_THERAPEUTIC_FAILURE
BUPROPION;CYP2B6;*1/*22;CYP2B6*1, CYP2B6*22;METABOLISM/PK;INCREASED;METABOLISM;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
VORICONAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2;METABOLISM/PK;INCREASED;METABOLISM;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*2/*2;CYP2C19*1, CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;;CHILDREN;;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;*1/*3;CYP2C9*1, CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
FLUOXETINE;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);SLC6A4 HTTLPR LONG FORM (L ALLELE), SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
VORICONAZOLE;CYP2C19;*1/*2;CYP2C19*1, CYP2C19*2, CYP2C19*17;DOSAGE;DECREASED;DOSE;;PEOPLE;DISEASE:CYSTIC_FIBROSIS, DISEASE:LUNG_TRANSPLANTATION;CAUTION_DOSE_ADJUST
PAROXETINE;SLC6A4;HTTLPR long form (L allele);SLC6A4 HTTLPR LONG FORM (L ALLELE), SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;RESPONSE;;WOMEN;DISEASE:PANIC_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;*2;CYP2C9*1, CYP2C9*2;DOSAGE;DECREASED;DOSE;;CHILDREN;;CAUTION_DOSE_ADJUST
FLUOXETINE, PAROXETINE;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
HYDRALAZINE;NAT2;;SLOW_ACETYLATOR;METABOLISM/PK;DECREASED;METABOLISM;;MEN;OTHER:HYPERTENSION;CAUTION_DRUG_ACCUMULATION
CLOPIDOGREL;CYP2C19;*1/*17 + *17/*17;CYP2C19*1, CYP2C19*17;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY, TOXICITY;DECREASED;RESPONSE;;PEOPLE;OTHER:PERCUTANEOUS_CORONARY_INTERVENTION;LIKELIHOOD_THERAPEUTIC_FAILURE
PIOGLITAZONE;CYP2C8;*1/*1;CYP2C8*1, CYP2C8*3;METABOLISM/PK;DECREASED;CLEARANCE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;HLA-A;*01:01;HLA-A*01:01;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
CITALOPRAM, FLUOXETINE, PAROXETINE;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);SLC6A4 HTTLPR LONG FORM (L ALLELE), SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;TT;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2B6;CA/CA;rs70950385;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
ASPIRIN, CLOPIDOGREL;CYP2C19;*2/*2;CYP2C19*1, CYP2C19*2;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;LIKELIHOOD_THERAPEUTIC_FAILURE
ACENOCOUMAROL;CYP2C9;*1/*3 + *3/*3;CYP2C9*1, CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
MEPHENYTOIN;CYP2C19;G;rs28399504;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
ACENOCOUMAROL;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *3/*3;CYP2C9*1, CYP2C9*2, CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*3 + *3/*3;CYP2C9*1, CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
4-HYDROXYTAMOXIFEN, ENDOXIFEN;CYP2D6;*10/*10 + *5/*5;CYP2D6*1, CYP2D6*5, CYP2D6*10;METABOLISM/PK;DECREASED;CONCENTRATIONS;;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*1/*3 + *2/*3 + *3/*3 + *2/*2;CYP2C9*1, CYP2C9*2, CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*2 + *2/*2;CYP2C9*1, CYP2C9*2;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;CYP2C9;*1/*3 + *3/*3;CYP2C9*1, CYP2C9*2, CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
LAMIVUDINE, NEVIRAPINE, STAVUDINE;HLA-B;*40:01;HLA-B*40:01;EFFICACY;;RESPONSE;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*2 + *2/*2 + *1/*3 + *3/*3;CYP2C9*1, CYP2C9*2, CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
VORICONAZOLE;CYP2C19;*2/*2;CYP2C19*1, CYP2C19*2;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
BELINOSTAT;UGT1A1;*1/*60 + *60/*60;UGT1A1*1, UGT1A1*60;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:NEOPLASMS;CAUTION_DRUG_ACCUMULATION
BELINOSTAT;UGT1A1;*1/*60 + *60/*60;UGT1A1*1, UGT1A1*60;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:NEOPLASMS;CAUTION_DRUG_ACCUMULATION
DOXEPIN;CYP2C19;*2/*2;CYP2C19*1, CYP2C19*2;METABOLISM/PK;DECREASED;CLEARANCE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
NORTRIPTYLINE;CYP2D6;*2/*2 + *2/*10 + *1/*3 + *1/*4 + *2/*4 + *5/*10 + *4/*4 + *3/*4;CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*10;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DRUG_ACCUMULATION
BOCEPREVIR, PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIR;IFNL4;TT;rs11322783;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;*2 + *3 + *5 + *6 + *11;CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*5, CYP2C9*6, CYP2C9*11;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1, CYP2C9*2, CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
AMITRIPTYLINE;CYP2C19;*2/*2 + *2/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2;METABOLISM/PK;INCREASED;CLEARANCE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
DEFERASIROX;UGT1A1;*1/*28 + *28/*28;UGT1A1*1, UGT1A1*28;METABOLISM/PK;DECREASED;CONCENTRATIONS;;PEOPLE;DISEASE:ANEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL, PRASUGREL, TICAGRELOR;CYP2C19;A;rs4244285;EFFICACY;;RESPONSE;;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;*2/*2;CYP2C19*1, CYP2C19*2;EFFICACY;INCREASED;RESISTANCE;;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME, DISEASE:STROKE;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;*11;CYP2B6*1, CYP2B6*11;METABOLISM/PK;DECREASED;CLEARANCE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
VALPROIC ACID;CYP2C9;*1/*2 + *1/*3;CYP2C9*1, CYP2C9*2, CYP2C9*3;DOSAGE;DECREASED;DOSE;;PEOPLE;DISEASE:BIPOLAR_DISORDER, DISEASE:PSYCHOTIC_DISORDER;CAUTION_DOSE_ADJUST
WARFARIN;POR;CT + TT;rs41301394;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
METHADONE;DRD2;AA + AG;rs6275;;INCREASED;DOSE;;PEOPLE;OTHER:TREATMENT_FOR_HEROIN_ADDICTION;CAUTION_DOSE_ADJUST
CARBOPLATIN, PACLITAXEL;GSTP1;G;rs1695;TOXICITY;DECREASED;RESPONSE;;PEOPLE;OTHER:OVARIAN_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
VORICONAZOLE;CYP2C19;;ULTRARAPID_METABOLIZER;METABOLISM/PK;DECREASED;TROUGH_CONCENTRATION;;PEOPLE;DISEASE:FUNGAL_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;*1/*6 + *6/*6;CYP2B6*1, CYP2B6*6;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
ACENOCOUMAROL;CYP2C9;*2;CYP2C9*1, CYP2C9*2;DOSAGE;DECREASED;DOSE;;PEOPLE;DISEASE:ATRIAL_FIBRILLATION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A4;*1/*1;CYP3A4*1, CYP3A4*18;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
CISPLATIN;MIR335;AA + AG;rs3807348;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:MESOTHELIOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CELECOXIB;CYP2C9;*1/*3;CYP2C9*1, CYP2C9*3;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
CYCLOPHOSPHAMIDE, DOXORUBICIN;ALDH1A1;CTGGTGAGGAGAGAACC/del;rs6151031;EFFICACY;DECREASED;RESPONSE;;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
BUPRENORPHINE, METHADONE;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR LONG FORM (L ALLELE), SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:OPIOID-RELATED_DISORDERS;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;VKORC1;;LOW ACTIVITY;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1, CYP2C9*2, CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*2 + *2/*17;CYP2C19*1, CYP2C19*2, CYP2C19*17;EFFICACY;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
VORICONAZOLE;CYP2C19;*1/*2 + *1/*3 + *2/*17;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:FUNGAL_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;INCREASED;TROUGH_CONCENTRATION;;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
ATAZANAVIR;CYP3A5;*3 + *6 + *7;CYP3A5*1, CYP3A5*3, CYP3A5*6, CYP3A5*7;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
CLOZAPINE;CYP3A5;*1/*3;CYP3A5*1, CYP3A5*3;DOSAGE;DECREASED;CONCENTRATIONS;;PEOPLE;DISEASE:SCHIZOAFFECTIVE_DISORDER, DISEASE:SCHIZOPHRENIA;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;DOSAGE;DECREASED;DOSE;;PEOPLE;OTHER:HEART_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;DOSAGE;INCREASED;DOSE;;CHILDREN;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;DOSAGE;DECREASED;TROUGH_CONCENTRATION;;PEOPLE;DISEASE:HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION;CAUTION_DOSE_ADJUST
SIROLIMUS, TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;DOSAGE;INCREASED;DOSE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
NIMODIPINE;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;EFFICACY;INCREASED;EXPOSURE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;DECREASED;CLEARANCE;;PEOPLE;DISEASE:HEART_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;INCREASED;TROUGH_CONCENTRATION;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;DOSAGE;INCREASED;DOSE;;PEOPLE;DISEASE:ULCERATIVE_COLITIS;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;INCREASED;CLEARANCE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1;CYP3A5*1, CYP3A5*3;DOSAGE;INCREASED;DOSE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;INCREASED;DOSE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
CARBAMAZEPINE;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;DECREASED;CLEARANCE;;PEOPLE;DISEASE:EPILEPSY;CAUTION_DRUG_ACCUMULATION
FENTANYL;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:NEOPLASMS, DISEASE:PAIN;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
FENTANYL;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;DECREASED;CLEARANCE;;PEOPLE;DISEASE:POSTOPERATIVE_PAIN;CAUTION_DRUG_ACCUMULATION
MIDAZOLAM;CYP3A5;*1/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;INCREASED;METABOLISM;;PEOPLE;DISEASE:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;INCREASED;METABOLISM;;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOSPORINE;CYP3A5;*3;CYP3A5*1, CYP3A5*3;DOSAGE;DECREASED;DOSE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;DOSAGE;INCREASED;DOSE;;PEOPLE;DISEASE:HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1;CYP3A5*1, CYP3A5*3;DOSAGE;INCREASED;DOSE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
FENTANYL;CYP2D6;*9;CYP2D6*1, CYP2D6*9;METABOLISM/PK;DECREASED;CLEARANCE;;PEOPLE;OTHER:BURNS;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;DOSAGE;INCREASED;DOSE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
SIMVASTATIN;F3;CT;rs3917643;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:MYOCARDIAL_ISCHEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
IVACAFTOR / LUMACAFTOR;CFTR;del/del;rs113993960;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:CYSTIC_FIBROSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACETYLCHOLINE, NITROPRUSSIDE;ACE;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;rs1799752;EFFICACY;INCREASED;RESPONSE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUVASTATIN;ACE;del/del;rs1799752;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
IVACAFTOR;CFTR;CTT/del;rs113993960;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:CYSTIC_FIBROSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ENALAPRIL;ACE;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del + del/del;rs1799752;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:ARTERIOSCLEROSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
BEVACIZUMAB, CAPECITABINE, CISPLATIN, DOCETAXEL, EPIRUBICIN, OXALIPLATIN, TRASTUZUMAB;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:STOMACH_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
IMATINIB;CYP3A5;C;rs776746;EFFICACY;INCREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A4;*1/*22 + *22/*22;CYP3A4*1, CYP3A4*22;DOSAGE;DECREASED;DOSE;;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
METOCLOPRAMIDE;CYP2D6;*1/*10 + *10/*10 + *5/*10;CYP2D6*1, CYP2D6*2, CYP2D6*5, CYP2D6*10;METABOLISM/PK;DECREASED;CLEARANCE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A4;*1/*22 + *22/*22;CYP3A4*1, CYP3A4*22;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
FENTANYL, MEPERIDINE, MIDAZOLAM;CYP3A5;;POOR_METABOLIZER;METABOLISM/PK;DECREASED;DOSE;;PEOPLE;OTHER:SEDATION;CAUTION_DOSE_ADJUST
FENTANYL, MEPERIDINE, MIDAZOLAM;CYP2C19;;CYP2C19 POOR METABOLIZER, INTERMEDIATE METABOLIZER;METABOLISM/PK;DECREASED;DOSE;;PEOPLE;OTHER:SEDATION;CAUTION_DOSE_ADJUST
FENTANYL, MEPERIDINE, MIDAZOLAM;UGT1A1;;POOR_METABOLIZER;METABOLISM/PK;DECREASED;DOSE;;PEOPLE;OTHER:SEDATION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A4;AG;rs35599367;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
4-HYDROXYTAMOXIFEN;CYP2C19;*1/*17 + *17/*17;CYP2C19*1, CYP2C19*17;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;OTHER:BREAST_NEOPLASMS;CAUTION_DRUG_ACCUMULATION
TAMSULOSIN;CYP2D6;*1/*4 + *4/*10;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*9, CYP2D6*10, CYP2D6*41;EFFICACY;INCREASED;CLINICAL_BENEFIT;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IMATINIB;CYP3A4;C;rs2242480;EFFICACY;INCREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;LIKELIHOOD_THERAPEUTIC_SUCCESS
FULVESTRANT;CYP2C9;;CYP2C9 POOR_METABOLIZER;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;OTHER:BREAST_NEOPLASMS, OTHER:METASTATIC_NEOPLASM;CAUTION_DRUG_ACCUMULATION
ANASTROZOLE;CYP2C9;;CYP2C9 INTERMEDIATE_METABOLIZER;METABOLISM/PK;DECREASED;CONCENTRATIONS;;PEOPLE;OTHER:BREAST_NEOPLASMS, OTHER:METASTATIC_NEOPLASM;LIKELIHOOD_THERAPEUTIC_FAILURE
ANASTROZOLE;CYP3A4;*1/*22;CYP3A4*1, CYP3A4*22;METABOLISM/PK;DECREASED;CONCENTRATIONS;;PEOPLE;OTHER:BREAST_NEOPLASMS, OTHER:METASTATIC_NEOPLASM;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C9*1, CYP2C9*2, CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
VORICONAZOLE;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;CHILDREN;OTHER:LEUKEMIA;CAUTION_DRUG_ACCUMULATION
ABATACEPT;HLA-DRB1;*04:05;HLA-DRB1*04:05;EFFICACY;INCREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESOMEPRAZOLE;CYP2C19;;POOR_METABOLIZER;METABOLISM/PK;INCREASED;EXPOSURE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
ESOMEPRAZOLE;CYP2C19;;RAPID_METABOLIZER;METABOLISM/PK;DECREASED;EXPOSURE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
ETANERCEPT;SLCO1C1;G;rs3794271;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
APATINIB;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;DECREASED;CLEARANCE;;PEOPLE;OTHER:NEOPLASMS;CAUTION_DRUG_ACCUMULATION
ESCITALOPRAM;CYP2C19;;CYP2C19 RAPID_METABOLIZER;METABOLISM/PK;INCREASED;CLEARANCE;;CHILDREN;;LIKELIHOOD_THERAPEUTIC_FAILURE
ESCITALOPRAM;CYP2C19;;CYP2C19 POOR_METABOLIZER;METABOLISM/PK;DECREASED;CLEARANCE;;CHILDREN;;CAUTION_DRUG_ACCUMULATION
SERTRALINE;CYP2C19;;CYP2C19 POOR_METABOLIZER;METABOLISM/PK;DECREASED;CLEARANCE;;CHILDREN;;CAUTION_DRUG_ACCUMULATION
DULOXETINE;CYP2D6;;POOR_METABOLIZER;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
AMOXICILLIN, CLARITHROMYCIN, OMEPRAZOLE;VDR;A;rs7975232;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:HELICOBACTER_INFECTIONS;LIKELIHOOD_THERAPEUTIC_SUCCESS
AMOXICILLIN, CLARITHROMYCIN, OMEPRAZOLE;VDR;A;rs2228570;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:HELICOBACTER_INFECTIONS;LIKELIHOOD_THERAPEUTIC_SUCCESS
METOPROLOL;CYP2D6;A;rs1065852;METABOLISM/PK;INCREASED;CONCENTRATIONS;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
BUPROPION, NALTREXONE;ANKK1, DRD2;AA + AG;rs1800497;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:OBESITY;LIKELIHOOD_THERAPEUTIC_SUCCESS
ALPHA-HYDROXYMETOPROLOL;CYP2D6;A;rs1065852;METABOLISM/PK;DECREASED;CLEARANCE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
TOLPERISONE;CYP2D6;*10/*10;CYP2D6*1, CYP2D6*10;METABOLISM/PK;DECREASED;CLEARANCE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
TOLPERISONE;CYP2C19;;POOR_METABOLIZER;METABOLISM/PK;DECREASED;CLEARANCE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;DECREASED;CLEARANCE;;PEOPLE;OTHER:HEART_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
DAPOXETINE;CYP2D6;*10/*10;CYP2D6*1, CYP2D6*10;METABOLISM/PK;DECREASED;CLEARANCE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;CYP2D6;;INTERMEDIATE_METABOLIZER;METABOLISM/PK;INCREASED;CONCENTRATIONS;;CHILDREN;OTHER:AUTISM_SPECTRUM_DISORDER;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A4;*1/*1;CYP3A4*1, CYP3A4*22;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
DAPOXETINE;CYP2D6;*10/*41;CYP2D6*1, CYP2D6*10, CYP2D6*41;METABOLISM/PK;DECREASED;CLEARANCE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
DOCETAXEL, THALIDOMIDE;PPARD;G;rs6922548;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:PROSTATIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN_SN-38;UGT1A1;*6;UGT1A1*1, UGT1A1*6;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;OTHER:RECTAL_NEOPLASMS;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*1;CYP3A5*1;METABOLISM/PK;INCREASED;TIME_RESPONSE;;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
O-DESMETHYLTRAMADOL;CYP2D6;;CYP2D6 INTERMEDIATE_METABOLIZER;METABOLISM/PK;DECREASED;CONCENTRATIONS;;PEOPLE;OTHER:POSTOPERATIVE_PAIN;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A4;*1/*22;CYP3A4*1, CYP3A4*22;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
NALDEMEDINE;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;OTHER:NEOPLASMS, OTHER:PAIN,OTHER:CONSTIPATION;CAUTION_DRUG_ACCUMULATION
METHADONE;CYP2B6;*6/*6;CYP2B6*1, CYP2B6*6;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;CYP2D6;*10/*10 + *10/*65 + *10/*41;CYP2D6*1, CYP2D6*2, CYP2D6*10, CYP2D6*41, CYP2D6*65;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;OTHER:SCHIZOPHRENIA;CAUTION_DRUG_ACCUMULATION
DOCETAXEL, THALIDOMIDE;PPARD;G;rs7769719;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:PROSTATIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;TT;rs776746;METABOLISM/PK;INCREASED;DOSE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
WARFARIN;NEDD4;G;rs2288344;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
QUETIAPINE;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;DECREASED;CLEARANCE;;PEOPLE;OTHER:BIPOLAR_DISORDER;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;TT;rs776746;METABOLISM/PK;INCREASED;DOSE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
WARFARIN;DDHD1;G;rs17126068;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;;CYP3A5 INTERMEDIATE_METABOLIZER;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;OTHER:LUNG_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
PRIMAQUINE 5,6-ORTHOQUINONE;CYP2D6;;INTERMEDIATE_METABOLIZER;METABOLISM/PK;DECREASED;CONCENTRATIONS;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
CISPLATIN, IRINOTECAN;UGT1A1;AA;rs4148323;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
PRIMAQUINE;CYP2D6;;INTERMEDIATE_METABOLIZER;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
DESVENLAFAXINE, VENLAFAXINE;CYP2D6;;POOR_METABOLIZER;METABOLISM/PK;INCREASED;EXPOSURE;;PEOPLE;OTHER:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;CT;rs776746;METABOLISM/PK;INCREASED;DOSE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;VKORC1;T;rs9923231;EFFICACY;INCREASED;RESPONSE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;INCREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A4;*22;CYP3A4*1, CYP3A4*22;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
SALBUTAMOL;;T;rs7903366;EFFICACY;DECREASED;RESPONSE;;CHILDREN;OTHER:ASTHMA;LIKELIHOOD_THERAPEUTIC_FAILURE
PRAZIQUANTEL;CYP2C19;*1/*2 + *1/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;METABOLISM/PK;INCREASED;EXPOSURE;;CHILDREN;OTHER:SCHISTOSOMIASIS;CAUTION_DRUG_ACCUMULATION
PALIPERIDONE, RISPERIDONE;ABCB1;GG;rs1045642;METABOLISM/PK;INCREASED;EXPOSURE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
LOSARTAN;CYP2C9;C;rs1057910;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;PK:NO_DISEASE;CAUTION_DRUG_ACCUMULATION
SULFAPYRIDINE;NAT2;*5/*5;NAT2*5;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:STROKE;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;CYP2D6;;POOR_METABOLIZER;METABOLISM/PK;INCREASED;EXPOSURE;;PEOPLE;DISEASE:BIPOLAR_DISORDER, DISEASE:DEPRESSION,DISEASE:PSYCHOTIC_DISORDER, DISEASE:SUBSTANCE-RELATED_DISORDERS;CAUTION_DRUG_ACCUMULATION
ISONIAZID;NAT2;*16/*16 + *16/*6 + *6/*6 + *6/*7 + *7/*7;NAT2*4, NAT2*6, NAT2*7, NAT2*16;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_DRUG_ACCUMULATION
SALBUTAMOL;;A;rs7081864;EFFICACY;DECREASED;RESPONSE;;CHILDREN;OTHER:ASTHMA;LIKELIHOOD_THERAPEUTIC_FAILURE
SULFINPYRAZONE;UGT1A9;T;rs72551330;METABOLISM/PK;INCREASED;METABOLISM;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
SULFAMETHOXAZOLE;NAT2;*4/*4;NAT2*4, NAT2*6, NAT2*7, NAT2*16;METABOLISM/PK;INCREASED;METABOLISM;;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
ICOTINIB;CYP2C19;*1/*2 + *1/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;MICA;AA;rs1051792;EFFICACY;DECREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:SPONDYLARTHROPATHIES;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;VKORC1;GG;rs9923231;DOSAGE;INCREASED;DOSE;;PEOPLE;OTHER:ATRIAL_FIBRILLATION, OTHER:PULMONARY_EMBOLISM,OTHER:VENOUS_THROMBOSIS;CAUTION_DOSE_ADJUST
TRAMADOL;CYP2D6;*1/*4 + *1/*9;CYP2D6*1, CYP2D6*4, CYP2D6*9;METABOLISM/PK;INCREASED;EXPOSURE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
IMIPRAMINE;CYP2C19;;POOR METABOLIZER;METABOLISM/PK;DECREASED;CLEARANCE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
SULFAPYRIDINE;NAT2;*5;NAT2*4, NAT2*5;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
3,4-METHYLENEDIOXYMETHAMPHETAMINE;CYP2C19;;ULTRARAPID_METABOLIZER;METABOLISM/PK;INCREASED;METABOLISM;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
METHADONE;CYP2D6;*1/*2xN + *2/*2xN;CYP2D6*1, CYP2D6*2, CYP2D6*2XN;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;OTHER:OPIOID-RELATED_DISORDERS;CAUTION_DRUG_ACCUMULATION
LITHIUM;GSK3B;GG;rs6438552;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:BIPOLAR_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;ABCB1;AA;rs1045642;DOSAGE;DECREASED;DOSE;;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
LITHIUM;NR1D1, THRA;TT;rs2071427;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:BIPOLAR_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;;POOR METABOLIZER;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
MORPHINE;CYP2D6;;POOR_METABOLIZER;METABOLISM/PK;DECREASED;EXPOSURE;;INFANTS;;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;;POOR METABOLIZER;METABOLISM/PK;DECREASED;CONCENTRATIONS;;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
SULFAPYRIDINE;NAT2;*5/*5;NAT2*5;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
ARIPIPRAZOLE;CYP2D6;;POOR_METABOLIZER;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;DISEASE:PSYCHOTIC_DISORDER;CAUTION_DRUG_ACCUMULATION
ATOMOXETINE;CYP2C19;;POOR METABOLIZER;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
SULFAPYRIDINE;NAT2;*6;NAT2*4, NAT2*6;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;DOSAGE;DECREASED;DOSE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3 + *1/*6 + *1/*7;CYP3A5*1, CYP3A5*3, CYP3A5*6, CYP3A5*7;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;OTHER:HEART_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
ISONIAZID;NAT2;*5/*7 + *5/*5 + *5/*6 + *5/*6J + *5/*7G + *6/*7;NAT2*1, NAT2*4, NAT2*5, NAT2*6, NAT2*6J, NAT2*7, NAT2*7G, NAT2*39;METABOLISM/PK;DECREASED;CLEARANCE;;CHILDREN;DISEASE:TUBERCULOSIS;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;ABCB1;GG;rs1045642;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
INFLIXIMAB;HLA-DQA1;*05;HLA-DQA1*05;EFFICACY;INCREASED;DISCONTINUATION;;PEOPLE;EFFICACY:CROHN_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;ABCB1;AA;rs1045642;METABOLISM/PK;DECREASED;CLEARANCE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
SULFAPYRIDINE;NAT2;*6/*6;NAT2*6;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
ENZYME INHIBITORS;CYP19A1;CC;rs700518;OTHER;;RESPONSE;;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_DOSE_ADJUST
TACROLIMUS;ABCB1;AA;rs1128503;METABOLISM/PK;DECREASED;CLEARANCE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
CORTICOSTEROIDS;FCER2;G;rs28364072;DOSAGE;INCREASED;DOSE;;CHILDREN;DISEASE:ASTHMA;CAUTION_DOSE_ADJUST
TACROLIMUS;ABCB1;AA;rs2032582;METABOLISM/PK;DECREASED;CLEARANCE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
HYDROCHLOROTHIAZIDE, OLMESARTAN;SLC22A1;AG;rs34059508;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;ABCB1;AG + GG;rs1045642;METABOLISM/PK;INCREASED;CLEARANCE;;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
HYDRALAZINE;NAT2;*4/*16 + *4/*6 + *4/*7;NAT2*4, NAT2*6, NAT2*7, NAT2*16;METABOLISM/PK;INCREASED;METABOLISM;;WOMEN;OTHER:HYPERTENSION, OTHER:PREGNANCY;LIKELIHOOD_THERAPEUTIC_FAILURE
HALOPERIDOL;CYP2D6;;POOR_METABOLIZER;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;DISEASE:PSYCHOTIC_DISORDER;CAUTION_DRUG_ACCUMULATION
ESCITALOPRAM;;G;rs12154537;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
MORPHINE;ABCB1;AG + GG;rs1128503;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
SULFAPYRIDINE;NAT2;*16/*16 + *16/*5 + *16/*6 + *6/*6 + *6/*7 + *7/*7;NAT2*4, NAT2*5, NAT2*6, NAT2*7, NAT2*16;METABOLISM/PK;INCREASED;CONCENTRATIONS;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
ISONIAZID;NAT2;*4/*4;NAT2*4, NAT2*6, NAT2*7, NAT2*14, NAT2*16, NAT2*19;DOSAGE, METABOLISM/PK;INCREASED;DOSE;;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_DOSE_ADJUST
DOCETAXEL;SLCO1B3;G;rs11045585;OTHER, METABOLISM/PK;DECREASED;CLEARANCE;;PEOPLE;DISEASE:NASOPHARYNGEAL_NEOPLASMS;CAUTION_DRUG_ACCUMULATION
SULFAPYRIDINE;NAT2;*5/*7;NAT2*5, NAT2*7;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
DOCETAXEL;SLCO1B3;A;rs7311358;OTHER, METABOLISM/PK;DECREASED;CLEARANCE;;PEOPLE;DISEASE:NASOPHARYNGEAL_NEOPLASMS;CAUTION_DRUG_ACCUMULATION
DOCETAXEL;SLCO1B3;G;rs4149118;OTHER, METABOLISM/PK;DECREASED;CLEARANCE;;PEOPLE;DISEASE:NASOPHARYNGEAL_NEOPLASMS;CAUTION_DRUG_ACCUMULATION
ISONIAZID;NAT2;*5/*7 + *5/*5 + *5/*6 + *5/*6J + *5/*7G + *6/*7;NAT2*4, NAT2*5, NAT2*6, NAT2*6J, NAT2*7, NAT2*7G;METABOLISM/PK;DECREASED;METABOLISM;;CHILDREN;DISEASE:TUBERCULOSIS;CAUTION_DRUG_ACCUMULATION
SULFAPYRIDINE;NAT2;*7;NAT2*4, NAT2*7;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;A;rs9934438;DOSAGE, METABOLISM/PK;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A4;*1/*22 + *22/*22;CYP3A4*1, CYP3A4*22;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;OTHER:HEART_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;METABOLISM/PK;INCREASED;METABOLISM;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
MIDAZOLAM;VDR;C;rs1544410;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;KLRC4;GG;rs1154831;EFFICACY;INCREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:SPONDYLARTHROPATHIES;LIKELIHOOD_THERAPEUTIC_SUCCESS
DIAZEPAM;CYP2C19;;POOR_METABOLIZER;METABOLISM/PK;DECREASED;CLEARANCE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
ESCITALOPRAM;CYP2C19;;INTERMEDIATE_METABOLIZER;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;CHILDREN;OTHER:DEPRESSION, OTHER:ANXIETY_DISORDERS;CAUTION_DRUG_ACCUMULATION
METHADONE;CYP2D6;;ULTRARAPID_METABOLIZER;EFFICACY;DECREASED;RESPONSE;;PEOPLE;OTHER:HEROIN_DEPENDENCE;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOXETINE;CYP2D6;;ULTRARAPID_METABOLIZER;EFFICACY;DECREASED;CLINICAL_BENEFIT;;CHILDREN;EFFICACY:MAJOR_DEPRESSIVE_DISORDER, EFFICACY:OBSESSIVE_COMPULSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
HYDRALAZINE;NAT2;*16/*14 + *16/*16 + *16/*6 + *16/*7 + *6/*14 + *6/*6 + *7/*6;NAT2*6, NAT2*7, NAT2*14, NAT2*16;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:RESISTANT_HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ISONIAZID;NAT2;*16/*14 + *16/*16 + *16/*6 + *16/*7 + *6/*14 + *6/*6 + *6/*7;NAT2*4, NAT2*6, NAT2*7, NAT2*14, NAT2*16;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;OTHER:TUBERCULOSIS;CAUTION_DRUG_ACCUMULATION
SULFAPYRIDINE;NAT2;*5/*6;NAT2*5, NAT2*6;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
ACETYLISONIAZID;NAT2;*16/*14 + *16/*16 + *16/*6 + *16/*7 + *6/*14 + *6/*6 + *6/*7;NAT2*4, NAT2*6, NAT2*7, NAT2*14, NAT2*16;METABOLISM/PK;DECREASED;CONCENTRATIONS;;PEOPLE;OTHER:TUBERCULOSIS;LIKELIHOOD_THERAPEUTIC_FAILURE
DIPYRONE;NAT2;*16 + *6 + *7 + *14;NAT2*6, NAT2*7, NAT2*14, NAT2*16;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
BUPROPION;CYP2B6;*6;CYP2B6*6;METABOLISM/PK;INCREASED;EXPOSURE;;PEOPLE;OTHER:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DRUG_ACCUMULATION
CODEINE;CYP2D6;*1xN/*41;CYP2D6*1, CYP2D6*1XN, CYP2D6*41;METABOLISM/PK;INCREASED;METABOLISM;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;VKORC1;T;rs7294;DOSAGE, METABOLISM/PK;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
PARAMETHOXYMETHAMPHETAMINE;CYP2D6;;NORMAL_METABOLIZER;METABOLISM/PK;INCREASED;METABOLISM;;PEOPLE;DISEASE:SUBSTANCE-RELATED_DISORDERS;LIKELIHOOD_THERAPEUTIC_FAILURE
MARAVIROC;CYP3A5;;INTERMEDIATE METABOLIZER;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
CLOPIDOGREL;CYP2C19;;CYP2C19 POOR_METABOLIZER, INTERMEDIATE_METABOLIZER;EFFICACY;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
CODEINE;CYP2D6;*1/*2xN;CYP2D6*1, CYP2D6*2, CYP2D6*2XN;METABOLISM/PK;INCREASED;METABOLISM;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;;POOR_METABOLIZER;EFFICACY;DECREASED;RESPONSE;;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
CODEINE;CYP2D6;*2xN/*41;CYP2D6*2, CYP2D6*2XN, CYP2D6*41;METABOLISM/PK;INCREASED;METABOLISM;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
CODEINE;CYP2D6;*1xN/*10;CYP2D6*1, CYP2D6*1XN, CYP2D6*10;METABOLISM/PK;INCREASED;METABOLISM;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;;POOR_METABOLIZER;METABOLISM/PK;DECREASED;CONCENTRATIONS;;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
VORICONAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;METABOLISM/PK;DECREASED;TROUGH_CONCENTRATION;;PEOPLE;DISEASE:FUNGAL_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
CITALOPRAM, ESCITALOPRAM;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *3/*17;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;METABOLISM/PK;INCREASED;EXPOSURE;;;;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;TT;rs3745274;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
NORTRIPTYLINE;CYP2D6;;ULTRARAPID_METABOLIZER;METABOLISM/PK;INCREASED;METABOLISM;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
HALOPERIDOL, OLANZAPINE, PERPHENAZINE, QUETIAPINE, RISPERIDONE;DRD2;C;rs1799978;EFFICACY;INCREASED;RESISTANCE;;PEOPLE;OTHER:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_FAILURE
MARAVIROC;CYP3A5;;POOR METABOLIZER;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
CITALOPRAM, ESCITALOPRAM;CYP2C19;*17/*17;CYP2C19*1, CYP2C19*17;METABOLISM/PK;DECREASED;EXPOSURE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;;CYP3A5 INTERMEDIATE_METABOLIZER, NORMAL_METABOLIZER;DOSAGE, METABOLISM/PK;INCREASED;TIME_RESPONSE;;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
NORTRIPTYLINE;CYP2D6;;INTERMEDIATE METABOLIZER;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A4;*1/*22;CYP3A4*1, CYP3A4*22;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
HYDROCODONE;CYP2D6;;POOR METABOLIZER;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
IMIPRAMINE;CYP2D6;;POOR METABOLIZER;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
ATOMOXETINE;CYP2C19;;POOR METABOLIZER;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
IMIPRAMINE;CYP2C19;;POOR METABOLIZER;METABOLISM/PK;DECREASED;CLEARANCE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
IMIPRAMINE;CYP2C19;;POOR METABOLIZER;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DRUG_ACCUMULATION
IMIPRAMINE;CYP2C19;;POOR METABOLIZER;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
ENDOXIFEN;CYP2D6;;POOR METABOLIZER;METABOLISM/PK;DECREASED;CONCENTRATIONS;;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;CYP2D6;;POOR_METABOLIZER;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;DISEASE:PSYCHOTIC_DISORDER;CAUTION_DRUG_ACCUMULATION
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*8 + *2/*2;CYP2C19*1, CYP2C19*2, CYP2C19*8, CYP2C19*17;EFFICACY, METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
DEXTROMETHORPHAN;CYP2D6;*10/*10;CYP2D6*1, CYP2D6*10;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
TAMOXIFEN;CYP2D6;;INTERMEDIATE METABOLIZER;METABOLISM/PK;INCREASED;DOSE;;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_DOSE_ADJUST
PROPAFENONE;CYP2D6;*1/*5 + *2/*36 + *5/*10 + *5/*5;CYP2D6*1, CYP2D6*2, CYP2D6*5, CYP2D6*10, CYP2D6*36;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;OTHER:TACHYCARDIA;CAUTION_DRUG_ACCUMULATION
IMIPRAMINE;CYP2D6;*4/*4 + *4/*5;CYP2D6*1, CYP2D6*2, CYP2D6*4, CYP2D6*5;DOSAGE;DECREASED;DOSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DOSE_ADJUST
CITALOPRAM, ESCITALOPRAM;CYP2C19;*1/*17;CYP2C19*1, CYP2C19*17;METABOLISM/PK;DECREASED;EXPOSURE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*8 + *2/*2;CYP2C19*1, CYP2C19*2, CYP2C19*8, CYP2C19*17;EFFICACY, METABOLISM/PK;DECREASED;RESPONSE;;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
METHAMPHETAMINE;CYP2D6;*4/*10 + *5/*10 + *5/*14 + *10/*10 + *10/*18 + *10/*36;CYP2D6*1, CYP2D6*2, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*14, CYP2D6*18, CYP2D6*36;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
TOLTERODINE;CYP2D6;;POOR METABOLIZER;METABOLISM/PK;DECREASED;CLEARANCE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;CYP2D6;;CYP2D6 POOR_METABOLIZER, INTERMEDIATE_METABOLIZER;METABOLISM/PK;INCREASED;EXPOSURE;;PEOPLE;OTHER:PSYCHOTIC_DISORDER, OTHER:SCHIZOPHRENIA;CAUTION_DRUG_ACCUMULATION
4-HYDROXYTAMOXIFEN, ENDOXIFEN;CYP2C9;*2 + *3;CYP2C9*1, CYP2C9*2, CYP2C9*3;METABOLISM/PK;DECREASED;CONCENTRATIONS;;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;CYP2D6;*5/*10 + *4/*10 + *10/*10 + *10/*41;CYP2D6*1, CYP2D6*2, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*41;METABOLISM/PK;DECREASED;METABOLISM;;CHILDREN;;CAUTION_DRUG_ACCUMULATION
VENLAFAXINE;CYP2D6;;POOR_METABOLIZER;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
METHADONE;CYP2D6;*1/*2xN + *2/*2xN;CYP2D6*1, CYP2D6*2, CYP2D6*2XN;DOSAGE;INCREASED;DOSE;;PEOPLE;OTHER:OPIOID-RELATED_DISORDERS;CAUTION_DOSE_ADJUST
DESIPRAMINE, IMIPRAMINE;CYP2D6;*4/*4 + *4/*5;CYP2D6*4, CYP2D6*5;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DRUG_ACCUMULATION
TRANS 4-HYDROXYPRAZIQUANTEL;CYP2J2;AA + AC;rs890293;METABOLISM/PK;INCREASED;CONCENTRATIONS;;CHILDREN;OTHER:SCHISTOSOMIASIS;CAUTION_DRUG_ACCUMULATION
VENLAFAXINE;CYP2D6;;POOR_METABOLIZER;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
PERPHENAZINE;CYP2D6;;POOR_METABOLIZER;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP2C19;*1/*2 + *1/*3 + *2/*2 +*2/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;DOSAGE, METABOLISM/PK;DECREASED;DOSE;;PEOPLE;OTHER:HEART_TRANSPLANTATION;CAUTION_DOSE_ADJUST
VORTIOXETINE;CYP2D6;*4/*4;CYP2D6*1, CYP2D6*4;TOXICITY;INCREASED;DISCONTINUATION;;;;CAUTION_SIDE_EFFECT
FENTANYL;;;METABOLIZER;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:PAIN;CAUTION_DRUG_ACCUMULATION
ESCITALOPRAM;CYP2C19;;ULTRARAPID_METABOLIZER;METABOLISM/PK;INCREASED;METABOLISM;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*1/*1;CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*8;METABOLISM/PK;INCREASED;DOSE;;HEALTHY;;CAUTION_DOSE_ADJUST
NORTRIPTYLINE;CYP2D6;;POOR METABOLIZER;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DRUG_ACCUMULATION
PAROXETINE;CYP2D6;*1/*5 + *5/*10 + *10/*10 + *10/*14 + *10/*41;CYP2D6*1, CYP2D6*2, CYP2D6*5, CYP2D6*10, CYP2D6*14, CYP2D6*41;METABOLISM/PK;DECREASED;CLEARANCE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
ESCITALOPRAM;CYP2C19;;POOR METABOLIZER;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DRUG_ACCUMULATION
ETHANOL;OPRM1;G;rs2075572;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PROTON PUMP INHIBITORS;CYP2C19;;CYP2C19 POOR_METABOLIZER, INTERMEDIATE_METABOLIZER;EFFICACY;INCREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:HELICOBACTER_INFECTIONS;LIKELIHOOD_THERAPEUTIC_SUCCESS
TRAMADOL;CYP2D6;;ULTRARAPID_METABOLIZER;METABOLISM/PK;INCREASED;METABOLISM;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
METOPROLOL;CYP2D6;;POOR METABOLIZER;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ETHANOL;OPRM1;T;rs548646;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
GLICLAZIDE;KCNQ1;T;rs2237892;EFFICACY;INCREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;DRD2;G/del + del/del;rs1799732;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:TOBACCO_USE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
PAROXETINE;CYP2D6;;POOR METABOLIZER;METABOLISM/PK;DECREASED;CLEARANCE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
DESIPRAMINE;CYP2D6;;POOR METABOLIZER;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
LINAGLIPTIN;TCF7L2;CC + CT;rs7903146;EFFICACY;INCREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
CITALOPRAM, ESCITALOPRAM;CYP2C19;;POOR_METABOLIZER;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHANOL;OPRM1;T;rs681243;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DEXTROMETHORPHAN;CYP2D6;;NORMAL_METABOLIZER;METABOLISM/PK;INCREASED;METABOLISM;;CHILDREN;;LIKELIHOOD_THERAPEUTIC_FAILURE
TRAMADOL;CYP2D6;;ULTRARAPID_METABOLIZER;METABOLISM/PK;INCREASED;METABOLISM;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
HYDROXYBUPROPION;CYP2B6;;CYP2B6 POOR_METABOLIZER, INTERMEDIATE_METABOLIZER;METABOLISM/PK;DECREASED;EXPOSURE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
TRAMADOL;CYP2D6;;NORMAL_METABOLIZER;METABOLISM/PK;INCREASED;METABOLISM;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
AMOXICILLIN, CLARITHROMYCIN, ESOMEPRAZOLE;CYP2C19;;NORMAL_METABOLIZER;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:GASTRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
DABIGATRAN;CYP2D6;;POOR METABOLIZER;METABOLISM/PK;DECREASED;CLEARANCE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
ESCITALOPRAM;CYP2C19;;POOR METABOLIZER;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
VENLAFAXINE;CYP2D6;;POOR METABOLIZER;EFFICACY;DECREASED;RESPONSE;;PEOPLE;EFFICACY:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
BUPROPION;COMT;AG + GG;rs4680;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
ARIPIPRAZOLE;CYP2D6;;INTERMEDIATE_METABOLIZER;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
CODEINE, FENTANYL, HYDROCODONE, HYDROMORPHONE, METHADONE, MORPHINE, OXYCODONE, TRAMADOL;CYP2D6;;CYP2D6 POOR METABOLIZER, INTERMEDIATE METABOLIZER;EFFICACY;DECREASED;RESPONSE;;PEOPLE;OTHER:NEOPLASMS, OTHER:PAIN;LIKELIHOOD_THERAPEUTIC_FAILURE
VENLAFAXINE;CYP2D6;;POOR METABOLIZER;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;OTHER:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DRUG_ACCUMULATION
PAROXETINE;CYP2D6;*1/*5 + *5/*10 + *10/*10 + *10/*14 + *10/*41;CYP2D6*1, CYP2D6*2, CYP2D6*5, CYP2D6*10, CYP2D6*14, CYP2D6*41;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
ETHANOL;OPRM1;A;rs1461773;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
3,4-METHYLENEDIOXYMETHAMPHETAMINE;CYP2D6;*4/*4 + *3/*5;CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*9, CYP2D6*10, CYP2D6*41;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ENDOXIFEN;CYP2D6;;POOR METABOLIZER;METABOLISM/PK;DECREASED;CONCENTRATIONS;;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
ETHANOL;OPRM1;T;rs3778148;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
AMOXICILLIN, CLARITHROMYCIN, LANSOPRAZOLE;CYP2C19;;NORMAL_METABOLIZER;EFFICACY;DECREASED;CLINICAL_BENEFIT;;PEOPLE;EFFICACY:HELICOBACTER_INFECTIONS;LIKELIHOOD_THERAPEUTIC_FAILURE
AMOXICILLIN, CLARITHROMYCIN, OMEPRAZOLE;CYP2C19;;NORMAL_METABOLIZER;EFFICACY;DECREASED;CLINICAL_BENEFIT;;PEOPLE;EFFICACY:HELICOBACTER_INFECTIONS;LIKELIHOOD_THERAPEUTIC_FAILURE
MIDAZOLAM;VDR;T;rs4516035;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
CODEINE;CYP2D6;*1xN/*1;CYP2D6*1, CYP2D6*1XN, CYP2D6*3, CYP2D6*4, CYP2D6*6;METABOLISM/PK;INCREASED;METABOLISM;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
OXYCODONE;CYP2D6;;POOR_METABOLIZER;METABOLISM/PK;INCREASED;EXPOSURE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
OXYMORPHONE;CYP2D6;;POOR_METABOLIZER;METABOLISM/PK;DECREASED;EXPOSURE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
OXYMORPHONE;CYP2D6;;POOR_METABOLIZER;METABOLISM/PK;DECREASED;EXPOSURE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
NOROXYMORPHONE;CYP2D6;;POOR_METABOLIZER;METABOLISM/PK;DECREASED;CONCENTRATIONS;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
AMITRIPTYLINE;CYP2D6;;POOR_METABOLIZER;EFFICACY;DECREASED;RESPONSE;;PEOPLE;OTHER:PHANTOM_LIMB_SYNDROME;LIKELIHOOD_THERAPEUTIC_FAILURE
NOROXYMORPHONE;CYP2D6;;POOR_METABOLIZER;METABOLISM/PK;DECREASED;CONCENTRATIONS;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
TRAMADOL;CYP2D6;;POOR_METABOLIZER;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:PHANTOM_LIMB_SYNDROME;LIKELIHOOD_THERAPEUTIC_SUCCESS
TAMSULOSIN;CYP2D6;;CYP2D6 INTERMEDIATE_METABOLIZER, NORMAL_METABOLIZER;METABOLISM/PK;DECREASED;CONCENTRATIONS;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
NOROXYCODONE;CYP2D6;;ULTRARAPID_METABOLIZER;METABOLISM/PK;DECREASED;EXPOSURE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
MORPHINE;COMT;A;rs4680;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:LOW_BACK_PAIN;LIKELIHOOD_THERAPEUTIC_SUCCESS
VORICONAZOLE;CYP2C19;;POOR METABOLIZER;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TAMSULOSIN;CYP2D6;;CYP2D6 INTERMEDIATE_METABOLIZER, NORMAL_METABOLIZER;METABOLISM/PK;DECREASED;CONCENTRATIONS;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIDEPRESSANTS;FKBP5;AC + CC;rs3800373;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
TAMSULOSIN;CYP2D6;;CYP2D6 INTERMEDIATE_METABOLIZER, NORMAL_METABOLIZER;METABOLISM/PK;DECREASED;CONCENTRATIONS;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
VENLAFAXINE;CYP2D6;;POOR_METABOLIZER;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;;CYP2C19 POOR METABOLIZER, INTERMEDIATE METABOLIZER;METABOLISM/PK;INCREASED;TROUGH_CONCENTRATION;;;;CAUTION_DRUG_ACCUMULATION
OPIOIDS;COMT;GG;rs4680;DOSAGE;INCREASED;DOSE;;PEOPLE;DISEASE:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
ATENOLOL, METOPROLOL;ADRB2;CC;rs1042714;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:TACHYCARDIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
TRIMIPRAMINE;CYP2D6;*3/*3 + *3/*5 + *4/*4;CYP2D6*1, CYP2D6*2XN, CYP2D6*3, CYP2D6*4, CYP2D6*5;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
TAMSULOSIN;CYP2D6;;POOR_METABOLIZER;EFFICACY;INCREASED;RESPONSE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_SUCCESS
GLICLAZIDE;KCNQ1;C;rs2237895;EFFICACY;INCREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;;NORMAL METABOLIZER;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
SOLANIDINE;CYP2D6;;POOR_METABOLIZER;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;OTHER:DEPRESSION;CAUTION_DRUG_ACCUMULATION
FLECAINIDE;CYP2D6;;NORMAL_METABOLIZER;METABOLISM/PK;;CONCENTRATIONS;;PEOPLE;DISEASE:TACHYCARDIA, SUPRAVENTRICULAR;CAUTION_DOSE_ADJUST
TRIMIPRAMINE;CYP2D6;*3/*3 + *3/*5 + *4/*4;CYP2D6*1, CYP2D6*2XN, CYP2D6*3, CYP2D6*4, CYP2D6*5;METABOLISM/PK;DECREASED;CLEARANCE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*2/*2 + *2/*3 + *3/*3;POOR METABOLIZER;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:FUNGAL_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
PRIDOPIDINE;CYP2D6;;POOR METABOLIZER;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
MORPHINE;CYP2D6;;ULTRARAPID_METABOLIZER;METABOLISM/PK;INCREASED;EXPOSURE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
TRAMADOL;CYP2D6;;POOR_METABOLIZER;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
RABEPRAZOLE;CYP2C19;;POOR METABOLIZER;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
BUPROPION;CYP2C19;*2 + *3;CYP2C19*2, CYP2C19*3, CYP2C19*17;METABOLISM/PK;DECREASED;METABOLISM;;WOMEN;DISEASE:PREGNANCY;CAUTION_DRUG_ACCUMULATION
(R)-METHADONE, (S)-METHADONE;CYP2D6;*1/*1xN;CYP2D6*1, CYP2D6*1XN, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6;METABOLISM/PK;DECREASED;CONCENTRATIONS;;PEOPLE;OTHER:HEROIN_DEPENDENCE;LIKELIHOOD_THERAPEUTIC_FAILURE
METHADONE;OPRM1;AA;rs1799971;EFFICACY;INCREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:OPIOID-RELATED_DISORDERS;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;CYP2A6;*1/*2 + *1/*9 + *1/*17;CYP2A6*1, CYP2A6*2, CYP2A6*9, CYP2A6*17;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
METRONIDAZOLE;CYP2A6;*1/*2 + *1/*9 + *1/*17;CYP2A6*1, CYP2A6*2, CYP2A6*9, CYP2A6*17;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
ARSENIC COMPOUNDS;CBS;AA + AG;rs4920037;TOXICITY, METABOLISM/PK;INCREASED;METABOLISM;;;;CAUTION_SIDE_EFFECT
(R)-METHADONE, (S)-METHADONE;CYP2D6;*3/*4 + *4/*4 + *4/*6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;OTHER:HEROIN_DEPENDENCE;CAUTION_DRUG_ACCUMULATION
MORPHINE;CYP2D6;;ULTRARAPID_METABOLIZER;DOSAGE, EFFICACY;DECREASED;DOSE;;WOMEN;DISEASE:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
CODEINE;CYP2D6;;POOR METABOLIZER;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
CLOMIPRAMINE;CYP2C19;;POOR METABOLIZER;METABOLISM/PK;DECREASED;CLEARANCE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
O-DESMETHYLTRAMADOL;CYP2D6;;CYP2D6 POOR METABOLIZER, INTERMEDIATE METABOLIZER;METABOLISM/PK;DECREASED;CONCENTRATIONS;;PEOPLE;OTHER:NEOPLASMS, OTHER:PAIN;LIKELIHOOD_THERAPEUTIC_FAILURE
(S)-METHADONE;CYP2D6;;ULTRARAPID_METABOLIZER;METABOLISM/PK;DECREASED;CONCENTRATIONS;;PEOPLE;DISEASE:OPIOID-RELATED_DISORDERS;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;VKORC1;GG;rs9934438;DOSAGE;INCREASED;DOSE;;PEOPLE;OTHER:HEART_VALVE_REPLACEMENT;CAUTION_DOSE_ADJUST
VORICONAZOLE;CYP2C19;;CYP2C19 POOR_METABOLIZER, INTERMEDIATE_METABOLIZER;EFFICACY;INCREASED;CLINICAL_BENEFIT;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TRAMADOL;CYP2D6;*4/*4;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*6, CYP2D6*9;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;FOXP3;G;rs3761548;OTHER;DECREASED;RESPONSE;;PEOPLE;DISEASE:PSORIASIS;LIKELIHOOD_THERAPEUTIC_FAILURE
ATENOLOL, METOPROLOL;ADRB2;AA;rs1042713;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:TACHYCARDIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
VORICONAZOLE;CYP2C19;*2/*2 + *2/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;METABOLISM/PK;INCREASED;TROUGH_CONCENTRATION;;PEOPLE;DISEASE:FUNGAL_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
N-DESMETHYLTRAMADOL;CYP2D6;;CYP2D6 POOR METABOLIZER, INTERMEDIATE METABOLIZER;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;OTHER:NEOPLASMS, OTHER:PAIN;CAUTION_DRUG_ACCUMULATION
4-HYDROXYTAMOXIFEN, ENDOXIFEN;CYP2D6;;POOR METABOLIZER;METABOLISM/PK;DECREASED;CONCENTRATIONS;;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
GEMCITABINE;NT5C2;TT;rs11598702;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
GEMCITABINE;CDA;TT;rs1048977;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
OMEPRAZOLE;CYP2C19;;POOR METABOLIZER;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
OXYMORPHONE;CYP2D6;*1/*1 + *1/*9 + *2/*9 + *1/*2 + *2/*2;CYP2D6*1, CYP2D6*2, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*9, CYP2D6*17, CYP2D6*41;METABOLISM/PK;INCREASED;EXPOSURE;;CHILDREN;;CAUTION_DRUG_ACCUMULATION
DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS;CTRB1, CTRB2;GG + GT;rs7202877;EFFICACY;DECREASED;RESPONSE;;PEOPLE;OTHER:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE, OMEPRAZOLE;CYP2C19;;CYP2C19 POOR_METABOLIZER, INTERMEDIATE_METABOLIZER;EFFICACY;INCREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:HELICOBACTER_INFECTIONS;LIKELIHOOD_THERAPEUTIC_SUCCESS
SERTRALINE;CYP2B6;*6/*6 + *6/*9;CYP2B6*1, CYP2B6*6, CYP2B6*9;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
OLANZAPINE;CYP2C9;;POOR METABOLIZER;METABOLISM/PK;INCREASED;EXPOSURE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
ENDOXIFEN;CYP2D6;*3 + *4 + *5 + *6 + *9 + *10 + *17 + *29 + *41;CYP2D6 POOR METABOLIZER, INTERMEDIATE METABOLIZER;METABOLISM/PK;DECREASED;CONCENTRATIONS;;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
ARSENIC COMPOUNDS;CBS;CT + TT;rs234709;TOXICITY, METABOLISM/PK;INCREASED;METABOLISM;;;;CAUTION_SIDE_EFFECT
3-HYDROXYCOTININE, 3-HYDROXYCOTININE GLUCURONIDE;CYP2A6;*1 + *2;CYP2A6*1, CYP2A6*2, CYP2A6*9, CYP2A6*10;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;OTHER:TOBACCO_USE_DISORDER;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;CYP2D6;;ULTRARAPID_METABOLIZER;METABOLISM/PK;INCREASED;CLEARANCE;;PEOPLE;DISEASE:PSYCHOTIC_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;CYP2D6;;POOR METABOLIZER;METABOLISM/PK;DECREASED;METABOLISM;;CHILDREN;;CAUTION_DRUG_ACCUMULATION
SELECTIVE BETA-2-ADRENORECEPTOR AGONISTS;VDR;C;rs2239179;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_FAILURE
SELECTIVE BETA-2-ADRENORECEPTOR AGONISTS;VDR;C;rs1540339;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2C9;;POOR METABOLIZER;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;CT + TT;rs12248560;DOSAGE, EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;CAUTION_DOSE_ADJUST
VORICONAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;METABOLISM/PK;INCREASED;TROUGH_CONCENTRATION;;PEOPLE;DISEASE:HEMATOLOGIC_DISORDER, DISEASE:INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
ENDOXIFEN;CYP2D6;;POOR METABOLIZER;METABOLISM/PK;DECREASED;CONCENTRATIONS;;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
CARISOPRODOL;CYP2C19;*1/*2;CYP2C19*1, CYP2C19*2;METABOLISM/PK;INCREASED;CONCENTRATIONS;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
LANSOPRAZOLE;CYP2C19;;POOR METABOLIZER;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
IMIPRAMINE;CYP2C19;;POOR METABOLIZER;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DRUG_ACCUMULATION
GEMIGLIPTIN, LINAGLIPTIN, SAXAGLIPTIN, SITAGLIPTIN, VILDAGLIPTIN;GLP1R;AA + AG;rs3765467;EFFICACY;INCREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHADONE;ABCB1;AA;rs1045642;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
FENTANYL;CYP3A5;*1/*3 + *1/*6 + *3/*3 + *3/*6 + *6/*6;CYP3A5*1, CYP3A5*3, CYP3A5*6;METABOLISM/PK;DECREASED;CLEARANCE;;CHILDREN;;CAUTION_DRUG_ACCUMULATION
GLICLAZIDE;CYP2C9;;INTERMEDIATE METABOLIZER;METABOLISM/PK;DECREASED;CLEARANCE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
NORQUETIAPINE;CYP2D6;;CYP2D6 POOR_METABOLIZER, INTERMEDIATE_METABOLIZER;METABOLISM/PK;INCREASED;EXPOSURE;;;;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*1/*2 + *1/*3;INTERMEDIATE METABOLIZER;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:FUNGAL_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
TROPISETRON;CYP2D6;*1/*2xN;CYP2D6*1, CYP2D6*2XN;METABOLISM/PK;INCREASED;METABOLISM;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
CITALOPRAM, ESCITALOPRAM;CYP2C19;*2/*2 + *3/*3 + *2/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;METABOLISM/PK;INCREASED;EXPOSURE;;;;CAUTION_DRUG_ACCUMULATION
INDOMETHACIN;CYP2C9;G;rs2153628;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEMCITABINE;CDA;AA;rs2072671;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;;POOR_METABOLIZER;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
VENLAFAXINE;SLC6A4;TT;rs25531;EFFICACY;INCREASED;CLINICAL_BENEFIT;;PEOPLE;DISEASE:ANXIETY_DISORDERS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ENDOXIFEN;CYP2D6;;POOR METABOLIZER;METABOLISM/PK;DECREASED;CONCENTRATIONS;;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;;POOR METABOLIZER;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
NIMODIPINE;CACNA1C;CC;rs2239128;EFFICACY;INCREASED;RESPONSE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ENDOXIFEN;CYP2D6;;INTERMEDIATE METABOLIZER;METABOLISM/PK;DECREASED;CONCENTRATIONS;;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
NIMODIPINE;CACNA1C;CG;rs2239050;EFFICACY;INCREASED;RESPONSE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OMEPRAZOLE;CYP2C19;;POOR METABOLIZER;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
TRAMADOL;CYP2D6;;ULTRARAPID_METABOLIZER;METABOLISM/PK;INCREASED;METABOLISM;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;;POOR METABOLIZER;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
TRAMADOL;CYP2D6;;POOR_METABOLIZER;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
MARAVIROC;CYP3A5;;POOR METABOLIZER;METABOLISM/PK;DECREASED;CONCENTRATIONS;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
VENLAFAXINE;GABRQ;AA + AT;rs3810651;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
METOPROLOL;CYP2D6;;NORMAL METABOLIZER;METABOLISM/PK;INCREASED;CLEARANCE;;WOMEN;OTHER:PREGNANCY;LIKELIHOOD_THERAPEUTIC_FAILURE
CYTARABINE, IDARUBICIN;DCK;G;rs80143932;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:ACUTE_MYELOID_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
FENTANYL, HYDROMORPHONE, OPIOIDS, OXYCODONE, TRAMADOL;CYP2D6;;ULTRARAPID_METABOLIZER;DOSAGE;INCREASED;DOSE;;WOMEN;OTHER:SURGERY;CAUTION_DOSE_ADJUST
2-HYDROXYATORVASTATIN, 4-HYDROXYATORVASTATIN, ATORVASTATIN;UGT1A3;*2;UGT1A3*1, UGT1A3*2;METABOLISM/PK;DECREASED;EXPOSURE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOZAPINE, N-DESMETHYLCLOZAPINE;SLC6A4;HTTLPR short form (S allele);SLC6A4 HTTLPR LONG FORM (L ALLELE), SLC6A4 HTTLPR SHORT FORM (S ALLELE);METABOLISM/PK;DECREASED;CONCENTRATIONS;;PEOPLE;OTHER:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_FAILURE
IBOGAINE;CYP2D6;;POOR_METABOLIZER;METABOLISM/PK;DECREASED;CLEARANCE;;PEOPLE;OTHER:OPIOID-RELATED_DISORDERS;CAUTION_DRUG_ACCUMULATION
ATORVASTATIN, ATORVASTATIN LACTONE;CYP3A4;*2 + *22;CYP3A4*1, CYP3A4*2, CYP3A4*22;METABOLISM/PK;INCREASED;EXPOSURE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
ATOMOXETINE;CYP2D6;*10/*10;CYP2D6*10;METABOLISM/PK;INCREASED;EXPOSURE;;CHILDREN;OTHER:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY;CAUTION_DRUG_ACCUMULATION
ATOMOXETINE;CYP2D6;*10/*10;CYP2D6*10;EFFICACY;INCREASED;CLINICAL_BENEFIT;;CHILDREN;OTHER:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS
AMPHETAMINE, LISDEXAMFETAMINE;CYP2D6;;POOR_METABOLIZER;EFFICACY;INCREASED;CLINICAL_BENEFIT;;CHILDREN;OTHER:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS
SELECTIVE SEROTONIN REUPTAKE INHIBITORS, VENLAFAXINE;GRIA3;CC;rs502434;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
NICOTINE;CYP2A6;*41;CYP2A6*1, CYP2A6*41;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
NICOTINE;CYP2A6;*39;CYP2A6*1, CYP2A6*39;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
ISONIAZID;NAT2;;SLOW_ACETYLATOR;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;OTHER:TUBERCULOSIS;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;INCREASED;EXPOSURE;;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;HLA-DQA1;*05;HLA-DQA1*05;EFFICACY;DECREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:INFLAMMATORY_BOWEL_DISEASES, OTHER:INFLAMMATION;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;DOSAGE, EFFICACY;;DOSE;;PEOPLE;OTHER:PERCUTANEOUS_CORONARY_INTERVENTION;CAUTION_DOSE_ADJUST
METOPROLOL;CYP2D6;*10/*87 + *10/*95 + *97/*97;CYP2D6*1, CYP2D6*10, CYP2D6*87, CYP2D6*95, CYP2D6*97;METABOLISM/PK;INCREASED;EXPOSURE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;;POOR_METABOLIZER;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
1-HYDROXYMIDAZOLAM, MIDAZOLAM;CYP3A4;*1/*22;CYP3A4*1, CYP3A4*22;METABOLISM/PK;INCREASED;CONCENTRATIONS;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*1/*17;CYP2C19*1, CYP2C19*17;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
SELECTIVE SEROTONIN REUPTAKE INHIBITORS, VENLAFAXINE;GRIA3;TT;rs3761554;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CALU;G;rs339097;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ISONIAZID;NAT2;;NAT2 INTERMEDIATE_ACETYLATOR;METABOLISM/PK;INCREASED;CLEARANCE;;PEOPLE;OTHER:TUBERCULOSIS;LIKELIHOOD_THERAPEUTIC_FAILURE
DIHYDROARTEMISININ;CYP2B6;*6/*6 + *18/*18 + *1/*6;CYP2B6*1, CYP2B6*6, CYP2B6*18;METABOLISM/PK;DECREASED;CONCENTRATIONS;;PEOPLE;OTHER:MALARIA_FALCIPARUM;LIKELIHOOD_THERAPEUTIC_FAILURE
DESBUTYL LUMEFANTRINE;CYP3A5;*1/*3;CYP3A5*1, CYP3A5*3, CYP3A5*6;METABOLISM/PK;DECREASED;CONCENTRATIONS;;PEOPLE;OTHER:MALARIA_FALCIPARUM;LIKELIHOOD_THERAPEUTIC_FAILURE
SERTRALINE;CYP2D6;*2;CYP2D6*1, CYP2D6*2;METABOLISM/PK;DECREASED;CLEARANCE;;PEOPLE;OTHER:SUBSTANCE-RELATED_DISORDERS, OTHER:MAJOR_DEPRESSIVE_DISORDER,OTHER:ANXIETY_DISORDERS, OTHER:BORDERLINE_PERSONALITY_DISORDER;CAUTION_DRUG_ACCUMULATION
SERTRALINE;CYP2C19;*1/*2 + *2/*2 + *2/*17;CYP2C19*1, CYP2C19*2, CYP2C19*17;METABOLISM/PK;DECREASED;CLEARANCE;;PEOPLE;OTHER:SUBSTANCE-RELATED_DISORDERS, OTHER:MAJOR_DEPRESSIVE_DISORDER,OTHER:ANXIETY_DISORDERS, OTHER:BORDERLINE_PERSONALITY_DISORDER;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;ABCC2;TT;rs3740066;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
LEVONORGESTREL;CYP2B6;;POOR_METABOLIZER;METABOLISM/PK;INCREASED;CLEARANCE;;WOMEN;OTHER:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
SELECTIVE SEROTONIN REUPTAKE INHIBITORS, VENLAFAXINE;GRIA3;TT;rs3761555;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;NKX2-6;AG + GG;rs310279;DOSAGE;INCREASED;DOSE;;PEOPLE;OTHER:HEART_VALVE_REPLACEMENT;CAUTION_DOSE_ADJUST
CYTARABINE, IDARUBICIN;DCK;T;rs2306744;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:ACUTE_MYELOID_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
VENLAFAXINE;HTR2A;AG + GG;rs7997012;EFFICACY;INCREASED;CLINICAL_BENEFIT;;PEOPLE;DISEASE:ANXIETY_DISORDERS;LIKELIHOOD_THERAPEUTIC_SUCCESS
VORICONAZOLE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;OTHER:THERAPEUTIC_DRUG_MONITORING_ANALYSES;CAUTION_DRUG_ACCUMULATION
ANTIEPILEPTICS;;CC + CT;rs16935279;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:BIPOLAR_DISORDER, DISEASE:PSYCHOTIC_DISORDER;CAUTION_DRUG_ACCUMULATION
FOLLITROPIN BETA, UROFOLLITROPIN;FSHR;CC + CT;rs6166;DOSAGE;INCREASED;DOSE;;WOMEN;;CAUTION_DOSE_ADJUST
PAROXETINE;CYP2D6;;ULTRARAPID_METABOLIZER;METABOLISM/PK;DECREASED;STEADY-STATE_CONCENTRATION;;PEOPLE;OTHER:MAJOR_DEPRESSIVE_DISORDER, OTHER:ANXIETY_DISORDERS,OTHER:PANIC_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
PAROXETINE;CYP2D6;;ULTRARAPID_METABOLIZER;EFFICACY;DECREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C19;*1/*17 + *17/*17;CYP2C19*1, CYP2C19*2, CYP2C19*17;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
ATORVASTATIN;CYP2C19;*2 + *4 + *8;CYP2C19*1, CYP2C19*2, CYP2C19*4, CYP2C19*8, CYP2C19*11;EFFICACY;DECREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:CARDIOVASCULAR_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
CISPLATIN, IRINOTECAN;UBE2I;CG;rs9597;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;FRAS1;AA + AG;rs4386623;DOSAGE;INCREASED;DOSE;;PEOPLE;OTHER:HEART_VALVE_REPLACEMENT;CAUTION_DOSE_ADJUST
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:GASTROESOPHAGEAL_REFLUX;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;FAM201A;AG + GG;rs1890109;DOSAGE;INCREASED;DOSE;;PEOPLE;OTHER:HEART_VALVE_REPLACEMENT;CAUTION_DOSE_ADJUST
METHOTREXATE;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
VALPROIC ACID;SCN1A;T;rs3812718;EFFICACY;INCREASED;CLINICAL_BENEFIT;;CHILDREN;OTHER:EPILEPSY;LIKELIHOOD_THERAPEUTIC_SUCCESS
PANTOPRAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:ULCER;LIKELIHOOD_THERAPEUTIC_FAILURE
PANTOPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:ULCER;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;CYP2D6;*10;CYP2D6*1, CYP2D6*10;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
CAPECITABINE;DPYD;CC + CT;rs1801159;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:GASTROESOPHAGEAL_CANCER;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;DRD2;A;rs6277;EFFICACY;INCREASED;RESPONSE;;MEN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPTOPRIL;ACE;del/del;rs1799752;EFFICACY;INCREASED;RESISTANCE;;PEOPLE;DISEASE:DIABETES_MELLITUS;LIKELIHOOD_THERAPEUTIC_FAILURE
APIXABAN, DABIGATRAN, EDOXABAN, RIVAROXABAN;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;OTHER:THROMBOEMBOLISM;CAUTION_DRUG_ACCUMULATION
BUPROPION;SLC6A4;HTTLPR long form (L allele)/HTTLPR short form (S allele) + HTTLPR long form (L allele)/HTTLPR long form (L allele);SLC6A4 HTTLPR LONG FORM (L ALLELE), SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:TOBACCO_USE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
LOSARTAN;CYP2C9;*1/*5 + *5/*6;CYP2C9*1, CYP2C9*5, CYP2C9*6;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
ETHANOL;OPRM1;A;rs648007;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FAMOTIDINE, OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED;RESPONSE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
RABEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED;RESPONSE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
ESOMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;METABOLISM/PK;INCREASED;METABOLISM;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
MIDAZOLAM;CYP3A4;*1/*22;CYP3A4*1, CYP3A4*22;METABOLISM/PK;DECREASED;CLEARANCE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
RABEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED;RESPONSE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
ETHANOL;OPRM1;AG + GG;rs1799971;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CC;rs776746;DOSAGE;INCREASED;EXPOSURE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
PRIMAQUINE;CYP2D6;*4/*41 + *5/*6;CYP2D6*1, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*10, CYP2D6*41;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:MALARIA;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;T;rs1799853;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
NICOTINE;CHRNA7;CC;rs2337980;EFFICACY;INCREASED;RESPONSE;;WOMEN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUPROPION;DRD2;GG;rs1799732;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:TOBACCO_USE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;CT + TT;rs7294;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
SIMVASTATIN;CYP3A4;*1/*22 + *22/*22;CYP3A4*1, CYP3A4*22;METABOLISM/PK;;CONCENTRATIONS;;;;CAUTION_DOSE_ADJUST
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED;RESPONSE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED;RESPONSE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
VORICONAZOLE;CYP2C19;*1/*17;CYP2C19*1, CYP2C19*2, CYP2C19*17;METABOLISM/PK;DECREASED;CONCENTRATIONS;;PEOPLE;DISEASE:FUNGAL_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
QUETIAPINE;CYP3A4;*1/*22 + *22/*22;CYP3A4*1, CYP3A4*22;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;OTHER:PSYCHOTIC_DISORDER;CAUTION_DRUG_ACCUMULATION
WARFARIN;EPHX1;A;rs1131873;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
TRIMIPRAMINE;CYP2C19;*2;CYP2C19*1, CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
FAMOTIDINE, OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED;RESPONSE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
METFORMIN;SLC2A2;C;rs8192675;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:DIABETES_MELLITUS;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;G;rs28371686;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;METABOLISM;;PEOPLE;DISEASE:CONNECTIVE_TISSUE_DISEASES;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;T;rs28371685;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
DULOXETINE;CYP2D6;CC;rs3892097;EFFICACY;INCREASED;CLINICAL_BENEFIT;;MEN;OTHER:ALCOHOL_ABUSE, OTHER:DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN_SN-38;UGT1A1;*1/*28 + *28/*28;UGT1A1*1, UGT1A1*28;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:NEOPLASMS;CAUTION_DRUG_ACCUMULATION
RABEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;METABOLISM/PK;INCREASED;METABOLISM;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;del;rs9332131;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
HYDROXYUREA;BCL11A;A;rs4671393;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:BETA-THALASSEMIA_AND_RELATED_DISEASES;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;A;rs7900194;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ROSIGLITAZONE;CYP2C8;*3;CYP2C8*1, CYP2C8*3;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:DIABETES_MELLITUS;LIKELIHOOD_THERAPEUTIC_FAILURE
PHENYTOIN;CYP2C9;*1/*3;CYP2C9*1, CYP2C9*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:EPILEPSY;CAUTION_DRUG_ACCUMULATION
PANTOPRAZOLE;CYP2C19;*1/*2;CYP2C19*1, CYP2C19*2;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
BETA BLOCKING AGENTS;KL;A/del + del/del;rs36217263;EFFICACY;DECREASED;RESPONSE;;PEOPLE;OTHER:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;*6/*6 + *1/*6;CYP2B6*1, CYP2B6*6;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*2/*2 + *1/*2 + *1/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:FUNGAL_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
GEMCITABINE;RRM1;AC;rs12806698;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOXETINE, SERTRALINE;SLC6A4;(CCCACCCGA)12/(CCCACCCGA)12;rs57098334;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUPROPION;ACE;TT;rs8075924;EFFICACY;DECREASED;RESPONSE;;PEOPLE;OTHER:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
LORAZEPAM, VALPROIC ACID;UGT2B7;A;rs7438284;EFFICACY;INCREASED;RESPONSE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RABEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;METABOLISM/PK;INCREASED;METABOLISM;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
LORAZEPAM, VALPROIC ACID;UGT2B7;T;rs7439366;EFFICACY;INCREASED;RESPONSE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
SERTRALINE;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);SLC6A4 HTTLPR LONG FORM (L ALLELE), SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
SUNITINIB;CYP3A4;*1/*22 + *22/*22;CYP3A4*1, CYP3A4*22;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
HYDROXYCHLOROQUINE;CYP3A4;CC;rs3735451;METABOLISM/PK;DECREASED;CONCENTRATIONS;;PEOPLE;OTHER:RHEUMATOID_ARTHRITIS, OTHER:SYSTEMIC_LUPUS_ERYTHEMATOSUS;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL;XRCC1;CC;rs25487;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:RECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
MIRTAZAPINE;CYP2B6;*6/*6;CYP2B6*6;METABOLISM/PK;INCREASED;METABOLISM;;PEOPLE;DISEASE:DEPRESSION;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOBAZAM;CYP2C19;*1/*2 + *1/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:EPILEPSY;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEMCITABINE;RRM1;CT;rs11030918;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ROSUVASTATIN;HNF4A;C;rs3212207;METABOLISM/PK;INCREASED;EXPOSURE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;ABCB1;AG + GG;rs1045642;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
ACENOCOUMAROL;CYP2C9;*1/*3 + *2/*3;CYP2C9*1, CYP2C9*2, CYP2C9*3;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;CYP2D6;;INTERMEDIATE_METABOLIZER;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
ROSUVASTATIN;ABCC2;A;rs8187710;METABOLISM/PK;DECREASED;EXPOSURE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;DOSAGE, EFFICACY;DECREASED;RESPONSE;;PEOPLE;OTHER:PERCUTANEOUS_CORONARY_INTERVENTION;CAUTION_DOSE_ADJUST
RABEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED;RESPONSE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOSPORINE;CYP3A5;*1/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;DECREASED;CONCENTRATIONS;;MEN;;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOSPORINE;CYP3A4;A;rs35599367;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
FLUOXETINE;CYP2D6;*1/*1 + *10/*10 + *1/*4 + *1/*10;CYP2D6*1, CYP2D6*4, CYP2D6*10;METABOLISM/PK;DECREASED;CONCENTRATIONS;;PEOPLE;OTHER:ANXIETY_DISORDERS, OTHER:DEPRESSION,OTHER:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
CODEINE;CYP2D6;*4/*4;CYP2D6*1, CYP2D6*4;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:CHRONIC_KIDNEY_FAILURE;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*1/*17 + *17/*17;CYP2C19*1, CYP2C19*17;METABOLISM/PK;INCREASED;METABOLISM;;;OTHER:PATIENTS_WITH_DECREASED_CONCENTRATIONS_OF_VORICONAZOLE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
DOCETAXEL, THALIDOMIDE;PPARD;T;rs3734254;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:PROSTATIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATENOLOL, METOPROLOL;OR10P1;G;rs17117817;PD;DECREASED;RESPONSE;;PEOPLE;OTHER:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_FAILURE
ARIPIPRAZOLE;CYP2D6;*5 + *10 + *41;CYP2D6*1, CYP2D6*5, CYP2D6*10, CYP2D6*41;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
TRIMIPRAMINE;CYP2C19;*2;CYP2C19*1, CYP2C19*2;METABOLISM/PK;DECREASED;CLEARANCE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
PIOGLITAZONE;CYP2C8;*1/*1;CYP2C8*1, CYP2C8*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
ARIPIPRAZOLE;CYP2D6;*3/*3 + *4/*4;CYP2D6*1, CYP2D6*1X2, CYP2D6*3, CYP2D6*4;METABOLISM/PK;INCREASED;CONCENTRATIONS;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;*1/*2 + *1/*3;CYP2C9*1, CYP2C9*2, CYP2C9*3;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
CARBOPLATIN, GEMCITABINE;RRM1;AC;rs12806698;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
FAMOTIDINE, LANSOPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED;RESPONSE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
FAMOTIDINE, LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED;RESPONSE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
ABATACEPT;HLA-DRB1;*04:01 + *04:04 + *04:05 + *04:10 + *10:01;HLA-DRB1*04:01, HLA-DRB1*04:04, HLA-DRB1*04:05, HLA-DRB1*04:10, HLA-DRB1*10:01;EFFICACY;INCREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHADONE;;AG + GG;rs17180299;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:OPIOID-RELATED_DISORDERS;CAUTION_DRUG_ACCUMULATION
WARFARIN;CALU;G;rs339097;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
NOSCAPINE;CYP2C9;*1/*1 + *1/*9;CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*9;METABOLISM/PK;INCREASED;CLEARANCE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;METABOLISM;;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
ATENOLOL, METOPROLOL;SNX9;A;rs2364349;PD;DECREASED;RESPONSE;;PEOPLE;OTHER:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;;GT + TT;rs11265572;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
WARFARIN;STX4;T;rs10871454;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
SIROLIMUS, TEMSIROLIMUS;CYP3A5;CT;rs776746;METABOLISM/PK;DECREASED;CONCENTRATIONS;;PEOPLE;DISEASE:URINARY_BLADDER_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
PERAMPANEL;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;CHILDREN;OTHER:EPILEPSY;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*2 + *3;CYP2C19*1, CYP2C19*2, CYP2C19*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
ENALAPRIL;ACE;del/del;rs1799752;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:ESSENTIAL_HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
URACIL;DPYD;c.295_298delTCAT (*7);DPYD C.295_298DELTCAT (*7), DPYD REFERENCE;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
URACIL;DPYD;c.2846A>T;DPYD C.2846A>T, DPYD REFERENCE;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
URACIL;DPYD;c.1679T>G (*13);DPYD C.1679T>G (*13), DPYD REFERENCE;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
URACIL;DPYD;c.1905+1G>A (*2A);DPYD C.1905+1G>A (*2A), DPYD REFERENCE;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
N-DESMETHYLTAMOXIFEN;CYP2D6;*1/*29 + *1/*41 + *2/*41 + *35/*41 + *1/*4 + *1/*5 + *2/*4 + *1/*3 + *35/*4 + *1/*6 + *35/*5 + *2/*9 + *1/*10 + *2/*10 + *35/*10;CYP2D6*1, CYP2D6*1XN, CYP2D6*2, CYP2D6*2XN, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*9, CYP2D6*10, CYP2D6*29, CYP2D6*35, CYP2D6*41;METABOLISM/PK;DECREASED;METABOLISM;;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_DRUG_ACCUMULATION
N-DESMETHYLTAMOXIFEN;CYP2D6;*4/*4 + *41/*4 + *41/*3 + *10/*4 + *9/*41 + *17/*41 + *41/*41 + *9/*5 + *1/*29;CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*9, CYP2D6*10, CYP2D6*17, CYP2D6*29, CYP2D6*35, CYP2D6*41;METABOLISM/PK;DECREASED;METABOLISM;;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_DRUG_ACCUMULATION
ATORVASTATIN;CYP3A5;*3/*3;CYP3A5*3;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:HYPERCHOLESTEROLEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
N-DESMETHYLTAMOXIFEN;CYP2D6;*10/*10 + *1/*10;CYP2D6*1, CYP2D6*10;METABOLISM/PK;INCREASED;CONCENTRATIONS;;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_DRUG_ACCUMULATION
ESCITALOPRAM;CYP2D6;;POOR_METABOLIZER;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
ESCITALOPRAM;CYP2D6;;INTERMEDIATE_METABOLIZER;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;ABCB1;CC;rs3842;METABOLISM/PK;INCREASED;EXPOSURE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;;POOR_METABOLIZER;METABOLISM/PK;INCREASED;EXPOSURE;;INFANTS;;CAUTION_DRUG_ACCUMULATION
BCR-ABL TYROSINE KINASE INHIBITORS;HLA-A;*03:01;HLA-A*03:01;EFFICACY;DECREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;LIKELIHOOD_THERAPEUTIC_FAILURE
BCR-ABL TYROSINE KINASE INHIBITORS;HLA-A;*23:17;HLA-A*23:17;EFFICACY;DECREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;LIKELIHOOD_THERAPEUTIC_FAILURE
BCR-ABL TYROSINE KINASE INHIBITORS;HLA-B;*57:03;HLA-B*57:03;EFFICACY;INCREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3, CYP3A5*7;METABOLISM/PK;INCREASED;CLEARANCE;;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;CYP2D6;*2 + *9 + *10 + *35 + *41;CYP2D6*1, CYP2D6*2, CYP2D6*9, CYP2D6*10, CYP2D6*35, CYP2D6*41;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
ANTIDEPRESSANTS;CYP2C19;;POOR_METABOLIZER;EFFICACY;INCREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHADONE;CYP2B6;*6 + *18;CYP2B6*1, CYP2B6*6, CYP2B6*18;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;OTHER:OPIOID-RELATED_DISORDERS;CAUTION_DRUG_ACCUMULATION
LAMOTRIGINE;UGT1A4;*3b;UGT1A4*3B;EFFICACY;DECREASED;CLINICAL_BENEFIT;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
DOCETAXEL, THALIDOMIDE;PPARD;C;rs2016520;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:PROSTATIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;CHILDREN;OTHER:LIVER_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
INFLIXIMAB;HLA-DQA1;*05;HLA-DQA1*05;EFFICACY;DECREASED;RESPONSE;;PEOPLE;OTHER:CROHN_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*2 + *4;CYP2C19*1, CYP2C19*2, CYP2C19*4, CYP2C19*17;EFFICACY;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
DOCETAXEL, THALIDOMIDE;CHST3;A;rs1871450;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:PROSTATIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
PROPOFOL;CYP2B6;*6;CYP2B6*1, CYP2B6*6;TOXICITY;DECREASED;RESPONSE;;PEOPLE;OTHER:BRAIN_INJURY;LIKELIHOOD_THERAPEUTIC_SUCCESS
TILDRAKIZUMAB;PDE4D;CT/CT;rs10556657;EFFICACY;DECREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:PSORIASIS;LIKELIHOOD_THERAPEUTIC_FAILURE
BUPRENORPHINE, DIHYDROCODEINE, FENTANYL, HYDROMORPHONE, METHADONE, MORPHINE, OXYCODONE, PIRITRAMIDE, TILIDINE, TRAMADOL;ABCB1;A;rs1045642;DOSAGE;DECREASED;DOSE;;PEOPLE;DISEASE:PAIN;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;DOSAGE;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;OTHER:HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A4;*1/*22;CYP3A4*1, CYP3A4*22;METABOLISM/PK;DECREASED;CLEARANCE;;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
SIROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
DOCETAXEL, THALIDOMIDE;PPARD;C;rs1883322;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:PROSTATIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
PHENYTOIN;CYP2C19;;CYP2C19 INTERMEDIATE_METABOLIZER;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
VALPROIC ACID;CYP2C19;;CYP2C19 INTERMEDIATE_METABOLIZER;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
CARBAMAZEPINE;CYP3A5;;POOR_METABOLIZER;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
VALPROIC ACID;CYP2C9;;INTERMEDIATE_METABOLIZER;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
VALPROIC ACID;UGT1A6;*2a;UGT1A6*1A, UGT1A6*2A;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
PHENYTOIN;CYP2C9;;INTERMEDIATE_METABOLIZER;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
IRINOTECAN_SN-38;UGT1A1;*1/*28;UGT1A1*1, UGT1A1*28;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;OTHER:COLORECTAL_NEOPLASMS, OTHER:METASTATIC_NEOPLASM;CAUTION_DRUG_ACCUMULATION
DOCETAXEL, THALIDOMIDE;CHST3;A;rs12418;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:PROSTATIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
FOLFIRI, IRINOTECAN;UGT1A1;*28 + *60;UGT1A1*1, UGT1A1*28, UGT1A1*60;DOSAGE;DECREASED;DOSE;;PEOPLE;OTHER:COLORECTAL_NEOPLASMS;CAUTION_DOSE_ADJUST
MIRABEGRON;CYP2D6;;INTERMEDIATE_METABOLIZER;METABOLISM/PK;INCREASED;HALF-LIFE_TIME;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;METABOLISM/PK;INCREASED;METABOLISM;;PEOPLE;OTHER:PEPTIC_ULCER_DISEASE, OTHER:GASTROESOPHAGEAL_REFLUX,OTHER:ESOPHAGITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
MERCAPTOPURINE;TPMT;*1/*8;TPMT*1, TPMT*8;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;*1/*1;CYP2C9*1;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2 + *3 + *8;CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*8;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ARIPIPRAZOLE;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *1/*9;CYP2D6*1, CYP2D6*1X2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*9;METABOLISM/PK;INCREASED;CONCENTRATIONS;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
PANTOPRAZOLE;CYP2C19;*1/*2;CYP2C19*1, CYP2C19*2;METABOLISM/PK;DECREASED;CLEARANCE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
OPIOIDS;OPRM1;GG;rs1799971;DOSAGE;INCREASED;DOSE;;WOMEN;OTHER:CAESARIAN_SECTION, OTHER:PAIN;CAUTION_DOSE_ADJUST
DULOXETINE;DRD3;GG;rs963468;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:ANXIETY_DISORDERS;LIKELIHOOD_THERAPEUTIC_FAILURE
METFORMIN;C11orf65;C;rs11212617;EFFICACY;INCREASED;CLINICAL_BENEFIT;;PEOPLE;DISEASE:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOSPORINE;CYP3A5;CC;rs776746;DOSAGE, METABOLISM/PK;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
EFAVIRENZ, NEVIRAPINE;NR1I3;AA + AG;rs2307424;EFFICACY;INCREASED;RESPONSE;;PEOPLE;EFFICACY:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
VORICONAZOLE;CYP2C19;*1/*1 + *1/*2;CYP2C19*1, CYP2C19*2, CYP2C19*17;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;CHILDREN;OTHER:HEMATOLOGIC_NEOPLASMS, OTHER:HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
ARIPIPRAZOLE;CYP3A4;*1/*22 + *22/*22;CYP3A4*1, CYP3A4*22;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
ARIPIPRAZOLE, DEHYDROARIPIPRAZOLE;CYP2D6;;POOR_METABOLIZER;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
PIMOZIDE;CYP3A4;*22;CYP3A4*1, CYP3A4*22;METABOLISM/PK;DECREASED;CONCENTRATIONS;;PEOPLE;DISEASE:PSYCHOTIC_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
DOCETAXEL, THALIDOMIDE;CHST3;C;rs4148943;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:PROSTATIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOCETAXEL, THALIDOMIDE;CHST3;C;rs4148945;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:PROSTATIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
GLYBURIDE;ABCB11;G;rs4148776;EFFICACY;INCREASED;RESPONSE;;PEOPLE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IMATINIB;SLCO1B3;AA + AG;rs7311358;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;LIKELIHOOD_THERAPEUTIC_FAILURE
IMATINIB;SLCO1B3;GG + GT;rs4149117;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;LIKELIHOOD_THERAPEUTIC_FAILURE
PRAZIQUANTEL;CYP2C19;*1/*2 + *2/*2 + *1/*3 + *3/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;METABOLISM/PK;INCREASED;CONCENTRATIONS;;CHILDREN;OTHER:SCHISTOSOMIASIS;CAUTION_DRUG_ACCUMULATION
ARIPIPRAZOLE;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *1/*9;CYP2D6*1, CYP2D6*1X2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*9;METABOLISM/PK;DECREASED;CLEARANCE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
ARIPIPRAZOLE;CYP2D6;*3/*3 + *4/*4;CYP2D6*1, CYP2D6*1X2, CYP2D6*3, CYP2D6*4;METABOLISM/PK;DECREASED;CLEARANCE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
FESOTERODINE;CYP2D6;;ULTRARAPID_METABOLIZER;METABOLISM/PK;INCREASED;CLEARANCE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
VORICONAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA_OTHER:LYMPHOMA,OTHER:ACUTE_MYELOID_LEUKEMIA;CAUTION_DRUG_ACCUMULATION
GLYBURIDE;CHST13;C;rs1054097;EFFICACY;INCREASED;RESPONSE;;PEOPLE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
LACOSAMIDE;CYP2C19;;NORMAL_METABOLIZER;METABOLISM/PK;DECREASED;EXPOSURE;;CHILDREN;OTHER:EPILEPSY;LIKELIHOOD_THERAPEUTIC_FAILURE
FESOTERODINE;CYP2D6;;CYP2D6 INTERMEDIATE_METABOLIZER;METABOLISM/PK;DECREASED;CLEARANCE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
ROSIGLITAZONE;CYP2C8;C;rs10509681;DOSAGE, METABOLISM/PK;INCREASED;METABOLISM;;HEALTHY;;CAUTION_DOSE_ADJUST
LACOSAMIDE;ABCC2;T;rs717620;METABOLISM/PK;DECREASED;EXPOSURE;;CHILDREN;OTHER:EPILEPSY;LIKELIHOOD_THERAPEUTIC_FAILURE
FESOTERODINE;CYP3A4;;INTERMEDIATE_METABOLIZER;METABOLISM/PK;INCREASED;CLEARANCE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
ZUCLOPENTHIXOL;CYP2D6;*1/*3 + *1/*4;CYP2D6*1, CYP2D6*3, CYP2D6*4;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
ZUCLOPENTHIXOL;CYP2D6;*4/*4;CYP2D6*1, CYP2D6*3, CYP2D6*4;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
PHENYTOIN;CYP2C9;*1/*1;CYP2C9*1, CYP2C9*2, CYP2C9*3;METABOLISM/PK;DECREASED;CONCENTRATIONS;;PEOPLE;OTHER:SURGERY;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOZAPINE;CYP2D6;;NORMAL_METABOLIZER;DOSAGE;INCREASED;DOSE;;PEOPLE;OTHER:SCHIZOPHRENIA, OTHER:PSYCHOTIC_DISORDER;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2B6;;CYP2B6 INTERMEDIATE_METABOLIZER;METABOLISM/PK;INCREASED;CONCENTRATIONS;;CHILDREN;OTHER:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
THIOGUANOSINE DIPHOSPHATE, THIOGUANOSINE MONOPHOSPHATE, THIOGUANOSINE TRIPHOSPHATE;TPMT;*3A + *3B + *3C;TPMT*1, TPMT*3A, TPMT*3B, TPMT*3C;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;OTHER:INFLAMMATORY_BOWEL_DISEASES;CAUTION_DRUG_ACCUMULATION
METOPROLOL;CYP2D6;;POOR_METABOLIZER;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
CLOZAPINE;ITIH3;AA;rs2535629;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATOMOXETINE;CYP2D6;;POOR_METABOLIZER;EFFICACY;INCREASED;RESPONSE;;CHILDREN;DISEASE:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS
COTININE;CYP2A6;;LOW ACTIVITY;METABOLISM/PK;INCREASED;METABOLISM;;PEOPLE;OTHER:TOBACCO_USE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
COTININE;CYP2A6;;LOW ACTIVITY;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
NICOTINE;CYP2A6;*2 + *4 + *9 + *17 + *20 + *23 + *25 + *26 + *27 + *28 + *35 + *12 + *24;CYP2A6*1, CYP2A6*2, CYP2A6*4, CYP2A6*9, CYP2A6*12, CYP2A6*17, CYP2A6*20, CYP2A6*23, CYP2A6*24, CYP2A6*25, CYP2A6*26, CYP2A6*27, CYP2A6*28, CYP2A6*35;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
ESCITALOPRAM;SLC6A4;HTTLPR short form (S allele);SLC6A4 HTTLPR LONG FORM (L ALLELE), SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;DECREASED;RESPONSE;;PEOPLE;OTHER:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;;CYP2D6 POOR_METABOLIZER;METABOLISM/PK;DECREASED;CONCENTRATIONS;;PEOPLE;OTHER:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
CAFFEINE;ADORA1;CC;rs10920573;EFFICACY;DECREASED;CLINICAL_BENEFIT;;INFANTS;OTHER:APNEA_OF_PREMATURITY;LIKELIHOOD_THERAPEUTIC_FAILURE
NORQUETIAPINE;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
QUETIAPINE;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
AMLODIPINE;CACNA1D;GG;rs312481;EFFICACY;INCREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2A;ZHX2;C;rs17289471;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:HEPATITIS_B_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
BERBERINE;CYP2D6;;POOR_METABOLIZER;METABOLISM/PK;DECREASED;METABOLISM;;WOMEN;;CAUTION_DRUG_ACCUMULATION
CLOPIDOGREL;CYP2C19;T;rs12248560;EFFICACY, OTHER;;RESPONSE;;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;CAUTION_DOSE_ADJUST
RANIBIZUMAB;VEGFA;CC + CT;rs833069;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:MACULAR_DEGENERATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CC;rs4646449;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
ONDANSETRON;CYP2D6;;POOR_METABOLIZER;DOSAGE;INCREASED;DOSE;;PEOPLE;OTHER:SURGERY;CAUTION_DOSE_ADJUST
IMATINIB;ABCA3;GG + GT;rs150929;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;LIKELIHOOD_THERAPEUTIC_FAILURE
METFORMIN;CBARP, STK11;TT;rs2301759;EFFICACY;DECREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_FAILURE
METFORMIN;SLC22A3;T;rs3127602;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
METFORMIN;PRKAA1;A;rs11749180;EFFICACY;DECREASED;RESPONSE;;PEOPLE;OTHER:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_FAILURE
METFORMIN;SLC29A4;A;rs10234709;EFFICACY;DECREASED;RESPONSE;;PEOPLE;OTHER:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_FAILURE
METFORMIN;PRKAG2;T;rs4725434;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
METFORMIN;SLC47A1;A;rs2120274;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
METFORMIN;STK11;C;rs2301759;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
METFORMIN;SLC47A2;C;rs4621031;EFFICACY;DECREASED;RESPONSE;;PEOPLE;OTHER:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_FAILURE
ALECTINIB;CYP3A4;*1/*22 + *22/*22;CYP3A4*1, CYP3A4*22;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_DRUG_ACCUMULATION
METFORMIN;TCF7L2;T;rs7903146;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHADONE;OPRK1;CC;rs3802279;DOSAGE;DECREASED;DOSE;;PEOPLE;OTHER:HEROIN_DEPENDENCE;CAUTION_DOSE_ADJUST
LACOSAMIDE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;CHILDREN;OTHER:EPILEPSY;CAUTION_DRUG_ACCUMULATION
N-DESMETHYLTRAMADOL, O-DESMETHYLTRAMADOL;SLC22A1;AG;rs41267797;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;OTHER:DEATH;CAUTION_DRUG_ACCUMULATION
N,N-DIDESMETHYLTRAMADOL;CYP2D6;*4/*6 + *4/*5;CYP2D6*1, CYP2D6*2, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*10, CYP2D6*17, CYP2D6*29, CYP2D6*41, CYP2D6*45;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*1/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;CHILDREN;DISEASE:IMMUNOGLOBULIN_A_VASCULITIS;CAUTION_DRUG_ACCUMULATION
TOCILIZUMAB;IL6R;AG + GG;rs35717427;EFFICACY;DECREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
N-DESMETHYLTRAMADOL, O-DESMETHYLTRAMADOL;ABCC2;CT;rs17216317;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;OTHER:DEATH;CAUTION_DRUG_ACCUMULATION
TOCILIZUMAB;IL6R;CG + GG;rs6690230;EFFICACY;DECREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
TOCILIZUMAB;IL6R;AA + AG;rs11265621;EFFICACY;DECREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
TOCILIZUMAB;;AA;rs10108210;EFFICACY;DECREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
TOCILIZUMAB;CLEC2D;GG;rs1560011;EFFICACY;INCREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
TOCILIZUMAB;KCNMB1;AA + AG;rs703505;EFFICACY;DECREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
ESCITALOPRAM;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;OTHER:ELDERLY_ADULT, OTHER:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DRUG_ACCUMULATION
MORPHINE;CCL11;AA;rs17809012;EFFICACY;DECREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:NEOPLASMS, OTHER:PAIN;LIKELIHOOD_THERAPEUTIC_FAILURE
MORPHINE;IL16;TT;rs4778889;EFFICACY;INCREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:NEOPLASMS, OTHER:PAIN;LIKELIHOOD_THERAPEUTIC_SUCCESS
N-DESMETHYLTRAMADOL, O-DESMETHYLTRAMADOL;SLC22A1;CT;rs35235578;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;OTHER:DEATH;CAUTION_DRUG_ACCUMULATION
VALPROIC ACID;SLC16A1;GG;rs7169;EFFICACY;INCREASED;CLINICAL_BENEFIT;;CHILDREN;OTHER:EPILEPSY;LIKELIHOOD_THERAPEUTIC_SUCCESS
N-DESMETHYLTRAMADOL, O-DESMETHYLTRAMADOL;SLC22A1;C;rs9457841;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;OTHER:DEATH;CAUTION_DRUG_ACCUMULATION
N-DESMETHYLTRAMADOL, O-DESMETHYLTRAMADOL;SLC22A1;CC;rs34134157;METABOLISM/PK;DECREASED;CONCENTRATIONS;;PEOPLE;OTHER:DEATH;LIKELIHOOD_THERAPEUTIC_FAILURE
TENOFOVIR;ABCC4;AC + CC;rs3742106;TOXICITY;INCREASED;CONCENTRATIONS;;PEOPLE;OTHER:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
ANTIDEPRESSANTS;FKBP5;CT + TT;rs1360780;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACETAMINOPHEN SULFATE;CYP2E1;*1/*5B;CYP2E1*1, CYP2E1*5B;METABOLISM/PK;INCREASED;CONCENTRATIONS;;INFANTS;OTHER:PATENT_DUCTUS_ARTERIOSUS, OTHER:PREMATURE_BIRTH;CAUTION_DRUG_ACCUMULATION
FENTANYL;ABCC1;(A)14;rs58572178;METABOLISM/PK;INCREASED;CLEARANCE;;CHILDREN;OTHER:PAIN, OTHER:PREMATURE_BIRTH;LIKELIHOOD_THERAPEUTIC_FAILURE
VORICONAZOLE;CYP2C19;*2 + *17;CYP2C19*2, CYP2C19*17;DOSAGE;;DOSE;;CHILDREN;OTHER:HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION;CAUTION_DOSE_ADJUST
ROSUVASTATIN;ABCG2;;ABCG2 POOR_METABOLIZER;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
ROSUVASTATIN;NAT2;;NAT2 SLOW_ACETYLATOR;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
ROSUVASTATIN;TPMT;;INTERMEDIATE_METABOLIZER;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
DOXORUBICIN;CBR1;T;rs20572;METABOLISM/PK;INCREASED;CONCENTRATIONS;;WOMEN;OTHER:BREAST_NEOPLASMS;CAUTION_DRUG_ACCUMULATION
SUNITINIB;KDR;AG;rs34231037;EFFICACY;INCREASED;CLINICAL_BENEFIT;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIDEPRESSANTS;FKBP5;CC;rs3800373;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
GLICLAZIDE, GLIMEPIRIDE, GLIPIZIDE, GLYBURIDE;KCNQ1;GT + TT;rs163184;EFFICACY;INCREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
ISONIAZID;NAT2;;SLOW_ACETYLATOR;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;OTHER:TUBERCULOSIS;CAUTION_DRUG_ACCUMULATION
RAMIPRIL;SLCO1B1;;LOW ACTIVITY;METABOLISM/PK;INCREASED;CONCENTRATIONS;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
RAMIPRIL;ABCG2;;ABCG2 POOR_METABOLIZER;METABOLISM/PK;INCREASED;CONCENTRATIONS;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;DOSAGE;INCREASED;DOSE;;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
DULOXETINE;DRD3;CC + CT;rs324026;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:ANXIETY_DISORDERS;LIKELIHOOD_THERAPEUTIC_FAILURE
CYTARABINE, DAUNORUBICIN;RAD50;AA + AC;rs2299014;EFFICACY;INCREASED;RESISTANCE;;PEOPLE;OTHER:ACUTE_MYELOID_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
TENOFOVIR;ABCC4;TT;rs1751034;TOXICITY;INCREASED;CONCENTRATIONS;;PEOPLE;OTHER:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
DULOXETINE;DRD3;CT;rs324023;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:ANXIETY_DISORDERS;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ, NEVIRAPINE;NR1I2;AA + AC;rs1523127;EFFICACY;DECREASED;RESPONSE;;PEOPLE;EFFICACY:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
EZETIMIBE;ABCG8;;DEFICIENCY;EFFICACY;INCREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:FAMILIAL_HYPERCHOLESTEROLEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
EZETIMIBE;ABCG5;;DEFICIENCY;EFFICACY;INCREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:FAMILIAL_HYPERCHOLESTEROLEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
RABEPRAZOLE;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HELICOBACTER_INFECTIONS;LIKELIHOOD_THERAPEUTIC_SUCCESS
PANTOPRAZOLE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
DULOXETINE;DRD3;AG;rs167770;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:ANXIETY_DISORDERS;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;CYP2D6;;POOR_METABOLIZER;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:BIPOLAR_DISORDER, DISEASE:SCHIZOAFFECTIVE_DISORDER,DISEASE:SCHIZOPHRENIA;CAUTION_DRUG_ACCUMULATION
TAMSULOSIN;CYP2D6;*10 + *41;CYP2D6*10, CYP2D6*41;EFFICACY;INCREASED;CLINICAL_BENEFIT;;MEN;OTHER:PROSTATIC_HYPERPLASIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
HYDROXYUREA;HBG2;AA + AG;rs7482144;EFFICACY;INCREASED;CLINICAL_BENEFIT;;CHILDREN;OTHER:BETA-THALASSEMIA_AND_RELATED_DISEASES;LIKELIHOOD_THERAPEUTIC_SUCCESS
HYDROXYUREA;HBG2;AA;rs7482144;EFFICACY;INCREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:BETA-THALASSEMIA_AND_RELATED_DISEASES;LIKELIHOOD_THERAPEUTIC_SUCCESS
HYDROXYUREA;BCL11A;C;rs766432;EFFICACY;INCREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:BETA-THALASSEMIA_AND_RELATED_DISEASES;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;MTHFR;A;rs1801133;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
VORTIOXETINE;CYP2D6;*4/*4 + *4/*10;CYP2D6*1, CYP2D6*4, CYP2D6*10;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
ANTIEPILEPTICS;SCN1A;AA + AT;rs121917953;EFFICACY;INCREASED;RESISTANCE;;PEOPLE;OTHER:EPILEPSY;LIKELIHOOD_THERAPEUTIC_FAILURE
DEXTROMETHORPHAN;CYP2D6;*10/*10;CYP2D6*1, CYP2D6*10;METABOLISM/PK;INCREASED;CONCENTRATIONS;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;ENG;G;rs1800956;METABOLISM/PK;DECREASED;CLEARANCE;;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;PKD1L2;A;rs16954698;METABOLISM/PK;DECREASED;CLEARANCE;;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DRUG_ACCUMULATION
MERCAPTOPURINE;NUDT15;*1/*2 + *1/*3 + *1/*4 + *2/*4 + *3/*3;NUDT15*1, NUDT15*2, NUDT15*3, NUDT15*4;DOSAGE;DECREASED;DOSE;;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DOSE_ADJUST
PREGABALIN;NAT2;;SLOW_ACETYLATOR;METABOLISM/PK;INCREASED;EXPOSURE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
ANTIDEPRESSANTS;FKBP5;TT;rs1360780;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
PITAVASTATIN;CYP2C9;;CYP2C9 POOR_METABOLIZER;METABOLISM/PK;INCREASED;EXPOSURE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ, NEVIRAPINE;NR1I3;AG + GG;rs3003596;EFFICACY;DECREASED;RESPONSE;;PEOPLE;EFFICACY:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIDEPRESSANTS;FKBP5;AA;rs4713916;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
ENDOXIFEN;CYP2D6;*10/*10 + *2/*10;CYP2D6*1, CYP2D6*2, CYP2D6*10;METABOLISM/PK;DECREASED;CONCENTRATIONS;;WOMEN;OTHER:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
ENDOXIFEN;CYP2D6;;NORMAL_METABOLIZER;METABOLISM/PK;INCREASED;CONCENTRATIONS;;WOMEN;OTHER:BREAST_NEOPLASMS;CAUTION_DRUG_ACCUMULATION
CLOZAPINE;CYP2D6;C;rs202102799;METABOLISM/PK;DECREASED;CONCENTRATIONS;;PEOPLE;OTHER:SCHIZOPHRENIA, OTHER:PSYCHOTIC_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOZAPINE;CYP2D6;G;rs28371726;METABOLISM/PK;DECREASED;CONCENTRATIONS;;PEOPLE;OTHER:SCHIZOPHRENIA, OTHER:PSYCHOTIC_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOZAPINE, N-DESMETHYLCLOZAPINE;CYP2C19;*2/*2;CYP2C19*1, CYP2C19*2;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;OTHER:SCHIZOPHRENIA, OTHER:PSYCHOTIC_DISORDER;CAUTION_DRUG_ACCUMULATION
CLOZAPINE;DRD4;C;rs762502;EFFICACY;INCREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:SCHIZOPHRENIA, OTHER:PSYCHOTIC_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
NIFEDIPINE;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;CLEARANCE;;WOMEN;DISEASE:PREGNANCY;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOZAPINE;DRD4;del;rs2133251840;EFFICACY;INCREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:SCHIZOPHRENIA, OTHER:PSYCHOTIC_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOZAPINE, N-DESMETHYLCLOZAPINE;CYP1A2;;ULTRARAPID_METABOLIZER;METABOLISM/PK;DECREASED;CONCENTRATIONS;;PEOPLE;OTHER:SCHIZOPHRENIA, OTHER:PSYCHOTIC_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
EXENATIDE;SORCS1;GG;rs1416406;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
LINAGLIPTIN, SITAGLIPTIN, VILDAGLIPTIN;KCNJ11;GG;rs2285676;EFFICACY;INCREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
LINAGLIPTIN, SAXAGLIPTIN, SITAGLIPTIN, VILDAGLIPTIN;PRKD1;G;rs57803087;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
MIDAZOLAM;NR1I2;CC;rs2461817;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;OTHER:RESPIRATORY_FAILURE_REQUIRING_ASSISTED_VENTILATION;CAUTION_DRUG_ACCUMULATION
METHADONE, R-EDDP, S-EDDP;CYP2D6;;INTERMEDIATE_METABOLIZER;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;OTHER:DEATH;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;*10/*10;CYP2D6*1, CYP2D6*10;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;MTHFR;G;rs1801131;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
AZATHIOPRINE;NUDT15;CT + TT;rs116855232;DOSAGE;DECREASED;DOSE;;PEOPLE;DISEASE:ULCERATIVE_COLITIS, DISEASE:CROHN_DISEASE,DISEASE:AUTOIMMUNE_HEPATITIS;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;AA;rs1057910;DOSAGE;INCREASED;DOSE;;PEOPLE;OTHER:HEART_VALVE_REPLACEMENT;CAUTION_DOSE_ADJUST
WARFARIN;APOE;CC;rs7412;DOSAGE;INCREASED;DOSE;;PEOPLE;OTHER:ATRIAL_FIBRILLATION, OTHER:PULMONARY_EMBOLISM,OTHER:VENOUS_THROMBOSIS;CAUTION_DOSE_ADJUST
METFORMIN;SLC22A1;CC;rs2282143;METABOLISM/PK;INCREASED;CLEARANCE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
METFORMIN;SLC22A2;CC;rs316019;METABOLISM/PK;INCREASED;CLEARANCE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
METHACHOLINE;ADRB2;AA;rs1042713;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_FAILURE
ACENOCOUMAROL;VKORC1;CT;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
TEMSIROLIMUS;NR1I2;TT;rs3814055;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:URINARY_BLADDER_NEOPLASMS;CAUTION_DRUG_ACCUMULATION
TEMSIROLIMUS;ABCB1;CC;rs2032582;METABOLISM/PK;INCREASED;METABOLISM;;PEOPLE;DISEASE:URINARY_BLADDER_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;TT;rs776746;DOSAGE;INCREASED;DOSE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;;C;rs4646457;DOSAGE;;DOSE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;G;rs15524;DOSAGE;;DOSE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A4;A;rs12333983;DOSAGE;;DOSE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED;DOSE;;PEOPLE;DISEASE:RHEUMATIC_HEART_DISEASE;CAUTION_DOSE_ADJUST
ATENOLOL, METOPROLOL;;A;rs294610;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATENOLOL, METOPROLOL;SLC4A1;CC + CT;rs45545233;EFFICACY;DECREASED;RESPONSE;;PEOPLE;OTHER:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_FAILURE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;SLCO1C1;G;rs3794271;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
CAPECITABINE, FLUOROURACIL;DPYD;CT;rs56038477;DOSAGE;;DOSE;;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_DOSE_ADJUST
DICHLOROACETIC ACID;GSTZ1, POMT2;G;rs7975;OTHER, METABOLISM/PK;INCREASED;CLEARANCE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
DICHLOROACETIC ACID;GSTZ1, POMT2;C;rs1046428;OTHER, METABOLISM/PK;INCREASED;CLEARANCE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
DICHLOROACETIC ACID;GSTZ1, POMT2;G;rs7972;OTHER, METABOLISM/PK;INCREASED;METABOLISM;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
SUNITINIB;ABCB1;AA;rs2032582;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL;DPYD;AG + GG;rs17376848;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;C;rs1057910;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
HYDROCHLOROTHIAZIDE;;AA + AG;rs11065987;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHADONE;ABCB1;AA;rs1128503;DOSAGE;INCREASED;DOSE;;PEOPLE;OTHER:HEROIN_DEPENDENCE;CAUTION_DOSE_ADJUST
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAFFEINE;CYP1A2;CT;rs12720461;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
ETHANOL;OPRM1;T;rs553202;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHANOL;OPRM1;A;rs524731;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;HINT1;CT + TT;rs3852209;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:TOBACCO_USE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;OPRM1;AG;rs1799971;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:POSTOPERATIVE_PAIN;LIKELIHOOD_THERAPEUTIC_FAILURE
PHENPROCOUMON;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
FLUOXETINE;CYP2D6;CT;rs3892097;EFFICACY;INCREASED;CONCENTRATIONS;;MEN;EFFICACY:ALCOHOL_ABUSE, EFFICACY:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
LEVODOPA;DBH;CT + TT;rs1611115;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:COCAINE_DEPENDENCE;LIKELIHOOD_THERAPEUTIC_SUCCESS
QUETIAPINE;CYP1A2;AA;rs2069514;METABOLISM/PK;INCREASED;CONCENTRATIONS;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
VENLAFAXINE;COMT;GG;rs4680;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
AXITINIB;OR2B11;A;rs35305980;METABOLISM/PK;;CONCENTRATIONS;;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;CAUTION_DOSE_ADJUST
SULFONAMIDES, UREA DERIVATIVES;KCNJ11;CT;rs5219;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:DIABETES_MELLITUS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
SULFONAMIDES, UREA DERIVATIVES;ABCC8;AA + CC;rs757110;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:DIABETES_MELLITUS;LIKELIHOOD_THERAPEUTIC_SUCCESS
TIPIRACIL HYDROCHLORIDE, TRIFLURIDINE;SLC29A1;CT + TT;rs9394992;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
AXITINIB;UGT1A10, UGT1A8, UGT1A9;del;rs3832043;METABOLISM/PK;;CONCENTRATIONS;;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;CAUTION_DOSE_ADJUST
AXITINIB;UGT1A7;G;rs17868323;METABOLISM/PK;;CONCENTRATIONS;;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;CAUTION_DOSE_ADJUST
RISPERIDONE;HTR2C;A;rs3813928;EFFICACY;DECREASED;RESPONSE;;CHILDREN;DISEASE:AUTISM;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;MTRR;CT + TT;rs1532268;METABOLISM/PK;INCREASED;EXPOSURE;;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;HTR2A;CT + TT;rs6311;EFFICACY;INCREASED;RESPONSE;;CHILDREN;DISEASE:AUTISM;LIKELIHOOD_THERAPEUTIC_SUCCESS
AXITINIB;ABCB1;A;rs1045642;METABOLISM/PK;;CONCENTRATIONS;;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;CAUTION_DOSE_ADJUST
BUTORPHANOL;COMT;GG;rs6269;EFFICACY;DECREASED;RESPONSE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
AXITINIB;ABCG2;T;rs2231142;METABOLISM/PK;;CONCENTRATIONS;;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;CAUTION_DOSE_ADJUST
AXITINIB;ABCB1;T;rs2032582;METABOLISM/PK;;CONCENTRATIONS;;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;CAUTION_DOSE_ADJUST
VORICONAZOLE;CYP2C19;AA + AG;rs4244285;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;CHILDREN;;CAUTION_DRUG_ACCUMULATION
ERLOTINIB;EGFR;GT + TT;rs121434568;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;ABCB1;AA;rs1045642;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
CYTARABINE;SLC29A1;A;rs3734703;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:ACUTE_MYELOID_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUTORPHANOL;COMT;CC;rs4633;EFFICACY;DECREASED;RESPONSE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
SUNITINIB;ABCB1;AA + AG;rs1045642;METABOLISM/PK;INCREASED;CLEARANCE;;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA, DISEASE:METASTATIC_NEOPLASM;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;SLC19A1;CC + TT;rs1051266;EFFICACY;DECREASED;RESPONSE;;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
IRINOTECAN_SN-38;UGT1A9;TT;rs3832043;DOSAGE;INCREASED;METABOLISM;;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2B6;CC + CT;rs2279345;METABOLISM/PK;INCREASED;METABOLISM;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;ABCB1;AA + AG;rs1128503;EFFICACY;INCREASED;RESPONSE;;CHILDREN;DISEASE:AUTISM;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;CT;rs2279345;METABOLISM/PK;INCREASED;METABOLISM;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
GLUCOCORTICOIDS;CRHR1;T;rs1876828;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIDEPRESSANTS;ERICH3;C;rs11580409;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN_SN-38;SLCO1B1;CC + CT;rs4149056;DOSAGE;INCREASED;DOSE;;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_DOSE_ADJUST
SALMETEROL;ADRB2;AA;rs1042713;EFFICACY;DECREASED;RESPONSE;;CHILDREN;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_FAILURE
(S)-METHADONE;CYP3A4;CT;rs2740574;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:OPIOID-RELATED_DISORDERS;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;AA + AG;rs4986893;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;CHILDREN;;CAUTION_DRUG_ACCUMULATION
METHYLPHENIDATE;GRIN2B;CC;rs2284411;EFFICACY;INCREASED;RESPONSE;;CHILDREN;DISEASE:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS
FENTANYL;CYP3A4;C;rs2740574;METABOLISM/PK;DECREASED;CLEARANCE;;PEOPLE;OTHER:BURNS;CAUTION_DRUG_ACCUMULATION
SALBUTAMOL, SELECTIVE BETA-2-ADRENORECEPTOR AGONISTS;CRHR2;T;rs7793837;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_FAILURE
ATORVASTATIN, ROSUVASTATIN, SIMVASTATIN;ABCA1;T;rs2230806;EFFICACY;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
SALBUTAMOL, SELECTIVE BETA-2-ADRENORECEPTOR AGONISTS;CRHR2;T;rs7793837;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_FAILURE
ATORVASTATIN, ROSUVASTATIN, SIMVASTATIN;CYP2D6;T;rs3892097;EFFICACY;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
NICARDIPINE, NIMODIPINE;CACNA1B;AG + GG;rs2739258;EFFICACY;INCREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:BIPOLAR_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;MTHFR;TT;rs1801131;EFFICACY;DECREASED;RESPONSE;;CHILDREN;OTHER:NON-HODGKIN_LYMPHOMA, OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
IMATINIB;CYP3A5;C;rs776746;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;LIKELIHOOD_THERAPEUTIC_SUCCESS
IMATINIB;SLC22A1;CG + GG;rs683369;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;LIKELIHOOD_THERAPEUTIC_FAILURE
SIMVASTATIN;APOA5;AA;rs662799;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:DYSLIPIDAEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRBESARTAN;APOB;AG;rs1367117;EFFICACY, METABOLISM/PK;;RESPONSE;;PEOPLE;DISEASE:HYPERTENSION;CAUTION_DOSE_ADJUST
IRBESARTAN;APOB;GG;rs1367117;EFFICACY;;RESPONSE;;PEOPLE;DISEASE:HYPERTENSION;CAUTION_DOSE_ADJUST
ATORVASTATIN;APOA5;AA;rs662799;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:DYSLIPIDAEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2A6;C;rs28399433;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;MTHFR;AA;rs1801133;EFFICACY;INCREASED;RESPONSE;;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
BENAZEPRIL;PRCP;GG + GT;rs2229437;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;UGT2B7;GG;rs28365062;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;C;rs28399499;METABOLISM/PK;;METABOLISM;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY, OTHER;;RESPONSE;;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;CAUTION_DOSE_ADJUST
EFAVIRENZ, LAMIVUDINE, TENOFOVIR;CYP2B6;AG + GG;rs2279343;EFFICACY;INCREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;MTHFR;GG;rs1801131;EFFICACY;INCREASED;RESPONSE;;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;ABCB1;G;rs1045642;EFFICACY, OTHER;;RESPONSE;;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;CAUTION_DOSE_ADJUST
MIDAZOLAM;VDR;CT + TT;rs11568820;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
METHYLDOPA;ARG2;G;rs3742879;EFFICACY;INCREASED;RESPONSE;;WOMEN;OTHER:PREGNANCY, OTHER:PRE-ECLAMPSIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;MTHFR;AA + AG;rs1801133;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
REPAGLINIDE;CYP2C8;C;rs10509681;DOSAGE, METABOLISM/PK;INCREASED;METABOLISM;;HEALTHY;;CAUTION_DOSE_ADJUST
REPAGLINIDE;CYP2C8;T;rs11572080;DOSAGE, METABOLISM/PK;INCREASED;METABOLISM;;HEALTHY;;CAUTION_DOSE_ADJUST
ARIPIPRAZOLE;ABCB1;AA;rs1128503;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;OTHER:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DRUG_ACCUMULATION
OMEPRAZOLE;CYP2C19;TT;rs12248560;DOSAGE, METABOLISM/PK;INCREASED;METABOLISM;;PEOPLE;OTHER:NO_DISEASE;CAUTION_DOSE_ADJUST
MEPHENYTOIN;CYP2C19;TT;rs12248560;DOSAGE, METABOLISM/PK;INCREASED;METABOLISM;;PEOPLE;OTHER:NO_DISEASE;CAUTION_DOSE_ADJUST
OMEPRAZOLE;CYP2C19;TT;rs11188072;DOSAGE, METABOLISM/PK;INCREASED;METABOLISM;;PEOPLE;OTHER:NO_DISEASE;CAUTION_DOSE_ADJUST
MEPHENYTOIN;CYP2C19;TT;rs11188072;DOSAGE, METABOLISM/PK;INCREASED;METABOLISM;;PEOPLE;OTHER:NO_DISEASE;CAUTION_DOSE_ADJUST
METHADONE;CYP2B6;TT;rs3211371;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
MERCAPTOPURINE, METHOTREXATE;SLCO1B1;CC + CT;rs4149056;DOSAGE;DECREASED;DOSE;;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DOSE_ADJUST
GEMCITABINE;CMPK1;CC;rs1044457;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:PANCREATIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
DEXMEDETOMIDINE;ADRA2A;CG + GG;rs1800035;EFFICACY;DECREASED;RESPONSE;;WOMEN;OTHER:POSTOPERATIVE_PAIN;LIKELIHOOD_THERAPEUTIC_FAILURE
BUDESONIDE, FLUTICASONE / SALMETEROL, FORMOTEROL, OMALIZUMAB;IL10;CC + CT;rs3024498;EFFICACY;DECREASED;CLINICAL_BENEFIT;;CHILDREN;OTHER:ASTHMA;LIKELIHOOD_THERAPEUTIC_FAILURE
DEXMEDETOMIDINE;ADRA2A;CT + TT;rs775887911;EFFICACY;DECREASED;RESPONSE;;WOMEN;OTHER:POSTOPERATIVE_PAIN;LIKELIHOOD_THERAPEUTIC_FAILURE
DEXMEDETOMIDINE;ADRA2A;CT + TT;rs201376588;EFFICACY;DECREASED;RESPONSE;;WOMEN;OTHER:POSTOPERATIVE_PAIN;LIKELIHOOD_THERAPEUTIC_FAILURE
GEMCITABINE;CMPK1;GG;rs35687416;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:PANCREATIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEMCITABINE;DCTD;CC;rs12507552;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:PANCREATIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
BETA BLOCKING AGENTS;;T;rs139945292;EFFICACY;DECREASED;RESPONSE;;PEOPLE;OTHER:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_FAILURE
ROSUVASTATIN;APOA5;AA;rs662799;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:DYSLIPIDAEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEMCITABINE;TENT4A;GG;rs274713;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:PANCREATIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;FPGS;CT + TT;rs1544105;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
GEMCITABINE;CDC5L;CT + TT;rs992160;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:PANCREATIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;TYMS;AA;rs2853539;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
ATORVASTATIN, ROSUVASTATIN, SIMVASTATIN;APOA5;AA;rs662799;OTHER;;RESPONSE;;PEOPLE;DISEASE:DYSLIPIDAEMIA;CAUTION_DOSE_ADJUST
BUDESONIDE, FLUTICASONE / SALMETEROL, FORMOTEROL, OMALIZUMAB;IL17A;AG + GG;rs3819024;EFFICACY;DECREASED;CLINICAL_BENEFIT;;CHILDREN;OTHER:ASTHMA;LIKELIHOOD_THERAPEUTIC_FAILURE
GEMCITABINE;SH2D5;GT + TT;rs10916852;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:PANCREATIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ROSUVASTATIN;CETP;A;rs708272;EFFICACY;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
ATORVASTATIN;ABCB1;AA;rs1045642;EFFICACY;INCREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATORVASTATIN;SLCO1B1;AA;rs2306283;EFFICACY;INCREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
REPAGLINIDE;SLCO1B1;CT;rs4149056;METABOLISM/PK;INCREASED;CONCENTRATIONS;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
PHENPROCOUMON;VKORC1;TT;rs9923231;DOSAGE, TOXICITY;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
AZATHIOPRINE;TPMT;CT;rs1142345;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:INFLAMMATORY_BOWEL_DISEASES;CAUTION_DRUG_ACCUMULATION
AZATHIOPRINE;ITPA;AC;rs1127354;METABOLISM/PK;INCREASED;METABOLISM;;PEOPLE;DISEASE:INFLAMMATORY_BOWEL_DISEASES;LIKELIHOOD_THERAPEUTIC_FAILURE
REPAGLINIDE;SLCO1B1;TT;rs4149056;METABOLISM/PK;;EXPOSURE;;HEALTHY;;CAUTION_DOSE_ADJUST
BUPRENORPHINE;CYP3A4;TT;rs2740574;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:ISCHEMIA, DISEASE:PAIN;LIKELIHOOD_THERAPEUTIC_SUCCESS
PERINDOPRIL;AGTR1;AA;rs5186;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_FAILURE
NITRENDIPINE;AGTR1;AA;rs5186;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
HYDROMORPHONE;OPRM1;AG + GG;rs1799971;PD;INCREASED;RESPONSE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_SUCCESS
LAMOTRIGINE;HNF4A;AA;rs2071197;METABOLISM/PK;DECREASED;CONCENTRATIONS;;PEOPLE;DISEASE:EPILEPSY;LIKELIHOOD_THERAPEUTIC_FAILURE
LAMOTRIGINE;ABCG2;GT + TT;rs2231142;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:EPILEPSY;CAUTION_DRUG_ACCUMULATION
LAMOTRIGINE;ABCG2;CC + CT;rs3114020;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:EPILEPSY;CAUTION_DRUG_ACCUMULATION
CYCLOSPORINE;TSPYL1;AG + GG;rs3828743;METABOLISM/PK;INCREASED;CLEARANCE;;MEN;OTHER:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
GEMCITABINE;CMPK1;CC;rs7543016;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:PANCREATIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED;DOSE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
GEMCITABINE;ESR2;TT;rs944050;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:PANCREATIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
RISPERIDONE;DRD2;TT;rs1799978;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN;ABCC2;AA + AG;rs2273697;METABOLISM/PK;INCREASED;METABOLISM;;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;DRD2;T;rs1799978;OTHER;INCREASED;RESPONSE;;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIEPILEPTICS;ABCC2;CT + TT;rs717620;EFFICACY;INCREASED;RESISTANCE;;PEOPLE;DISEASE:EPILEPSY;LIKELIHOOD_THERAPEUTIC_FAILURE
GLUCOSE;SLCO1B1;TT;rs4149056;METABOLISM/PK;;CONCENTRATIONS;;HEALTHY;;CAUTION_DOSE_ADJUST
WARFARIN;;A;rs12777823;DOSAGE;;DOSE;;;;CAUTION_DOSE_ADJUST
METHOTREXATE;SLCO1B1;AA + AG;rs2306283;METABOLISM/PK;INCREASED;CLEARANCE;;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
IVACAFTOR;CFTR;AA + AG;rs75527207;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:CYSTIC_FIBROSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;SLCO1B1;CC + CT;rs4149056;METABOLISM/PK;DECREASED;CLEARANCE;;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DRUG_ACCUMULATION
CONJUGATED ESTROGENS;SLCO1B1;CT;rs4149056;EFFICACY;INCREASED;RESPONSE;;WOMEN;DISEASE:MENOPAUSE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN;ERCC1;A;rs3212986;EFFICACY;DECREASED;RESPONSE;;WOMEN;OTHER:OVARIAN_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIPSYCHOTICS;ABCB1;GG;rs1045642;DOSAGE, METABOLISM/PK;INCREASED;DOSE;;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_DOSE_ADJUST
ANTIPSYCHOTICS;ABCB1;AA;rs2032582;DOSAGE, METABOLISM/PK;INCREASED;DOSE;;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_DOSE_ADJUST
DIAZEPAM;CYP2C19;AA + AG;rs4244285;EFFICACY;INCREASED;CLINICAL_BENEFIT;;MEN;OTHER:ALCOHOL_ABUSE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ALPRAZOLAM;CYP3A4;AG;rs35599367;METABOLISM/PK;INCREASED;CONCENTRATIONS;;MEN;OTHER:ALCOHOL_ABUSE, OTHER:ANXIETY_DISORDERS;CAUTION_DRUG_ACCUMULATION
DIAZEPAM;CYP2C19;CT + TT;rs12248560;EFFICACY;DECREASED;CLINICAL_BENEFIT;;MEN;OTHER:ALCOHOL_ABUSE;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOZAPINE;POR;CT + TT;rs1057868;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;OTHER:SCHIZOPHRENIA, OTHER:TOBACCO_USE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
SALBUTAMOL;IGF2R;AG;rs8191725;EFFICACY;INCREASED;RESPONSE;;CHILDREN;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
SALBUTAMOL;SLC24A4;AG;rs77441273;EFFICACY;INCREASED;RESPONSE;;CHILDREN;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ALPRAZOLAM;CYP3A4;AG;rs35599367;EFFICACY;DECREASED;RESPONSE;;MEN;OTHER:ALCOHOL_ABUSE, OTHER:ANXIETY_DISORDERS;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE, OMEPRAZOLE, RABEPRAZOLE;IL1B;AG;rs16944;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HELICOBACTER_INFECTIONS;LIKELIHOOD_THERAPEUTIC_SUCCESS
LANSOPRAZOLE, OMEPRAZOLE, RABEPRAZOLE;IL1B;AA;rs16944;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HELICOBACTER_INFECTIONS;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;AA;rs2359612;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;METABOLISM;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
PLATINUM COMPOUNDS;ERCC1;AG + GG;rs11615;EFFICACY;INCREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:OVARIAN_NEOPLASMS, OTHER:NEOPLASM_OF_ESOPHAGUS,OTHER:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ULINASTATIN;MMP2;T;rs243865;EFFICACY;DECREASED;RESPONSE;;PEOPLE;OTHER:PANCREATITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIPSYCHOTICS;ABCB1;G;rs1128503;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ULINASTATIN;MMP9;T;rs3918242;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:PANCREATITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A4;AA + AG;rs35599367;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;NR1I2;CT + TT;rs2276707;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIPSYCHOTICS;ABCB1;G;rs1045642;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN;NR1I2;AA;rs10934498;TOXICITY, METABOLISM/PK;DECREASED;EXPOSURE;;PEOPLE;DISEASE:COLONIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;IL10;CC;rs1800896;DOSAGE;DECREASED;DOSE;;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
OLANZAPINE;DRD3;C;rs324026;EFFICACY;INCREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYTARABINE, FLUDARABINE, GEMTUZUMAB OZOGAMICIN, IDARUBICIN;ADH1A;A;rs6811453;EFFICACY;INCREASED;RESISTANCE;;PEOPLE;DISEASE:ACUTE_MYELOID_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
MEASLES VACCINES;TLR3;CT;rs3775291;EFFICACY;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
CYTARABINE, FLUDARABINE, GEMTUZUMAB OZOGAMICIN, IDARUBICIN;ADH1A;T;rs1826909;EFFICACY;INCREASED;RESISTANCE;;PEOPLE;DISEASE:ACUTE_MYELOID_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP4F2;CT + TT;rs2108622;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
TAMOXIFEN;ABCC2;CT;rs717620;EFFICACY;INCREASED;RESPONSE;;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
SALBUTAMOL;;CT;rs77149876;EFFICACY;INCREASED;RESPONSE;;CHILDREN;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETANERCEPT, INFLIXIMAB, TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;A;rs1800629;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
CARBAMAZEPINE;SCN1A;TT;rs3812718;DOSAGE;INCREASED;DOSE;;PEOPLE;DISEASE:EPILEPSY;CAUTION_DOSE_ADJUST
SALBUTAMOL;PAPPA2;CT;rs77977790;EFFICACY;INCREASED;RESPONSE;;CHILDREN;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
NORBUPRENORPHINE;OPRD1;GG;rs569356;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;OTHER:OPIOID-RELATED_DISORDERS;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A4;CT;rs2740574;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
SALMETEROL;ADRB2;G;rs1042713;EFFICACY;INCREASED;RESPONSE;;CHILDREN;OTHER:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
SALBUTAMOL;;AG;rs116551936;EFFICACY;INCREASED;RESPONSE;;CHILDREN;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
SALBUTAMOL;NCOA3;CT;rs115501901;EFFICACY;INCREASED;RESPONSE;;CHILDREN;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
SALBUTAMOL;;AG;rs74973995;EFFICACY;INCREASED;RESPONSE;;CHILDREN;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
SALBUTAMOL;CRHR2;CT;rs73294475;EFFICACY;INCREASED;RESPONSE;;CHILDREN;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
PHENPROCOUMON;CYP3A4;C;rs2740574;DOSAGE;DECREASED;DOSE;;CHILDREN;;CAUTION_DOSE_ADJUST
SALBUTAMOL;ADCY9;AG;rs144315541;EFFICACY;INCREASED;RESPONSE;;CHILDREN;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
PERPHENAZINE;MCPH1;A;rs17570753;EFFICACY;;RESPONSE;;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_DOSE_ADJUST
PERPHENAZINE;CDH13;G;rs2116971;EFFICACY;;RESPONSE;;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_DOSE_ADJUST
PERPHENAZINE;SKOR2;G;rs9952628;EFFICACY;;RESPONSE;;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_DOSE_ADJUST
METFORMIN;SLC47A2;AA;rs12943590;EFFICACY, METABOLISM/PK;DECREASED;RESPONSE;;PEOPLE;DISEASE:DIABETES_MELLITUS;LIKELIHOOD_THERAPEUTIC_FAILURE
QUETIAPINE;KCNMA1;G;rs35793;EFFICACY;;RESPONSE;;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_DOSE_ADJUST
PERPHENAZINE;MAML3;A;rs11100483;EFFICACY;;RESPONSE;;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_DOSE_ADJUST
VALPROIC ACID;UGT2B7;CC + CT;rs7668258;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:EPILEPSY;CAUTION_DRUG_ACCUMULATION
METHACHOLINE;RUNX1;AA;rs11702779;OTHER;INCREASED;RESPONSE;;CHILDREN;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
RISPERIDONE;LRP1B;G;rs874295;EFFICACY;;RESPONSE;;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_DOSE_ADJUST
BEVACIZUMAB;HTRA1;AA;rs11200638;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:MACULAR_DEGENERATION;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;PSMD14;A;rs9713;EFFICACY;;RESPONSE;;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_DOSE_ADJUST
RISPERIDONE;AGAP1;C;rs1869295;EFFICACY;;RESPONSE;;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_DOSE_ADJUST
BEVACIZUMAB;ARMS2;TT;rs10490924;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:MACULAR_DEGENERATION;LIKELIHOOD_THERAPEUTIC_FAILURE
VALPROIC ACID;APEH;CC;rs3816877;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:EPILEPSY;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;NPAS3;G;rs1315115;EFFICACY;;RESPONSE;;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_DOSE_ADJUST
RISPERIDONE;TMEFF2;G;rs3738883;EFFICACY;;RESPONSE;;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_DOSE_ADJUST
METFORMIN;PCK1;CT + TT;rs4810083;EFFICACY;INCREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
ZIPRASIDONE;CDH4;A;rs4925300;EFFICACY;;RESPONSE;;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_DOSE_ADJUST
ZIPRASIDONE;LYN;G;rs1546519;EFFICACY;;RESPONSE;;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_DOSE_ADJUST
BEVACIZUMAB;CFH;GG;rs800292;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:MACULAR_DEGENERATION;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;CT;rs1799853;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ZIPRASIDONE;NALCN;C;rs9585618;EFFICACY;;RESPONSE;;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_DOSE_ADJUST
ZIPRASIDONE;CNTN4;A;rs17194378;EFFICACY;;RESPONSE;;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_DOSE_ADJUST
OPIOIDS;COMT;GG;rs4680;DOSAGE;INCREASED;DOSE;;PEOPLE;DISEASE:NEOPLASMS, DISEASE:PAIN;CAUTION_DOSE_ADJUST
IMATINIB;SLCO1A2;CT + TT;rs4148978;TOXICITY, METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;OTHER:GASTROINTESTINAL_STROMAL_TUMORS;CAUTION_SIDE_EFFECT
IMATINIB;SLCO1B3;GG;rs4149117;TOXICITY, METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;OTHER:GASTROINTESTINAL_STROMAL_TUMORS;CAUTION_SIDE_EFFECT
HYDROCHLOROTHIAZIDE;ADD1;GT + TT;rs4961;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CALU;AA;rs2290228;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
OLANZAPINE;;T;rs12610827;EFFICACY;INCREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
REMIFENTANIL;OPRM1;AG + GG;rs1799971;DOSAGE;INCREASED;DOSE;;WOMEN;OTHER:SURGERY;CAUTION_DOSE_ADJUST
FENOFIBRATE;APOB;AA;rs676210;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HYPERTRIGLYCERIDEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHACHOLINE;RUNX1;AG + GG;rs11702779;OTHER;INCREASED;RESPONSE;;CHILDREN;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CITALOPRAM, FLUOXETINE;SERPINE1;G;rs1799889;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;MTR;G;rs1805087;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;OTHER:NON-HODGKIN_LYMPHOMA, OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DRUG_ACCUMULATION
CITALOPRAM, FLUOXETINE, MIRTAZAPINE, PAROXETINE, SELECTIVE SEROTONIN REUPTAKE INHIBITORS, VENLAFAXINE;FKBP5;A;rs4713916;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:MOOD_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
OLANZAPINE;CSMD1;A;rs17070785;EFFICACY;;RESPONSE;;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_DOSE_ADJUST
OLANZAPINE;PLAGL1;C;rs2247408;EFFICACY;;RESPONSE;;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_DOSE_ADJUST
SIROLIMUS;CYP3A5;AA;rs15524;METABOLISM/PK;INCREASED;TROUGH_CONCENTRATION;;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
OLANZAPINE;PLAGL1;A;rs3819811;EFFICACY;;RESPONSE;;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_DOSE_ADJUST
SIROLIMUS;CYP3A5;CC;rs4646453;METABOLISM/PK;INCREASED;TROUGH_CONCENTRATION;;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
ACETAMINOPHEN;OPRM1;AG + GG;rs1799971;DOSAGE;INCREASED;DOSE;;WOMEN;OTHER:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;AA;rs9934438;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
OLANZAPINE;PTPRN2;C;rs221253;EFFICACY;;RESPONSE;;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_DOSE_ADJUST
IMATINIB;SLC22A1;AA + AG;rs628031;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;NQO1;AA + AG;rs1800566;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
PERPHENAZINE;PRKCE;C;rs2278773;EFFICACY;;RESPONSE;;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_DOSE_ADJUST
PERPHENAZINE;;C;rs11774231;EFFICACY;;RESPONSE;;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
HYDROCHLOROTHIAZIDE;DOT1L;CT + TT;rs2269879;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
PAROXETINE;ADM;CC;rs11042725;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;VKORC1;A;rs9934438;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
TILDRAKIZUMAB;ATG5;CT;rs9373839;EFFICACY;DECREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:PSORIASIS;LIKELIHOOD_THERAPEUTIC_FAILURE
TILDRAKIZUMAB;IL17RC;CC;rs708567;EFFICACY;INCREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:PSORIASIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CITALOPRAM;BDNF;TT;rs7124442;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
ARIPIPRAZOLE;ABCB1;AA;rs2032582;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;CHILDREN;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOZAPINE;OXT;T;rs2740204;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;TT;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
DIAZEPAM;CYP3A4;GG;rs35599367;EFFICACY;INCREASED;CLINICAL_BENEFIT;;MEN;OTHER:ALCOHOL_ABUSE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;MTHFR;G;rs1801133;EFFICACY;DECREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:CROHN_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;DHFR;C;rs408626;EFFICACY;DECREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:CROHN_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
REPAGLINIDE;NOS1AP;T;rs10494366;DOSAGE, EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:DIABETES_MELLITUS_T2;CAUTION_DOSE_ADJUST
CITALOPRAM;BDNF;TT;rs7103411;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART);ABCB1;AA + AG;rs1045642;EFFICACY;INCREASED;RESISTANCE;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
CITALOPRAM;BDNF;CC;rs6265;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
LAMIVUDINE, LOPINAVIR, RITONAVIR, ZIDOVUDINE;ABCC1;CC + CT;rs212091;EFFICACY;INCREASED;RESISTANCE;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOXETINE;BDNF;CT;rs6265;EFFICACY;INCREASED;CLINICAL_BENEFIT;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
TILDRAKIZUMAB;TNFAIP3;GG;rs610604;EFFICACY;DECREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:PSORIASIS;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;A;rs4986893;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIDEPRESSANTS;ERICH3;CC;rs11580409;EFFICACY;INCREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;CT;rs12248560;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ARIPIPRAZOLE;ABCB1;AA;rs1045642;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;CHILDREN;;LIKELIHOOD_THERAPEUTIC_FAILURE
IVACAFTOR;CFTR;A;rs77932196;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:CYSTIC_FIBROSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
PAROXETINE;DRD3;CC + CT;rs6280;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
ENTACAPONE;COMT;GG;rs4680;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:PARKINSON_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOZAPINE;CYP2D6;AA;rs1065852;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;OTHER:SCHIZOPHRENIA;CAUTION_DRUG_ACCUMULATION
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
TELMISARTAN;SLCO1B3;C;rs60140950;METABOLISM/PK;INCREASED;CONCENTRATIONS;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
CLOZAPINE;CYP2D6;GG;rs16947;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;OTHER:SCHIZOPHRENIA;CAUTION_DRUG_ACCUMULATION
ATORVASTATIN, SIMVASTATIN;ABCG8;CC + CG;rs11887534;EFFICACY;DECREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:DYSLIPIDAEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
IVACAFTOR;CFTR;C;rs121909011;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:CYSTIC_FIBROSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
IMATINIB;ULK3;GG;rs2290573;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOZAPINE;DRD1;GT;rs265976;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_FAILURE
IVACAFTOR;CFTR;AA + AG;rs75527207;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:CYSTIC_FIBROSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
INTERFERONS;STAT3;GG;rs4796793;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
TAMOXIFEN;SLCO2B1;AA + AG;rs12422149;METABOLISM/PK;INCREASED;CONCENTRATIONS;;WOMEN;OTHER:BREAST_NEOPLASMS;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;AA + AG;rs2359612;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;DOSAGE, EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;CG + GG;rs8050894;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
RISPERIDONE;HRH3;TT;rs3787430;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;;AA + AG;rs12777823;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;AC + CC;rs2884737;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;CT + TT;rs7294;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
RISPERIDONE;HRH3;TT;rs3787429;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ARIPIPRAZOLE;TAAR6;AA + AG;rs4305746;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2A;IL6;G;rs1800795;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_FAILURE
SULFASALAZINE;ABCG2;TT;rs2231142;METABOLISM/PK;DECREASED;CLEARANCE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
PEGINTERFERON ALFA-2A;IL6;G;rs1800796;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON ALFA-2A;IL6;G;rs1800797;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_FAILURE
ROSUVASTATIN;ABCG2;AA + AG;rs2199936;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ILOPERIDONE;CNTF, ZFP91-CNTF;GG;rs1800169;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;A;rs9934438;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
DISULFIRAM;OPRD1;CC;rs678849;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:COCAINE_DEPENDENCE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ERYTHROPOIETIN;STIM1;AG + GG;rs1561876;EFFICACY;INCREASED;RESISTANCE;;PEOPLE;OTHER:KIDNEY_DISORDER, OTHER:ANEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
LATANOPROST;PTGFR;CC;rs3753380;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RANIBIZUMAB;VEGFA;AC + CC;rs699947;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:MACULAR_DEGENERATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
FUROSEMIDE;ABCC4;T;rs17268282;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HEART_FAILURE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METFORMIN;SLC22A1;CC;rs622342;EFFICACY;;RESPONSE;;PEOPLE;OTHER:GENETIC_VARIATION_AT_RS2289669;CAUTION_DOSE_ADJUST
MORPHINE;COMT;T;rs737866;DOSAGE, EFFICACY;DECREASED;DOSE;;PEOPLE;DISEASE:NEOPLASMS;CAUTION_DOSE_ADJUST
MORPHINE;COMT;G;rs2075507;DOSAGE, EFFICACY;DECREASED;DOSE;;PEOPLE;DISEASE:NEOPLASMS;CAUTION_DOSE_ADJUST
ANTIEPILEPTICS;CYP1A1;AA;rs2606345;EFFICACY;DECREASED;RESPONSE;;WOMEN;DISEASE:EPILEPSY;LIKELIHOOD_THERAPEUTIC_FAILURE
MORPHINE;COMT;A;rs5746849;DOSAGE, EFFICACY;DECREASED;DOSE;;PEOPLE;DISEASE:NEOPLASMS;CAUTION_DOSE_ADJUST
MORPHINE;COMT, TXNRD2;C;rs7287550;DOSAGE, EFFICACY;DECREASED;DOSE;;PEOPLE;DISEASE:NEOPLASMS;CAUTION_DOSE_ADJUST
MORPHINE;COMT;A;rs6269;DOSAGE, EFFICACY;DECREASED;DOSE;;PEOPLE;DISEASE:NEOPLASMS;CAUTION_DOSE_ADJUST
CARBAMAZEPINE;CYP3A4;TT;rs2740574;METABOLISM/PK;INCREASED;CLEARANCE;;PEOPLE;DISEASE:EPILEPSY;LIKELIHOOD_THERAPEUTIC_FAILURE
MORPHINE;COMT;A;rs740603;DOSAGE, EFFICACY;DECREASED;DOSE;;PEOPLE;DISEASE:NEOPLASMS;CAUTION_DOSE_ADJUST
MORPHINE;ABCC3;T;rs4793665;METABOLISM/PK;DECREASED;CLEARANCE;;CHILDREN;;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;POR;T;rs1057868;DOSAGE;INCREASED;DOSE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
N-DESMETHYLTRAMADOL, O-DESMETHYLTRAMADOL;CYP2D6;DELT/T;rs35742686;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;OTHER:DEATH;CAUTION_DRUG_ACCUMULATION
N-DESMETHYLTRAMADOL, TRAMADOL;CYP3A4;AG;rs35599367;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;OTHER:DEATH;CAUTION_DRUG_ACCUMULATION
CLOPIDOGREL;CYP2C19;AA;rs4244285;EFFICACY;DECREASED;RESPONSE;;PEOPLE;OTHER:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;AG;rs4986893;EFFICACY;DECREASED;RESPONSE;;PEOPLE;OTHER:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;ABCC2;CC;rs717620;EFFICACY;DECREASED;RESPONSE;;PEOPLE;OTHER:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
ATAZANAVIR;SORCS2;A;rs73208473;METABOLISM/PK;DECREASED;EXPOSURE;;WOMEN;OTHER:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;ZNF816;CC;rs9304742;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:PSORIASIS;LIKELIHOOD_THERAPEUTIC_FAILURE
CARBAMAZEPINE;UGT2B7;AA;rs28365063;METABOLISM/PK;DECREASED;CLEARANCE;;PEOPLE;DISEASE:EPILEPSY;CAUTION_DRUG_ACCUMULATION
CARBAMAZEPINE;NR1I2;T;rs3814055;METABOLISM/PK;DECREASED;CLEARANCE;;PEOPLE;DISEASE:EPILEPSY;CAUTION_DRUG_ACCUMULATION
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;PGLYRP4;CC + CT;rs2916205;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:PSORIASIS;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;MTHFR;AA + AG;rs1801133;METABOLISM/PK;INCREASED;EXPOSURE;;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DRUG_ACCUMULATION
SULFONAMIDES, UREA DERIVATIVES;CYP2C9;TT;rs1799853;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SUMATRIPTAN;GNB3;CT;rs5443;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:CLUSTER_HEADACHE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL12B;AG + GG;rs2546890;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:PSORIASIS;LIKELIHOOD_THERAPEUTIC_FAILURE
DESETHYL HYDROXYCHLOROQUINE;CYP2D6;G;rs1135840;METABOLISM/PK;DECREASED;CONCENTRATIONS;;PEOPLE;OTHER:SYSTEMIC_LUPUS_ERYTHEMATOSUS;LIKELIHOOD_THERAPEUTIC_FAILURE
CANNABINOIDS;TRPV1;CC;rs8065080;EFFICACY;INCREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:PAIN;LIKELIHOOD_THERAPEUTIC_SUCCESS
CANNABINOIDS;UGT2B7;AA;rs7438135;EFFICACY;INCREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:PAIN;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;CTNNA2;AA;rs11126740;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:PSORIASIS;LIKELIHOOD_THERAPEUTIC_FAILURE
IMATINIB;ABCG2;GT;rs2231142;OTHER, METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:NEOPLASMS;CAUTION_DRUG_ACCUMULATION
DESETHYL HYDROXYCHLOROQUINE;CYP2D6;AA;rs1065852;METABOLISM/PK;DECREASED;CONCENTRATIONS;;PEOPLE;OTHER:SYSTEMIC_LUPUS_ERYTHEMATOSUS;LIKELIHOOD_THERAPEUTIC_FAILURE
REPAGLINIDE;KCNJ11;T;rs5219;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
TRAMADOL;OPRM1;AG + GG;rs1799971;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:POSTOPERATIVE_PAIN;LIKELIHOOD_THERAPEUTIC_SUCCESS
REPAGLINIDE;TCF7L2;TT;rs290487;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
MORPHINE;COMT;A;rs4680;DOSAGE, EFFICACY;DECREASED;DOSE;;PEOPLE;DISEASE:NEOPLASMS;CAUTION_DOSE_ADJUST
CARBAMAZEPINE;EPHX1;TT;rs1051740;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:EPILEPSY;CAUTION_DRUG_ACCUMULATION
MORPHINE;COMT;C;rs4818;DOSAGE, EFFICACY;DECREASED;DOSE;;PEOPLE;DISEASE:NEOPLASMS;CAUTION_DOSE_ADJUST
ERYTHROPOIETIN;ORAI1;GG + GT;rs12320939;EFFICACY;INCREASED;RESISTANCE;;PEOPLE;OTHER:KIDNEY_DISORDER, OTHER:ANEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
CARBAMAZEPINE;ABCB1;AA + AG;rs1128503;METABOLISM/PK;INCREASED;CLEARANCE;;PEOPLE;DISEASE:EPILEPSY;LIKELIHOOD_THERAPEUTIC_FAILURE
MORPHINE;COMT;A;rs2239393;DOSAGE, EFFICACY;DECREASED;DOSE;;PEOPLE;DISEASE:NEOPLASMS;CAUTION_DOSE_ADJUST
MERCAPTOPURINE;NUDT15;CT;rs116855232;DOSAGE;DECREASED;DOSE;;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DOSE_ADJUST
MORPHINE;ARVCF, COMT;T;rs165728;DOSAGE, EFFICACY;DECREASED;DOSE;;PEOPLE;DISEASE:NEOPLASMS;CAUTION_DOSE_ADJUST
CARBAMAZEPINE;ABCB1;AG;rs4148740;METABOLISM/PK;INCREASED;METABOLISM;;PEOPLE;DISEASE:EPILEPSY;LIKELIHOOD_THERAPEUTIC_FAILURE
CARBAMAZEPINE;ABCB1;TT;rs4148739;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:EPILEPSY;CAUTION_DRUG_ACCUMULATION
MORPHINE;ARVCF, COMT;T;rs174699;DOSAGE, EFFICACY;DECREASED;DOSE;;PEOPLE;DISEASE:NEOPLASMS;CAUTION_DOSE_ADJUST
ANTIPSYCHOTICS;DRD2;del;rs1799732;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_FAILURE
HMG_COA_REDUCTASE_INHIBITORS;CETP;AA;rs1532624;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:HYPERLIPIDEMIAS;LIKELIHOOD_THERAPEUTIC_FAILURE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;CDKAL1;CT + TT;rs6908425;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:PSORIASIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE;ABCC2;AA + AG;rs2273697;METABOLISM/PK;INCREASED;CLEARANCE;;PEOPLE;DISEASE:EPILEPSY;LIKELIHOOD_THERAPEUTIC_FAILURE
HMG_COA_REDUCTASE_INHIBITORS;SIK3;AA;rs533556;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:HYPERLIPIDEMIAS;LIKELIHOOD_THERAPEUTIC_FAILURE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;HLA-C;CT + TT;rs12191877;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:PSORIASIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
RITODRINE;KCNMB2;TT;rs7624046;EFFICACY;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
CARBAMAZEPINE;ABCC2;AA + AG;rs4148386;METABOLISM/PK;INCREASED;CLEARANCE;;PEOPLE;DISEASE:EPILEPSY;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;VKORC1;AA + AC;rs61742245;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
CARBAMAZEPINE;ABCC2;CT + TT;rs3740066;METABOLISM/PK;DECREASED;METABOLISM;;MEN;DISEASE:EPILEPSY;CAUTION_DRUG_ACCUMULATION
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;MAP3K1;AG + GG;rs96844;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:PSORIASIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
RITODRINE;KCNMB2;CC;rs9839376;EFFICACY;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;GGCX;G;rs11676382;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
CARBAMAZEPINE;NR1I2;G;rs7643645;METABOLISM/PK;INCREASED;METABOLISM;;PEOPLE;DISEASE:EPILEPSY;LIKELIHOOD_THERAPEUTIC_FAILURE
MORPHINE;METTL21A;CC;rs2952768;DOSAGE;INCREASED;DOSE;;WOMEN;OTHER:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
CARBAMAZEPINE;NR1I2;T;rs4688040;METABOLISM/PK;INCREASED;METABOLISM;;PEOPLE;DISEASE:EPILEPSY;LIKELIHOOD_THERAPEUTIC_FAILURE
CANNABINOIDS;ABCB1;AG + GG;rs1045642;EFFICACY;INCREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:PAIN;LIKELIHOOD_THERAPEUTIC_SUCCESS
MORPHINE;OPRM1;AG + GG;rs1799971;DOSAGE;INCREASED;DOSE;;WOMEN;OTHER:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
CARBAMAZEPINE;NR1I2;C;rs2461817;METABOLISM/PK;INCREASED;METABOLISM;;PEOPLE;DISEASE:EPILEPSY;LIKELIHOOD_THERAPEUTIC_FAILURE
METOPROLOL;ADRB1;AA;rs1801252;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;TT;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;CC;rs2884737;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
CITALOPRAM, FLUOXETINE, PAROXETINE, SERTRALINE;SRP19;G;rs495794;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;AA;rs9934438;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
CITALOPRAM, FLUOXETINE, PAROXETINE, SERTRALINE;REEP5;G;rs153560;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;GG;rs8050894;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
CITALOPRAM, FLUOXETINE, PAROXETINE, SERTRALINE;REEP5;A;rs153549;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATAZANAVIR;ABCB1;AA + AG;rs1045642;DOSAGE;;DOSE;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DOSE_ADJUST
ATAZANAVIR;SLCO1B1;TT;rs4149056;DOSAGE;;DOSE;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DOSE_ADJUST
FLUOROURACIL;DPYD;CT;rs3918290;OTHER, METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:NEOPLASMS;CAUTION_DRUG_ACCUMULATION
ATAZANAVIR;NR1I2;TT;rs2472677;DOSAGE;;DOSE;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;AC;rs61742245;DOSAGE;INCREASED;DOSE;;PEOPLE;OTHER:WARFARIN_MAINTENANCE_TREATMENT;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;VKORC1;CT;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
DOCETAXEL, GEMCITABINE, PACLITAXEL, PLATINUM COMPOUNDS, VINORELBINE;CASP7;CG + GG;rs2227310;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOCETAXEL, GEMCITABINE, PACLITAXEL, PLATINUM COMPOUNDS, VINORELBINE;CASP7;CC + CT;rs4353229;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOCETAXEL, GEMCITABINE, PACLITAXEL, PLATINUM COMPOUNDS, VINORELBINE;CASP7;AA + AC;rs12415607;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOCETAXEL, GEMCITABINE, PACLITAXEL, PLATINUM COMPOUNDS, VINORELBINE;CASP7;CT;rs7921977;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
OLANZAPINE;SLC26A9;A;rs11240594;DOSAGE, EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_DOSE_ADJUST
SOLANIDINE;NFIB;CC + CT;rs28379954;METABOLISM/PK;INCREASED;METABOLISM;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
ZIPRASIDONE;EHF;A;rs286913;DOSAGE, EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_DOSE_ADJUST
CLOZAPINE;SLC6A3;A;rs2975226;DOSAGE, EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_DOSE_ADJUST
OLANZAPINE;IL1A;C;rs11677416;DOSAGE, EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_DOSE_ADJUST
CYCLOSPORINE;POR;TT;rs1057868;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
CARBAMAZEPINE;EPHX1;C;rs1051740;DOSAGE, METABOLISM/PK;INCREASED;METABOLISM;;PEOPLE;DISEASE:EPILEPSY;CAUTION_DOSE_ADJUST
FESOTERODINE;UGT1A1, UGT1A10, UGT1A3, UGT1A4, UGT1A5, UGT1A6, UGT1A7, UGT1A8, UGT1A9;AA;rs10929302;METABOLISM/PK;INCREASED;CLEARANCE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
PIOGLITAZONE;PTPRD;CC;rs17584499;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACENOCOUMAROL, WARFARIN;VKORC1;CC + CT;rs9923231;EFFICACY;INCREASED;DOSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHANOL;OPRM1;G;rs1799971;TOXICITY;INCREASED;RESPONSE;;PEOPLE;OTHER:ALCOHOL_ABUSE;CAUTION_SIDE_EFFECT
ACAMPROSATE;GRIN2B;A;rs2058878;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:ALCOHOL_ABUSE;LIKELIHOOD_THERAPEUTIC_SUCCESS
OLANZAPINE;ATP1A2;T;rs6688363;EFFICACY;DECREASED;RESPONSE;;PEOPLE;OTHER:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;;T;rs8050896;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
RISPERIDONE;TNFRSF11A;A;rs2980976;EFFICACY;DECREASED;RESPONSE;;PEOPLE;OTHER:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;PPA2;G;rs2636697;EFFICACY;DECREASED;RESPONSE;;PEOPLE;OTHER:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;;A;rs1232027;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:PSORIATIC_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
FENTANYL, HYDROMORPHONE, OPIOIDS, OXYCODONE, TRAMADOL;OPRM1;AA;rs1799971;DOSAGE;INCREASED;DOSE;;WOMEN;OTHER:SURGERY;CAUTION_DOSE_ADJUST
RISPERIDONE;PPA2;A;rs2636719;EFFICACY;DECREASED;RESPONSE;;PEOPLE;OTHER:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_FAILURE
REPAGLINIDE;IGF2BP2;GT + TT;rs4402960;DOSAGE, EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:DIABETES_MELLITUS_T2;CAUTION_DOSE_ADJUST
RASAGILINE;COMT;AA;rs4680;METABOLISM/PK;DECREASED;CONCENTRATIONS;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
REPAGLINIDE;IGF2BP2;AC + CC;rs1470579;DOSAGE, EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:DIABETES_MELLITUS_T2;CAUTION_DOSE_ADJUST
DISULFIRAM;MTHFR;AA + AG;rs1801133;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:COCAINE_DEPENDENCE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;FCGR2A;AG + GG;rs1801274;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:PSORIATIC_ARTHRITIS,  DISEASE:CROHN_DISEASE,DISEASE:PSORIASIS, DISEASE:SPONDYLITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ISONIAZID;NAT2;AT;rs4646244;TOXICITY, METABOLISM/PK;DECREASED;CLEARANCE;;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_DRUG_ACCUMULATION
PLATINUM COMPOUNDS;ERCC1;AA;rs11615;EFFICACY;DECREASED;RESPONSE;;WOMEN;DISEASE:OVARIAN_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
ISONIAZID;NAT2;AA;rs1799930;TOXICITY, METABOLISM/PK;DECREASED;CLEARANCE;;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_DRUG_ACCUMULATION
HYDROCHLOROTHIAZIDE;BEST3;AA + AG;rs61747221;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
DEFERIPRONE;UGT1A6;AA;rs2070959;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:BETA-THALASSEMIA_AND_RELATED_DISEASES;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;FCGR3A;C;rs396991;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:PSORIATIC_ARTHRITIS,  DISEASE:CROHN_DISEASE,DISEASE:PSORIASIS, DISEASE:SPONDYLITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
NIFEDIPINE;ADRA1A;AA + AG;rs1048101;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
DEFERIPRONE;UGT1A6;AA;rs2070959;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:BETA-THALASSEMIA_AND_RELATED_DISEASES;LIKELIHOOD_THERAPEUTIC_SUCCESS
DEFERIPRONE;UGT1A6;GG;rs6759892;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:BETA-THALASSEMIA_AND_RELATED_DISEASES;LIKELIHOOD_THERAPEUTIC_SUCCESS
PIOGLITAZONE;PPARG;CG;rs1801282;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
PACLITAXEL, PLATINUM COMPOUNDS;CASP7;CC + CT;rs4353229;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;TNF;GG;rs1800629;DOSAGE;INCREASED;DOSE;;CHILDREN;OTHER:NEOPLASMS, OTHER:PAIN;CAUTION_DOSE_ADJUST
CARBAMAZEPINE;SCN1A;CT;rs3812718;DOSAGE, METABOLISM/PK;INCREASED;DOSE;;PEOPLE;DISEASE:EPILEPSY;CAUTION_DOSE_ADJUST
PACLITAXEL, PLATINUM COMPOUNDS;CASP7;CG + GG;rs2227310;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
RISPERIDONE;TJP1;T;rs813676;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;IL6;A;rs1800797;DOSAGE;DECREASED;DOSE;;CHILDREN;OTHER:NEOPLASMS, OTHER:PAIN;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;AA + AG;rs9934438;DOSAGE, EFFICACY;DECREASED;DOSE;;PEOPLE;DISEASE:MYOCARDIAL_INFARCTION;CAUTION_DOSE_ADJUST
METHYLPHENIDATE;ADGRL3;CC + CT;rs734644;EFFICACY;INCREASED;RESPONSE;;CHILDREN;DISEASE:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS
PACLITAXEL, PLATINUM COMPOUNDS;CASP7;AA + AG;rs1127687;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUTICASONE PROPIONATE, MONTELUKAST;CA10;CC + CT;rs967676;EFFICACY;INCREASED;RESPONSE;;CHILDREN;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE;EPHX1;CT;rs1051740;DOSAGE, METABOLISM/PK;INCREASED;DOSE;;PEOPLE;DISEASE:EPILEPSY;CAUTION_DOSE_ADJUST
CARBAMAZEPINE;EPHX1;CC;rs1051740;DOSAGE, METABOLISM/PK;INCREASED;DOSE;;PEOPLE;DISEASE:EPILEPSY;CAUTION_DOSE_ADJUST
GEMCITABINE, PLATINUM COMPOUNDS;CASP7;AA + AG;rs1127687;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUTICASONE PROPIONATE, MONTELUKAST;;AA + AG;rs1786929;EFFICACY;INCREASED;RESPONSE;;CHILDREN;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;ABCB1;AA;rs2032582;METABOLISM/PK;DECREASED;CONCENTRATIONS;;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
CARBAMAZEPINE;SCN1A;TT;rs3812718;DOSAGE, METABOLISM/PK;INCREASED;DOSE;;PEOPLE;DISEASE:EPILEPSY;CAUTION_DOSE_ADJUST
ROSUVASTATIN;ABCG2;GT + TT;rs2231142;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
METHYLPHENIDATE;ADGRL3;AG + GG;rs1355368;EFFICACY;INCREASED;RESPONSE;;CHILDREN;DISEASE:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHYLPHENIDATE;ADGRL3;CC + CG;rs6813183;EFFICACY;INCREASED;RESPONSE;;CHILDREN;DISEASE:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS
RISPERIDONE;;C;rs7395555;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
RANIBIZUMAB;CFH;TT;rs1061170;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:MACULAR_DEGENERATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
OLANZAPINE;SPOPL;C;rs10170310;EFFICACY;DECREASED;RESPONSE;;PEOPLE;OTHER:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_FAILURE
QUETIAPINE;PDE4D;T;rs17382202;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACENOCOUMAROL;VKORC1;T;rs9923231;DOSAGE;;DOSE;;;;CAUTION_DOSE_ADJUST
QUETIAPINE;PDE4D;G;rs17742120;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
QUETIAPINE;PDE4D;A;rs2164660;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACENOCOUMAROL;VKORC1;CC;rs9923231;DOSAGE;INCREASED;DOSE;;PEOPLE;DISEASE:ATRIAL_FIBRILLATION, DISEASE:VENOUS_THROMBOEMBOLISM;CAUTION_DOSE_ADJUST
PERINDOPRIL;AGTR1;CC + CT;rs5182;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;TJP1;T;rs711355;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
RISPERIDONE;TJP1;A;rs785423;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
TENOFOVIR ALAFENAMIDE;ABCB1;CT;rs3842;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;OTHER:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
CLOZAPINE;SLC6A4;T;rs25531;EFFICACY;;RESPONSE;;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_DOSE_ADJUST
RALOXIFENE;UGT1A8;CC;rs1042597;EFFICACY;INCREASED;RESPONSE;;WOMEN;DISEASE:MENOPAUSE, DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESOMEPRAZOLE;STAT6;CC + CT;rs1059513;EFFICACY;INCREASED;RESPONSE;;CHILDREN;OTHER:EOSINOPHILIC_ESOPHAGITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
RISPERIDONE;WBP2NL;A;rs5758550;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
PACLITAXEL, PLATINUM COMPOUNDS;CASP7;AA + AC;rs12415607;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ADALIMUMAB;CD40LG;T;rs1126535;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
RALOXIFENE;ESR1;CC;rs11543791;EFFICACY;DECREASED;RESPONSE;;WOMEN;DISEASE:MENOPAUSE, DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_FAILURE
PERINDOPRIL;AGTR1;AA + AT;rs275651;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
LITHIUM;MYO1H;C;rs7959663;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:BIPOLAR_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
INFLIXIMAB;FCGR2A;G;rs1801274;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
LITHIUM;EPHX2;T;rs59724122;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:BIPOLAR_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
LOSARTAN, LOSARTAN E-3174;FBXW12;CT;rs17080138;METABOLISM/PK;INCREASED;CONCENTRATIONS;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
LITHIUM;GRAMD1B;A;rs61123830;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:BIPOLAR_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;VKORC1;T;rs7294;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
LITHIUM;;A;rs66486766;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:BIPOLAR_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
LITHIUM;;A;rs324899;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:BIPOLAR_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
LITHIUM;;T;rs1611259;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:BIPOLAR_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
LITHIUM;;A;rs6942227;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:BIPOLAR_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
NEVIRAPINE;CYP2D6;AA + AG;rs28371706;DOSAGE, METABOLISM/PK;DECREASED;CLEARANCE;;CHILDREN;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DOSE_ADJUST
NEVIRAPINE;CYP2B6;GT + TT;rs3745274;DOSAGE, METABOLISM/PK;DECREASED;CLEARANCE;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DOSE_ADJUST
CATECHOLAMINES;ADRB1;CC;rs1801253;DOSAGE;DECREASED;DOSE;;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;APOE;CC;rs429358;DOSAGE;INCREASED;DOSE;;PEOPLE;DISEASE:ATRIAL_FIBRILLATION, DISEASE:VENOUS_THROMBOEMBOLISM;CAUTION_DOSE_ADJUST
LOSARTAN, LOSARTAN E-3174;ZNF703;CT;rs79707182;METABOLISM/PK;INCREASED;CONCENTRATIONS;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
PERINDOPRIL;BDKRB1;AA + AG;rs12050217;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
LOSARTAN, LOSARTAN E-3174;SLC17A4;A;rs11754288;METABOLISM/PK;INCREASED;CONCENTRATIONS;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;A;rs17708472;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
DRUGS USED IN NICOTINE DEPENDENCE;CHRNA5;C;rs680244;OTHER;INCREASED;RESPONSE;;PEOPLE;DISEASE:TOBACCO_USE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
ADALIMUMAB, ETANERCEPT, INFLIXIMAB;NFATC2;CC + CT;rs3787186;EFFICACY;DECREASED;RESPONSE;;PEOPLE;OTHER:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
DRUGS USED IN NICOTINE DEPENDENCE;CHRNA3, CHRNA5;G;rs16969968;OTHER;INCREASED;RESPONSE;;PEOPLE;DISEASE:TOBACCO_USE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
DRUGS USED IN NICOTINE DEPENDENCE;CHRNA5;T;rs680244;OTHER;INCREASED;RESPONSE;;PEOPLE;DISEASE:TOBACCO_USE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
ALLOPURINOL;ABCG2;T;rs2231142;EFFICACY;DECREASED;RESPONSE;;PEOPLE;OTHER:GOUT;LIKELIHOOD_THERAPEUTIC_FAILURE
LITHIUM;FAM177A1;T;rs79403677;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:BIPOLAR_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;;A;rs2487032;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
METOPROLOL;ADRB1;CC;rs1801253;EFFICACY;INCREASED;RESPONSE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;A;rs9923231;DOSAGE;DECREASED;DOSE;;PEOPLE;OTHER:TOTAL_KNEE_OR_HIP_ARTHROPLASTY;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;C;rs1057910;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;CHUK;G;rs11591741;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;T;rs1799853;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
LITHIUM;ADCY1;A;rs1521470;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:BIPOLAR_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;VKORC1;CC;rs9923231;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
REPAGLINIDE;KCNQ1;CT + TT;rs2237892;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
LITHIUM;;A;rs7588746;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:BIPOLAR_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
LITHIUM;FAM178B;A;rs6728642;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:BIPOLAR_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
BETA BLOCKING AGENTS;GRK5;AT + TT;rs2230345;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:HEART_FAILURE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ZILEUTON;PRORP;AA;rs12436663;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_FAILURE
LOSARTAN, LOSARTAN E-3174;CYP2C9;GT;rs10509680;METABOLISM/PK;INCREASED;CONCENTRATIONS;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
LITHIUM;ZNF804A;T;rs62200793;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:BIPOLAR_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
LITHIUM;;A;rs1611255;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:BIPOLAR_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
LITHIUM;;A;rs209474;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:BIPOLAR_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
REPAGLINIDE;KCNQ1;AC + CC;rs2237895;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
LITHIUM;;A;rs3919583;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:BIPOLAR_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
PLATINUM COMPOUNDS;XRCC1;AA + AG;rs1799782;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
GLATIRAMER ACETATE;TGFB1;A;rs1800469;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:MULTIPLE_SCLEROSIS;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIEPILEPTICS;ABCC2;CT + TT;rs3740066;EFFICACY;INCREASED;RESISTANCE;;PEOPLE;DISEASE:EPILEPSY;LIKELIHOOD_THERAPEUTIC_FAILURE
N-DESMETHYLTAMOXIFEN;ABCG2;GT + TT;rs2231142;METABOLISM/PK;INCREASED;CONCENTRATIONS;;WOMEN;OTHER:BREAST_NEOPLASMS;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
GLUCOCORTICOIDS;GLCCI1;G;rs37973;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;AA + AG;rs9934438;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ANTIEPILEPTICS;ABCC2;CT + TT;rs717620;EFFICACY;INCREASED;RESISTANCE;;PEOPLE;DISEASE:EPILEPSY;LIKELIHOOD_THERAPEUTIC_FAILURE
AMLODIPINE;CYP3A4;AG + GG;rs2246709;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
TENELIGLIPTIN;FMO3;AG + GG;rs2266780;METABOLISM/PK;DECREASED;CLEARANCE;;MEN;;CAUTION_DRUG_ACCUMULATION
DRUGS USED IN NICOTINE DEPENDENCE;CHRNA3, CHRNA5;A;rs16969968;OTHER;INCREASED;RESPONSE;;PEOPLE;DISEASE:TOBACCO_USE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
QUETIAPINE;COMT;C;rs4818;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_FAILURE
HYDROCHLOROTHIAZIDE;GPR83;GG;rs3758785;EFFICACY;DECREASED;RESPONSE;;PEOPLE;EFFICACY:ESSENTIAL_HYPERTENSION;LIKELIHOOD_THERAPEUTIC_FAILURE
QUETIAPINE;COMT;T;rs5993883;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_FAILURE
TENELIGLIPTIN;FMO3;CT + TT;rs909530;METABOLISM/PK;DECREASED;CLEARANCE;;MEN;;CAUTION_DRUG_ACCUMULATION
MENOTROPINS;FSHR;CT;rs6166;;DECREASED;DOSE;;WOMEN;;CAUTION_DOSE_ADJUST
QUETIAPINE;COMT;A;rs6269;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_FAILURE
CANDESARTAN;GPR83;GG;rs3758785;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:ESSENTIAL_HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;IL6;GG;rs1800795;DOSAGE;INCREASED;DOSE;;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TENELIGLIPTIN;FMO3;AG + GG;rs2266782;METABOLISM/PK;DECREASED;CLEARANCE;;MEN;;CAUTION_DRUG_ACCUMULATION
PACLITAXEL;ABCB1;CT;rs2032582;METABOLISM/PK;INCREASED;METABOLISM;;PEOPLE;DISEASE:OVARIAN_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
HYDROCHLOROTHIAZIDE;HSD3B1;CC + CT;rs7553527;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
HYDROCHLOROTHIAZIDE;TTC6;CC + CT;rs177852;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
TENELIGLIPTIN;CYP3A4;CT + TT;rs2242480;METABOLISM/PK;DECREASED;CONCENTRATIONS;;MEN;;LIKELIHOOD_THERAPEUTIC_FAILURE
GLATIRAMER ACETATE;IFNAR1;G;rs1012335;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:MULTIPLE_SCLEROSIS;LIKELIHOOD_THERAPEUTIC_FAILURE
5-HYDROXYOMEPRAZOLE, OMEPRAZOLE;;A;rs12777823;METABOLISM/PK;INCREASED;CONCENTRATIONS;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
ATORVASTATIN;CYP3A4;CC;rs2740574;EFFICACY;DECREASED;RESPONSE;;PEOPLE;OTHER:CARDIOVASCULAR_DISEASE, OTHER:HYPERLIPIDEMIAS;LIKELIHOOD_THERAPEUTIC_FAILURE
IVACAFTOR;CFTR;A;rs75527207;EFFICACY;;RESPONSE;;PEOPLE;DISEASE:CYSTIC_FIBROSIS;CAUTION_DOSE_ADJUST
6-HYDROXY S-WARFARIN;;A;rs368245720;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;OTHER:ATRIAL_FIBRILLATION, OTHER:VENOUS_THROMBOEMBOLISM,OTHER:HEART_VALVE_DISEASES;CAUTION_DRUG_ACCUMULATION
ATORVASTATIN;CYP3A5;CC;rs776746;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:CARDIOVASCULAR_DISEASE, OTHER:HYPERLIPIDEMIAS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CITALOPRAM, ESCITALOPRAM, FLUOXETINE, SERTRALINE;BDNF;CC;rs6265;EFFICACY;INCREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
6-HYDROXY S-WARFARIN;PARP14;A;rs10433340;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;OTHER:ATRIAL_FIBRILLATION, OTHER:VENOUS_THROMBOEMBOLISM,OTHER:HEART_VALVE_DISEASES;CAUTION_DRUG_ACCUMULATION
METOPROLOL;ADRB1;C;rs1801253;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
SALBUTAMOL;ADRB2;AA;rs1042713;PD;DECREASED;RESPONSE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;NR1I3;GG;rs3003596;METABOLISM/PK;INCREASED;METABOLISM;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
IMATINIB;ABCG2;G;rs12505410;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;LIKELIHOOD_THERAPEUTIC_SUCCESS
IMATINIB;ABCG2;GG + GT;rs12505410;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TAMOXIFEN;CYP19A1;AA + AC;rs4646;EFFICACY;INCREASED;RESPONSE;;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
6-HYDROXY R-WARFARIN, 6-HYDROXY S-WARFARIN;GRID2;G;rs558364281;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;OTHER:ATRIAL_FIBRILLATION, OTHER:VENOUS_THROMBOEMBOLISM,OTHER:HEART_VALVE_DISEASES;CAUTION_DRUG_ACCUMULATION
IMATINIB;ABCG2;CC + CT;rs13120400;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;SLCO1B1;CT + TT;rs10841753;METABOLISM/PK;DECREASED;CONCENTRATIONS;;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
IMATINIB;ABCG2;AC + CC;rs2725252;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;LIKELIHOOD_THERAPEUTIC_SUCCESS
LACIDIPINE, NIFEDIPINE, NITRENDIPINE;CACNA1C;TT;rs2238032;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
LUMEFANTRINE;CYP3A4;C;rs2740574;METABOLISM/PK;INCREASED;CONCENTRATIONS;;WOMEN;DISEASE:MALARIA, OTHER:PREGNANCY;CAUTION_DRUG_ACCUMULATION
QUETIAPINE;HTR1A;TT;rs10042486;METABOLISM/PK;INCREASED;CONCENTRATIONS;;MEN;OTHER:SCHIZOPHRENIA;CAUTION_DRUG_ACCUMULATION
AMITRIPTYLINE, CLOMIPRAMINE, DULOXETINE, IMIPRAMINE, MILNACIPRAN, VENLAFAXINE;BDNF;CT + TT;rs6265;EFFICACY;INCREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
CHLORPROMAZINE, CLOZAPINE, HALOPERIDOL, OLANZAPINE, QUETIAPINE, RISPERIDONE, TRIFLUOPERAZINE;EPM2A;C;rs1415744;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
AMLODIPINE, FELODIPINE;CACNA1C;GG;rs2239050;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C18;A;rs41291550;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;OTHER:ATRIAL_FIBRILLATION, OTHER:VENOUS_THROMBOEMBOLISM,OTHER:HEART_VALVE_DISEASES;CAUTION_DRUG_ACCUMULATION
ATORVASTATIN;CYP3A4;TT;rs2740574;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;OTHER:CARDIOVASCULAR_DISEASE, OTHER:HYPERLIPIDEMIAS;CAUTION_DRUG_ACCUMULATION
CITALOPRAM, FLUOXETINE;GSK3B;GG;rs334558;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHANOL;SRPRB;CT;rs17376019;METABOLISM/PK;DECREASED;CONCENTRATIONS;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;T;rs9332241;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;OTHER:ATRIAL_FIBRILLATION, OTHER:VENOUS_THROMBOEMBOLISM,OTHER:HEART_VALVE_DISEASES;CAUTION_DRUG_ACCUMULATION
ETHANOL;ALDH2;AG;rs671;METABOLISM/PK;INCREASED;CONCENTRATIONS;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
LUMEFANTRINE;CYP3A5;T;rs10264272;METABOLISM/PK;INCREASED;CONCENTRATIONS;;WOMEN;DISEASE:MALARIA, OTHER:PREGNANCY;CAUTION_DRUG_ACCUMULATION
ATORVASTATIN;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;OTHER:CARDIOVASCULAR_DISEASE, OTHER:HYPERLIPIDEMIAS;CAUTION_DRUG_ACCUMULATION
ETHANOL;PGM1;CC;rs4643;METABOLISM/PK;DECREASED;CONCENTRATIONS;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;FPGS;G;rs7856096;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ACETALDEHYDE;ADH1A;CT;rs1229976;METABOLISM/PK;INCREASED;CONCENTRATIONS;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
WARFARIN;FPGS;G;rs7856096;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
LUMEFANTRINE;CYP3A5;C;rs776746;METABOLISM/PK;INCREASED;CONCENTRATIONS;;WOMEN;DISEASE:MALARIA, OTHER:PREGNANCY;CAUTION_DRUG_ACCUMULATION
ACETALDEHYDE;ALDH2;AG;rs671;METABOLISM/PK;INCREASED;CONCENTRATIONS;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
INFLIXIMAB;FCGR3A;A;rs396991;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CETUXIMAB;FCGR3A;A;rs396991;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACETALDEHYDE;PGM1;CC;rs4643;METABOLISM/PK;INCREASED;CONCENTRATIONS;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
VERAPAMIL;ABCB1;GG;rs1045642;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
ACETALDEHYDE;ADH1B;CT;rs1229984;METABOLISM/PK;INCREASED;CONCENTRATIONS;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
NALTREXONE;OPRM1;AG + GG;rs1799971;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:ALCOHOL_ABUSE;LIKELIHOOD_THERAPEUTIC_SUCCESS
AMLODIPINE, FELODIPINE;CACNA1C;C;rs2239128;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;DPYD;CT;rs3918290;TOXICITY, METABOLISM/PK;DECREASED;CLEARANCE;;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_DRUG_ACCUMULATION
SUNITINIB;CYP3A5;T;rs776746;DOSAGE;DECREASED;DOSE;;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;CAUTION_DOSE_ADJUST
N-DESMETHYLCLOZAPINE;UGT2B10;GT;rs61750900;METABOLISM/PK;DECREASED;CONCENTRATIONS;;PEOPLE;OTHER:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_FAILURE
LUMEFANTRINE;CYP3A4;T;rs2740574;EFFICACY;DECREASED;RESPONSE;;WOMEN;DISEASE:MALARIA, DISEASE:PREGNANCY;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;N6AMT1;G;rs2254638;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
VALPROIC ACID;UGT1A6;TT;rs6759892;METABOLISM/PK;INCREASED;EXPOSURE;;PEOPLE;OTHER:EPILEPSY;CAUTION_DRUG_ACCUMULATION
FENTANYL;ASTN2;CT + TT;rs7858836;DOSAGE;DECREASED;DOSE;;PEOPLE;OTHER:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
BENAZEPRIL, IMIDAPRIL;CYP11B2;AA + AG;rs1799998;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:ESSENTIAL_HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
FENTANYL;ASTN2;CC + CT;rs958804;DOSAGE;DECREASED;DOSE;;PEOPLE;OTHER:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
VALPROIC ACID;UGT1A6;AA;rs1105879;METABOLISM/PK;INCREASED;EXPOSURE;;PEOPLE;OTHER:EPILEPSY;CAUTION_DRUG_ACCUMULATION
VALPROIC ACID;UGT1A6;AA;rs2070959;METABOLISM/PK;INCREASED;EXPOSURE;;PEOPLE;OTHER:EPILEPSY;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A4;AA + AG;rs35599367;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;OTHER:LIVER_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
VERAPAMIL;ABCB1;CC;rs2032582;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3, IFNL4;CC + CT;rs12979860;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETIDRONIC ACID;COL1A1;AA + AC;rs1800012;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:METABOLIC_BONE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
VORICONAZOLE;ABCG2;CC;rs13120400;METABOLISM/PK;INCREASED;TROUGH_CONCENTRATION;;CHILDREN;;CAUTION_DRUG_ACCUMULATION
MORPHINE, NORTRIPTYLINE;ABCB1;GG;rs1045642;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:PAIN;LIKELIHOOD_THERAPEUTIC_SUCCESS
RISPERIDONE;HTR1A;CG + GG;rs6295;METABOLISM/PK;INCREASED;CONCENTRATIONS;;MEN;OTHER:SCHIZOPHRENIA;CAUTION_DRUG_ACCUMULATION
DULOXETINE;;G;rs4858478;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;DPYD;AT;rs67376798;TOXICITY, METABOLISM/PK;DECREASED;CLEARANCE;;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_DRUG_ACCUMULATION
VALPROIC ACID;UGT1A6;GG;rs6759892;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;OTHER:EPILEPSY;LIKELIHOOD_THERAPEUTIC_FAILURE
DULOXETINE;ZNF385D;T;rs13093500;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESCITALOPRAM, FLUOXETINE, PAROXETINE, SERTRALINE;BDNF;CC;rs6265;EFFICACY;INCREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
FOLIC ACID, HYDROXYCHLOROQUINE, METHOTREXATE, SULFASALAZINE;SLC19A1;T;rs1051266;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
DULOXETINE;ZNF385D;T;rs4334661;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
FOLIC ACID, HYDROXYCHLOROQUINE, METHOTREXATE, SULFASALAZINE;MTR;A;rs1805087;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
DULOXETINE;;G;rs7625956;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CC;rs4646453;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
TAMOXIFEN;SULT1A1;TT;rs1042028;EFFICACY;DECREASED;RESPONSE;;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
DULOXETINE;ZNF385D;G;rs7616119;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
TERBUTALINE;ADRB2;CT;rs1800888;EFFICACY;DECREASED;RESPONSE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
DULOXETINE;;T;rs2933304;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;VKORC1;CT;rs9923231;DOSAGE;INCREASED;DOSE;;PEOPLE;DISEASE:THROMBOEMBOLISM;CAUTION_DOSE_ADJUST
METHOTREXATE;SLC19A1;T;rs1051266;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
DULOXETINE;NRXN1;T;rs4971678;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
DULOXETINE;ZNF385D;G;rs12630569;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP4F2;CT + TT;rs2108622;DOSAGE;INCREASED;DOSE;;PEOPLE;DISEASE:THROMBOEMBOLISM;CAUTION_DOSE_ADJUST
BEVACIZUMAB, CAPECITABINE, FLUOROURACIL, IRINOTECAN, LEUCOVORIN, OXALIPLATIN;VEGFA;CC;rs699947;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ERYTHROPOIETIN;HFE;A;rs1800562;DOSAGE, METABOLISM/PK;DECREASED;DOSE;;PEOPLE;OTHER:HEMODIALYSIS_TREATMENT;CAUTION_DOSE_ADJUST
DULOXETINE;;C;rs6700741;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
ENALAPRIL;ADRB2;CG + GG;rs1042714;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HYPERTROPHY, LEFT_VENTRICULAR;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATENOLOL, ENALAPRIL;ADRB2;CG + GG;rs1042714;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HYPERTROPHY, LEFT_VENTRICULAR;LIKELIHOOD_THERAPEUTIC_SUCCESS
BEVACIZUMAB, CAPECITABINE, FLUOROURACIL, IRINOTECAN, LEUCOVORIN, OXALIPLATIN;VEGFA;TT;rs3025039;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
ERYTHROPOIETIN;HFE;G;rs1799945;DOSAGE, METABOLISM/PK;DECREASED;DOSE;;PEOPLE;OTHER:HEMODIALYSIS_TREATMENT;CAUTION_DOSE_ADJUST
DULOXETINE;TEX10;C;rs6479008;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;AA;rs15524;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
DULOXETINE;TEX10;A;rs7035619;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
DULOXETINE;TEX10;T;rs10989064;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
DIGOXIN;ABCB1;GG;rs1045642;METABOLISM/PK;INCREASED;METABOLISM;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
DULOXETINE;ATP10A;G;rs12595802;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
DULOXETINE;TEX10;G;rs7472;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
DULOXETINE;;G;rs56229625;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
DIGOXIN;ABCB1;CC;rs2032582;METABOLISM/PK;INCREASED;METABOLISM;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
DULOXETINE;;G;rs61692318;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
DULOXETINE;;A;rs62319299;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
DULOXETINE;TEX10;G;rs10124893;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
DULOXETINE;INVS;G;rs10123866;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
ABEMACICLIB, PALBOCICLIB, RIBOCICLIB;ABCB1;A;rs1045642;DOSAGE, TOXICITY;DECREASED;DOSE;;WOMEN;OTHER:BREAST_NEOPLASMS;CAUTION_DOSE_ADJUST
AMLODIPINE;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;METABOLISM;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
DULOXETINE;;C;rs10007051;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
IVACAFTOR;CFTR;A;rs75527207;EFFICACY;INCREASED;CLINICAL_BENEFIT;;CHILDREN;OTHER:CYSTIC_FIBROSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
DULOXETINE;ZNF385D;C;rs9879065;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
DULOXETINE;;C;rs55881666;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
INFLIXIMAB;;CC + CT;rs2097432;EFFICACY;DECREASED;RESPONSE;;PEOPLE;OTHER:CROHN_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
VALPROIC ACID;CYP2C9;CC + CT;rs4918758;METABOLISM/PK;INCREASED;EXPOSURE;;PEOPLE;OTHER:EPILEPSY;CAUTION_DRUG_ACCUMULATION
DULOXETINE;;A;rs11933890;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
VALPROIC ACID;CYP2C19;AA + AG;rs4244285;METABOLISM/PK;INCREASED;EXPOSURE;;PEOPLE;OTHER:EPILEPSY;CAUTION_DRUG_ACCUMULATION
DULOXETINE;ZNF385D;C;rs9310658;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
DULOXETINE;ZNF385D;A;rs7653345;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
VALPROIC ACID;ABAT;GG;rs1731017;METABOLISM/PK;INCREASED;EXPOSURE;;PEOPLE;OTHER:EPILEPSY;CAUTION_DRUG_ACCUMULATION
DULOXETINE;ZNF385D;T;rs9310657;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
DULOXETINE;ZNF385D;G;rs9824595;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
DULOXETINE;ZNF385D;C;rs9873889;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
DULOXETINE;ZNF385D;G;rs9819548;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;T;rs1799853;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
CAPECITABINE;CDA;CC;rs532545;EFFICACY;DECREASED;RESPONSE;;WOMEN;OTHER:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
HYDRALAZINE / ISOSORBIDE DINITRATE;NOS3;GG;rs1799983;EFFICACY;INCREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:HEART_FAILURE;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;C;rs56165452;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
TACROLIMUS;ABCB1;AA;rs1045642;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;GG + GT;rs8099917;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;C;rs1057910;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ADALIMUMAB;CRP;AG + GG;rs1130864;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:INFLAMMATORY_BOWEL_DISEASES;LIKELIHOOD_THERAPEUTIC_SUCCESS
OLANZAPINE;CYP3A43;AA;rs472660;DOSAGE, EFFICACY, TOXICITY, METABOLISM/PK;INCREASED;CLEARANCE;;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_DOSE_ADJUST
GLATIRAMER ACETATE;EOMES;T;rs2371108;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:MULTIPLE_SCLEROSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARVEDILOL;UGT1A1;A;rs4148323;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:ANGINA_PECTORIS;CAUTION_DRUG_ACCUMULATION
ETOPOSIDE;ABCB1;GG;rs1045642;METABOLISM/PK;INCREASED;METABOLISM;;PEOPLE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
ADALIMUMAB;ATG5;CC + CT;rs9373839;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:INFLAMMATORY_BOWEL_DISEASES;LIKELIHOOD_THERAPEUTIC_SUCCESS
DULOXETINE;MIEF2;G;rs56355515;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
DULOXETINE;MIEF2;G;rs12603700;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
ADALIMUMAB;ATG5;CT + TT;rs510432;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:INFLAMMATORY_BOWEL_DISEASES;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;ABCB1;GG;rs1045642;METABOLISM/PK;INCREASED;DOSE;;PEOPLE;DISEASE:TRANSPLANTATION;CAUTION_DOSE_ADJUST
DULOXETINE;MIEF2;G;rs3889402;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
AZATHIOPRINE;AOX1;G;rs55754655;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:INFLAMMATORY_BOWEL_DISEASES;LIKELIHOOD_THERAPEUTIC_FAILURE
AZATHIOPRINE;AOX1;AG + GG;rs55754655;DOSAGE;INCREASED;DOSE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
HYDRALAZINE / ISOSORBIDE DINITRATE;CYP11B2;AA;rs1799998;EFFICACY;INCREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:HEART_FAILURE;LIKELIHOOD_THERAPEUTIC_SUCCESS
DULOXETINE;;G;rs58042962;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A4;C;rs2740574;DOSAGE;INCREASED;DOSE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
DULOXETINE;;T;rs10771997;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
FENOFIBRATE;LPL;GG;rs320;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:HYPERTRIGLYCERIDEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
DULOXETINE;FCN2;T;rs3124955;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
FENOFIBRATE;APOA1;CG;rs2727786;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:HYPERTRIGLYCERIDEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
DULOXETINE;FCN2;A;rs3128624;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
DULOXETINE;;A;rs7306991;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
GLATIRAMER ACETATE;CLEC16A;A;rs6498169;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:MULTIPLE_SCLEROSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A4;C;rs2740574;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
DIGOXIN;ABCB1;AA;rs1045642;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
DULOXETINE;;C;rs10771999;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
DULOXETINE;;A;rs10771998;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
DULOXETINE;SKIC3;G;rs12657120;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
ETHOSUXIMIDE;CACNA1H;T;rs61734410;EFFICACY;DECREASED;CLINICAL_BENEFIT;;CHILDREN;EFFICACY:EPILEPSY;LIKELIHOOD_THERAPEUTIC_FAILURE
DULOXETINE;SKIC3;G;rs4639250;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
DULOXETINE;;A;rs4437856;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
ETHOSUXIMIDE;CACNA1I;T;rs3747178;EFFICACY;DECREASED;CLINICAL_BENEFIT;;CHILDREN;EFFICACY:EPILEPSY;LIKELIHOOD_THERAPEUTIC_FAILURE
DULOXETINE;TREML4;A;rs9369266;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
AZATHIOPRINE;MOCOS;AA + AC;rs594445;DOSAGE;DECREASED;DOSE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
DULOXETINE;TREML4;G;rs13204353;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
LAMOTRIGINE;ABCB1;A;rs2032582;EFFICACY;DECREASED;CLINICAL_BENEFIT;;CHILDREN;EFFICACY:EPILEPSY;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOSPORINE;CALM1;T;rs12885713;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:PSORIASIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRBESARTAN;AGT;GG;rs699;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HYPERTROPHY, LEFT_VENTRICULAR;LIKELIHOOD_THERAPEUTIC_SUCCESS
DULOXETINE;;C;rs2419128;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;SLC19A1;T;rs1051266;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
DULOXETINE;;G;rs12502866;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;GGH;AA + AG;rs3758149;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
DULOXETINE;;T;rs12094644;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
CAPECITABINE;CDA;AA + AC;rs2072671;EFFICACY;DECREASED;RESPONSE;;WOMEN;OTHER:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
LAMOTRIGINE;CACNA1H;A;rs2753326;EFFICACY;INCREASED;CLINICAL_BENEFIT;;CHILDREN;EFFICACY:EPILEPSY;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIVAROXABAN;ABCB1;GG;rs4728709;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;OTHER:ATRIAL_FIBRILLATION;CAUTION_DRUG_ACCUMULATION
ATENOLOL;ADRA2A;GG;rs1800545;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HYPERTROPHY, LEFT_VENTRICULAR;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;GT + TT;rs3745274;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
CYCLOSPORINE;;G;rs2874116;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:PSORIASIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRBESARTAN;APOB;CC;rs1801701;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HYPERTROPHY, LEFT_VENTRICULAR;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIVAROXABAN;ABCB1;CC;rs4148738;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;OTHER:ATRIAL_FIBRILLATION;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;C;rs28399499;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN;CYP2C19;T;rs183701923;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN;CYP2C19;A;rs140278421;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;T;rs4803419;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
CHLORPROMAZINE;DRD2;GG;rs1799732;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;AMPD1;AA + AG;rs17602729;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
BENAZEPRIL;AGT;TT;rs7079;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;T;rs3745274;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
OMEPRAZOLE;ABCB1;AA + AG;rs1045642;METABOLISM/PK;INCREASED;CONCENTRATIONS;;INFANTS;DISEASE:GASTROESOPHAGEAL_REFLUX;CAUTION_DRUG_ACCUMULATION
OPIOIDS;OPRM1;AA;rs1799971;DOSAGE, EFFICACY;DECREASED;DOSE;;PEOPLE;DISEASE:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
NELFINAVIR;CYP2C19;AA;rs4244285;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
TOLBUTAMIDE;CYP2C9;C;rs771237265;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;SLC19A1;TT;rs1051266;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
TOLBUTAMIDE;CYP2C9;T;rs762081829;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
METFORMIN;SLC22A1;A;rs628031;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_FAILURE
MEPHENYTOIN;CYP2C19;A;rs145119820;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
TOLBUTAMIDE;CYP2C9;C;rs761895497;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
WARFARIN;F7;AA + AG;rs510317;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
FLUOXETINE;HTR1A;GG;rs6295;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
MEPHENYTOIN;CYP2C19;T;rs61311738;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
SULFONAMIDES, UREA DERIVATIVES;TCF7L2;TT;rs7903146;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_FAILURE
BENAZEPRIL;AGT;G;rs4762;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
DIGOXIN;ABCB1;AA;rs1045642;METABOLISM/PK;DECREASED;CLEARANCE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
BENAZEPRIL;AGT;A;rs699;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL, OXALIPLATIN;GSTP1;AG + GG;rs1695;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACENOCOUMAROL;CYP4F2;CT + TT;rs2108622;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
BENAZEPRIL;AGT;T;rs7079;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;T;rs1799853;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
FENOFIBRATE;APOA5;CG + GG;rs3135506;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HYPERTRIGLYCERIDEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
PRAVASTATIN, SIMVASTATIN;RHOA;A;rs11716445;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:HYPERCHOLESTEROLEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;AG;rs35303484;METABOLISM/PK;INCREASED;CONCENTRATIONS;;CHILDREN;OTHER:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP4F2;CT + TT;rs2108622;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
CITALOPRAM;;CT;rs585719;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:DEPRESSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;GGCX;CG + GG;rs11676382;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;;A;rs12777823;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;OTHER:ATRIAL_FIBRILLATION, OTHER:VENOUS_THROMBOEMBOLISM,OTHER:HEART_VALVE_DISEASES;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;A;rs7900194;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;OTHER:ATRIAL_FIBRILLATION, OTHER:VENOUS_THROMBOEMBOLISM,OTHER:HEART_VALVE_DISEASES;CAUTION_DRUG_ACCUMULATION
ISONIAZID;CYP2E1;A;rs6413432;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;OTHER:TUBERCULOSIS;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;TT;rs4803419;METABOLISM/PK;INCREASED;CONCENTRATIONS;;CHILDREN;OTHER:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;AA;rs9934438;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;AC;rs1057910;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;GATA4;TT;rs2645400;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;T;rs28371685;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;OTHER:ATRIAL_FIBRILLATION, OTHER:VENOUS_THROMBOEMBOLISM,OTHER:HEART_VALVE_DISEASES;CAUTION_DRUG_ACCUMULATION
WARFARIN;GATA4;TT;rs4841588;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
MYCOPHENOLIC ACID ACYL GLUCURONIDE;UGT2B7;GG;rs7662029;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
BUPRENORPHINE;UGT2B7;CC;rs7439366;METABOLISM/PK;DECREASED;CONCENTRATIONS;;PEOPLE;OTHER:OPIOID-RELATED_DISORDERS;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;SLCO1B1;CC;rs4149056;EFFICACY;DECREASED;RESPONSE;;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
MYCOPHENOLIC ACID ACYL GLUCURONIDE;UGT2B7;CC;rs7439366;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;SLC19A1;AA;rs2838958;EFFICACY;DECREASED;RESPONSE;;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;AC + CC;rs1057910;DOSAGE, METABOLISM/PK;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
SILDENAFIL;VEGFA;AA;rs1570360;EFFICACY;DECREASED;RESPONSE;;MEN;DISEASE:ERECTILE_DYSFUNCTION;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;VKORC1;CC;rs9923231;DOSAGE;INCREASED;DOSE;;HEALTHY;;CAUTION_DOSE_ADJUST
SILDENAFIL;VEGFA;AA + AC;rs699947;EFFICACY;DECREASED;RESPONSE;;MEN;DISEASE:ERECTILE_DYSFUNCTION;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP4F2;CT + TT;rs2108622;METABOLISM/PK;INCREASED;DOSE;;HEALTHY;;CAUTION_DOSE_ADJUST
CAPTOPRIL;ACE2;GG;rs2106809;EFFICACY;INCREASED;RESPONSE;;WOMEN;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE, DOXORUBICIN, PACLITAXEL, TRASTUZUMAB;FCGR2A;AA;rs1801274;EFFICACY;INCREASED;RESPONSE;;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
TRASTUZUMAB;FCGR3A;CC;rs396991;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUPRENORPHINE;UGT2B7;GG;rs7662029;METABOLISM/PK;DECREASED;CONCENTRATIONS;;PEOPLE;OTHER:OPIOID-RELATED_DISORDERS;LIKELIHOOD_THERAPEUTIC_FAILURE
ECULIZUMAB;CR1;AG + GG;rs2274567;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:PAROXYSMAL_NOCTURNAL_HEMOGLOBINURIA;LIKELIHOOD_THERAPEUTIC_FAILURE
MIRABEGRON;UGT1A4;GT;rs2011425;METABOLISM/PK;INCREASED;HALF-LIFE_TIME;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A4;CT;rs2740574;METABOLISM/PK;INCREASED;EXPOSURE;;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
MYCOPHENOLIC ACID;UGT1A1;AG;rs4148323;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
MIRABEGRON;UGT1A3;AA;rs2008584;METABOLISM/PK;DECREASED;HALF-LIFE_TIME;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
MIRABEGRON;SLC6A2;CC;rs12708954;METABOLISM/PK;INCREASED;CLEARANCE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;VKORC1;TT;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
PHENPROCOUMON;VKORC1;TT;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
CLOZAPINE;DRD1;G;rs686;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
MYCOPHENOLIC ACID ACYL GLUCURONIDE;UGT2B7;AA;rs7438135;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
FLUVASTATIN;CYP2C9;CC;rs1057910;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
MIRABEGRON;SLC19A1;TT;rs1051266;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOZAPINE;DRD3;TT;rs6280;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
MERCAPTOPURINE;TPMT;G;rs12199316;DOSAGE;INCREASED;DOSE;;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DOSE_ADJUST
TICAGRELOR;CYP3A4;CC;rs56324128;METABOLISM/PK;DECREASED;CONCENTRATIONS;;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;LIKELIHOOD_THERAPEUTIC_FAILURE
CANDESARTAN;AGTR1;AA;rs5186;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HEART_FAILURE;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRBESARTAN;AGTR1;AC;rs5186;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:HYPERTROPHY, LEFT_VENTRICULAR;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;G;rs2256871;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;OTHER:ATRIAL_FIBRILLATION, OTHER:VENOUS_THROMBOEMBOLISM,OTHER:HEART_VALVE_DISEASES;CAUTION_DRUG_ACCUMULATION
DOCETAXEL, PACLITAXEL;CYP3A5;CC;rs776746;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
CAPECITABINE, FLUOROURACIL, TEGAFUR / GIMERACIL / OTERACIL;DPYD;CC + CT;rs1801159;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:STOMACH_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
CANDESARTAN;AGTR1;AC;rs5186;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HEART_FAILURE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TICAGRELOR;SLCO1B1;C;rs113681054;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;CAUTION_DRUG_ACCUMULATION
TICAGRELOR;SLCO1B1;T;rs4149056;METABOLISM/PK;DECREASED;CONCENTRATIONS;;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;LIKELIHOOD_THERAPEUTIC_FAILURE
GEMCITABINE, PACLITAXEL;SLC29A1;A;rs760370;EFFICACY;DECREASED;RESPONSE;;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
CITALOPRAM, ESCITALOPRAM, FLUOXETINE, FLUVOXAMINE, PAROXETINE, SERTRALINE;BDNF;CC;rs6265;EFFICACY;INCREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C19;T;rs11188082;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;OTHER:ATRIAL_FIBRILLATION, OTHER:VENOUS_THROMBOEMBOLISM,OTHER:HEART_VALVE_DISEASES;CAUTION_DRUG_ACCUMULATION
METHYLPHENIDATE;CES1;CT;rs71647871;DOSAGE, METABOLISM/PK;DECREASED;DOSE;;CHILDREN;DISEASE:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY;CAUTION_DOSE_ADJUST
TICAGRELOR;UGT2B7;TT;rs61361928;METABOLISM/PK;DECREASED;CONCENTRATIONS;;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;LIKELIHOOD_THERAPEUTIC_FAILURE
QUETIAPINE;HTR1A;GG;rs6295;METABOLISM/PK;INCREASED;CONCENTRATIONS;;MEN;OTHER:SCHIZOPHRENIA;CAUTION_DRUG_ACCUMULATION
TICAGRELOR;CYP3A43;G;rs62471956;METABOLISM/PK;DECREASED;CONCENTRATIONS;;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;LIKELIHOOD_THERAPEUTIC_FAILURE
ACENOCOUMAROL, WARFARIN;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED;DOSE;;PEOPLE;OTHER:HEART_VALVE_REPLACEMENT;CAUTION_DOSE_ADJUST
SIMVASTATIN;LEPR;GG;rs1137101;EFFICACY;DECREASED;RESPONSE;;MEN;DISEASE:HYPERLIPIDEMIAS;LIKELIHOOD_THERAPEUTIC_FAILURE
LAMOTRIGINE;ABCG2;T;rs2231142;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:EPILEPSY;CAUTION_DRUG_ACCUMULATION
ACETAMINOPHEN;SULT1A1;CC;rs1042028;EFFICACY;INCREASED;RESPONSE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;IL2;AA;rs2069762;DOSAGE;INCREASED;DOSE;;PEOPLE;OTHER:PAIN, OTHER:NEOPLASMS;CAUTION_DOSE_ADJUST
OPIOIDS;BDNF;CC;rs6265;DOSAGE;INCREASED;DOSE;;PEOPLE;OTHER:PAIN, OTHER:NEOPLASMS;CAUTION_DOSE_ADJUST
ACENOCOUMAROL, WARFARIN;CYP4F2;CT + TT;rs2108622;DOSAGE;INCREASED;DOSE;;PEOPLE;OTHER:HEART_VALVE_REPLACEMENT;CAUTION_DOSE_ADJUST
VORICONAZOLE;CYP3A4;AG;rs4646437;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:FUNGAL_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
OPIOIDS;IL6;CC;rs1800795;DOSAGE;INCREASED;DOSE;;PEOPLE;OTHER:PAIN, OTHER:NEOPLASMS;CAUTION_DOSE_ADJUST
ATENOLOL, IRBESARTAN;AGT;AG;rs4762;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:HYPERTROPHY, LEFT_VENTRICULAR;LIKELIHOOD_THERAPEUTIC_SUCCESS
TENOFOVIR;ABCC4;AA + AG;rs1059751;METABOLISM/PK;DECREASED;CONCENTRATIONS;;PEOPLE;OTHER:HEPATITIS_B, CHRONIC;LIKELIHOOD_THERAPEUTIC_FAILURE
CAFFEINE;CYP1A1;T;rs2472297;METABOLISM/PK;INCREASED;METABOLISM;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
DOCETAXEL;VEGFA;GG;rs1570360;EFFICACY;DECREASED;RESPONSE;;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
OPIOIDS;IL1B;AA + AG;rs1143634;EFFICACY;DECREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:PAIN, OTHER:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
FENOFIBRATE;SCARB1;CT + TT;rs4238001;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HYPERTRIGLYCERIDEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
TENOFOVIR;SLC22A6;TT;rs4149170;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;OTHER:HEPATITIS_B, CHRONIC;CAUTION_DRUG_ACCUMULATION
NEVIRAPINE;CYP2B6;TT;rs3745274;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
OPIOIDS;OPRD1;CC;rs678849;EFFICACY;DECREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:PAIN, OTHER:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
ACENOCOUMAROL, WARFARIN;CYP2C9;AC + CC;rs1057910;DOSAGE;DECREASED;DOSE;;PEOPLE;OTHER:HEART_VALVE_REPLACEMENT;CAUTION_DOSE_ADJUST
IRBESARTAN;AGT;AG + GG;rs699;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:HYPERTROPHY, LEFT_VENTRICULAR;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B;CXCL10;CT + TT;rs56061981;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATORVASTATIN;ABCB1;T;rs2032582;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HYPERCHOLESTEROLEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATORVASTATIN;ABCB1;T;rs2032582;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HYPERCHOLESTEROLEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATALUREN;CFTR;T;rs113993959;EFFICACY;;RESPONSE;;CHILDREN;DISEASE:CYSTIC_FIBROSIS;CAUTION_DOSE_ADJUST
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATALUREN;CFTR;T;rs75039782;EFFICACY;;RESPONSE;;CHILDREN;DISEASE:CYSTIC_FIBROSIS;CAUTION_DOSE_ADJUST
ATALUREN;CFTR;A;rs77010898;EFFICACY;;RESPONSE;;CHILDREN;DISEASE:CYSTIC_FIBROSIS;CAUTION_DOSE_ADJUST
PLATINUM COMPOUNDS;ERCC2;AA + AG;rs1052555;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
FENOFIBRATE;APOA5;CC + CG;rs3135506;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HYPERTRIGLYCERIDEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
INSULIN RECOMBINANT, ZINC ACETATE;SLC30A8;CT + TT;rs13266634;EFFICACY;INCREASED;RESPONSE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHYLPHENIDATE;DRD1;CT + TT;rs5326;EFFICACY;INCREASED;RESPONSE;;CHILDREN;DISEASE:AUTISM_SPECTRUM_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
METFORMIN;SLC22A1;T;rs12208357;METABOLISM/PK;INCREASED;EXPOSURE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
FENTANYL;ABCB1;GG;rs1045642;DOSAGE, EFFICACY;INCREASED;DOSE;;PEOPLE;DISEASE:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
FOLIC ACID, METHOTREXATE;ATIC;CC;rs2372536;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CORTICOSTEROIDS, SELECTIVE BETA-2-ADRENORECEPTOR AGONISTS;ADAM33;AA;rs2853209;EFFICACY;DECREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:ASTHMA;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
LITHIUM;GADL1;T;rs17026688;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:BIPOLAR_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;POR;CC;rs1057868;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
FOLIC ACID, METHOTREXATE;ITPA;CC;rs1127354;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;ATIC;C;rs4673993;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;TT;rs9923231;DOSAGE, METABOLISM/PK;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;GGCX;C;rs12714145;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;C;rs1057910;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
METHOTREXATE;ADA;C;rs244076;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;ADORA2A;T;rs5751876;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
FOLIC ACID, METHOTREXATE;AMPD1;A;rs17602729;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
RITUXIMAB;FCGR3A;CC;rs396991;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;A;rs9934438;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
FLUOROURACIL;EGFR;CC;rs2293347;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:STOMACH_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;T;rs1799853;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ANTIDEPRESSANTS;TGFBR3;TT;rs12082710;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:DEPRESSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;C;rs7294;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
METHOTREXATE;SLC19A1;TT;rs1051266;EFFICACY;INCREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ALLOPURINOL;ABCG2;T;rs2231142;DOSAGE;INCREASED;DOSE;;PEOPLE;DISEASE:GOUT;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;C;rs2884737;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;A;rs2359612;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
RIFAMPIN;AADAC;GG;rs1803155;METABOLISM/PK;DECREASED;EXPOSURE;;PEOPLE;OTHER:TUBERCULOSIS;LIKELIHOOD_THERAPEUTIC_FAILURE
ABIRATERONE;SLCO2B1;AA + AG;rs1077858;METABOLISM/PK;INCREASED;CONCENTRATIONS;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
CETUXIMAB, PANITUMUMAB;AREG;AA;rs9996584;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CETUXIMAB, PANITUMUMAB;AREG;GG;rs1353295;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;MTHFR;AA + AG;rs1801133;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:BURKITT_LYMPHOMA, DISEASE:T-CELL_LYMPHOMA,DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DRUG_ACCUMULATION
RIFAMPIN;ABCB1;CC;rs3842;METABOLISM/PK;INCREASED;EXPOSURE;;PEOPLE;OTHER:TUBERCULOSIS;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;ABCB1;AA;rs1045642;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:BURKITT_LYMPHOMA, DISEASE:T-CELL_LYMPHOMA,DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DRUG_ACCUMULATION
FENTANYL;P2RX7;CT + TT;rs1718125;DOSAGE;INCREASED;DOSE;;PEOPLE;OTHER:LUNG_NEOPLASMS, OTHER:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
METHYLPHENIDATE;DRD1;CC + CT;rs4867798;EFFICACY;INCREASED;RESPONSE;;CHILDREN;DISEASE:AUTISM_SPECTRUM_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHYLPHENIDATE;DRD3;TT;rs6280;EFFICACY;INCREASED;RESPONSE;;CHILDREN;DISEASE:AUTISM_SPECTRUM_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHYLPHENIDATE;DRD4;AA;rs11246226;EFFICACY;INCREASED;RESPONSE;;CHILDREN;DISEASE:AUTISM_SPECTRUM_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM COMPOUNDS;XRCC1;CT + TT;rs25487;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHYLPHENIDATE;ADRA2A;CC;rs1800544;EFFICACY;INCREASED;RESPONSE;;CHILDREN;DISEASE:AUTISM_SPECTRUM_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHYLPHENIDATE;COMT;AA + AG;rs4680;EFFICACY;INCREASED;RESPONSE;;CHILDREN;DISEASE:AUTISM_SPECTRUM_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESTRONE SULFATE;SLCO1B1;C;rs10841753;EFFICACY;DECREASED;CONCENTRATIONS;;WOMEN;OTHER:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
DOBUTAMINE;GNAS;CC + CT;rs62205366;EFFICACY;INCREASED;RESPONSE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESTRONE SULFATE;SLCO1B1;C;rs10841753;METABOLISM/PK;DECREASED;;;WOMEN;OTHER:BREAST_NEOPLASMS;CAUTION_DOSE_ADJUST
WARFARIN;GGCX;TT;rs12714145;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
NEVIRAPINE;CYP2B6;GT + TT;rs3745274;METABOLISM/PK;DECREASED;CLEARANCE;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
CETUXIMAB, PANITUMUMAB;AREG;GG;rs13104811;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CETUXIMAB, PANITUMUMAB;AREG;AA;rs11942466;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIDEPRESSANTS;CRHR1;AA + AG;rs28364032;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
TOPIRAMATE;UGT1A1, UGT1A10, UGT1A3, UGT1A4, UGT1A5, UGT1A6, UGT1A7, UGT1A8, UGT1A9;GG + GT;rs4148324;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;CHILDREN;OTHER:EPILEPSY;CAUTION_DRUG_ACCUMULATION
CYCLOSPORINE;POR;T;rs1057868;METABOLISM/PK;INCREASED;CONCENTRATIONS;;CHILDREN;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;SLC29A1;GG;rs760370;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;MTHFR;AA + AG;rs1801133;METABOLISM/PK;DECREASED;CLEARANCE;;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DRUG_ACCUMULATION
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
TIPIRACIL HYDROCHLORIDE, TRIFLURIDINE;SLC29A1;AG + GG;rs760370;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHANOL;ADH1B;A;rs2018417;TOXICITY, METABOLISM/PK;;METABOLISM;;;;CAUTION_DOSE_ADJUST
ETHANOL;ADH1B;C;rs17033;TOXICITY, METABOLISM/PK;;METABOLISM;;;;CAUTION_DOSE_ADJUST
ETHANOL;ADH1B;G;rs1229985;TOXICITY, METABOLISM/PK;;METABOLISM;;;;CAUTION_DOSE_ADJUST
PHENPROCOUMON;PPARA;A;rs4253728;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ETHANOL;ADH1A;A;rs931635;TOXICITY, METABOLISM/PK;;METABOLISM;;;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
METHADONE;KCNJ6;TT;rs2070995;;INCREASED;DOSE;;PEOPLE;DISEASE:SUBSTANCE-RELATED_DISORDERS;CAUTION_DOSE_ADJUST
ETHANOL;ADH1C;A;rs283416;TOXICITY, METABOLISM/PK;;METABOLISM;;;;CAUTION_DOSE_ADJUST
ROSIGLITAZONE;PPARG;CG;rs1801282;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHANOL;ADH1C;A;rs283411;TOXICITY, METABOLISM/PK;;METABOLISM;;;;CAUTION_DOSE_ADJUST
ETHANOL;ADH1C;C;rs1662060;TOXICITY, METABOLISM/PK;;METABOLISM;;;;CAUTION_DOSE_ADJUST
TACROLIMUS;SUMO4;AA;rs237025;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
ACENOCOUMAROL;VKORC1;TT;rs17878544;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
HMG_COA_REDUCTASE_INHIBITORS;LPA;G;rs10455872;EFFICACY;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
ACENOCOUMAROL;VKORC1;AA + AG;rs7200749;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
HMG_COA_REDUCTASE_INHIBITORS;ABCG2;G;rs2231142;EFFICACY;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
ACENOCOUMAROL;VKORC1;AA + AC;rs61742245;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;A;rs7200749;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;VKORC1;CC;rs9923231;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;T;rs7294;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
CITALOPRAM;NEDD4L;A;rs520210;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:DEPRESSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATORVASTATIN;SLCO1B1;CC + CT;rs4149056;METABOLISM/PK;INCREASED;CONCENTRATIONS;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
HMG_COA_REDUCTASE_INHIBITORS;TOMM40;G;rs2075650;EFFICACY;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
ACENOCOUMAROL;VKORC1;CT + TT;rs55894764;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
VALPROIC ACID;UGT1A10, UGT1A3, UGT1A4, UGT1A5, UGT1A6, UGT1A7, UGT1A8, UGT1A9;G;rs28898617;METABOLISM/PK;INCREASED;CONCENTRATIONS;;CHILDREN;DISEASE:EPILEPSY;CAUTION_DRUG_ACCUMULATION
IVACAFTOR;CFTR;AA + AG;rs78655421;EFFICACY;;RESPONSE;;PEOPLE;DISEASE:CYSTIC_FIBROSIS;CAUTION_DOSE_ADJUST
METHYLPHENIDATE;PEBP4;T;rs17685420;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS
ARIPIPRAZOLE;ABCB1;AA;rs1128503;METABOLISM/PK;DECREASED;CLEARANCE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED;DOSE;;PEOPLE;DISEASE:CARDIOVASCULAR_DISEASE;CAUTION_DOSE_ADJUST
VERAPAMIL;ITGAL;C;rs2230433;EFFICACY;INCREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:MIGRAINE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATORVASTATIN;SLCO1B1;CC + CT;rs4149056;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;OTHER:HYPERCHOLESTEROLEMIA;CAUTION_DRUG_ACCUMULATION
PAZOPANIB;KDR;AG;rs34231037;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;TT;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHANOL;ADH7;C;rs1154461;TOXICITY, METABOLISM/PK;;METABOLISM;;;;CAUTION_DOSE_ADJUST
HEPATITIS VACCINES;IL4R;C;rs1805015;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;;;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHANOL;ADH1A;C;rs1229967;TOXICITY, METABOLISM/PK;;METABOLISM;;;;CAUTION_DOSE_ADJUST
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHANOL;ADH1A;C;rs2276332;TOXICITY, METABOLISM/PK;;METABOLISM;;;;CAUTION_DOSE_ADJUST
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
BENAZEPRIL, IMIDAPRIL;AGT;CC;rs5051;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHANOL;ADH1A;C;rs1229976;TOXICITY, METABOLISM/PK;;METABOLISM;;;;CAUTION_DOSE_ADJUST
URSODEOXYCHOLIC ACID;MGAT5;TT;rs661899;EFFICACY;DECREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:CHOLANGITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL THIOL METABOLITE H4;CYP2C19;A;rs4244285;METABOLISM/PK;;EXPOSURE;;;;CAUTION_DOSE_ADJUST
HEPATITIS VACCINES;IL13;T;rs1295686;EFFICACY;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
PHENPROCOUMON;VKORC1;AA + AG;rs9934438;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
PHENPROCOUMON;VKORC1;CT + TT;rs7294;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
TACROLIMUS;ABCB1;AA;rs1045642;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_DRUG_ACCUMULATION
PEGINTERFERON ALFA-2B, RIBAVIRIN;CYP27B1;GT + TT;rs10877012;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
DABIGATRAN;CES1;AA + AG;rs8192935;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;OTHER:ATRIAL_FIBRILLATION;LIKELIHOOD_THERAPEUTIC_FAILURE
IRINOTECAN;VDR;TT;rs11574077;METABOLISM/PK;INCREASED;METABOLISM;;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
METHYLPHENIDATE;ADGRL3;AA;rs1868790;EFFICACY;DECREASED;RESPONSE;;CHILDREN;DISEASE:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY;LIKELIHOOD_THERAPEUTIC_FAILURE
METHYLPHENIDATE;SNAP25;GG + GT;rs3746544;EFFICACY;INCREASED;RESPONSE;;CHILDREN;DISEASE:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHYLPHENIDATE;SLC6A3;CC + CT;rs2550948;EFFICACY;INCREASED;RESPONSE;;CHILDREN;DISEASE:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS
PHENPROCOUMON;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ATORVASTATIN;SLCO1B1;C;rs4149056;METABOLISM/PK;INCREASED;EXPOSURE;;;;CAUTION_DRUG_ACCUMULATION
INTERFERONS, RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
MORPHINE;SLC22A1;AA + AG;rs34059508;METABOLISM/PK;DECREASED;CLEARANCE;;CHILDREN;;CAUTION_DRUG_ACCUMULATION
METHYLPHENIDATE;ADRA2A;G;rs1800544;EFFICACY;INCREASED;RESPONSE;;CHILDREN;DISEASE:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;METABOLISM;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
PLATINUM;XRCC1;CT + TT;rs25487;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:LUNG_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;;A;rs10514475;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:DEPRESSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;PLCB1;A;rs6108160;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:DEPRESSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;LRP1;TT;rs1800139;DOSAGE;INCREASED;DOSE;;PEOPLE;OTHER:HEART_VALVE_REPLACEMENT;CAUTION_DOSE_ADJUST
WARFARIN;CYP4F2;T;rs2108622;DOSAGE, EFFICACY;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;LRP1;CC;rs1800154;DOSAGE;INCREASED;DOSE;;PEOPLE;OTHER:HEART_VALVE_REPLACEMENT;CAUTION_DOSE_ADJUST
NICOTINE;CYP2A6;T;rs56113850;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;TT;rs9923231;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
INTERFERONS, RIBAVIRIN;IFNL3;GG;rs8099917;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
PHENPROCOUMON;VKORC1;AA + AG;rs2359612;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP4F2;T;rs2108622;DOSAGE, EFFICACY;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
PLATINUM COMPOUNDS;XRCC1;G;rs1799782;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:LUNG_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
MORPHINE;SLC22A1;TT;rs12208357;METABOLISM/PK;DECREASED;CLEARANCE;;CHILDREN;OTHER:ADENOTONSILLECTOMY;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;LGR5;CC + CT;rs17109924;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:COLONIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ROSUVASTATIN;ABCG2;GT + TT;rs2231142;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
MORPHINE;SLC22A1;AA;rs34059508;METABOLISM/PK;DECREASED;CLEARANCE;;CHILDREN;OTHER:ADENOTONSILLECTOMY;CAUTION_DRUG_ACCUMULATION
ACETAMINOPHEN;UGT2B15;A;rs1902023;METABOLISM/PK;DECREASED;CLEARANCE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
MORPHINE;SLC22A1;AA;rs34130495;METABOLISM/PK;DECREASED;CLEARANCE;;CHILDREN;OTHER:ADENOTONSILLECTOMY;CAUTION_DRUG_ACCUMULATION
ACETAMINOPHEN;UGT2B15;AA;rs1902023;METABOLISM/PK;INCREASED;METABOLISM;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
ATORVASTATIN, PRAVASTATIN;KIF6;AA + AC;rs9462535;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE, FLUOROURACIL;MTHFR;AA + AG;rs1801133;DOSAGE;DECREASED;DOSE;;WOMEN;OTHER:NEOPLASMS;CAUTION_DOSE_ADJUST
PITAVASTATIN, PITAVASTATIN LACTONE;SLCO1B1;A;rs4363657;METABOLISM/PK;INCREASED;EXPOSURE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
ROSUVASTATIN;ABCG2;AG + GG;rs1481012;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SOMATROPIN RECOMBINANT;CDK4;CC;rs2069502;EFFICACY;DECREASED;RESPONSE;;CHILDREN;DISEASE:TURNER_SYNDROME;LIKELIHOOD_THERAPEUTIC_FAILURE
ATORVASTATIN, PRAVASTATIN;KIF6;AG + GG;rs9471077;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METFORMIN;FMO5;A;rs7541245;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:DIABETES_MELLITUS;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;MTHFR;AA;rs1801133;TOXICITY;DECREASED;RESPONSE;;PEOPLE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ROSUVASTATIN;USP24;CC + CT;rs17111584;EFFICACY;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
PITAVASTATIN, PITAVASTATIN LACTONE;SLCO1B1;C;rs4149056;METABOLISM/PK;INCREASED;EXPOSURE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
METHYLPHENIDATE;SLC6A2;GG;rs5569;EFFICACY;INCREASED;RESPONSE;;CHILDREN;DISEASE:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS
INTERFERON BETA-1A;RORA;TT;rs4774388;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:MULTIPLE_SCLEROSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHYLPHENIDATE;SLC6A2;AT + TT;rs28386840;EFFICACY;INCREASED;RESPONSE;;CHILDREN;DISEASE:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS
REMIMAZOLAM;CES1;CT + TT;rs71647871;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
NICOTINE;;T;rs113288603;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
ROSUVASTATIN;APOE;CC + CT;rs71352238;EFFICACY;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
METHYLPHENIDATE;ADRA2A;GG;rs1800544;EFFICACY;INCREASED;RESPONSE;;CHILDREN;DISEASE:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;;A;rs12461964;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
ROSUVASTATIN;APOE;CT + TT;rs7412;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHYLPHENIDATE;ADRA2A;CG + GG;rs1800544;EFFICACY;INCREASED;RESPONSE;;CHILDREN;DISEASE:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS
IDARUBICIN;NCF4;AA;rs1883112;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:ACUTE_MYELOID_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
SIMVASTATIN;ABCC2;CT + TT;rs717620;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:HYPERCHOLESTEROLEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
IDARUBICIN;RAC2;AT;rs13058338;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:ACUTE_MYELOID_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:MYELOPROLIFERATIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
ROSUVASTATIN;LPA;AG + GG;rs10455872;EFFICACY;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
ATORVASTATIN;UGT1A1, UGT1A10, UGT1A3, UGT1A4, UGT1A5, UGT1A6, UGT1A7, UGT1A8, UGT1A9;T;rs887829;METABOLISM/PK;INCREASED;METABOLISM;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
METHYLPHENIDATE;BDNF;CC;rs6265;EFFICACY;INCREASED;RESPONSE;;CHILDREN;DISEASE:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;GG + GT;rs3745274;METABOLISM/PK;DECREASED;CONCENTRATIONS;;PEOPLE;OTHER:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
IVACAFTOR;CFTR;AA + AG;rs78655421;EFFICACY;;RESPONSE;;PEOPLE;DISEASE:CYSTIC_FIBROSIS;CAUTION_DOSE_ADJUST
ATORVASTATIN;CYP3A7;G;rs45446698;METABOLISM/PK;INCREASED;METABOLISM;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
ATALUREN;CFTR;A;rs77010898;EFFICACY;;RESPONSE;;PEOPLE;DISEASE:CYSTIC_FIBROSIS;CAUTION_DOSE_ADJUST
PRAVASTATIN;SLCO1B1;C;rs4149056;METABOLISM/PK;INCREASED;EXPOSURE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
CLOZAPINE;CYP1A2;AA;rs762551;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;OTHER:SCHIZOPHRENIA, OTHER:TOBACCO_USE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;G;rs2279343;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;OTHER:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;T;rs2279345;METABOLISM/PK;DECREASED;CONCENTRATIONS;;PEOPLE;OTHER:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
ATORVASTATIN, PRAVASTATIN;KIF6;AG + GG;rs20455;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATALUREN;CFTR;T;rs113993959;EFFICACY;;RESPONSE;;PEOPLE;DISEASE:CYSTIC_FIBROSIS;CAUTION_DOSE_ADJUST
METHYLPHENIDATE;COMT;GG;rs4680;EFFICACY;INCREASED;RESPONSE;;CHILDREN;DISEASE:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;ABCB1;AG;rs1045642;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;OTHER:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
SOMATROPIN RECOMBINANT;CDK4;TT;rs2270777;EFFICACY;INCREASED;RESPONSE;;CHILDREN;DISEASE:GROWTH_HORMONE_DEFICIENCY;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHYLPHENIDATE;ADRA2A;G;rs1800544;EFFICACY;INCREASED;RESPONSE;;CHILDREN;DISEASE:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACENOCOUMAROL;VKORC1;TT;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ATALUREN;CFTR;T;rs75039782;EFFICACY;;RESPONSE;;PEOPLE;DISEASE:CYSTIC_FIBROSIS;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;VKORC1;CT;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
METFORMIN;PRPF31;C;rs254271;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_FAILURE
GABAPENTIN;SLC7A5;AG;rs4240803;DOSAGE;INCREASED;DOSE;;PEOPLE;OTHER:NEUROPATHIC_PAIN;CAUTION_DOSE_ADJUST
ATALUREN;CFTR;A;rs77010898;EFFICACY;;RESPONSE;;PEOPLE;DISEASE:CYSTIC_FIBROSIS;CAUTION_DOSE_ADJUST
METFORMIN;NBEA;C;rs57081354;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_FAILURE
SUMATRIPTAN;SLC22A1;T;rs12208357;METABOLISM/PK;INCREASED;EXPOSURE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
METFORMIN;SLC22A1;AA + AG;rs628031;EFFICACY;INCREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
FENOTEROL;SLC22A1;A;rs34130495;METABOLISM/PK;INCREASED;EXPOSURE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
FENOTEROL;SLC22A1;T;rs12208357;METABOLISM/PK;INCREASED;EXPOSURE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
FENOTEROL;SLC22A1;C;rs55918055;METABOLISM/PK;INCREASED;EXPOSURE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
SUMATRIPTAN;SLC22A1;A;rs34059508;METABOLISM/PK;INCREASED;EXPOSURE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
CYCLOPHOSPHAMIDE;CYP2B6;GT + TT;rs3745274;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:LUPUS_NEPHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
SUMATRIPTAN;SLC22A1;A;rs34130495;METABOLISM/PK;INCREASED;EXPOSURE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
DRUGS USED IN DIABETES;IRS1;CT + TT;rs1801278;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_FAILURE
SUMATRIPTAN;SLC22A1;C;rs55918055;METABOLISM/PK;INCREASED;EXPOSURE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;XRCC1;CC;rs25487;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;MTRR;A;rs1801394;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;ERCC1;GG;rs11615;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
FENOTEROL;SLC22A1;A;rs34059508;METABOLISM/PK;INCREASED;EXPOSURE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
HYDROCHLOROTHIAZIDE;NEDD4L;A;rs4149601;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
METFORMIN;SLC22A1;AC + CC;rs622342;EFFICACY;INCREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP4F2;CT;rs2108622;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B;IFNL3;AA;rs12980275;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:MYELOPROLIFERATIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
EMTRICITABINE;ABCC2;TT;rs2273897;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE, OTHER:PREGNANCY;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;AA + AG;rs9934438;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CC;rs776746;DOSAGE, METABOLISM/PK;DECREASED;CLEARANCE;;CHILDREN;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
CYCLOGUANIL;SLC22A1;T;rs12208357;METABOLISM/PK;INCREASED;CONCENTRATIONS;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
ATALUREN;CFTR;T;rs113993959;EFFICACY;;RESPONSE;;PEOPLE;DISEASE:CYSTIC_FIBROSIS;CAUTION_DOSE_ADJUST
CYCLOGUANIL;SLC22A1;A;rs34130495;METABOLISM/PK;INCREASED;CONCENTRATIONS;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
GABAPENTIN, PREGABALIN;SLC7A5;AG;rs4240803;EFFICACY;DECREASED;RESPONSE;;PEOPLE;OTHER:NEUROPATHIC_PAIN;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;SLC19A1;CT + TT;rs1051266;TOXICITY;DECREASED;DISCONTINUATION;;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
MORPHINE;COMT;AA;rs4680;DOSAGE, EFFICACY;DECREASED;DOSE;;PEOPLE;DISEASE:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
METFORMIN;CPA6;T;rs2162145;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
SALBUTAMOL;DUSP1;G;rs881152;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
IVACAFTOR;CFTR;AA + AG;rs75527207;EFFICACY;;RESPONSE;;PEOPLE;DISEASE:CYSTIC_FIBROSIS;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A4;CC;rs2242480;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;OTHER:LUNG_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;AA + AC;rs61742245;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
TRAMADOL;SLC22A1;A;rs34059508;DOSAGE;DECREASED;DOSE;;PEOPLE;DISEASE:PAIN;CAUTION_DOSE_ADJUST
TACROLIMUS;SLCO1B3;GG + GT;rs4149117;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;OTHER:LUNG_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
ESCITALOPRAM;IL11;CT + TT;rs1126757;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:DEPRESSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;AA;rs9934438;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CES1;CT + TT;rs2307240;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;SLC2A2;CC;rs1499821;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;OTHER:LUNG_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP4F2;CT + TT;rs2108622;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ABIRATERONE;YBX1;AC + CC;rs10493112;EFFICACY;INCREASED;CLINICAL_BENEFIT;;MEN;OTHER:PROSTATIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;NFATC4;CC + CT;rs1955915;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;OTHER:LUNG_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
GRAZOPREVIR;SLCO1B1;C;rs4149056;PD;INCREASED;EXPOSURE;;PEOPLE;OTHER:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;CAUTION_DRUG_ACCUMULATION
BISOPROLOL;CYP2D6;CC;rs1080985;METABOLISM/PK;DECREASED;CONCENTRATIONS;;PEOPLE;OTHER:CARDIOVASCULAR_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
GRAZOPREVIR;SLCO1B1;A;rs11045819;PD;INCREASED;EXPOSURE;;PEOPLE;OTHER:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP4F2;TT;rs2108622;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;C;rs9923231;METABOLISM/PK;INCREASED;STEADY-STATE_CONCENTRATION;;;;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;C;rs9923231;METABOLISM/PK;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;;AA + AG;rs12777823;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
METHADONE;BDNF, BDNF-AS;C;rs7127507;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:OPIOID-RELATED_DISORDERS;LIKELIHOOD_THERAPEUTIC_FAILURE
O-DESMETHYLTRAMADOL;SLC22A1;T;rs12208357;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:PAIN;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ENALAPRIL;NOS3;CC + CT;rs2070744;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHADONE;BDNF, BDNF-AS;G;rs11030118;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:OPIOID-RELATED_DISORDERS;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;VKORC1;AG + GG;rs2359612;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;T;rs7089580;DOSAGE;DECREASED;DOSE;;CHILDREN;;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;AA + AG;rs9934438;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;AA;rs9934438;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
METHADONE;BDNF, BDNF-AS;C;rs1967554;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:OPIOID-RELATED_DISORDERS;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;VKORC1;CG + GG;rs8050894;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
BISOPROLOL;CYP2D6;G;rs1080985;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;OTHER:ACUTE_CORONARY_SYNDROME;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;CT + TT;rs7294;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
METHADONE;BDNF;G;rs2030324;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:OPIOID-RELATED_DISORDERS;LIKELIHOOD_THERAPEUTIC_FAILURE
BISOPROLOL;CYP2D6;CT + TT;rs3892097;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;OTHER:ACUTE_CORONARY_SYNDROME;CAUTION_DRUG_ACCUMULATION
BUSULFAN;GSTA1;AA;rs3957357;METABOLISM/PK;INCREASED;CLEARANCE;;CHILDREN;DISEASE:TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
O-DESMETHYLTRAMADOL;SLC22A1;A;rs34130495;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:PAIN;CAUTION_DRUG_ACCUMULATION
O-DESMETHYLTRAMADOL;SLC22A1;A;rs34059508;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:PAIN;CAUTION_DRUG_ACCUMULATION
ENALAPRIL;BDKRB2;TT;rs1799722;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_FAILURE
METHADONE;BDNF;C;rs988748;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:OPIOID-RELATED_DISORDERS;LIKELIHOOD_THERAPEUTIC_FAILURE
O-DESMETHYLTRAMADOL;SLC22A1;C;rs55918055;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:PAIN;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;A;rs61742245;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
TRAMADOL;SLC22A1;C;rs55918055;DOSAGE;DECREASED;DOSE;;PEOPLE;DISEASE:PAIN;CAUTION_DOSE_ADJUST
CELECOXIB;CYP2C9;CC;rs1057910;METABOLISM/PK;DECREASED;CLEARANCE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
METHADONE;BDNF;G;rs11030119;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:OPIOID-RELATED_DISORDERS;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;OTHER:LUNG_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
TRAMADOL;SLC22A1;T;rs12208357;DOSAGE;DECREASED;DOSE;;PEOPLE;DISEASE:PAIN;CAUTION_DOSE_ADJUST
FENTANYL;CYP3A4;T;rs2242480;DOSAGE, EFFICACY;DECREASED;DOSE;;WOMEN;DISEASE:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
CELECOXIB;CYP2C9;CC;rs1057910;METABOLISM/PK;DECREASED;METABOLISM;;CHILDREN;;CAUTION_DRUG_ACCUMULATION
BISOPROLOL;CYP3A5;TT;rs776746;METABOLISM/PK;DECREASED;CONCENTRATIONS;;PEOPLE;OTHER:ACUTE_CORONARY_SYNDROME;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP4F2;CT + TT;rs2108622;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
TRAMADOL;SLC22A1;A;rs34130495;DOSAGE;DECREASED;DOSE;;PEOPLE;DISEASE:PAIN;CAUTION_DOSE_ADJUST
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNFRSF1A;AA;rs4149570;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:CROHN_DISEASE, DISEASE:INFLAMMATORY_BOWEL_DISEASES;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TLR4;AA + AG;rs5030728;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:INFLAMMATORY_BOWEL_DISEASES;LIKELIHOOD_THERAPEUTIC_SUCCESS
METFORMIN;SLC47A1;CT + TT;rs8065082;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:GLUCOSE_INTOLERANCE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TLR2;TT;rs4696480;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:ULCERATIVE_COLITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;T;rs1799853;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IFNG;AA + AT;rs2430561;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:CROHN_DISEASE, DISEASE:INFLAMMATORY_BOWEL_DISEASES;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TLR9;TT;rs352139;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:CROHN_DISEASE, DISEASE:INFLAMMATORY_BOWEL_DISEASES;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;VKORC1L1;AA;rs4072879;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TLR2;CC + CT;rs3804099;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:INFLAMMATORY_BOWEL_DISEASES;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TLR2;CT + TT;rs1816702;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:CROHN_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A4;A;rs35599367;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
SUFENTANIL;OPRM1;G;rs1799971;DOSAGE;DECREASED;DOSE;;WOMEN;DISEASE:PAIN;CAUTION_DOSE_ADJUST
OPIOIDS;ENPP2;AA;rs2249015;DOSAGE;INCREASED;DOSE;;PEOPLE;OTHER:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
DONEPEZIL, GALANTAMINE, RIVASTIGMINE;APOE;CC + CT;rs429358;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:ALZHEIMER_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
ROSIGLITAZONE;PAX4;AA + AG;rs6467136;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
ROSIGLITAZONE;PAX4;AA + AG;rs6467136;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATORVASTATIN;APOE;CT;rs429358;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:HYPERCHOLESTEROLEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
OPIOIDS;ABCB1;AA;rs1045642;DOSAGE, EFFICACY;DECREASED;DOSE;;PEOPLE;DISEASE:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL6;CC + CT;rs10499563;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:ULCERATIVE_COLITIS, DISEASE:INFLAMMATORY_BOWEL_DISEASES;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL17A;AA + AG;rs2275913;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:ULCERATIVE_COLITIS, DISEASE:INFLAMMATORY_BOWEL_DISEASES;LIKELIHOOD_THERAPEUTIC_FAILURE
LATANOPROST;ABCC4;AC;rs11568658;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:OPEN-ANGLE_GLAUCOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
ADALIMUMAB, ETANERCEPT, INFLIXIMAB, USTEKINUMAB;TNFRSF1B;GG + GT;rs1061622;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:PSORIASIS;LIKELIHOOD_THERAPEUTIC_FAILURE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;CNPY4;CC + CT;rs1554973;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:INFLAMMATORY_BOWEL_DISEASES;LIKELIHOOD_THERAPEUTIC_FAILURE
BOTULINUM TOXIN TYPE A;CALCA;G;rs3781719;EFFICACY;DECREASED;RESPONSE;;WOMEN;OTHER:MIGRAINE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;CD14;AA + AG;rs2569190;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:ULCERATIVE_COLITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TLR2;AA + AC;rs11938228;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:ULCERATIVE_COLITIS, DISEASE:INFLAMMATORY_BOWEL_DISEASES;LIKELIHOOD_THERAPEUTIC_FAILURE
BOTULINUM TOXIN TYPE A;TRPV1;A;rs222749;EFFICACY;DECREASED;RESPONSE;;WOMEN;OTHER:MIGRAINE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
OPIOIDS;ENPP2;AA;rs7832704;DOSAGE;INCREASED;DOSE;;PEOPLE;OTHER:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL1B;AA + AG;rs4848306;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:ULCERATIVE_COLITIS, DISEASE:INFLAMMATORY_BOWEL_DISEASES;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL1RN;CC + CT;rs4251961;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:ULCERATIVE_COLITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNFAIP3;CG + GG;rs6927172;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:ULCERATIVE_COLITIS, DISEASE:INFLAMMATORY_BOWEL_DISEASES;LIKELIHOOD_THERAPEUTIC_FAILURE
HMG_COA_REDUCTASE_INHIBITORS;APOE;CC;rs429358;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:ALZHEIMER_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
LOSARTAN;ABCB1;AA + AG;rs1045642;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEMETREXED;FOLR3;CT + TT;rs61734430;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA, DISEASE:MESOTHELIOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3;AC + CC;rs4803217;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
METOPROLOL;GRK4;CT;rs1801058;EFFICACY;DECREASED;RESPONSE;;WOMEN;DISEASE:HYPERTENSIVE_NEPHROSCLEROSIS;LIKELIHOOD_THERAPEUTIC_FAILURE
HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART);IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOXETINE;HTR2A;GG;rs7997012;EFFICACY;INCREASED;CLINICAL_BENEFIT;;CHILDREN;OTHER:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;GG;rs1800629;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:INFLAMMATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
DIRECT ACTING ANTIVIRALS, ELBASVIR / GRAZOPREVIR, LEDIPASVIR / SOFOSBUVIR;IFNL3, IFNL4;GG + GT;rs8099917;EFFICACY;DECREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_FAILURE
METOPROLOL;GRK4;GT + TT;rs2960306;EFFICACY;DECREASED;RESPONSE;;MEN;DISEASE:HYPERTENSIVE_NEPHROSCLEROSIS;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;ABCC2;CT + TT;rs3740066;METABOLISM/PK;DECREASED;DOSE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;ABCC2;CT + TT;rs3740066;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;ABCC2;CT + TT;rs717620;METABOLISM/PK;INCREASED;CLEARANCE;;PEOPLE;DISEASE:LYMPHOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;ABCC2;CT + TT;rs717620;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
METOPROLOL;GRK4;CC;rs1024323;EFFICACY;DECREASED;RESPONSE;;MEN;DISEASE:HYPERTENSIVE_NEPHROSCLEROSIS;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;CC;rs1799724;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:INFLAMMATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHADONE;GAD1;G;rs3762556;DOSAGE;INCREASED;DOSE;;PEOPLE;OTHER:HEROIN_DEPENDENCE;CAUTION_DOSE_ADJUST
INFLIXIMAB;IL1B;GG;rs1143634;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:CROHN_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
METHADONE;GAD1;TT;rs769404;DOSAGE;DECREASED;DOSE;;PEOPLE;OTHER:HEROIN_DEPENDENCE;CAUTION_DOSE_ADJUST
ROCURONIUM;SLCO1A2;T/del + TT;rs3834939;METABOLISM/PK;DECREASED;CLEARANCE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
CLOZAPINE;CYP1A2;AA + AC;rs762551;METABOLISM/PK;DECREASED;CONCENTRATIONS;;PEOPLE;OTHER:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_FAILURE
ARIPIPRAZOLE;CYP2D6;GG;rs1058164;METABOLISM/PK;INCREASED;CONCENTRATIONS;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
ARIPIPRAZOLE;CYP2D6;AA;rs28371699;METABOLISM/PK;INCREASED;CONCENTRATIONS;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
TICAGRELOR;CYP4F2;AA;rs2074900;METABOLISM/PK;DECREASED;CLEARANCE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
ACENOCOUMAROL;VKORC1;GG;rs9934438;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
CAPECITABINE;DPYD;AT;rs67376798;DOSAGE;DECREASED;DOSE;;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_DOSE_ADJUST
CLOZAPINE;UGT1A4;C;rs2011404;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;OTHER:SCHIZOPHRENIA, OTHER:PSYCHOTIC_DISORDER;CAUTION_DRUG_ACCUMULATION
CAPECITABINE;DPYD;CT;rs3918290;DOSAGE;DECREASED;DOSE;;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_DOSE_ADJUST
URIC ACID;VEGFC;C;rs1002976;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:HYPERTENSION;CAUTION_DRUG_ACCUMULATION
LETERMOVIR;SLCO1B1;TT;rs4149032;METABOLISM/PK;DECREASED;EXPOSURE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOZAPINE;UGT1A1;T;rs34946978;METABOLISM/PK;DECREASED;CONCENTRATIONS;;PEOPLE;OTHER:SCHIZOPHRENIA, OTHER:PSYCHOTIC_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
METFORMIN;CAPN10;G;rs3792269;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:DIABETES_MELLITUS;LIKELIHOOD_THERAPEUTIC_FAILURE
LETERMOVIR;SLCO1B1;CC + CT;rs4149056;METABOLISM/PK;INCREASED;EXPOSURE;;;;CAUTION_DRUG_ACCUMULATION
LETERMOVIR;UGT1A1;AA + AG;rs4148323;METABOLISM/PK;INCREASED;EXPOSURE;;;;CAUTION_DRUG_ACCUMULATION
INTERFERON BETA-1A, INTERFERON BETA-1B;FHIT;C;rs760316;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:MULTIPLE_SCLEROSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
GLYBURIDE;FMO2;T;rs7512785;EFFICACY;INCREASED;RESPONSE;;PEOPLE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;MTRR;AG + GG;rs1801394;EFFICACY;INCREASED;RESPONSE;;CHILDREN;DISEASE:JUVENILE_RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
PROPRANOLOL;ADRB2;GG;rs1042713;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:LIVER_CIRRHOSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;ABCB1;AA;rs1128503;EFFICACY;INCREASED;RESPONSE;;CHILDREN;DISEASE:JUVENILE_RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;ABCB1;AA;rs1045642;EFFICACY;INCREASED;RESPONSE;;CHILDREN;DISEASE:JUVENILE_RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOZAPINE;ABCB1;G;rs10248420;EFFICACY;INCREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:SCHIZOPHRENIA, OTHER:PSYCHOTIC_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;SLC16A7;A;rs3763980;EFFICACY;DECREASED;RESPONSE;;CHILDREN;DISEASE:JUVENILE_RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B;IFNL3, IFNL4;C;rs12979860;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HEPATITIS_B, CHRONIC;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;SLC16A7;T;rs12231740;EFFICACY;DECREASED;RESPONSE;;CHILDREN;DISEASE:JUVENILE_RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;ARID5B;CC;rs4948496;METABOLISM/PK;INCREASED;CONCENTRATIONS;;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DRUG_ACCUMULATION
CLOZAPINE;UGT1A1;A;rs4148323;METABOLISM/PK;DECREASED;CONCENTRATIONS;;PEOPLE;OTHER:SCHIZOPHRENIA, OTHER:PSYCHOTIC_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
FENOFIBRATE;APOE;CT + TT;rs7412;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HYPERTRIGLYCERIDEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;SLCO1B1;TT;rs4149056;METABOLISM/PK;DECREASED;CONCENTRATIONS;;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B;IFNL3, IFNL4;T;rs8099917;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HEPATITIS_B, CHRONIC;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHADONE;GAD1;G;rs3762555;DOSAGE;INCREASED;DOSE;;PEOPLE;OTHER:HEROIN_DEPENDENCE;CAUTION_DOSE_ADJUST
METHOTREXATE;MTHFR;AA;rs1801133;EFFICACY;DECREASED;RESPONSE;;CHILDREN;DISEASE:JUVENILE_RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
METHADONE;GAD1;G;rs3749034;DOSAGE;INCREASED;DOSE;;PEOPLE;OTHER:HEROIN_DEPENDENCE;CAUTION_DOSE_ADJUST
CLOZAPINE;ABCB1;A;rs7787082;EFFICACY;INCREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:SCHIZOPHRENIA, OTHER:PSYCHOTIC_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
IGURATIMOD;NAT2;AG + GG;rs1495741;EFFICACY;DECREASED;CLINICAL_BENEFIT;;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
INTERFERON BETA-1A, INTERFERON BETA-1B;;T;rs4278350;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:MULTIPLE_SCLEROSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ARIPIPRAZOLE;CYP2D6;CC;rs28371702;METABOLISM/PK;INCREASED;CONCENTRATIONS;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
SITAGLIPTIN, VILDAGLIPTIN;KCNQ1;GG + GT;rs163184;EFFICACY;DECREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_FAILURE
IGURATIMOD;ABCG2;GT + TT;rs2231142;EFFICACY;INCREASED;CLINICAL_BENEFIT;;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
DESIPRAMINE;CYP2D6;;POOR_METABOLIZER;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
INTERFERON BETA-1A, INTERFERON BETA-1B;GAPVD1;G;rs2291858;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:MULTIPLE_SCLEROSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHADONE;OPRD1;GG;rs204047;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
METHADONE;OPRD1;AA;rs797397;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
METHADONE;OPRD1;GG;rs204047;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
ANTIPSYCHOTICS;ZNF804A;AA;rs1344706;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_FAILURE
PLATINUM COMPOUNDS;XRCC1;CC + CT;rs25487;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
INTERFERON BETA-1A, INTERFERON BETA-1B;GAPVD1;T;rs10819043;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:MULTIPLE_SCLEROSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
INTERFERON BETA-1A, INTERFERON BETA-1B;;A;rs3133084;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:MULTIPLE_SCLEROSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE, DOCETAXEL;CYP1A1;AG + GG;rs1048943;EFFICACY;INCREASED;RESPONSE;;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;CLEARANCE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
GLYBURIDE;CYP51A1;G;rs7793861;EFFICACY;INCREASED;RESPONSE;;PEOPLE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
INTERFERON BETA-1A, INTERFERON BETA-1B;;G;rs1448673;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:MULTIPLE_SCLEROSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
GLYBURIDE;FMO2;T;rs7515157;EFFICACY;INCREASED;RESPONSE;;PEOPLE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANASTROZOLE;ABCB1;AA;rs2032582;METABOLISM/PK;INCREASED;CONCENTRATIONS;;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_DRUG_ACCUMULATION
AMISULPRIDE, ANTIPSYCHOTICS, OLANZAPINE, QUETIAPINE, RISPERIDONE;HTR1A;TT;rs10042486;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
URIC ACID;BRINP3;T;rs950569;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:HYPERTENSION;CAUTION_DRUG_ACCUMULATION
GLYBURIDE;UGT2B15;G;rs4148269;EFFICACY;INCREASED;RESPONSE;;PEOPLE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
INTERFERON BETA-1A, INTERFERON BETA-1B;GAPVD1;C;rs10760397;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:MULTIPLE_SCLEROSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
URIC ACID;PADI4;G;rs2477134;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:HYPERTENSION;CAUTION_DRUG_ACCUMULATION
INTERFERON BETA-1A, INTERFERON BETA-1B;ZNF697;A;rs10494227;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:MULTIPLE_SCLEROSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOXORUBICIN;ABCC5;TT;rs1533682;METABOLISM/PK;INCREASED;CLEARANCE;;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
PLATINUM COMPOUNDS;XRCC3;AA + AG;rs861539;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
GLYBURIDE;MAPK1;A;rs1803545;EFFICACY;INCREASED;RESPONSE;;PEOPLE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
GLYBURIDE;ABCC5;A;rs3749442;EFFICACY;INCREASED;RESPONSE;;PEOPLE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ARIPIPRAZOLE;CYP2D6;GG;rs1135840;METABOLISM/PK;INCREASED;CONCENTRATIONS;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
GLYBURIDE;SPINK5;T;rs2303070;EFFICACY;INCREASED;RESPONSE;;PEOPLE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
GLYBURIDE;BDKRB2;A;rs5224;EFFICACY;INCREASED;RESPONSE;;PEOPLE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
GLYBURIDE;MAPK1;G;rs3729910;EFFICACY;INCREASED;RESPONSE;;PEOPLE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IGURATIMOD;ABCB1;CT + TT;rs2032582;EFFICACY;INCREASED;CLINICAL_BENEFIT;;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP4F2;TT;rs2108622;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ETHANOL;KLB;A;rs11940694;TOXICITY;DECREASED;DOSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM COMPOUNDS;XRCC1;AA + AG;rs1799782;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
GLYBURIDE;ESR1;T;rs2077647;EFFICACY;INCREASED;RESPONSE;;PEOPLE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;G;rs1800629;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:RHEUMATOID_ARTHRITIS, OTHER:AUTOIMMUNE_DISEASES,OTHER:PSORIASIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIDEPRESSANTS;BDNF;C;rs6265;EFFICACY;INCREASED;RESISTANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUNISOLIDE;TBXT;TT;rs2305089;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
GRANISETRON, PALONOSETRON;ERCC1;AC + CC;rs3212986;EFFICACY;INCREASED;RESPONSE;;PEOPLE;SIDE_EFFECT:NAUSEA, SIDE_EFFECT:VOMITING;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;IL6;GG;rs1800795;EFFICACY;DECREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
VALPROIC ACID;CYP2D6;CT + TT;rs3892097;EFFICACY;DECREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:EPILEPSY;LIKELIHOOD_THERAPEUTIC_FAILURE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNFRSF1B;T;rs1061622;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:PSORIASIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;IL6;GG;rs1800795;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;C;rs1799724;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:PSORIASIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A4;GG;rs4646437;METABOLISM/PK;INCREASED;EXPOSURE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
RASAGILINE;DRD2;CC;rs1076560;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:PARKINSON_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;EXPOSURE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A4;CC;rs2242480;METABOLISM/PK;INCREASED;EXPOSURE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
RASAGILINE;DRD2;CC;rs2283265;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:PARKINSON_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A4;GG;rs4646437;METABOLISM/PK;INCREASED;EXPOSURE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CTLA4;AG + GG;rs4553808;METABOLISM/PK;INCREASED;EXPOSURE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
ANTIDEPRESSANTS;BDNF-AS;T;rs10501087;EFFICACY;INCREASED;RESISTANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;IL3;AA;rs181781;METABOLISM/PK;INCREASED;EXPOSURE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
DESIPRAMINE;CYP2D6;;POOR_METABOLIZER;METABOLISM/PK;DECREASED;CLEARANCE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;CLEARANCE;;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
LAMOTRIGINE;UGT1A4;CC;rs6755571;METABOLISM/PK;DECREASED;CONCENTRATIONS;;WOMEN;OTHER:EPILEPSY;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;C;rs4917639;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
TELAPREVIR;CYP24A1;C;rs2585428;METABOLISM/PK;DECREASED;TROUGH_CONCENTRATION;;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CTLA4;AA;rs4553808;METABOLISM/PK;INCREASED;EXPOSURE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A4;CC;rs2242480;METABOLISM/PK;INCREASED;EXPOSURE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
VARENICLINE;CHRNA4;GG;rs1044396;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:TOBACCO_USE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
ESCITALOPRAM;CYP1A2;T;rs4646425;METABOLISM/PK;INCREASED;METABOLISM;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
ESCITALOPRAM;CYP1A2;G;rs2069526;METABOLISM/PK;INCREASED;METABOLISM;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
ESCITALOPRAM;CYP1A2;C;rs4646427;METABOLISM/PK;INCREASED;METABOLISM;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
PLATINUM COMPOUNDS;HSPA5;TT;rs430397;EFFICACY;INCREASED;RESISTANCE;;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;FCGR2A;A;rs1801274;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;FCGR3A;C;rs396991;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:SPONDYLARTHROPATHIES;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;GG;rs2279343;METABOLISM/PK;DECREASED;CLEARANCE;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
MORPHINE;ABCB1;AA;rs1045642;METABOLISM/PK;INCREASED;METABOLISM;;CHILDREN;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;P2RY12;AA + AG;rs6785930;EFFICACY;INCREASED;RESISTANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;TT;rs3745274;METABOLISM/PK;DECREASED;CLEARANCE;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;TT;rs3745274;METABOLISM/PK;DECREASED;CLEARANCE;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;GT;rs3745274;METABOLISM/PK;DECREASED;CLEARANCE;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
CLOPIDOGREL;P2RY12;AA + AC;rs6809699;EFFICACY;INCREASED;RESISTANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;AG;rs2279343;METABOLISM/PK;DECREASED;CLEARANCE;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;G;rs361525;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:PSORIASIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUTICASONE PROPIONATE;ORMDL3;AA + AG;rs2872507;EFFICACY;INCREASED;RESPONSE;;CHILDREN;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;A;rs9934438;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
RITUXIMAB;FCGR3A;AC + CC;rs396991;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ABATACEPT, RITUXIMAB, TOCILIZUMAB, TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;FCGR2A;AG + GG;rs1801274;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
VALPROIC ACID;CYP2C9;AC;rs1057910;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;OTHER:EPILEPSY;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;CC;rs776746;DOSAGE, METABOLISM/PK;DECREASED;DOSE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
WARFARIN;CALU;G;rs339097;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ATAZANAVIR / RITONAVIR;SLCO1B1;CC + CT;rs4149056;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
DEFERASIROX;ABCG2;CT + TT;rs13120400;METABOLISM/PK;INCREASED;EXPOSURE;;CHILDREN;DISEASE:BETA-THALASSEMIA_AND_RELATED_DISEASES;CAUTION_DRUG_ACCUMULATION
ATAZANAVIR / RITONAVIR;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;T;rs10509680;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ADALIMUMAB, CERTOLIZUMAB PEGOL, ETANERCEPT, GOLIMUMAB, INFLIXIMAB;VDR;AA + AC;rs7975232;EFFICACY;INCREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANGIOTENSIN II;AGTR1;AA;rs5186;EFFICACY;INCREASED;RESPONSE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DESIPRAMINE;CYP2D6;;POOR_METABOLIZER;METABOLISM/PK;DECREASED;CLEARANCE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
ANTIEPILEPTICS;NR3C1;GG;rs41423247;EFFICACY;DECREASED;CLINICAL_BENEFIT;;CHILDREN;OTHER:EPILEPSY;LIKELIHOOD_THERAPEUTIC_FAILURE
DEFERASIROX;ABCC2;AG;rs2273697;METABOLISM/PK;INCREASED;EXPOSURE;;CHILDREN;DISEASE:BETA-THALASSEMIA_AND_RELATED_DISEASES;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED;DOSE;;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;CAUTION_DOSE_ADJUST
FLUVASTATIN;APOE;CT;rs7412;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METFORMIN;SLC47A1;A;rs2289669;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_FAILURE
TALINOLOL;ABCB1;AA;rs1045642;METABOLISM/PK;INCREASED;CLEARANCE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
LAMOTRIGINE;UGT2B7;TT;rs7439366;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;OTHER:EPILEPSY;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A4;CC + CT;rs2740574;DOSAGE, METABOLISM/PK;INCREASED;DOSE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
RITODRINE;PDE4B;AA;rs598961;EFFICACY;DECREASED;CLINICAL_BENEFIT;;WOMEN;OTHER:PREMATURE_BIRTH;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A4;G;rs4986910;DOSAGE, METABOLISM/PK;DECREASED;DOSE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
ACENOCOUMAROL, WARFARIN;CYP4F2;CT + TT;rs2108622;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
LAMOTRIGINE;UGT2B15;AA;rs1902023;METABOLISM/PK;DECREASED;CONCENTRATIONS;;WOMEN;OTHER:EPILEPSY;LIKELIHOOD_THERAPEUTIC_FAILURE
DESIPRAMINE;CYP2D6;;POOR_METABOLIZER;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
PLATINUM COMPOUNDS;XPA;CC;rs1800975;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ARIPIPRAZOLE, DEHYDROARIPIPRAZOLE;ABCB1;CC;rs2032582;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
ARIPIPRAZOLE, DEHYDROARIPIPRAZOLE;ABCB1;GG;rs1045642;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ARIPIPRAZOLE, DEHYDROARIPIPRAZOLE;ABCB1;GG;rs1128503;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
TACROLIMUS;IL10;AA;rs1800871;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
ANTIHYPERTENSIVES, HYDRALAZINE, METHYLDOPA, NIFEDIPINE;MMP9;CT;rs3918242;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:GESTATIONAL_HYPERTENSION;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP4F2;T;rs2108622;DOSAGE;INCREASED;DOSE;;PEOPLE;OTHER:RHEUMATIC_HEART_DISEASE, OTHER:ATRIAL_FIBRILLATION,OTHER:HEART_VALVE_DISEASES, OTHER:CORONARY_ARTERY_DISEASE;CAUTION_DOSE_ADJUST
DACLATASVIR;VDR;TT;rs11568820;METABOLISM/PK;DECREASED;CONCENTRATIONS;;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_FAILURE
MORPHINE;COMT;AG + GG;rs4680;EFFICACY;INCREASED;DOSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHYLDOPA;MMP9;CT + TT;rs3918242;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:GESTATIONAL_HYPERTENSION;LIKELIHOOD_THERAPEUTIC_FAILURE
DACLATASVIR;CYP24A1;CT + TT;rs2248359;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;ABCB1;AG + GG;rs1045642;METABOLISM/PK;INCREASED;CLEARANCE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
CARBAMAZEPINE, OXCARBAZEPINE;SCN1A;TT;rs3812718;EFFICACY;;RESISTANCE;;PEOPLE;DISEASE:EPILEPSY;CAUTION_DOSE_ADJUST
METOPROLOL;ADRB1;AA;rs1801252;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:ESSENTIAL_HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
METOPROLOL;ADRB1;CC;rs1801253;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:ESSENTIAL_HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
CALCIUM CHANNEL BLOCKERS;NUMA1;GG;rs10898815;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE, OXCARBAZEPINE;SCN1A;TT;rs3812718;EFFICACY;;RESISTANCE;;PEOPLE;DISEASE:EPILEPSY;CAUTION_DOSE_ADJUST
CALCIUM CHANNEL BLOCKERS;TANC2;GG;rs2429427;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
SIBUTRAMINE;GNB3;CC;rs5443;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:OBESITY;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE, OXCARBAZEPINE;ABCC2;AG;rs2273697;EFFICACY;;RESISTANCE;;PEOPLE;DISEASE:EPILEPSY;CAUTION_DOSE_ADJUST
BUSULFAN;GSTA1;T;rs3957356;METABOLISM/PK;DECREASED;CLEARANCE;;CHILDREN;OTHER:HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
S-EDDP;CYP2B6;CT;rs8192709;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
BUSULFAN;GSTA1;A;rs3957357;METABOLISM/PK;DECREASED;CLEARANCE;;CHILDREN;OTHER:HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
SIMVASTATIN;UGT1A9;T;rs12052787;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CT + TT;rs776746;EFFICACY, METABOLISM/PK;INCREASED;DOSE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
SIMVASTATIN;UGT1A9;A;rs2003569;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM COMPOUNDS;ERCC4;TT;rs1799801;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
PLATINUM COMPOUNDS;ERCC1;AA + AG;rs11615;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
AMITRIPTYLINE, CLOMIPRAMINE, DOXEPIN, IMIPRAMINE, MAPROTILINE, NORTRIPTYLINE, OPIPRAMOL;CYP2D6;TT;rs3892097;DOSAGE, EFFICACY;DECREASED;DOSE;;PEOPLE;DISEASE:DEPRESSION;CAUTION_DOSE_ADJUST
PLATINUM COMPOUNDS;ERCC3;AG + GG;rs3738948;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
TEGAFUR;CYP2A6;AA + AG;rs8192720;METABOLISM/PK;INCREASED;METABOLISM;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
DIGOXIN;ABCB1;AA + AG;rs1045642;METABOLISM/PK;DECREASED;DOSE;;HEALTHY;;CAUTION_DOSE_ADJUST
ANTIPSYCHOTICS, CHLORPROMAZINE, CLOZAPINE, HALOPERIDOL, OLANZAPINE, QUETIAPINE, RISPERIDONE;MTHFR;AG;rs1801133;EFFICACY;DECREASED;CLINICAL_BENEFIT;;WOMEN;OTHER:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_FAILURE
OXYCODONE;UGT2B7;TT;rs7439366;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:NEOPLASMS, DISEASE:PAIN;LIKELIHOOD_THERAPEUTIC_FAILURE
TERBUTALINE;ADRB2;GG;rs1042714;METABOLISM/PK;INCREASED;RESPONSE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;C;rs1057910;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
BUPROPION;CYP2B6;T;rs3745274;METABOLISM/PK;INCREASED;EXPOSURE;;PEOPLE;OTHER:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;HRH4;TT;rs4483927;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_FAILURE
ATENOLOL;GRK4;T;rs2960306;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_FAILURE
ATENOLOL;GRK4;T;rs1024323;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_FAILURE
CALCIUM CHANNEL BLOCKERS;PICALM;GG;rs588076;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
DELEOBUVIR, FALDAPREVIR;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED;DOSE;;CHILDREN;;CAUTION_DOSE_ADJUST
PROPOFOL;GABRA2;CC;rs11503014;OTHER;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;HNF4A;T;rs3212198;DOSAGE;INCREASED;DOSE;;PEOPLE;DISEASE:HEART_VALVE_REPLACEMENT;CAUTION_DOSE_ADJUST
CODEINE, TRAMADOL;CYP1B1;C;rs1056836;EFFICACY;DECREASED;CLINICAL_BENEFIT;;MEN;OTHER:PAIN;LIKELIHOOD_THERAPEUTIC_FAILURE
ERLOTINIB, GEFITINIB;EGFR;G;rs121434568;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;NR1I3;TT;rs2501873;DOSAGE;INCREASED;DOSE;;PEOPLE;DISEASE:HEART_VALVE_REPLACEMENT;CAUTION_DOSE_ADJUST
VERAPAMIL;PCDHB8;G;rs3733694;EFFICACY;DECREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:MIGRAINE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
RIVAROXABAN;POR;TT;rs1057868;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;OTHER:ATRIAL_FIBRILLATION;LIKELIHOOD_THERAPEUTIC_FAILURE
VERAPAMIL;PCDHB6;A;rs17844444;EFFICACY;DECREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:MIGRAINE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
CAPECITABINE, CETUXIMAB, OXALIPLATIN;KRAS;AC;rs61764370;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:RECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
SIMVASTATIN ACID;SLCO1B1;CT;rs4149056;METABOLISM/PK;INCREASED;EXPOSURE;;;;CAUTION_DRUG_ACCUMULATION
ATORVASTATIN;AGTR1;AC;rs5186;METABOLISM/PK;INCREASED;EXPOSURE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
ATORVASTATIN;BDKRB2;CT;rs1799722;METABOLISM/PK;INCREASED;EXPOSURE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
LOSARTAN;AGTR1;AA;rs5186;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:LIVER_CIRRHOSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE, METABOLISM/PK;INCREASED;METABOLISM;;CHILDREN;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
HEROIN;OPRM1;AG;rs9479757;DOSAGE;INCREASED;DOSE;;PEOPLE;DISEASE:HEROIN_DEPENDENCE;CAUTION_DOSE_ADJUST
5-HYDROXYINDOLE-3-ACETIC ACID, SEROTONIN;MAOB;T;rs1799836;METABOLISM/PK;INCREASED;CONCENTRATIONS;;MEN;OTHER:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DRUG_ACCUMULATION
ANTIDEPRESSANTS;GRIK4;CC;rs1954787;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIVAROXABAN;ABCB1;CT;rs4148738;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;OTHER:ATRIAL_FIBRILLATION;CAUTION_DRUG_ACCUMULATION
5-HYDROXYINDOLE-3-ACETIC ACID, SEROTONIN;MAOB;TT;rs1799836;METABOLISM/PK;INCREASED;CONCENTRATIONS;;WOMEN;OTHER:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DRUG_ACCUMULATION
APIXABAN;POR;T;rs1057868;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;OTHER:ATRIAL_FIBRILLATION;LIKELIHOOD_THERAPEUTIC_FAILURE
OXCARBAZEPINE;UGT1A9;CC;rs2741049;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:SEIZURES;LIKELIHOOD_THERAPEUTIC_SUCCESS
CODEINE, TRAMADOL;CYP1B1;A;rs1056837;EFFICACY;DECREASED;CLINICAL_BENEFIT;;MEN;OTHER:PAIN;LIKELIHOOD_THERAPEUTIC_FAILURE
CANDESARTAN;CYP11B2;GG;rs1799998;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
3-HYDROXYCOTININE;;CC + CT;rs4105144;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;OTHER:TOBACCO_USE_DISORDER;CAUTION_DRUG_ACCUMULATION
HYDROCODONE, OXYCODONE;CYP2D6;DELT;rs35742686;EFFICACY;INCREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:PAIN;LIKELIHOOD_THERAPEUTIC_SUCCESS
3-HYDROXYCOTININE;EGLN2;AA + AG;rs3733829;METABOLISM/PK;DECREASED;CONCENTRATIONS;;PEOPLE;OTHER:TOBACCO_USE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
HYDROCODONE, OXYCODONE;MACROD2;G;rs76026520;EFFICACY;INCREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:PAIN;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLONIDINE;GNB3;CT + TT;rs5443;EFFICACY;INCREASED;RESPONSE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_SUCCESS
BENAZEPRIL;MTHFR;AA;rs1801133;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;DOSE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
DEFERASIROX;CYP1A1;AC + CC;rs2606345;METABOLISM/PK;INCREASED;TROUGH_CONCENTRATION;;CHILDREN;DISEASE:BETA-THALASSEMIA_AND_RELATED_DISEASES;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;METABOLISM;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
PITRAKINRA;IL4R;GG;rs1029489;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;METABOLISM;;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;DOSE;;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;CAUTION_DOSE_ADJUST
RADIOTHERAPY;CACNA2D3;AG + GG;rs11130424;EFFICACY;INCREASED;RESISTANCE;;PEOPLE;OTHER:NASOPHARYNGEAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
HYDROXYUREA;MAP3K5;CC;rs9483947;EFFICACY;INCREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:BETA-THALASSEMIA_AND_RELATED_DISEASES;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIHYPERTENSIVES;CLNK;G;rs13144136;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
HYDROXYUREA;MAP3K5;CC;rs9376230;EFFICACY;INCREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:BETA-THALASSEMIA_AND_RELATED_DISEASES;LIKELIHOOD_THERAPEUTIC_SUCCESS
IMATINIB;ABCB1;GG;rs1128503;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;LIKELIHOOD_THERAPEUTIC_FAILURE
IMATINIB;ABCB1;AA;rs1045642;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATORVASTATIN;ABCC2;CT + TT;rs717620;EFFICACY;DECREASED;RESPONSE;;MEN;DISEASE:HYPERCHOLESTEROLEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED;DOSE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE, METABOLISM/PK;INCREASED;METABOLISM;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
LENALIDOMIDE, THALIDOMIDE;FGF2;CG + GG;rs308395;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:MULTIPLE_MYELOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE, METABOLISM/PK;INCREASED;DOSE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
METHOTREXATE;ABCC2;CT + TT;rs717620;METABOLISM/PK;DECREASED;CONCENTRATIONS;;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIDEPRESSANTS;MAOA;AA;rs979605;METABOLISM/PK;DECREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;ABCB1;GG;rs1045642;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIDEPRESSANTS;GRIK4;C;rs1954787;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHANOL;ALDH2;AG;rs671;OTHER;INCREASED;EXPOSURE;;MEN;;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;CC;rs776746;DOSAGE;DECREASED;DOSE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
HYDROCHLOROTHIAZIDE;NEDD4L;CC + CG;rs292449;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
PITRAKINRA;IL4R;GG;rs8832;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;T;rs776746;DOSAGE;INCREASED;DOSE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
PITRAKINRA;IL4R;AA;rs3024530;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
PITRAKINRA;IL4R;AA;rs1110470;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
PITRAKINRA;IL4R;AA;rs2239347;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
IVACAFTOR;CFTR;A;rs75527207;EFFICACY;;RESPONSE;;PEOPLE;DISEASE:CYSTIC_FIBROSIS;CAUTION_DOSE_ADJUST
BENAZEPRIL;MTR;AG + GG;rs1805087;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:ESSENTIAL_HYPERTENSION;LIKELIHOOD_THERAPEUTIC_FAILURE
PITRAKINRA;IL4R;AA;rs1805010;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
VORICONAZOLE;ABCC2;CT + TT;rs717620;METABOLISM/PK;INCREASED;TROUGH_CONCENTRATION;;CHILDREN;;CAUTION_DRUG_ACCUMULATION
ACENOCOUMAROL, PHENPROCOUMON;VKORC1;GG;rs9934438;DOSAGE, TOXICITY;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
SULINDAC;FMO3;AA;rs2266782;METABOLISM/PK;INCREASED;EXPOSURE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
MYCOPHENOLATE MOFETIL;SLCO1B3;A;rs7311358;METABOLISM/PK;DECREASED;CLEARANCE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
SULINDAC;FMO3;GG;rs2266780;METABOLISM/PK;INCREASED;EXPOSURE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
MORPHINE;ABCC3;CC;rs4793665;METABOLISM/PK;INCREASED;METABOLISM;;CHILDREN;;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3;C;rs8105790;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATORVASTATIN;SLCO1B1;CT;rs4149056;METABOLISM/PK;INCREASED;EXPOSURE;;;;CAUTION_DRUG_ACCUMULATION
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3;C;rs8103142;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
MEMANTINE;NR1I2;CT + TT;rs1523130;METABOLISM/PK;DECREASED;CLEARANCE;;PEOPLE;DISEASE:DEMENTIA;CAUTION_DRUG_ACCUMULATION
BENAZEPRIL;ADRB2;AG + GG;rs1042713;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:ESSENTIAL_HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3;G;rs11881222;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3;A;rs7248668;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
AMISULPRIDE;ANKS1B;CC;rs7968606;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3;C;rs28416813;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3;C;rs4803219;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
MORPHINE;OPRM1;AG;rs1799971;DOSAGE;INCREASED;DOSE;;PEOPLE;DISEASE:NEOPLASMS;CAUTION_DOSE_ADJUST
ESCITALOPRAM;;A;rs2069521;METABOLISM/PK;INCREASED;METABOLISM;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
IMATINIB;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ROSUVASTATIN;SCARB1;CC;rs4238001;EFFICACY;INCREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:MYOCARDIAL_ISCHEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
IMATINIB;ABCB1;AA;rs1045642;METABOLISM/PK;INCREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;LIKELIHOOD_THERAPEUTIC_SUCCESS
IMATINIB;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;CAUTION_DRUG_ACCUMULATION
LACOSAMIDE;ABCC2;GG;rs2273697;METABOLISM/PK;INCREASED;CONCENTRATIONS;;CHILDREN;OTHER:EPILEPSY;CAUTION_DRUG_ACCUMULATION
IMATINIB;ABCB1;AA;rs1045642;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;CAUTION_DRUG_ACCUMULATION
SIMVASTATIN;SLCO1B1;CC + CT;rs4149056;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:DYSLIPIDAEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
OLANZAPINE;SV2C;TT;rs11960832;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_FAILURE
CORTICOSTEROIDS;TBX21;CG;rs2240017;EFFICACY;INCREASED;RESPONSE;;CHILDREN;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;ABCC1;GG;rs2238476;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:PSORIASIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIDEPRESSANTS;HTR2A;AG + GG;rs6314;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE, LAMOTRIGINE, PHENYTOIN, PRIMIDONE, VALPROIC ACID;CYP2D6;A;rs1065852;EFFICACY;INCREASED;RESPONSE;;CHILDREN;DISEASE:EPILEPSY;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE, LAMOTRIGINE, PHENYTOIN, PRIMIDONE, VALPROIC ACID;CYP2C9;C;rs9332120;EFFICACY;INCREASED;RESPONSE;;CHILDREN;DISEASE:EPILEPSY;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;C;rs776746;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
CARBAMAZEPINE, LAMOTRIGINE, PHENYTOIN, PRIMIDONE, VALPROIC ACID;CYP2D6;C;rs3892097;EFFICACY;INCREASED;RESPONSE;;CHILDREN;DISEASE:EPILEPSY;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE, LAMOTRIGINE, PHENYTOIN, PRIMIDONE, VALPROIC ACID;CYP3A4;C;rs2740574;EFFICACY;INCREASED;RESPONSE;;CHILDREN;DISEASE:EPILEPSY;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE, LAMOTRIGINE, PHENYTOIN, PRIMIDONE, VALPROIC ACID;CYP3A4;C;rs2687116;EFFICACY;INCREASED;RESPONSE;;CHILDREN;DISEASE:EPILEPSY;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE, METABOLISM/PK;INCREASED;DOSE;;CHILDREN;DISEASE:LIVER_TRANSPLANTATION;CAUTION_DOSE_ADJUST
DULOXETINE;ANO2;C;rs61908411;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
DULOXETINE;ANO2;C;rs61908409;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
DULOXETINE;ANO2;T;rs61908410;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
DULOXETINE;ANO2;A;rs78615940;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
DULOXETINE;ANO2;G;rs78482393;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
DULOXETINE;ANO2;C;rs61908405;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
DULOXETINE;ANO2;G;rs61908406;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
SELECTIVE BETA-2-ADRENORECEPTOR AGONISTS;ARG1;A;rs2781659;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;LIKELIHOOD_THERAPEUTIC_FAILURE
DULOXETINE;ANO2;C;rs61908404;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
DULOXETINE;ANO2;A;rs61908408;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
DULOXETINE;ANO2;A;rs61908407;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
DULOXETINE;ANO2;G;rs17786412;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
DULOXETINE;ANO2;A;rs17786400;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
METHADONE;ABCB1;C;rs9282564;METABOLISM/PK;DECREASED;CONCENTRATIONS;;PEOPLE;DISEASE:OPIOID-RELATED_DISORDERS;LIKELIHOOD_THERAPEUTIC_FAILURE
DULOXETINE;ANO2;G;rs61908403;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
DULOXETINE;ANO2;T;rs61908402;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
DOBUTAMINE;ADRB1;CC;rs1801253;EFFICACY;INCREASED;RESPONSE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DULOXETINE;ANO2;C;rs17724452;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
GLATIRAMER ACETATE;PVT1;A;rs2114358;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:MULTIPLE_SCLEROSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
DULOXETINE;;G;rs7316769;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
DULOXETINE;ANO2;C;rs17724494;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;CT;rs56165452;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
METHADONE;ABCB1;A;rs1045642;METABOLISM/PK;DECREASED;CONCENTRATIONS;;PEOPLE;DISEASE:OPIOID-RELATED_DISORDERS;LIKELIHOOD_THERAPEUTIC_FAILURE
DULOXETINE;ANO2;T;rs17786394;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
DULOXETINE;ANO2;G;rs17724464;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
METHADONE;UGT2B7;CT;rs7439366;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:OPIOID-RELATED_DISORDERS;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;A;rs9934438;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
PEMETREXED, PLATINUM COMPOUNDS;CCND1;A;rs9344;EFFICACY;INCREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:LUNG_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;A;rs2359612;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
METOPROLOL;ADRB1;CC;rs1801253;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HEART_FAILURE;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;T;rs7294;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
LIRAGLUTIDE;GLP1R;CT + TT;rs10305420;EFFICACY;DECREASED;RESPONSE;;WOMEN;DISEASE:OBESITY, DISEASE:POLYCYSTIC_OVARY_SYNDROME;LIKELIHOOD_THERAPEUTIC_FAILURE
LAMOTRIGINE;CACNA1H;A;rs2753325;EFFICACY;INCREASED;CLINICAL_BENEFIT;;CHILDREN;EFFICACY:EPILEPSY;LIKELIHOOD_THERAPEUTIC_SUCCESS
AZATHIOPRINE;TPMT;;LOW ACTIVITY;METABOLISM/PK;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
FLUOROURACIL;DPYD;CT;rs3918290;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:NEOPLASMS;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;CC + CT;rs2297595;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:NEOPLASMS;CAUTION_DRUG_ACCUMULATION
ASPIRIN;GP1BA;CT + TT;rs6065;EFFICACY;INCREASED;RESPONSE;;MEN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;DPYD;CT + TT;rs1801160;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:NEOPLASMS;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;GG;rs1801265;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:NEOPLASMS;CAUTION_DRUG_ACCUMULATION
LACOSAMIDE;ABCC2;CC;rs717620;METABOLISM/PK;INCREASED;CONCENTRATIONS;;CHILDREN;OTHER:EPILEPSY;CAUTION_DRUG_ACCUMULATION
ANASTROZOLE;;G;rs11648166;METABOLISM/PK;INCREASED;CONCENTRATIONS;;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;TT;rs9923231;DOSAGE;DECREASED;DOSE;;CHILDREN;;CAUTION_DOSE_ADJUST
LACOSAMIDE;ABCC2;A;rs2273697;EFFICACY;INCREASED;RESISTANCE;;CHILDREN;OTHER:EPILEPSY;LIKELIHOOD_THERAPEUTIC_FAILURE
LACOSAMIDE;ABCC2;T;rs717620;EFFICACY;INCREASED;RESISTANCE;;CHILDREN;OTHER:EPILEPSY;LIKELIHOOD_THERAPEUTIC_FAILURE
ANASTROZOLE;;T;rs28845026;METABOLISM/PK;INCREASED;CONCENTRATIONS;;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_DRUG_ACCUMULATION
TRAZODONE;ABCB1;AA;rs1045642;METABOLISM/PK;INCREASED;CLEARANCE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;AC + CC;rs1057910;DOSAGE;DECREASED;DOSE;;PEOPLE;OTHER:HEART_VALVE_REPLACEMENT;CAUTION_DOSE_ADJUST
CYCLOPHOSPHAMIDE;CYP2B6;C;rs4802101;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:LUPUS_ERYTHEMATOSUS;CAUTION_DRUG_ACCUMULATION
DOBUTAMINE;ADRB1;CC;rs1801253;EFFICACY;INCREASED;RESPONSE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SIMVASTATIN ACID;SLCO1B1;C;rs4149056;METABOLISM/PK;INCREASED;CONCENTRATIONS;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;ARID5B;A;rs10994982;METABOLISM/PK;DECREASED;CLEARANCE;;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DRUG_ACCUMULATION
OXYCODONE;OPRM1;AG + GG;rs1799971;EFFICACY;DECREASED;RESPONSE;;PEOPLE;OTHER:POSTOPERATIVE_PAIN;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOPHOSPHAMIDE;CYP2C19;A;rs4244285;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:LUPUS_ERYTHEMATOSUS;CAUTION_DRUG_ACCUMULATION
IMATINIB;ABCB1;AG + GG;rs1045642;METABOLISM/PK;INCREASED;TROUGH_CONCENTRATION;;PEOPLE;OTHER:GASTROINTESTINAL_STROMAL_TUMORS;CAUTION_DRUG_ACCUMULATION
FENOFIBRATE;PPARA;GG;rs4253778;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:DIABETES_MELLITUS;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;SLC22A11;AT + TT;rs11231809;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;ABCC1;AG + GG;rs246240;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
HMG_COA_REDUCTASE_INHIBITORS;HMGCR;AA;rs3846662;EFFICACY;DECREASED;RESPONSE;;WOMEN;DISEASE:FAMILIAL_HYPERCHOLESTEROLEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;ABCC1;AG + GG;rs3784864;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOPHOSPHAMIDE;CYP2C19;AG + GG;rs4244285;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:LUPUS_NEPHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
4-HYDROXYCYCLOPHOSPHAMIDE;CYP3A5;CC + CT;rs776746;METABOLISM/PK;DECREASED;CONCENTRATIONS;;PEOPLE;DISEASE:LUPUS_NEPHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOPHOSPHAMIDE;CYP2B6;C;rs7254579;METABOLISM/PK;;METABOLISM;;PEOPLE;DISEASE:LUPUS_ERYTHEMATOSUS;CAUTION_DOSE_ADJUST
HMG_COA_REDUCTASE_INHIBITORS;;A;rs445925;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;TT;rs3745274;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;GT;rs3745274;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
HMG_COA_REDUCTASE_INHIBITORS;LPA;G;rs10455872;EFFICACY;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
FENOFIBRATE;IL6;CC + CG;rs1800795;EFFICACY;INCREASED;RESPONSE;;;OTHER:PATIENTS_WITH_A_HIGH_RISK_OF_CARDIOVASCULAR_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RANIBIZUMAB;NRP1;T;rs2070296;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:MACULAR_DEGENERATION;LIKELIHOOD_THERAPEUTIC_FAILURE
ATORVASTATIN;CETP;GG;rs708272;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;MICB;CC;rs3828913;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;ABCG2;CC;rs13120400;EFFICACY;INCREASED;RESPONSE;;PEOPLE;SIDE_EFFECT:PSORIASIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;DBH;GG;rs77905;DOSAGE;DECREASED;DOSE;;PEOPLE;DISEASE:TOBACCO_USE_DISORDER;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;CC + CT;rs9923231;DOSAGE;INCREASED;DOSE;;PEOPLE;OTHER:HEART_VALVE_REPLACEMENT;CAUTION_DOSE_ADJUST
NICOTINE;MAOA;TT;rs1137070;DOSAGE;INCREASED;DOSE;;PEOPLE;DISEASE:TOBACCO_USE_DISORDER;CAUTION_DOSE_ADJUST
OMEPRAZOLE, PANTOPRAZOLE;ABCB1;AA;rs1045642;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HELICOBACTER_INFECTIONS;LIKELIHOOD_THERAPEUTIC_SUCCESS
DEFERASIROX;VDR;AA;rs7975232;METABOLISM/PK;;METABOLISM;;CHILDREN;DISEASE:BETA-THALASSEMIA_AND_RELATED_DISEASES;CAUTION_DOSE_ADJUST
FLUVOXAMINE, MILNACIPRAN, PAROXETINE;HTR1A;TT;rs1364043;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
DEFERASIROX;VDR;G;rs2228570;METABOLISM/PK;;METABOLISM;;CHILDREN;DISEASE:BETA-THALASSEMIA_AND_RELATED_DISEASES;CAUTION_DOSE_ADJUST
ANTIPSYCHOTICS;GRM3;AA;rs6465084;TOXICITY;INCREASED;RESPONSE;;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
METFORMIN;SLC47A1;AA;rs2289669;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP4F2;CC + CT;rs2108622;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2B6;TT;rs3745274;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
METFORMIN;SLC47A1;AA;rs2289669;METABOLISM/PK;DECREASED;CLEARANCE;;PEOPLE;DISEASE:DIABETES_MELLITUS_T2;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;AC;rs1057910;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;T;rs3745274;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;NR1I3;G;rs2307424;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;NR1I3;AG;rs2307424;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
ANTIHYPERTENSIVES;ATP2B1;CT + TT;rs12817819;EFFICACY;INCREASED;RESISTANCE;;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE, DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;EPHX1;CT;rs1051741;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;TT;rs8103142;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;AA;rs12980275;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;AA;rs9934438;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;AA;rs11881222;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;AC;rs1057910;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ISONIAZID;NAT2;AA;rs1799930;METABOLISM/PK;INCREASED;EXPOSURE;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE, DISEASE:TUBERCULOSIS;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;C;rs1057910;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
MERCAPTOPURINE;NUDT15;T;rs73189762;DOSAGE;DECREASED;DOSE;;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DOSE_ADJUST
WARFARIN;PRSS53, VKORC1;CT;rs7294;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2B6;TT;rs3745274;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ISONIAZID;NR1I2;TT;rs2472677;METABOLISM/PK;INCREASED;EXPOSURE;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE, DISEASE:TUBERCULOSIS;CAUTION_DRUG_ACCUMULATION
AMLODIPINE, FELODIPINE;CACNA1C;TT;rs2238032;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ISONIAZID;SLCO1B1;CC;rs4149032;METABOLISM/PK;DECREASED;EXPOSURE;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE, DISEASE:TUBERCULOSIS;LIKELIHOOD_THERAPEUTIC_FAILURE
CALCIUM CHANNEL BLOCKERS;CACNA1C;C;rs2239128;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
MORPHINE;OPRM1;AG + GG;rs1799971;EFFICACY;INCREASED;DOSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEFITINIB;EGFR;G;rs121434568;EFFICACY;;RESPONSE;;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_DOSE_ADJUST
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ERLOTINIB;EGFR;G;rs121434568;EFFICACY;;RESPONSE;;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_DOSE_ADJUST
HMG_COA_REDUCTASE_INHIBITORS;SLCO1B1;A;rs2900478;EFFICACY;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
CALCIUM CHANNEL BLOCKERS;CACNA1C;GG;rs2239050;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
HMG_COA_REDUCTASE_INHIBITORS;CELSR2;C;rs646776;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
VALPROIC ACID;UGT2B7;GG;rs12233719;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:EPILEPSY;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2A6;T;rs28399454;METABOLISM/PK;;METABOLISM;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2B6;T;rs3745274;METABOLISM/PK;;METABOLISM;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2B6;C;rs28399499;METABOLISM/PK;;METABOLISM;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2B6;TT;rs3745274;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
CALCIUM CHANNEL BLOCKERS;CACNA1C;TT;rs2238032;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;GT;rs3745274;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;TT;rs9923231;DOSAGE;DECREASED;DOSE;;PEOPLE;DISEASE:VENOUS_THROMBOEMBOLISM;CAUTION_DOSE_ADJUST
PHENPROCOUMON, WARFARIN;VKORC1;TT;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2B6;GG;rs2279343;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
ATAZANAVIR;ABCB1;GG;rs1045642;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;T;rs1799853;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;A;rs7900194;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2B6;AG;rs2279343;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
VALPROIC ACID;UGT2B7;CT;rs7668258;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:EPILEPSY;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;G;rs28371686;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;APOC1, APOE;T;rs429358;DOSAGE;DECREASED;DOSE;;PEOPLE;OTHER:HAPLOTYPE_EPSILON2;CAUTION_DOSE_ADJUST
VALPROIC ACID;UGT2B7;TT;rs7668258;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:EPILEPSY;CAUTION_DRUG_ACCUMULATION
WARFARIN;APOC1, APOE;T;rs7412;DOSAGE;DECREASED;DOSE;;PEOPLE;OTHER:HAPLOTYPE_EPSILON2;CAUTION_DOSE_ADJUST
INFLIXIMAB;;CC + CT;rs2097432;EFFICACY;INCREASED;DISCONTINUATION;;PEOPLE;EFFICACY:CROHN_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;C;rs1057910;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
PHOTODYNAMIC THERAPY;CFH;TT;rs1061170;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:MACULAR_DEGENERATION;LIKELIHOOD_THERAPEUTIC_FAILURE
VALPROIC ACID;UGT2B7;TT;rs7439366;METABOLISM/PK;;CONCENTRATIONS;;PEOPLE;DISEASE:EPILEPSY;CAUTION_DOSE_ADJUST
RISPERIDONE;ABCG2;GT + TT;rs2231142;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;CHILDREN;;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOXETINE;HTR1B;CC + TT;rs9361233;EFFICACY;INCREASED;RESPONSE;;CHILDREN;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;CC;rs8192709;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
INFLIXIMAB;;T;rs73277969;EFFICACY;INCREASED;DISCONTINUATION;;PEOPLE;EFFICACY:CROHN_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
IVACAFTOR;CFTR;C;rs121908757;EFFICACY;;RESPONSE;;PEOPLE;DISEASE:CYSTIC_FIBROSIS;CAUTION_DOSE_ADJUST
IVACAFTOR;CFTR;G;rs121909005;EFFICACY;;RESPONSE;;PEOPLE;DISEASE:CYSTIC_FIBROSIS;CAUTION_DOSE_ADJUST
ASPIRIN, CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
ASPIRIN, CLOPIDOGREL;CYP2C19;T;rs12248560;;INCREASED;RESPONSE;;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
IVACAFTOR;CFTR;A;rs121908755;EFFICACY;;RESPONSE;;PEOPLE;DISEASE:CYSTIC_FIBROSIS;CAUTION_DOSE_ADJUST
ASPIRIN, PRASUGREL;PEAR1;AC + CC;rs2768759;EFFICACY;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOSPORINE;ABCB1;AC + CC;rs2032582;DOSAGE;INCREASED;DOSE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
ASPIRIN, CLOPIDOGREL, PRASUGREL;PEAR1;AA + AG;rs12041331;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOSPORINE;CYP3A4;AG + GG;rs4646437;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
HYDRALAZINE / ISOSORBIDE DINITRATE;GNB3;TT;rs5443;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HEART_FAILURE;LIKELIHOOD_THERAPEUTIC_SUCCESS
IVACAFTOR;CFTR;C;rs397508453;EFFICACY;;RESPONSE;;PEOPLE;DISEASE:CYSTIC_FIBROSIS;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CC;rs776746;DOSAGE;INCREASED;CONCENTRATIONS;;CHILDREN;OTHER:LIVER_TRANSPLANTATION;CAUTION_DOSE_ADJUST
IVACAFTOR;CFTR;A;rs121909013;EFFICACY;;RESPONSE;;PEOPLE;DISEASE:CYSTIC_FIBROSIS;CAUTION_DOSE_ADJUST
LOVASTATIN ACID;SLCO1B1;CC + CT;rs4149056;METABOLISM/PK;INCREASED;CONCENTRATIONS;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
SIMVASTATIN;CYP3A5;CC;rs776746;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
IVACAFTOR;CFTR;C;rs121909041;EFFICACY;;RESPONSE;;PEOPLE;DISEASE:CYSTIC_FIBROSIS;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A4;T;rs2242480;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
SIMVASTATIN;CYP3A5;CC;rs776746;METABOLISM/PK;DECREASED;CLEARANCE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
ASPIRIN, CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
IVACAFTOR;CFTR;A;rs74503330;EFFICACY;;RESPONSE;;PEOPLE;DISEASE:CYSTIC_FIBROSIS;CAUTION_DOSE_ADJUST
LOVASTATIN;PPARA;AG + GG;rs4823613;METABOLISM/PK;INCREASED;CONCENTRATIONS;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
NEVIRAPINE;CYP1A2;CC;rs762551;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
FENTANYL;OPRM1;AG + GG;rs1799971;EFFICACY;INCREASED;RESPONSE;;WOMEN;DISEASE:PAIN;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANASTROZOLE, LETROZOLE, TAMOXIFEN;CYP19A1;AA;rs4646;EFFICACY;DECREASED;RESPONSE;;WOMEN;DISEASE:BREAST_NEOPLASMS, DISEASE:MENOPAUSE;LIKELIHOOD_THERAPEUTIC_FAILURE
IVACAFTOR;CFTR;A;rs267606723;EFFICACY;;RESPONSE;;PEOPLE;DISEASE:CYSTIC_FIBROSIS;CAUTION_DOSE_ADJUST
SEROTONIN;ERICH3;T;rs696692;OTHER;DECREASED;CONCENTRATIONS;;PEOPLE;DISEASE:DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
IVACAFTOR;CFTR;A;rs80282562;EFFICACY;;RESPONSE;;PEOPLE;DISEASE:CYSTIC_FIBROSIS;CAUTION_DOSE_ADJUST
TACROLIMUS;ABCB1;AG + GG;rs1045642;DOSAGE;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
CYCLOSPORINE;CYP3A4;AG + GG;rs4646437;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANASTROZOLE, LETROZOLE, TAMOXIFEN;CYP19A1;AA;rs4646;EFFICACY;INCREASED;RESPONSE;;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM COMPOUNDS;ERCC2;CT + TT;rs1799793;EFFICACY;INCREASED;RESISTANCE;;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
SEROTONIN;TSPAN5;G;rs11947402;OTHER;DECREASED;CONCENTRATIONS;;PEOPLE;DISEASE:DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
NEVIRAPINE;CYP2B6;TT;rs3745274;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TRAF1;G;rs3761847;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
THALIDOMIDE;CTNNB1;AA;rs4533622;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:MULTIPLE_MYELOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;AG;rs9934438;DOSAGE;INCREASED;DOSE;;PEOPLE;DISEASE:ATRIAL_FIBRILLATION, DISEASE:CARDIOMYOPATHIES,DISEASE:HEART_VALVE_REPLACEMENT, DISEASE:PERIPHERAL_VASCULAR_DISEASES, DISEASE:PULMONARY_EMBOLISM;CAUTION_DOSE_ADJUST
FENTANYL;OPRM1;AG + GG;rs1799971;DOSAGE;DECREASED;DOSE;;WOMEN;DISEASE:PAIN;CAUTION_DOSE_ADJUST
IVACAFTOR;CFTR;A;rs193922525;EFFICACY;;RESPONSE;;PEOPLE;DISEASE:CYSTIC_FIBROSIS;CAUTION_DOSE_ADJUST
CYCLOPHOSPHAMIDE, DEXAMETHASONE, THALIDOMIDE;CTNNB1;AA;rs4135385;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:MULTIPLE_MYELOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;IL17A;A;rs2275913;DOSAGE, EFFICACY;INCREASED;DOSE;;PEOPLE;DISEASE:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
PLATINUM COMPOUNDS;CYP1A1;CC + CT;rs1048943;EFFICACY;INCREASED;RESISTANCE;;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP4F2;C;rs2108622;DOSAGE;DECREASED;DOSE;;PEOPLE;DISEASE:VENOUS_THROMBOEMBOLISM;CAUTION_DOSE_ADJUST
TACROLIMUS;ABCB1;AC + CC;rs2032582;DOSAGE;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED;DOSE;;PEOPLE;DISEASE:VENOUS_THROMBOEMBOLISM;CAUTION_DOSE_ADJUST
ANTIDEPRESSANTS, CITALOPRAM, ESCITALOPRAM;ERICH3;C;rs11580409;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHANOL;OPRM1;AG + GG;rs1799971;OTHER;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
CYCLOSPORINE;ABCB1;AC + CC;rs2032582;DOSAGE;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A7;TT;rs10211;METABOLISM/PK;INCREASED;CONCENTRATIONS;;CHILDREN;OTHER:NULL;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;C;rs9923231;DOSAGE, EFFICACY;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;T;rs9923231;DOSAGE, EFFICACY;INCREASED;RESPONSE;;;;CAUTION_DOSE_ADJUST
ACETAMINOPHEN, TRAMADOL;OPRM1;AA;rs1799971;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:NEUROPATHIC_PAIN;LIKELIHOOD_THERAPEUTIC_SUCCESS
RITUXIMAB;FCGR2A;AA;rs1801274;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHADONE;CYP2B6;T;rs3745274;METABOLISM/PK;DECREASED;CLEARANCE;;PEOPLE;DISEASE:OPIOID-RELATED_DISORDERS;CAUTION_DRUG_ACCUMULATION
COTININE;UGT2B10;CC;rs2942857;METABOLISM/PK;DECREASED;CLEARANCE;;PEOPLE;DISEASE:TOBACCO_USE_DISORDER;CAUTION_DRUG_ACCUMULATION
FENTANYL;;GG;rs6961071;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:POSTOPERATIVE_PAIN;LIKELIHOOD_THERAPEUTIC_SUCCESS
RITUXIMAB;FCGR3A;AC + CC;rs396991;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;G;rs2359612;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
CYCLOPHOSPHAMIDE, DOXORUBICIN, FEC100, FLUOROURACIL;ALDH1A1;AG + GG;rs13959;EFFICACY;INCREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;POR;CC;rs1057868;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
METHADONE;ABCB1;CC;rs2032582;METABOLISM/PK;DECREASED;CLEARANCE;;PEOPLE;DISEASE:OPIOID-RELATED_DISORDERS;CAUTION_DRUG_ACCUMULATION
TOCILIZUMAB;FCGR3A;AA;rs396991;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARVEDILOL;ADRB2;GG;rs1042714;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HEART_FAILURE;LIKELIHOOD_THERAPEUTIC_SUCCESS
FENTANYL;;GG;rs13093031;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:POSTOPERATIVE_PAIN;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATORVASTATIN, LOVASTATIN, SIMVASTATIN;CYP3A5;CC;rs776746;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:ARTERIOSCLEROSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
COTININE;UGT2B10;CC;rs2942857;METABOLISM/PK;INCREASED;EXPOSURE;;PEOPLE;DISEASE:TOBACCO_USE_DISORDER;CAUTION_DRUG_ACCUMULATION
CLOPIDOGREL;ABCB1;A;rs1045642;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:ACUTE_CORONARY_SYNDROME;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN;ERCC1;A;rs11615;EFFICACY;DECREASED;RESPONSE;;WOMEN;OTHER:OVARIAN_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;VKORC1;C;rs2884737;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;PRSS53, VKORC1;TT;rs7294;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;G;rs8050894;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
PHENOBARBITAL;ABCB1;GG;rs1045642;EFFICACY;INCREASED;RESISTANCE;;PEOPLE;DISEASE:EPILEPSY;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;FMO3;CC;rs1800822;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
IVACAFTOR;CFTR;A;rs75527207;EFFICACY;;RESPONSE;;PEOPLE;DISEASE:CYSTIC_FIBROSIS;CAUTION_DOSE_ADJUST
FENOFIBRATE;CRP;TT;rs1417938;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:METABOLIC_SYNDROME;LIKELIHOOD_THERAPEUTIC_SUCCESS
PRAVASTATIN;SLCO1B1;CC + CT;rs4149056;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:DYSLIPIDAEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
METFORMIN;SLC22A3;G;rs2076828;EFFICACY;DECREASED;RESPONSE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOXETINE;HTR1B;CC + TT;rs9361235;EFFICACY;INCREASED;RESPONSE;;CHILDREN;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
N-DESMETHYLCLOZAPINE;UGT2B10;T;rs61750900;METABOLISM/PK;DECREASED;CONCENTRATIONS;;PEOPLE;OTHER:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;NQO1;GG;rs10517;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
FENOFIBRATE;CRP;AG + GG;rs3091244;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:METABOLIC_SYNDROME;LIKELIHOOD_THERAPEUTIC_SUCCESS
PRAVASTATIN;MMP3;A/del + AA;rs35068180;EFFICACY;INCREASED;RESPONSE;;MEN;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
N-DESMETHYLCLOZAPINE;UGT1A4;G;rs2011425;METABOLISM/PK;DECREASED;CONCENTRATIONS;;PEOPLE;OTHER:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_FAILURE
FENOFIBRATE;CRP;GG + GT;rs3091244;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:METABOLIC_SYNDROME;LIKELIHOOD_THERAPEUTIC_SUCCESS
FENTANYL;ABCB1;AA;rs1128503;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:NEOPLASMS, DISEASE:PAIN;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP4F2;T;rs2108622;DOSAGE;INCREASED;DOSE;;PEOPLE;DISEASE:CARDIOVASCULAR_DISEASE;CAUTION_DOSE_ADJUST
CLOZAPINE;CYP2C18;T;rs1126545;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;OTHER:SCHIZOPHRENIA;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;A;rs9934438;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
SIMVASTATIN;SLCO1B1;C;rs4149056;EFFICACY;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
DESLORATADINE, MIZOLASTINE;FCER1A;AA;rs2298805;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:URTICARIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATORVASTATIN;CYP3A5;TT;rs17161788;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:HYPERCHOLESTEROLEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;G;rs8099917;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_FAILURE
CAPECITABINE, FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;SELE;CC;rs3917412;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:COLONIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
ATORVASTATIN;CYP3A5;CC;rs776746;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:HYPERCHOLESTEROLEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
OPIOIDS;;CC;rs2952768;EFFICACY;DECREASED;RESPONSE;;PEOPLE;OTHER:POSTOPERATIVE_PAIN;LIKELIHOOD_THERAPEUTIC_FAILURE
HMG_COA_REDUCTASE_INHIBITORS;PCSK9;T;rs11591147;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HYPERCHOLESTEROLEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
IMATINIB;CYP3A4;AG;rs28371759;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;LIKELIHOOD_THERAPEUTIC_SUCCESS
DIGOXIN;ABCB1;CC;rs2032582;METABOLISM/PK;INCREASED;CLEARANCE;;PEOPLE;DISEASE:HEART_FAILURE;LIKELIHOOD_THERAPEUTIC_FAILURE
CAPECITABINE, FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;MTHFR;AA;rs1801133;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:COLONIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
PLATINUM;ERCC5;GG;rs17655;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ELEXACAFTOR / TEZACAFTOR / IVACAFTOR, IVACAFTOR / TEZACAFTOR;CFTR;AG + GG;rs75389940;EFFICACY;INCREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:CYSTIC_FIBROSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARVEDILOL;UGT2B7;T;rs12233719;METABOLISM/PK;DECREASED;CLEARANCE;;PEOPLE;DISEASE:HEART_DISEASES;CAUTION_DRUG_ACCUMULATION
BUPROPION, NICOTINE, VARENICLINE;CHRNA5;AA + AG;rs2036527;EFFICACY;INCREASED;RESPONSE;;WOMEN;OTHER:TOBACCO_USE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUPROPION, NICOTINE, VARENICLINE;CHRNA5;AA + AG;rs16969968;EFFICACY;INCREASED;RESPONSE;;WOMEN;OTHER:TOBACCO_USE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARVEDILOL;UGT2B7;G;rs28365063;METABOLISM/PK;DECREASED;CLEARANCE;;PEOPLE;DISEASE:HEART_DISEASES;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;FMO3;CC;rs909530;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
DIGOXIN;ABCB1;AA + AT;rs2032582;METABOLISM/PK;DECREASED;CLEARANCE;;PEOPLE;DISEASE:HEART_FAILURE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;NR1I2;CT + TT;rs3814055;METABOLISM/PK;INCREASED;CONCENTRATIONS;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
LUMACAFTOR;CFTR;AA;rs121909047;EFFICACY;;RESPONSE;;;;CAUTION_DOSE_ADJUST
METHADONE;CDH2;AA;rs8094439;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PERTUSSIS VACCINES;TLR4;AA;rs4986790;EFFICACY;INCREASED;RESPONSE;;CHILDREN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;POR;CT + TT;rs1057868;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
METHADONE;CDH2;CC;rs17446819;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;C;rs1057910;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
SORAFENIB;ABCG2;CT;rs2231137;METABOLISM/PK;;CONCENTRATIONS;;PEOPLE;DISEASE:HEPATOCELLULAR_CARCINOMA;CAUTION_DOSE_ADJUST
NICOTINE;CYP2A6;CT + TT;rs376817657;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
SORAFENIB;ABCG2;GT;rs2231142;METABOLISM/PK;;CONCENTRATIONS;;PEOPLE;DISEASE:HEPATOCELLULAR_CARCINOMA;CAUTION_DOSE_ADJUST
IMATINIB;SLC22A1;CC;rs683369;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;LIKELIHOOD_THERAPEUTIC_FAILURE
IMATINIB;ABCB1;GG;rs1045642;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;LIKELIHOOD_THERAPEUTIC_FAILURE
SIMVASTATIN;SLCO1B1;CC + CT;rs4149056;EFFICACY;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
FENTANYL;OPRM1;GG;rs1799971;DOSAGE, EFFICACY;INCREASED;DOSE;;WOMEN;DISEASE:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;AC;rs1057910;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
BILIRUBIN;UGT1A1;TT;rs887829;METABOLISM/PK;INCREASED;CONCENTRATIONS;;CHILDREN;;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;CT;rs1799853;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
METHOTREXATE;GGH;AA + AG;rs3758149;EFFICACY;INCREASED;RESPONSE;;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
MERCAPTOPURINE;NUDT15;A;rs186364861;DOSAGE;DECREASED;DOSE;;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DOSE_ADJUST
IMIQUIMOD;TLR7;A;rs179008;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:BASAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
MERCAPTOPURINE;NUDT15;T;rs116855232;DOSAGE;DECREASED;DOSE;;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DOSE_ADJUST
IVACAFTOR;CFTR;A;rs75527207;EFFICACY;;RESPONSE;;PEOPLE;DISEASE:CYSTIC_FIBROSIS;CAUTION_DOSE_ADJUST
METHOTREXATE;GGH;CC + CT;rs11545077;EFFICACY;INCREASED;RESPONSE;;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;T;rs9923231;DOSAGE, OTHER;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
CLONIDINE;GNB3;CT + TT;rs5443;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:LIVER_CIRRHOSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
IVACAFTOR;CFTR;A;rs75527207;EFFICACY;;RESPONSE;;PEOPLE;DISEASE:CYSTIC_FIBROSIS;CAUTION_DOSE_ADJUST
CLOZAPINE;UGT2B10;T;rs61750900;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;OTHER:SCHIZOPHRENIA;CAUTION_DRUG_ACCUMULATION
OPIOIDS;TAOK3;AG + GG;rs1277441;DOSAGE;INCREASED;DOSE;;PEOPLE;OTHER:NEOPLASMS, OTHER:PAIN;CAUTION_DOSE_ADJUST
IVACAFTOR;CFTR;A;rs75527207;EFFICACY;;RESPONSE;;PEOPLE;DISEASE:CYSTIC_FIBROSIS;CAUTION_DOSE_ADJUST
OPIOIDS;TAOK3;TT;rs795484;DOSAGE;DECREASED;RESPONSE;;PEOPLE;OTHER:NEOPLASMS, OTHER:PAIN;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2B6;TT;rs3745274;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
FENTANYL;OPRM1;GG;rs1799971;DOSAGE;INCREASED;DOSE;;WOMEN;DISEASE:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
OPIOIDS;TAOK3;CT + TT;rs795484;DOSAGE;INCREASED;DOSE;;PEOPLE;OTHER:NEOPLASMS, OTHER:PAIN;CAUTION_DOSE_ADJUST
FENTANYL;ABCB1;AA;rs1128503;DOSAGE;INCREASED;DOSE;;WOMEN;DISEASE:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
TENOFOVIR;ABCC4;AC + CC;rs3742106;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
VITAMIN B12 AND FOLIC ACID;MTHFR;A;rs1801133;EFFICACY;DECREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:HYPERHOMOCYSTEINEMIA, OTHER:STROKE;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;MTHFR;AA + AG;rs1801133;TOXICITY, METABOLISM/PK;INCREASED;EXPOSURE;;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
CAPTOPRIL;AGTR1;AC + CC;rs5186;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTHRACYCLINES AND RELATED SUBSTANCES;GSTP1;A;rs1695;EFFICACY;INCREASED;RESPONSE;;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
SIMVASTATIN;SLCO1B1;CC + CT;rs4149056;EFFICACY;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
DAUNORUBICIN;CBR1;CC;rs25678;METABOLISM/PK;DECREASED;EXPOSURE;;PEOPLE;DISEASE:ACUTE_MYELOID_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
SILIBININ;ABCB1;GG;rs1045642;METABOLISM/PK;INCREASED;EXPOSURE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
IVACAFTOR;CFTR;A;rs78655421;EFFICACY;;RESPONSE;;PEOPLE;DISEASE:CYSTIC_FIBROSIS;CAUTION_DOSE_ADJUST
MERCAPTOPURINE;TPMT;CC;rs1142345;DOSAGE;DECREASED;DOSE;;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DOSE_ADJUST
CITALOPRAM;CYP2C19;AG;rs4244285;EFFICACY;DECREASED;RESPONSE;;MEN;OTHER:ALCOHOL_ABUSE, OTHER:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
BILIRUBIN;SLCO1B1, SLCO1B3, SLCO1B7;C;rs1910167;METABOLISM/PK;INCREASED;CONCENTRATIONS;;CHILDREN;;CAUTION_DRUG_ACCUMULATION
CITALOPRAM;CYP2C19;AG;rs4244285;METABOLISM/PK;INCREASED;CONCENTRATIONS;;MEN;OTHER:ALCOHOL_ABUSE, OTHER:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DRUG_ACCUMULATION
IVACAFTOR;CFTR;A;rs75527207;EFFICACY;;RESPONSE;;PEOPLE;DISEASE:CYSTIC_FIBROSIS;CAUTION_DOSE_ADJUST
ATENOLOL;GNB3;CC;rs5443;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:ESSENTIAL_HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETANERCEPT;PSORS1C1;C;rs2233945;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;POR;CT + TT;rs1057868;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
MERCAPTOPURINE;ABCC4;AA;rs2274407;DOSAGE;DECREASED;DOSE;;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2B6;TT;rs3745274;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE, DISEASE:TUBERCULOSIS;CAUTION_DRUG_ACCUMULATION
DISULFIRAM;TPH2;AA + AT;rs4290270;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:COCAINE_DEPENDENCE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATENOLOL;GNB3;AA;rs11064426;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:ESSENTIAL_HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ENALAPRIL;NR3C2;TT;rs5522;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATENOLOL;GNB3;GG;rs2301339;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:ESSENTIAL_HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATENOLOL;GNB3;CC;rs5443;EFFICACY;INCREASED;RESPONSE;;WOMEN;DISEASE:ESSENTIAL_HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
MERCAPTOPURINE;NUDT15;TT;rs116855232;DOSAGE;DECREASED;DOSE;;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DOSE_ADJUST
ATENOLOL;GNB3;AA;rs11064426;EFFICACY;INCREASED;RESPONSE;;WOMEN;DISEASE:ESSENTIAL_HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACENOCOUMAROL;CYP2C9;T;rs4086116;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ATENOLOL;GNB3;AA;rs11064426;EFFICACY;INCREASED;RESPONSE;;WOMEN;DISEASE:ESSENTIAL_HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETANERCEPT;STAT4;T;rs7574865;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
ATENOLOL;GNB3;GG;rs2301339;EFFICACY;INCREASED;RESPONSE;;WOMEN;DISEASE:ESSENTIAL_HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;GGH;AC + CC;rs11545076;EFFICACY;INCREASED;RESPONSE;;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
DIGOXIN;ABCB1;AG;rs1128503;METABOLISM/PK;DECREASED;CLEARANCE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
ALLOPURINOL;ABCG2;T;rs2231142;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:GOUT;LIKELIHOOD_THERAPEUTIC_FAILURE
PRAVASTATIN;SLCO1B1;AG;rs4149015;EFFICACY, METABOLISM/PK;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
DIGOXIN;ABCB1;GG;rs1045642;METABOLISM/PK;INCREASED;CLEARANCE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
IVACAFTOR;CFTR;A;rs75527207;EFFICACY;;RESPONSE;;PEOPLE;DISEASE:CYSTIC_FIBROSIS;CAUTION_DOSE_ADJUST
DIGOXIN;ABCB1;CC;rs2032582;METABOLISM/PK;INCREASED;CLEARANCE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
IVACAFTOR, TEZACAFTOR;CFTR;A;rs75527207;EFFICACY;;RESPONSE;;PEOPLE;DISEASE:CYSTIC_FIBROSIS;CAUTION_DOSE_ADJUST
ATORVASTATIN, HMG COA REDUCTASE INHIBITORS, PRAVASTATIN, SIMVASTATIN;SLCO1B1;CC + CT;rs4149056;EFFICACY;DECREASED;RESPONSE;;PEOPLE;OTHER:HYPERLIPIDEMIAS;LIKELIHOOD_THERAPEUTIC_FAILURE
FENOFIBRATE;ABCA1;CT;rs2230806;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HYPERTRIGLYCERIDEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
SERTRALINE;HTR2A;AA + AG;rs6313;DOSAGE;INCREASED;DOSE;;CHILDREN;OTHER:DEPRESSION, OTHER:ANXIETY_DISORDERS;CAUTION_DOSE_ADJUST
FENOFIBRATE;ABCA1;CC;rs2230808;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HYPERTRIGLYCERIDEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM COMPOUNDS;NUP107;C;rs79419059;EFFICACY;INCREASED;RESISTANCE;;WOMEN;DISEASE:OVARIAN_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
FENOFIBRATE;ABCA1;TT;rs2230806;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HYPERTRIGLYCERIDEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
VENLAFAXINE;COMT;AA + AG;rs4680;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:ANXIETY_DISORDERS;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;NQO1;AA;rs1800566;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
KETOPROFEN;CYP2C9;CC;rs1799853;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:POSTOPERATIVE_PAIN;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;GT + TT;rs3745274;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;TROUGH_CONCENTRATION;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
ETANERCEPT;TNF;AG + GG;rs1800629;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIDEPRESSANTS;CHL1;TT;rs1516338;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:BIPOLAR_DISORDER, DISEASE:DEPRESSIVE_DISORDER,DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
ADALIMUMAB;TANK;CC;rs1267067;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;AA + AG;rs9934438;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;AA;rs15524;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
ADALIMUMAB;VEGFA;T;rs25648;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARVEDILOL;ADRB1;GG;rs1801253;DOSAGE;INCREASED;DOSE;;PEOPLE;DISEASE:HEART_FAILURE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;GG;rs4646450;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
INFLIXIMAB;TNF;GG;rs361525;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;SLCO1B1;CC + CT;rs11045879;METABOLISM/PK;INCREASED;EXPOSURE;;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A4;GG;rs4646437;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
HYDROCHLOROTHIAZIDE;VASP;AG + GG;rs10995;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ADALIMUMAB;TNFAIP3;T;rs2230926;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;SLC19A1;AA + AG;rs2838958;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DRUG_ACCUMULATION
SIMVASTATIN, SIMVASTATIN ACID;SLCO1B1;C;rs4149056;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:HYPERCHOLESTEROLEMIA;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;AC;rs1057910;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;AA;rs9934438;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
IVACAFTOR;CFTR;C;rs121908757;EFFICACY;;RESPONSE;;PEOPLE;DISEASE:CYSTIC_FIBROSIS;CAUTION_DOSE_ADJUST
METHOTREXATE;SLC19A1;AG + GG;rs3788200;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DRUG_ACCUMULATION
LITHIUM;NR1D1, THRA;T;rs2314339;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:BIPOLAR_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP4F2;TT;rs2108622;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CT;rs776746;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;C;rs1057910;DOSAGE;DECREASED;DOSE;;PEOPLE;DISEASE:VENOUS_THROMBOEMBOLISM;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ATENOLOL;GNB3;GG;rs2301339;EFFICACY;INCREASED;RESPONSE;;WOMEN;DISEASE:ESSENTIAL_HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
BEVACIZUMAB, CAPECITABINE, CISPLATIN, DOCETAXEL, EPIRUBICIN, OXALIPLATIN, TRASTUZUMAB;ERCC2;GG;rs13181;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:STOMACH_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACENOCOUMAROL;APOE;C;rs429358;DOSAGE;DECREASED;DOSE;;PEOPLE;DISEASE:VENOUS_THROMBOEMBOLISM;CAUTION_DOSE_ADJUST
WARFARIN;CYP4F2;T;rs2108622;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;CG + GG;rs8050894;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP4F2;CC;rs2108622;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;AA + AG;rs2359612;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ATAZANAVIR;SORCS2;A;rs73208473;METABOLISM/PK;DECREASED;EXPOSURE;;WOMEN;DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
ROSUVASTATIN;ABCG2;GT + TT;rs2231142;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
BEVACIZUMAB, CAPECITABINE, CISPLATIN, DOCETAXEL, EPIRUBICIN, OXALIPLATIN, TRASTUZUMAB;ERCC1;GG;rs11615;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:STOMACH_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP4F2;T;rs2108622;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
BEVACIZUMAB, CAPECITABINE, CISPLATIN, DOCETAXEL, EPIRUBICIN, OXALIPLATIN, TRASTUZUMAB;MTHFR;AA;rs1801133;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:STOMACH_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
METHADONE;CNR1;CT + TT;rs806368;DOSAGE;INCREASED;DOSE;;PEOPLE;OTHER:HEROIN_DEPENDENCE;CAUTION_DOSE_ADJUST
METHADONE;TPH2;GG;rs1386493;DOSAGE;INCREASED;DOSE;;PEOPLE;OTHER:HEROIN_DEPENDENCE;CAUTION_DOSE_ADJUST
BUMETANIDE, FUROSEMIDE, TORASEMIDE;NPPA-AS1;GG;rs5065;EFFICACY;DECREASED;RESPONSE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
MORPHINE;UGT2B7;CT + TT;rs7439366;METABOLISM/PK;DECREASED;CONCENTRATIONS;;PEOPLE;OTHER:NEOPLASMS, OTHER:PAIN;LIKELIHOOD_THERAPEUTIC_FAILURE
ATORVASTATIN, SIMVASTATIN;KIF6;GG;rs20455;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:HYPERCHOLESTEROLEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;GG;rs35303484;METABOLISM/PK;INCREASED;CONCENTRATIONS;;CHILDREN;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
METHADONE;CYP2B6;CT;rs16974799;DOSAGE;INCREASED;DOSE;;PEOPLE;OTHER:HEROIN_DEPENDENCE;CAUTION_DOSE_ADJUST
METHADONE;OPRL1;CT;rs2229205;DOSAGE;INCREASED;DOSE;;PEOPLE;OTHER:HEROIN_DEPENDENCE;CAUTION_DOSE_ADJUST
ROSUVASTATIN;KIF6;GG;rs20455;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:HYPERCHOLESTEROLEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
ADRENERGICS, INHALANTS;;T;rs34548976;EFFICACY;DECREASED;RESPONSE;;CHILDREN;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_FAILURE
TOPIRAMATE;GRIK1;AA + AC;rs2832407;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:ALCOHOL-RELATED_DISORDERS;CAUTION_DRUG_ACCUMULATION
BUMETANIDE, FUROSEMIDE, TORASEMIDE;ADD1;TT;rs4961;EFFICACY;INCREASED;RESPONSE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN, GEMCITABINE;CDA;AA;rs2072671;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
TOPIRAMATE;GRIK1;AA + AC;rs2832407;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:ALCOHOL-RELATED_DISORDERS;LIKELIHOOD_THERAPEUTIC_FAILURE
ATORVASTATIN;KIF6;GG;rs20455;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:HYPERCHOLESTEROLEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
CISPLATIN, GEMCITABINE;ERCC1;AA;rs11615;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUMETANIDE, FUROSEMIDE, TORASEMIDE;SLC12A3;CC;rs1529927;EFFICACY;INCREASED;RESPONSE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;TT;rs3745274;METABOLISM/PK;INCREASED;CONCENTRATIONS;;CHILDREN;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
FLUVASTATIN;ABCB1;AA;rs1922242;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HYPERCHOLESTEROLEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
GLICLAZIDE;KCNQ1;CT + TT;rs2237897;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP4F11;G;rs1060467;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
CARBOPLATIN, TAXANES;VEGFA;CC + CT;rs9369421;EFFICACY;INCREASED;RESPONSE;;WOMEN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DEBRISOQUINE;CYP2D6;C;rs1080985;METABOLISM/PK;INCREASED;METABOLISM;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A4;AA + AG;rs35599367;METABOLISM/PK;DECREASED;CLEARANCE;;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2A6;AC;rs28399433;METABOLISM/PK;INCREASED;CONCENTRATIONS;;CHILDREN;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
FLUVASTATIN;CETP;GG;rs4783961;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HYPERCHOLESTEROLEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;CLEARANCE;;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;ABCB1;CC + CT;rs9282564;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;MTRR;AG + GG;rs1801394;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
TENOFOVIR;IFNL3, IFNL4;C;rs12979860;METABOLISM/PK;INCREASED;CLEARANCE;;PEOPLE;OTHER:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
GLUCOCORTICOIDS;ABCB1;GG;rs1128503;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:CROHN_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
METFORMIN;SLC22A1;A;rs622342;EFFICACY;INCREASED;RESPONSE;;PEOPLE;EFFICACY:DIABETES_MELLITUS;LIKELIHOOD_THERAPEUTIC_SUCCESS
GLUCOCORTICOIDS;ABCB1;GG;rs1045642;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:CROHN_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
HYDROXYUREA;BCL11A;T;rs1427407;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:BETA-THALASSEMIA_AND_RELATED_DISEASES;LIKELIHOOD_THERAPEUTIC_SUCCESS
HYDROXYUREA;BCL11A;C;rs766432;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:BETA-THALASSEMIA_AND_RELATED_DISEASES;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;A;rs2860905;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
FENTANYL;UGT2B7;TT;rs7439366;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:POSTOPERATIVE_PAIN;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;AC + CC;rs1057910;DOSAGE, EFFICACY;DECREASED;DOSE;;MEN;;CAUTION_DOSE_ADJUST
TIOTROPIUM;ADRB2;AA;rs1042713;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
LUMEFANTRINE;ABCC2;AA;rs8187710;METABOLISM/PK;INCREASED;CONCENTRATIONS;;CHILDREN;OTHER:MALARIA;CAUTION_DRUG_ACCUMULATION
ELEXACAFTOR / TEZACAFTOR / IVACAFTOR;CFTR;G;rs80034486;EFFICACY;INCREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:CYSTIC_FIBROSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATORVASTATIN;APOE;CT;rs7412;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHADONE;ABCB1;AG;rs1045642;METABOLISM/PK;INCREASED;CONCENTRATIONS;;MEN;DISEASE:OPIOID-RELATED_DISORDERS;CAUTION_DRUG_ACCUMULATION
BUMETANIDE, FUROSEMIDE, TORASEMIDE;NPPA-AS1;GG;rs5065;EFFICACY;INCREASED;RESPONSE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;A;rs9934438;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
CLOPIDOGREL;ABCB1;GG;rs1045642;EFFICACY;INCREASED;RESISTANCE;;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_FAILURE
BUMETANIDE, FUROSEMIDE, TORASEMIDE;GNB3;TT;rs5443;EFFICACY;DECREASED;RESPONSE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
MORPHINE;UGT2B7;CT + TT;rs7439366;EFFICACY;DECREASED;RESPONSE;;PEOPLE;OTHER:NEOPLASMS, OTHER:PAIN;LIKELIHOOD_THERAPEUTIC_FAILURE
BUMETANIDE, FUROSEMIDE, TORASEMIDE;NPPA-AS1;TT;rs5063;EFFICACY;DECREASED;RESPONSE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
VALPROIC ACID;UGT1A6;AG + GG;rs2070959;METABOLISM/PK;DECREASED;CONCENTRATIONS;;PEOPLE;OTHER:EPILEPSY;LIKELIHOOD_THERAPEUTIC_FAILURE
VALPROIC ACID;UGT1A6;AC + CC;rs1105879;METABOLISM/PK;DECREASED;CONCENTRATIONS;;PEOPLE;OTHER:EPILEPSY;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOZAPINE;HTR2A;AA + AG;rs6314;EFFICACY;INCREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUVASTATIN;SLCO1B1;TT;rs4149056;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PRAVASTATIN;ACE;CG + GG;rs4341;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PRAVASTATIN;LPL;GG;rs328;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
LOVASTATIN;CETP;AG;rs708272;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
FENTANYL;UGT2B7;CC;rs10028494;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:POSTOPERATIVE_PAIN;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;MTHFR;AA;rs1801133;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DRUG_ACCUMULATION
NICOTINE;CHRNA3;A;rs1051730;METABOLISM/PK;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
FLUVASTATIN;LIPC;CC + CT;rs1800588;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOZAPINE;CYP1A1;T;rs2472297;METABOLISM/PK;DECREASED;CONCENTRATIONS;;PEOPLE;OTHER:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_FAILURE
METHYLPHENIDATE;CES1;CG;rs114119971;DOSAGE;DECREASED;DOSE;;CHILDREN;OTHER:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY;CAUTION_DOSE_ADJUST
SIMVASTATIN;LIPC;CT;rs1800588;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN, FLUOROURACIL, OXALIPLATIN;VEGFA;CT + TT;rs25648;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:STOMACH_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP4F2;T;rs2108622;DOSAGE;INCREASED;DOSE;;PEOPLE;DISEASE:CARDIOVASCULAR_DISEASE;CAUTION_DOSE_ADJUST
ATORVASTATIN;ABCB1;CC;rs2032582;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IVACAFTOR;CFTR;A;rs75527207;EFFICACY;;RESPONSE;;CHILDREN;DISEASE:CYSTIC_FIBROSIS;CAUTION_DOSE_ADJUST
ATORVASTATIN;SLCO1B1;AC + CC;rs4149036;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATORVASTATIN;CYP3A5;CC + CT;rs776746;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PERTUSSIS VACCINES;TLR4;GG;rs2770150;EFFICACY;DECREASED;RESPONSE;;CHILDREN;;LIKELIHOOD_THERAPEUTIC_FAILURE
CISPLATIN, FLUOROURACIL, MITOXANTRONE;;CC + TT;rs6025211;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:LIVER_CANCER;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;ABCB1;AA + TT;rs2032582;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:NEPHROTIC_SYNDROME;LIKELIHOOD_THERAPEUTIC_SUCCESS
LOVASTATIN;SLCO1B1;GT + TT;rs2291073;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;ABCB1;AA;rs1128503;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:NEPHROTIC_SYNDROME;LIKELIHOOD_THERAPEUTIC_SUCCESS
CATECHOLAMINES, METFORMIN;SLC22A3;T;rs8187725;OTHER, METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
LOVASTATIN;LDLR;TT;rs688;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
AMLODIPINE;CACNA1C;GG;rs2239050;EFFICACY;INCREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUVASTATIN;CYP3A4;AG;rs4986910;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NALTREXONE;ADH1C;C;rs698;EFFICACY;INCREASED;RESPONSE;;MEN;OTHER:ALCOHOL_ABUSE;LIKELIHOOD_THERAPEUTIC_SUCCESS
NALTREXONE;ADH1B;A;rs2066702;EFFICACY;DECREASED;RESPONSE;;MEN;OTHER:ALCOHOL_ABUSE;LIKELIHOOD_THERAPEUTIC_FAILURE
LOVASTATIN;LDLR;CC;rs5925;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN, FLUOROURACIL, MITOXANTRONE;GALNT14;TT;rs9679162;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:LIVER_CANCER;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOXETINE;HTR2A;GG;rs6313;EFFICACY;DECREASED;TIME_RESPONSE;;CHILDREN;OTHER:DEPRESSION, OTHER:ANXIETY_DISORDERS;LIKELIHOOD_THERAPEUTIC_FAILURE
NALTREXONE;ALDH2;G;rs671;EFFICACY;INCREASED;RESPONSE;;MEN;OTHER:ALCOHOL_ABUSE;LIKELIHOOD_THERAPEUTIC_SUCCESS
VARENICLINE;CYP2B6;AG + GG;rs8109525;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:TOBACCO_USE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;ABCB1;AG;rs1128503;DOSAGE;INCREASED;DOSE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;T;rs7089580;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
CLOPIDOGREL;P2RY12;AA;rs2046934;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:CORONARY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;CONCENTRATIONS;;CHILDREN;OTHER:NULL;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;ABCB1;AA;rs1045642;DOSAGE;INCREASED;DOSE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C19;C;rs3814637;DOSAGE;;DOSE;;;;CAUTION_DOSE_ADJUST
TACROLIMUS;ABCB1;AA;rs2032582;DOSAGE;INCREASED;DOSE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;A;rs4917639;DOSAGE;;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;A;rs2359612;DOSAGE;;DOSE;;;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A7;CG + GG;rs2257401;METABOLISM/PK;DECREASED;CONCENTRATIONS;;CHILDREN;OTHER:NULL;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;P2RY12;GG;rs3732759;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:CORONARY_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIBIOTICS, ESOMEPRAZOLE;ABCB1;AA;rs1045642;EFFICACY;DECREASED;CLINICAL_BENEFIT;;CHILDREN;OTHER:HELICOBACTER_INFECTIONS;LIKELIHOOD_THERAPEUTIC_FAILURE
CARFILZOMIB, DEXAMETHASONE, LENALIDOMIDE;VEGFA;CT + TT;rs833061;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:MULTIPLE_MYELOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOLUTEGRAVIR;ABCG2;TT;rs2231142;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
QUETIAPINE;DRD3;TT;rs6280;METABOLISM/PK;INCREASED;CLEARANCE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;ABCB1;AA + AG;rs1128503;EFFICACY;INCREASED;RESISTANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
CISPLATIN, FLUOROURACIL;GALNT14;GG;rs9679162;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:LIVER_CANCER;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARFILZOMIB, DEXAMETHASONE, LENALIDOMIDE;KDR;CT + TT;rs2305948;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:MULTIPLE_MYELOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARFILZOMIB, DEXAMETHASONE, LENALIDOMIDE;KDR;AT + TT;rs1870377;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:MULTIPLE_MYELOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
MORPHINE;OPRM1;AG + GG;rs1799971;DOSAGE;INCREASED;DOSE;;PEOPLE;OTHER:LIVER_CANCER, OTHER:PAIN;CAUTION_DOSE_ADJUST
SORAFENIB;GALNT14;GG;rs9679162;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:HEPATITIS_C_VIRUS_INFECTION, OTHER:LIVER_CANCER;LIKELIHOOD_THERAPEUTIC_SUCCESS
MYCOPHENOLIC ACID;ABCC2;A;rs2273697;METABOLISM/PK;DECREASED;EXPOSURE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CC;rs776746;DOSAGE;DECREASED;DOSE;;CHILDREN;OTHER:LIVER_TRANSPLANTATION;CAUTION_DOSE_ADJUST
MYCOPHENOLIC ACID;ABCC2;T;rs717620;METABOLISM/PK;;EXPOSURE;;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
FENTANYL;ATF2;A;rs7583431;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:POSTOPERATIVE_PAIN;LIKELIHOOD_THERAPEUTIC_SUCCESS
MYCOPHENOLIC ACID;ABCC2;T;rs717620;METABOLISM/PK;;EXPOSURE;;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
TACROLIMUS;NR1I2;CT + TT;rs3814055;DOSAGE;DECREASED;DOSE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
AFLIBERCEPT, RANIBIZUMAB;ANO2;TT;rs2110166;EFFICACY;INCREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:MACULAR_DEGENERATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;NR1I2;CT + TT;rs3814055;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
VENLAFAXINE;SLC6A2;CC;rs2242446;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
MYCOPHENOLIC ACID;ABCC2;A;rs2273697;METABOLISM/PK;DECREASED;EXPOSURE;;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
BOCEPREVIR, PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIR;IFNL3, IFNL4;C;rs12979860;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;TT;rs1799724;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
DONEPEZIL, GALANTAMINE, RIVASTIGMINE;CHRNA7;T;rs6494223;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:ALZHEIMER_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ADALIMUMAB;FCGR2A;A;rs1801274;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;ENOSF1;CC;rs2612091;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:STOMACH_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
SIMVASTATIN ACID;SLCO1B1;CT;rs4149056;METABOLISM/PK;INCREASED;CONCENTRATIONS;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
DOBUTAMINE;ADRB1;CC;rs1801253;EFFICACY;INCREASED;RESPONSE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DACLATASVIR, SOFOSBUVIR;HINT1;CT + TT;rs7728773;EFFICACY;INCREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
MERCAPTOPURINE;NUDT15;CT + TT;rs116855232;DOSAGE;DECREASED;DOSE;;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DOSE_ADJUST
ADALIMUMAB, ETANERCEPT, INFLIXIMAB;IL6;G;rs1800795;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
LITHIUM;;T;rs78015114;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:BIPOLAR_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUPRENORPHINE;OPRD1;CC;rs678849;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:OPIOID-RELATED_DISORDERS;LIKELIHOOD_THERAPEUTIC_FAILURE
CARBAMAZEPINE, PHENOBARBITAL, PHENYTOIN, VALPROIC ACID;SCN2A;A;rs17183814;EFFICACY;;RESISTANCE;;;;CAUTION_DOSE_ADJUST
QUETIAPINE;CYP3A5;CC;rs776746;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
LITHIUM;;T;rs79663003;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:BIPOLAR_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
APREMILAST;CYP3A4, TMEM130;C;rs1203844;EFFICACY;INCREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:PSORIASIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
APREMILAST;CYP3A4;A;rs35599367;EFFICACY;INCREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:PSORIASIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATORVASTATIN;MYLIP;AA;rs9370867;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HYPERCHOLESTEROLEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
LITHIUM;;T;rs75222709;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:BIPOLAR_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
LITHIUM;;G;rs74795342;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:BIPOLAR_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
APREMILAST;PDE4D;T;rs295943;EFFICACY;DECREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:PSORIASIS;LIKELIHOOD_THERAPEUTIC_FAILURE
METHYLPHENIDATE;ADRA2A;CG + GG;rs1800544;EFFICACY;INCREASED;RESPONSE;;CHILDREN;DISEASE:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS
SIMVASTATIN;SCAP;TT;rs12487736;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:HYPERCHOLESTEROLEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;C;rs1057910;DOSAGE;DECREASED;DOSE;;PEOPLE;OTHER:TOTAL_KNEE_OR_HIP_ARTHROPLASTY;CAUTION_DOSE_ADJUST
CAFFEINE;CYP1A2;AA + AG;rs2069514;OTHER, METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
APREMILAST;CDKN2B, CDKN2B-AS1;G;rs1063192;EFFICACY;INCREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:PSORIASIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
PRAVASTATIN;LIPC;CT + TT;rs1800588;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HYPERCHOLESTEROLEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;T;rs1799853;DOSAGE;DECREASED;DOSE;;PEOPLE;OTHER:TOTAL_KNEE_OR_HIP_ARTHROPLASTY;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2B6;CT;rs28399499;METABOLISM/PK;INCREASED;CONCENTRATIONS;;CHILDREN;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
LOSARTAN;AGTR1;AC + CC;rs5186;EFFICACY;INCREASED;RESPONSE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_SUCCESS
(R)-METHADONE;NR1I3;GG;rs2307424;METABOLISM/PK;INCREASED;CLEARANCE;;PEOPLE;OTHER:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
OLANZAPINE;HTR2A;GG;rs6314;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
SIMVASTATIN;ABCB1;GG;rs1128503;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:HYPERCHOLESTEROLEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
AZATHIOPRINE, MERCAPTOPURINE;NUDT15;CT;rs116855232;TOXICITY;INCREASED;DISCONTINUATION;;PEOPLE;DISEASE:INFLAMMATORY_BOWEL_DISEASES;CAUTION_SIDE_EFFECT
WARFARIN;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
(R)-METHADONE;NR1I3;GG;rs3003596;METABOLISM/PK;INCREASED;CLEARANCE;;PEOPLE;OTHER:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
BEVACIZUMAB;CFH;CT;rs1061170;DOSAGE;INCREASED;DOSE;;PEOPLE;DISEASE:MACULAR_DEGENERATION;CAUTION_DOSE_ADJUST
METHADONE;OPRD1;CC;rs678849;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:OPIOID-RELATED_DISORDERS;LIKELIHOOD_THERAPEUTIC_SUCCESS
AZATHIOPRINE, MERCAPTOPURINE;NUDT15;CT;rs116855232;DOSAGE;DECREASED;DOSE;;PEOPLE;DISEASE:INFLAMMATORY_BOWEL_DISEASES;CAUTION_DOSE_ADJUST
BEVACIZUMAB;ARMS2;GT + TT;rs10490924;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:MACULAR_DEGENERATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
PRAVASTATIN;SLCO1B1;C;rs4149056;METABOLISM/PK;DECREASED;CLEARANCE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
SIMVASTATIN;ABCB1;CC;rs2032582;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:HYPERCHOLESTEROLEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;NQO1;AA + AG;rs1800566;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ATORVASTATIN;SLCO1B1;CC + CT;rs4149056;METABOLISM/PK;INCREASED;CONCENTRATIONS;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
ATORVASTATIN;SLCO1B1;CC + CT;rs4149056;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
DEFERASIROX;ABCC2;AG;rs2273697;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:BETA-THALASSEMIA_AND_RELATED_DISEASES;CAUTION_DRUG_ACCUMULATION
BUDESONIDE;;AG + GG;rs2392165;EFFICACY;INCREASED;RESPONSE;;CHILDREN;OTHER:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
THIORIDAZINE;CYP2D6;CC + CG;rs1080985;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
PRAVASTATIN;SLCO1B1;G;rs2306283;METABOLISM/PK;DECREASED;CLEARANCE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
DEFERASIROX;CYP1A2;CC + CT;rs2470890;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:BETA-THALASSEMIA_AND_RELATED_DISEASES;CAUTION_DRUG_ACCUMULATION
MERCAPTOPURINE;NUDT15;CT + TT;rs116855232;DOSAGE;DECREASED;DOSE;;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DOSE_ADJUST
DEFERASIROX;CYP1A2;AC + CC;rs762551;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:BETA-THALASSEMIA_AND_RELATED_DISEASES;CAUTION_DRUG_ACCUMULATION
ATORVASTATIN;ABCC2;AG;rs2273697;EFFICACY;DECREASED;RESPONSE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
OLANZAPINE;DRD2;AA + AC;rs1076560;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
DEFERASIROX;CYP1A1;AC + CC;rs2606345;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:BETA-THALASSEMIA_AND_RELATED_DISEASES;CAUTION_DRUG_ACCUMULATION
DEFERASIROX;UGT1A1;TT;rs887829;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:BETA-THALASSEMIA_AND_RELATED_DISEASES;CAUTION_DRUG_ACCUMULATION
PRAVASTATIN;SLC10A1;A;rs2296651;METABOLISM/PK;INCREASED;CLEARANCE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
ADALIMUMAB, ETANERCEPT, INFLIXIMAB;FCGR2A;GG;rs1801274;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:PSORIASIS;LIKELIHOOD_THERAPEUTIC_FAILURE
CAPECITABINE;MTHFR;GG;rs1801133;METABOLISM/PK;INCREASED;EXPOSURE;;PEOPLE;DISEASE:NEOPLASMS;CAUTION_DRUG_ACCUMULATION
DACLATASVIR, SOFOSBUVIR;IFNL3;CC;rs12979860;EFFICACY;INCREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUPRENORPHINE;;T;rs6973474;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:OPIOID-RELATED_DISORDERS;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUPRENORPHINE;;T;rs13169373;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:OPIOID-RELATED_DISORDERS;LIKELIHOOD_THERAPEUTIC_SUCCESS
HALOPERIDOL;CYP2D6;CC;rs3892097;EFFICACY;DECREASED;RESPONSE;;MEN;DISEASE:ALCOHOLIC_PSYCHOSIS, DISEASE:ALCOHOL_ABUSE,DISEASE:ALCOHOL-RELATED_DISORDERS;LIKELIHOOD_THERAPEUTIC_FAILURE
NEVIRAPINE;CYP2B6;C;rs28399499;METABOLISM/PK;INCREASED;CONCENTRATIONS;;WOMEN;;CAUTION_DRUG_ACCUMULATION
IMATINIB;SLC22A1;GG;rs628031;METABOLISM/PK;DECREASED;CLEARANCE;;PEOPLE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;CAUTION_DRUG_ACCUMULATION
NICOTINE;CHRNA5;A;rs16969968;DOSAGE;INCREASED;DOSE;;PEOPLE;DISEASE:TOBACCO_USE_DISORDER;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED;DOSE;;CHILDREN;DISEASE:LIVER_TRANSPLANTATION;CAUTION_DOSE_ADJUST
BUPRENORPHINE;;G;rs62368105;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:OPIOID-RELATED_DISORDERS;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUPRENORPHINE;;T;rs11782370;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:OPIOID-RELATED_DISORDERS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ADALIMUMAB, ETANERCEPT, INFLIXIMAB;FCGR3A;AA;rs396991;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:PSORIASIS;LIKELIHOOD_THERAPEUTIC_FAILURE
BUPRENORPHINE;;T;rs7205113;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:OPIOID-RELATED_DISORDERS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETANERCEPT;IL10;CC;rs1800896;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUPRENORPHINE;ADAMTSL2;A;rs756770;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:OPIOID-RELATED_DISORDERS;LIKELIHOOD_THERAPEUTIC_SUCCESS
(R)-METHADONE;ABCB1;AA;rs2032582;METABOLISM/PK;DECREASED;CLEARANCE;;PEOPLE;OTHER:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
ETANERCEPT;TGFB1;CG;rs1800471;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
ATORVASTATIN;SLCO1B1;AG + GG;rs2306283;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HYPERCHOLESTEROLEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ, NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS;CYP2B6;T;rs3745274;EFFICACY;INCREASED;RESPONSE;;WOMEN;DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;CC + CT;rs2279345;METABOLISM/PK;INCREASED;CLEARANCE;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;TT;rs3745274;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE, DISEASE:TUBERCULOSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;SLCO1B1;TT;rs4149056;METABOLISM/PK;INCREASED;EXPOSURE;;PEOPLE;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DRUG_ACCUMULATION
XK469;AOX1;G;rs10931910;METABOLISM/PK;DECREASED;CLEARANCE;;PEOPLE;DISEASE:NEOPLASMS;CAUTION_DRUG_ACCUMULATION
SIMVASTATIN;PON1;CC;rs662;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:CORONARY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;TT;rs3745274;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE, DISEASE:TUBERCULOSIS;CAUTION_DRUG_ACCUMULATION
MERCAPTOPURINE;NUDT15;T;rs116855232;DOSAGE;DECREASED;DOSE;;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DOSE_ADJUST
ETANERCEPT;TNF;GG;rs1800629;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
MERCAPTOPURINE;TPMT;CT;rs1142345;DOSAGE;DECREASED;DOSE;;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DOSE_ADJUST
NEVIRAPINE;CYP2B6;T;rs3745274;METABOLISM/PK;INCREASED;CONCENTRATIONS;;WOMEN;;CAUTION_DRUG_ACCUMULATION
BUCINDOLOL;ADRB1;CC;rs1801253;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HEART_FAILURE;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;GT + TT;rs3745274;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A4;CT;rs4986907;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
NEVIRAPINE;CYP2B6;TT;rs3745274;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;TT;rs3745274;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
PHENPROCOUMON;VKORC1;CC;rs9923231;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP4F2;AG + GG;rs2189784;DOSAGE;INCREASED;DOSE;;PEOPLE;DISEASE:HEART_VALVE_REPLACEMENT;CAUTION_DOSE_ADJUST
PHENPROCOUMON;EPHX1;CC;rs1051740;DOSAGE, METABOLISM/PK;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ASPIRIN, DICLOFENAC, IBUPROFEN, INDOMETHACIN, KETOROLAC, NAPROXEN;TNF;A;rs1800629;EFFICACY;DECREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:MIGRAINE_WITHOUT_AURA;LIKELIHOOD_THERAPEUTIC_FAILURE
PHENPROCOUMON;PROC;CC;rs1799808;DOSAGE, METABOLISM/PK;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
LAMOTRIGINE;UGT2B7;CT + TT;rs7668258;METABOLISM/PK;INCREASED;STEADY-STATE_CONCENTRATION;;PEOPLE;DISEASE:EPILEPSY;CAUTION_DRUG_ACCUMULATION
INFLIXIMAB;TNF;GG;rs1800629;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
IMATINIB;SLC22A4;TT;rs1050152;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:GASTROINTESTINAL_STROMAL_TUMORS;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED;DOSE;;PEOPLE;DISEASE:HEART_VALVE_REPLACEMENT;CAUTION_DOSE_ADJUST
ATORVASTATIN;TNF;AA + AG;rs1800629;METABOLISM/PK;INCREASED;CONCENTRATIONS;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
IMATINIB;SLC22A5;CG + GG;rs2631367;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:GASTROINTESTINAL_STROMAL_TUMORS;LIKELIHOOD_THERAPEUTIC_SUCCESS
IMATINIB;SLC22A5;CG + GG;rs2631372;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:GASTROINTESTINAL_STROMAL_TUMORS;LIKELIHOOD_THERAPEUTIC_SUCCESS
METFORMIN;SP1;G;rs784888;METABOLISM/PK;DECREASED;CLEARANCE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
ETANERCEPT;TNF;CT + TT;rs1799724;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;EPHX1;CG;rs2260863;DOSAGE;INCREASED;DOSE;;PEOPLE;DISEASE:HEART_VALVE_REPLACEMENT;CAUTION_DOSE_ADJUST
WARFARIN;APOE;CC;rs7412;DOSAGE;DECREASED;DOSE;;PEOPLE;DISEASE:HEART_VALVE_REPLACEMENT;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
CYCLOPHOSPHAMIDE;CYP2B6;AG + GG;rs2279343;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:NON-HODGKIN_LYMPHOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP3A4;AA;rs28371759;DOSAGE;DECREASED;DOSE;;PEOPLE;DISEASE:HEART_VALVE_REPLACEMENT;CAUTION_DOSE_ADJUST
CLOPIDOGREL;ABCB1;AA;rs1045642;EFFICACY;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP1A2;GG;rs2069514;DOSAGE;DECREASED;DOSE;;PEOPLE;DISEASE:HEART_VALVE_REPLACEMENT;CAUTION_DOSE_ADJUST
IMATINIB;ABCC4;AG;rs9561765;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:GASTROINTESTINAL_STROMAL_TUMORS;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;CC;rs9923231;DOSAGE;INCREASED;DOSE;;CHILDREN;;CAUTION_DOSE_ADJUST
ATORVASTATIN;DRD3;TT;rs6280;METABOLISM/PK;INCREASED;CONCENTRATIONS;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
WARFARIN;SLC15A2;TT;rs1143671;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ATORVASTATIN;MTHFR;AA + AG;rs1801133;METABOLISM/PK;DECREASED;CONCENTRATIONS;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
LAMOTRIGINE;UGT1A4;GG + GT;rs2011425;METABOLISM/PK;DECREASED;STEADY-STATE_CONCENTRATION;;PEOPLE;DISEASE:EPILEPSY;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;EPHX1;CC;rs2260863;DOSAGE;DECREASED;DOSE;;PEOPLE;OTHER:ATRIAL_FIBRILLATION;CAUTION_DOSE_ADJUST
RITONAVIR;NR1I2;CC + CT;rs1523130;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;TT;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
L-TRYPTOPHAN;SLC22A2;CC;rs316019;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;VKORC1;AA;rs9923231;DOSAGE;INCREASED;DOSE;;PEOPLE;OTHER:ATRIAL_FIBRILLATION;CAUTION_DOSE_ADJUST
PHENPROCOUMON;VKORC1;A;rs9934438;DOSAGE;DECREASED;DOSE;;CHILDREN;;CAUTION_DOSE_ADJUST
RITONAVIR;SLCO1B1;CC + CT;rs4149056;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
RITONAVIR;ABCB1;AC + CC;rs2032582;METABOLISM/PK;;CONCENTRATIONS;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DOSE_ADJUST
ERENUMAB;RAMP1;A;rs13386048;EFFICACY;DECREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:MIGRAINE_WITH_AURA, OTHER:MIGRAINE_WITHOUT_AURA;LIKELIHOOD_THERAPEUTIC_FAILURE
ADALIMUMAB, INFLIXIMAB;TNF;GG;rs1800629;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:ANKYLOSING_SPONDYLITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ERLOTINIB;CYP1A2;AA + AG;rs2472304;METABOLISM/PK;INCREASED;CONCENTRATIONS;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
SIROLIMUS;POR;CT + TT;rs1057868;METABOLISM/PK;DECREASED;TROUGH_CONCENTRATION;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;AC;rs1057910;DOSAGE;DECREASED;DOSE;;PEOPLE;OTHER:ATRIAL_FIBRILLATION;CAUTION_DOSE_ADJUST
OLANZAPINE;BDNF;CC;rs6265;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
RITONAVIR;NR1I2;AA + AG;rs6785049;METABOLISM/PK;;CONCENTRATIONS;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DOSE_ADJUST
ERENUMAB;RAMP1;G;rs6431564;EFFICACY;INCREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:MIGRAINE_WITH_AURA, OTHER:MIGRAINE_WITHOUT_AURA;LIKELIHOOD_THERAPEUTIC_SUCCESS
INFLIXIMAB;TNF;GG;rs1800629;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
LOSARTAN;SLC22A12;CC + CT;rs1529909;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:HYPERTENSION, DISEASE:HYPERURICEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP4F2;T;rs2108622;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ERENUMAB;RAMP1;G;rs12465864;EFFICACY;DECREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:MIGRAINE_WITH_AURA, OTHER:MIGRAINE_WITHOUT_AURA;LIKELIHOOD_THERAPEUTIC_FAILURE
ADALIMUMAB, ETANERCEPT, INFLIXIMAB;TNF;GG;rs1800629;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
LOSARTAN;SLC22A12;CT + TT;rs3825016;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:HYPERTENSION, DISEASE:HYPERURICEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
ETHANOL;OPRM1;AG + GG;rs1799971;METABOLISM/PK;INCREASED;CONCENTRATIONS;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
ADALIMUMAB;TNF;GG;rs1800629;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;GT + TT;rs3745274;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
SIROLIMUS;IL10;CC;rs1800896;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
CYCLOSPORINE;ABCB1;CT;rs9282564;TOXICITY, METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;OTHER:HEART_TRANSPLANTATION;CAUTION_SIDE_EFFECT
CLADRIBINE, CYTARABINE;RRM1;AT;rs1042919;EFFICACY;DECREASED;RESPONSE;;CHILDREN;DISEASE:ACUTE_MYELOID_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
CLADRIBINE, CYTARABINE;RRM2B;AA;rs1265138;EFFICACY;INCREASED;RESPONSE;;CHILDREN;DISEASE:ACUTE_MYELOID_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;DPYD;AA;rs1801265;EFFICACY;INCREASED;RESPONSE;;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLADRIBINE, CYTARABINE;RRM1;AC + CC;rs2898950;EFFICACY;INCREASED;RESPONSE;;CHILDREN;DISEASE:ACUTE_MYELOID_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""INTERFERON ALFA-2A, RECOMBINANT"", ""INTERFERON ALFA-2B, RECOMBINANT"", ""RIBAVIRIN""";IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUPROPION;CYP2B6;AA;rs2279343;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:TOBACCO_USE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""INTERFERON ALFA-2A, RECOMBINANT"", ""INTERFERON ALFA-2B, RECOMBINANT"", ""RIBAVIRIN""";IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLADRIBINE, CYTARABINE;RRM1;GG;rs1561876;EFFICACY;DECREASED;RESPONSE;;CHILDREN;DISEASE:ACUTE_MYELOID_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
COTININE;PSMA4;A;rs57064725;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:TOBACCO_USE_DISORDER;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;ATIC;GG;rs16853826;TOXICITY;INCREASED;DISCONTINUATION;;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
METHOTREXATE;ABCC1;TT;rs35592;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:PSORIASIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
COTININE;CHRNA5;A;rs16969968;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:TOBACCO_USE_DISORDER;CAUTION_DRUG_ACCUMULATION
INFLIXIMAB;TNFRSF10A;CC;rs20575;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLADRIBINE, CYTARABINE;RRM2;GT + TT;rs1130609;EFFICACY;DECREASED;RESPONSE;;CHILDREN;DISEASE:ACUTE_MYELOID_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
"""INTERFERON ALFA-2A, RECOMBINANT"", ""INTERFERON ALFA-2B, RECOMBINANT"", ""RIBAVIRIN""";FTO;AA + AT;rs9939609;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION, DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
COTININE;;G;rs77107237;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:TOBACCO_USE_DISORDER;CAUTION_DRUG_ACCUMULATION
CLOZAPINE;DTNBP1;CT + TT;rs742105;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLADRIBINE, CYTARABINE;RRM2;CG + GG;rs5030743;EFFICACY;DECREASED;RESPONSE;;CHILDREN;DISEASE:ACUTE_MYELOID_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
COTININE;CHRNB4;A;rs10851907;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:TOBACCO_USE_DISORDER;CAUTION_DRUG_ACCUMULATION
SIROLIMUS;ABCB1;AA + AG;rs1045642;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
WARFARIN;SLCO1B3;AA;rs7311358;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;SLC15A2;AA;rs1143672;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
"""INTERFERON ALFA-2A, RECOMBINANT"", ""INTERFERON ALFA-2B, RECOMBINANT"", ""RIBAVIRIN""";IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;SLCO1B3;GG;rs4149117;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ETANERCEPT;TNF;GG;rs1800629;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
COTININE;CHRNA3;A;rs7170068;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:TOBACCO_USE_DISORDER;CAUTION_DRUG_ACCUMULATION
SUNITINIB;ABCB1;AA;rs1045642;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP4F2;CC;rs2108622;DOSAGE, EFFICACY;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
"""INTERFERON ALFA-2A, RECOMBINANT"", ""INTERFERON ALFA-2B, RECOMBINANT"", ""RIBAVIRIN""";IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUPENTHIXOL;NFKB1;CT + TT;rs230504;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
MONTELUKAST;SLCO2B1;AG;rs12422149;EFFICACY, METABOLISM/PK;DECREASED;RESPONSE;;PEOPLE;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_FAILURE
DEFERASIROX;CYP24A1;CT + TT;rs927650;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:BETA-THALASSEMIA_AND_RELATED_DISEASES;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP4F2;T;rs2108622;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
DEFERASIROX;CYP24A1;CT + TT;rs2585428;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:BETA-THALASSEMIA_AND_RELATED_DISEASES;CAUTION_DRUG_ACCUMULATION
FLUPENTHIXOL;NFKB1;AG;rs3774959;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIDEPRESSANTS;TPH2;C;rs10879346;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE POLYGLUTAMATE;IMPDH1;GG;rs4731448;METABOLISM/PK;INCREASED;CONCENTRATIONS;;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DRUG_ACCUMULATION
CARBOPLATIN, CISPLATIN;EIF3A;AA + AG;rs3740556;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE POLYGLUTAMATE;CEP72;TT;rs924607;METABOLISM/PK;INCREASED;CONCENTRATIONS;;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;IL10;TT;rs1800896;DOSAGE;DECREASED;DOSE;;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;CAUTION_DOSE_ADJUST
MIRTAZAPINE, VENLAFAXINE;TPH2;C;rs1487278;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:DEPRESSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;ABCB1;GG;rs1045642;DOSAGE;INCREASED;DOSE;;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;CAUTION_DOSE_ADJUST
BILIRUBIN;UGT1A1;GG + GT;rs4124874;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:NEOPLASMS;CAUTION_DRUG_ACCUMULATION
CARBOPLATIN, CISPLATIN;EIF3A;AA + AG;rs3740556;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:LUNG_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
DEFERASIROX;CYP24A1;CT + TT;rs2248359;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:BETA-THALASSEMIA_AND_RELATED_DISEASES;CAUTION_DRUG_ACCUMULATION
FLUPENTHIXOL;NFKB1;AT;rs230493;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE POLYGLUTAMATE;SLCO1B3;AA + AG;rs7311358;METABOLISM/PK;INCREASED;CONCENTRATIONS;;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DRUG_ACCUMULATION
NICOTINE;FMO3;AA;rs2266780;METABOLISM/PK;INCREASED;METABOLISM;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
PAZOPANIB;VEGFA;A;rs699947;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE POLYGLUTAMATE;FSTL5;AA + AC;rs3749598;METABOLISM/PK;INCREASED;CONCENTRATIONS;;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DRUG_ACCUMULATION
METHOTREXATE POLYGLUTAMATE;ATG16L1;AG + GG;rs2241880;METABOLISM/PK;INCREASED;CONCENTRATIONS;;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;CC;rs3918290;EFFICACY;INCREASED;RESPONSE;;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CT;rs776746;METABOLISM/PK;INCREASED;METABOLISM;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
THEOPHYLLINE;CYP1A2;AA + AG;rs2069514;OTHER, METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:ASTHMA;CAUTION_DRUG_ACCUMULATION
INFLIXIMAB;TNFRSF10A;CC;rs20575;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:PSORIATIC_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ADALIMUMAB, ETANERCEPT, INFLIXIMAB;TNFRSF1A;TT;rs767455;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:PSORIATIC_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
PAZOPANIB;VEGFA;G;rs2010963;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
ADALIMUMAB, ETANERCEPT, INFLIXIMAB;TNFRSF10A;CC;rs20575;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ADALIMUMAB, ETANERCEPT, INFLIXIMAB;TNFRSF1A;TT;rs767455;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
PAZOPANIB;VEGFA;T;rs833061;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
ETANERCEPT;PTTG1;CC + CT;rs2431697;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:PSORIASIS;LIKELIHOOD_THERAPEUTIC_FAILURE
CISPLATIN, GEMCITABINE;CMPK1;CC;rs4492666;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
BUPROPION, NICOTINE, VARENICLINE;CHRNA5;A;rs503464;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:TOBACCO_USE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
VORICONAZOLE;NR1I2;GG;rs6785049;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
ETANERCEPT;HLA-B;TT;rs13437088;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:PSORIASIS;LIKELIHOOD_THERAPEUTIC_FAILURE
ETANERCEPT;MAP3K1;AG + GG;rs96844;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:PSORIASIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOZAPINE;COMT;GG;rs4680;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOZAPINE;HTR1A;GG;rs6295;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETANERCEPT;GBP6;AG + GG;rs928655;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:PSORIASIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CELIPROLOL;ABCB1;G;rs1045642;METABOLISM/PK;DECREASED;CONCENTRATIONS;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
ATORVASTATIN;SLCO1B1;TT;rs4149056;EFFICACY;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
CELIPROLOL;SLCO1A2;G;rs11568563;METABOLISM/PK;DECREASED;CONCENTRATIONS;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
ETANERCEPT;IL12B;AG + GG;rs2546890;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:PSORIASIS;LIKELIHOOD_THERAPEUTIC_FAILURE
TEMOZOLOMIDE;ABCB1;AA + AG;rs1128503;METABOLISM/PK;DECREASED;CONCENTRATIONS;;PEOPLE;OTHER:GLIOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
IVACAFTOR;SLC26A9;CC + CT;rs7512462;EFFICACY;INCREASED;RESPONSE;;CHILDREN;DISEASE:CYSTIC_FIBROSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEMCITABINE;DCK;AG + GG;rs66878317;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
VORICONAZOLE;NR1I2;CC;rs3814057;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
NICOTINE;COMT;GG;rs4680;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:TOBACCO_USE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
MILNACIPRAN;ADRA2A;CC + CG;rs1800544;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM COMPOUNDS;IGF2, IGF2-AS, INS-IGF2;GG;rs4244809;EFFICACY;DECREASED;RESISTANCE;;WOMEN;DISEASE:OVARIAN_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
VORICONAZOLE;FMO3;AA;rs2266780;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
HMG_COA_REDUCTASE_INHIBITORS;SLCO1B1;GG;rs2306283;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUVOXAMINE;FGF2;CC + CT;rs1449683;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
VORICONAZOLE;POR;GG;rs10954732;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
PLATINUM COMPOUNDS;INS-IGF2;GG;rs3842761;EFFICACY;DECREASED;RESISTANCE;;WOMEN;DISEASE:OVARIAN_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
MILNACIPRAN;HTR1A;CC + CG;rs6295;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
VALPROIC ACID;SCN2A;AA + AG;rs17183814;EFFICACY;INCREASED;RESISTANCE;;CHILDREN;OTHER:EPILEPSY;LIKELIHOOD_THERAPEUTIC_FAILURE
VALPROIC ACID;SCN1A;TT;rs2298771;EFFICACY;INCREASED;CLINICAL_BENEFIT;;CHILDREN;OTHER:EPILEPSY;LIKELIHOOD_THERAPEUTIC_SUCCESS
VORICONAZOLE;NR1I2;AA;rs2461817;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
VORICONAZOLE;NR1I2;GG;rs3732359;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;ABCC2;TT;rs3740066;METABOLISM/PK;DECREASED;CONCENTRATIONS;;CHILDREN;DISEASE:OSTEOSARCOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
CISPLATIN, GEMCITABINE;RRM1;TT;rs720106;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
VORICONAZOLE;NR1I2;AA;rs7643645;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
SIMVASTATIN;SLCO1B1;AA;rs2306283;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN, GEMCITABINE;RRM1;AA;rs232043;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
CISPLATIN, GEMCITABINE;CMPK1;CC;rs11211524;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
SIMVASTATIN;SLCO1B1;GG;rs2306283;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN, GEMCITABINE;RRM1;TT;rs2284449;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
ACENOCOUMAROL;GGCX;G;rs11676382;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;CYP4F2;T;rs2108622;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;VKORC1;T;rs7294;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
METHOTREXATE;NR1I2;G;rs6785049;METABOLISM/PK;INCREASED;CONCENTRATIONS;;CHILDREN;DISEASE:OSTEOSARCOMA;CAUTION_DRUG_ACCUMULATION
RITUXIMAB;TGFB1;AG;rs1800470;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
RITUXIMAB;TGFB1;CG;rs1800471;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;A;rs12980275;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;T;rs8099917;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
SIMVASTATIN;CYP3A4;A;rs35599367;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:HYPERCHOLESTEROLEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
PIOGLITAZONE;ADIPOQ;GT;rs2241766;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:DIABETES_MELLITUS;LIKELIHOOD_THERAPEUTIC_SUCCESS
MORPHINE;OPRM1;GG;rs1799971;DOSAGE, EFFICACY;INCREASED;DOSE;;PEOPLE;DISEASE:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
MORPHINE;OPRM1;GG;rs1799971;DOSAGE, EFFICACY;INCREASED;DOSE;;WOMEN;DISEASE:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;VKORC1;T;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ROSUVASTATIN;CYP3A5;C;rs776746;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:MYOCARDIAL_INFARCTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;GSK3B;A;rs3732361;METABOLISM/PK;INCREASED;CONCENTRATIONS;;CHILDREN;DISEASE:OSTEOSARCOMA;CAUTION_DRUG_ACCUMULATION
NALOXONE;OPRM1;AG + GG;rs1799971;OTHER;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TIPIFARNIB;ABCB1;AA;rs1128503;OTHER, METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
ETANERCEPT;ZNF816;CC;rs9304742;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:PSORIASIS;LIKELIHOOD_THERAPEUTIC_FAILURE
ROSUVASTATIN;ABCG2;T;rs2231142;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:MYOCARDIAL_INFARCTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
NALTREXONE;OPRM1;G;rs1799971;EFFICACY;INCREASED;RESPONSE;;MEN;DISEASE:ALCOHOL_ABUSE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIPSYCHOTICS;NRG1;G;rs13250975;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;AA;rs9934438;DOSAGE;DECREASED;DOSE;;CHILDREN;DISEASE:HEART_DISEASES;CAUTION_DOSE_ADJUST
METHOTREXATE;SLCO1A2;CC + CT;rs4149009;METABOLISM/PK;DECREASED;CLEARANCE;;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DRUG_ACCUMULATION
ANTIPSYCHOTICS;;A;rs2513265;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIPSYCHOTICS;ADCY2;C;rs1544938;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIPSYCHOTICS;NRG1;A;rs17716295;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_FAILURE
NICOTINE;CHRNA5;GG;rs16969968;OTHER;DECREASED;DOSE;;PEOPLE;DISEASE:TOBACCO_USE_DISORDER;CAUTION_DOSE_ADJUST
METHADONE;DAO;TT;rs55944529;DOSAGE;INCREASED;DOSE;;PEOPLE;OTHER:HEROIN_DEPENDENCE;CAUTION_DOSE_ADJUST
ANTIPSYCHOTICS;CCL2;G;rs4795893;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIPSYCHOTICS;CCL2;T;rs4586;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_FAILURE
METHADONE;DAO;TT;rs55944529;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;OTHER:HEROIN_DEPENDENCE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
ESCITALOPRAM, FLUOXETINE, FLUVOXAMINE, SERTRALINE;HTR2A;GG + GT;rs3803189;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;T;rs3745274;METABOLISM/PK;INCREASED;CONCENTRATIONS;;WOMEN;OTHER:HIV_INFECTIOUS_DISEASE, OTHER:MALARIA;CAUTION_DRUG_ACCUMULATION
IVACAFTOR;CFTR;A;rs121908755;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHADONE;DRD1;TT;rs5326;DOSAGE;INCREASED;DOSE;;PEOPLE;OTHER:HEROIN_DEPENDENCE;CAUTION_DOSE_ADJUST
IVACAFTOR;CFTR;C;rs121908757;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IVACAFTOR;CFTR;A;rs80282562;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIFAMPIN;SLCO1B1;CT;rs4149056;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_DRUG_ACCUMULATION
METHYLPHENIDATE;CYP2D6;GG;rs1065852;EFFICACY;INCREASED;CLINICAL_BENEFIT;;CHILDREN;OTHER:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS
HMG_COA_REDUCTASE_INHIBITORS;SLCO1B1;CC;rs11045819;EFFICACY;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
METHYLPHENIDATE;CYP2D6;CG;rs1135840;EFFICACY;INCREASED;CLINICAL_BENEFIT;;CHILDREN;OTHER:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS
IVACAFTOR;CFTR;C;rs121909041;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PRAVASTATIN;SLCO1B1;GG;rs2306283;EFFICACY;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;AA;rs1057910;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
IVACAFTOR;CFTR;A;rs193922525;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;AA + AG;rs7196161;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
IVACAFTOR;CFTR;A;rs267606723;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP4F2;CT + TT;rs2108622;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
IVACAFTOR;CFTR;A;rs74503330;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IVACAFTOR;CFTR;G;rs121909005;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IVACAFTOR;CFTR;A;rs121909013;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SUNITINIB;GLP1R;A;rs6923761;METABOLISM/PK;DECREASED;CONCENTRATIONS;;PEOPLE;OTHER:RENAL_CELL_CARCINOMA, OTHER:GASTROINTESTINAL_STROMAL_TUMORS;LIKELIHOOD_THERAPEUTIC_FAILURE
DOXORUBICIN;ABCB1;AA;rs1128503;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:BREAST_NEOPLASMS;CAUTION_DRUG_ACCUMULATION
ATOMOXETINE;CYP2D6;CC;rs1135840;EFFICACY;INCREASED;CLINICAL_BENEFIT;;CHILDREN;OTHER:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS
BETA BLOCKING AGENTS;GRK5;A;rs3740563;EFFICACY;DECREASED;RESPONSE;;PEOPLE;OTHER:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IFNG;G;rs2069705;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
MONTELUKAST;MLLT3;AA;rs6475448;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
BETA BLOCKING AGENTS;GRK5;A;rs10787959;EFFICACY;DECREASED;RESPONSE;;PEOPLE;OTHER:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
BUPROPION;;C;rs1908557;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:DEPRESSION;LIKELIHOOD_THERAPEUTIC_FAILURE
BETA BLOCKING AGENTS;GRK5;A;rs11198893;EFFICACY;DECREASED;RESPONSE;;PEOPLE;OTHER:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
RIFAMPIN;CYP27B1;AG + GG;rs4646536;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_DRUG_ACCUMULATION
CORTICOSTEROIDS;ST13;G;rs138335;EFFICACY;DECREASED;RESPONSE;;CHILDREN;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_FAILURE
RIFAMPIN;VDR;TT;rs1544410;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_DRUG_ACCUMULATION
DOCETAXEL;CYP3A4;C;rs2740574;METABOLISM/PK;INCREASED;CLEARANCE;;PEOPLE;DISEASE:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
METHADONE;CYP2B6;GG + GT;rs3745274;DOSAGE;INCREASED;DOSE;;PEOPLE;DISEASE:HEROIN_DEPENDENCE;CAUTION_DOSE_ADJUST
DOCETAXEL;CYP3A5;T;rs776746;METABOLISM/PK;INCREASED;CLEARANCE;;PEOPLE;DISEASE:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
HMG_COA_REDUCTASE_INHIBITORS;SLCO1B1;C;rs4149056;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:CARDIOVASCULAR_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
RAMIPRIL;ADRB2;AA + AG;rs2053044;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;COMT;GG;rs4680;DOSAGE;INCREASED;DOSE;;WOMEN;OTHER:BREAST_NEOPLASMS, OTHER:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
METHADONE;NGF;AA;rs2239622;DOSAGE;DECREASED;DOSE;;PEOPLE;DISEASE:OPIOID-RELATED_DISORDERS;CAUTION_DOSE_ADJUST
NICOTINE;CYP1A2;T/del + del/del;rs35694136;EFFICACY;INCREASED;EXPOSURE;;MEN;OTHER:URINARY_BLADDER_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHADONE;CYP2B6;AA + AG;rs2279343;DOSAGE;INCREASED;DOSE;;PEOPLE;DISEASE:HEROIN_DEPENDENCE;CAUTION_DOSE_ADJUST
GEMCITABINE;NT5C3A;AA;rs3750117;OTHER, METABOLISM/PK;INCREASED;CLEARANCE;;PEOPLE;DISEASE:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
GEMCITABINE;NT5C2;TT;rs11598702;OTHER, METABOLISM/PK;DECREASED;CLEARANCE;;PEOPLE;DISEASE:NEOPLASMS;CAUTION_DRUG_ACCUMULATION
FENTANYL, REMIFENTANIL;PGAP6;T;rs199670311;EFFICACY;INCREASED;DOSE;;PEOPLE;DISEASE:PAIN;LIKELIHOOD_THERAPEUTIC_SUCCESS
OLANZAPINE;UGT1A4;GT;rs2011425;METABOLISM/PK;DECREASED;CONCENTRATIONS;;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIDEPRESSANTS;ADCY9;CC;rs2230739;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
DABIGATRAN;CES1;GG + GT;rs2244613;METABOLISM/PK;DECREASED;CONCENTRATIONS;;PEOPLE;OTHER:STROKE;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIPSYCHOTICS;PI4KA;AG + GG;rs165854;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIPSYCHOTICS;GRM3;AA + AT;rs1468412;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_FAILURE
BUDESONIDE, CORTICOSTEROIDS, FLUTICASONE / SALMETEROL, FLUTICASONE PROPIONATE;ZNF432;TT;rs3752120;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_FAILURE
AZATHIOPRINE;ITPA;AA + AC;rs1127354;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:SYSTEMIC_LUPUS_ERYTHEMATOSUS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBOPLATIN, DOCETAXEL, TRASTUZUMAB;ERBB2;G;rs1136201;EFFICACY;DECREASED;RESPONSE;;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIPSYCHOTICS;SLC1A3;AA + AG;rs1529461;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIPSYCHOTICS;GRM3;CC;rs2299214;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBOPLATIN, DOCETAXEL, TRASTUZUMAB;RNF8;A;rs2284922;EFFICACY;INCREASED;RESPONSE;;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIPSYCHOTICS;GRM3;AG + GG;rs6465084;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBOPLATIN, DOCETAXEL, TRASTUZUMAB;BARD1;A;rs2070096;EFFICACY;DECREASED;RESPONSE;;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
GEMCITABINE;CDA;CC;rs1048977;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBOPLATIN, DOCETAXEL, TRASTUZUMAB;ERBB3;C;rs2229046;EFFICACY;DECREASED;RESPONSE;;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
CORTICOSTEROIDS;ST13;G;rs138337;EFFICACY;DECREASED;RESPONSE;;CHILDREN;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_FAILURE
CARBOPLATIN, DOCETAXEL, TRASTUZUMAB;ERBB3;A;rs773123;EFFICACY;DECREASED;RESPONSE;;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIPSYCHOTICS;SLC1A4;AA;rs10211524;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;GRM3;CC + CT;rs2299214;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_FAILURE
PRAVASTATIN;SLCO1B1;CC + CT;rs4149056;EFFICACY;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
SUFENTANIL;COMT;AA;rs4680;DOSAGE, EFFICACY;DECREASED;DOSE;;CHILDREN;;CAUTION_DOSE_ADJUST
FLUINDIONE;VKORC1;TT;rs9923231;METABOLISM/PK;;DOSE;;CHILDREN;;CAUTION_DOSE_ADJUST
APREMILAST;LEPR, LEPROT;AA + AG;rs1045895;EFFICACY;DECREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:PSORIASIS;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;AC;rs1057910;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
OPIOIDS;ABCB1;AA;rs1045642;DOSAGE, EFFICACY;DECREASED;DOSE;;PEOPLE;DISEASE:NEOPLASMS, DISEASE:PAIN;CAUTION_DOSE_ADJUST
CARBOPLATIN, CISPLATIN;AKT1;AG;rs2494752;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
QUINAPRIL;AGT;GG;rs699;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;KCNJ6;CC;rs6517442;DOSAGE;INCREASED;DOSE;;PEOPLE;OTHER:LOW_BACK_PAIN;CAUTION_DOSE_ADJUST
OLANZAPINE;CYP1A2;T/del;rs35694136;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_DRUG_ACCUMULATION
OPIOIDS;OPRM1;AG + GG;rs1799971;DOSAGE, EFFICACY;INCREASED;DOSE;;PEOPLE;DISEASE:NEOPLASMS, DISEASE:PAIN;CAUTION_DOSE_ADJUST
OLANZAPINE;CYP1A2;AA;rs762551;METABOLISM/PK;DECREASED;CONCENTRATIONS;;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_FAILURE
FENTANYL;OPRM1;GG;rs1799971;DOSAGE, EFFICACY;INCREASED;DOSE;;PEOPLE;DISEASE:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
ROSUVASTATIN;ABCG2;GT + TT;rs2231142;METABOLISM/PK;INCREASED;EXPOSURE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
PHENPROCOUMON;CYP4F2;TT;rs2108622;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
CAPECITABINE, FLUOROURACIL, TEGAFUR;TYMS;C;rs183205964;TOXICITY;INCREASED;DISCONTINUATION;;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
KETOPROFEN;CYP2C9;AC;rs1057910;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:POSTOPERATIVE_PAIN;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATORVASTATIN;ABCB1;GG;rs1045642;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
IMATINIB;SLC22A1;CC;rs683369;METABOLISM/PK;INCREASED;CLEARANCE;;PEOPLE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;LIKELIHOOD_THERAPEUTIC_FAILURE
CAFFEINE;CYP1A2;AA;rs762551;OTHER, METABOLISM/PK;INCREASED;METABOLISM;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
IMATINIB;SLC22A1;CC;rs683369;METABOLISM/PK;DECREASED;CONCENTRATIONS;;PEOPLE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;LIKELIHOOD_THERAPEUTIC_FAILURE
ETANERCEPT;TNFRSF1B;GT;rs1061622;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:ANKYLOSING_SPONDYLITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
FENTANYL, REMIFENTANIL;SLC9A9;GG;rs4839603;EFFICACY;DECREASED;DOSE;;PEOPLE;DISEASE:PAIN;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;T;rs3745274;EFFICACY;DECREASED;CLEARANCE;;CHILDREN;DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
APREMILAST;PDE4B;T;rs12745871;EFFICACY;INCREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:PSORIASIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATORVASTATIN;SCARB1;AA;rs5888;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HYPERCHOLESTEROLEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
APREMILAST;TSPAN16;C;rs322144;EFFICACY;DECREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:PSORIASIS;LIKELIHOOD_THERAPEUTIC_FAILURE
PRAVASTATIN;FCAR;AA + AG;rs11666735;EFFICACY;INCREASED;RESPONSE;;MEN;DISEASE:MYOCARDIAL_INFARCTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE, EPIRUBICIN;GSTP1;AA + AG;rs1695;EFFICACY;INCREASED;RESPONSE;;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
FENOFIBRATE;APOA1;G;rs964184;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HYPERTRIGLYCERIDEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIEPILEPTICS;SCN1A;CT;rs10188577;EFFICACY;INCREASED;RESISTANCE;;PEOPLE;DISEASE:EPILEPSY;LIKELIHOOD_THERAPEUTIC_FAILURE
APREMILAST;DOCK6;G;rs12979813;EFFICACY;INCREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:PSORIASIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
DAPTOMYCIN;ABCB1;AA;rs1045642;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
NALTREXONE;DBH;CT + TT;rs1611115;EFFICACY;INCREASED;RESPONSE;;MEN;DISEASE:ALCOHOL_ABUSE;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEMCITABINE;SLC28A2;CC;rs11854484;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTINEOPLASTIC AGENTS;ABCG2;GG;rs2231142;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
GEMCITABINE;SLC28A2;CC;rs1060896;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
APREMILAST;EIF3G, P2RY11, PPAN-P2RY11;G;rs2305795;EFFICACY;INCREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:PSORIASIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNFRSF1A;TT;rs767455;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
ACENOCOUMAROL;VKORC1;TT;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
METHOTREXATE;SLCO1B1;CC + CT;rs4149056;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:OSTEOSARCOMA;CAUTION_DRUG_ACCUMULATION
DRUGS FOR TREATMENT OF TUBERCULOSIS;METTL3;GG;rs1139130;EFFICACY;INCREASED;RESISTANCE;;PEOPLE;OTHER:TUBERCULOSIS;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;SLCO1B1;CC + CT;rs11045879;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:OSTEOSARCOMA;CAUTION_DRUG_ACCUMULATION
SUFENTANIL;OPRM1;AG;rs1799971;DOSAGE;INCREASED;DOSE;;PEOPLE;OTHER:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
APREMILAST;ILF3;T;rs76966440;EFFICACY;INCREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:PSORIASIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;AA;rs9934438;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;GSTP1;A;rs1695;EFFICACY;INCREASED;RESPONSE;;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
SULFASALAZINE;ABCG2;GT + TT;rs2231142;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;TT;rs9923231;DOSAGE;DECREASED;DOSE;;CHILDREN;;CAUTION_DOSE_ADJUST
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;T;rs8099917;EFFICACY;INCREASED;RESPONSE;;CHILDREN;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;CC + CT;rs9923231;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
TACROLIMUS;ABCB1;AG + GG;rs1128503;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:ULCERATIVE_COLITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP4F2;TT;rs2108622;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ROSUVASTATIN;SLCO1B1;CC + CT;rs4149056;METABOLISM/PK;INCREASED;EXPOSURE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;PRSS53, VKORC1;AA + AG;rs9934438;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;T;rs12979860;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON ALFA-2B, RIBAVIRIN;VDR;A;rs2228570;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
NORTRIPTYLINE;NOS3;TT;rs1799983;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:MIGRAINE_WITHOUT_AURA, OTHER:MIGRAINE_WITH_AURA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ALLOPURINOL;GREM2;T;rs1934341;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
COTININE;NAT1;AG + GG;rs13253389;METABOLISM/PK;INCREASED;CONCENTRATIONS;;CHILDREN;;CAUTION_DRUG_ACCUMULATION
ALLOPURINOL;GREM2;G;rs77567654;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;ABCB1;CC;rs2032582;DOSAGE;INCREASED;DOSE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
ALLOPURINOL;ABCG2;C;rs45499402;EFFICACY;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ALLOPURINOL;ABCG2;T;rs2231142;EFFICACY;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
EXENATIDE;GLP1R;T;rs10305420;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_FAILURE
TOPIRAMATE;ABCB1;AA;rs1045642;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:MIGRAINE_WITHOUT_AURA, OTHER:MIGRAINE_WITH_AURA;LIKELIHOOD_THERAPEUTIC_SUCCESS
LAMOTRIGINE;UGT2B7;TT;rs7668258;METABOLISM/PK;DECREASED;CLEARANCE;;PEOPLE;DISEASE:EPILEPSY;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;TT;rs7294;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
BENAZEPRIL;AGT;GG;rs4762;EFFICACY;;RESPONSE;;MEN;DISEASE:HYPERTENSION;CAUTION_DOSE_ADJUST
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION, DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
IMATINIB;ABCB1;GG;rs1128503;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;LIKELIHOOD_THERAPEUTIC_SUCCESS
LAMOTRIGINE;UGT2B7;GG;rs28365063;METABOLISM/PK;INCREASED;CLEARANCE;;PEOPLE;DISEASE:EPILEPSY;LIKELIHOOD_THERAPEUTIC_FAILURE
3,4-METHYLENEDIOXYMETHAMPHETAMINE;CYP2B6;TT;rs3745274;METABOLISM/PK;INCREASED;CONCENTRATIONS;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;TT;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
METHOTREXATE;ABCC4;GG;rs7317112;METABOLISM/PK;INCREASED;CLEARANCE;;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
BENAZEPRIL;AGTR1;GG;rs2640543;EFFICACY;;RESPONSE;;WOMEN;DISEASE:HYPERTENSION;CAUTION_DOSE_ADJUST
ALENDRONATE;MVK;GG;rs10161126;EFFICACY;INCREASED;RESPONSE;;WOMEN;DISEASE:BONE_DISEASES;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B, RIBAVIRIN;ITPA;A;rs1127354;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
SARILUMAB;IL6R;CC;rs11265618;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;LDLR;GG;rs14158;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION, DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
BENAZEPRIL;SPTA1;G;rs2106089;EFFICACY;;RESPONSE;;MEN;DISEASE:HYPERTENSION;CAUTION_DOSE_ADJUST
IMATINIB;ABCB1;GG;rs1045642;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;TT;rs776746;METABOLISM/PK;INCREASED;CLEARANCE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
SARILUMAB;IL6R;TT;rs4329505;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
LOSARTAN;CYP2C9;AT + TT;rs1934969;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
IMATINIB;ABCB1;C;rs2032582;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUPRENORPHINE;OPRD1;CC;rs678849;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:OPIOID-RELATED_DISORDERS;LIKELIHOOD_THERAPEUTIC_FAILURE
PHENPROCOUMON;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ADALIMUMAB, CERTOLIZUMAB PEGOL, ETANERCEPT, INFLIXIMAB, TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;NCR3;AT + TT;rs1052248;EFFICACY;INCREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
SALBUTAMOL;COL2A1;GT + TT;rs3809324;PD;DECREASED;RESPONSE;;CHILDREN;OTHER:ASTHMA;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIPSYCHOTICS;CACNA1C;CC;rs2238087;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""DIURETICS"", ""HYDROCHLOROTHIAZIDE"", ""THIAZIDES, PLAIN""";PRKCA;T;rs4791040;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIPSYCHOTICS;CACNA1B;CC;rs2229949;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACENOCOUMAROL;STX4;T;rs10871454;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP4F2;CT + TT;rs2108622;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;;AA + AG;rs12777823;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
CORTICOSTEROIDS;GLCCI1;GG;rs37973;EFFICACY;DECREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:RHINITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
DEFERASIROX;GC;AA;rs7041;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:BETA-THALASSEMIA_AND_RELATED_DISEASES;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACENOCOUMAROL;VKORC1;TT;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;VKORC1;AA + AG;rs9934438;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;GG + GT;rs8099917;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_FAILURE
ASPIRIN, CLOPIDOGREL;CYP4F2;CC + CT;rs2108622;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;LIKELIHOOD_THERAPEUTIC_FAILURE
ACENOCOUMAROL;CYP4F2;T;rs2108622;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;AA + AG;rs9934438;DOSAGE;DECREASED;DOSE;;PEOPLE;DISEASE:CARDIOVASCULAR_DISEASE;CAUTION_DOSE_ADJUST
METHYLPHENIDATE;CES1;T;rs71647871;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;CT + TT;rs7294;DOSAGE;INCREASED;DOSE;;PEOPLE;DISEASE:CARDIOVASCULAR_DISEASE;CAUTION_DOSE_ADJUST
INTERFERON BETA-1A, INTERFERON BETA-1B;CD58;CC;rs12044852;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:MULTIPLE_SCLEROSIS;LIKELIHOOD_THERAPEUTIC_FAILURE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNFAIP3;GG + GT;rs610604;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:PSORIATIC_ARTHRITIS,  OTHER:PSORIASIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
MORPHINE;OPRM1;AG + GG;rs1799971;EFFICACY;DECREASED;RESPONSE;;CHILDREN;;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;VKORC1;TT;rs9923231;DOSAGE;DECREASED;DOSE;;PEOPLE;DISEASE:CARDIOVASCULAR_DISEASE;CAUTION_DOSE_ADJUST
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNFAIP3;AA;rs6920220;EFFICACY;DECREASED;RESPONSE;;PEOPLE;OTHER:PSORIATIC_ARTHRITIS,  OTHER:PSORIASIS;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP4F2;CC + CT;rs2108622;DOSAGE;DECREASED;DOSE;;PEOPLE;DISEASE:CARDIOVASCULAR_DISEASE;CAUTION_DOSE_ADJUST
ANTIPSYCHOTICS;CACNB2;TT;rs12245847;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A7;C;rs2257401;METABOLISM/PK;;TROUGH_CONCENTRATION;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION, DISEASE:TRANSPLANTATION;CAUTION_DOSE_ADJUST
DEFERASIROX;UGT1A1;CC;rs887829;EFFICACY;DECREASED;RESPONSE;;PEOPLE;OTHER:BETA-THALASSEMIA_AND_RELATED_DISEASES;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIPSYCHOTICS;CACNG3;TT;rs1859204;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;C;rs776746;METABOLISM/PK;;TROUGH_CONCENTRATION;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION, DISEASE:TRANSPLANTATION;CAUTION_DOSE_ADJUST
DEFERASIROX;UGT1A3;TT;rs1983023;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:BETA-THALASSEMIA_AND_RELATED_DISEASES;LIKELIHOOD_THERAPEUTIC_SUCCESS
DEFERASIROX;CYP27B1;GG;rs10877012;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:BETA-THALASSEMIA_AND_RELATED_DISEASES;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A4;A;rs4646437;METABOLISM/PK;;TROUGH_CONCENTRATION;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION, DISEASE:TRANSPLANTATION;CAUTION_DOSE_ADJUST
ADALIMUMAB;ATG16L1;CT + TT;rs10210302;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:CROHN_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIPSYCHOTICS;CACNB2;CC;rs982003;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A4;T;rs2242480;METABOLISM/PK;;TROUGH_CONCENTRATION;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION, DISEASE:TRANSPLANTATION;CAUTION_DOSE_ADJUST
DEFERASIROX;VDR;GG;rs731236;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:BETA-THALASSEMIA_AND_RELATED_DISEASES;LIKELIHOOD_THERAPEUTIC_SUCCESS
DEFERASIROX;VDR;TT;rs1544410;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:BETA-THALASSEMIA_AND_RELATED_DISEASES;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;A;rs41303343;METABOLISM/PK;;TROUGH_CONCENTRATION;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION, DISEASE:TRANSPLANTATION;CAUTION_DOSE_ADJUST
CAPECITABINE, FLUOROURACIL, IRINOTECAN, LEUCOVORIN;SLC19A1;CC;rs1051266;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE, FLUOROURACIL, IRINOTECAN, LEUCOVORIN;SLCO1B1;AA + AG;rs2306283;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;A;rs4646450;METABOLISM/PK;;TROUGH_CONCENTRATION;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION, DISEASE:TRANSPLANTATION;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2B6;TT;rs3745274;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
SIMVASTATIN ACID;SLCO1B1;CC + CT;rs4149056;METABOLISM/PK;INCREASED;CONCENTRATIONS;;CHILDREN;;CAUTION_DRUG_ACCUMULATION
"""DIURETICS"", ""HYDROCHLOROTHIAZIDE"", ""THIAZIDES, PLAIN""";;A;rs2776546;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;CG;rs28371686;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ANTIPSYCHOTICS;CACNB2;TT;rs10741058;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATAZANAVIR;UGT1A1;TT;rs887829;TOXICITY;INCREASED;DISCONTINUATION;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
"""DIURETICS"", ""HYDROCHLOROTHIAZIDE"", ""THIAZIDES, PLAIN""";;A;rs238;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIPSYCHOTICS;CACNA2D3;AA;rs4505744;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""DIURETICS"", ""HYDROCHLOROTHIAZIDE"", ""THIAZIDES, PLAIN""";;T;rs4815273;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
IBUPROFEN;CYP2C9;AC;rs1057910;EFFICACY;DECREASED;TIME_RESPONSE;;INFANTS;OTHER:PATENT_DUCTUS_ARTERIOSUS;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIPSYCHOTICS;CACNA1E;TT;rs12060765;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CORTICOSTEROIDS;TAAR6;GG;rs7772821;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
SALBUTAMOL;VEGFA;CT + TT;rs3025039;PD;DECREASED;RESPONSE;;CHILDREN;OTHER:ASTHMA;LIKELIHOOD_THERAPEUTIC_FAILURE
BEVACIZUMAB, RANIBIZUMAB;CFH;CC;rs1061170;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:MACULAR_DEGENERATION;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP4F2;T;rs2108622;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
MORPHINE;TAOK3;TT;rs795484;DOSAGE, EFFICACY;INCREASED;DOSE;;CHILDREN;DISEASE:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
PREDNISONE;NR3C1;G;rs6196;EFFICACY;DECREASED;RESISTANCE;;PEOPLE;DISEASE:NEPHROTIC_SYNDROME;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACENOCOUMAROL;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
IRINOTECAN_SN-38;UGT1A1;AA;rs4148323;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_DRUG_ACCUMULATION
DOCETAXEL;;G;rs4842198;METABOLISM/PK;INCREASED;METABOLISM;;PEOPLE;DISEASE:NASOPHARYNGEAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUVOXAMINE;HTR2A;CC;rs6311;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;SLCO1C1;AG + GG;rs3794271;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:PSORIASIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACENOCOUMAROL;VKORC1;AA + AG;rs9934438;DOSAGE, EFFICACY;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
PREDNISONE;NR3C1;A;rs258751;EFFICACY;DECREASED;RESISTANCE;;PEOPLE;DISEASE:NEPHROTIC_SYNDROME;LIKELIHOOD_THERAPEUTIC_SUCCESS
LEDIPASVIR, SOFOSBUVIR;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN_SN-38;UGT1A9;del/del;rs3832043;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_DRUG_ACCUMULATION
PHENYTOIN;CYP2C9;G;rs28371686;OTHER, METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;OTHER:NO_DISEASE;CAUTION_DRUG_ACCUMULATION
IMATINIB;ABCG2;CT + TT;rs2231137;DOSAGE;DECREASED;DOSE;;PEOPLE;OTHER:GASTROINTESTINAL_STROMAL_TUMORS;CAUTION_DOSE_ADJUST
PREDNISONE;NR3C1;A;rs10052957;EFFICACY;DECREASED;RESISTANCE;;PEOPLE;DISEASE:NEPHROTIC_SYNDROME;LIKELIHOOD_THERAPEUTIC_SUCCESS
IMATINIB;CYP1A2;CC;rs762551;DOSAGE;DECREASED;DOSE;;PEOPLE;OTHER:GASTROINTESTINAL_STROMAL_TUMORS;CAUTION_DOSE_ADJUST
PHENYTOIN;CYP2C9;A;rs7900194;OTHER, METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;OTHER:NO_DISEASE;CAUTION_DRUG_ACCUMULATION
LURASIDONE;HTR1A;CG + GG;rs6295;EFFICACY;DECREASED;RESPONSE;;PEOPLE;OTHER:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_FAILURE
PHENYTOIN;CYP2C9;T;rs28371685;OTHER, METABOLISM/PK;INCREASED;METABOLISM;;PEOPLE;PK:NO_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
PHENYTOIN;CYP2C9;del;rs9332131;OTHER, METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;PK:NO_DISEASE;CAUTION_DRUG_ACCUMULATION
DOCETAXEL;RXRA;A;rs3132291;METABOLISM/PK;INCREASED;METABOLISM;;PEOPLE;DISEASE:NASOPHARYNGEAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
INFLIXIMAB;TNFRSF1B;G;rs1061622;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
METFORMIN;SLC22A1;TT;rs12208357;METABOLISM/PK;DECREASED;EXPOSURE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
CODEINE;OPRM1;AA;rs1799971;DOSAGE;DECREASED;DOSE;;WOMEN;;CAUTION_DOSE_ADJUST
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
CODEINE;UGT2B7;TT;rs7439366;DOSAGE;DECREASED;DOSE;;WOMEN;;CAUTION_DOSE_ADJUST
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIPSYCHOTICS;CACNB2;CC;rs4237348;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A4;T;rs2740574;METABOLISM/PK;;TROUGH_CONCENTRATION;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION, DISEASE:TRANSPLANTATION;CAUTION_DOSE_ADJUST
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIPSYCHOTICS;CACNB4;AA + AC;rs3768652;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A4;A;rs35599367;METABOLISM/PK;;TROUGH_CONCENTRATION;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION, DISEASE:TRANSPLANTATION;CAUTION_DOSE_ADJUST
ANTIPSYCHOTICS;CACNA2D3;CC;rs7427395;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIPSYCHOTICS;CACNB2;TT;rs1277733;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
SOFOSBUVIR;CES1;A;rs4513095;EFFICACY;DECREASED;RESPONSE;;PEOPLE;OTHER:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CT;rs776746;METABOLISM/PK;INCREASED;CLEARANCE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
PROPOFOL;SCN9A;AA + AG;rs6746030;OTHER;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CC;rs776746;DOSAGE;DECREASED;DOSE;;CHILDREN;DISEASE:TRANSPLANTATION;CAUTION_DOSE_ADJUST
SALBUTAMOL;PRKG1;A;rs7081864;EFFICACY;DECREASED;CLINICAL_BENEFIT;;CHILDREN;OTHER:ASTHMA;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;C;rs776746;DOSAGE;DECREASED;DOSE;;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TOCILIZUMAB;IL6R;AA;rs12083537;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIPSYCHOTICS;BDNF;AG + GG;rs11030104;EFFICACY;INCREASED;RESISTANCE;;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_FAILURE
SUNITINIB;ABCB1;GG;rs1045642;METABOLISM/PK;INCREASED;EXPOSURE;;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;CAUTION_DRUG_ACCUMULATION
PROPOFOL;HTR2A;AA;rs6313;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ANTIPSYCHOTICS;BDNF-AS;CC + CT;rs10501087;EFFICACY;INCREASED;RESISTANCE;;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_FAILURE
PROPOFOL;GABRA1;GG;rs2279020;OTHER;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SUNITINIB;ABCB1;GG;rs1045642;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;DECREASED;CLEARANCE;;CHILDREN;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
OPIOIDS;COMT;AA + AG;rs4680;EFFICACY;INCREASED;RESPONSE;;CHILDREN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CT;rs776746;DOSAGE;INCREASED;DOSE;;CHILDREN;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
DOXORUBICIN, METHOTREXATE, PREDNISOLONE, VINCRISTINE;ABCB1;AA;rs1045642;EFFICACY;DECREASED;RESISTANCE;;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIPSYCHOTICS;BDNF;CT + TT;rs6265;EFFICACY;INCREASED;RESISTANCE;;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_FAILURE
OPIOIDS;COMT;AG;rs4680;DOSAGE;DECREASED;DOSE;;CHILDREN;;CAUTION_DOSE_ADJUST
"""METFORMIN"", ""SULFONAMIDES, UREA DERIVATIVES""";ABCC8, KCNJ11;CT + TT;rs5219;EFFICACY;INCREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
PALIPERIDONE, RISPERIDONE;NFIB;CT;rs28379954;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
REMIFENTANIL, SEVOFLURANE;ABCB1;GG;rs1128503;EFFICACY;INCREASED;RESPONSE;;CHILDREN;OTHER:TONSILLECTOMY;LIKELIHOOD_THERAPEUTIC_SUCCESS
MORPHINE;TAOK3;GG;rs1277441;DOSAGE, EFFICACY;INCREASED;DOSE;;CHILDREN;DISEASE:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
DOXORUBICIN, METHOTREXATE, PREDNISOLONE, VINCRISTINE;ABCB1;CT;rs2229109;EFFICACY;INCREASED;RESISTANCE;;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
HYDROXYUREA;KLF4;C;rs2236599;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:SICKLE_CELL_ANEMIA,  OTHER:BETA-THALASSEMIA_AND_RELATED_DISEASES;LIKELIHOOD_THERAPEUTIC_SUCCESS
OXYCODONE;OPRM1;GG;rs1799971;DOSAGE;INCREASED;DOSE;;WOMEN;OTHER:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A4;CT + TT;rs2242480;METABOLISM/PK;INCREASED;CLEARANCE;;PEOPLE;OTHER:HEART_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;SLCO1B1;A;rs11045821;EFFICACY, TOXICITY, METABOLISM/PK;DECREASED;CLEARANCE;;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
METHYLPHENIDATE;SLC6A2;AT + TT;rs28386840;EFFICACY;INCREASED;RESPONSE;;CHILDREN;DISEASE:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS
BILIRUBIN;UGT1A;AG + GG;rs11563250;METABOLISM/PK;DECREASED;CONCENTRATIONS;;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
DEFERASIROX;UGT1A3;CT + TT;rs1983023;METABOLISM/PK;DECREASED;CONCENTRATIONS;;PEOPLE;DISEASE:BETA-THALASSEMIA_AND_RELATED_DISEASES;LIKELIHOOD_THERAPEUTIC_FAILURE
ADALIMUMAB, CERTOLIZUMAB PEGOL, ETANERCEPT, INFLIXIMAB, TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;CERS6;A;rs13393173;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
MORPHINE;SLC22A1;CT + TT;rs12208357;METABOLISM/PK;DECREASED;CLEARANCE;;CHILDREN;;CAUTION_DRUG_ACCUMULATION
MIDAZOLAM;CYP3A4;AG;rs35599367;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:NEOPLASMS;CAUTION_DRUG_ACCUMULATION
MORPHINE;SLC22A1;CC + CT;rs55918055;METABOLISM/PK;DECREASED;CLEARANCE;;CHILDREN;;CAUTION_DRUG_ACCUMULATION
BUPROPION, DRUGS USED IN NICOTINE DEPENDENCE;CYP2A6;T;rs4803381;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:TOBACCO_USE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
METFORMIN;SRR;CC + CT;rs391300;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHYLPHENIDATE;SLC6A2;AG + GG;rs5569;EFFICACY;INCREASED;RESPONSE;;CHILDREN;DISEASE:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS
ERYTHROMYCIN;CYP3A4;AG;rs35599367;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:NEOPLASMS;CAUTION_DRUG_ACCUMULATION
NICOTINE;CYP2A6;T;rs4803381;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
CLOZAPINE;ABCB1;G;rs7787082;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_FAILURE
CAFFEINE;CYP1A2;AA + AC;rs762551;METABOLISM/PK;INCREASED;METABOLISM;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
ATENOLOL;;AA + AC;rs12346562;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
HYDROCHLOROTHIAZIDE;;AA + AC;rs12346562;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_FAILURE
ATENOLOL;;AA + AG;rs1104514;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
MORPHINE;SLC22A1;AA + AG;rs34130495;METABOLISM/PK;DECREASED;CLEARANCE;;CHILDREN;;CAUTION_DRUG_ACCUMULATION
ATENOLOL;;GG + GT;rs10739150;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOZAPINE;ABCB1;A;rs10248420;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_FAILURE
DEFERASIROX;UGT1A3;CC;rs3806596;EFFICACY, METABOLISM/PK;INCREASED;RESPONSE;;PEOPLE;DISEASE:BETA-THALASSEMIA_AND_RELATED_DISEASES;LIKELIHOOD_THERAPEUTIC_SUCCESS
TRANDOLAPRIL, VERAPAMIL;PTPRD;T;rs4742610;EFFICACY;;RESISTANCE;;PEOPLE;DISEASE:HYPERTENSION;CAUTION_DOSE_ADJUST
DEFERASIROX;ABCG2;CC;rs13120400;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:BETA-THALASSEMIA_AND_RELATED_DISEASES;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED;DOSE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
"""METFORMIN"", ""SULFONAMIDES, UREA DERIVATIVES""";SLC47A1;A;rs2289669;EFFICACY;INCREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
SUNITINIB;ABCG2;GT + TT;rs2231142;METABOLISM/PK;INCREASED;EXPOSURE;;PEOPLE;DISEASE:NEOPLASMS;CAUTION_DRUG_ACCUMULATION
WARFARIN;VDR;GG;rs11168292;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
4-HYDROXYTAMOXIFEN, ENDOXIFEN;SULT1A2;AA;rs1136703;METABOLISM/PK;DECREASED;CONCENTRATIONS;;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
ARA-CTP;SLC28A3;AA;rs17343066;METABOLISM/PK;INCREASED;CONCENTRATIONS;;CHILDREN;DISEASE:ACUTE_MYELOID_LEUKEMIA;CAUTION_DRUG_ACCUMULATION
WARFARIN;VDR;GG;rs4760658;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;VDR;TT;rs11168293;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ADALIMUMAB, CERTOLIZUMAB PEGOL, ETANERCEPT, INFLIXIMAB, TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;ALPL;T;rs885814;EFFICACY;DECREASED;RESPONSE;;PEOPLE;OTHER:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
ETOPOSIDE;SLIT1;AA;rs2784917;METABOLISM/PK;DECREASED;INHIBITION;;;;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;SLCO1B1;C;rs4149056;EFFICACY, TOXICITY, METABOLISM/PK;DECREASED;CLEARANCE;;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;SLCO1B1;A;rs2306283;EFFICACY, TOXICITY, METABOLISM/PK;DECREASED;CLEARANCE;;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
ADALIMUMAB, CERTOLIZUMAB PEGOL, ETANERCEPT, INFLIXIMAB, TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;;A;rs1350948;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
4-HYDROXYTAMOXIFEN, ENDOXIFEN;SULT1A2;TT;rs1059491;METABOLISM/PK;DECREASED;CONCENTRATIONS;;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;SLCO1B1;A;rs4149081;EFFICACY, TOXICITY, METABOLISM/PK;DECREASED;CLEARANCE;;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
ADALIMUMAB, CERTOLIZUMAB PEGOL, ETANERCEPT, INFLIXIMAB, TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;EYA4;C;rs17301249;EFFICACY;DECREASED;RESPONSE;;PEOPLE;OTHER:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP4F2;CT + TT;rs2108622;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ADALIMUMAB, CERTOLIZUMAB PEGOL, ETANERCEPT, INFLIXIMAB, TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;;G;rs12081765;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;SLCO1B1;C;rs11045879;EFFICACY, TOXICITY, METABOLISM/PK;DECREASED;CLEARANCE;;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
PHENYLEPHRINE;ADRB2;AA;rs1042713;DOSAGE;INCREASED;DOSE;;WOMEN;;CAUTION_DOSE_ADJUST
WARFARIN;CYP4F2;CT + TT;rs2108622;DOSAGE, EFFICACY;INCREASED;DOSE;;PEOPLE;OTHER:MECHANICAL_HEART_VALVE_REPLACEMENT;CAUTION_DOSE_ADJUST
ANASTROZOLE;CSMD1;G;rs6990851;EFFICACY;INCREASED;RESPONSE;;WOMEN;OTHER:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
N-DESMETHYLTRAMADOL, O-DESMETHYLTRAMADOL;ABCC2;AA;rs2273697;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;OTHER:DEATH;CAUTION_DRUG_ACCUMULATION
PEGINTERFERON ALFA-2B, RIBAVIRIN;;C;rs6806020;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_FAILURE
NICOTINE;CYP2A6;C;rs28399433;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
ATORVASTATIN;ABCB1;AA + AC;rs2032582;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HYPERCHOLESTEROLEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;CT + TT;rs7294;DOSAGE, EFFICACY;INCREASED;DOSE;;PEOPLE;OTHER:MECHANICAL_HEART_VALVE_REPLACEMENT;CAUTION_DOSE_ADJUST
PEGINTERFERON ALFA-2B, RIBAVIRIN;;A;rs1931704;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_FAILURE
ACAMPROSATE;CHDH, IL17RB;A;rs6801605;EFFICACY;INCREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:ALCOHOL_ABUSE;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;TT;rs9923231;DOSAGE, EFFICACY;DECREASED;DOSE;;PEOPLE;OTHER:MECHANICAL_HEART_VALVE_REPLACEMENT;CAUTION_DOSE_ADJUST
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;GG;rs8099917;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOPHOSPHAMIDE;CYP2B6;GG;rs3745274;EFFICACY;INCREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:CHRONIC_B-CELL_LYMPHOCITIC_LEUKEMIA,;LIKELIHOOD_THERAPEUTIC_SUCCESS
FENTANYL;ABCB1;AG;rs1128503;METABOLISM/PK;DECREASED;EXPOSURE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CT;rs776746;METABOLISM/PK;INCREASED;DOSE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;AA + AG;rs9934438;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
COUMARIN;CYP2A6;C;rs28399433;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
PEGINTERFERON ALFA-2B, RIBAVIRIN;IL21R;C;rs3093390;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_FAILURE
BEVACIZUMAB, IRINOTECAN;VEGFA;GG;rs1570360;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON ALFA-2B, RIBAVIRIN;;A;rs7512595;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON ALFA-2B, RIBAVIRIN;CARD16;C;rs1792774;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C19;CC;rs3814637;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;AA + AC;rs1057910;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
N-DESMETHYLTRAMADOL;ABCC2;TT;rs3740066;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;OTHER:DEATH;CAUTION_DRUG_ACCUMULATION
PEGINTERFERON ALFA-2B, RIBAVIRIN;;G;rs7750468;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;GGCX;CT + TT;rs699664;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ATORVASTATIN;SLCO1B1;AA;rs2306283;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HYPERCHOLESTEROLEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
FENTANYL;ABCC3;C;rs11079921;METABOLISM/PK;INCREASED;CLEARANCE;;CHILDREN;OTHER:PAIN, OTHER:PREMATURE_BIRTH;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON ALFA-2B, RIBAVIRIN;CARD16;A;rs1503391;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON ALFA-2B, RIBAVIRIN;CASP1;T;rs557905;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON ALFA-2B, RIBAVIRIN;;A;rs2066911;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_FAILURE
HMG_COA_REDUCTASE_INHIBITORS;CFAP44;G;rs13064411;EFFICACY;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
ATORVASTATIN;CYP7A1;TT;rs3808607;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HYPERCHOLESTEROLEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B, RIBAVIRIN;CASP1;A;rs568910;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_FAILURE
NICOTINE;CHRNB2;AG;rs2072658;OTHER;INCREASED;RESPONSE;;PEOPLE;OTHER:DAILY_SMOKING;LIKELIHOOD_THERAPEUTIC_SUCCESS
METFORMIN;SLC22A1;AC + CC;rs622342;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_FAILURE
N-DESMETHYLTRAMADOL;UGT1A8;CC;rs8330;METABOLISM/PK;DECREASED;CONCENTRATIONS;;PEOPLE;OTHER:DEATH;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;CC + CT;rs12979860;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;CC + CT;rs12979860;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;CHRNA4;C;rs2229959;OTHER;INCREASED;RESPONSE;;PEOPLE;OTHER:DAILY_SMOKING;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B, RIBAVIRIN;TUT7;C;rs17461620;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_FAILURE
ACETYLCYSTEINE;TOLLIP;TT;rs3750920;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:PULMONARY_FIBROSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
OXCARBAZEPINE;ABCB1;A;rs1045642;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:EPILEPSY;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIR;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
OXCARBAZEPINE;UGT2B7;C;rs7439366;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:EPILEPSY;LIKELIHOOD_THERAPEUTIC_FAILURE
ARA-CTP;CDA;AG + GG;rs12404655;METABOLISM/PK;INCREASED;CONCENTRATIONS;;CHILDREN;DISEASE:ACUTE_MYELOID_LEUKEMIA;CAUTION_DRUG_ACCUMULATION
PEGINTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIR;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ARA-CTP;RRM1;CT + TT;rs11030918;METABOLISM/PK;DECREASED;CONCENTRATIONS;;CHILDREN;DISEASE:ACUTE_MYELOID_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOZAPINE;CYP1A2;AA;rs762551;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;OTHER:SCHIZOPHRENIA;CAUTION_DRUG_ACCUMULATION
CLOPIDOGREL;CYP3A5;CC + CT;rs776746;EFFICACY;INCREASED;RESISTANCE;;PEOPLE;DISEASE:STROKE;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ARA-CTP;CTPS1;AG;rs11577910;METABOLISM/PK;INCREASED;CONCENTRATIONS;;CHILDREN;DISEASE:ACUTE_MYELOID_LEUKEMIA;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;METABOLISM;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
ARA-CTP;CTPS1;AA + AG;rs12067645;METABOLISM/PK;INCREASED;CONCENTRATIONS;;CHILDREN;DISEASE:ACUTE_MYELOID_LEUKEMIA;CAUTION_DRUG_ACCUMULATION
ARA-CTP;CTPS1;CT + TT;rs4364871;METABOLISM/PK;DECREASED;CONCENTRATIONS;;CHILDREN;DISEASE:ACUTE_MYELOID_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
N-DESMETHYLTRAMADOL;UGT1A8;CC;rs10929303;METABOLISM/PK;DECREASED;CONCENTRATIONS;;PEOPLE;OTHER:DEATH;LIKELIHOOD_THERAPEUTIC_FAILURE
ACENOCOUMAROL;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
N-DESMETHYLTRAMADOL, O-DESMETHYLTRAMADOL;UGT1A8;CC;rs34650714;METABOLISM/PK;DECREASED;CONCENTRATIONS;;PEOPLE;OTHER:DEATH;LIKELIHOOD_THERAPEUTIC_FAILURE
ARA-CTP;SLC28A1;TT;rs11853372;METABOLISM/PK;DECREASED;CONCENTRATIONS;;CHILDREN;DISEASE:ACUTE_MYELOID_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
ARA-CTP;DCTD;GG;rs4742;METABOLISM/PK;DECREASED;CONCENTRATIONS;;CHILDREN;DISEASE:ACUTE_MYELOID_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;METABOLISM;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
ALLOPURINOL;ABCG2;GT + TT;rs2231142;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:GOUT;LIKELIHOOD_THERAPEUTIC_FAILURE
OXCARBAZEPINE;ABCB1;GG;rs1045642;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:EPILEPSY;CAUTION_DRUG_ACCUMULATION
AMANTADINE, ANTICHOLINERGICS, LEVODOPA, SELEGILINE;SLC22A1;C;rs622342;DOSAGE, EFFICACY;INCREASED;DOSE;;PEOPLE;DISEASE:PARKINSON_DISEASE;CAUTION_DOSE_ADJUST
ARA-CTP;DCK;CC + CT;rs4643786;METABOLISM/PK;DECREASED;CONCENTRATIONS;;CHILDREN;DISEASE:ACUTE_MYELOID_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3;AA;rs12980275;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
MORPHINE-3-GLUCURONIDE, MORPHINE-6-GLUCURONIDE;ABCC3;CC;rs4793665;METABOLISM/PK;INCREASED;CONCENTRATIONS;;CHILDREN;DISEASE:SCOLIOSIS, DISEASE:TONSILLECTOMY;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;ABCB1;GG;rs1128503;METABOLISM/PK;DECREASED;CONCENTRATIONS;;CHILDREN;DISEASE:LIVER_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
MORPHINE-3-GLUCURONIDE;ABCC3;TT;rs4148412;METABOLISM/PK;INCREASED;CONCENTRATIONS;;CHILDREN;DISEASE:TONSILLECTOMY;CAUTION_DRUG_ACCUMULATION
GLUCOSE;CRTC2;AA + AG;rs8450;TOXICITY;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:TRANSPLANTATION;CAUTION_SIDE_EFFECT
ACENOCOUMAROL;CYP4F2;CT + TT;rs2108622;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;SLCO1C1;AG + GG;rs3794271;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:PSORIATIC_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;ABCB1;GG;rs1128503;METABOLISM/PK;INCREASED;DOSE;;CHILDREN;DISEASE:LIVER_TRANSPLANTATION;CAUTION_DOSE_ADJUST
SERTRALINE;GNB3;GG;rs5441;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2B6;GT + TT;rs3745274;METABOLISM/PK;INCREASED;CONCENTRATIONS;;CHILDREN;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
FENTANYL;CYP3A4;TT;rs2242480;EFFICACY;INCREASED;RESPONSE;;WOMEN;OTHER:POSTOPERATIVE_PAIN;LIKELIHOOD_THERAPEUTIC_SUCCESS
SUFENTANIL;OPRM1;AG + GG;rs1799971;DOSAGE;INCREASED;DOSE;;PEOPLE;OTHER:LUNG_NEOPLASMS, OTHER:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
SUFENTANIL;OPRM1;AG + GG;rs1323040;DOSAGE;INCREASED;DOSE;;PEOPLE;OTHER:LUNG_NEOPLASMS, OTHER:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
SUFENTANIL;ABCB1;AA + AG;rs1128503;DOSAGE;INCREASED;DOSE;;PEOPLE;OTHER:LUNG_NEOPLASMS, OTHER:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
CYCLOSPORINE;ABCB1;A;rs1045642;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:PSORIASIS;LIKELIHOOD_THERAPEUTIC_FAILURE
SUFENTANIL;ABCB1;AA + AC;rs2032582;DOSAGE;INCREASED;DOSE;;PEOPLE;OTHER:LUNG_NEOPLASMS, OTHER:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
MORPHINE;OPRM1;GG;rs1799971;DOSAGE;INCREASED;DOSE;;WOMEN;OTHER:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
HDL CHOLESTEROL;CRTC2;AA;rs8450;TOXICITY;DECREASED;CONCENTRATIONS;;PEOPLE;DISEASE:TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
O-DESMETHYLTRAMADOL;SLC22A1;GG;rs34130495;METABOLISM/PK;DECREASED;CONCENTRATIONS;;PEOPLE;OTHER:DEATH;LIKELIHOOD_THERAPEUTIC_FAILURE
MYCOPHENOLIC ACID;ABCC2;TT;rs717620;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
METHYLPHENIDATE;COMT;GG;rs4680;EFFICACY;INCREASED;RESPONSE;;CHILDREN;DISEASE:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS
N-DESMETHYLTRAMADOL, O-DESMETHYLTRAMADOL;SLC22A1;TT;rs1867351;METABOLISM/PK;DECREASED;CONCENTRATIONS;;PEOPLE;OTHER:DEATH;LIKELIHOOD_THERAPEUTIC_FAILURE
PHENYTOIN;CYP2C9;AA + AG;rs12782374;DOSAGE, METABOLISM/PK;DECREASED;DOSE;;PEOPLE;DISEASE:EPILEPSY;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;C;rs1057910;DOSAGE, METABOLISM/PK;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
FENTANYL;ABCC3;T;rs8077268;METABOLISM/PK;INCREASED;CLEARANCE;;CHILDREN;OTHER:PAIN, OTHER:PREMATURE_BIRTH;LIKELIHOOD_THERAPEUTIC_FAILURE
METHYLPHENIDATE;COMT;G;rs4680;EFFICACY;INCREASED;CLEARANCE;;CHILDREN;DISEASE:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;T;rs1799853;DOSAGE, METABOLISM/PK;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
PLATINUM COMPOUNDS;XRCC1;CC;rs25487;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP4F2;T;rs2108622;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
CYCLOSPORINE;ABCB1;GG;rs1045642;METABOLISM/PK;DECREASED;CONCENTRATIONS;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
NICOTINE;CYP1A2;T/del + del/del;rs35694136;EFFICACY;DECREASED;EXPOSURE;;MEN;;LIKELIHOOD_THERAPEUTIC_FAILURE
SIROLIMUS;CYP3A5;CC;rs776746;DOSAGE, METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:TRANSPLANTATION;CAUTION_DOSE_ADJUST
PLATINUM COMPOUNDS;ERCC1;CC;rs3212986;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
MYCOPHENOLIC ACID;UGT2B7;G;rs7662029;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
METHYLPHENIDATE;TH;GG;rs2070762;EFFICACY;DECREASED;RESPONSE;;CHILDREN;DISEASE:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY;LIKELIHOOD_THERAPEUTIC_FAILURE
ATORVASTATIN;SLCO1B1;CC + CT;rs4149056;EFFICACY;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;IL18;CC + CG;rs5744247;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
SIROLIMUS;CYP3A4;CC + CT;rs2740574;DOSAGE, METABOLISM/PK;INCREASED;DOSE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
SIROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE, METABOLISM/PK;INCREASED;DOSE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
CETUXIMAB;FCGR2A;AA;rs1801274;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE;CYP3A4;CC;rs2242480;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:EPILEPSY;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;HTR2C;CC;rs518147;EFFICACY;INCREASED;RESPONSE;;WOMEN;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:EPILEPSY;CAUTION_DRUG_ACCUMULATION
SITAGLIPTIN, VILDAGLIPTIN;GLP1R;AA;rs6923761;EFFICACY;DECREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_FAILURE
DESETHYLCHLOROQUINE, HYDROXYCHLOROQUINE;CYP2C8;C;rs7910936;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;OTHER:SYSTEMIC_LUPUS_ERYTHEMATOSUS;CAUTION_DRUG_ACCUMULATION
CARBAMAZEPINE;ABCB1;GG;rs1045642;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:EPILEPSY;CAUTION_DRUG_ACCUMULATION
CARBAMAZEPINE;EPHX1;CG;rs3738046;METABOLISM/PK;;CONCENTRATIONS;;PEOPLE;DISEASE:EPILEPSY;CAUTION_DOSE_ADJUST
ROSUVASTATIN;SLCO1B1;CC + CT;rs4149056;METABOLISM/PK;INCREASED;CONCENTRATIONS;;CHILDREN;OTHER:HYPERCHOLESTEROLEMIA;CAUTION_DRUG_ACCUMULATION
PHENYTOIN;CYP2C9;CT;rs1799853;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:EPILEPSY;CAUTION_DRUG_ACCUMULATION
SIMVASTATIN ACID;SLCO1B1;CC;rs4149056;METABOLISM/PK;INCREASED;CONCENTRATIONS;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
PHENYTOIN;CYP2C19;AG;rs4244285;OTHER, METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:EPILEPSY;CAUTION_DRUG_ACCUMULATION
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION, DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOZAPINE;HTR2C;C;rs6318;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE;EPHX1;AG + GG;rs2234922;METABOLISM/PK;;CONCENTRATIONS;;PEOPLE;DISEASE:EPILEPSY;CAUTION_DOSE_ADJUST
CARBAMAZEPINE;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED;DOSE;;PEOPLE;DISEASE:EPILEPSY;CAUTION_DOSE_ADJUST
SULFONAMIDES, UREA DERIVATIVES;TCF7L2;TT;rs12255372;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_FAILURE
SIMVASTATIN;SLCO1B1;TT;rs4149056;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:HYPERCHOLESTEROLEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBOPLATIN, CISPLATIN, FLUOROURACIL;XRCC1;T;rs25487;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:UTERINE_CERVICAL_NEOPLASM;LIKELIHOOD_THERAPEUTIC_FAILURE
TRAMADOL;ABCB1;AA;rs2032582;METABOLISM/PK;INCREASED;EXPOSURE;;;;CAUTION_DRUG_ACCUMULATION
TRAMADOL;ABCB1;AA;rs1045642;METABOLISM/PK;INCREASED;EXPOSURE;;;;CAUTION_DRUG_ACCUMULATION
CARBOPLATIN, CISPLATIN, FLUOROURACIL;SLC19A1;A;rs12659;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:UTERINE_CERVICAL_NEOPLASM;LIKELIHOOD_THERAPEUTIC_FAILURE
TRAMADOL;ABCB1;AA;rs1128503;METABOLISM/PK;INCREASED;EXPOSURE;;;;CAUTION_DRUG_ACCUMULATION
TOCILIZUMAB;IL6R;AA;rs12083537;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
CAFFEINE;ADORA1;CC;rs16851030;EFFICACY;INCREASED;RESPONSE;;INFANTS;OTHER:APNEA_OF_PREMATURITY;LIKELIHOOD_THERAPEUTIC_SUCCESS
TOCILIZUMAB;IL6R;CC + CT;rs4329505;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;HTR2C;CC;rs1023574;EFFICACY;INCREASED;RESPONSE;;WOMEN;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
RISPERIDONE;HTR2C;TT;rs9698290;EFFICACY;INCREASED;RESPONSE;;WOMEN;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""DIURETICS"", ""HYDROCHLOROTHIAZIDE"", ""THIAZIDES, PLAIN""";PRKCA;A;rs16960228;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIDEPRESSANTS;RGS17;A;rs672170;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;AT;rs7089580;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;AT;rs7089580;DOSAGE;INCREASED;CLEARANCE;;;;CAUTION_DOSE_ADJUST
VORICONAZOLE;SLCO1B3;GT + TT;rs4149117;METABOLISM/PK;DECREASED;TROUGH_CONCENTRATION;;CHILDREN;;LIKELIHOOD_THERAPEUTIC_FAILURE
OXALIPLATIN;TP53;CG + GG;rs1042522;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIDEPRESSANTS;NBEA;T;rs9315310;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIDEPRESSANTS;CRH;C;rs4737771;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIDEPRESSANTS;FHIT;C;rs49411;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIDEPRESSANTS;PARP11;G;rs2532560;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIDEPRESSANTS;;T;rs2831440;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
SILDENAFIL;GNB3;TT;rs5443;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:ERECTILE_DYSFUNCTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIDEPRESSANTS;MTRF1L;G;rs766127;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATORVASTATIN;POR;CT + TT;rs1057868;EFFICACY;DECREASED;RESPONSE;;CHILDREN;DISEASE:FAMILIAL_HYPERCHOLESTEROLEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;HSD11B1;AA;rs846908;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
SARILUMAB;IL6R;CC;rs4845625;EFFICACY;DECREASED;RESPONSE;;PEOPLE;OTHER:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
SALVIANOLIC ACID B;NOS3;GG;rs1799983;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:CORONARY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUPROPION;COMT;AA + AG;rs165599;EFFICACY;INCREASED;RESPONSE;;;OTHER:SMOKERS;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUPROPION;COMT;AA;rs737865;EFFICACY;DECREASED;RESPONSE;;;OTHER:SMOKERS;LIKELIHOOD_THERAPEUTIC_FAILURE
SALBUTAMOL;CRHR2;G;rs2267715;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_FAILURE
DESETHYLCHLOROQUINE, HYDROXYCHLOROQUINE;CYP2C8;T;rs10882521;METABOLISM/PK;DECREASED;CONCENTRATIONS;;PEOPLE;OTHER:SYSTEMIC_LUPUS_ERYTHEMATOSUS;LIKELIHOOD_THERAPEUTIC_FAILURE
SALMETEROL;ADRB2;AA;rs1042713;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;STX1B;AG + GG;rs4889606;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ADALIMUMAB;HFE;CC + CT;rs2071303;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:CROHN_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ROSIGLITAZONE;LPIN1;G;rs10192566;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;HSD11B1;AA;rs4844880;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
DESETHYLCHLOROQUINE, HYDROXYCHLOROQUINE;CYP2D6;AA;rs1065852;METABOLISM/PK;DECREASED;CONCENTRATIONS;;PEOPLE;OTHER:SYSTEMIC_LUPUS_ERYTHEMATOSUS;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;HSD11B1;AA;rs846910;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACENOCOUMAROL;GATA4;AG + GG;rs3735814;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
"""BETA BLOCKING AGENTS, SELECTIVE"", ""DIURETICS""";NEDD4L;AG + GG;rs4149601;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIDEPRESSANTS;CTNNA3;C;rs10997242;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
ALDOSTERONE ANTAGONISTS, AMILORIDE;NEDD4L;G;rs4149601;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIDEPRESSANTS;HTR2A;AG + GG;rs7997012;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
SALBUTAMOL;CRHR2;A;rs255100;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIDEPRESSANTS;HTR2A;GG;rs6313;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIDEPRESSANTS;CACNA1A;A;rs2112460;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
SALBUTAMOL;CRHR2;G;rs2284220;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;ORM1;AG + GG;rs17650;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ANTIDEPRESSANTS;;T;rs521093;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
MORPHINE;UGT2B7;CC;rs7439366;DOSAGE;DECREASED;DOSE;;WOMEN;DISEASE:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;C;rs7294;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ANTIDEPRESSANTS;RAPGEF5;C;rs16873129;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
VALPROIC ACID;ABCB1;AA;rs1128503;EFFICACY;DECREASED;CLINICAL_BENEFIT;;CHILDREN;OTHER:EPILEPSY;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIDEPRESSANTS;PON2;G;rs2299267;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;C;rs776746;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;C;rs776746;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
CISPLATIN;GALNT18;GG;rs7937567;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:URINARY_BLADDER_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;AG + GG;rs2279343;METABOLISM/PK;INCREASED;CONCENTRATIONS;;CHILDREN;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
RITUXIMAB;;CC;rs3759467;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:VASCULITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIPSYCHOTICS, ARIPIPRAZOLE, CLOZAPINE, HALOPERIDOL, OLANZAPINE, QUETIAPINE, RISPERIDONE;CYP3A43;CG;rs680055;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:SCHIZOAFFECTIVE_DISORDER, DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE, METABOLISM/PK;INCREASED;METABOLISM;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CT;rs776746;METABOLISM/PK;INCREASED;CLEARANCE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE, METABOLISM/PK;INCREASED;CLEARANCE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;STEADY-STATE_CONCENTRATION;;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;METABOLISM;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;METABOLISM;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;METABOLISM;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
CORTICOSTEROIDS;HDAC1;CC;rs1741981;EFFICACY;DECREASED;RESPONSE;;CHILDREN;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;GT + TT;rs3745274;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
VINCRISTINE;MTNR1B;AG;rs8192552;METABOLISM/PK;INCREASED;EXPOSURE;;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA_OTHER:HODGKIN_DISEASE,OTHER:RHABDOMYOSARCOMA, OTHER:MEDULLOBLASTOMA, OTHER:GLIOMA;CAUTION_DRUG_ACCUMULATION
MORPHINE;TLR2;CC + CT;rs3804100;DOSAGE, EFFICACY;DECREASED;DOSE;;WOMEN;DISEASE:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CT;rs776746;OTHER, METABOLISM/PK;INCREASED;METABOLISM;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
DOCETAXEL, THALIDOMIDE;CHST3;T;rs4148947;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:PROSTATIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
MORPHINE;IL1B;A;rs1143634;DOSAGE, EFFICACY;DECREASED;DOSE;;WOMEN;DISEASE:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2B6;GT + TT;rs3745274;METABOLISM/PK;INCREASED;CONCENTRATIONS;;CHILDREN;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
CISPLATIN;MLLT3;AA + AC;rs10964552;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:URINARY_BLADDER_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE, METABOLISM/PK;INCREASED;METABOLISM;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;T;rs776746;DOSAGE, METABOLISM/PK;INCREASED;METABOLISM;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
MORPHINE;IL1B;A;rs1143634;DOSAGE, EFFICACY;INCREASED;DOSE;;WOMEN;DISEASE:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2B6;CT;rs28399499;METABOLISM/PK;INCREASED;CONCENTRATIONS;;CHILDREN;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
DOCETAXEL, THALIDOMIDE;CHST3;A;rs4148950;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:PROSTATIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE, METABOLISM/PK;INCREASED;METABOLISM;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;TT;rs776746;DOSAGE, METABOLISM/PK;INCREASED;CLEARANCE;;;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
ATORVASTATIN;MTTP;TT;rs1800591;EFFICACY;INCREASED;RESPONSE;;MEN;DISEASE:HYPERLIPOPROTEINEMIA_TYPE_II;LIKELIHOOD_THERAPEUTIC_SUCCESS
NITROGLYCERIN;ALDH2;AA + AG;rs671;EFFICACY;DECREASED;RESPONSE;;CHILDREN;DISEASE:CONGENITAL_HEART_DEFECTS;LIKELIHOOD_THERAPEUTIC_FAILURE
TOCILIZUMAB;GALNT18;CC;rs4910008;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;GT + TT;rs3745274;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
CISPLATIN;RARS1;TT;rs244898;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:URINARY_BLADDER_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CT;rs776746;DOSAGE, METABOLISM/PK;INCREASED;CLEARANCE;;;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2B6;GT + TT;rs3745274;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;CC;rs776746;DOSAGE, METABOLISM/PK;DECREASED;CLEARANCE;;CHILDREN;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2B6;GT + TT;rs3745274;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;ABCB1;AG + GG;rs2235048;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CT;rs776746;METABOLISM/PK;INCREASED;DOSE;;CHILDREN;OTHER:HEART_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;METABOLISM;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED;DOSE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CC;rs776746;DOSAGE, METABOLISM/PK;DECREASED;DOSE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
NITROGLYCERIN;ALDH2;AA + AG;rs671;METABOLISM/PK;INCREASED;CONCENTRATIONS;;CHILDREN;DISEASE:CONGENITAL_HEART_DEFECTS, DISEASE:PULMONARY_HYPERTENSION;CAUTION_DRUG_ACCUMULATION
DIGOXIN;ABCB1;AT;rs2032582;METABOLISM/PK;INCREASED;CLEARANCE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;METABOLISM;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;DECREASED;CLEARANCE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;CC;rs776746;DOSAGE;DECREASED;DOSE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TOCILIZUMAB;CD69;A;rs11052877;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;METABOLISM;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
PHENAZEPAM;CYP2C19;CC + CT;rs12248560;EFFICACY;INCREASED;RESPONSE;;MEN;DISEASE:ALCOHOL-RELATED_DISORDERS;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE, METABOLISM/PK;INCREASED;CLEARANCE;;;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;TT;rs776746;METABOLISM/PK;INCREASED;CLEARANCE;;;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
VINCRISTINE;SNU13;G;rs6519270;METABOLISM/PK;INCREASED;CONCENTRATIONS;;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA_OTHER:HODGKIN_DISEASE,OTHER:RHABDOMYOSARCOMA, OTHER:MEDULLOBLASTOMA, OTHER:GLIOMA;CAUTION_DRUG_ACCUMULATION
ATENOLOL;;A;rs7184292;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATENOLOL;XIRP2;C;rs7606603;EFFICACY;DECREASED;RESPONSE;;PEOPLE;OTHER:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOSPORINE;CYP3A7;TT;rs10211;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
CYCLOSPORINE;CYP3A7;CC;rs2257401;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;JAK2;CC;rs12343867;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:ULCERATIVE_COLITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
NILOTINIB;GSTP1;A;rs1695;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;LIKELIHOOD_THERAPEUTIC_SUCCESS
HYDROCHLOROTHIAZIDE;;C;rs16872401;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL12B;GG;rs3212217;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:INFLAMMATORY_BOWEL_DISEASES;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOSPORINE;CYP3A4;GG;rs4646437;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
CARVEDILOL;ADRB1;G;rs1801252;EFFICACY;INCREASED;RESPONSE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PAROXETINE;ABCB1;CC + CT;rs2032582;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:DEPRESSION;LIKELIHOOD_THERAPEUTIC_FAILURE
NILOTINIB;CYP1A1;CT + TT;rs1048943;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;NLRP3;CG + GG;rs10754558;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:INFLAMMATORY_BOWEL_DISEASES;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATENOLOL;;GG;rs7184292;DOSAGE;DECREASED;DOSE;;PEOPLE;OTHER:HYPERTENSION;CAUTION_DOSE_ADJUST
ATORVASTATIN;SLCO1B1;GG;rs2306283;EFFICACY;DECREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:HYPERLIPIDEMIAS;LIKELIHOOD_THERAPEUTIC_FAILURE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL18;GT + TT;rs1946518;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:ULCERATIVE_COLITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARVEDILOL;ADRB1;C;rs1801253;EFFICACY;INCREASED;RESPONSE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RISPERIDONE;AKT1;CT;rs3803300;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
RISPERIDONE;AKT1;TT;rs2494732;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;GT + TT;rs3745274;METABOLISM/PK;INCREASED;EXPOSURE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IFNGR1;AG;rs2234711;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:ULCERATIVE_COLITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
IMATINIB;CYP2B6;GG + TT;rs3745274;EFFICACY;INCREASED;RESISTANCE;;PEOPLE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C19;AA + AG;rs4986893;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
CYCLOSPORINE;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C19;CT + TT;rs3814637;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
CANNABIDIOL;AOC1;CT + TT;rs12539;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:EPILEPSY;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;CT + TT;rs3211371;METABOLISM/PK;DECREASED;EXPOSURE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TBX21;CC;rs17250932;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:ULCERATIVE_COLITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
VINCRISTINE;RAB7A;CT;rs4548;METABOLISM/PK;INCREASED;EXPOSURE;;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA_OTHER:HODGKIN_DISEASE,OTHER:RHABDOMYOSARCOMA, OTHER:MEDULLOBLASTOMA, OTHER:GLIOMA;CAUTION_DRUG_ACCUMULATION
DOCETAXEL, THALIDOMIDE;CHST3;C;rs730720;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:PROSTATIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IFNGR2;CC;rs8126756;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:CROHN_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
CANNABIDIOL;SLC15A1;TT;rs1339067;EFFICACY;DECREASED;RESPONSE;;PEOPLE;OTHER:EPILEPSY;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;;T;rs12772169;DOSAGE;;DOSE;;;;CAUTION_DOSE_ADJUST
ROSIGLITAZONE;SLCO1B1;C;rs4149056;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:DIABETES_MELLITUS;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL12B;CG + GG;rs3212217;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:CROHN_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
CORTICOSTEROIDS FOR SYSTEMIC USE;HDAC1;CC;rs1741981;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;COMT;G;rs165599;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
RISPERIDONE;GRM3;G;rs724226;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TLR5;AG;rs5744174;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:CROHN_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
MORPHINE;KCNJ6;CC;rs6517442;EFFICACY;INCREASED;RESPONSE;;INFANTS;DISEASE:PAIN;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;ABCG2;GT;rs2231142;METABOLISM/PK;INCREASED;CONCENTRATIONS;;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;CC;rs776746;DOSAGE;DECREASED;DOSE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;POR;CT + TT;rs1057868;METABOLISM/PK;DECREASED;TROUGH_CONCENTRATION;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
MORPHINE, REMIFENTANIL;KCNJ6;TT;rs6517442;EFFICACY;DECREASED;RESPONSE;;INFANTS;DISEASE:PAIN;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED;DOSE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
LOW DENSITY LIPOPROTEIN;SH2B1;CC;rs3888190;OTHER;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:BIPOLAR_DISORDER, DISEASE:DEPRESSIVE_DISORDER,DISEASE:PSYCHOTIC_DISORDER, DISEASE:SCHIZOAFFECTIVE_DISORDER;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;T;rs776746;DOSAGE;INCREASED;DOSE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
ENALAPRIL;VEGFA;AA + AC;rs699947;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIR;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED;DOSE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2B6;GT + TT;rs3745274;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
LITHIUM;CACNG2;TT;rs2284018;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:BIPOLAR_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CC;rs776746;DOSAGE;DECREASED;DOSE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
EFAVIRENZ;ABCB1;GG;rs1045642;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;GT + TT;rs3745274;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
ANASTROZOLE;;T;rs1437153;EFFICACY;DECREASED;RESPONSE;;WOMEN;OTHER:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED;DOSE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;DOSE;;CHILDREN;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
DOCETAXEL;ORM2;AA;rs2250242;METABOLISM/PK;INCREASED;CLEARANCE;;MEN;DISEASE:PROSTATIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED;DOSE;;;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
ETANERCEPT, INFLIXIMAB;CARD8;TT;rs2043211;EFFICACY;DECREASED;RESPONSE;;PEOPLE;OTHER:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;TT;rs3745274;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;ABCB1;AA + AG;rs1045642;EFFICACY;DECREASED;RESPONSE;;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIR;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;TT;rs776746;DOSAGE, METABOLISM/PK;INCREASED;DOSE;;;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IFNGR1;AG;rs2234711;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:INFLAMMATORY_BOWEL_DISEASES;LIKELIHOOD_THERAPEUTIC_FAILURE
ETANERCEPT, INFLIXIMAB;NLRP3;TT;rs4612666;EFFICACY;DECREASED;RESPONSE;;PEOPLE;OTHER:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED;DOSE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED;DOSE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
ANASTROZOLE;DLG2;T;rs2449598;EFFICACY;DECREASED;RESPONSE;;WOMEN;OTHER:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED;DOSE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2B6;TT;rs3745274;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;CHILDREN;OTHER:NEPHROTIC_SYNDROME;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;GG;rs2279343;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED;DOSE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;METABOLISM;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;VKORC1;TT;rs9923231;DOSAGE;DECREASED;DOSE;;CHILDREN;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED;DOSE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A4;CC;rs2242480;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;CHILDREN;OTHER:NEPHROTIC_SYNDROME;CAUTION_DRUG_ACCUMULATION
DIGOXIN;ABCB1;AA;rs2032582;METABOLISM/PK;INCREASED;CLEARANCE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;MTHFR;AA;rs1801133;METABOLISM/PK;INCREASED;CONCENTRATIONS;;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DRUG_ACCUMULATION
PEGINTERFERON ALFA-2B;HLA-DPA1;GG;rs3077;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HEPATITIS_B, CHRONIC;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIVASTIGMINE;BCHE;CC;rs1803274;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:ALZHEIMER_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
DIGOXIN;ABCB1;AG;rs1045642;METABOLISM/PK;INCREASED;CLEARANCE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;GT + TT;rs3745274;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP4F2;CC;rs2108622;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
METHOTREXATE;ABCB1;AG;rs1045642;METABOLISM/PK;INCREASED;CONCENTRATIONS;;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DRUG_ACCUMULATION
ADALIMUMAB, ETANERCEPT, INFLIXIMAB, TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;A;rs1800629;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
CANNABIDIOL;ABCC5;AA + AG;rs3749442;EFFICACY;DECREASED;RESPONSE;;PEOPLE;OTHER:EPILEPSY;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;CC;rs4803217;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION, DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;CLEARANCE;;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;CLEARANCE;;;DISEASE:LIVER_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;CC + CT;rs3181842;METABOLISM/PK;INCREASED;METABOLISM;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;AA + AG;rs707265;METABOLISM/PK;INCREASED;METABOLISM;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;CT + TT;rs7246465;METABOLISM/PK;INCREASED;METABOLISM;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
SUFENTANIL;NFKBIA;TT;rs696;DOSAGE;INCREASED;DOSE;;PEOPLE;OTHER:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2B6;TT;rs1042389;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;AA;rs11881222;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION, DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
GLUCOSE;RABEP1;AG + GG;rs1000940;OTHER;DECREASED;CONCENTRATIONS;;PEOPLE;DISEASE:BIPOLAR_DISORDER, DISEASE:DEPRESSIVE_DISORDER,DISEASE:PSYCHOTIC_DISORDER, DISEASE:SCHIZOAFFECTIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE, METABOLISM/PK;INCREASED;DOSE;;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;CAUTION_DOSE_ADJUST
PAROXETINE;BDNF;TT;rs6265;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE, METABOLISM/PK;INCREASED;DOSE;;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;CAUTION_DOSE_ADJUST
REMIFENTANIL;COMT;AA;rs4680;EFFICACY;INCREASED;RESPONSE;;INFANTS;DISEASE:PAIN;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CT;rs776746;METABOLISM/PK;INCREASED;CLEARANCE;;;DISEASE:LIVER_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
MORPHINE;COMT;GG;rs4680;EFFICACY;DECREASED;RESPONSE;;INFANTS;DISEASE:PAIN;LIKELIHOOD_THERAPEUTIC_FAILURE
MORPHINE, REMIFENTANIL;COMT;AA + AG;rs4680;EFFICACY;INCREASED;RESPONSE;;INFANTS;DISEASE:PAIN;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CT;rs776746;DOSAGE, METABOLISM/PK;INCREASED;CLEARANCE;;;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
ANTIPSYCHOTICS;ABCB1;CC;rs2032582;DOSAGE, METABOLISM/PK;INCREASED;DOSE;;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_DOSE_ADJUST
ADALIMUMAB, INFLIXIMAB;TLR2;T;rs3804099;EFFICACY;DECREASED;RESPONSE;;PEOPLE;OTHER:CROHN_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
INTERFERON ALFA-N1, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
MORPHINE;COMT;G;rs4680;DOSAGE, EFFICACY;INCREASED;DOSE;;PEOPLE;OTHER:CORONARY_ARTERY_DISEASE, EFFICACY:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2B6;TT;rs3745274;METABOLISM/PK;INCREASED;EXPOSURE;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
INTERFERON ALFA-N1, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;TT;rs8103142;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION, DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;CLEARANCE;;PEOPLE;OTHER:HSCT;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;CC;rs28416813;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION, DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;METABOLISM;;PEOPLE;OTHER:KIDNEY_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;METABOLISM;;CHILDREN;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
IMATINIB;ABCG2;GT;rs2231142;EFFICACY;INCREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;CLEARANCE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;GT + TT;rs3745274;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
PEGINTERFERON ALFA-2B, RIBAVIRIN;;AA;rs8113007;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION, DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE, METABOLISM/PK;INCREASED;CLEARANCE;;;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION, DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOZAPINE;CHRM1;CC;rs2075748;DOSAGE;DECREASED;DOSE;;PEOPLE;OTHER:SCHIZOPHRENIA;CAUTION_DOSE_ADJUST
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;CYP1B1;CC;rs1056836;EFFICACY;DECREASED;RESPONSE;;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;GT + TT;rs3745274;METABOLISM/PK;INCREASED;EXPOSURE;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;G;rs28416813;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
INTERFERON ALFA-N1, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
INTERFERON ALFA-N1, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ERENUMAB, FREMANEZUMAB, GALCANEZUMAB;;G;rs12615320;EFFICACY;DECREASED;RESPONSE;;PEOPLE;OTHER:MIGRAINE_WITHOUT_AURA, OTHER:MIGRAINE_WITH_AURA;LIKELIHOOD_THERAPEUTIC_FAILURE
ROSUVASTATIN;SLCO1B1;CC + CT;rs4149056;EFFICACY;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;VKORC1;A;rs9934438;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
HYDROXYUREA;ASS1;T;rs10901080;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:SICKLE_CELL_ANEMIA,  DISEASE:BETA-THALASSEMIA_AND_RELATED_DISEASES;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANASTROZOLE;CSMD1;T;rs6981827;EFFICACY;DECREASED;RESPONSE;;WOMEN;OTHER:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
HYDROXYUREA;ASS1;T;rs10793902;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:SICKLE_CELL_ANEMIA,  DISEASE:BETA-THALASSEMIA_AND_RELATED_DISEASES;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;GG + GT;rs8099917;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_FAILURE
DOXORUBICIN;ABCB1;AA;rs2032582;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:BREAST_NEOPLASMS;CAUTION_DRUG_ACCUMULATION
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;GG + GT;rs8099917;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;T;rs8103142;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CT;rs776746;DOSAGE;INCREASED;DOSE;;CHILDREN;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE, METABOLISM/PK;INCREASED;DOSE;;;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CC;rs776746;DOSAGE;DECREASED;DOSE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
EPIRUBICIN;NQO1;AA;rs1800566;EFFICACY, TOXICITY;DECREASED;RESPONSE;;;OTHER:BREAST_CANCER_CELL_LINES;LIKELIHOOD_THERAPEUTIC_FAILURE
DOCETAXEL, EPIRUBICIN;MDM4;AA;rs1563828;EFFICACY;INCREASED;RESPONSE;;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEMCITABINE;CDA;C;rs2072671;METABOLISM/PK;DECREASED;CLEARANCE;;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_DRUG_ACCUMULATION
HYDROCHLOROTHIAZIDE;NEDD4L;AG + GG;rs75982813;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
GLICLAZIDE;KCNJ11;TT;rs5219;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;;AA + AG;rs12777823;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
DOXORUBICIN;ABCB1;AA;rs1045642;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:BREAST_NEOPLASMS;CAUTION_DRUG_ACCUMULATION
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ARIPIPRAZOLE;DRD2;GG;rs6277;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CC;rs776746;DOSAGE;DECREASED;DOSE;;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;CAUTION_DOSE_ADJUST
DIGOXIN;ABCB1;AA;rs1045642;METABOLISM/PK;INCREASED;CLEARANCE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
CAPECITABINE, RADIOTHERAPY;AREG;AA + AC;rs11942466;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:RECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
(S)-METHADONE;CYP2B6;GT + TT;rs3745274;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:OPIOID-RELATED_DISORDERS;CAUTION_DRUG_ACCUMULATION
(R)-METHADONE;CYP2B6;GT + TT;rs3745274;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:OPIOID-RELATED_DISORDERS;CAUTION_DRUG_ACCUMULATION
CAPECITABINE, RADIOTHERAPY;ERCC1;AG + GG;rs11615;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:RECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
CAPECITABINE, OXALIPLATIN;VEGFA;CG;rs2010963;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACETAMINOPHEN;UGT2B15;AA;rs1902023;EFFICACY;INCREASED;RESPONSE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ARIPIPRAZOLE;ANKK1;AA + AG;rs1800497;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
MORPHINE;COMT;C;rs4633;DOSAGE, EFFICACY;INCREASED;DOSE;;PEOPLE;OTHER:CORONARY_ARTERY_DISEASE, EFFICACY:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
ACETAMINOPHEN;TRPV1;AA + AG;rs224534;EFFICACY;INCREASED;RESPONSE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOZAPINE;HTR3A;G;rs1150226;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
RISPERIDONE;GRM7;CC;rs2069062;EFFICACY;INCREASED;RESPONSE;;PEOPLE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;ABCB1;AA + AG;rs1045642;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;CLEARANCE;;;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOZAPINE;HTR3A;A;rs2276302;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
GLUCOSE;COMT;AA + AG;rs4680;TOXICITY;INCREASED;CONCENTRATIONS;;CHILDREN;;CAUTION_SIDE_EFFECT
CLOZAPINE;HTR3A;C;rs1062613;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;ABCB1;AA + AG;rs1045642;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;METABOLISM;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
ADALIMUMAB, ETANERCEPT, INFLIXIMAB;PTPRC;G;rs10919563;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;DISCONTINUATION;;PEOPLE;DISEASE:KIDNEY_DISORDER;CAUTION_SIDE_EFFECT
RISPERIDONE;GRID2;GG;rs1875705;EFFICACY;INCREASED;RESPONSE;;PEOPLE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;CLEARANCE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;ABCB1;AA + AG;rs1045642;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;LIKELIHOOD_THERAPEUTIC_FAILURE
PACLITAXEL;ABCB1;CC;rs2032582;EFFICACY;DECREASED;RESPONSE;;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;NR1I2;CC;rs2276707;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;OTHER:HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;CT;rs776746;DOSAGE, METABOLISM/PK;INCREASED;CLEARANCE;;;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
CAPECITABINE, OXALIPLATIN;VEGFA;AC;rs699947;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;PRSS53, VKORC1;A;rs17886199;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
4-HYDROXYATORVASTATIN, 4-HYDROXYATORVASTATIN LACTONE;SLCO2B1;AG;rs12422149;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;OTHER:CORONARY_DISEASE;CAUTION_DRUG_ACCUMULATION
PACLITAXEL;ABCB1;AA + AT;rs2032582;EFFICACY;INCREASED;RESPONSE;;WOMEN;DISEASE:OVARIAN_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;CLEARANCE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;AG + GG;rs11881222;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CT + TT;rs776746;OTHER, METABOLISM/PK;INCREASED;METABOLISM;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
2-HYDROXYATORVASTATIN LACTONE, 4-HYDROXYATORVASTATIN LACTONE, ATORVASTATIN LACTONE;UGT1A1;CC;rs887829;METABOLISM/PK;DECREASED;CONCENTRATIONS;;PEOPLE;OTHER:CORONARY_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
BEVACIZUMAB, FLUOROURACIL, IRINOTECAN, LEUCOVORIN;RGS5;TT;rs1056515;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN_SN-38;UGT1A1;AA;rs4148323;DOSAGE;DECREASED;METABOLISM;;PEOPLE;DISEASE:NEOPLASMS;CAUTION_DOSE_ADJUST
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;CC + CT;rs8105790;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;AG + GG;rs12980275;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_FAILURE
VALPROIC ACID;GABRA1;AA + AG;rs10068980;EFFICACY;INCREASED;CLINICAL_BENEFIT;;CHILDREN;OTHER:EPILEPSY;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;CT + TT;rs12979860;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOZAPINE;CHRM1;GG;rs1942499;DOSAGE;DECREASED;DOSE;;PEOPLE;OTHER:SCHIZOPHRENIA;CAUTION_DOSE_ADJUST
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;GG + GT;rs8099917;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;CLEARANCE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
ROSUVASTATIN;SCAP;C;rs12487736;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:METABOLIC_SYNDROME;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;DECREASED;CLEARANCE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;CT;rs4803219;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_FAILURE
BEVACIZUMAB, FLUOROURACIL, IRINOTECAN, LEUCOVORIN;RALBP1;GG;rs329007;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
IVACAFTOR;CFTR;A;rs75527207;EFFICACY;;RESPONSE;;CHILDREN;DISEASE:CYSTIC_FIBROSIS;CAUTION_DOSE_ADJUST
ROCURONIUM;ABCB1;AA;rs1128503;EFFICACY;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
MYCOPHENOLIC ACID;UGT1A9;AA + AT;rs6714486;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;CHILDREN;OTHER:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
ACENOCOUMAROL;VKORC1;T;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;DECREASED;CLEARANCE;;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
ROCURONIUM;SLCO1B1;AA;rs2306283;EFFICACY;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;G;rs8099917;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_FAILURE
PERAMPANEL;CYP3A5, ZSCAN25;C;rs776746;METABOLISM/PK;INCREASED;CONCENTRATIONS;;CHILDREN;OTHER:EPILEPSY;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;CLEARANCE;;CHILDREN;DISEASE:LIVER_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
MORPHINE;UGT2B7;AA + AG;rs7438135;METABOLISM/PK;DECREASED;CONCENTRATIONS;;INFANTS;;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;DECREASED;CLEARANCE;;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;GT;rs8099917;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;AA + AG;rs7248668;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON ALFA-2B, RIBAVIRIN;;GG;rs10853728;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_FAILURE
PRAVASTATIN;SLCO1B1;CC + CT;rs4149056;METABOLISM/PK;INCREASED;CONCENTRATIONS;;CHILDREN;OTHER:HYPERCHOLESTEROLEMIA;CAUTION_DRUG_ACCUMULATION
PEGINTERFERON ALFA-2B, RIBAVIRIN;;CG + GG;rs10853728;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_FAILURE
ACENOCOUMAROL;CYP4F2;TT;rs2108622;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
IMATINIB;ABCG2;C;rs2725252;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PHENPROCOUMON;CYP4F2;T;rs2108622;DOSAGE;INCREASED;DOSE;;;OTHER:MAINTENANCE_DOSAGE_BY_1.5_MG/WEEK;CAUTION_DOSE_ADJUST
ATENOLOL, IRBESARTAN;EDN1;GT;rs5370;EFFICACY;INCREASED;RESPONSE;;MEN;DISEASE:ESSENTIAL_HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
PAROXETINE;HTR2A;CC;rs6311;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:OBSESSIVE_COMPULSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
PHENPROCOUMON;CYP2C9;T;rs4086116;DOSAGE;DECREASED;DOSE;;;OTHER:MAINTENANCE_DOSAGE_BY_2.2_MG/WEEK;CAUTION_DOSE_ADJUST
ATORVASTATIN, PRAVASTATIN, SIMVASTATIN;APOE;C;rs7412;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:HYPERLIPIDEMIAS;LIKELIHOOD_THERAPEUTIC_FAILURE
IMATINIB;ABCG2;C;rs2725252;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATAZANAVIR;NR1I2;CT;rs2472677;METABOLISM/PK;DECREASED;CONCENTRATIONS;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
PRAVASTATIN;SLCO1B1;AG;rs4149015;METABOLISM/PK;INCREASED;METABOLISM;;CHILDREN;DISEASE:HYPERLIPOPROTEINEMIA_TYPE_II;LIKELIHOOD_THERAPEUTIC_FAILURE
APIXABAN;CYP3A5;CC + CT;rs776746;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:ATRIAL_FIBRILLATION;CAUTION_DRUG_ACCUMULATION
IMATINIB;ABCG2;G;rs12505410;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;LIKELIHOOD_THERAPEUTIC_SUCCESS
NIACIN;HCAR2;CT + TT;rs2454727;EFFICACY;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
ATORVASTATIN, PRAVASTATIN, SIMVASTATIN;ABCA1;C;rs12003906;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:HYPERLIPIDEMIAS;LIKELIHOOD_THERAPEUTIC_FAILURE
CEFTRIAXONE;ABCG2;TT;rs13120400;METABOLISM/PK;;CONCENTRATIONS;;PEOPLE;DISEASE:CENTRAL_NERVOUS_SYSTEM_INFECTIOUS_DISORDER;CAUTION_DOSE_ADJUST
RIBAVIRIN;ITPA;CC;rs1127354;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CT;rs776746;METABOLISM/PK;DECREASED;EXPOSURE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
PRAVASTATIN;SLCO1B1;AG;rs4149015;METABOLISM/PK;INCREASED;RESPONSE;;CHILDREN;DISEASE:HYPERLIPOPROTEINEMIA_TYPE_II;LIKELIHOOD_THERAPEUTIC_SUCCESS
CREATINE;MOBP;AA + AG;rs616147;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:AMYOTROPHIC_LATERAL_SCLEROSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEMETREXED;EXO1;AA + AG;rs1047840;EFFICACY;DECREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:LUNG_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
PRAVASTATIN;SLCO1B1;CT;rs4149056;EFFICACY;INCREASED;RESPONSE;;CHILDREN;DISEASE:TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
PHENPROCOUMON;STX4;T;rs10871454;DOSAGE;DECREASED;DOSE;;;OTHER:MAINTENANCE_DOSAGE_BY_4.8_MG/WEEK;CAUTION_DOSE_ADJUST
PRAVASTATIN;SLCO1B1;CT;rs4149056;METABOLISM/PK;INCREASED;METABOLISM;;CHILDREN;DISEASE:TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
PROPOFOL;CYP2B6;GT + TT;rs3745274;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ADALIMUMAB, ETANERCEPT, INFLIXIMAB, TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TLR9;CT + TT;rs352139;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
VALPROIC ACID;CYP2C19;AA + AG;rs4244285;DOSAGE, METABOLISM/PK;INCREASED;DOSE;;PEOPLE;DISEASE:MYELODYSPLASTIC_SYNDROMES;CAUTION_DOSE_ADJUST
APIXABAN;ABCG2;TT;rs2231142;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:ATRIAL_FIBRILLATION;CAUTION_DRUG_ACCUMULATION
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
3,4-METHYLENEDIOXYMETHAMPHETAMINE;SLC6A2;TT;rs2242446;OTHER;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
ATENOLOL;AGT;AG + GG;rs699;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRBESARTAN;CYP2C9;AC;rs1057910;METABOLISM/PK;DECREASED;CLEARANCE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
3,4-METHYLENEDIOXYMETHAMPHETAMINE;SLC6A2;GG;rs1861647;OTHER;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
3,4-METHYLENEDIOXYMETHAMPHETAMINE;SLC6A2;AA;rs36029;OTHER;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATENOLOL;AGT;CT + TT;rs5051;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRBESARTAN;CYP2C9;AC;rs1057910;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
IRBESARTAN;CYP2C9;CT;rs72558187;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
IRBESARTAN;CYP2C9;AC;rs1057910;METABOLISM/PK;INCREASED;CONCENTRATIONS;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
ADALIMUMAB, CERTOLIZUMAB PEGOL, ETANERCEPT, GLUCOCORTICOIDS, INFLIXIMAB, METHOTREXATE;HLA-E;AA;rs1264457;EFFICACY;INCREASED;RESPONSE;;WOMEN;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
REPAGLINIDE;SLC30A8;CT + TT;rs13266634;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
DISULFIRAM;ADRA1A;AA + AG;rs1048101;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:COCAINE_DEPENDENCE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ADALIMUMAB, CERTOLIZUMAB PEGOL, ETANERCEPT, GLUCOCORTICOIDS, INFLIXIMAB, METHOTREXATE;ATP5F1E;GG;rs1059150;EFFICACY;DECREASED;RESPONSE;;WOMEN;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
SIROLIMUS;ABCB1;AG;rs1045642;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
MERCAPTOPURINE;NUDT15;TT;rs116855232;DOSAGE;DECREASED;DOSE;;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DOSE_ADJUST
FELODIPINE;ABCG2;TT;rs2231142;METABOLISM/PK;INCREASED;EXPOSURE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
DEXMEDETOMIDINE;CYP2A6;C;rs28399433;METABOLISM/PK;DECREASED;CLEARANCE;;WOMEN;;CAUTION_DRUG_ACCUMULATION
IRBESARTAN;CYP2C9;CT;rs1799853;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
FENTANYL;CALCA;GG;rs145837941;DOSAGE;INCREASED;DOSE;;PEOPLE;OTHER:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
NITRIC OXIDE;NAMPT;TT;rs1319501;EFFICACY;INCREASED;CONCENTRATIONS;;WOMEN;OTHER:PRE-ECLAMPSIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
TOCILIZUMAB;GALNT18;CC + CT;rs4910008;EFFICACY;INCREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUPRENORPHINE;OPRD1;AA;rs529520;EFFICACY;DECREASED;RESPONSE;;WOMEN;DISEASE:OPIOID-RELATED_DISORDERS;LIKELIHOOD_THERAPEUTIC_FAILURE
NICOTINE;;C;rs12459249;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
WARFARIN;GGCX;AA + AG;rs2592551;DOSAGE;INCREASED;DOSE;;PEOPLE;DISEASE:ATRIAL_FIBRILLATION;CAUTION_DOSE_ADJUST
ARSENIC COMPOUNDS;AS3MT;C;rs11191439;TOXICITY, METABOLISM/PK;INCREASED;METABOLISM;;HEALTHY;;CAUTION_SIDE_EFFECT
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;HTR7;TT;rs7905446;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:DEPRESSION;LIKELIHOOD_THERAPEUTIC_FAILURE
ESCITALOPRAM;HTR7;TT;rs7905446;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:DEPRESSION;LIKELIHOOD_THERAPEUTIC_FAILURE
ATOMOXETINE, DESVENLAFAXINE, DULOXETINE, SELECTIVE SEROTONIN REUPTAKE INHIBITORS, VENLAFAXINE;HTR7;TT;rs7905446;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:DEPRESSION;LIKELIHOOD_THERAPEUTIC_FAILURE
IRBESARTAN;CYP2C9;CT;rs72558187;METABOLISM/PK;DECREASED;CLEARANCE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
TOCILIZUMAB;IL6;CC;rs2069840;EFFICACY;DECREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIDEPRESSANTS;HTR7;TT;rs7905446;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:DEPRESSION;LIKELIHOOD_THERAPEUTIC_FAILURE
IRBESARTAN;CYP2C9;CT;rs72558187;METABOLISM/PK;INCREASED;CONCENTRATIONS;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
BENAZEPRIL;MTHFR;G;rs1801131;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOXETINE, PAROXETINE;HTR7;TT;rs7905446;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:BIPOLAR_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
BENAZEPRIL;MTHFR;G;rs1801133;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_FAILURE
TRAMADOL;CYP2B6;TT;rs3745274;METABOLISM/PK;INCREASED;EXPOSURE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
IRBESARTAN;CYP2C9;AC;rs1057910;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:ESSENTIAL_HYPERTENSION;CAUTION_DRUG_ACCUMULATION
PAROXETINE;HTR7;TT;rs7905446;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:BIPOLAR_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
FENTANYL;CALCA;AG + GG;rs145837941;DOSAGE;INCREASED;DOSE;;WOMEN;OTHER:POSTOPERATIVE_PAIN, OTHER:CAESARIAN_SECTION;CAUTION_DOSE_ADJUST
PEMETREXED;CAMKK2;GT;rs1653586;EFFICACY;DECREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:LUNG_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
ABIRATERONE;SRD5A2;CC;rs523349;EFFICACY;INCREASED;RESPONSE;;MEN;OTHER:PROSTATIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUPRENORPHINE;OPRD1;AA + AG;rs581111;EFFICACY;DECREASED;RESPONSE;;WOMEN;DISEASE:OPIOID-RELATED_DISORDERS;LIKELIHOOD_THERAPEUTIC_FAILURE
CARBOPLATIN, LONAFARNIB, PACLITAXEL;FNTB;GG;rs11623866;EFFICACY;;RESPONSE;;WOMEN;DISEASE:OVARIAN_NEOPLASMS;CAUTION_DOSE_ADJUST
METHOTREXATE;ABCG2;GG;rs12505410;METABOLISM/PK;INCREASED;CLEARANCE;;PEOPLE;DISEASE:OSTEOSARCOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
ESCITALOPRAM;BMP5;A;rs41271330;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
ENALAPRIL;CES1;CT;rs71647871;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;ABCG2;GT + TT;rs13137622;METABOLISM/PK;INCREASED;CLEARANCE;;PEOPLE;DISEASE:OSTEOSARCOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;ABCG2;CC;rs13120400;METABOLISM/PK;INCREASED;CLEARANCE;;PEOPLE;DISEASE:OSTEOSARCOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
AMLODIPINE;CYP3A4;CT + TT;rs2740574;EFFICACY;INCREASED;RESPONSE;;WOMEN;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;IL18;GG + GT;rs1946518;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;DISEASE:LUNG_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;IL10;TT;rs1800896;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;DISEASE:LUNG_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
RIVASTIGMINE;BCHE;CT + TT;rs1803274;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:ALZHEIMER_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;GT + TT;rs3745274;METABOLISM/PK;;CONCENTRATIONS;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2B6;G;rs35303484;METABOLISM/PK;;CONCENTRATIONS;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DOSE_ADJUST
VALPROIC ACID;CYP2C9;C;rs1057910;METABOLISM/PK;INCREASED;CONCENTRATIONS;;CHILDREN;OTHER:EPILEPSY;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;MTHFR;AG + GG;rs1801133;METABOLISM/PK;INCREASED;STEADY-STATE_CONCENTRATION;;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DRUG_ACCUMULATION
AZATHIOPRINE;NUDT15;TT;rs116855232;TOXICITY;DECREASED;DOSE;;PEOPLE;DISEASE:LEUKOPENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CELECOXIB;PTGS2;CC;rs689466;EFFICACY;INCREASED;RESPONSE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOZAPINE;NFIB;CT;rs28379954;METABOLISM/PK;DECREASED;CONCENTRATIONS;;PEOPLE;OTHER:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;DISEASE:LUNG_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
METFORMIN;SLC22A1;AA + AG;rs594709;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN;TDP1;GG;rs2401863;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
LOSARTAN;CYP2C9;AA;rs1934969;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
METFORMIN;SLC47A1;GG;rs2289669;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;IL18;CC + CG;rs5744247;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;DISEASE:LUNG_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;SLC19A1;TT;rs1051266;METABOLISM/PK;INCREASED;STEADY-STATE_CONCENTRATION;;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DRUG_ACCUMULATION
DEXMEDETOMIDINE;CYP2D6;GG;rs16947;DOSAGE;INCREASED;DOSE;;PEOPLE;OTHER:SURGERY;CAUTION_DOSE_ADJUST
CARBAMAZEPINE;CYP1A2;AA;rs762551;METABOLISM/PK;INCREASED;CLEARANCE;;CHILDREN;DISEASE:EPILEPSY;LIKELIHOOD_THERAPEUTIC_FAILURE
RIVAROXABAN;CYP3A4;T;rs2242480;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;OTHER:ATRIAL_FIBRILLATION;CAUTION_DRUG_ACCUMULATION
CYCLOSPORINE, TACROLIMUS;CYP3A5;CC;rs776746;DOSAGE, METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;OTHER:LIVER_TRANSPLANTATION;CAUTION_DOSE_ADJUST
METHOTREXATE;UGT1A1, UGT1A10, UGT1A3, UGT1A4, UGT1A5, UGT1A6, UGT1A7, UGT1A8, UGT1A9;GG + GT;rs4148324;METABOLISM/PK;DECREASED;CLEARANCE;;PEOPLE;DISEASE:OSTEOSARCOMA;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;ABCB1;C;rs3842;METABOLISM/PK;;CONCENTRATIONS;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DOSE_ADJUST
CYCLOSPORINE, TACROLIMUS;CYP3A5;CC;rs776746;DOSAGE, METABOLISM/PK;DECREASED;DOSE;;PEOPLE;OTHER:LIVER_TRANSPLANTATION;CAUTION_DOSE_ADJUST
DEXMEDETOMIDINE;WBP2NL;AG + GG;rs5758550;TOXICITY;INCREASED;RESPONSE;;PEOPLE;OTHER:SURGERY;CAUTION_SIDE_EFFECT
MEMANTINE, RIVASTIGMINE;BCHE;CT + TT;rs1803274;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:ALZHEIMER_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP4F2;CC;rs2108622;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;GGCX;CC;rs699664;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
METHOTREXATE;MTHFR;GT;rs1801131;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;ABCB1;AA;rs1045642;METABOLISM/PK;DECREASED;EXPOSURE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;POR;CT + TT;rs1057868;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;VKORC1;GG;rs9934438;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
RIVASTIGMINE;BCHE;CT;rs1803274;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:LEWY_BODY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
FENTANYL;CALCA;GG;rs145837941;DOSAGE;INCREASED;DOSE;;PEOPLE;OTHER:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
APIXABAN;ABCG2;G;rs2231142;METABOLISM/PK;DECREASED;CONCENTRATIONS;;PEOPLE;OTHER:ATRIAL_FIBRILLATION;LIKELIHOOD_THERAPEUTIC_FAILURE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNFRSF1B;GG;rs1061622;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNFRSF1B;CC;rs3397;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
AMLODIPINE;ABCB1;GG;rs1045642;METABOLISM/PK;DECREASED;CLEARANCE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
LATANOPROST;PTGFR;CC;rs3766355;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:GLAUCOMA, DISEASE:OCULAR_HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNFRSF1B;AA;rs1061631;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;MTHFR;AG;rs1801133;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNFRSF1B;C;rs3397;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
AMLODIPINE;ABCB1;CC;rs2032582;METABOLISM/PK;DECREASED;CLEARANCE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
METHADONE;NECTIN4;AA;rs11265549;METABOLISM/PK;DECREASED;CONCENTRATIONS;;PEOPLE;OTHER:OPIOID-RELATED_DISORDERS;LIKELIHOOD_THERAPEUTIC_FAILURE
OPIOID ANESTHETICS, OTHER GENERAL ANESTHETICS, VOLATILE ANESTHETICS;OPRM1;GG;rs1799971;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOID ANESTHETICS, OTHER GENERAL ANESTHETICS, VOLATILE ANESTHETICS;ABCG2;TT;rs2231142;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHADONE;NECTIN4;AA;rs11265549;DOSAGE;DECREASED;DOSE;;PEOPLE;OTHER:OPIOID-RELATED_DISORDERS;CAUTION_DOSE_ADJUST
DEXMEDETOMIDINE;KCNMA1;AA + AG;rs16934182;DOSAGE;DECREASED;DOSE;;PEOPLE;OTHER:SURGERY;CAUTION_DOSE_ADJUST
DABIGATRAN;CES1;GG + GT;rs2244613;METABOLISM/PK;DECREASED;CONCENTRATIONS;;PEOPLE;OTHER:ATRIAL_FIBRILLATION;LIKELIHOOD_THERAPEUTIC_FAILURE
ATORVASTATIN;ABCG8;CC + CG;rs11887534;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HYPERCHOLESTEROLEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
DEXMEDETOMIDINE;ADRA2A;GG;rs1800544;DOSAGE;DECREASED;DOSE;;PEOPLE;OTHER:SURGERY;CAUTION_DOSE_ADJUST
TAMOXIFEN-N-GLUCURONIDE;UGT1A4;GG + GT;rs2011425;METABOLISM/PK;INCREASED;CONCENTRATIONS;;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_DRUG_ACCUMULATION
IMATINIB;CYP2B6;GG + GT;rs3745274;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;ATIC;CC;rs4673993;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
BENAZEPRIL;AGT;GG;rs7079;EFFICACY;;RESPONSE;;WOMEN;DISEASE:HYPERTENSION;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;GG;rs9332098;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
CANNABIDIOL;;CC;rs6729738;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:EPILEPSY;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;MTHFR;AG + GG;rs1801133;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
DEXMEDETOMIDINE;ADRB2;AA;rs1042713;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:SURGERY;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;TT;rs9332092;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
HYDROCHLOROTHIAZIDE;TXNDC11;G;rs3784921;EFFICACY;DECREASED;RESPONSE;;PEOPLE;OTHER:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;CC;rs1057910;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
PAROXETINE;CYP1A2;A;rs762551;METABOLISM/PK;INCREASED;DOSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;TT;rs1799853;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;TT;rs3745274;METABOLISM/PK;DECREASED;CLEARANCE;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
DEXMEDETOMIDINE;KCNMA1;AA + AG;rs16934182;TOXICITY;INCREASED;RESPONSE;;PEOPLE;OTHER:SURGERY;CAUTION_SIDE_EFFECT
TOPOTECAN;ABCG2;AA + AG;rs4148157;METABOLISM/PK;INCREASED;CONCENTRATIONS;;CHILDREN;DISEASE:BRAIN_NEOPLASMS;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;CC + CT;rs28399499;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
RIVAROXABAN;CYP3A4;G;rs2246709;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;OTHER:ATRIAL_FIBRILLATION;CAUTION_DRUG_ACCUMULATION
DULOXETINE;KMT2E;GG;rs117986340;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIVASTIGMINE;ACHE;TT;rs2571598;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:ALZHEIMER_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
MORPHINE;OPRM1;AG + GG;rs1799971;DOSAGE, EFFICACY;INCREASED;DOSE;;WOMEN;DISEASE:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
DULOXETINE;NCAM1;TT;rs2303377;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIVAROXABAN;CYP3A5;T;rs776746;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;OTHER:ATRIAL_FIBRILLATION;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;DISEASE:HEART_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;GT + TT;rs3745274;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
DULOXETINE;ZNF385D;TT;rs4261893;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;AG + GG;rs2279343;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
RIVAROXABAN;CYP3A4;C;rs3735451;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;OTHER:ATRIAL_FIBRILLATION;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;GG;rs2359612;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;TT;rs7294;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
DEXMEDETOMIDINE;;CC;rs141294036;TOXICITY;INCREASED;RESPONSE;;PEOPLE;OTHER:SURGERY;CAUTION_SIDE_EFFECT
AMPHETAMINE;CDH13;AG + GG;rs3784943;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
EVEROLIMUS;CYP3A4;AG;rs35599367;METABOLISM/PK;INCREASED;CONCENTRATIONS;;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_DRUG_ACCUMULATION
PRAVASTATIN;SLCO1B1;CT;rs4149056;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:CORONARY_STENOSIS;LIKELIHOOD_THERAPEUTIC_FAILURE
DEXMEDETOMIDINE;KCNMB1;CC + CT;rs11739136;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:SURGERY;LIKELIHOOD_THERAPEUTIC_SUCCESS
MORPHINE;UGT2B7;CC + CT;rs7668282;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:SICKLE_CELL_ANEMIA;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2A7P1, CYP2B6;T;rs3745274;METABOLISM/PK;INCREASED;CONCENTRATIONS;;WOMEN;OTHER:PREGNANCY;CAUTION_DRUG_ACCUMULATION
DABIGATRAN;CES1;GG;rs8192935;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;OTHER:ATRIAL_FIBRILLATION;CAUTION_DRUG_ACCUMULATION
ETHANOL;OPRM1;AG + GG;rs1799971;DOSAGE;DECREASED;DOSE;;WOMEN;;CAUTION_DOSE_ADJUST
METHOTREXATE;CLCN6, MTHFR;AA;rs1801133;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;C1orf167, CLCN6, MTHFR;TT;rs1801131;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;MTR;AA;rs1805087;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
RANIBIZUMAB;CXCL8;AA;rs4073;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:MACULAR_DEGENERATION;LIKELIHOOD_THERAPEUTIC_FAILURE
ETHANOL;OPRM1;AA;rs10485057;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;A;rs9934438;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
OPIOIDS;COMT;AA + AG;rs4680;DOSAGE;DECREASED;DOSE;;PEOPLE;OTHER:PAIN, OTHER:NEOPLASMS;CAUTION_DOSE_ADJUST
METHOTREXATE;BIRC5;CG;rs9904341;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACENOCOUMAROL;VKORC1;GG;rs9934438;EFFICACY;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
SALBUTAMOL;;A;rs17834628;EFFICACY;INCREASED;RESPONSE;;CHILDREN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;CHRNA3;A;rs1051730;DOSAGE;DECREASED;DOSE;;PEOPLE;OTHER:TOBACCO_USE_DISORDER;CAUTION_DOSE_ADJUST
ABIRATERONE, PREDNISOLONE;TSPYL1;A;rs3828743;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:PROSTATIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
PLATINUM;RICTOR;GG;rs6878291;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;GT;rs3745274;METABOLISM/PK;DECREASED;CLEARANCE;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
CLOZAPINE;DRD2;T;rs2514218;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;FASTKD3, MTRR;AA + AG;rs1801394;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
RANIBIZUMAB;KDR;AA + AG;rs2071559;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:MACULAR_DEGENERATION;LIKELIHOOD_THERAPEUTIC_FAILURE
ETHANOL;OPRM1;AG;rs1799971;OTHER;INCREASED;RESPONSE;;PEOPLE;OTHER:ALCOHOL_ABUSE;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUSULFAN;GSTA1;CT;rs3957356;METABOLISM/PK;DECREASED;CLEARANCE;;PEOPLE;OTHER:HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;ATIC;CT + TT;rs12995526;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOZAPINE;HTR3A;T;rs1062613;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;ATIC;CT + TT;rs7563206;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP4F2;CC;rs2108622;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
METHOTREXATE;ATIC;CC + CG;rs2372536;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;ATIC;CT + TT;rs4673993;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
CANDESARTAN;KCNK3;C;rs1275988;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
RISPERIDONE;NR1I2;CC;rs1523130;METABOLISM/PK;DECREASED;CLEARANCE;;PEOPLE;DISEASE:BIPOLAR_DISORDER, DISEASE:DEPRESSION,DISEASE:SUBSTANCE-RELATED_DISORDERS;CAUTION_DRUG_ACCUMULATION
SUFENTANIL;ABCB1;GG;rs1045642;DOSAGE;INCREASED;DOSE;;CHILDREN;OTHER:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
ADALIMUMAB;IL17F;TT;rs763780;EFFICACY;INCREASED;RESPONSE;;PEOPLE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IMMUNOGLOBULINS;CASP3, PRIMPOL;CT + TT;rs113420705;EFFICACY;DECREASED;RESPONSE;;CHILDREN;DISEASE:MUCOCUTANEOUS_LYMPH_NODE_SYNDROME;LIKELIHOOD_THERAPEUTIC_FAILURE
SUFENTANIL;COMT;AA;rs4680;DOSAGE;INCREASED;DOSE;;CHILDREN;OTHER:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;CC;rs7294;DOSAGE;DECREASED;CONCENTRATIONS;;PEOPLE;OTHER:HEART_VALVE_REPLACEMENT;CAUTION_DOSE_ADJUST
IMMUNOGLOBULINS;COQ8B, ITPKC;CC + CG;rs28493229;EFFICACY;DECREASED;RESPONSE;;CHILDREN;DISEASE:MUCOCUTANEOUS_LYMPH_NODE_SYNDROME;LIKELIHOOD_THERAPEUTIC_FAILURE
USTEKINUMAB;IL17F;TT;rs763780;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:PSORIASIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;AA;rs1057910;DOSAGE;INCREASED;DOSE;;PEOPLE;OTHER:HEART_VALVE_REPLACEMENT;CAUTION_DOSE_ADJUST
INFLIXIMAB;IL17F;CT;rs763780;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:PSORIASIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
HYDROCHLOROTHIAZIDE;CSK;C;rs1378942;EFFICACY;DECREASED;RESPONSE;;PEOPLE;OTHER:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_FAILURE
SALBUTAMOL;;G;rs35661809;EFFICACY;INCREASED;RESPONSE;;CHILDREN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIPSYCHOTICS;DRD3;CT + TT;rs6280;EFFICACY;INCREASED;RESISTANCE;;PEOPLE;OTHER:MOOD_DISORDER, OTHER:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_FAILURE
HYDROCHLOROTHIAZIDE;PDE3A;C;rs12579720;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
CANDESARTAN;SULT1C3;T;rs6722745;EFFICACY;DECREASED;RESPONSE;;PEOPLE;OTHER:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_FAILURE
ATENOLOL;STN1;A;rs4387287;EFFICACY;DECREASED;RESPONSE;;PEOPLE;OTHER:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_FAILURE
METFORMIN;;TT;rs10783050;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:DIABETES_MELLITUS;LIKELIHOOD_THERAPEUTIC_SUCCESS
METFORMIN;IL1B;GG;rs1143623;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:DIABETES_MELLITUS;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;TT;rs9923231;DOSAGE;DECREASED;DOSE;;PEOPLE;;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;TT;rs9923231;METABOLISM/PK;DECREASED;CONCENTRATIONS;;PEOPLE;;LIKELIHOOD_THERAPEUTIC_FAILURE
CISPLATIN, PACLITAXEL;TP53;CG + GG;rs1042522;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:STOMACH_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
RIFAPENTINE;ABCB1;AA + AG;rs1045642;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
BEVACIZUMAB, PEGAPTANIB, RANIBIZUMAB;VEGFA;CC;rs2010963;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:CHOROIDAL_NEOVASCULARIZATION;LIKELIHOOD_THERAPEUTIC_FAILURE
EPIRUBICIN, FLUOROURACIL, OXALIPLATIN;NQO1;AA + AG;rs1800566;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:METASTATIC_NEOPLASM, DISEASE:STOMACH_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;VKORC1;CT;rs9923231;EFFICACY;INCREASED;DOSE;;PEOPLE;OTHER:LEFT_VENTRICULAR_DYSFUNCTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
EPIRUBICIN, FLUOROURACIL, OXALIPLATIN;PON1;CC;rs662;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:METASTATIC_NEOPLASM, DISEASE:STOMACH_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
RISPERIDONE;NR1I2;CC;rs2276707;METABOLISM/PK;DECREASED;CLEARANCE;;PEOPLE;DISEASE:BIPOLAR_DISORDER, DISEASE:DEPRESSION,DISEASE:SUBSTANCE-RELATED_DISORDERS;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;C;rs28399499;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;OTHER:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;CT;rs9923231;EFFICACY;DECREASED;RESPONSE;;PEOPLE;OTHER:LEFT_VENTRICULAR_DYSFUNCTION;LIKELIHOOD_THERAPEUTIC_FAILURE
RITUXIMAB;FCGR3A;C;rs396991;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:AUTOIMMUNE_DISEASES;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;CHRNA3, CHRNA5;AA + AG;rs16969968;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:TOBACCO_USE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOZAPINE;HTR3A;G;rs2276302;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
IMATINIB;ABCB1;AT + TT;rs2032582;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;LIKELIHOOD_THERAPEUTIC_FAILURE
IMATINIB;ABCG2;T;rs2231142;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;LIKELIHOOD_THERAPEUTIC_FAILURE
TELMISARTAN;GNB3;TT;rs5443;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:ESSENTIAL_HYPERTENSION;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;T;rs8192719;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;OTHER:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
LITHIUM, VALPROIC ACID;;CC;rs2769605;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:BIPOLAR_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
CISPLATIN, FLUOROURACIL;GNAS;CC;rs7121;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:NEOPLASM_OF_ESOPHAGUS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATENOLOL, METOPROLOL;ZMAT4;T;rs1367094;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;T;rs3745274;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;OTHER:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
ATENOLOL, HYDROCHLOROTHIAZIDE, METOPROLOL;LRRC15;del;rs11313667;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ONDANSETRON;CYP3A5;CC;rs776746;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
LITHIUM, OLANZAPINE;DRD2;GG;rs1800497;EFFICACY;INCREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:BIPOLAR_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
HMG_COA_REDUCTASE_INHIBITORS;;T;rs247616;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
BOCEPREVIR, PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIR;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ADALIMUMAB, CERTOLIZUMAB PEGOL, ETANERCEPT, GLUCOCORTICOIDS, INFLIXIMAB, METHOTREXATE;KLRC1;CC;rs7301582;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
HYDROCHLOROTHIAZIDE;PRKAG2;A;rs10224002;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
AGOMELATINE, MELATONIN RECEPTOR AGONISTS, SELECTIVE SEROTONIN REUPTAKE INHIBITORS, VENLAFAXINE;ABCB1;GG;rs1045642;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
ADALIMUMAB, CERTOLIZUMAB PEGOL, ETANERCEPT, GLUCOCORTICOIDS, INFLIXIMAB, METHOTREXATE;KLRD1;TT;rs2302489;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;;CHILDREN;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
HYDROCHLOROTHIAZIDE;PLCE1;A;rs932764;EFFICACY;DECREASED;RESPONSE;;PEOPLE;OTHER:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN, SIMEPREVIR;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
METOPROLOL;;T;rs1446468;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATENOLOL;RRP1B;T;rs9306160;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATENOLOL;TBX2;C;rs8068318;EFFICACY;DECREASED;RESPONSE;;PEOPLE;OTHER:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_FAILURE
AMISULPRIDE;DRD2;C;rs1079597;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
USTEKINUMAB;NFKBIA;CC;rs2145623;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:PSORIASIS;LIKELIHOOD_THERAPEUTIC_FAILURE
HYDROCHLOROTHIAZIDE;ADO;C;rs10995311;EFFICACY;DECREASED;RESPONSE;;PEOPLE;OTHER:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_FAILURE
PLATINUM COMPOUNDS;XBP1;CC;rs2269577;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CANDESARTAN;DOT1L, PLEKHJ1;A;rs740406;EFFICACY;DECREASED;RESPONSE;;PEOPLE;OTHER:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_FAILURE
USTEKINUMAB;ADAM33;CC;rs2787094;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:PSORIASIS;LIKELIHOOD_THERAPEUTIC_FAILURE
HYDROCHLOROTHIAZIDE;NUCB2;C;rs757081;EFFICACY;DECREASED;RESPONSE;;PEOPLE;OTHER:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_FAILURE
USTEKINUMAB;;AG + GG;rs1975974;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:PSORIASIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
EXENATIDE;KCNQ1;G;rs163184;EFFICACY;DECREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;TT;rs3745274;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE, DISEASE:TUBERCULOSIS;CAUTION_DRUG_ACCUMULATION
USTEKINUMAB;AGBL4;CC + CT;rs191190;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:PSORIASIS;LIKELIHOOD_THERAPEUTIC_FAILURE
NORTRIPTYLINE;SLC39A14;C;rs17060812;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:DEPRESSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACENOCOUMAROL;VKORC1;CC;rs9923231;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
USTEKINUMAB;CHUK;CC + CG;rs11591741;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:PSORIASIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
USTEKINUMAB;HTR2A;CT + TT;rs6311;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:PSORIASIS;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;VKORC1;CC + CT;rs9923231;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
HYDROCHLOROTHIAZIDE;C5orf56;G;rs12521868;EFFICACY;DECREASED;RESPONSE;;PEOPLE;OTHER:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_FAILURE
PITAVASTATIN;SLCO1B1;CC + CT;rs4149056;METABOLISM/PK;INCREASED;CONCENTRATIONS;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
CANDESARTAN;SH2B3;T;rs3184504;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:EPILEPSY;CAUTION_DRUG_ACCUMULATION
2-HYDROXYATORVASTATIN, 2-HYDROXYATORVASTATIN LACTONE, 4-HYDROXYATORVASTATIN, 4-HYDROXYATORVASTATIN LACTONE, ATORVASTATIN, ATORVASTATIN LACTONE;SLCO1B1;C;rs4149056;METABOLISM/PK;INCREASED;EXPOSURE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
CARBAMAZEPINE;CYP3A5;AA;rs15524;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:EPILEPSY;CAUTION_DRUG_ACCUMULATION
PAROXETINE;COMT;A;rs4680;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE, PACLITAXEL;TP53;GG;rs1042522;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:STOMACH_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
SUFENTANIL;CYP3A4;CC;rs2242480;DOSAGE;INCREASED;DOSE;;WOMEN;OTHER:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
TRIGLYCERIDES;CYP19A1;A;rs749292;OTHER;DECREASED;CONCENTRATIONS;;WOMEN;DISEASE:BREAST_NEOPLASMS, DISEASE:MENOPAUSE;LIKELIHOOD_THERAPEUTIC_FAILURE
HDL CHOLESTEROL;CYP19A1;G;rs1062033;OTHER;INCREASED;CONCENTRATIONS;;WOMEN;DISEASE:BREAST_NEOPLASMS, DISEASE:MENOPAUSE;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;C;rs28399499;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;AA;rs1057910;DOSAGE;INCREASED;DOSE;;PEOPLE;DISEASE:HEART_VALVE_DISEASES;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;AA;rs9934438;DOSAGE;DECREASED;DOSE;;PEOPLE;OTHER:HEART_VALVE_REPLACEMENT;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2B6;T;rs3745274;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
NORTRIPTYLINE;PPM1A;AA;rs2273623;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:DEPRESSION;LIKELIHOOD_THERAPEUTIC_FAILURE
AMILORIDE, SPIRONOLACTONE;CYP4A11;GG;rs1126742;EFFICACY;DECREASED;RESPONSE;;PEOPLE;OTHER:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_FAILURE
AZATHIOPRINE, MERCAPTOPURINE;NUDT15;TT;rs116855232;DOSAGE;DECREASED;DOSE;;PEOPLE;DISEASE:INFLAMMATORY_BOWEL_DISEASES;CAUTION_DOSE_ADJUST
DEFERASIROX;UGT1A3;CC;rs3806596;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:BETA-THALASSEMIA_AND_RELATED_DISEASES;CAUTION_DRUG_ACCUMULATION
LOPINAVIR;CYP3A5;C;rs776746;METABOLISM/PK;INCREASED;TROUGH_CONCENTRATION;;PEOPLE;OTHER:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
PROPOFOL;CYP2B6;AA + AG;rs2279343;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
SPIRONOLACTONE;CYP4A11;CC;rs3890011;EFFICACY;DECREASED;RESPONSE;;PEOPLE;OTHER:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_FAILURE
OPIOIDS;OPRM1;AG + GG;rs1799971;DOSAGE, EFFICACY;INCREASED;DOSE;;PEOPLE;OTHER:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
ATAZANAVIR;NR1I2;TT;rs2472677;METABOLISM/PK;INCREASED;METABOLISM;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;DECREASED;CONCENTRATIONS;;PEOPLE;OTHER:LIVER_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
RIFAMPIN;AADAC;AA;rs1803155;METABOLISM/PK;DECREASED;CLEARANCE;;PEOPLE;OTHER:TUBERCULOSIS;CAUTION_DRUG_ACCUMULATION
APATINIB, APATINIB METABOLITE M1-1;CYP2C9;GG;rs1934968;METABOLISM/PK;INCREASED;EXPOSURE;;PEOPLE;OTHER:NEOPLASMS;CAUTION_DRUG_ACCUMULATION
PD-1/PDL-1 (PROGRAMMED CELL DEATH PROTEIN 1/DEATH LIGAND 1) INHIBITORS;FTO;AT + TT;rs11075995;EFFICACY;INCREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
AMPRENAVIR;SLCO1B1;C;rs4149056;METABOLISM/PK;DECREASED;TROUGH_CONCENTRATION;;PEOPLE;OTHER:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
ACAMPROSATE;;G;rs77583603;EFFICACY;DECREASED;RESPONSE;;PEOPLE;OTHER:ALCOHOL_ABUSE;LIKELIHOOD_THERAPEUTIC_FAILURE
EVEROLIMUS;CYP3A5;CC + CT;rs776746;METABOLISM/PK;DECREASED;CLEARANCE;;PEOPLE;DISEASE:HEART_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
NALTREXONE;;A;rs12749274;EFFICACY;DECREASED;RESPONSE;;PEOPLE;OTHER:ALCOHOL_ABUSE;LIKELIHOOD_THERAPEUTIC_FAILURE
DEFERASIROX;ABCG2;CC;rs13120400;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:BETA-THALASSEMIA_AND_RELATED_DISEASES;CAUTION_DRUG_ACCUMULATION
FLUVASTATIN;SLCO1B1;CC + CT;rs4149056;EFFICACY;INCREASED;CLINICAL_BENEFIT;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RITONAVIR;ABCB1;AA;rs1128503;METABOLISM/PK;INCREASED;CLEARANCE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
RITONAVIR;ABCB1;AA;rs2032582;METABOLISM/PK;INCREASED;CLEARANCE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUVASTATIN;APOE;CC;rs429358;EFFICACY;INCREASED;CLINICAL_BENEFIT;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RITONAVIR;ABCB1;AA;rs1045642;METABOLISM/PK;INCREASED;CLEARANCE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
DOXORUBICIN;CBR1;CC;rs20572;METABOLISM/PK;INCREASED;CLEARANCE;;PEOPLE;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
DEHYDROARIPIPRAZOLE;CYP1A2;AA;rs762551;METABOLISM/PK;DECREASED;CONCENTRATIONS;;PEOPLE;OTHER:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOZAPINE;CYP1A2;AA;rs762551;METABOLISM/PK;DECREASED;EXPOSURE;;PEOPLE;OTHER:SCHIZOPHRENIA, OTHER:TOBACCO_USE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
ETHANOL;OPRM1;AA;rs1799971;DOSAGE;INCREASED;DOSE;;CHILDREN;;CAUTION_DOSE_ADJUST
PREDNISOLONE;GATA3;AA;rs3824662;EFFICACY;DECREASED;CLINICAL_BENEFIT;;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;GSTM3;TT;rs7483;METABOLISM/PK;DECREASED;CONCENTRATIONS;;PEOPLE;OTHER:LIVER_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;MICA;AG;rs1051792;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ADALIMUMAB;TNF;CC;rs1799724;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;MICA;GG;rs1051792;EFFICACY;DECREASED;RESPONSE;;PEOPLE;OTHER:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOXETINE;HTR1B;AA + TT;rs130058;EFFICACY;INCREASED;RESPONSE;;CHILDREN;DISEASE:MENTAL_DISORDERS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ADALIMUMAB;TNF;GG;rs1800629;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOZAPINE;CYP1A2;AA;rs762551;EFFICACY;DECREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUVASTATIN;APOE;TT;rs7412;EFFICACY;INCREASED;CLINICAL_BENEFIT;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ADALIMUMAB;TNF;GG;rs361525;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
MORPHINE;SLC6A4;CC;rs1042173;DOSAGE;DECREASED;DOSE;;PEOPLE;OTHER:LUNG_NEOPLASMS, OTHER:PAIN;CAUTION_DOSE_ADJUST
FLUOXETINE;TPH2;TT;rs4570625;EFFICACY;INCREASED;RESPONSE;;CHILDREN;DISEASE:MENTAL_DISORDERS;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;ADORA2A-AS1;CT + TT;rs17004921;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIEPILEPTICS;ABCB1;AA;rs2032582;EFFICACY;INCREASED;CLINICAL_BENEFIT;;CHILDREN;OTHER:EPILEPSY;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIEPILEPTICS;ABCB1;AA;rs1045642;EFFICACY;INCREASED;CLINICAL_BENEFIT;;CHILDREN;OTHER:EPILEPSY;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATENOLOL, HYDROCHLOROTHIAZIDE;ALDH1A2;T;rs261316;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_FAILURE
CISPLATIN;REV3L;AG + GG;rs462779;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:OSTEOSARCOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
CISPLATIN;REV1;CT + TT;rs3087403;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:OSTEOSARCOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIEPILEPTICS;SCN1A;CC + CT;rs2298771;EFFICACY;INCREASED;RESISTANCE;;CHILDREN;OTHER:EPILEPSY;LIKELIHOOD_THERAPEUTIC_FAILURE
AZITHROMYCIN;ABCB1;AA;rs2032582;METABOLISM/PK;DECREASED;CONCENTRATIONS;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
AZITHROMYCIN;ABCB1;AA;rs1045642;METABOLISM/PK;DECREASED;CONCENTRATIONS;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
LOPINAVIR;SLCO1B1;C;rs4149056;METABOLISM/PK;INCREASED;TROUGH_CONCENTRATION;;PEOPLE;OTHER:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
FENTANYL;OPRM1;AA;rs9384179;DOSAGE, EFFICACY;INCREASED;DOSE;;PEOPLE;SIDE_EFFECT:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED;DOSE;;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED;DOSE;;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
FLUVASTATIN;CYP2C9;AC;rs1057910;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
FENTANYL;KCNJ6;TT;rs2835859;DOSAGE, EFFICACY;INCREASED;DOSE;;PEOPLE;SIDE_EFFECT:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
ABIRATERONE;HSD3B1;AC;rs1047303;METABOLISM/PK;INCREASED;METABOLISM;;MEN;OTHER:PROSTATIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
FENTANYL;;CC;rs2952768;DOSAGE, EFFICACY;INCREASED;DOSE;;PEOPLE;SIDE_EFFECT:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
FENTANYL;;AA;rs11959113;DOSAGE, EFFICACY;INCREASED;DOSE;;PEOPLE;SIDE_EFFECT:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED;DOSE;;PEOPLE;DISEASE:HEART_TRANSPLANTATION;CAUTION_DOSE_ADJUST
CYCLOPHOSPHAMIDE;GSTA1;CT;rs3957356;EFFICACY, TOXICITY, METABOLISM/PK;DECREASED;RESPONSE;;PEOPLE;DISEASE:LUPUS_NEPHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;T;rs3745274;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
BILIRUBIN;SOD2;GG;rs4880;TOXICITY;INCREASED;CONCENTRATIONS;;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;DISEASE:HEART_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;CHILDREN;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
ETHANOL;OPRM1;AG + GG;rs1799971;OTHER;INCREASED;EXPOSURE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
METHYLPHENIDATE;SLC6A2;GG;rs5569;EFFICACY;INCREASED;RESPONSE;;CHILDREN;DISEASE:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;POR;CT + TT;rs1057868;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;DISEASE:HEART_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
MONTELUKAST;UGT1A3;T;rs7604115;METABOLISM/PK;DECREASED;CONCENTRATIONS;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
MONTELUKAST;ABCC9;T;rs704212;METABOLISM/PK;DECREASED;CONCENTRATIONS;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
IVACAFTOR;CFTR;AA;rs77010898;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:CYSTIC_FIBROSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOCETAXEL, DOXORUBICIN;AKR1C3;GG;rs1937840;EFFICACY;INCREASED;RESPONSE;;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE, DOXORUBICIN;CYP2C19;AA + AG;rs4244285;EFFICACY;DECREASED;RESPONSE;;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIDEPRESSANTS;GRIK4;TT;rs1954787;EFFICACY;DECREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;OTHER:HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIDEPRESSANTS;GRIK4;C;rs1954787;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;CLEARANCE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED;DOSE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;AC;rs1057910;DOSAGE;DECREASED;DOSE;;PEOPLE;OTHER:AN_INTERNATIONAL_NORMALIZED_RATIO_(INR)_OF_2.0-3.0;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;T;rs7294;DOSAGE;INCREASED;DOSE;;PEOPLE;DISEASE:HEART_VALVE_REPLACEMENT;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;A;rs1057910;DOSAGE;INCREASED;DOSE;;PEOPLE;DISEASE:HEART_VALVE_REPLACEMENT;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;AG + GG;rs9934438;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
BUPRENORPHINE;OPRM1;CC + CG;rs2075572;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;OTHER:OPIOID-RELATED_DISORDERS;CAUTION_DRUG_ACCUMULATION
SELECTIVE SEROTONIN (5HT1) AGONISTS;PRDM16;C;rs2651899;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:MIGRAINE_WITH_AURA, OTHER:MIGRAINE_WITHOUT_AURA;LIKELIHOOD_THERAPEUTIC_SUCCESS
AFATINIB;NR1I2;AA + AG;rs6785049;METABOLISM/PK;DECREASED;CLEARANCE;;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;C;rs4917639;DOSAGE;DECREASED;DOSE;;PEOPLE;DISEASE:HEART_VALVE_REPLACEMENT;CAUTION_DOSE_ADJUST
RIVAROXABAN;ABCG2;TT;rs2231142;METABOLISM/PK;INCREASED;HALF-LIFE_TIME;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
LOPINAVIR;SLCO1B1;CT;rs4149056;METABOLISM/PK;INCREASED;EXPOSURE;;CHILDREN;OTHER:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
NALTREXONE;OPRM1;AG + GG;rs1799971;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:ALCOHOL_ABUSE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATAZANAVIR;ABCB1;AG + GG;rs1128503;METABOLISM/PK;DECREASED;CLEARANCE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
ANTIDEPRESSANTS;ABCB1;A;rs1128503;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHADONE;COMT;CC + CT;rs933271;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:OPIOID-RELATED_DISORDERS;LIKELIHOOD_THERAPEUTIC_SUCCESS
VALPROIC ACID;UGT1A10, UGT1A6, UGT1A7, UGT1A8, UGT1A9;AG;rs2070959;DOSAGE, METABOLISM/PK;INCREASED;DOSE;;PEOPLE;DISEASE:EPILEPSY;CAUTION_DOSE_ADJUST
ATAZANAVIR;ABCB1;AC + CC;rs2032582;METABOLISM/PK;DECREASED;CLEARANCE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
ATAZANAVIR;ABCB1;AG + GG;rs1045642;METABOLISM/PK;DECREASED;CLEARANCE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;MTHFR;GT + TT;rs1801131;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
VALPROIC ACID;GRIN2B;AC;rs1019385;DOSAGE, METABOLISM/PK;DECREASED;DOSE;;PEOPLE;DISEASE:EPILEPSY;CAUTION_DOSE_ADJUST
VALPROIC ACID;GRIN2B;CC;rs1019385;DOSAGE, METABOLISM/PK;DECREASED;DOSE;;PEOPLE;DISEASE:EPILEPSY;CAUTION_DOSE_ADJUST
METHOTREXATE;SLC19A1;CT + TT;rs1051266;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE, CLOBAZAM, ETHOSUXIMIDE, LAMOTRIGINE, LEVETIRACETAM, OXCARBAZEPINE, VALPROIC ACID;SCN1A;C;rs2298771;EFFICACY;INCREASED;RESPONSE;;CHILDREN;DISEASE:EPILEPSY;LIKELIHOOD_THERAPEUTIC_SUCCESS
LOPINAVIR;SLCO1B1;C;rs4149056;METABOLISM/PK;INCREASED;TROUGH_CONCENTRATION;;PEOPLE;OTHER:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
VALPROIC ACID;UGT1A6;AC;rs1105879;DOSAGE, METABOLISM/PK;INCREASED;DOSE;;PEOPLE;DISEASE:EPILEPSY;CAUTION_DOSE_ADJUST
FLUVASTATIN;SLCO1B1;TT;rs4149056;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
EVEROLIMUS;CYP3A5;CT;rs776746;METABOLISM/PK;DECREASED;TROUGH_CONCENTRATION;;PEOPLE;OTHER:BREAST_NEOPLASMS, OTHER:KIDNEY_NEOPLASMS,OTHER:NEUROENDOCRINE_TUMORS;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP4F2;C;rs2108622;DOSAGE;DECREASED;DOSE;;PEOPLE;DISEASE:HEART_VALVE_REPLACEMENT;CAUTION_DOSE_ADJUST
AMISULPRIDE;SNAP25;CT;rs8636;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;ABCA1;A;rs2487032;METABOLISM/PK;INCREASED;METABOLISM;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;N6AMT1;G;rs2254638;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
TENOFOVIR;ABCG2;GT + TT;rs2231142;METABOLISM/PK;INCREASED;CONCENTRATIONS;;WOMEN;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
SIROLIMUS;ABCB1;A;rs2032582;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
ANTIPSYCHOTICS;NRXN1;AA;rs12467557;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIPSYCHOTICS;NRXN1;TT;rs10490162;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;AA;rs4986893;EFFICACY;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
DABIGATRAN;CES1;GG;rs8192935;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:ATRIAL_FIBRILLATION;CAUTION_DRUG_ACCUMULATION
ATAZANAVIR;ABCB1;AA;rs2032582;METABOLISM/PK;INCREASED;CLEARANCE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
ADALIMUMAB, CERTOLIZUMAB PEGOL, GOLIMUMAB, INFLIXIMAB;TNF;GG;rs1800629;EFFICACY;INCREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:BEHCET_SYNDROME;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;AA;rs4244285;EFFICACY;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CC;rs776746;OTHER, METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
ATAZANAVIR;ABCB1;AA;rs1045642;METABOLISM/PK;INCREASED;CLEARANCE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;GT + TT;rs3745274;METABOLISM/PK;INCREASED;CONCENTRATIONS;;CHILDREN;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
BEVACIZUMAB;CFH;CC;rs1061170;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:MACULAR_DEGENERATION;LIKELIHOOD_THERAPEUTIC_FAILURE
VALPROIC ACID;UGT1A10, UGT1A6, UGT1A7, UGT1A8, UGT1A9;GG;rs2070959;DOSAGE, METABOLISM/PK;INCREASED;DOSE;;PEOPLE;DISEASE:EPILEPSY;CAUTION_DOSE_ADJUST
CISPLATIN, FLUOROURACIL;DPYD;CT;rs3918290;EFFICACY;DECREASED;RESPONSE;;MEN;DISEASE:HEAD_AND_NECK_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
CISPLATIN, DOCETAXEL, IRINOTECAN;XRCC3;AA;rs861539;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:STOMACH_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
VALPROIC ACID;UGT1A10, UGT1A6, UGT1A7, UGT1A8, UGT1A9;GG;rs6759892;DOSAGE, METABOLISM/PK;INCREASED;DOSE;;PEOPLE;DISEASE:EPILEPSY;CAUTION_DOSE_ADJUST
VALPROIC ACID;UGT1A10, UGT1A6, UGT1A7, UGT1A8, UGT1A9;GT;rs6759892;DOSAGE, METABOLISM/PK;INCREASED;DOSE;;PEOPLE;DISEASE:EPILEPSY;CAUTION_DOSE_ADJUST
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
VALPROIC ACID;UGT1A6;CC;rs1105879;DOSAGE, METABOLISM/PK;INCREASED;DOSE;;PEOPLE;DISEASE:EPILEPSY;CAUTION_DOSE_ADJUST
10-MONOHYDROXY OXCARBAZEPINE;INSR;C;rs2396185;METABOLISM/PK;DECREASED;CLEARANCE;;CHILDREN;OTHER:EPILEPSY;CAUTION_DRUG_ACCUMULATION
ATAZANAVIR;ABCB1;AA;rs1128503;METABOLISM/PK;INCREASED;CLEARANCE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;HTR1A;GG;rs6295;DOSAGE, EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_DOSE_ADJUST
FENTANYL;CACNA1E;CC + CT;rs3845446;DOSAGE;DECREASED;DOSE;;PEOPLE;OTHER:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
FENTANYL;LAMB3;G;rs2076222;DOSAGE, EFFICACY;INCREASED;DOSE;;PEOPLE;DISEASE:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
CETUXIMAB;VEGFA;TT;rs833061;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CETUXIMAB;VEGFA;GG;rs1570360;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN, FLUOROURACIL, MITOXANTRONE;MECP2;A;rs1734791;EFFICACY;;RESPONSE;;PEOPLE;DISEASE:HEPATOCELLULAR_CARCINOMA;CAUTION_DOSE_ADJUST
CISPLATIN, FLUOROURACIL, MITOXANTRONE;MECP2;A;rs1734787;EFFICACY;;RESPONSE;;PEOPLE;DISEASE:HEPATOCELLULAR_CARCINOMA;CAUTION_DOSE_ADJUST
CISPLATIN, FLUOROURACIL, MITOXANTRONE;MECP2;A;rs17435;EFFICACY;;RESPONSE;;PEOPLE;DISEASE:HEPATOCELLULAR_CARCINOMA;CAUTION_DOSE_ADJUST
VORICONAZOLE;CYP3A4;CT;rs2242480;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
CISPLATIN, FLUOROURACIL, MITOXANTRONE;;T;rs5906072;EFFICACY;;RESPONSE;;PEOPLE;DISEASE:HEPATOCELLULAR_CARCINOMA;CAUTION_DOSE_ADJUST
PROCHLORPERAZINE;ANKK1, DRD2;AA + AG;rs1800497;EFFICACY;DECREASED;RESPONSE;;PEOPLE;OTHER:NAUSEA;LIKELIHOOD_THERAPEUTIC_FAILURE
PROCHLORPERAZINE;DRD2;CT + TT;rs1079597;EFFICACY;DECREASED;RESPONSE;;PEOPLE;OTHER:NAUSEA;LIKELIHOOD_THERAPEUTIC_FAILURE
METFORMIN;ATM;AC;rs11212617;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
MORPHINE;OPRK1;A;rs1051660;DOSAGE, EFFICACY;DECREASED;DOSE;;PEOPLE;DISEASE:PAIN;CAUTION_DOSE_ADJUST
CISPLATIN, FLUOROURACIL, MITOXANTRONE;GALNT14;G;rs12613732;EFFICACY;;RESPONSE;;PEOPLE;DISEASE:HEPATOCELLULAR_CARCINOMA;CAUTION_DOSE_ADJUST
CISPLATIN, FLUOROURACIL, MITOXANTRONE;GALNT14;C;rs5009910;EFFICACY;;RESPONSE;;PEOPLE;DISEASE:HEPATOCELLULAR_CARCINOMA;CAUTION_DOSE_ADJUST
ATORVASTATIN;HMGCR;CT + TT;rs17671591;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HYPERCHOLESTEROLEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESCITALOPRAM;TPH1;GT + TT;rs1800532;EFFICACY;DECREASED;RESPONSE;;PEOPLE;OTHER:DEPRESSION;LIKELIHOOD_THERAPEUTIC_FAILURE
CISPLATIN, FLUOROURACIL, MITOXANTRONE;GALNT14;C;rs6752303;EFFICACY;;RESPONSE;;PEOPLE;DISEASE:HEPATOCELLULAR_CARCINOMA;CAUTION_DOSE_ADJUST
TENOFOVIR ALAFENAMIDE;CYP3A4;AG;rs35599367;METABOLISM/PK;DECREASED;CONCENTRATIONS;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
CISPLATIN, FLUOROURACIL, MITOXANTRONE;GALNT14;C;rs10209881;EFFICACY;;RESPONSE;;PEOPLE;DISEASE:HEPATOCELLULAR_CARCINOMA;CAUTION_DOSE_ADJUST
DABIGATRAN;CES1;GG;rs2244613;METABOLISM/PK;DECREASED;CONCENTRATIONS;;PEOPLE;DISEASE:ATRIAL_FIBRILLATION;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;A;rs4244285;METABOLISM/PK;INCREASED;DOSE;;HEALTHY;;CAUTION_DOSE_ADJUST
CISPLATIN, FLUOROURACIL, MITOXANTRONE;GALNT14;A;rs12999804;EFFICACY;;RESPONSE;;PEOPLE;DISEASE:HEPATOCELLULAR_CARCINOMA;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A4;TT;rs2740574;DOSAGE;DECREASED;DOSE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
APATINIB, APATINIB METABOLITE M1-1;CYP2C9;TT;rs34532201;METABOLISM/PK;INCREASED;EXPOSURE;;PEOPLE;OTHER:NEOPLASMS;CAUTION_DRUG_ACCUMULATION
CISPLATIN, FLUOROURACIL, MITOXANTRONE;;C;rs5934731;EFFICACY;;RESPONSE;;PEOPLE;DISEASE:HEPATOCELLULAR_CARCINOMA;CAUTION_DOSE_ADJUST
CISPLATIN, FLUOROURACIL, MITOXANTRONE;;C;rs715171;EFFICACY;;RESPONSE;;PEOPLE;DISEASE:HEPATOCELLULAR_CARCINOMA;CAUTION_DOSE_ADJUST
CISPLATIN, FLUOROURACIL, MITOXANTRONE;;C;rs4932551;EFFICACY;;RESPONSE;;PEOPLE;DISEASE:HEPATOCELLULAR_CARCINOMA;CAUTION_DOSE_ADJUST
CISPLATIN, FLUOROURACIL, MITOXANTRONE;;T;rs7170769;EFFICACY;;RESPONSE;;PEOPLE;DISEASE:HEPATOCELLULAR_CARCINOMA;CAUTION_DOSE_ADJUST
CISPLATIN, FLUOROURACIL, MITOXANTRONE;;C;rs6458232;EFFICACY;;RESPONSE;;PEOPLE;DISEASE:HEPATOCELLULAR_CARCINOMA;CAUTION_DOSE_ADJUST
CISPLATIN, FLUOROURACIL, MITOXANTRONE;GALNT14;C;rs7608731;EFFICACY;;RESPONSE;;PEOPLE;DISEASE:HEPATOCELLULAR_CARCINOMA;CAUTION_DOSE_ADJUST
ALLOPURINOL, FEBUXOSTAT;AOX1;G;rs3731722;DOSAGE;;DOSE;;PEOPLE;DISEASE:GOUT;CAUTION_DOSE_ADJUST
PAZOPANIB;CYP3A4;AG;rs35599367;METABOLISM/PK;DECREASED;CLEARANCE;;PEOPLE;OTHER:NEOPLASMS;CAUTION_DRUG_ACCUMULATION
RITUXIMAB;IL2;GG;rs6822844;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:AUTOIMMUNE_DISEASES;LIKELIHOOD_THERAPEUTIC_SUCCESS
RITUXIMAB;IL2;GG;rs6822844;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:SYSTEMIC_LUPUS_ERYTHEMATOSUS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ALLOPURINOL, FEBUXOSTAT;AOX1;T;rs11678615;DOSAGE;;DOSE;;PEOPLE;DISEASE:GOUT;CAUTION_DOSE_ADJUST
METHOTREXATE;MTHFR;GG;rs1801131;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
DIAZEPAM;ABCB1;AA;rs1128503;METABOLISM/PK;INCREASED;EXPOSURE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
ALLOPURINOL, FEBUXOSTAT;UGT1A1, UGT1A10, UGT1A3, UGT1A4, UGT1A5, UGT1A6, UGT1A7, UGT1A8, UGT1A9;T;rs34650714;DOSAGE;DECREASED;DOSE;;PEOPLE;DISEASE:GOUT;CAUTION_DOSE_ADJUST
ALLOPURINOL, FEBUXOSTAT;XDH;G;rs1884725;DOSAGE;DECREASED;DOSE;;PEOPLE;DISEASE:GOUT;CAUTION_DOSE_ADJUST
ALLOPURINOL, FEBUXOSTAT;AOX1;T;rs75995567;DOSAGE;INCREASED;DOSE;;PEOPLE;DISEASE:GOUT;CAUTION_DOSE_ADJUST
METFORMIN;SLC22A1;AC;rs622342;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
PROPOFOL, REMIFENTANIL;ABCB1;GG;rs1128503;EFFICACY;INCREASED;RESPONSE;;CHILDREN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;ABCC3;TT;rs4148416;METABOLISM/PK;INCREASED;CLEARANCE;;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A4;TT;rs2740574;METABOLISM/PK;INCREASED;CONCENTRATIONS;;CHILDREN;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;SLC19A1;CG;rs17004785;METABOLISM/PK;INCREASED;CLEARANCE;;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
DONEPEZIL;BCHE;T;rs1803274;EFFICACY;INCREASED;RESPONSE;;WOMEN;DISEASE:ALZHEIMER_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN, DOXORUBICIN, METHOTREXATE;MTHFD1;AA + AG;rs2236225;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:OSTEOSARCOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN, FLUOROURACIL, MITOXANTRONE;GALNT14;TT;rs9679162;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HEPATOCELLULAR_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
PAROXETINE;GDNF;CT + TT;rs2973049;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
PAROXETINE;GDNF;AA + AG;rs2216711;EFFICACY;DECREASED;RESPONSE;;WOMEN;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL17RA;AA;rs4819554;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:PSORIASIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATOMOXETINE;SLC6A2;T;rs3785143;EFFICACY;DECREASED;RESPONSE;;CHILDREN;DISEASE:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY;LIKELIHOOD_THERAPEUTIC_FAILURE
PAROXETINE;BDNF;CC + CT;rs6265;EFFICACY;DECREASED;RESPONSE;;WOMEN;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;FCGR3A;AC + CC;rs396991;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:PSORIASIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ROSUVASTATIN;CETP;G;rs5882;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOXETINE;CYP2D6;GT;rs28371703;METABOLISM/PK;INCREASED;HALF-LIFE_TIME;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOXETINE;CYP2D6;C;rs1135840;METABOLISM/PK;INCREASED;CONCENTRATIONS;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
DISULFIRAM;DBH;CC;rs1611115;EFFICACY;INCREASED;RESPONSE;;MEN;DISEASE:ALCOHOL_ABUSE;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOXETINE;CYP2D6;A;rs1065852;METABOLISM/PK;INCREASED;HALF-LIFE_TIME;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
RIVAROXABAN;CYP3A5;TT;rs776746;METABOLISM/PK;INCREASED;STEADY-STATE_CONCENTRATION;;PEOPLE;OTHER:ATRIAL_FIBRILLATION;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;COMT;GG;rs9606186;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIVAROXABAN;ABCB1;AA + AG;rs1045642;METABOLISM/PK;INCREASED;CLEARANCE;;PEOPLE;OTHER:ATRIAL_FIBRILLATION;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;C6;CC + TT;rs10052999;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;VKORC1;GG;rs9934438;DOSAGE;INCREASED;DOSE;;CHILDREN;;CAUTION_DOSE_ADJUST
TACROLIMUS;C6;CC + CT;rs9200;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
CISPLATIN, DOXORUBICIN, METHOTREXATE;ABCC2;CT + TT;rs717620;EFFICACY;DECREASED;RESPONSE;;PEOPLE;OTHER:OSTEOSARCOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;RGS4;C;rs2661319;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_FAILURE
LAMOTRIGINE;SLC22A1;AA + AG;rs628031;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:EPILEPSY;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;ANKK1;A;rs1800497;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A4;CT;rs2740574;METABOLISM/PK;INCREASED;DOSE;;PEOPLE;OTHER:TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;CC;rs776746;DOSAGE;DECREASED;DOSE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
CISPLATIN, DOXORUBICIN, METHOTREXATE;GSTP1;AG + GG;rs1695;EFFICACY;DECREASED;RESPONSE;;PEOPLE;OTHER:OSTEOSARCOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
PHENYTOIN;CYP2C9;C;rs1057910;DOSAGE, METABOLISM/PK;INCREASED;DOSE;;PEOPLE;DISEASE:EPILEPSY;CAUTION_DOSE_ADJUST
CARBAMAZEPINE;SCN1A;TT;rs3812718;DOSAGE;INCREASED;DOSE;;PEOPLE;DISEASE:EPILEPSY;CAUTION_DOSE_ADJUST
PHENYTOIN;SCN1A;T;rs3812718;DOSAGE;INCREASED;DOSE;;PEOPLE;DISEASE:EPILEPSY;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;VKORC1;TT;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
TACROLIMUS;ABCB1;T;rs2032582;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
ALPHA-HYDROXYMETOPROLOL;CYP2D6;A;rs28371738;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
RIVAROXABAN;ABCB1;AG + GG;rs1128503;METABOLISM/PK;DECREASED;CONCENTRATIONS;;PEOPLE;OTHER:ATRIAL_FIBRILLATION;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUVOXAMINE, MILNACIPRAN, PAROXETINE;HTR1A;GG;rs6295;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
LANSOPRAZOLE;ABCB1;G;rs1045642;OTHER, METABOLISM/PK;INCREASED;METABOLISM;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUVOXAMINE, MILNACIPRAN, PAROXETINE;HTR1A;CC;rs10042486;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
LAMOTRIGINE;ABCG2;TT;rs2231142;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:EPILEPSY;CAUTION_DRUG_ACCUMULATION
RIVAROXABAN;ABCB1;AG + GG;rs1045642;METABOLISM/PK;DECREASED;CONCENTRATIONS;;PEOPLE;OTHER:ATRIAL_FIBRILLATION;LIKELIHOOD_THERAPEUTIC_FAILURE
RIVAROXABAN;ABCB1;T;rs4148738;METABOLISM/PK;DECREASED;CONCENTRATIONS;;PEOPLE;OTHER:ATRIAL_FIBRILLATION;LIKELIHOOD_THERAPEUTIC_FAILURE
PHENYTOIN;CYP2C9;AT + TT;rs1934969;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;DISEASE:EPILEPSY;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED;DOSE;;PEOPLE;DISEASE:ATRIAL_FIBRILLATION, DISEASE:HEART_VALVE_REPLACEMENT,DISEASE:PULMONARY_HYPERTENSION, DISEASE:PULMONARY_EMBOLISM, DISEASE:VENOUS_THROMBOSIS;CAUTION_DOSE_ADJUST
HMG_COA_REDUCTASE_INHIBITORS;APOC1;G;rs4420638;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:CARDIOVASCULAR_DISEASE, DISEASE:HYPERCHOLESTEROLEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;AC + CC;rs1057910;DOSAGE;DECREASED;DOSE;;PEOPLE;DISEASE:ATRIAL_FIBRILLATION, DISEASE:HEART_VALVE_REPLACEMENT,DISEASE:PULMONARY_HYPERTENSION, DISEASE:PULMONARY_EMBOLISM, DISEASE:VENOUS_THROMBOSIS;CAUTION_DOSE_ADJUST
PHOTODYNAMIC THERAPY;F13A1;AA + AC;rs5985;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:CHOROIDAL_NEOVASCULARIZATION;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP4F2;TT;rs2108622;DOSAGE;INCREASED;DOSE;;PEOPLE;DISEASE:ATRIAL_FIBRILLATION, DISEASE:HEART_VALVE_REPLACEMENT,DISEASE:PULMONARY_HYPERTENSION, DISEASE:PULMONARY_EMBOLISM, DISEASE:VENOUS_THROMBOSIS;CAUTION_DOSE_ADJUST
CITALOPRAM;TPH1;GT + TT;rs1800532;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
HMG_COA_REDUCTASE_INHIBITORS;NPC1L1;G;rs2072183;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:CARDIOVASCULAR_DISEASE, DISEASE:HYPERCHOLESTEROLEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
HMG_COA_REDUCTASE_INHIBITORS;SORT1;T;rs629301;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:CARDIOVASCULAR_DISEASE, DISEASE:HYPERCHOLESTEROLEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
MYCOPHENOLIC ACID;UGT1A9;del;rs3832043;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
BISOPROLOL;ACY3;T;rs2514036;EFFICACY;INCREASED;RESPONSE;;MEN;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
MYCOPHENOLIC ACID;SLCO1B1;AA + AG;rs2306283;METABOLISM/PK;DECREASED;CLEARANCE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
IMATINIB;BCL2L11;T;rs724710;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL;DPYD;CT;rs3918290;METABOLISM/PK;DECREASED;CLEARANCE;;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_DRUG_ACCUMULATION
ITOPRIDE;FMO3;AA;rs2266782;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
METOPROLOL;SEPTIN3;G;rs56234624;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
ITOPRIDE;FMO3;GG;rs2266780;METABOLISM/PK;DECREASED;METABOLISM;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
ALEMTUZUMAB, CHLORAMBUCIL, CYCLOPHOSPHAMIDE, FLUDARABINE, PREDNISONE, RITUXIMAB, VINCRISTINE;CXCL12;CT + TT;rs1801157;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_B-CELL_LYMPHOCITIC_LEUKEMIA,;LIKELIHOOD_THERAPEUTIC_FAILURE
MYCOPHENOLIC ACID;ABCC2;CT;rs3740066;METABOLISM/PK;DECREASED;CONCENTRATIONS;;PEOPLE;DISEASE:LUNG_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
GEMCITABINE;RRM1;AA;rs9937;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:PANCREATIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;ABCB1;AA + AG;rs1045642;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:LUNG_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
BEVACIZUMAB;CXCL8;AA;rs4073;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:MACULAR_DEGENERATION;LIKELIHOOD_THERAPEUTIC_FAILURE
GEMCITABINE;RRM1;AC;rs183484;EFFICACY, TOXICITY;DECREASED;RESPONSE;;PEOPLE;DISEASE:PANCREATIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
HYDROCHLOROTHIAZIDE;NEDD4L;AG + GG;rs4149601;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN_SN-38;UGT1A1;AA;rs4148323;DOSAGE;INCREASED;CONCENTRATIONS;;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_DOSE_ADJUST
COTININE GLUCURONIDE;UGT1A9;CT;rs12471326;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
NICOTINE;CYP2A6;GT;rs145014075;METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
BEVACIZUMAB, RANIBIZUMAB;VEGFA;CT + TT;rs3025000;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:MACULAR_DEGENERATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOSPORINE;CYP3A5;CC + CT;rs776746;METABOLISM/PK;INCREASED;METABOLISM;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
GRANISETRON;ABCB1;AA;rs1045642;EFFICACY;INCREASED;RESPONSE;;PEOPLE;SIDE_EFFECT:NAUSEA, SIDE_EFFECT:VOMITING;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;CC + CT;rs9923231;DOSAGE;INCREASED;DOSE;;PEOPLE;OTHER:HEART_FAILURE;CAUTION_DOSE_ADJUST
CARBAMAZEPINE;SCN1A;CC + CT;rs3812718;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:EPILEPSY;LIKELIHOOD_THERAPEUTIC_SUCCESS
BEVACIZUMAB, RANIBIZUMAB;VEGFA;CT + TT;rs3025000;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:MACULAR_DEGENERATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE;SCN1A;TT;rs3812718;DOSAGE;INCREASED;DOSE;;PEOPLE;DISEASE:EPILEPSY;CAUTION_DOSE_ADJUST
ETANERCEPT;CD84;AG;rs6427528;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:PSORIASIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
LOPINAVIR;SLCO1B1;CC + CT;rs4149056;METABOLISM/PK;INCREASED;TROUGH_CONCENTRATION;;MEN;OTHER:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
CARBAMAZEPINE;SCN1A;TT;rs2298771;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:EPILEPSY;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHADONE;OPRM1;AA;rs10485058;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:OPIOID-RELATED_DISORDERS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE;GABRA1;AA + AG;rs2290732;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:EPILEPSY;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
USTEKINUMAB;IL12B;CT;rs3213094;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:PSORIASIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEMCITABINE;CDA;AA;rs2072671;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:PANCREATIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
TOCILIZUMAB;IL6R;CC;rs11265618;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
TOCILIZUMAB;IL6R;AA;rs12083537;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;ABCB1;AA;rs2032582;METABOLISM/PK;DECREASED;CONCENTRATIONS;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
ALFENTANIL;OPRM1;AG + GG;rs1799971;DOSAGE;INCREASED;DOSE;;PEOPLE;DISEASE:PAIN;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2B6;TT;rs3745274;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;ABCB1;AA;rs1045642;METABOLISM/PK;DECREASED;CONCENTRATIONS;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
CETUXIMAB;FCGR3A;AA;rs396991;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HEAD_AND_NECK_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CETUXIMAB;FCGR2A;GG;rs1801274;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HEAD_AND_NECK_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;HNF4A;CC;rs1884613;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
METHADONE;ALDH5A1;CT + TT;rs2760118;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:OPIOID-RELATED_DISORDERS;LIKELIHOOD_THERAPEUTIC_FAILURE
ATAZANAVIR;UGT1A1;TT;rs887829;TOXICITY;INCREASED;DISCONTINUATION;;;;CAUTION_SIDE_EFFECT
PLATINUM COMPOUNDS;XRCC1;CT + TT;rs25487;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS, DISEASE:STOMACH_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
OLANZAPINE;CHAT;A;rs1880676;DOSAGE, EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_DOSE_ADJUST
PRAVASTATIN;ABCC2;CG;rs113646094;METABOLISM/PK;INCREASED;CLEARANCE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
RAMIPRIL;ACE;CC + TT;rs4359;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
RAMIPRIL;ACE;AA + GG;rs4344;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP4F2;T;rs2108622;DOSAGE;;DOSE;;;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CT + TT;rs776746;EFFICACY;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;OTHER:GLOMERULONEPHRITIS, MEMBRANOUS;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIR;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
OXYCODONE;OPRD1;AA + AG;rs581111;EFFICACY;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON ALFA-2B, RIBAVIRIN;KLRK1;GG;rs1049174;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
CITALOPRAM;CRHR2;CC + CG;rs2270007;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
RIFAMPIN;NR1I2;AA + AG;rs3732357;METABOLISM/PK;DECREASED;EXPOSURE;;PEOPLE;OTHER:TUBERCULOSIS;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;SLC19A1;CT + TT;rs1051266;METABOLISM/PK;DECREASED;CONCENTRATIONS;;CHILDREN;OTHER:OSTEOSARCOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIR;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
OXYCODONE;;CT;rs6848893;EFFICACY;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
PLATINUM COMPOUNDS;ATP7B;G;rs9535826;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:LUNG_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
DEXAMETHASONE;NR3C1;CC;rs6198;EFFICACY;INCREASED;TIME_RESPONSE;;PEOPLE;OTHER:COVID-19;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIDEPRESSANTS;HTR2A;AA + AG;rs6313;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:BIPOLAR_DISORDER, OTHER:DEPRESSION,OTHER:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM COMPOUNDS;ATP7B;A;rs9535828;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:LUNG_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
DEXAMETHASONE;NR3C1;AA;rs33388;EFFICACY;INCREASED;TIME_RESPONSE;;PEOPLE;OTHER:COVID-19;LIKELIHOOD_THERAPEUTIC_SUCCESS
RISPERIDONE;CCL2;AA + AG;rs4795893;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
RISPERIDONE;CCL2;CC + CT;rs4586;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHANOL;OPRM1;AG + GG;rs1799971;TOXICITY;DECREASED;EXPOSURE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;FPGS;TT;rs1544105;EFFICACY;INCREASED;RESPONSE;;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACENOCOUMAROL;VKORC1;T;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
METHOTREXATE;FPGS;TT;rs1544105;METABOLISM/PK;INCREASED;CONCENTRATIONS;;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DRUG_ACCUMULATION
DEXAMETHASONE;NR3C1;TT;rs33389;EFFICACY;INCREASED;TIME_RESPONSE;;PEOPLE;OTHER:COVID-19;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ATORVASTATIN, ROSUVASTATIN, SIMVASTATIN;ABCA1;AAAA;rs769705621;EFFICACY;DECREASED;RESPONSE;;PEOPLE;OTHER:FAMILIAL_HYPERCHOLESTEROLEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
CORTICOSTEROIDS, SELECTIVE BETA-2-ADRENORECEPTOR AGONISTS;ADRB2;A;rs1042713;EFFICACY;DECREASED;RESPONSE;;CHILDREN;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;CCL2;GG;rs2857657;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
LAMOTRIGINE;UGT1A4;TT;rs2011425;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:EPILEPSY;LIKELIHOOD_THERAPEUTIC_SUCCESS
MERCAPTOPURINE;ITPA;A;rs1127354;METABOLISM/PK;;METABOLISM;;PEOPLE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DOSE_ADJUST
LAMOTRIGINE;UGT1A4;TT;rs2011425;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:EPILEPSY;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;C;rs1057910;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
OLANZAPINE;SLC22A1;AG;rs34059508;METABOLISM/PK;INCREASED;EXPOSURE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;CC;rs28399499;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
NICOTINE;CHRNB3;G;rs4950;EFFICACY, OTHER;INCREASED;RESPONSE;;;OTHER:SMOKERS;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;T;rs3745274;METABOLISM/PK;DECREASED;CLEARANCE;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
PLATINUM COMPOUNDS;HMGB1;CC;rs1412125;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:LUNG_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TLR9;CT + TT;rs352139;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:PSORIASIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;CHRNB3;G;rs13280604;EFFICACY, OTHER;INCREASED;RESPONSE;;;OTHER:SMOKERS;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;G;rs749671;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
DEXAMETHASONE;CYP3A4;AG;rs35599367;EFFICACY;INCREASED;TIME_RESPONSE;;PEOPLE;OTHER:COVID-19;LIKELIHOOD_THERAPEUTIC_SUCCESS
OLANZAPINE;ABCB1;T;rs3842;METABOLISM/PK;INCREASED;CLEARANCE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
PLATINUM COMPOUNDS;HMGB1;GG;rs2249825;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:LUNG_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;T;rs3745274;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;G;rs2279343;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
CISPLATIN, RADIOTHERAPY;XRCC1;TT;rs25487;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:NASOPHARYNGEAL_NEOPLASMS, DISEASE:TOBACCO_USE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
LOSARTAN;ACE;AT + TT;rs4291;EFFICACY;INCREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
VEGF/VEGFR (VASCULAR ENDOTHELIAL GROWTH FACTOR) INHIBITORS;VEGFA;AC + CC;rs699947;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:MACULAR_DEGENERATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
OXYCODONE;COMT;AA + AG;rs4680;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ADALIMUMAB, INFLIXIMAB;IL12B;AA + AG;rs2546890;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:PSORIASIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A4;T;rs2740574;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
ADALIMUMAB, INFLIXIMAB;IVL;CT + TT;rs6661932;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:PSORIASIS;LIKELIHOOD_THERAPEUTIC_FAILURE
OPIOIDS;COMT;AA + AG;rs4680;DOSAGE;INCREASED;DOSE;;PEOPLE;OTHER:PAIN;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
USTEKINUMAB;TIRAP;CT + TT;rs8177374;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:PSORIASIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;OPRM1;AG + GG;rs1799971;OTHER;INCREASED;EXPOSURE;;PEOPLE;OTHER:SCHIZOPHRENIA;CAUTION_DRUG_ACCUMULATION
USTEKINUMAB;TLR5;AG + GG;rs5744174;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:PSORIASIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TLR2;AA + AC;rs11938228;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:PSORIASIS;LIKELIHOOD_THERAPEUTIC_FAILURE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;LY96;CG + GG;rs11465996;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:PSORIASIS;LIKELIHOOD_THERAPEUTIC_FAILURE
RIVAROXABAN;BRD3;AA;rs467387;PD;INCREASED;RESPONSE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TLR2;AT + TT;rs4696480;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:PSORIASIS;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;C;rs776746;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS, USTEKINUMAB;IL1B;CG + GG;rs1143623;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:PSORIASIS;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;ABCB1;A;rs1045642;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;APOE;CC + CT;rs429358;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS, USTEKINUMAB;IL1B;AG + GG;rs1143627;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:PSORIASIS;LIKELIHOOD_THERAPEUTIC_FAILURE
REPAGLINIDE;NR1I2;GG;rs2276706;METABOLISM/PK;DECREASED;METABOLISM;;MEN;;CAUTION_DRUG_ACCUMULATION
COTININE;OPRM1;T;rs510769;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:HEROIN_DEPENDENCE;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;COMT;C;rs9606186;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_FAILURE
REPAGLINIDE;NR1I2;CC;rs3814058;METABOLISM/PK;DECREASED;METABOLISM;;MEN;;CAUTION_DRUG_ACCUMULATION
ATEZOLIZUMAB, BEVACIZUMAB;IL7;AA;rs16906115;EFFICACY;DECREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:HEPATOCELLULAR_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
COTININE;OPRM1;T;rs12209447;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:HEROIN_DEPENDENCE;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;COMT;C;rs2020917;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_FAILURE
COTININE;OPRM1;T;rs3798676;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:HEROIN_DEPENDENCE;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;A;rs2359612;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
FENTANYL;ABCB1;AA;rs1045642;DOSAGE;DECREASED;DOSE;;CHILDREN;;CAUTION_DOSE_ADJUST
RISPERIDONE;COMT;C;rs933271;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_FAILURE
COTININE;OPRM1;T;rs553202;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:HEROIN_DEPENDENCE;CAUTION_DRUG_ACCUMULATION
COTININE;OPRM1;G;rs1074287;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:HEROIN_DEPENDENCE;CAUTION_DRUG_ACCUMULATION
METHADONE;OPRD1;AA + AC;rs529520;DOSAGE;INCREASED;DOSE;;PEOPLE;DISEASE:HEROIN_DEPENDENCE;CAUTION_DOSE_ADJUST
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
COTININE;OPRM1;A;rs1799971;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:HEROIN_DEPENDENCE;CAUTION_DRUG_ACCUMULATION
COTININE;OPRM1;T;rs6912029;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:HEROIN_DEPENDENCE;CAUTION_DRUG_ACCUMULATION
PREDNISONE;EDNRA;CC + CT;rs5333;EFFICACY;INCREASED;RESISTANCE;;CHILDREN;DISEASE:NEPHROTIC_SYNDROME;LIKELIHOOD_THERAPEUTIC_FAILURE
REPAGLINIDE;NR1I2;CC;rs3814058;METABOLISM/PK;INCREASED;METABOLISM;;MEN;;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;TLR4;CC;rs1927907;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
PAZOPANIB;NR1I2;T;rs3814055;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
ACENOCOUMAROL;CYP4F2;T;rs2108622;DOSAGE;INCREASED;DOSE;;PEOPLE;DISEASE:ATRIAL_FIBRILLATION;CAUTION_DOSE_ADJUST
ADALIMUMAB, INFLIXIMAB;ZNF816;CC + CT;rs9304742;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:PSORIASIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACENOCOUMAROL;CALU;G;rs1043550;DOSAGE;INCREASED;DOSE;;PEOPLE;DISEASE:ATRIAL_FIBRILLATION;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2B6;GT + TT;rs3745274;METABOLISM/PK;INCREASED;CONCENTRATIONS;;CHILDREN;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;IL18;GG + GT;rs1946518;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
ADALIMUMAB, INFLIXIMAB;NFKBIA;CC + CG;rs2145623;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:PSORIASIS;LIKELIHOOD_THERAPEUTIC_FAILURE
ADALIMUMAB, INFLIXIMAB;TNFRSF1B;AG + GG;rs1061624;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:PSORIASIS;LIKELIHOOD_THERAPEUTIC_FAILURE
REPAGLINIDE;NR1I2;GG;rs2276706;METABOLISM/PK;INCREASED;METABOLISM;;MEN;;LIKELIHOOD_THERAPEUTIC_FAILURE
ADALIMUMAB, INFLIXIMAB;SLC9A8;GG;rs645544;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:PSORIASIS;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL, PLATINUM COMPOUNDS, RADIOTHERAPY;XRCC4;G;rs10040363;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:STOMACH_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL, PLATINUM COMPOUNDS, RADIOTHERAPY;XRCC4;T;rs2075685;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:STOMACH_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
MYCOPHENOLIC ACID;SLCO1B1;TT;rs4149056;METABOLISM/PK;INCREASED;EXPOSURE;;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
HMG_COA_REDUCTASE_INHIBITORS;SLCO1B1;TT;rs4149056;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL, PLATINUM COMPOUNDS, RADIOTHERAPY;ERCC1;A;rs2298881;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:STOMACH_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
COTININE;OPRM1;T;rs563649;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:HEROIN_DEPENDENCE;CAUTION_DRUG_ACCUMULATION
COTININE;OPRM1;G;rs2075572;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:HEROIN_DEPENDENCE;CAUTION_DRUG_ACCUMULATION
SIMVASTATIN;SLCO1B1;TT;rs4149056;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
COTININE;OPRM1;G;rs7748401;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:HEROIN_DEPENDENCE;CAUTION_DRUG_ACCUMULATION
COTININE;OPRM1;G;rs495491;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:HEROIN_DEPENDENCE;CAUTION_DRUG_ACCUMULATION
COTININE;OPRM1;G;rs10457090;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:HEROIN_DEPENDENCE;CAUTION_DRUG_ACCUMULATION
COTININE;OPRM1;G;rs3778152;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:HEROIN_DEPENDENCE;CAUTION_DRUG_ACCUMULATION
PRAVASTATIN;SLCO1B1;TT;rs4149056;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
COTININE;OPRM1;T;rs589046;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:HEROIN_DEPENDENCE;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;NR1I2;T;rs3814055;METABOLISM/PK;DECREASED;METABOLISM;;CHILDREN;DISEASE:OSTEOSARCOMA;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;SLCO1B1;AA + AG;rs2306283;METABOLISM/PK;DECREASED;CONCENTRATIONS;;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;ABCC3;C;rs4793665;METABOLISM/PK;DECREASED;CONCENTRATIONS;;CHILDREN;DISEASE:OSTEOSARCOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;NR1I2;G;rs7643038;METABOLISM/PK;DECREASED;METABOLISM;;CHILDREN;DISEASE:OSTEOSARCOMA;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;ABCB1;C;rs9282564;METABOLISM/PK;INCREASED;CONCENTRATIONS;;CHILDREN;;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;ABCG2;T;rs2231142;METABOLISM/PK;DECREASED;METABOLISM;;CHILDREN;DISEASE:OSTEOSARCOMA;CAUTION_DRUG_ACCUMULATION
GLUCOCORTICOIDS;;AA;rs17446593;EFFICACY;INCREASED;CLINICAL_BENEFIT;;CHILDREN;OTHER:THROMBOCYTOPENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
DABIGATRAN GLUCURONIDE;UGT2B15;AA;rs1902023;METABOLISM/PK;DECREASED;CONCENTRATIONS;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
SUNITINIB;CYP3A5;CC;rs776746;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
CLOZAPINE;NTRK2;CC;rs10465180;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;G;rs9332238;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
CLOPIDOGREL;P2RY12;AA + AC;rs6809699;EFFICACY;INCREASED;RESISTANCE;;PEOPLE;OTHER:CORONARY_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;T;rs3745274;METABOLISM/PK;INCREASED;CONCENTRATIONS;;WOMEN;OTHER:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
DOXORUBICIN;CBR1;CC;rs20572;METABOLISM/PK;DECREASED;CONCENTRATIONS;;PEOPLE;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;ADRA2A;CG;rs1800544;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
ERLOTINIB;ABCB1;AA;rs1045642;TOXICITY, METABOLISM/PK;DECREASED;CLEARANCE;;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_DRUG_ACCUMULATION
ERLOTINIB;ABCB1;AA;rs1128503;TOXICITY, METABOLISM/PK;DECREASED;CLEARANCE;;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;ABCC1;GG;rs28364006;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:PSORIASIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOLUTEGRAVIR;NR1I2;TT;rs2472677;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;OTHER:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
ERLOTINIB;ABCB1;AA;rs2032582;TOXICITY, METABOLISM/PK;DECREASED;CLEARANCE;;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;TT;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
LOSARTAN;AGTR1;CC;rs5186;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:ESSENTIAL_HYPERTENSION;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;KDR;T;rs2305948;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:CORONARY_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
LAMOTRIGINE;UGT2B7;CT + TT;rs7668258;DOSAGE;INCREASED;DOSE;;PEOPLE;OTHER:EPILEPSY;CAUTION_DOSE_ADJUST
MERCAPTOPURINE;NUDT15;T;rs73189762;DOSAGE;DECREASED;DOSE;;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DOSE_ADJUST
METFORMIN;ARFGEF3;AC;rs143276236;EFFICACY;DECREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_FAILURE
TRASTUZUMAB;ERBB2;G;rs1136201;TOXICITY;;RESPONSE;;;;CAUTION_DOSE_ADJUST
DOXORUBICIN;CBR1;GG;rs9024;METABOLISM/PK;INCREASED;CLEARANCE;;PEOPLE;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
METFORMIN;PRKAB2;A;rs7541245;EFFICACY;DECREASED;RESPONSE;;PEOPLE;OTHER:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_FAILURE
AZATHIOPRINE;NUDT15;CT + TT;rs116855232;DOSAGE;DECREASED;DOSE;;PEOPLE;DISEASE:INFLAMMATORY_BOWEL_DISEASES, DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE, METABOLISM/PK;INCREASED;DOSE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;POR;CT + TT;rs1057868;DOSAGE, METABOLISM/PK;INCREASED;DOSE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
DOXORUBICIN;CBR1;GG;rs9024;METABOLISM/PK;DECREASED;CONCENTRATIONS;;PEOPLE;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
DOXORUBICIN;CBR1;GG;rs9024;METABOLISM/PK;DECREASED;EXPOSURE;;PEOPLE;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
PRAMIPEXOLE;DRD3;T;rs6280;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP4F2;TT;rs2108622;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;GG;rs7196161;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
ANTIDEPRESSANTS, BENZODIAZEPINE DERIVATIVES, MIRTAZAPINE, SELECTIVE SEROTONIN REUPTAKE INHIBITORS;GAL;C;rs948854;EFFICACY;DECREASED;RESPONSE;;WOMEN;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;DECREASED;DOSE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;GG;rs9934438;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
SUFENTANIL;OPRM1;AG + GG;rs1799971;DOSAGE;INCREASED;DOSE;;PEOPLE;OTHER:PREGNANCY;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;CC;rs9923231;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;A;rs41303343;DOSAGE, METABOLISM/PK;DECREASED;CLEARANCE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
METFORMIN;SLC22A1;GG;rs628031;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;T;rs10264272;DOSAGE, METABOLISM/PK;DECREASED;CLEARANCE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;AA;rs2884737;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;A;rs61742245;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;C;rs776746;DOSAGE, METABOLISM/PK;DECREASED;CLEARANCE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
MYCOPHENOLIC ACID;ABCC2;CC;rs717620;METABOLISM/PK;INCREASED;EXPOSURE;;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
WARFARIN;PRSS53, VKORC1;A;rs2359612;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
CAFFEINE;CYP1A2;AA;rs762551;OTHER, METABOLISM/PK;INCREASED;METABOLISM;;PEOPLE;DISEASE:TOBACCO_USE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
DOXORUBICIN;CBR1;CC;rs20572;METABOLISM/PK;DECREASED;EXPOSURE;;PEOPLE;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;GGCX;CG;rs11676382;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
CAFFEINE;CYP1A2;AA;rs762551;OTHER, METABOLISM/PK;INCREASED;METABOLISM;;PEOPLE;OTHER:HEAVY_COFFEE_CONSUMPTION;LIKELIHOOD_THERAPEUTIC_FAILURE
TICAGRELOR;PEAR1;GT + TT;rs4661012;EFFICACY;DECREASED;RESPONSE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;ATIC;GG;rs2372536;EFFICACY;DECREASED;RESPONSE;;PEOPLE;OTHER:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A4;AA + AG;rs35599367;METABOLISM/PK;DECREASED;CLEARANCE;;CHILDREN;OTHER:LIVER_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
TICAGRELOR;PEAR1;TT;rs12566888;EFFICACY;INCREASED;RESPONSE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A4;C;rs2740574;METABOLISM/PK;DECREASED;CONCENTRATIONS;;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A4;A;rs35599367;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
TICAGRELOR;PEAR1;AA;rs12041331;EFFICACY;INCREASED;RESPONSE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE, METABOLISM/PK;INCREASED;CLEARANCE;;CHILDREN;OTHER:LIVER_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TICAGRELOR;PEAR1;AA;rs12041331;EFFICACY;INCREASED;RESPONSE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
WARFARIN;PRSS53, VKORC1;T;rs7294;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL9;AA + AG;rs2069885;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:ANKYLOSING_SPONDYLITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
RITUXIMAB;FCGR3A;AA;rs396991;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:NEUROMYELITIS_OPTICA;LIKELIHOOD_THERAPEUTIC_FAILURE
PREDNISOLONE;CD40;CC;rs1883832;EFFICACY;DECREASED;CLINICAL_BENEFIT;;CHILDREN;OTHER:THROMBOCYTOPENIA;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE, METABOLISM/PK;INCREASED;METABOLISM;;CHILDREN;OTHER:LIVER_TRANSPLANTATION;CAUTION_DOSE_ADJUST
METFORMIN;SLC47A1;AA;rs2289669;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
ERENUMAB;CALCRL;G;rs6710852;EFFICACY;INCREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:MIGRAINE_WITH_AURA, OTHER:MIGRAINE_WITHOUT_AURA;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;ABCB1;AA + TT;rs2032582;DOSAGE, METABOLISM/PK;DECREASED;CLEARANCE;;CHILDREN;OTHER:LIVER_TRANSPLANTATION;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;CC;rs7294;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
HALOTHANE;RYR1;T;rs118192161;OTHER;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;CC;rs8050894;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;GG;rs2359612;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
2-HYDROXYATORVASTATIN;CYP3A4;AG;rs35599367;METABOLISM/PK;DECREASED;CONCENTRATIONS;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL5;AA + AG;rs2069812;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:ANKYLOSING_SPONDYLITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
BETA BLOCKING AGENTS, SELECTIVE;BST1;A;rs28404156;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
TAMOXIFEN;CYP19A1;AA;rs4646;EFFICACY;DECREASED;RESPONSE;;WOMEN;DISEASE:BREAST_NEOPLASMS, DISEASE:MENOPAUSE;LIKELIHOOD_THERAPEUTIC_FAILURE
BISPHOSPHONATES;FDPS;T;rs2297480;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:OSTEOPOROSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
SIMVASTATIN;CETP;A;rs5882;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:HYPERCHOLESTEROLEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;APOE;TT;rs405509;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;ABCG2;GG;rs17731538;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:PSORIASIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;C;rs1799724;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:CROHN_DISEASE, DISEASE:INFLAMMATORY_BOWEL_DISEASES,DISEASE:PSORIASIS, DISEASE:SPONDYLARTHROPATHIES;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOSPORINE;UMOD;GT + TT;rs12917707;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
MODAFINIL;ABCB1;AC + CT;rs2032582;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:NARCOLEPSY;LIKELIHOOD_THERAPEUTIC_SUCCESS
MODAFINIL;ABCB1;AG;rs1045642;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:NARCOLEPSY;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;MYC;CT;rs4645962;DOSAGE;DECREASED;DOSE;;PEOPLE;DISEASE:HEART_VALVE_REPLACEMENT;CAUTION_DOSE_ADJUST
WARFARIN;MYC;CT + TT;rs4645943;DOSAGE;INCREASED;DOSE;;PEOPLE;DISEASE:HEART_VALVE_REPLACEMENT;CAUTION_DOSE_ADJUST
CARBAMAZEPINE;EPHX1;G;rs2234922;DOSAGE, METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:EPILEPSY;CAUTION_DOSE_ADJUST
MODAFINIL;ABCB1;AG;rs1128503;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:NARCOLEPSY;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;G;rs361525;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:CROHN_DISEASE, DISEASE:INFLAMMATORY_BOWEL_DISEASES,DISEASE:PSORIASIS, DISEASE:SPONDYLARTHROPATHIES;LIKELIHOOD_THERAPEUTIC_SUCCESS
BISPHOSPHONATES;FDPS;A;rs11264359;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:OSTEOPOROSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;MYC;CC;rs4645974;DOSAGE;INCREASED;DOSE;;PEOPLE;DISEASE:HEART_VALVE_REPLACEMENT;CAUTION_DOSE_ADJUST
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;G;rs1800629;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:CROHN_DISEASE, DISEASE:INFLAMMATORY_BOWEL_DISEASES,DISEASE:PSORIASIS, DISEASE:SPONDYLARTHROPATHIES;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATORVASTATIN, SIMVASTATIN;ABCC2;T;rs717620;EFFICACY;DECREASED;DOSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
LEFLUNOMIDE;DHODH;CC;rs3213422;EFFICACY;INCREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIPSYCHOTICS;DRD2;G;rs1799732;EFFICACY;INCREASED;RESISTANCE;;PEOPLE;OTHER:MOOD_DISORDER, OTHER:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_FAILURE
IMATINIB;SLC22A4;TT;rs1050152;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;HTR2A;AA + AG;rs6313;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIPSYCHOTICS;HTR2A;AG;rs7997012;EFFICACY;INCREASED;RESISTANCE;;PEOPLE;OTHER:MOOD_DISORDER, OTHER:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_FAILURE
METHADONE;CYP2B6;TT;rs3745274;DOSAGE, METABOLISM/PK;DECREASED;DOSE;;PEOPLE;DISEASE:HEROIN_DEPENDENCE;CAUTION_DOSE_ADJUST
METHADONE;ABCB1;AA + AG;rs1045642;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;OTHER:OPIOID-RELATED_DISORDERS;CAUTION_DRUG_ACCUMULATION
OLANZAPINE;HTR2A;AG + GG;rs6313;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
OLANZAPINE;HTR2A;AA + AG;rs6313;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE;EPHX1;CC;rs1051740;METABOLISM/PK;INCREASED;METABOLISM;;PEOPLE;DISEASE:EPILEPSY;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;GG;rs3745274;METABOLISM/PK;INCREASED;CLEARANCE;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
CARBAMAZEPINE;EPHX1;GG;rs2234922;METABOLISM/PK;INCREASED;METABOLISM;;PEOPLE;DISEASE:EPILEPSY;LIKELIHOOD_THERAPEUTIC_FAILURE
AZATHIOPRINE, MERCAPTOPURINE;ITPA;AC + CC;rs7270101;TOXICITY, METABOLISM/PK;INCREASED;METABOLISM;;PEOPLE;DISEASE:INFLAMMATORY_BOWEL_DISEASES, DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
IMATINIB;ABCB1;AA + AG;rs1045642;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;LIKELIHOOD_THERAPEUTIC_FAILURE
IMATINIB;SLC22A4;TT;rs1050152;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE, METABOLISM/PK;INCREASED;DOSE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
ETHANOL;OPRM1;CC + CT;rs3778150;;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
CARBAMAZEPINE;ABCB1;AG;rs1045642;METABOLISM/PK;INCREASED;DOSE;;PEOPLE;DISEASE:EPILEPSY;CAUTION_DOSE_ADJUST
ANTIEPILEPTICS;ABCB1;AG;rs1045642;EFFICACY;INCREASED;RESISTANCE;;PEOPLE;DISEASE:EPILEPSY;LIKELIHOOD_THERAPEUTIC_FAILURE
RALOXIFENE;COMT;AG;rs737865;EFFICACY;INCREASED;CLINICAL_BENEFIT;;MEN;OTHER:SCHIZOPHRENIA, OTHER:SCHIZOAFFECTIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
PACLITAXEL;ABCC2;CT;rs717620;TOXICITY;DECREASED;DOSE;;PEOPLE;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;LIKELIHOOD_THERAPEUTIC_SUCCESS
RALOXIFENE;COMT;AA;rs737865;EFFICACY;INCREASED;CLINICAL_BENEFIT;;MEN;OTHER:SCHIZOPHRENIA, OTHER:SCHIZOAFFECTIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUPRENORPHINE;OPRD1;CT + TT;rs678849;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:OPIOID-RELATED_DISORDERS;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHADONE;ABCB1;AC;rs2032582;METABOLISM/PK;INCREASED;CONCENTRATIONS;;MEN;DISEASE:OPIOID-RELATED_DISORDERS;CAUTION_DRUG_ACCUMULATION
ETHANOL;OPRM1;AG + GG;rs1799971;OTHER;INCREASED;EXPOSURE;;;;CAUTION_DRUG_ACCUMULATION
ANTIEPILEPTICS;ABCB1;AA;rs1045642;EFFICACY;INCREASED;RESISTANCE;;PEOPLE;DISEASE:EPILEPSY;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;TNIK;CC;rs7627954;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
RALOXIFENE;COMT;CG;rs4818;EFFICACY;INCREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:SCHIZOPHRENIA, OTHER:SCHIZOAFFECTIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHADONE;CYP3A4;AG;rs35599367;METABOLISM/PK;DECREASED;CLEARANCE;;PEOPLE;DISEASE:OPIOID-RELATED_DISORDERS;CAUTION_DRUG_ACCUMULATION
SUNITINIB;ABCB1;AA + AT;rs2032582;DOSAGE, TOXICITY;INCREASED;DOSE;;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED;DOSE;;PEOPLE;OTHER:SYSTEMIC_LUPUS_ERYTHEMATOSUS;CAUTION_DOSE_ADJUST
ADALIMUMAB, ETANERCEPT, INFLIXIMAB;TNF;AG + GG;rs1800629;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
SUNITINIB;ABCB1;AA;rs1128503;DOSAGE, TOXICITY;INCREASED;DOSE;;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;CAUTION_DOSE_ADJUST
METHADONE;ABCB1;AA;rs1045642;METABOLISM/PK;INCREASED;CLEARANCE;;PEOPLE;DISEASE:OPIOID-RELATED_DISORDERS;LIKELIHOOD_THERAPEUTIC_FAILURE
METHADONE;ABCB1;AG;rs1128503;METABOLISM/PK;INCREASED;CONCENTRATIONS;;MEN;DISEASE:OPIOID-RELATED_DISORDERS;CAUTION_DRUG_ACCUMULATION
METHADONE;POR;CT + TT;rs1057868;METABOLISM/PK;INCREASED;CLEARANCE;;PEOPLE;DISEASE:OPIOID-RELATED_DISORDERS;LIKELIHOOD_THERAPEUTIC_FAILURE
METHADONE;CYP2B6;AA;rs2279343;DOSAGE;INCREASED;DOSE;;PEOPLE;OTHER:HEROIN_DEPENDENCE;CAUTION_DOSE_ADJUST
DOLUTEGRAVIR;ABCG2;TT;rs2231142;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;OTHER:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
METHADONE;CYP2B6;GG;rs3745274;DOSAGE;INCREASED;DOSE;;PEOPLE;OTHER:HEROIN_DEPENDENCE;CAUTION_DOSE_ADJUST
PREDNISOLONE;TLR4;T;rs4986791;EFFICACY;DECREASED;CLINICAL_BENEFIT;;CHILDREN;OTHER:THROMBOCYTOPENIA;LIKELIHOOD_THERAPEUTIC_FAILURE
PERAMPANEL;CYP3A4;CG;rs4986908;EFFICACY;DECREASED;CLINICAL_BENEFIT;;CHILDREN;OTHER:EPILEPSY;LIKELIHOOD_THERAPEUTIC_FAILURE
TELBIVUDINE;TK2;CC + CT;rs3826160;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;OTHER:HEPATITIS_B, CHRONIC;CAUTION_DRUG_ACCUMULATION
WARFARIN;EPHX1;TT;rs1877724;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
NEVIRAPINE;CYP2B6;TT;rs3745274;TOXICITY, METABOLISM/PK;DECREASED;CLEARANCE;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
ETHANOL;OPRM1;CC + CT;rs3778150;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
OLANZAPINE;GSTP1;AA;rs1695;METABOLISM/PK;INCREASED;CLEARANCE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
CEFOTAXIME;SLC22A8;AT;rs11568482;METABOLISM/PK;DECREASED;CLEARANCE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
IVACAFTOR;CFTR;A;rs75527207;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;TT;rs9923231;DOSAGE;DECREASED;DOSE;;CHILDREN;;CAUTION_DOSE_ADJUST
ESCITALOPRAM;CYP2C18;G;rs11188059;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
DONEPEZIL, GALANTAMINE, RIVASTIGMINE;PRKCE;T;rs6720975;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:ALZHEIMER_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESCITALOPRAM;CYP2C18;T;rs2860840;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;TT;rs2279345;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
PERAMPANEL;CYP3A4;CT + TT;rs2242480;EFFICACY;DECREASED;CLINICAL_BENEFIT;;CHILDREN;OTHER:EPILEPSY;LIKELIHOOD_THERAPEUTIC_FAILURE
DONEPEZIL, GALANTAMINE, RIVASTIGMINE;;T;rs17798800;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:ALZHEIMER_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED;DOSE;;CHILDREN;;CAUTION_DOSE_ADJUST
PREDNISOLONE;TLR4;G;rs4986790;EFFICACY;DECREASED;CLINICAL_BENEFIT;;CHILDREN;OTHER:THROMBOCYTOPENIA;LIKELIHOOD_THERAPEUTIC_FAILURE
METHADONE;ABCB1;CC;rs2032582;DOSAGE;DECREASED;DOSE;;PEOPLE;OTHER:HEROIN_DEPENDENCE;CAUTION_DOSE_ADJUST
METHADONE;ABCB1;AA;rs1045642;DOSAGE, METABOLISM/PK;INCREASED;DOSE;;PEOPLE;DISEASE:HEROIN_DEPENDENCE;CAUTION_DOSE_ADJUST
IRINOTECAN_SN-38;ABCB1;AC + CC;rs12720066;METABOLISM/PK;DECREASED;EXPOSURE;;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIPSYCHOTICS;GABRB1;T;rs4627835;DOSAGE;INCREASED;DOSE;;PEOPLE;DISEASE:SCHIZOAFFECTIVE_DISORDER, DISEASE:SCHIZOPHRENIA;CAUTION_DOSE_ADJUST
ANTIPSYCHOTICS;GABRB1;A;rs16860087;DOSAGE;INCREASED;DOSE;;PEOPLE;DISEASE:SCHIZOAFFECTIVE_DISORDER, DISEASE:SCHIZOPHRENIA;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;CC;rs9923231;DOSAGE;INCREASED;DOSE;;PEOPLE;OTHER:A_STABLE_INTERNATIONAL_NORMALIZED_RATIO_OF_BETWEEN_TWO_AND_THREE;CAUTION_DOSE_ADJUST
IRINOTECAN_SN-38;ABCC1;CT + TT;rs35621;METABOLISM/PK;INCREASED;EXPOSURE;;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_DRUG_ACCUMULATION
CARBAMAZEPINE;ABCB1;AA;rs1045642;DOSAGE;INCREASED;DOSE;;PEOPLE;OTHER:EPILEPSY;CAUTION_DOSE_ADJUST
LITHIUM;ASIC2;CC;rs11869731;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:BIPOLAR_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN_SN-38;ABCC1;AT + TT;rs6498588;METABOLISM/PK;INCREASED;EXPOSURE;;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_DRUG_ACCUMULATION
CAPECITABINE, FLUOROURACIL;HLA-G;GG;rs9380142;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIDEPRESSANTS;MAPK1;AG;rs8136867;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:MENTAL_DISORDERS;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;G;rs8050894;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
CAPECITABINE, FLUOROURACIL;HLA-G;CT;rs17179108;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;CC;rs9923231;DOSAGE, EFFICACY;INCREASED;DOSE;;CHILDREN;DISEASE:HEART_DISEASES;CAUTION_DOSE_ADJUST
DONEPEZIL, GALANTAMINE, RIVASTIGMINE;CHAT;G;rs3793790;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:ALZHEIMER_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUVOXAMINE;COMT;GG;rs4680;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
2-HYDROXYATORVASTATIN;PPARA;AA + AG;rs4253728;METABOLISM/PK;DECREASED;CONCENTRATIONS;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
LITHIUM;OR52E2;TT;rs16909440;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:BIPOLAR_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
LITHIUM;OR52J3;GG;rs2499984;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:BIPOLAR_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIDEPRESSANTS;CREB1;GG;rs889895;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
LITHIUM;;CC;rs16973410;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:BIPOLAR_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
MERCAPTOPURINE;TPMT;C;rs1142345;EFFICACY;;EXPOSURE;;CHILDREN;DISEASE:LEUKEMIA;CAUTION_DOSE_ADJUST
IVACAFTOR;CFTR;A;rs75527207;EFFICACY;INCREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DONEPEZIL, GALANTAMINE, RIVASTIGMINE;CHAT;A;rs2177370;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:ALZHEIMER_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;ATIC;GG;rs2372536;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ZIDOVUDINE;UGT2B7;G;rs28365062;METABOLISM/PK;INCREASED;METABOLISM;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
ROSUVASTATIN;ABCG2;CT;rs2231142;EFFICACY;INCREASED;RESPONSE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CHOLESTEROL;APOE;TT;rs429358;TOXICITY;INCREASED;CONCENTRATIONS;;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
METHADONE;DRD2;AA;rs6275;DOSAGE, METABOLISM/PK;DECREASED;DOSE;;PEOPLE;DISEASE:HEROIN_DEPENDENCE;CAUTION_DOSE_ADJUST
METFORMIN;SLC47A2;AA + AG;rs12943590;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATENOLOL, CARVEDILOL, DILTIAZEM, METOPROLOL, VERAPAMIL;ADRB1;CG + GG;rs1801253;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:ATRIAL_FIBRILLATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHADONE;DRD2;CC;rs1799978;DOSAGE, METABOLISM/PK;DECREASED;DOSE;;PEOPLE;DISEASE:HEROIN_DEPENDENCE;CAUTION_DOSE_ADJUST
METFORMIN;SLC22A2;AA + AC;rs316019;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE;ABCB1;AA + AG;rs1128503;EFFICACY;DECREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:EPILEPSY;LIKELIHOOD_THERAPEUTIC_FAILURE
CARBAMAZEPINE;ABCB1;AA + AC;rs2032582;EFFICACY;DECREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:EPILEPSY;LIKELIHOOD_THERAPEUTIC_FAILURE
ERYTHROMYCIN;ABCC2;TT;rs717620;OTHER, METABOLISM/PK;INCREASED;METABOLISM;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;GGCX;CG + GG;rs11676382;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
CARBAMAZEPINE;ABCB1;AA + AG;rs1045642;EFFICACY;DECREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:EPILEPSY;LIKELIHOOD_THERAPEUTIC_FAILURE
ABIRATERONE, DUTASTERIDE;HSD3B1;AC;rs1047303;EFFICACY;DECREASED;RESPONSE;;MEN;OTHER:PROSTATIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
AZATHIOPRINE;PACSIN2;CT + TT;rs2413739;EFFICACY;DECREASED;RESPONSE;;CHILDREN;OTHER:IRRITABLE_BOWEL_SYNDROME;LIKELIHOOD_THERAPEUTIC_FAILURE
ROSUVASTATIN;SLCO2B1;AA + AG;rs12422149;EFFICACY;DECREASED;RESPONSE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
GEFITINIB;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;CONCENTRATIONS;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
SILDENAFIL;NOS3;CC + CT;rs2070744;EFFICACY;INCREASED;RESPONSE;;MEN;DISEASE:ERECTILE_DYSFUNCTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
NEVIRAPINE;CYP2B6;TT;rs3745274;TOXICITY, METABOLISM/PK;DECREASED;CLEARANCE;;CHILDREN;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
ABIRATERONE;SRD5A2;CC;rs523349;METABOLISM/PK;INCREASED;METABOLISM;;MEN;OTHER:PROSTATIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
GEFITINIB;CYP2C9;AC;rs1057910;METABOLISM/PK;INCREASED;CONCENTRATIONS;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
TRIGLYCERIDES;CYP19A1;A;rs10046;OTHER;DECREASED;CONCENTRATIONS;;WOMEN;DISEASE:BREAST_NEOPLASMS, DISEASE:MENOPAUSE;LIKELIHOOD_THERAPEUTIC_FAILURE
TRIGLYCERIDES;CYP19A1;C;rs3759811;OTHER;DECREASED;CONCENTRATIONS;;WOMEN;DISEASE:BREAST_NEOPLASMS, DISEASE:MENOPAUSE;LIKELIHOOD_THERAPEUTIC_FAILURE
HDL CHOLESTEROL;CYP19A1;G;rs1008805;OTHER;DECREASED;CONCENTRATIONS;;WOMEN;DISEASE:BREAST_NEOPLASMS, DISEASE:MENOPAUSE;LIKELIHOOD_THERAPEUTIC_FAILURE
OPIOIDS;OPRM1;AG + GG;rs1799971;DOSAGE;INCREASED;DOSE;;PEOPLE;OTHER:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
TRIGLYCERIDES;CYP19A1;C;rs2289105;OTHER;DECREASED;CONCENTRATIONS;;WOMEN;DISEASE:BREAST_NEOPLASMS, DISEASE:MENOPAUSE;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;SLC19A1;AC + CC;rs1051296;METABOLISM/PK;DECREASED;CONCENTRATIONS;;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
HDL CHOLESTEROL;CYP19A1;G;rs10046;OTHER;DECREASED;CONCENTRATIONS;;WOMEN;DISEASE:BREAST_NEOPLASMS, DISEASE:MENOPAUSE;LIKELIHOOD_THERAPEUTIC_FAILURE
FENTANYL;CYP3A4;T;rs2242480;DOSAGE;DECREASED;DOSE;;PEOPLE;OTHER:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
HDL CHOLESTEROL;CYP19A1;T;rs2289105;OTHER;DECREASED;CONCENTRATIONS;;WOMEN;DISEASE:BREAST_NEOPLASMS, DISEASE:MENOPAUSE;LIKELIHOOD_THERAPEUTIC_FAILURE
LEFLUNOMIDE;ESR1;TT;rs2234693;EFFICACY;INCREASED;RESPONSE;;WOMEN;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
NEVIRAPINE;CYP2B6;GT;rs3745274;TOXICITY, METABOLISM/PK;DECREASED;CLEARANCE;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
LEFLUNOMIDE;ESR1;AA;rs9340799;EFFICACY;INCREASED;RESPONSE;;WOMEN;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
2-HYDROXYATORVASTATIN, 4-HYDROXYATORVASTATIN, ATORVASTATIN, ATORVASTATIN LACTONE;LPP;A;rs1975991;METABOLISM/PK;DECREASED;EXPOSURE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
USTEKINUMAB;C9orf72;CC + CT;rs774359;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:PSORIASIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;GGH;GG;rs3758149;METABOLISM/PK;DECREASED;CONCENTRATIONS;;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
HDL CHOLESTEROL;CYP19A1;A;rs4646;OTHER;DECREASED;CONCENTRATIONS;;WOMEN;DISEASE:BREAST_NEOPLASMS, DISEASE:MENOPAUSE;LIKELIHOOD_THERAPEUTIC_FAILURE
USTEKINUMAB;IL13;AA + AC;rs848;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:PSORIASIS;LIKELIHOOD_THERAPEUTIC_FAILURE
TRIGLYCERIDES;CYP19A1;C;rs700518;OTHER;DECREASED;CONCENTRATIONS;;WOMEN;DISEASE:BREAST_NEOPLASMS, DISEASE:MENOPAUSE;LIKELIHOOD_THERAPEUTIC_FAILURE
USTEKINUMAB;ZNF816;CC + CT;rs9304742;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:PSORIASIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
TRIGLYCERIDES;CYP19A1;C;rs4775936;OTHER;DECREASED;CONCENTRATIONS;;WOMEN;DISEASE:BREAST_NEOPLASMS, DISEASE:MENOPAUSE;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;GGCX;CG + GG;rs11676382;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
USTEKINUMAB;STAT4;GT + TT;rs7574865;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:PSORIASIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
USTEKINUMAB;SLC22A4;CT;rs1050152;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:PSORIASIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;CHRNA5;GG;rs16969968;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:TOBACCO_USE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;STX1B;AA + AG;rs72800847;DOSAGE;DECREASED;DOSE;;PEOPLE;DISEASE:HEART_VALVE_REPLACEMENT;CAUTION_DOSE_ADJUST
WARFARIN;CYP1A1;CC;rs3826041;DOSAGE;INCREASED;DOSE;;PEOPLE;DISEASE:HEART_VALVE_REPLACEMENT;CAUTION_DOSE_ADJUST
VARENICLINE;CHRNA5;AA + AG;rs16969968;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:TOBACCO_USE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;DNMT3A;TT;rs2304429;DOSAGE;INCREASED;DOSE;;PEOPLE;DISEASE:HEART_VALVE_REPLACEMENT;CAUTION_DOSE_ADJUST
WARFARIN;NQO1;AA;rs10517;DOSAGE;INCREASED;DOSE;;PEOPLE;DISEASE:HEART_VALVE_REPLACEMENT;CAUTION_DOSE_ADJUST
RALOXIFENE;ESR1;TT;rs2234693;EFFICACY;INCREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:SCHIZOPHRENIA, OTHER:SCHIZOAFFECTIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACENOCOUMAROL, PHENPROCOUMON;VKORC1;AA + AG;rs9934438;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
FENTANYL;DRD1;AG + GG;rs966775;EFFICACY;INCREASED;CONCENTRATIONS;;PEOPLE;OTHER:POSTOPERATIVE_PAIN;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUTICASONE / SALMETEROL;CHRM2;A;rs8191992;EFFICACY;;RESPONSE;;PEOPLE;DISEASE:ASTHMA;CAUTION_DOSE_ADJUST
METHOTREXATE;MTHFR;AA + AG;rs1801133;METABOLISM/PK;INCREASED;CONCENTRATIONS;;CHILDREN;OTHER:NON-HODGKIN_LYMPHOMA;CAUTION_DRUG_ACCUMULATION
PHENPROCOUMON;VKORC1;TT;rs9923231;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;AA;rs1057910;DOSAGE;INCREASED;DOSE;;PEOPLE;DISEASE:HEART_VALVE_REPLACEMENT;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;AG + GG;rs9934438;DOSAGE;INCREASED;DOSE;;PEOPLE;DISEASE:HEART_VALVE_REPLACEMENT;CAUTION_DOSE_ADJUST
ARIPIPRAZOLE, RISPERIDONE;DRD2;CC;rs2514218;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:PSYCHOTIC_DISORDER, OTHER:SCHIZOAFFECTIVE_DISORDER,OTHER:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
VORICONAZOLE;ABCG2;GT + TT;rs2231142;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;OTHER:LEUKEMIA_OTHER:LYMPHOMA,OTHER:MYELODYSPLASTIC_SYNDROMES;CAUTION_DRUG_ACCUMULATION
WARFARIN;STX1B;AG + GG;rs4889606;DOSAGE;DECREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;UGT1A1;CC;rs887829;DOSAGE;DECREASED;DOSE;;PEOPLE;DISEASE:HEART_VALVE_REPLACEMENT;CAUTION_DOSE_ADJUST
WARFARIN;CYP4F2;CC + CT;rs2108622;DOSAGE;DECREASED;DOSE;;PEOPLE;DISEASE:HEART_VALVE_REPLACEMENT;CAUTION_DOSE_ADJUST
AZATHIOPRINE, MERCAPTOPURINE;ITPA;AA + AC;rs1127354;METABOLISM/PK;DECREASED;METABOLISM;;PEOPLE;DISEASE:INFLAMMATORY_BOWEL_DISEASES;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;TT;rs9923231;DOSAGE;DECREASED;DOSE;;PEOPLE;OTHER:ATRIAL_FIBRILLATION, OTHER:HEART_VALVE_REPLACEMENT,OTHER:PULMONARY_EMBOLISM;CAUTION_DOSE_ADJUST
BEVACIZUMAB, FLUOROURACIL, IRINOTECAN, LEUCOVORIN;SHMT1;A;rs1979277;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL6;G;rs1800795;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:PSORIASIS;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;AC + CC;rs1057910;DOSAGE;INCREASED;DOSE;;PEOPLE;OTHER:ATRIAL_FIBRILLATION, OTHER:HEART_VALVE_REPLACEMENT,OTHER:PULMONARY_EMBOLISM;CAUTION_DOSE_ADJUST
WARFARIN;CYP4F2;CT + TT;rs2108622;DOSAGE;INCREASED;DOSE;;PEOPLE;OTHER:ATRIAL_FIBRILLATION, OTHER:HEART_VALVE_REPLACEMENT,OTHER:PULMONARY_EMBOLISM;CAUTION_DOSE_ADJUST
PLATINUM COMPOUNDS;;GG + GT;rs6983267;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:LUNG_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUVASTATIN;CYP2C9;G;rs77760615;METABOLISM/PK;INCREASED;CONCENTRATIONS;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
METFORMIN;SLC22A2;TT;rs316009;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:DIABETES_MELLITUS;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;OPRM1;AG + GG;rs1799971;DOSAGE, EFFICACY;INCREASED;DOSE;;PEOPLE;OTHER:PAIN, OTHER:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
FLUVASTATIN;SLCO1B1;T;rs58310495;METABOLISM/PK;INCREASED;CONCENTRATIONS;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
ATORVASTATIN;SLCO1B1;C;rs4149056;METABOLISM/PK;INCREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;CHILDREN;OTHER:HYPERCHOLESTEROLEMIA;CAUTION_DRUG_ACCUMULATION
CYCLOSPORINE;CYP3A4;AA + AG;rs35599367;TOXICITY, METABOLISM/PK;DECREASED;CLEARANCE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DRUG_ACCUMULATION
FLUVASTATIN;SLCO1B1;C;rs4149056;METABOLISM/PK;INCREASED;CONCENTRATIONS;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
PLATINUM COMPOUNDS;MALAT1;AG + GG;rs619586;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:LUNG_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
PLATINUM COMPOUNDS;HOTAIR;CC + CG;rs7958904;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:LUNG_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
PLATINUM COMPOUNDS;H19;AA + AG;rs2839698;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:LUNG_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A4;AG;rs35599367;DOSAGE;DECREASED;DOSE;;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
CARBAMAZEPINE;EPHX1;C;rs1051740;DOSAGE, METABOLISM/PK;INCREASED;DOSE;;PEOPLE;DISEASE:EPILEPSY;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;AG + GG;rs9934438;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
FLUTICASONE / SALMETEROL;CHRM2;A;rs6962027;EFFICACY;;RESPONSE;;PEOPLE;DISEASE:ASTHMA;CAUTION_DOSE_ADJUST
NICOTINE;OPRM1;AG + GG;rs1799971;OTHER;INCREASED;EXPOSURE;;;;CAUTION_DRUG_ACCUMULATION
BETA BLOCKING AGENTS;ADRB1;C;rs1801253;EFFICACY;INCREASED;RESPONSE;;CHILDREN;OTHER:CARDIOMYOPATHY, DILATED;LIKELIHOOD_THERAPEUTIC_SUCCESS
SIMVASTATIN ACID;SLCO1B1;CC;rs4149056;METABOLISM/PK;INCREASED;CONCENTRATIONS;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
BETA BLOCKING AGENTS;ADRB2;A;rs1042713;EFFICACY;INCREASED;RESPONSE;;CHILDREN;OTHER:CARDIOMYOPATHY, DILATED;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUTICASONE / SALMETEROL;CHRM2;A;rs6962027;EFFICACY;;RESPONSE;;PEOPLE;DISEASE:ASTHMA;CAUTION_DOSE_ADJUST
CARBAMAZEPINE;EPHX1;G;rs2234922;DOSAGE, METABOLISM/PK;INCREASED;DOSE;;PEOPLE;DISEASE:EPILEPSY;CAUTION_DOSE_ADJUST
FLUTICASONE PROPIONATE;CRHR1;T;rs1876831;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
RISPERIDONE;TNIK;AA;rs2088885;EFFICACY;INCREASED;RESPONSE;;PEOPLE;OTHER:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUTICASONE PROPIONATE;CRHR1;T;rs1876828;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
METFORMIN;CSMD1;AC + CC;rs2617102;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:DIABETES_MELLITUS;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUTICASONE PROPIONATE;CRHR1;C;rs1876829;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUTICASONE PROPIONATE;CRHR1;G;rs739645;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;CT + TT;rs9923231;DOSAGE;;DOSE;;;;CAUTION_DOSE_ADJUST
NEVIRAPINE;CYP2B6;T;rs3745274;TOXICITY, METABOLISM/PK;DECREASED;CLEARANCE;;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DRUG_ACCUMULATION
NICOTINE;POR;CT + TT;rs1057868;METABOLISM/PK;INCREASED;METABOLISM;;;PK:CYP2A6_NORMAL_METABOLIZERS;LIKELIHOOD_THERAPEUTIC_FAILURE
CARBAMAZEPINE;SCN1A;TT;rs3812718;METABOLISM/PK;INCREASED;METABOLISM;;PEOPLE;DISEASE:EPILEPSY;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP4F2;TT;rs2108622;DOSAGE;INCREASED;DOSE;;PEOPLE;DISEASE:ATRIAL_FIBRILLATION;CAUTION_DOSE_ADJUST
VORICONAZOLE;CYP2C18;T;rs2860840;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;OTHER:LEUKEMIA_OTHER:LYMPHOMA,OTHER:MYELODYSPLASTIC_SYNDROMES;LIKELIHOOD_THERAPEUTIC_FAILURE
VORICONAZOLE;CYP2C18;G;rs11188059;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;OTHER:LEUKEMIA_OTHER:LYMPHOMA,OTHER:MYELODYSPLASTIC_SYNDROMES;LIKELIHOOD_THERAPEUTIC_FAILURE
REMIFENTANIL;ABCB1;GG;rs1045642;DOSAGE;INCREASED;DOSE;;;;CAUTION_DOSE_ADJUST
WARFARIN;GGCX;CT + TT;rs12714145;DOSAGE;DECREASED;DOSE;;PEOPLE;OTHER:ATRIAL_FIBRILLATION, OTHER:HEART_VALVE_REPLACEMENT,OTHER:PULMONARY_EMBOLISM;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;AG + GG;rs9934438;DOSAGE;INCREASED;DOSE;;PEOPLE;DISEASE:ATRIAL_FIBRILLATION;CAUTION_DOSE_ADJUST
REMIFENTANIL;ABCB1;GG;rs1045642;EFFICACY;DECREASED;RESPONSE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL;DPYD;CC + CT;rs1801159;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_DRUG_ACCUMULATION
WARFARIN;VKORC1;AA;rs9934438;DOSAGE;DECREASED;DOSE;;PEOPLE;DISEASE:ATRIAL_FIBRILLATION;CAUTION_DOSE_ADJUST
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CES1;CT + TT;rs71647871;METABOLISM/PK;INCREASED;EXPOSURE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
CLOPIDOGREL;CES1;CT + TT;rs71647871;EFFICACY;INCREASED;RESPONSE;;HEALTHY;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE;SCN1A;TT;rs3812718;METABOLISM/PK;INCREASED;DOSE;;PEOPLE;DISEASE:EPILEPSY;CAUTION_DOSE_ADJUST
NALTREXONE;OPRM1;AA;rs1799971;EFFICACY;INCREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:OPIOID-RELATED_DISORDERS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;P2RY1;T;rs1371097;EFFICACY;DECREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:STROKE;LIKELIHOOD_THERAPEUTIC_FAILURE
GEMCITABINE;CMPK1;TT;rs1044457;EFFICACY;DECREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
MERCAPTOPURINE;NUDT15;CC;rs55713253;DOSAGE;INCREASED;DOSE;;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DOSE_ADJUST
CYCLOPHOSPHAMIDE, DOXORUBICIN, PACLITAXEL;ABCC2;AA;rs145008610;EFFICACY;DECREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
DEOXY-THIOGUANOSINE TRIPHOSPHATE, THIOGUANOSINE TRIPHOSPHATE;TPMT;CT;rs1142345;METABOLISM/PK;INCREASED;CONCENTRATIONS;;CHILDREN;OTHER:INFLAMMATORY_BOWEL_DISEASES;CAUTION_DRUG_ACCUMULATION
AZATHIOPRINE;PACSIN2;CC + CT;rs2413739;EFFICACY;INCREASED;CLINICAL_BENEFIT;;CHILDREN;OTHER:INFLAMMATORY_BOWEL_DISEASES;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL CARBOXYLIC ACID;ABCB1;AA + AG;rs1045642;METABOLISM/PK;DECREASED;CONCENTRATIONS;;PEOPLE;OTHER:CARDIOVASCULAR_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
THIORIDAZINE;CYP2D6;*3/*4 + *4/*4 + *4/*5 + *4/*6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;OTHER:MENTAL_DISORDERS;CAUTION_DRUG_ACCUMULATION
PRIMAQUINE;CYP2D6;*4/*4 + *4/*5 + *4/*9 + *2/*4 + *1/*4 + *1/*5 + *9/*9;CYP2D6*1, CYP2D6*2, CYP2D6*4, CYP2D6*5, CYP2D6*9, CYP2D6*17, CYP2D6*29, CYP2D6*34, CYP2D6*39, CYP2D6*41;EFFICACY;INCREASED;CONCENTRATIONS;;PEOPLE;OTHER:MALARIA_VIVAX;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOSPORINE;CYP3A5;CT;rs776746;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOZAPINE;CYP1A2;AA;rs762551;METABOLISM/PK;DECREASED;CLEARANCE;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
N-DESMETHYLCLOZAPINE;ABCB1;CC;rs2032582;METABOLISM/PK;INCREASED;CONCENTRATIONS;;HEALTHY;;CAUTION_DRUG_ACCUMULATION
DULAGLUTIDE, LIRAGLUTIDE, SEMAGLUTIDE;GLP1R;GG;rs6923761;EFFICACY;INCREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
N-DESMETHYLCLOZAPINE;SLCO1B1;CC + CT;rs4149056;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;OTHER:SCHIZOPHRENIA;CAUTION_DRUG_ACCUMULATION
NORCLOBAZAM;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;METABOLISM/PK;DECREASED;CLEARANCE;;CHILDREN;OTHER:EPILEPSY;CAUTION_DRUG_ACCUMULATION
ARTEMETHER, LUMEFANTRINE;CYP2B6;GT;rs3745274;EFFICACY;DECREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:MALARIA;LIKELIHOOD_THERAPEUTIC_FAILURE
4-ENE VALPROIC ACID;CPT1A;GG;rs2228502;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;OTHER:EPILEPSY;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;ATIC;CC + CT;rs4673991;EFFICACY;INCREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;ATIC;CT + TT;rs4673993;EFFICACY;INCREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;ADA;GT + TT;rs2057638;EFFICACY;INCREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;ATIC;CC + CG;rs2372536;EFFICACY;INCREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;ADA;CG + GG;rs6017375;EFFICACY;INCREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;ADA;AA;rs371927;EFFICACY;INCREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
LOSARTAN;CYP2C9;*1/*1;CYP2C9*1, CYP2C9*2, CYP2C9*3;;INCREASED;CLINICAL_BENEFIT;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CODEINE, HYDROCODONE, OXYCODONE, TRAMADOL;CYP2D6;;POOR_METABOLIZER;EFFICACY;DECREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:PAIN;LIKELIHOOD_THERAPEUTIC_FAILURE
ZUCLOPENTHIXOL;CYP2D6;;CYP2D6 NORMAL_METABOLIZER;METABOLISM/PK;DECREASED;DOSE-ADJUST_TROUGH_CONCENTRATIONS;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
SITAGLIPTIN;GLP1R;GG;rs6923761;EFFICACY;INCREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:HYPERTENSION, OTHER:DIABETES_MELLITUS;LIKELIHOOD_THERAPEUTIC_SUCCESS
SALBUTAMOL;ADRB2;AA;rs1042717;EFFICACY;DECREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:ASTHMA;LIKELIHOOD_THERAPEUTIC_FAILURE
SALBUTAMOL;ADRB2;GG;rs1042714;EFFICACY;DECREASED;CLINICAL_BENEFIT;;PEOPLE;OTHER:ASTHMA;LIKELIHOOD_THERAPEUTIC_FAILURE
ZUCLOPENTHIXOL;CYP2D6;;CYP2D6 INTERMEDIATE_METABOLIZER;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;OTHER:MENTAL_DISORDERS;CAUTION_DRUG_ACCUMULATION
PERPHENAZINE;CYP2D6;;CYP2D6 INTERMEDIATE_METABOLIZER;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;OTHER:MENTAL_DISORDERS;CAUTION_DRUG_ACCUMULATION
DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS;CDKAL1;CC;rs7754840;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:DIABETES_MELLITUS;LIKELIHOOD_THERAPEUTIC_SUCCESS
DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS;CDKAL1;GG;rs7756992;EFFICACY;INCREASED;RESPONSE;;PEOPLE;DISEASE:DIABETES_MELLITUS;LIKELIHOOD_THERAPEUTIC_SUCCESS
SITAGLIPTIN, VILDAGLIPTIN;GLP1R;AA;rs6923761;EFFICACY;DECREASED;RESPONSE;;PEOPLE;DISEASE:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_FAILURE
NORTRIPTYLINE;CYP2D6;*1/*4 + *2/*4 + *2/*5 + *4/*41 + *4/*10;CYP2D6*1, CYP2D6*1XN, CYP2D6*2, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*41;METABOLISM/PK;INCREASED;CONCENTRATIONS;;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DRUG_ACCUMULATION
ANTIDEPRESSANTS, ANTIPSYCHOTICS;CYP2C19;*17;CYP2C19*17;EFFICACY;INCREASED;RESISTANCE;;PEOPLE;OTHER:SCHIZOPHRENIA, OTHER:MENTAL_DISORDERS,OTHER:NEUROTIC_DISORDER, OTHER:PERSONALITY_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIDEPRESSANTS, ANTIPSYCHOTICS;CYP2D6;*3;CYP2D6*3;EFFICACY;INCREASED;RESISTANCE;;PEOPLE;OTHER:SCHIZOPHRENIA, OTHER:MENTAL_DISORDERS,OTHER:NEUROTIC_DISORDER, OTHER:PERSONALITY_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIDEPRESSANTS, ANTIPSYCHOTICS;CYP1A2;*30;CYP1A2*30;EFFICACY;INCREASED;RESISTANCE;;PEOPLE;OTHER:SCHIZOPHRENIA, OTHER:MENTAL_DISORDERS,OTHER:NEUROTIC_DISORDER, OTHER:PERSONALITY_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3 + *1/*6 + *1/*7;CYP3A5*1, CYP3A5*3, CYP3A5*6, CYP3A5*7;DOSAGE;INCREASED;DOSE;;PEOPLE;OTHER:LIVER_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A4;AG;rs35599367;DOSAGE;DECREASED;DOSE;;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;DOSAGE;INCREASED;DOSE;;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A4;CC + CT;rs2740574;DOSAGE;INCREASED;DOSE;;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
ANTIDEPRESSANTS;SLC22A3;AG + GG;rs2292334;DOSAGE;INCREASED;DOSE;;PEOPLE;OTHER:DEPRESSION;CAUTION_DOSE_ADJUST
BUPROPION;CYP2B6;*1/*1;CYP2B6*1, CYP2B6*6;EFFICACY;INCREASED;ACTIVITY;;;CYP2B6;LIKELIHOOD_THERAPEUTIC_SUCCESS
RANITIDINE;SLC22A1;del;rs72552763;METABOLISM/PK;DECREASED;TRANSPORT;;;;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*32;CYP2C19*1, CYP2C19*32;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*31;CYP2C19*1, CYP2C19*31;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*30;CYP2C19*1, CYP2C19*30;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;A;rs1349931378;METABOLISM/PK;DECREASED;ACTIVITY;;;CYP2C19;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*29;CYP2C19*1, CYP2C19*29;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*3;CYP2C19*1, CYP2C19*3;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*2;CYP2C19*1, CYP2C19*2;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;C;rs1267723490;METABOLISM/PK;DECREASED;ACTIVITY;;;CYP2C19;CAUTION_DRUG_ACCUMULATION
DICLOFENAC;CYP2C9;*54;CYP2C9*54;METABOLISM/PK;INCREASED;CATALYTIC_ACTIVITY;;;CYP2C9;LIKELIHOOD_THERAPEUTIC_FAILURE
DICLOFENAC;CYP2C9;*44;CYP2C9*44;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;;;CYP2C9;CAUTION_DRUG_ACCUMULATION
DICLOFENAC;CYP2C9;*42;CYP2C9*42;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;;;CYP2C9;CAUTION_DRUG_ACCUMULATION
DICLOFENAC;CYP2C9;*40;CYP2C9*40;METABOLISM/PK;INCREASED;CATALYTIC_ACTIVITY;;;CYP2C9;LIKELIHOOD_THERAPEUTIC_FAILURE
DICLOFENAC;CYP2C9;*52;CYP2C9*52;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;;;CYP2C9;CAUTION_DRUG_ACCUMULATION
DICLOFENAC;CYP2C9;*43;CYP2C9*43;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;;;CYP2C9;CAUTION_DRUG_ACCUMULATION
DICLOFENAC;CYP2C9;*45;CYP2C9*45;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;;;CYP2C9;CAUTION_DRUG_ACCUMULATION
DICLOFENAC;CYP2C9;*46;CYP2C9*46;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;;;CYP2C9;CAUTION_DRUG_ACCUMULATION
DICLOFENAC;CYP2C9;*39;CYP2C9*39;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;;;CYP2C9;CAUTION_DRUG_ACCUMULATION
DICLOFENAC;CYP2C9;*36;CYP2C9*36;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;;;CYP2C9;CAUTION_DRUG_ACCUMULATION
DICLOFENAC;CYP2C9;*55;CYP2C9*55;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;;;CYP2C9;CAUTION_DRUG_ACCUMULATION
DICLOFENAC;CYP2C9;*38;CYP2C9*38;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;;;CYP2C9;CAUTION_DRUG_ACCUMULATION
DICLOFENAC;CYP2C9;*48;CYP2C9*48;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;;;CYP2C9;CAUTION_DRUG_ACCUMULATION
DICLOFENAC;CYP2C9;*53;CYP2C9*53;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;;;CYP2C9;CAUTION_DRUG_ACCUMULATION
DICLOFENAC;CYP2C9;*47;CYP2C9*47;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;;;CYP2C9;CAUTION_DRUG_ACCUMULATION
DICLOFENAC;CYP2C9;*50;CYP2C9*50;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;;;CYP2C9;CAUTION_DRUG_ACCUMULATION
DICLOFENAC;CYP2C9;*37;CYP2C9*37;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;;;CYP2C9;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;*3;CYP2C9*1, CYP2C9*3;METABOLISM/PK;DECREASED;ENZYME_ACTIVITY;;;CYP2C9;CAUTION_DRUG_ACCUMULATION
DICLOFENAC;CYP2C9;*60;CYP2C9*1, CYP2C9*60;METABOLISM/PK;DECREASED;ENZYME_ACTIVITY;;;CYP2C9;CAUTION_DRUG_ACCUMULATION
DICLOFENAC;CYP2C9;*3;CYP2C9*1, CYP2C9*3;METABOLISM/PK;DECREASED;ENZYME_ACTIVITY;;;CYP2C9;CAUTION_DRUG_ACCUMULATION
TOLBUTAMIDE;CYP2C9;*3;CYP2C9*1, CYP2C9*3;METABOLISM/PK;DECREASED;ENZYME_ACTIVITY;;;CYP2C9;CAUTION_DRUG_ACCUMULATION
TOLBUTAMIDE;CYP2C9;*60;CYP2C9*1, CYP2C9*60;METABOLISM/PK;DECREASED;ENZYME_ACTIVITY;;;CYP2C9;CAUTION_DRUG_ACCUMULATION
WARFARIN;CYP2C9;*60;CYP2C9*1, CYP2C9*60;METABOLISM/PK;DECREASED;ENZYME_ACTIVITY;;;CYP2C9;CAUTION_DRUG_ACCUMULATION
;CYP2B6;*1/*1;CYP2B6*1, CYP2B6*6;EFFICACY;INCREASED;ACTIVITY;;;CYP2B6;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*10;CYP2C19*1, CYP2C19*10;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;;;CYP2C19;CAUTION_DRUG_ACCUMULATION
;CYP2E1;*7B;CYP2E1*7A, CYP2E1*7B;METABOLISM/PK;INCREASED;TRANSCRIPTION;;;CYP2E1;LIKELIHOOD_THERAPEUTIC_FAILURE
;ACE;del;rs1799752;;INCREASED;ENZYME_ACTIVITY;;;ACE;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOXETINE;CYP2C19;*32;CYP2C19*1, CYP2C19*32;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
FLUOXETINE;CYP2C19;*31;CYP2C19*1, CYP2C19*31;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
FLUOXETINE;CYP2C19;*29;CYP2C19*1, CYP2C19*29;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
REMIMAZOLAM;CES1;C;rs200707504;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;;;CES1;CAUTION_DRUG_ACCUMULATION
IRINOTECAN_SN-38;UGT1A9;A;rs35350960;METABOLISM/PK;DECREASED;ENZYME_ACTIVITY;;;UGT1A1;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;*26;CYP2D6*1, CYP2D6*26;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
ESTRONE SULFATE, ROSUVASTATIN;SLCO2B1;T;rs1621378;METABOLISM/PK;DECREASED;TRANSPORT;;;SLCO2B1;CAUTION_DRUG_ACCUMULATION
ESTRONE SULFATE, ROSUVASTATIN;SLCO2B1;C;rs1009122956;METABOLISM/PK;DECREASED;TRANSPORT;;;SLCO2B1;CAUTION_DRUG_ACCUMULATION
ESTRONE SULFATE, ROSUVASTATIN;SLCO2B1;T;rs199654337;METABOLISM/PK;DECREASED;TRANSPORT;;;SLCO2B1;CAUTION_DRUG_ACCUMULATION
ESTRONE SULFATE;SLCO2B1;T;rs2306168;METABOLISM/PK;DECREASED;TRANSPORT;;;SLCO2B1;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;*6;CYP2B6*6;METABOLISM/PK;INCREASED;ACTIVITY;;;CYP3A4;LIKELIHOOD_THERAPEUTIC_FAILURE
;CYP2B6;CA/CA;rs70950385;OTHER;DECREASED;ACTIVITY;;;CYP2B6;LIKELIHOOD_THERAPEUTIC_FAILURE
LOSARTAN;AGTR1;A;rs12721226;OTHER;DECREASED;AFFINITY;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL;DPYD;CT;rs3918290;OTHER;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;T;rs1463550071;METABOLISM/PK;DECREASED;ACTIVITY;;;CYP2C19;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;C;rs749678783;METABOLISM/PK;DECREASED;ACTIVITY;;;CYP2C19;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;T;rs764137538;METABOLISM/PK;DECREASED;ACTIVITY;;;CYP2C19;CAUTION_DRUG_ACCUMULATION
;NAMPT;CC + CT;rs3801266;OTHER;INCREASED;STEADY-STATE_LEVEL;;;NAMPT;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;A;rs200346442;METABOLISM/PK;DECREASED;ACTIVITY;;;CYP2C19;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;G;rs200150287;METABOLISM/PK;DECREASED;ACTIVITY;;;CYP2C19;CAUTION_DRUG_ACCUMULATION
;CYP2E1;*7A;CYP2E1*7, CYP2E1*7A;METABOLISM/PK;INCREASED;TRANSCRIPTION;;;CYP2E1;LIKELIHOOD_THERAPEUTIC_FAILURE
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;T;rs150152656;METABOLISM/PK;DECREASED;ACTIVITY;;;CYP2C19;CAUTION_DRUG_ACCUMULATION
RALOXIFENE;UGT1A8;*2/*2;UGT1A8*1A, UGT1A8*2;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
RALOXIFENE-6'-GLUCURONIDE;UGT1A1;*28;UGT1A1*1, UGT1A1*28;METABOLISM/PK;DECREASED;FORMATION;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
PRIMAQUINE;CYP2D6;*17 + *18 + *35 + *39 + *53;CYP2D6*1, CYP2D6*17, CYP2D6*18, CYP2D6*35, CYP2D6*39, CYP2D6*53;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
PRIMAQUINE;CYP2D6;*22 + *48;CYP2D6*1, CYP2D6*22, CYP2D6*26, CYP2D6*48;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
METHADONE;CYP2C19;A;rs200346442;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
METHADONE;CYP2C19;G;rs200150287;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
METHADONE;CYP2C19;A;rs778258371;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
METHADONE;CYP2C19;A;rs770829708;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
METHADONE;CYP2C19;T;rs550527959;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;T;rs550527959;METABOLISM/PK;DECREASED;ACTIVITY;;;CYP2C19;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;A;rs763625282;METABOLISM/PK;DECREASED;ACTIVITY;;;CYP2C19;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;A;rs770829708;METABOLISM/PK;DECREASED;ACTIVITY;;;CYP2C19;CAUTION_DRUG_ACCUMULATION
METHADONE;CYP2C19;A;rs72552267;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
METHADONE;CYP2C19;C;rs118203756;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
METHADONE;CYP2C19;T;rs764137538;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
METHADONE;CYP2C19;A;rs1349931378;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
METHADONE;CYP2C19;C;rs1267723490;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
METHADONE;CYP2C19;T;rs1463550071;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
CAFFEINE;RYR1;T;rs118192177;OTHER;INCREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DEXTROMETHORPHAN;CYP2D6;*169;CYP2D6*1, CYP2D6*169;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;G;rs76187628;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
;CYP2D6;*169;CYP2D6*1, CYP2D6*169;METABOLISM/PK;DECREASED;EXPRESSION;;;CYP2D6;CAUTION_DRUG_ACCUMULATION
;CYP2D6;G;rs76187628;METABOLISM/PK;INCREASED;EXPRESSION;;;CYP2D6;LIKELIHOOD_THERAPEUTIC_FAILURE
RANITIDINE;SLC22A1;A;rs34130495;METABOLISM/PK;DECREASED;TRANSPORT;;;;CAUTION_DRUG_ACCUMULATION
RANITIDINE;SLC22A1;T;rs12208357;METABOLISM/PK;DECREASED;TRANSPORT;;;;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;METABOLISM/PK;INCREASED;EXPRESSION;;;TYMS;LIKELIHOOD_THERAPEUTIC_FAILURE
;ABCC2;CG;rs113646094;OTHER;INCREASED;EXPRESSION;;;ABCC2;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN_SN-38;UGT1A1;A;rs4148323;METABOLISM/PK;DECREASED;ENZYME_ACTIVITY;;;UGT1A1;CAUTION_DRUG_ACCUMULATION
MIDAZOLAM;NR1I2;G;rs1464603;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
MIDAZOLAM;NR1I2;G;rs1464602;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
;CDA;del/del;rs3215400;;INCREASED;EXPRESSION;;;CDA;LIKELIHOOD_THERAPEUTIC_SUCCESS
PHENYTOIN;CYP2C9;del;rs71486745;;DECREASED;EXPRESSION;;;CYP2C9;LIKELIHOOD_THERAPEUTIC_FAILURE
DEXTROMETHORPHAN;CYP2D6;*2;CYP2D6*1, CYP2D6*2;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;*10;CYP2D6*1, CYP2D6*10;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
;CYP3A4;*8;CYP3A4*8;;DECREASED;STEADY-STATE_LEVEL;;;CYP3A4;LIKELIHOOD_THERAPEUTIC_FAILURE
DEXTROMETHORPHAN;CYP2D6;*10;CYP2D6*1, CYP2D6*10;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;;;CYP2D6;CAUTION_DRUG_ACCUMULATION
;CYP3A4;*12;CYP3A4*12;;DECREASED;ENZYME_ACTIVITY;;;CYP3A4;LIKELIHOOD_THERAPEUTIC_FAILURE
;CYP3A4;*11;CYP3A4*11;;DECREASED;STEADY-STATE_LEVEL;;;CYP3A4;LIKELIHOOD_THERAPEUTIC_FAILURE
IRINOTECAN_SN-38;UGT1A9;C;rs11692021;METABOLISM/PK;DECREASED;ENZYME_ACTIVITY;;;UGT1A1;CAUTION_DRUG_ACCUMULATION
;CYP2A6;*46;CYP2A6*46;;INCREASED;EXPRESSION;;;CYP2A6;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN_SN-38;UGT1A9;G;rs34993780;METABOLISM/PK;DECREASED;ENZYME_ACTIVITY;;;UGT1A1;CAUTION_DRUG_ACCUMULATION
COUMARIN, NICOTINE, TEGAFUR;CYP2A6;*7 + *19;CYP2A6*1, CYP2A6*7, CYP2A6*19;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;;;CYP2A6;CAUTION_DRUG_ACCUMULATION
;CYP2A6;*4;CYP2A6*1, CYP2A6*4;;DECREASED;EXPRESSION;;;CYP2A6;LIKELIHOOD_THERAPEUTIC_FAILURE
COUMARIN;CYP2A6;*4/*9;CYP2A6*4, CYP2A6*9;METABOLISM/PK;DECREASED;ENZYME_ACTIVITY;;;CYP2A6;CAUTION_DRUG_ACCUMULATION
;CYP2A6;*4/*9;CYP2A6*4, CYP2A6*9;;DECREASED;EXPRESSION;;;CYP2A6;LIKELIHOOD_THERAPEUTIC_FAILURE
COUMARIN, TEGAFUR;CYP2A6;*18;CYP2A6*1, CYP2A6*18;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;;;CYP2A6;CAUTION_DRUG_ACCUMULATION
IRINOTECAN_SN-38;UGT1A9;G;rs72551344;METABOLISM/PK;DECREASED;ENZYME_ACTIVITY;;;UGT1A1;CAUTION_DRUG_ACCUMULATION
NIMESULIDE;PTGS2;G;rs5273;METABOLISM/PK;INCREASED;ENZYME_ACTIVITY;;;PTGS2;LIKELIHOOD_THERAPEUTIC_FAILURE
NIMESULIDE;PTGS2;C;rs5272;METABOLISM/PK;INCREASED;ENZYME_ACTIVITY;;;PTGS2;LIKELIHOOD_THERAPEUTIC_FAILURE
;CYP2A6;*46;CYP2A6*46;;INCREASED;EXPRESSION;;;CYP2A6;LIKELIHOOD_THERAPEUTIC_SUCCESS
LETROZOLE;CYP2A6;*1/*4 + *1/*7 + *4/*4 + *4/*9;CYP2A6*1, CYP2A6*4, CYP2A6*7, CYP2A6*9;METABOLISM/PK;DECREASED;ENZYME_ACTIVITY;;;CYP2A6;CAUTION_DRUG_ACCUMULATION
;CYP2A6;*46;CYP2A6*46;;INCREASED;TRANSCRIPTION;;;CYP2A6;LIKELIHOOD_THERAPEUTIC_SUCCESS
VANDETANIB;CYP3A4;*6 + *30;CYP3A4*1, CYP3A4*6, CYP3A4*30;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;;;CYP3A4;CAUTION_DRUG_ACCUMULATION
AMIODARONE;CYP3A4;*17 + *24;CYP3A4*1, CYP3A4*17, CYP3A4*24;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
BREXPIPRAZOLE;CYP3A4;*2 + *7 + *8 + *17 + *20;CYP3A4*1, CYP3A4*2, CYP3A4*7, CYP3A4*8, CYP3A4*17, CYP3A4*20;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
BREXPIPRAZOLE;CYP3A4;*3 + *4 + *5 + *9 + *10 + *11 + *12 + *13 + *16 + *18 + *23 + *29 + *31 + *32 + *33 + *34;CYP3A4*1, CYP3A4*3, CYP3A4*4, CYP3A4*5, CYP3A4*9, CYP3A4*10, CYP3A4*11, CYP3A4*12, CYP3A4*13, CYP3A4*16, CYP3A4*18, CYP3A4*23, CYP3A4*29, CYP3A4*31, CYP3A4*32, CYP3A4*33, CYP3A4*34;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
SILDENAFIL;CYP3A4;*2 + *5 + *24 + *28 + *29;CYP3A4*1, CYP3A4*2, CYP3A4*5, CYP3A4*24, CYP3A4*28, CYP3A4*29;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
BREXPIPRAZOLE;CYP3A4;*14 + *15;CYP3A4*1, CYP3A4*14, CYP3A4*15;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
TESTOSTERONE;CYP3A4;*5 + *10 + *14 + *16 + *17 + *23 + *24 + *28 +*29 + *32 + *33 + *34;CYP3A4*1, CYP3A4*5, CYP3A4*10, CYP3A4*14, CYP3A4*16, CYP3A4*17, CYP3A4*23, CYP3A4*24, CYP3A4*28, CYP3A4*29, CYP3A4*32, CYP3A4*33, CYP3A4*34;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
SILDENAFIL;CYP3A4;*3 + *10 + *14 + *32;CYP3A4*1, CYP3A4*3, CYP3A4*10, CYP3A4*14, CYP3A4*32;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
REGORAFENIB;CYP3A4;*20;CYP3A4*1, CYP3A4*20;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;;;CYP3A4;CAUTION_DRUG_ACCUMULATION
;ERCC2;TT;rs1799793;;INCREASED;EXPRESSION;;;ERCC2;LIKELIHOOD_THERAPEUTIC_SUCCESS
;ERCC2;GG;rs13181;;INCREASED;EXPRESSION;;;ERCC2;LIKELIHOOD_THERAPEUTIC_SUCCESS
VORICONAZOLE;CYP2C19;*23;CYP2C19*1, CYP2C19*23;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*33;CYP2C19*1, CYP2C19*33;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;GGH;A;rs11545078;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
;ERCC1;GG;rs11615;;INCREASED;EXPRESSION;;;ERCC1;LIKELIHOOD_THERAPEUTIC_SUCCESS
;CDA;C/del + del/del;rs3215400;OTHER;INCREASED;EXPRESSION;;;CDA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CHLOROCRESOL;RYR1;del;rs121918596;OTHER;INCREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ELEXACAFTOR, IVACAFTOR, TEZACAFTOR;CFTR;del/del;rs113993960;OTHER;INCREASED;TRANSPORT;;;CFTR;LIKELIHOOD_THERAPEUTIC_FAILURE
PHENYTOIN;CYP2C9;*31;CYP2C9*1, CYP2C9*31;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
PHENYTOIN;CYP2C9;*19;CYP2C9*1, CYP2C9*19;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
PHENYTOIN;CYP2C9;*27;CYP2C9*1, CYP2C9*27;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
PHENYTOIN;CYP2C9;*54;CYP2C9*1, CYP2C9*54;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
PHENYTOIN;CYP2C9;*53;CYP2C9*1, CYP2C9*53;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
PHENYTOIN;CYP2C9;*56;CYP2C9*1, CYP2C9*56;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
PHENYTOIN;CYP2C9;*55;CYP2C9*1, CYP2C9*55;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
EBASTINE;CYP2J2;(CTC)1;rs757528200;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
BUPROPION;CYP2B6;*1/*30;CYP2B6*1, CYP2B6*30;OTHER;DECREASED;ACTIVITY;;;CYP2B6;LIKELIHOOD_THERAPEUTIC_FAILURE
FENTANYL;CYP3A4;T/T;rs2242480;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
NEBIVOLOL;CYP2C19;*30 + *31 + *32 + *33 + *6 + *18;CYP2C19*1, CYP2C19*6, CYP2C19*18, CYP2C19*30, CYP2C19*31, CYP2C19*32, CYP2C19*33;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
CYTARABINE;CDA;AA + AG;rs60369023;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;;;CDA;CAUTION_DRUG_ACCUMULATION
CISPLATIN;ERCC2;GG;rs13181;TOXICITY;DECREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN;ERCC1;GG;rs11615;TOXICITY;DECREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN;GSTP1;AG;rs1695;TOXICITY;DECREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATRASENTAN;SLCO1B1;*5;SLCO1B1*1, SLCO1B1*5, SLCO1B1*37;METABOLISM/PK;DECREASED;TRANSPORT;;;;CAUTION_DRUG_ACCUMULATION
ATRASENTAN;SLCO1B1;*9;SLCO1B1*1, SLCO1B1*9, SLCO1B1*37;METABOLISM/PK;DECREASED;TRANSPORT;;;;CAUTION_DRUG_ACCUMULATION
ATRASENTAN;SLCO1B1;*14;SLCO1B1*1, SLCO1B1*14, SLCO1B1*37;METABOLISM/PK;DECREASED;TRANSPORT;;;;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;*26;CYP2C19*1, CYP2C19*26;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;*26;CYP2C19*1, CYP2C19*26;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;;;CYP2C19;CAUTION_DRUG_ACCUMULATION
ATRASENTAN;SLCO1B1;*15;SLCO1B1*1, SLCO1B1*15, SLCO1B1*37;METABOLISM/PK;DECREASED;TRANSPORT;;;;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN;CYP2C19;*10;CYP2C19*1, CYP2C19*10;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;;;CYP2C19;CAUTION_DRUG_ACCUMULATION
;CD38;T;rs1130169;;DECREASED;EXPRESSION;;;CD38;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*19;CYP2C19*1, CYP2C19*19;METABOLISM/PK;DECREASED;AFFINITY;;;;CAUTION_DRUG_ACCUMULATION
OMEPRAZOLE;CYP2C19;*19;CYP2C19*1, CYP2C19*19;METABOLISM/PK;INCREASED;CATALYTIC_ACTIVITY;;;CYP2C19;LIKELIHOOD_THERAPEUTIC_FAILURE
MERCAPTOPURINE;TPMT;*1/*3A + *1/*3B;TPMT*1, TPMT*3A, TPMT*3B;METABOLISM/PK;DECREASED;ENZYME_ACTIVITY;;;TPMT;CAUTION_DRUG_ACCUMULATION
;DPYD;CG;rs75017182;OTHER;DECREASED;ACTIVITY;;;DPYD;LIKELIHOOD_THERAPEUTIC_FAILURE
;TPMT;*1/*2 + *1/*3A + *1/*3C;TPMT*1, TPMT*2, TPMT*3A, TPMT*3C;;DECREASED;ENZYME_ACTIVITY;;;TPMT;LIKELIHOOD_THERAPEUTIC_FAILURE
MERCAPTOPURINE;TPMT;*1/*2 + *1/*3A + *1/*3C;TPMT*1, TPMT*2, TPMT*3A, TPMT*3C;METABOLISM/PK;DECREASED;ACTIVITY;;;TPMT;CAUTION_DRUG_ACCUMULATION
CELECOXIB, FLUCONAZOLE;CYP2C19;*14;CYP2C19*1, CYP2C19*14;METABOLISM/PK;INCREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOXETINE, SERTRALINE;CYP2C19;*14;CYP2C19*1, CYP2C19*14;METABOLISM/PK;DECREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUCONAZOLE, FLUVOXAMINE;CYP2C19;*13;CYP2C19*1, CYP2C19*13;METABOLISM/PK;INCREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SERTRALINE;CYP2C19;*13;CYP2C19*1, CYP2C19*13;METABOLISM/PK;DECREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOXSALEN;CYP2A6;*15 + *21 + *22;CYP2A6*15, CYP2A6*21, CYP2A6*22;OTHER;DECREASED;ENZYME_ACTIVITY;;;CYP2A6;LIKELIHOOD_THERAPEUTIC_FAILURE
;SLCO1B1;*37;SLCO1B1*1, SLCO1B1*37;OTHER;INCREASED;EXPRESSION;;;SLCO1B1;LIKELIHOOD_THERAPEUTIC_SUCCESS
;SLCO1B1;*20;SLCO1B1*1, SLCO1B1*20;OTHER;INCREASED;EXPRESSION;;;SLCO1B1;LIKELIHOOD_THERAPEUTIC_SUCCESS
;SLCO1B1;*14;SLCO1B1*1, SLCO1B1*14;OTHER;INCREASED;EXPRESSION;;;SLCO1B1;LIKELIHOOD_THERAPEUTIC_SUCCESS
THIOGUANINE;TPMT;*16;TPMT*1, TPMT*16;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
MERCAPTOPURINE;TPMT;*1/*3A + *1/*3B + *1/*3C;TPMT*1, TPMT*3A, TPMT*3B, TPMT*3C;METABOLISM/PK;DECREASED;ENZYME_ACTIVITY;;;TPMT;CAUTION_DRUG_ACCUMULATION
MERCAPTOPURINE;TPMT;*3B/*3C;TPMT*1, TPMT*3B, TPMT*3C;METABOLISM/PK;DECREASED;ENZYME_ACTIVITY;;;TPMT;CAUTION_DRUG_ACCUMULATION
;CYP2C19;*19;CYP2C19*1, CYP2C19*19;OTHER;DECREASED;EXPRESSION;;;CYP2C19;LIKELIHOOD_THERAPEUTIC_FAILURE
MERCAPTOPURINE;TPMT;*1/*3A;TPMT*1, TPMT*3A, TPMT*3C;METABOLISM/PK;DECREASED;ENZYME_ACTIVITY;;;TPMT;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN;CYP2C19;*19;CYP2C19*1, CYP2C19*19;OTHER;DECREASED;CATALYTIC_ACTIVITY;;;CYP2C19;LIKELIHOOD_THERAPEUTIC_FAILURE
MERCAPTOPURINE;TPMT;*1/*3C;TPMT*1, TPMT*3C;METABOLISM/PK;DECREASED;ENZYME_ACTIVITY;;;TPMT;CAUTION_DRUG_ACCUMULATION
FLUVOXAMINE, OMEPRAZOLE;CYP2C19;*15;CYP2C19*1, CYP2C19*15;METABOLISM/PK;INCREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUVOXAMINE, OMEPRAZOLE;CYP2C19;*18;CYP2C19*1, CYP2C19*18;METABOLISM/PK;INCREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
;DPYD;CT;rs3918290;OTHER;DECREASED;ACTIVITY;;;DPYD;LIKELIHOOD_THERAPEUTIC_FAILURE
CELECOXIB, FLUOXETINE, KETOCONAZOLE, TICLOPIDINE;CYP2C19;*18;CYP2C19*1, CYP2C19*18;METABOLISM/PK;DECREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
CELECOXIB;CYP2C19;*19;CYP2C19*1, CYP2C19*19;METABOLISM/PK;INCREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOXETINE, TRANYLCYPROMINE;CYP2C19;*15;CYP2C19*1, CYP2C19*15;METABOLISM/PK;DECREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
CELECOXIB, FLUOXETINE, KETOCONAZOLE, SERTRALINE, TICLOPIDINE;CYP2C19;*16;CYP2C19*1, CYP2C19*16;METABOLISM/PK;DECREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOXETINE, FLUVOXAMINE, KETOCONAZOLE, OMEPRAZOLE, SERTRALINE, TICLOPIDINE, TRANYLCYPROMINE;CYP2C19;*19;CYP2C19*1, CYP2C19*19;METABOLISM/PK;DECREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
MERCAPTOPURINE;TPMT;*2 + *3A + *3B + *3C + *5 + *6 + *8 + *10 + *11 + *12 + *13;TPMT*1, TPMT*2, TPMT*3A, TPMT*3B, TPMT*3C, TPMT*5, TPMT*6, TPMT*8, TPMT*10, TPMT*11, TPMT*12, TPMT*13;METABOLISM/PK;DECREASED;ENZYME_ACTIVITY;;;TPMT;CAUTION_DRUG_ACCUMULATION
CARBAMAZEPINE;HLA-DRB1;*07:01;HLA-DRB1*07:01;OTHER;INCREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
3-CYANO-7-ETHOXYCOUMARIN;CYP2C19;*8 + *10;CYP2C19*1, CYP2C19*8, CYP2C19*10;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;;;CYP2C19;CAUTION_DRUG_ACCUMULATION
3-CYANO-7-ETHOXYCOUMARIN;CYP2C19;*8 + *9 + *10 + *16 + *19;CYP2C19*1, CYP2C19*8, CYP2C19*9, CYP2C19*10, CYP2C19*16, CYP2C19*19;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
FLUCONAZOLE, FLUVOXAMINE, SERTRALINE;CYP2C19;*11;CYP2C19*1, CYP2C19*11;METABOLISM/PK;INCREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOXETINE;CYP2C19;*10;CYP2C19*1, CYP2C19*10;METABOLISM/PK;DECREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
CELECOXIB, FLUOXETINE, KETOCONAZOLE, SERTRALINE, TROGLITAZONE;CYP2C19;*9;CYP2C19*1, CYP2C19*9;METABOLISM/PK;DECREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUCONAZOLE, FLUVOXAMINE;CYP2C19;*9;CYP2C19*1, CYP2C19*9;METABOLISM/PK;INCREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUCONAZOLE, FLUOXETINE, FLUVOXAMINE, KETOCONAZOLE, OMEPRAZOLE, SERTRALINE, TICLOPIDINE, TRANYLCYPROMINE, TROGLITAZONE;CYP2C19;*8;CYP2C19*1, CYP2C19*8;METABOLISM/PK;DECREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
THIOGUANINE;TPMT;*2 + *3A + *3B + *3C + *5 + *6 + *7 + *9 + *10 + *12 + *14 + *17 + *18 + *19 + *20 + *21 + *22 + *23 + *30;TPMT*1, TPMT*2, TPMT*3A, TPMT*3B, TPMT*3C, TPMT*5, TPMT*6, TPMT*7, TPMT*9, TPMT*10, TPMT*12, TPMT*14, TPMT*17, TPMT*18, TPMT*19, TPMT*20, TPMT*21, TPMT*22, TPMT*23, TPMT*30;METABOLISM/PK;DECREASED;ENZYME_ACTIVITY;;;TPMT;CAUTION_DRUG_ACCUMULATION
;TPMT;*2 + *3A + *5 + *12 + *14 + *18 + *22;TPMT*1, TPMT*2, TPMT*3A, TPMT*5, TPMT*12, TPMT*14, TPMT*18, TPMT*22;METABOLISM/PK;DECREASED;EXPRESSION;;;TPMT;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN;CYP2C19;*9;CYP2C19*1, CYP2C19*9;METABOLISM/PK;DECREASED;ACTIVITY;;;CYP2C19;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN;CYP2C19;*10;CYP2C19*1, CYP2C19*10;METABOLISM/PK;DECREASED;ACTIVITY;;;CYP2C19;CAUTION_DRUG_ACCUMULATION
THIOGUANINE;TPMT;*7 + *10 + *12 + *13;TPMT*1, TPMT*7, TPMT*10, TPMT*12, TPMT*13;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
MERCAPTOPURINE;TPMT;*1/*1;TPMT*1, TPMT*3A, TPMT*3C;METABOLISM/PK;INCREASED;ENZYME_ACTIVITY;;;TPMT;LIKELIHOOD_THERAPEUTIC_FAILURE
MEPHENYTOIN;CYP2C19;*10 + *14 + *19 + *25 + *26;CYP2C19*1, CYP2C19*10, CYP2C19*14, CYP2C19*19, CYP2C19*25, CYP2C19*26;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;;;CYP2C19;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN;CYP2C19;*10 + *14 + *19 + *25 + *26;CYP2C19*1, CYP2C19*10, CYP2C19*14, CYP2C19*19, CYP2C19*25, CYP2C19*26;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
CLOPIDOGREL;CYP2C19;*28;CYP2C19*1, CYP2C19*28;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
MEPHENYTOIN;CYP2C19;*23;CYP2C19*1, CYP2C19*23;METABOLISM/PK;INCREASED;CATALYTIC_ACTIVITY;;;CYP2C19;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*10 + *14 + *19 + *23 + *25 + *26;CYP2C19*1, CYP2C19*10, CYP2C19*14, CYP2C19*19, CYP2C19*23, CYP2C19*25, CYP2C19*26;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN;CYP2C19;*23;CYP2C19*1, CYP2C19*23;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*28;CYP2C19*1, CYP2C19*28;METABOLISM/PK;INCREASED;CATALYTIC_ACTIVITY;;;CYP2C19;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*10 + *13 + *14 + *15 + *18 + *19 + *23 + *25 + *26;CYP2C19*1, CYP2C19*10, CYP2C19*13, CYP2C19*14, CYP2C19*15, CYP2C19*18, CYP2C19*19, CYP2C19*23, CYP2C19*25, CYP2C19*26;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;;;CYP2C19;CAUTION_DRUG_ACCUMULATION
RISPERIDONE;CYP2D6;*2 + *28 + *35;CYP2D6*1, CYP2D6*2, CYP2D6*28, CYP2D6*35;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
N-DESMETHYLTAMOXIFEN;CYP2D6;*2 + *28 + *35;CYP2D6*1, CYP2D6*2, CYP2D6*28, CYP2D6*35;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
;ABCB1;AC + CC;rs2032582;METABOLISM/PK;INCREASED;ACTIVITY;;;ABCB1;LIKELIHOOD_THERAPEUTIC_FAILURE
;ABCB1;AG + GG;rs1128503;METABOLISM/PK;INCREASED;ACTIVITY;;;ABCB1;LIKELIHOOD_THERAPEUTIC_FAILURE
N-DESMETHYLTAMOXIFEN;CYP2D6;*53;CYP2D6*1, CYP2D6*53;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
ALECTINIB;CYP3A4;*4 + *7 + *8 + *12 + *14 + *16 + *17 + *18 + *19 + *20 + *23 + *24;CYP3A4*1, CYP3A4*4, CYP3A4*7, CYP3A4*8, CYP3A4*12, CYP3A4*14, CYP3A4*16, CYP3A4*17, CYP3A4*18, CYP3A4*19, CYP3A4*20, CYP3A4*23, CYP3A4*24;METABOLISM/PK;DECREASED;METABOLISM;;;POOR_METABOLIZER;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;*87 + *90 + *91 + *93 + *94 + *95 + *97 + *98 + *134 + *153;CYP2D6*1, CYP2D6*87, CYP2D6*90, CYP2D6*91, CYP2D6*93, CYP2D6*94, CYP2D6*95, CYP2D6*97, CYP2D6*98, CYP2D6*134, CYP2D6*153;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
BUFURALOL, DEXTROMETHORPHAN;CYP2D6;*17;CYP2D6*1, CYP2D6*17;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
;IFNL4;TT/TT;rs11322783;OTHER;INCREASED;EXPRESSION;;;IFNAR1;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUFURALOL;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98 + *134 + *153;CYP2D6*1, CYP2D6*2, CYP2D6*10, CYP2D6*87, CYP2D6*88, CYP2D6*89, CYP2D6*90, CYP2D6*91, CYP2D6*93, CYP2D6*94, CYP2D6*95, CYP2D6*97, CYP2D6*98, CYP2D6*134, CYP2D6*153;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
OMEPRAZOLE;CYP2C19;*10;CYP2C19*1, CYP2C19*10;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;*10;CYP2C19*1, CYP2C19*10;METABOLISM/PK;DECREASED;ACTIVITY;;;CYP2C19;CAUTION_DRUG_ACCUMULATION
TAMOXIFEN;CYP2D6;*2;CYP2D6*1, CYP2D6*2;OTHER;DECREASED;ACTIVITY;;;CYP2D6;LIKELIHOOD_THERAPEUTIC_FAILURE
BUFURALOL;CYP2D6;*49 + *55;CYP2D6*1, CYP2D6*49, CYP2D6*55;METABOLISM/PK;DECREASED;ENZYME_ACTIVITY;;;CYP2D6;CAUTION_DRUG_ACCUMULATION
BUFURALOL;CYP2D6;*54;CYP2D6*1, CYP2D6*54;METABOLISM/PK;DECREASED;ENZYME_ACTIVITY;;;CYP2D6;CAUTION_DRUG_ACCUMULATION
;CYP2C19;*16;CYP2C19*1, CYP2C19*16;OTHER;DECREASED;FORMATION;;;CYP2C19;LIKELIHOOD_THERAPEUTIC_FAILURE
DEXTROMETHORPHAN;CYP2D6;*10 + *18 + *36 + *47 + *49 + *50 + *51 + *54 + *55 + *114;CYP2D6*1, CYP2D6*10, CYP2D6*18, CYP2D6*36, CYP2D6*47, CYP2D6*49, CYP2D6*50, CYP2D6*51, CYP2D6*54, CYP2D6*55, CYP2D6*114;METABOLISM/PK;DECREASED;ENZYME_ACTIVITY;;;CYP2D6;CAUTION_DRUG_ACCUMULATION
BUFURALOL;CYP2D6;*47;CYP2D6*1, CYP2D6*47;METABOLISM/PK;DECREASED;ENZYME_ACTIVITY;;;CYP2D6;CAUTION_DRUG_ACCUMULATION
BUFURALOL;CYP2D6;*18;CYP2D6*1, CYP2D6*18;METABOLISM/PK;DECREASED;ENZYME_ACTIVITY;;;CYP2D6;CAUTION_DRUG_ACCUMULATION
;TPMT;*3A + *3C + *24;TPMT*1, TPMT*3A, TPMT*3C, TPMT*24;OTHER;DECREASED;EXPRESSION;;;TPMT;LIKELIHOOD_THERAPEUTIC_FAILURE
BUFURALOL;CYP2D6;*50;CYP2D6*1, CYP2D6*50;METABOLISM/PK;DECREASED;ENZYME_ACTIVITY;;;CYP2D6;CAUTION_DRUG_ACCUMULATION
BUFURALOL;CYP2D6;*36;CYP2D6*1, CYP2D6*36;METABOLISM/PK;DECREASED;ENZYME_ACTIVITY;;;CYP2D6;CAUTION_DRUG_ACCUMULATION
BUFURALOL;CYP2D6;*10;CYP2D6*1, CYP2D6*10;METABOLISM/PK;DECREASED;ENZYME_ACTIVITY;;;CYP2D6;CAUTION_DRUG_ACCUMULATION
BUFURALOL;CYP2D6;*51;CYP2D6*1, CYP2D6*51;METABOLISM/PK;DECREASED;ENZYME_ACTIVITY;;;CYP2D6;CAUTION_DRUG_ACCUMULATION
ACALABRUTINIB;CYP3A4;*2 + *3 + *11 + *29 + *33;CYP3A4*1, CYP3A4*2, CYP3A4*3, CYP3A4*11, CYP3A4*29, CYP3A4*33;METABOLISM/PK;INCREASED;CATALYTIC_ACTIVITY;;;CYP3A4;LIKELIHOOD_THERAPEUTIC_FAILURE
ATORVASTATIN, CERIVASTATIN, PRAVASTATIN;SLCO1B1;*15;SLCO1B1*1, SLCO1B1*15;METABOLISM/PK;DECREASED;UPTAKE;;;;CAUTION_DRUG_ACCUMULATION
ATORVASTATIN, CERIVASTATIN, PRAVASTATIN;SLCO1B1;*5;SLCO1B1*1, SLCO1B1*5;METABOLISM/PK;DECREASED;UPTAKE;;;;CAUTION_DRUG_ACCUMULATION
VANDETANIB;CYP3A4;*5 + *7 + *8 + *10 + *11 + *12 + *13 + *14 + *17 + *18 + *19 + *20 + *23 + *24 + *31 + *34;CYP3A4*1, CYP3A4*5, CYP3A4*7, CYP3A4*8, CYP3A4*10, CYP3A4*11, CYP3A4*12, CYP3A4*13, CYP3A4*14, CYP3A4*17, CYP3A4*18, CYP3A4*19, CYP3A4*20, CYP3A4*23, CYP3A4*24, CYP3A4*31, CYP3A4*34;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
AMIODARONE;CYP3A4;*2 + *9 + *10 + *11 + *16 + *18 + *19 + *23 + *29 + *31 + *32 + *34;CYP3A4*1, CYP3A4*2, CYP3A4*9, CYP3A4*10, CYP3A4*11, CYP3A4*16, CYP3A4*18, CYP3A4*19, CYP3A4*23, CYP3A4*29, CYP3A4*31, CYP3A4*32, CYP3A4*34;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
R-EDDP, S-EDDP;CYP2B6;*5+ *17 + *6+ *7 + *9+ *19 + *26 + *18;CYP2B6*1, CYP2B6*5, CYP2B6*6, CYP2B6*7, CYP2B6*9, CYP2B6*17, CYP2B6*18, CYP2B6*19, CYP2B6*26;METABOLISM/PK;DECREASED;FORMATION;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
BUFURALOL;CYP2D6;*14;CYP2D6*1, CYP2D6*14;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
BUFURALOL;CYP2D6;*53;CYP2D6*1, CYP2D6*53;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
;;C;rs9999111;OTHER;DECREASED;EXPRESSION;;;ABCG2;LIKELIHOOD_THERAPEUTIC_FAILURE
R-EDDP, S-EDDP;CYP2B6;*4;CYP2B6*1, CYP2B6*4;METABOLISM/PK;INCREASED;FORMATION;;;;CAUTION_DRUG_ACCUMULATION
VANDETANIB;CYP3A4;*2 + *3 + *9 + *15 + *16 + *29 + *32 + *33;CYP3A4*1, CYP3A4*2, CYP3A4*3, CYP3A4*9, CYP3A4*15, CYP3A4*16, CYP3A4*29, CYP3A4*32, CYP3A4*33;METABOLISM/PK;INCREASED;CLEARANCE;;;CYP3A4;LIKELIHOOD_THERAPEUTIC_FAILURE
DICLOFENAC;CYP2C9;*3;CYP2C9*3;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;;;CYP2C9;CAUTION_DRUG_ACCUMULATION
LIDOCAINE;CYP3A4;*2 + *5 + *9 + *16 + *24;CYP3A4*1, CYP3A4*2, CYP3A4*5, CYP3A4*9, CYP3A4*16, CYP3A4*24;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
BUFURALOL, DEBRISOQUINE;CYP2D6;*29;CYP2D6*1, CYP2D6*29;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;;;CYP2D6;CAUTION_DRUG_ACCUMULATION
ACETAMINOPHEN;UGT1A6;*2a;UGT1A6*1A, UGT1A6*2A;METABOLISM/PK;INCREASED;ACTIVITY;;;UGT1A6;LIKELIHOOD_THERAPEUTIC_FAILURE
LIDOCAINE;CYP3A4;*11 + *14 + *15 + *18 + *19 + *23 + *29 + *31 + *32 + *34;CYP3A4*1, CYP3A4*11, CYP3A4*14, CYP3A4*15, CYP3A4*18, CYP3A4*19, CYP3A4*23, CYP3A4*29, CYP3A4*31, CYP3A4*32, CYP3A4*34;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
BUFURALOL, DEBRISOQUINE, DEXTROMETHORPHAN;CYP2D6;*17;CYP2D6*1, CYP2D6*17;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
TESTOSTERONE;CYP3A4;*2 + *3 + *11 + *15 + *31;CYP3A4*1, CYP3A4*2, CYP3A4*3, CYP3A4*11, CYP3A4*15, CYP3A4*31;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
ACALABRUTINIB;CYP3A4;*9 + *14 + *16 + *19 + *23 + *24 + *28 + *32;CYP3A4*1, CYP3A4*9, CYP3A4*14, CYP3A4*16, CYP3A4*19, CYP3A4*23, CYP3A4*24, CYP3A4*28, CYP3A4*32;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;;;CYP3A4;CAUTION_DRUG_ACCUMULATION
REGORAFENIB;CYP3A4;*2 + *3 + *4 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *17 + *18 + *23 + *32 + *33 + *34;CYP3A4*1, CYP3A4*2, CYP3A4*3, CYP3A4*4, CYP3A4*7, CYP3A4*8, CYP3A4*9, CYP3A4*10, CYP3A4*11, CYP3A4*12, CYP3A4*13, CYP3A4*17, CYP3A4*18, CYP3A4*23, CYP3A4*32, CYP3A4*33, CYP3A4*34;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
REGORAFENIB;CYP3A4;*14 + *15 + *28 + *31;CYP3A4*1, CYP3A4*14, CYP3A4*15, CYP3A4*28, CYP3A4*31;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
MEPHENYTOIN;CYP2C19;*10;CYP2C19*1, CYP2C19*10;METABOLISM/PK;DECREASED;ACTIVITY;;;CYP2C19;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;*16;CYP2C19*1, CYP2C19*16;METABOLISM/PK;DECREASED;ACTIVITY;;;CYP2C19;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN;CYP2C19;*18;CYP2C19*1, CYP2C19*18;METABOLISM/PK;DECREASED;ACTIVITY;;;CYP2C19;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;*8;CYP2C19*1, CYP2C19*8;METABOLISM/PK;DECREASED;ACTIVITY;;;CYP2C19;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;*9;CYP2C19*1, CYP2C19*9;METABOLISM/PK;DECREASED;ACTIVITY;;;CYP2C19;CAUTION_DRUG_ACCUMULATION
SAXAGLIPTIN;CYP3A4;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 +  *14 + *15 + *16 + *17 + *18 + *19 + *20 + *23 + *24 + *28 + *29 + *31 + *32 + *34;CYP3A4*1, CYP3A4*2, CYP3A4*3, CYP3A4*4, CYP3A4*5, CYP3A4*7, CYP3A4*8, CYP3A4*9, CYP3A4*10, CYP3A4*11, CYP3A4*12, CYP3A4*13, CYP3A4*14, CYP3A4*15, CYP3A4*16, CYP3A4*17, CYP3A4*18, CYP3A4*19, CYP3A4*20, CYP3A4*23, CYP3A4*24, CYP3A4*28, CYP3A4*29, CYP3A4*31, CYP3A4*32, CYP3A4*34;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN;CYP2C19;*19;CYP2C19*1, CYP2C19*19;METABOLISM/PK;DECREASED;ACTIVITY;;;CYP2C19;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN;CYP2C19;*13;CYP2C19*1, CYP2C19*13;METABOLISM/PK;DECREASED;ACTIVITY;;;CYP2C19;CAUTION_DRUG_ACCUMULATION
MERCAPTOPURINE, THIOGUANINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*32 + *1/*33 + *1/*34;TPMT*1, TPMT*2, TPMT*3A, TPMT*3C, TPMT*9, TPMT*21, TPMT*32, TPMT*33, TPMT*34;METABOLISM/PK;DECREASED;ACTIVITY;;;TPMT;CAUTION_DRUG_ACCUMULATION
OMEPRAZOLE;CYP2C19;*19;CYP2C19*1, CYP2C19*19;METABOLISM/PK;DECREASED;CLEARANCE;;;CYP2C19;CAUTION_DRUG_ACCUMULATION
IBRUTINIB;CYP3A4;*3 + *4 + *9 + *19 +*34;CYP3A4*1, CYP3A4*3, CYP3A4*4, CYP3A4*9, CYP3A4*19, CYP3A4*34;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;*9 + *10 + *16;CYP2C19*1, CYP2C19*9, CYP2C19*10, CYP2C19*16;METABOLISM/PK;DECREASED;CLEARANCE;;;CYP2C19;CAUTION_DRUG_ACCUMULATION
BUFURALOL;CYP2D6;*2 + *10 + *89 + *92 + *93 + *96;CYP2D6*1, CYP2D6*2, CYP2D6*10, CYP2D6*89, CYP2D6*92, CYP2D6*93, CYP2D6*96;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;;;CYP2D6;CAUTION_DRUG_ACCUMULATION
IBRUTINIB;CYP3A4;*2 + *5 + *14 + *15 + *16 + *28 + *29 + *31+ *32;CYP3A4*1, CYP3A4*2, CYP3A4*5, CYP3A4*14, CYP3A4*15, CYP3A4*16, CYP3A4*28, CYP3A4*29, CYP3A4*31, CYP3A4*32;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;*89 + *92 + *93 + *96;CYP2D6*1, CYP2D6*89, CYP2D6*92, CYP2D6*93, CYP2D6*96;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;;;CYP2D6;CAUTION_DRUG_ACCUMULATION
IBRUTINIB;CYP3A4;*17 + *24;CYP3A4*1, CYP3A4*17, CYP3A4*24;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;;;CYP3A4;CAUTION_DRUG_ACCUMULATION
CABOZANTINIB;CYP3A4;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *11 + *12 + *13 + *16 + *17 + *18 + *19 + *23 + *24+ *28 + *29 + *31 + *32 + *33 + *34;CYP3A4*1, CYP3A4*2, CYP3A4*3, CYP3A4*4, CYP3A4*5, CYP3A4*7, CYP3A4*8, CYP3A4*9, CYP3A4*11, CYP3A4*12, CYP3A4*13, CYP3A4*16, CYP3A4*17, CYP3A4*18, CYP3A4*19, CYP3A4*23, CYP3A4*24, CYP3A4*28, CYP3A4*29, CYP3A4*31, CYP3A4*32, CYP3A4*33, CYP3A4*34;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
CABOZANTINIB;CYP3A4;*14 + *15;CYP3A4*1, CYP3A4*14, CYP3A4*15;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
;CYP2D6;*92 + *96;CYP2D6*1, CYP2D6*92, CYP2D6*96;METABOLISM/PK;DECREASED;ACTIVITY;;;CYP2D6;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*18;CYP2C19*1, CYP2C19*18;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;*6;CYP2C19*1, CYP2C19*6;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
MACITENTAN;CYP3A4;*3 + *4 + *5 + *10 +*15 + *16;CYP3A4*1, CYP3A4*3, CYP3A4*4, CYP3A4*5, CYP3A4*10, CYP3A4*15, CYP3A4*16;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
MACITENTAN;CYP3A4;*9 + *11 + *12 + *13 +*17 + *20 + *23 + *24 + *28 + *29 + *33 + *34;CYP3A4*1, CYP3A4*9, CYP3A4*11, CYP3A4*12, CYP3A4*13, CYP3A4*17, CYP3A4*20, CYP3A4*23, CYP3A4*24, CYP3A4*28, CYP3A4*29, CYP3A4*33, CYP3A4*34;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
OLANZAPINE;UGT1A4;*3a;UGT1A4*1A, UGT1A4*3A;METABOLISM/PK;INCREASED;GLUCURONIDATION;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;G;rs1361528097;METABOLISM/PK;DECREASED;ACTIVITY;;;CYP2C19;CAUTION_DRUG_ACCUMULATION
;ABCB1;AG + GG;rs1045642;METABOLISM/PK;INCREASED;ACTIVITY;;;ABCB1;LIKELIHOOD_THERAPEUTIC_FAILURE
BERBERINE, COPTISINE;CYP2D6;*1/*1;CYP2D6*1;METABOLISM/PK;INCREASED;INHIBITION;;;CYP2D6;LIKELIHOOD_THERAPEUTIC_FAILURE
BERBERINE, COPTISINE;CYP2D6;*1/*10;CYP2D6*1, CYP2D6*10;METABOLISM/PK;INCREASED;INHIBITION;;;CYP2D6;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;T;rs1431015009;METABOLISM/PK;DECREASED;ACTIVITY;;;CYP2C19;CAUTION_DRUG_ACCUMULATION
;SLCO1B1;*15;SLCO1B1*1, SLCO1B1*15;OTHER;DECREASED;EXPRESSION;;;SLCO1B1;LIKELIHOOD_THERAPEUTIC_FAILURE
BUFURALOL;CYP2D6;A;rs1230912765;METABOLISM/PK;DECREASED;ACTIVITY;;;CYP2D6;CAUTION_DRUG_ACCUMULATION
;CYP2B6;*27;CYP2B6*1, CYP2B6*27;;DECREASED;EXPRESSION;;;CYP2B6;LIKELIHOOD_THERAPEUTIC_FAILURE
AMITRIPTYLINE;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;CYP2D6*1, CYP2D6*2, CYP2D6*10, CYP2D6*87, CYP2D6*88, CYP2D6*89, CYP2D6*90, CYP2D6*91, CYP2D6*93, CYP2D6*94, CYP2D6*95, CYP2D6*97, CYP2D6*98;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
OMEPRAZOLE;CYP2C19;G;rs1466428833;METABOLISM/PK;DECREASED;ACTIVITY;;;CYP2C19;CAUTION_DRUG_ACCUMULATION
BUFURALOL;CYP2D6;T;rs1058171;METABOLISM/PK;DECREASED;ACTIVITY;;;CYP2D6;CAUTION_DRUG_ACCUMULATION
CORR-4A, IVACAFTOR, LUMACAFTOR;CFTR;del/del;rs113993960;EFFICACY;INCREASED;ACTIVITY;;;CFTR;LIKELIHOOD_THERAPEUTIC_SUCCESS
OMEPRAZOLE;CYP2C19;G;rs148247410;METABOLISM/PK;DECREASED;ACTIVITY;;;CYP2C19;CAUTION_DRUG_ACCUMULATION
METHADONE;CYP2D6;*2 + *10 + *87 + *89 + *90 + *93 + *95 + *97 + *98;CYP2D6*1, CYP2D6*2, CYP2D6*10, CYP2D6*87, CYP2D6*89, CYP2D6*90, CYP2D6*93, CYP2D6*95, CYP2D6*97, CYP2D6*98;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
EXEMESTANE;AKR1C3;T;rs62621365;METABOLISM/PK;DECREASED;AFFINITY;;;;CAUTION_DRUG_ACCUMULATION
EXEMESTANE;AKR1C4;A;rs11253043;METABOLISM/PK;DECREASED;AFFINITY;;;;CAUTION_DRUG_ACCUMULATION
OMEPRAZOLE;CYP2C19;T;rs1393133490;METABOLISM/PK;DECREASED;ACTIVITY;;;CYP2C19;CAUTION_DRUG_ACCUMULATION
TAMOXIFEN;CYP2D6;*2 + *10 + *87 + *90 + *91 + *93 + *95 + *98;CYP2D6*1, CYP2D6*2, CYP2D6*10, CYP2D6*87, CYP2D6*90, CYP2D6*91, CYP2D6*93, CYP2D6*95, CYP2D6*98;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
MIDAZOLAM;CYP3A5;*1/*1;CYP3A5*1, CYP3A5*3;METABOLISM/PK;INCREASED;METABOLISM;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
SIROLIMUS;CYP3A4;*1/*22 + *22/*22;CYP3A4*1, CYP3A4*22;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;*24;CYP2C19*1, CYP2C19*24;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
;DPYD;AC;rs55886062;OTHER;DECREASED;ACTIVITY;;;DPYD;LIKELIHOOD_THERAPEUTIC_FAILURE
DOCETAXEL;ABCC10;TT;rs2125739;TOXICITY;INCREASED;SENSITIVITY;;;;CAUTION_SIDE_EFFECT
RISPERIDONE;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;CYP2D6*1, CYP2D6*2, CYP2D6*10, CYP2D6*87, CYP2D6*88, CYP2D6*89, CYP2D6*90, CYP2D6*91, CYP2D6*93, CYP2D6*94, CYP2D6*95, CYP2D6*97, CYP2D6*98;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP2D6;*10/*10;CYP2D6*1, CYP2D6*10;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
TOLBUTAMIDE;CYP2C9;*1/*3;CYP2C9*1, CYP2C9*3;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
COUMARIN;CYP2A6;*1/*9;CYP2A6*1, CYP2A6*9;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
COUMARIN;CYP2A6;*1/*4;CYP2A6*1, CYP2A6*4;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
DEBRISOQUINE;CYP2D6;*75;CYP2D6*1, CYP2D6*75;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;;;CYP2D6;CAUTION_DRUG_ACCUMULATION
DEBRISOQUINE;CYP2D6;*10;CYP2D6*1, CYP2D6*10;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;;;CYP2D6;CAUTION_DRUG_ACCUMULATION
DACARBAZINE;CYP1A1;*4;CYP1A1*1, CYP1A1*4;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
DACARBAZINE;CYP1A1;*2C;CYP1A1*1, CYP1A1*2C;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
DACARBAZINE;CYP1A2;*11;CYP1A2*1, CYP1A2*11;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
;TPMT;*3A + *3C;TPMT*1, TPMT*3A, TPMT*3C;OTHER;DECREASED;ACTIVITY;;;TPMT;LIKELIHOOD_THERAPEUTIC_FAILURE
NICOTINE;CYP2A6;*17 + *35;CYP2A6*1, CYP2A6*17, CYP2A6*35;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;;;CYP2A6;CAUTION_DRUG_ACCUMULATION
VENLAFAXINE;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;CYP2D6*1, CYP2D6*2, CYP2D6*10, CYP2D6*87, CYP2D6*88, CYP2D6*89, CYP2D6*90, CYP2D6*91, CYP2D6*93, CYP2D6*94, CYP2D6*95, CYP2D6*97, CYP2D6*98;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
METHADONE;CYP2C19;*29 + *30 + *31 + *32 + *33;CYP2C19*1, CYP2C19*29, CYP2C19*30, CYP2C19*31, CYP2C19*32, CYP2C19*33;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;*3;CYP2C19*1, CYP2C19*3;METABOLISM/PK;DECREASED;ACTIVITY;;;CYP2C19;CAUTION_DRUG_ACCUMULATION
DAPOXETINE;CYP2D6;*2 + *10 + *87 + *88 + *91 + *93 + *95 + *97 + *98;CYP2D6*1, CYP2D6*2, CYP2D6*10, CYP2D6*87, CYP2D6*88, CYP2D6*91, CYP2D6*93, CYP2D6*95, CYP2D6*97, CYP2D6*98;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
MERCAPTOPURINE;ABCC4;;ABCC4 DEFICIENCY;TOXICITY, METABOLISM/PK;INCREASED;CONCENTRATIONS;;;DEFICIENCY;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;TPMT;;TPMT DEFICIENCY;TOXICITY, METABOLISM/PK;INCREASED;CONCENTRATIONS;;;DEFICIENCY;CAUTION_SIDE_EFFECT
OMEPRAZOLE;CYP2C19;A;rs140278421;METABOLISM/PK;DECREASED;ACTIVITY;;;CYP2C19;CAUTION_DRUG_ACCUMULATION
DICLOFENAC;CYP2C9;*3;CYP2C9*1, CYP2C9*3;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
DICLOFENAC;CYP2C9;*13;CYP2C9*1, CYP2C9*13;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
GEFITINIB;CYP2D6;*10 + *87 + *90 + *93 + *95 + *98;CYP2D6*1, CYP2D6*10, CYP2D6*87, CYP2D6*90, CYP2D6*93, CYP2D6*95, CYP2D6*98;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
GEFITINIB;CYP2D6;*92 + *96;CYP2D6*92, CYP2D6*96;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;;;CYP2D6;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;*29 + *30 + *31 + *33;CYP2C19*1, CYP2C19*29, CYP2C19*30, CYP2C19*31, CYP2C19*33;METABOLISM/PK;DECREASED;ACTIVITY;;;CYP2C19;CAUTION_DRUG_ACCUMULATION
MEPHENYTOIN;CYP2C19;*32;CYP2C19*1, CYP2C19*32;METABOLISM/PK;DECREASED;ACTIVITY;;;CYP2C19;CAUTION_DRUG_ACCUMULATION
TOLTERODINE;CYP2D6;*92 + *96;CYP2D6*92, CYP2D6*96;METABOLISM/PK;DECREASED;ACTIVITY;;;CYP2D6;CAUTION_DRUG_ACCUMULATION
OLANZAPINE;CYP2D6;*10 + *87 + *88 + *90 + *91 + *93 + *95 + *97;CYP2D6*1, CYP2D6*10, CYP2D6*87, CYP2D6*88, CYP2D6*90, CYP2D6*91, CYP2D6*93, CYP2D6*95, CYP2D6*97;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
CISPLATIN;TPMT;*3A;TPMT*1, TPMT*3A;TOXICITY;INCREASED;SENSITIVITY;;;;CAUTION_SIDE_EFFECT
CISPLATIN;TPMT;*3A;TPMT*1, TPMT*3A;TOXICITY;INCREASED;SENSITIVITY;;;;CAUTION_SIDE_EFFECT
CISPLATIN;TPMT;*3A;TPMT*1, TPMT*3A;OTHER;INCREASED;EXPRESSION;;;TLR4;LIKELIHOOD_THERAPEUTIC_SUCCESS
TAMOXIFEN;CYP2D6;*5/*10 + *5/*21 + *41/*41 + *10/*10 + *10/*41;CYP2D6*1, CYP2D6*5, CYP2D6*10, CYP2D6*14, CYP2D6*18, CYP2D6*21, CYP2D6*41;EFFICACY;INCREASED;EXPRESSION;;;MKI67;LIKELIHOOD_THERAPEUTIC_SUCCESS
ADEFOVIR DIPIVOXIL;SLC22A6;T;rs11568634;OTHER;DECREASED;UPTAKE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
CITALOPRAM;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *98;CYP2D6*1, CYP2D6*2, CYP2D6*10, CYP2D6*87, CYP2D6*88, CYP2D6*89, CYP2D6*90, CYP2D6*91, CYP2D6*93, CYP2D6*98;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
ATOMOXETINE;CYP2D6;*90 + *91 + *88 + *97 + *2 + *95 + *87 + *93 + *10;CYP2D6*1, CYP2D6*2, CYP2D6*10, CYP2D6*87, CYP2D6*88, CYP2D6*90, CYP2D6*91, CYP2D6*93, CYP2D6*95, CYP2D6*97;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
TOLTERODINE;CYP2D6;*10 + *93 + *94 + *95;CYP2D6*1, CYP2D6*10, CYP2D6*93, CYP2D6*94, CYP2D6*95;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;OTHER;DECREASED;EXPRESSION;;;CYP3A5;LIKELIHOOD_THERAPEUTIC_FAILURE
;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;OTHER;DECREASED;EXPRESSION;;;CYP3A5;LIKELIHOOD_THERAPEUTIC_FAILURE
METHADONE;CYP2C19;C;rs181297724;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
METHADONE;CYP2C19;A;rs138142612;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
ATORVASTATIN;SCAP;TT;rs12487736;OTHER;DECREASED;TRANSCRIPTION;;;SCAP;LIKELIHOOD_THERAPEUTIC_FAILURE
;NAMPT;CC + CT;rs1319501;OTHER;DECREASED;STEADY-STATE_LEVEL;;;NAMPT;LIKELIHOOD_THERAPEUTIC_FAILURE
METHADONE;CYP2C19;C;rs749678783;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
GEMCITABINE;FKBP5;CT;rs73748206;OTHER;INCREASED;EXPRESSION;;;FKBP5;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOZAPINE 5-N-GLUCURONIDE, DESMETHYLCLOZAPINE GLUCURONIDE;UGT1A4;G;rs2011425;METABOLISM/PK;INCREASED;FORMATION;;;;CAUTION_DRUG_ACCUMULATION
;UGT1A1;*28;UGT1A1*1, UGT1A1*28;OTHER;DECREASED;CONCENTRATIONS;;;UGT1A1;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOZAPINE;UGT1A1;*28/*28;UGT1A1*1, UGT1A1*28;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
BELINOSTAT;UGT1A1;*28;UGT1A1*1, UGT1A1*28;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
IRINOTECAN_SN-38;UGT1A1;*1/*28 + *28/*28 + *1/*37;UGT1A1*1, UGT1A1*28, UGT1A1*37;METABOLISM/PK;DECREASED;ENZYME_ACTIVITY;;;UGT1A1;CAUTION_DRUG_ACCUMULATION
DICLOFENAC, LOSARTAN, TOLBUTAMIDE;CYP2C9;*62;CYP2C9*1, CYP2C9*62;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
DICLOFENAC, LOSARTAN, TOLBUTAMIDE;CYP2C9;*2;CYP2C9*1, CYP2C9*2;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
DICLOFENAC, LOSARTAN, TOLBUTAMIDE;CYP2C9;*3;CYP2C9*1, CYP2C9*3;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
SIPONIMOD;CYP2C9;*3/*3 + *2/*2;CYP2C9*1, CYP2C9*2, CYP2C9*3;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
PHENYTOIN;CYP2C9;*47;CYP2C9*1, CYP2C9*47;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
PHENYTOIN;CYP2C9;*49;CYP2C9*1, CYP2C9*49;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
PHENYTOIN;CYP2C9;*43;CYP2C9*1, CYP2C9*43;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
PHENYTOIN;CYP2C9;*45;CYP2C9*1, CYP2C9*45;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
PHENYTOIN;CYP2C9;*39;CYP2C9*1, CYP2C9*39;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
PHENYTOIN;CYP2C9;*42;CYP2C9*1, CYP2C9*42;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
PHENYTOIN;CYP2C9;*41;CYP2C9*1, CYP2C9*41;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
PHENYTOIN;CYP2C9;*37;CYP2C9*1, CYP2C9*37;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
PHENYTOIN;CYP2C9;*36;CYP2C9*1, CYP2C9*36;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
PHENYTOIN;CYP2C9;*33;CYP2C9*1, CYP2C9*33;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
PHENYTOIN;CYP2C9;*13;CYP2C9*1, CYP2C9*13;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
PHENYTOIN;CYP2C9;*16;CYP2C9*1, CYP2C9*16;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
PHENYTOIN;CYP2C9;*14;CYP2C9*1, CYP2C9*14;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
PHENYTOIN;CYP2C9;*3;CYP2C9*1, CYP2C9*3;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
PHENYTOIN;CYP2C9;*8;CYP2C9*1, CYP2C9*8;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
PHENYTOIN;CYP2C9;*50;CYP2C9*1, CYP2C9*50;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
PHENYTOIN;CYP2C9;*52;CYP2C9*1, CYP2C9*52;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
PHENYTOIN;CYP2C9;*51;CYP2C9*1, CYP2C9*51;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
IVACAFTOR;CFTR;del;rs113993960;EFFICACY;;ACTIVITY;;;CFTR;CAUTION_DOSE_ADJUST
;CYP2C9;AT + TT;rs7089580;OTHER;INCREASED;EXPRESSION;;;CYP2C9;LIKELIHOOD_THERAPEUTIC_SUCCESS
DICLOFENAC, LOSARTAN, TOLBUTAMIDE;CYP2C9;*3;CYP2C9*1, CYP2C9*3;METABOLISM/PK;DECREASED;ENZYME_ACTIVITY;;;CYP2C9;CAUTION_DRUG_ACCUMULATION
DICLOFENAC, LOSARTAN, TOLBUTAMIDE;CYP2C9;*72;CYP2C9*1, CYP2C9*72;METABOLISM/PK;DECREASED;ENZYME_ACTIVITY;;;CYP2C9;CAUTION_DRUG_ACCUMULATION
LOSARTAN;CYP2C9;*75;CYP2C9*1, CYP2C9*75;METABOLISM/PK;DECREASED;ENZYME_ACTIVITY;;;CYP2C9;CAUTION_DRUG_ACCUMULATION
DICLOFENAC, LOSARTAN, TOLBUTAMIDE;CYP2C9;*74;CYP2C9*1, CYP2C9*74;METABOLISM/PK;DECREASED;ENZYME_ACTIVITY;;;CYP2C9;CAUTION_DRUG_ACCUMULATION
DICLOFENAC, LOSARTAN;CYP2C9;*73;CYP2C9*1, CYP2C9*73;METABOLISM/PK;DECREASED;ENZYME_ACTIVITY;;;CYP2C9;CAUTION_DRUG_ACCUMULATION
OXYCODONE;CYP3A4;*2 + *3 + *4+ *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *14 + *15 + *16 + *18 + *19 + *23 + *24 + *28 + *29 + *31 + *32 + *33 + *34;CYP3A4*1, CYP3A4*2, CYP3A4*3, CYP3A4*4, CYP3A4*5, CYP3A4*7, CYP3A4*8, CYP3A4*9, CYP3A4*10, CYP3A4*11, CYP3A4*12, CYP3A4*13, CYP3A4*14, CYP3A4*15, CYP3A4*16, CYP3A4*18, CYP3A4*19, CYP3A4*23, CYP3A4*24, CYP3A4*28, CYP3A4*29, CYP3A4*31, CYP3A4*32, CYP3A4*33, CYP3A4*34;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
OXYCODONE;CYP3A4;*6 + *17 + *20 + *21 + *26 + *30;CYP3A4*1, CYP3A4*6, CYP3A4*17, CYP3A4*20, CYP3A4*21, CYP3A4*26, CYP3A4*30;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;MIR27A;C;rs895819;METABOLISM/PK;DECREASED;ENZYME_ACTIVITY;;;DPYD;CAUTION_DRUG_ACCUMULATION
;CYP2D6;G;rs1058164;OTHER;DECREASED;EXPRESSION;;;CYP2D6;LIKELIHOOD_THERAPEUTIC_FAILURE
IBUPROFEN;CYP2C19;*33 + *30 + *31 + *32;CYP2C19*1, CYP2C19*30, CYP2C19*31, CYP2C19*32, CYP2C19*33;OTHER;DECREASED;CATALYTIC_ACTIVITY;;;CYP2C19;LIKELIHOOD_THERAPEUTIC_FAILURE
IBUPROFEN;CYP3A4;*4 + *5 + *18 + *23 +  *32 + *34 + *28 + *29 + *31 + *33;CYP3A4*1, CYP3A4*4, CYP3A4*5, CYP3A4*18, CYP3A4*23, CYP3A4*28, CYP3A4*29, CYP3A4*31, CYP3A4*32, CYP3A4*33, CYP3A4*34;OTHER;DECREASED;CLEARANCE;;;CYP3A4;CAUTION_DRUG_ACCUMULATION
IBUPROFEN;CYP2C19;*3 + *35;CYP2C19*1, CYP2C19*3, CYP2C19*35;OTHER;DECREASED;CATALYTIC_ACTIVITY;;;CYP2C19;LIKELIHOOD_THERAPEUTIC_FAILURE
BUFURALOL;CYP2D6;*36;CYP2D6*1, CYP2D6*36;METABOLISM/PK;DECREASED;ENZYME_ACTIVITY;;;CYP2D6;CAUTION_DRUG_ACCUMULATION
11ALPHA-HYDROXYTESTOSTERONE;CYP2C19;*9 + *11 + *23;CYP2C19*1, CYP2C19*9, CYP2C19*11, CYP2C19*23;METABOLISM/PK;INCREASED;FORMATION;;;;CAUTION_DRUG_ACCUMULATION
ANDROSTENEDIONE;CYP2C19;*9 + *11 + *23;CYP2C19*1, CYP2C19*9, CYP2C19*11, CYP2C19*23;METABOLISM/PK;INCREASED;FORMATION;;;;CAUTION_DRUG_ACCUMULATION
16ALPHA-HYDROXYTESTOSTERONE;CYP2C19;*11 + *23;CYP2C19*1, CYP2C19*11, CYP2C19*23;METABOLISM/PK;INCREASED;FORMATION;;;;CAUTION_DRUG_ACCUMULATION
BLONANSERIN;CYP3A4;*20;CYP3A4*1, CYP3A4*20;METABOLISM/PK;DECREASED;ACTIVITY;;;CYP3A4;CAUTION_DRUG_ACCUMULATION
BLONANSERIN;CYP3A4;*4 + *5 + *7 + *8 + *9 + *10 + *12 + *13 + *14 + *16 + *17 + *18 + *23 + *24 + *28 + *31 + *33 + *34;CYP3A4*1, CYP3A4*4, CYP3A4*5, CYP3A4*7, CYP3A4*8, CYP3A4*9, CYP3A4*10, CYP3A4*12, CYP3A4*13, CYP3A4*14, CYP3A4*16, CYP3A4*17, CYP3A4*18, CYP3A4*23, CYP3A4*24, CYP3A4*28, CYP3A4*31, CYP3A4*33, CYP3A4*34;METABOLISM/PK;DECREASED;ACTIVITY;;;CYP3A4;CAUTION_DRUG_ACCUMULATION
BLONANSERIN;CYP3A4;*29;CYP3A4*1, CYP3A4*29;METABOLISM/PK;INCREASED;ACTIVITY;;;CYP3A4;LIKELIHOOD_THERAPEUTIC_FAILURE
MIDAZOLAM;CYP3A4;*39 + *40 + *41 + *42 + *43 + *44 + *46;CYP3A4*1, CYP3A4*39, CYP3A4*40, CYP3A4*41, CYP3A4*42, CYP3A4*43, CYP3A4*44, CYP3A4*46;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
HYDRALAZINE;NAT2;*4/*4;NAT2*4, NAT2*5, NAT2*6;OTHER;INCREASED;ACTIVITY;;;NAT2_RAPID_ACETYLATOR;LIKELIHOOD_THERAPEUTIC_SUCCESS
SOLITHROMYCIN;NAT2;*4;NAT2*4, NAT2*5, NAT2*6, NAT2*7, NAT2*14;METABOLISM/PK;INCREASED;METABOLISM;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
HYDRALAZINE;NAT2;*4/*5 + *4/*6;NAT2*4, NAT2*5, NAT2*6, NAT2*7;OTHER;INCREASED;ACTIVITY;;;NAT2;LIKELIHOOD_THERAPEUTIC_SUCCESS
;ALDH1A2;AA + AG;rs12915901;OTHER;DECREASED;EXPRESSION;;;ALDH1A2;LIKELIHOOD_THERAPEUTIC_FAILURE
DEXAMETHASONE;BCL2L11;CC;rs724710;TOXICITY;INCREASED;SENSITIVITY;;;;CAUTION_SIDE_EFFECT
DEXAMETHASONE;BCL2L11;AA;rs2241843;TOXICITY;INCREASED;SENSITIVITY;;;;CAUTION_SIDE_EFFECT
THIOXANTHINE;XDH;T;rs45442092;METABOLISM/PK;DECREASED;CLEARANCE;;;XDH;CAUTION_DRUG_ACCUMULATION
THIOXANTHINE;XDH;T;rs2295474;METABOLISM/PK;DECREASED;CLEARANCE;;;XDH;CAUTION_DRUG_ACCUMULATION
;HLA-G;C;rs1063320;OTHER;INCREASED;EXPRESSION;;;HLA-G;LIKELIHOOD_THERAPEUTIC_SUCCESS
SIMVASTATIN;HLA-G;GG;rs1063320;OTHER;INCREASED;EXPRESSION;;;HLA-G;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUPROPION;CYP2B6;*46;CYP2B6*46;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;;;CYP2B6;CAUTION_DRUG_ACCUMULATION
BUPROPION;CYP2B6;*47;CYP2B6*47;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;;;CYP2B6;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;*47;CYP2B6*47;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;;;CYP2B6;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;*46;CYP2B6*46;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;;;CYP2B6;CAUTION_DRUG_ACCUMULATION
;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;PD;DECREASED;EXPRESSION;;;HDAC2;LIKELIHOOD_THERAPEUTIC_FAILURE
;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;PD;DECREASED;EXPRESSION;;;FKBP5;LIKELIHOOD_THERAPEUTIC_FAILURE
;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;PD;DECREASED;EXPRESSION;;;GLCCI1;LIKELIHOOD_THERAPEUTIC_FAILURE
;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;PD;DECREASED;EXPRESSION;;;NR3C1;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOXETINE;CYP2D6;*10 + *92 + *93 + *96 + *87 + *2;CYP2D6*2, CYP2D6*10, CYP2D6*87, CYP2D6*92, CYP2D6*93, CYP2D6*96;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;;;CYP2D6;CAUTION_DRUG_ACCUMULATION
;CDA;GG;rs602950;OTHER;INCREASED;EXPRESSION;;;CDA;LIKELIHOOD_THERAPEUTIC_SUCCESS
;TPH2;T;rs4290270;OTHER;INCREASED;EXPRESSION;;;TPH2;LIKELIHOOD_THERAPEUTIC_SUCCESS
;CDA;TT;rs532545;OTHER;INCREASED;EXPRESSION;;;CDA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAFFEINE, CHLOROCRESOL, HALOTHANE;RYR1;C;rs118204423;OTHER;INCREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAFFEINE, CHLOROCRESOL, HALOTHANE;RYR1;A;rs121918594;OTHER;INCREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DIHYDROERGOTAMINE, METHYSERGIDE, SUMATRIPTAN;HTR1B;C;rs130060;PD;INCREASED;AFFINITY;;;HTR1B;LIKELIHOOD_THERAPEUTIC_SUCCESS
KETANSERIN;HTR1B;C;rs130060;PD;DECREASED;AFFINITY;;;HTR1B;LIKELIHOOD_THERAPEUTIC_FAILURE
;CDA;TT;rs1048977;OTHER;INCREASED;EXPRESSION;;;CDA;LIKELIHOOD_THERAPEUTIC_SUCCESS
;TPH2;AA;rs7305115;OTHER;INCREASED;EXPRESSION;;;TPH2;LIKELIHOOD_THERAPEUTIC_SUCCESS
;CDA;CC;rs2072671;OTHER;INCREASED;EXPRESSION;;;CDA;LIKELIHOOD_THERAPEUTIC_SUCCESS
;CYP2D6;*1/*4;CYP2D6*1, CYP2D6*4;METABOLISM/PK;DECREASED;EXPRESSION;;;CYP2D6;CAUTION_DRUG_ACCUMULATION
;DPYD;A;rs547099198;OTHER;DECREASED;CATALYTIC_ACTIVITY;;;DPYD;LIKELIHOOD_THERAPEUTIC_FAILURE
;DPYD;A;rs568132506;OTHER;DECREASED;CATALYTIC_ACTIVITY;;;DPYD;LIKELIHOOD_THERAPEUTIC_FAILURE
;DPYD;A;rs760663364;OTHER;DECREASED;CATALYTIC_ACTIVITY;;;DPYD;LIKELIHOOD_THERAPEUTIC_FAILURE
;DPYD;A;rs780025995;OTHER;DECREASED;CATALYTIC_ACTIVITY;;;DPYD;LIKELIHOOD_THERAPEUTIC_FAILURE
;DPYD;T;rs114096998;OTHER;DECREASED;CATALYTIC_ACTIVITY;;;DPYD;LIKELIHOOD_THERAPEUTIC_FAILURE
;DPYD;G;rs748639205;OTHER;DECREASED;CATALYTIC_ACTIVITY;;;DPYD;LIKELIHOOD_THERAPEUTIC_FAILURE
;;AA;rs2784917;OTHER;INCREASED;EXPRESSION;;;WNT5B;LIKELIHOOD_THERAPEUTIC_SUCCESS
;;GG;rs6539870;OTHER;INCREASED;EXPRESSION;;;IL1B;LIKELIHOOD_THERAPEUTIC_SUCCESS
IVACAFTOR;CFTR;A;rs75527207;EFFICACY;;PROTEIN_STABILITY;;;CFTR;CAUTION_DOSE_ADJUST
IVACAFTOR;CFTR;A;rs121909047;EFFICACY;;ACTIVITY;;;CFTR;CAUTION_DOSE_ADJUST
NICOTINE;CYP2A6;CC + CT;rs56113850;METABOLISM/PK;INCREASED;ACTIVITY;;;CYP2A6;LIKELIHOOD_THERAPEUTIC_FAILURE
NICOTINE;CYP2A6;TT;rs7259706;METABOLISM/PK;INCREASED;ACTIVITY;;;CYP2A6;LIKELIHOOD_THERAPEUTIC_FAILURE
NICOTINE;CYP2A6;AA + AG;rs28399453;METABOLISM/PK;INCREASED;ACTIVITY;;;CYP2A6;LIKELIHOOD_THERAPEUTIC_FAILURE
NICOTINE;CYP2A6;CC + CG;rs8192733;METABOLISM/PK;INCREASED;ACTIVITY;;;CYP2A6;LIKELIHOOD_THERAPEUTIC_FAILURE
LURASIDONE;CYP3A4;*15 + *19 + *23 + *24 + *28 + *29 + *32 + *33;CYP3A4*1, CYP3A4*15, CYP3A4*19, CYP3A4*23, CYP3A4*24, CYP3A4*28, CYP3A4*29, CYP3A4*32, CYP3A4*33;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
LURASIDONE;CYP3A4;*12;CYP3A4*1, CYP3A4*12;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
TICAGRELOR;CYP3A4;*2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31;CYP3A4*1, CYP3A4*2, CYP3A4*3, CYP3A4*4, CYP3A4*5, CYP3A4*9, CYP3A4*14, CYP3A4*15, CYP3A4*16, CYP3A4*17, CYP3A4*19, CYP3A4*24, CYP3A4*28, CYP3A4*29, CYP3A4*31;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
TICAGRELOR;CYP3A4;*11 + *18 + *33;CYP3A4*1, CYP3A4*11, CYP3A4*18, CYP3A4*33;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
;;C;rs9999111;OTHER;DECREASED;EXPRESSION;;;ABCG2;LIKELIHOOD_THERAPEUTIC_FAILURE
;ABCG2;C;rs2725263;OTHER;INCREASED;EXPRESSION;;;ABCG2;LIKELIHOOD_THERAPEUTIC_SUCCESS
;;A;rs149713212;OTHER;DECREASED;EXPRESSION;;;ABCG2;LIKELIHOOD_THERAPEUTIC_FAILURE
IVACAFTOR;CFTR;A;rs74503330;OTHER;INCREASED;ACTIVITY;;;CFTR;LIKELIHOOD_THERAPEUTIC_SUCCESS
;;G;rs12508471;OTHER;DECREASED;EXPRESSION;;;ABCG2;LIKELIHOOD_THERAPEUTIC_FAILURE
;ABCA12;A;rs2888327;;INCREASED;EXPRESSION;;;ABCA12;LIKELIHOOD_THERAPEUTIC_SUCCESS
;ABCA12;C;rs10182702;;INCREASED;EXPRESSION;;;ABCA12;LIKELIHOOD_THERAPEUTIC_SUCCESS
DAUNORUBICINOL;AKR1A1;C;rs6690497;METABOLISM/PK;DECREASED;FORMATION;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
DOXORUBICINOL;AKR1A1;C;rs6690497;METABOLISM/PK;DECREASED;FORMATION;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
;ABCA8;T;rs11656365;;DECREASED;EXPRESSION;;;ABCA8;LIKELIHOOD_THERAPEUTIC_FAILURE
;;G;rs2000068;;INCREASED;EXPRESSION;;;ABCA1;LIKELIHOOD_THERAPEUTIC_SUCCESS
;PITPNM2;C;rs12425009;;DECREASED;EXPRESSION;;;ABCB9;LIKELIHOOD_THERAPEUTIC_FAILURE
DOXORUBICINOL;AKR1A1;G;rs2229540;METABOLISM/PK;DECREASED;FORMATION;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
;PSMB8, TAP1, TAP2;T;rs2071543;;INCREASED;EXPRESSION;;;TAP2;LIKELIHOOD_THERAPEUTIC_SUCCESS
;PSMB8, TAP2;A;rs9357155;;INCREASED;EXPRESSION;;;TAP2;LIKELIHOOD_THERAPEUTIC_SUCCESS
;ABCB9;T;rs4148866;;INCREASED;EXPRESSION;;;ABCB9;LIKELIHOOD_THERAPEUTIC_SUCCESS
DAUNORUBICINOL;AKR1A1;G;rs2229540;METABOLISM/PK;DECREASED;FORMATION;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
;ABCA1;G;rs2515629;;INCREASED;EXPRESSION;;;ABCA1;LIKELIHOOD_THERAPEUTIC_SUCCESS
;ABCA1;G;rs4149297;;INCREASED;EXPRESSION;;;ABCA1;LIKELIHOOD_THERAPEUTIC_SUCCESS
;;T;rs2487030;;INCREASED;EXPRESSION;;;ABCA1;LIKELIHOOD_THERAPEUTIC_SUCCESS
;ABCA1;C;rs2472507;;INCREASED;EXPRESSION;;;ABCA1;LIKELIHOOD_THERAPEUTIC_SUCCESS
;F3;T;rs841698;;INCREASED;EXPRESSION;;;ABCD3;LIKELIHOOD_THERAPEUTIC_SUCCESS
;ABCD2;C;rs4284427;;DECREASED;EXPRESSION;;;ABCD2;LIKELIHOOD_THERAPEUTIC_FAILURE
;REDIC1;T;rs10783969;;INCREASED;EXPRESSION;;;ABCD2;LIKELIHOOD_THERAPEUTIC_SUCCESS
;;G;rs4285917;;DECREASED;EXPRESSION;;;ABCD2;LIKELIHOOD_THERAPEUTIC_FAILURE
;ABCC10;A;rs2487663;;DECREASED;EXPRESSION;;;ABCC10;LIKELIHOOD_THERAPEUTIC_FAILURE
;ABCC4;T;rs4773866;;INCREASED;EXPRESSION;;;ABCC4;LIKELIHOOD_THERAPEUTIC_SUCCESS
;ABCC10;A;rs2185631;;DECREASED;EXPRESSION;;;ABCC10;LIKELIHOOD_THERAPEUTIC_FAILURE
;;G;rs12195350;;DECREASED;EXPRESSION;;;ABCC10;LIKELIHOOD_THERAPEUTIC_FAILURE
;ABCD1, BCAP31;C;rs17091297;;INCREASED;EXPRESSION;;;ABCD1;LIKELIHOOD_THERAPEUTIC_SUCCESS
;ABCC10;G;rs9394952;;DECREASED;EXPRESSION;;;ABCC10;LIKELIHOOD_THERAPEUTIC_FAILURE
;PLXNB3;A;rs4898439;;INCREASED;EXPRESSION;;;ABCD1;LIKELIHOOD_THERAPEUTIC_SUCCESS
;;C;rs4898437;;INCREASED;EXPRESSION;;;ABCD1;LIKELIHOOD_THERAPEUTIC_SUCCESS
;TMPRSS11E;T;rs2168047;;INCREASED;EXPRESSION;;;UGT2B4;LIKELIHOOD_THERAPEUTIC_SUCCESS
;;CC;rs6822259;;INCREASED;EXPRESSION;;;UGT2B17;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;CYP2A6;AG + GG;rs57837628;METABOLISM/PK;INCREASED;ACTIVITY;;;CYP2A6;LIKELIHOOD_THERAPEUTIC_FAILURE
;UGT2B4;T;rs4557343;;INCREASED;EXPRESSION;;;UGT2B15;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;CYP2A6;GG;rs7260629;METABOLISM/PK;INCREASED;ACTIVITY;;;CYP2A6;LIKELIHOOD_THERAPEUTIC_FAILURE
CLADRIBINE, FLUOROURACIL, GEMCITABINE;NT5C1A;G;rs201045130;OTHER;DECREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLADRIBINE, FLUOROURACIL, GEMCITABINE;NT5C1A;A;rs374150125;OTHER;DECREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLADRIBINE, FLUOROURACIL, GEMCITABINE;NT5C1A;T;rs370457585;OTHER;DECREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
NICOTINE;CYP2A6;CC + CT;rs4803381;METABOLISM/PK;INCREASED;ACTIVITY;;;CYP2A6;LIKELIHOOD_THERAPEUTIC_FAILURE
ETHANOL;OPRM1;GG;rs1799971;EFFICACY;DECREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
DOXORUBICIN;RARG;A;rs2229774;TOXICITY;INCREASED;SENSITIVITY;;;;CAUTION_SIDE_EFFECT
;IL18;GG + GT;rs1946518;OTHER;INCREASED;EXPRESSION;;;IL18;LIKELIHOOD_THERAPEUTIC_SUCCESS
;IL18;CC + CG;rs5744247;OTHER;INCREASED;EXPRESSION;;;IL18;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHADONE;CYP3A4;*11 + *32 + *34;CYP3A4*1, CYP3A4*11, CYP3A4*32, CYP3A4*34;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
METHADONE;CYP3A4;*2 + *3  + *5  + *14 + *15 + *16 + *17 + *18 + *19 + *24 + *29 + *31;CYP3A4*1, CYP3A4*2, CYP3A4*3, CYP3A4*5, CYP3A4*14, CYP3A4*15, CYP3A4*16, CYP3A4*17, CYP3A4*18, CYP3A4*19, CYP3A4*24, CYP3A4*29, CYP3A4*31;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
DACARBAZINE;CYP1A2;*3;CYP1A2*1, CYP1A2*3;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
REMIMAZOLAM;CES1;T;rs71647871;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;;;CES1;CAUTION_DRUG_ACCUMULATION
REMIMAZOLAM;CES1;C;rs151291296;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;;;CES1;CAUTION_DRUG_ACCUMULATION
REMIMAZOLAM;CES1;T;rs2307240;METABOLISM/PK;INCREASED;CATALYTIC_ACTIVITY;;;CES1;LIKELIHOOD_THERAPEUTIC_FAILURE
REMIMAZOLAM;CES1;G;rs143718310;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;;;CES1;CAUTION_DRUG_ACCUMULATION
ELEXACAFTOR / TEZACAFTOR / IVACAFTOR, IVACAFTOR / TEZACAFTOR;CFTR;A;rs35516286;PD;INCREASED;ACTIVITY;;;CFTR;LIKELIHOOD_THERAPEUTIC_SUCCESS
SITAGLIPTIN;DPP4;CC;rs759717;PD;INCREASED;ACTIVITY;;;DPP4;LIKELIHOOD_THERAPEUTIC_SUCCESS
SITAGLIPTIN;DPP4;TT;rs2909451;PD;INCREASED;ACTIVITY;;;DPP4;LIKELIHOOD_THERAPEUTIC_SUCCESS
IVACAFTOR;CFTR;C;rs113993958;EFFICACY;;ACTIVITY;;;CFTR;CAUTION_DOSE_ADJUST
IVACAFTOR;CFTR;G;rs397508288;EFFICACY;;ACTIVITY;;;CFTR;CAUTION_DOSE_ADJUST
IVACAFTOR;CFTR;A;rs397508537;EFFICACY;;ACTIVITY;;;CFTR;CAUTION_DOSE_ADJUST
IVACAFTOR;CFTR;A;rs78769542;EFFICACY;;ACTIVITY;;;CFTR;CAUTION_DOSE_ADJUST
IVACAFTOR;CFTR;C;rs1800111;EFFICACY;;ACTIVITY;;;CFTR;CAUTION_DOSE_ADJUST
IVACAFTOR;CFTR;A;rs121909020;EFFICACY;;ACTIVITY;;;CFTR;CAUTION_DOSE_ADJUST
IVACAFTOR;CFTR;T;rs397508442;EFFICACY;;ACTIVITY;;;CFTR;CAUTION_DOSE_ADJUST
IVACAFTOR;CFTR;A;rs74551128;EFFICACY;;ACTIVITY;;;CFTR;CAUTION_DOSE_ADJUST
IVACAFTOR;CFTR;A;rs186045772;EFFICACY;;ACTIVITY;;;CFTR;CAUTION_DOSE_ADJUST
IVACAFTOR;CFTR;A;rs397508256;EFFICACY;;ACTIVITY;;;CFTR;CAUTION_DOSE_ADJUST
IVACAFTOR;CFTR;T;rs368505753;EFFICACY;;ACTIVITY;;;CFTR;CAUTION_DOSE_ADJUST
IVACAFTOR;CFTR;T;rs202179988;EFFICACY;;ACTIVITY;;;CFTR;CAUTION_DOSE_ADJUST
IVACAFTOR;CFTR;A;rs121909019;EFFICACY;;ACTIVITY;;;CFTR;CAUTION_DOSE_ADJUST
IVACAFTOR;CFTR;A;rs121908753;EFFICACY;;ACTIVITY;;;CFTR;CAUTION_DOSE_ADJUST
DAUNORUBICIN;AKR1C4;G;rs17134592;METABOLISM/PK;DECREASED;ENZYME_ACTIVITY;;;AKR1C4;CAUTION_DRUG_ACCUMULATION
IVACAFTOR;CFTR;T;rs77834169;EFFICACY;;ACTIVITY;;;CFTR;CAUTION_DOSE_ADJUST
IVACAFTOR;CFTR;G;rs121908752;EFFICACY;;ACTIVITY;;;CFTR;CAUTION_DOSE_ADJUST
ELEXACAFTOR / TEZACAFTOR / IVACAFTOR;CFTR;CT;rs186089140;PD;INCREASED;ACTIVITY;;;CFTR;LIKELIHOOD_THERAPEUTIC_SUCCESS
DAUNORUBICIN, DOXORUBICIN;AKR7A2;T;rs1043657;METABOLISM/PK;DECREASED;ENZYME_ACTIVITY;;;AKR7A2;CAUTION_DRUG_ACCUMULATION
IVACAFTOR;CFTR;A;rs77932196;EFFICACY;;ACTIVITY;;;CFTR;CAUTION_DOSE_ADJUST
IVACAFTOR;CFTR;T;rs141033578;EFFICACY;;ACTIVITY;;;CFTR;CAUTION_DOSE_ADJUST
DAUNORUBICIN, DOXORUBICIN;AKR1C3;T;rs34186955;METABOLISM/PK;DECREASED;ENZYME_ACTIVITY;;;AKR1C3;CAUTION_DRUG_ACCUMULATION
IVACAFTOR;CFTR;T;rs121909011;EFFICACY;;ACTIVITY;;;CFTR;CAUTION_DOSE_ADJUST
DAUNORUBICIN, DOXORUBICIN;AKR1C3;T;rs35575889;METABOLISM/PK;DECREASED;ENZYME_ACTIVITY;;;AKR1C3;CAUTION_DRUG_ACCUMULATION
IVACAFTOR;CFTR;T;rs77409459;EFFICACY;;ACTIVITY;;;CFTR;CAUTION_DOSE_ADJUST
DAUNORUBICIN;AKR1C3;A;rs4987102;METABOLISM/PK;DECREASED;ENZYME_ACTIVITY;;;AKR1C3;CAUTION_DRUG_ACCUMULATION
IVACAFTOR;CFTR;C;rs397508510;EFFICACY;;ACTIVITY;;;CFTR;CAUTION_DOSE_ADJUST
IVACAFTOR;CFTR;A;rs397508139;EFFICACY;;ACTIVITY;;;CFTR;CAUTION_DOSE_ADJUST
;DPYD;C;rs2297595;OTHER;DECREASED;ACTIVITY;;;DPYD;LIKELIHOOD_THERAPEUTIC_FAILURE
;DPYD;A;rs67376798;OTHER;DECREASED;ACTIVITY;;;DPYD;LIKELIHOOD_THERAPEUTIC_FAILURE
IVACAFTOR;CFTR;C;rs397508435;EFFICACY;;ACTIVITY;;;CFTR;CAUTION_DOSE_ADJUST
IVACAFTOR;CFTR;A;rs121908751;EFFICACY;;ACTIVITY;;;CFTR;CAUTION_DOSE_ADJUST
;EPO;AA;rs1617640;OTHER;INCREASED;EXPRESSION;;;EPO;LIKELIHOOD_THERAPEUTIC_SUCCESS
IVACAFTOR;CFTR;G;rs397508328;EFFICACY;;ACTIVITY;;;CFTR;CAUTION_DOSE_ADJUST
DOXORUBICIN;AKR1C3;T;rs34186955;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
DOXORUBICIN;AKR1C3;A;rs28943579;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
DOXORUBICIN;AKR1C3;T;rs62621365;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
;CYP4F2;A;rs2189784;OTHER;INCREASED;EXPRESSION;;;CYP4F2;LIKELIHOOD_THERAPEUTIC_SUCCESS
;CYP4F11;A;rs1060467;OTHER;INCREASED;EXPRESSION;;;CYP4F2;LIKELIHOOD_THERAPEUTIC_SUCCESS
;CYP4F2;T;rs2108622;OTHER;INCREASED;EXPRESSION;;;CYP4F11;LIKELIHOOD_THERAPEUTIC_SUCCESS
;CYP4F2;T;rs2108622;OTHER;INCREASED;EXPRESSION;;;CYP4F2;LIKELIHOOD_THERAPEUTIC_SUCCESS
;CYP4F2;A;rs2189784;OTHER;DECREASED;EXPRESSION;;;CYP4F12;LIKELIHOOD_THERAPEUTIC_FAILURE
IVACAFTOR;CFTR;T;rs11971167;EFFICACY;;ACTIVITY;;;CFTR;CAUTION_DOSE_ADJUST
IVACAFTOR;CFTR;C;rs75541969;EFFICACY;;ACTIVITY;;;CFTR;CAUTION_DOSE_ADJUST
IVACAFTOR;CFTR;G;rs34911792;EFFICACY;;ACTIVITY;;;CFTR;CAUTION_DOSE_ADJUST
IVACAFTOR;CFTR;G;rs150212784;EFFICACY;;ACTIVITY;;;CFTR;CAUTION_DOSE_ADJUST
IVACAFTOR;CFTR;A;rs397508759;EFFICACY;;ACTIVITY;;;CFTR;CAUTION_DOSE_ADJUST
IVACAFTOR;CFTR;A;rs78655421;EFFICACY;;ACTIVITY;;;CFTR;CAUTION_DOSE_ADJUST
IVACAFTOR;CFTR;T;rs115545701;EFFICACY;;ACTIVITY;;;CFTR;CAUTION_DOSE_ADJUST
IVACAFTOR;CFTR;C;rs397508513;EFFICACY;;ACTIVITY;;;CFTR;CAUTION_DOSE_ADJUST
IVACAFTOR;CFTR;T;rs1800100;EFFICACY;;ACTIVITY;;;CFTR;CAUTION_DOSE_ADJUST
ADALIMUMAB;TNF;AG;rs1800629;METABOLISM/PK;DECREASED;STEADY-STATE_LEVEL;;;TNF;LIKELIHOOD_THERAPEUTIC_FAILURE
;TNF;AA + AG;rs1800629;METABOLISM/PK;INCREASED;ACTIVITY;;;TNF;LIKELIHOOD_THERAPEUTIC_FAILURE
;VKORC1;C;rs56314408;OTHER;INCREASED;TRANSCRIPTION;;;VKORC1;LIKELIHOOD_THERAPEUTIC_SUCCESS
;NFATC2;T;rs6021191;OTHER;INCREASED;EXPRESSION;;;NFATC2;LIKELIHOOD_THERAPEUTIC_SUCCESS
;SLC22A3;G;rs2076828;OTHER;DECREASED;EXPRESSION;;;SLC22A3;LIKELIHOOD_THERAPEUTIC_FAILURE
;CYP4F2;CT;rs2108622;OTHER;INCREASED;CONCENTRATIONS;;;CYP4F2;CAUTION_DRUG_ACCUMULATION
BUPROPION;POR;AG + GG;rs2868177;METABOLISM/PK;INCREASED;ACTIVITY;;;CYP2B6;LIKELIHOOD_THERAPEUTIC_FAILURE
VITAMIN K AND ANALOGUES;CYP4F2;CT + TT;rs2108622;OTHER, METABOLISM/PK;INCREASED;CONCENTRATIONS;;;;CAUTION_DRUG_ACCUMULATION
;WBP2NL;AG + GG;rs5758550;OTHER;INCREASED;EXPRESSION;;;CYP2D6;LIKELIHOOD_THERAPEUTIC_SUCCESS
;CYP2D6;AA + AG;rs16947;OTHER;DECREASED;EXPRESSION;;;CYP2D6;LIKELIHOOD_THERAPEUTIC_FAILURE
PHENYTOIN;CYP2C9;A;rs12782374;;DECREASED;EXPRESSION;;;CYP2C9;LIKELIHOOD_THERAPEUTIC_FAILURE
;RALGAPA2;GG;rs3827963;OTHER;INCREASED;TRANSCRIPTION;;;ABCB1;LIKELIHOOD_THERAPEUTIC_SUCCESS
;DISP1;TT;rs61840266;OTHER;INCREASED;TRANSCRIPTION;;;ABCC1;LIKELIHOOD_THERAPEUTIC_SUCCESS
;SPAG16;CC;rs35945601;OTHER;INCREASED;TRANSCRIPTION;;;ABCB1;LIKELIHOOD_THERAPEUTIC_SUCCESS
;DISP1;GG;rs17535305;OTHER;INCREASED;TRANSCRIPTION;;;ABCB1;LIKELIHOOD_THERAPEUTIC_SUCCESS
;TXLNB;CC;rs9495425;OTHER;INCREASED;TRANSCRIPTION;;;ABCB1;LIKELIHOOD_THERAPEUTIC_SUCCESS
;ZNF890P;AA;rs62442010;OTHER;INCREASED;TRANSCRIPTION;;;ABCB1;LIKELIHOOD_THERAPEUTIC_SUCCESS
;NAF1;AA;rs17571991;OTHER;INCREASED;TRANSCRIPTION;;;ABCC1;LIKELIHOOD_THERAPEUTIC_SUCCESS
;ECHDC1;AA;rs6569487;OTHER;INCREASED;TRANSCRIPTION;;;ABCB1;LIKELIHOOD_THERAPEUTIC_SUCCESS
;ZBED5;GG;rs10840501;OTHER;INCREASED;TRANSCRIPTION;;;ABCB1;LIKELIHOOD_THERAPEUTIC_SUCCESS
;DHRS4L1;GG;rs10147475;OTHER;INCREASED;TRANSCRIPTION;;;ABCB1;LIKELIHOOD_THERAPEUTIC_SUCCESS
;KCNQ3;AA;rs7818112;OTHER;INCREASED;TRANSCRIPTION;;;ABCB1;LIKELIHOOD_THERAPEUTIC_SUCCESS
;AMPH;CC;rs12701634;OTHER;INCREASED;TRANSCRIPTION;;;ABCB1;LIKELIHOOD_THERAPEUTIC_SUCCESS
;STXBP4;AA;rs9303363;OTHER;INCREASED;TRANSCRIPTION;;;ABCB1;LIKELIHOOD_THERAPEUTIC_SUCCESS
;ADCYAP1;AA;rs304400;OTHER;INCREASED;TRANSCRIPTION;;;ABCB1;LIKELIHOOD_THERAPEUTIC_SUCCESS
;CHD2;TT;rs28458425;OTHER;INCREASED;TRANSCRIPTION;;;ABCB1;LIKELIHOOD_THERAPEUTIC_SUCCESS
;RGMA;GG;rs7165938;OTHER;INCREASED;TRANSCRIPTION;;;ABCB1;LIKELIHOOD_THERAPEUTIC_SUCCESS
;UGT1A1;AG;rs4148323;METABOLISM/PK;DECREASED;FORMATION;;;UGT1A1;LIKELIHOOD_THERAPEUTIC_FAILURE
IRINOTECAN_SN-38;UGT1A1;AG;rs4148323;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
ROSUVASTATIN;SLCO2B1;T;rs2306168;METABOLISM/PK;DECREASED;UPTAKE;;;;CAUTION_DRUG_ACCUMULATION
;CYP2C19;A;rs7902257;OTHER;DECREASED;EXPRESSION;;;CYP2C19;LIKELIHOOD_THERAPEUTIC_FAILURE
CARBOCISTEINE;PAH;G;rs75193786;METABOLISM/PK;DECREASED;ACTIVITY;;;PAH;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;A;rs143154602;METABOLISM/PK;DECREASED;ACTIVITY;;;DPYD;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;C;rs186169810;METABOLISM/PK;DECREASED;ACTIVITY;;;DPYD;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;C;rs190577302;METABOLISM/PK;DECREASED;ACTIVITY;;;DPYD;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;G;rs183105782;METABOLISM/PK;DECREASED;ACTIVITY;;;DPYD;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;T;rs183385770;METABOLISM/PK;DECREASED;ACTIVITY;;;DPYD;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;C;rs146356975;METABOLISM/PK;DECREASED;ACTIVITY;;;DPYD;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;T;rs137999090;METABOLISM/PK;DECREASED;ACTIVITY;;;DPYD;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;A;rs59086055;METABOLISM/PK;DECREASED;ACTIVITY;;;DPYD;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;T;rs145773863;METABOLISM/PK;DECREASED;ACTIVITY;;;DPYD;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;T;rs138616379;METABOLISM/PK;DECREASED;ACTIVITY;;;DPYD;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;A;rs72549304;METABOLISM/PK;DECREASED;ACTIVITY;;;DPYD;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;C;rs111858276;METABOLISM/PK;DECREASED;ACTIVITY;;;DPYD;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;T;rs200687447;METABOLISM/PK;INCREASED;ACTIVITY;;;DPYD;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL;DPYD;C;rs72549307;METABOLISM/PK;DECREASED;ACTIVITY;;;DPYD;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;A;rs1801266;METABOLISM/PK;DECREASED;ACTIVITY;;;DPYD;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;C;rs115232898;METABOLISM/PK;DECREASED;ACTIVITY;;;DPYD;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;G;rs72549308;METABOLISM/PK;DECREASED;ACTIVITY;;;DPYD;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;C;rs143986398;METABOLISM/PK;DECREASED;ACTIVITY;;;DPYD;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;C;rs60139309;METABOLISM/PK;INCREASED;ACTIVITY;;;DPYD;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL;DPYD;T;rs114096998;METABOLISM/PK;INCREASED;ACTIVITY;;;DPYD;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL;DPYD;C;rs2297595;METABOLISM/PK;INCREASED;ACTIVITY;;;DPYD;LIKELIHOOD_THERAPEUTIC_FAILURE
VALPROIC ACID;UGT1A6;C;rs1105879;METABOLISM/PK;INCREASED;GLUCURONIDATION;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
;UGT1A1;GG + GT;rs4124874;METABOLISM/PK;DECREASED;FORMATION;;;UGT1A1;LIKELIHOOD_THERAPEUTIC_FAILURE
IRINOTECAN_SN-38;UGT1A1;GG + GT;rs4124874;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
DEXTROMETHORPHAN;CYP3A4;AG;rs35599367;METABOLISM/PK;DECREASED;ACTIVITY;;;CYP3A4;CAUTION_DRUG_ACCUMULATION
CALCIUM;RYR1;AG;rs118192167;OTHER;INCREASED;STEADY-STATE_LEVEL;;;;CAUTION_DRUG_ACCUMULATION
;XRCC4;T;rs2075685;OTHER;INCREASED;EXPRESSION;;;XRCC4;LIKELIHOOD_THERAPEUTIC_SUCCESS
TESTOSTERONE;CYP3A4;AG;rs35599367;METABOLISM/PK;DECREASED;ACTIVITY;;;CYP3A4;CAUTION_DRUG_ACCUMULATION
;UGT1A9;T/del + TT;rs3832043;METABOLISM/PK;INCREASED;FORMATION;;;UGT1A1;CAUTION_DRUG_ACCUMULATION
MIDAZOLAM;CYP3A4;AG;rs35599367;METABOLISM/PK;DECREASED;ACTIVITY;;;CYP3A4;CAUTION_DRUG_ACCUMULATION
;XRCC4;G;rs10040363;OTHER;INCREASED;EXPRESSION;;;ERCC1;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESTRADIOL;TCL1A;A;rs7159713;OTHER;INCREASED;EXPRESSION;;;IL12RB2;LIKELIHOOD_THERAPEUTIC_SUCCESS
;ERCC1;A;rs2298881;OTHER;DECREASED;EXPRESSION;;;ERCC1;LIKELIHOOD_THERAPEUTIC_FAILURE
ESTRADIOL;TCL1A;A;rs7159713;OTHER;INCREASED;EXPRESSION;;;IL1R2;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESTRADIOL;TCL1A;A;rs7159713;OTHER;INCREASED;EXPRESSION;;;IL17A;LIKELIHOOD_THERAPEUTIC_SUCCESS
;;T;rs247616;OTHER;DECREASED;EXPRESSION;;;CETP;LIKELIHOOD_THERAPEUTIC_FAILURE
ESTRADIOL;TCL1A;G;rs7159713;OTHER;INCREASED;EXPRESSION;;;TCL1A;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESTRADIOL;TCL1A;G;rs7159713;OTHER;INCREASED;EXPRESSION;;;IL17RA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESTRADIOL;TCL1A;A;rs7158782;OTHER;INCREASED;EXPRESSION;;;IL12RB2;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESTRADIOL;TCL1A;G;rs7158782;OTHER;INCREASED;EXPRESSION;;;IL17RA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESTRADIOL;TCL1A;A;rs7158782;OTHER;INCREASED;EXPRESSION;;;IL1R2;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESTRADIOL;TCL1A;A;rs7158782;OTHER;INCREASED;EXPRESSION;;;IL17A;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESTRADIOL;;A;rs2369049;OTHER;INCREASED;EXPRESSION;;;IL1R2;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESTRADIOL;;A;rs2369049;OTHER;INCREASED;EXPRESSION;;;IL17A;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESTRADIOL;;A;rs2369049;OTHER;INCREASED;EXPRESSION;;;IL12RB2;LIKELIHOOD_THERAPEUTIC_SUCCESS
;SLC22A3;AA;rs555754;;INCREASED;EXPRESSION;;;SLC22A3;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESTRADIOL;;G;rs2369049;OTHER;INCREASED;EXPRESSION;;;IL17RA;LIKELIHOOD_THERAPEUTIC_SUCCESS
;PROM1;CC;rs2286455;;DECREASED;EXPRESSION;;;PROM1;LIKELIHOOD_THERAPEUTIC_FAILURE
ESTRADIOL;;G;rs2369049;OTHER;INCREASED;EXPRESSION;;;TCL1A;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESTRADIOL;;C;rs11849538;OTHER;INCREASED;EXPRESSION;;;IL12RB2;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESTRADIOL;;C;rs11849538;OTHER;INCREASED;EXPRESSION;;;IL1R2;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESTRADIOL;;G;rs11849538;OTHER;INCREASED;EXPRESSION;;;IL17RA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESTRADIOL;;C;rs11849538;OTHER;INCREASED;EXPRESSION;;;IL17A;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESTRADIOL;;G;rs11849538;OTHER;INCREASED;EXPRESSION;;;TCL1A;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEMCITABINE;MTHFR;GG + GT;rs1801131;TOXICITY;INCREASED;SENSITIVITY;;;;CAUTION_SIDE_EFFECT
ESTRADIOL;TCL1A;G;rs7158782;OTHER;INCREASED;EXPRESSION;;;TCL1A;LIKELIHOOD_THERAPEUTIC_SUCCESS
;RARG;A;rs2229774;OTHER;DECREASED;PROTEIN_STABILITY;;;RARG;LIKELIHOOD_THERAPEUTIC_FAILURE
IRINOTECAN_SN-38;UGT1A9;T/del + TT;rs3832043;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
;NRP2;C;rs10932125;;INCREASED;EXPRESSION;;;CYP1B1;LIKELIHOOD_THERAPEUTIC_SUCCESS
;UGT1A9;T/del + TT;rs3832043;METABOLISM/PK;INCREASED;FORMATION;;;UGT1A9;CAUTION_DRUG_ACCUMULATION
CAFFEINE;RYR1;AG;rs118192167;OTHER;INCREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
REMIMAZOLAM;CES1;T;rs71647871;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
CAFFEINE;RYR1;T;rs118192161;OTHER;INCREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
VORICONAZOLE;CYP2C19;A;rs770829708;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
SACUBITRIL;CES1;CT;rs71647871;EFFICACY;DECREASED;CATALYTIC_ACTIVITY;;;CES1;LIKELIHOOD_THERAPEUTIC_FAILURE
VORICONAZOLE;CYP2C19;G;rs3758581;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;A;rs763625282;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;T;rs550527959;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
VORICONAZOLE;CYP2C19;C;rs181297724;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
FLUVOXAMINE;CYP2C19;G;rs3758581;METABOLISM/PK;INCREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CELECOXIB, FLUCONAZOLE, FLUVOXAMINE;CYP2C19;C;rs17878459;METABOLISM/PK;INCREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOXETINE;CYP2C19;C;rs17878459;METABOLISM/PK;DECREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUVOXAMINE, OMEPRAZOLE;CYP2C19;C;rs181297724;METABOLISM/PK;INCREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOXETINE, KETOCONAZOLE, SERTRALINE, TICLOPIDINE;CYP2C19;C;rs181297724;METABOLISM/PK;DECREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
L-PHENYLALANINE;PAH;T;rs62516101;METABOLISM/PK;DECREASED;ACTIVITY;;;PAH;CAUTION_DRUG_ACCUMULATION
CARBOCISTEINE;PAH;T;rs62516101;METABOLISM/PK;DECREASED;ACTIVITY;;;PAH;CAUTION_DRUG_ACCUMULATION
BUPRENORPHINE;OPRM1;G;rs1799971;EFFICACY;DECREASED;ACTIVITY;;;OPRM1;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL;DPYD;C;rs72547601;METABOLISM/PK;DECREASED;ACTIVITY;;;DPYD;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;A;rs61757362;METABOLISM/PK;DECREASED;ACTIVITY;;;DPYD;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;A;rs67376798;METABOLISM/PK;DECREASED;ACTIVITY;;;DPYD;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;C;rs141044036;METABOLISM/PK;DECREASED;ACTIVITY;;;DPYD;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;C;rs188052243;METABOLISM/PK;DECREASED;ACTIVITY;;;DPYD;CAUTION_DRUG_ACCUMULATION
CARBOCISTEINE;PAH;C;rs5030860;METABOLISM/PK;DECREASED;ACTIVITY;;;PAH;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;A;rs112766203;METABOLISM/PK;DECREASED;ACTIVITY;;;DPYD;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;A;rs55674432;METABOLISM/PK;DECREASED;ACTIVITY;;;DPYD;CAUTION_DRUG_ACCUMULATION
L-PHENYLALANINE;PAH;C;rs5030860;METABOLISM/PK;DECREASED;ACTIVITY;;;PAH;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;A;rs1801268;METABOLISM/PK;DECREASED;ACTIVITY;;;DPYD;CAUTION_DRUG_ACCUMULATION
BUSULFAN;GSTM1;C;rs3754446;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
CARBOCISTEINE;PAH;A;rs76394784;METABOLISM/PK;DECREASED;ACTIVITY;;;PAH;CAUTION_DRUG_ACCUMULATION
L-PHENYLALANINE;PAH;A;rs76394784;METABOLISM/PK;DECREASED;ACTIVITY;;;PAH;CAUTION_DRUG_ACCUMULATION
ROSUVASTATIN;SLCO2B1;A;rs142693902;METABOLISM/PK;DECREASED;UPTAKE;;;;CAUTION_DRUG_ACCUMULATION
ROSUVASTATIN;SLCO2B1;A;rs35199625;METABOLISM/PK;DECREASED;UPTAKE;;;;CAUTION_DRUG_ACCUMULATION
METHOTREXATE;SOD2;G;rs4880;TOXICITY;DECREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OLANZAPINE;UGT2B10;GT + TT;rs61750900;METABOLISM/PK;DECREASED;GLUCURONIDATION;;;;CAUTION_DRUG_ACCUMULATION
;NOS3;GT + TT;rs1799983;;DECREASED;EXPRESSION;;;NOS3;LIKELIHOOD_THERAPEUTIC_FAILURE
;IL7;AA + AG;rs16906115;OTHER;INCREASED;EXPRESSION;;;IL7;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBOCISTEINE;PAH;T;rs5030849;METABOLISM/PK;DECREASED;ACTIVITY;;;PAH;CAUTION_DRUG_ACCUMULATION
L-PHENYLALANINE;PAH;T;rs5030849;METABOLISM/PK;DECREASED;ACTIVITY;;;PAH;CAUTION_DRUG_ACCUMULATION
BUPRENORPHINE;UGT2B7;A;rs7438135;METABOLISM/PK;INCREASED;GLUCURONIDATION;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
;CYP3A5;CC;rs776746;OTHER;DECREASED;EXPRESSION;;;CYP3A5;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL;DPYD;A;rs4294451;TOXICITY;INCREASED;SENSITIVITY;;;;CAUTION_SIDE_EFFECT
;DPYD;T;rs4294451;OTHER;INCREASED;EXPRESSION;;;DPYD;LIKELIHOOD_THERAPEUTIC_SUCCESS
MIDAZOLAM;CYP3A4;C;rs12721627;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
;PACSIN2;CT + TT;rs2413739;METABOLISM/PK;DECREASED;ACTIVITY;;;TPMT;CAUTION_DRUG_ACCUMULATION
FLUOXETINE;CYP2C19;C;rs181297724;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
FLUOXETINE;CYP2C19;A;rs138142612;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
TAMOXIFEN;UGT1A4;CC;rs8330;METABOLISM/PK;DECREASED;ACTIVITY;;;UGT1A4;CAUTION_DRUG_ACCUMULATION
FLUOXETINE;CYP2C19;C;rs749678783;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
FLUOXETINE;CYP2C19;G;rs200150287;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
FLUOXETINE;CYP2C19;A;rs72552267;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
FLUOXETINE;CYP2C19;C;rs118203756;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
ANASTROZOLE, EXEMESTANE, LETROZOLE;CYP19A1;AG;rs6493497;OTHER;;ACTIVITY;;;CYP19A1;CAUTION_DOSE_ADJUST
FLUOXETINE;CYP2C19;A;rs200346442;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
ANASTROZOLE, EXEMESTANE, LETROZOLE;CYP19A1;CT;rs7176005;OTHER;;ACTIVITY;;;CYP19A1;CAUTION_DOSE_ADJUST
FLUOXETINE;CYP2C19;C;rs1267723490;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
FLUOXETINE;CYP2C19;T;rs1463550071;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
FLUOXETINE;CYP2C19;A;rs1349931378;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
FLUOXETINE;CYP2C19;T;rs764137538;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
FLUOXETINE;CYP2C19;A;rs559628884;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
FLUOXETINE;CYP2C19;G;rs3758581;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
;UGT1A1;CG;rs11568319;METABOLISM/PK;DECREASED;FORMATION;;;UGT1A1;LIKELIHOOD_THERAPEUTIC_FAILURE
;UGT1A9;TT;rs2741049;METABOLISM/PK;INCREASED;FORMATION;;;UGT1A1;CAUTION_DRUG_ACCUMULATION
GEMCITABINE;DCTD;C;rs35932500;METABOLISM/PK;DECREASED;ENZYME_ACTIVITY;;;DCTD;CAUTION_DRUG_ACCUMULATION
IRINOTECAN_SN-38;UGT1A9;CT + TT;rs2741049;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
;UGT1A9;CT + TT;rs2741049;METABOLISM/PK;INCREASED;FORMATION;;;UGT1A9;CAUTION_DRUG_ACCUMULATION
FLUOXETINE;CYP2C19;T;rs147255955;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
FLUOXETINE;CYP2C19;A;rs763625282;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
FLUOXETINE;CYP2C19;T;rs145328984;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
FLUOXETINE;CYP2C19;A;rs370803989;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
IRINOTECAN_SN-38;UGT1A9;AA;rs3806598;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOXETINE;CYP2C19;A;rs770829708;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
FLUOXETINE;CYP2C19;T;rs550527959;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
FLUOXETINE;CYP2C19;A;rs778258371;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
GEMCITABINE;CDA;C;rs2072671;METABOLISM/PK;DECREASED;ENZYME_ACTIVITY;;;CDA;CAUTION_DRUG_ACCUMULATION
MERCAPTOPURINE;ABCC4;TT;rs3765534;TOXICITY, METABOLISM/PK;INCREASED;SENSITIVITY;;;;CAUTION_SIDE_EFFECT
;DPYD;C;rs75017182;METABOLISM/PK;DECREASED;ACTIVITY;;;DPYD;CAUTION_DRUG_ACCUMULATION
;DPYD;G;rs1801265;METABOLISM/PK;INCREASED;ACTIVITY;;;DPYD;LIKELIHOOD_THERAPEUTIC_FAILURE
;DPYD;C;rs2297595;METABOLISM/PK;DECREASED;ACTIVITY;;;DPYD;CAUTION_DRUG_ACCUMULATION
;NT5E;A;rs9450278;;DECREASED;EXPRESSION;;;NT5E;LIKELIHOOD_THERAPEUTIC_FAILURE
;ARNT;GG;rs2134688;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;CYP3A4;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;;CC;rs478437;OTHER;INCREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TAMOXIFEN;E2F7;CC;rs310786;OTHER;INCREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
;;CC;rs478437;OTHER;INCREASED;EXPRESSION;;;USP7;LIKELIHOOD_THERAPEUTIC_SUCCESS
;PPARA;AA;rs4253728;METABOLISM/PK;DECREASED;CONCENTRATIONS;;;CYP3A4;LIKELIHOOD_THERAPEUTIC_FAILURE
;CYP2C9;C;rs9332094;OTHER;DECREASED;TRANSCRIPTION;;;CYP2C9;LIKELIHOOD_THERAPEUTIC_FAILURE
;CYP2C9;C;rs4918758;OTHER;DECREASED;TRANSCRIPTION;;;CYP2C9;LIKELIHOOD_THERAPEUTIC_FAILURE
;UGT1A1;A;rs28967009;OTHER;INCREASED;EXPRESSION;;;UGT1A1;LIKELIHOOD_THERAPEUTIC_SUCCESS
;CYP3A4;TT;rs2242480;METABOLISM/PK;DECREASED;ACTIVITY;;;CYP3A4;CAUTION_DRUG_ACCUMULATION
;CYP2B6;TT;rs3745274;OTHER;DECREASED;EXPRESSION;;;CYP2B6;LIKELIHOOD_THERAPEUTIC_FAILURE
HYDROCHLOROTHIAZIDE;YEATS4;CC;rs7297610;METABOLISM/PK;DECREASED;EXPRESSION;;;YEATS4;CAUTION_DRUG_ACCUMULATION
;YEATS4;CC;rs7297610;METABOLISM/PK;INCREASED;EXPRESSION;;;YEATS4;LIKELIHOOD_THERAPEUTIC_FAILURE
;NQO1;A;rs1800566;;DECREASED;EXPRESSION;;;NQO1;LIKELIHOOD_THERAPEUTIC_FAILURE
;NQO1;AA;rs1800566;;DECREASED;ENZYME_ACTIVITY;;;NQO1;LIKELIHOOD_THERAPEUTIC_FAILURE
;DPYD;T;rs1212037891;OTHER;INCREASED;EXPRESSION;;;DPYD;LIKELIHOOD_THERAPEUTIC_SUCCESS
;DPYD;A;rs143879757;OTHER;INCREASED;EXPRESSION;;;DPYD;LIKELIHOOD_THERAPEUTIC_SUCCESS
;DPYD;A;rs72549306;OTHER;INCREASED;EXPRESSION;;;DPYD;LIKELIHOOD_THERAPEUTIC_SUCCESS
;DPYD;G;rs748620513;OTHER;INCREASED;EXPRESSION;;;DPYD;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;DPYD;C;rs1335150891;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;;;DPYD;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;C;rs188052243;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;;;DPYD;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;A;rs72549306;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;;;DPYD;CAUTION_DRUG_ACCUMULATION
;DPYD;T;rs1801160;OTHER;INCREASED;EXPRESSION;;;DPYD;LIKELIHOOD_THERAPEUTIC_SUCCESS
PACLITAXEL;SLCO1B3;A;rs7311358;OTHER;DECREASED;TRANSPORT;;;;CAUTION_DRUG_ACCUMULATION
;ABCC11;AA + AG;rs17822471;OTHER;DECREASED;EXPRESSION;;;ABCC11;LIKELIHOOD_THERAPEUTIC_FAILURE
CAFFEINE, HALOTHANE;RYR1;CT;rs118192172;OTHER;;SENSITIVITY;;;;CAUTION_DOSE_ADJUST
CAFFEINE, HALOTHANE;RYR1;GT;rs193922772;OTHER;;SENSITIVITY;;;;CAUTION_DOSE_ADJUST
CAFFEINE, HALOTHANE;RYR1;CT;rs118192175;OTHER;;SENSITIVITY;;;;CAUTION_DOSE_ADJUST
CAFFEINE, HALOTHANE;RYR1;AG;rs118192176;OTHER;;SENSITIVITY;;;;CAUTION_DOSE_ADJUST
CAFFEINE, HALOTHANE;RYR1;CT;rs28933397;OTHER;;SENSITIVITY;;;;CAUTION_DOSE_ADJUST
;VDR;T;rs11568820;OTHER;INCREASED;STEADY-STATE_LEVEL;;;CYP3A4;CAUTION_DRUG_ACCUMULATION
;DPYD;T;rs1801158;OTHER;DECREASED;ACTIVITY;;;DPYD;LIKELIHOOD_THERAPEUTIC_FAILURE
;DPYD;T;rs1801160;OTHER;DECREASED;ACTIVITY;;;DPYD;LIKELIHOOD_THERAPEUTIC_FAILURE
;DPYD;G;rs1801265;OTHER;DECREASED;ACTIVITY;;;DPYD;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL;DPYD;G;rs748620513;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;;;DPYD;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;T;rs148994843;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;;;DPYD;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;A;rs59086055;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;;;DPYD;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;T;rs56005131;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;;;DPYD;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;A;rs143879757;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;;;DPYD;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;del;rs1184321568;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;;;DPYD;CAUTION_DRUG_ACCUMULATION
CEFOTAXIME;SLC22A8;A;rs11568482;METABOLISM/PK;DECREASED;TRANSPORT;;;;CAUTION_DRUG_ACCUMULATION
;NCOA1;T;rs1804645;;INCREASED;HALF-LIFE;;;NCOA1;CAUTION_DRUG_ACCUMULATION
TAMOXIFEN;NCOA1;T;rs1804645;;DECREASED;ACTIVITY;;;NCOA1;LIKELIHOOD_THERAPEUTIC_FAILURE
;A2M;T;rs669;METABOLISM/PK;INCREASED;STEADY-STATE_LEVEL;;;A2M;CAUTION_DRUG_ACCUMULATION
ENDOXIFEN;;C;rs4386686;TOXICITY;INCREASED;SENSITIVITY;;;;CAUTION_SIDE_EFFECT
;F12;G;rs1801020;METABOLISM/PK;INCREASED;ENZYME_ACTIVITY;;;F12;LIKELIHOOD_THERAPEUTIC_FAILURE
;;C;rs4386686;TOXICITY, OTHER;INCREASED;EXPRESSION;;;MIRLET7I;CAUTION_SIDE_EFFECT
;;C;rs4386686;TOXICITY, OTHER;DECREASED;EXPRESSION;;;TRAF1;LIKELIHOOD_THERAPEUTIC_SUCCESS
;DPYD;CT;rs1801158;OTHER;DECREASED;CATALYTIC_ACTIVITY;;;DPYD;LIKELIHOOD_THERAPEUTIC_FAILURE
;ABCC9;T;rs704212;OTHER;INCREASED;EXPRESSION;;;ABCC9;LIKELIHOOD_THERAPEUTIC_SUCCESS
;SLCO1B1;C;rs4149056;OTHER;DECREASED;EXPRESSION;;;SLCO1B1;LIKELIHOOD_THERAPEUTIC_FAILURE
IVACAFTOR;CFTR;A;rs77010898;EFFICACY;INCREASED;ACTIVITY;;;CFTR;LIKELIHOOD_THERAPEUTIC_SUCCESS
;UGT1A3;T;rs7604115;OTHER;INCREASED;EXPRESSION;;;UGT1A3;LIKELIHOOD_THERAPEUTIC_SUCCESS
TESTOSTERONE;CYP3A5;A;rs55817950;METABOLISM/PK;DECREASED;ENZYME_ACTIVITY;;;CYP3A5;CAUTION_DRUG_ACCUMULATION
;IMPDH2;A;rs121434586;OTHER;DECREASED;ENZYME_ACTIVITY;;;IMPDH2;LIKELIHOOD_THERAPEUTIC_FAILURE
;ORMDL3;AG + GG;rs2872507;METABOLISM/PK;INCREASED;EXPRESSION;;;ORMDL3;LIKELIHOOD_THERAPEUTIC_FAILURE
;ABCC2;T;rs717620;;INCREASED;TRANSCRIPTION;;;ABCC2;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAFFEINE;RYR1;T;rs193922753;OTHER;INCREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NIFEDIPINE;CYP3A5;C;rs72552791;METABOLISM/PK;DECREASED;ENZYME_ACTIVITY;;;CYP3A5;CAUTION_DRUG_ACCUMULATION
CAFFEINE;RYR1;A;rs118192176;OTHER;INCREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAFFEINE;RYR1;A;rs193922809;OTHER;INCREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAFFEINE;RYR1;A;rs118192122;OTHER;INCREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAFFEINE;RYR1;T;rs193922816;OTHER;INCREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAFFEINE;RYR1;G;rs118192167;OTHER;INCREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUMETANIDE;SLC17A3;A;rs34376145;METABOLISM/PK;DECREASED;TRANSPORT;;;SLC17A3;CAUTION_DRUG_ACCUMULATION
BUMETANIDE;SLC17A3;A;rs34902660;METABOLISM/PK;DECREASED;TRANSPORT;;;SLC17A3;CAUTION_DRUG_ACCUMULATION
BUMETANIDE;SLC17A3;A;rs11966370;METABOLISM/PK;DECREASED;TRANSPORT;;;SLC17A3;CAUTION_DRUG_ACCUMULATION
BUMETANIDE;SLC17A3;T;rs56027330;METABOLISM/PK;DECREASED;TRANSPORT;;;SLC17A3;CAUTION_DRUG_ACCUMULATION
CLOPIDOGREL, ENALAPRIL, SACUBITRIL;CES1;C;rs200707504;METABOLISM/PK;DECREASED;ENZYME_ACTIVITY;;;;CAUTION_DRUG_ACCUMULATION
CLOPIDOGREL, ENALAPRIL, SACUBITRIL;CES1;G;rs143718310;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
CLOPIDOGREL, ENALAPRIL, SACUBITRIL;CES1;A;rs201065375;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
ENALAPRIL;CES1;T;rs2307243;METABOLISM/PK;DECREASED;ENZYME_ACTIVITY;;;;CAUTION_DRUG_ACCUMULATION
ENALAPRIL;CES1;C;rs202121317;METABOLISM/PK;DECREASED;ENZYME_ACTIVITY;;;;CAUTION_DRUG_ACCUMULATION
CLOPIDOGREL;CES1;A;rs202001817;METABOLISM/PK;DECREASED;ENZYME_ACTIVITY;;;;CAUTION_DRUG_ACCUMULATION
CYTARABINE;NT5C2;G;rs1163075;EFFICACY;DECREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
;NT5C2;G;rs1163075;METABOLISM/PK;INCREASED;TRANSCRIPTION;;;NT5C2;LIKELIHOOD_THERAPEUTIC_FAILURE
CYTARABINE;NT5C2;GG;rs11191612;EFFICACY;DECREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
;NT5C2;GG;rs11191612;METABOLISM/PK;INCREASED;TRANSCRIPTION;;;NT5C2;LIKELIHOOD_THERAPEUTIC_FAILURE
AMISULPRIDE, ARIPIPRAZOLE, OLANZAPINE, RISPERIDONE;ABCB1;T;rs2229109;METABOLISM/PK;DECREASED;TRANSPORT;;;ABCB1;CAUTION_DRUG_ACCUMULATION
ACETAMINOPHEN;UGT1A;CC;rs10929303;METABOLISM/PK;DECREASED;ACTIVITY;;;UGT1A;CAUTION_DRUG_ACCUMULATION
CHLOROCRESOL;RYR1;T;rs193922803;OTHER;INCREASED;ACTIVITY;;;RYR1;LIKELIHOOD_THERAPEUTIC_SUCCESS
ARACHIDONIC ACID;CYP4F2;G;rs753169154;PD;DECREASED;CATALYTIC_ACTIVITY;;;CYP4F2;LIKELIHOOD_THERAPEUTIC_FAILURE
ARACHIDONIC ACID;CYP4F2;T;rs2108622;PD;DECREASED;CATALYTIC_ACTIVITY;;;CYP4F2;LIKELIHOOD_THERAPEUTIC_FAILURE
ARACHIDONIC ACID;CYP4F2;A;rs114396708;PD;DECREASED;CATALYTIC_ACTIVITY;;;CYP4F2;LIKELIHOOD_THERAPEUTIC_FAILURE
CAFFEINE, HALOTHANE;RYR1;CT;rs193922747;OTHER;;SENSITIVITY;;;;CAUTION_DOSE_ADJUST
ACETAMINOPHEN;UGT1A;CC;rs1042640;METABOLISM/PK;DECREASED;ACTIVITY;;;UGT1A;CAUTION_DRUG_ACCUMULATION
;DPYD;CT;rs3918290;OTHER;DECREASED;ACTIVITY;;;DPYD;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL;DPYD;CC;rs1801159;TOXICITY, METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
ACETAMINOPHEN;UGT1A;CC;rs8330;METABOLISM/PK;DECREASED;ACTIVITY;;;UGT1A;CAUTION_DRUG_ACCUMULATION
;DPYD;CT;rs3918290;OTHER;DECREASED;ACTIVITY;;;DPYD;LIKELIHOOD_THERAPEUTIC_FAILURE
CAFFEINE, CHLOROCRESOL;RYR1;T;rs118192178;OTHER;INCREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
;SLCO1A2;T;rs4148981;;DECREASED;EXPRESSION;;;SLCO1A2;LIKELIHOOD_THERAPEUTIC_FAILURE
ALDOSTERONE, INSULIN RECOMBINANT;SCNN1B;A;rs34241435;OTHER;INCREASED;TRANSCRIPTION;;;SCNN1B;LIKELIHOOD_THERAPEUTIC_SUCCESS
;BCL2L11;T;rs724710;OTHER;DECREASED;EXPRESSION;;;BCL2L11;LIKELIHOOD_THERAPEUTIC_FAILURE
ESCITALOPRAM;IL11;CT + TT;rs1126757;OTHER;DECREASED;EXPRESSION;;;IL11;LIKELIHOOD_THERAPEUTIC_FAILURE
LORAZEPAM;UGT2B15;AA;rs1902023;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
LOSARTAN;CYP2C9;C;rs1057910;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
;UMPS;C;rs1801019;METABOLISM/PK;INCREASED;EXPRESSION;;;UMPS;LIKELIHOOD_THERAPEUTIC_FAILURE
PAROMOMYCIN;MT-RNR1;G;rs267606617;PD;DECREASED;ACTIVITY;;;MT-RNR1;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOZAPINE;UGT1A4;G;rs2011425;METABOLISM/PK;INCREASED;CATALYTIC_ACTIVITY;;;UGT1A4;LIKELIHOOD_THERAPEUTIC_FAILURE
CAFFEINE, CHLOROCRESOL;RYR1;G;rs118192178;OTHER;INCREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IVACAFTOR;CFTR;A;rs75527207;EFFICACY;;ACTIVITY;;;CFTR;CAUTION_DOSE_ADJUST
IVACAFTOR;CFTR;A;rs75527207;EFFICACY;INCREASED;ACTIVITY;;;CFTR;LIKELIHOOD_THERAPEUTIC_SUCCESS
;CYP1A2;AA + AC;rs762551;METABOLISM/PK;INCREASED;TRANSCRIPTION;;;CYP1A2;LIKELIHOOD_THERAPEUTIC_FAILURE
;EGFR;TT;rs712829;;INCREASED;EXPRESSION;;;EGFR;LIKELIHOOD_THERAPEUTIC_SUCCESS
DEXTROMETHORPHAN;;GG;rs729559;METABOLISM/PK;INCREASED;ENZYME_ACTIVITY;;;CYP2D6;LIKELIHOOD_THERAPEUTIC_FAILURE
;;GG;rs729559;METABOLISM/PK;INCREASED;EXPRESSION;;;CYP2D6;LIKELIHOOD_THERAPEUTIC_FAILURE
;;TT;rs4073010;METABOLISM/PK;INCREASED;EXPRESSION;;;CYP2D6;LIKELIHOOD_THERAPEUTIC_FAILURE
;SEPTIN3, WBP2NL;G;rs1062753;METABOLISM/PK;INCREASED;EXPRESSION;;;CYP2D6;LIKELIHOOD_THERAPEUTIC_FAILURE
DEXTROMETHORPHAN;PHETA2, SMDT1;G;rs1807493;METABOLISM/PK;INCREASED;ENZYME_ACTIVITY;;;CYP2D6;LIKELIHOOD_THERAPEUTIC_FAILURE
DEXTROMETHORPHAN;;TT;rs4073010;METABOLISM/PK;INCREASED;ENZYME_ACTIVITY;;;CYP2D6;LIKELIHOOD_THERAPEUTIC_FAILURE
DEXTROMETHORPHAN;SEPTIN3, WBP2NL;G;rs1062753;METABOLISM/PK;INCREASED;ENZYME_ACTIVITY;;;CYP2D6;LIKELIHOOD_THERAPEUTIC_FAILURE
TERFENADINE;CYP2J2;A;rs199717190;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
CLOPIDOGREL, ENALAPRIL, SACUBITRIL;CES1;C;rs151291296;METABOLISM/PK;DECREASED;ENZYME_ACTIVITY;;;;CAUTION_DRUG_ACCUMULATION
CLOPIDOGREL, ENALAPRIL, SACUBITRIL;CES1;A;rs146456965;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
17BETA-ESTRADIOL GLUCURONIDE;ABCC4;T;rs200858900;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;;;ABCC4;CAUTION_DRUG_ACCUMULATION
;ABCC4;C;rs11568684;METABOLISM/PK;INCREASED;CATALYTIC_ACTIVITY;;;ABCC4;LIKELIHOOD_THERAPEUTIC_FAILURE
17BETA-ESTRADIOL GLUCURONIDE;ABCC4;T;rs11568681;METABOLISM/PK;INCREASED;CATALYTIC_ACTIVITY;;;ABCC4;LIKELIHOOD_THERAPEUTIC_FAILURE
17BETA-ESTRADIOL GLUCURONIDE;ABCC4;T;rs142211148;METABOLISM/PK;INCREASED;CATALYTIC_ACTIVITY;;;ABCC4;LIKELIHOOD_THERAPEUTIC_FAILURE
17BETA-ESTRADIOL GLUCURONIDE;ABCC4;A;rs11568644;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;;;ABCC4;CAUTION_DRUG_ACCUMULATION
;TBXAS1;AA;rs6962291;OTHER;DECREASED;EXPRESSION;;;TBXAS1;LIKELIHOOD_THERAPEUTIC_FAILURE
EBASTINE, TERFENADINE;CYP2J2;A;rs201379188;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
CAFFEINE;RYR1;G;rs193922878;OTHER;INCREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
;TBXAS1;AA;rs6962291;OTHER;DECREASED;STEADY-STATE_LEVEL;;;TBX2;LIKELIHOOD_THERAPEUTIC_FAILURE
;PHETA2, SMDT1;G;rs1807493;METABOLISM/PK;INCREASED;EXPRESSION;;;CYP2D6;LIKELIHOOD_THERAPEUTIC_FAILURE
;ABCC4;A;rs11568658;METABOLISM/PK;INCREASED;CATALYTIC_ACTIVITY;;;ABCC4;LIKELIHOOD_THERAPEUTIC_FAILURE
;CCND1;AA + AG;rs9344;OTHER;INCREASED;TRANSCRIPTION;;;CCND1;LIKELIHOOD_THERAPEUTIC_SUCCESS
EBASTINE, TERFENADINE;CYP2J2;A;rs759510111;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
;DPYD;AT;rs67376798;OTHER;DECREASED;CATALYTIC_ACTIVITY;;;DPYD;LIKELIHOOD_THERAPEUTIC_FAILURE
;GSK3B;A;rs334558;;INCREASED;TRANSCRIPTION;;;GSK3B;LIKELIHOOD_THERAPEUTIC_SUCCESS
;FCER2;GG;rs28364072;;DECREASED;EXPRESSION;;;FCER2;LIKELIHOOD_THERAPEUTIC_FAILURE
GENTAMICIN;MT-RNR1;T;rs267606619;PD;DECREASED;ACTIVITY;;;MT-RNR1;LIKELIHOOD_THERAPEUTIC_FAILURE
;MIR27A;CC;rs895819;OTHER;INCREASED;EXPRESSION;;;MIR27A;LIKELIHOOD_THERAPEUTIC_SUCCESS
;ADRB2;G;rs1042713;OTHER;DECREASED;ACTIVITY;;;ADRB2;LIKELIHOOD_THERAPEUTIC_FAILURE
CHLOROCRESOL;RYR1;T;rs118192124;OTHER;INCREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CHLOROCRESOL;RYR1;T;rs118192124;OTHER;INCREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PAROMOMYCIN;MT-RNR1;T;rs267606619;PD;INCREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PROPOFOL;CYP2B6;T;rs553968231;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
PROPOFOL;CYP2B6;T;rs1969376664;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
PROPOFOL;CYP2B6;C;rs773494867;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
CISPLATIN, IRINOTECAN;UBE2I;CG;rs9597;METABOLISM/PK;INCREASED;EXPRESSION;;;SAE1;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;T;rs553968231;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;T;rs752695347;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;A;rs772413158;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;C;rs1969136524;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;T;rs142421637;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;A;rs373442191;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
PROPOFOL;CYP2B6;T;rs752695347;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
PROPOFOL;CYP2B6;T;rs142421637;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
PROPOFOL;CYP2B6;T;rs1282926098;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
PROPOFOL;CYP2B6;C;rs1969136524;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;C;rs773494867;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;T;rs1969376664;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
PROPOFOL;CYP2B6;T;rs138264188;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
PROPOFOL;CYP2B6;A;rs373442191;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
CAFFEINE, CHLOROCRESOL;RYR1;A;rs193922818;OTHER;INCREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
;ABCB1;AA;rs2032582;OTHER;DECREASED;EXPRESSION;;;ABCB1;LIKELIHOOD_THERAPEUTIC_FAILURE
;ABCB1;AA;rs1128503;OTHER;DECREASED;EXPRESSION;;;ABCB1;LIKELIHOOD_THERAPEUTIC_FAILURE
;ABCB1;AA;rs1045642;OTHER;DECREASED;EXPRESSION;;;ABCB1;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;T;rs1969255598;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;G;rs1248477767;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;T;rs1282926098;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;G;rs750671397;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
;;G;rs4355801;;INCREASED;EXPRESSION;;;TNFRSF11B;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;A;rs141666881;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
;PLG;G;rs783145;METABOLISM/PK;DECREASED;TRANSCRIPTION;;;PRSS55;CAUTION_DRUG_ACCUMULATION
;PLG;G;rs783145;METABOLISM/PK;INCREASED;TRANSCRIPTION;;;PLG;LIKELIHOOD_THERAPEUTIC_FAILURE
;;C;rs10871454;METABOLISM/PK;INCREASED;TRANSCRIPTION;;;VKORC1;LIKELIHOOD_THERAPEUTIC_FAILURE
;GCLC;CC;rs761142;OTHER;DECREASED;EXPRESSION;;;GCLC;LIKELIHOOD_THERAPEUTIC_FAILURE
;CYP3A4;A;rs4986909;;DECREASED;STEADY-STATE_LEVEL;;;CYP3A4;LIKELIHOOD_THERAPEUTIC_FAILURE
;;AA;rs446112;OTHER;INCREASED;EXPRESSION;;;AGPAT2;LIKELIHOOD_THERAPEUTIC_SUCCESS
;SQSTM1;C;rs10277;METABOLISM/PK;INCREASED;TRANSCRIPTION;;;SQSTM1;LIKELIHOOD_THERAPEUTIC_FAILURE
;SLC22A3;C;rs884742;METABOLISM/PK;INCREASED;TRANSCRIPTION;;;SLC22A3;LIKELIHOOD_THERAPEUTIC_FAILURE
;MGMT;G;rs4751104;METABOLISM/PK;INCREASED;TRANSCRIPTION;;;MGMT;LIKELIHOOD_THERAPEUTIC_FAILURE
;KDR;G;rs34231037;OTHER;DECREASED;STEADY-STATE_LEVEL;;;KDR;LIKELIHOOD_THERAPEUTIC_FAILURE
;GSTT1;T;rs1007888;METABOLISM/PK;INCREASED;TRANSCRIPTION;;;GSTT1;LIKELIHOOD_THERAPEUTIC_FAILURE
;;AG;rs10242455;METABOLISM/PK;INCREASED;TRANSCRIPTION;;;CYP3A5;LIKELIHOOD_THERAPEUTIC_FAILURE
;ABCC11;C;rs11861379;METABOLISM/PK;INCREASED;TRANSCRIPTION;;;ABCC11;LIKELIHOOD_THERAPEUTIC_FAILURE
;NAT2;A;rs4646244;OTHER;DECREASED;TRANSCRIPTION;;;NAT2;LIKELIHOOD_THERAPEUTIC_FAILURE
NICOTINE;CYP2A6;C;rs72549435;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;;;CYP2A6;CAUTION_DRUG_ACCUMULATION
TOLBUTAMIDE;CYP2C9;T;rs9332239;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;;;CYP2C9;CAUTION_DRUG_ACCUMULATION
PAROMOMYCIN;MT-RNR1;G;rs267606617;PD;DECREASED;ACTIVITY;;;MT-RNR1;LIKELIHOOD_THERAPEUTIC_FAILURE
PURINE ANALOGUES;TPMT;CT;rs1142345;OTHER, METABOLISM/PK;DECREASED;ACTIVITY;;;TPMT;LIKELIHOOD_THERAPEUTIC_FAILURE
DOXORUBICIN;SLC28A3;AA;rs11140490;TOXICITY;INCREASED;SENSITIVITY;;;;CAUTION_SIDE_EFFECT
PURINE ANALOGUES;PACSIN2;C;rs2413739;OTHER, METABOLISM/PK;INCREASED;ACTIVITY;;;TPMT;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;G;rs1968919352;METABOLISM/PK;INCREASED;CLEARANCE;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
COUMARIN;CYP2A6;T;rs28399454;METABOLISM/PK;DECREASED;METABOLISM;;;;CAUTION_DRUG_ACCUMULATION
QUINIDINE;KCNH2;T;rs104894021;EFFICACY;DECREASED;INHIBITION;;;KCNH2;LIKELIHOOD_THERAPEUTIC_FAILURE
VORICONAZOLE;CYP2C19;A;rs778258371;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
IVACAFTOR / LUMACAFTOR;CFTR;A;rs78655421;EFFICACY;INCREASED;ACTIVITY;;;CFTR;LIKELIHOOD_THERAPEUTIC_SUCCESS
IVACAFTOR, NPPB;CFTR;A;rs75527207;EFFICACY;INCREASED;ACTIVITY;;;CFTR;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESLICARBAZEPINE ACETATE;AADAC;G;rs144650170;METABOLISM/PK;INCREASED;CATALYTIC_ACTIVITY;;;AADAC;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL;DPYD;G;rs368146607;METABOLISM/PK;DECREASED;ACTIVITY;;;DPYD;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;T;rs371258350;METABOLISM/PK;DECREASED;ACTIVITY;;;DPYD;CAUTION_DRUG_ACCUMULATION
ESLICARBAZEPINE ACETATE;AADAC;A;rs35084477;METABOLISM/PK;INCREASED;CATALYTIC_ACTIVITY;;;AADAC;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL;DPYD;T;rs575853463;METABOLISM/PK;DECREASED;ACTIVITY;;;DPYD;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;G;rs569661196;METABOLISM/PK;DECREASED;ACTIVITY;;;DPYD;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;T;rs548783838;METABOLISM/PK;DECREASED;ACTIVITY;;;DPYD;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;T;rs374825099;METABOLISM/PK;DECREASED;ACTIVITY;;;DPYD;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;G;rs140989814;METABOLISM/PK;DECREASED;ACTIVITY;;;DPYD;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;A;rs568367673;METABOLISM/PK;DECREASED;ACTIVITY;;;DPYD;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;A;rs538336580;METABOLISM/PK;DECREASED;ACTIVITY;;;DPYD;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;G;rs374527058;METABOLISM/PK;DECREASED;ACTIVITY;;;DPYD;CAUTION_DRUG_ACCUMULATION
CAFFEINE;RYR1;A;rs112563513;DOSAGE;INCREASED;SENSITIVITY;;;;CAUTION_DOSE_ADJUST
ESLICARBAZEPINE ACETATE;AADAC;A;rs1803155;METABOLISM/PK;INCREASED;CATALYTIC_ACTIVITY;;;AADAC;LIKELIHOOD_THERAPEUTIC_FAILURE
ESLICARBAZEPINE ACETATE;AADAC;G;rs140197497;METABOLISM/PK;INCREASED;CATALYTIC_ACTIVITY;;;AADAC;LIKELIHOOD_THERAPEUTIC_FAILURE
CAFFEINE;RYR1;A;rs193922832;DOSAGE;INCREASED;SENSITIVITY;;;;CAUTION_DOSE_ADJUST
CAFFEINE;RYR1;A;rs118192168;DOSAGE;INCREASED;SENSITIVITY;;;;CAUTION_DOSE_ADJUST
DISOPYRAMIDE;KCNH2;T;rs104894021;EFFICACY;DECREASED;INHIBITION;;;KCNH2;LIKELIHOOD_THERAPEUTIC_FAILURE
DISOPYRAMIDE;KCNH2;C;rs104894021;EFFICACY;DECREASED;INHIBITION;;;KCNH2;LIKELIHOOD_THERAPEUTIC_FAILURE
QUINIDINE;KCNH2;C;rs104894021;EFFICACY;DECREASED;INHIBITION;;;KCNH2;LIKELIHOOD_THERAPEUTIC_FAILURE
ELEXACAFTOR / TEZACAFTOR / IVACAFTOR;CFTR;CG;rs80034486;PD;INCREASED;ACTIVITY;;;CFTR;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAFFEINE;RYR1;T;rs193922843;DOSAGE;INCREASED;SENSITIVITY;;;;CAUTION_DOSE_ADJUST
CAFFEINE;RYR1;T;rs193922803;DOSAGE;INCREASED;SENSITIVITY;;;;CAUTION_DOSE_ADJUST
ESLICARBAZEPINE ACETATE;AADAC;T;rs186388618;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;;;AADAC;CAUTION_DRUG_ACCUMULATION
ESLICARBAZEPINE ACETATE;AADAC;C;rs61733692;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;;;AADAC;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;C;rs536577604;METABOLISM/PK;DECREASED;ACTIVITY;;;DPYD;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;A;rs558354142;METABOLISM/PK;DECREASED;ACTIVITY;;;DPYD;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;A;rs538703919;METABOLISM/PK;DECREASED;ACTIVITY;;;DPYD;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;C;rs55886062;METABOLISM/PK;DECREASED;ACTIVITY;;;DPYD;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;T;rs372307932;METABOLISM/PK;DECREASED;ACTIVITY;;;DPYD;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;C;rs527580106;METABOLISM/PK;DECREASED;ACTIVITY;;;DPYD;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;T;rs201268750;METABOLISM/PK;DECREASED;ACTIVITY;;;DPYD;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;A;rs570122671;METABOLISM/PK;DECREASED;ACTIVITY;;;DPYD;CAUTION_DRUG_ACCUMULATION
;CBR3;A;rs8133052;;DECREASED;EXPRESSION;;;CBR3;LIKELIHOOD_THERAPEUTIC_FAILURE
;CBR3;A;rs1056892;;INCREASED;EXPRESSION;;;CBR3;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;DPYD;A;rs528152707;METABOLISM/PK;DECREASED;ACTIVITY;;;DPYD;CAUTION_DRUG_ACCUMULATION
;VKORC1;T;rs9923231;;DECREASED;EXPRESSION;;;VKORC1;LIKELIHOOD_THERAPEUTIC_FAILURE
;DPYD;CT + TT;rs56038477;METABOLISM/PK;DECREASED;ACTIVITY;;;DPYD;CAUTION_DRUG_ACCUMULATION
;SLC29A1;G;rs731780;OTHER;INCREASED;EXPRESSION;;;SLC29A1;LIKELIHOOD_THERAPEUTIC_SUCCESS
;SLC29A1;A;rs70914;;INCREASED;EXPRESSION;;;SLC29A1;LIKELIHOOD_THERAPEUTIC_SUCCESS
;DPYD;CT + TT;rs1801160;METABOLISM/PK;DECREASED;ACTIVITY;;;DPYD;CAUTION_DRUG_ACCUMULATION
;DPYD;CC + CT;rs2297595;METABOLISM/PK;DECREASED;ACTIVITY;;;DPYD;CAUTION_DRUG_ACCUMULATION
;MIR6076;G;rs1463411;OTHER;DECREASED;EXPRESSION;;;P2RY12;LIKELIHOOD_THERAPEUTIC_FAILURE
;UGT2B17;C;rs6817882;OTHER;INCREASED;EXPRESSION;;;UGT2B17;LIKELIHOOD_THERAPEUTIC_SUCCESS
;DPYD;CT;rs115232898;OTHER;DECREASED;ACTIVITY;;;DPYD;LIKELIHOOD_THERAPEUTIC_FAILURE
BUPROPION;POR;AA;rs2868177;OTHER, METABOLISM/PK;DECREASED;ENZYME_ACTIVITY;;;CYP2B6;LIKELIHOOD_THERAPEUTIC_FAILURE
;POR;AA;rs2868177;OTHER, METABOLISM/PK;DECREASED;ACTIVITY;;;CYP2B6;LIKELIHOOD_THERAPEUTIC_FAILURE
;ABCB1;GG;rs1128503;;INCREASED;EXPRESSION;;;ABCB1;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACETAMINOPHEN;CYP2E1;T;rs2515641;OTHER;INCREASED;EXPRESSION;;;CYP2E1;LIKELIHOOD_THERAPEUTIC_SUCCESS
;CYP2E1;T;rs2515641;OTHER;DECREASED;EXPRESSION;;;CYP2E1;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL;DPYD;T;rs376073289;METABOLISM/PK;DECREASED;ACTIVITY;;;DPYD;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;G;rs369103276;METABOLISM/PK;DECREASED;ACTIVITY;;;DPYD;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;C;rs367619008;METABOLISM/PK;DECREASED;ACTIVITY;;;DPYD;CAUTION_DRUG_ACCUMULATION
BUPROPION;POR;GG;rs2868177;OTHER, METABOLISM/PK;INCREASED;ACTIVITY;;;CYP2B6;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;DPYD;T;rs758649719;METABOLISM/PK;DECREASED;ACTIVITY;;;DPYD;CAUTION_DRUG_ACCUMULATION
HALOTHANE, ISOFLURANE;CACNA1S;A;rs772226819;OTHER;INCREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;DPYD;G;rs187713395;METABOLISM/PK;DECREASED;ACTIVITY;;;DPYD;CAUTION_DRUG_ACCUMULATION
FLUOROURACIL;DPYD;G;rs140039091;METABOLISM/PK;DECREASED;ACTIVITY;;;DPYD;CAUTION_DRUG_ACCUMULATION
CAFFEINE;CACNA1S;T;rs1800559;OTHER;INCREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
;CACNA1S;T;rs1800559;OTHER;INCREASED;ACTIVITY;;;CACNA1S;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUFURALOL, DEXTROMETHORPHAN;CYP2D6;A;rs777560972;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
GEMCITABINE;FKBP5;CT;rs73748206;OTHER;INCREASED;EXPRESSION;;;NR3C1;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUFURALOL, DEXTROMETHORPHAN;CYP2D6;T;rs138417770;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
BUFURALOL, DEXTROMETHORPHAN;CYP2D6;G;rs371793722;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
BUFURALOL, DEXTROMETHORPHAN;CYP2D6;T;rs745746329;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
;HSPA5;TT;rs430397;OTHER;INCREASED;EXPRESSION;;;HSPA5;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUFURALOL, DEXTROMETHORPHAN;CYP2D6;T;rs750996195;METABOLISM/PK;DECREASED;CLEARANCE;;;;CAUTION_DRUG_ACCUMULATION
;POR;AG;rs2868177;EFFICACY;INCREASED;ENZYME_ACTIVITY;;;CYP2B6;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEMCITABINE TRIPHOSPHATE;SLC28A3;CC;rs7867504;METABOLISM/PK;INCREASED;FORMATION;;;;CAUTION_DRUG_ACCUMULATION
MERCAPTOPURINE;TPMT;AT;rs3931660;METABOLISM/PK;DECREASED;ENZYME_ACTIVITY;;;TPMT;CAUTION_DRUG_ACCUMULATION
MERCAPTOPURINE;TPMT;CT;rs1142345;METABOLISM/PK;DECREASED;ENZYME_ACTIVITY;;;TPMT;CAUTION_DRUG_ACCUMULATION
VITAMIN E;CYP4F2;T;rs2108622;METABOLISM/PK;INCREASED;STEADY-STATE_LEVEL;;;;CAUTION_DRUG_ACCUMULATION
VITAMIN E;CYP4F2;T;rs2108622;METABOLISM/PK;INCREASED;STEADY-STATE_LEVEL;;;;CAUTION_DRUG_ACCUMULATION
;HPR;G;rs2000999;OTHER;INCREASED;EXPRESSION;;;HP;LIKELIHOOD_THERAPEUTIC_SUCCESS
;;G;rs35283911;OTHER;INCREASED;EXPRESSION;;;HP;LIKELIHOOD_THERAPEUTIC_SUCCESS
;DCK;T;rs2306744;OTHER;INCREASED;EXPRESSION;;;DCK;LIKELIHOOD_THERAPEUTIC_SUCCESS
XENOBIOTICS;AHR;A;rs2066853;METABOLISM/PK;INCREASED;EXPRESSION;;;CYP1A1;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE, XENOBIOTICS;AHR;G;rs75519181;METABOLISM/PK;DECREASED;EXPRESSION;;;CYP1A1;CAUTION_DRUG_ACCUMULATION
VITAMIN E;CYP4F2;C;rs3093105;METABOLISM/PK;INCREASED;CATALYTIC_ACTIVITY;;;CYP4F2;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;A;rs200458614;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;;;CYP2B6;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;A;rs200238771;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;;;CYP2B6;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;A;rs764288403;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;;;CYP2B6;CAUTION_DRUG_ACCUMULATION
;NHLH1;T;rs11265375;OTHER;INCREASED;LUCIFERASE_ACTIVITY;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
VITAMIN E;CYP4F2;T;rs2108622;OTHER;DECREASED;ENZYME_ACTIVITY;;;CYP4F2;LIKELIHOOD_THERAPEUTIC_FAILURE
BUPROPION;CYP2B6;T;rs535039125;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;;;CYP2B6;CAUTION_DRUG_ACCUMULATION
BUPROPION;CYP2B6;A;rs200458614;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;;;CYP2B6;CAUTION_DRUG_ACCUMULATION
BUPROPION;CYP2B6;A;rs148009906;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;;;CYP2B6;CAUTION_DRUG_ACCUMULATION
BUPROPION;CYP2B6;C;rs201500445;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;;;CYP2B6;CAUTION_DRUG_ACCUMULATION
BUPROPION;CYP2B6;A;rs58871670;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;;;CYP2B6;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;C;rs201500445;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;;;CYP2B6;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;A;rs58871670;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;;;CYP2B6;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;A;rs117872433;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;;;CYP2B6;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;A;rs374099483;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;;;CYP2B6;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;A;rs148009906;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;;;CYP2B6;CAUTION_DRUG_ACCUMULATION
;SEMA6A;A;rs3806915;OTHER;INCREASED;LUCIFERASE_ACTIVITY;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUPROPION;CYP2B6;A;rs117872433;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;;;CYP2B6;CAUTION_DRUG_ACCUMULATION
BUPROPION;CYP2B6;A;rs200238771;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;;;CYP2B6;CAUTION_DRUG_ACCUMULATION
BUPROPION;CYP2B6;A;rs764288403;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;;;CYP2B6;CAUTION_DRUG_ACCUMULATION
BUPROPION;CYP2B6;A;rs374099483;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;;;CYP2B6;CAUTION_DRUG_ACCUMULATION
EFAVIRENZ;CYP2B6;T;rs535039125;METABOLISM/PK;DECREASED;CATALYTIC_ACTIVITY;;;CYP2B6;CAUTION_DRUG_ACCUMULATION
ETHANOL;ADH1B;CT + TT;rs1229984;METABOLISM/PK;INCREASED;ENZYME_ACTIVITY;;;ADH1B;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;MTHFR;GT;rs1801131;;INCREASED;CATALYTIC_ACTIVITY;;;TYMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;SHMT1;AA;rs1979277;METABOLISM/PK;INCREASED;CATALYTIC_ACTIVITY;;;TYMS;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;FASTKD3, MTRR;AG + GG;rs1801394;;INCREASED;CATALYTIC_ACTIVITY;;;TYMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;DPYD;G;rs755692084;METABOLISM/PK;DECREASED;ACTIVITY;;;DPYD;CAUTION_DRUG_ACCUMULATION
;CYP1A2;A;rs2069514;;DECREASED;ACTIVITY;;;CYP1A2;LIKELIHOOD_THERAPEUTIC_FAILURE
;CYP1A2;A;rs762551;;INCREASED;ACTIVITY;;;CYP1A2;LIKELIHOOD_THERAPEUTIC_SUCCESS
;CYP3A4;A;rs35599367;OTHER;DECREASED;EXPRESSION;;;CYP3A4;LIKELIHOOD_THERAPEUTIC_FAILURE
;CYP1A2;del;rs35694136;;DECREASED;ACTIVITY;;;CYP1A2;LIKELIHOOD_THERAPEUTIC_FAILURE
GLYBURIDE;KCNJ11;T;rs5219;METABOLISM/PK;DECREASED;ACTIVITY;;;KCNJ11;CAUTION_DRUG_ACCUMULATION
DOXORUBICIN;CBR1;GG;rs9024;METABOLISM/PK;INCREASED;CATALYTIC_ACTIVITY;;;CBR1;LIKELIHOOD_THERAPEUTIC_FAILURE
DOXORUBICIN;CBR1;GG;rs9024;METABOLISM/PK;INCREASED;CATALYTIC_ACTIVITY;;;CBR1;LIKELIHOOD_THERAPEUTIC_FAILURE
;ATP2B1;CT + TT;rs12817819;;DECREASED;EXPRESSION;;;ATP2B1;LIKELIHOOD_THERAPEUTIC_FAILURE
;IFNL3;C;rs4803217;OTHER;INCREASED;EXPRESSION;;;IFNL3;LIKELIHOOD_THERAPEUTIC_SUCCESS
;CETP;GG;rs708272;OTHER;INCREASED;EXPRESSION;;;CETP;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACETAMINOPHEN;SULT1A1;A;rs1042008;METABOLISM/PK;DECREASED;SULFATION;;;;CAUTION_DRUG_ACCUMULATION
ACETAMINOPHEN;SULT1A1;C;rs767487725;METABOLISM/PK;DECREASED;SULFATION;;;;CAUTION_DRUG_ACCUMULATION
ACETAMINOPHEN;SULT1A1;A;rs544820732;METABOLISM/PK;DECREASED;SULFATION;;;;CAUTION_DRUG_ACCUMULATION
PALBOCICLIB;CDKN2A;C;rs759922342;EFFICACY;INCREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACETAMINOPHEN;SULT1A1;T;rs72547527;METABOLISM/PK;DECREASED;SULFATION;;;;CAUTION_DRUG_ACCUMULATION
DESMETHYLNAPROXEN;SULT1A1;C;rs767487725;METABOLISM/PK;DECREASED;SULFATION;;;;CAUTION_DRUG_ACCUMULATION
DESMETHYLNAPROXEN;SULT1A1;T;rs758145522;METABOLISM/PK;DECREASED;SULFATION;;;;CAUTION_DRUG_ACCUMULATION
DESMETHYLNAPROXEN;SULT1A1;T;rs72547527;METABOLISM/PK;DECREASED;SULFATION;;;;CAUTION_DRUG_ACCUMULATION
DESMETHYLNAPROXEN;SULT1A1;A;rs1042008;METABOLISM/PK;DECREASED;SULFATION;;;;CAUTION_DRUG_ACCUMULATION
ACETAMINOPHEN;SULT1A1;G;rs28374453;METABOLISM/PK;INCREASED;SULFATION;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
DESMETHYLNAPROXEN;SULT1A1;G;rs28374453;METABOLISM/PK;INCREASED;SULFATION;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
ACETAMINOPHEN;SULT1A1;T;rs765399160;METABOLISM/PK;INCREASED;SULFATION;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
ACETAMINOPHEN;SULT1A1;G;rs552524124;METABOLISM/PK;DECREASED;SULFATION;;;;CAUTION_DRUG_ACCUMULATION
ACETAMINOPHEN;SULT1A1;T;rs758145522;METABOLISM/PK;DECREASED;SULFATION;;;;CAUTION_DRUG_ACCUMULATION
ACETAMINOPHEN;SULT1A1;T;rs1042028;METABOLISM/PK;DECREASED;SULFATION;;;;CAUTION_DRUG_ACCUMULATION
;UGT1A1;G;rs4124874;OTHER;DECREASED;CONCENTRATIONS;;;UGT1A1;LIKELIHOOD_THERAPEUTIC_FAILURE
TAPENTADOL;SULT1A1;T;rs758145522;METABOLISM/PK;DECREASED;SULFATION;;;;CAUTION_DRUG_ACCUMULATION
TAPENTADOL;SULT1A1;A;rs544820732;METABOLISM/PK;DECREASED;SULFATION;;;;CAUTION_DRUG_ACCUMULATION
TAPENTADOL;SULT1A1;C;rs767487725;METABOLISM/PK;DECREASED;SULFATION;;;;CAUTION_DRUG_ACCUMULATION
;UGT1A1;T;rs887829;OTHER;DECREASED;CONCENTRATIONS;;;UGT1A1;LIKELIHOOD_THERAPEUTIC_FAILURE
OXAZEPAM;UGT2B15;A;rs1902023;OTHER;DECREASED;GLUCURONIDATION;;;;CAUTION_DRUG_ACCUMULATION
TAPENTADOL;SULT1A1;A;rs1042008;METABOLISM/PK;DECREASED;SULFATION;;;;CAUTION_DRUG_ACCUMULATION
TAPENTADOL;SULT1A1;T;rs72547527;METABOLISM/PK;DECREASED;SULFATION;;;;CAUTION_DRUG_ACCUMULATION
DESMETHYLNAPROXEN;SULT1A1;G;rs552524124;METABOLISM/PK;DECREASED;SULFATION;;;;CAUTION_DRUG_ACCUMULATION
DESMETHYLNAPROXEN;SULT1A1;T;rs1042028;METABOLISM/PK;DECREASED;SULFATION;;;;CAUTION_DRUG_ACCUMULATION
DESMETHYLNAPROXEN;SULT1A1;A;rs544820732;METABOLISM/PK;DECREASED;SULFATION;;;;CAUTION_DRUG_ACCUMULATION
;UGT1A1;A;rs10929302;OTHER;DECREASED;CONCENTRATIONS;;;UGT1A1;LIKELIHOOD_THERAPEUTIC_FAILURE
TAPENTADOL;SULT1A1;G;rs552524124;METABOLISM/PK;DECREASED;SULFATION;;;;CAUTION_DRUG_ACCUMULATION
TAPENTADOL;SULT1A1;G;rs28374453;METABOLISM/PK;INCREASED;SULFATION;;;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAPENTADOL;SULT1A1;T;rs1042028;METABOLISM/PK;DECREASED;SULFATION;;;;CAUTION_DRUG_ACCUMULATION
PREGNENOLONE;SULT2B1;G;rs777924668;METABOLISM/PK;DECREASED;ENZYME_ACTIVITY;;;SULT2B1;CAUTION_DRUG_ACCUMULATION
PREGNENOLONE;SULT2B1;T;rs746398875;METABOLISM/PK;DECREASED;ENZYME_ACTIVITY;;;SULT2B1;CAUTION_DRUG_ACCUMULATION
ESTRADIOL;;GG;rs3802201;OTHER;INCREASED;EXPRESSION;;;MIR2052;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESTRADIOL;;CC;rs4476990;OTHER;INCREASED;EXPRESSION;;;MIR2052;LIKELIHOOD_THERAPEUTIC_SUCCESS
PREGNENOLONE;SULT2B1;T;rs527454384;METABOLISM/PK;DECREASED;ENZYME_ACTIVITY;;;SULT2B1;CAUTION_DRUG_ACCUMULATION
PREGNENOLONE;SULT2B1;A;rs777140014;METABOLISM/PK;DECREASED;ENZYME_ACTIVITY;;;SULT2B1;CAUTION_DRUG_ACCUMULATION
PREGNENOLONE;SULT2B1;T;rs774212320;METABOLISM/PK;DECREASED;ENZYME_ACTIVITY;;;SULT2B1;CAUTION_DRUG_ACCUMULATION
PREGNENOLONE;SULT2B1;A;rs762765702;METABOLISM/PK;DECREASED;ENZYME_ACTIVITY;;;SULT2B1;CAUTION_DRUG_ACCUMULATION
;CYP2C19;A;rs140278421;OTHER;DECREASED;EXPRESSION;;;CYP2C19;LIKELIHOOD_THERAPEUTIC_FAILURE
;CYP2C19;T;rs61311738;OTHER;DECREASED;EXPRESSION;;;CYP2C19;LIKELIHOOD_THERAPEUTIC_FAILURE
;CYP2C19;T;rs183701923;OTHER;DECREASED;EXPRESSION;;;CYP2C19;LIKELIHOOD_THERAPEUTIC_FAILURE
;CYP2C9;C;rs761895497;OTHER;DECREASED;EXPRESSION;;;CYP2C9;LIKELIHOOD_THERAPEUTIC_FAILURE
;CYP2C9;C;rs771237265;OTHER;DECREASED;EXPRESSION;;;CYP2C9;LIKELIHOOD_THERAPEUTIC_FAILURE
;CYP2C9;T;rs762081829;OTHER;DECREASED;EXPRESSION;;;CYP2C9;LIKELIHOOD_THERAPEUTIC_FAILURE
;CYP3A5;TT;rs776746;OTHER;INCREASED;EXPRESSION;;;CYP3A5;LIKELIHOOD_THERAPEUTIC_SUCCESS
SUMATRIPTAN;HTR1B;C;rs130060;PD;INCREASED;CONCENTRATIONS;;;cAMP;CAUTION_DRUG_ACCUMULATION
;CYP2A6;AA + AG;rs8192720;;INCREASED;EXPRESSION;;;CYP2A6;LIKELIHOOD_THERAPEUTIC_SUCCESS
;CYP2A6;AG + GG;rs8192725;;INCREASED;EXPRESSION;;;CYP2A6;LIKELIHOOD_THERAPEUTIC_SUCCESS
;CYP2A6;AC + CC;rs28399433;;DECREASED;EXPRESSION;;;CYP2A6;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL;DPYD;TT;rs1801158;OTHER;INCREASED;ACTIVITY;;;DPYD;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;DPYD;GG;rs1801265;OTHER;INCREASED;ACTIVITY;;;DPYD;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;DPYD;CC;rs55886062;OTHER;DECREASED;ACTIVITY;;;DPYD;LIKELIHOOD_THERAPEUTIC_FAILURE
OXAZEPAM;UGT1A1;A;rs10929302;OTHER;DECREASED;GLUCURONIDATION;;;;CAUTION_DRUG_ACCUMULATION
OXAZEPAM;UGT1A1;G;rs4124874;OTHER;;GLUCURONIDATION;;;;CAUTION_DOSE_ADJUST
OXAZEPAM;;G;rs1976391;OTHER;DECREASED;GLUCURONIDATION;;;;CAUTION_DRUG_ACCUMULATION
OXAZEPAM;UGT1A1;T;rs887829;OTHER;DECREASED;GLUCURONIDATION;;;;CAUTION_DRUG_ACCUMULATION
;;G;rs1976391;OTHER;DECREASED;CONCENTRATIONS;;;UGT1A1;LIKELIHOOD_THERAPEUTIC_FAILURE
;PKNOX1;A;rs2839629;OTHER;INCREASED;EXPRESSION;;;PKNOX1;LIKELIHOOD_THERAPEUTIC_SUCCESS
;PKNOX1;A;rs2839629;OTHER;INCREASED;EXPRESSION;;;CBS;LIKELIHOOD_THERAPEUTIC_SUCCESS
;CBS;C;rs915854;OTHER;INCREASED;EXPRESSION;;;PKNOX1;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAFFEINE, CHLOROCRESOL;RYR1;T;rs186983396;METABOLISM/PK;INCREASED;SENSITIVITY;;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
;CDA;CC;rs532545;OTHER;DECREASED;ACTIVITY;;;CDA;LIKELIHOOD_THERAPEUTIC_FAILURE
;CDA;AA;rs602950;OTHER;DECREASED;ACTIVITY;;;CDA;LIKELIHOOD_THERAPEUTIC_FAILURE
;CDA;AA;rs2072671;OTHER;DECREASED;ACTIVITY;;;CDA;LIKELIHOOD_THERAPEUTIC_FAILURE
;YAP1;C;rs1820453;;DECREASED;TRANSCRIPTION;;;YAP1;LIKELIHOOD_THERAPEUTIC_FAILURE
ELEXACAFTOR, TEZACAFTOR;CFTR;A;rs397508609;EFFICACY;INCREASED;ACTIVITY;;;CFTR;LIKELIHOOD_THERAPEUTIC_SUCCESS
ELEXACAFTOR, TEZACAFTOR;CFTR;A;rs397508139;EFFICACY;INCREASED;ACTIVITY;;;CFTR;LIKELIHOOD_THERAPEUTIC_SUCCESS
ELEXACAFTOR, TEZACAFTOR;CFTR;T;rs758900656;EFFICACY;INCREASED;ACTIVITY;;;CFTR;LIKELIHOOD_THERAPEUTIC_SUCCESS
ELEXACAFTOR, TEZACAFTOR;CFTR;T;rs397508293;EFFICACY;INCREASED;ACTIVITY;;;CFTR;LIKELIHOOD_THERAPEUTIC_SUCCESS
ELEXACAFTOR, TEZACAFTOR;CFTR;T;rs1792306355;EFFICACY;INCREASED;ACTIVITY;;;CFTR;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;CYP2A6;AA + AT;rs1801272;TOXICITY;DECREASED;RISK;OTHER:TOBACCO_USE_DISORDER;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SACITUZUMAB GOVITECAN;UGT1A1;*1/*28 + *28/*28;UGT1A1*1, UGT1A1*28;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:NEUTROPENIA;PEOPLE;OTHER:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A4;T;rs2740574;METABOLISM/PK;;;PK:TACROLIMUS_CONCENTRATION_TO_DOSE_RATIO_(C/D_RATIO);;;CAUTION_DOSE_ADJUST
ARIPIPRAZOLE;CYP2D6;;CYP2D6 ULTRARAPID_METABOLIZER;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS;PEOPLE;OTHER:SCHIZOPHRENIA, OTHER:SCHIZOAFFECTIVE_DISORDER,OTHER:BIPOLAR_DISORDER, OTHER:PSYCHOTIC_DISORDER;CAUTION_SIDE_EFFECT
SULFAMETHOXAZOLE / TRIMETHOPRIM;NAT2;A;rs1799930;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ADVERSE_REACTIONS;CHILDREN;DISEASE:PNEUMONIA;CAUTION_SIDE_EFFECT
ATORVASTATIN, FLUVASTATIN, HMG COA REDUCTASE INHIBITORS, PITAVASTATIN, PRAVASTATIN, ROSUVASTATIN, SIMVASTATIN;HLA-DRB1;*04:06;HLA-DRB1*01:01, HLA-DRB1*04:06;TOXICITY;INCREASED;RISK;SIDE_EFFECT:MUSCULAR_DISEASES;;;CAUTION_SIDE_EFFECT
ETHANOL;CHRNA5;T;rs615470;TOXICITY, OTHER;DECREASED;LIKELIHOOD;DISEASE:ALCOHOL_ABUSE;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
LIRAGLUTIDE;GLP1R;AT + TT;rs2254336;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:NAUSEA, SIDE_EFFECT:VOMITING, SIDE_EFFECT:DIARRHEA, SIDE_EFFECT:GASTROINTESTINAL_TOXICITY;PEOPLE;OTHER:DIABETES_MELLITUS_T2;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2A, RIBAVIRIN, SIMEPREVIR;IFNL3, IFNL4;TT;rs8099917;EFFICACY;INCREASED;;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;T;rs1041983;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;PEOPLE;OTHER:TUBERCULOSIS;CAUTION_SIDE_EFFECT
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;A;rs1799931;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;PEOPLE;OTHER:TUBERCULOSIS;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;DECREASED;;PK:DOSE-ADJUSTED_AUC24;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
GEFITINIB;ABCG2;GG;rs2231142;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DIARRHEA;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
LIRAGLUTIDE;GLP1R;AA + AG;rs3765467;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:NAUSEA, SIDE_EFFECT:VOMITING, SIDE_EFFECT:DIARRHEA, SIDE_EFFECT:GASTROINTESTINAL_TOXICITY;PEOPLE;OTHER:DIABETES_MELLITUS_T2;CAUTION_SIDE_EFFECT
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *3/*3;CYP2C9*1, CYP2C9*2, CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OVER-ANTICOAGULATION;;;CAUTION_SIDE_EFFECT
WARFARIN;VKORC1;TT;rs9923231;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:HEMORRHAGE;;;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*4/*4;CYP2D6*4;EFFICACY;DECREASED;;EFFICACY:EVENT-FREE_SURVIVAL;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
ATORVASTATIN, PRAVASTATIN, SIMVASTATIN;HTR3B;G;rs2276307;TOXICITY;INCREASED;RISK;DISEASE:MYALGIA;PEOPLE;DISEASE:HYPERCHOLESTEROLEMIA;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;INCREASED;LIKELIHOOD;PK:ACHIEVING_OPTIMAL_TROUGH_LEVEL;PEOPLE;DISEASE:ULCERATIVE_COLITIS;CAUTION_DOSE_ADJUST
NORTRIPTYLINE;UST;A;rs2500535;EFFICACY;DECREASED;;EFFICACY:IMPROVEMENT_OF_DEPRESSION_SYMPTOMS;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A4;G;rs1851426;METABOLISM/PK;;;PK:TACROLIMUS_CONCENTRATION_TO_DOSE_RATIO_(C/D_RATIO);;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1, CYP2C9*2, CYP2C9*3;EFFICACY;;;EFFICACY:TIME_TO_THERAPEUTIC_INR;PEOPLE;DISEASE:ATRIAL_FIBRILLATION;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;CT + TT;rs9923231;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:OVER-ANTICOAGULATION;;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*17;CYP2C19*1, CYP2C19*17;TOXICITY;INCREASED;RISK;SIDE_EFFECT:BLEEDING;;;CAUTION_SIDE_EFFECT
OSIMERTINIB;IL6;CG + GG;rs1800796;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:OVERALL_SURVIVAL;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUCLOXACILLIN;HLA-DQB1;*03:03;HLA-DQB1*03:03;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;;;CAUTION_SIDE_EFFECT
RISPERIDONE;HTR2A;CT + TT;rs6311;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:WEIGHT_GAIN;PEOPLE;OTHER:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*6/*6;CYP2D6*6;EFFICACY;DECREASED;;EFFICACY:EVENT-FREE_SURVIVAL;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*5/*5;CYP2D6*5;EFFICACY;DECREASED;;EFFICACY:EVENT-FREE_SURVIVAL;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;TOXICITY;INCREASED;SEVERITY;OTHER:INTERSTITIAL_INFLAMMATORY_CELL_INFILTRATION;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
RISPERIDONE;HTR2A;AA + AG;rs6313;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:WEIGHT_GAIN;PEOPLE;OTHER:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
OXAZEPAM;UGT2B15;AA;rs1902023;METABOLISM/PK;DECREASED;;PK:S-OXAZEPAM_GLUCURONIDATION_IN_HUMAN_LIVER_MICROSOMES;;;CAUTION_DOSE_ADJUST
METHOTREXATE;MTHFR;AA + AG;rs1801133;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;CHILDREN;DISEASE:JUVENILE_RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
OXAZEPAM;UGT2B15;AA;rs1902023;METABOLISM/PK;DECREASED;;PK:OXAZEPAM_ORAL_CLEARANCE;;;CAUTION_DOSE_ADJUST
SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-C;*08:01;HLA-C*08:01;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;;;CAUTION_SIDE_EFFECT
EFAVIRENZ, ISONIAZID;CYP2B6;;CYP2B6 POOR_METABOLIZER;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HYPERCHOLESTEROLEMIA;PEOPLE;OTHER:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
PHENYTOIN;CYP2C9;*3;CYP2C9*3;TOXICITY;INCREASED;RISK;DISEASE:DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS;;;CAUTION_SIDE_EFFECT
PHENYTOIN;CYP2C9;*3;CYP2C9*3;TOXICITY;INCREASED;RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;;;CAUTION_SIDE_EFFECT
TACROLIMUS;PPARA;GG;rs4823613;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:ACUTE_CELLULAR_REJECTION;PEOPLE;OTHER:LIVER_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
MERCAPTOPURINE, METHOTREXATE;TPMT;*1/*3A;TPMT*1, TPMT*3A;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:DRUG_TOXICITY, DISEASE:INFECTIOUS_DISEASE, DISEASE:STOMATITIS;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
NITROUS OXIDE;MTHFR;AA;rs1801133;TOXICITY;INCREASED;;SIDE_EFFECT:PLASMA_TOTAL_HOMOCYSTEINE_CONCENTRATIONS;PEOPLE;OTHER:SURGERY;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *3/*17 + *2/*2 + *2/*3 + *3/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:STROKE, EFFICACY:MYOCARDIAL_INFARCTION, EFFICACY:DEATH;PEOPLE;OTHER:STROKE;LIKELIHOOD_THERAPEUTIC_SUCCESS
RISPERIDONE;DRD3;G;rs167771;TOXICITY;INCREASED;RISK;SIDE_EFFECT:EXTRAPYRAMIDAL_SYMPTOMS;PEOPLE;DISEASE:BIPOLAR_DISORDER, DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;CYP2D6;*1/*10 + *10/*10;CYP2D6*1, CYP2D6*10;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TARDIVE_DYSKINESIA;MEN;DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
FLUCLOXACILLIN;HLA-DQA1;*02:01;HLA-DQA1*02:01;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;;;CAUTION_SIDE_EFFECT
FLUCLOXACILLIN;HLA-A;*01:01;HLA-A*01:01;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;;;CAUTION_SIDE_EFFECT
AMOXICILLIN;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;;;CAUTION_SIDE_EFFECT
CISPLATIN, PACLITAXEL;GGT1;CC;rs5751901;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA, SIDE_EFFECT:LEUKOPENIA;PEOPLE;OTHER:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTITHYROID PREPARATIONS;HLA-B;*27:05;HLA-B*27:05;TOXICITY;INCREASED;RISK;SIDE_EFFECT:AGRANULOCYTOSIS;;;CAUTION_SIDE_EFFECT
FLUCLOXACILLIN;HLA-DRB1;*07:01;HLA-DRB1*07:01;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;;;CAUTION_SIDE_EFFECT
BUSULFAN;CYP2B6;*1/*1 + *1/*5 + *1/*9;CYP2B6*1, CYP2B6*5, CYP2B6*9;EFFICACY;INCREASED;;EFFICACY:EVENT-FREE_SURVIVAL;CHILDREN;DISEASE:HEMOPOIETIC_STEM_CELL_TRANSPLANT;LIKELIHOOD_THERAPEUTIC_SUCCESS
TAMOXIFEN;CYP2D6;;CYP2D6 POOR_METABOLIZER;TOXICITY;INCREASED;RISK;SIDE_EFFECT:UTERINE_DISORDER, SIDE_EFFECT:LEIOMYOMA, SIDE_EFFECT:ENDOMETRIAL_HYPERPLASIA, SIDE_EFFECT:POLYPS;PEOPLE;OTHER:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1, CYP2C9*2, CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TIME_ABOVE_THERAPEUTIC_RANGE;PEOPLE;DISEASE:VENOUS_THROMBOEMBOLISM;CAUTION_SIDE_EFFECT
CAPECITABINE, FLUOROURACIL;ABCC11;AA + AG;rs17822471;TOXICITY;INCREASED;RISK;SIDE_EFFECT:LEUKOPENIA;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;;;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;CYP2D6;*1/*4 + *1/*5;CYP2D6*1, CYP2D6*4, CYP2D6*5;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TARDIVE_DYSKINESIA;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
FLUVOXAMINE;CYP2D6;*1/*10 + *1/*5 + *10/*10 + *5/*10;CYP2D6*1, CYP2D6*5, CYP2D6*10;METABOLISM/PK;;;PK:DIFFERENCES_IN_THE_FLUVOXAMINE_PLASMA_LEVEL_AT_50_MG/DAY;PEOPLE;;CAUTION_DOSE_ADJUST
DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS;HLA-DQA1;*05;HLA-DQA1*05;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:BULLOUS_PEMPHIGOID;PEOPLE;OTHER:DIABETES_MELLITUS;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B;IDO1;CC;rs9657182;TOXICITY;INCREASED;;SIDE_EFFECT:DEPRESSION;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;CAUTION_SIDE_EFFECT
DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS;;AA + AG;rs3129763;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:BULLOUS_PEMPHIGOID;PEOPLE;OTHER:DIABETES_MELLITUS;CAUTION_SIDE_EFFECT
DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS;HLA-DQB1;*03:01;HLA-DQB1*03:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:BULLOUS_PEMPHIGOID;PEOPLE;OTHER:DIABETES_MELLITUS;CAUTION_SIDE_EFFECT
NITROUS OXIDE;MTHFR;GG;rs1801131;TOXICITY;INCREASED;;SIDE_EFFECT:PLASMA_TOTAL_HOMOCYSTEINE_CONCENTRATIONS;PEOPLE;OTHER:SURGERY;CAUTION_SIDE_EFFECT
CIPROFLOXACIN, LEVOFLOXACIN, MOXIFLOXACIN;HLA-B;*57:01;HLA-B*57:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;;;CAUTION_SIDE_EFFECT
OMEPRAZOLE;CYP2C19;TT;rs11188072;DOSAGE, METABOLISM/PK;DECREASED;;PK:AUC;PEOPLE;OTHER:NO_DISEASE;CAUTION_DOSE_ADJUST
METHADONE;CYP3A4;C;rs3735451;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:SIDE_EFFECTS;PEOPLE;DISEASE:HEROIN_DEPENDENCE;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1, CYP2C19*2;EFFICACY;INCREASED;;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBOPLATIN, PACLITAXEL;ABCB1;AA;rs2032582;EFFICACY;DECREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;OTHER:OVARIAN_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*1/*1;CYP2D6*1, CYP2D6*10;EFFICACY;DECREASED;;EFFICACY:EVENT-FREE_SURVIVAL;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
IRINOTECAN;UGT1A1;*1/*6 + *6/*6;UGT1A1*1, UGT1A1*6;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUTROPENIA;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-B;*13:01;HLA-B*13:01;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS;;;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;CYP2D6;*10;CYP2D6*1, CYP2D6*10;TOXICITY;;RISK;SIDE_EFFECT:TARDIVE_DYSKINESIA;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_DOSE_ADJUST
ANTIDEPRESSANTS;CYP2D6;*2/*2xN;CYP2D6*2, CYP2D6*2XN;EFFICACY;INCREASED;RISK;EFFICACY:NON-RESPONSE;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*10/*10;CYP2D6*1, CYP2D6*10;EFFICACY;DECREASED;;EFFICACY:EVENT-FREE_SURVIVAL;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1, CYP2C9*2, CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OVER-ANTICOAGULATION;;;CAUTION_SIDE_EFFECT
ASPARAGINASE;ATL2;T;rs59569490;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_HYPERSENSITIVITY;CHILDREN;OTHER:NEOPLASMS;CAUTION_SIDE_EFFECT
AZATHIOPRINE, MERCAPTOPURINE;HLA-DQA1;*02:01;HLA-DQA1*02:01;TOXICITY;INCREASED;RISK;SIDE_EFFECT:PANCREATITIS;PEOPLE;DISEASE:INFLAMMATORY_BOWEL_DISEASES;CAUTION_SIDE_EFFECT
ASPIRIN, CILOSTAZOL, CLOPIDOGREL;CYP2C19;*2/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;METABOLISM/PK;INCREASED;;EFFICACY:MAXIMAL_PLATELET_AGGREGATION;;OTHER:HIGH_RISK_PATIENTS_(ACUTE_MYOCARIDAL_INFARCTION, DIABETES_E.G.);CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1, CYP2C19*2;TOXICITY;INCREASED;RISK;SIDE_EFFECT:STENT_THROMBOSIS_(ST)_AFTER_1_YEAR;;;CAUTION_SIDE_EFFECT
ESCITALOPRAM;CYP2C19;A;rs4986893;DOSAGE, METABOLISM/PK;INCREASED;;PK:SERUM_CONCENTRATION;PEOPLE;DISEASE:MENTAL_DISORDERS;CAUTION_DOSE_ADJUST
PLATINUM COMPOUNDS;RETN;GG;rs1862513;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY;PEOPLE;OTHER:LUNG_NEOPLASMS;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*4/*4;CYP2D6*1, CYP2D6*4;EFFICACY;DECREASED;;EFFICACY:EVENT-FREE_SURVIVAL, EFFICACY:RECURRENCE_FREE_SURVIVAL;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
IRINOTECAN;UGT1A1;*1/*6 + *6/*6;UGT1A1*1, UGT1A1*6;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DIARRHEA;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*4/*4 + *1/*4;CYP2D6*1, CYP2D6*4;EFFICACY;DECREASED;;EFFICACY:EVENT-FREE_SURVIVAL, EFFICACY:RECURRENCE_FREE_SURVIVAL;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
NILOTINIB;UGT1A1;*6/*6 + *6/*28;UGT1A1*1, UGT1A1*6, UGT1A1*27, UGT1A1*28;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HYPERBILIRUBINEMIA;PEOPLE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;CAUTION_SIDE_EFFECT
PRIMAQUINE;MAOA;CC + CT;rs1137070;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:RECURRENCE;PEOPLE;OTHER:MALARIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
OMEPRAZOLE;CYP2C19;TT;rs12248560;DOSAGE, METABOLISM/PK;DECREASED;;PK:AUC;PEOPLE;OTHER:NO_DISEASE;CAUTION_DOSE_ADJUST
PRIMAQUINE;CYP2D6;;CYP2D6 NORMAL_METABOLIZER;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:RECURRENCE;PEOPLE;OTHER:MALARIA;LIKELIHOOD_THERAPEUTIC_FAILURE
AZATHIOPRINE, MERCAPTOPURINE;NUDT15;GGAGTC;rs746071566;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:LEUKOPENIA;PEOPLE;DISEASE:INFLAMMATORY_BOWEL_DISEASES;CAUTION_SIDE_EFFECT
PRIMAQUINE;CYP2D6;*4;CYP2D6*4;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:RECURRENCE;PEOPLE;OTHER:MALARIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESCITALOPRAM;CYP2C19;TT;rs11188072;DOSAGE, METABOLISM/PK;DECREASED;;PK:SERUM_CONCENTRATION;PEOPLE;DISEASE:MENTAL_DISORDERS;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;DECREASED;;PK:CONCENTRATION/DOSE_RATIO;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;DECREASED;;PK:CONCENTRATION/DOSE_RATIO;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TENOFOVIR;ABCC10;C;rs2125739;TOXICITY;INCREASED;;SIDE_EFFECT:KIDNEY_TUBULAR_DYSFUNCTION;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*1/*3 + *3/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;INCREASED;;PK:BLOOD_CONCENTRATION/DOSAGE_RATIO;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;DECREASED;;PK:CONCENTRATION/DOSE_RATIO;CHILDREN;OTHER:HEART_TRANSPLANTATION;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;*5;CYP2C19*1, CYP2C19*5;TOXICITY;INCREASED;RISK;SIDE_EFFECT:CARDIOVASCULAR_EVENTS;PEOPLE;DISEASE:MYOCARDIAL_INFARCTION;CAUTION_SIDE_EFFECT
EFAVIRENZ, ISONIAZID;CYP2B6;;CYP2B6 POOR_METABOLIZER;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE;PEOPLE;OTHER:HIV_INFECTIOUS_DISEASE, OTHER:PREGNANCY;CAUTION_SIDE_EFFECT
ROSUVASTATIN;ABCG2;GT + TT;rs2231142;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ELEVATED_LIVER_ENZYMES;PEOPLE;OTHER:ACUTE_CORONARY_SYNDROME, OTHER:DYSLIPIDAEMIA,OTHER:DIABETES_MELLITUS, OTHER:CARDIOVASCULAR_DISEASE;CAUTION_SIDE_EFFECT
AZATHIOPRINE;TPMT;*1/*3A + *1/*3C;TPMT*1, TPMT*3A, TPMT*3C;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HAEMATOLOGICAL_TOXICITY_OR_HEPATOTOXICITY;PEOPLE;OTHER:NEUROLOGICAL_PROBLEMS;CAUTION_SIDE_EFFECT
ATORVASTATIN;SLCO1B1;CC + CT;rs4149056;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:STATIN-RELATED_MYOPATHY;PEOPLE;OTHER:CARDIOVASCULAR_DISEASE, OTHER:DIABETES_MELLITUS,OTHER:ACUTE_CORONARY_SYNDROME, OTHER:DYSLIPIDAEMIA;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A4;A;rs2687116;METABOLISM/PK;;;PK:TACROLIMUS_CONCENTRATION_TO_DOSE_RATIO_(C/D_RATIO);;;CAUTION_DOSE_ADJUST
CARBOPLATIN, PACLITAXEL;ABCB1;AG + GG;rs1128503;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NAUSEA;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
CARBOPLATIN, PACLITAXEL;ABCB1;AG + GG;rs1128503;TOXICITY;INCREASED;RISK;SIDE_EFFECT:VOMITING;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
ESCITALOPRAM;CYP2C19;A;rs4244285;DOSAGE, METABOLISM/PK;INCREASED;;PK:SERUM_CONCENTRATION;PEOPLE;DISEASE:MENTAL_DISORDERS;CAUTION_DOSE_ADJUST
NAN;IFNL4;TT/TT;rs11322783;OTHER;INCREASED;;OTHER:SPONTANEOUS_HCV_CLEARANCE;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;CAUTION_DOSE_ADJUST
MERCAPTOPURINE;SLC22A1;del;rs72552763;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:INFECTIOUS_DISEASE;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
CARBOPLATIN, CISPLATIN;;AA + AG;rs6856089;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:MYELOSUPPRESSION;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
MERCAPTOPURINE;TPMT;*1/*2 + *1/*3A + *1/*3C;TPMT*1, TPMT*2, TPMT*3A, TPMT*3C;METABOLISM/PK;DECREASED;;PK:6-MMPN_LEVELS;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DOSE_ADJUST
NAN;SOD1;GCCCAGTAAAGCATGGGGCCTGGGGCCAGGGACCCCCTTGTTCAGGTGTG/del + del/del;rs36232792;OTHER;DECREASED;LIKELIHOOD;OTHER:OPIOID-RELATED_DISORDERS;;;LIKELIHOOD_THERAPEUTIC_FAILURE
AZATHIOPRINE, MERCAPTOPURINE, PURINE ANALOGUES;TPMT;*1/*3A + *3A/*3A + *1/*3C + *3C/*3C;TPMT*1, TPMT*3A, TPMT*3C;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:BONE_MARROW_TOXICITY;PEOPLE;DISEASE:INFLAMMATORY_BOWEL_DISEASES;CAUTION_SIDE_EFFECT
ETHAMBUTOL, ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;*5/*5 + *5/*6 + *5/*7 + *6/*6 + *6/*7 + *6/*14 + *7/*7;NAT2*1, NAT2*5, NAT2*6, NAT2*7, NAT2*14;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE;PEOPLE;OTHER:TUBERCULOSIS;CAUTION_SIDE_EFFECT
LACOSAMIDE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY, TOXICITY;INCREASED;LIKELIHOOD;EFFICACY:DISCONTINUATION;PEOPLE;OTHER:EPILEPSY;LIKELIHOOD_THERAPEUTIC_SUCCESS
AZATHIOPRINE, MERCAPTOPURINE, PURINE ANALOGUES;TPMT;*1/*3A + *3A/*3A + *1/*3C + *3C/*3C;TPMT*1, TPMT*3A, TPMT*3C;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:OVERALL_ADRS;PEOPLE;DISEASE:INFLAMMATORY_BOWEL_DISEASES;CAUTION_SIDE_EFFECT
NAN;CYP3A5;*1/*3 + *3/*3;CYP3A5*1, CYP3A5*3;OTHER;INCREASED;LIKELIHOOD;OTHER:DECREASED_GLOMERULAR_FILTRATION_RATE;PEOPLE;OTHER:KIDNEY_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESCITALOPRAM;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3 + *3/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;METABOLISM/PK;INCREASED;LIKELIHOOD;OTHER:DISCONTINUATION, OTHER:TREATMENT_MODIFICATION;PEOPLE;OTHER:DEPRESSIVE_DISORDER;CAUTION_DOSE_ADJUST
PHENYTOIN;CYP2C9;*3;CYP2C9*1, CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE_EFFECT:EXANTHEMA;;;CAUTION_SIDE_EFFECT
SERTRALINE;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3 + *3/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;METABOLISM/PK;INCREASED;LIKELIHOOD;OTHER:DISCONTINUATION, OTHER:TREATMENT_MODIFICATION;PEOPLE;OTHER:DEPRESSIVE_DISORDER;CAUTION_DOSE_ADJUST
AZATHIOPRINE;TPMT;*1/*3A + *1/*3B + *1/*3C;TPMT*1, TPMT*3A, TPMT*3B, TPMT*3C;TOXICITY;DECREASED;;SIDE_EFFECT:HEMATOLOGICAL_INDICES;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTINEOPLASTIC AGENTS, TAMOXIFEN;CYP2D6;*10/*10;CYP2D6*10;EFFICACY;DECREASED;;EFFICACY:EVENT-FREE_SURVIVAL;WOMEN;SIDE_EFFECT:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOSPORINE;TPMT;*1/*3A + *1/*3B + *1/*3C;TPMT*1, TPMT*3A, TPMT*3B, TPMT*3C;TOXICITY;INCREASED;;PK:PLASMA_LEVELS;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;;EFFICACY:RESPONSE_(RAPID_AND_SUSTAINED_VIROLOGICAL_RESPONSE)_FOR_PATIENTS_WITH_HEPATITIS_C_VIRUS_GENOTYPE_1;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN, PEMETREXED;MTHFR;GG + GT;rs1801131;EFFICACY;DECREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:STOMACH_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
ESCITALOPRAM;CYP2C19;TT;rs12248560;DOSAGE, METABOLISM/PK;DECREASED;;PK:SERUM_CONCENTRATION;PEOPLE;DISEASE:MENTAL_DISORDERS;CAUTION_DOSE_ADJUST
PHENYTOIN;HLA-B;*13:01;HLA-B*13:01;TOXICITY;INCREASED;RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;;;CAUTION_SIDE_EFFECT
SUFENTANIL;ADRB1;GG;rs1801253;EFFICACY;DECREASED;SEVERITY;EFFICACY:PAIN, POSTOPERATIVE;CHILDREN;OTHER:SURGERY;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTINEOPLASTIC AGENTS, TAMOXIFEN;CYP2D6;*10/*5 + *10/*10 + *10/*41;CYP2D6*1, CYP2D6*2, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*35, CYP2D6*36, CYP2D6*41;EFFICACY;DECREASED;;EFFICACY:EVENT-FREE_SURVIVAL;WOMEN;SIDE_EFFECT:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;DISEASE:TOXIC_EPIDERMAL_NECROLYSIS, DISEASE:STEVENS-JOHNSON_SYNDROME;;;CAUTION_SIDE_EFFECT
TENOFOVIR;ABCC10;G;rs9349256;TOXICITY;INCREASED;;SIDE_EFFECT:KIDNEY_TUBULAR_DYSFUNCTION;;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*17;CYP2C19*1, CYP2C19*17;TOXICITY;INCREASED;RISK;SIDE_EFFECT:MORTALITY;PEOPLE;DISEASE:MYOCARDIAL_INFARCTION;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*1, CYP2C19*2, CYP2C19*3;TOXICITY;INCREASED;RISK;DISEASE:MYOCARDIAL_INFARCTION;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;CAUTION_SIDE_EFFECT
IMATINIB;ABCB1;A;rs1045642;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:MYELOSUPPRESSION;PEOPLE;OTHER:CHRONIC_MYELOMONOCYTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
IMATINIB;NR1I2;TT;rs3814055;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:MYELOSUPPRESSION;PEOPLE;OTHER:CHRONIC_MYELOMONOCYTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY, TOXICITY;INCREASED;RISK;SIDE_EFFECT:ADVERSE_CLINICAL_EVENTS;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;CAUTION_SIDE_EFFECT
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;HTR1A;C;rs6295;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:TREATMENT_FAILURE;PEOPLE;OTHER:ANXIETY_DISORDERS, OTHER:DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;CYP2A6;*1/*4 + *1/*7 + *1/*9 + *4/*4 + *7/*7 + *9/*9;CYP2A6*1, CYP2A6*4, CYP2A6*7, CYP2A6*9;METABOLISM/PK;DECREASED;;PK:AREA_UNDER_THE_PLASMA_CONCENTRATION-TIME_CURVE;PEOPLE;DISEASE:NEOPLASMS;CAUTION_DOSE_ADJUST
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;MTRR;G;rs1801394;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;CHILDREN;DISEASE:JUVENILE_RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
TEGAFUR / GIMERACIL / OTERACIL;CYP2A6;*4 + *7 + *9 + *10;CYP2A6*1, CYP2A6*4, CYP2A6*7, CYP2A6*9, CYP2A6*10;EFFICACY;DECREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL, EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:STOMACH_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*1, CYP2C19*2, CYP2C19*3;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ADVERSE_CLINICAL_EVENTS;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;CAUTION_SIDE_EFFECT
CLOPIDOGREL, ROSUVASTATIN;CYP2C19;*2 + *3;CYP2C19*1, CYP2C19*2, CYP2C19*3;OTHER;INCREASED;;OTHER:P2Y12_REACTION_UNIT(PRU)_VALUES;;OTHER:PATIENTS_UNDERGOING_PERCUTANEOUS_CORONARY_INTERVENTION;CAUTION_DOSE_ADJUST
METHADONE;CYP3A4;A;rs4646437;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:SIDE_EFFECTS;PEOPLE;DISEASE:HEROIN_DEPENDENCE;CAUTION_SIDE_EFFECT
TEGAFUR;CYP2A6;*1/*4 + *1/*7 + *1/*9 + *4/*4 + *7/*7 + *9/*9;CYP2A6*1, CYP2A6*4, CYP2A6*7, CYP2A6*9;METABOLISM/PK;INCREASED;;PK:AREA_UNDER_THE_PLASMA_CONCENTRATION-TIME_CURVE;PEOPLE;DISEASE:NEOPLASMS;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;*17/*17;CYP2C19*1, CYP2C19*17;TOXICITY;DECREASED;RISK;SIDE_EFFECT:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE);;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIPSYCHOTICS;CYP2D6;*3 + *4 + *5 + *6 + *7 + *14;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*7, CYP2D6*14;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TARDIVE_DYSKINESIA;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
AZATHIOPRINE;C18orf56, TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;rs45445694;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA;CHILDREN;DISEASE:INFLAMMATORY_BOWEL_DISEASES;CAUTION_SIDE_EFFECT
LAMOTRIGINE;HLA-C;*07:18;HLA-C*07:18;TOXICITY;INCREASED;RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;;;CAUTION_SIDE_EFFECT
LAMOTRIGINE;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED;RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;;;CAUTION_SIDE_EFFECT
RIVAROXABAN;ABCB1;CC;rs4148738;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HEMORRHAGE;PEOPLE;OTHER:ATRIAL_FIBRILLATION;CAUTION_SIDE_EFFECT
LAMOTRIGINE;HLA-DQB1;*06:09;HLA-DQB1*06:09;TOXICITY;INCREASED;RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;;;CAUTION_SIDE_EFFECT
RIVAROXABAN;ABCB1;AA;rs1045642;EFFICACY;INCREASED;RISK;SIDE_EFFECT:THROMBOEMBOLISM;PEOPLE;OTHER:ATRIAL_FIBRILLATION;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*10;CYP2D6*10;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ENDOMETRIAL_HYPERPLASIA;PEOPLE;OTHER:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;TOXICITY;INCREASED;RISK;SIDE_EFFECT:CLOPIDOGREL_RESISTANCE;PEOPLE;DISEASE:CORONARY_DISEASE;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFD1;A;rs2236225;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;CHILDREN;DISEASE:JUVENILE_RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHADONE;CYP3A4;T;rs2242480;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:SIDE_EFFECTS;PEOPLE;DISEASE:HEROIN_DEPENDENCE;CAUTION_SIDE_EFFECT
CARBOPLATIN, CISPLATIN;CD274;AG + GG;rs2297136;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;OTHER:SMALL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*17/*17;CYP2C19*1, CYP2C19*17;TOXICITY;INCREASED;RISK;SIDE_EFFECT:BLEEDING_EVENTS;PEOPLE;DISEASE:MYOCARDIAL_INFARCTION;CAUTION_SIDE_EFFECT
CARBOPLATIN, CISPLATIN;CD274;CC + CG;rs822336;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;OTHER:SMALL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBOPLATIN, CISPLATIN;CD274;GT + TT;rs2282055;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;OTHER:SMALL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
HYDROMORPHONE, MORPHINE;OPRM1;AA;rs1799971;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:PRURITUS;;;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;CYP2D6;*2;CYP2D6*1, CYP2D6*2;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:EXTRAPYRAMIDAL_SYMPTOMS;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
PHENYTOIN;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;;;CAUTION_SIDE_EFFECT
DOXORUBICIN;NCF4;AA + AG;rs1883112;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:CARDIOTOXICITY;WOMEN;OTHER:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
AZATHIOPRINE;NUDT15;*1/*2 + *1/*3;NUDT15*1, NUDT15*2, NUDT15*3;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DISCONTINUATION, SIDE_EFFECT:MYELOSUPPRESSION;PEOPLE;OTHER:INFLAMMATION;CAUTION_SIDE_EFFECT
AZATHIOPRINE;TPMT;*1/*2 + *1/*3A +*1/*3C +*1/*8 +*1/*9 +*1/*12 +*1/*24 +*2/*3A +*3A/*3A +*3C/*3C;TPMT*1, TPMT*2, TPMT*3A, TPMT*3C, TPMT*8, TPMT*9, TPMT*12, TPMT*24;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DISCONTINUATION, SIDE_EFFECT:MYELOSUPPRESSION;PEOPLE;OTHER:INFLAMMATION;CAUTION_SIDE_EFFECT
DOXORUBICIN;CBR1;CT + TT;rs3787728;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:PROGRESSION-FREE_SURVIVAL, EFFICACY:OVERALL_SURVIVAL;PEOPLE;OTHER:HEPATOCELLULAR_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
INFLIXIMAB;HLA-DRB1;*04:04;HLA-DRB1*04:04;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;;;CAUTION_SIDE_EFFECT
DOXORUBICIN;CBR1;CG + GG;rs1005695;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:PROGRESSION-FREE_SURVIVAL, EFFICACY:OVERALL_SURVIVAL;PEOPLE;OTHER:HEPATOCELLULAR_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
ATORVASTATIN;SLCO1B1;*1/*5 + *5/*5;SLCO1B1*1, SLCO1B1*5;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DISCONTINUATION, SIDE_EFFECT:STATIN-RELATED_MYOPATHY;;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1, CYP2C19*2;OTHER;INCREASED;;OTHER:PLATELET_REACTIVITY_BY_P2Y12_REACTION_UNITS;;OTHER:PATIENTS_UNDERGOING_PERCUTANEOUS_CORONARY_INTERVENTION;CAUTION_DOSE_ADJUST
DABIGATRAN;CES1;GG + GT;rs2244613;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE;PEOPLE;OTHER:ATRIAL_FIBRILLATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
OLANZAPINE, QUETIAPINE, RISPERIDONE;SLC6A4;HTTLPR long form (L allele);SLC6A4 HTTLPR LONG FORM (L ALLELE), SLC6A4 HTTLPR SHORT FORM (S ALLELE);TOXICITY;INCREASED;RISK;DISEASE:DIZZINESS;HEALTHY;;CAUTION_SIDE_EFFECT
RIVAROXABAN;ABCB1;AA + AG;rs1045642;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:THROMBOEMBOLISM;PEOPLE;OTHER:ATRIAL_FIBRILLATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
PHENYTOIN;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;DISEASE:TOXIC_EPIDERMAL_NECROLYSIS, DISEASE:STEVENS-JOHNSON_SYNDROME;;;CAUTION_SIDE_EFFECT
CAPECITABINE, PLATINUM;C18orf56, TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;DECREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS, DISEASE:GASTROESOPHAGEAL_CANCER;LIKELIHOOD_THERAPEUTIC_FAILURE
ONDANSETRON;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);SLC6A4 HTTLPR LONG FORM (L ALLELE), SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;;OTHER:PERCENTAGE_OF_DAYS_ABSTINENT_AND_LOWER_NUMBER_OF_DRINKS_PER_DRINKING_DAY;PEOPLE;DISEASE:ALCOHOL_ABUSE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CHOP, RITUXIMAB;CBR3;AA + AG;rs8133052;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:CARDIOTOXICITY;PEOPLE;OTHER:NON-HODGKIN_LYMPHOMA;CAUTION_SIDE_EFFECT
LAMOTRIGINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;DISEASE:TOXIC_EPIDERMAL_NECROLYSIS, DISEASE:STEVENS-JOHNSON_SYNDROME;;;CAUTION_SIDE_EFFECT
CHOP, RITUXIMAB;ABCC2;AA + AG;rs8187710;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:CARDIOTOXICITY;PEOPLE;OTHER:NON-HODGKIN_LYMPHOMA;CAUTION_SIDE_EFFECT
FLUOROURACIL;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;rs45445694;EFFICACY;DECREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;OTHER:STOMACH_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOPHOSPHAMIDE;CYP2B6;*5/*6;CYP2B6*1, CYP2B6*5, CYP2B6*6;EFFICACY;DECREASED;;EFFICACY:RECURRENCE_FREE_SURVIVAL;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;SLC19A1;T;rs1051266;EFFICACY;;;EFFICACY:WORSE_PROGNOSES;PEOPLE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DOSE_ADJUST
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);SLC6A4 HTTLPR LONG FORM (L ALLELE), SLC6A4 HTTLPR SHORT FORM (S ALLELE);TOXICITY;INCREASED;RISK;SIDE_EFFECT:SEXUAL_DYSFUNCTION;;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*1/*11;CYP2C9*1, CYP2C9*11;EFFICACY;INCREASED;;EFFICACY:INTERNATIONAL_NORMALIZED_RATIO_VARIABILITY_(INR-VAR);HEALTHY;;LIKELIHOOD_THERAPEUTIC_SUCCESS
AZATHIOPRINE, MERCAPTOPURINE, PURINE ANALOGUES;TPMT;*1/*3C;TPMT*1, TPMT*3C;TOXICITY;INCREASED;RISK;SIDE_EFFECT:LEUKOPENIA;PEOPLE;DISEASE:INFLAMMATORY_BOWEL_DISEASES;CAUTION_SIDE_EFFECT
GEMCITABINE, PLATINUM COMPOUNDS;RRM1;C;rs1042927;EFFICACY;DECREASED;;EFFICACY:OVERALL_SURVIVAL_PROBABILITY;PEOPLE;DISEASE:MESOTHELIOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;SLC19A1;CC;rs1051266;TOXICITY;INCREASED;RISK;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;HTR2A;CC + TT;rs6311;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:TREMOR, SIDE_EFFECT:DIARRHEA;PEOPLE;OTHER:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
AMOXICILLIN, CLAVULANATE;HLA-B;*15:18;HLA-B*15:18;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*28/*28 + *28/*37;UGT1A1*1, UGT1A1*28, UGT1A1*37;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:ASTHENIA, SIDE_EFFECT:DIARRHEA, SIDE_EFFECT:NEUTROPENIA;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
CAPECITABINE, PACLITAXEL;TYMS;TTAAAGTTA/TTAAAGTTA;rs11280056;EFFICACY;DECREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:STOMACH_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
AZATHIOPRINE, MERCAPTOPURINE;PTPN2;C;rs11664064;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA;PEOPLE;OTHER:INFLAMMATORY_BOWEL_DISEASES, OTHER:LUPUS_ERYTHEMATOSUS,OTHER:AUTOIMMUNE_DISEASES;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC AGENTS, TAMOXIFEN;CYP2D6;*3/*4 + *4/*4 + *4/*5;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*41;EFFICACY;DECREASED;;EFFICACY:OVERALL_SURVIVAL;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
BEVACIZUMAB, FLUOROURACIL, IRINOTECAN, LEUCOVORIN;SHMT1;A;rs1979277;EFFICACY;INCREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL_(PFS)_(P=0.00004)_AND_OVERALL_SURVIVAL_(OS)_(P=0.034);PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;MTHFD1;AA;rs2236225;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA_OTHER:OSTEOSARCOMA,OTHER:NON-HODGKIN_LYMPHOMA, OTHER:SARCOMA;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;CT + TT;rs3892097;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:OVERALL_SURVIVAL;WOMEN;OTHER:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;ABCB1;GG;rs1045642;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
METHOTREXATE;GSTP1;AA;rs1695;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:MYELOSUPPRESSION;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA_OTHER:OSTEOSARCOMA,OTHER:NON-HODGKIN_LYMPHOMA, OTHER:SARCOMA;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;AA + AG;rs1801133;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:MYELOSUPPRESSION;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA_OTHER:OSTEOSARCOMA,OTHER:NON-HODGKIN_LYMPHOMA, OTHER:SARCOMA;CAUTION_SIDE_EFFECT
MERCAPTOPURINE, METHOTREXATE;TPMT;C;rs1142345;TOXICITY;INCREASED;;SIDE_EFFECT:GI_TOXICITY;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
METHOTREXATE;SLCO1B1;T;rs11045879;TOXICITY;INCREASED;RISK;DISEASE:MUCOSITIS;PEOPLE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
AMOXICILLIN, CLAVULANATE;HLA-DRB1;*15:01;HLA-DRB1*15:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;;;CAUTION_SIDE_EFFECT
AMOXICILLIN, CLAVULANATE;HLA-A;*02:01;HLA-A*02:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;;;CAUTION_SIDE_EFFECT
AMOXICILLIN, CLAVULANATE;ERAP1, ERAP2;G;rs1363907;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;GSTT1;;GSTT1 NON-NULL, GSTT1 NULL;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:GRAFT_VS_HOST_DISEASE;PEOPLE;OTHER:HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION;CAUTION_SIDE_EFFECT
AMOXICILLIN, CLAVULANATE;PTPN22;A;rs2476601;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;GSTM1;;GSTM1 NON-NULL, GSTM1 NULL;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;OTHER:HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION;CAUTION_SIDE_EFFECT
CAPECITABINE;TYMS;G;rs3786362;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME;PEOPLE;OTHER:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE;TYMS;C;rs699517;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME;PEOPLE;OTHER:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
CAPECITABINE;ENOSF1, TYMS;TTAAAGTTA;rs11280056;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME;PEOPLE;OTHER:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
CAPECITABINE;C18orf56, TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;rs45445694;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME;PEOPLE;OTHER:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
CAPECITABINE;ENOSF1, TYMS;G;rs2790;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME;PEOPLE;OTHER:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;NME1, NME1-NME2;TT;rs2302254;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:OVERALL_SURVIVAL, EFFICACY:RECURRENCE_FREE_SURVIVAL;PEOPLE;OTHER:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
IRINOTECAN;UGT1A7;*1a/*3 + *2/*3 + *3/*3;UGT1A7*1A, UGT1A7*2, UGT1A7*3;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DIARRHEA;PEOPLE;OTHER:STOMACH_NEOPLASMS;CAUTION_SIDE_EFFECT
RIVAROXABAN;SUSD3;TT;rs76292544;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE;PEOPLE;OTHER:VENOUS_THROMBOEMBOLISM;CAUTION_SIDE_EFFECT
NAN;CYP3A5, ZSCAN25;CC;rs776746;NAN;;;SIDE_EFFECT:DRUG_TOXICITY;;;CAUTION_DOSE_ADJUST
IRINOTECAN;UGT1A1;*1/*6 + *6/*6;UGT1A1*1, UGT1A1*6;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DIARRHEA;PEOPLE;OTHER:STOMACH_NEOPLASMS;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*1/*6 + *6/*6;UGT1A1*1, UGT1A1*6;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA;PEOPLE;OTHER:STOMACH_NEOPLASMS;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A7;*1a/*3 + *2/*3 + *3/*3;UGT1A7*1A, UGT1A7*2, UGT1A7*3;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA;PEOPLE;OTHER:STOMACH_NEOPLASMS;CAUTION_SIDE_EFFECT
METHOTREXATE;SLCO1B1;G;rs4149081;TOXICITY;INCREASED;RISK;SIDE_EFFECT:GI_TOXICITY;PEOPLE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-A;*02:07;HLA-A*02:07;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:EXANTHEMA, SIDE_EFFECT:DRUG_HYPERSENSITIVITY;;;CAUTION_SIDE_EFFECT
ASPIRIN;FCER1G;AA;rs11587213;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ASPIRIN-INTOLERANT_ASTHMA;PEOPLE;DISEASE:ASTHMA;CAUTION_SIDE_EFFECT
LAPATINIB;HLA-DQA1;*02:01;HLA-DQA1*02:01;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*1/*1 + *1/*3 + *1/*6 + *1/*7;CYP3A5*1, CYP3A5*3, CYP3A5*6, CYP3A5*7;EFFICACY;INCREASED;RISK;EFFICACY:TRANSPLANT_REJECTION;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
LAPATINIB;HLA-DQA1;*02:01;HLA-DQA1*02:01;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE;PEOPLE;OTHER:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;C;rs776746;METABOLISM/PK;INCREASED;;PK:TACROLIMUS_CONCENTRATION_TO_DOSE_RATIO_(C/D_RATIO);;;CAUTION_DOSE_ADJUST
LAPATINIB;HLA-DRB1;*07:01;HLA-DRB1*07:01;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE;PEOPLE;OTHER:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
NAN;MS4A2;AG + GG;rs569108;TOXICITY;INCREASED;LIKELIHOOD;OTHER:ATOPY_IN_PATIENTS_WITH_ASPIRIN-INTOLERANT_CHRONIC_URTICARIA;;;CAUTION_SIDE_EFFECT
LAPATINIB;HLA-DRB1;*07:01;HLA-DRB1*07:01;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
PACLITAXEL;ABCB1;AA;rs2032582;EFFICACY;INCREASED;;EFFICACY:CHANCE_OF_POSITIVE_RESPONSE_TO_PACLITAXEL;PEOPLE;DISEASE:OVARIAN_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHAMBUTOL, ISONIAZID / PYRAZINAMIDE / RIFAMPIN;FECH;CC;rs536560;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;PEOPLE;OTHER:TUBERCULOSIS;CAUTION_SIDE_EFFECT
NAN;FCER1G;AG + GG;rs11587213;TOXICITY;INCREASED;LIKELIHOOD;OTHER:ATOPY_IN_PATIENTS_WITH_ASPIRIN-INTOLERANT_CHRONIC_URTICARIA;;;CAUTION_SIDE_EFFECT
PHENYTOIN;CYP2C9;*1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C9*1, CYP2C9*2, CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;;;CAUTION_SIDE_EFFECT
ACENOCOUMAROL;CYP2C9;*3;CYP2C9*1, CYP2C9*3;EFFICACY;INCREASED;RISK;SIDE_EFFECT:OVER-ANTICOAGULATION;;;CAUTION_SIDE_EFFECT
CISPLATIN, RADIOTHERAPY;EPHX1;CT + TT;rs1051740;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:NEPHROTOXICITY;PEOPLE;OTHER:HEAD_AND_NECK_NEOPLASMS;CAUTION_SIDE_EFFECT
CISPLATIN, RADIOTHERAPY;ERCC2;GG + GT;rs13181;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:OVERALL_SURVIVAL;PEOPLE;OTHER:HEAD_AND_NECK_NEOPLASMS, OTHER:LUNG_NEOPLASMS,OTHER:NEOPLASM_OF_ESOPHAGUS;LIKELIHOOD_THERAPEUTIC_FAILURE
CISPLATIN, RADIOTHERAPY;ERCC2;CT + TT;rs1799793;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:OVERALL_SURVIVAL;PEOPLE;OTHER:HEAD_AND_NECK_NEOPLASMS, OTHER:LUNG_NEOPLASMS,OTHER:NEOPLASM_OF_ESOPHAGUS;LIKELIHOOD_THERAPEUTIC_FAILURE
GEMCITABINE, PLATINUM COMPOUNDS;CDA;C;rs2072671;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:NAUSEA;PEOPLE;DISEASE:MESOTHELIOMA;CAUTION_SIDE_EFFECT
NAN;CYP2A6;*4/*4;CYP2A6*4;OTHER;INCREASED;LIKELIHOOD;OTHER:SMOKING_CESSATION;PEOPLE;OTHER:TOBACCO_USE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTHRACYCLINES AND RELATED SUBSTANCES;CYP3A5;AA;rs4646450;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:CARDIOTOXICITY;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA_OTHER:OSTEOSARCOMA;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;NUDT15;*1/*2 + *1/*3 + *1/*6 + *2/*2;NUDT15*1, NUDT15*2, NUDT15*3, NUDT15*6;TOXICITY;INCREASED;;SIDE_EFFECT:NEUTROPENIA;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
ANTHRACYCLINES AND RELATED SUBSTANCES;SLC28A3;AA;rs7853758;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:CARDIOTOXICITY;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
AZATHIOPRINE;TPMT;*1/*3C;TPMT*1, TPMT*3C;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:MYELOSUPPRESSION;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
OMEPRAZOLE;CYP2C19;*1/*1 + *1/*2 + *1/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED;;DISEASE:GASTRIC_PH;PEOPLE;DISEASE:HELICOBACTER_INFECTIONS;LIKELIHOOD_THERAPEUTIC_FAILURE
ETHAMBUTOL, ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;;NAT2 SLOW_ACETYLATOR;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;PEOPLE;OTHER:TUBERCULOSIS;CAUTION_SIDE_EFFECT
PHENPROCOUMON;VKORC1;TT;rs9923231;DOSAGE, OTHER;INCREASED;RISK;SIDE_EFFECT:ADVERSE_EVENTS;;;CAUTION_DOSE_ADJUST
METHOTREXATE;TYMS;TTAAAGTTA/TTAAAGTTA;rs11280056;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
CARBOPLATIN, GEMCITABINE;TYMS;TTAAAGTTA/TTAAAGTTA;rs11280056;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:THROMBOCYTOPENIA;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
METHOTREXATE;SLCO1B1;C;rs4149056;OTHER, METABOLISM/PK;DECREASED;;PK:CLEARANCE;PEOPLE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DOSE_ADJUST
ASPARAGINASE;HLA-DRB1;*07:01;HLA-DRB1*07:01;TOXICITY;INCREASED;;SIDE_EFFECT:DRUG_HYPERSENSITIVITY;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
ENALAPRIL;ACE;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;rs1799752;EFFICACY;INCREASED;LIKELIHOOD;DISEASE:CHRONIC_KIDNEY_FAILURE;PEOPLE;DISEASE:GLOMERULONEPHRITIS, IGA;LIKELIHOOD_THERAPEUTIC_SUCCESS
SUCCINYLCHOLINE, VOLATILE ANESTHETICS;RYR1;G;rs193922752;TOXICITY;INCREASED;RISK;SIDE_EFFECT:MALIGT_HYPERTHERMIA;;;CAUTION_SIDE_EFFECT
EGFR INHIBITORS;EGFR;GG;rs2227983;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:EXANTHEMA;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
GEMCITABINE, PLATINUM COMPOUNDS;RRM1;A;rs12806698;TOXICITY;DECREASED;LIKELIHOOD;DISEASE:NAUSEA;PEOPLE;DISEASE:MESOTHELIOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEMCITABINE, PLATINUM COMPOUNDS;RRM1;C;rs11030918;TOXICITY;DECREASED;LIKELIHOOD;DISEASE:NAUSEA;PEOPLE;DISEASE:MESOTHELIOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;DISEASE:STEVENS-JOHNSON_SYNDROME;CHILDREN;;CAUTION_SIDE_EFFECT
VERAPAMIL;ADRB1;AA + AG;rs1801252;EFFICACY;INCREASED;RISK;DISEASE:DEATH;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;CAUTION_SIDE_EFFECT
HEROIN;DRD2;G;rs12364283;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HEROIN_DEPENDENCE;;;CAUTION_SIDE_EFFECT
REPAGLINIDE;CYP2C8;*3;CYP2C8*3;METABOLISM/PK;DECREASED;;PK:REPAGLINIDE_AUC;HEALTHY;;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;INCREASED;;EFFICACY:PLATELET_REACTIVITY;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
AZATHIOPRINE;TPMT;*1/*3C;TPMT*1, TPMT*3C;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HAEMATOPOIETIC_TOXICITY;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
SULFAMETHOXAZOLE / TRIMETHOPRIM;NAT2;;NAT2 SLOW_ACETYLATOR;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;NUDT15;*3/*3;NUDT15*1, NUDT15*2, NUDT15*3, NUDT15*5, NUDT15*6;TOXICITY;INCREASED;RISK;SIDE_EFFECT:LEUKOPENIA;CHILDREN;DISEASE:INFLAMMATORY_BOWEL_DISEASES;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A7;C;rs2257401;METABOLISM/PK;;;PK:TACROLIMUS_CONCENTRATION_TO_DOSE_RATIO_(C/D_RATIO);;;CAUTION_DOSE_ADJUST
SIMVASTATIN;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:MUSCULAR_DISEASES;PEOPLE;OTHER:CORONARY_ARTERY_DISEASE;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;INCREASED;;EFFICACY:PLATELET_REACTIVITY;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PHENYTOIN;CYP2C19;A;rs4986893;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS;;;CAUTION_SIDE_EFFECT
TRAMADOL;CYP2D6;*3/*5;CYP2D6*1, CYP2D6*3, CYP2D6*5;DOSAGE, EFFICACY;INCREASED;RISK;EFFICACY:NON-RESPONSE_AND_REQUIRED_HIGHER_DOSE;;;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;TOXICITY;INCREASED;RISK;SIDE_EFFECT:CARDIOVASCULAR_EVENTS;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;CAUTION_SIDE_EFFECT
TRAMADOL;CYP2D6;*4/*4;CYP2D6*1, CYP2D6*4;DOSAGE, EFFICACY;INCREASED;RISK;EFFICACY:NON-RESPONSE_AND_REQUIRED_HIGHER_DOSE;;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A4;G;rs4646437;METABOLISM/PK;;;PK:TACROLIMUS_CONCENTRATION_TO_DOSE_RATIO_(C/D_RATIO);;;CAUTION_DOSE_ADJUST
ISONIAZID, RIFAMPIN;NAT2;*4;NAT2*4;TOXICITY, METABOLISM/PK;DECREASED;LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:TUBERCULOSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPARAGINASE;SOD2;GG;rs4880;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
NAN;CYP1A2;AC + CC;rs762551;OTHER;INCREASED;RISK;DISEASE:MYOCARDIAL_INFARCTION;PEOPLE;OTHER:INCREASED_COFFEE_INTAKE;CAUTION_SIDE_EFFECT
ANTITHYROID PREPARATIONS;HLA-B;*39:01;HLA-B*39:01;TOXICITY;INCREASED;RISK;SIDE_EFFECT:AGRANULOCYTOSIS;PEOPLE;OTHER:GRAVES_DISEASE;CAUTION_SIDE_EFFECT
TRASTUZUMAB;ERBB2;AG + GG;rs1136201;TOXICITY;INCREASED;RISK;SIDE_EFFECT:CARDIOTOXICITY;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
SIMVASTATIN;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;PEOPLE;OTHER:CORONARY_ARTERY_DISEASE;CAUTION_SIDE_EFFECT
PHENYTOIN;CYP2C9;T;rs1799853;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:STEVENS-JOHNSON_SYNDROME;;;CAUTION_SIDE_EFFECT
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED;RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;;;CAUTION_SIDE_EFFECT
BETA BLOCKING AGENTS;ADRA2C;GGGGCGGGGCCG/GGGGCGGGGCCG;rs61767072;EFFICACY;INCREASED;RISK;EFFICACY:DEATH;PEOPLE;OTHER:ACUTE_CORONARY_SYNDROME;CAUTION_SIDE_EFFECT
PACLITAXEL;FZD3;A;rs7001034;TOXICITY;DECREASED;RISK;SIDE_EFFECT:SENSORY_PERIPHERAL_NEUROPATHY;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE, FLUOROURACIL;TYMS;TTA/TTA;rs11280056;TOXICITY;INCREASED;RISK;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;;RISK;DISEASE:TOXIC_EPIDERMAL_NECROLYSIS, DISEASE:STEVENS-JOHNSON_SYNDROME;;;CAUTION_DOSE_ADJUST
SERTRALINE;SLC6A4;HTTLPR long form (L allele);SLC6A4 HTTLPR LONG FORM (L ALLELE), SLC6A4 HTTLPR SHORT FORM (S ALLELE);TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:PHYSIOLOGICAL_SEXUAL_DISORDER;PEOPLE;OTHER:MAJOR_DEPRESSIVE_DISORDER;CAUTION_SIDE_EFFECT
CLOZAPINE;HLA-DRB1;*04:02;HLA-DRB1*04:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:AGRANULOCYTOSIS;PEOPLE;OTHER:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
DIRECT ACTING ANTIVIRALS;IFNL3, IFNL4;TT;rs12979860;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HEPATOCELLULAR_CARCINOMA;PEOPLE;OTHER:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;CAUTION_SIDE_EFFECT
GLICLAZIDE, GLIMEPIRIDE, GLIPIZIDE, GLIQUIDONE, GLYBURIDE;CYP2C9;*2 + *3;CYP2C9*1, CYP2C9*2, CYP2C9*3;OTHER;INCREASED;RISK;DISEASE:HYPOGLYCEMIA;PEOPLE;DISEASE:DIABETES_MELLITUS;CAUTION_SIDE_EFFECT
TRAMADOL;CYP2D6;*5/*5;CYP2D6*1, CYP2D6*5;DOSAGE, EFFICACY;INCREASED;RISK;EFFICACY:NON-RESPONSE_AND_REQUIRED_HIGHER_DOSE;;;CAUTION_DOSE_ADJUST
ASPIRIN, BETA BLOCKING AGENTS, CLOPIDOGREL, HMG COA REDUCTASE INHIBITORS;NOS3;T;rs1799983;OTHER;INCREASED;RISK;OTHER:IN-STENT_RESTENOSIS;MEN;DISEASE:CORONARY_ARTERY_DISEASE;CAUTION_SIDE_EFFECT
CISPLATIN, IRINOTECAN;UGT1A1;AA;rs4148323;EFFICACY;DECREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTHRACYCLINES AND RELATED SUBSTANCES, TAMOXIFEN;CYP2D6;*4/*4;CYP2D6*1, CYP2D6*4;EFFICACY;DECREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
ASPIRIN, CLOPIDOGREL;CYP2C9;AC + CC;rs1057910;EFFICACY;INCREASED;RISK;SIDE_EFFECT:STENT_THROMBOSIS;PEOPLE;OTHER:PERCUTANEOUS_CORONARY_INTERVENTIONS;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A4;C;rs6956344;METABOLISM/PK;;;PK:TACROLIMUS_CONCENTRATION_TO_DOSE_RATIO_(C/D_RATIO);;;CAUTION_DOSE_ADJUST
TAMOXIFEN;CYP2D6;*4/*4;CYP2D6*1, CYP2D6*4;EFFICACY;DECREASED;;EFFICACY:EVENT-FREE_SURVIVAL, EFFICACY:RECURRENCE_FREE_SURVIVAL;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
CISPLATIN, IRINOTECAN;UGT1A1;AA;rs4148323;EFFICACY;DECREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
IRINOTECAN;UGT1A1;*1/*28;UGT1A1*1, UGT1A1*28;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:DIARRHEA;PEOPLE;OTHER:NEOPLASMS;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*15:21;HLA-B*15:21;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;PEOPLE;OTHER:EPILEPSY, OTHER:MOOD_DISORDER,OTHER:NEUROPATHIC_PAIN;CAUTION_SIDE_EFFECT
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED;RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;;;CAUTION_SIDE_EFFECT
FOLFIRI;UGT1A1;*28/*28;UGT1A1*1, UGT1A1*28;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:NEUTROPENIA;PEOPLE;OTHER:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
PACLITAXEL;ABCB1;AG;rs1045642;EFFICACY;DECREASED;;EFFICACY:DISEASE_CONTROL_RATE_AND_LOWER_OVERALL_SURVIVAL_RATE;PEOPLE;OTHER:METASTATIC_BREAST_CANCER;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*2;CYP2C19*2;METABOLISM/PK;DECREASED;;PK:CLOPIDOGREL_ACTIVE_METABOLITE_LEVEL;HEALTHY;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;INCREASED;LIKELIHOOD;PK:ACHIEVING_TARGET_CONCENTRATIONS;CHILDREN;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;*2;CYP2C19*2;EFFICACY;INCREASED;;EFFICACY:POST-TREATMENT_ADP-STIMULATED_PLATELET_AGGREGATION;HEALTHY;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PACLITAXEL;CYP3A5;C;rs776746;TOXICITY;DECREASED;RISK;DISEASE:NEUROTOXICITY_SYNDROMES;PEOPLE;DISEASE:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ABACAVIR;HLA-B;*57:01;HLA-B*57:01;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_HYPERSENSITIVITY;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*4/*4;CYP2D6*1, CYP2D6*4;TOXICITY;DECREASED;RISK;SIDE_EFFECT:HOT_FLASHES;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
INFLIXIMAB;HLA-DQB1;*02:01;HLA-DQB1*02:01;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;;;CAUTION_SIDE_EFFECT
INFLIXIMAB;HLA-DPB1;*10:01;HLA-DPB1*10:01;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;;;CAUTION_SIDE_EFFECT
INFLIXIMAB;HLA-DRB1;*03:01;HLA-DRB1*03:01;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;;;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*1/*4 + *1/*5 + *1/*10 + *1/*10x2 + *10/*10x2 + *1/*14 + *1/*21 + *1/*36 + *1/*41 + *1xN/*10 + *5/*5 + *5/*10 + *5/*21 + *5/*41 + *10/*10 + *10/*21 + *10/*36 + *10/*41;CYP2D6*1, CYP2D6*1XN, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*10X2, CYP2D6*14, CYP2D6*21, CYP2D6*36, CYP2D6*41;EFFICACY;DECREASED;;EFFICACY:RECURRENCE_FREE_SURVIVAL;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
NAN;HLA-DPB1;*03:01;HLA-DPB1*03:01;TOXICITY;INCREASED;RISK;DISEASE:ASPIRIN-INDUCED_ASTHMA;;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;;;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC AGENTS, TAMOXIFEN;CYP2D6;*4/*4 + *4/*5 + *4/*10;CYP2D6*1, CYP2D6*2, CYP2D6*4, CYP2D6*5, CYP2D6*10;EFFICACY;INCREASED;RISK;EFFICACY:RECURRENCE;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
TRAMADOL;CYP2D6;*6/*6;CYP2D6*1, CYP2D6*6;DOSAGE, EFFICACY;INCREASED;RISK;EFFICACY:NON-RESPONSE_AND_REQUIRED_HIGHER_DOSE;;;CAUTION_DOSE_ADJUST
TRAMADOL;CYP2D6;*4/*5;CYP2D6*1, CYP2D6*4, CYP2D6*5;DOSAGE, EFFICACY;INCREASED;RISK;EFFICACY:NON-RESPONSE_AND_REQUIRED_HIGHER_DOSE;;;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;*2/*2;CYP2C19*2;EFFICACY;DECREASED;;EFFICACY:ANTIPLATELET_RESPONSE_AND_REDUCED_CLOPIDOGREL_ACTIVE_METABOLITE_FORMATION;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED;RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;PEOPLE;DISEASE:GOUTY_ARTHRITIS;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE, CYTARABINE, DAUNORUBICIN, DOXORUBICIN, MERCAPTOPURINE, METHOTREXATE, PEGASPARGASE, THIOGUANINE, VINCRISTINE;CPT1A, IGHMBP2;T;rs12283870;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ELEVATED_LIVER_ENZYMES;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
FOLFIRINOX;UGT1A1;*28;UGT1A1*1, UGT1A1*28;TOXICITY;INCREASED;RISK;SIDE_EFFECT:THROMBOCYTOPENIA;PEOPLE;OTHER:PANCREATIC_NEOPLASMS;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*4 + *5 + *10 + *14 + *21 + *36 + *41;CYP2D6*1, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*14, CYP2D6*21, CYP2D6*36, CYP2D6*41;EFFICACY;INCREASED;RISK;EFFICACY:RECURRENCE;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED;RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;;;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;INCREASED;;PK:DOSE-ADJUSTED_BLOOD_LEVELS;PEOPLE;OTHER:LUNG_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;INCREASED;;PK:DOSE-ADJUSTED_TROUGH_CONCENTRATION;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;INCREASED;;PK:TROUGH_CONCENTRATION;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A4;C;rs2242480;METABOLISM/PK;;;PK:TACROLIMUS_CONCENTRATION_TO_DOSE_RATIO_(C/D_RATIO);;;CAUTION_DOSE_ADJUST
TAMOXIFEN;CYP2D6;*10/*10;CYP2D6*1, CYP2D6*10;EFFICACY;INCREASED;RISK;EFFICACY:RECURRENCE;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;TPMT;*1/*2 + *1/*3A;TPMT*1, TPMT*2, TPMT*3A;TOXICITY;INCREASED;RISK;SIDE_EFFECT:LEUKOPENIA;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
METHAZOLAMIDE;HLA-C;*01:02;HLA-C*01:02;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;;;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;;EFFICACY:RESPONSE_RATE_TO_PEGIFN-ALPHA/RBV_TREATMENT_AT_WEEK_20/24;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;*1/*1;CYP3A5*1, CYP3A5*3;OTHER;INCREASED;;OTHER:CREATININE_CLEARANCE;CHILDREN;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
FLECAINIDE;CYP2D6;*4 + *5 + *10 + *21 + *36;CYP2D6*1, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*21, CYP2D6*36;METABOLISM/PK;INCREASED;;PK:AGE-RELATED_DECLINE_IN_FLECAINIDE_CLEARANCE_PATIENTS_TREATED_WITH_ORAL_FLECAINIDE_FOR_SUPRAVENTRICULAR_TACHYARRHYTHMIAS;;;CAUTION_DOSE_ADJUST
TRANILAST;UGT1A1;*28/*28;UGT1A1*1, UGT1A1*28;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HYPERBILIRUBINEMIA;PEOPLE;OTHER:MYOCARDIAL_ISCHEMIA;CAUTION_SIDE_EFFECT
NORTRIPTYLINE;CYP2D6;*3;CYP2D6*1, CYP2D6*3;METABOLISM/PK;INCREASED;;PK:MEAN_NORTRIPTYLINE_CONCENTRATIONS_AND_NORTRIPTYLINE_CONCENTRATIONS_PER_UNIT_DOSE_OF_THE_MEDICATION;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DOSE_ADJUST
FLECAINIDE;CYP2D6;*5/*36 + *10/*10 + *10/*36 + *21/*36;CYP2D6*1, CYP2D6*2, CYP2D6*5, CYP2D6*10, CYP2D6*21, CYP2D6*36;METABOLISM/PK;DECREASED;;PK:ORAL_CLEARANCE_(CL/F)_OF_FLECAINIDE_IN_PATIENTS_WITH_SUPRAVENTRICULAR_TACHYARRHYTHMIA;;;CAUTION_DOSE_ADJUST
ANTITHYROID PREPARATIONS;HLA-DRB1;*08:03;HLA-DRB1*08:03;TOXICITY;INCREASED;RISK;SIDE_EFFECT:AGRANULOCYTOSIS;PEOPLE;OTHER:GRAVES_DISEASE;CAUTION_SIDE_EFFECT
ANTITHYROID PREPARATIONS;HLA-DQA1;*01:03;HLA-DQA1*01:03;TOXICITY;INCREASED;RISK;SIDE_EFFECT:AGRANULOCYTOSIS;PEOPLE;OTHER:GRAVES_DISEASE;CAUTION_SIDE_EFFECT
ANTITHYROID PREPARATIONS;HLA-DQB1;*06:01;HLA-DQB1*06:01;TOXICITY;INCREASED;RISK;SIDE_EFFECT:AGRANULOCYTOSIS;PEOPLE;OTHER:GRAVES_DISEASE;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*1/*3;CYP2C9*1, CYP2C9*3;EFFICACY;DECREASED;;EFFICACY:TIME_TO_THERAPEUTIC_INR;;;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTINEOPLASTIC AGENTS, TAMOXIFEN;CYP2D6;*4/*4 + *4/*41 + *1/*5 + *2/*5;CYP2D6*1, CYP2D6*1XN, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*9, CYP2D6*10, CYP2D6*20, CYP2D6*35, CYP2D6*41;EFFICACY;DECREASED;;EFFICACY:EVENT-FREE_SURVIVAL;PEOPLE;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
CAPECITABINE;DPYD;AT;rs67376798;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;AA;rs1801133;TOXICITY;INCREASED;RISK;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY, SIDE_EFFECT:LEUKOPENIA, SIDE_EFFECT:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
CYTARABINE, IDARUBICIN;ABCB1;CC;rs2032582;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:3_YEAR_EVENT_FREE_SURVIVAL;PEOPLE;DISEASE:ACUTE_MYELOID_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP1A2;A;rs2069514;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HEMORRHAGE;PEOPLE;DISEASE:MYOCARDIAL_INFARCTION;CAUTION_SIDE_EFFECT
OPIOIDS;OPRM1;T;rs548646;TOXICITY;DECREASED;RISK;OTHER:OPIOID-RELATED_DISORDERS;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;DECREASED;;PK:TROUGH_CONCENTRATIONS;CHILDREN;OTHER:HEART_TRANSPLANTATION;CAUTION_DOSE_ADJUST
NORTRIPTYLINE;CYP2D6;*10;CYP2D6*1, CYP2D6*2, CYP2D6*10;METABOLISM/PK;INCREASED;;PK:NORTRIPTYLINE_CONCENTRATIONS_CORRECTED_FOR_DOSE_AND_WEIGHT;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A4;C/T + T/T;rs2242480;TOXICITY;INCREASED;RISK;DISEASE:ACUTE_CELLULAR_REJECTION;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;CAUTION_SIDE_EFFECT
RHODAMINE 123;ABCB1;GG;rs1045642;METABOLISM/PK;INCREASED;;PK:EFFLUX_OF_RHODAMINE_FROM_CD56+_NATURAL_KILLER_CELLS;;;CAUTION_DOSE_ADJUST
ASPIRIN, CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;EFFICACY;INCREASED;RISK;SIDE_EFFECT:STENT_THROMBOSIS;PEOPLE;OTHER:PERCUTANEOUS_CORONARY_INTERVENTIONS;CAUTION_SIDE_EFFECT
MERCAPTOPURINE, THIOGUANINE;TPMT;*1/*3A;TPMT*1, TPMT*3A;TOXICITY;;;SIDE_EFFECT:NEUTROPENIA, SIDE_EFFECT:THROMBOCYTOPENIA;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DOSE_ADJUST
ASPIRIN, CLOPIDOGREL, TICAGRELOR;PEAR1;AC;rs2768759;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HEMORRHAGE;PEOPLE;OTHER:STROKE;CAUTION_SIDE_EFFECT
LAMOTRIGINE;HLA-A;*68:01;HLA-A*68:01;TOXICITY;INCREASED;RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;;;CAUTION_SIDE_EFFECT
CELECOXIB;CYP2C9;*1/*3;CYP2C9*1, CYP2C9*3;EFFICACY;DECREASED;;EFFICACY:PAIN;CHILDREN;;LIKELIHOOD_THERAPEUTIC_FAILURE
AZATHIOPRINE, MERCAPTOPURINE;NUDT15;*2 + *3 + *4 + *5 + *6;NUDT15*1, NUDT15*2, NUDT15*3, NUDT15*4, NUDT15*5, NUDT15*6;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA;PEOPLE;DISEASE:INFLAMMATORY_BOWEL_DISEASES;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-A;*01:01;HLA-A*01:01;TOXICITY;INCREASED;RISK;SIDE_EFFECT:MACULOPAPULAR_EXANTHEMA;;;CAUTION_SIDE_EFFECT
TETANUS ANTITOXIN;HLA-A;*02:06;HLA-A*02:06;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_HYPERSENSITIVITY;;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-A;*11:01;HLA-A*11:01;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;;;CAUTION_SIDE_EFFECT
ACETAMINOPHEN;HLA-A;*24:02;HLA-A*24:02;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME, SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE;HLA-A;*24:02;HLA-A*24:02;TOXICITY;INCREASED;RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;;;CAUTION_SIDE_EFFECT
INFLIXIMAB;HLA-B;*08:01;HLA-B*08:01;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-A;*31:01;HLA-A*31:01;TOXICITY;INCREASED;RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-A;*31:01;HLA-A*31:01;TOXICITY;INCREASED;RISK;DISEASE:TOXIC_EPIDERMAL_NECROLYSIS, DISEASE:STEVENS-JOHNSON_SYNDROME;;;CAUTION_SIDE_EFFECT
VANCOMYCIN;HLA-A;*32:01;HLA-A*32:01;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS;;;CAUTION_SIDE_EFFECT
PHENYTOIN;HLA-B;*38:02;HLA-B*38:02;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;;;CAUTION_SIDE_EFFECT
NEVIRAPINE;HLA-B;*14:02;HLA-B*14:02;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_HYPERSENSITIVITY;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
PHENYTOIN;HLA-B;*15:01;HLA-B*15:01;TOXICITY;INCREASED;RISK;SIDE_EFFECT:EXANTHEMA;;;CAUTION_SIDE_EFFECT
ANTIEPILEPTICS;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;SIDE_EFFECT:MACULOPAPULAR_EXANTHEMA;PEOPLE;OTHER:EPILEPSY;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;;;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;INCREASED;;PK:DOSE-ADJUSTED_TROUGH_CONCENTRATIONS;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;DISEASE:STEVENS-JOHNSON_SYNDROME;PEOPLE;DISEASE:EPILEPSY;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;DISEASE:TOXIC_EPIDERMAL_NECROLYSIS, DISEASE:STEVENS-JOHNSON_SYNDROME;;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;;;CAUTION_SIDE_EFFECT
ANTIEPILEPTICS;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;PEOPLE;DISEASE:EPILEPSY;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;;;CAUTION_SIDE_EFFECT
PHENYTOIN;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;;;CAUTION_SIDE_EFFECT
PHENYTOIN;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*15:11;HLA-B*15:11;TOXICITY;INCREASED;RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;;;CAUTION_SIDE_EFFECT
PHENYTOIN;HLA-B;*15:13;HLA-B*15:13;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS, SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;;;CAUTION_SIDE_EFFECT
AZATHIOPRINE, MERCAPTOPURINE;TPMT;*3A + *3C;TPMT*1, TPMT*3A, TPMT*3C;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA, SIDE_EFFECT:NEUTROPENIA;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;NUDT15;*1/*2 + *1/*3 + *1/*4 + *1/*6;NUDT15*1, NUDT15*2, NUDT15*3, NUDT15*4, NUDT15*6;TOXICITY;INCREASED;RISK;SIDE_EFFECT:LEUKOPENIA;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
CLINDAMYCIN;HLA-B;*15:27;HLA-B*15:27;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;;;CAUTION_SIDE_EFFECT
NEVIRAPINE;HLA-B;*35:01;HLA-B*35:01;TOXICITY;INCREASED;RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;;;CAUTION_SIDE_EFFECT
CLOZAPINE;HLA-B;*38:01;HLA-B*38:01;TOXICITY;INCREASED;RISK;SIDE_EFFECT:AGRANULOCYTOSIS;PEOPLE;DISEASE:SCHIZOAFFECTIVE_DISORDER, DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
LAMOTRIGINE;HLA-B;*38:01;HLA-B*38:01;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;;;CAUTION_SIDE_EFFECT
SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-B;*38:02;HLA-B*38:02;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;;;CAUTION_SIDE_EFFECT
INFLIXIMAB;HLA-B;*39:01;HLA-B*39:01;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*40:01;HLA-B*40:01;TOXICITY;DECREASED;RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OXCARBAZEPINE;HLA-B;*40:02;HLA-B*40:02;TOXICITY;INCREASED;RISK;SIDE_EFFECT:MACULOPAPULAR_EXANTHEMA;PEOPLE;DISEASE:EPILEPSY;CAUTION_SIDE_EFFECT
MIRTAZAPINE;CYP2D6;*3/*4 + *4/*6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*6;METABOLISM/PK;INCREASED;;PK:S-MIRTAZAPINE_PLASMA_LEVELS_IN_NON-SMOKERS_AT_DAY_14_OF_TREATMENT;PEOPLE;DISEASE:DEPRESSION;CAUTION_DOSE_ADJUST
PHENYTOIN;HLA-B;*51:01;HLA-B*51:01;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS;;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*51:01;HLA-B*51:01;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;;;CAUTION_SIDE_EFFECT
NILOTINIB;UGT1A1;*28/*28;UGT1A1*1, UGT1A1*28;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HYPERBILIRUBINEMIA;PEOPLE;OTHER:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;CAUTION_SIDE_EFFECT
CLINDAMYCIN;HLA-B;*51:01;HLA-B*51:01;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;;;CAUTION_SIDE_EFFECT
PHENYTOIN;HLA-B;*51:01;HLA-B*51:01;TOXICITY;INCREASED;RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;;;CAUTION_SIDE_EFFECT
PHENYTOIN;HLA-B;*51:01;HLA-B*51:01;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;;;CAUTION_SIDE_EFFECT
ISONIAZID;HLA-B;*52:01;HLA-B*52:01;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;PEOPLE;OTHER:TUBERCULOSIS;CAUTION_SIDE_EFFECT
ABACAVIR;HLA-B;*57:01;HLA-B*57:01;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HYPERSENSITIVITY;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
ABACAVIR;HLA-B;*57:01;HLA-B*57:01;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_HYPERSENSITIVITY;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
ABACAVIR;HLA-B;*57:01;HLA-B*57:01;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_HYPERSENSITIVITY;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
ABACAVIR;HLA-B;*57:01;HLA-B*57:01;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_HYPERSENSITIVITY;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
METHAZOLAMIDE;HLA-B;*59:01;HLA-B*59:01;TOXICITY;INCREASED;RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;;;CAUTION_SIDE_EFFECT
METHAZOLAMIDE;HLA-B;*59:01;HLA-B*59:01;TOXICITY;INCREASED;RISK;DISEASE:TOXIC_EPIDERMAL_NECROLYSIS, DISEASE:STEVENS-JOHNSON_SYNDROME;;;CAUTION_SIDE_EFFECT
MIRTAZAPINE;CYP2D6;*4 + *5;CYP2D6*1, CYP2D6*4, CYP2D6*5;METABOLISM/PK;INCREASED;;PK:SERUM_CONCENTRATIONS_OF_S(+)-MIRTAZAPINE, _MIRTAZAPINE_S(+)/R(-)_RATIOS_AND_S(+)-N-DESMETHYLMIRTAZAPINE;PEOPLE;DISEASE:MENTAL_DISORDERS;CAUTION_DOSE_ADJUST
OPIOIDS;OPRM1;A;rs609148;TOXICITY;DECREASED;RISK;OTHER:OPIOID-RELATED_DISORDERS;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATAZANAVIR;UGT1A1;*1/*28;UGT1A1*1, UGT1A1*28;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HYPERBILIRUBINEMIA;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
METHAZOLAMIDE;HLA-C;*01:02;HLA-C*01:02;TOXICITY;INCREASED;RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;;;CAUTION_SIDE_EFFECT
CYCLOSPORINE;CYP3A4;*1/*1 + *1/*18;CYP3A4*1, CYP3A4*18;METABOLISM/PK;INCREASED;;PK:TROUGH_CONCENTRATIONS;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-C;*07:27;HLA-C*07:27;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;;;CAUTION_SIDE_EFFECT
NEVIRAPINE;HLA-C;*08:02;HLA-C*08:02;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_HYPERSENSITIVITY;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
INFLIXIMAB;HLA-C;*12:03;HLA-C*12:03;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;;;CAUTION_SIDE_EFFECT
NAN;HLA-DPB1;*03:01;HLA-DPB1*03:01;TOXICITY;INCREASED;RISK;DISEASE:ASPIRIN-INDUCED_ASTHMA;;;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;DECREASED;;PK:DOSE-ADJUSTED_TROUGH_CONCENTRATIONS;CHILDREN;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
PHENYTOIN;HLA-C;*15:02;HLA-C*15:02;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;;;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP2J2;AA + AC;rs890293;TOXICITY;INCREASED;RISK;DISEASE:NAUSEA, DISEASE:VOMITING;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-DQB1;*03:03;HLA-DQB1*03:03;TOXICITY;INCREASED;RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;PEOPLE;DISEASE:EPILEPSY;CAUTION_SIDE_EFFECT
ABACAVIR;HLA-DQB1;*03:03;HLA-DQB1*03:03;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HYPERSENSITIVITY;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
NEVIRAPINE;HLA-DQB1;*05:01;HLA-DQB1*05:01;TOXICITY;DECREASED;RISK;SIDE_EFFECT:DRUG_HYPERSENSITIVITY;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUPIRTINE;HLA-DQB1;*05:02;HLA-DQB1*05:02;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;;;CAUTION_SIDE_EFFECT
AMOXICILLIN, CLAVULANATE;HLA-DQB1;*06:02;HLA-DQB1*06:02;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HEPATITIS;PEOPLE;DISEASE:INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
NEVIRAPINE;HLA-DRB1;*01:01;HLA-DRB1*01:01;TOXICITY;INCREASED;RISK;DISEASE:DRUG_HYPERSENSITIVITY;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
NEVIRAPINE;HLA-DRB1;*01:01;HLA-DRB1*01:01;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE;;;CAUTION_SIDE_EFFECT
NEVIRAPINE;HLA-DRB1;*01:02;HLA-DRB1*01:02;TOXICITY;INCREASED;RISK;DISEASE:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
HYDRALAZINE;HLA-DRB1;*04:01;HLA-DRB1*04:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LUPUS_ERYTHEMATOSUS_DUE_TO_HYDRALAZINE;PEOPLE;OTHER:HYPERTENSION;CAUTION_SIDE_EFFECT
OXCARBAZEPINE;HLA-DRB1;*04:03;HLA-DRB1*04:03;TOXICITY;INCREASED;RISK;SIDE_EFFECT:MACULOPAPULAR_EXANTHEMA;PEOPLE;DISEASE:EPILEPSY;CAUTION_SIDE_EFFECT
ABACAVIR;HLA-DRB1;*07:01;HLA-DRB1*07:01;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HYPERSENSITIVITY;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
ASPARAGINASE;HLA-DRB1;*07:01;HLA-DRB1*07:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HYPERSENSITIVITY;PEOPLE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
LAPATINIB;HLA-DRB1;*07:01;HLA-DRB1*07:01;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;;;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;;AA;rs4969170;TOXICITY;DECREASED;RISK;DISEASE:THROMBOCYTOPENIA;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PRAVASTATIN;LDLR;G;rs2738466;EFFICACY;INCREASED;RISK;DISEASE:CORONARY_DISEASE;MEN;;CAUTION_SIDE_EFFECT
LAMOTRIGINE;HLA-DRB1;*13:01;HLA-DRB1*13:01;TOXICITY;INCREASED;RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;;;CAUTION_SIDE_EFFECT
FLUPIRTINE;HLA-DRB1;*16:01;HLA-DRB1*16:01;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;;;CAUTION_SIDE_EFFECT
THALIDOMIDE;GSTT1;AA;rs4630;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:NEUROTOXICITY;PEOPLE;DISEASE:MULTIPLE_MYELOMA;CAUTION_SIDE_EFFECT
MINOCYCLINE;HLA-B;*35:02;HLA-B*35:02;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;PEOPLE;;CAUTION_SIDE_EFFECT
PHENYTOIN;CYP2C9;*1/*2 + *1/*3;CYP2C9*1, CYP2C9*2, CYP2C9*3;METABOLISM/PK;DECREASED;;PK:DOSE;;DISEASE:EPILEPSY;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*3;CYP2C9*1, CYP2C9*3;EFFICACY;INCREASED;;EFFICACY:PROTHROMBIN_TIME_(PT)_AT_INDUCTION;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED;RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;PEOPLE;DISEASE:HYPERURICEMIA;CAUTION_SIDE_EFFECT
ROSIGLITAZONE;CYP2C8;*3;CYP2C8*1, CYP2C8*3;TOXICITY;DECREASED;;SIDE_EFFECT:WEIGHT_GAIN;PEOPLE;DISEASE:DIABETES_MELLITUS;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP2C8;*3;CYP2C8*1, CYP2C8*3;TOXICITY;INCREASED;RISK;DISEASE:KIDNEY_DISORDER;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;CAUTION_SIDE_EFFECT
CALCINEURIN INHIBITORS, CYCLOSPORINE, TACROLIMUS;CYP2C8;*3;CYP2C8*1, CYP2C8*3;TOXICITY;INCREASED;RISK;DISEASE:KIDNEY_DISORDER;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;CAUTION_SIDE_EFFECT
ASPIRIN, CILOSTAZOL, CLOPIDOGREL;CYP2C19;*2/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;METABOLISM/PK;INCREASED;;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY;;OTHER:HIGH_RISK_PATIENTS_(ACUTE_MYOCARIDAL_INFARCTION, DIABETES_E.G.);CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C9*1, CYP2C9*2, CYP2C9*3;EFFICACY, TOXICITY;INCREASED;RISK;SIDE_EFFECT:HEMORRHAGE, SIDE_EFFECT:OVER-ANTICOAGULATION;;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*3/*3;CYP2C9*1, CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HEMORRHAGE;MEN;;CAUTION_SIDE_EFFECT
PACLITAXEL, PLATINUM COMPOUNDS;NAT2;AA;rs1799931;EFFICACY;DECREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;OTHER:LUNG_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
CAFFEINE;CYP1A2;;CYP1A2 LOW ACTIVITY;OTHER;INCREASED;;OTHER:INTAKE;WOMEN;DISEASE:PREGNANCY;CAUTION_DOSE_ADJUST
HMG_COA_REDUCTASE_INHIBITORS;GNB3;CT + TT;rs5443;EFFICACY;DECREASED;RISK;DISEASE:MYOCARDIAL_INFARCTION;PEOPLE;DISEASE:HYPERCHOLESTEROLEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;HMGCR;AA;rs3846662;OTHER;DECREASED;;OTHER:HMGCRV_1_EXPRESSION_AND_AN_INCREASE_IN_THE_EXPRESSION_OF_THE_FULL-LENGTH_TRANSCRIPT;;;CAUTION_DOSE_ADJUST
ATAZANAVIR, RITONAVIR;UGT1A1;*28;UGT1A1*28;METABOLISM/PK;;;DISEASE:HYPERBILIRUBINEMIA;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DOSE_ADJUST
ACYCLOVIR;NUDT15;*2/*2 +*2/*3 +*3/*3 + *5/*5;NUDT15*1, NUDT15*2, NUDT15*3, NUDT15*4, NUDT15*5;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:PRIMARY_GRAFT_FAILURE;PEOPLE;OTHER:HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;SLCO1B1;*15;SLCO1B1*15;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:NAUSEA;CHILDREN;OTHER:INFLAMMATORY_BOWEL_DISEASES;CAUTION_SIDE_EFFECT
CAFFEINE;ADORA2A;T/del + TT;rs35320474;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:BRONCHOPULMONARY_DYSPLASIA;INFANTS;OTHER:APNEA_OF_PREMATURITY, OTHER:PREMATURE_BIRTH;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;*2;CYP2C9*1, CYP2C9*2;EFFICACY;;;EFFICACY:HIGHER_MEAN_PEAK_INR_DURING_WEEK_1_OF_WARFARIN_THERAPY;CHILDREN;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*3;CYP2C9*1, CYP2C9*3;EFFICACY;;;EFFICACY:HIGHER_MEAN_PEAK_INR_DURING_WEEK_1_OF_WARFARIN_THERAPY;CHILDREN;;CAUTION_DOSE_ADJUST
NAN;DHFR;del/del;rs70991108;OTHER;INCREASED;;OTHER:SERUM_AND_RED_BLOOD_CELL_FOLATE_CONCENTRATIONS;;;CAUTION_DOSE_ADJUST
CISPLATIN, IRINOTECAN;UGT1A1;AA;rs4148323;TOXICITY;INCREASED;;DISEASE:NEUTROPENIA;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
FLUOXETINE;CYP2C19;*1/*17 + *17/*17;CYP2C19*1, CYP2C19*2, CYP2C19*17;EFFICACY;DECREASED;SEVERITY;EFFICACY:DEPRESSION;PEOPLE;OTHER:ANXIETY_DISORDERS, OTHER:DEPRESSION,OTHER:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOXETINE;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;EFFICACY;DECREASED;SEVERITY;EFFICACY:ANXIETY_DISORDERS;PEOPLE;OTHER:ANXIETY_DISORDERS, OTHER:DEPRESSION,OTHER:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;CYP2A6;*20 + *26 + *24+ *9 + *27 + *17;CYP2A6*1, CYP2A6*9, CYP2A6*17, CYP2A6*20, CYP2A6*24, CYP2A6*26, CYP2A6*27;OTHER, METABOLISM/PK;DECREASED;;PK:METABOLISM;;;CAUTION_DOSE_ADJUST
COCAINE, ETHANOL, OPIOIDS;OPRM1;A;rs3823010;TOXICITY;INCREASED;RISK;OTHER:ALCOHOL_ABUSE, OTHER:COCAINE_DEPENDENCE, OTHER:OPIOID-RELATED_DISORDERS;;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*15:11;HLA-B*15:11;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;;;CAUTION_SIDE_EFFECT
CAPECITABINE, FLUOROURACIL, FOLFOX, XELOX;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS;WOMEN;OTHER:BREAST_NEOPLASMS, OTHER:COLORECTAL_NEOPLASMS,OTHER:NEOPLASMS;CAUTION_SIDE_EFFECT
COCAINE, ETHANOL, OPIOIDS;OPRM1;G;rs495491;TOXICITY;INCREASED;RISK;OTHER:ALCOHOL_ABUSE, OTHER:COCAINE_DEPENDENCE, OTHER:OPIOID-RELATED_DISORDERS;;;CAUTION_SIDE_EFFECT
INTERFERON BETA-1A, INTERFERON BETA-1B;HLA-DQA1;G;rs9272105;EFFICACY;INCREASED;;EFFICACY:ANTI-IFN-BETA_ANTIBODIES;PEOPLE;DISEASE:MULTIPLE_SCLEROSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE, FLUOROURACIL, FOLFOX, XELOX;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;rs45445694;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DISCONTINUATION;WOMEN;OTHER:BREAST_NEOPLASMS, OTHER:COLORECTAL_NEOPLASMS,OTHER:NEOPLASMS;CAUTION_SIDE_EFFECT
REPAGLINIDE;SLCO1B1;*37/*37;SLCO1B1*1, SLCO1B1*5, SLCO1B1*15, SLCO1B1*37;METABOLISM/PK;DECREASED;;PK:REPAGLINIDE_EXPOSURE_(DECREASED_AUC_AND_INCREASED_CLEARANCE);HEALTHY;;CAUTION_DOSE_ADJUST
NEVIRAPINE;HLA-C;*04:01;HLA-C*04:01;TOXICITY;INCREASED;RISK;DISEASE:DRUG_HYPERSENSITIVITY;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
EGFR INHIBITORS;EGFR;A;rs2227983;EFFICACY;;;EFFICACY:CYTOTOXICITY;;;CAUTION_DOSE_ADJUST
ATAZANAVIR, RITONAVIR;UGT1A1;*28/*28 + *1/*28;UGT1A1*1, UGT1A1*28;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HYPERBILIRUBINEMIA;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
NEVIRAPINE;HLA-C;*08:01;HLA-C*08:01;TOXICITY;INCREASED;RISK;DISEASE:DRUG_HYPERSENSITIVITY;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
INTERFERON BETA-1A, INTERFERON BETA-1B;;G;rs4961252;EFFICACY;INCREASED;;EFFICACY:ANTI-IFN-BETA_ANTIBODIES;PEOPLE;DISEASE:MULTIPLE_SCLEROSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;TOXICITY;DECREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGASPARGASE;HLA-DRB1;*16:02;HLA-DRB1*16:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_HYPERSENSITIVITY;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
ASPARAGINASE, CYTARABINE, DAUNORUBICIN, ETOPOSIDE, MERCAPTOPURINE, METHOTREXATE, PREDNISONE, VINCRISTINE;C18orf56, TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;INCREASED;RISK;EFFICACY:CNS_RELAPSE, EFFICACY:HEMATOLOGIC_RELAPSE;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
METHOTREXATE;C18orf56, TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;DECREASED;;EFFICACY:EVENT_FREE_SURVIVAL;PEOPLE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
GEMCITABINE;RRM1;G;rs9937;TOXICITY;DECREASED;RISK;DISEASE:NEUTROPENIA;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;ACE;del/del;rs1799752;OTHER;INCREASED;SEVERITY;OTHER:COVID-19;PEOPLE;OTHER:COVID-19;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*1/*3 + *3/*3;CYP2C9*1, CYP2C9*3;PD;DECREASED;LIKELIHOOD;OTHER:TIME_TO_THERAPEUTIC_INR;PEOPLE;;LIKELIHOOD_THERAPEUTIC_FAILURE
ETHANOL;OPRM1;T;rs1381376;TOXICITY;INCREASED;RISK;OTHER:ALCOHOL_ABUSE;;;CAUTION_SIDE_EFFECT
NEVIRAPINE;HLA-B;*35:01;HLA-B*35:01;TOXICITY;INCREASED;RISK;DISEASE:DRUG_HYPERSENSITIVITY;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
PEGASPARGASE;HLA-DQA1;*02:01;HLA-DQA1*02:01;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HYPERSENSITIVITY;;;CAUTION_SIDE_EFFECT
PEGASPARGASE;HLA-DQB1;*02:02;HLA-DQB1*02:02;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HYPERSENSITIVITY;;;CAUTION_SIDE_EFFECT
PEGASPARGASE;HLA-DRB1;*07:01;HLA-DRB1*07:01;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HYPERSENSITIVITY;;;CAUTION_SIDE_EFFECT
METHOTREXATE;DHFR, MSH3;TGGCGCGTCCCGCCCAGGT/TGGCGCGTCCCGCCCAGGT;rs70991108;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:LEUKOPENIA;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
METHOTREXATE;ENOSF1, TYMS;TTA/TTA + TTA/TTAAAGTTA;rs11280056;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUTROPENIA;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
NAN;ACE;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;rs1799752;OTHER;DECREASED;LIKELIHOOD;OTHER:COVID-19;;;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOSPORINE, TACROLIMUS;ABCB1;GG;rs1128503;EFFICACY;INCREASED;RISK;EFFICACY:TRANSPLANT_REJECTION;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;CAUTION_SIDE_EFFECT
NAN;ACE;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;rs1799752;OTHER;DECREASED;SEVERITY;OTHER:COVID-19;PEOPLE;OTHER:COVID-19;LIKELIHOOD_THERAPEUTIC_SUCCESS
AMITRIPTYLINE, CLOMIPRAMINE;CYP2C19;*2/*2 + *2/*1 + *2/*17;CYP2C19*1, CYP2C19*2, CYP2C19*17;EFFICACY;INCREASED;RISK;EFFICACY:TREATMENT_EMERGENT_MANIA;PEOPLE;OTHER:BIPOLAR_DISORDER;CAUTION_SIDE_EFFECT
NAN;ACE;del;rs1799752;OTHER;INCREASED;LIKELIHOOD;OTHER:COVID-19;PEOPLE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN, BETA BLOCKING AGENTS, CLOPIDOGREL, HMG COA REDUCTASE INHIBITORS;;A;rs1050450;OTHER;INCREASED;RISK;OTHER:IN-STENT_RESTENOSIS;MEN;DISEASE:CORONARY_ARTERY_DISEASE;CAUTION_SIDE_EFFECT
NAN;ACE;del/del;rs1799752;OTHER;INCREASED;RISK;OTHER:DEATH;PEOPLE;OTHER:COVID-19;CAUTION_SIDE_EFFECT
SERTRALINE;CYP2C19;*2/*2 + *2/*1 + *2/*17;CYP2C19*1, CYP2C19*2, CYP2C19*17;EFFICACY;INCREASED;RISK;EFFICACY:TREATMENT_EMERGENT_MANIA;PEOPLE;OTHER:BIPOLAR_DISORDER;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;NUDT15;*1/*2 + *1/*3 + *1/*5 + *1/*6;NUDT15*1, NUDT15*2, NUDT15*3, NUDT15*5, NUDT15*6;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;;CYP2C19 POOR METABOLIZER, INTERMEDIATE METABOLIZER;TOXICITY;DECREASED;;SIDE_EFFECT:HEMORRHAGE;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
LEFLUNOMIDE;CYP2C19;*1/*17 + *17/*17;CYP2C19*1, CYP2C19*2, CYP2C19*17;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:DISCONTINUATION;PEOPLE;OTHER:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANAKINRA, CANAKINUMAB, RILONACEPT, TOCILIZUMAB;HLA-DRB1;*15:01;HLA-DRB1*15:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS;PEOPLE;OTHER:JUVENILE_RHEUMATOID_ARTHRITIS, OTHER:ADULT-ONSET_STILL_DISEASE;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL4;GG;rs11322783;EFFICACY;INCREASED;RISK;EFFICACY:TREATMENT_FAILURE_TO_PEGYLATED_INTERFERON-ALPHA/RIBAVIRIN_THERAPY_IN_HCV/HIV-1_COINFECTED_PATIENTS;;;CAUTION_SIDE_EFFECT
NORTRIPTYLINE;CYP2D6;*3;CYP2D6*1, CYP2D6*3;METABOLISM/PK;INCREASED;;PK:_APPARENT_TERMINAL_ELIMINATION_HALF-LIFE;HEALTHY;;CAUTION_DOSE_ADJUST
FLUCLOXACILLIN;HLA-B;*57:03;HLA-B*57:03;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;;;CAUTION_SIDE_EFFECT
CISPLATIN;TPMT;*3B + *3C;TPMT*1, TPMT*3B, TPMT*3C;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OTOTOXICITY;CHILDREN;OTHER:NEOPLASMS;CAUTION_SIDE_EFFECT
PREDNISONE, TACROLIMUS;ABCB1;GG;rs1045642;EFFICACY;INCREASED;RISK;OTHER:REMAINING_ON_STEROIDS_AT_1_YEAR_AFTER_TRANSPLANTATION;PEOPLE;OTHER:HEART_TRANSPLANTATION;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-A;*11:01;HLA-A*11:01;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;;;CAUTION_SIDE_EFFECT
FLUCLOXACILLIN;HLA-B;*57:01;HLA-B*57:01;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;;;CAUTION_SIDE_EFFECT
ATAZANAVIR;CYP3A5;*1/*3 + *1/*1;CYP3A5*1, CYP3A5*3;METABOLISM/PK;INCREASED;;PK:ORAL_CLEARANCE_(CL)_OF_ATAZANAVIR;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DOSE_ADJUST
MERCAPTOPURINE;TPMT;*1/*3A + *1/*3B + *1/*3C + *1/*2;TPMT*1, TPMT*2, TPMT*3A, TPMT*3B, TPMT*3C;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:FEBRILE_NEUTROPENIA;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
ANTIINFLAMMATORY AGENTS, NON-STEROIDS;CYP2C9;*3;CYP2C9*3;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:GASTROINTESTINAL_HEMORRHAGE;;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;;;CAUTION_SIDE_EFFECT
EGFR INHIBITORS;EGFR;T;rs712829;TOXICITY;;;EFFICACY:CYTOTOXICITY;;;CAUTION_DOSE_ADJUST
ANTINEOPLASTIC AGENTS;TYMS;TTA;rs11280056;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE;HLA-A;*74:01;HLA-A*74:01;TOXICITY;INCREASED;RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-C;*08:01;HLA-C*08:01;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-A;*24:07;HLA-A*24:07;TOXICITY;INCREASED;RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-A;*24:02;HLA-A*24:02;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS;;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;TPMT;*1/*3A;TPMT*1, TPMT*2, TPMT*3A;TOXICITY;INCREASED;RISK;SIDE_EFFECT:LOW_LEUKOCYTE_COUNTS;PEOPLE;DISEASE:RHEUMATIC_DISEASES;CAUTION_SIDE_EFFECT
AZATHIOPRINE;TPMT;*1/*1;TPMT*1, TPMT*2, TPMT*3A;EFFICACY;INCREASED;;EFFICACY:TREATMENT_DURATION;PEOPLE;DISEASE:RHEUMATIC_DISEASES;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE;HLA-A;*31:01;HLA-A*31:01;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS;;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*4;CYP2C19*1, CYP2C19*4;TOXICITY;INCREASED;RISK;SIDE_EFFECT:CARDIOVASCULAR_EVENTS;PEOPLE;DISEASE:MYOCARDIAL_INFARCTION;CAUTION_SIDE_EFFECT
ATAZANAVIR;UGT1A1;*28;UGT1A1*28;TOXICITY;INCREASED;RISK;DISEASE:HYPERBILIRUBINEMIA;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
ATORVASTATIN, PRAVASTATIN;APOE;CC + CT;rs429358;EFFICACY;INCREASED;;EFFICACY:REDUCTION_IN_C-REACTIVE_PROTEIN_(CRP);PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOZAPINE;GSTM1;null/null;GSTM1 NON-NULL, GSTM1 NULL;TOXICITY;DECREASED;RISK;SIDE_EFFECT:NEUTROPENIA;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN, CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 + *2/*17 + *3/*17;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:THROMBOTIC_DISEASE, EFFICACY:SUDDEN_CARDIAC_DEATH, EFFICACY:MYOCARDIAL_INFARCTION;PEOPLE;OTHER:ACUTE_CORONARY_SYNDROME;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;OPRM1;AA;rs1799971;TOXICITY;DECREASED;RISK;SIDE_EFFECT:OPIOID-RELATED_DISORDERS;MEN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;*3;CYP2C9*1, CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HEMORRHAGE;;;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*4/*5;CYP2D6*4, CYP2D6*5;EFFICACY;DECREASED;;EFFICACY:EVENT-FREE_SURVIVAL;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*4/*7;CYP2D6*4, CYP2D6*7;EFFICACY;DECREASED;;EFFICACY:EVENT-FREE_SURVIVAL;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
TRAMADOL;CYP2D6;;CYP2D6 POOR_METABOLIZER;EFFICACY, METABOLISM/PK;DECREASED;;EFFICACY:METABOLISM_OF_TRAMADOL_AND_DECREASED_RESPONSE_TO_TRAMADOL;;;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;SLCO1B1;CC + CT;rs4149056;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:NON-HODGKIN_LYMPHOMA;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*4/*6;CYP2D6*4, CYP2D6*6;EFFICACY;DECREASED;;EFFICACY:EVENT-FREE_SURVIVAL;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
CARBAMAZEPINE;HLA-DRB1;*07:01;HLA-DRB1*07:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME, SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS;;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-DRB1;*12:02;HLA-DRB1*12:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME, SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS;;;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*4/*4 + *4/*5 + *10/*41 + *4/*41 + *1/*4 + *1/*5;CYP2D6*1, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*41;EFFICACY;INCREASED;RISK;EFFICACY:RECURRENCE;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-DRB1;*04:05;HLA-DRB1*04:05;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME, SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OMEPRAZOLE;CYP2C19;*1/*2;CYP2C19*1, CYP2C19*2;EFFICACY;INCREASED;;OTHER:INTRAGASTRIC_PH;PEOPLE;DISEASE:ULCER;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE;HLA-A;*31:01;HLA-A*31:01;TOXICITY;INCREASED;RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-A;*31:01;HLA-A*31:01;TOXICITY;INCREASED;RISK;DISEASE:DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS;;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*46:01;HLA-B*46:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_HYPERSENSITIVITY;PEOPLE;OTHER:EPILEPSY;CAUTION_SIDE_EFFECT
NORTRIPTYLINE;CYP2D6;*5;CYP2D6*1, CYP2D6*5;METABOLISM/PK;INCREASED;;PK:APPARENT_TERMINAL_ELIMINATION_HALF-LIFE;HEALTHY;;CAUTION_DOSE_ADJUST
CARBAMAZEPINE;HLA-DRB1;*09:01;HLA-DRB1*09:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_HYPERSENSITIVITY;PEOPLE;OTHER:EPILEPSY;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-DQA1;*03:02;HLA-DQA1*03:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_HYPERSENSITIVITY;PEOPLE;OTHER:EPILEPSY;CAUTION_SIDE_EFFECT
TICAGRELOR;CYP3A4;*1/*22;CYP3A4*1, CYP3A4*22;EFFICACY;INCREASED;;EFFICACY:PLATELET_AGGREGATION_INHIBITION;HEALTHY;;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;HLA-DRB1;*08:03;HLA-DRB1*08:03;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_HYPERSENSITIVITY;PEOPLE;OTHER:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;HLA-C;*01:02;HLA-C*01:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_HYPERSENSITIVITY;PEOPLE;OTHER:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
NEVIRAPINE;HLA-DRB1;*04:05;HLA-DRB1*04:05;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_HYPERSENSITIVITY;PEOPLE;OTHER:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*4/*11;CYP2D6*4, CYP2D6*11;EFFICACY;DECREASED;;EFFICACY:EVENT-FREE_SURVIVAL;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOSPORINE;ABCB1;AA;rs1128503;DOSAGE, METABOLISM/PK;INCREASED;;PK:TROUGH_BLOOD_CONCENTRATION;PEOPLE;DISEASE:MYASTHENIA_GRAVIS;CAUTION_DOSE_ADJUST
NAN;TMPRSS2;CC;rs383510;OTHER;INCREASED;LIKELIHOOD;OTHER:COVID-19;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
LAPATINIB;HLA-DRB1;*07:01;HLA-DRB1*07:01;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*3/*4;CYP2D6*3, CYP2D6*4;EFFICACY;DECREASED;;EFFICACY:EVENT-FREE_SURVIVAL;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUVASTATIN;CYP2C9;*2 + *3;CYP2C9*1, CYP2C9*2, CYP2C9*3;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
NORTRIPTYLINE;CYP2D6;*4;CYP2D6*1, CYP2D6*4;METABOLISM/PK;INCREASED;;PK:APPARENT_TERMINAL_ELIMINATION_HALF-LIFE;HEALTHY;;CAUTION_DOSE_ADJUST
TAMOXIFEN;CYP2D6;*3/*5;CYP2D6*3, CYP2D6*5;EFFICACY;DECREASED;;EFFICACY:EVENT-FREE_SURVIVAL;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
ATAZANAVIR / RITONAVIR;UGT1A1;*28/*28;UGT1A1*1, UGT1A1*28, UGT1A1*36;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HYPERBILIRUBINEMIA;PEOPLE;OTHER:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
CYCLOSPORINE;ABCB1;AA;rs2032582;DOSAGE, METABOLISM/PK;INCREASED;;PK:TROUGH_BLOOD_CONCENTRATION;PEOPLE;DISEASE:MYASTHENIA_GRAVIS;CAUTION_DOSE_ADJUST
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;;;CAUTION_SIDE_EFFECT
SERTRALINE;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;METABOLISM/PK;INCREASED;;PK:MEAN_SERUM_CONCENTRATIONS_OF_SERTRALINE_AND_N-DESMETHYL_SERTRALINE;PEOPLE;DISEASE:MENTAL_DISORDERS;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C9*1, CYP2C9*2, CYP2C9*3;DOSAGE, EFFICACY;INCREASED;;EFFICACY:TIME_TO_ACHIEVE_STABLE_DOSE;;;CAUTION_DOSE_ADJUST
METHADONE;CYP3A4;G;rs2246709;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:SIDE_EFFECTS;PEOPLE;DISEASE:HEROIN_DEPENDENCE;CAUTION_SIDE_EFFECT
FLUVOXAMINE;CYP2D6;*10/*10 + *5/*10;CYP2D6*1, CYP2D6*5, CYP2D6*10;METABOLISM/PK;INCREASED;;PK:FLUVOXAMINE_PLASMA_CONCENTRATIONS;PEOPLE;DISEASE:MENTAL_DISORDERS;CAUTION_DOSE_ADJUST
ESCITALOPRAM;CYP2C19;*2/*2 + *2/*4;CYP2C19*1, CYP2C19*2, CYP2C19*4;METABOLISM/PK;INCREASED;;PK:AREA_UNDER_THE_TIME-PLASMA_CONCENTRATION_CURVE_(AUC(0-24));;;CAUTION_DOSE_ADJUST
PRAVASTATIN;KIF6;AG + GG;rs20455;EFFICACY;DECREASED;RISK;DISEASE:CORONARY_DISEASE;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TAMOXIFEN;CYP2D6;*4/*4 + *4/*5 + *10/*41 + *4/*41;CYP2D6*1, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*41;EFFICACY;INCREASED;RISK;EFFICACY:RECURRENCE;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
METHAZOLAMIDE;HLA-B;*55:02;HLA-B*55:02;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;;;CAUTION_SIDE_EFFECT
METHAZOLAMIDE;HLA-B;*59:01;HLA-B*59:01;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;;;CAUTION_SIDE_EFFECT
ACETAMINOPHEN, CODEINE, LEVOMEPROMAZINE;CYP2D6;*1/*1;CYP2D6*1;EFFICACY, METABOLISM/PK;;;PK:INHIBITION_OF_METABOLISM;PEOPLE;DISEASE:BACK_PAIN;CAUTION_DOSE_ADJUST
LAMOTRIGINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME, SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS;;;CAUTION_SIDE_EFFECT
METHADONE;CYP3A4;T;rs2242480;OTHER;INCREASED;SEVERITY;SIDE_EFFECT:OPIOID_WITHDRAWAL_SYMPTOMS;PEOPLE;DISEASE:HEROIN_DEPENDENCE;CAUTION_SIDE_EFFECT
DOCETAXEL, THALIDOMIDE;RPL13, SNORD68, SPG7;G;rs12960;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXICITY;PEOPLE;DISEASE:PROSTATIC_NEOPLASMS;CAUTION_SIDE_EFFECT
DOCETAXEL, THALIDOMIDE;CHST3;A;rs1871450;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXICITY;PEOPLE;DISEASE:PROSTATIC_NEOPLASMS;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*1/*2+ *2/*2+ *1/*3 + *3/*3 + *2/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;INCREASED;RISK;EFFICACY:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE);PEOPLE;OTHER:ACUTE_CORONARY_SYNDROME;CAUTION_SIDE_EFFECT
CITALOPRAM;CYP2C19;*2/*2;CYP2C19*1, CYP2C19*2;METABOLISM/PK;INCREASED;;PK:METABOLIC_RATIO_CIT/DCIT_VALUES_AND_MEAN_CITALOPRAM_DOSE;;;CAUTION_DOSE_ADJUST
PEGINTERFERON ALFA-2B, RIBAVIRIN;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);SLC6A4 HTTLPR LONG FORM (L ALLELE), SLC6A4 HTTLPR SHORT FORM (S ALLELE);TOXICITY;DECREASED;RISK;DISEASE:DEPRESSION;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHADONE;CYP3A4;A;rs4646440;OTHER;INCREASED;SEVERITY;SIDE_EFFECT:OPIOID_WITHDRAWAL_SYMPTOMS;PEOPLE;DISEASE:HEROIN_DEPENDENCE;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *1/*17;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:ADVERSE_CARDIOVASCULAR_EVENTS;PEOPLE;OTHER:CARDIOVASCULAR_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE;HLA-C;*03:02;HLA-C*03:02;TOXICITY;INCREASED;RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;PEOPLE;DISEASE:EPILEPSY;CAUTION_SIDE_EFFECT
ETHANOL, OPIOIDS;OPRM1;T;rs511435;TOXICITY;INCREASED;RISK;OTHER:ALCOHOL_ABUSE, OTHER:OPIOID-RELATED_DISORDERS;;;CAUTION_SIDE_EFFECT
DOCETAXEL, THALIDOMIDE;NAT2;G;rs1799931;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXICITY;PEOPLE;DISEASE:PROSTATIC_NEOPLASMS;CAUTION_SIDE_EFFECT
ESCITALOPRAM;CYP2C19;*1/*17;CYP2C19*1, CYP2C19*17;METABOLISM/PK;DECREASED;;PK:MEAN_LOGARITHM_ESCITALOPRAM_CONCENTRATION;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DOSE_ADJUST
DOCETAXEL, THALIDOMIDE;CYP4B1;T;rs4646487;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXICITY;PEOPLE;DISEASE:PROSTATIC_NEOPLASMS;CAUTION_SIDE_EFFECT
SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-B;*07:02;HLA-B*07:02;TOXICITY;INCREASED;RISK;SIDE_EFFECT:RESPIRATORY_INSUFFICIENCY;;;CAUTION_SIDE_EFFECT
SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-C;*07:02;HLA-C*07:02;TOXICITY;INCREASED;RISK;SIDE_EFFECT:RESPIRATORY_INSUFFICIENCY;;;CAUTION_SIDE_EFFECT
SULFAMETHOXAZOLE / TRIMETHOPRIM;GSTM1;null/null;GSTM1 NULL;TOXICITY;INCREASED;RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;PEOPLE;DISEASE:ACQUIRED_IMMUNODEFICIENCY_SYNDROME;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED;RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;PEOPLE;DISEASE:EPILEPSY;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-DRB1;*07:01;HLA-DRB1*07:01;TOXICITY;INCREASED;RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;PEOPLE;DISEASE:EPILEPSY;CAUTION_SIDE_EFFECT
OLANZAPINE;UGT1A1;*1/*28 + *28/*28;UGT1A1*1, UGT1A1*28;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:FATIGUE;HEALTHY;;CAUTION_SIDE_EFFECT
FOLFIRINOX;UGT1A1;*1/*6 + *1/*28 + *6/*28 + *6/*6 + *28/*28;UGT1A1*1, UGT1A1*6, UGT1A1*28;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:FEBRILE_NEUTROPENIA;PEOPLE;OTHER:PANCREATIC_NEOPLASMS;CAUTION_SIDE_EFFECT
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED;RISK;DISEASE:STEVENS-JOHNSON_SYNDROME;;;CAUTION_SIDE_EFFECT
METHOTREXATE;DHFR;GGGAGCTGG/del + del/del;rs3045983;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;OPRM1;CC;rs589046;TOXICITY;DECREASED;RISK;SIDE_EFFECT:OPIOID-RELATED_DISORDERS;MEN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED;RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;;;CAUTION_SIDE_EFFECT
ALLOPURINOL;HLA-C;*03:02;HLA-C*03:02;TOXICITY;INCREASED;RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-A;*31:01;HLA-A*31:01;TOXICITY;INCREASED;RISK;DISEASE:DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS;;;CAUTION_SIDE_EFFECT
EFAVIRENZ, OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;METABOLISM/PK;INCREASED;;PK:METABOLIC_RATIO_(DEFINED_AS_RATIO_OF_OMEPRAZOLE_TO_ITS_METABOLITES)_OF_5-HYDROXYOMEPRAZOLE, R-5-HYDROXYOMEPRAZOLE_AND_S-5-HYDROXYOMEPRAZOLE;HEALTHY;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;TOXICITY;INCREASED;RISK;SIDE_EFFECT:GRAFT_VS_HOST_DISEASE;PEOPLE;DISEASE:HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION;CAUTION_SIDE_EFFECT
AZATHIOPRINE;TPMT;*1/*3A + *1/*3C;TPMT*1, TPMT*3A, TPMT*3C;TOXICITY;DECREASED;;SIDE_EFFECT:LEUKOCYTES_AND_NEUTROPHILS;PEOPLE;DISEASE:HEART_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ, OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;METABOLISM/PK;INCREASED;;PK:METABOLIC_RATIO_(DEFINED_AS_RATIO_OF_OMEPRAZOLE_TO_ITS_METABOLITES)_OF_5-HYDROXYOMEPRAZOLE_AND_R-5-HYDROXYOMEPRAZOLE;HEALTHY;;CAUTION_DOSE_ADJUST
AMITRIPTYLINE;CYP2C19;*1/*2 + *2/*2;CYP2C19*1, CYP2C19*2;METABOLISM/PK;INCREASED;;PK:AMITRIPTYLINE/NORTRIPTYLINE_RATIO_CORRECTED_FOR_DOSE_AND_WEIGHT;PEOPLE;DISEASE:MENTAL_DISORDERS;CAUTION_DOSE_ADJUST
ALPRAZOLAM;CYP3A4;;CYP3A4 LOW ACTIVITY;EFFICACY;INCREASED;RISK;SIDE_EFFECT:ADVERSE_EVENTS;MEN;OTHER:ALCOHOL_ABUSE, OTHER:ANXIETY_DISORDERS;CAUTION_SIDE_EFFECT
ASPIRIN, CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PACLITAXEL;CYP3A4;*1/*8 + *1/*20;CYP3A4*1, CYP3A4*8, CYP3A4*20;TOXICITY;INCREASED;RISK;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES, SIDE_EFFECT:TREATMENT_MODIFICATION;PEOPLE;DISEASE:BREAST_NEOPLASMS, DISEASE:OVARIAN_NEOPLASMS;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*4/*4 + *4/*5 + *10/*41 + *4/*41;CYP2D6*1, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*41;EFFICACY;DECREASED;;EFFICACY:EVENT-FREE_SURVIVAL;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
CARBAMAZEPINE;HLA-A;*33:03;HLA-A*33:03;TOXICITY;INCREASED;RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;PEOPLE;DISEASE:EPILEPSY;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;PEOPLE;DISEASE:EPILEPSY;CAUTION_SIDE_EFFECT
DOCETAXEL;VEGFA;del/del;rs144854329;EFFICACY;DECREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*3/*3 + *3/*2 + *2/*3;CYP2C9*2, CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HEMORRHAGE;PEOPLE;DISEASE:ATRIAL_FIBRILLATION;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*1/*3;CYP2C9*1, CYP2C9*3;METABOLISM/PK;DECREASED;;PK:UNBOUND_ORAL_CLEARANCE_FOR_S-WARFARIN;;;CAUTION_DOSE_ADJUST
CITALOPRAM;SLC6A4;L allele-rs25531T/L allele-rs25531T;SLC6A4 HTTLPR SHORT FORM (S ALLELE), SLC6A4 L ALLELE-rs25531C, SLC6A4 L ALLELE-rs25531T;TOXICITY;DECREASED;;SIDE_EFFECT:ADVERSE_EFFECT_BURDEN;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
AZATHIOPRINE, MERCAPTOPURINE;NUDT15;*1/*3 + *3/*3 + *1/*6;NUDT15*1, NUDT15*3, NUDT15*6;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA;PEOPLE;OTHER:INFLAMMATORY_BOWEL_DISEASES;CAUTION_SIDE_EFFECT
ANTIDEPRESSANTS;SLC6A4;HTTLPR short form (S allele);SLC6A4 HTTLPR LONG FORM (L ALLELE), SLC6A4 HTTLPR SHORT FORM (S ALLELE);TOXICITY;INCREASED;RISK;SIDE_EFFECT:SIDE_EFFECTS;PEOPLE;DISEASE:DEPRESSIVE_DISORDER;CAUTION_SIDE_EFFECT
FLUOROURACIL;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;rs45445694;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;OTHER:ADENOCARCINOMA;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*2/*3 + *3/*3 + *2/*2;CYP2C9*2, CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OVER-ANTICOAGULATION;PEOPLE;DISEASE:ATRIAL_FIBRILLATION;CAUTION_SIDE_EFFECT
HALOPERIDOL;CYP2D6;*1/*4;CYP2D6*1, CYP2D6*4;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;MEN;OTHER:ALCOHOLIC_PSYCHOSIS;CAUTION_SIDE_EFFECT
HMG_COA_REDUCTASE_INHIBITORS;SLCO1B1;CC;rs4149056;TOXICITY;INCREASED;RISK;SIDE_EFFECT:STATIN-RELATED_MYOPATHY;;;CAUTION_SIDE_EFFECT
NAN;HLA-DPB1;*04:01;HLA-DPB1*04:01;TOXICITY;DECREASED;RISK;DISEASE:ASPIRIN-INDUCED_ASTHMA;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBOPLATIN, CISPLATIN;DPYD;Reference;DPYD REFERENCE;EFFICACY;INCREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL, EFFICACY:OVERALL_SURVIVAL;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHAMPHETAMINE;DAOA;T;rs947267;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:PSYCHOTIC_DISORDER;;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE, OXCARBAZEPINE, PHENOBARBITAL;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;DISEASE:STEVENS-JOHNSON_SYNDROME;CHILDREN;DISEASE:EPILEPSY;CAUTION_SIDE_EFFECT
TRAMADOL;CYP2D6;*10/*10 + *5/*10 + *36;CYP2D6*1, CYP2D6*2, CYP2D6*5, CYP2D6*10, CYP2D6*10X2, CYP2D6*36;EFFICACY;INCREASED;SEVERITY;EFFICACY:PAIN;PEOPLE;OTHER:POSTOPERATIVE_PAIN;CAUTION_SIDE_EFFECT
EFAVIRENZ, OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;METABOLISM/PK;INCREASED;;PK:AREA_UNDER_CURVE_(AUC)_OF_OMEPRAZOLE_RACEMATE, OMEPRAZOLE_SULFONE, R-OMEPRAZOLE_AND_S-OMEPRAZOLE;HEALTHY;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;TT;rs776746;DOSAGE, METABOLISM/PK;;;OTHER:HIGHER_STABLE_DOSE_LEVELS;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
METHAMPHETAMINE;OPRM1;C;rs2075572;TOXICITY;DECREASED;RISK;OTHER:METHAMPHETAMINE_DEPENDENCE;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACETAMINOPHEN;HLA-B;*13:01;HLA-B*13:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME, SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS;;;CAUTION_SIDE_EFFECT
ACETAMINOPHEN;HLA-A;*02:06;HLA-A*02:06;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME, SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS;;;CAUTION_SIDE_EFFECT
ACETAMINOPHEN;HLA-B;*44:03;HLA-B*44:03;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME, SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS;;;CAUTION_SIDE_EFFECT
EFAVIRENZ, OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;METABOLISM/PK;INCREASED;;PK:AREA_UNDER_CURVE_(AUC)_OF_OMEPRAZOLE_RACEMATE, OMEPRAZOLE_SULFONE, R-OMEPRAZOLE_AND_S-OMEPRAZOLE;HEALTHY;;CAUTION_DOSE_ADJUST
ACETAMINOPHEN;HLA-C;*14:03;HLA-C*14:03;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME, SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS;;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1, CYP2C19*2;TOXICITY;INCREASED;RISK;DISEASE:THROMBOTIC_DISEASE;;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*3;CYP2C19*1, CYP2C19*3;TOXICITY;INCREASED;RISK;DISEASE:THROMBOTIC_DISEASE;;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE, LAMOTRIGINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;;;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*4/*4 + *4/*5 + *10/*41 + *4/*41 + *1/*4 + *1/*5;CYP2D6*1, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*41;EFFICACY;DECREASED;;EFFICACY:EVENT-FREE_SURVIVAL;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
MERCAPTOPURINE, THIOGUANINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TPMT*1, TPMT*2, TPMT*3A, TPMT*3C, TPMT*9, TPMT*21, TPMT*33, TPMT*34;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUTROPENIA, SIDE_EFFECT:THROMBOCYTOPENIA;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
METHADONE;CYP3A4;A;rs2246709;OTHER;DECREASED;SEVERITY;SIDE_EFFECT:OPIOID_WITHDRAWAL_SYMPTOMS;PEOPLE;DISEASE:HEROIN_DEPENDENCE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;DECREASED;;EFFICACY:CLOPI-H4_CONCENTRATIONS_AFTER_300_OR_900_MG_CLOPIDOGREL_LOADING_DOSE;MEN;DISEASE:MYOCARDIAL_INFARCTION;LIKELIHOOD_THERAPEUTIC_FAILURE
ATORVASTATIN, PRAVASTATIN;APOE;CT + TT;rs7412;EFFICACY;INCREASED;;EFFICACY:PERCENT_REDUCTION_IN_LDL-CHOLESTEROL;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATORVASTATIN, PRAVASTATIN, SIMVASTATIN;SLCO1B1;*5;SLCO1B1*1, SLCO1B1*5;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:HYPERCHOLESTEROLEMIA;CAUTION_SIDE_EFFECT
PHENYTOIN;CYP2C9;*3;CYP2C9*3;TOXICITY;INCREASED;RISK;DISEASE:MACULOPAPULAR_EXANTHEMA;;;CAUTION_SIDE_EFFECT
ANTIVIRALS FOR TREATMENT OF HIV INFECTIONS, COMBINATIONS;UGT1A1;*28;UGT1A1*1, UGT1A1*28;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HYPERBILIRUBINEMIA;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
PHENYTOIN;CYP2C9;*3;CYP2C9*3;TOXICITY;INCREASED;RISK;DISEASE:TOXIC_EPIDERMAL_NECROLYSIS, DISEASE:STEVENS-JOHNSON_SYNDROME;;;CAUTION_SIDE_EFFECT
ATENOLOL, HYDROCHLOROTHIAZIDE, TRANDOLAPRIL, VERAPAMIL;GRK5;AT + TT;rs2230345;OTHER;DECREASED;RISK;OTHER:ADVERSE_CARDIOVASCULAR_OUTCOMES;PEOPLE;OTHER:HYPERTENSION_AND_CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
DAPSONE;HLA-B;*13:01;HLA-B*13:01;TOXICITY;INCREASED;RISK;DISEASE:DRUG_HYPERSENSITIVITY;PEOPLE;DISEASE:LEPROSY;CAUTION_SIDE_EFFECT
PHENYTOIN;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;DISEASE:TOXIC_EPIDERMAL_NECROLYSIS, DISEASE:STEVENS-JOHNSON_SYNDROME;;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;A;rs4244285;TOXICITY;INCREASED;RISK;SIDE_EFFECT:MAJOR_CARDIOVASCULAR_EVENTS;PEOPLE;DISEASE:MYOCARDIAL_INFARCTION;CAUTION_SIDE_EFFECT
METHAMPHETAMINE;BDNF;CC;rs6265;TOXICITY;DECREASED;SEVERITY;OTHER:METHAMPHETAMINE_DEPENDENCE;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED;RISK;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;;;CAUTION_SIDE_EFFECT
TACROLIMUS;ABCB1;GG;rs1045642;EFFICACY, METABOLISM/PK;INCREASED;LIKELIHOOD;DISEASE:DELAYED_GRAFT_FUNCTION;PEOPLE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;*4;NAT2*4;TOXICITY;DECREASED;RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:TUBERCULOSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTICHOLINERGIC AGENTS;CYP2D6;;CYP2D6 POOR METABOLIZER;METABOLISM/PK;INCREASED;;PK:SERUM_ANTICHOLINERGIC_ACTIVITY;;;CAUTION_DOSE_ADJUST
ANTIEPILEPTICS;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;;;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*1/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;INCREASED;;PK:FORMATION_OF_METABOLITES;;OTHER:HUMAN_LIVER_MICROSOMES;CAUTION_DOSE_ADJUST
AZATHIOPRINE;NUDT15;*2 + *3 + *5 + *6;NUDT15*2, NUDT15*3, NUDT15*5, NUDT15*6;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA, SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;OTHER:INFLAMMATORY_BOWEL_DISEASES;CAUTION_SIDE_EFFECT
NAN;GSTT1;;GSTT1 NON-NULL, GSTT1 NULL;OTHER;INCREASED;LIKELIHOOD;OTHER:ASTHMA;CHILDREN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NEVIRAPINE;HLA-C;*04:01;HLA-C*04:01;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HYPERSENSITIVITY;;;CAUTION_SIDE_EFFECT
NAN;GSTM1;;GSTM1 NON-NULL, GSTM1 NULL;OTHER;INCREASED;LIKELIHOOD;OTHER:ASTHMA;CHILDREN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHAMPHETAMINE;DAOA;A;rs2391191;TOXICITY;DECREASED;LIKELIHOOD;DISEASE:PSYCHOTIC_DISORDER;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE;CYP2B6;*1/*6 + *6/*6 + *4/*6 + *5/*6;CYP2B6*1, CYP2B6*4, CYP2B6*5, CYP2B6*6, CYP2B6*22;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:ELEVATED_LIVER_ENZYMES;CHILDREN;OTHER:NEUROBLASTOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE;CYP2B6;*1/*1 + *1/*5 + *1/*4 + *1/*22;CYP2B6*1, CYP2B6*4, CYP2B6*5, CYP2B6*6, CYP2B6*22;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:MYELOSUPPRESSION;CHILDREN;OTHER:NEUROBLASTOMA;CAUTION_SIDE_EFFECT
IRINOTECAN;HLA-DQB3;C;rs2859101;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:NEUTROPENIA;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOSPORINE, METHOTREXATE;MTHFR;GG;rs3737967;EFFICACY;INCREASED;RISK;SIDE_EFFECT:GRAFT_VS_HOST_DISEASE;PEOPLE;OTHER:HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION;CAUTION_SIDE_EFFECT
NEVIRAPINE;HLA-DRB1;*01:01;HLA-DRB1*01:01;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HYPERSENSITIVITY;;;CAUTION_SIDE_EFFECT
ANTIDEPRESSANTS;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2;METABOLISM/PK;DECREASED;;PK:PLASMA_CONCENTRATIONS;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DOSE_ADJUST
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;PIK3R2;T;rs55633228;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUTROPENIA;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;AA;rs4244285;TOXICITY;INCREASED;RISK;SIDE_EFFECT:STENT_THROMBOSIS;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;CAUTION_SIDE_EFFECT
CARBOPLATIN, DEXAMETHASONE, ETOPOSIDE, IRINOTECAN;UGT1A1;*6;UGT1A1*6;EFFICACY;INCREASED;;EFFICACY:OVERALL_SURVIVAL, EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:LYMPHOMA, LARGE_B-CELL*^DIFFUSE;LIKELIHOOD_THERAPEUTIC_SUCCESS
SULFASALAZINE;HLA-B;*13:01;HLA-B*13:01;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS;;;CAUTION_SIDE_EFFECT
ACENOCOUMAROL, WARFARIN;CYP2C9;*1/*3 + *3/*3;CYP2C9*1, CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OVER-ANTICOAGULATION;;;CAUTION_SIDE_EFFECT
AZATHIOPRINE, MERCAPTOPURINE;NUDT15;GGAGTC;rs746071566;TOXICITY;INCREASED;RISK;SIDE_EFFECT:PANCYTOPENIA, SIDE_EFFECT:THROMBOCYTOPENIA;PEOPLE;OTHER:AUTOIMMUNE_DISEASES, OTHER:INFLAMMATORY_BOWEL_DISEASES;CAUTION_SIDE_EFFECT
CYCLOSPORINE, METHOTREXATE;MTHFR;CC;rs2274976;EFFICACY;INCREASED;RISK;SIDE_EFFECT:GRAFT_VS_HOST_DISEASE;PEOPLE;OTHER:HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION;CAUTION_SIDE_EFFECT
NAN;G6PD;T;rs1050828;NAN;INCREASED;;OTHER:PROTECTION_AGAINST_SEVERE_MALARIA;;;CAUTION_DOSE_ADJUST
TAMOXIFEN;CYP2D6;*4/*4;CYP2D6*4;EFFICACY;INCREASED;LIKELIHOOD;DISEASE:BREAST_NEOPLASMS;WOMEN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;PERP;T;rs117101815;TOXICITY;DECREASED;RISK;SIDE_EFFECT:NEUTROPENIA;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
AZATHIOPRINE;TPMT;*3A + *3B + *3C;TPMT*1, TPMT*3A, TPMT*3B, TPMT*3C;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:MYELOSUPPRESSION;PEOPLE;DISEASE:INFLAMMATORY_BOWEL_DISEASES;CAUTION_SIDE_EFFECT
CISPLATIN;ERCC1;GG;rs11615;TOXICITY;DECREASED;LIKELIHOOD;DISEASE:NEPHROTOXICITY;PEOPLE;DISEASE:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATAZANAVIR / RITONAVIR;UGT1A1;*28/*28;UGT1A1*1, UGT1A1*28, UGT1A1*36;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:JAUNDICE;PEOPLE;OTHER:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
PRAVASTATIN;SLCO1B1;*15/*15;SLCO1B1*15, SLCO1B1*37;METABOLISM/PK;INCREASED;;PK:PRAVASTATIN_PLASMA_CONCENTRATIONS_(AUC);HEALTHY;;CAUTION_DOSE_ADJUST
CAPECITABINE, FLUOROURACIL;DPYD;;DPYD LOW ACTIVITY;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY, SIDE_EFFECT:TREATMENT_MODIFICATION;PEOPLE;OTHER:NEOPLASMS;CAUTION_SIDE_EFFECT
ACENOCOUMAROL;CYP2C9;*3;CYP2C9*1, CYP2C9*3;EFFICACY;INCREASED;;EFFICACY:TIME_TO_ACHIEVE_STABLE_DOSE;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN, RADIOTHERAPY;GSTM1;null/null;GSTM1 NON-NULL, GSTM1 NULL;EFFICACY;DECREASED;LIKELIHOOD;OTHER:DEATH, OTHER:RECURRENCE;WOMEN;DISEASE:UTERINE_CERVICAL_NEOPLASM;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*3 + *1/*3 + *2/*17;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;TOXICITY;INCREASED;RISK;SIDE_EFFECT:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE);;;CAUTION_SIDE_EFFECT
ACENOCOUMAROL;CYP2C9;*1/*3 + *3/*3;CYP2C9*1, CYP2C9*3;EFFICACY;DECREASED;;EFFICACY:TIME_IN_THERAPEUTIC_RANGE;;;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIDEPRESSANTS, ANTIEPILEPTICS, BETA BLOCKING AGENTS, CALCIUM CHANNEL BLOCKERS;ACE;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;rs1799752;OTHER;DECREASED;;OTHER:USE;PEOPLE;OTHER:CHRONIC_MIGRAINE;CAUTION_DOSE_ADJUST
ANTIDEPRESSANTS, ANTIEPILEPTICS, BETA BLOCKING AGENTS, CALCIUM CHANNEL BLOCKERS;ACE;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;rs1799752;OTHER;DECREASED;;OTHER:USE;PEOPLE;DISEASE:MIGRAINE_WITH_AURA;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1;CYP3A5*1, CYP3A5*3;METABOLISM/PK;DECREASED;;PK:C/D_RATIO;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1;CYP3A5*1, CYP3A5*3;EFFICACY;INCREASED;RISK;EFFICACY:ACUTE_CELLULAR_REJECTION;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;CAUTION_SIDE_EFFECT
IRINOTECAN;DPYD;T;rs1042482;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:NEUTROPENIA;;;CAUTION_SIDE_EFFECT
PAZOPANIB;UGT1A1;*28 + *37 + *6;UGT1A1*6, UGT1A1*28, UGT1A1*37;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HYPERBILIRUBINEMIA;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;CAUTION_SIDE_EFFECT
METHADONE;CYP3A4;A;rs4646440;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:SIDE_EFFECTS;PEOPLE;DISEASE:HEROIN_DEPENDENCE;CAUTION_SIDE_EFFECT
WARFARIN;VKORC1;CC;rs9923231;OTHER;INCREASED;LIKELIHOOD;OTHER:HAVING_WARFARIN_DOSE_GREATER_THAN_7.5_MG/DAY;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PHENPROCOUMON;CYP2C9;*2 + *3;CYP2C9*1, CYP2C9*2, CYP2C9*3;EFFICACY;DECREASED;;EFFICACY:TIME_TO_ACHIEVE_STABLE_DOSE;;;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;PPP2R5D;C;rs3805945;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUTROPENIA;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1, CYP2C19*2;EFFICACY;INCREASED;RISK;EFFICACY:STROKE;PEOPLE;DISEASE:CEREBROVASCULAR_DISORDERS;CAUTION_SIDE_EFFECT
ATAZANAVIR / RITONAVIR, LAMIVUDINE, ZIDOVUDINE;UGT1A1;*1/*36 + *28/*36 + *36/*37 + *1/*1;UGT1A1*1, UGT1A1*28, UGT1A1*36, UGT1A1*37;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:HYPERBILIRUBINEMIA;WOMEN;OTHER:HIV_INFECTIOUS_DISEASE, OTHER:PREGNANCY;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;CCNK;G;rs77769901;TOXICITY;DECREASED;RISK;SIDE_EFFECT:NEUTROPENIA;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE;SCN1A;TT;rs3812718;EFFICACY;INCREASED;RISK;EFFICACY:DISCONTINUATION;PEOPLE;OTHER:EPILEPSY;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN, SIMEPREVIR;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;*2;CYP2C9*1, CYP2C9*2;TOXICITY;INCREASED;RISK;SIDE_EFFECT:MAJOR_BUT_NOT_MINOR_HEMORRHAGE;;;CAUTION_SIDE_EFFECT
NAN;CHRNB2;GG;rs2072661;NAN;INCREASED;LIKELIHOOD;OTHER:SMOKING_CESSATION;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*3;CYP2C9*1, CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE_EFFECT:MAJOR_BUT_NOT_MINOR_HEMORRHAGE;;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*28/*28;UGT1A1*1, UGT1A1*28;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:DIARRHEA;PEOPLE;OTHER:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
ROSIGLITAZONE;PLIN1;CT + TT;rs894160;TOXICITY;DECREASED;;SIDE_EFFECT:WEIGHT_GAIN;PEOPLE;OTHER:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM;;T;rs836554;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:LUNG_NEOPLASMS;CAUTION_SIDE_EFFECT
CYCLOSPORINE, METHOTREXATE;ABCC1;GG + GT;rs17264736;EFFICACY;DECREASED;RISK;SIDE_EFFECT:GRAFT_VS_HOST_DISEASE;PEOPLE;OTHER:HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHADONE;CYP2B6;*6;CYP2B6*6;TOXICITY;INCREASED;SEVERITY;DISEASE:PAIN;MEN;DISEASE:OPIOID-RELATED_DISORDERS;CAUTION_SIDE_EFFECT
OXCARBAZEPINE;HLA-B;*15:01;HLA-B*15:01;TOXICITY;DECREASED;RISK;SIDE_EFFECT:MACULOPAPULAR_EXANTHEMA;PEOPLE;DISEASE:EPILEPSY;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;LRP5;T;rs3736228;NAN;INCREASED;RISK;OTHER:OSTEOPOROTIC_FRACTURE;;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;PIK3R2;A;rs118129530;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUTROPENIA;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
CITALOPRAM;CYP2D6;*1/*4;CYP2D6*1, CYP2D6*4;METABOLISM/PK;INCREASED;;PK:AUC_OF_CITALOPRAM;HEALTHY;;CAUTION_DOSE_ADJUST
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;PIK3R2;T;rs148013902;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUTROPENIA;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
DRUGS USED IN NICOTINE DEPENDENCE;COMT;AA;rs4680;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:SMOKING_CESSATION;PEOPLE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;*1/*3 + *3/*3;CYP3A5*1, CYP3A5*3;EFFICACY;DECREASED;RISK;EFFICACY:TRANSPLANT_REJECTION;PEOPLE;DISEASE:HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;ANKK1;AA + AG;rs1800497;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:SMOKING_CESSATION;PEOPLE;OTHER:FEMALE_GENDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
VALGANCICLOVIR;ABCC4;AC;rs11568658;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUTROPENIA;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;INCREASED;;EFFICACY:PLATELET_REACTIVITY;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;PIK3R2;T;rs145623321;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUTROPENIA;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
CYCLOSPORINE, METHOTREXATE;NFATC1;CC;rs1017860;EFFICACY;INCREASED;RISK;SIDE_EFFECT:GRAFT_VS_HOST_DISEASE;PEOPLE;OTHER:HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;CYP2C8;A;rs117458836;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUTROPENIA;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
PRASUGREL;PEAR1;AA;rs822442;EFFICACY;DECREASED;;EFFICACY:INHIBITION_OF_ADP-INDUCED_PLATELET_AGGREGATION;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP2C8;*3;CYP2C8*1, CYP2C8*3;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:DELAYED_GRAFT_FUNCTION;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
CARBAMAZEPINE;HLA-B;*15:21;HLA-B*07:02, HLA-B*15:21;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;;;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;COMT;G;rs4680;TOXICITY, OTHER;DECREASED;RISK;DISEASE:TOBACCO_USE_DISORDER;;OTHER:SMOKERS;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;DPYD;;DPYD DEFICIENCY;TOXICITY;;;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_DOSE_ADJUST
TAMOXIFEN;CYP2D6;*3 + *4 + *5 + *10 + *41;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*41;EFFICACY;INCREASED;RISK;EFFICACY:RECURRENCE;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
AMOXICILLIN, CLAVULANATE;HLA-DRB1;*15:01;HLA-DRB1*15:01;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;;;CAUTION_SIDE_EFFECT
RISPERIDONE;CYP2D6;*4/*4;CYP2D6*1, CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ADVERSE_EVENTS;;;CAUTION_SIDE_EFFECT
RISPERIDONE;CYP2D6;*4/*4 + *4/*5 + *4/*6;CYP2D6*4, CYP2D6*5, CYP2D6*6;EFFICACY;DECREASED;;EFFICACY:REDUCTION_IN_PSYCHOTIC_SYMPTOMS;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1, CYP2C9*2, CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HEMORRHAGE;PEOPLE;DISEASE:VENOUS_THROMBOEMBOLISM;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-A;*31:01;HLA-A*31:01;TOXICITY;INCREASED;RISK;DISEASE:STEVENS-JOHNSON_SYNDROME;;;CAUTION_SIDE_EFFECT
PHENPROCOUMON;CYP2C9;*1/*2 + *2/*2 + *1/*3 + *3/*3;CYP2C9*1, CYP2C9*2, CYP2C9*3;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:OVER-ANTICOAGULATION;;;CAUTION_SIDE_EFFECT
PHENYTOIN;HLA-A;*02:01;HLA-A*02:01;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;;;CAUTION_SIDE_EFFECT
LAMOTRIGINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:MACULOPAPULAR_EXANTHEMA, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;PEOPLE;SIDE_EFFECT:EPILEPSY;CAUTION_SIDE_EFFECT
BOSENTAN;CYP2C9;*3;CYP2C9*1, CYP2C9*3;METABOLISM/PK;DECREASED;;PK:BOSENTAN_METABOLISM_IN_VITRO;;;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;CYP2C9;*1/*2 + *2/*2 + *3/*3 + *1/*3 + *2/*3;CYP2C9*1, CYP2C9*2, CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HEMORRHAGE;;;CAUTION_SIDE_EFFECT
CLOZAPINE;CYP2C19;*2;CYP2C19*1, CYP2C19*2;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:METABOLIC_SYNDROME;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
BOSENTAN;CYP2C9;*2;CYP2C9*1, CYP2C9*2;METABOLISM/PK;DECREASED;;PK:BOSENTAN_METABOLISM_IN_VITRO;;;CAUTION_DOSE_ADJUST
CAPECITABINE, FLUOROURACIL;DPYD;CT;rs3918290;TOXICITY;INCREASED;;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
FOLFIRI;UGT1A1;*1/*28 + *28/*28;UGT1A1*1, UGT1A1*28;TOXICITY;INCREASED;;SIDE_EFFECT:NEUTROPENIA;PEOPLE;OTHER:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED;RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-A;*31:01;HLA-A*31:01;TOXICITY;INCREASED;RISK;DISEASE:DRUG_HYPERSENSITIVITY;;;CAUTION_SIDE_EFFECT
ATORVASTATIN;TNF;GG;rs1800629;EFFICACY;INCREASED;;EFFICACY:BONE_MARROW_DENSITY_IN_THE_LUMBAR_SPINE;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1, CYP2C9*2, CYP2C9*3;EFFICACY;DECREASED;;EFFICACY:TIME_IN_THERAPEUTIC_RANGE;;;LIKELIHOOD_THERAPEUTIC_FAILURE
ACENOCOUMAROL;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *3/*3;CYP2C9*1, CYP2C9*2, CYP2C9*3;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE;;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-A;*31:01;HLA-A*31:01;TOXICITY;INCREASED;RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;;;CAUTION_SIDE_EFFECT
LAMOTRIGINE;HLA-B;*44:03;HLA-B*44:03;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:MACULOPAPULAR_EXANTHEMA;PEOPLE;DISEASE:EPILEPSY;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*15:11;HLA-B*15:11;TOXICITY;INCREASED;RISK;DISEASE:STEVENS-JOHNSON_SYNDROME;;;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL4;G/TT + GG;rs11322783;EFFICACY;INCREASED;RISK;EFFICACY:TREATMENT_FAILURE_IN_JAPANESE_PATIENTS_WITH_WITH_CHRONIC_GENOTYPE_1_HCV_INFECTION;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIR;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;;EFFICACY:RESPONSE_(SVR_RATE)_TO_HCV_TRIPLE_THERAPY_(TELAPREVIR_(TVR), PEG-INTERFERON_(PEG-IFN)_PLUS_RIBAVIRIN_(RBV)_COMBINATION_THERAPY);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN;UGT1A1;*28;UGT1A1*1, UGT1A1*28;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUTROPENIA;PEOPLE;OTHER:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;DISEASE:STEVENS-JOHNSON_SYNDROME;;;CAUTION_SIDE_EFFECT
LAMOTRIGINE;HLA-A;*02:07;HLA-A*02:07;TOXICITY;INCREASED;RISK;SIDE_EFFECT:MACULOPAPULAR_EXANTHEMA, SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;PEOPLE;DISEASE:EPILEPSY;CAUTION_SIDE_EFFECT
FLUCLOXACILLIN;HLA-C;*06:02;HLA-C*06:02;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;;;CAUTION_SIDE_EFFECT
NICOTINE;CYP2A6;;CYP2A6 LOW ACTIVITY;TOXICITY;DECREASED;RISK;OTHER:RECURRENCE;PEOPLE;OTHER:TOBACCO_USE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUVOXAMINE, PAROXETINE;SLC6A4;HTTLPR long form (L allele);SLC6A4 HTTLPR LONG FORM (L ALLELE), SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;;EFFICACY:IMPROVEMENT_BASED_ON_HAM-D_SCORE_PERCENTAGE_REDUCTION;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;CYP2A6;;CYP2A6 LOW ACTIVITY;TOXICITY;DECREASED;RISK;DISEASE:TOBACCO_USE_DISORDER;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PHENYTOIN;CYP2C9;*3;CYP2C9*1, CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE_EFFECT:MACULOPAPULAR_EXANTHEMA, SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;;;CAUTION_SIDE_EFFECT
METHAZOLAMIDE;HLA-C;*01:02;HLA-C*01:02;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;;;CAUTION_SIDE_EFFECT
METHAZOLAMIDE;HLA-B;*59:01;HLA-B*59:01;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*6;CYP2C9*1, CYP2C9*6;TOXICITY;INCREASED;RISK;SIDE_EFFECT:MAJOR__BUT_NOT_MINOR_HEMORRHAGE;;;CAUTION_SIDE_EFFECT
METHOTREXATE;SLCO1B1;T;rs11045879;OTHER, METABOLISM/PK;INCREASED;;PK:CLEARANCE;PEOPLE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;*17/*17;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HEMORRHAGE;;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*11;CYP2C9*1, CYP2C9*11;TOXICITY;INCREASED;RISK;SIDE_EFFECT:MAJOR__BUT_NOT_MINOR_HEMORRHAGE;;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*5;CYP2C9*1, CYP2C9*5;TOXICITY;INCREASED;RISK;SIDE_EFFECT:MAJOR_BUT_NOT_MINOR_HEMORRHAGE;;;CAUTION_SIDE_EFFECT
CODEINE, TRAMADOL;CYP2D6;;CYP2D6 POOR_METABOLIZER;EFFICACY;INCREASED;LIKELIHOOD;DISEASE:PAIN;PEOPLE;DISEASE:PAIN;LIKELIHOOD_THERAPEUTIC_SUCCESS
BOSENTAN;CYP2C9;*2;CYP2C9*1, CYP2C9*2;TOXICITY;INCREASED;RISK;DISEASE:DRUG-INDUCED_LIVER_INJURY;;;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;TOXICITY;INCREASED;RISK;DISEASE:DIARRHEA;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*1/*3 + *3/*3;CYP3A5*1, CYP3A5*3;TOXICITY;INCREASED;SEVERITY;OTHER:TUBULAR_VACUOLAR_DEGENERATION;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*1/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;DECREASED;;PK:DOSE-ADJUSTED_TROUGH_LEVELS;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;TOXICITY;INCREASED;SEVERITY;DISEASE:INTERSTITIAL_FIBROSIS;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;DECREASED;;PK:CONCENTRATION/DOSE_RATIO;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;DECREASED;;PK:C/D_RATIO;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;EFFICACY;INCREASED;;EFFICACY:PLATELET_REACTIVITY_AFTER_9MONTH_OF_TREATMENT;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;*1/*1;CYP3A5*1, CYP3A5*3;TOXICITY;INCREASED;RISK;PK:ACUTE_REJECTION;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*1/*1 + *1/*3 + *1/*6 + *1/*7;CYP3A5*1, CYP3A5*3, CYP3A5*6, CYP3A5*7;EFFICACY;INCREASED;RISK;EFFICACY:DELAYED_GRAFT_FUNCTION;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*1/*3 + *3/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;INCREASED;;PK:BLOOD_CONCENTRATIONS;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEPHROTOXICITY;PEOPLE;DISEASE:HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION;CAUTION_SIDE_EFFECT
ACENOCOUMAROL;CYP2C9;*1/*2 + *2/*2 + *2/*3 + *1/*3;CYP2C9*1, CYP2C9*2, CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OVER-ANTICOAGULATION;;;CAUTION_SIDE_EFFECT
ACE INHIBITORS, PLAIN;BDKRB2;(GGTGGGGAC)2/(GGTGGGGAC)2 + (GGTGGGGAC)2/GGTGGGGACGGTGGGGACGGTGGGGAC;rs71103505;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ANGIOEDEMA, SIDE_EFFECT:COUGH;;;CAUTION_SIDE_EFFECT
CODEINE, TRAMADOL;CYP2D6;;CYP2D6 POOR, ULTRARAPID METABOLIZER;EFFICACY, TOXICITY, METABOLISM/PK;INCREASED;LIKELIHOOD;SIDE_EFFECT:DISCONTINUATION;PEOPLE;DISEASE:PAIN;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;KCNE1;T;rs727957;OTHER;INCREASED;;OTHER:QT_INTERVAL;;;CAUTION_DOSE_ADJUST
AMOXICILLIN, CLAVULANATE;HLA-DRB1;*07:01;HLA-DRB1*07:01;TOXICITY;DECREASED;RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OXCARBAZEPINE;HLA-B;*38:02;HLA-B*38:02;TOXICITY;INCREASED;RISK;DISEASE:MACULOPAPULAR_EXANTHEMA;;;CAUTION_SIDE_EFFECT
HYDROCHLOROTHIAZIDE;ACE;del/del;rs1799752;EFFICACY;INCREASED;;EFFICACY:REDUCTION_IN_SYSTOLIC_BLOOD_PRESSURE;PEOPLE;DISEASE:ESSENTIAL_HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;TYMS;del/del;rs11280056;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:MUCOSITIS;PEOPLE;OTHER:HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION;CAUTION_SIDE_EFFECT
PERINDOPRIL;ACE;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;rs1799752;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ACEI-RELATED_COUGH;PEOPLE;DISEASE:DIABETES_MELLITUS_T2;CAUTION_SIDE_EFFECT
METHOTREXATE;TYMS;del/del;rs11280056;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;RGS2;TC/del + del/del;rs34717272;OTHER;INCREASED;RISK;DISEASE:HYPERTENSION;;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-A;*02:01;HLA-A*02:01;TOXICITY;INCREASED;RISK;DISEASE:MACULOPAPULAR_EXANTHEMA;;;CAUTION_SIDE_EFFECT
METHOTREXATE;C18orf56, TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;rs45445694;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:MYELOSUPPRESSION;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-DRB1;*14:05;HLA-DRB1*14:05;TOXICITY;INCREASED;RISK;DISEASE:MACULOPAPULAR_EXANTHEMA;;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;CBR3;T;rs74743371;TOXICITY;DECREASED;RISK;SIDE_EFFECT:NEUTROPENIA;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE;HLA-B;*58:01;HLA-B*58:01;TOXICITY;DECREASED;RISK;DISEASE:MACULOPAPULAR_EXANTHEMA;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACENOCOUMAROL;CYP2C9;*1/*3 + *3/*3;CYP2C9*1, CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OVER-ANTICOAGULATION;;;CAUTION_SIDE_EFFECT
METHOTREXATE;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;rs45445694;TOXICITY;INCREASED;RISK;DISEASE:STOMATITIS;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
LAMOTRIGINE;HLA-A;*30:01;HLA-A*30:01;TOXICITY;INCREASED;RISK;DISEASE:MACULOPAPULAR_EXANTHEMA;;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-DRB1;*03:01;HLA-DRB1*03:01;TOXICITY;DECREASED;RISK;DISEASE:MACULOPAPULAR_EXANTHEMA;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OXCARBAZEPINE;HLA-B;*13:02;HLA-B*13:02;TOXICITY;INCREASED;RISK;DISEASE:MACULOPAPULAR_EXANTHEMA;PEOPLE;DISEASE:EPILEPSY;CAUTION_SIDE_EFFECT
OXCARBAZEPINE;HLA-B;*15:27;HLA-B*15:27;TOXICITY;INCREASED;RISK;DISEASE:MACULOPAPULAR_EXANTHEMA;PEOPLE;DISEASE:EPILEPSY;CAUTION_SIDE_EFFECT
OXCARBAZEPINE;HLA-B;*15:19;HLA-B*15:19;TOXICITY;INCREASED;RISK;DISEASE:MACULOPAPULAR_EXANTHEMA;PEOPLE;DISEASE:EPILEPSY;CAUTION_SIDE_EFFECT
OXCARBAZEPINE;HLA-B;*48:04;HLA-B*48:04;TOXICITY;INCREASED;RISK;DISEASE:MACULOPAPULAR_EXANTHEMA;PEOPLE;DISEASE:EPILEPSY;CAUTION_SIDE_EFFECT
RALOXIFENE;UGT1A1;*28/*28;UGT1A1*1, UGT1A1*28;EFFICACY;INCREASED;;EFFICACY:BONE_MINERAL_DENSITY;WOMEN;DISEASE:OSTEOPOROSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;HLA-DQB1;*03:02;HLA-DQB1*03:02;EFFICACY, TOXICITY;DECREASED;SEVERITY;DISEASE:ASPIRIN-INDUCED_ASTHMA;PEOPLE;SIDE_EFFECT:ASPIRIN-INDUCED_ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
OXCARBAZEPINE;HLA-B;*27:09;HLA-B*27:09;TOXICITY;INCREASED;RISK;DISEASE:MACULOPAPULAR_EXANTHEMA;PEOPLE;DISEASE:EPILEPSY;CAUTION_SIDE_EFFECT
NEVIRAPINE;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED;RISK;DISEASE:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
TAMOXIFEN;ABCB1;AG;rs1045642;OTHER;INCREASED;RISK;OTHER:DISEASE_RECURRENCE;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
NEVIRAPINE;HLA-B;*58:02;HLA-B*58:02;TOXICITY;DECREASED;RISK;DISEASE:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;CC;rs12979860;EFFICACY;;;EFFICACY:HIGHER_MEAN_BASELINE_HCV_RNA_LEVEL_AND_STEEPER_1ST_PHASE_HCV_RNA_DECLINE_IN_GENOTYPE_2_AND_3_HCV_INFECTED_PATIENTS;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;CAUTION_DOSE_ADJUST
PRASUGREL;PEAR1;TT;rs3737224;EFFICACY;DECREASED;;EFFICACY:INHIBITION_OF_ADP-INDUCED_PLATELET_AGGREGATION;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
NEVIRAPINE;HLA-C;*02:10;HLA-C*02:10;TOXICITY;DECREASED;RISK;DISEASE:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOSPORINE, METHOTREXATE;ABCC1;AA + AG;rs4781712;EFFICACY;DECREASED;RISK;SIDE_EFFECT:GRAFT_VS_HOST_DISEASE;PEOPLE;OTHER:HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE;HLA-A;*31:01;HLA-A*31:01;TOXICITY;INCREASED;RISK;DISEASE:MACULOPAPULAR_EXANTHEMA;;;CAUTION_SIDE_EFFECT
CAPECITABINE, FLUOROURACIL;MIR27A;CT;rs895819;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;OTHER:NEOPLASMS;CAUTION_SIDE_EFFECT
OLANZAPINE;ABCB1;GG;rs4728709;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ASTHENIA;HEALTHY;;CAUTION_SIDE_EFFECT
BUPROPION;CYP2B6;TT;rs3211371;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:SMOKING_CESSATION;PEOPLE;OTHER:FEMALE_GENDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;TP53AIP1;T;rs118088833;TOXICITY;DECREASED;RISK;SIDE_EFFECT:NEUTROPENIA;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN, SULFASALAZINE;CYP2D6;*3 + *4;CYP2D6*3, CYP2D6*4, CYP2D6*5;DOSAGE, TOXICITY;INCREASED;LIKELIHOOD;DISEASE:BRAIN_NEOPLASMS;CHILDREN;SIDE_EFFECT:RUSSITIS;CAUTION_DOSE_ADJUST
PRASUGREL;PEAR1;TT;rs41273215;EFFICACY;DECREASED;;EFFICACY:INHIBITION_OF_ADP-INDUCED_PLATELET_AGGREGATION;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
PAROXETINE;SLC6A4;HTTLPR short form (S allele);SLC6A4 HTTLPR LONG FORM (L ALLELE), SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;;EFFICACY:TIME_TO_IMPROVE_(BASED_ON_MEAN_REDUCTIONS_FROM_BASELINE_IN_HRSD);PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
TAMOXIFEN;ABCB1;AG;rs1045642;OTHER;INCREASED;RISK;OTHER:DISEASE_RECURRENCE;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;GNL3;T;rs112242273;TOXICITY;DECREASED;RISK;SIDE_EFFECT:NEUTROPENIA;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
TRAMADOL;CYP2D6;*10/*10;CYP2D6*1, CYP2D6*10;DOSAGE;;;OTHER:SIGNIFICANTLY_HIGHER_TRAMADOL_CONSUMPTION_IN_CHINESE_GASTRIC_CANCER_PATIENTS_RECOVERING_FROM_GASTRECTOMY;;;CAUTION_DOSE_ADJUST
PRASUGREL;PEAR1;CC;rs822441;EFFICACY;DECREASED;;EFFICACY:INHIBITION_OF_ADP-INDUCED_PLATELET_AGGREGATION;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
FOLFIRI;UGT1A1;*1/*28 + *28/*28;UGT1A1*1, UGT1A1*28;TOXICITY, METABOLISM/PK;INCREASED;SEVERITY;SIDE_EFFECT:NEUTROPENIA;PEOPLE;OTHER:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
VORICONAZOLE;CYP2C19;*1/*17 + *17/*17;CYP2C19*1, CYP2C19*17;TOXICITY;INCREASED;RISK;DISEASE:CARCINOMA, SQUAMOUS_CELL;PEOPLE;DISEASE:LUNG_TRANSPLANTATION;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C9;*2;CYP2C9*1, CYP2C9*2;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ADVERSE_CARDIOVASCULAR_EVENTS;;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*1/*2 + *1/*3;CYP2C9*1, CYP2C9*2, CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HEMORRHAGE;;;CAUTION_SIDE_EFFECT
CYTARABINE, IDARUBICIN;ABCB1;CC;rs2032582;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:COMPLETE_REMISSION;PEOPLE;DISEASE:ACUTE_MYELOID_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIDEPRESSANTS;SLC6A4;HTTLPR short form (S allele)/HTTLPR long form (L allele) + HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR LONG FORM (L ALLELE), SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;;;EFFICACY:NON-RESPONSE;PEOPLE;DISEASE:MOOD_DISORDER;CAUTION_DOSE_ADJUST
CAFFEINE;CYP1A2;;CYP1A2 HIGH ACTIVITY;TOXICITY;INCREASED;RISK;DISEASE:ABORTION, SPONTANEOUS;WOMEN;DISEASE:PREGNANCY;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*1/*3;CYP2C9*1, CYP2C9*3;DOSAGE;DECREASED;;OTHER:WARFARIN_DOSE_IN_KOREAN_PATIENTS_WITH_MECHANICAL_HEART_VALVE_REPLACEMENT_SINCE_DAY_7_OF_WARFARIN_THERAPY;;;CAUTION_DOSE_ADJUST
ANTIDEPRESSANTS;SLC6A4;HTTLPR short form (S allele)/HTTLPR long form (L allele) + HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR LONG FORM (L ALLELE), SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;;;EFFICACY:NON-RESPONSE;PEOPLE;DISEASE:MOOD_DISORDER;CAUTION_DOSE_ADJUST
ANTIDEPRESSANTS;SLC6A4;HTTLPR short form (S allele)/HTTLPR long form (L allele) + HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR LONG FORM (L ALLELE), SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;;;EFFICACY:NON-RESPONSE;PEOPLE;DISEASE:MOOD_DISORDER;CAUTION_DOSE_ADJUST
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;CHILDREN;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;TOP2A;A;rs181501757;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUTROPENIA;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
LAMOTRIGINE;HLA-B;*13:02;HLA-B*13:02;TOXICITY;INCREASED;RISK;DISEASE:MACULOPAPULAR_EXANTHEMA;;;CAUTION_SIDE_EFFECT
ANTIDEPRESSANTS;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR LONG FORM (L ALLELE), SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:REMISSION_AFTER_SECOND_TREATMENT_SWITCH;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
LAMOTRIGINE;HLA-A;*33:03;HLA-A*33:03;TOXICITY;DECREASED;RISK;DISEASE:MACULOPAPULAR_EXANTHEMA;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIDEPRESSANTS;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR LONG FORM (L ALLELE), SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;;;EFFICACY:IMPROVED_SECOND_TREATMENT_SWITCH_RESPONSE;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DOSE_ADJUST
BELINOSTAT;UGT1A1;*1/*60 + *60/*60;UGT1A1*1, UGT1A1*60;TOXICITY;INCREASED;RISK;SIDE_EFFECT:THROMBOCYTOPENIA;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;;;CAUTION_SIDE_EFFECT
ANTIDEPRESSANTS;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR LONG FORM (L ALLELE), SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:RESPONSE;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;PERP;T;rs9402944;TOXICITY;DECREASED;RISK;SIDE_EFFECT:NEUTROPENIA;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIDEPRESSANTS;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR LONG FORM (L ALLELE), SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;;;EFFICACY:NON-REMISSION;PEOPLE;DISEASE:MOOD_DISORDER;CAUTION_DOSE_ADJUST
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;OAS1;AG;rs2660;TOXICITY;DECREASED;RISK;DISEASE:ANEMIA;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIDEPRESSANTS;SLC6A4;HTTLPR short form (S allele)/HTTLPR long form (L allele) + HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR LONG FORM (L ALLELE), SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;;;EFFICACY:NON-RESPONSE;PEOPLE;DISEASE:MOOD_DISORDER;CAUTION_DOSE_ADJUST
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;;;CAUTION_SIDE_EFFECT
NAN;VDR;A;rs731236;NAN;INCREASED;RISK;DISEASE:ASTHMA;;;CAUTION_SIDE_EFFECT
OLANZAPINE;ABCB1;CC;rs3842;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:CARDIAC_RHYTHM_DISEASE;HEALTHY;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;A;rs10929302;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:NEUTROPENIA;;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;CBR3;T;rs112783657;TOXICITY;DECREASED;RISK;SIDE_EFFECT:NEUTROPENIA;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUPROPION;GALR1;CC + CT;rs2717162;EFFICACY;DECREASED;LIKELIHOOD;OTHER:SMOKING_CESSATION;;;LIKELIHOOD_THERAPEUTIC_FAILURE
CARBAMAZEPINE;HLA-B;*46:01;HLA-B*46:01;TOXICITY;DECREASED;RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
HEROIN;OPRM1;AG;rs1799971;TOXICITY;INCREASED;RISK;OTHER:HEROIN_DEPENDENCE;;;CAUTION_SIDE_EFFECT
CYCLOSPORINE, METHOTREXATE;NFATC1;GG;rs8090560;EFFICACY;INCREASED;RISK;SIDE_EFFECT:GRAFT_VS_HOST_DISEASE;PEOPLE;OTHER:HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION;CAUTION_SIDE_EFFECT
VINCRISTINE;CYP3A5;*1/*3;CYP3A5*1, CYP3A5*3;TOXICITY;DECREASED;LIKELIHOOD;DISEASE:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ALLOPURINOL;HLA-A;*33:03;HLA-A*33:03;TOXICITY;INCREASED;RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;;;CAUTION_SIDE_EFFECT
ALLOPURINOL;HLA-C;*03:02;HLA-C*03:02;TOXICITY;INCREASED;RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;TPMT;*1/*3A;TPMT*1, TPMT*3A;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:NAUSEA_AND_VOMITING;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
RISPERIDONE;LEP;A;rs7799039;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:WEIGHT_GAIN;CHILDREN;;CAUTION_SIDE_EFFECT
BUPROPION;GALR1;CC + CT;rs2717162;EFFICACY;INCREASED;RISK;EFFICACY:RECURRENCE;PEOPLE;DISEASE:TOBACCO_USE_DISORDER;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;CTLA4;AG;rs231775;TOXICITY;DECREASED;RISK;DISEASE:ANEMIA;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;NOS1;G;rs149212925;TOXICITY;DECREASED;RISK;SIDE_EFFECT:NEUTROPENIA;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOSPORINE, METHOTREXATE;DHFR;GG;rs34965641;EFFICACY;DECREASED;RISK;SIDE_EFFECT:GRAFT_VS_HOST_DISEASE;PEOPLE;OTHER:HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETRAVIRINE;CYP2C19;AA + AG;rs4244285;METABOLISM/PK;DECREASED;;PK:ETRAVIRINE_CLEARANCE;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DOSE_ADJUST
CISPLATIN;ERCC1;A;rs3212986;EFFICACY;INCREASED;;EFFICACY:OVERALL_SURVIVAL_AND_PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:NEOPLASM_OF_ESOPHAGUS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ROSUVASTATIN;ABCG2;T;rs2231142;EFFICACY;INCREASED;;EFFICACY:REDUCTION_IN_LOW-DENSITY_LIPOPROTEIN_CHOLESTEROL_(LDL-C)_LEVEL, IN_A_GENE-DOSE-DEPENDENT_MANNER,;PEOPLE;DISEASE:HYPERCHOLESTEROLEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;MTHFR;TT;rs1801131;TOXICITY;INCREASED;RISK;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:RECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
FLUOXETINE, PAROXETINE;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR LONG FORM (L ALLELE), SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;;EFFICACY:IMPROVEMENT_BASED_ON_CHANGE_OF_HAM-D_SCORE_AFTER_ANTIDEPRESSANT_MEDICATION;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;PIK3R2;T;rs58695150;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUTROPENIA;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
PEMETREXED;GGH;A;rs11545078;TOXICITY;DECREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA, DISEASE:MESOTHELIOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
METFORMIN;SLC22A1;GAT/del;rs72552763;OTHER, METABOLISM/PK;DECREASED;;EFFICACY:TROUGH_METFORMIN_STEADY-STATE_CONCENTRATION;PEOPLE;DISEASE:DIABETES_MELLITUS_T2;CAUTION_DOSE_ADJUST
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;PEOPLE;DISEASE:NEUROPATHIC_PAIN;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-A;*31:01;HLA-A*31:01;TOXICITY;INCREASED;RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;;;CAUTION_SIDE_EFFECT
PHENAZEPAM;CYP2C19;*2;CYP2C19*1, CYP2C19*2;TOXICITY;INCREASED;;SIDE_EFFECT:DRUG_TOXICITY;MEN;OTHER:ALCOHOL_ABUSE, OTHER:ANXIETY_DISORDERS;CAUTION_SIDE_EFFECT
CAPECITABINE;CDA;AG + GG;rs602950;TOXICITY;INCREASED;RISK;DISEASE:DEHYDRATION;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
METHOTREXATE;C18orf56, TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;DECREASED;;EFFICACY:PROGRESSION_FREE_SURVIVAL;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL, IRINOTECAN, LEUCOVORIN;DPYD;;DPYD LOW ACTIVITY;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
PHENYTOIN;HLA-C;*08:01;HLA-C*08:01;TOXICITY;INCREASED;RISK;SIDE_EFFECT:MACULOPAPULAR_EXANTHEMA;;;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;;DPYD DEFICIENCY;TOXICITY;;;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:NEOPLASMS;CAUTION_DOSE_ADJUST
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;PIK3R2;G;rs150688309;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUTROPENIA;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
CAPECITABINE;CDA;AG + GG;rs602950;TOXICITY;INCREASED;RISK;DISEASE:DIARRHEA;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;;;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*2;CYP2D6*2;EFFICACY;DECREASED;LIKELIHOOD;DISEASE:BREAST_NEOPLASMS;WOMEN;;LIKELIHOOD_THERAPEUTIC_FAILURE
CARBAMAZEPINE;HLA-A;*31:01;HLA-A*31:01;TOXICITY;INCREASED;RISK;DISEASE:MACULOPAPULAR_EXANTHEMA;;;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP3A4;*22;CYP3A4*1, CYP3A4*22;TOXICITY;DECREASED;;SIDE_EFFECT:HOT_FLASHES;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE;HLA-A;*31:01;HLA-A*31:01;TOXICITY;INCREASED;RISK;DISEASE:DRUG_HYPERSENSITIVITY;;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-A;*74:01;HLA-A*74:01;TOXICITY;INCREASED;RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*3;CYP2C9*1, CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOTAL_HEMORRHAGE_AND_MAJOR_HEMORRHAGE;;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1, CYP2C19*2;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:CORONARY_RESTENOSIS;PEOPLE;DISEASE:PERIPHERAL_VASCULAR_DISEASES;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE;HLA-A;*02:01;HLA-A*02:01;TOXICITY;DECREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CODEINE;SLC22A1;;SLC22A1 LOW ACTIVITY;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DIZZINESS, SIDE_EFFECT:DRUG_TOXICITY, SIDE_EFFECT:HEADACHE, SIDE_EFFECT:NAUSEA, SIDE_EFFECT:SEDATION;HEALTHY;;CAUTION_SIDE_EFFECT
DAPSONE;HLA-B;*13:01;HLA-B*13:01;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS;PEOPLE;DISEASE:SKIN_DISORDER;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*3;CYP2C9*1, CYP2C9*3;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:OVER_ANTI-COAGULATION;;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;TPMT;*1/*3A + *1/*3C + *3A/*3A;TPMT*1, TPMT*3A, TPMT*3C;TOXICITY;INCREASED;RISK;DISEASE:LEUKOPENIA;PEOPLE;DISEASE:INFLAMMATORY_BOWEL_DISEASES;CAUTION_SIDE_EFFECT
OXCARBAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;DISEASE:MACULOPAPULAR_EXANTHEMA;PEOPLE;DISEASE:EPILEPSY;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*6/*6;UGT1A1*1, UGT1A1*6;TOXICITY;INCREASED;RISK;DISEASE:NEUTROPENIA;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
ETHANOL;OPRM1;G;rs1799971;NAN;INCREASED;;OTHER:ALCOHOL_RESPONSE, CONSUMPTION, AND_PREFERENCE;;;CAUTION_DOSE_ADJUST
IRINOTECAN;UGT1A1;*6/*6;UGT1A1*1, UGT1A1*6;TOXICITY;INCREASED;RISK;DISEASE:DIARRHEA;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;INCREASED;;OTHER:PLATELET_REACTIVITY;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;LIKELIHOOD_THERAPEUTIC_SUCCESS
AZATHIOPRINE;TPMT;*1/*2 + *1/*3A + *1/*3C;TPMT*1, TPMT*2, TPMT*3A, TPMT*3C;TOXICITY;INCREASED;RISK;DISEASE:TRANSPLANT_REJECTION;;DISEASE:HEART_TRANSPLANTATION;CAUTION_SIDE_EFFECT
VENLAFAXINE;CYP2D6;*4/*4;CYP2D6*4;METABOLISM/PK;INCREASED;;PK:VENLAFAXINE_LEVELS;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DOSE_ADJUST
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;HMMR;T;rs299293;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUTROPENIA;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
EXEMESTANE;;AA;rs934635;TOXICITY;;;SIDE_EFFECT:A_SIGNIFICANTLY_HIGHER_ODDS_OF_VASOMOTOR_SYMPTOMS_IN_POSTMENOPAUSAL_HORMONE_RECEPTOR_(HR)-POSITIVE_BREAST_CANCER_PATIENTS;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_DOSE_ADJUST
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;PERP;C;rs9389568;TOXICITY;DECREASED;RISK;SIDE_EFFECT:NEUTROPENIA;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;INCREASED;;OTHER:PLATELET_REACTIVITY;PEOPLE;DISEASE:CORONARY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;FOXO1;T;rs144991623;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUTROPENIA;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*1/*6;UGT1A1*1, UGT1A1*6;TOXICITY;INCREASED;RISK;DISEASE:NEUTROPENIA;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
PRASUGREL;PEAR1;AA;rs12407843;EFFICACY;DECREASED;;EFFICACY:INHIBITION_OF_ADP-INDUCED_PLATELET_AGGREGATION;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
DIGOXIN;ABCB1;AA;rs1045642;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:SUDDEN_CARDIAC_DEATH;;;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
PRASUGREL;PEAR1;AA;rs77235035;EFFICACY;DECREASED;;EFFICACY:INHIBITION_OF_ADP-INDUCED_PLATELET_AGGREGATION;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
VENLAFAXINE;CYP2D6;*4/*4;CYP2D6*1, CYP2D6*4;METABOLISM/PK;INCREASED;;PK:VENLAFAXINE_LEVELS;PEOPLE;DISEASE:OBSESSIVE_COMPULSIVE_DISORDER;CAUTION_DOSE_ADJUST
VENLAFAXINE;CYP2D6;*1/*4;CYP2D6*1, CYP2D6*4;METABOLISM/PK;INCREASED;;PK:VENLAFAXINE_LEVELS;PEOPLE;DISEASE:OBSESSIVE_COMPULSIVE_DISORDER;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;CYP2C9;*1/*2 + *2/*2;CYP2C9*1, CYP2C9*2;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:OVER-ANTICOAGULATION;;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*17/*17 + *1/*17;CYP2C19*1, CYP2C19*17;EFFICACY;INCREASED;;EFFICACY:PLATELET_AGGREGATION_INHIBITION;HEALTHY;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DIGOXIN;ABCB1;AA;rs2032582;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:SUDDEN_CARDIAC_DEATH;;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*1, CYP2C19*2, CYP2C19*3;TOXICITY;INCREASED;RISK;SIDE_EFFECT:CARDIOVASCULAR_DISEASE;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*6 + *28;UGT1A1*6, UGT1A1*28;TOXICITY;;RISK;DISEASE:NEUTROPENIA;PEOPLE;DISEASE:NEOPLASMS;CAUTION_DOSE_ADJUST
DIGOXIN;ABCB1;AA;rs1128503;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:SUDDEN_CARDIAC_DEATH;;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;METABOLISM/PK;DECREASED;;PK:CMAX_AND_AUC_OF_THIOL_METABOLITE;HEALTHY;;CAUTION_DOSE_ADJUST
CAPECITABINE;MTHFR;GG;rs1801131;TOXICITY;INCREASED;RISK;DISEASE:HAND-FOOT_SYNDROME;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED;RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*3;CYP2C9*1, CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ALL_AND_MINOR_HEMORRHAGE;;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*1/*6 + *6/*6;UGT1A1*1, UGT1A1*6;TOXICITY;INCREASED;RISK;DISEASE:NEUTROPENIA;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;PIK3R2;A;rs8110364;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUTROPENIA;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
OLANZAPINE;ABCB1;G;rs10248420;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:SOMNOLENCE;HEALTHY;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;PEOPLE;DISEASE:EPILEPSY;CAUTION_SIDE_EFFECT
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*6/*6 + *28/*28 + *6/*28;UGT1A1*1, UGT1A1*6, UGT1A1*28;TOXICITY;INCREASED;RISK;DISEASE:NEUTROPENIA;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;AG + GG;rs56293913;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:BREAST_NEOPLASMS, DISEASE:GASTROESOPHAGEAL_CANCER;CAUTION_SIDE_EFFECT
FLUTICASONE PROPIONATE;CD14, TMCO6;AA;rs2569190;EFFICACY;INCREASED;;EFFICACY:PC20;CHILDREN;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;PIK3R2;T;rs117341846;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUTROPENIA;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*3;CYP2C9*1, CYP2C9*3;DOSAGE;DECREASED;;OTHER:WARFARIN_DOSE_REQUIREMENT;;;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;EFFICACY;;;EFFICACY:SIGNIFICANTLY_DELAYED_TIME_TO_INHIBITION_OF_PLATELET_AGGREGATION_(IPA);HEALTHY;;CAUTION_DOSE_ADJUST
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;;EFFICACY:COMPLETE_EARLY_VIROLOGICAL_RESPONSE;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESCITALOPRAM;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);SLC6A4 HTTLPR LONG FORM (L ALLELE), SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:REMISSION;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;IRS1;A;rs115457081;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUTROPENIA;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*40:01;HLA-B*40:01;TOXICITY;DECREASED;RISK;DISEASE:STEVENS-JOHNSON_SYNDROME;PEOPLE;DISEASE:EPILEPSY;LIKELIHOOD_THERAPEUTIC_SUCCESS
LAMOTRIGINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;DISEASE:STEVENS-JOHNSON_SYNDROME;PEOPLE;DISEASE:EPILEPSY;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;EFFICACY;;;EFFICACY:SIGNIFICANTLY_DELAYED_TIME_TO_INHIBITION_OF_PLATELET_AGGREGATION_(IPA);HEALTHY;;CAUTION_DOSE_ADJUST
PHENYTOIN;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;DISEASE:STEVENS-JOHNSON_SYNDROME;PEOPLE;DISEASE:EPILEPSY;CAUTION_SIDE_EFFECT
ESCITALOPRAM;CYP2C19;*1/*17 + *17/*17;CYP2C19*1, CYP2C19*17;EFFICACY;INCREASED;RISK;EFFICACY:TREATMENT_FAILURE;;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;INSR;T;rs142244113;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUTROPENIA;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
CITALOPRAM;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);SLC6A4 HTTLPR LONG FORM (L ALLELE), SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:REMISSION;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN, CLOPIDOGREL;CYP2C9;*1/*3 + *3/*3;CYP2C9*1, CYP2C9*3;EFFICACY;INCREASED;RISK;SIDE_EFFECT:STENT_THROMBOSIS;PEOPLE;OTHER:PERCUTANEOUS_CORONARY_INTERVENTIONS;CAUTION_SIDE_EFFECT
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED;RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;TOXICITY;INCREASED;RISK;SIDE_EFFECT:MAJOR_ADVERSE_CARDIAC_AND_CEREBROVASCULAR_EVENTS;PEOPLE;DISEASE:MYOCARDIAL_INFARCTION;CAUTION_SIDE_EFFECT
METHOTREXATE;ATIC;GG;rs2372536;EFFICACY;DECREASED;;EFFICACY:DISEASE_ACTIVITY_AS_ASSESSED_BY_THE_PHYSICIAN;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
DOXEPIN;CYP2D6;*4/*4;CYP2D6*4;METABOLISM/PK;DECREASED;;PK:MEDIAN_ORAL_CLEARANCE_OF_DOXEPIN;HEALTHY;;CAUTION_DOSE_ADJUST
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;PIK3R2;T;rs79430272;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUTROPENIA;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
OLANZAPINE;CYP2D6;*1/*3 + *1/*4;CYP2D6*1, CYP2D6*3, CYP2D6*4;TOXICITY;INCREASED;;DISEASE:WEIGHT_GAIN;MEN;DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;TP53;T;rs4968187;TOXICITY;DECREASED;RISK;SIDE_EFFECT:NEUTROPENIA;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CITALOPRAM, FLUOXETINE, PAROXETINE;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);SLC6A4 HTTLPR LONG FORM (L ALLELE), SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:REMISSION;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN;ERCC1;AA;rs3212986;TOXICITY;DECREASED;LIKELIHOOD;DISEASE:NEPHROTOXICITY;PEOPLE;DISEASE:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
PALBOCICLIB;ABCG2;CT;rs2231137;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA;PEOPLE;OTHER:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;PIK3R2;T;rs117951771;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUTROPENIA;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
ACENOCOUMAROL;CYP2C9;*2/*2 + *2/*3 + *3/*3;CYP2C9*1, CYP2C9*2, CYP2C9*3;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:OVER-ANTICOAGULATION;;;CAUTION_SIDE_EFFECT
ESCITALOPRAM;CYP2C19;*2/*2 + *2/*3 + *3/*3 + *4/*4 + *2/*4 + *3/*4;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*4;EFFICACY;INCREASED;RISK;EFFICACY:TREATMENT_FAILURE;;;CAUTION_SIDE_EFFECT
EXEMESTANE;;AA;rs934635;TOXICITY;;;SIDE_EFFECT:A_SIGNIFICANTLY_HIGHER_ODDS_OF_MUSCULOSKELETAL_ADVERSE_EVENTS_(MSAES)_IN_POSTMENOPAUSAL_HORMONE_RECEPTOR_(HR)-POSITIVE_BREAST_CANCER_PATIENTS;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_DOSE_ADJUST
PRIMAQUINE;G6PD;;G6PD DEFICIENCY;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DECREASED_HEMOCRIT_LEVELS;PEOPLE;DISEASE:MALARIA_VIVAX;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;PIK3R2;A;rs148235907;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUTROPENIA;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
METHAMPHETAMINE;DAOA;C;rs3916965;TOXICITY;DECREASED;LIKELIHOOD;DISEASE:PSYCHOTIC_DISORDER;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;UGT1A1;G;rs34993780;OTHER;INCREASED;LIKELIHOOD;OTHER:GILBERT_SYNDROME, OTHER:CRIGLER-NAJJAR_SYNDROME;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE;CYP2C9;*2 + *3;CYP2C9 POOR_METABOLIZER;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA;PEOPLE;DISEASE:VASCULITIS, DISEASE:WEGENER_GRANULOMATOSIS;CAUTION_SIDE_EFFECT
CAPECITABINE;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;rs45445694;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:GASTROINTESTINAL_NEOPLASMS;CAUTION_SIDE_EFFECT
DESIPRAMINE;CYP2D6;*10/*10 + *5/*10;CYP2D6*1, CYP2D6*2, CYP2D6*5, CYP2D6*10;METABOLISM/PK;INCREASED;;PK:DESIPRAMINE/2-HYDROXY-DESIPRAMINE_RATIO;PEOPLE;DISEASE:MENTAL_DISORDERS;CAUTION_DOSE_ADJUST
PHENYTOIN;CYP2C9;*1/*1;CYP2C9*1;METABOLISM/PK;INCREASED;;PK:THE_INTRINSIC_METABOLIC_ACTIVITY_(V(MAX)/K(M));CHILDREN;DISEASE:EPILEPSY;CAUTION_DOSE_ADJUST
PHENYTOIN;CYP2C9;*1/*1;CYP2C9*1;METABOLISM/PK;INCREASED;;PK:THE_MEAN_MAXIMAL_ELIMINATION_RATES_(V(MAX));CHILDREN;DISEASE:EPILEPSY;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED;;OTHER:WARFARIN_DOSE;;;CAUTION_DOSE_ADJUST
ATAZANAVIR, RITONAVIR;UGT1A1;*28;UGT1A1*28;OTHER;INCREASED;RISK;SIDE_EFFECT:HYPERBILIRUBINEMIA;HEALTHY;;CAUTION_SIDE_EFFECT
ATAZANAVIR;UGT1A1;*28;UGT1A1*28;OTHER;INCREASED;RISK;SIDE_EFFECT:HYPERBILIRUBINEMIA;HEALTHY;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*1/*28;UGT1A1*1, UGT1A1*28;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUTROPENIA;;OTHER:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*28/*28;UGT1A1*1, UGT1A1*28;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUTROPENIA;;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED;RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;;;CAUTION_SIDE_EFFECT
PALBOCICLIB;SULT2A1;CC;rs182420;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DOSE_REDUCTION, SIDE_EFFECT:DISCONTINUATION;PEOPLE;OTHER:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*28/*28;UGT1A1*1, UGT1A1*28;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUTROPENIA;;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC AGENTS, TAMOXIFEN;CYP2D6;*1/*4 + *4/*4;CYP2D6*1, CYP2D6*4;EFFICACY;INCREASED;;EFFICACY:RECURRENCE_FREE_SURVIVAL;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
IMIPRAMINE;CYP2C19;*1/*17 + *17/*17;CYP2C19*1, CYP2C19*17;METABOLISM/PK;DECREASED;;PK:DOSE-CORRECTED_PLASMA_CONCENTRATIONS;PEOPLE;DISEASE:DEPRESSIVE_DISORDER;CAUTION_DOSE_ADJUST
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;HMMR;A;rs299313;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUTROPENIA;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
PRIMAQUINE;G6PD;;G6PD DEFICIENCY;OTHER;INCREASED;;OTHER:REDUCTIONS_IN_GLUTATHIONE_LEVELS;;;CAUTION_DOSE_ADJUST
SULFANILAMIDE;G6PD;;G6PD DEFICIENCY;OTHER;INCREASED;;OTHER:REDUCTIONS_IN_GLUTATHIONE_LEVELS;;;CAUTION_DOSE_ADJUST
CHLORAMPHENICOL;G6PD;;G6PD DEFICIENCY;OTHER;INCREASED;;OTHER:REDUCTIONS_IN_GLUTATHIONE_LEVELS;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*3 + *2/*3;CYP2C9*1, CYP2C9*2, CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HEMORRHAGE;;;CAUTION_SIDE_EFFECT
FOLFIRI, IRINOTECAN;UGT1A1;*28/*28 + *6/*6 + *1/*6 + *1/*28;UGT1A1*1, UGT1A1*6, UGT1A1*28;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA;PEOPLE;OTHER:BILIARY_TRACT_NEOPLASM, OTHER:PANCREATIC_NEOPLASMS;CAUTION_SIDE_EFFECT
CODEINE, MORPHINE, TRAMADOL;UGT2B7;A;rs73823859;EFFICACY;INCREASED;;EFFICACY:PAIN;CHILDREN;OTHER:SICKLE_CELL_ANEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN, DOCETAXEL;ALDH2;AA + AG;rs671;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:NAUSEA, SIDE_EFFECT:VOMITING;PEOPLE;OTHER:NEOPLASMS;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;HMMR;C;rs299314;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUTROPENIA;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*8;CYP2C9*1, CYP2C9*8;METABOLISM/PK;DECREASED;;PK:IN_VITRO_INTRINSIC_CLEARANCE_OF_S-WARFARIN_WITH_THE_CDNA-EXPRESSED_R150H_PROTEIN;;;CAUTION_DOSE_ADJUST
IRINOTECAN;UGT1A1;*28;UGT1A1*1, UGT1A1*28;TOXICITY, METABOLISM/PK;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;OTHER:NEOPLASMS;CAUTION_SIDE_EFFECT
ANTHRACYCLINES AND RELATED SUBSTANCES;CBR3;G;rs1056892;TOXICITY;INCREASED;RISK;DISEASE:HEART_FAILURE;;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*28/*28;UGT1A1*1, UGT1A1*28;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DIARRHEA;;OTHER:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
CISPLATIN;ERCC2;G;rs13181;EFFICACY;INCREASED;;EFFICACY:OVERALL_SURVIVAL_AND_PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:NEOPLASM_OF_ESOPHAGUS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ALLOPURINOL;HLA-A;*33:03;HLA-A*33:03;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, DISEASE:STEVENS-JOHNSON_SYNDROME;PEOPLE;DISEASE:DRUG_HYPERSENSITIVITY;CAUTION_SIDE_EFFECT
ALLOPURINOL;HLA-C;*03:02;HLA-C*03:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;PEOPLE;DISEASE:DRUG_HYPERSENSITIVITY;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*2;CYP2C19*1, CYP2C19*2;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS;PEOPLE;DISEASE:STROKE;CAUTION_SIDE_EFFECT
ALLOPURINOL;HLA-C;*08:01;HLA-C*08:01;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:STEVENS-JOHNSON_SYNDROME;PEOPLE;DISEASE:DRUG_HYPERSENSITIVITY;CAUTION_SIDE_EFFECT
ANTHRACYCLINES AND RELATED SUBSTANCES;CAT;CC;rs10836235;TOXICITY;INCREASED;RISK;SIDE_EFFECT:CARDIAC_DAMAGE;PEOPLE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
ACENOCOUMAROL;CYP2C9;*1/*3 + *3/*3;CYP2C9*1, CYP2C9*3;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:OVER-ANTICOAGULATION;;;CAUTION_SIDE_EFFECT
EXEMESTANE;UGT2B17;;UGT2B17 DEFICIENCY;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:FATIGUE;WOMEN;OTHER:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
PAROXETINE;SLC6A4;HTTLPR short form (S allele) + L allele-rs25531C + L allele-rs25531T;SLC6A4 HTTLPR SHORT FORM (S ALLELE), SLC6A4 L ALLELE-rs25531C, SLC6A4 L ALLELE-rs25531T;TOXICITY;INCREASED;;SIDE_EFFECT:BLEEDING_TIME;PEOPLE;DISEASE:MOOD_DISORDER;CAUTION_SIDE_EFFECT
ACENOCOUMAROL;CYP2C9;*1/*3 + *3/*3 + *2/*3;CYP2C9*1, CYP2C9*2, CYP2C9*3;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:OVER-ANTICOAGULATION;;;CAUTION_SIDE_EFFECT
VALPROIC ACID;XBP1;G;rs2269577;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:PROPHYLACTIC_TREATMENT_RESPONSE;PEOPLE;DISEASE:BIPOLAR_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACE INHIBITORS, PLAIN;ACE;del;rs1799752;TOXICITY;INCREASED;;SIDE_EFFECT:MAJOR_CARDIOVASCULAR_EVENTS_(MACE)_RATE;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;CAUTION_SIDE_EFFECT
PACLITAXEL;CYP1B1;GG;rs1056836;EFFICACY;INCREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
TAMOXIFEN;CYP2D6;*10/*10 + *4/*10 + *5/*10;CYP2D6*1, CYP2D6*4, CYP2D6*5, CYP2D6*10;EFFICACY;INCREASED;RISK;EFFICACY:RECURRENCE;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
DOCETAXEL;CYP1B1;CC;rs1056836;EFFICACY;DECREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:PROSTATIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*8;CYP2C9*1, CYP2C9*8;DOSAGE, METABOLISM/PK;DECREASED;;PK:UNBOUND_ORAL_CLEARANCE_OF_S-WARFARIN_AND_LOWER_R-_TO_S-WARFARIN_PLASMA_CONCENTRATION_RATIO;;;CAUTION_DOSE_ADJUST
CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;ABCC4;T;rs9561778;TOXICITY, METABOLISM/PK;INCREASED;RISK;SIDE_EFFECT:ADR;PEOPLE;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;ABCC4;T;rs9561778;TOXICITY, METABOLISM/PK;INCREASED;SEVERITY;DISEASE:NEUTROPENIA;PEOPLE;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;ABCC4;T;rs9561778;TOXICITY, METABOLISM/PK;INCREASED;RISK;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY;PEOPLE;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*1/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;INCREASED;;EFFICACY:ADP-INDUCED_PLATELET_AGGREGATION_(PA);;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*1/*3;CYP2C19*1, CYP2C19*3;EFFICACY;INCREASED;;EFFICACY:ADP-INDUCED_PLATELET_AGGREGATION_(PA);;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*1/*2;CYP2C19*1, CYP2C19*2;EFFICACY;INCREASED;;EFFICACY:ADP-INDUCED_PLATELET_AGGREGATION_(PA);;;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1, CYP2C9*2, CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OVER-ANTICOAGULATION;;;CAUTION_SIDE_EFFECT
ABACAVIR;HLA-B;*57:01;HLA-B*57:01;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_HYPERSENSITIVITY;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
HYDROCHLOROTHIAZIDE;ACE;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;rs1799752;OTHER;INCREASED;;OTHER:HYDROCHLOROTHIAZIDE_INDUCED_POTASSIUM_EXCRETION;MEN;DISEASE:HYPERTENSION;CAUTION_DOSE_ADJUST
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;F5;T;rs6025;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:VENOUS_THROMBOEMBOLISM;;;CAUTION_SIDE_EFFECT
ENALAPRIL;ACE;del/del;rs1799752;EFFICACY;INCREASED;;EFFICACY:BONE_MINERAL_DENSITY_RESPONSE;WOMEN;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
TAMOXIFEN;CYP2D6;*4/*4;CYP2D6*1, CYP2D6*4;EFFICACY;INCREASED;RISK;EFFICACY:DEATH;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
CLOZAPINE;HLA-B;*38:01;HLA-B*38:01;TOXICITY;INCREASED;RISK;SIDE_EFFECT:AGRANULOCYTOSIS;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
PAROXETINE;CYP2D6;*1/*1xN;CYP2D6*1, CYP2D6*1XN;METABOLISM/PK;DECREASED;;PK:PAROXETINE_SERUM_CONCENTRATION;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DOSE_ADJUST
FLUCLOXACILLIN;HLA-B;*57:01;HLA-B*57:01;TOXICITY;INCREASED;RISK;DISEASE:DRUG-INDUCED_LIVER_INJURY;;;CAUTION_SIDE_EFFECT
FLUCLOXACILLIN;HLA-B;*57:01;HLA-B*57:01;TOXICITY;INCREASED;RISK;DISEASE:DRUG-INDUCED_LIVER_INJURY;;;CAUTION_SIDE_EFFECT
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;*4;NAT2*4;TOXICITY;DECREASED;RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;PEOPLE;DISEASE:TUBERCULOSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE;ANK3;T;rs143414470;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME;PEOPLE;DISEASE:BREAST_NEOPLASMS, DISEASE:COLORECTAL_NEOPLASMS,DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
GEFITINIB;CYP2D6;*10/*10 + *5/*10;CYP2D6*1, CYP2D6*2, CYP2D6*5, CYP2D6*10, CYP2D6*14;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
LANSOPRAZOLE;CYP2C19;*2 + *3 + *8 + *9;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*8, CYP2C19*9;OTHER;INCREASED;RISK;DISEASE:RESPIRATORY_TRACT_INFECTIONS;CHILDREN;DISEASE:ASTHMA;CAUTION_SIDE_EFFECT
NEVIRAPINE;CCHCR1;T;rs130072;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEVIRAPINE-INDUCED_RASH;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
NEVIRAPINE;HLA-B;*35:05;HLA-B*35:05;TOXICITY;INCREASED;RISK;DISEASE:EXANTHEMA;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
RITONAVIR;APOC3;G;rs5128;TOXICITY;INCREASED;;SIDE_EFFECT:TRIGLYCERIDE_LEVELS;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
EFAVIRENZ;CYP2B6;T;rs3745274;TOXICITY, METABOLISM/PK;INCREASED;;PK:PLASMA_CONCENTRATION;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
METFORMIN;BDNF;C;rs6265;EFFICACY;INCREASED;LIKELIHOOD;OTHER:WEIGHT_REGAIN_AFTER_INTENTIONAL_WEIGHT_LOSS;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;*1/*18;CYP2B6*1, CYP2B6*18;METABOLISM/PK;INCREASED;;PK:PLASMA_EFAVIRENZ_LEVELS;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DOSE_ADJUST
LUMIRACOXIB;HLA-DRB1;*15:01;HLA-DRB1*01:01, HLA-DRB1*15:01;TOXICITY;INCREASED;RISK;DISEASE:TOXIC_LIVER_DISEASE;;;CAUTION_SIDE_EFFECT
METHADONE;CYP2B6;*6/*6;CYP2B6*1, CYP2B6*6;METABOLISM/PK;INCREASED;;PK:TROUGH_(_R_, S_)-METHADONE_PLASMA_CONCENTRATIONS;;;CAUTION_DOSE_ADJUST
MERCAPTOPURINE, METHOTREXATE;TPMT;*12;TPMT*1, TPMT*12;TOXICITY;INCREASED;SEVERITY;DISEASE:DRUG_TOXICITY;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
MYCOPHENOLATE MOFETIL;IMPDH1;CT + TT;rs2278293;TOXICITY;DECREASED;RISK;SIDE_EFFECT:BIOPSY-PROVEN_ACUTE_REJECTION;PEOPLE;DISEASE:TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
MITOXANTRONE;ABCB1;AA;rs2032582;OTHER;INCREASED;;OTHER:SENSITIVITY_IN_VITRO;;;CAUTION_DOSE_ADJUST
LUMIRACOXIB;HLA-DQB1;*06:02;HLA-DQB1*06:02;TOXICITY;INCREASED;RISK;DISEASE:TOXIC_LIVER_DISEASE;;;CAUTION_SIDE_EFFECT
ACENOCOUMAROL;CYP2C9;*3;CYP2C9*3;METABOLISM/PK;INCREASED;RISK;OTHER:OVERANTICOAGULATION;;;CAUTION_SIDE_EFFECT
ASPIRIN, CLOPIDOGREL;PON1;CT + TT;rs662;EFFICACY;DECREASED;;EFFICACY:RELATIVE_INHIBITION_OF_ADP-INDUCED_PLATELET_AGGREGATION;PEOPLE;DISEASE:ANGINA_PECTORIS;LIKELIHOOD_THERAPEUTIC_FAILURE
ACENOCOUMAROL;CYP2C9;*2;CYP2C9*2;METABOLISM/PK;INCREASED;RISK;OTHER:OVERANTICOAGULATION;;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*1/*3;CYP2C9*1, CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HEMORRHAGE;CHILDREN;;CAUTION_SIDE_EFFECT
METHADONE;CYP2B6;*6/*6;CYP2B6*1, CYP2B6*6;TOXICITY;INCREASED;RISK;SIDE_EFFECT:PROLONGED_QTC;;;CAUTION_SIDE_EFFECT
METHADONE;CYP2B6;*6/*6;CYP2B6*1, CYP2B6*6;METABOLISM/PK;INCREASED;;PK:(S)-METHADONE_PLASMA_LEVELS;;;CAUTION_DOSE_ADJUST
TRIMIPRAMINE;CYP2D6;*4/*4 + *3/*5 + *3/*3;CYP2D6*1, CYP2D6*2XN, CYP2D6*3, CYP2D6*4, CYP2D6*5;TOXICITY;INCREASED;;SIDE_EFFECT:SEDATION;HEALTHY;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;ABCB1;A;rs1045642;OTHER;INCREASED;RISK;SIDE_EFFECT:HEMORRHAGE;PEOPLE;DISEASE:CORONARY_DISEASE;CAUTION_SIDE_EFFECT
NEVIRAPINE;HLA-C;T;rs9461684;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEVIRAPINE-INDUCED_RASH;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
ASPIRIN;IL1B;A;rs1143627;TOXICITY;;;DISEASE:PEPTIC_ULCER_DISEASE;PEOPLE;DISEASE:CARDIOVASCULAR_DISEASE;CAUTION_DOSE_ADJUST
PACLITAXEL;CYP3A4;AA + AG;rs35599367;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE, DOXORUBICIN;SLC22A16;CC + CT;rs714368;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA, SIDE_EFFECT:NEUTROPENIA;WOMEN;OTHER:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
PHENYTOIN;EPHX1;G;rs2234922;TOXICITY;INCREASED;RISK;DISEASE:DISORDER_OF_FACIAL_SKELETON;PEOPLE;OTHER:FIRST_TRIMESTER_PREGNANCY;CAUTION_SIDE_EFFECT
PHENYTOIN;EPHX1;T;rs1051740;TOXICITY;INCREASED;RISK;DISEASE:DISORDER_OF_FACIAL_SKELETON;PEOPLE;OTHER:FIRST_TRIMESTER_PREGNANCY;CAUTION_SIDE_EFFECT
NEVIRAPINE;TCF19;T;rs2073724;TOXICITY;INCREASED;RISK;SIDE_EFFECT:EXANTHEMA;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
RISPERIDONE;CYP2D6;*10;CYP2D6*1, CYP2D6*10;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:WEIGHT_GAIN;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
CARBOPLATIN, PACLITAXEL;NRG3;G;rs1649942;EFFICACY;DECREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL;WOMEN;OTHER:OVARIAN_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
PHENPROCOUMON;EPHX1;CC;rs1051740;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:BEING_OVERANTICOAGULATED;;;CAUTION_SIDE_EFFECT
NAN;SLCO1B1;C;rs4149056;METABOLISM/PK;INCREASED;;PK:STEROL/BILE_ACID_METABOLITES;PEOPLE;DISEASE:HYPERCHOLESTEROLEMIA;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2B6;*6/*6;CYP2B6*6;METABOLISM/PK;INCREASED;;PK:PLASMA_EFAVIRENZ_LEVELS;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DOSE_ADJUST
ASPIRIN, CLOPIDOGREL;CYP2C19;*1/*2 + *2/*2;CYP2C19*1, CYP2C19*2;EFFICACY;INCREASED;;EFFICACY:NON-RESPONSIVENESS;PEOPLE;DISEASE:ANGINA_PECTORIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUTROPENIA;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
CAFFEINE;ADORA2A;TT;rs5751876;TOXICITY;INCREASED;;DISEASE:ANXIETY_DISORDERS;;;CAUTION_SIDE_EFFECT
PACLITAXEL, PLATINUM COMPOUNDS;NAT2;AG + GG;rs1208;EFFICACY;DECREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;OTHER:LUNG_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
DRUGS FOR TREATMENT OF TUBERCULOSIS;HLA-DQB1;*05:01 + *05:02 + *05:03;HLA-DQB1*05:01, HLA-DQB1*05:02, HLA-DQB1*05:03;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
VENLAFAXINE;CYP2D6;*5/*4 + *6/*6 + *6/*4;CYP2D6*1, CYP2D6*4, CYP2D6*5, CYP2D6*6;TOXICITY, METABOLISM/PK;INCREASED;RISK;SIDE_EFFECT:SIDE_EFFECTS;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_SIDE_EFFECT
FLUVOXAMINE;CYP2D6;*1/*5 + *10/*10 + *5/*10;CYP2D6*1, CYP2D6*5, CYP2D6*10;TOXICITY;INCREASED;RISK;SIDE_EFFECT:GASTROINTESTINAL_SIDE_EFFECTS;PEOPLE;DISEASE:DEPRESSIVE_DISORDER;CAUTION_SIDE_EFFECT
NEMONAPRIDE;ANKK1;A;rs1800497;TOXICITY;INCREASED;;SIDE_EFFECT:PROLACTIN_CONCENTRATIONS;WOMEN;OTHER:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*3/*3 + *4/*4;CYP2D6*1, CYP2D6*3, CYP2D6*4;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:RECURRENCE;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;SLC19A1;TT;rs1051266;OTHER, METABOLISM/PK;INCREASED;;PK:METHOTREXATE_POLYGLUTAMATE_(MTXPG3-5)_LEVELS;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_DOSE_ADJUST
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;DISEASE:STEVENS-JOHNSON_SYNDROME;;;CAUTION_SIDE_EFFECT
FLUVOXAMINE;CYP2D6;;CYP2D6 POOR_METABOLIZER;METABOLISM/PK;INCREASED;;PK:AREAS_UNDER_THE_SERUM_CONCENTRATION-TIME_CURVE;HEALTHY;;CAUTION_DOSE_ADJUST
METHOTREXATE;GGH;AA;rs3758149;METABOLISM/PK;DECREASED;;PK:METHOTREXATE_POLYGLUTAMATE_(MTXPG3-5)_LEVELS;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_DOSE_ADJUST
RISPERIDONE;DRD2;C;rs1799978;TOXICITY;INCREASED;RISK;DISEASE:HYPERPROLACTINEMIA;;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*1, CYP2C19*2, CYP2C19*3;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DEATH, SIDE_EFFECT:MYOCARDIAL_INFARCTION, SIDE_EFFECT:STROKE;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;CAUTION_SIDE_EFFECT
RISPERIDONE;ANKK1;AA + AG;rs1800497;TOXICITY;INCREASED;RISK;DISEASE:HYPERPROLACTINEMIA;;;CAUTION_SIDE_EFFECT
MYCOPHENOLATE MOFETIL;IMPDH2;G;rs11706052;OTHER;INCREASED;;OTHER:INOSINE_MONOPHOSPHATE_DEHYDROGENASE_ACTIVITY;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
MERCAPTOPURINE;XDH;CC + CT;rs2281547;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:TREATMENT_INTERRUPTION;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
ASPIRIN, CLOPIDOGREL;CYP2C19;*2/*2 + *1/*2;CYP2C19*1, CYP2C19*2;EFFICACY;INCREASED;;EFFICACY:_ADP-INDUCED_ON_TREATMENT_PLATELET_AGGREGATION_(OTPR);PEOPLE;DISEASE:ANGINA_PECTORIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
MYCOPHENOLATE MOFETIL;SLCO1B3;G;rs4149117;METABOLISM/PK;DECREASED;;PK:DOSE-NORMALIZED__CMAX_AND_DOSE-NORMALIZED__AUC0TO12_H;PEOPLE;OTHER:KIDNEY_TRANSPLANTS;CAUTION_DOSE_ADJUST
ASPIRIN, CLOPIDOGREL;CYP2C19;*2/*2;CYP2C19*1, CYP2C19*2;EFFICACY;DECREASED;;EFFICACY:RELATIVE_INHIBITION_OF_ADP-INDUCED_PLATELET_AGGREGATION;PEOPLE;DISEASE:ANGINA_PECTORIS;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;INCREASED;;EFFICACY:ON-CLOPIDOGREL_PLATELET_REACTIVITY_(HPR);PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;LIKELIHOOD_THERAPEUTIC_SUCCESS
INDINAVIR;UGT1A1;*6/*28;UGT1A1*1, UGT1A1*6, UGT1A1*28;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HYPERBILIRUBINEMIA;PEOPLE;OTHER:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
ANASTROZOLE;ABCB1;AA;rs1045642;OTHER;DECREASED;LIKELIHOOD;SIDE_EFFECT:ARTHRALGIA;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;MTHFR;GG;rs1801131;EFFICACY;DECREASED;;OTHER:EVENT-FREE_SURVIVAL;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*2;CYP2C9*1, CYP2C9*2;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:HAVING_INR_ABOVE_TARGET_RANGE_IN_WEEK_1;CHILDREN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;OPRM1;AG + GG;rs1799971;TOXICITY;INCREASED;RISK;OTHER:SUBSTANCE-RELATED_DISORDERS;MEN;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;ITPA;AC;rs1127354;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:FEBRILE_NEUTROPENIA;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY, SIDE_EFFECT:NEPHROTOXICITY;PEOPLE;DISEASE:ULCERATIVE_COLITIS;CAUTION_SIDE_EFFECT
FLECAINIDE;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;INCREASED;;PK:SYSTEMIC_EXPOSURE_(AUC)_AND_LOWER_ORAL_CLEARANCE_OF_FLECAINIDE;HEALTHY;;CAUTION_DOSE_ADJUST
ETHANOL;ALDH2;GG;rs671;TOXICITY;INCREASED;RISK;OTHER:ALCOHOL_ABUSE;;;CAUTION_SIDE_EFFECT
DIDANOSINE;XDH;AA;rs1429376;TOXICITY;INCREASED;RISK;DISEASE:HYPERTENSION, PORTAL;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
DAUNORUBICIN;SZRD1;T;rs6603859;OTHER, METABOLISM/PK;DECREASED;;PK:IC50;;;CAUTION_DOSE_ADJUST
DIDANOSINE;NT5C2;CC + CT;rs11598702;TOXICITY;INCREASED;RISK;DISEASE:HYPERTENSION, PORTAL;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*2;CYP2C19*1, CYP2C19*2, CYP2C19*17;EFFICACY;INCREASED;;OTHER:PLATELET_REACTIVITY;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
DIDANOSINE;XDH;AA;rs1594160;TOXICITY;INCREASED;RISK;DISEASE:HYPERTENSION, PORTAL;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*6;CYP2C19*1, CYP2C19*6;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ISCHAEMIC_EVENTS;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;CAUTION_SIDE_EFFECT
DAUNORUBICIN;;GG;rs7929521;OTHER, METABOLISM/PK;INCREASED;;PK:IC50;;;CAUTION_DOSE_ADJUST
IRINOTECAN;UGT1A1;*28/*28;UGT1A1*1, UGT1A1*28, UGT1A1*37;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUTROPENIA;PEOPLE;OTHER:NEOPLASMS;CAUTION_SIDE_EFFECT
AZACITIDINE;TYMS;del/del;rs11280056;EFFICACY;DECREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:MYELODYSPLASTIC_SYNDROMES;LIKELIHOOD_THERAPEUTIC_FAILURE
DAUNORUBICIN;MAN1B1;T;rs3750518;OTHER, METABOLISM/PK;INCREASED;;PK:IC50;;;CAUTION_DOSE_ADJUST
OXYCODONE;CYP2D6;*3/*4 + *4/*4 + *4/*5 + *4/*6 + *4/*7;CYP2D6*1, CYP2D6*1XN, CYP2D6*2, CYP2D6*2XN, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*7;METABOLISM/PK;DECREASED;;PK:MEAN_OXYMORPHONE/OXYCODONE_RATIOS;;;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1, CYP2C19*2;EFFICACY;INCREASED;;OTHER:PLATELET_REACTIVITY;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;LIKELIHOOD_THERAPEUTIC_SUCCESS
DIDANOSINE;NT5C2;CG + GG;rs11191561;TOXICITY;INCREASED;RISK;DISEASE:HYPERTENSION, PORTAL;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
DRUGS FOR TREATMENT OF TUBERCULOSIS;HLA-DQA1;*01:02;HLA-DQA1*01:02;TOXICITY;DECREASED;LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:TUBERCULOSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
IGURATIMOD;CYP2C19;A;rs4244285;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
CYCLOSPORINE;CYP3A4;*1/*22;CYP3A4*1, CYP3A4*22;EFFICACY;INCREASED;RISK;EFFICACY:TRANSPLANT_REJECTION;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;CAUTION_SIDE_EFFECT
PHENYTOIN;HLA-C;*14:02;HLA-C*14:02;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;;;CAUTION_SIDE_EFFECT
PHENYTOIN;HLA-B;*56:02;HLA-B*56:02;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;;;CAUTION_SIDE_EFFECT
NICOTINE;CYP2A6;AT + TT;rs1801272;TOXICITY;INCREASED;SEVERITY;OTHER:TOBACCO_USE_DISORDER;;;CAUTION_SIDE_EFFECT
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;;;CAUTION_SIDE_EFFECT
OLANZAPINE;CYP2C9;*1/*3 + *2/*3 + *3/*6;CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*6;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:HYPOTENSIVE_DISORDER;HEALTHY;;CAUTION_SIDE_EFFECT
DESIPRAMINE;CYP2D6;*10/*10 + *5/*10;CYP2D6*1, CYP2D6*2, CYP2D6*5, CYP2D6*10;METABOLISM/PK;INCREASED;;PK:STEADY-STATE_PLASMA_CONCENTRATIONS_OF_DESIPRAMINE/DAILY_DOSE_OF_DESIPRAMINE/BODY_WEIGHT;PEOPLE;DISEASE:MENTAL_DISORDERS;CAUTION_DOSE_ADJUST
GEFITINIB;EGFR;(CA)16/(CA)16;rs11568315;EFFICACY;INCREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL_(PFS)_TIME;;EFFICACY:ADVANCED_NON-SMALL-CELL_LUNG_CANCER_PATIENTS;LIKELIHOOD_THERAPEUTIC_SUCCESS
OLANZAPINE;TPMT;*1/*3A + *1/*3C;TPMT*1, TPMT*3A, TPMT*3C;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:FATIGUE;HEALTHY;;CAUTION_SIDE_EFFECT
NAN;NAT1;*11B/*4;NAT1*4, NAT1*11B;OTHER;INCREASED;RISK;OTHER:ADENOMATOUS_AND_HYPERPLASTIC_POLYPS;PEOPLE;OTHER:A_NAT1_RAPID_ACETYLATOR_GENOTYPE_AND_HIGH_MEAT_CONSUMPTION_AND_RS2066853_GENOTYPE_AA_OR_GA;CAUTION_SIDE_EFFECT
MERCAPTOPURINE, THIOGUANINE;TPMT;*1/*3C;TPMT*1, TPMT*2, TPMT*3A, TPMT*3C, TPMT*9, TPMT*21, TPMT*32, TPMT*33, TPMT*34;EFFICACY;DECREASED;;EFFICACY:EVENT-FREE_SURVIVAL;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
OLANZAPINE;GSTM3;CCT/CCT;rs1799735;METABOLISM/PK;DECREASED;;PK:AREA_UNDER_THE_CURVE;HEALTHY;;CAUTION_DOSE_ADJUST
OLANZAPINE;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;INCREASED;;PK:AREA_UNDER_THE_CURVE;HEALTHY;;CAUTION_DOSE_ADJUST
MERCAPTOPURINE;XDH;CC + CT;rs2281547;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:NEUTROPENIA;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
ANASTROZOLE;CYP19A1;AA;rs727479;EFFICACY;INCREASED;;OTHER:RECURRENCE_FREE_SURVIVAL;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
OXYCODONE;CYP2D6;*4/*4 + *4/*6;CYP2D6*1, CYP2D6*2, CYP2D6*4, CYP2D6*6;METABOLISM/PK;DECREASED;;PK:SERUM_CONCENTRATIONS_OF_OXYMORPHONE_AND_NOROXYMORPHONE_AND_OXYMORPHONE/OXYCODONE_RATIOS;PEOPLE;DISEASE:NEOPLASMS;CAUTION_DOSE_ADJUST
FLUVASTATIN;SLCO1B1;CC;rs11045819;EFFICACY;DECREASED;;EFFICACY:LDL-C_REDUCTION;PEOPLE;DISEASE:HYPERCHOLESTEROLEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
OXYCODONE;CYP2D6;*4/*4 + *3/*4;CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4;METABOLISM/PK;DECREASED;;PK:SERUM_CONCENTRATIONS_OF_OXYMORPHONE_AND_NOROXYMORPHONE_AND_OXYMORPHONE/OXYCODONE_RATIOS;PEOPLE;DISEASE:NEOPLASMS;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2B6;*18/*18;CYP2B6*18;METABOLISM/PK;INCREASED;;PK:PLASMA_EFAVIRENZ_LEVELS;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DOSE_ADJUST
CYCLOPHOSPHAMIDE, DOXORUBICIN;NQO2;C;rs1143684;EFFICACY;;;EFFICACY:WORSE_PROGNOSIS_(OVERALL_SURVIVAL_AND_PROGRESSION-FREE_SURVIVAL)_IN_PATIENTS_WHO_WERE_ER-VE/PR-VE_NEGATIVE;PEOPLE;DISEASE:BREAST_NEOPLASMS;CAUTION_DOSE_ADJUST
PIOGLITAZONE;CYP2C8;*1/*2 + *2/*2;CYP2C8*1, CYP2C8*2;METABOLISM/PK;DECREASED;;PK:M-III:PIOGLITAZONE_AUC0-48_RATIO_AND_M-III:M-IV_AUC0-48_RATIO_IN_HEALTHY_AFRICAN-AMERICAN_VOLUNTEERS;HEALTHY;;CAUTION_DOSE_ADJUST
PHENYTOIN;CYP2C9;*3;CYP2C9*1, CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;;;CAUTION_SIDE_EFFECT
DICLOFENAC;UGT2B7;T;rs7668258;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE;;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*3;CYP2C9*1, CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OVER-ANTICOAGULATION;;;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIR;IFNL3;TT;rs8099917;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:HEPATITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*1/*17 + *17/*17;CYP2C19*1, CYP2C19*17;TOXICITY;INCREASED;RISK;DISEASE:HEMORRHAGE;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*1/*17 + *17/*17;CYP2C19*1, CYP2C19*17;EFFICACY;DECREASED;RISK;OTHER:NON-FATAL_MYOCARDIAL_INFARCTION,STROKE, REVASCULARIZATION_OR_DEATH;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
IBUPROFEN;CYP2C8;*1/*2;CYP2C8*1, CYP2C8*2;METABOLISM/PK;INCREASED;;PK:R-IBUPROFEN_METABOLISM;HEALTHY;;CAUTION_DOSE_ADJUST
CISPLATIN, CYCLOPHOSPHAMIDE;GSTM3;TCCTC/TCCTC;rs36120609;TOXICITY;DECREASED;RISK;SIDE_EFFECT:ANEMIA;PEOPLE;DISEASE:OVARIAN_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN, CLOPIDOGREL;CYP2C19;A;rs4244285;TOXICITY;;;SIDE_EFFECT:HIGHER_COMPOSITE_HAR_OUTCOME_(CARDIAC_DEATH, NON_FATAL_MYOCARDIAL_INFARCTION_AND_STENT_THROMBOSIS)_UP_TO_12_MONTHS'_FOLLOW_UP;PEOPLE;OTHER:DRUG-ELUTING_STENTS;CAUTION_DOSE_ADJUST
NAN;IRS1;C;rs1801123;OTHER;;;OTHER:LYMPH_NODE_INVOLVEMENT;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_DOSE_ADJUST
ESTRADIOL;;A;rs1864729;OTHER;INCREASED;;OTHER:PLASMA_LEVEL;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_DOSE_ADJUST
FOLFIRI;UGT1A1;*1/*28 + *28/*28;UGT1A1*1, UGT1A1*28;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:DIARRHEA;PEOPLE;OTHER:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
GEFITINIB;EGFR;(CA)16/(CA)16 + (CA)16/(CA)17;rs11568315;EFFICACY;INCREASED;;EFFICACY:MEDIAN_SURVIVAL_TIME;;EFFICACY:ADVANCED_NON-SMALL-CELL_LUNG_CANCER_PATIENTS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACENOCOUMAROL, WARFARIN;CYP2C9;*3;CYP2C9*1, CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HEMORRHAGE, SIDE_EFFECT:STROKE;PEOPLE;DISEASE:ATRIAL_FIBRILLATION, DISEASE:VENOUS_THROMBOEMBOLISM;CAUTION_SIDE_EFFECT
GEFITINIB;EGFR;(CA)16/(CA)16 + (CA)16/(CA)17;rs11568315;EFFICACY;INCREASED;;EFFICACY:RESPONSE_RATE_(RR);;EFFICACY:ADVANCED_NON-SMALL-CELL_LUNG_CANCER_PATIENTS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBIMAZOLE, METHIMAZOLE, PROPYLTHIOURACIL;HLA-DRB1;*08:03;HLA-DRB1*08:03;TOXICITY;INCREASED;RISK;SIDE_EFFECT:AGRANULOCYTOSIS;PEOPLE;DISEASE:GRAVES_DISEASE;CAUTION_SIDE_EFFECT
ANTHRACYCLINES AND RELATED SUBSTANCES;GSTM1;;GSTM1 NON-NULL, GSTM1 NULL;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:CARDIOMYOPATHIES;CHILDREN;OTHER:NEOPLASMS;CAUTION_SIDE_EFFECT
NAN;EGFR;(CA)16/(CA)16 + (CA)16/(CA)17;rs11568315;NAN;INCREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL_(PFS)_TIME;;EFFICACY:ADVANCED_NON-SMALL-CELL_LUNG_CANCER_PATIENTS;CAUTION_DOSE_ADJUST
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;;NAT2 SLOW_ACETYLATOR;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;PEOPLE;OTHER:TUBERCULOSIS;CAUTION_SIDE_EFFECT
CITALOPRAM;CYP2C19;*2;CYP2C19*1, CYP2C19*2;METABOLISM/PK;DECREASED;;PK:CITALOPRAM_ORAL_CLEARANCES_OF_CITALOPRAM;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DOSE_ADJUST
DICLOFENAC;ABCC2;T;rs717620;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE;;;CAUTION_SIDE_EFFECT
ANTIARRHYTHMICS, CLASS I AND III;;GG;rs10033464;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:SUCCESSFUL_RHYTHM_CONTROL;PEOPLE;DISEASE:ATRIAL_FIBRILLATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBIMAZOLE, METHIMAZOLE;HLA-B;*38:02;HLA-B*38:02;TOXICITY;INCREASED;RISK;SIDE_EFFECT:AGRANULOCYTOSIS;PEOPLE;DISEASE:GRAVES_DISEASE;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*3;CYP2C9*1, CYP2C9*2, CYP2C9*3;EFFICACY;DECREASED;;EFFICACY:TIME_TO_THERAPEUTIC_INR;;;LIKELIHOOD_THERAPEUTIC_FAILURE
GEFITINIB;EGFR;(CA)16/(CA)16 + (CA)16/(CA)17;rs11568315;EFFICACY;INCREASED;;EFFICACY:SURVIVAL_TIME;;EFFICACY:ADVANCED_NON-SMALL-CELL_LUNG_CANCER_PATIENTS;LIKELIHOOD_THERAPEUTIC_SUCCESS
HYDRALAZINE;NAT2;;NAT2 SLOW_ACETYLATOR;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS;PEOPLE;OTHER:HYPERTENSION;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*3;CYP2C19*1, CYP2C19*3;EFFICACY;;;EFFICACY:MORE_FREQUENT_HIGH_PLATELET_REACTIVITY_IN_JAPANESE_PATIENTS_IN_A_STEADY_STATE_RECEIVING_DUAL_ANTIPLATELET_THERAPY_AFTER_CORONARY_STENT_IMPLANTATION;;;CAUTION_DOSE_ADJUST
GEFITINIB;EGFR;(CA)16/(CA)16 + (CA)16/(CA)17;rs11568315;EFFICACY;INCREASED;;EFFICACY:BETTER_CLINICAL_RESPONSE;;EFFICACY:ADVANCED_NON-SMALL-CELL_LUNG_CANCER_PATIENTS;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;*1/*3;CYP2C9*1, CYP2C9*3;METABOLISM/PK;DECREASED;;PK:UNBOUND_ORAL_CLEARANCE_FOR_S-WARFARIN;CHILDREN;;CAUTION_DOSE_ADJUST
RIFAMPIN;SLCO1B1;*15;SLCO1B1*15;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1, CYP2C19*2;EFFICACY;;;EFFICACY:MORE_FREQUENT_HIGH_PLATELET_REACTIVITY_IN_JAPANESE_PATIENTS_IN_A_STEADY_STATE_RECEIVING_DUAL_ANTIPLATELET_THERAPY_AFTER_CORONARY_STENT_IMPLANTATION;;;CAUTION_DOSE_ADJUST
FLUVOXAMINE, PAROXETINE;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele) + HTTLPR short form (S allele)/L allele-rs25531C;SLC6A4 HTTLPR SHORT FORM (S ALLELE), SLC6A4 L ALLELE-rs25531C, SLC6A4 L ALLELE-rs25531T;EFFICACY;DECREASED;;EFFICACY:HAM-D_SCORE_CHANGES_IN_FLUVOXAMINE-TREATED_PATIENTS_COMPARED_TO_PAROXETINE-TREATED_PATIENTS;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;CYP2D6;*4/*5 + *4/*6 + *3/*4 + *4/*4;CYP2D6*1, CYP2D6*1XN, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6;OTHER;DECREASED;;OTHER:WAKEFULNESS_ACTIVITY_LEVEL;HEALTHY;;CAUTION_DOSE_ADJUST
NAN;IGFBP3;T;rs2854744;OTHER;;;OTHER:TUMOR_SIZE;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1, CYP2C9*2, CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OVER-ANTICOAGULATION;;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1, CYP2C9*2, CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OVER-ANTICOAGULATION;;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*6 + *28;UGT1A1*6, UGT1A1*28;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUTROPENIA;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-A;*24:02;HLA-A*24:02;TOXICITY;DECREASED;RISK;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME_AND_TOXIC_EPIDERMAL_NECROLYSIS-BULLOUS_LESIONS;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE;HLA-B;*15:11;HLA-B*15:11;TOXICITY;INCREASED;RISK;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME_AND_TOXIC_EPIDERMAL_NECROLYSIS-BULLOUS_LESIONS;;;CAUTION_SIDE_EFFECT
NEVIRAPINE;GSTM1;;GSTM1 NON-NULL, GSTM1 NULL;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;WOMEN;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
CISPLATIN, CYCLOPHOSPHAMIDE;GSTM3;TCCTC/TCCTC;rs36120609;TOXICITY;DECREASED;RISK;SIDE_EFFECT:THROMBOCYTOPENIA;PEOPLE;DISEASE:OVARIAN_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME_AND_TOXIC_EPIDERMAL_NECROLYSIS-BULLOUS_LESIONS;;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*40:01;HLA-B*40:01;TOXICITY;DECREASED;RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN, CYCLOPHOSPHAMIDE;GSTM3;TCCTC/TCCTC;rs36120609;TOXICITY;DECREASED;RISK;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES;PEOPLE;DISEASE:OVARIAN_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
PAROXETINE;CYP2D6;*4/*5;CYP2D6*1, CYP2D6*4, CYP2D6*5;METABOLISM/PK;INCREASED;;PK:PAROXETINE_PLASMA_CONCENTRATION;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*1, CYP2C19*2, CYP2C19*3;TOXICITY;INCREASED;RISK;SIDE_EFFECT:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE);;;CAUTION_SIDE_EFFECT
NAN;GSTM3;TC/TC + TC/TCCTC;rs36120609;OTHER;INCREASED;LIKELIHOOD;OTHER:METASTATIC_NEOPLASM;CHILDREN;OTHER:OSTEOSARCOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOXETINE;CYP2D6;*5/*4 + *1/*3 + *1/*4 + *1/*5 + *1/*6;CYP2D6*1, CYP2D6*1XN, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6;METABOLISM/PK;INCREASED;;PK:FLUOXETINE/(S)-NORFLUOXETINE_RATIO;CHILDREN;DISEASE:DEPRESSIVE_DISORDER;CAUTION_DOSE_ADJUST
PEGINTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIR;ITPA;CC;rs1127354;OTHER;;;SIDE_EFFECT:REQUIREMENT_FOR_EARLIER_DOSE_REDUCTION_OF_RIBAVIRIN;PEOPLE;DISEASE:HEPATITIS;CAUTION_DOSE_ADJUST
CARBOPLATIN, CYCLOPHOSPHAMIDE, THIOTEPA;ALDH1A1;CTGGTGAGGAGAGAACC/del;rs6151031;TOXICITY;INCREASED;SEVERITY;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
ANTITHYROID PREPARATIONS;HLA-B;*27:05;HLA-B*27:05;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:AGRANULOCYTOSIS;;;CAUTION_SIDE_EFFECT
ASPIRIN, CLOPIDOGREL;CYP2C19;*1/*2 + *2/*2;CYP2C19*1, CYP2C19*2;EFFICACY;INCREASED;RISK;EFFICACY:HIGH_PLATELET_REACTIVITY;PEOPLE;OTHER:PERCUTANEOUS_CORONARY_INTERVENTION;CAUTION_SIDE_EFFECT
NAN;IFNL3;TT;rs8099917;NAN;INCREASED;;OTHER:BASELINE_VIRAL_LOAD;PEOPLE;DISEASE:HEPATITIS;CAUTION_DOSE_ADJUST
IRINOTECAN;UGT1A1;*1/*28 + *6/*28;UGT1A1*1, UGT1A1*6, UGT1A1*28;TOXICITY;INCREASED;RISK;SIDE_EFFECT:LEUKOPENIA, SIDE_EFFECT:NEUTROPENIA;PEOPLE;DISEASE:LUNG_NEOPLASMS;CAUTION_SIDE_EFFECT
PAROXETINE;CYP2D6;*1/*4 + *1/*5;CYP2D6*1, CYP2D6*4, CYP2D6*5;METABOLISM/PK;INCREASED;;PK:PAROXETINE_PLASMA_CONCENTRATIONS_INCREASED_DURING_THE_COURSE_OF_PREGCY;WOMEN;;CAUTION_DOSE_ADJUST
DICLOFENAC;CYP2C8;*1/*3 + *3/*3;CYP2C8*1, CYP2C8*3;METABOLISM/PK;INCREASED;;PK:DICLOFENAC/5-HYDROXYDICLOFENAC_URINARY_CONCENTRATION_RATIO;HEALTHY;;CAUTION_DOSE_ADJUST
PAROXETINE;CYP2D6;*3/*4;CYP2D6*1, CYP2D6*3, CYP2D6*4;METABOLISM/PK;INCREASED;;PK:PAROXETINE_PLASMA_CONCENTRATION;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DOSE_ADJUST
HEPARIN;HLA-DRB3;*01:01;HLA-DRB3*01:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HEPARIN-INDUCED_THROMBOCYTOPENIA;;;CAUTION_SIDE_EFFECT
ACENOCOUMAROL;CYP2C9;*1/*3 + *3/*3;CYP2C9*1, CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OVER-ANTICOAGULATION;;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-A;*31:01;HLA-A*31:01;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;;;CAUTION_SIDE_EFFECT
ACENOCOUMAROL;CYP2C9;*1/*2 + *2/*2;CYP2C9*1, CYP2C9*2;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OVER-ANTICOAGULATION;;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*6 + *28;UGT1A1*6, UGT1A1*28;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DIARRHEA;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2B, RIBAVIRIN, SIMEPREVIR;IFNL4;TT/TT;rs11322783;TOXICITY;INCREASED;;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;CAUTION_SIDE_EFFECT
CITALOPRAM;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR LONG FORM (L ALLELE), SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;RISK;EFFICACY:NON-REMISSION;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1, CYP2C9*2, CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OVER-ANTICOAGULATION;CHILDREN;;CAUTION_SIDE_EFFECT
IBUPROFEN;CYP2C9;*1/*3;CYP2C9*1, CYP2C9*3;METABOLISM/PK;DECREASED;;PK:RACEMIC, S-IBUPROFEN_AND_R-IBUPROFEN_METABOLISM, WITH_INCREASE_OF_AUC(0-INFINITY)_AND_REDUCTION_OF_CLEARANCE;HEALTHY;;CAUTION_DOSE_ADJUST
TENOXICAM;CYP2C9;*1/*2;CYP2C9*1, CYP2C9*2;METABOLISM/PK;INCREASED;;PK:EXPOSURE_(AREA_UNDER_THE_PLASMA_CONCENTRATION-TIME_CURVE_(AUC))_AND_DECREASED_ORAL_CLEARANCE;HEALTHY;;CAUTION_DOSE_ADJUST
ASPIRIN, CLOPIDOGREL;CYP2C19;*2;CYP2C19*1, CYP2C19*2;EFFICACY;INCREASED;;EFFICACY:PLATELET_REACTIVITY;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TENOXICAM;CYP2C9;*1/*3;CYP2C9*1, CYP2C9*3;METABOLISM/PK;INCREASED;;PK:EXPOSURE_(AREA_UNDER_THE_PLASMA_CONCENTRATION-TIME_CURVE_(AUC))_AND_DECREASED_ORAL_CLEARANCE;HEALTHY;;CAUTION_DOSE_ADJUST
EFAVIRENZ, LAMIVUDINE, STAVUDINE, ZIDOVUDINE;CYP2B6;*6;CYP2B6*1, CYP2B6*6;METABOLISM/PK;INCREASED;;PK:PLASMA_4BETA-OHC/CHOL_RATIO;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DOSE_ADJUST
TAMOXIFEN;CYP2D6;;CYP2D6 LOW ACTIVITY;EFFICACY;INCREASED;RISK;EFFICACY:RECURRENCE;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
PIROXICAM;CYP2C9;*1/*3;CYP2C9*1, CYP2C9*3;EFFICACY;INCREASED;;EFFICACY:INHIBITORY_EFFECT_ON_CYCLOOXYGENASE_1_ACTIVITY;HEALTHY;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;CYP2A6;*4 + *10 + *9;CYP2A6*1, CYP2A6*4, CYP2A6*9, CYP2A6*10;METABOLISM/PK;DECREASED;;PK:PLASMA_AND_URINARY_RATIO_OF_METABOLITES_TRANS-3'-HYDROXYCOTININE_TO_COTININE_(3HC/COT);HEALTHY;;CAUTION_DOSE_ADJUST
ASPIRIN, CLOPIDOGREL;CYP2C19;*17;CYP2C19*1, CYP2C19*17;EFFICACY;DECREASED;;EFFICACY:PLATELET_REACTIVITY;;;LIKELIHOOD_THERAPEUTIC_FAILURE
LUMIRACOXIB;HLA-DQA1;*01:02;HLA-DQA1*01:01, HLA-DQA1*01:02;TOXICITY;INCREASED;RISK;DISEASE:TOXIC_LIVER_DISEASE;;;CAUTION_SIDE_EFFECT
ASPIRIN, CLOPIDOGREL;CYP2C19;*2;CYP2C19*1, CYP2C19*2;TOXICITY;INCREASED;RISK;SIDE_EFFECT:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE);;;CAUTION_SIDE_EFFECT
PAROXETINE;CYP2D6;*4/*4;CYP2D6*1, CYP2D6*4;METABOLISM/PK;INCREASED;;PK:PAROXETINE_LEVELS;PEOPLE;DISEASE:OBSESSIVE_COMPULSIVE_DISORDER;CAUTION_DOSE_ADJUST
IBUPROFEN;CYP2C9;*1/*2;CYP2C9*1, CYP2C9*2;OTHER;DECREASED;;OTHER:INOS_EXPRESSION;HEALTHY;;CAUTION_DOSE_ADJUST
IRINOTECAN;UGT1A6;A;rs2070959;TOXICITY;INCREASED;RISK;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
IBUPROFEN;CYP2C8;*1/*3;CYP2C8*1, CYP2C8*3;METABOLISM/PK;INCREASED;;PK:R-IBUPROFEN_METABOLISM;HEALTHY;;CAUTION_DOSE_ADJUST
FLUOROURACIL;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;rs45445694;EFFICACY;INCREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;OTHER:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
IMATINIB;EGFR;CC;rs2072454;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:PERIORBITAL_EDEMA;PEOPLE;OTHER:GASTROINTESTINAL_STROMAL_TUMORS;CAUTION_SIDE_EFFECT
FLUOROURACIL;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:SIDE_EFFECTS;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
KETOPROFEN, TRAMADOL;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *4/*41 + *6/*10 + *10/*10 + *41/*41;CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*9, CYP2D6*10, CYP2D6*17, CYP2D6*41;TOXICITY;INCREASED;RISK;SIDE_EFFECT:SEDATION;PEOPLE;OTHER:POSTOPERATIVE_PAIN;CAUTION_SIDE_EFFECT
PIROXICAM;CYP2C9;*1/*2;CYP2C9*1, CYP2C9*2;EFFICACY;INCREASED;;EFFICACY:INHIBITORY_EFFECT_ON_CYCLOOXYGENASE_1_ACTIVITY;HEALTHY;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PIROXICAM;CYP2C9;*1/*3;CYP2C9*1, CYP2C9*3;METABOLISM/PK;INCREASED;;PK:PIROXICAM'S_AREA_UNDER_THE_PLASMA_CONCENTRATION-TIME_CURVE_AND_DECREASED_ORAL_CLEARANCE;HEALTHY;;CAUTION_DOSE_ADJUST
PIROXICAM;CYP2C9;*1/*2;CYP2C9*1, CYP2C9*2;METABOLISM/PK;INCREASED;;PK:PIROXICAM'S_AREA_UNDER_THE_PLASMA_CONCENTRATION-TIME_CURVE_AND_DECREASED_ORAL_CLEARANCE;HEALTHY;;CAUTION_DOSE_ADJUST
GEFITINIB;CYP2D6;*10/*10;CYP2D6*1, CYP2D6*2, CYP2D6*10, CYP2D6*114;TOXICITY;INCREASED;RISK;SIDE_EFFECT:EXANTHEMA;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL4;G;rs11322783;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_FAILURE
CITALOPRAM, ESCITALOPRAM;CYP2D6;A;rs1065852;OTHER;;;OTHER:PLASMA_CONCENTRATION_OF_S-DIDESMETHYL-CITALOPRAM;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DOSE_ADJUST
HYDROCHLOROTHIAZIDE;ACE;del/del;rs1799752;EFFICACY;INCREASED;;EFFICACY:REDUCTION_IN_BLOOD_PRESSURE;MEN;DISEASE:ESSENTIAL_HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN, CLOPIDOGREL;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2;EFFICACY;DECREASED;;EFFICACY:PLATELET_AGGREGATION;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME, DISEASE:MYOCARDIAL_INFARCTION;LIKELIHOOD_THERAPEUTIC_FAILURE
CARBAMAZEPINE, LAMOTRIGINE, PHENYTOIN;HLA-B;*15:02;HLA-B*15:02;TOXICITY;;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;;;CAUTION_DOSE_ADJUST
MIRTAZAPINE;CYP2D6;*1/*1xN;CYP2D6*1, CYP2D6*1XN;METABOLISM/PK;INCREASED;;PK:CLEARANCE_OF_S(+)_MIRTAZAPINE;HEALTHY;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:MYASTHENIA_GRAVIS;CAUTION_SIDE_EFFECT
NAN;CYP2D6;*2xN;CYP2D6*2XN;OTHER;INCREASED;RISK;DISEASE:SUICIDE;PEOPLE;OTHER:GENE_DUPLICATION/MULTIDUPLICATION;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;INCREASED;;PK:DOSE-ADJUSTED_TROUGH_CONCENTRATIONS;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*2 + *1/*3;CYP2C9*1, CYP2C9*2, CYP2C9*3;EFFICACY;INCREASED;RISK;SIDE_EFFECT:OVER-ANTICOAGULATION;CHILDREN;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;CHILDREN;DISEASE:LIVER_TRANSPLANTATION;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*28/*28;UGT1A1*1, UGT1A1*28;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUTROPENIA;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1, CYP2C9*2, CYP2C9*3;EFFICACY;DECREASED;;EFFICACY:TIME_IN_THERAPEUTIC_RANGE;;;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1, CYP2C9*2, CYP2C9*3;EFFICACY;INCREASED;;SIDE_EFFECT:TIME_ABOVE_THERAPEUTIC_RANGE;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
MIRTAZAPINE;CYP2D6;*4/*4;CYP2D6*1, CYP2D6*4;METABOLISM/PK;DECREASED;;PK:TOTAL_CLEARANCE_OF_RACEMIC_MIRTAZAPINE;HEALTHY;;CAUTION_DOSE_ADJUST
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;;;CAUTION_SIDE_EFFECT
NAN;CYP2C19;*2/*2;CYP2C19*1, CYP2C19*2;OTHER;DECREASED;SEVERITY;DISEASE:DEPRESSION;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1, CYP2C9*2, CYP2C9*3;EFFICACY;DECREASED;;EFFICACY:TIME_TO_THERAPEUTIC_INR;;;LIKELIHOOD_THERAPEUTIC_FAILURE
IRINOTECAN;UGT1A9;C;rs11692021;TOXICITY;INCREASED;RISK;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
METOPROLOL;ADRB2;CG;rs1042714;TOXICITY;INCREASED;;SIDE_EFFECT:TRIGLYCERIDES;PEOPLE;DISEASE:HYPERTENSION;CAUTION_SIDE_EFFECT
LAMOTRIGINE;HLA-A;*33:03;HLA-A*33:03;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:MACULOPAPULAR_EXANTHEMA;PEOPLE;DISEASE:EPILEPSY;CAUTION_SIDE_EFFECT
TAMOXIFEN;IGF1R;GG;rs2016347;EFFICACY;INCREASED;RISK;DISEASE:RECURRENCE;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
IRINOTECAN, RALTITREXED;UGT1A1;*1/*28 + *28/*28;UGT1A1*1, UGT1A1*28;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DIARRHEA;PEOPLE;OTHER:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*1/*2 + *1/*3;CYP2C9*1, CYP2C9*2, CYP2C9*3;EFFICACY;DECREASED;;EFFICACY:TIME_TO_THERAPEUTIC_INR;CHILDREN;DISEASE:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
NAN;CYP2D6;*1xN;CYP2D6*1XN;OTHER;INCREASED;RISK;DISEASE:SUICIDE;PEOPLE;OTHER:GENE_DUPLICATION/MULTIDUPLICATION;CAUTION_SIDE_EFFECT
ALLOPURINOL;HLA-B;*48:01;HLA-B*48:01;TOXICITY;INCREASED;RISK;DISEASE:DRUG_HYPERSENSITIVITY;PEOPLE;DISEASE:HEMATOLOGIC_NEOPLASMS;CAUTION_SIDE_EFFECT
PACLITAXEL;CYP2C8;C;rs10509681;TOXICITY;INCREASED;RISK;DISEASE:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
IRINOTECAN, RALTITREXED;UGT1A1;*1/*28 + *28/*28;UGT1A1*1, UGT1A1*28;TOXICITY;INCREASED;RISK;SIDE_EFFECT:VOMITING;PEOPLE;OTHER:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
PAZOPANIB;HLA-B;*57:01;HLA-B*57:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA, DISEASE:OVARIAN_NEOPLASMS,DISEASE:SARCOMA, DISEASE:SOFT_TISSUE_NEOPLASMS;CAUTION_SIDE_EFFECT
IRINOTECAN, RALTITREXED;UGT1A1;*1/*28 + *28/*28;UGT1A1*1, UGT1A1*28;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ASTHENIA;PEOPLE;OTHER:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;INCREASED;;PK:TROUGH_CONCENTRATIONS;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
CITALOPRAM;CYP2C19;*2;CYP2C19*1, CYP2C19*2;TOXICITY;INCREASED;;SIDE_EFFECT:INTOLERANCE;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1, CYP2C9*2, CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OVER-ANTICOAGULATION;;;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;INCREASED;;PK:DOSE-ADJUSTED_TROUGH_CONCENTRATIONS;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
QUETIAPINE;CYP2C19;*1/*2 + *2/*2 + *2/*4;CYP2C19*1, CYP2C19*2, CYP2C19*4;METABOLISM/PK;INCREASED;SEVERITY;SIDE_EFFECT:HYPERPROLACTINEMIA;HEALTHY;;CAUTION_SIDE_EFFECT
CAFFEINE;ADORA2A;TTTTTTT/TTTTTTT;rs35060421;TOXICITY;INCREASED;;SIDE_EFFECT:ANXIETY;HEALTHY;;CAUTION_SIDE_EFFECT
ALLOPURINOL;HLA-DRB1;*14:01;HLA-DRB1*14:01;TOXICITY;INCREASED;RISK;DISEASE:DRUG_HYPERSENSITIVITY;PEOPLE;DISEASE:HEMATOLOGIC_NEOPLASMS;CAUTION_SIDE_EFFECT
ALLOPURINOL;HLA-DRB1;*09:01;HLA-DRB1*09:01;TOXICITY;INCREASED;RISK;DISEASE:DRUG_HYPERSENSITIVITY;PEOPLE;DISEASE:HEMATOLOGIC_NEOPLASMS;CAUTION_SIDE_EFFECT
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;;NAT2 SLOW_ACETYLATOR;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
ZONISAMIDE;HLA-A;*02:07;HLA-A*02:07;TOXICITY;;;DISEASE:STEVENS-JOHNSON_SYNDROME;;;CAUTION_DOSE_ADJUST
PHENOBARBITAL;HLA-B;*51:01;HLA-B*51:01;TOXICITY;;;DISEASE:STEVENS-JOHNSON_SYNDROME;;;CAUTION_DOSE_ADJUST
IRINOTECAN;UGT1A1;*1/*28 + *28/*28;UGT1A1*1, UGT1A1*28;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUTROPENIA;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
ESCITALOPRAM;CYP2C19;*17/*17;CYP2C19*1, CYP2C19*17;METABOLISM/PK;DECREASED;;PK:MEAN_LOGARITHM_ESCITALOPRAM_CONCENTRATION_AND_HIGHER_MEAN_METABOLIC_RATIO;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DOSE_ADJUST
TRAMADOL;CYP2D6;*10/*10;CYP2D6*1, CYP2D6*10;EFFICACY;INCREASED;SEVERITY;OTHER:PAIN;PEOPLE;OTHER:POSTOPERATIVE_PAIN;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;DECREASED;;PK:TROUGH_CONCENTRATIONS;CHILDREN;DISEASE:LIVER_TRANSPLANTATION;CAUTION_DOSE_ADJUST
LAMIVUDINE, NEVIRAPINE, STAVUDINE;HLA-B;*35:05;HLA-B*35:05;TOXICITY;;;SIDE_EFFECT:EXANTHEMA;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;DECREASED;;PK:DOSE-ADJUSTED_TROUGH_CONCENTRATIONS;CHILDREN;DISEASE:LIVER_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;INCREASED;;PK:TIME_TO_ACHIEVE_THERAPEUTIC_WINDOW;CHILDREN;DISEASE:LIVER_TRANSPLANTATION;CAUTION_DOSE_ADJUST
FOLFIRI;UGT1A1;*1/*28 + *28/*28;UGT1A1*1, UGT1A1*28;TOXICITY;INCREASED;;SIDE_EFFECT:DEATH;PEOPLE;OTHER:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
METHOTREXATE;ABCC2;AG + GG;rs3740065;METABOLISM/PK;INCREASED;;PK:PLASMA_LEVEL;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DOSE_ADJUST
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;PEOPLE;DISEASE:HYPERURICEMIA;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;DECREASED;;PK:DOSE-ADJUSTED_TROUGH_CONCENTRATIONS;CHILDREN;DISEASE:LIVER_TRANSPLANTATION;CAUTION_DOSE_ADJUST
METOPROLOL;ADRB2;CC;rs1042714;TOXICITY;DECREASED;;SIDE_EFFECT:TOTAL_CHOLESTEROL;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED;RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;;;CAUTION_SIDE_EFFECT
METHOTREXATE;ABCC4;GG + GT;rs9516519;METABOLISM/PK;DECREASED;;PK:PLASMA_LEVEL;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DOSE_ADJUST
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED;RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;PEOPLE;DISEASE:CHRONIC_KIDNEY_FAILURE;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;DECREASED;;PK:DOSE-ADJUSTED_TROUGH_CONCENTRATIONS;CHILDREN;DISEASE:LIVER_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;DECREASED;;PK:DOSE-ADJUSTED_TROUGH_CONCENTRATIONS;CHILDREN;DISEASE:LIVER_TRANSPLANTATION;CAUTION_DOSE_ADJUST
AZATHIOPRINE, MERCAPTOPURINE, THIOGUANINE;NUDT15;del;rs746071566;TOXICITY;INCREASED;RISK;SIDE_EFFECT:MYELOSUPPRESSION;PEOPLE;DISEASE:INFLAMMATORY_BOWEL_DISEASES;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;DECREASED;;PK:TROUGH_CONCENTRATIONS;CHILDREN;DISEASE:LIVER_TRANSPLANTATION;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;EFFICACY;INCREASED;RISK;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY;;;CAUTION_SIDE_EFFECT
ESCITALOPRAM;CYP2C19;*2/*2 + *2/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;METABOLISM/PK;INCREASED;;PK:S-CIT_SERUM_CONCENTRATIONS;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DOSE_ADJUST
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED;RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;;;CAUTION_SIDE_EFFECT
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;;;CAUTION_SIDE_EFFECT
FOLFIRI;UGT1A1;*1/*28 + *28/*28;UGT1A1*1, UGT1A1*28;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:NEUTROPENIA;PEOPLE;OTHER:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
ESCITALOPRAM;CYP2C19;*2/*2 + *2/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;METABOLISM/PK;INCREASED;;PK:MEAN_ESCITALOPRAM_CONCENTRATION;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DOSE_ADJUST
PAROXETINE;SLC6A4;HTTLPR short form (S allele);SLC6A4 HTTLPR LONG FORM (L ALLELE), SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;DECREASED;;EFFICACY:RESPONSE_WHEN_MEASURED_BY_THE_GERIATRIC_DEPRESSION_SCALE_AT_DAY_7_AND_DAY_28;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
PAROXETINE;SLC6A4;HTTLPR short form (S allele);SLC6A4 HTTLPR LONG FORM (L ALLELE), SLC6A4 HTTLPR SHORT FORM (S ALLELE);TOXICITY;INCREASED;RISK;SIDE_EFFECT:SIDE_EFFECTS;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_SIDE_EFFECT
PAROXETINE;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR LONG FORM (L ALLELE), SLC6A4 HTTLPR SHORT FORM (S ALLELE);TOXICITY;INCREASED;RISK;SIDE_EFFECT:LOWER_FINAL_DAILY_DOSE, DECREASED_DOSING_COMPLIANCE_AND_LOWER_PLASMA_LEVELS_AT_DAY_28;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_SIDE_EFFECT
ESCITALOPRAM;CYP2C19;*17/*17;CYP2C19*1, CYP2C19*17;DOSAGE, METABOLISM/PK;DECREASED;;PK:SERUM_CONCENTRATION;PEOPLE;DISEASE:MENTAL_DISORDERS;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;TOXICITY;INCREASED;RISK;SIDE_EFFECT:CARDIOVASCULAR_DISEASE;;;CAUTION_SIDE_EFFECT
MIRTAZAPINE;SLC6A4;HTTLPR long form (L allele);SLC6A4 HTTLPR LONG FORM (L ALLELE), SLC6A4 HTTLPR SHORT FORM (S ALLELE);TOXICITY;INCREASED;RISK;SIDE_EFFECT:SIDE_EFFECTS;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_SIDE_EFFECT
ESCITALOPRAM;CYP2C19;*3;CYP2C19*1, CYP2C19*3;DOSAGE, METABOLISM/PK;INCREASED;;PK:SERUM_CONCENTRATION;PEOPLE;DISEASE:MENTAL_DISORDERS;CAUTION_DOSE_ADJUST
LISINOPRIL;MMP3;del/del;rs35068180;EFFICACY;DECREASED;RISK;SIDE_EFFECT:STROKE;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;INCREASED;RISK;DISEASE:INFECTIOUS_DISEASE;CHILDREN;DISEASE:LIVER_TRANSPLANTATION;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;INCREASED;RISK;DISEASE:TOXIC_LIVER_DISEASE;CHILDREN;DISEASE:LIVER_TRANSPLANTATION;CAUTION_SIDE_EFFECT
PAROXETINE;SLC6A4;HTTLPR short form (S allele);SLC6A4 HTTLPR LONG FORM (L ALLELE), SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;;;EFFICACY:POSITIVE_CORRELATION_OF_PAROXETINE_CONCENTRATION_WITH_IMPROVEMENT_IN_HAMD_SCORES_AT_WEEK_2;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DOSE_ADJUST
ACENOCOUMAROL, WARFARIN;CYP2C9;*2;CYP2C9*1, CYP2C9*2;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HEMORRHAGE, SIDE_EFFECT:STROKE;PEOPLE;DISEASE:ATRIAL_FIBRILLATION, DISEASE:VENOUS_THROMBOEMBOLISM;CAUTION_SIDE_EFFECT
ESCITALOPRAM;CYP2D6;*4/*41;CYP2D6*1, CYP2D6*4, CYP2D6*41;METABOLISM/PK;INCREASED;;PK:MEAN_LOGARITHM_ESCITALOPRAM_CONCENTRATION;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DOSE_ADJUST
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*1/*3 + *2/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;TOXICITY;INCREASED;;EFFICACY:RISK_OF_RECURRENT_CARDIOVASCULAR_(CV)_EVENTS_1_YEAR_AFTER_PCI_IN_CHINESE_PATIENTS;;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*2;CYP2C19*1, CYP2C19*2;TOXICITY;INCREASED;;EFFICACY:RISK_OF_RECURRENT_CARDIOVASCULAR_(CV)_EVENTS_1_YEAR_AFTER_PCI_IN_CHINESE_PATIENTS;;;CAUTION_SIDE_EFFECT
FENTANYL;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ADVERSE_EVENTS;PEOPLE;DISEASE:NEOPLASMS, DISEASE:PAIN;CAUTION_SIDE_EFFECT
DIRECT ACTING ANTIVIRALS, SOFOSBUVIR;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE;HLA-A;*31:01;HLA-A*31:01;TOXICITY;INCREASED;RISK;DISEASE:MACULOPAPULAR_EXANTHEMA;CHILDREN;;CAUTION_SIDE_EFFECT
ESCITALOPRAM;CYP2C19;*2;CYP2C19*1, CYP2C19*2, CYP2C19*3;DOSAGE, METABOLISM/PK;INCREASED;;PK:SERUM_CONCENTRATION;PEOPLE;DISEASE:MENTAL_DISORDERS;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1, CYP2C19*2;EFFICACY;INCREASED;;OTHER:PLATELET_REACTIVITY;PEOPLE;DISEASE:MYOCARDIAL_INFARCTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
FOLFIRI;UGT1A1;*1/*28 + *28/*28;UGT1A1*1, UGT1A1*28;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA;PEOPLE;OTHER:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
CITALOPRAM;CYP2D6;;CYP2D6 POOR_METABOLIZER;METABOLISM/PK;DECREASED;;PK:DEMETHYLATION_CLEARANCE_OF_DESMETHYLCITALOPRAM;HEALTHY;;CAUTION_DOSE_ADJUST
ALLOPURINOL;HLA-C;*03:02;HLA-C*03:02;TOXICITY;INCREASED;RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;PEOPLE;DISEASE:CHRONIC_KIDNEY_FAILURE;CAUTION_SIDE_EFFECT
EFAVIRENZ;CYP2B6;*6;CYP2B6*1, CYP2B6*6;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
EFAVIRENZ;CYP2B6;*6/*6;CYP2B6*1, CYP2B6*6;TOXICITY;INCREASED;RISK;SIDE_EFFECT:LONG_QT_SYNDROME;HEALTHY;;CAUTION_SIDE_EFFECT
ALLOPURINOL;HLA-A;*33:03;HLA-A*33:03;TOXICITY;INCREASED;RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;PEOPLE;DISEASE:CHRONIC_KIDNEY_FAILURE;CAUTION_SIDE_EFFECT
ALLOPURINOL;HLA-C;*03:02;HLA-C*03:02;TOXICITY;INCREASED;RISK;SIDE_EFFECT:EXANTHEMA;PEOPLE;DISEASE:CHRONIC_KIDNEY_FAILURE;CAUTION_SIDE_EFFECT
FOLFIRI;UGT1A1;*28/*28;UGT1A1*1, UGT1A1*28;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:NEUTROPENIA;PEOPLE;DISEASE:COLONIC_NEOPLASMS;CAUTION_SIDE_EFFECT
EFAVIRENZ;CYP2B6;*9;CYP2B6*1, CYP2B6*9;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:DISCONTINUATION;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE, FLUOROURACIL;DPYD;CT;rs56038477;TOXICITY;INCREASED;RISK;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2/*2;CYP2C19*2;EFFICACY;INCREASED;;EFFICACY:PLATELET_REACTIVITY;PEOPLE;DISEASE:ANGINA_PECTORIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN, OXALIPLATIN, TEGAFUR / GIMERACIL / OTERACIL;UGT1A6;*2a;UGT1A6*2A;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:VOMITING;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*6/*6 + *28/*28 + *6/*28;UGT1A1*1, UGT1A1*6, UGT1A1*28;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
IRINOTECAN, OXALIPLATIN, TEGAFUR / GIMERACIL / OTERACIL;UGT1A1;*28;UGT1A1*28;EFFICACY;DECREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
FOLFOX;TYMS;TTA/TTA;rs11280056;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES;PEOPLE;OTHER:NEOPLASMS;CAUTION_SIDE_EFFECT
IRINOTECAN, OXALIPLATIN, TEGAFUR / GIMERACIL / OTERACIL;UGT1A1;*60;UGT1A1*60;EFFICACY;DECREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*10/*10;CYP2D6*1, CYP2D6*10;EFFICACY;DECREASED;;EFFICACY:EVENT-FREE_SURVIVAL;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1, CYP2C9*2, CYP2C9*3;EFFICACY;DECREASED;;EFFICACY:TIME_TO_THERAPEUTIC_INR;;;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1, CYP2C9*2, CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OVER-ANTICOAGULATION;;;CAUTION_SIDE_EFFECT
DRUGS FOR TREATMENT OF TUBERCULOSIS;HLA-C;*04:01;HLA-C*04:01;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_HYPERSENSITIVITY;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
ISONIAZID, RIFAMPIN;NAT2;*4;NAT2*4;TOXICITY, METABOLISM/PK;DECREASED;LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:TUBERCULOSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;*3/*3;CYP2C9*1, CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HEMORRHAGE;;;CAUTION_SIDE_EFFECT
METHOTREXATE;TYMS;TTA/TTA;rs11280056;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
EFAVIRENZ;CYP2B6;*9/*9 + *1/*9;CYP2B6*1, CYP2B6*9;EFFICACY;INCREASED;RISK;EFFICACY:DISCONTINUATION;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2 + *3 + *8;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*8, CYP2C19*17;EFFICACY;INCREASED;RISK;EFFICACY:STROKE;PEOPLE;DISEASE:TRANSIENT_ISCHEMIC_ATTACK, DISEASE:STROKE;CAUTION_SIDE_EFFECT
FOLFOX;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;rs45445694;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:ANEMIA;PEOPLE;OTHER:NEOPLASMS;CAUTION_SIDE_EFFECT
MERCAPTOPURINE, METHOTREXATE;TPMT;*1/*2 + *1/*3A + *3A/*3B;TPMT*1, TPMT*2, TPMT*3A, TPMT*3B;TOXICITY;INCREASED;RISK;SIDE_EFFECT:LEUKOPENIA;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
EGFR INHIBITORS;HLA-A;*02:01;HLA-A*02:01;TOXICITY;DECREASED;RISK;SIDE_EFFECT:EXANTHEMA;PEOPLE;DISEASE:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE, FLUDARABINE;CYP2B6;*1/*6 + *6/*6;CYP2B6*1, CYP2B6*6;TOXICITY;DECREASED;RISK;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:CHRONIC_B-CELL_LYMPHOCITIC_LEUKEMIA,;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1, CYP2C9*2, CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HEMORRHAGE;;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1, CYP2C9*2, CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HEMORRHAGE;;;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC AGENTS, TAMOXIFEN;UGT2B15;*2/*2 + *1/*2;UGT2B15*1, UGT2B15*2;EFFICACY;INCREASED;;EFFICACY:EVENT-FREE_SURVIVAL;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
EGFR INHIBITORS;HLA-A;*03:01;HLA-A*03:01;TOXICITY;DECREASED;RISK;SIDE_EFFECT:EXANTHEMA;PEOPLE;DISEASE:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN;UGT1A1;*1/*28 + *28/*28;UGT1A1*1, UGT1A1*28;TOXICITY;INCREASED;;SIDE_EFFECT:ASTHENIA;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
DOCETAXEL;SLCO1B3;A;rs3834935;OTHER, METABOLISM/PK;INCREASED;;PK:AUC;PEOPLE;DISEASE:NASOPHARYNGEAL_NEOPLASMS;CAUTION_DOSE_ADJUST
CARBAMAZEPINE, PHENYTOIN, VALPROIC ACID;GABRA1;GG;rs2279020;EFFICACY;;;EFFICACY:DRUG-RESISTANT_PHENOTYPE;PEOPLE;DISEASE:EPILEPSY;CAUTION_DOSE_ADJUST
PACLITAXEL;CYP2C8;*2 + *3 + *4;CYP2C8*2, CYP2C8*3, CYP2C8*4;TOXICITY;INCREASED;RISK;DISEASE:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEPHROTOXICITY;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;CYP2B6;*6/*6;CYP2B6*1, CYP2B6*6;TOXICITY;DECREASED;RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;MEN;DISEASE:TUBERCULOSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
AMOXICILLIN, CLAVULANATE;HLA-A;*30:02;HLA-A*30:02;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;;;CAUTION_SIDE_EFFECT
CITALOPRAM, ESCITALOPRAM;;A;rs1074145;OTHER;;;OTHER:CONCENTRATIONS_OF_S-CITALOPRAM_AND_METABOLIC_RATIO_OF_OF_S-DESMETHYLCITALOPRAM/CITALOPRAM;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DOSE_ADJUST
NEVIRAPINE;HLA-DQB1;*06:02;HLA-DQB1*06:02;TOXICITY;DECREASED;RISK;SIDE_EFFECT:DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
NEVIRAPINE;HLA-DQB1;*06:03;HLA-DQB1*06:03;TOXICITY;DECREASED;RISK;SIDE_EFFECT:DRUG_HYPERSENSITIVITY;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTINEOPLASTIC AGENTS, TAMOXIFEN;CYP2C19;*2/*2;CYP2C19*1, CYP2C19*2;EFFICACY;DECREASED;;EFFICACY:EVENT-FREE_SURVIVAL;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
NEVIRAPINE;HLA-DQB1;*06:02;HLA-DQB1*06:02;TOXICITY;DECREASED;RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
NEVIRAPINE;HLA-DRB1;*15:03;HLA-DRB1*15:03;TOXICITY;DECREASED;RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
NEVIRAPINE;HLA-DQB1;*06:09;HLA-DQB1*06:09;TOXICITY;DECREASED;RISK;SIDE_EFFECT:DRUG_HYPERSENSITIVITY;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
NEVIRAPINE;HLA-DQB1;*02:01;HLA-DQB1*02:01;TOXICITY;DECREASED;RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
IMATINIB;CYP1A2;AA;rs11636419;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:PERIORBITAL_EDEMA;PEOPLE;OTHER:GASTROINTESTINAL_STROMAL_TUMORS;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1, CYP2C19*2;EFFICACY;INCREASED;;OTHER:PLATELET_REACTIVITY;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NEVIRAPINE;HLA-DQB1;*02:01;HLA-DQB1*02:01;TOXICITY;DECREASED;RISK;SIDE_EFFECT:DRUG_HYPERSENSITIVITY;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
NEVIRAPINE;HLA-DQB1;*03:02;HLA-DQB1*03:02;TOXICITY;DECREASED;RISK;SIDE_EFFECT:DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
NEVIRAPINE;HLA-DQB1;*06:02;HLA-DQB1*06:02;TOXICITY;DECREASED;RISK;SIDE_EFFECT:DRUG_HYPERSENSITIVITY;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
NEVIRAPINE;HLA-DQB1;*03:02;HLA-DQB1*03:02;TOXICITY;DECREASED;RISK;SIDE_EFFECT:DRUG_HYPERSENSITIVITY;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
NEVIRAPINE;HLA-C;*04:01;HLA-C*04:01;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
NEVIRAPINE;HLA-C;*04:01;HLA-C*04:01;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_HYPERSENSITIVITY;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
ETHANOL;SLC6A4;HTTLPR short form (S allele);SLC6A4 HTTLPR LONG FORM (L ALLELE), SLC6A4 HTTLPR SHORT FORM (S ALLELE);TOXICITY;INCREASED;RISK;SIDE_EFFECT:ALCOHOL_ABUSE;;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*1/*17;CYP2C19*1, CYP2C19*17;EFFICACY;INCREASED;;EFFICACY:PLATELET_AGGREGATION_INHIBITION;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NEVIRAPINE;HLA-DQB1;*05:01;HLA-DQB1*05:01;TOXICITY;DECREASED;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE, PHENYTOIN, VALPROIC ACID;GABRA1;G;rs2279020;EFFICACY;;;EFFICACY:DRUG-RESISTANT_PHENOTYPE;PEOPLE;DISEASE:EPILEPSY;CAUTION_DOSE_ADJUST
METOPROLOL;CYP2D6;*3/*17 + *3/*4 + *4/*10 + *4/*17 + *4/*4 + *4/*41 + *4/*5 + *4/*6 + *5/*10 + *5/*17;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*10, CYP2D6*17, CYP2D6*41;OTHER;;;OTHER:GREATER_HEART_RATE_(HR)_REDUCTION;;;CAUTION_DOSE_ADJUST
BUCILLAMINE;HLA-DRB1;*08:02;HLA-DRB1*08:02;TOXICITY;INCREASED;RISK;SIDE_EFFECT:PROTEINURIA;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;TPMT;;TPMT DEFICIENCY;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DEATH;;;CAUTION_SIDE_EFFECT
AZATHIOPRINE, CYCLOSPORINE, PREDNISONE;TPMT;*1/*2 + *1/*3A + *1/*3C;TPMT*1, TPMT*2, TPMT*3A, TPMT*3C;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*1/*28 + *28/*28;UGT1A1*1, UGT1A1*28;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DIARRHEA;PEOPLE;OTHER:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
BUCILLAMINE;HLA-DQB1;*04:02;HLA-DQB1*04:02;TOXICITY;INCREASED;RISK;SIDE_EFFECT:PROTEINURIA;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;CYP2B6;CT;rs3211371;EFFICACY;INCREASED;;EFFICACY:RECURRENCE;PEOPLE;DISEASE:LYMPHOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*2 + *2/*17;CYP2C19*1, CYP2C19*2, CYP2C19*17;EFFICACY;INCREASED;;EFFICACY:PLATELET_AGGREGATION;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*1, CYP2C19*2, CYP2C19*3;TOXICITY;INCREASED;RISK;SIDE_EFFECT:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE);;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*2 + *3 + *5 + *6 + *11;CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*5, CYP2C9*6, CYP2C9*11;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OVER-ANTICOAGULATION;;;CAUTION_SIDE_EFFECT
SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-C;*06:02;HLA-C*06:02;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;;;CAUTION_SIDE_EFFECT
DAPSONE;HLA-B;*13:01;HLA-B*13:01;TOXICITY;INCREASED;RISK;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;;;CAUTION_SIDE_EFFECT
DAPSONE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;;;CAUTION_SIDE_EFFECT
LAPATINIB;HLA-DQA1;*02:01;HLA-DQA1*02:01;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
DAPSONE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;;;CAUTION_SIDE_EFFECT
LAPATINIB;HLA-DRB1;*07:01;HLA-DRB1*07:01;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
DAPSONE;HLA-B;*13:01;HLA-B*13:01;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS;;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1, CYP2C19*2;TOXICITY;INCREASED;RISK;;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;ABCC4;;ABCC4 DEFICIENCY;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DEATH;;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;;;OTHER:HIGH_PLATELET_REACTIVITY_(HPR);;;CAUTION_DOSE_ADJUST
AMOXICILLIN, CLAVULANATE;HLA-DQB1;*06:02;HLA-DQB1*06:02;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;;;CAUTION_SIDE_EFFECT
CLOZAPINE;HLA-DQB1;*05:02;HLA-DQB1*05:02;TOXICITY;INCREASED;RISK;SIDE_EFFECT:AGRANULOCYTOSIS;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
ASPIRIN, CLOPIDOGREL;CYP2C19;*2;CYP2C19*1, CYP2C19*2;EFFICACY;INCREASED;RISK;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY;;OTHER:PATIENTS_UNDERGOING_PCI;CAUTION_SIDE_EFFECT
ASPIRIN;HLA-DQB1;*06:09;HLA-DQB1*06:09;TOXICITY;INCREASED;RISK;SIDE_EFFECT:URTICARIA;;;CAUTION_SIDE_EFFECT
ASPIRIN, CLOPIDOGREL;CYP2C19;*3;CYP2C19*1, CYP2C19*3;EFFICACY;INCREASED;RISK;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY;;OTHER:PATIENTS_UNDERGOING_PCI;CAUTION_SIDE_EFFECT
ASPIRIN;HLA-DRB1;*13:02;HLA-DRB1*13:02;TOXICITY;INCREASED;RISK;SIDE_EFFECT:URTICARIA;;;CAUTION_SIDE_EFFECT
SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;;;CAUTION_SIDE_EFFECT
FOLFIRI, IRINOTECAN;UGT1A1;*1/*28 + *28/*28;UGT1A1*1, UGT1A1*28;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DIARRHEA;PEOPLE;OTHER:NEOPLASMS;CAUTION_SIDE_EFFECT
CLOZAPINE;HLA-DQB1;*05:02;HLA-DQB1*05:02;TOXICITY;INCREASED;RISK;SIDE_EFFECT:AGRANULOCYTOSIS;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
CLOZAPINE;HLA-DPB1;*04:01;HLA-DPB1*04:01;TOXICITY;INCREASED;RISK;SIDE_EFFECT:AGRANULOCYTOSIS;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
CLOZAPINE;HLA-DRB5;*02:02;HLA-DRB5*02:02;TOXICITY;INCREASED;RISK;SIDE_EFFECT:AGRANULOCYTOSIS;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-C;*08:01;HLA-C*08:01;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;;;CAUTION_SIDE_EFFECT
ASPIRIN, CLOPIDOGREL, PRASUGREL;CYP2C19;*17/*17 + *1/*17;CYP2C19*1, CYP2C19*17;EFFICACY;DECREASED;LIKELIHOOD;DISEASE:INFLAMMATION;PEOPLE;DISEASE:TOBACCO_USE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
OXCARBAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;;;CAUTION_SIDE_EFFECT
AMOXICILLIN, CLAVULANATE;HLA-DRB1;*15:01;HLA-DRB1*15:01;TOXICITY;INCREASED;RISK;SIDE_EFFECT:JAUNDICE;;;CAUTION_SIDE_EFFECT
PAROXETINE;SLC6A4;L allele-rs25531T/L allele-rs25531T;SLC6A4 HTTLPR SHORT FORM (S ALLELE), SLC6A4 L ALLELE-rs25531C, SLC6A4 L ALLELE-rs25531T;OTHER;;;OTHER:A_CORRELATION_OF_BRAIN_SERT_OCCUPANCY_WAS_ASSOCIATED_WITH_LARGER_PROPORTIONAL_HDRS17_DECREASES;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DOSE_ADJUST
AMOXICILLIN, CLAVULANATE;HLA-DRB5;*01:01;HLA-DRB5*01:01;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HEPATITIS;PEOPLE;DISEASE:INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
SORAFENIB;UGT1A1;*1/*28 + *28/*28;UGT1A1*1, UGT1A1*28;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HYPERBILIRUBINEMIA;;;CAUTION_SIDE_EFFECT
SORAFENIB;UGT1A1;*1/*28 + *28/*28;UGT1A1*1, UGT1A1*28;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:TREATMENT_INTERRUPTION;;;CAUTION_SIDE_EFFECT
AMOXICILLIN, CLAVULANATE;HLA-DRB1;*15:01;HLA-DRB1*15:01;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HEPATITIS;PEOPLE;DISEASE:INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
SUNITINIB;ABCB1;AA + AG;rs1128503;TOXICITY;DECREASED;RISK;SIDE_EFFECT:DIARRHEA;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED;RISK;SIDE_EFFECT:MACULOPAPULAR_EXANTHEMA, SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*1/*3;CYP2C9*1, CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OVER-ANTICOAGULATION;;;CAUTION_SIDE_EFFECT
TICLOPIDINE;HLA-DRB1;*13:02;HLA-DRB1*13:02;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE;;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1, CYP2C19*2;EFFICACY;DECREASED;;EFFICACY:EFFICACY;;OTHER:PATIENTS_THAT_HAD_UNDERGONE_CORONARY_ANGIOGRAPHY_OR_HAD_AN_UNEVENTFUL_PCI;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*3;CYP2C19*1, CYP2C19*3;EFFICACY;DECREASED;;EFFICACY:EFFICACY;;OTHER:PATIENTS_THAT_HAD_UNDERGONE_CORONARY_ANGIOGRAPHY_OR_HAD_AN_UNEVENTFUL_PCI;LIKELIHOOD_THERAPEUTIC_FAILURE
AMITRIPTYLINE;CYP2D6;*41;CYP2D6*1, CYP2D6*41;OTHER, METABOLISM/PK;INCREASED;;PK:PLASMA_NORTRIPTYLINE;PEOPLE;DISEASE:MENTAL_DISORDERS;CAUTION_DOSE_ADJUST
TICLOPIDINE;HLA-C;*14:03;HLA-C*14:03;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE;;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;CYP2B6;CT;rs3211371;EFFICACY;DECREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:LYMPHOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
ATORVASTATIN;LEPR;GG;rs1805094;OTHER;INCREASED;;OTHER:BONE_MARROW_DENSITY_IN_THE_LUMBAR_SPINE;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;CAUTION_DOSE_ADJUST
TICLOPIDINE;HLA-DQB1;*06:04;HLA-DQB1*06:04;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE;;;CAUTION_SIDE_EFFECT
TICLOPIDINE;HLA-A;*33:03;HLA-A*33:03;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE;;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*28/*28;UGT1A1*1, UGT1A1*28;TOXICITY;INCREASED;RISK;DISEASE:NEUTROPENIA;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
BUSULFAN, CYTARABINE, ETOPOSIDE;ABCC3;G;rs4148405;EFFICACY, TOXICITY;DECREASED;;OTHER:DISEASE-FREE_SURVIVAL;PEOPLE;DISEASE:ACUTE_MYELOID_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
TICLOPIDINE;HLA-B;*44:03;HLA-B*44:03;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE;;;CAUTION_SIDE_EFFECT
COCAINE, ETHANOL, NICOTINE;OPRM1;TT;rs1799972;TOXICITY;INCREASED;RISK;DISEASE:SUBSTANCE-RELATED_DISORDERS;WOMEN;;CAUTION_SIDE_EFFECT
NEVIRAPINE;HLA-C;*08:01;HLA-C*08:01;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HYPERSENSITIVITY;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;COMT;A;rs4680;OTHER;INCREASED;;OTHER:METHYLATION_AT_SITES_1_AND_2_IN_THE_COMT_PROMOTER;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_DOSE_ADJUST
ISONIAZID;NAT2;;NAT2 SLOW_ACETYLATOR;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
ASPIRIN;HLA-DRB1;*09:01;HLA-DRB1*09:01;TOXICITY;DECREASED;RISK;SIDE_EFFECT:URTICARIA;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;*3;CYP2C9*1, CYP2C9*3;EFFICACY;DECREASED;;EFFICACY:TIME_TO_THERAPEUTIC_INR;;;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;*6/*6;CYP2B6*1, CYP2B6*6;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
ASPIRIN;HLA-DPB1;*05:01;HLA-DPB1*05:01;TOXICITY;DECREASED;RISK;SIDE_EFFECT:URTICARIA;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;;CYP2C19 POOR_METABOLIZER, INTERMEDIATE_METABOLIZER;TOXICITY;INCREASED;RISK;SIDE_EFFECT:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE);;;CAUTION_SIDE_EFFECT
DRUGS FOR TREATMENT OF TUBERCULOSIS;CYP2E1;*1A/*5B;CYP2E1*1A, CYP2E1*5B;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
ASPIRIN;HLA-DQB1;*03:03;HLA-DQB1*03:03;TOXICITY;DECREASED;RISK;SIDE_EFFECT:URTICARIA;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;;NAT2 SLOW_ACETYLATOR;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;;;CAUTION_SIDE_EFFECT
ASPIRIN;HLA-DRB1;*13:02;HLA-DRB1*13:02;TOXICITY;INCREASED;RISK;SIDE_EFFECT:URTICARIA;;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE, THIOGUANINE;TPMT;*1/*3C;TPMT*1, TPMT*3C;TOXICITY;;;SIDE_EFFECT:THROMBOCYTOPENIA;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DOSE_ADJUST
ASPIRIN;HLA-DQB1;*06:09;HLA-DQB1*06:09;TOXICITY;INCREASED;RISK;SIDE_EFFECT:URTICARIA;;;CAUTION_SIDE_EFFECT
FLUTICASONE PROPIONATE;CD14, TMCO6;AA + AG;rs2569190;OTHER;DECREASED;;EFFICACY:FEV1/FVC_RATIO;CHILDREN;DISEASE:ASTHMA;CAUTION_DOSE_ADJUST
BLEOMYCIN, DACARBAZINE, DOXORUBICIN, VINBLASTINE;GSTM1;non-null/non-null;GSTM1 NON-NULL, GSTM1 NULL;TOXICITY;DECREASED;RISK;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:HODGKIN_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ, NEVIRAPINE;HLA-DRB1;*01:01;HLA-DRB1*01:01;TOXICITY;INCREASED;RISK;SIDE_EFFECT:EXANTHEMA;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
NEVIRAPINE;HLA-DRB1;*15:01;HLA-DRB1*15:01;TOXICITY;DECREASED;RISK;SIDE_EFFECT:DRUG_HYPERSENSITIVITY;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHANOL;ADH1B;T;rs1229984;TOXICITY;DECREASED;RISK;OTHER:ALCOHOL_ABUSE;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NEVIRAPINE;HLA-C;*04:01;HLA-C*04:01;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_HYPERSENSITIVITY;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*28/*28;UGT1A1*1, UGT1A1*28;TOXICITY;INCREASED;RISK;DISEASE:NEUTROPENIA;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
ISONIAZID, RIFAMPIN;GSTT1;;GSTT1 NULL;METABOLISM/PK;DECREASED;;PK:SERUM_HYDRAZINE_CONCENTRATIONS;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_DOSE_ADJUST
CAPECITABINE, FLUOROURACIL, TEGAFUR;DPYD;T;rs56038477;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
ISONIAZID, RIFAMPIN;GSTM1;;GSTM1 NULL;METABOLISM/PK;INCREASED;;PK:SERUM_HYDRAZINE_CONCENTRATIONS;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_DOSE_ADJUST
ALLOPURINOL;HLA-DQB1;*05:02;HLA-DQB1*05:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;PEOPLE;DISEASE:DRUG_HYPERSENSITIVITY;CAUTION_SIDE_EFFECT
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;GSTM1;;GSTM1 NULL;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;TPMT;*1/*3A;TPMT*1, TPMT*3A;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HEMATOLOGIC_DISORDER;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
NEVIRAPINE;HLA-B;*35:01;HLA-B*35:01;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;TPMT;*1/*3A;TPMT*1, TPMT*3A;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DOSE_REDUCTION;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED;RISK;SIDE_EFFECT:MACULOPAPULAR_EXANTHEMA, SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;;;CAUTION_SIDE_EFFECT
METHADONE;CYP3A4;C;rs3735451;OTHER;INCREASED;SEVERITY;SIDE_EFFECT:OPIOID_WITHDRAWAL_SYMPTOMS;PEOPLE;DISEASE:HEROIN_DEPENDENCE;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*1/*27;UGT1A1*1, UGT1A1*27;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:LEUKOPENIA;PEOPLE;DISEASE:LUNG_NEOPLASMS;CAUTION_SIDE_EFFECT
CLOZAPINE;CYP2C19;*17/*17;CYP2C19*17;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:DIABETES_MELLITUS;PEOPLE;DISEASE:SCHIZOAFFECTIVE_DISORDER, DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
NEVIRAPINE;HLA-DRB1;*01:01;HLA-DRB1*01:01;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
CLOZAPINE;HLA-B;*59:01;HLA-B*59:01;TOXICITY;INCREASED;RISK;SIDE_EFFECT:AGRANULOCYTOSIS;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*1/*6;UGT1A1*1, UGT1A1*6;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:LEUKOPENIA;PEOPLE;DISEASE:LUNG_NEOPLASMS;CAUTION_SIDE_EFFECT
NEVIRAPINE;HLA-C;*04:01;HLA-C*04:01;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
PHENYTOIN;HLA-B;*13:01;HLA-B*07:02, HLA-B*13:01;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS;;;CAUTION_SIDE_EFFECT
FLUOXETINE;CYP2D6;*4/*4;CYP2D6*1, CYP2D6*4;METABOLISM/PK;;;PK:SIGNIFICANTLY_HIGHER_(S)-FLUOXETINE_AND_LOWER_AND_(S)-NORFLUOXETINE_CONCENTRATIONS;PEOPLE;DISEASE:MENTAL_DISORDERS;CAUTION_DOSE_ADJUST
NAN;TRPA1;CT + TT;rs920829;OTHER;INCREASED;LIKELIHOOD;DISEASE:PAIN;PEOPLE;DISEASE:SICKLE_CELL_ANEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHANOL;ALDH2;A;rs671;TOXICITY;DECREASED;RISK;OTHER:ALCOHOL_ABUSE;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;NAT2;;NAT2 DEFICIENCY;OTHER;;;DISEASE:INSULIN_RESISTANCE;;;CAUTION_DOSE_ADJUST
FLUOXETINE;CYP2C9;*1/*2 + *1/*3;CYP2C9*1, CYP2C9*2, CYP2C9*3;METABOLISM/PK;INCREASED;;PK:DOSE-CORRECTED_PLASMA_CONCENTRATIONS_OF_FLUOXETINE_AND_THE_ACTIVE_MOIETY_IN_PATIENTS_WITH_TWO_FUNCTIONAL_CYP2D6_ALLELES;PEOPLE;DISEASE:MENTAL_DISORDERS;CAUTION_DOSE_ADJUST
NORTRIPTYLINE;CYP2D6;*1/*4 + *1/*5;CYP2D6*1, CYP2D6*4, CYP2D6*5;METABOLISM/PK;DECREASED;;PK:CONCENTRATIONS_OF_10-OH-NORTRIPTYLINE_AND_HIGHER_NORTRIPTYLINE/10-OH-NORTRIPTYLINE_RATIO;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DOSE_ADJUST
RITODRINE;CACNA1C;AA + AG;rs10774053;OTHER;DECREASED;LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS;WOMEN;DISEASE:PREMATURE_BIRTH;LIKELIHOOD_THERAPEUTIC_FAILURE
SPIRONOLACTONE;ACE;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC + ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del;rs1799752;EFFICACY;;;EFFICACY:IMPROVEMENT_IN_LEFT_VENTRICULAR_EJECTION_FRACTION, END-SYSTOLIC_AND_END-DIASTOLIC_VOLUME;PEOPLE;OTHER:CHRONIC_HEART_FAILURE;CAUTION_DOSE_ADJUST
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;APOE;TT;rs429358;EFFICACY;INCREASED;;EFFICACY:TIME_TO_ACHIEVE_STABLE_DOSE;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;APOE;CC;rs7412;EFFICACY;INCREASED;;EFFICACY:TIME_TO_ACHIEVE_STABLE_DOSE;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
AMOXICILLIN, CLAVULANATE, FLUCLOXACILLIN;HLA-DQB1;*06:02;HLA-DQB1*06:02;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;;;CAUTION_SIDE_EFFECT
ATORVASTATIN, QUINAPRIL;ACE;del/del;rs1799752;EFFICACY;DECREASED;;EFFICACY:REDUCTION_IN_D-DIMER_LEVELS;MEN;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
TIMOLOL;CYP2D6;;CYP2D6 POOR_METABOLIZER;EFFICACY, METABOLISM/PK;INCREASED;;PK:PLASMA_TIMOLOL_CONCENTRATION_AND_EXCERICE_HEART_RATE_REDUCTION;MEN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
LANSOPRAZOLE;CYP2C19;;CYP2C19 NORMAL_METABOLIZER;METABOLISM/PK;DECREASED;;OTHER:GASTRIC_PH;HEALTHY;;CAUTION_DOSE_ADJUST
AMOXICILLIN, CLAVULANATE, FLUCLOXACILLIN;HLA-C;*06:02;HLA-C*06:02;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;;;CAUTION_SIDE_EFFECT
RABEPRAZOLE;CYP2C19;;CYP2C19 NORMAL_METABOLIZER;EFFICACY;DECREASED;;OTHER:GASTRIC_PH;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
NAN;AREG;A;rs1615111;OTHER;DECREASED;;OTHER:OVERALL_SURVIVAL;PEOPLE;DISEASE:ADENOCARCINOMA;CAUTION_DOSE_ADJUST
CISPLATIN, EPIRUBICIN, FLUOROURACIL;C18orf56, TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;rs45445694;EFFICACY;INCREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:NEOPLASM_OF_ESOPHAGUS, DISEASE:STOMACH_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;INCREASED;RISK;EFFICACY:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE);;;CAUTION_SIDE_EFFECT
ATORVASTATIN, QUINAPRIL;ACE;del/del;rs1799752;EFFICACY;DECREASED;;EFFICACY:REDUCTION_IN_IL-6_LEVELS;MEN;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
ATORVASTATIN, QUINAPRIL;ACE;del/del;rs1799752;EFFICACY;INCREASED;;EFFICACY:REDUCTION_IN_CRP_LEVELS;MEN;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
AMOXICILLIN, CLAVULANATE, FLUCLOXACILLIN;HLA-B;*57:01;HLA-B*57:01;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C9;*2/*2;CYP2C9*1, CYP2C9*2;EFFICACY;INCREASED;;EFFICACY:PLATELET_AGGREGATION;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
VINCRISTINE;CYP3A5;*1/*3;CYP3A5*1, CYP3A5*3;TOXICITY;DECREASED;;SIDE_EFFECT:AVERAGE_CUMULATIVE_NEUROTOXICITY_GRADE;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN, CLOPIDOGREL;CYP2C19;*2;CYP2C19*1, CYP2C19*2, CYP2C19*17;EFFICACY;INCREASED;;EFFICACY:PLATELET_AGGREGATION;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHANOL;CYP2E1;T;rs2031920;TOXICITY;INCREASED;RISK;OTHER:ALCOHOL_ABUSE;;;CAUTION_SIDE_EFFECT
CISPLATIN, IRINOTECAN;UGT1A1;*1/*28 + *28/*28;UGT1A1*1, UGT1A1*28;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DIARRHEA;WOMEN;DISEASE:OVARIAN_NEOPLASMS;CAUTION_SIDE_EFFECT
ACENOCOUMAROL;CYP2C9;*3;CYP2C9*1, CYP2C9*3;OTHER;INCREASED;LIKELIHOOD;OTHER:BLOOD_COAGULATION_DISORDERS;PEOPLE;DISEASE:ATRIAL_FIBRILLATION, DISEASE:ATRIAL_FLUTTER,DISEASE:VENOUS_THROMBOSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
TOLTERODINE;CYP2D6;*10/*10 + *5/*10;CYP2D6*1, CYP2D6*5, CYP2D6*10;METABOLISM/PK;INCREASED;;PK:TOLTERODINE_EXPOSURE_AND_INCREASED_ACTIVE_METABOLITE_(5-HM)_CONCENTRATIONS;HEALTHY;;CAUTION_DOSE_ADJUST
AMOXICILLIN, CLAVULANATE, FLUCLOXACILLIN;HLA-DQB1;*03:03;HLA-DQB1*03:03;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;;;CAUTION_SIDE_EFFECT
PHENYTOIN;CYP2C9;*3;CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;CHILDREN;DISEASE:EPILEPSY;CAUTION_SIDE_EFFECT
ANASTROZOLE;CYP19A1;GG;rs1008805;OTHER;DECREASED;LIKELIHOOD;SIDE_EFFECT:ARTHRALGIA;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
ACE INHIBITORS, PLAIN;ACE;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;rs1799752;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:COUGH;;;CAUTION_SIDE_EFFECT
OLANZAPINE;CYP3A5;*1/*1;CYP3A5*1, CYP3A5*3;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:SOMNOLENCE;HEALTHY;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;INSR;A;rs41412545;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUTROPENIA;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
CYCLOSPORINE, METHOTREXATE;ATIC;AA;rs2177735;EFFICACY;INCREASED;RISK;SIDE_EFFECT:GRAFT_VS_HOST_DISEASE;PEOPLE;OTHER:HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION;CAUTION_SIDE_EFFECT
LEVETIRACETAM;HLA-A;*11:01;HLA-A*11:01;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ADVERSE_EVENTS;PEOPLE;DISEASE:EPILEPSY;CAUTION_SIDE_EFFECT
ALLOPURINOL;HLA-DRB1;*03:01;HLA-DRB1*03:01;TOXICITY;INCREASED;RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;PIK3R2;T;rs56022120;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUTROPENIA;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
VALPROIC ACID;UGT1A10, UGT1A6, UGT1A7, UGT1A8, UGT1A9;G;rs6759892;DOSAGE, METABOLISM/PK;INCREASED;;PK:GLUCURONIDATION;;;CAUTION_DOSE_ADJUST
VALPROIC ACID;UGT1A10, UGT1A6, UGT1A7, UGT1A8, UGT1A9;G;rs2070959;DOSAGE, METABOLISM/PK;INCREASED;;PK:GLUCURONIDATION;;;CAUTION_DOSE_ADJUST
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;PIK3R2;A;rs138602176;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUTROPENIA;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
ALLOPURINOL;HLA-C;*03:02;HLA-C*03:02;TOXICITY;INCREASED;RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;;;CAUTION_SIDE_EFFECT
PHENYTOIN;HLA-A;*02:01;HLA-A*02:01;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;;;CAUTION_SIDE_EFFECT
NEVIRAPINE;HLA-DRB1;*01:01;HLA-DRB1*01:01;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_HYPERSENSITIVITY;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
CLOPIDOGREL;MED12L, P2RY12;T/del;rs5853517;EFFICACY;DECREASED;;EFFICACY:PLATELET_AGGREGATION;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*2/*2;CYP2C19*1, CYP2C19*2;EFFICACY;INCREASED;;EFFICACY:PLATELET_REACTIVITY;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PHENYTOIN;HLA-A;*24:02;HLA-A*24:02;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;;;CAUTION_SIDE_EFFECT
EXEMESTANE;;TT;rs16964189;TOXICITY;;;SIDE_EFFECT:A_SIGNIFICANTLY_HIGHER_ODDS_OF_VASOMOTOR_SYMPTOMS_IN_POSTMENOPAUSAL_HORMONE_RECEPTOR_(HR)-POSITIVE_BREAST_CANCER_PATIENTS;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_DOSE_ADJUST
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;PERP;A;rs78428806;TOXICITY;DECREASED;RISK;SIDE_EFFECT:NEUTROPENIA;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN, CLOPIDOGREL, PRASUGREL;CYP2C9;*2;CYP2C9*1, CYP2C9*2;EFFICACY;INCREASED;LIKELIHOOD;DISEASE:INFLAMMATION;PEOPLE;DISEASE:TOBACCO_USE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1, CYP2C9*2, CYP2C9*3;EFFICACY;INCREASED;;EFFICACY:TIME_TO_ACHIEVE_STABLE_DOSE;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;DPYD;;DPYD DEFICIENCY;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1, CYP2C9*2, CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OVER-ANTICOAGULATION;;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1, CYP2C9*2, CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HEMORRHAGE;;;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;INSIG2;CC;rs11123469;EFFICACY;INCREASED;LIKELIHOOD;DISEASE:METABOLIC_SYNDROME;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1, CYP2C19*2;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ADVERSE_CARDIOVASCULAR_EVENTS;;;CAUTION_SIDE_EFFECT
FENOFIBRATE, SERTRALINE, TERBINAFINE, TICLOPIDINE;HLA-A;*33:01;HLA-A*33:01;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE, PHENYTOIN, VALPROIC ACID;ABCB1;T;rs2032582;EFFICACY;;;EFFICACY:DRUG-RESISTANT_PHENOTYPE;PEOPLE;DISEASE:EPILEPSY;CAUTION_DOSE_ADJUST
FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;TYMS;(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2 + (CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/3;rs45445694;EFFICACY;INCREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP4F2;*3;CYP4F2*1, CYP4F2*3;EFFICACY;;;EFFICACY:TIME_TO_THERAPEUTIC_INR;PEOPLE;DISEASE:ATRIAL_FIBRILLATION;CAUTION_DOSE_ADJUST
ASPIRIN;CYP2C9;*1/*3;CYP2C9*1, CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE_EFFECT:GASTRITIS;PEOPLE;DISEASE:CARDIOVASCULAR_DISEASE;CAUTION_SIDE_EFFECT
CAPECITABINE, FLUOROURACIL, TEGAFUR;DPYD;A;rs67376798;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
METOPROLOL;CYP2D6;*1/*4 + *4/*4;CYP2D6*1, CYP2D6*4;METABOLISM/PK;INCREASED;;PK:PLASMA_METOPROLOL_CONCENTRATIONS;;;CAUTION_DOSE_ADJUST
FLUOROURACIL;DPYD;;DPYD DEFICIENCY;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUTROPENIA;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
ATAZANAVIR;UGT1A1;*28;UGT1A1*1, UGT1A1*28;OTHER;INCREASED;LIKELIHOOD;SIDE_EFFECT:HYPERBILIRUBINEMIA;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;ACE2;C;rs2285666;OTHER;INCREASED;SEVERITY;OTHER:COVID-19;;;CAUTION_SIDE_EFFECT
"""ACE INHIBITORS, PLAIN"", ""BETA BLOCKING AGENTS"", ""CALCIUM CHANNEL BLOCKERS"", ""DIGOXIN"", ""DIURETICS""";ACE;del;rs1799752;EFFICACY;INCREASED;;EFFICACY:MORTALITY;PEOPLE;DISEASE:HEART_FAILURE;LIKELIHOOD_THERAPEUTIC_SUCCESS
IVACAFTOR, TEZACAFTOR;CFTR;del/del;rs113993960;OTHER;DECREASED;;SIDE_EFFECT:CYSTIC_FIBROSIS_PULMONARY_EXACERBATION;PEOPLE;DISEASE:CYSTIC_FIBROSIS;CAUTION_DOSE_ADJUST
MERCAPTOPURINE;TPMT;*1/*3C;TPMT*1, TPMT*3C;TOXICITY;INCREASED;RISK;SIDE_EFFECT:SEVERE_LEUKOPENIA;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
DESIPRAMINE;CYP2D6;*1/*1;CYP2D6*1, CYP2D6*4, CYP2D6*5;METABOLISM/PK;DECREASED;;PK:METABOLIC_RATIOS_OF_DESIPAMINE;HEALTHY;;CAUTION_DOSE_ADJUST
PAMAQUINE;G6PD;;G6PD DEFICIENCY;TOXICITY;;;DISEASE:HEMOLYSIS;;OTHER:G6PD_DEFICIENT_MICE;CAUTION_DOSE_ADJUST
METOPROLOL;CYP2D6;*1/*4 + *4/*4;CYP2D6*1, CYP2D6*4;EFFICACY, OTHER;INCREASED;;OTHER:HEART_RATE_(HR)_AND_DIASTOLIC_BLOOD_PRESSURE_(DBP)_REDUCTIONS_DURING_EARLY_TITRATION;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PRIMAQUINE;G6PD;;G6PD DEFICIENCY;TOXICITY;;;DISEASE:HEMOLYSIS;;OTHER:G6PD_DEFICIENT_MICE;CAUTION_DOSE_ADJUST
ITRACONAZOLE, KETOCONAZOLE;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;OTHER, METABOLISM/PK;DECREASED;SEVERITY;OTHER:INHIBITION_OF_CYP3A-CATALYZED_METABOLISM_OF_MIDAZOLAM_OR_TESTOSTERONE;;OTHER:HUMAN_LIVER_MICROSOMES;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*1, CYP2C19*2, CYP2C19*3;TOXICITY;INCREASED;RISK;SIDE_EFFECT:STENT_THROMBOSIS;PEOPLE;DISEASE:CORONARY_DISEASE;CAUTION_SIDE_EFFECT
HMG_COA_REDUCTASE_INHIBITORS;;A;rs3764261;EFFICACY;DECREASED;;EFFICACY:PROTECTION_AGAINST_MYOCARDIAL_INFARCTION;;;LIKELIHOOD_THERAPEUTIC_FAILURE
CAPECITABINE;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;rs45445694;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DIARRHEA, SIDE_EFFECT:DRUG_TOXICITY, SIDE_EFFECT:HAND-FOOT_SYNDROME;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;INCREASED;RISK;EFFICACY:ON-TREATMENT_PLATELET_ACTIVITY;PEOPLE;DISEASE:CORONARY_DISEASE;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1, CYP2C9*2, CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HEMORRHAGE;;;CAUTION_SIDE_EFFECT
PHENPROCOUMON;CYP2C9;*2 + *3;CYP2C9*1, CYP2C9*2, CYP2C9*3;EFFICACY;DECREASED;;SIDE_EFFECT:TIME_BELOW_THERAPEUTIC_RANGE;;;LIKELIHOOD_THERAPEUTIC_FAILURE
OSIMERTINIB;CYP2A6;CC;rs28399433;EFFICACY;DECREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*3;CYP2C19*1, CYP2C19*3;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
AMITRIPTYLINE, FLUOXETINE;CYP2D6;*1/*1xN + *2/*2xN;CYP2D6*1, CYP2D6*1XN, CYP2D6*2, CYP2D6*2XN;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DISCONTINUATION;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_SIDE_EFFECT
PAZOPANIB, PEMETREXED;VEGFA;CC + CT;rs833061;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:NEUTROPENIA;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*3/*3 + *1/*3;CYP2C9*1, CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OVER-ANTICOAGULATION;;;CAUTION_SIDE_EFFECT
PENICILLIN G, PENICILLIN V;HLA-B;*55:01;HLA-B*55:01;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_HYPERSENSITIVITY;;;CAUTION_SIDE_EFFECT
ETHANOL;GHSR;AG;rs2948694;OTHER;;;OTHER:WEIGHT;;;CAUTION_DOSE_ADJUST
OPIOIDS;OPRM1;AG + GG;rs495491;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OPIOID-RELATED_DISORDERS;MEN;;CAUTION_SIDE_EFFECT
NICOTINE;CYP2A6;*46/*46;CYP2A6*1, CYP2A6*46;NAN;INCREASED;;OTHER:CIGARETTES_PER_DAY;;;CAUTION_DOSE_ADJUST
OPIOIDS;OPRM1;AA + AG;rs10457090;TOXICITY;DECREASED;RISK;SIDE_EFFECT:OPIOID-RELATED_DISORDERS;MEN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;DISEASE:STEVENS-JOHNSON_SYNDROME;PEOPLE;DISEASE:EPILEPSY;CAUTION_SIDE_EFFECT
PHENYTOIN;CYP2C9;*1/*3;CYP2C9*1, CYP2C9*3;METABOLISM/PK;INCREASED;;PK:STEADY_STATE_CONCENTRATION_PER_DOSAGE;;DISEASE:EPILEPSY;CAUTION_DOSE_ADJUST
ALLOPURINOL;HLA-B;*58:01/*58:01;HLA-B*58:01;TOXICITY;INCREASED;RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;PEOPLE;DISEASE:GOUTY_ARTHRITIS;CAUTION_SIDE_EFFECT
PHENYTOIN;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;SIDE_EFFECT:EPIDERMAL_NECROLYSIS, TOXIC_OR_STEVENS-JOHNSON_SYNDROME;;DISEASE:EPILEPSY;CAUTION_SIDE_EFFECT
CARBAMAZEPINE, PHENYTOIN, VALPROIC ACID;SCN2A;A;rs17183814;EFFICACY;;;EFFICACY:NON-RESPONSE;PEOPLE;DISEASE:EPILEPSY;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2;CYP2C9*2;EFFICACY;;;EFFICACY:SHORTER_TIME_TO_THE_FIRST_INR_OF_MORE_THAN_4;;;CAUTION_DOSE_ADJUST
ATORVASTATIN, PRAVASTATIN, SIMVASTATIN;HTR7;T;rs1935349;TOXICITY;INCREASED;RISK;DISEASE:MYALGIA;PEOPLE;DISEASE:HYPERCHOLESTEROLEMIA;CAUTION_SIDE_EFFECT
METHOTREXATE;TYMS;CCGCGCCACTTGGCCTGCCTCCGTCCCGCCGCGCCACTTGGCCTGCCTCCGTCCCGCCGCGCCACTTCGCCTGCCTCCGTCCCCC;rs45445694;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:PSORIASIS;CAUTION_SIDE_EFFECT
NEVIRAPINE;CYP2B6;*6/*18;CYP2B6*1, CYP2B6*6, CYP2B6*18;TOXICITY, METABOLISM/PK;INCREASED;LIKELIHOOD;PK:ELEVATED_PLASMA_CONCENTRATIONS;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
DOCETAXEL, TEGAFUR;CYP2A6;*4/*4;CYP2A6*1, CYP2A6*4;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:EFFICACY;PEOPLE;DISEASE:STOMACH_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
CISPLATIN;ERCC2;T;rs1799793;EFFICACY;INCREASED;;EFFICACY:OVERALL_SURVIVAL_AND_PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:NEOPLASM_OF_ESOPHAGUS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE;HLA-B;*40:01;HLA-B*40:01;TOXICITY;DECREASED;LIKELIHOOD;DISEASE:STEVENS-JOHNSON_SYNDROME;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
COCAINE;SLC6A3;CACATACCATGCAACATACACACTCAGACA/CACATACCATGCAACATACACACTCAGACA;rs3836790;TOXICITY;INCREASED;RISK;DISEASE:DEATH;PEOPLE;DISEASE:COCAINE_DEPENDENCE;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;DISEASE:STEVENS-JOHNSON_SYNDROME;PEOPLE;DISEASE:EPILEPSY;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*2;CYP2C9*1, CYP2C9*2;DOSAGE;;;EFFICACY:LOWER_WARFARIN_DOSE_REQUIREMENT;;;CAUTION_DOSE_ADJUST
PHENYTOIN;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;DISEASE:STEVENS-JOHNSON_SYNDROME;PEOPLE;DISEASE:EPILEPSY;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1, CYP2C19*2;TOXICITY;INCREASED;RISK;SIDE_EFFECT:STENT_THROMBOSIS_IN_TAIWANESE_PATIENTS_RECEIVING_CLOPIDOGREL_AFTER_PERCUTANEOUS_CORONARY_INTERVENTION_(PCI);;;CAUTION_SIDE_EFFECT
PHENYTOIN;HLA-DRB1;*16:02;HLA-DRB1*16:02;TOXICITY;INCREASED;RISK;SIDE_EFFECT:EPIDERMAL_NECROLYSIS, TOXIC_OR_STEVENS-JOHNSON_SYNDROME;;DISEASE:EPILEPSY;CAUTION_SIDE_EFFECT
PAROXETINE;CYP2D6;*1/*4;CYP2D6*1, CYP2D6*4, CYP2D6*41;METABOLISM/PK;INCREASED;;PK:PAROXETINE_SERUM_CONCENTRATIONS_(CMIN);HEALTHY;;CAUTION_DOSE_ADJUST
PHENYTOIN;CYP2C9;*1/*3;CYP2C9*1, CYP2C9*3;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DIPHENYLHYDANTOIN-INDUCED_SKIN_RASH;;SIDE_EFFECT:NEUROLOGICAL_PATIENTS;CAUTION_SIDE_EFFECT
IBUPROFEN;CYP2C9;*3;CYP2C9*3;EFFICACY;INCREASED;;EFFICACY:DURATION_OF_INHIBITION_OF_PROSTANOIDS;HEALTHY;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PHENYTOIN;CYP2C9;*1/*1;CYP2C9*1;METABOLISM/PK;DECREASED;;PK:PLASMA_CONCENTRATION;HEALTHY;;CAUTION_DOSE_ADJUST
PHENYTOIN;CYP2C9;*1/*1;CYP2C9*1;METABOLISM/PK;INCREASED;;PK:THE_MAXIMAL_ELIMINATION_RATE_(VMAX);;DISEASE:EPILEPSY;CAUTION_DOSE_ADJUST
ACETAMINOPHEN;CYP2E1;*1/*5B;CYP2E1*1, CYP2E1*5B;METABOLISM/PK;INCREASED;;PK:ELIMINATION_RATE;PEOPLE;DISEASE:ALCOHOLIC_LIVER_DISEASES;CAUTION_DOSE_ADJUST
MERCAPTOPURINE;TPMT;*1/*3A;TPMT*1, TPMT*3A;TOXICITY;INCREASED;;PK:PLASMA_METHYLMERCAPTOPURINE_NUCLEOTIDES_LEVELS;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED;;OTHER:WARFARIN_DOSE;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED;;OTHER:WARFARIN_DOSE;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED;;OTHER:WARFARIN_DOSE;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*3 + *3/*3;CYP2C9*1, CYP2C9*3;DOSAGE;DECREASED;;OTHER:WARFARIN_DOSE_IN_JAPANESE_PATIENTS;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2;CYP2C9*2;DOSAGE, EFFICACY;;;EFFICACY:DECREASED_WARFARIN_DOSE_AND_INCREASED_RISK_OF_OVER-ANTICOAGULATION;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED;;OTHER:WARFARIN_DOSE;;;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;*1/*2;CYP2C19*1, CYP2C19*2;EFFICACY;INCREASED;;EFFICACY:ADP-INDUCED_MAXIMUM_PLATELET_AGGREGATION;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;*1/*3 + *1/*4;CYP2C9*1, CYP2C9*3, CYP2C9*4;DOSAGE;DECREASED;;OTHER:WARFARIN_DOSE;;;CAUTION_DOSE_ADJUST
ABACAVIR;HLA-B;*57:01;HLA-B*57:01;TOXICITY;INCREASED;RISK;DISEASE:DRUG_HYPERSENSITIVITY;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;CYP2A7;C;rs73032311;TOXICITY;INCREASED;RISK;SIDE_EFFECT:LEUKOPENIA;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*2;CYP2C19*1, CYP2C19*2;EFFICACY;DECREASED;;EFFICACY:RESPONSE_TO_CLOPIDOGREL_AND_POORER_OUTCOMES_IN_CHINESE_PATIENTS_WITH_ACUTE_ISCHEMIC_STROKE;;;LIKELIHOOD_THERAPEUTIC_FAILURE
BUPROPION;CYP2B6;*18;CYP2B6*18;METABOLISM/PK;DECREASED;;PK:HYDROXYBUPROPION_CONCENTRATIONS;HEALTHY;;CAUTION_DOSE_ADJUST
PHENYTOIN;CYP2C9;*1/*1;CYP2C9*1;METABOLISM/PK;DECREASED;;PK:PLASMA_CONCENTRATION;HEALTHY;;CAUTION_DOSE_ADJUST
ABACAVIR;HLA-B;*57:01;HLA-B*57:01;TOXICITY;INCREASED;RISK;DISEASE:DRUG_HYPERSENSITIVITY;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
PHENYTOIN;CYP2C9;*1/*1;CYP2C9*1;METABOLISM/PK;DECREASED;;PK:PLASMA_CONCENTRATION;HEALTHY;;CAUTION_DOSE_ADJUST
ANTIEPILEPTICS, CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;SIDE_EFFECT:CUTANEOUS_REACTIONS;;DISEASE:EPILEPSY;CAUTION_SIDE_EFFECT
AMITRIPTYLINE;CYP2C19;*2/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;METABOLISM/PK;INCREASED;;PK:MEAN_AMITRIPTYLINE_CONCENTRATIONS_CORRECTED_FOR_DOSE_AND_WEIGHT;PEOPLE;DISEASE:MENTAL_DISORDERS;CAUTION_DOSE_ADJUST
PHENYTOIN;HLA-B;*13:01;HLA-B*13:01;TOXICITY;INCREASED;RISK;SIDE_EFFECT:EPIDERMAL_NECROLYSIS, TOXIC_OR_STEVENS-JOHNSON_SYNDROME;;DISEASE:EPILEPSY;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*3;CYP2C19*1, CYP2C19*3;TOXICITY;INCREASED;RISK;SIDE_EFFECT:STENT_THROMBOSIS;;;CAUTION_SIDE_EFFECT
NAN;NAT1;*10/*11A;NAT1*10, NAT1*11A;OTHER;INCREASED;RISK;OTHER:ADENOMATOUS_AND_HYPERPLASTIC_POLYPS;PEOPLE;OTHER:A_NAT1_RAPID_ACETYLATOR_GENOTYPE_AND_HIGH_MEAT_CONSUMPTION_AND_RS2066853_GENOTYPE_AA_OR_GA;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*2;CYP2C9*2;DOSAGE;DECREASED;;OTHER:WARFARIN_DOSE;;;CAUTION_DOSE_ADJUST
NAN;NAT1;*10/*4;NAT1*4, NAT1*10;OTHER;INCREASED;RISK;OTHER:ADENOMATOUS_AND_HYPERPLASTIC_POLYPS;PEOPLE;OTHER:A_NAT1_RAPID_ACETYLATOR_GENOTYPE_AND_HIGH_MEAT_CONSUMPTION_AND_RS2066853_GENOTYPE_AA_OR_GA;CAUTION_SIDE_EFFECT
ISONIAZID, PYRAZINAMIDE, RIFAMPIN;GSTT1;;GSTT1 NULL;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;*5;NAT2 SLOW_ACETYLATOR;TOXICITY;INCREASED;RISK;DISEASE:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
PACLITAXEL;CYP2C8;*3;CYP2C8*3;METABOLISM/PK;DECREASED;;PK:CLERANCE_OF_PACLITAXEL;WOMEN;DISEASE:OVARIAN_NEOPLASMS;CAUTION_DOSE_ADJUST
BUPROPION;CYP2B6;*6;CYP2B6*1, CYP2B6*6;METABOLISM/PK;DECREASED;;PK:HYDROXYBUPROPION_CONCENTRATIONS_AND_HYDROXYBUPROPION/BUPROPION_RATIO;HEALTHY;;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;*2;CYP2C19*2;EFFICACY;;;EFFICACY:ADP-INDUCED_MAXIMUM_PLATELET_AGGREGATION_(MPA)_IN_CLOPIDOGREL-TREATED_PATIENTS_UNDERGOING_PE_RCUTANEOUS_CORONARY_INTERVENTION;;;CAUTION_DOSE_ADJUST
IRINOTECAN, RALTITREXED;TYMS;(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2;rs45445694;TOXICITY;DECREASED;RISK;DISEASE:ASTHENIA;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*3;CYP2C19*3;EFFICACY;;;EFFICACY:ADP-INDUCED_MAXIMUM_PLATELET_AGGREGATION_(MPA)_IN_CLOPIDOGREL-TREATED_PATIENTS_UNDERGOING_PE_RCUTANEOUS_CORONARY_INTERVENTION;;;CAUTION_DOSE_ADJUST
TEMSIROLIMUS;NR1I2;AG + GG;rs6785049;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS;PEOPLE;DISEASE:URINARY_BLADDER_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A4;C/C;rs2242480;METABOLISM/PK;INCREASED;;PK:DOSE-ADJUSTED_TROUGH_CONCENTRATIONS;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
NAN;NAT1;*11B/*3;NAT1*3, NAT1*11B;OTHER;INCREASED;RISK;OTHER:ADENOMATOUS_AND_HYPERPLASTIC_POLYPS;PEOPLE;OTHER:A_NAT1_RAPID_ACETYLATOR_GENOTYPE_AND_HIGH_MEAT_CONSUMPTION_AND_RS2066853_GENOTYPE_AA_OR_GA;CAUTION_SIDE_EFFECT
NAN;NAT1;*10/*10;NAT1*10;OTHER;INCREASED;RISK;OTHER:ADENOMATOUS_AND_HYPERPLASTIC_POLYPS;PEOPLE;OTHER:A_NAT1_RAPID_ACETYLATOR_GENOTYPE_AND_HIGH_MEAT_CONSUMPTION_AND_RS2066853_GENOTYPE_AA_OR_GA;CAUTION_SIDE_EFFECT
OXCARBAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;;DISEASE:EPILEPSY;CAUTION_SIDE_EFFECT
CALCINEURIN INHIBITORS, CYCLOSPORINE, TACROLIMUS;CYP2C8;*3;CYP2C8*3;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ALLOGRAFT_DYSFUNCTION_IN_KIDNEY_TRANSPLANT_RECIPIENTS_TREATED_WITH_CALCINEURIN_INHIBITORS;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
DAUNORUBICIN;NRP2;C;rs10932125;DOSAGE, METABOLISM/PK;INCREASED;;PK:IC50;;;CAUTION_DOSE_ADJUST
CISPLATIN, CYCLOPHOSPHAMIDE;GSTM3;CCT/CCT;rs1799735;TOXICITY, METABOLISM/PK;DECREASED;RISK;DISEASE:THROMBOCYTOPENIA;PEOPLE;DISEASE:OVARIAN_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN, CYCLOPHOSPHAMIDE;GSTM3;CCT/CCT;rs1799735;TOXICITY, METABOLISM/PK;DECREASED;RISK;DISEASE:ANEMIA;PEOPLE;DISEASE:OVARIAN_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN, CYCLOPHOSPHAMIDE;GSTM3;CCT/CCT;rs1799735;TOXICITY, METABOLISM/PK;DECREASED;RISK;DISEASE:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;PEOPLE;DISEASE:OVARIAN_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
METOPROLOL;CYP2D6;del/del;rs5030655;OTHER;INCREASED;;PK:PLASMA_CONCENTRATIONS_OF_METOPROLOL;;;CAUTION_DOSE_ADJUST
ANTIDEPRESSANTS;SLC6A4;(CCCACCCGA)12/(CCCACCCGA)12;rs57098334;NAN;;;EFFICACY:LACK_OF_REMISSION_AND_LACK_OF_RESPONSE;PEOPLE;DISEASE:DEPRESSION;CAUTION_DOSE_ADJUST
ANTIDEPRESSANTS;SLC6A4;(CCCACCCGA)12/(CCCACCCGA)12;rs57098334;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ADVERSE_DRUG_REACTION_AFTER_THE_SECOND_SWITCH_IN_TREATMENT;PEOPLE;DISEASE:DEPRESSION;CAUTION_SIDE_EFFECT
VALPROIC ACID;UGT1A10, UGT1A6, UGT1A7, UGT1A8, UGT1A9;C;rs1105879;METABOLISM/PK;INCREASED;;PK:GLUCURONIDATION;;;CAUTION_DOSE_ADJUST
NEVIRAPINE;CYP2B6;*6/*6;CYP2B6*1, CYP2B6*6;TOXICITY, METABOLISM/PK;INCREASED;LIKELIHOOD;PK:ELEVATED_PLASMA_CONCENTRATIONS;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
ISONIAZID, PYRIDOXAL PHOSPHATE;CYP2E1;*1A/*1A;CYP2E1*1A;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
ATENOLOL;ADRB1;CC;rs1801253;EFFICACY;INCREASED;;EFFICACY:REDUCTION_IN_BLOOD_PRESSURE;HEALTHY;;LIKELIHOOD_THERAPEUTIC_SUCCESS
AMITRIPTYLINE;CYP2D6;*4/*4;CYP2D6*1, CYP2D6*4;METABOLISM/PK;INCREASED;;PK:AMITRIPTYLINE/(E)-10-_OH-AT_RATIO;;;CAUTION_DOSE_ADJUST
AMITRIPTYLINE;CYP2D6;*4/*4;CYP2D6*1, CYP2D6*4;METABOLISM/PK;INCREASED;;PK:NORTRIPTYLINE/(E)-10-OH-NT_RATIO;;;CAUTION_DOSE_ADJUST
REPAGLINIDE;SLCO1B1;*37/*37;SLCO1B1*1, SLCO1B1*37;METABOLISM/PK;DECREASED;;PK:REPAGLINIDE_EXPOSURE_(DECREASED_AUC_AND_INCREASED_CLEARANCE);HEALTHY;;CAUTION_DOSE_ADJUST
PHENYTOIN;HLA-C;*08:01;HLA-C*08:01;TOXICITY;INCREASED;RISK;SIDE_EFFECT:EPIDERMAL_NECROLYSIS, TOXIC_OR_STEVENS-JOHNSON_SYNDROME;;DISEASE:EPILEPSY;CAUTION_SIDE_EFFECT
BENZENE;NQO1;AA;rs1800566;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HEMATOTOXICITY;;;CAUTION_SIDE_EFFECT
ATAZANAVIR, EFAVIRENZ;TPH2;TT;rs4570625;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:DEPRESSION;MEN;OTHER:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
METHOTREXATE;DHFR;TGGCGCGTCCCGCCCAGGT/TGGCGCGTCCCGCCCAGGT;rs70991108;TOXICITY;INCREASED;RISK;DISEASE:THROMBOCYTOPENIA;PEOPLE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
ALLOPURINOL;HLA-C;*03:02;HLA-C*03:02;TOXICITY;INCREASED;RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;;;CAUTION_SIDE_EFFECT
EFAVIRENZ;CYP2B6;*1;CYP2B6*1;EFFICACY, METABOLISM/PK;DECREASED;;PK:PLASMA_CONCENTRATION_OF_EFAVIRENZ;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTITHYROID PREPARATIONS;HLA-B;*08:01;HLA-B*08:01;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:AGRANULOCYTOSIS;;;CAUTION_SIDE_EFFECT
TEGAFUR;CYP2A6;*1;CYP2A6*1;OTHER, METABOLISM/PK;INCREASED;;PK:PLASMA_FLUOROURACIL;PEOPLE;DISEASE:NEOPLASMS;CAUTION_DOSE_ADJUST
PHENYTOIN;CYP2C9;*1/*2 + *1/*3;CYP2C9*1, CYP2C9*2, CYP2C9*3;TOXICITY;INCREASED;;SIDE_EFFECT:ADVERSE_DRUG_REACTIONS;;DISEASE:EPILEPSY;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*6/*6;UGT1A1*1, UGT1A1*6;TOXICITY;INCREASED;RISK;DISEASE:NEUTROPENIA;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
CYCLOSPORINE;CYP3A4;*1/*1;CYP3A4*1, CYP3A4*18;TOXICITY;INCREASED;RISK;SIDE_EFFECT:LIVER_INJURY;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
ANTIEPILEPTICS;CYP2C9;*1/*3;CYP2C9*1, CYP2C9*3;EFFICACY;DECREASED;LIKELIHOOD;DISEASE:DRUG_RESISTANCE;PEOPLE;DISEASE:EPILEPSY;LIKELIHOOD_THERAPEUTIC_FAILURE
ATORVASTATIN;UGT1A3;*2/*2;UGT1A3*1, UGT1A3*2;EFFICACY, METABOLISM/PK;INCREASED;;PK:ATORVASTATIN_LACTONIZATION;HEALTHY;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATORVASTATIN;UGT1A3;*2;UGT1A3*1, UGT1A3*2;EFFICACY, METABOLISM/PK;DECREASED;;EFFICACY:TOTAL_AND_THE_LOW-DENSITY_LIPOPROTEIN_CHOLESTEROL_MAXIMUM_PERCENT_DECREASES_FROM_BASELINE;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;;;CAUTION_SIDE_EFFECT
DOXEPIN;CYP2C9;*3/*3;CYP2C9*3;METABOLISM/PK;DECREASED;;PK:MEDIAN_ORAL_CLEARANCE_OF_DOXEPIN;HEALTHY;;CAUTION_DOSE_ADJUST
EFAVIRENZ, OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;METABOLISM/PK;DECREASED;;PK:ORAL_CLEARANCE_(CL/F)_OF_OMEPRAZOLE_RACEMATE, 5-HYDROXYOMEPRAZOLE, R-OMEPRAZOLE_AND_S-OMEPRAZOLE;HEALTHY;;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP2C19;*2/*2;CYP2C19*2;OTHER;INCREASED;;OTHER:HOSPITAL_STAY;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
MERCAPTOPURINE;COMT;A;rs4680;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
ROSIGLITAZONE;CYP2C8;*3;CYP2C8*3;EFFICACY;DECREASED;;EFFICACY:MEAN_ABSOLUTE_DIFFERENCE_IN_HBA1C;PEOPLE;DISEASE:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_FAILURE
NORTRIPTYLINE;CYP2D6;*1/*2xN;CYP2D6*1, CYP2D6*2XN;METABOLISM/PK;INCREASED;;PK:MAXIMUM_PLASMA_CONCENTRATION_OF_10-HYDROXY_NORTRIPTYLINE;HEALTHY;;CAUTION_DOSE_ADJUST
PRAVASTATIN;SLCO1B1;*15;SLCO1B1*1, SLCO1B1*15;METABOLISM/PK;INCREASED;;PK:RELATIVE_BIOAVAILABILITY_OF_PRAVASTATIN;HEALTHY;;CAUTION_DOSE_ADJUST
ABACAVIR;HLA-B;*57:01;HLA-B*57:01;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:DRUG_HYPERSENSITIVITY;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*1/*3;CYP2C19*1, CYP2C19*3;EFFICACY;DECREASED;;EFFICACY:ANTIPLATELET_RESPONSE_AND_REDUCED_CLOPIDOGREL_ACTIVE_METABOLITE_FORMATION;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
AMITRIPTYLINE;CYP2C19;*2/*2;CYP2C19*1, CYP2C19*2;METABOLISM/PK;INCREASED;;PK:MEAN_AMITRIPTYLINE_CONCENTRATIONS_CORRECTED_FOR_DOSE_AND_WEIGHT;PEOPLE;DISEASE:MENTAL_DISORDERS;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;*3;CYP2C19*1, CYP2C19*3;EFFICACY;DECREASED;;EFFICACY:CLOPIDOGREL_RESPONSE_IN_CHINESE_PATIENTS_UNDERGOING_PERCUTANEOUS_CORONARY_INTERVENTION_(PCI);;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1, CYP2C19*2;EFFICACY;DECREASED;;EFFICACY:CLOPIDOGREL_RESPONSE_IN_CHINESE_PATIENTS_UNDERGOING_PERCUTANEOUS_CORONARY_INTERVENTION_(PCI);;;LIKELIHOOD_THERAPEUTIC_FAILURE
NAN;CYP2C19;*17;CYP2C19*1, CYP2C19*17;OTHER;;RISK;DISEASE:PEPTIC_ULCER_DISEASE;;;CAUTION_DOSE_ADJUST
CAFFEINE;ADORA2A;TT;rs5751876;OTHER;INCREASED;;SIDE_EFFECT:ANXIETY;HEALTHY;;CAUTION_DOSE_ADJUST
METHOTREXATE;TYMS;(CCGCGCCACTTCGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;INCREASED;SEVERITY;DISEASE:RHEUMATOID_ARTHRITIS;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*3;CYP2C19*1, CYP2C19*3;TOXICITY;INCREASED;RISK;SIDE_EFFECT:COMPOSITE_ISCHEMIC_EVENTS;;OTHER:PATIENTS_THAT_HAD_UNDERGONE_CORONARY_ANGIOGRAPHY_OR_HAD_AN_UNEVENTFUL_PCI;CAUTION_SIDE_EFFECT
EFAVIRENZ;CYP2B6;*6/*6;CYP2B6*6;TOXICITY, METABOLISM/PK;INCREASED;;PK:PLASMA_CONCENTRATION;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1, CYP2C19*2;TOXICITY;INCREASED;RISK;SIDE_EFFECT:COMPOSITE_ISCHEMIC_EVENTS;;OTHER:PATIENTS_THAT_HAD_UNDERGONE_CORONARY_ANGIOGRAPHY_OR_HAD_AN_UNEVENTFUL_PCI;CAUTION_SIDE_EFFECT
ATORVASTATIN;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;TOXICITY;INCREASED;;SIDE_EFFECT:SERUM_CREATINE_KINASE_LEVELS_(INCREASED_RISK_OF_MYALGIA_AND_GREATER_DEGREE_OF_MUSCLE_DAMAGE);;;CAUTION_SIDE_EFFECT
NEVIRAPINE;ABCC10;CC;rs2125739;EFFICACY, METABOLISM/PK;INCREASED;LIKELIHOOD;PK:LOWER_NEVIRAPINE_PLASMA_CONCENTRATIONS;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE;HLA-A;*31:01;HLA-A*31:01;TOXICITY;INCREASED;RISK;SIDE_EFFECT:CARBAMAZEPINE-INDUCED_HYPERSENSITIVITY;;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;SIDE_EFFECT:CARBAMAZEPINE-INDUCED_STEVENS-JOHNSON_SYNDROME_(SJS)_AND_TOXIC_EPIDERMAL_NECROLYSIS_(TEN);;;CAUTION_SIDE_EFFECT
METFORMIN;SLC22A1;GTAAGTTG;rs36056065;TOXICITY, METABOLISM/PK;;;SIDE_EFFECT:GASTROINTESTINAL_SIDE_EFFECTS;PEOPLE;DISEASE:DIABETES_MELLITUS_T2;CAUTION_DOSE_ADJUST
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:STEVENS-JOHNSON_SYNDROME;;;CAUTION_SIDE_EFFECT
DRUGS FOR TREATMENT OF TUBERCULOSIS;CYP2E1;*1A/*1A;CYP2E1*1A;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-A;*31:01;HLA-A*31:01;TOXICITY;INCREASED;RISK;SIDE_EFFECT:CARBAMAZEPINE-INDUCED_HYPERSENSITIVITY_SYNDROME;CHILDREN;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*17;CYP2C19*17;EFFICACY;;;EFFICACY:ENHANCED_RESPONSE_TO_CLOPIDOGREL_(AS_MEASURED_BY_INHIBITION_OF_ADP-INDUCED_PLATELET_AGGREGATION);;;CAUTION_DOSE_ADJUST
PHENYTOIN;CYP2C9;*1/*3;CYP2C9*1, CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE_EFFECT:PHENYTOIN_TOXICITY;;DISEASE:EPILEPSY;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*1/*2;CYP2C19*1, CYP2C19*2;EFFICACY;DECREASED;;EFFICACY:ANTIPLATELET_RESPONSE_AND_REDUCED_CLOPIDOGREL_ACTIVE_METABOLITE_FORMATION;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
NAN;NAT1;*10/*11B;NAT1*10, NAT1*11B;OTHER;INCREASED;RISK;OTHER:ADENOMATOUS_AND_HYPERPLASTIC_POLYPS;PEOPLE;OTHER:A_NAT1_RAPID_ACETYLATOR_GENOTYPE_AND_HIGH_MEAT_CONSUMPTION_AND_RS2066853_GENOTYPE_AA_OR_GA;CAUTION_SIDE_EFFECT
EFAVIRENZ, OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;METABOLISM/PK;DECREASED;;PK:ORAL_CLEARANCE_(CL/F)_OF_OMEPRAZOLE_RACEMATE, 5-HYDROXYOMEPRAZOLE, R-OMEPRAZOLE_AND_S-OMEPRAZOLE;HEALTHY;;CAUTION_DOSE_ADJUST
DRUGS FOR TREATMENT OF TUBERCULOSIS;HLA-DQB1;*02:01;HLA-DQB1*02:01;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
NAN;NAT1;*11A/*4;NAT1*4, NAT1*11A;OTHER;INCREASED;RISK;OTHER:ADENOMATOUS_AND_HYPERPLASTIC_POLYPS;PEOPLE;OTHER:A_NAT1_RAPID_ACETYLATOR_GENOTYPE_AND_HIGH_MEAT_CONSUMPTION_AND_RS2066853_GENOTYPE_AA_OR_GA;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*3;CYP2C9*3;EFFICACY;;;EFFICACY:SHORTER_TIME_TO_THE_FIRST_INR_OF_MORE_THAN_4;;;CAUTION_DOSE_ADJUST
MERCAPTOPURINE;TPMT;*1/*3A;TPMT*1, TPMT*3A;TOXICITY;INCREASED;;PK:PLASMA_THIOGUANINE_NUCLEOTIDES_METABOLITES;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
PRAVASTATIN;SLCO1B1;*1/*15;SLCO1B1*1, SLCO1B1*15, SLCO1B1*37;METABOLISM/PK;INCREASED;;PK:PRAVASTATIN_PLASMA_CONCENTRATIONS_(AUC)_AND_CMAX;HEALTHY;;CAUTION_DOSE_ADJUST
PRAVASTATIN;SLCO1B1;*1/*15;SLCO1B1*1, SLCO1B1*15;METABOLISM/PK;INCREASED;;PK:PRAVASTATIN_PLASMA_CONCENTRATIONS_(AUC)_AND_CMAX;HEALTHY;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*13;CYP2C9*1, CYP2C9*13;DOSAGE;DECREASED;;OTHER:WARFARIN_DOSE_IN_KOREAN_PATIENTS_WITH_MECHANICAL_HEART_VALVE_REPLACEMENT_SINCE_DAY_7_OF_WARFARIN_THERAPY;;;CAUTION_DOSE_ADJUST
PHENPROCOUMON;CYP2C9;*2 + *3;CYP2C9*1, CYP2C9*2, CYP2C9*3;DOSAGE, TOXICITY;INCREASED;RISK;OTHER:COMPLICATIONS;;;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;*1/*3;CYP2C19*1, CYP2C19*3;EFFICACY;INCREASED;;EFFICACY:ADP-INDUCED_MAXIMUM_PLATELET_AGGREGATION;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METOPROLOL;CYP2D6;*4;CYP2D6*4;DOSAGE, TOXICITY;INCREASED;RISK;DISEASE:BRADYCARDIA;;;CAUTION_DOSE_ADJUST
PRAVASTATIN;SLCO1B1;*15/*15;SLCO1B1*1, SLCO1B1*15;METABOLISM/PK;INCREASED;;PK:PRAVASTATIN_PLASMA_CONCENTRATIONS_(AUC);HEALTHY;;CAUTION_DOSE_ADJUST
DRUGS FOR TREATMENT OF TUBERCULOSIS;GSTM1;;GSTM1 NULL;TOXICITY;DECREASED;SEVERITY;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:TUBERCULOSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED;;OTHER:WARFARIN_DOSE;;;CAUTION_DOSE_ADJUST
ASPIRIN, CLOPIDOGREL;CYP2C19;*2;CYP2C19*2;EFFICACY;INCREASED;RISK;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY;;OTHER:PATIENTS_UNDERGOING_PCI;CAUTION_SIDE_EFFECT
ASPIRIN, CLOPIDOGREL;CYP2C19;*3;CYP2C19*3;EFFICACY;INCREASED;RISK;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY;;OTHER:PATIENTS_UNDERGOING_PCI;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*1/*3;CYP2C9*1, CYP2C9*3;DOSAGE;DECREASED;;OTHER:WARFARIN_DOSE;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED;;OTHER:WARFARIN_DOSE_AFTER_ADJUSTMENT_FOR_VKORC1*1173;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*3;CYP2C9*1, CYP2C9*3;DOSAGE;DECREASED;;OTHER:WARFARIN_DOSE;;;CAUTION_DOSE_ADJUST
DOXEPIN;CYP2D6;*3/*5;CYP2D6*3, CYP2D6*5;METABOLISM/PK;DECREASED;;PK:MEDIAN_ORAL_CLEARANCE_OF_DOXEPIN;HEALTHY;;CAUTION_DOSE_ADJUST
HALOPERIDOL;COMT;AG;rs4680;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:EXTRAPYRAMIDAL_SYMPTOMS;MEN;DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
ATORVASTATIN;CYP2D6;*4;CYP2D6*4;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:MUSCLE_EFFECTS;;;CAUTION_SIDE_EFFECT
DOXEPIN;CYP2D6;*4/*5;CYP2D6*4, CYP2D6*5;METABOLISM/PK;DECREASED;;PK:MEDIAN_ORAL_CLEARANCE_OF_DOXEPIN;HEALTHY;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*13;CYP2C9*1, CYP2C9*13;EFFICACY;;;EFFICACY:DELAYED_TIME_TO_REACH_STABLE_DOSE_AND_AND_TENDED_TO_HAVE_HIGH_RISK_FOR_THE_FIRST_INR_GREATER_THAN_3.5;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*3;CYP2C9*3;DOSAGE, EFFICACY;;;EFFICACY:DECREASED_WARFARIN_DOSE_AND_INCREASED_RISK_OF_OVER-ANTICOAGULATION;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED;;OTHER:WARFARIN_DOSE;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2;CYP2C9*2;DOSAGE;DECREASED;;OTHER:WARFARIN_DOSE;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2;CYP2C9*2;DOSAGE;DECREASED;;OTHER:WARFARIN_DOSE;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*14;CYP2C9*1, CYP2C9*14;DOSAGE;DECREASED;;OTHER:WARFARIN_DOSE_IN_KOREAN_PATIENTS_WITH_MECHANICAL_HEART_VALVE_REPLACEMENT_SINCE_DAY_7_OF_WARFARIN_THERAPY;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2;CYP2C9*2;DOSAGE;DECREASED;;OTHER:WARFARIN_DOSE;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*3;CYP2C9*1, CYP2C9*3;EFFICACY;INCREASED;;EFFICACY:MEAN_INR_VALUES_IN_PATIENTS_WITH_HEART_VALVE_REPLACEMENT;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2B6;*5;CYP2B6*5;EFFICACY;;;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY_IN_CYP2C19*1/*1_CARRIERS;;OTHER:PATIENTS_UNDERGOING_PERCUTANEOUS_CORONARY_INTERVENTION;CAUTION_DOSE_ADJUST
VENLAFAXINE;CYP2D6;*10/*10;CYP2D6*10;METABOLISM/PK;INCREASED;;PK:CMAX_AND_AUC_OF_VENLAFAXINE;HEALTHY;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*2/*3;CYP2C9*2, CYP2C9*3;EFFICACY;INCREASED;;EFFICACY:MEAN_INR_VALUE;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;*2;CYP2C9*2;DOSAGE;DECREASED;;OTHER:WARFARIN_DOSE;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED;;OTHER:WARFARIN_DOSE;;;CAUTION_DOSE_ADJUST
VENLAFAXINE;CYP2D6;*1/*10;CYP2D6*1, CYP2D6*10;METABOLISM/PK;INCREASED;;PK:CMAX_AND_AUC_OF_VENLAFAXINE;HEALTHY;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*14;CYP2C9*1, CYP2C9*14;EFFICACY;;;EFFICACY:DELAYED_TIME_TO_REACH_STABLE_DOSE_AND_AND_TENDED_TO_HAVE_HIGH_RISK_FOR_THE_FIRST_INR_GREATER_THAN_3.5;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;*1/*3;CYP2C9*1, CYP2C9*3;EFFICACY;;;EFFICACY:DELAYED_TIME_TO_REACH_STABLE_DOSE_AND_AND_TENDED_TO_HAVE_HIGH_RISK_FOR_THE_FIRST_INR_GREATER_THAN_3.5;;;CAUTION_DOSE_ADJUST
PHENPROCOUMON;CYP2C9;*3;CYP2C9*1, CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HEMORRHAGE;;;CAUTION_SIDE_EFFECT
PHENPROCOUMON;CYP2C9;*3;CYP2C9*3;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:ACHIEVING_A_STABLE_DOSE;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PHENPROCOUMON;CYP2C9;*2;CYP2C9*2;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:ACHIEVING_A_STABLE_DOSE;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESCITALOPRAM;CYP2D6;*4/*10;CYP2D6*1, CYP2D6*4, CYP2D6*10;EFFICACY;INCREASED;;EFFICACY:FREQUENCY_OF_REMITTERS;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED;;OTHER:INTRAGASTRIC_PH;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
LANSOPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED;;OTHER:INTRAGASTRIC_PH;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1, CYP2C19*2;EFFICACY;INCREASED;;EFFICACY:ON-CLOPIDOGREL_PLATELET_AGGREGATION_(PA)_AND_HIGHER_PLATELET_REACTIVITY_INDEX_(PRI)_IN_PATIENTS_UNDERGOING_ELECTIVE_PERCUTANEOUS_CORONARY_INTERVENTION_(PCI);;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TRAMADOL;CYP2D6;*10/*10;CYP2D6*1, CYP2D6*10;METABOLISM/PK;DECREASED;;PK:TRAMADOL_CLEARANCE_IN_CHINESE_VOLUNTEERS;HEALTHY;;CAUTION_DOSE_ADJUST
TRAMADOL;CYP2D6;*4/*4;CYP2D6*1, CYP2D6*4;EFFICACY, METABOLISM/PK;DECREASED;;EFFICACY:TRAMADOL_METABOLISM_AND_RESPONSE;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEPRAZOLE;CYP2C19;*1/*2;CYP2C19*1, CYP2C19*2;EFFICACY;INCREASED;;OTHER:MEAL-STIMULATED_PLASMA_GASTRIN_CONCENTRATIONS;PEOPLE;DISEASE:ULCER;LIKELIHOOD_THERAPEUTIC_SUCCESS
PAROXETINE;CYP2D6;*4/*4 + *3/*4;CYP2D6*3, CYP2D6*4;METABOLISM/PK;INCREASED;;PK:PAROXETINE_PLASMA_CONCENTRATIONS_INCREASED_DURING_THE_COURSE_OF_PREGCY;WOMEN;;CAUTION_DOSE_ADJUST
TRAMADOL;CYP2D6;*4/*4;CYP2D6*1, CYP2D6*4;DOSAGE, EFFICACY;DECREASED;;EFFICACY:METABOLISM_AND_DECREASED_RESPONSE_TO_TRAMADOL;;;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;*1/*3 + *3/*3;CYP2C19*1, CYP2C19*3;EFFICACY;DECREASED;;EFFICACY:RESPONSE_TO_CLOPIDOGREL_AND_POORER_OUTCOMES_IN_CHINESE_PATIENTS_WITH_ACUTE_ISCHEMIC_STROKE;;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;*6/*7;CYP2D6*6, CYP2D6*7;EFFICACY;DECREASED;;EFFICACY:EVENT-FREE_SURVIVAL;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
ESCITALOPRAM;CYP2D6;*5/*10;CYP2D6*1, CYP2D6*5, CYP2D6*10;EFFICACY;INCREASED;;EFFICACY:FREQUENCY_OF_REMITTERS;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
TAMOXIFEN;CYP2D6;*3/*6;CYP2D6*3, CYP2D6*6;EFFICACY;DECREASED;;EFFICACY:EVENT-FREE_SURVIVAL;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
TRAMADOL;CYP2D6;*3/*4;CYP2D6*1, CYP2D6*3, CYP2D6*4;DOSAGE, EFFICACY;DECREASED;;EFFICACY:METABOLISM_AND_DECREASED_RESPONSE_TO_TRAMADOL;;;CAUTION_DOSE_ADJUST
CLOMIPRAMINE;CYP2C19;*2;CYP2C19*1, CYP2C19*2;EFFICACY;INCREASED;;EFFICACY:MEAN_CLOMIPRAMINE_CONCENTRATIONS_CORRECTED_FOR_DOSE_AND_WEIGHT_AND_HIGHER_METABOLIC_RATIO_OF_CLOMIPRAMINE/DESMETHYLCLOMIPRAMINE;PEOPLE;DISEASE:MENTAL_DISORDERS;LIKELIHOOD_THERAPEUTIC_SUCCESS
NORTRIPTYLINE;CYP2D6;*4;CYP2D6*1, CYP2D6*4;METABOLISM/PK;INCREASED;;PK:MEAN_NORTRIPTYLINE_CONCENTRATIONS_AND_NORTRIPTYLINE_CONCENTRATIONS_PER_UNIT_DOSE_OF_THE_MEDICATION;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DOSE_ADJUST
OXYCODONE;CYP2D6;*4/*4 + *3/*4;CYP2D6*1, CYP2D6*3, CYP2D6*4;METABOLISM/PK;;;PK:MEAN_PLASMA_CONCENTRATION_OF_OXYMORPHONE_AND_LOWER_MEAN_OXYMORPHONE/OXYCODONE_RATIO;;;CAUTION_DOSE_ADJUST
PAROXETINE;CYP2D6;*1/*1 + *1/*41;CYP2D6*1, CYP2D6*41;METABOLISM/PK;DECREASED;;PK:PAROXETINE_PLASMA_CONCENTRATIONS_INCREASED_DURING_THE_COURSE_OF_PREGCY;WOMEN;;CAUTION_DOSE_ADJUST
NORTRIPTYLINE;CYP2D6;*5/*10;CYP2D6*1, CYP2D6*5, CYP2D6*10;METABOLISM/PK;INCREASED;;PK:MEAN_NORTRIPTYLINE_CONCENTRATIONS_AND_NORTRIPTYLINE_CONCENTRATIONS_PER_UNIT_DOSE_OF_THE_MEDICATION;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DOSE_ADJUST
DESIPRAMINE;CYP2D6;*1/*1;CYP2D6*1, CYP2D6*3, CYP2D6*4;METABOLISM/PK;DECREASED;;PK:METABOLIC_RATIOS_OF_DESIPAMINE;HEALTHY;;CAUTION_DOSE_ADJUST
TRAMADOL;CYP2D6;*2/*10;CYP2D6*1, CYP2D6*2, CYP2D6*10;METABOLISM/PK;DECREASED;;PK:TRAMADOL_CLEARANCE_IN_CHINESE_VOLUNTEERS;HEALTHY;;CAUTION_DOSE_ADJUST
TRAMADOL;CYP2D6;*3/*5;CYP2D6*1, CYP2D6*3, CYP2D6*5;DOSAGE, EFFICACY;DECREASED;;EFFICACY:METABOLISM_AND_DECREASED_RESPONSE_TO_TRAMADOL;;;CAUTION_DOSE_ADJUST
NORTRIPTYLINE;CYP2D6;*5;CYP2D6*1, CYP2D6*2, CYP2D6*5;METABOLISM/PK;INCREASED;;PK:NORTRIPTYLINE_CONCENTRATIONS_CORRECTED_FOR_DOSE_AND_WEIGHT;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DOSE_ADJUST
PAROXETINE;CYP2D6;*1/*10 + *1/*5;CYP2D6*1, CYP2D6*5, CYP2D6*10;METABOLISM/PK;INCREASED;;PK:PAROXETINE_PLASMA_CONCENTRATION_AT_AN_ADMINISTERED_DOSE_OF_30MG/DAY;PEOPLE;DISEASE:MENTAL_DISORDERS;CAUTION_DOSE_ADJUST
COTININE;CYP2A6;*1/*1;CYP2A6*1, CYP2A6*2, CYP2A6*9, CYP2A6*17, CYP2A6*20;METABOLISM/PK;;;PK:SHORTER_CONTININ_HALF-LIFE;CHILDREN;;CAUTION_DOSE_ADJUST
MIRTAZAPINE;CYP2D6;*4/*4;CYP2D6*1, CYP2D6*4;METABOLISM/PK;DECREASED;;PK:CLEARANCE_OF_S(+)_MIRTAZAPINE;HEALTHY;;CAUTION_DOSE_ADJUST
PAROXETINE;CYP2D6;*1/*4;CYP2D6*1, CYP2D6*4;METABOLISM/PK;INCREASED;;PK:PAROXETINE_LEVELS;PEOPLE;DISEASE:OBSESSIVE_COMPULSIVE_DISORDER;CAUTION_DOSE_ADJUST
CLOMIPRAMINE;CYP2C19;*3;CYP2C19*1, CYP2C19*3;EFFICACY;INCREASED;;EFFICACY:MEAN_CLOMIPRAMINE_CONCENTRATIONS_CORRECTED_FOR_DOSE_AND_WEIGHT_AND_HIGHER_METABOLIC_RATIO_OF_CLOMIPRAMINE/DESMETHYLCLOMIPRAMINE;PEOPLE;DISEASE:MENTAL_DISORDERS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CITALOPRAM;CYP2C19;*2/*2 + *2/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;METABOLISM/PK;DECREASED;;PK:ORAL_CLEARANCE_OF_CITALOPRAM;HEALTHY;;CAUTION_DOSE_ADJUST
PAROXETINE;CYP2D6;*10/*10 + *1/*10;CYP2D6*1, CYP2D6*10;METABOLISM/PK;INCREASED;;PK:_PLASMA_PAROXETINE_CONCENTRATIONS_AT_ADMINISTERED_DOSE_OF_10MG/DAY;PEOPLE;DISEASE:MENTAL_DISORDERS;CAUTION_DOSE_ADJUST
MIRTAZAPINE;CYP2D6;*1/*1xN;CYP2D6*1, CYP2D6*1XN;METABOLISM/PK;INCREASED;;PK:TOTAL_CLEARANCE_OF_RACEMIC_MIRTAZAPINE;HEALTHY;;CAUTION_DOSE_ADJUST
CODEINE;CYP2D6;*36;CYP2D6*1, CYP2D6*36;METABOLISM/PK;DECREASED;;PK:CODEINE_METABOLISM_AND_MORPHINE_AND_GLUCURONIDES_FORMATION;HEALTHY;;CAUTION_DOSE_ADJUST
CODEINE;CYP2D6;*1/*1 + *1/*4;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5;METABOLISM/PK;INCREASED;;PK:PLASMA_LEVEL_OF_MORPHINE;HEALTHY;;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*2;CYP2C19*1, CYP2C19*2;EFFICACY;INCREASED;;EFFICACY:ON-TREATMENT_PLATELET_AGGREGATION;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;*2/*2 + *2/*3 + *3/*3;CYP2C9*2, CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OVER-ANTICOAGULATION;;;CAUTION_SIDE_EFFECT
NAN;UGT1A1;T;rs34946978;OTHER;INCREASED;LIKELIHOOD;OTHER:GILBERT_SYNDROME, OTHER:CRIGLER-NAJJAR_SYNDROME;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE;HLA-A;*31:01;HLA-A*31:01;TOXICITY;INCREASED;RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;;;CAUTION_SIDE_EFFECT
FLURBIPROFEN;CYP2C9;*1/*3;CYP2C9*1, CYP2C9*3;METABOLISM/PK;INCREASED;;PK:AUC, HIGHER_HALF-LIFE_AND_LOWER_FLURBIPROFEN_CLEARANCE;HEALTHY;;CAUTION_DOSE_ADJUST
DICLOFENAC;CYP2C8;*1/*4 + *4/*4;CYP2C8*1, CYP2C8*4;METABOLISM/PK;INCREASED;;PK:DICLOFENAC/5-HYDROXYDICLOFENAC_URINARY_CONCENTRATION_RATIO;HEALTHY;;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;TOXICITY;INCREASED;RISK;SIDE_EFFECT:MAJOR_ADVERSE_CARDIAC_AND_CEREBROVASCULAR_EVENTS;PEOPLE;DISEASE:MYOCARDIAL_INFARCTION;CAUTION_SIDE_EFFECT
PYRIMIDINE ANALOGUES;MIR27A;CC + CT;rs895819;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;TOXICITY;INCREASED;RISK;SIDE_EFFECT:MAJOR_ADVERSE_CARDIAC_AND_CEREBROVASCULAR_EVENTS;PEOPLE;DISEASE:MYOCARDIAL_INFARCTION;CAUTION_SIDE_EFFECT
CITALOPRAM;CYP2C19;;CYP2C19 POOR_METABOLIZER;METABOLISM/PK;INCREASED;;PK:PLASMA_RATIO_CITALOPRAM_(CIT)/N-DESMETHYLCIT_(DCIT);PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DOSE_ADJUST
TIMOLOL;CYP2D6;*3/*3 + *3/*4 + *4/*4 + *5/*4;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5;METABOLISM/PK;INCREASED;;PK:EXPOSURE_TO_TIMOLOL_(HIGHER_AREA-UNDER-CURVE, LONGER_ELIMINATION_HALF-LIVES_);HEALTHY;;CAUTION_DOSE_ADJUST
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;DISEASE:STEVENS-JOHNSON_SYNDROME;PEOPLE;DISEASE:EPILEPSY;CAUTION_SIDE_EFFECT
CLOPIDOGREL;PON1;C;rs662;EFFICACY;INCREASED;RISK;SIDE_EFFECT:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE);;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*2;CYP2C9*1, CYP2C9*2;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOTAL_HEMORRHAGE_AND_MAJOR_HEMORRHAGE;;;CAUTION_SIDE_EFFECT
TENOXICAM;CYP2C9;*3;CYP2C9*1, CYP2C9*2, CYP2C9*3;METABOLISM/PK;INCREASED;;PK:AUC_AND_HALF-LIFE_TIME_(T1/2);HEALTHY;;CAUTION_DOSE_ADJUST
IBUPROFEN;CYP2C8;*1/*3;CYP2C8*1, CYP2C8*3;TOXICITY;DECREASED;;SIDE_EFFECT:INOS_EXPRESSION_AND_FEWER_ADVERSE_EVENTS;HEALTHY;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED;RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;P2RY12;A;rs2046934;EFFICACY;INCREASED;RISK;SIDE_EFFECT:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE);;;CAUTION_SIDE_EFFECT
ANTIEPILEPTICS;HLA-B;*58:01;HLA-B*58:01;TOXICITY;DECREASED;RISK;DISEASE:STEVENS-JOHNSON_SYNDROME;PEOPLE;DISEASE:EPILEPSY;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;HLA-DPB1;*03:01;HLA-DPB1*03:01;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ASTHMA;;;CAUTION_SIDE_EFFECT
SULFONAMIDES, UREA DERIVATIVES;TCF7L2;CC;rs7903146;EFFICACY;INCREASED;;EFFICACY:RESPONSE_(REDUCTIONS_IN_HAEMOGLOBIN_A1C_(HBA1C)_AND_FASTING_PLASMA_GLUCOSE_(FPG)_LEVELS);PEOPLE;DISEASE:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C9*1, CYP2C9*2, CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HEMORRHAGE;;;CAUTION_SIDE_EFFECT
LUMACAFTOR;CFTR;del/del;rs113993960;TOXICITY;INCREASED;;EFFICACY:CHANGE_IN_SWEAT_CHLORIDE;PEOPLE;DISEASE:CYSTIC_FIBROSIS;CAUTION_SIDE_EFFECT
CAFFEINE;CYP1A2;AA;rs762551;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:ABORTION, SPONTANEOUS;WOMEN;;CAUTION_SIDE_EFFECT
DAPSONE;HLA-B;*13:01;HLA-B*13:01;TOXICITY;INCREASED;RISK;DISEASE:DRUG_HYPERSENSITIVITY;PEOPLE;DISEASE:LEPROSY;CAUTION_SIDE_EFFECT
ACENOCOUMAROL;CYP2C9;*2/*2 + *2/*3 + *3/*3;CYP2C9*1, CYP2C9*2, CYP2C9*3;DOSAGE;DECREASED;;EFFICACY:ACENOCOUMAROL_DOSE;PEOPLE;DISEASE:ATRIAL_FIBRILLATION;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;*3;CYP2C19*1, CYP2C19*3;EFFICACY;INCREASED;;EFFICACY:ON-CLOPIDOGREL_PLATELET_AGGREGATION_(PA)_AND_HIGHER_PLATELET_REACTIVITY_INDEX_(PRI)_IN_PATIENTS_UNDERGOING_ELECTIVE_PERCUTANEOUS_CORONARY_INTERVENTION_(PCI);;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CODEINE;CYP2D6;*1/*10 + *10/*10;CYP2D6*1, CYP2D6*10;METABOLISM/PK;DECREASED;;PK:PLASMA_LEVELS_OF_MORPHINE, M3G_AND_M6G_LEVELS_BUT_NOT_THOSE_OF_CODEINE;HEALTHY;;CAUTION_DOSE_ADJUST
AZATHIOPRINE;TPMT;*1/*2 + *1/*3A + *1/*3C;TPMT*1, TPMT*2, TPMT*3A, TPMT*3C;TOXICITY;INCREASED;RISK;DISEASE:TRANSPLANT_REJECTION;;DISEASE:HEART_TRANSPLANTATION;CAUTION_SIDE_EFFECT
BOSENTAN;CYP2C9;*2;CYP2C9*1, CYP2C9*2;TOXICITY;INCREASED;RISK;DISEASE:DRUG-INDUCED_LIVER_INJURY;;;CAUTION_SIDE_EFFECT
CODEINE;CYP2D6;*1/*1 + *1/*4;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5;OTHER;INCREASED;;OTHER:OROCECCAL_TRANSIT_TIME;HEALTHY;;CAUTION_DOSE_ADJUST
NAN;CYP1B1;CC + CG;rs1056836;NAN;DECREASED;;EFFICACY:EVENT-FREE_SURVIVAL, EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:NEOPLASM_OF_ESOPHAGUS;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;*2/*2;CYP2C19*1, CYP2C19*2;TOXICITY;INCREASED;RISK;SIDE_EFFECT:MAJOR_ADVERSE_CARDIAC_AND_CEREBROVASCULAR_EVENTS;PEOPLE;DISEASE:MYOCARDIAL_INFARCTION;CAUTION_SIDE_EFFECT
TETRABENAZINE;CYP2D6;;CYP2D6 INTERMEDIATE_METABOLIZER;EFFICACY;;;EFFICACY:LESS_ROBUST_TREATMENT_RESPONSE;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP4F2;*3;CYP4F2*1, CYP4F2*3;TOXICITY;DECREASED;RISK;SIDE_EFFECT:HEMORRHAGE;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CITALOPRAM;SLC6A4;HTTLPR short form (S allele)/L allele-rs25531C;SLC6A4 HTTLPR SHORT FORM (S ALLELE), SLC6A4 L ALLELE-rs25531C, SLC6A4 L ALLELE-rs25531T;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:SIDE_EFFECTS;PEOPLE;DISEASE:DEMENTIA;CAUTION_SIDE_EFFECT
CITALOPRAM;CYP2C19;*1/*17;CYP2C19*1, CYP2C19*17;METABOLISM/PK;DECREASED;;PK:METABOLIC_RATIO_CIT/DCIT_VALUES;;;CAUTION_DOSE_ADJUST
CLOPIDOGREL;PTGS1;T;rs1330344;EFFICACY;INCREASED;RISK;SIDE_EFFECT:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE);;;CAUTION_SIDE_EFFECT
CLOMIPRAMINE;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);SLC6A4 HTTLPR LONG FORM (L ALLELE), SLC6A4 HTTLPR SHORT FORM (S ALLELE);TOXICITY;INCREASED;;SIDE_EFFECT:CLOMIPRAMINE-INDUCED_PROLACTIN_RELEASE;HEALTHY;;CAUTION_SIDE_EFFECT
CITALOPRAM;CYP2C19;*1/*2 + *2/*2;CYP2C19*1, CYP2C19*2;METABOLISM/PK;INCREASED;;PK:AUC_OF_CITALOPRAM;HEALTHY;;CAUTION_DOSE_ADJUST
PAROXETINE;SLC6A4;HTTLPR short form (S allele);SLC6A4 HTTLPR LONG FORM (L ALLELE), SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;;EFFICACY:PRESENTATION_IN_THE_NON-REPONDER_GROUP;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
PHENOBARBITAL;CYP2C19;*2;CYP2C19*2;TOXICITY;INCREASED;RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_DRUG_REACTIONS;CHILDREN;;CAUTION_SIDE_EFFECT
OLANZAPINE;TPMT;*1/*3A + *1/*3C;TPMT*1, TPMT*3A, TPMT*3C;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:DIZZINESS;HEALTHY;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*1, CYP2C19*2, CYP2C19*3;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ISCHAEMIC_STROKE;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2/*2;CYP2C19*1, CYP2C19*2;EFFICACY;INCREASED;;EFFICACY:PRU;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*2/*2 + *1/*2;CYP2C19*1, CYP2C19*2;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:MAJOR_ADVERSE_CARDIOVASCULAR_EVENTS;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*07:02;HLA-B*07:02, HLA-B*08:01;TOXICITY;DECREASED;RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TRICHLOROETHYLENE;HLA-B;*13:01;HLA-B*13:01;TOXICITY;INCREASED;RISK;DISEASE:DRUG_HYPERSENSITIVITY;;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-A;*31:01;HLA-A*31:01;TOXICITY;INCREASED;RISK;DISEASE:DRUG_HYPERSENSITIVITY;;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*1, CYP2C19*2, CYP2C19*3;TOXICITY;INCREASED;RISK;SIDE_EFFECT:STENT_THROMBOSIS;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY, TOXICITY;INCREASED;RISK;SIDE_EFFECT:ADVERSE_CLINICAL_EVENTS;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;CAUTION_SIDE_EFFECT
AZATHIOPRINE, CYCLOSPORINE, PREDNISONE;TPMT;*3A/*3C;TPMT*3A, TPMT*3C;TOXICITY;;SEVERITY;SIDE_EFFECT:LEUKOPENIA;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
ALLOPURINOL;HLA-A;*02:01;HLA-A*02:01;TOXICITY;DECREASED;RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;*3;CYP2C9*1, CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OVER-ANTICOAGULATION;;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;INCREASED;RISK;EFFICACY:CARDIOVASCULAR_EVENT_OCCURRENCE;PEOPLE;DISEASE:MYOCARDIAL_INFARCTION;CAUTION_SIDE_EFFECT
ALLOPURINOL;HLA-C;*08:01;HLA-C*08:01;TOXICITY;INCREASED;RISK;DISEASE:DRUG_HYPERSENSITIVITY;PEOPLE;DISEASE:HEMATOLOGIC_NEOPLASMS;CAUTION_SIDE_EFFECT
IRINOTECAN, OXALIPLATIN, TEGAFUR / GIMERACIL / OTERACIL;UGT1A7;*3;UGT1A7*3;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:VOMITING;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
ASPIRIN, CLOPIDOGREL;CYP2C19;*1/*2 + *2/*2;CYP2C19*1, CYP2C19*2;EFFICACY;INCREASED;RISK;SIDE_EFFECT:STENT_THROMBOSIS;PEOPLE;OTHER:PERCUTANEOUS_CORONARY_INTERVENTIONS;CAUTION_SIDE_EFFECT
OSIMERTINIB;CYP2C9;CC;rs1057910;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS, SIDE_EFFECT:EXANTHEMA;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
CITALOPRAM;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);SLC6A4 HTTLPR LONG FORM (L ALLELE), SLC6A4 HTTLPR SHORT FORM (S ALLELE);EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:REMISSION;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
MYCOPHENOLATE MOFETIL;CYP2C8;CC;rs11572076;TOXICITY;DECREASED;RISK;DISEASE:LEUKOPENIA;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ALLOPURINOL;HLA-A;*33:03;HLA-A*33:03;TOXICITY;INCREASED;RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;;;CAUTION_SIDE_EFFECT
CLOZAPINE;HLA-DRB3;*02:02;HLA-DRB3*02:02;TOXICITY;INCREASED;RISK;SIDE_EFFECT:AGRANULOCYTOSIS;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;TPMT;C;rs1142345;TOXICITY;INCREASED;RISK;SIDE_EFFECT:LEUKOPENIA;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
MYCOPHENOLATE MOFETIL;UGT2B7;G;rs7438135;TOXICITY;INCREASED;RISK;DISEASE:ANEMIA;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
CLOZAPINE;HLA-C;*07:01;HLA-C*07:01;TOXICITY;INCREASED;RISK;SIDE_EFFECT:AGRANULOCYTOSIS;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
CLOZAPINE;HLA-DRB1;*01:01;HLA-DRB1*01:01;TOXICITY;DECREASED;RISK;SIDE_EFFECT:AGRANULOCYTOSIS;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
AZATHIOPRINE, MERCAPTOPURINE;HLA-DRB1;*07:01;HLA-DRB1*07:01;TOXICITY;INCREASED;RISK;SIDE_EFFECT:PANCREATITIS;PEOPLE;DISEASE:INFLAMMATORY_BOWEL_DISEASES;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1, CYP2C19*2;EFFICACY;INCREASED;;OTHER:PLATELET_REACTIVITY;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACENOCOUMAROL;CYP2C9;*1/*3 + *3/*3;CYP2C9*1, CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OVER-ANTICOAGULATION;;;CAUTION_SIDE_EFFECT
SULFASALAZINE;HLA-B;*39:01;HLA-B*39:01;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS;;;CAUTION_SIDE_EFFECT
METHAZOLAMIDE;HLA-C;*01:02;HLA-C*01:02;TOXICITY;INCREASED;RISK;DISEASE:TOXIC_EPIDERMAL_NECROLYSIS, DISEASE:STEVENS-JOHNSON_SYNDROME;;;CAUTION_SIDE_EFFECT
CARBIMAZOLE, METHIMAZOLE, PROPYLTHIOURACIL;HLA-B;*38:02;HLA-B*38:02;TOXICITY;INCREASED;RISK;SIDE_EFFECT:AGRANULOCYTOSIS;PEOPLE;DISEASE:GRAVES_DISEASE;CAUTION_SIDE_EFFECT
PLATINUM COMPOUNDS, PYRIMIDINE ANALOGUES;DPYD;AG + GG;rs1801265;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;OTHER:STOMACH_NEOPLASMS;CAUTION_SIDE_EFFECT
CILOSTAZOL, CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED;;EFFICACY:PLATELET_REACTIVITY;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
PHENYTOIN;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;PEOPLE;DISEASE:EPILEPSY;CAUTION_SIDE_EFFECT
ACENOCOUMAROL;CYP2C9;*3;CYP2C9*1, CYP2C9*3;EFFICACY;INCREASED;;EFFICACY:TIME_TO_ACHIEVE_STABLE_DOSE;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1, CYP2C9*2, CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HEMORRHAGE;;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:EXANTHEMA, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;PEOPLE;DISEASE:BIPOLAR_DISORDER, DISEASE:EPILEPSY;CAUTION_SIDE_EFFECT
CAPECITABINE, FLUOROURACIL;DPYD;;DPYD DEFICIENCY;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUTROPENIA;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
DOLASETRON;CYP2D6;*1/*1xN;CYP2D6*1, CYP2D6*1XN;EFFICACY;INCREASED;LIKELIHOOD;SIDE_EFFECT:VOMITING;PEOPLE;DISEASE:POSTOPERATIVE_NAUSEA_AND_VOMITING;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOSPORINE, METHOTREXATE;NFATC2;AA;rs6123048;EFFICACY;INCREASED;RISK;SIDE_EFFECT:GRAFT_VS_HOST_DISEASE;PEOPLE;OTHER:HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE, EPIRUBICIN, PACLITAXEL;CYP2C8;*4;CYP2C8*1, CYP2C8*4;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2C19;*1/*2;CYP2C19*1, CYP2C19*2;EFFICACY;INCREASED;;EFFICACY:OVERALL_SURVIVAL;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ABACAVIR;HLA-B;*57:01;HLA-B*57:01;TOXICITY;;;SIDE_EFFECT:DRUG_HYPERSENSITIVITY;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DOSE_ADJUST
IFOSFAMIDE;ALDH1A1;AA;rs3764435;EFFICACY;DECREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;OTHER:SOFT_TISSUE_NEOPLASMS, OTHER:SARCOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
ASPIRIN, CLOPIDOGREL;CYP2C19;*17;CYP2C19*1, CYP2C19*17;TOXICITY;DECREASED;RISK;SIDE_EFFECT:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE);;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DAPSONE;HLA-B;*13:01;HLA-B*13:01;TOXICITY;INCREASED;RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;;;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;;EFFICACY:RAPID_VIROLOGICAL_RESPONSE_(RVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOZAPINE;GSTT1;null/null;GSTT1 NON-NULL, GSTT1 NULL;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUTROPENIA;;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*3;CYP2C19*1, CYP2C19*3;TOXICITY;INCREASED;RISK;SIDE_EFFECT:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE);PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIR;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:ACHIEVING_SVR_IN_OLDER_PATIENTS_WITH_GENOTYPE_1B_CHRONIC_HEPATITIS_C;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;;EFFICACY:RAPID_VIROLOGICAL_RESPONSE_(RVR), EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
AZATHIOPRINE, MERCAPTOPURINE;NUDT15;del;rs746071566;TOXICITY;INCREASED;RISK;SIDE_EFFECT:PANCYTOPENIA, SIDE_EFFECT:THROMBOCYTOPENIA;PEOPLE;OTHER:AUTOIMMUNE_DISEASES, OTHER:INFLAMMATORY_BOWEL_DISEASES;CAUTION_SIDE_EFFECT
HMG_COA_REDUCTASE_INHIBITORS;ADAMTS1;CC;rs402007;EFFICACY;;;EFFICACY:THE_MOST_BENEFIT_FROM_STATIN_TREATMENT_IN_REDUCING_THE_RISK_OF_MYOCARDIAL_INFARCTION;;;CAUTION_DOSE_ADJUST
CARBAMAZEPINE;HLA-A;*31:01;HLA-A*31:01;TOXICITY;INCREASED;RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-A;*31:01;HLA-A*31:01;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;;;CAUTION_SIDE_EFFECT
NICOTINE;CYP2B6;*1/*4 + *4/*4;CYP2B6*1, CYP2B6*4;TOXICITY;INCREASED;SEVERITY;OTHER:TOBACCO_USE_DISORDER;;;CAUTION_SIDE_EFFECT
NICOTINE;CYP2A6;*1/*1;CYP2A6*1, CYP2A6*12;TOXICITY;DECREASED;RISK;OTHER:TOBACCO_USE_DISORDER;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTITHYROID PREPARATIONS;HLA-B;*38:02;HLA-B*38:02;TOXICITY;INCREASED;RISK;SIDE_EFFECT:AGRANULOCYTOSIS;;;CAUTION_SIDE_EFFECT
ANTITHYROID PREPARATIONS;HLA-DRB1;*08:03;HLA-DRB1*08:03;TOXICITY;INCREASED;RISK;SIDE_EFFECT:AGRANULOCYTOSIS;;;CAUTION_SIDE_EFFECT
AMOXICILLIN, CLAVULANATE, FLUCLOXACILLIN;HLA-DRB1;*15:01;HLA-DRB1*15:01;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;;;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*1/*3;CYP3A5*1, CYP3A5*3;TOXICITY;INCREASED;RISK;DISEASE:VIRUS_DISEASES;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;TOXICITY;INCREASED;RISK;DISEASE:INFECTIOUS_DISEASE;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;CAUTION_SIDE_EFFECT
GEFITINIB;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;EFFICACY;DECREASED;RISK;EFFICACY:ALLOGRAFT_REJECTION;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBOPLATIN, PACLITAXEL;CYP3A5;*1/*3;CYP3A5*1, CYP3A5*3;TOXICITY;INCREASED;RISK;SIDE_EFFECT:LEUKOPENIA, SIDE_EFFECT:NEUTROPENIA;WOMEN;DISEASE:OVARIAN_NEOPLASMS;CAUTION_SIDE_EFFECT
LAMOTRIGINE;SCN1A;C;rs3812718;EFFICACY;INCREASED;;EFFICACY:TONIC_BLOCK_OF_NA(V)_1.1_CHANNELS;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;*1/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;INCREASED;;PK:FORMATION_OF_METABOLITES;;OTHER:HUMAN_KIDNEY_MICROSOMES;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;EFFICACY;INCREASED;RISK;EFFICACY:TRANSPLANT_REJECTION;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;CAUTION_SIDE_EFFECT
PEMETREXED;TYMS;TTAAAGTTA/TTAAAGTTA;rs11280056;EFFICACY;DECREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:MESOTHELIOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;TYMS;del;rs11280056;TOXICITY;INCREASED;RISK;DISEASE:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:PSORIASIS;CAUTION_SIDE_EFFECT
NAN;SLCO1B1;C;rs4149056;OTHER;DECREASED;;OTHER:ERYTHROMYCIN_TRANSPORT;;;CAUTION_DOSE_ADJUST
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME, SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS;;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-A;*31:01;HLA-A*31:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS;;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;PEOPLE;OTHER:EPILEPSY;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-A;*31:01;HLA-A*31:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:MACULOPAPULAR_EXANTHEMA;;;CAUTION_SIDE_EFFECT
LEVOFLOXACIN;HLA-B;*13:01 + *13:02;HLA-B*13:01, HLA-B*13:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;;;CAUTION_SIDE_EFFECT
PHENYTOIN;HLA-A;*03:01;HLA-A*03:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;;;CAUTION_SIDE_EFFECT
ASPIRIN, CLOPIDOGREL;CYP2C19;;CYP2C19 INTERMEDIATE_METABOLIZER;EFFICACY;INCREASED;RISK;SIDE_EFFECT:THROMBOTIC_DISEASE;PEOPLE;;CAUTION_SIDE_EFFECT
BETA-LACTAM ANTIBACTERIALS, PENICILLINS;HLA-DRB1;*10:01;HLA-DRB1*10:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_HYPERSENSITIVITY;;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2 + *3 + *8;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*8, CYP2C19*17;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ADVERSE_CARDIOVASCULAR_EVENTS;PEOPLE;OTHER:CORONARY_ARTERY_DISEASE;CAUTION_SIDE_EFFECT
CLOPIDOGREL, PROTON PUMP INHIBITORS;CYP2C19;*1/*1 + *1/*17 + *17/*17;CYP2C19*1, CYP2C19*17;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ADVERSE_CARDIOVASCULAR_EVENTS;PEOPLE;OTHER:CORONARY_ARTERY_DISEASE;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*10/*10  + *1/*10;CYP2D6*1, CYP2D6*10;EFFICACY;DECREASED;;EFFICACY:RECURRENCE_FREE_SURVIVAL;PEOPLE;OTHER:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*1/*1 + *1/*17 + *17/*17;CYP2C19*1, CYP2C19*17;TOXICITY;DECREASED;RISK;SIDE_EFFECT:HEMORRHAGE;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN, CLOPIDOGREL;CYP2C19;;CYP2C19 POOR_METABOLIZER;EFFICACY;INCREASED;RISK;SIDE_EFFECT:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE);PEOPLE;OTHER:HIGH_ON-TREATMENT_PLATELET_REACTIVITY;CAUTION_SIDE_EFFECT
CYCLOSPORINE, METHOTREXATE;SLC19A1;TT;rs4818789;EFFICACY;DECREASED;RISK;SIDE_EFFECT:GRAFT_VS_HOST_DISEASE;PEOPLE;OTHER:HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATENOLOL, METOPROLOL;ADRB2;GG;rs1042714;TOXICITY;INCREASED;RISK;DISEASE:HYPERTRIGLYCERIDEMIA;PEOPLE;DISEASE:HYPERTENSION;CAUTION_SIDE_EFFECT
ZOLEDRONATE;;CC;rs1152003;TOXICITY;INCREASED;RISK;DISEASE:OSTEONECROSIS;PEOPLE;DISEASE:MULTIPLE_MYELOMA;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;;;CAUTION_SIDE_EFFECT
ANTIDEPRESSANTS, ANTIPSYCHOTICS;CYP2C19;;CYP2C19 INTERMEDIATE_METABOLIZER;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:NAUSEA, SIDE_EFFECT:VOMITING;PEOPLE;OTHER:DRUG-DRUG_PHARMACOKINETIC_INTERACTION;CAUTION_SIDE_EFFECT
ATORVASTATIN;HMGCR;T;rs17671591;EFFICACY;;;EFFICACY:LDL-C_RESPONSE;PEOPLE;DISEASE:CORONARY_DISEASE;CAUTION_DOSE_ADJUST
ANTIDEPRESSANTS, ANTIPSYCHOTICS;CYP2D6;;CYP2D6 INTERMEDIATE_METABOLIZER;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DEPRESSION;PEOPLE;OTHER:DRUG-DRUG_PHARMACOKINETIC_INTERACTION;CAUTION_SIDE_EFFECT
TACROLIMUS, VORICONAZOLE;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;METABOLISM/PK;INCREASED;SEVERITY;SIDE_EFFECT:DRUG-DRUG_PHARMACOKINETIC_INTERACTION;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
CARBOPLATIN, PACLITAXEL;LIG3;T;rs1052536;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES;PEOPLE;OTHER:OVARIAN_NEOPLASMS;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP1A2;A;rs2069514;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DEATH;PEOPLE;DISEASE:MYOCARDIAL_INFARCTION;CAUTION_SIDE_EFFECT
CYCLOSPORINE, METHOTREXATE;SLC19A1;TT;rs4819128;EFFICACY;DECREASED;RISK;SIDE_EFFECT:GRAFT_VS_HOST_DISEASE;PEOPLE;OTHER:HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHAMBUTOL, ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;;NAT2 SLOW_ACETYLATOR;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;PEOPLE;OTHER:TUBERCULOSIS;CAUTION_SIDE_EFFECT
ATORVASTATIN;HMGCR;T;rs10474433;EFFICACY;;;EFFICACY:LDL-C_RESPONSE;PEOPLE;DISEASE:CORONARY_DISEASE;CAUTION_DOSE_ADJUST
VANCOMYCIN;HLA-A;*32:01;HLA-A*32:01;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS, SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;NUDT15;T;rs116855232;TOXICITY;INCREASED;RISK;SIDE_EFFECT:LEUKOPENIA;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
ATORVASTATIN;PCSK9;T;rs11591147;EFFICACY;;;EFFICACY:LDL-C_RESPONSE;PEOPLE;DISEASE:CORONARY_DISEASE;CAUTION_DOSE_ADJUST
"""BETA-LACTAM ANTIBACTERIALS, PENICILLINS"", ""OTHER BETA-LACTAM ANTIBACTERIALS""";HLA-A;*02:07;HLA-A*02:07;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""BETA-LACTAM ANTIBACTERIALS, PENICILLINS"", ""OTHER BETA-LACTAM ANTIBACTERIALS""";HLA-A;*01:01;HLA-A*01:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;;;CAUTION_SIDE_EFFECT
"""BETA-LACTAM ANTIBACTERIALS, PENICILLINS"", ""OTHER BETA-LACTAM ANTIBACTERIALS""";HLA-C;*06:02;HLA-C*06:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;;;CAUTION_SIDE_EFFECT
"""BETA-LACTAM ANTIBACTERIALS, PENICILLINS"", ""OTHER BETA-LACTAM ANTIBACTERIALS""";HLA-DRB1;*15:01;HLA-DRB1*15:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;;;CAUTION_SIDE_EFFECT
"""BETA-LACTAM ANTIBACTERIALS, PENICILLINS"", ""OTHER BETA-LACTAM ANTIBACTERIALS""";HLA-DQB1;*03:02;HLA-DQB1*03:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;;CYP2C19 POOR_METABOLIZER;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:RECURRENCE;PEOPLE;OTHER:MYOCARDIAL_INFARCTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
VALPROIC ACID;CYP2C9;*1/*3 + *3/*3;CYP2C9*1, CYP2C9*3;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS;PEOPLE;OTHER:EPILEPSY;CAUTION_SIDE_EFFECT
ATORVASTATIN;APOE;T;rs429358;EFFICACY;;;EFFICACY:LDL-C_RESPONSE;PEOPLE;DISEASE:CORONARY_DISEASE;CAUTION_DOSE_ADJUST
ENALAPRIL;;TT;rs495828;TOXICITY;INCREASED;RISK;DISEASE:COUGH;WOMEN;DISEASE:HYPERTENSION;CAUTION_SIDE_EFFECT
RIBAVIRIN, SOFOSBUVIR;ITPA;AC;rs1127354;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;OTHER:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ENALAPRIL;;TT;rs495828;TOXICITY;INCREASED;RISK;DISEASE:COUGH;PEOPLE;DISEASE:HYPERTENSION;CAUTION_SIDE_EFFECT
ATORVASTATIN;APOE;T;rs7412;EFFICACY;;;EFFICACY:LDL-C_RESPONSE;PEOPLE;DISEASE:CORONARY_DISEASE;CAUTION_DOSE_ADJUST
NAN;GSTT1;;GSTT1 NON-NULL, GSTT1 NULL;EFFICACY, TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:TRANSPLANT_REJECTION;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
SIMVASTATIN;ABCG2;TT;rs2231142;METABOLISM/PK;INCREASED;;PK:EXPOSURE_TO_DRUG;HEALTHY;;CAUTION_DOSE_ADJUST
CISPLATIN, DOCETAXEL, FLUOROURACIL;TYMS;TTA/TTA;rs11280056;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:HYPONATREMIA;PEOPLE;OTHER:CARCINOMA, SQUAMOUS_CELL,OTHER:ADENOCARCINOMA, OTHER:ADENOSQUAMOUS_CARCINOMA, OTHER:NEOPLASM_OF_ESOPHAGUS;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-A;*31:01;HLA-A*31:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME, SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:MACULOPAPULAR_EXANTHEMA, SIDE_EFFECT:DRUG_HYPERSENSITIVITY, SIDE_EFFECT:DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS, SIDE_EFFECT:ERYTHEMA_MULTIFORME;;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*15:11;HLA-B*15:11;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME, SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS;;;CAUTION_SIDE_EFFECT
NAN;CYP2C19;*2 + *3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;INCREASED;LIKELIHOOD;SIDE_EFFECT:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE);PEOPLE;OTHER:ACUTE_CORONARY_SYNDROME;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;;CYP2B6 POOR_METABOLIZER;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:WEIGHT_GAIN;PEOPLE;OTHER:DISCONTINUATION, OTHER:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
CAPECITABINE, FLUOROURACIL;DPYS;(T)7/(T)8;rs143004875;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;OTHER:NEOPLASMS;CAUTION_SIDE_EFFECT
FLUVASTATIN;ABCG2;TT;rs2231142;METABOLISM/PK;INCREASED;;PK:EXPOSURE_TO_DRUG;HEALTHY;;CAUTION_DOSE_ADJUST
CAPECITABINE, FLUOROURACIL;DPYD;c.1129-5923C>G, c.1236G>A (HapB3);DPYD C.1129-5923C>G, C.1236G>A (HAPB3);TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;OTHER:NEOPLASMS;CAUTION_SIDE_EFFECT
OSIMERTINIB;CYP2A6;*4;CYP2A6*4;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DIARRHEA;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
OSIMERTINIB;ABCG2;TT;rs2622604;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DIARRHEA;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
L-ASPARAGINE, PREDNISONE, VINCRISTINE;CYP3A5;*3/*3 + *3/*6 + *3/*7;CYP3A5*1, CYP3A5*3, CYP3A5*6, CYP3A5*7;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:MUCOSITIS;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
L-ASPARAGINE, PREDNISONE, VINCRISTINE;ASNS;(GCGGGGCGCAGGGC)3/(GCGGGGCGCAGGGC)3;rs3832526;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:MUCOSITIS;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
PRAVASTATIN;NPC1L1;CC;rs17655652;EFFICACY;DECREASED;;EFFICACY:REDUCTION_IN_LDL-C;WOMEN;;LIKELIHOOD_THERAPEUTIC_FAILURE
PRAVASTATIN;NPC1L1;CC;rs17655652;EFFICACY;INCREASED;;EFFICACY:REDUCTION_IN_LDL-C;MEN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHAMBUTOL, ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;;NAT2 SLOW_ACETYLATOR;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;PEOPLE;OTHER:TUBERCULOSIS;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2;CYP2C19*2;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HIGH_ON-TREATMENT_PLATELET_REACTIVITY;PEOPLE;OTHER:CARDIOVASCULAR_DISEASE;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2;CYP2C19*2;TOXICITY;DECREASED;RISK;SIDE_EFFECT:HEMORRHAGE;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*2;CYP2C19*2;TOXICITY;INCREASED;RISK;SIDE_EFFECT:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE);;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*17;CYP2C19*17;TOXICITY;DECREASED;RISK;SIDE_EFFECT:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE);;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TRAMADOL;CYP2B6;;CYP2B6 POOR_METABOLIZER;EFFICACY;DECREASED;SEVERITY;EFFICACY:PAIN, POSTOPERATIVE;PEOPLE;OTHER:POSTOPERATIVE_PAIN;LIKELIHOOD_THERAPEUTIC_SUCCESS
TRAMADOL;CYP3A4;;CYP3A4 POOR_METABOLIZER;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DIZZINESS, SIDE_EFFECT:SOMNOLENCE;PEOPLE;OTHER:POSTOPERATIVE_PAIN;CAUTION_SIDE_EFFECT
CITALOPRAM, ESCITALOPRAM;CYP2C19;;CYP2C19 POOR_METABOLIZER;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS;PEOPLE;OTHER:MAJOR_DEPRESSIVE_DISORDER;CAUTION_SIDE_EFFECT
IRINOTECAN;HLA-B;C;rs9266271;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:NEUTROPENIA;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIINFLAMMATORY AGENTS, NON-STEROIDS;HLA-A;*02:01;HLA-A*02:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_HYPERSENSITIVITY;;;CAUTION_SIDE_EFFECT
ANTIINFLAMMATORY AGENTS, NON-STEROIDS;HLA-A;*34:01;HLA-A*34:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_HYPERSENSITIVITY;;;CAUTION_SIDE_EFFECT
ANTIINFLAMMATORY AGENTS, NON-STEROIDS;HLA-DRB1;*16:02;HLA-DRB1*16:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_HYPERSENSITIVITY;;;CAUTION_SIDE_EFFECT
ATORVASTATIN;HMGCR;GG;rs3846662;EFFICACY;INCREASED;;EFFICACY:LOW-DENSITY_LIPOPROTEIN_CHOLESTEROL_LEVEL_IN_BASAL_STATE_AND_POSSIBLY_IN_RESPONSE_TO_ATORVASTATIN.;HEALTHY;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;ABCB1;GG;rs1128503;EFFICACY;DECREASED;;EFFICACY:PLATELET_REACTIVITY;PEOPLE;OTHER:STROKE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:NEPHROTOXICITY, SIDE_EFFECT:TREMOR, SIDE_EFFECT:DIABETES_MELLITUS;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;*6;NAT2*4, NAT2*6;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:ACUTE_CELLULAR_REJECTION;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
AZATHIOPRINE;NUDT15;CT + TT;rs116855232;TOXICITY;INCREASED;RISK;SIDE_EFFECT:LEUKOPENIA;PEOPLE;DISEASE:ULCERATIVE_COLITIS, DISEASE:CROHN_DISEASE,DISEASE:AUTOIMMUNE_HEPATITIS;CAUTION_SIDE_EFFECT
BETA BLOCKING AGENTS, METOPROLOL;ADRB1;AG + GG;rs1801252;EFFICACY;INCREASED;;EFFICACY:IMPROVEMENT_IN_LEFT_VENTRICULAR(LV)_REMODELING;PEOPLE;DISEASE:HEART_FAILURE;LIKELIHOOD_THERAPEUTIC_SUCCESS
LANSOPRAZOLE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:NEPHROTOXICITY;;;CAUTION_SIDE_EFFECT
FOLFIRI, FOLFOX, XELOX;TYMS;del/del;rs11280056;EFFICACY;DECREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;OTHER:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
IRINOTECAN;ALOX5;T;rs1051713;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:NEUTROPENIA;;;CAUTION_SIDE_EFFECT
ETOPOSIDE;;GG;rs6539870;OTHER;INCREASED;;OTHER:SENSITIVITY_TO_ETOPOSIDE;;;CAUTION_DOSE_ADJUST
"""INTERFERON ALFA-2B, RECOMBINANT"", ""RIBAVIRIN""";ITPA;CC;rs1127354;EFFICACY;DECREASED;;EFFICACY:FREQUENCY_OF_PATIENTS_WHO_RECEIVED_AT_LEAST_THE_RECOMMENDED_80%_OF_SCHEDULED_RIBAVIRIN;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;INCREASED;RISK;EFFICACY:STROKE;;;CAUTION_SIDE_EFFECT
"""INTERFERON ALFA-2B, RECOMBINANT"", ""RIBAVIRIN""";ITPA;CC;rs1127354;EFFICACY;;;EFFICACY:CUMULATIVE_REDUCTION_OF_RIBAVIRIN;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;CAUTION_DOSE_ADJUST
ASPARAGINASE;F5;CT;rs6025;TOXICITY;INCREASED;RISK;SIDE_EFFECT:VENOUS_THROMBOEMBOLISM;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
DABIGATRAN;CES1;GG + GT;rs2244613;METABOLISM/PK;DECREASED;;PK:ADJUSTED_TROUGH_CONCENTRATIONS;PEOPLE;DISEASE:ATRIAL_FIBRILLATION;CAUTION_DOSE_ADJUST
DESIPRAMINE;MC1R;G;rs2228478;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:REMISSION;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;ABCB1;A;rs1045642;NAN;INCREASED;;OTHER:LEVEL_OF_APOLIPOPROTEIN_A1;;;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;VKORC1;AA;rs9934438;DOSAGE, EFFICACY, TOXICITY;DECREASED;;EFFICACY:DOSE_REQUIREMENT;;;CAUTION_DOSE_ADJUST
DESIPRAMINE;MC1R;A;rs2228479;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:REMISSION;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;*16/*7;NAT2*4, NAT2*7, NAT2*16;TOXICITY, METABOLISM/PK;INCREASED;LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;LTA, TNF;A;rs1800629;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:SERIOUS_HYPERSENSITIVITY;;;CAUTION_SIDE_EFFECT
ASPARAGINASE;IL16;GG + GT;rs11556218;TOXICITY;INCREASED;RISK;SIDE_EFFECT:THROMBOTIC_DISEASE;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;PACSIN2;TT;rs2413739;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HEMATOLOGIC_DISORDER;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
GEMCITABINE;SLC29A1;CT + TT;rs9394992;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUTROPENIA;PEOPLE;DISEASE:PANCREATIC_NEOPLASMS;CAUTION_SIDE_EFFECT
DOCETAXEL, THALIDOMIDE;SPG7;A;rs2292954;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXICITY;PEOPLE;DISEASE:PROSTATIC_NEOPLASMS;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC AGENTS;CTH;CC;rs648743;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOCETAXEL, THALIDOMIDE;ABCC6;C;rs2238472;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXICITY;PEOPLE;DISEASE:PROSTATIC_NEOPLASMS;CAUTION_SIDE_EFFECT
DOCETAXEL, THALIDOMIDE;ATP7A;G;rs2227291;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXICITY;PEOPLE;DISEASE:PROSTATIC_NEOPLASMS;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;GNMT;CT + TT;rs10948059;TOXICITY;DECREASED;RISK;SIDE_EFFECT:HEMATOLOGIC_DISORDER;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACENOCOUMAROL;CYP4F2;CC;rs2108622;OTHER, METABOLISM/PK;DECREASED;;OTHER:LEVELS_OF_VITAMIN_K-DEPENDENT_PROTEINS;PEOPLE;DISEASE:ATRIAL_FIBRILLATION;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;CYP4F2;CT;rs2108622;OTHER, METABOLISM/PK;DECREASED;;OTHER:LEVELS_OF_VITAMIN_K-DEPENDENT_PROTEINS;PEOPLE;DISEASE:ATRIAL_FIBRILLATION;CAUTION_DOSE_ADJUST
DABIGATRAN;CES1;GG + GT;rs2244613;TOXICITY;DECREASED;RISK;SIDE_EFFECT:BLEEDING_EVENTS;PEOPLE;DISEASE:ATRIAL_FIBRILLATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;A;rs4244285;TOXICITY;INCREASED;RISK;SIDE_EFFECT:CARDIOVASCULAR_EVENT;PEOPLE;DISEASE:MYOCARDIAL_INFARCTION;CAUTION_SIDE_EFFECT
ACENOCOUMAROL;CYP4F2;CC;rs2108622;DOSAGE, EFFICACY, TOXICITY;DECREASED;;EFFICACY:DOSAGE_REQUIREMENT;PEOPLE;DISEASE:ATRIAL_FIBRILLATION;CAUTION_DOSE_ADJUST
CLOPIDOGREL;ABCB1;AA;rs1045642;TOXICITY;INCREASED;RISK;SIDE_EFFECT:CARDIOVASCULAR_EVENTS;PEOPLE;DISEASE:MYOCARDIAL_INFARCTION;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*1/*4 + *1/*10 + *1/*5 + *1/*41 + *1/*3;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*41;EFFICACY;INCREASED;RISK;EFFICACY:RECURRENCE;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
IRINOTECAN;SLCO1B1;AA + AG;rs4149015;TOXICITY;INCREASED;;DISEASE:NEUTROPENIA;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
NAN;CHRM3;AA + AG;rs2165870;NAN;INCREASED;RISK;DISEASE:POSTOPERATIVE_NAUSEA_AND_VOMITING;;;CAUTION_SIDE_EFFECT
ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;*16/*16;NAT2*4, NAT2*16;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:A_MILD_INCREASE_OF_LIVER_ENZYMES;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
SALBUTAMOL, SALMETEROL;ADRB2;AA;rs1042713;EFFICACY;INCREASED;RISK;EFFICACY:ASTHMA_EXACERBATIONS;CHILDREN;DISEASE:ASTHMA;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A9;del/del;rs3832043;TOXICITY;INCREASED;RISK;DISEASE:DIARRHEA;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS, ARIPIPRAZOLE, CLOZAPINE, OLANZAPINE, QUETIAPINE, RISPERIDONE;HTR2C;C;rs1414334;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:METABOLIC_SYNDROME;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
CISPLATIN;SLC16A5;T;rs4788863;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:OTOTOXICITY;MEN;DISEASE:TESTICULAR_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ISONIAZID, RIFAMPIN;NAT2;*5 + *5G + *6 + *17 + *16 + *7 + *34 + *14 + *5J + *30;NAT2*1, NAT2*4, NAT2*5, NAT2*5G, NAT2*5J, NAT2*6, NAT2*7, NAT2*14, NAT2*16, NAT2*17, NAT2*30, NAT2*34;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ADVERSE_REACTIONS;PEOPLE;OTHER:TUBERCULOSIS;CAUTION_SIDE_EFFECT
IRINOTECAN;ABCC2;CC;rs3740066;TOXICITY;INCREASED;RISK;DISEASE:DIARRHEA;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
ETHAMBUTOL, ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;*6/*6 + *6/*7 + *7/*7;NAT2*4, NAT2*6, NAT2*7, NAT2*16;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;PEOPLE;OTHER:TUBERCULOSIS;CAUTION_SIDE_EFFECT
ENALAPRIL, IMIDAPRIL, LISINOPRIL;BDKRB2;CT + TT;rs1799722;TOXICITY;INCREASED;RISK;DISEASE:COUGH;PEOPLE;DISEASE:ESSENTIAL_HYPERTENSION;CAUTION_SIDE_EFFECT
IRINOTECAN;ABCG2;CT + TT;rs2231137;TOXICITY;INCREASED;RISK;DISEASE:DIARRHEA;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
CLOZAPINE, RISPERIDONE;HTR2C;C;rs1414334;TOXICITY;INCREASED;RISK;SIDE_EFFECT:METABOLIC_SYNDROME;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
HMG_COA_REDUCTASE_INHIBITORS;SREBF1;AA + AG;rs11868035;OTHER;INCREASED;;OTHER:TOTAL_CHOLESTEROL;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_DOSE_ADJUST
OXYCODONE;CYP2D6;*3/*4 + *4/*4 + *4/*5 + *4/*6 + *4/*7;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*7;DOSAGE;INCREASED;;PK:OXYCODONE_CONSUMPTION_UP_TO_THE_12(TH)_HOUR_IN_POSTOPERATIVE_PATIENTS;;;CAUTION_DOSE_ADJUST
CISPLATIN;GSTP1;G;rs1695;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:OTOTOXICITY;MEN;DISEASE:TESTICULAR_NEOPLASMS;CAUTION_SIDE_EFFECT
ACE INHIBITORS, PLAIN;BDKRB2;T;rs1799722;TOXICITY;INCREASED;RISK;DISEASE:COUGH;PEOPLE;DISEASE:HYPERTENSION;CAUTION_SIDE_EFFECT
ATORVASTATIN;ABCG2;TT;rs2231142;DOSAGE, METABOLISM/PK;INCREASED;;PK:AUC;PEOPLE;OTHER:NO_DISEASE;CAUTION_DOSE_ADJUST
LANSOPRAZOLE;CYP2C19;;CYP2C19 INTERMEDIATE METABOLIZER;METABOLISM/PK;DECREASED;;OTHER:GASTRIC_PH;HEALTHY;;CAUTION_DOSE_ADJUST
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;*5/*7 + *6/*6 + *6/*7 + *7/*7;NAT2*5, NAT2*6, NAT2*7;TOXICITY, METABOLISM/PK;INCREASED;RISK;DISEASE:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;*6/*7;NAT2*6, NAT2*7;TOXICITY;INCREASED;RISK;DISEASE:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
IRBESARTAN;AGTR1;AC + CC;rs5186;EFFICACY;INCREASED;;EFFICACY:BLOOD_PRESSURE_RESPONSE;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;*6/*6;NAT2*6;TOXICITY;INCREASED;RISK;DISEASE:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
OPIOIDS;PDE3A;A;rs12305038;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:NAUSEA, SIDE_EFFECT:VOMITING;PEOPLE;OTHER:NEOPLASMS, OTHER:PAIN;LIKELIHOOD_THERAPEUTIC_SUCCESS
ISONIAZID, RIFAMPIN;NAT2;*5/*7 + *6/*6 + *6/*7;NAT2*1, NAT2*4, NAT2*5, NAT2*6, NAT2*7;TOXICITY, METABOLISM/PK;INCREASED;RISK;DISEASE:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
DEXMEDETOMIDINE;ADRA2A;G;rs1800544;EFFICACY;INCREASED;;EFFICACY:BISPECTRAL_INDEX_AND_RAMSAY_SEDATION_SCORES, INDICATING_A_LONGER_PERIOD_FOR_FALLING_ASLEEP;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PACLITAXEL;CYP2C8;G;rs1113129;TOXICITY;DECREASED;RISK;DISEASE:NEUROTOXICITY_SYNDROMES;PEOPLE;DISEASE:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;MUC16;T;rs11882256;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:NAUSEA, SIDE_EFFECT:VOMITING;PEOPLE;OTHER:NEOPLASMS, OTHER:PAIN;CAUTION_SIDE_EFFECT
ISONIAZID, RIFAMPIN;NAT2;*6;NAT2*6;TOXICITY, METABOLISM/PK;INCREASED;LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
ROSUVASTATIN;ABCG2;TT;rs2231142;DOSAGE, METABOLISM/PK;INCREASED;;PK:AUC;PEOPLE;OTHER:NO_DISEASE;CAUTION_DOSE_ADJUST
ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;*6/*6;NAT2*6;TOXICITY, METABOLISM/PK;INCREASED;RISK;DISEASE:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
SULFAMETHOXAZOLE / TRIMETHOPRIM;NAT2;*16 + *5 + *6 + *6 + *7 + *7 + *14 + *14;NAT2*5, NAT2*6, NAT2*7, NAT2*14, NAT2*16;TOXICITY;INCREASED;RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;PEOPLE;DISEASE:ACQUIRED_IMMUNODEFICIENCY_SYNDROME;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;AA;rs4148323;TOXICITY;INCREASED;RISK;DISEASE:NEUTROPENIA;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
ROSUVASTATIN;ABCG2;GG;rs2231142;DOSAGE, METABOLISM/PK;DECREASED;;PK:AUC;PEOPLE;OTHER:NO_DISEASE;CAUTION_DOSE_ADJUST
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;*6;NAT2*6;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
ISONIAZID, RIFAMPIN;NAT2;*6/*7;NAT2*6, NAT2*7;TOXICITY, METABOLISM/PK;INCREASED;LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
SORAFENIB;TNF;GG;rs1800629;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HAND-FOOT_SYNDROME;PEOPLE;DISEASE:HEPATOCELLULAR_CARCINOMA;CAUTION_SIDE_EFFECT
OPIOIDS;PDE3A;A;rs12305038;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:NAUSEA, SIDE_EFFECT:VOMITING;PEOPLE;OTHER:NEOPLASMS, OTHER:PAIN;CAUTION_SIDE_EFFECT
IRINOTECAN;SLCO1B1;CC + CT;rs4149056;TOXICITY;INCREASED;RISK;DISEASE:NEUTROPENIA;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
ALFENTANIL;OPRM1;AG + GG;rs1799971;EFFICACY;INCREASED;RISK;DISEASE:PAIN;PEOPLE;OTHER:EXTRACORPOREAL_SHOCK_WAVE_LITHOTRIPSY_(ESWL);CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7 + *7/*7;NAT2*4, NAT2*6, NAT2*7, NAT2*16;TOXICITY;INCREASED;RISK;DISEASE:DRUG-INDUCED_LIVER_INJURY;;;CAUTION_SIDE_EFFECT
"""INTERFERON ALFA-2B, RECOMBINANT"", ""RIBAVIRIN""";ITPA;CC;rs1127354;TOXICITY;DECREASED;;SIDE_EFFECT:HEMOGLOBIN_LEVELS;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;*6;NAT2*6;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
ALFENTANIL;OPRM1;AG + GG;rs1799971;METABOLISM/PK;INCREASED;;PK:PLASMA_CONCENTRATION;PEOPLE;DISEASE:PAIN;CAUTION_DOSE_ADJUST
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;*16 + *6 + *7;NAT2*4, NAT2*6, NAT2*7, NAT2*16;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
SALMETEROL;ADRB2;AA;rs1042713;EFFICACY;INCREASED;RISK;OTHER:ASTHMA_EXACERBATIONS;CHILDREN;DISEASE:ASTHMA;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2B, RIBAVIRIN;DNAAF9, ITPA;C;rs6051702;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:ANEMIA;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;MIR6076;GG + GT;rs1463411;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE;PEOPLE;OTHER:ACUTE_CORONARY_SYNDROME;CAUTION_SIDE_EFFECT
LANSOPRAZOLE;CYP2C19;;CYP2C19 INTERMEDIATE METABOLIZER;METABOLISM/PK;DECREASED;;OTHER:GASTRIC_PH;HEALTHY;;CAUTION_DOSE_ADJUST
TAMOXIFEN;LRMDA;C;rs10509373;EFFICACY;DECREASED;;OTHER:RECURRENCE-FREE_SURVIVAL;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
OPIOIDS;CRYBG2;T;rs36024412;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:NAUSEA, SIDE_EFFECT:VOMITING;PEOPLE;OTHER:NEOPLASMS, OTHER:PAIN;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHAMBUTOL, ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;G;rs1799930;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE;PEOPLE;OTHER:TUBERCULOSIS;CAUTION_SIDE_EFFECT
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;*6/*7;NAT2*6, NAT2*7;TOXICITY, METABOLISM/PK;INCREASED;LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
OPIOIDS;CLCC1;T;rs168107;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:NAUSEA, SIDE_EFFECT:VOMITING;PEOPLE;OTHER:NEOPLASMS, OTHER:PAIN;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE;CDA;CT + TT;rs1048977;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HYPERBILIRUBINEMIA;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
BOCEPREVIR, PEGINTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIR;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM COMPOUNDS;SLC31A1;AC;rs10759637;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
OPIOIDS;POM121L2;T;rs41269255;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:NAUSEA, SIDE_EFFECT:VOMITING;PEOPLE;OTHER:NEOPLASMS, OTHER:PAIN;CAUTION_SIDE_EFFECT
"""ANTIVIRALS FOR TREATMENT OF HIV INFECTIONS, COMBINATIONS"", ""DRUGS FOR TREATMENT OF TUBERCULOSIS""";NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;NAT2*1, NAT2*4, NAT2*6, NAT2*7, NAT2*16;TOXICITY, METABOLISM/PK;INCREASED;RISK;DISEASE:DRUG-INDUCED_LIVER_INJURY;PEOPLE;OTHER:HIV_AND_TUBERCULOSIS_CO-INFECTION;CAUTION_SIDE_EFFECT
DIPYRONE;NAT2;*16 + *6 + *7 + *14;NAT2*6, NAT2*7, NAT2*14, NAT2*16;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HYPERSENSITIVITY;;;CAUTION_SIDE_EFFECT
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;*16 + *6 + *7 + *14;NAT2*6, NAT2*7, NAT2*14, NAT2*16;TOXICITY, METABOLISM/PK;INCREASED;LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
METHOTREXATE;ABCC2;AG + GG;rs3740065;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXICITY;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
IRINOTECAN;NR3C1;A;rs61754806;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:NEUTROPENIA;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN;VKORC1;T;rs7294;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:NEUTROPENIA;;;CAUTION_SIDE_EFFECT
PLATINUM COMPOUNDS;SLC31A1;AA;rs2233914;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;ZNF165;C;rs9393888;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:NAUSEA, SIDE_EFFECT:VOMITING;PEOPLE;OTHER:NEOPLASMS, OTHER:PAIN;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN, CYCLOPHOSPHAMIDE;TPMT;CT;rs1142345;EFFICACY;DECREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL;WOMEN;DISEASE:OVARIAN_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
HMG_COA_REDUCTASE_INHIBITORS;SLCO1B1;*5;SLCO1B1*5;TOXICITY;DECREASED;RISK;SIDE_EFFECT:CATARACT;PEOPLE;OTHER:CARDIO-METABOLIC_CONDITIONS;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEMCITABINE;RRM1;AA;rs9937;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUTROPENIA;PEOPLE;DISEASE:PANCREATIC_NEOPLASMS;CAUTION_SIDE_EFFECT
OLANZAPINE, RISPERIDONE;DRD2;C;rs1799978;EFFICACY;DECREASED;;EFFICACY:TIME_UNTIL_RESPONSE;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_FAILURE
PLATINUM COMPOUNDS;SLC31A1;AA;rs2233914;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;CT + TT;rs12248560;TOXICITY;INCREASED;RISK;SIDE_EFFECT:BLEEDING_EVENTS;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;CAUTION_SIDE_EFFECT
ETHAMBUTOL, ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;*16/*6 + *16/*7 + *5/*5 + *5/*6 + *6/*6 + *6/*7 + *6/*6J + *6J/*7 + *7/*7;NAT2*5, NAT2*6, NAT2*6J, NAT2*7, NAT2*16;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;PEOPLE;OTHER:TUBERCULOSIS;CAUTION_SIDE_EFFECT
METHOTREXATE;ABCC4;GG + GT;rs9516519;TOXICITY;DECREASED;RISK;SIDE_EFFECT:TOXICITY;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESCITALOPRAM;CYP2D6;;CYP2D6 POOR_METABOLIZER;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:PSYCHOMOTOR_AGITATION, SIDE_EFFECT:HYPERKINESIS, SIDE_EFFECT:IMPULSE_CONTROL_DISORDER;CHILDREN;OTHER:DEPRESSION, OTHER:ANXIETY_DISORDERS;CAUTION_SIDE_EFFECT
RISPERIDONE;CYP2D6;;CYP2D6 NORMAL_METABOLIZER;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:DISCONTINUATION;CHILDREN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PALIPERIDONE;CYP2D6;;CYP2D6 POOR_METABOLIZER;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DISCONTINUATION, SIDE_EFFECT:WEIGHT_GAIN;CHILDREN;;CAUTION_SIDE_EFFECT
ETHAMBUTOL, ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;*6/*6 + *6/*7 + *7/*7;NAT2*4, NAT2*6, NAT2*7;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;PEOPLE;OTHER:TUBERCULOSIS;CAUTION_SIDE_EFFECT
TRAMADOL;CYP2D6;*10/*10;CYP2D6*10;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS;PEOPLE;OTHER:PAIN;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;CT + TT;rs12248560;EFFICACY;DECREASED;;EFFICACY:MAGNITUDE_OF_PLATELET_REACTIVITY;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
ISONIAZID;NAT2;*6 + *7;NAT2*6, NAT2*7;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;PEOPLE;OTHER:TUBERCULOSIS;CAUTION_SIDE_EFFECT
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;*6 + *7;NAT2*4, NAT2*6, NAT2*7;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;NAT2*4, NAT2*6, NAT2*7, NAT2*16;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HEPATOTOXICITY;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;*16;NAT2*16;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;*6/*6 + *6/*7;NAT2*6, NAT2*7;TOXICITY, METABOLISM/PK;INCREASED;RISK;DISEASE:HEPATITIS;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
ANTIINFLAMMATORY AGENTS, NON-STEROIDS;HLA-DRB1;*04:03;HLA-DRB1*04:03;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;EFFICACY;INCREASED;RISK;EFFICACY:ON-TREATMENT_PLATELET_REACTIVITY;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;CAUTION_SIDE_EFFECT
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;*16/*4;NAT2*4, NAT2*16;TOXICITY, METABOLISM/PK;DECREASED;LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:TUBERCULOSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM COMPOUNDS;SLC31A1;AC;rs10759637;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
CAPECITABINE;CDA;AC + CC;rs2072671;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY, DISEASE:HAND-FOOT_SYNDROME;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;*16/*7 + *6/*7;NAT2*4, NAT2*6, NAT2*7, NAT2*16;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HEPATOTOXICITY;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;*16;NAT2*16;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;PEOPLE;OTHER:TUBERCULOSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;*16 + *6 + *7;NAT2*4, NAT2*6, NAT2*7, NAT2*16;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
OLANZAPINE, RISPERIDONE;DRD2;del;rs1799732;EFFICACY;INCREASED;;EFFICACY:TIME_TO_RESPOND;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;*5/*6 + *5/*7 + *6/*6 + *6/*7 + *7/*7;NAT2*4, NAT2*5, NAT2*6, NAT2*7;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
OPIOIDS;CYP2A7P1, CYP2B6;GG;rs3745274;TOXICITY;INCREASED;RISK;OTHER:OPIOID-RELATED_DISORDERS;MEN;;CAUTION_SIDE_EFFECT
ETHAMBUTOL, ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7 + *7/*7;NAT2*4, NAT2*6, NAT2*7, NAT2*16;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE;PEOPLE;OTHER:TUBERCULOSIS;CAUTION_SIDE_EFFECT
ANTIINFLAMMATORY AGENTS, NON-STEROIDS;HLA-B;*35:03;HLA-B*35:03;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;;;CAUTION_SIDE_EFFECT
PLATINUM COMPOUNDS;SLC31A1;AC;rs4979223;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
NAN;CHRNA3;A;rs1051730;OTHER;INCREASED;LIKELIHOOD;OTHER:TOBACCO_USE_DISORDER;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIBAVIRIN, SOFOSBUVIR;ITPA;CC;rs1127354;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HEMOLYTIC_ANEMIA;PEOPLE;OTHER:HEPATITIS_C_VIRUS_INFECTION;CAUTION_SIDE_EFFECT
PROTON PUMP INHIBITORS;CYP2C19;;CYP2C19 RAPID, ULTRARAPID_METABOLIZER;TOXICITY;DECREASED;RISK;SIDE_EFFECT:INFECTIOUS_DISEASE;CHILDREN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTINEOPLASTIC AGENTS;TYMS;AG + GG;rs2853539;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE, DACTINOMYCIN, VINCRISTINE;CYP2B6;AG + GG;rs2279343;EFFICACY;INCREASED;;EFFICACY:EVENT-FREE_SURVIVAL;CHILDREN;DISEASE:RHABDOMYOSARCOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIPSYCHOTICS;CYP2D6;;CYP2D6 POOR_METABOLIZER;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:TARDIVE_DYSKINESIA;PEOPLE;OTHER:SCHIZOAFFECTIVE_DISORDER, OTHER:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
OMEPRAZOLE;CYP2C19;;CYP2C19 NORMAL METABOLIZER;METABOLISM/PK;DECREASED;;OTHER:GASTRIC_PH;HEALTHY;;CAUTION_DOSE_ADJUST
TAMOXIFEN;CYP2D6;;CYP2D6 POOR METABOLIZER, INTERMEDIATE METABOLIZER;EFFICACY, TOXICITY;INCREASED;RISK;SIDE_EFFECT:HOT_FLASHES;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC AGENTS;AKR1C3;G;rs1937840;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIHYPERTENSIVES;ADIPOQ;CG + GG;rs266729;EFFICACY;INCREASED;SEVERITY;EFFICACY:HYPERTENSION;PEOPLE;OTHER:HYPERTENSION;CAUTION_SIDE_EFFECT
MYCOPHENOLIC ACID, TACROLIMUS;IMPDH1;T;rs2278293;EFFICACY;DECREASED;LIKELIHOOD;OTHER:SUBCLINICAL_ACUTE_REJECTION;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
GEMCITABINE;CDA;AA;rs2072671;TOXICITY;DECREASED;RISK;SIDE_EFFECT:NEUTROPENIA;PEOPLE;DISEASE:PANCREATIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATOMOXETINE;CYP2D6;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;CYP2D6*1, CYP2D6*1XN, CYP2D6*3, CYP2D6*4, CYP2D6*4XN, CYP2D6*5, CYP2D6*6, CYP2D6*7, CYP2D6*10, CYP2D6*17;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRY_MOUTH, SIDE_EFFECT:ERECTILE_DYSFUNCTION, SIDE_EFFECT:HYPERHIDROSIS, SIDE_EFFECT:INSOMNIA, SIDE_EFFECT:URINARY_RETENTION;PEOPLE;DISEASE:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY;CAUTION_SIDE_EFFECT
CODEINE;CYP2D6;;CYP2D6 POOR METABOLIZER;TOXICITY;DECREASED;RISK;SIDE_EFFECT:ADVERSE_EVENTS;CHILDREN;OTHER:POSTOPERATIVE_PAIN;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;CYP2D6;*2xN;CYP2D6*2XN, CYP2D6*4, CYP2D6*5;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOBACCO_USE_DISORDER;;;CAUTION_SIDE_EFFECT
GEMCITABINE;DCK;TT;rs4694362;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUTROPENIA;PEOPLE;DISEASE:PANCREATIC_NEOPLASMS;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;RBX1;A;rs141084494;TOXICITY;DECREASED;RISK;SIDE_EFFECT:NEUTROPENIA;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHAMBUTOL, ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;T;rs1801280;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE;PEOPLE;OTHER:TUBERCULOSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM COMPOUNDS;SLC31A1;AG + GG;rs4978536;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
OPIOIDS;BDNF-AS;CC + CT;rs11030096;TOXICITY;INCREASED;RISK;OTHER:OPIOID-RELATED_DISORDERS;WOMEN;;CAUTION_SIDE_EFFECT
IRINOTECAN, PLATINUM COMPOUNDS;NAT2;AA;rs1799930;EFFICACY;INCREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;OTHER:LUNG_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM COMPOUNDS;SLC31A1;CC + CT;rs10817464;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:DRUG_TOXICITY, SIDE_EFFECT:HEMATOLOGIC_DISORDER, SIDE_EFFECT:LEUKOPENIA, SIDE_EFFECT:THROMBOCYTOPENIA;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
VORICONAZOLE;CYP2C19;;CYP2C19 POOR_METABOLIZER;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS;;;CAUTION_SIDE_EFFECT
PLATINUM COMPOUNDS;SLC31A1;AC;rs4979223;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
COCAINE;SYT1;G;rs2251214;TOXICITY;INCREASED;RISK;SIDE_EFFECT:COCAINE_DEPENDENCE;;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;NUDT15;CT + TT;rs116855232;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA;PEOPLE;OTHER:AUTOIMMUNE_HEPATITIS;CAUTION_SIDE_EFFECT
VALGANCICLOVIR;ABCB1;CT;rs2229109;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUTROPENIA;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
FLUOXETINE;CYP2D6;*4/*4;CYP2D6*1, CYP2D6*4;METABOLISM/PK;INCREASED;;PK:FLUOXETINE_PLASMA_CONCENTRATION;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DOSE_ADJUST
TETRABENAZINE;CYP2D6;;CYP2D6 ULTRARAPID_METABOLIZER;EFFICACY;;;OTHER:LONGER_TITRATION_TO_ACHIEVE_OPTIMAL_BENEFIT;;;CAUTION_DOSE_ADJUST
MYCOPHENOLATE MOFETIL;UGT1A9;T;rs3832043;METABOLISM/PK;INCREASED;;PK:DOSE-ADJUSTED_AREA_UNDER_THE_CONCENTRATION_VERSUS_TIME_CURVE_(AUC6-12)_LEVEL_OF_MYCOPHENOLIC_ACID;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
OLANZAPINE;CYP2C9;;CYP2C9 POOR METABOLIZER;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DIZZINESS;HEALTHY;;CAUTION_SIDE_EFFECT
"""FOLIC ACID"", ""VITAMIN B-COMPLEX, PLAIN""";MTRR;AA + AG;rs1801394;EFFICACY;DECREASED;SEVERITY;DISEASE:PAIN;WOMEN;DISEASE:MIGRAINE_WITH_AURA;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;HTR3B;TT;rs3758987;TOXICITY;INCREASED;SEVERITY;OTHER:TOBACCO_USE_DISORDER;;;CAUTION_SIDE_EFFECT
CAPECITABINE;TYMS;TTAAAGTTA;rs11280056;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:DIARRHEA, SIDE_EFFECT:DRUG_TOXICITY, SIDE_EFFECT:HAND-FOOT_SYNDROME;PEOPLE;OTHER:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
CAPECITABINE;DPYD;AT;rs67376798;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:DIARRHEA;PEOPLE;DISEASE:GASTROESOPHAGEAL_CANCER;CAUTION_SIDE_EFFECT
ANTIDEPRESSANTS;CYP2D6;*3/*4 + *4/*4 + *4/*5 + *4/*6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6;METABOLISM/PK;INCREASED;;PK:PLASMA_CONCENTRATIONS;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DOSE_ADJUST
ENALAPRIL;PCGF3;A;rs1044147;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:COUGH;PEOPLE;OTHER:HYPERTENSION;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*3/*4 + *3/*5 + *3/*6 + *4/*11 + *4/*4 + *4/*5 + *4/*6 + *4/*7 + *5/*5 + *6/*6 + *6/*7;CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*7, CYP2D6*11;EFFICACY;DECREASED;;EFFICACY:EVENT-FREE_SURVIVAL;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
PAROXETINE;CYP2D6;*3/*4 + *4/*4 + *4/*5;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5;METABOLISM/PK;INCREASED;;PK:PAROXETINE_PLASMA_CONCENTRATION;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DOSE_ADJUST
TRAMADOL;COMT;AA + AG;rs4680;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:SEDATION;PEOPLE;OTHER:SURGERY;CAUTION_SIDE_EFFECT
ANTICHOLINERGIC AGENTS;CYP2C19;;CYP2C19 POOR METABOLIZER;METABOLISM/PK;INCREASED;;PK:SERUM_ANTICHOLINERGIC_ACTIVITY;;;CAUTION_DOSE_ADJUST
VENLAFAXINE;CYP2D6;;CYP2D6 NORMAL METABOLIZER;TOXICITY;INCREASED;RISK;SIDE_EFFECT:SIDE_EFFECTS;PEOPLE;DISEASE:OBSESSIVE_COMPULSIVE_DISORDER;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC AGENTS;ABCG2;CC + CT;rs2231164;EFFICACY;INCREASED;;EFFICACY:SURVIVAL;PEOPLE;DISEASE:PANCREATIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CITALOPRAM, CLOMIPRAMINE, DULOXETINE, ESCITALOPRAM, FLUOXETINE, FLUVOXAMINE, MIRTAZAPINE, PAROXETINE, SERTRALINE, VENLAFAXINE;CYP2D6;;CYP2D6 NORMAL METABOLIZER;EFFICACY;DECREASED;;EFFICACY:NUMBER_OF_FAILED_MEDICATION_TRAILS;PEOPLE;DISEASE:OBSESSIVE_COMPULSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
MYCOPHENOLATE MOFETIL;UGT1A9;T;rs3832043;METABOLISM/PK;INCREASED;;PK:DOSE-ADJUSTED_AREA_UNDER_THE_CONCENTRATION_VERSUS_TIME_CURVE_(AUC6-12)_LEVEL_OF_MYCOPHENOLIC_ACID-7-O-GLUCURONIDE;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
MYCOPHENOLATE MOFETIL;ABCC2;AG;rs2273697;METABOLISM/PK;INCREASED;;PK:_AREA_UNDER_THE_CONCENTRATION_VERSUS_TIME_CURVE_(AUC6-12)_LEVEL_OF_THE_ACYL_GLUCURONIDE_OF_MYCOPHENOLIC_ACID;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
CAPECITABINE;DPYD;CT;rs2297595;EFFICACY;DECREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
OPIOIDS;OPRM1;GG;rs1799971;TOXICITY;DECREASED;;SIDE_EFFECT:NAUSEA, SIDE_EFFECT:VOMITING;PEOPLE;OTHER:PAIN;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*3 + *2/*2 + *3/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:RECURRENCE;PEOPLE;OTHER:STROKE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*1/*17 + *17/*17;CYP2C19*1, CYP2C19*2, CYP2C19*17;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HEMORRHAGE;;;CAUTION_SIDE_EFFECT
ATENOLOL;PAH;AA;rs2245360;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:INSULIN_RESISTANCE;PEOPLE;OTHER:HYPERTENSION;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*3/*4 + *3/*5 + *4/*4 + *4/*5;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5;EFFICACY;INCREASED;RISK;EFFICACY:RECURRENCE;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*3/*4 + *3/*5 + *4/*4 + *4/*5 + *4/*7;CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*7;EFFICACY;INCREASED;LIKELIHOOD;DISEASE:BREAST_NEOPLASMS;WOMEN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN, CLOPIDOGREL;PON1;CT + TT;rs662;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;DRD2;CC + CT;rs1125394;TOXICITY;INCREASED;RISK;OTHER:OPIOID-RELATED_DISORDERS;WOMEN;;CAUTION_SIDE_EFFECT
OPIOIDS;OPRM1;G;rs1799971;TOXICITY;DECREASED;;SIDE_EFFECT:ADVERSE_EVENTS;PEOPLE;OTHER:PAIN;LIKELIHOOD_THERAPEUTIC_SUCCESS
SORAFENIB;VEGFA;CC;rs3025040;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HAND-FOOT_SYNDROME;PEOPLE;DISEASE:HEPATOCELLULAR_CARCINOMA;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC AGENTS, TAMOXIFEN;CYP2D6;*5/*10;CYP2D6*1, CYP2D6*2, CYP2D6*5, CYP2D6*10;EFFICACY;DECREASED;;EFFICACY:OVERALL_SURVIVAL;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
OPIOIDS;DRD2;CT + TT;rs1079596;TOXICITY;INCREASED;RISK;OTHER:OPIOID-RELATED_DISORDERS;WOMEN;;CAUTION_SIDE_EFFECT
TRAMADOL;COMT;AA + AG;rs4680;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:POSTOPERATIVE_NAUSEA_AND_VOMITING;PEOPLE;OTHER:SURGERY;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC AGENTS, TAMOXIFEN;CYP2D6;*5/*10;CYP2D6*1, CYP2D6*2, CYP2D6*5, CYP2D6*10;EFFICACY;DECREASED;;EFFICACY:OVERALL_SURVIVAL;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;;CYP2B6 POOR_METABOLIZER, INTERMEDIATE_METABOLIZER;OTHER;INCREASED;RISK;SIDE_EFFECT:SUICIDE;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
ANTHRACYCLINES AND RELATED SUBSTANCES;ABCC2;TT;rs3740066;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:FEBRILE_NEUTROPENIA;PEOPLE;OTHER:SOFT_TISSUE_NEOPLASMS, OTHER:SARCOMA;CAUTION_SIDE_EFFECT
AZATHIOPRINE, MERCAPTOPURINE, PURINE ANALOGUES;TPMT;;TPMT INTERMEDIATE METABOLIZER;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS;PEOPLE;DISEASE:INFLAMMATORY_BOWEL_DISEASES;CAUTION_SIDE_EFFECT
FLUOROURACIL;TYMS;AG + GG;rs2847153;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:SURVIVAL;PEOPLE;DISEASE:PANCREATIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
MORPHINE;ABCC3;T;rs4148412;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:HYPOVENTILATION;CHILDREN;DISEASE:SLEEP_APNEA_SYNDROMES, DISEASE:TONSILLECTOMY;CAUTION_SIDE_EFFECT
SORAFENIB;UGT1A9;AA;rs7574296;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HAND-FOOT_SYNDROME;PEOPLE;DISEASE:HEPATOCELLULAR_CARCINOMA;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*1/*1 + *1/*28;UGT1A1*1, UGT1A1*28;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:DIARRHEA;PEOPLE;OTHER:LUNG_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
SORAFENIB;KDR;AA;rs2071559;EFFICACY;DECREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;;CYP3A5 INTERMEDIATE_METABOLIZER, NORMAL_METABOLIZER;DOSAGE;INCREASED;LIKELIHOOD;OTHER:DRUG_DOSAGE_ALTERED;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TRAMADOL;COMT;GG;rs4680;EFFICACY;INCREASED;SEVERITY;EFFICACY:PAIN, POSTOPERATIVE;PEOPLE;OTHER:SURGERY;CAUTION_SIDE_EFFECT
"""FOLIC ACID"", ""VITAMIN B-COMPLEX, PLAIN""";MTHFR;AG + GG;rs1801133;EFFICACY;;;EFFICACY:GREATER_REDUCTION_IN_HOMOCYSTEINE;WOMEN;DISEASE:MIGRAINE_WITH_AURA;CAUTION_DOSE_ADJUST
AMITRIPTYLINE, CLOMIPRAMINE, DOXEPIN, IMIPRAMINE, TRIMIPRAMINE;CYP2D6;;CYP2D6 POOR METABOLIZER;METABOLISM/PK;INCREASED;;PK:ANTIDEPRESSANT_SERUM_LEVELS;PEOPLE;DISEASE:MENTAL_DISORDERS;CAUTION_DOSE_ADJUST
SORAFENIB;SLC15A2;CC;rs2257212;EFFICACY;DECREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:HEPATOCELLULAR_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL;CCND1;AA;rs9344;EFFICACY;DECREASED;;EFFICACY:TIME-TO-TUMOR_RECURRENCE;;DISEASE:COLONIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
AZATHIOPRINE;TPMT;;TPMT INTERMEDIATE_METABOLIZER;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ADVERSE_EFFECTS;PEOPLE;DISEASE:INFLAMMATORY_BOWEL_DISEASES;CAUTION_SIDE_EFFECT
CAPECITABINE;UMPS;CC + CT;rs2279199;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:NAUSEA, SIDE_EFFECT:VOMITING;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
METFORMIN;;TT;rs578427;METABOLISM/PK;INCREASED;;PK:RENAL_CLEARANCE_AND_SECRETION_CLEARANCE_OF_METFORMIN;HEALTHY;;CAUTION_DOSE_ADJUST
CAPECITABINE;TYMS;CT + TT;rs2853741;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:DIARRHEA;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;;CYP2C19 RAPID, ULTRARAPID_METABOLIZER;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE;PEOPLE;OTHER:CARDIOVASCULAR_DISEASE;CAUTION_SIDE_EFFECT
CAPECITABINE;SLC22A7;AG + GG;rs4149178;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:DIARRHEA;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN;ABCC3;G;rs1051640;TOXICITY;INCREASED;RISK;DISEASE:OTOTOXICITY;CHILDREN;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
GALANTAMINE;CYP2D6;*3/*4 + *4/*4 + *4/*5;CYP2D6*1, CYP2D6*1XN, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*41;METABOLISM/PK;INCREASED;;PK:DOSE-ADJUSTED_PLASMA_LEVELS;PEOPLE;DISEASE:DEMENTIA;CAUTION_DOSE_ADJUST
TAMOXIFEN;CYP2D6;*3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*5 + *4/*6 + *6/*7;CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*7, CYP2D6*35;EFFICACY;DECREASED;;EFFICACY:RECURRENCE_FREE_SURVIVAL;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;;CYP2C19 NORMAL METABOLIZER;OTHER;DECREASED;RISK;OTHER:MAJOR_ADVERSE_CARDIAC_EVENTS;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;SLC19A1;T;rs1051266;TOXICITY;INCREASED;;DISEASE:DRUG-INDUCED_LIVER_INJURY;PEOPLE;DISEASE:PSORIASIS;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;;CYP2C19 POOR_METABOLIZER, INTERMEDIATE_METABOLIZER;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE);PEOPLE;OTHER:CARDIOVASCULAR_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ABT-751;UGT1A4;AC;rs6755571;METABOLISM/PK;DECREASED;;PK:PLASMA_PREDOSE_CONCENTRATION_(CTROUGH);PEOPLE;DISEASE:NEOPLASMS;CAUTION_DOSE_ADJUST
CAPECITABINE;UMPS;CC + CG;rs4678145;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ASTHENIA;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
ABT-751;UGT1A8;CC + CT;rs6431558;METABOLISM/PK;INCREASED;;PK:GLUCURONIDATION_METABOLIC_RATIOS;PEOPLE;DISEASE:NEOPLASMS;CAUTION_DOSE_ADJUST
IMIPRAMINE;CYP2D6;;CYP2D6 POOR METABOLIZER;METABOLISM/PK;INCREASED;;PK:MEAN_AREA_UNDER_THE_PLASMA_CONCENTRATION-TIME_CURVE_(AUC)_OF_DESIPRAMINE;HEALTHY;;CAUTION_DOSE_ADJUST
ANTINEOPLASTIC AGENTS;DPYD;AA + AG;rs1760217;EFFICACY;DECREASED;;EFFICACY:SURVIVAL;PEOPLE;DISEASE:PANCREATIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
AZATHIOPRINE;TPMT;CC + CT;rs1142345;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE;;;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC AGENTS;SERPINA3;AC + CC;rs17091162;EFFICACY;DECREASED;;EFFICACY:SURVIVAL;PEOPLE;DISEASE:PANCREATIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*17;CYP2C19*1, CYP2C19*2, CYP2C19*17;METABOLISM/PK;DECREASED;;PK:MEAN_PEAK_PLASMA_CONCENTRATION_OF_H4;PEOPLE;DISEASE:CARDIOVASCULAR_DISEASE;CAUTION_DOSE_ADJUST
VALPROIC ACID;CYP2C19;;CYP2C19 POOR_METABOLIZER, INTERMEDIATE_METABOLIZER;TOXICITY;INCREASED;RISK;SIDE_EFFECT:WEIGHT_GAIN;WOMEN;DISEASE:EPILEPSY;CAUTION_SIDE_EFFECT
ASPIRIN, CLOPIDOGREL;PTGS1;AG + GG;rs10306114;TOXICITY;INCREASED;RISK;SIDE_EFFECT:CARDIOVASCULAR_EVENTS;PEOPLE;OTHER:ST-SEGMENT_ELEVATION_MYOCARDIAL_INFARCTION_(STEMI);CAUTION_SIDE_EFFECT
METFORMIN;SLC47A2;AA;rs12943590;METABOLISM/PK;INCREASED;;PK:RENAL_CLEARANCE_AND_SECRETION_CLEARANCE_OF_METFORMIN;HEALTHY;;CAUTION_DOSE_ADJUST
TAMOXIFEN;NCOA1;CT;rs1804645;OTHER;INCREASED;SEVERITY;SIDE_EFFECT:CHANGE_IN_LUMBAR_BONE_MINERAL_DENSITY;;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;;CYP2C19 INTERMEDIATE_METABOLIZER;EFFICACY;INCREASED;RISK;OTHER:CARDIOVASCULAR_DEATH,MYOCARDIAL_INFARCTION_OR_STROKE;PEOPLE;OTHER:PERCUTANEOUS_CORONARY_INTERVENTION_(MOST_OF_THE_PATIENTS);CAUTION_SIDE_EFFECT
CITALOPRAM, ESCITALOPRAM;;A;rs352428;EFFICACY;;;EFFICACY:POOR_RESPONSE_AT_8_WEEK_OF_TREATMENT;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;;CYP2C19 INTERMEDIATE_METABOLIZER;EFFICACY;INCREASED;RISK;DISEASE:THROMBOTIC_DISEASE;PEOPLE;OTHER:PERCUTANEOUS_CORONARY_INTERVENTION_(MOST_OF_THE_PATIENTS);CAUTION_SIDE_EFFECT
CITALOPRAM;;A;rs352428;EFFICACY;;;EFFICACY:POOR_RESPONSE_AT_6_WEEK_OF_TREATMENT;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;;CYP2C19 POOR_METABOLIZER;EFFICACY;INCREASED;RISK;OTHER:CARDIOVASCULAR_DEATH,MYOCARDIAL_INFARCTION_OR_STROKE;PEOPLE;OTHER:PERCUTANEOUS_CORONARY_INTERVENTION_(MOST_OF_THE_PATIENTS);CAUTION_SIDE_EFFECT
MIDAZOLAM;POR;CT;rs1057868;METABOLISM/PK;DECREASED;;PK:MIDAZOLAM_METABOLIC_RATIOS_BY_45%;;;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;;CYP2C19 POOR_METABOLIZER;EFFICACY;INCREASED;RISK;DISEASE:THROMBOTIC_DISEASE;PEOPLE;OTHER:PERCUTANEOUS_CORONARY_INTERVENTION_(MOST_OF_THE_PATIENTS);CAUTION_SIDE_EFFECT
LENVATINIB;ABCG2;GG;rs2231142;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:DRY_MOUTH, SIDE_EFFECT:MUCOSITIS;PEOPLE;OTHER:THYROID_TUMOR;CAUTION_SIDE_EFFECT
NICOTINE;CHRNA3;G;rs578776;METABOLISM/PK;INCREASED;;PK:PLASMA_LEVEL;;OTHER:TOBACCO_USERS;CAUTION_DOSE_ADJUST
GALANTAMINE;CYP2D6;*3/*4 + *4/*4 + *4/*5;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*41;METABOLISM/PK;INCREASED;;PK:DOSE-ADJUSTED_PLASMA_LEVELS;PEOPLE;DISEASE:DEMENTIA;CAUTION_DOSE_ADJUST
TRAZODONE;CYP2D6;;CYP2D6 NORMAL_METABOLIZER;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DIZZINESS;HEALTHY;;CAUTION_SIDE_EFFECT
CAPECITABINE;DPYD;AG;rs17376848;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:STOMATITIS;PEOPLE;DISEASE:GASTROESOPHAGEAL_CANCER;CAUTION_SIDE_EFFECT
RISPERIDONE;CYP2D6;;CYP2D6 ULTRARAPID_METABOLIZER;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:WEIGHT_GAIN;CHILDREN;DISEASE:AUTISM;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN, CLOPIDOGREL;CYP2C19;AA;rs4244285;TOXICITY;INCREASED;RISK;SIDE_EFFECT:CARDIOVASCULAR_EVENTS;PEOPLE;OTHER:ST-SEGMENT_ELEVATION_MYOCARDIAL_INFARCTION_(STEMI);CAUTION_SIDE_EFFECT
LENVATINIB;CYP3A4;C;rs2242480;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:DIARRHEA;PEOPLE;OTHER:THYROID_TUMOR;CAUTION_SIDE_EFFECT
LENVATINIB;CYP3A5;C;rs776746;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:DIARRHEA;PEOPLE;OTHER:THYROID_TUMOR;CAUTION_SIDE_EFFECT
CAPECITABINE;ENOSF1, TYMS;TT;rs699517;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:NAUSEA, SIDE_EFFECT:VOMITING;PEOPLE;;CAUTION_SIDE_EFFECT
HEROIN;OPRK1;C;rs6473797;TOXICITY;DECREASED;RISK;OTHER:HEROIN_DEPENDENCE;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
HEROIN;CSNK1E;T;rs1534891;TOXICITY;DECREASED;RISK;OTHER:HEROIN_DEPENDENCE;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE;DPYD;AG;rs12119882;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HYPERBILIRUBINEMIA;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
ETHANOL;CHRNA5;G;rs16969968;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:ALCOHOL_ABUSE;;;CAUTION_SIDE_EFFECT
HEROIN;GAL;A;rs694066;TOXICITY;INCREASED;RISK;OTHER:HEROIN_DEPENDENCE;;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2/*2 + *3/*3 + *2/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;INCREASED;;OTHER:PLATELET_REACTIVITY;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
HEROIN;OPRD1;A;rs2236861;TOXICITY;INCREASED;RISK;OTHER:HEROIN_DEPENDENCE;;;CAUTION_SIDE_EFFECT
CAPECITABINE;SLC22A7;TT;rs2270860;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
HEROIN;OPRD1;C;rs3766951;TOXICITY;INCREASED;RISK;OTHER:HEROIN_DEPENDENCE;;;CAUTION_SIDE_EFFECT
METHADONE;CRHBP;G;rs1500;OTHER;DECREASED;;OTHER:RECURRENCE;PEOPLE;DISEASE:HEROIN_DEPENDENCE;CAUTION_DOSE_ADJUST
METHAMPHETAMINE;FAAH;A;rs324420;OTHER;INCREASED;LIKELIHOOD;OTHER:DEPENDENCE;MEN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHANOL;CHRNA3;G;rs1051730;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:ALCOHOL_ABUSE;;;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*5 + *4/*6 + *6/*7;CYP2D6*1, CYP2D6*1XN, CYP2D6*2, CYP2D6*2XN, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*7, CYP2D6*35;EFFICACY;INCREASED;RISK;EFFICACY:RECURRENCE;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
HEROIN;OPRD1;C;rs2236857;TOXICITY;INCREASED;RISK;OTHER:HEROIN_DEPENDENCE;;;CAUTION_SIDE_EFFECT
NALOXONE;OPRM1;AG + GG;rs1799971;EFFICACY;INCREASED;;EFFICACY:PEAK_CORTISOL_RESPONSE;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TAMOXIFEN;CYP2D6;;CYP2D6 ULTRARAPID_METABOLIZER;TOXICITY;INCREASED;RISK;SIDE_EFFECT:WEIGHT_GAIN;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
CAPECITABINE;ENOSF1, TYMS;CT + TT;rs699517;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:ASTHENIA;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
TAMOXIFEN;CYP2D6;*1/*1 + *1/*10;CYP2D6*1, CYP2D6*10;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:LEIOMYOMA, SIDE_EFFECT:LIVER_DISORDER, SIDE_EFFECT:OVARIAN_CYSTS;WOMEN;OTHER:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
HEROIN;HTR3B;C;rs3758987;TOXICITY;INCREASED;RISK;OTHER:HEROIN_DEPENDENCE;;;CAUTION_SIDE_EFFECT
METOPROLOL;CYP2D6;;CYP2D6 POOR_METABOLIZER;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:BRADYCARDIA;;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;TOXICITY;INCREASED;RISK;SIDE_EFFECT:CARDIOVASCULAR_DISEASE;;;CAUTION_SIDE_EFFECT
OSIMERTINIB;ABCG2;GG;rs2231142;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DIARRHEA;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;;CYP2D6 NORMAL METABOLIZER;EFFICACY;INCREASED;;EFFICACY:RECURRENCE_FREE_SURVIVAL;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESCITALOPRAM;HTR2C;C;rs6318;EFFICACY;DECREASED;;DISEASE:PAIN;MEN;DISEASE:NEUROPATHIC_PAIN;LIKELIHOOD_THERAPEUTIC_FAILURE
OXYCODONE;CYP2D6;;CYP2D6 POOR_METABOLIZER;METABOLISM/PK;DECREASED;;PK:PLASMA_OXYMORPHONE/OXYCODONE_RATIO;HEALTHY;;CAUTION_DOSE_ADJUST
OXYCODONE;CYP2D6;;CYP2D6 POOR_METABOLIZER;EFFICACY;DECREASED;;EFFICACY:REDUCTION_IN_PAIN_AUC;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
MERCAPTOPURINE;GNMT;CT + TT;rs10948059;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:DOSE_REDUCTION;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;CHRNA5;A;rs16969968;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:TOBACCO_USE_DISORDER;;;CAUTION_SIDE_EFFECT
OXYCODONE;CYP2D6;;CYP2D6 POOR_METABOLIZER;EFFICACY;DECREASED;;PK:PLASMA_OXYMORPHONE/OXYCODONE_RATIO;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
NICOTINE;CHRNA3;A;rs1051730;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:TOBACCO_USE_DISORDER;;;CAUTION_SIDE_EFFECT
PAROXETINE;CYP2D6;;CYP2D6 NORMAL METABOLIZER;OTHER;INCREASED;;OTHER:METABOLIC_RATIO_DEM/DOR;PEOPLE;DISEASE:ANXIETY_DISORDERS;CAUTION_DOSE_ADJUST
IRINOTECAN, PLATINUM COMPOUNDS;NAT2;AA;rs1799931;EFFICACY;DECREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;OTHER:LUNG_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
PAROXETINE;CYP2D6;;CYP2D6 POOR METABOLIZER;TOXICITY;INCREASED;RISK;SIDE_EFFECT:SEXUAL_DYSFUNCTION;WOMEN;DISEASE:MENTAL_DISORDERS;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;INCREASED;;OTHER:PLATELET_REACTIVITY;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
HEROIN;OPRM1;C;rs3778151;TOXICITY;INCREASED;RISK;OTHER:HEROIN_DEPENDENCE;;;CAUTION_SIDE_EFFECT
ESCITALOPRAM;CYP2D6;;CYP2D6 INTERMEDIATE METABOLIZER;METABOLISM/PK;INCREASED;;PK:MEAN_LOGARITHM_ESCITALOPRAM_CONCENTRATION;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DOSE_ADJUST
PAROXETINE;CYP2D6;;CYP2D6 POOR METABOLIZER;METABOLISM/PK;INCREASED;;PK:MEDIAN_AUC, PLASMA_HALF-LIFE_AND_STEADY-STATE_PLASMA_CONCENTRATIONS_OF_PAROXETINE;HEALTHY;;CAUTION_DOSE_ADJUST
CAPECITABINE;DPYD;AG + GG;rs1801265;TOXICITY;INCREASED;RISK;DISEASE:HAND-FOOT_SYNDROME;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
PAROXETINE;CYP2D6;;CYP2D6 POOR METABOLIZER;TOXICITY;INCREASED;RISK;SIDE_EFFECT:SEXUAL_DYSFUNCTION;PEOPLE;DISEASE:DEPRESSIVE_DISORDER;CAUTION_SIDE_EFFECT
FLUOXETINE;CYP2D6;*1/*1;CYP2D6*1, CYP2D6*1XN;METABOLISM/PK;INCREASED;;PK:FLUOXETINE/(S)-NORFLUOXETINE_RATIO;CHILDREN;DISEASE:DEPRESSIVE_DISORDER;CAUTION_DOSE_ADJUST
CAPECITABINE;DPYD;AG + GG;rs1801265;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DIARRHEA;PEOPLE;DISEASE:GASTROESOPHAGEAL_CANCER;CAUTION_SIDE_EFFECT
ALKYLATING AGENTS, CISPLATIN;ESR1;A;rs2207396;TOXICITY;INCREASED;RISK;DISEASE:OLIGOSPERMIA;PEOPLE;OTHER:CHILDHOOD_CANCER;CAUTION_SIDE_EFFECT
HEROIN;OPRM1;T;rs510769;TOXICITY;INCREASED;RISK;OTHER:HEROIN_DEPENDENCE;;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2/*2 + *3/*3 + *2/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;TOXICITY;INCREASED;RISK;SIDE_EFFECT:CARDIOVASCULAR_DISEASE;;;CAUTION_SIDE_EFFECT
ANTIDEPRESSANTS;CYP2D6;;CYP2D6 POOR METABOLIZER;TOXICITY;INCREASED;RISK;SIDE_EFFECT:SIDE_EFFECTS;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_SIDE_EFFECT
CITALOPRAM;CYP2C19;;CYP2C19 POOR METABOLIZER;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:REMISSION_IF_TOLERANT_TO_CITALOPRAM_TREATMENT;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
TAMOXIFEN;CYP2D6;*1/*1;CYP2D6 NORMAL METABOLIZER;EFFICACY;INCREASED;;EFFICACY:EVENT-FREE_SURVIVAL, EFFICACY:OVERALL_SURVIVAL;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
TAMOXIFEN;CYP2D6;;CYP2D6 NORMAL METABOLIZER;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DISCONTINUATION;WOMEN;;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;CYP2D6;;CYP2D6 POOR METABOLIZER, INTERMEDIATE METABOLIZER;TOXICITY;INCREASED;RISK;SIDE_EFFECT:PARKINSONIAN_DISORDER, SIDE_EFFECT:TARDIVE_DYSKINESIA;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
OSIMERTINIB;STAT3;GG;rs4796793;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:NAIL_DISORDER;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
ESCITALOPRAM;CYP2D6;AA;rs1065852;EFFICACY;DECREASED;;EFFICACY:RESPONSE_AND_REMISSION_RATE;PEOPLE;DISEASE:DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
3,4-METHYLENEDIOXYMETHAMPHETAMINE;CYP2C19;;CYP2C19 POOR_METABOLIZER;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:HYPERTENSION;HEALTHY;;CAUTION_SIDE_EFFECT
DRUGS FOR TREATMENT OF TUBERCULOSIS;SLCO1B1;GG + GT;rs4149014;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;PEOPLE;OTHER:TUBERCULOSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOCETAXEL, EPIRUBICIN;;;POOR_METABOLIZER;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
NAN;;T;rs6968865;DOSAGE;INCREASED;;OTHER:COFFEE_CONSUMPTION;;;CAUTION_DOSE_ADJUST
SULFAMETHOXAZOLE;GCLC;AA;rs761142;TOXICITY;DECREASED;RISK;DISEASE:DRUG_HYPERSENSITIVITY;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
AZATHIOPRINE, MERCAPTOPURINE;TPMT;;TPMT INTERMEDIATE_METABOLIZER;EFFICACY, TOXICITY, METABOLISM/PK;INCREASED;;PK:6-TG_LEVELS;PEOPLE;DISEASE:INFLAMMATORY_BOWEL_DISEASES;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DEATH, SIDE_EFFECT:MYOCARDIAL_INFARCTION, SIDE_EFFECT:STROKE;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;CAUTION_SIDE_EFFECT
NAN;CYP1A1;T;rs2472297;DOSAGE;INCREASED;;OTHER:COFFEE_CONSUMPTION;;;CAUTION_DOSE_ADJUST
SULFAMETHOXAZOLE;GCLC;A;rs761142;TOXICITY;DECREASED;RISK;DISEASE:DRUG_HYPERSENSITIVITY;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
APIXABAN, DABIGATRAN, EDOXABAN, RIVAROXABAN;CES1;GT + TT;rs2244613;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HEMORRHAGE;PEOPLE;OTHER:THROMBOEMBOLISM;CAUTION_SIDE_EFFECT
TRAMADOL;CYP2D6;;CYP2D6 NORMAL_METABOLIZER, ULTRARAPID_METABOLIZER;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:LOW_BACK_PAIN, DISEASE:OSTEOARTHRITIS;CAUTION_SIDE_EFFECT
ANTHRACYCLINES AND RELATED SUBSTANCES;ABCC2;AG + GG;rs2273697;EFFICACY;INCREASED;;EFFICACY:RECURRENCE_FREE_SURVIVAL;PEOPLE;OTHER:SOFT_TISSUE_NEOPLASMS, OTHER:SARCOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
SORAFENIB;KDR;TT;rs1870377;EFFICACY;INCREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:HEPATOCELLULAR_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A4;AG;rs35599367;OTHER;INCREASED;;PK:CREATININE_CLEARANCE;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
ANTHRACYCLINES AND RELATED SUBSTANCES;ABCC2;TT;rs3740066;EFFICACY;DECREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;OTHER:SOFT_TISSUE_NEOPLASMS, OTHER:SARCOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;PON1;CC;rs662;EFFICACY;DECREASED;;EFFICACY:ON-CLOPIDOGREL_PLATELET_REACTIVITY_(PR)_AT_1_MONTH_AND_AT_6_MONTHS_AFTER_PERCUTANEOUS_CORONARY_INTERVENTION_(PCI);PEOPLE;DISEASE:MYOCARDIAL_ISCHEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIPSYCHOTICS;CYP2D6;;CYP2D6 ULTRARAPID_METABOLIZER;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:TARDIVE_DYSKINESIA;PEOPLE;OTHER:SCHIZOAFFECTIVE_DISORDER, OTHER:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
ISONIAZID;ASTN2;C;rs117491755;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;PEOPLE;OTHER:TUBERCULOSIS;CAUTION_SIDE_EFFECT
ALECTINIB;PPARA;AA + AG;rs4253728;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
VALPROIC ACID;SCN1A;TT;rs2298771;EFFICACY;DECREASED;LIKELIHOOD;SIDE_EFFECT:WEIGHT_GAIN;CHILDREN;OTHER:EPILEPSY;LIKELIHOOD_THERAPEUTIC_FAILURE
SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-B;*13:01;HLA-B*13:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME, SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS;;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*6;UGT1A1*1, UGT1A1*6;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:NEUTROPENIA, SIDE_EFFECT:LEUKOPENIA, SIDE_EFFECT:DIARRHEA;PEOPLE;OTHER:STOMACH_NEOPLASMS;CAUTION_SIDE_EFFECT
ATOMOXETINE;CYP2D6;*10/*10;CYP2D6*10;EFFICACY;INCREASED;LIKELIHOOD;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY;CHILDREN;OTHER:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN;GSTT1;;GSTT1 NON-NULL, GSTT1 NULL;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:OTOTOXICITY;PEOPLE;OTHER:HEAD_AND_NECK_NEOPLASMS;CAUTION_SIDE_EFFECT
CISPLATIN;GSTM1;;GSTM1 NON-NULL, GSTM1 NULL;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:OTOTOXICITY;PEOPLE;OTHER:HEAD_AND_NECK_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ARIPIPRAZOLE, OLANZAPINE, RISPERIDONE;CYP2D6;*1/*4 + *4/*4;CYP2D6*1, CYP2D6*4;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS;CHILDREN;OTHER:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
CODEINE;ABCB1;AA;rs2032582;TOXICITY, METABOLISM/PK;INCREASED;LIKELIHOOD;SIDE_EFFECT:CNS_DEPRESSION_IN_BREAST-FEEDING_INFANTS;WOMEN;DISEASE:PAIN;CAUTION_SIDE_EFFECT
ETHANOL;CRHBP;TT;rs10055255;TOXICITY;INCREASED;SEVERITY;OTHER:ALCOHOL_ABUSE;;;CAUTION_SIDE_EFFECT
SUNITINIB;NR1I2;TT;rs2276707;EFFICACY;DECREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIPSYCHOTICS;DRD2;del;rs1799732;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:SEXUAL_DYSFUNCTION;MEN;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
LAMOTRIGINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;;;CAUTION_SIDE_EFFECT
OXALIPLATIN;HLA-DRB1;*12:01;HLA-DRB1*12:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_HYPERSENSITIVITY;;;CAUTION_SIDE_EFFECT
TEGAFUR / GIMERACIL / OTERACIL;CYP2A6;*4 + *7 + *9 + *10;CYP2A6*1, CYP2A6*4, CYP2A6*7, CYP2A6*9, CYP2A6*10;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:OVERALL_SURVIVAL, EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;OTHER:STOMACH_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
CEFACLOR;HLA-DRB1;*14:54;HLA-DRB1*14:54;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_HYPERSENSITIVITY;;;CAUTION_SIDE_EFFECT
ETHANOL;OPRM1;AG + GG;rs1799971;TOXICITY;INCREASED;SEVERITY;OTHER:ALCOHOL_ABUSE;;;CAUTION_SIDE_EFFECT
SULFASALAZINE;HLA-A;*11:01;HLA-A*11:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS, SIDE_EFFECT:DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS;;;CAUTION_SIDE_EFFECT
SULFASALAZINE;HLA-B;*39:01;HLA-B*39:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS, SIDE_EFFECT:DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS;;;CAUTION_SIDE_EFFECT
SULFASALAZINE;HLA-B;*56:03;HLA-B*56:03;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS, SIDE_EFFECT:DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS;;;CAUTION_SIDE_EFFECT
METOPROLOL;CYP2D6;*1/*2;CYP2D6*1, CYP2D6*2;EFFICACY;DECREASED;;EFFICACY:HEART_RATE;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
METHAMPHETAMINE;DAOA;C;rs778293;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:PSYCHOTIC_DISORDER;;;CAUTION_SIDE_EFFECT
CEFACLOR;HLA-DRB1;*04:03;HLA-DRB1*04:03;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ANAPHYLAXIS;;;CAUTION_SIDE_EFFECT
CEFACLOR;HLA-DRB1;*04:03;HLA-DRB1*04:03;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_HYPERSENSITIVITY;;;CAUTION_SIDE_EFFECT
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;;;CAUTION_SIDE_EFFECT
ATORVASTATIN, SIMVASTATIN;SLCO1B1;*15;SLCO1B1*15;EFFICACY, TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DISCONTINUATION;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATORVASTATIN, SIMVASTATIN;SLCO1B1;*20;SLCO1B1*20;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:STATIN-RELATED_MYOPATHY;;;CAUTION_SIDE_EFFECT
ATORVASTATIN, SIMVASTATIN;SLCO1B1;*37;SLCO1B1*37;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:MYOCARDIAL_INFARCTION, EFFICACY:ANGINA_PECTORIS;;;LIKELIHOOD_THERAPEUTIC_FAILURE
ATORVASTATIN, SIMVASTATIN;SLCO1B1;*5;SLCO1B1*5;EFFICACY;INCREASED;SEVERITY;EFFICACY:HYPERCHOLESTEROLEMIA;;;CAUTION_SIDE_EFFECT
ATORVASTATIN, SIMVASTATIN;SLCO1B1;*15;SLCO1B1*15;EFFICACY;INCREASED;SEVERITY;EFFICACY:HYPERCHOLESTEROLEMIA;;;CAUTION_SIDE_EFFECT
ATORVASTATIN, SIMVASTATIN;SLCO1B1;*5;SLCO1B1*5;EFFICACY, TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DISCONTINUATION;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SORAFENIB;KDR;GG;rs2071559;EFFICACY;DECREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:HEPATOCELLULAR_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
ATORVASTATIN, SIMVASTATIN;SLCO1B1;*15;SLCO1B1*15;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:STATIN-RELATED_MYOPATHY;;;CAUTION_SIDE_EFFECT
ATORVASTATIN, SIMVASTATIN;SLCO1B1;*14;SLCO1B1*14;EFFICACY;DECREASED;SEVERITY;EFFICACY:HYPERCHOLESTEROLEMIA;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;ABCB1;AG;rs1045642;EFFICACY;INCREASED;RISK;DISEASE:HYPOKALEMIA;CHILDREN;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
RISPERIDONE;ADRB2;G;rs1042713;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:SEXUAL_ADVERSE_EVENTS;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
BECLOMETHASONE, BUDESONIDE, FLUTICASONE, FLUTICASONE PROPIONATE, MOMETASONE;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:STATUS_ASTHMATICUS;PEOPLE;OTHER:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;CYP2A6;*1/*1x2;CYP2A6*1, CYP2A6*1X2;TOXICITY;INCREASED;SEVERITY;OTHER:TOBACCO_USE_DISORDER;;;CAUTION_SIDE_EFFECT
CYTARABINE;GLI1;AA;rs2228224;EFFICACY;DECREASED;;EFFICACY:RECURRENCE_FREE_SURVIVAL;PEOPLE;OTHER:ACUTE_MYELOID_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
CYTARABINE;ARHGAP9, GLI1;GT + TT;rs2229300;EFFICACY;DECREASED;;EFFICACY:RECURRENCE_FREE_SURVIVAL, EFFICACY:OVERALL_SURVIVAL;PEOPLE;OTHER:ACUTE_MYELOID_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
CODEINE;ABCB1;A;rs1128503;TOXICITY, METABOLISM/PK;INCREASED;LIKELIHOOD;SIDE_EFFECT:CNS_DEPRESSION_IN_BREAST-FEEDING_INFANTS;WOMEN;DISEASE:PAIN;CAUTION_SIDE_EFFECT
CAPECITABINE, FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;TYMS;(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2;rs45445694;TOXICITY;INCREASED;RISK;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
SORAFENIB;KDR;TT;rs1870377;EFFICACY;INCREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:HEPATOCELLULAR_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED;RISK;DISEASE:STEVENS-JOHNSON_SYNDROME;PEOPLE;DISEASE:DRUG_HYPERSENSITIVITY;CAUTION_SIDE_EFFECT
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;PEOPLE;DISEASE:HYPERURICEMIA;CAUTION_SIDE_EFFECT
CODEINE;ABCB1;AA;rs2032582;TOXICITY, METABOLISM/PK;INCREASED;LIKELIHOOD;SIDE_EFFECT:CNS_DEPRESSION;WOMEN;DISEASE:PAIN;CAUTION_SIDE_EFFECT
CODEINE;ABCB1;A;rs1045642;TOXICITY, METABOLISM/PK;INCREASED;LIKELIHOOD;SIDE_EFFECT:CNS_DEPRESSION_IN_BREAST-FEEDING_INFANTS;WOMEN;DISEASE:PAIN;CAUTION_SIDE_EFFECT
CLOPIDOGREL, RESPIRATORY SYSTEM;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE);PEOPLE;OTHER:ELDERLY_ADULT, OTHER:CARDIOVASCULAR_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;CELSR2, PSRC1;T;rs602633;METABOLISM/PK;;;PK:BASELINE_LDL_CHOLESTEROL;PEOPLE;DISEASE:VASCULAR_DISEASES;CAUTION_DOSE_ADJUST
COCAINE, ETHANOL, OPIOIDS;OPRM1;A;rs524731;TOXICITY;INCREASED;RISK;OTHER:ALCOHOL_ABUSE, OTHER:COCAINE_DEPENDENCE, OTHER:OPIOID-RELATED_DISORDERS;;;CAUTION_SIDE_EFFECT
ATAZANAVIR, INDINAVIR;UGT1A1;*28/*28;UGT1A1*1, UGT1A1*28;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HYPERBILIRUBINEMIA;PEOPLE;OTHER:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
ATAZANAVIR, RITONAVIR;UGT1A1;*28/*28;UGT1A1*28;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HYPERBILIRUBINEMIA;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
PHENPROCOUMON;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *3/*3 + *2/*3;CYP2C9*1, CYP2C9*2, CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OVER-ANTICOAGULATION;;;CAUTION_SIDE_EFFECT
ATAZANAVIR / RITONAVIR;UGT1A1;*1/*28 + *28/*28;UGT1A1*1, UGT1A1*28;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HYPERBILIRUBINEMIA;PEOPLE;OTHER:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
METHOTREXATE;SLCO1B1;G;rs4149081;OTHER, METABOLISM/PK;INCREASED;;PK:CLEARANCE;PEOPLE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DOSE_ADJUST
BETA BLOCKING AGENTS;GRK5;AA;rs2230345;EFFICACY;DECREASED;RISK;EFFICACY:DEATH;PEOPLE;OTHER:HEART_FAILURE;LIKELIHOOD_THERAPEUTIC_SUCCESS
VALPROIC ACID;SCN1A;AA;rs10167228;EFFICACY;DECREASED;LIKELIHOOD;SIDE_EFFECT:WEIGHT_GAIN;CHILDREN;OTHER:EPILEPSY;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:GRAFT_VS_HOST_DISEASE;PEOPLE;OTHER:HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;ABCB1;AG;rs1045642;EFFICACY;INCREASED;RISK;DISEASE:TRANSPLANT_REJECTION;CHILDREN;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*5;CYP2C19*1, CYP2C19*5;TOXICITY;INCREASED;RISK;DISEASE:DEATH;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;CAUTION_SIDE_EFFECT
MIRTAZAPINE;CYP2D6;*4/*4 + *4/*6;CYP2D6*1, CYP2D6*4, CYP2D6*6;METABOLISM/PK;INCREASED;;PK:DOSE/WEIGHT_ADJUSTED_AUC_FOR_MIRTAZAPINE;HEALTHY;;CAUTION_DOSE_ADJUST
TROGLITAZONE;;C;rs10811661;EFFICACY;INCREASED;;EFFICACY:BETA_CELL_FUNCTION;PEOPLE;OTHER:HIGH_RISK_FOR_TYPE_2_DIABETES;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM COMPOUNDS;ERCC2;CC + CT;rs1799793;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
NEVIRAPINE;CYP2B6;T;rs3745274;METABOLISM/PK;INCREASED;;OTHER:PLASMA_LEVEL;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DOSE_ADJUST
CITALOPRAM;CYP2C19;*3;CYP2C19*1, CYP2C19*3;METABOLISM/PK;DECREASED;;PK:CITALOPRAM_ORAL_CLEARANCES_OF_CITALOPRAM;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DOSE_ADJUST
METHAMPHETAMINE;PICK1;T;rs713729;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:SUBSTANCE-RELATED_DISORDERS;;;CAUTION_SIDE_EFFECT
IMATINIB;ABCG2;T;rs2231142;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:EXANTHEMA;PEOPLE;OTHER:GASTROINTESTINAL_STROMAL_TUMORS;CAUTION_SIDE_EFFECT
CAFFEINE;DRD2;GG;rs1110976;OTHER;DECREASED;;SIDE_EFFECT:ANXIETY;PEOPLE;OTHER:NO_DISEASE;CAUTION_DOSE_ADJUST
OPIOIDS;;AG + GG;rs4530637;TOXICITY;INCREASED;RISK;OTHER:OPIOID-RELATED_DISORDERS;MEN;;CAUTION_SIDE_EFFECT
NEVIRAPINE;ABCB1;A;rs1045642;TOXICITY;DECREASED;RISK;DISEASE:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
COCAINE, ETHANOL, OPIOIDS;OPRM1;G;rs3778156;TOXICITY;INCREASED;RISK;OTHER:ALCOHOL_ABUSE, OTHER:COCAINE_DEPENDENCE, OTHER:OPIOID-RELATED_DISORDERS;;;CAUTION_SIDE_EFFECT
NAN;;C;rs1111875;METABOLISM/PK;DECREASED;;PK:INSULIN_SECRETION_AT_BASELINE;PEOPLE;OTHER:HIGH_RISK_OF_TYPE_2_DIABETES;CAUTION_DOSE_ADJUST
CISPLATIN;COMT;T;rs9332377;TOXICITY;INCREASED;RISK;DISEASE:OTOTOXICITY;CHILDREN;;CAUTION_SIDE_EFFECT
FLUOXETINE;CYP2D6;*4 + *6;CYP2D6*1, CYP2D6*4, CYP2D6*6;METABOLISM/PK;INCREASED;;PK:DOSE-CORRECTED_PLASMA_CONCENTRATIONS_OF_FLUOXETINE;PEOPLE;DISEASE:MENTAL_DISORDERS;CAUTION_DOSE_ADJUST
OPIOIDS;TACR3;AG + GG;rs1384401;TOXICITY;INCREASED;RISK;OTHER:OPIOID-RELATED_DISORDERS;MEN;;CAUTION_SIDE_EFFECT
CISPLATIN;COMT;C;rs4646316;TOXICITY;INCREASED;RISK;DISEASE:OTOTOXICITY;CHILDREN;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
FOLFIRI;ABCC2;GG;rs2273697;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:DIARRHEA;PEOPLE;OTHER:PANCREATIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CITALOPRAM;CYP2C19;*2/*2 + *2/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;METABOLISM/PK;INCREASED;;PK:CITALOPRAM_AUC_AND_TERMINAL_ELIMINATION_HALF-LIFE;HEALTHY;;CAUTION_DOSE_ADJUST
PLATINUM COMPOUNDS;SLC22A2;CT + TT;rs316003;EFFICACY;INCREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL, EFFICACY:OVERALL_SURVIVAL;PEOPLE;OTHER:LUNG_NEOPLASMS, OTHER:TOBACCO_USE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;ABCC2;T;rs717620;TOXICITY;INCREASED;RISK;DISEASE:DRUG_TOXICITY;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*4/*4;CYP2D6*1, CYP2D6*4;EFFICACY;INCREASED;;EFFICACY:RECURRENCE_FREE_SURVIVAL;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHAMPHETAMINE;PICK1;T;rs713729;OTHER;INCREASED;LIKELIHOOD;SIDE_EFFECT:RECURRENCE;PEOPLE;DISEASE:SUBSTANCE-RELATED_DISORDERS;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;CYP2D6;AA;rs1065852;TOXICITY;INCREASED;RISK;OTHER:OPIOID-RELATED_DISORDERS;MEN;;CAUTION_SIDE_EFFECT
FOLFIRI;ABCC2;AA;rs1885301;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:NAUSEA;PEOPLE;OTHER:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
CITALOPRAM, ESCITALOPRAM;CYP2C19;*1/*2;CYP2C19*1, CYP2C19*2;METABOLISM/PK;INCREASED;;PK:MEDIAN_CONCENTRATION/DOSE_RATIO_AND_MEDIAN_PARENT_DRUG/METABOLITE_RATIO;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DOSE_ADJUST
OPIOIDS;DRD3;CC + CT;rs6280;TOXICITY;INCREASED;RISK;OTHER:OPIOID-RELATED_DISORDERS;MEN;;CAUTION_SIDE_EFFECT
HYDROCHLOROTHIAZIDE;;CC + CT;rs17137967;TOXICITY;INCREASED;;SIDE_EFFECT:FASTING_GLUCOSE;PEOPLE;DISEASE:HYPERTENSION;CAUTION_SIDE_EFFECT
NAN;CYP2A6;*4/*4 + *4/*7 + *4/*9 + *7/*7 + *7/*9 + *9/*9;CYP2A6*1, CYP2A6*4, CYP2A6*7, CYP2A6*9;OTHER;DECREASED;SEVERITY;OTHER:TOBACCO_USE_DISORDER;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;DRD3;AA + AG;rs324029;TOXICITY;INCREASED;RISK;OTHER:OPIOID-RELATED_DISORDERS;MEN;;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;;CYP2D6 POOR METABOLIZER, INTERMEDIATE METABOLIZER;TOXICITY;DECREASED;SEVERITY;DISEASE:BREAST_TENDERNESS, DISEASE:VAGINAL_DRYNESS, DISEASE:VOMITING;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;EXOC4;TT;rs718656;TOXICITY;INCREASED;RISK;OTHER:OPIOID-RELATED_DISORDERS;MEN;;CAUTION_SIDE_EFFECT
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;A;rs4646244;TOXICITY, METABOLISM/PK;INCREASED;RISK;DISEASE:HEPATITIS;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
AMISULPRIDE, CLOZAPINE, HALOPERIDOL, OLANZAPINE, QUETIAPINE, RISPERIDONE, ZIPRASIDONE, ZUCLOPENTHIXOL;CYP2D6;*4/*4;CYP2D6*1, CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE_EFFECT:EXTRAPYRAMIDAL_SYMPTOMS;PEOPLE;OTHER:SCHIZOPHRENIA, OTHER:BIPOLAR_DISORDER,OTHER:PERSONALITY_DISORDER, OTHER:PSYCHOTIC_DISORDER, OTHER:OBSESSIVE_COMPULSIVE_DISORDER;CAUTION_SIDE_EFFECT
NICOTINE;CHRNB2;T;rs2072660;OTHER;INCREASED;SEVERITY;DISEASE:TOBACCO_USE_DISORDER;;OTHER:SMOKERS;CAUTION_SIDE_EFFECT
DIRECT ACTING ANTIVIRALS;IFNL4;GG;rs11322783;EFFICACY;DECREASED;;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_FAILURE
PLATINUM COMPOUNDS;APLF;CCGG/CCGG + CCGG/del;rs3213239;EFFICACY;DECREASED;;EFFICACY:OVERALL_SURVIVAL, EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3;GG;rs8099917;EFFICACY;;;EFFICACY:LACK_OF_TREATMENT_RESPONSE;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;CAUTION_DOSE_ADJUST
ATAZANAVIR / RITONAVIR;UGT1A1;*1/*28 + *28/*28;UGT1A1*1, UGT1A1*28;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HYPERBILIRUBINEMIA;PEOPLE;OTHER:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM COMPOUNDS;ERCC2;GG;rs50872;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
PLATINUM COMPOUNDS;ABCG2;GG;rs1448784;EFFICACY;DECREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;OTHER:LUNG_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;A;rs1799930;TOXICITY, METABOLISM/PK;INCREASED;RISK;DISEASE:HEPATITIS;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
NICOTINE;CHRNB2;A;rs2072661;OTHER;INCREASED;SEVERITY;DISEASE:TOBACCO_USE_DISORDER;;OTHER:SMOKERS;CAUTION_SIDE_EFFECT
CODEINE, HYDROCODONE, OXYCODONE;CYP2D6;*3/*3 + *4/*4;CYP2D6*1, CYP2D6*3, CYP2D6*4;TOXICITY;DECREASED;RISK;SIDE_EFFECT:OPIOID-RELATED_DISORDERS;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN;UGT1A1;*1/*1 + *1/*28;UGT1A1*1, UGT1A1*28;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:DIARRHEA;PEOPLE;OTHER:LUNG_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
BOCEPREVIR, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM COMPOUNDS;ERCC1;AA + AG;rs11615;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*15:11;HLA-B*15:11;TOXICITY;INCREASED;RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;;;CAUTION_SIDE_EFFECT
HYDROXYCHLOROQUINE;CYP2C8;GG;rs10882526;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ADVERSE_EVENTS;PEOPLE;OTHER:RHEUMATOID_ARTHRITIS, OTHER:SYSTEMIC_LUPUS_ERYTHEMATOSUS;CAUTION_SIDE_EFFECT
OPIUM ALKALOIDS AND DERIVATIVES;CHRNA5;GG;rs660652;TOXICITY;INCREASED;;DISEASE:TOBACCO_USE_DISORDER;PEOPLE;DISEASE:PAIN;CAUTION_SIDE_EFFECT
METHAMPHETAMINE;;T;rs1421292;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:PSYCHOTIC_DISORDER;;;CAUTION_SIDE_EFFECT
ACE INHIBITORS, PLAIN;ABO;GT + TT;rs495828;TOXICITY;;;DISEASE:COUGH;;;CAUTION_DOSE_ADJUST
AMITRIPTYLINE, CLOMIPRAMINE, DOXEPIN, IMIPRAMINE, MAPROTILINE, NORTRIPTYLINE, OPIPRAMOL;CYP2D6;*4/*4;CYP2D6*1, CYP2D6*4;TOXICITY;INCREASED;RISK;SIDE_EFFECT:SIDE_EFFECTS;PEOPLE;DISEASE:DEPRESSION;CAUTION_SIDE_EFFECT
GLICLAZIDE;KCNJ11;CT + TT;rs5219;EFFICACY;INCREASED;;EFFICACY:EFFICACY_AS_MEASURED_BY_DECREASE_IN_HBA1C;PEOPLE;DISEASE:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*1 + *17;CYP2C19*1, CYP2C19*2, CYP2C19*17;EFFICACY;DECREASED;;OTHER:PLATELET_REACTIVITY;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
PLATINUM COMPOUNDS;ABCB1;AA;rs1128503;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;;NAT2 SLOW_ACETYLATOR;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;TOXICITY;INCREASED;RISK;SIDE_EFFECT:CARDIOVASCULAR_DISEASE;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;CAUTION_SIDE_EFFECT
OPIOIDS;ZNF804A;CC;rs7597593;TOXICITY;INCREASED;RISK;OTHER:OPIOID-RELATED_DISORDERS;WOMEN;;CAUTION_SIDE_EFFECT
NORTRIPTYLINE;CYP2D6;*4/*4;CYP2D6*1, CYP2D6*4;METABOLISM/PK;DECREASED;;PK:MAXIMUM_PLASMA_CONCENTRATION_OF_10-HYDROXY_NORTRIPTYLINE;HEALTHY;;CAUTION_DOSE_ADJUST
OPIUM ALKALOIDS AND DERIVATIVES;CHRNA3;AA;rs1051730;TOXICITY;INCREASED;SEVERITY;DISEASE:SUBSTANCE-RELATED_DISORDERS;PEOPLE;DISEASE:PAIN;CAUTION_SIDE_EFFECT
HYDROXYCHLOROQUINE;CYP3A5;TT;rs776746;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ADVERSE_EVENTS;PEOPLE;OTHER:RHEUMATOID_ARTHRITIS, OTHER:SYSTEMIC_LUPUS_ERYTHEMATOSUS;CAUTION_SIDE_EFFECT
PLATINUM COMPOUNDS;IL16;GT + TT;rs7170924;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
INDOMETHACIN;CYP2C9;*2;CYP2C9*1, CYP2C9*2;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:TREATMENT_FAILURE;INFANTS;OTHER:PATENT_DUCTUS_ARTERIOSUS;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;CHRNA3;AA + AG;rs1051730;OTHER;INCREASED;LIKELIHOOD;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NEVIRAPINE;HLA-B;*15:10;HLA-B*15:10;TOXICITY;DECREASED;RISK;DISEASE:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACENOCOUMAROL;CYP2C9;*1/*3 + *3/*3;CYP2C9*1, CYP2C9*3;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:OVER-ANTICOAGULATION;;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2 + *3 + *8;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*8, CYP2C19*17;EFFICACY;INCREASED;RISK;EFFICACY:STROKE, EFFICACY:MYOCARDIAL_INFARCTION, EFFICACY:DEATH;PEOPLE;OTHER:TRANSIENT_ISCHEMIC_ATTACK, OTHER:STROKE;CAUTION_SIDE_EFFECT
ASPIRIN;TBXA2R;A;rs1131882;EFFICACY, TOXICITY;INCREASED;RISK;SIDE_EFFECT:DEATH;PEOPLE;DISEASE:DIABETES_MELLITUS_T2;CAUTION_SIDE_EFFECT
OPIOIDS;CNR1;TT;rs2023239;TOXICITY;INCREASED;RISK;OTHER:OPIOID-RELATED_DISORDERS;MEN;;CAUTION_SIDE_EFFECT
NAN;NQO1;AA;rs1800566;OTHER;;;OTHER:SIGNIFICANTLY_SHORTER_SURVIVAL;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_DOSE_ADJUST
BUSULFAN;CYP2C9;*2 + *3;CYP2C9*1, CYP2C9*2, CYP2C9*3;METABOLISM/PK;INCREASED;;PK:METABOLIC_RATIO;CHILDREN;DISEASE:HEMOPOIETIC_STEM_CELL_TRANSPLANT;CAUTION_DOSE_ADJUST
PLATINUM COMPOUNDS;ABCB1;AA;rs1128503;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
METFORMIN;SLC29A4;G;rs3889348;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY;PEOPLE;OTHER:DIABETES_MELLITUS_T2;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*1/*28 + *28/*28;UGT1A1*1, UGT1A1*28;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:DIARRHEA;PEOPLE;OTHER:NEOPLASMS;CAUTION_SIDE_EFFECT
FOLFIRI, IRINOTECAN;UGT1A1;*1/*28 + *28/*28;UGT1A1*1, UGT1A1*28;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:DIARRHEA;PEOPLE;OTHER:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
NAN;NQO1;A;rs1800566;TOXICITY;INCREASED;RISK;DISEASE:LEUKEMIA;;;CAUTION_SIDE_EFFECT
HYDROCHLOROTHIAZIDE;ACE;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;rs1799752;EFFICACY;INCREASED;;EFFICACY:REDUCTION_IN_BLOOD_PRESSURE;WOMEN;DISEASE:ESSENTIAL_HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
DRUGS FOR TREATMENT OF TUBERCULOSIS;GSTM1;;GSTM1 NULL;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
DRUGS FOR TREATMENT OF TUBERCULOSIS;GSTT1;;GSTT1 NULL;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
OPIOIDS;CNR1;CC;rs6928499;TOXICITY;INCREASED;RISK;OTHER:OPIOID-RELATED_DISORDERS;MEN;;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC AGENTS, TAMOXIFEN;CYP2D6;*5/*10;CYP2D6*1, CYP2D6*2, CYP2D6*5, CYP2D6*10;EFFICACY;DECREASED;;EFFICACY:RECURRENCE_FREE_SURVIVAL;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
NEVIRAPINE;CYP2B6;CC + CG;rs58425034;OTHER;INCREASED;LIKELIHOOD;SIDE_EFFECT:ELEVATED_LIVER_ENZYMES;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;TYMS;TTAAAGTTA/TTAAAGTTA;rs11280056;EFFICACY;DECREASED;;DISEASE:EVENT-FREE_SURVIVAL, DISEASE:OVERALL_SURVIVAL;PEOPLE;DISEASE:RECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*2/*2;CYP2C19*2;EFFICACY;INCREASED;RISK;SIDE_EFFECT:DEATH, SIDE_EFFECT:MYOCARDIAL_INFARCTION;PEOPLE;DISEASE:ANGINA_PECTORIS;CAUTION_SIDE_EFFECT
DOCETAXEL, THALIDOMIDE;CHST3;C;rs4148945;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXICITY;PEOPLE;DISEASE:PROSTATIC_NEOPLASMS;CAUTION_SIDE_EFFECT
"""FOLIC ACID"", ""VITAMIN B-COMPLEX, PLAIN""";MTHFR;AG + GG;rs1801133;EFFICACY;DECREASED;SEVERITY;DISEASE:PAIN;WOMEN;DISEASE:MIGRAINE_WITH_AURA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE;HLA-B;*51:01;HLA-B*51:01;TOXICITY;INCREASED;RISK;DISEASE:DRUG_HYPERSENSITIVITY;;;CAUTION_SIDE_EFFECT
DOCETAXEL, THALIDOMIDE;SLC10A2;A;rs2301159;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXICITY;PEOPLE;DISEASE:PROSTATIC_NEOPLASMS;CAUTION_SIDE_EFFECT
AXITINIB, SORAFENIB;HIF1A;CT;rs11549465;EFFICACY;DECREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL, IRINOTECAN, LEUCOVORIN;TYMS;TTAAAGTTA/TTAAAGTTA;rs11280056;EFFICACY;INCREASED;RISK;EFFICACY:DISEASE_PROGRESSION;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
EFAVIRENZ;CYP2B6;*6/*6;CYP2B6*1, CYP2B6*6;TOXICITY, METABOLISM/PK;INCREASED;RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
METHOTREXATE;SLC19A1;CC + CT;rs1051266;EFFICACY;INCREASED;SEVERITY;DISEASE:RHEUMATOID_ARTHRITIS;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
SORAFENIB;KDR;AA;rs2071559;EFFICACY;DECREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;*2;CYP2C9*1, CYP2C9*2;EFFICACY;DECREASED;;EFFICACY:TIME_IN_THERAPEUTIC_RANGE;;;LIKELIHOOD_THERAPEUTIC_FAILURE
NICOTINE;DBH;AA + AG;rs77905;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:SMOKING_CESSATION;PEOPLE;DISEASE:TOBACCO_USE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;ADORA2A;GG;rs2298383;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES;CHILDREN;DISEASE:HEMATOLOGIC_NEOPLASMS;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC AGENTS, TAMOXIFEN;CYP2D6;*5/*10;CYP2D6*1, CYP2D6*2, CYP2D6*5, CYP2D6*10;EFFICACY;DECREASED;;EFFICACY:RECURRENCE_FREE_SURVIVAL;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*1/*2;CYP2C19*1, CYP2C19*2;OTHER;INCREASED;;OTHER:PLATELET_AGGREGATION_WITH_ADP;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;CAUTION_DOSE_ADJUST
RISPERIDONE;CYP2D6;CT + TT;rs3892097;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:EXTRAPYRAMIDAL_SYMPTOMS, SIDE_EFFECT:TREMOR, SIDE_EFFECT:MUSCLE_RIGIDITY;PEOPLE;OTHER:SCHIZOPHRENIA, OTHER:SCHIZOAFFECTIVE_DISORDER;CAUTION_SIDE_EFFECT
NAN;CYP2B6;TT;rs3211371;OTHER;INCREASED;LIKELIHOOD;OTHER:SMOKING_CESSATION;PEOPLE;OTHER:RS1800497_GG_GENOTYPES;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;CYP2B6;CT;rs3211371;OTHER;INCREASED;LIKELIHOOD;OTHER:SMOKING_CESSATION;PEOPLE;OTHER:RS1800497_GG_GENOTYPES;LIKELIHOOD_THERAPEUTIC_SUCCESS
TAMOXIFEN;CYP2D6;*3 + *4 + *5 + *10 + *41;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*41;EFFICACY;DECREASED;;EFFICACY:EVENT-FREE_SURVIVAL;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOXETINE;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR LONG FORM (L ALLELE), SLC6A4 HTTLPR SHORT FORM (S ALLELE);TOXICITY;INCREASED;RISK;SIDE_EFFECT:PSYCHOMOTOR_AGITATION, SIDE_EFFECT:INSOMNIA;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;G;rs4124874;TOXICITY;INCREASED;RISK;DISEASE:NEUTROPENIA;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
NAN;CYP24A1;C;rs2762939;OTHER;DECREASED;RISK;DISEASE:CORONARY_ARTERY_DISEASE;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIUM ALKALOIDS AND DERIVATIVES;CHRNA5;A;rs16969968;TOXICITY;INCREASED;SEVERITY;DISEASE:SUBSTANCE-RELATED_DISORDERS;PEOPLE;DISEASE:PAIN;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*3;CYP2C9*1, CYP2C9*2, CYP2C9*3;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ADVERSE_OUTCOME;;OTHER:ORTHOPEDIC_PATIENTS;CAUTION_SIDE_EFFECT
MORPHINE;ABCC3;G;rs739923;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:HYPOVENTILATION;CHILDREN;DISEASE:SLEEP_APNEA_SYNDROMES, DISEASE:TONSILLECTOMY;CAUTION_SIDE_EFFECT
CITALOPRAM;PAPLN;T;rs11628713;TOXICITY;INCREASED;RISK;SIDE_EFFECT:SUICIDAL_IDEATION;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;*2;CYP2C9*1, CYP2C9*2;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:OVER_ANTI-COAGULATION;;;CAUTION_SIDE_EFFECT
SULFONAMIDES, UREA DERIVATIVES;KCNJ11;CT + TT;rs5219;EFFICACY;INCREASED;;EFFICACY:EFFICACY_AS_MEASURED_BY_DECREASE_IN_HBA1C_AFTER_6-MONTH_TREATMENT;PEOPLE;DISEASE:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOXETINE;CYP2D6;*1/*1xN;CYP2D6*1, CYP2D6*1XN;METABOLISM/PK;DECREASED;;PK:DOSE-CORRECTED_PLASMA_CONCENTRATIONS_OF_FLUOXETINE;PEOPLE;DISEASE:MENTAL_DISORDERS;CAUTION_DOSE_ADJUST
IMATINIB;SLC22A1;TT;rs1867351;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:PERIORBITAL_EDEMA;PEOPLE;OTHER:GASTROINTESTINAL_STROMAL_TUMORS;CAUTION_SIDE_EFFECT
FLUOROURACIL, LEUCOVORIN;ERCC2;GG + GT;rs13181;EFFICACY;INCREASED;RISK;EFFICACY:RECURRENCE;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
VERAPAMIL;KCNIP1, KCNMB1;CT + TT;rs11739136;EFFICACY;;;EFFICACY:EARLIER_ACHIEVEMENT_OF_BLOOD_PRESSURE_CONTROL;PEOPLE;DISEASE:HYPERTENSION;CAUTION_DOSE_ADJUST
OPIOIDS;DRD3;AG + GG;rs9288993;TOXICITY;INCREASED;RISK;OTHER:OPIOID-RELATED_DISORDERS;WOMEN;;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED;;EFFICACY:RAPID_VIROLOGICAL_RESPONSE_(RVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
OSIMERTINIB;CYP2C9;AC;rs1057910;EFFICACY;DECREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
OPIOIDS;DRD3;AG + GG;rs2654754;TOXICITY;INCREASED;RISK;OTHER:OPIOID-RELATED_DISORDERS;WOMEN;;CAUTION_SIDE_EFFECT
OPIOIDS;ZNF568;G;rs10405238;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:NAUSEA, SIDE_EFFECT:VOMITING;PEOPLE;OTHER:NEOPLASMS, OTHER:PAIN;CAUTION_SIDE_EFFECT
ANTIEPILEPTICS;HLA-B;*53:01;HLA-B*53:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;;;CAUTION_SIDE_EFFECT
SULFAMETHOXAZOLE, SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME, SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;;;CAUTION_SIDE_EFFECT
PENICILLIN G;HLA-DPB1;*05:01;HLA-DPB1*05:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_HYPERSENSITIVITY;;;CAUTION_SIDE_EFFECT
SULFAMETHOXAZOLE, SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-B;*13:01;HLA-B*13:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;;;CAUTION_SIDE_EFFECT
SULFAMETHOXAZOLE, SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-B;*38:02;HLA-B*38:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME, SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;;;CAUTION_SIDE_EFFECT
APIXABAN, DABIGATRAN, EDOXABAN, RIVAROXABAN;ABCB1;CC;rs3842;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE;;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:CORONARY_RESTENOSIS, SIDE_EFFECT:THROMBOTIC_DISEASE;PEOPLE;OTHER:CEREBROVASCULAR_DISORDERS, OTHER:CAROTID_STENOSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
METFORMIN;AMHR2;G;rs784892;METABOLISM/PK;DECREASED;;PK:METFORMIN_SECRETORY_CLEARANCE;HEALTHY;;CAUTION_DOSE_ADJUST
MYCOPHENOLATE MOFETIL;SLCO1B3;GG;rs4149117;METABOLISM/PK;INCREASED;;PK:DOSE-ADJUSTED_AREA_UNDER_THE_CURVE_(AUC6-12)_OF_MYCOPHENOLIC_ACID_(MPA);PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;;CYP2C19 INTERMEDIATE_METABOLIZER;TOXICITY;INCREASED;RISK;SIDE_EFFECT:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE);PEOPLE;OTHER:PERCUTANEOUS_CORONARY_INTERVENTION;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*17 + *1/*9 + *2/*13 + *9/*17 + *2/*2;CYP2C19*1, CYP2C19*2, CYP2C19*9, CYP2C19*13, CYP2C19*17;EFFICACY;INCREASED;RISK;EFFICACY:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE), EFFICACY:DEATH, EFFICACY:MYOCARDIAL_INFARCTION, EFFICACY:STROKE, SIDE_EFFECT:UNSTABLE_ANGINA;PEOPLE;OTHER:ACUTE_CORONARY_SYNDROME;CAUTION_SIDE_EFFECT
ASPIRIN, CLOPIDOGREL;PON1;CT + TT;rs662;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:THROMBOTIC_DISEASE;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;OPRM1;AA;rs1799971;TOXICITY;INCREASED;RISK;OTHER:OPIOID-RELATED_DISORDERS;WOMEN;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2 + *4;CYP2C19*1, CYP2C19*2, CYP2C19*4, CYP2C19*17;OTHER;INCREASED;RISK;DISEASE:MYOCARDIAL_INFARCTION;;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*8;CYP2C19*1, CYP2C19*8;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ISCHAEMIC_EVENTS;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*5;CYP2C19*1, CYP2C19*5;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ISCHAEMIC_EVENTS;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;CAUTION_SIDE_EFFECT
ACENOCOUMAROL;CYP2C9;*2;CYP2C9*1, CYP2C9*2;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:INTERNATIONAL_NORMALIZED_RATIO_VARIABILITY_(INR-VAR);PEOPLE;OTHER:STROKE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATEZOLIZUMAB, DURVALUMAB, IPILIMUMAB, NIVOLUMAB, PEMBROLIZUMAB;HLA-A;*26:01;HLA-A*26:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:THYROTOXICOSIS, SIDE_EFFECT:HYPOTHYROIDISM;PEOPLE;OTHER:LUNG_NEOPLASMS, OTHER:UROLOGIC_NEOPLASMS,OTHER:MELANOMA, OTHER:BREAST_NEOPLASMS, OTHER:HEAD_AND_NECK_NEOPLASMS;CAUTION_SIDE_EFFECT
CARBOPLATIN, GEMCITABINE;RRM1;GG;rs9937;TOXICITY;;RISK;DISEASE:HEMATOLOGIC_DISORDER;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_DOSE_ADJUST
ETHANOL;OPRM1;AA;rs1799971;TOXICITY;INCREASED;SEVERITY;OTHER:ALCOHOL_ABUSE;;;CAUTION_SIDE_EFFECT
METFORMIN;SLC22A1;A;rs628031;TOXICITY, METABOLISM/PK;;;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY;PEOPLE;DISEASE:DIABETES_MELLITUS_T2;CAUTION_DOSE_ADJUST
OPIOIDS;GABRB3;AA;rs4906902;TOXICITY;INCREASED;RISK;OTHER:OPIOID-RELATED_DISORDERS;WOMEN;;CAUTION_SIDE_EFFECT
AMITRIPTYLINE;CYP2D6;*4;CYP2D6*1, CYP2D6*4;OTHER, METABOLISM/PK;INCREASED;;PK:PLASMA_NORTRIPTYLINE;PEOPLE;DISEASE:MENTAL_DISORDERS;CAUTION_DOSE_ADJUST
AMITRIPTYLINE;CYP2D6;*10;CYP2D6*1, CYP2D6*10;OTHER, METABOLISM/PK;INCREASED;;PK:PLASMA_NORTRIPTYLINE;PEOPLE;DISEASE:MENTAL_DISORDERS;CAUTION_DOSE_ADJUST
BECLOMETHASONE DIPROPIONATE, FLUTICASONE PROPIONATE;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:STATUS_ASTHMATICUS, EFFICACY:EMERGENCIES;CHILDREN;OTHER:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
AMITRIPTYLINE;CYP2C19;*1/*3 + *2/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;METABOLISM/PK;INCREASED;;PK:AMITRIPTYLINE/NORTRIPTYLINE_RATIO_CORRECTED_FOR_DOSE_AND_WEIGHT;PEOPLE;DISEASE:MENTAL_DISORDERS;CAUTION_DOSE_ADJUST
MYCOPHENOLATE MOFETIL;SLCO1B3;AA;rs7311358;METABOLISM/PK;INCREASED;;PK:DOSE-ADJUSTED_AREA_UNDER_THE_CURVE_(AUC6-12)_OF_MYCOPHENOLIC_ACID_(MPA);PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN, SOFOSBUVIR;IFNL3, IFNL4;TT;rs12979860;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;OTHER:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_FAILURE
ISONIAZID, RIFAMPIN;HLA-DPB1;*05:01;HLA-DPB1*05:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE;PEOPLE;OTHER:TUBERCULOSIS;CAUTION_SIDE_EFFECT
ISONIAZID, RIFAMPIN;HLA-A;*11:01;HLA-A*11:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_HYPERSENSITIVITY;PEOPLE;OTHER:TUBERCULOSIS;CAUTION_SIDE_EFFECT
ETHANOL;DRD2;GG;rs1799732;TOXICITY;INCREASED;SEVERITY;OTHER:ALCOHOL_ABUSE;;;CAUTION_SIDE_EFFECT
SALBUTAMOL;THRB;A;rs892940;EFFICACY;INCREASED;;EFFICACY:BRONCHODILATOR_RESPONSE_(BDR);CHILDREN;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;TACR1;AA;rs735668;TOXICITY;INCREASED;RISK;OTHER:OPIOID-RELATED_DISORDERS;WOMEN;;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;*3 + *4 + *5 + *6 + *7 + *9 + *10 + *41;CYP2D6*1, CYP2D6*1XN, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*7, CYP2D6*9, CYP2D6*10, CYP2D6*35, CYP2D6*41;EFFICACY;DECREASED;;EFFICACY:RECURRENCE_FREE_SURVIVAL;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
ASPIRIN, CLOPIDOGREL;ABCB1;AA + AG;rs1045642;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN, CLOPIDOGREL;ABCB1;AA + AG;rs1045642;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:THROMBOTIC_DISEASE;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
APIXABAN, DABIGATRAN, EDOXABAN, RIVAROXABAN;APOB;AA + AG;rs13306198;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE;;;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC AGENTS, TAMOXIFEN;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *41/*41 + *4/*4 + *4/*5 + *3/*4 + *3/*3 + *3/*5 + *4/*10 + *4/*41 + *5/*41 + *5/*5;CYP2D6*1, CYP2D6*1XN, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*41;EFFICACY;INCREASED;RISK;EFFICACY:DEATH, EFFICACY:RECURRENCE;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC AGENTS, TAMOXIFEN;CYP2D6;*10/*10;CYP2D6*1, CYP2D6*10;EFFICACY;DECREASED;;EFFICACY:EVENT-FREE_SURVIVAL;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
OPIOIDS;OPRM1;CC;rs510769;TOXICITY;INCREASED;RISK;OTHER:OPIOID-RELATED_DISORDERS;WOMEN;;CAUTION_SIDE_EFFECT
ETHANOL;OPRM1;G;rs1799971;TOXICITY;INCREASED;RISK;OTHER:ALCOHOL_ABUSE;CHILDREN;;CAUTION_SIDE_EFFECT
FIRST-GENERATION CEPHALOSPORINS, FOURTH-GENERATION CEPHALOSPORINS, OTHER CEPHALOSPORINS, THIRD-GENERATION CEPHALOSPORINS;HLA-B;*55:02;HLA-B*55:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_HYPERSENSITIVITY;;;CAUTION_SIDE_EFFECT
AMOXICILLIN;HLA-B;*15:01;HLA-B*15:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;;;CAUTION_SIDE_EFFECT
"""METFORMIN"", ""SULFONAMIDES, UREA DERIVATIVES""";SLC22A1;GAT/del;rs72552763;EFFICACY;INCREASED;LIKELIHOOD;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY;PEOPLE;OTHER:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;*4;NAT2*4;TOXICITY;DECREASED;RISK;SIDE_EFFECT:HEPATOTOXICITY;PEOPLE;DISEASE:TUBERCULOSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *7/*7;NAT2*6, NAT2*7, NAT2*16;TOXICITY, METABOLISM/PK;INCREASED;RISK;DISEASE:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
FIRST-GENERATION CEPHALOSPORINS, FOURTH-GENERATION CEPHALOSPORINS, OTHER CEPHALOSPORINS, THIRD-GENERATION CEPHALOSPORINS;HLA-C;*01:02;HLA-C*01:02;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:DRUG_HYPERSENSITIVITY;;;CAUTION_SIDE_EFFECT
FIRST-GENERATION CEPHALOSPORINS, FOURTH-GENERATION CEPHALOSPORINS, OTHER CEPHALOSPORINS, THIRD-GENERATION CEPHALOSPORINS;HLA-DQB1;*06:09;HLA-DQB1*06:09;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_HYPERSENSITIVITY;;;CAUTION_SIDE_EFFECT
INFLIXIMAB;HLA-DQA1;*05;HLA-DQA1*05;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:DISCONTINUATION;PEOPLE;OTHER:CROHN_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;CYP2A13;CT;rs72552266;TOXICITY;INCREASED;SEVERITY;OTHER:TOBACCO_USE_DISORDER;;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED;;EFFICACY:PLATELET_REACTIVITY;PEOPLE;;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOPHOSPHAMIDE;CYP3A5;*1/*3 + *1/*6 + *3/*3 + *3/*6;CYP3A5*1, CYP3A5*3, CYP3A5*6;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:CYSTITIS;CHILDREN;OTHER:RHABDOMYOSARCOMA;CAUTION_SIDE_EFFECT
NAN;UGT1A1;*28;UGT1A1*28;OTHER;INCREASED;LIKELIHOOD;OTHER:GILBERT_SYNDROME, OTHER:CRIGLER-NAJJAR_SYNDROME;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOXORUBICIN;GSTT1;;GSTT1 NON-NULL, GSTT1 NULL;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA;WOMEN;OTHER:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS;HLA-DQB1;*03:01;HLA-DQB1*03:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:BULLOUS_PEMPHIGOID;PEOPLE;OTHER:DIABETES_MELLITUS_T2;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;AA + AG;rs4148323;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DIARRHEA, SIDE_EFFECT:NEUTROPENIA;PEOPLE;DISEASE:LUNG_NEOPLASMS;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*1/*1;CYP3A5*1, CYP3A5*3;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:GRAFT_VS_HOST_DISEASE;PEOPLE;OTHER:HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN;UGT1A1;*1/*6 + *6/*6;UGT1A1*1, UGT1A1*6;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:NEUTROPENIA;PEOPLE;OTHER:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
FOLFIRI, IRINOTECAN;UGT1A1;*28/*28 + *6/*6 + *6/*28;UGT1A1*1, UGT1A1*6, UGT1A1*28;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:NEUTROPENIA;PEOPLE;OTHER:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
FOLFIRI;UGT1A1;*1/*6 + *6/*6;UGT1A1*1, UGT1A1*6;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:MYELOSUPPRESSION;PEOPLE;OTHER:METASTATIC_NEOPLASM, OTHER:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
FOLFIRI;UGT1A1;*28/*28;UGT1A1*1, UGT1A1*28;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:MYELOSUPPRESSION;;;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:ACUTE_CELLULAR_REJECTION;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
SACITUZUMAB GOVITECAN;UGT1A1;*28/*28;UGT1A1*1, UGT1A1*28;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DISCONTINUATION, SIDE_EFFECT:DRUG_TOXICITY, SIDE_EFFECT:NEUTROPENIA, SIDE_EFFECT:DIARRHEA;PEOPLE;OTHER:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
FOLFIRI;UGT1A1;*28/*28 + *6/*6 + *6/*28;UGT1A1*1, UGT1A1*6, UGT1A1*28;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:NEUTROPENIA;PEOPLE;OTHER:COLORECTAL_NEOPLASMS, OTHER:METASTATIC_NEOPLASM;CAUTION_SIDE_EFFECT
FOLFIRI, IRINOTECAN;UGT1A1;*28/*28;UGT1A1*1, UGT1A1*28;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:NEUTROPENIA, SIDE_EFFECT:FEBRILE_NEUTROPENIA, SIDE_EFFECT:LEUKOPENIA;PEOPLE;OTHER:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*1/*28 + *28/*28;UGT1A1*1, UGT1A1*28;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:NEUTROPENIA;PEOPLE;OTHER:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
FOLFIRI, IRINOTECAN;UGT1A1;*28/*28 + *1/*28;UGT1A1*1, UGT1A1*28;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:NEUTROPENIA;PEOPLE;OTHER:COLORECTAL_NEOPLASMS, OTHER:METASTATIC_NEOPLASM;CAUTION_SIDE_EFFECT
FOLFIRI, IRINOTECAN;UGT1A1;*28/*28 + *1/*28;UGT1A1*1, UGT1A1*28;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DIARRHEA;PEOPLE;OTHER:COLORECTAL_NEOPLASMS, OTHER:METASTATIC_NEOPLASM;CAUTION_SIDE_EFFECT
SUNITINIB;KDR;TT;rs1870377;EFFICACY;DECREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
IRINOTECAN;UGT1A1;*28 + *6;UGT1A1*6, UGT1A1*28;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA;;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*28;UGT1A1*1, UGT1A1*28;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DIARRHEA;;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;*6/*6;UGT1A1*1, UGT1A1*6;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DIARRHEA;;;CAUTION_SIDE_EFFECT
FOLFIRI, IRINOTECAN;UGT1A1;*1/*28 + *28/*28 + *1/*6 + *6/*6 + *6/*28;UGT1A1*1, UGT1A1*6, UGT1A1*28;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:DIARRHEA;PEOPLE;OTHER:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
MIRABEGRON;CYP2D6;;CYP2D6 INTERMEDIATE_METABOLIZER;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:NAUSEA, SIDE_EFFECT:HEADACHE, SIDE_EFFECT:INSOMNIA, SIDE_EFFECT:DRUG_TOXICITY;HEALTHY;;CAUTION_SIDE_EFFECT
MIRABEGRON;SLCO1B1;;SLCO1B1 DEFICIENCY;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:NAUSEA, SIDE_EFFECT:HEADACHE, SIDE_EFFECT:INSOMNIA, SIDE_EFFECT:DRUG_TOXICITY;HEALTHY;;CAUTION_SIDE_EFFECT
TRAMADOL;CYP2D6;;CYP2D6 ULTRARAPID_METABOLIZER;EFFICACY;DECREASED;SEVERITY;EFFICACY:PAIN;PEOPLE;OTHER:POSTOPERATIVE_PAIN;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;MTR;GG;rs3768142;TOXICITY;INCREASED;RISK;SIDE_EFFECT:AGRANULOCYTOSIS;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*13:01;HLA-B*13:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS;;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-B;*15:01;HLA-B*15:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME, SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS;;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HLA-A;*31:01;HLA-A*31:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS;;;CAUTION_SIDE_EFFECT
AZATHIOPRINE, MERCAPTOPURINE, PURINE ANALOGUES;TPMT;*1/*3A + *3A/*3C;TPMT*1, TPMT*3A, TPMT*3C;TOXICITY, METABOLISM/PK;INCREASED;;PK:LEVELS_OF_ERYTHROCYTE_6-THIOGUANINE_NUCLEOTIDE_METABOLITES;PEOPLE;DISEASE:INFLAMMATORY_BOWEL_DISEASES;CAUTION_SIDE_EFFECT
CISPLATIN;GSTT1;non-null;GSTT1 NON-NULL, GSTT1 NULL;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HEARING_LOSS;CHILDREN;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
SULFAMETHOXAZOLE / TRIMETHOPRIM;NAT2;*4;NAT2*4, NAT2*5, NAT2*6, NAT2*7, NAT2*16;TOXICITY;DECREASED;RISK;SIDE_EFFECT:ADVERSE_REACTIONS;CHILDREN;DISEASE:PNEUMONIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
MERCAPTOPURINE;TPMT;*1/*3A + *1/*3C + *3A/*3A;TPMT*1, TPMT*3A, TPMT*3C;DOSAGE;INCREASED;LIKELIHOOD;SIDE_EFFECT:DOSE_REDUCTION;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DOSE_ADJUST
ASPIRIN, CLOPIDOGREL;CYP2C19;*2 + *3 + *8;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*8;EFFICACY;DECREASED;RISK;EFFICACY:TRANSIENT_ISCHEMIC_ATTACK, EFFICACY:DEATH, EFFICACY:STROKE, EFFICACY:MYOCARDIAL_INFARCTION;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A4;AG + GG;rs4646437;METABOLISM/PK;INCREASED;;PK:DOSE-ADJUSTED_TROUGH_CONCENTRATIONS;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
DIHYDROPYRIDINE DERIVATIVES;RYR3;TT;rs877087;EFFICACY;INCREASED;RISK;EFFICACY:HEART_FAILURE, EFFICACY:MYOCARDIAL_INFARCTION, EFFICACY:ANGINA_PECTORIS;PEOPLE;OTHER:CORONARY_DISEASE;CAUTION_SIDE_EFFECT
NAN;CYP4A11;AG + GG;rs1126742;METABOLISM/PK;DECREASED;;PK:HDL-C_CONCENTRATION;WOMEN;;CAUTION_DOSE_ADJUST
CODEINE;CYP2D6;*1/*1x2  + *1/*2x2 + *1x2/*41 + *2/*2x2 + *2xN/*4 + *1/*1 + *1/*10 + *1/*2 + *1/*41 + *1/*41x2 + *1/*9 + *2/*2 + *2/*41 + *2/*9;CYP2D6*1, CYP2D6*1X2, CYP2D6*2, CYP2D6*2X2, CYP2D6*2XN, CYP2D6*4, CYP2D6*9, CYP2D6*10, CYP2D6*41, CYP2D6*41X2;OTHER;INCREASED;LIKELIHOOD;SIDE_EFFECT:OPIOID-RELATED_DISORDERS;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TICAGRELOR;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *3/*17;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE;;;CAUTION_SIDE_EFFECT
PEMETREXED;SLC19A1;TT;rs914232;EFFICACY;DECREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA, DISEASE:MESOTHELIOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
IRINOTECAN;UGT1A1;*6 + *28;UGT1A1*1, UGT1A1*6, UGT1A1*28;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:DIARRHEA;PEOPLE;OTHER:COLORECTAL_NEOPLASMS, OTHER:LUNG_NEOPLASMS;CAUTION_SIDE_EFFECT
FLUOROURACIL, IRINOTECAN;UGT1A1;*1/*28 + *28/*28 + *6/*6;UGT1A1*1, UGT1A1*6, UGT1A1*28;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:NEUTROPENIA;PEOPLE;OTHER:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
FLUOROURACIL, IRINOTECAN;DPYD;c.1627A>G (*5);DPYD C.1627A>G (*5);TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:DIARRHEA;PEOPLE;OTHER:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
CITALOPRAM;CYP2C19;*2/*2 + *2/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;METABOLISM/PK;INCREASED;;PK:AUC_OF_THE_S-ETIOMER_OF_CITALOPRAM_(NO_EFFECT_ON_R-CT);HEALTHY;;CAUTION_DOSE_ADJUST
PEMETREXED;SLC19A1;AA + AG;rs1051298;EFFICACY;DECREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA, DISEASE:MESOTHELIOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;CYP2C19;*1/*1 + *1/*2;CYP2C19*1, CYP2C19*2, CYP2C19*4;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HEADACHE, SIDE_EFFECT:MUSCLE_SPASM, SIDE_EFFECT:SOMNOLENCE, SIDE_EFFECT:DIZZINESS;HEALTHY;;CAUTION_SIDE_EFFECT
CETUXIMAB;FCGR2A;GG;rs1801274;EFFICACY;INCREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
AMOXICILLIN, AMPICILLIN, BACAMPICILLIN;HLA-A;*02:01;HLA-A*02:01;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_HYPERSENSITIVITY;;;CAUTION_SIDE_EFFECT
METHAMPHETAMINE;DRD3;CC + CT;rs6280;TOXICITY;INCREASED;RISK;SIDE_EFFECT:COGNITIVE_DISORDER;MEN;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
NICOTINE;CYP2A6;;CYP2A6 LOW ACTIVITY;OTHER;DECREASED;RISK;DISEASE:LUNG_NEOPLASMS;MEN;DISEASE:TOBACCO_USE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
VINCRISTINE;ACTN1;T;rs2268979;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES;CHILDREN;OTHER:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE, FLUOROURACIL;UPB1;GG;rs2070474;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:MUCOSITIS;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
PEMETREXED;MTHFR;AA + AG;rs1801133;EFFICACY;DECREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA, DISEASE:MESOTHELIOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
CAPECITABINE, FLUOROURACIL, FOLFIRI, FOLFIRINOX, FOLFOX;DPYD;c.2194G>A (*6);DPYD C.2194G>A (*6);TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA, SIDE_EFFECT:DIARRHEA, SIDE_EFFECT:STOMATITIS, SIDE_EFFECT:LEUKOPENIA, SIDE_EFFECT:NAUSEA, SIDE_EFFECT:VOMITING;PEOPLE;OTHER:COLORECTAL_NEOPLASMS, OTHER:BREAST_NEOPLASMS,OTHER:STOMACH_NEOPLASMS;CAUTION_SIDE_EFFECT
VINCRISTINE;PAPPA;A;rs12235805;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES;CHILDREN;OTHER:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE, FLUOROURACIL;UPB1;GG;rs2070474;TOXICITY;DECREASED;SEVERITY;DISEASE:DIARRHEA;PEOPLE;DISEASE:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE, FLUOROURACIL;DPYD;AA + AG;rs1801265;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DIARRHEA;PEOPLE;DISEASE:GASTROINTESTINAL_NEOPLASMS;CAUTION_SIDE_EFFECT
PEMETREXED;SLC19A1;GG + GT;rs3788189;EFFICACY;DECREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA, DISEASE:MESOTHELIOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY;CHILDREN;OTHER:MUCOCUTANEOUS_LYMPH_NODE_SYNDROME;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;ANKK1, DRD2;AA + AG;rs1800497;TOXICITY;DECREASED;SEVERITY;OTHER:TOBACCO_USE_DISORDER;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE, FLUOROURACIL, FOLFOX;DPYD;c.2846A>T + c.1129-5923C>G, c.1236G>A (HapB3) + c.1679T>G (*13);DPYD C.1129-5923C>G, C.1236G>A (HAPB3), DPYD C.1679T>G (*13), DPYD C.2846A>T;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DEATH;PEOPLE;OTHER:COLORECTAL_NEOPLASMS, OTHER:BREAST_NEOPLASMS,OTHER:NEOPLASMS;CAUTION_SIDE_EFFECT
AMITRIPTYLINE, ANTIDEPRESSANTS, CLOMIPRAMINE, DESIPRAMINE, FLUOXETINE, IMIPRAMINE, NORTRIPTYLINE, PAROXETINE, VENLAFAXINE;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:DEPRESSION;CAUTION_SIDE_EFFECT
SIROLIMUS;ABCB1;AA + AG;rs1045642;TOXICITY;INCREASED;;SIDE_EFFECT:TOTAL_CHOLESTEROL;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
FOLFIRI, IRINOTECAN;UGT1A1;*28/*28 + *1/*28 + *1/*6 + *6/*28;UGT1A1*1, UGT1A1*6, UGT1A1*28;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:NEUTROPENIA;PEOPLE;OTHER:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
FOLFIRI;UGT1A1;*1/*1;UGT1A1*1, UGT1A1*6, UGT1A1*28;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:NEUTROPENIA, SIDE_EFFECT:DIARRHEA;PEOPLE;OTHER:COLORECTAL_NEOPLASMS, OTHER:METASTATIC_NEOPLASM;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATOMOXETINE;CYP2D6;;CYP2D6 POOR_METABOLIZER;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;CHILDREN;DISEASE:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY;CAUTION_SIDE_EFFECT
VINCRISTINE;NRG3;T;rs12253008;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES;CHILDREN;OTHER:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN;UGT1A1;*28/*28 + *6/*6 + *6/*28;UGT1A1*1, UGT1A1*6, UGT1A1*28;EFFICACY;DECREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;OTHER:COLORECTAL_NEOPLASMS, OTHER:METASTATIC_NEOPLASM;LIKELIHOOD_THERAPEUTIC_FAILURE
AZATHIOPRINE;TPMT;*1/*3A + *1/*3B + *1/*3C + *3A/*3B;TPMT*1, TPMT*3A, TPMT*3B, TPMT*3C;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA, SIDE_EFFECT:MYELOSUPPRESSION;PEOPLE;OTHER:INFLAMMATORY_BOWEL_DISEASES;CAUTION_SIDE_EFFECT
MERCAPTOPURINE, METHOTREXATE;TPMT;;TPMT INTERMEDIATE_METABOLIZER;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DISCONTINUATION;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
VINCRISTINE;LRRTM3;G;rs10997459;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES;CHILDREN;OTHER:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
AZATHIOPRINE;TPMT;*1/*3A + *1/*3C;TPMT*1, TPMT*3A, TPMT*3C;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;OTHER:INFLAMMATORY_BOWEL_DISEASES;CAUTION_SIDE_EFFECT
VINCRISTINE;ARHGAP5;G;rs8006511;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES;CHILDREN;OTHER:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
MERCAPTOPURINE, METHOTREXATE;TPMT;;TPMT NORMAL_METABOLIZER;EFFICACY;INCREASED;RISK;EFFICACY:RECURRENCE;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
NICOTINE;CYP2A6;CC;rs28399433;TOXICITY;DECREASED;SEVERITY;OTHER:TOBACCO_USE_DISORDER;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
VINCRISTINE;METTL8;G;rs79802223;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES;CHILDREN;OTHER:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:DEATH, EFFICACY:STROKE, EFFICACY:HEART_FAILURE, EFFICACY:MYOCARDIAL_INFARCTION;PEOPLE;OTHER:ACUTE_CORONARY_SYNDROME;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;UGT1A1;CT;rs4148325;METABOLISM/PK;DECREASED;LIKELIHOOD;OTHER:NEONATAL_HYPERBILIRUBINEMIA;INFANTS;;CAUTION_DOSE_ADJUST
NAN;UGT1A1;G;rs11888492;METABOLISM/PK;DECREASED;LIKELIHOOD;OTHER:NEONATAL_HYPERBILIRUBINEMIA;INFANTS;;CAUTION_DOSE_ADJUST
NALOXONE;OPRM1;AG + GG;rs1799971;EFFICACY;INCREASED;;EFFICACY:CORTISOL_RESPONSE;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN;CERS6;T;rs13022792;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:OTOTOXICITY;CHILDREN;OTHER:NEOPLASMS;CAUTION_SIDE_EFFECT
CISPLATIN;TLR4;C;rs10759932;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:OTOTOXICITY;CHILDREN;OTHER:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
VINCRISTINE;NFIB;G;rs10961381;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES;CHILDREN;OTHER:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIARRHYTHMICS, CLASS I AND III;;GT + TT;rs10033464;EFFICACY;INCREASED;;EFFICACY:RECURRENCE;PEOPLE;DISEASE:ATRIAL_FIBRILLATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
VINCRISTINE;MCM3AP;T;rs1815857;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES;CHILDREN;OTHER:NEOPLASMS;CAUTION_SIDE_EFFECT
VINCRISTINE;SPDYA;T;rs12474420;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES;CHILDREN;OTHER:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
VINCRISTINE;PDE4D;C;rs12658429;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES;CHILDREN;OTHER:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
VINCRISTINE;FBN2;T;rs12656510;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES;CHILDREN;OTHER:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
VINCRISTINE;VTI1A;T;rs17129858;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES;CHILDREN;OTHER:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
VINCRISTINE;ZFAND3;C;rs200858088;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES;CHILDREN;OTHER:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIINFLAMMATORY AGENTS, NON-STEROIDS;HLA-DRB1;*11:01;HLA-DRB1*11:01;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ANAPHYLAXIS;;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1, CYP2C19*2;TOXICITY;INCREASED;RISK;EFFICACY:PERIPHERAL_VASCULAR_DISEASES;;;CAUTION_SIDE_EFFECT
MYCOPHENOLATE MOFETIL, PREDNISONE, TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;OTHER;INCREASED;LIKELIHOOD;SIDE_EFFECT:VIRUS_DISEASES;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
SIROLIMUS;ABCB1;AA + AG;rs1045642;TOXICITY;INCREASED;;SIDE_EFFECT:LOW-DENSITY_LIPOPROTEIN_CHOLESTEROL;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
ACETAMINOPHEN / CODEINE;CYP2D6;;CYP2D6 POOR_METABOLIZER;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:CONSTIPATION;PEOPLE;OTHER:POSTOPERATIVE_PAIN;LIKELIHOOD_THERAPEUTIC_SUCCESS
RASBURICASE;G6PD;;G6PD DEFICIENCY;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HEMOLYTIC_ANEMIA;PEOPLE;OTHER:HYPERURICEMIA;CAUTION_SIDE_EFFECT
NEVIRAPINE;CYP2B6;*1/*6 + *6/*6;CYP2B6*1, CYP2B6*6;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;PEOPLE;OTHER:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;*1/*6 + *6/*6;CYP2B6*1, CYP2B6*6;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;PEOPLE;OTHER:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
SIROLIMUS;ABCB1;AA;rs1128503;TOXICITY;INCREASED;;SIDE_EFFECT:TRIGLYCERIDES;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ATRIAL_FIBRILLATION;PEOPLE;OTHER:CORONARY_DISEASE, OTHER:SURGERY;CAUTION_SIDE_EFFECT
RISPERIDONE;CYP2D6;;CYP2D6 POOR_METABOLIZER;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS;CHILDREN;;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;*5/*7 + *5/*6 + *6/*6;NAT2*5, NAT2*6, NAT2*7;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;PEOPLE;OTHER:TUBERCULOSIS;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*1/*3;CYP3A5*1, CYP3A5*3;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DECREASED_GLOMERULAR_FILTRATION_RATE;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
ADALIMUMAB, AMIODARONE, BEVACIZUMAB, BICALUTAMIDE, CARBOPLATIN, CYCLOPHOSPHAMIDE, DOCETAXEL, ERLOTINIB, EVEROLIMUS, FLUOROURACIL, GEFITINIB, GEMCITABINE, IRINOTECAN, LEUCOVORIN, METHOTREXATE, OXALIPLATIN, PACLITAXEL, PEMBROLIZUMAB, SITAGLIPTIN, TEGAFUR / GIMERACIL / OTERACIL, TRASTUZUMAB;HLA-DRB1;*04:05;HLA-DRB1*04:05;TOXICITY;INCREASED;RISK;SIDE_EFFECT:INTERSTITIAL_LUNG_DISEASES;;;CAUTION_SIDE_EFFECT
TAMSULOSIN;CYP2D6;;CYP2D6 INTERMEDIATE_METABOLIZER;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:INTERSTITIAL_LUNG_DISEASES;MEN;;CAUTION_SIDE_EFFECT
ANASTROZOLE, EXEMESTANE, LETROZOLE;CCDC148;CT + TT;rs79048288;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:MUSCULOSKELETAL_PAIN;WOMEN;OTHER:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED;RISK;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME, SIDE_EFFECT:ERYTHEMA_MULTIFORME;PEOPLE;DISEASE:HYPERURICEMIA;CAUTION_SIDE_EFFECT
PEMETREXED;DHFR;AA + AG;rs1650697;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA, DISEASE:MESOTHELIOMA;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*3/*3 + *3/*6 + *3/*7 + *6/*6 + *6/*7 + *7/*7;CYP3A5*1, CYP3A5*3, CYP3A5*6, CYP3A5*7;EFFICACY;;;EFFICACY:DECREASED_GLOMERULAR_FILTRATION_RATE;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP2C8;*1/*1;CYP2C8*1, CYP2C8*3;EFFICACY;;;EFFICACY:DECREASED_GLOMERULAR_FILTRATION_RATE;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
FLUOROURACIL, FOLFIRI, FOLFOX;DPYD;c.85T>C (*9A)/c.85T>C (*9A);DPYD C.85T>C (*9A);TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA, SIDE_EFFECT:LEUKOPENIA, SIDE_EFFECT:THROMBOCYTOPENIA;PEOPLE;OTHER:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
LACOSAMIDE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:SOMNOLENCE, SIDE_EFFECT:DIZZINESS, SIDE_EFFECT:DRUG_TOXICITY;CHILDREN;OTHER:EPILEPSY;CAUTION_SIDE_EFFECT
FLUOROURACIL, FOLFIRI, FOLFOX;DPYD;c.1627A>G (*5)/c.1627A>G (*5);DPYD C.1627A>G (*5);TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA, SIDE_EFFECT:LEUKOPENIA, SIDE_EFFECT:THROMBOCYTOPENIA;PEOPLE;OTHER:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE;HLA-A;*31:01;HLA-A*31:01;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;;;CAUTION_SIDE_EFFECT
ASPIRIN;PTGS2;GG;rs12042763;EFFICACY;DECREASED;RISK;DISEASE:PROSTATIC_NEOPLASMS;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;SLCO1B1;*37/*37 + *37/*15;SLCO1B1*1, SLCO1B1*15, SLCO1B1*37;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;PEOPLE;OTHER:PRECURSOR_T-CELL_LYMPHOBLASTIC_LEUKEMIA-LYMPHOMA, OTHER:OSTEOSARCOMA,OTHER:NON-HODGKIN_LYMPHOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;CYP2A6;G;rs56267346;OTHER;DECREASED;LIKELIHOOD;OTHER:SMOKING_CESSATION;WOMEN;OTHER:TOBACCO_USE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
NAN;DBH;C;rs6479643;OTHER;DECREASED;LIKELIHOOD;OTHER:SMOKING_CESSATION;WOMEN;OTHER:TOBACCO_USE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;*16 + *6 + *7;NAT2*6, NAT2*7, NAT2*16;TOXICITY, METABOLISM/PK;INCREASED;RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;*16 + *6 + *7;NAT2*4, NAT2*6, NAT2*7, NAT2*16;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;*16 + *5 + *6 + *7 + *14;NAT2*1, NAT2*4, NAT2*5, NAT2*6, NAT2*7, NAT2*14, NAT2*16;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
FLURBIPROFEN, IRINOTECAN;UGT1A1;*1/*36;UGT1A1*1, UGT1A1*36;EFFICACY;DECREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;OTHER:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
ISONIAZID, RIFAMPIN;NAT2;*5/*5 + *5/*6 + *5/*7 + *6/*6 + *6/*7 + *6/*14 + *7/*7;NAT2*1, NAT2*5, NAT2*6, NAT2*7, NAT2*14;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;PEOPLE;OTHER:TUBERCULOSIS;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:GRAFT_VS_HOST_DISEASE;PEOPLE;OTHER:HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
IRINOTECAN;UGT1A1;A;rs4148323;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DIARRHEA;PEOPLE;DISEASE:LUNG_NEOPLASMS;CAUTION_SIDE_EFFECT
NAN;CASP9;T;rs1052576;EFFICACY;INCREASED;SEVERITY;EFFICACY:LEUKOCYTOSIS;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
CAPECITABINE, FLUOROURACIL;DPYD;AA + AG;rs1801265;TOXICITY;DECREASED;;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN;UGT1A1;A;rs4148323;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA;PEOPLE;DISEASE:LUNG_NEOPLASMS;CAUTION_SIDE_EFFECT
CYCLOSPORINE, METHOTREXATE;SLC19A1;CC;rs1051266;EFFICACY;DECREASED;RISK;SIDE_EFFECT:GRAFT_VS_HOST_DISEASE;PEOPLE;OTHER:HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOSPORINE, METHOTREXATE;ATIC;CC;rs17514110;EFFICACY;INCREASED;RISK;SIDE_EFFECT:GRAFT_VS_HOST_DISEASE;PEOPLE;OTHER:HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION;CAUTION_SIDE_EFFECT
CYCLOSPORINE, METHOTREXATE;NFATC2;TT;rs3787186;EFFICACY;INCREASED;RISK;SIDE_EFFECT:GRAFT_VS_HOST_DISEASE;PEOPLE;OTHER:HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION;CAUTION_SIDE_EFFECT
CYCLOSPORINE, METHOTREXATE;ABCC2;AA;rs3740065;EFFICACY;INCREASED;RISK;SIDE_EFFECT:GRAFT_VS_HOST_DISEASE;PEOPLE;OTHER:HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION;CAUTION_SIDE_EFFECT
CETUXIMAB;FCGR3A;CC;rs396991;EFFICACY;INCREASED;;EFFICACY:ANTIBODY-DEPENDENT_CELLULAR_CYTOTOXICITY;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOSPORINE, METHOTREXATE;ABCC1;AA;rs8058040;EFFICACY;INCREASED;RISK;SIDE_EFFECT:GRAFT_VS_HOST_DISEASE;PEOPLE;OTHER:HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION;CAUTION_SIDE_EFFECT
CARBAMAZEPINE, LAMOTRIGINE, PHENYTOIN;HLA-A;*24:02;HLA-A*24:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE, LAMOTRIGINE, PHENYTOIN;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME, SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS;;;CAUTION_SIDE_EFFECT
ATAZANAVIR, EFAVIRENZ;TPH2;GG;rs7305115;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:DEPRESSION;MEN;OTHER:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
CARBAMAZEPINE, LAMOTRIGINE, PHENYTOIN;HLA-A;*01:02;HLA-A*01:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS;;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE, LAMOTRIGINE, PHENYTOIN;HLA-B;*52:01;HLA-B*52:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS;;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE, LAMOTRIGINE, PHENYTOIN;HLA-DRB1;*03:01;HLA-DRB1*03:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS;;;CAUTION_SIDE_EFFECT
ATAZANAVIR, EFAVIRENZ;TPH2;GG;rs1386493;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:DEPRESSION;MEN;OTHER:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
CARBAMAZEPINE, LAMOTRIGINE, PHENYTOIN;HLA-DRB1;*13:01;HLA-DRB1*13:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;;;CAUTION_SIDE_EFFECT
CAPECITABINE;ENOSF1;TT;rs2612091;EFFICACY;INCREASED;;EFFICACY:RECURRENCE_FREE_SURVIVAL;PEOPLE;OTHER:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE, LAMOTRIGINE, PHENYTOIN;HLA-A;*02:01;HLA-A*02:01;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE, LAMOTRIGINE, PHENYTOIN;HLA-B;*40:02;HLA-B*40:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS;;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE, LAMOTRIGINE, PHENYTOIN;HLA-A;*31:03;HLA-A*31:03;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBOPLATIN, PACLITAXEL;OPRM1;GG + GT;rs544093;EFFICACY;DECREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;OTHER:OVARIAN_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
MYCOPHENOLATE MOFETIL;IMPDH1;T;rs2228075;EFFICACY, TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:GI_INTOLERANCE;CHILDREN;DISEASE:ORGAN_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE, FLUOROURACIL;DPYD;CT + TT;rs1801160;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY, SIDE_EFFECT:NEUTROPENIA;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;;NAT2 SLOW_ACETYLATOR;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE;PEOPLE;OTHER:TUBERCULOSIS;CAUTION_SIDE_EFFECT
ERLOTINIB, GEFITINIB;USP36;CC;rs3744797;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
OSIMERTINIB;HLA-B;*51:02;HLA-B*51:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME, SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS;PEOPLE;OTHER:LUNG_NEOPLASMS;CAUTION_SIDE_EFFECT
DEXMEDETOMIDINE;CACNB2;CT;rs10764319;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:BRADYCARDIA, SIDE_EFFECT:HYPOTENSIVE_DISORDER;CHILDREN;OTHER:SURGERY;LIKELIHOOD_THERAPEUTIC_SUCCESS
DEXMEDETOMIDINE;CACNA2D2;AA;rs2236957;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:BRADYCARDIA, SIDE_EFFECT:HYPOTENSIVE_DISORDER;CHILDREN;OTHER:SURGERY;LIKELIHOOD_THERAPEUTIC_SUCCESS
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;;NAT2 SLOW_ACETYLATOR;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;;;CAUTION_SIDE_EFFECT
DEXMEDETOMIDINE;UGT2B10;AA;rs1841042;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:BRADYCARDIA, SIDE_EFFECT:HYPOTENSIVE_DISORDER;CHILDREN;OTHER:SURGERY;LIKELIHOOD_THERAPEUTIC_SUCCESS
DEXMEDETOMIDINE;ADRA2B;AA + CC;rs3813662;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:BRADYCARDIA, SIDE_EFFECT:HYPOTENSIVE_DISORDER;CHILDREN;OTHER:SURGERY;CAUTION_SIDE_EFFECT
METHYLPHENIDATE;CES1;T;rs2307227;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS;CHILDREN;OTHER:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY;CAUTION_SIDE_EFFECT
PURINE ANALOGUES;NUDT15;*1/*3;NUDT15*1, NUDT15*3;TOXICITY;INCREASED;RISK;SIDE_EFFECT:MYELOSUPPRESSION;PEOPLE;OTHER:INFLAMMATORY_BOWEL_DISEASES;CAUTION_SIDE_EFFECT
CLOPIDOGREL;THSD7A;G;rs7807369;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;;C;rs1149515;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY, EFFICACY:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE);;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ONDANSETRON;CYP2D6;;CYP2D6 NORMAL_METABOLIZER;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:POSTOPERATIVE_NAUSEA_AND_VOMITING;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;ERAP2;TT;rs17524572;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;PEOPLE;OTHER:TUBERCULOSIS;CAUTION_SIDE_EFFECT
MYCOPHENOLATE MOFETIL;UGT1A8;CC;rs1042597;TOXICITY;INCREASED;RISK;DISEASE:DIARRHEA;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
PEMBROLIZUMAB;HLA-DRB1;*13:01;HLA-DRB1*13:01;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;OTHER:ADENOCARCINOMA, OTHER:NON-SMALL_CELL_LUNG_CARCINOMA,OTHER:CARCINOMA_ SQUAMOUS_CELL, OTHER:NEUROENDOCRINE_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
PEMBROLIZUMAB;HLA-DPB1;*02:02;HLA-DPB1*02:02;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:PNEUMONITIS;PEOPLE;OTHER:ADENOCARCINOMA, OTHER:NON-SMALL_CELL_LUNG_CARCINOMA,OTHER:CARCINOMA_ SQUAMOUS_CELL, OTHER:NEUROENDOCRINE_CARCINOMA;CAUTION_SIDE_EFFECT
CAPECITABINE, FLUOROURACIL;DPYD;CT;rs1801158;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
MORPHINE;SLC22A1;del/del;rs72552763;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HYPOVENTILATION;CHILDREN;;CAUTION_SIDE_EFFECT
DRUGS FOR TREATMENT OF TUBERCULOSIS;GSTM1;;GSTM1 NON-NULL, GSTM1 NULL;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;;;CAUTION_SIDE_EFFECT
NAN;CASP9;C;rs4661636;EFFICACY;INCREASED;SEVERITY;EFFICACY:LEUKOCYTOSIS;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
NAN;CASP8;G;rs6736233;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:RECURRENCE;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOZAPINE;LEPR;AG + GG;rs6657868;TOXICITY;INCREASED;RISK;SIDE_EFFECT:PNEUMONIA;PEOPLE;OTHER:SCHIZOPHRENIA, OTHER:SCHIZOAFFECTIVE_DISORDER;CAUTION_SIDE_EFFECT
CLOZAPINE;CYP1A2;AA;rs762551;TOXICITY;INCREASED;RISK;DISEASE:SEIZURES;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
CISPLATIN, PACLITAXEL;GGT1;CC;rs2017869;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA, SIDE_EFFECT:LEUKOPENIA;PEOPLE;OTHER:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN;TPMT;T;rs12201199;TOXICITY;INCREASED;RISK;DISEASE:OTOTOXICITY;CHILDREN;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
NAN;UGT1A1;A;rs4148323;OTHER;INCREASED;LIKELIHOOD;OTHER:GILBERT_SYNDROME, OTHER:CRIGLER-NAJJAR_SYNDROME;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOZAPINE;LEPR, LEPROT;AA;rs1137101;TOXICITY;INCREASED;RISK;SIDE_EFFECT:PNEUMONIA;PEOPLE;OTHER:SCHIZOPHRENIA, OTHER:SCHIZOAFFECTIVE_DISORDER;CAUTION_SIDE_EFFECT
DOLUTEGRAVIR;NR1I2;CT + TT;rs2472677;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:DISCONTINUATION, SIDE_EFFECT:ADVERSE_EVENTS;PEOPLE;OTHER:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN;TPMT;T;rs1800460;TOXICITY;INCREASED;RISK;DISEASE:OTOTOXICITY;CHILDREN;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
CLOZAPINE;LEPR;GG;rs1805096;TOXICITY;INCREASED;RISK;SIDE_EFFECT:PNEUMONIA;PEOPLE;OTHER:SCHIZOPHRENIA, OTHER:SCHIZOAFFECTIVE_DISORDER;CAUTION_SIDE_EFFECT
CLOZAPINE;LEPR;AC + CC;rs9436746;TOXICITY;INCREASED;RISK;SIDE_EFFECT:PNEUMONIA;PEOPLE;OTHER:SCHIZOPHRENIA, OTHER:SCHIZOAFFECTIVE_DISORDER;CAUTION_SIDE_EFFECT
RISPERIDONE;DRD2;AA + AG;rs1800497;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:WEIGHT_GAIN;PEOPLE;OTHER:PSYCHOTIC_DISORDER;CAUTION_SIDE_EFFECT
NAN;UGT1A1;A;rs35350960;OTHER;INCREASED;LIKELIHOOD;OTHER:GILBERT_SYNDROME, OTHER:CRIGLER-NAJJAR_SYNDROME;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN;TPMT;C;rs1142345;TOXICITY;INCREASED;RISK;DISEASE:OTOTOXICITY;CHILDREN;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
WARFARIN;ASPH;T;rs4379440;EFFICACY;DECREASED;;EFFICACY:TIME_IN_THERAPEUTIC_RANGE;;;LIKELIHOOD_THERAPEUTIC_FAILURE
CARBOPLATIN, PACLITAXEL;SLCO1B3;AA;rs7311358;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;OTHER:OVARIAN_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN, CLOPIDOGREL, TICAGRELOR;PEAR1;AA + AG;rs12041331;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HEMORRHAGE;PEOPLE;OTHER:STROKE;CAUTION_SIDE_EFFECT
CAPECITABINE, FLUOROURACIL;DPYD;AT;rs67376798;TOXICITY;INCREASED;;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;G;rs1801131;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:NEUROTOXICITY;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;ITPA;AC;rs1127354;TOXICITY;INCREASED;RISK;SIDE_EFFECT:GASTROINTESTINAL_DISTURBANCES_IN_HCV-HIV_COINFECTED_PATIENTS;;;CAUTION_SIDE_EFFECT
HMG_COA_REDUCTASE_INHIBITORS;CETP;A;rs3764261;EFFICACY, METABOLISM/PK;INCREASED;;OTHER:HDL_CHOLESTEROL;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PYRIMIDINE ANALOGUES;MTHFR;AA + AC;rs1801133;NAN;INCREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;OTHER:COLORECTAL_NEOPLASMS;CAUTION_DOSE_ADJUST
METHOTREXATE;ITPA;A;rs1127354;TOXICITY;;;SIDE_EFFECT:GASTROINTESTINAL_TOXICITIES;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_DOSE_ADJUST
GEFITINIB;ABCB1;AA;rs1128503;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:EXANTHEMA;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;CTLA4;A;rs231775;EFFICACY;INCREASED;;EFFICACY:RAPID_VIROLOGICAL_RESPONSE_(RVR)_IN_HCV-HIV_COINFECTED_PATIENTS;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAFFEINE;;T;rs4410790;OTHER;;;OTHER:HABITUAL_CONSUMPTION;;;CAUTION_DOSE_ADJUST
LIRAGLUTIDE;GLP1R;AA + AG;rs6923761;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:WEIGHT_LOSS;PEOPLE;OTHER:DIABETES_MELLITUS_T2, OTHER:OBESITY;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHAMPHETAMINE;ESR1;CC;rs2234693;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:PSYCHOTIC_DISORDER;MEN;;CAUTION_SIDE_EFFECT
NAN;ABCG8;CG;rs11887534;OTHER;INCREASED;RISK;DISEASE:CORONARY_ARTERY_DISEASE;;;CAUTION_SIDE_EFFECT
PLATINUM;ERCC5;GG;rs17655;EFFICACY;INCREASED;;EFFICACY:SURVIVAL;WOMEN;DISEASE:OVARIAN_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM;ERCC5;GG;rs17655;EFFICACY;DECREASED;;EFFICACY:SURVIVAL;WOMEN;DISEASE:OVARIAN_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;HTR2C;T;rs3813929;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:WEIGHT_GAIN;CHILDREN;DISEASE:AUTISM_SPECTRUM_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
PACLITAXEL;FGD4;A;rs10771973;TOXICITY;INCREASED;RISK;SIDE_EFFECT:SENSORY_PERIPHERAL_NEUROPATHY;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
CAFFEINE;CYP1A1;T;rs2470893;OTHER;;;OTHER:HABITUAL_CONSUMPTION;;;CAUTION_DOSE_ADJUST
CITALOPRAM;SLC6A4;C;rs25531;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:SIDE_EFFECTS;PEOPLE;DISEASE:DEMENTIA;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;SOCS3;AG;rs4969170;TOXICITY;DECREASED;RISK;SIDE_EFFECT:NEUTROPENIA_IN_HCV-HIV_COINFECTED_PATIENTS;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
MIDAZOLAM;POR;TT;rs1057868;OTHER, METABOLISM/PK;INCREASED;;PK:METABOLIC_RATIO_OF_MIDAZOLAM;;;CAUTION_DOSE_ADJUST
ENALAPRIL;PNPT1;G;rs13009649;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:COUGH;PEOPLE;OTHER:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;ITPA;A;rs1127354;EFFICACY;;;EFFICACY:RESPONSE_TO_METHOTREXATE;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_DOSE_ADJUST
NICOTINE;HTR3B;CT + TT;rs11606194;TOXICITY;INCREASED;SEVERITY;OTHER:TOBACCO_USE_DISORDER;;;CAUTION_SIDE_EFFECT
ASPIRIN;SLC6A12;A;rs499368;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:ASTHMA;PEOPLE;DISEASE:ASTHMA;CAUTION_SIDE_EFFECT
GEFITINIB;ABCB1;AA;rs1045642;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DIARRHEA;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
WARFARIN;CYP4F2;GG;rs2189784;EFFICACY;DECREASED;;EFFICACY:TIME_TO_THERAPEUTIC_INR;;;LIKELIHOOD_THERAPEUTIC_FAILURE
ASPIRIN;SLC6A12;G;rs557881;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:ASTHMA;PEOPLE;DISEASE:ASTHMA;CAUTION_SIDE_EFFECT
PLATINUM COMPOUNDS;WIF1;GG + GT;rs10878232;EFFICACY;DECREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIEPILEPTICS;ABCB1;G;rs1045642;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:NON-RESPONSE;PEOPLE;DISEASE:EPILEPSY;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTHRACYCLINES AND RELATED SUBSTANCES;CBR3;AG;rs1056892;TOXICITY;INCREASED;RISK;SIDE_EFFECT:CARDIOTOXICITY;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
PLATINUM COMPOUNDS;WNT5B;AG + GG;rs12819505;EFFICACY;DECREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
PLATINUM COMPOUNDS;AXIN2;AA + AC;rs4541111;EFFICACY;INCREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
MERCAPTOPURINE, METHOTREXATE;PACSIN2;T;rs2413739;TOXICITY;INCREASED;;SIDE_EFFECT:GI_TOXICITY;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;SLCO1B1;T;rs11045879;TOXICITY;INCREASED;;SIDE_EFFECT:GI_TOXICITY;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
MERCAPTOPURINE, METHOTREXATE;ITPA;CC;rs1127354;EFFICACY;INCREASED;;EFFICACY:EVENT_FREE_SURVIVAL;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM COMPOUNDS;CXXC4;AA + AG;rs4413407;EFFICACY;DECREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
ENALAPRIL;PNPT1;C;rs13015243;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:COUGH;PEOPLE;OTHER:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
AZATHIOPRINE, MERCAPTOPURINE, THIOGUANINE;;T;rs11969064;TOXICITY;INCREASED;RISK;SIDE_EFFECT:MYELOSUPPRESSION;PEOPLE;DISEASE:INFLAMMATORY_BOWEL_DISEASES;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;T;rs8099917;EFFICACY;INCREASED;;EFFICACY:RESPONSE_(SVR_AND_RVR)_IN_HCV-HIV_COINFECTED_PATIENTS;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM COMPOUNDS;ERCC2;GG;rs13181;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:PNEUMONITIS;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
PLATINUM COMPOUNDS;ERCC2;CT + TT;rs1799793;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:PNEUMONITIS;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
DOXORUBICIN;NCF4;AA + AG;rs1883112;TOXICITY;INCREASED;RISK;SIDE_EFFECT:CARDIOTOXICITY;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
AMPHETAMINE;DRD2;AA;rs12364283;EFFICACY;DECREASED;;OTHER:STOP_REACTION_TIME;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIEPILEPTICS;ABCB1;AA;rs1045642;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:DRUG-RESISTANCE;PEOPLE;DISEASE:EPILEPSY;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIEPILEPTICS;ABCB1;GG;rs1045642;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:DRUG-RESISTANCE;PEOPLE;DISEASE:EPILEPSY;LIKELIHOOD_THERAPEUTIC_SUCCESS
PAROXETINE;HTR2A;GG;rs6313;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DISCONTINUATIONS_DUE_TO_ADVERSE_EVENTS_AND_GREATER_SEVERITY_OF_SIDE_EFFECTS;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CD80;AA;rs34394661;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY;PEOPLE;OTHER:ACUTE_CORONARY_SYNDROME;LIKELIHOOD_THERAPEUTIC_SUCCESS
MYCOPHENOLATE MOFETIL;UGT1A9;A;rs6714486;METABOLISM/PK;;;PK:CHANGES_IN_MYCOPHENOLIC_ACID_EXPOSURE-RELATED_PARAMETERS_ON_DAY_7_AFTER_TRANSPLANTATION_(TREATMENT_WITH_2G_PER_DAY);PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
CARBAMAZEPINE;;TT;rs1633021;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;;;CAUTION_SIDE_EFFECT
PLATINUM COMPOUNDS;AXIN2;CC + CG;rs11868547;EFFICACY;INCREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
MYCOPHENOLATE MOFETIL;UGT1A9;T;rs17868320;METABOLISM/PK;;;PK:CHANGES_IN_MYCOPHENOLIC_ACID_EXPOSURE-RELATED_PARAMETERS_ON_DAY_7_AFTER_TRANSPLANTATION_(TREATMENT_WITH_2G_PER_DAY);PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
MORPHINE;ABCB1;GG;rs1045642;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:NAUSEA, SIDE_EFFECT:VOMITING;PEOPLE;DISEASE:POSTOPERATIVE_PAIN;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOSPORINE, MYCOPHENOLATE MOFETIL;UGT1A8;CC;rs1042597;TOXICITY;INCREASED;RISK;DISEASE:DIARRHEA;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
TACROLIMUS;IL10;AA;rs1800871;METABOLISM/PK;INCREASED;LIKELIHOOD;PK:ACHIEVING_TARGET_CONCENTRATIONS;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
METHOTREXATE;ARID5B;CC + CT;rs4948496;TOXICITY;INCREASED;RISK;SIDE_EFFECT:LEUKOPENIA;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
NAN;CYP2B6;AA;rs3760657;OTHER;DECREASED;LIKELIHOOD;OTHER:SMOKING_CESSATION;PEOPLE;OTHER:TOBACCO_USE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
FOLLITROPIN BETA, THYROTROPIN ALFA, UROFOLLITROPIN;FSHR;T;rs6166;EFFICACY, METABOLISM/PK;;;EFFICACY:GOOD_RESPONSE_TO_CONTROLLED_OVARIAN_HYPERSTIMULATION;;;CAUTION_DOSE_ADJUST
ASPIRIN, CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;EFFICACY, OTHER;INCREASED;RISK;DISEASE:THROMBOTIC_DISEASE;PEOPLE;OTHER:PERCUTANEOUS_CORONARY_INTERVENTION;CAUTION_SIDE_EFFECT
NAN;UGT2B10;CC;rs11726322;OTHER;INCREASED;LIKELIHOOD;OTHER:SMOKING_CESSATION;PEOPLE;OTHER:TOBACCO_USE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;F5;T;rs6025;TOXICITY;INCREASED;RISK;SIDE_EFFECT:VENOUS_THROMBOEMBOLISM;WOMEN;;CAUTION_SIDE_EFFECT
ASPIRIN, CLOPIDOGREL;CYP2C19;CT + TT;rs12248560;EFFICACY, OTHER;DECREASED;RISK;DISEASE:THROMBOTIC_DISEASE;PEOPLE;OTHER:PERCUTANEOUS_CORONARY_INTERVENTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;F2;A;rs1799963;TOXICITY;INCREASED;RISK;SIDE_EFFECT:VENOUS_THROMBOEMBOLISM;WOMEN;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;ABCB1;AG;rs1045642;EFFICACY;INCREASED;;EFFICACY:PLATELET_REACTIVITY;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE, FLUOROURACIL;TYMP;AA + AG;rs11479;TOXICITY;INCREASED;RISK;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
WARFARIN;CYP4F2;CT + TT;rs2108622;METABOLISM/PK;INCREASED;;PK:PLASMA_MK-4_CONCENTRATION;CHILDREN;;CAUTION_DOSE_ADJUST
CAPECITABINE, FLUOROURACIL;DPYD;AT;rs67376798;TOXICITY;INCREASED;RISK;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
CAPECITABINE, FLUOROURACIL;DPYD;CT;rs3918290;TOXICITY;INCREASED;RISK;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
CAPECITABINE, FLUOROURACIL;DPYD;CG;rs75017182;TOXICITY;INCREASED;RISK;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
ALENDRONATE;VDR;CC;rs1544410;EFFICACY;INCREASED;;EFFICACY:BONE_MINERAL_DENSITY;PEOPLE;DISEASE:OSTEOPOROSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
FENOFIBRATE;PPARA;TT;rs135543;EFFICACY;INCREASED;;EFFICACY:REDUCTION_IN_FASTING_LDL-C;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FENOFIBRATE;PPARA;CC + CT;rs9626730;EFFICACY;DECREASED;;EFFICACY:REDUCTION_IN_FASTING_IL-2;;;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP4F2;CT + TT;rs2108622;DOSAGE;DECREASED;;OTHER:WARFARIN_SENSITIVITY_INDEX_(INR/CPSS);CHILDREN;;CAUTION_DOSE_ADJUST
NAN;VDR;CC;rs1544410;NAN;DECREASED;;EFFICACY:BONE_MINERAL_DENSITY;PEOPLE;;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;EFFICACY;INCREASED;RISK;OTHER:MAJOR_ADVERSE_CARDIOVASCULAR_EVENTS;;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;EFFICACY;INCREASED;RISK;DISEASE:DEATH;;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;EFFICACY;INCREASED;RISK;DISEASE:THROMBOTIC_DISEASE;;;CAUTION_SIDE_EFFECT
FENOFIBRATE;PPARA;TT;rs135550;EFFICACY;INCREASED;;EFFICACY:REDUCTION_IN_FASTING_LDL-C;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ALENDRONATE;VDR;CC;rs1544410;EFFICACY;DECREASED;;EFFICACY:URINARY_DPD/CR_LEVELS;PEOPLE;DISEASE:OSTEOPOROSIS;LIKELIHOOD_THERAPEUTIC_FAILURE
EXEMESTANE;CYP19A1;TT;rs7176005;TOXICITY;;;SIDE_EFFECT:A_SIGNIFICANTLY_HIGHER_ODDS_OF_VASOMOTOR_SYMPTOMS_IN_POSTMENOPAUSAL_HORMONE_RECEPTOR_(HR)-POSITIVE_BREAST_CANCER_PATIENTS;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_DOSE_ADJUST
TACROLIMUS;PPARA;GG;rs4253728;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:ACUTE_CELLULAR_REJECTION;PEOPLE;OTHER:LIVER_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
VINCRISTINE;SLC5A7;AG + GG;rs1013940;TOXICITY;INCREASED;RISK;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;;;CAUTION_SIDE_EFFECT
ETHANOL;ADH1B;T;rs1229984;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HYPERURICEMIA;;;CAUTION_SIDE_EFFECT
VINCRISTINE;NKAIN3;A;rs10504361;TOXICITY;INCREASED;RISK;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;;;CAUTION_SIDE_EFFECT
SIMVASTATIN;SLCO1B1;C;rs4149056;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:MUSCULAR_DISEASES;PEOPLE;OTHER:CORONARY_ARTERY_DISEASE;CAUTION_SIDE_EFFECT
ATENOLOL;PROX1;C;rs340874;TOXICITY;INCREASED;;SIDE_EFFECT:GLUCOSE_ELEVATION;PEOPLE;DISEASE:HYPERTENSION;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A4;AA + AG;rs35599367;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:SEPSIS, SIDE_EFFECT:SEIZURES, SIDE_EFFECT:NEPHROTOXICITY;PEOPLE;OTHER:LIVER_TRANSPLANTATION;CAUTION_SIDE_EFFECT
ABEMACICLIB, PALBOCICLIB, RIBOCICLIB;ABCB1;AA;rs1128503;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA;WOMEN;OTHER:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
SIMVASTATIN;ABCG2;GT;rs2231142;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;PEOPLE;OTHER:CORONARY_ARTERY_DISEASE;CAUTION_SIDE_EFFECT
VINCRISTINE;ABCC1;T;rs3784867;TOXICITY;INCREASED;RISK;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;AG;rs4244285;EFFICACY;INCREASED;RISK;EFFICACY:SIGNIFICANTLY_HIGHER_ON-TREATMENT_PLATELET_REACTIVITY_WITH_A_MAINTECE_DOSE_OF_75_MG_DAILY;PEOPLE;DISEASE:CARDIOVASCULAR_DISEASE;CAUTION_SIDE_EFFECT
OPIOIDS;COMT;AA + AG;rs4680;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:SOMNOLENCE, SIDE_EFFECT:NAUSEA, SIDE_EFFECT:ADVERSE_EVENTS;PEOPLE;OTHER:PAIN, OTHER:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;IL6;CG + GG;rs1800795;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:SOMNOLENCE, SIDE_EFFECT:NAUSEA, SIDE_EFFECT:ADVERSE_EVENTS;PEOPLE;OTHER:PAIN, OTHER:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;DPYD;A;rs67376798;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:DRUG_TOXICITY;;;CAUTION_SIDE_EFFECT
SUNITINIB;CYP3A5;CT + TT;rs776746;EFFICACY;INCREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ABEMACICLIB, PALBOCICLIB, RIBOCICLIB;CYP3A4;AG;rs35599367;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY, SIDE_EFFECT:TREATMENT_INTERRUPTION;WOMEN;OTHER:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
VINCRISTINE;CEP72;TT;rs924607;TOXICITY;INCREASED;RISK;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;;;CAUTION_SIDE_EFFECT
METOPROLOL;CYP2D6;GG;rs1065852;EFFICACY;DECREASED;;EFFICACY:HEART_RATE;PEOPLE;;LIKELIHOOD_THERAPEUTIC_FAILURE
CONJUGATED ESTROGENS, MEDROXYPROGESTERONE;VDR;TT;rs1544410;EFFICACY;INCREASED;;OTHER:SPINE_BONE_MINERAL_DENSITY;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
VERAPAMIL;CACNB2;GG;rs2357928;EFFICACY, TOXICITY;INCREASED;RISK;EFFICACY:ADVERSE_OUTCOME;PEOPLE;OTHER:HYPERTENSION_AND_CORONARY_ARTERY_DISEASE;CAUTION_SIDE_EFFECT
METFORMIN;SLC47A1;CC;rs2252281;EFFICACY;INCREASED;;EFFICACY:RESPONSE_TO_METFORMIN;PEOPLE;DISEASE:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;A;rs4646450;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DISCONTINUATION;PEOPLE;OTHER:LIVER_TRANSPLANTATION;CAUTION_SIDE_EFFECT
METFORMIN;SLC47A1;CC;rs2252281;EFFICACY;INCREASED;;EFFICACY:RESPONSE_TO_METFORMIN;HEALTHY;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TRAZODONE;ABCB1;AA;rs1045642;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:PROLONGED_QTC_INTERVAL;HEALTHY;;CAUTION_SIDE_EFFECT
INTERFERONS, RIBAVIRIN;BCL2;T;rs1800477;EFFICACY;INCREASED;;EFFICACY:FREQUENCY_(ABOUT_DOUBLE)_IN_NON-RESPONDER_PATIENTS_COMPARED_WITH_RESPONDER_PATIENTS_(HCV_GENOTYPE_4);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
CETUXIMAB, FLUOROURACIL, IRINOTECAN, OXALIPLATIN;KRAS;T;rs112445441;EFFICACY;INCREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;MSH6;GG;rs3136228;TOXICITY;INCREASED;SEVERITY;DISEASE:NEUTROPENIA;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;XRCC3;CC;rs1799794;TOXICITY;INCREASED;SEVERITY;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
NAN;NR1I2;GG;rs7643645;OTHER;INCREASED;RISK;OTHER:DEATH;PEOPLE;OTHER:FATTY_LIVER_DISEASE;CAUTION_SIDE_EFFECT
PLATINUM COMPOUNDS;CCND1;AA;rs9344;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:NAUSEA, SIDE_EFFECT:VOMITING;PEOPLE;OTHER:LUNG_NEOPLASMS;CAUTION_SIDE_EFFECT
VERAPAMIL;CACNB2;AT + TT;rs11014166;EFFICACY, TOXICITY;INCREASED;RISK;EFFICACY:ADVERSE_OUTCOME;PEOPLE;OTHER:HYPERTENSION_AND_CORONARY_ARTERY_DISEASE;CAUTION_SIDE_EFFECT
FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;ABCC1;C;rs2074087;TOXICITY;DECREASED;SEVERITY;DISEASE:NEUROTOXICITY_SYNDROMES;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;;AA;rs2960436;EFFICACY;;;OTHER:BETTER_SURVIVAL_OUTCOME;PEOPLE;DISEASE:STOMACH_NEOPLASMS;CAUTION_DOSE_ADJUST
FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;ABCC2;AA;rs1885301;TOXICITY;INCREASED;SEVERITY;DISEASE:NEUROTOXICITY_SYNDROMES;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
FLUOROURACIL;IGFBP3;TT;rs2854744;EFFICACY;;;OTHER:BETTER_SURVIVAL_OUTCOME;PEOPLE;DISEASE:STOMACH_NEOPLASMS;CAUTION_DOSE_ADJUST
FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;ABCC2;TT;rs717620;TOXICITY;INCREASED;SEVERITY;DISEASE:NEUROTOXICITY_SYNDROMES;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;ABCC2;TT;rs3740066;TOXICITY;INCREASED;SEVERITY;DISEASE:NEUROTOXICITY_SYNDROMES;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
COCAINE;DRD2;C;rs1125394;TOXICITY;INCREASED;RISK;DISEASE:COCAINE_DEPENDENCE;;;CAUTION_SIDE_EFFECT
COCAINE;DRD2;A;rs1076560;TOXICITY;INCREASED;RISK;DISEASE:COCAINE_DEPENDENCE;;;CAUTION_SIDE_EFFECT
COCAINE;DRD2;A;rs2283265;TOXICITY;INCREASED;RISK;DISEASE:COCAINE_DEPENDENCE;;;CAUTION_SIDE_EFFECT
MYCOPHENOLATE MOFETIL;SLCO1B1;A;rs4149015;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ADVERSE_DRUG_REACTIONS;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;CC;rs4646453;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;CC;rs776746;EFFICACY;INCREASED;RISK;EFFICACY:TRANSPLANT_REJECTION;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
MYCOPHENOLATE MOFETIL;SLCO1B1;TT;rs4149056;TOXICITY, METABOLISM/PK;INCREASED;RISK;SIDE_EFFECT:ADVERSE_DRUG_REACTION;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
OPIOIDS;COMT;CC;rs4633;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:PHYSIOLOGICAL_SEXUAL_DISORDER;WOMEN;OTHER:PAIN;CAUTION_SIDE_EFFECT
MYCOPHENOLATE MOFETIL;SLCO1B1;C;rs4149056;TOXICITY, METABOLISM/PK;DECREASED;RISK;SIDE_EFFECT:ADVERSE_DRUG_REACTIONS;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACETAMINOPHEN / TRAMADOL;OPRM1;AG + GG;rs1799971;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:CONSTIPATION;PEOPLE;OTHER:POSTOPERATIVE_PAIN;CAUTION_SIDE_EFFECT
NAN;VDR;AA + AG;rs2228570;NAN;DECREASED;;EFFICACY:BONE_MINERAL_DENSITY;;;CAUTION_DOSE_ADJUST
OPIOIDS;COMT;CT;rs4633;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DIZZINESS;PEOPLE;OTHER:PAIN;CAUTION_SIDE_EFFECT
CAPECITABINE;ABCB1;AA;rs1128503;TOXICITY;DECREASED;RISK;SIDE_EFFECT:HAND-FOOT_SYNDROME, SIDE_EFFECT:NEUTROPENIA;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;OPRM1;G;rs1799971;TOXICITY;DECREASED;LIKELIHOOD;DISEASE:OPIOID-RELATED_DISORDERS;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE;ABCB1;CC;rs2032582;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HAND-FOOT_SYNDROME;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
OPIOIDS;OPRM1;AG + GG;rs1799971;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ERECTILE_DYSFUNCTION, SIDE_EFFECT:INSOMNIA, SIDE_EFFECT:SEDATION, SIDE_EFFECT:PHYSIOLOGICAL_SEXUAL_DISORDER, SIDE_EFFECT:VOMITING;PEOPLE;OTHER:PAIN;CAUTION_SIDE_EFFECT
FLUOROURACIL;ABCB1;GG;rs1045642;TOXICITY;DECREASED;RISK;DISEASE:DIARRHEA;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE;ABCB1;GG;rs1045642;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HAND-FOOT_SYNDROME;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;A;rs7900194;DOSAGE, METABOLISM/PK;;;OTHER:WARFARIN_VARIABILITY;;;CAUTION_DOSE_ADJUST
SUNITINIB;NR1I2;TT;rs3814055;EFFICACY;DECREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
AMPHETAMINE;OPRM1;TT;rs510769;OTHER;DECREASED;;OTHER:STIMULATION_AND_EUPHORIA_SCORES_AFTER_AMPHETAMINE;HEALTHY;;CAUTION_DOSE_ADJUST
SIMVASTATIN;SLCO1B1;CC + CT;rs4149056;TOXICITY;INCREASED;RISK;DISEASE:MUSCULAR_DISEASES;PEOPLE;DISEASE:HYPERLIPIDEMIAS;CAUTION_SIDE_EFFECT
SUNITINIB;ABCG2;CT;rs2231137;EFFICACY;INCREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;LRP5;T;rs3736228;NAN;DECREASED;;OTHER:BONE_MINERAL_DENSITY;;;CAUTION_DOSE_ADJUST
CISPLATIN;NHLH1;CT + TT;rs11265375;EFFICACY;INCREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;OTHER:SMALL_CELL_CARCINOMA, OTHER:LUNG_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;;A;rs4355801;NAN;DECREASED;;OTHER:LUMBAR_SPINE_BONE_MINERAL_DENSITY;;;CAUTION_DOSE_ADJUST
NAN;;A;rs4355801;NAN;INCREASED;RISK;DISEASE:OSTEOPOROSIS;;;CAUTION_SIDE_EFFECT
NAN;LRP5;T;rs3736228;NAN;INCREASED;RISK;DISEASE:OSTEOPOROSIS;;;CAUTION_SIDE_EFFECT
BORTEZOMIB;CBS;TT;rs915854;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES, SIDE_EFFECT:PAIN, SIDE_EFFECT:NEUROPATHIC_PAIN;PEOPLE;OTHER:MULTIPLE_MYELOMA;CAUTION_SIDE_EFFECT
NAN;UGT2B15;AA;rs3100;OTHER;INCREASED;LIKELIHOOD;OTHER:SMOKING_CESSATION;PEOPLE;OTHER:TOBACCO_USE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
AMPHETAMINE;OPRM1;CC;rs2281617;OTHER;INCREASED;;OTHER:EUPHORIC_AND_ENERGETIC_AFTER_AMPHETAMINE_(10_MG);HEALTHY;;CAUTION_DOSE_ADJUST
WARFARIN;HNF4A;CC;rs6130615;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HEMORRHAGE;;;CAUTION_SIDE_EFFECT
CISPLATIN;SEMA6A;A;rs3806915;EFFICACY;INCREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;OTHER:SMALL_CELL_CARCINOMA, OTHER:LUNG_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN, CLOPIDOGREL;ABCB1;AA;rs1045642;EFFICACY, OTHER;INCREASED;RISK;DISEASE:THROMBOTIC_DISEASE;PEOPLE;OTHER:PERCUTANEOUS_CORONARY_INTERVENTION;CAUTION_SIDE_EFFECT
WARFARIN;HNF4A;GG;rs1884613;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HEMORRHAGE;;;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN, CLOPIDOGREL;ITGB3;CC + CT;rs5918;EFFICACY, OTHER;DECREASED;RISK;DISEASE:THROMBOTIC_DISEASE;PEOPLE;OTHER:PERCUTANEOUS_CORONARY_INTERVENTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;HNF4A;TT;rs3212191;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HEMORRHAGE;;;CAUTION_SIDE_EFFECT
ONDANSETRON;SLC6A4;AA;rs1042173;EFFICACY;INCREASED;;EFFICACY:TREATMENT_RESPONSE_AMONG_PATIENTS_CARRYING_THE_SLC6A4_PROMOTER_LENGTH_POLYMORPHISM_LONG/LONG_GENOTYPE;PEOPLE;DISEASE:ALCOHOL_ABUSE;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;;G;rs61162043;OTHER;INCREASED;LIKELIHOOD;OTHER:HAVING_WARFARIN_DOSE_GREATER_THAN_7.5_MG/DAY;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RISPERIDONE;HTR2A;GG;rs6313;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:WEIGHT_GAIN;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
HEROIN;OPRM1;G;rs2075572;TOXICITY;INCREASED;RISK;DISEASE:HEROIN_DEPENDENCE;;;CAUTION_SIDE_EFFECT
RISPERIDONE;;TT;rs1805054;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:WEIGHT_GAIN;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIHYPERTENSIVES;NEDD4L;AA;rs4149601;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:RESISTANT_HYPERTENSION;PEOPLE;OTHER:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIHYPERTENSIVES;ADRB1;GG;rs1801252;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:RESISTANT_HYPERTENSION;PEOPLE;OTHER:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;MTHFR;AA + AG;rs1801133;TOXICITY;DECREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
RISPERIDONE;HTR2C;CT + TT;rs3813929;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:WEIGHT_GAIN;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
HEROIN;OPRM1;G;rs1799971;TOXICITY;INCREASED;RISK;DISEASE:HEROIN_DEPENDENCE;;;CAUTION_SIDE_EFFECT
BLEOMYCIN, CYCLOPHOSPHAMIDE, DOXORUBICIN, PREDNISONE, RITUXIMAB, VINCRISTINE, VINDESINE;ABCB1;CT;rs2229109;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DIARRHEA, SIDE_EFFECT:VOMITING;PEOPLE;DISEASE:NON-HODGKIN_LYMPHOMA;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;CYP2B6;C;rs4802101;TOXICITY;DECREASED;RISK;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY, SIDE_EFFECT:LEUKOPENIA;PEOPLE;DISEASE:LUPUS_ERYTHEMATOSUS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIHYPERTENSIVES;CYP3A5, ZSCAN25;CC;rs776746;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:RESISTANT_HYPERTENSION;PEOPLE;OTHER:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_FAILURE
CISPLATIN;XPC;GG + GT;rs2228001;TOXICITY;INCREASED;RISK;DISEASE:NEUTROPENIA;PEOPLE;DISEASE:URINARY_BLADDER_NEOPLASMS;CAUTION_SIDE_EFFECT
METHADONE;OPRM1;G;rs1799971;OTHER;DECREASED;LIKELIHOOD;DISEASE:RECURRENCE;PEOPLE;DISEASE:HEROIN_DEPENDENCE;LIKELIHOOD_THERAPEUTIC_FAILURE
NAN;CYP2C9;C;rs1057910;NAN;DECREASED;RISK;DISEASE:CORONARY_ARTERY_DISEASE;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;CYP2C9;C;rs1057910;NAN;INCREASED;RISK;DISEASE:MYOCARDIAL_INFARCTION;;;CAUTION_SIDE_EFFECT
SUFENTANIL;CYP3A4;TT;rs2242480;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HYPOVENTILATION;PEOPLE;OTHER:POSTOPERATIVE_PAIN;CAUTION_SIDE_EFFECT
NAN;ADRA2A;A;rs3750625;OTHER;INCREASED;LIKELIHOOD;DISEASE:DIABETES, GESTATIONAL;WOMEN;OTHER:PREGNANCY;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;ADRA2A;G;rs11195418;OTHER;DECREASED;LIKELIHOOD;DISEASE:DIABETES, GESTATIONAL;WOMEN;OTHER:PREGNANCY;LIKELIHOOD_THERAPEUTIC_FAILURE
MURAGLITAZAR;REN;TT;rs2368564;TOXICITY;DECREASED;RISK;DISEASE:EDEMA;PEOPLE;DISEASE:DIABETES_MELLITUS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CHLOROQUINE, PRIMAQUINE;SLCO2B1;GG;rs12422149;EFFICACY;INCREASED;SEVERITY;EFFICACY:PARASITEMIA;PEOPLE;DISEASE:MALARIA;CAUTION_SIDE_EFFECT
ASPIRIN;IL4;TT;rs2243250;OTHER;DECREASED;;SIDE_EFFECT:ASPIRIN-INDUCED_ASTHMA;PEOPLE;DISEASE:ASTHMA;CAUTION_DOSE_ADJUST
ANTIPSYCHOTICS;CNR1;CC;rs806374;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:TARDIVE_DYSKINESIA;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;AC + CC;rs1057910;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE;PEOPLE;OTHER:HEART_VALVE_REPLACEMENT;CAUTION_SIDE_EFFECT
METHOTREXATE;SLC16A7;A;rs3763980;EFFICACY;INCREASED;RISK;EFFICACY:NON-RESPONSE_TO_METHOTREXATE;CHILDREN;DISEASE:JUVENILE_RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
METFORMIN;AMHR2;G;rs784892;EFFICACY;DECREASED;;EFFICACY:POST-HBA1C_LEVELS;PEOPLE;DISEASE:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_FAILURE
ACETAMINOPHEN, ASPIRIN, DICLOFENAC, PROPIONIC ACID DERIVATIVES, PYRAZOLONES;PLA2G4A;G;rs12746200;TOXICITY;INCREASED;RISK;SIDE_EFFECT:URTICARIA;;;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;CNR1;CC;rs806374;TOXICITY;INCREASED;SEVERITY;DISEASE:TARDIVE_DYSKINESIA;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
WARFARIN;VKORC1;TT;rs9923231;EFFICACY;;;EFFICACY:SHORTER_TIME_TO_FIRST_THERAPEUTIC_INR_AND_TIME_TO_FIRST_INR>4;CHILDREN;;CAUTION_DOSE_ADJUST
FLUOROURACIL;DPYD;C;rs75017182;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
ETHANOL;OPRM1;AA;rs1799971;TOXICITY;INCREASED;RISK;DISEASE:ALCOHOL_ABUSE;;;CAUTION_SIDE_EFFECT
NEVIRAPINE;CYCSP5;A;rs3099844;TOXICITY, OTHER;INCREASED;RISK;DISEASE:STEVENS-JOHNSON_SYNDROME;WOMEN;DISEASE:ACQUIRED_IMMUNODEFICIENCY_SYNDROME;CAUTION_SIDE_EFFECT
ACETAMINOPHEN, ASPIRIN, DICLOFENAC, PROPIONIC ACID DERIVATIVES, PYRAZOLONES;PLCG1;G;rs2228246;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ANGIOEDEMA;;;CAUTION_SIDE_EFFECT
ACETAMINOPHEN, ASPIRIN, DICLOFENAC, PROPIONIC ACID DERIVATIVES, PYRAZOLONES;TNFRSF11A;C;rs1805034;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ANGIOEDEMA, SIDE_EFFECT:URTICARIA;;;CAUTION_SIDE_EFFECT
ANTIHYPERTENSIVES;NOS3;G;rs1799983;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:RESPONSE;PEOPLE;DISEASE:PRE-ECLAMPSIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIHYPERTENSIVES;NOS3;C;rs2070744;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:RESPONSE;PEOPLE;DISEASE:PRE-ECLAMPSIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;ABCB1;AG;rs1045642;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
NAN;ADRA2A;A;rs1800038;OTHER;INCREASED;LIKELIHOOD;DISEASE:DIABETES, GESTATIONAL;WOMEN;OTHER:PREGNANCY;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;T;rs776746;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DISCONTINUATION;PEOPLE;OTHER:LIVER_TRANSPLANTATION;CAUTION_SIDE_EFFECT
CISPLATIN;SLC22A1;CG + GG;rs683369;EFFICACY;INCREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;OTHER:NEOPLASM_OF_ESOPHAGUS;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;;G;rs4887074;TOXICITY;DECREASED;RISK;DISEASE:TOBACCO_USE_DISORDER;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL, IRINOTECAN, LEUCOVORIN;ABCC5;T;rs10937158;TOXICITY;DECREASED;RISK;SIDE_EFFECT:DIARRHEA;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL, IRINOTECAN, LEUCOVORIN;ABCC5;A;rs3749438;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DIARRHEA;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
FLUOROURACIL, IRINOTECAN, LEUCOVORIN;ABCG1;T;rs225440;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUTROPENIA;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
CLOPIDOGREL;PON1;CC;rs854552;EFFICACY;INCREASED;;EFFICACY:PLATELET_REACTIVITY;PEOPLE;OTHER:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL, IRINOTECAN, LEUCOVORIN;;A;rs2292997;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUTROPENIA;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
CISPLATIN;PPARD;AG + GG;rs2038067;EFFICACY;DECREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;OTHER:NEOPLASM_OF_ESOPHAGUS;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;C;rs6977165;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DISCONTINUATION;PEOPLE;OTHER:LIVER_TRANSPLANTATION;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;CYP2C19;A;rs4244285;TOXICITY;DECREASED;RISK;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY, SIDE_EFFECT:LEUKOPENIA;PEOPLE;DISEASE:LUPUS_ERYTHEMATOSUS;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;CT;rs9923231;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HEMORRHAGE;CHILDREN;;CAUTION_SIDE_EFFECT
WARFARIN;VKORC1;T;rs9923231;EFFICACY;INCREASED;;EFFICACY:PROPERTION_OF_THE_FIRST_6_MONTHS'_TREATMENT_TIME_SPENT_WITHIN_THE_TARGET_INR_RANGE_(PTIR);CHILDREN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;DPYD;CT + TT;rs3918290;TOXICITY;INCREASED;SEVERITY;DISEASE:MYELOSUPPRESSION;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
NAN;OPRM1;AA;rs1799971;TOXICITY;INCREASED;SEVERITY;DISEASE:SUBSTANCE-RELATED_DISORDERS;;;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;CT + TT;rs3918290;TOXICITY;INCREASED;SEVERITY;DISEASE:HAND-FOOT_SYNDROME;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;CT + TT;rs3918290;TOXICITY;INCREASED;SEVERITY;DISEASE:DIARRHEA;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;G;rs17376848;TOXICITY;INCREASED;RISK;DISEASE:NEUTROPENIA;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
OPIOIDS;CYP3A5;CC + CT;rs776746;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OPIOID-RELATED_DISORDERS;;;CAUTION_SIDE_EFFECT
ACETAMINOPHEN / TRAMADOL;MIR107;AA + AG;rs2296616;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:NAUSEA;PEOPLE;OTHER:POSTOPERATIVE_PAIN;LIKELIHOOD_THERAPEUTIC_SUCCESS
LITHIUM;GSK3B;AA;rs334558;EFFICACY;DECREASED;;EFFICACY:RESPONSE;PEOPLE;DISEASE:BIPOLAR_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOPHOSPHAMIDE, DOXORUBICIN, EPIRUBICIN, FLUOROURACIL, METHOTREXATE;NQO1;AA;rs1800566;TOXICITY;DECREASED;RISK;SIDE_EFFECT:ANEMIA, SIDE_EFFECT:DRUG_TOXICITY;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACETAMINOPHEN / TRAMADOL;MIR23B;GG;rs1011784;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:NAUSEA;PEOPLE;OTHER:POSTOPERATIVE_PAIN;CAUTION_SIDE_EFFECT
ACETAMINOPHEN / TRAMADOL;MIR23B;CG + GG;rs1011784;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:NEUROPATHIC_PAIN;PEOPLE;OTHER:POSTOPERATIVE_PAIN;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;CYP1A2;AA + AG;rs2069514;TOXICITY;DECREASED;RISK;SIDE_EFFECT:OPIOID-RELATED_DISORDERS;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;DRD3;AA + AG;rs2654754;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OPIOID-RELATED_DISORDERS;;;CAUTION_SIDE_EFFECT
SIMVASTATIN;SLCO1B1;CC;rs4149056;TOXICITY;INCREASED;RISK;SIDE_EFFECT:STATIN-RELATED_MYOPATHY;;;CAUTION_SIDE_EFFECT
OPIOIDS;DRD3;AG + GG;rs324029;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OPIOID-RELATED_DISORDERS;;;CAUTION_SIDE_EFFECT
METHAMPHETAMINE;FAAH;A;rs324420;TOXICITY;INCREASED;RISK;SIDE_EFFECT:METHAMPHETAMINE_DEPENDENCE;;;CAUTION_SIDE_EFFECT
OPIOIDS;CYP3A4;CC + CT;rs2740574;TOXICITY;DECREASED;RISK;SIDE_EFFECT:OPIOID-RELATED_DISORDERS;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RISPERIDONE;ABCG2;GT + TT;rs2231142;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ADVERSE_EVENTS;CHILDREN;;CAUTION_SIDE_EFFECT
ASPIRIN;UGT1A6;AC + CC;rs1105879;EFFICACY;INCREASED;RISK;DISEASE:COLONIC_NEOPLASMS;;;CAUTION_SIDE_EFFECT
ACETAMINOPHEN / TRAMADOL;OPRM1;CT + TT;rs677830;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:CONSTIPATION;PEOPLE;OTHER:POSTOPERATIVE_PAIN;CAUTION_SIDE_EFFECT
OPIOIDS;CYP3A5;AA + AG;rs15524;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OPIOID-RELATED_DISORDERS;;;CAUTION_SIDE_EFFECT
REGORAFENIB;KDR;A;rs4864950;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;OTHER:NEOPLASMS;CAUTION_SIDE_EFFECT
EFAVIRENZ, ETHAMBUTOL, ISONIAZID, RIFAMPIN;NR1I2;TT;rs2472677;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DEATH;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE, DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
WARFARIN;VKORC1;TT;rs9923231;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TIME_ABOVE_THERAPEUTIC_RANGE;PEOPLE;DISEASE:VENOUS_THROMBOEMBOLISM;CAUTION_SIDE_EFFECT
EFAVIRENZ, ETHAMBUTOL, ISONIAZID, RIFAMPIN;NR1I2;TT;rs2472677;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE, DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE, DOXORUBICIN;ABCB1;AA + TT;rs2032582;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUTROPENIA;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
TAXANES;NR1I3;CC;rs11584174;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATAZANAVIR, RITONAVIR;UGT1A1;G;rs8330;OTHER;INCREASED;RISK;SIDE_EFFECT:NEPHROLITHIASIS;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE, DOXORUBICIN;ABCB1;AC + CT;rs2032582;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUTROPENIA;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
EFAVIRENZ;CYP2B6;TT;rs28399499;TOXICITY;INCREASED;RISK;DISEASE:CENTRAL_NERVOUS_SYSTEM_DISORDER;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
NEVIRAPINE;ABCB1;TT;rs10276036;TOXICITY;INCREASED;RISK;DISEASE:DRUG_HYPERSENSITIVITY;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
TAXANES;UGT2B7;AA;rs7438284;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATAZANAVIR, RITONAVIR;UGT1A1;T;rs10929303;OTHER;INCREASED;RISK;SIDE_EFFECT:NEPHROLITHIASIS;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
TAXANES;UGT2B7;TT;rs7439366;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATAZANAVIR, RITONAVIR;UGT1A1;G;rs1042640;OTHER;INCREASED;RISK;SIDE_EFFECT:NEPHROLITHIASIS;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
TAXANES;UGT2B7;AA;rs7662029;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
TAXANES;UGT2B7;TT;rs7668258;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;TT;rs3745274;TOXICITY;INCREASED;RISK;DISEASE:CENTRAL_NERVOUS_SYSTEM_DISORDER;MEN;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;GRM3;TT;rs1468412;TOXICITY;INCREASED;RISK;SIDE_EFFECT:MEMORY_IMPAIRMENT;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
ASPIRIN, CLOPIDOGREL;PON1;CT + TT;rs662;EFFICACY;INCREASED;;EFFICACY:NON-RESPONSIVENESS;PEOPLE;DISEASE:ANGINA_PECTORIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;TT;rs9923231;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HEMORRHAGE;PEOPLE;DISEASE:VENOUS_THROMBOEMBOLISM;CAUTION_SIDE_EFFECT
RISPERIDONE;BDNF;TT;rs6265;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:WEIGHT_GAIN;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CORTICOSTEROIDS;FCER2;G;rs28364072;EFFICACY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ASTHMA-RELATED_ER_VISIT_OR_HOSPITALIZATION;CHILDREN;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL, RADIOTHERAPY;CXCL8;AA;rs4073;EFFICACY;DECREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:RECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;ABCB1;AA + AG;rs1045642;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
FLUOROURACIL, RADIOTHERAPY;KDR;AA;rs1870377;TOXICITY;;RISK;SIDE_EFFECT:MUCOSITIS;PEOPLE;DISEASE:RECTAL_NEOPLASMS;CAUTION_DOSE_ADJUST
PEGINTERFERON ALFA-2B, RIBAVIRIN;IL6;CC;rs1800795;TOXICITY;DECREASED;RISK;DISEASE:DEPRESSION;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATORVASTATIN;CYP7A1;TT;rs3808607;EFFICACY;INCREASED;;EFFICACY:MEAN_PERCENTAGE_REDUCTION_OF_TRIGLYCERIDES_LEVEL;PEOPLE;DISEASE:HYPERLIPIDEMIAS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CANGRELOR;P2RY12;G;rs6787801;OTHER;;;OTHER:5%_LOWER_ADP-INDUCED_PEAK_PLATELET_AGGREGATION_IN-VITRO;;;CAUTION_DOSE_ADJUST
NAN;APOC1, APOE;A;rs445925;METABOLISM/PK;;;PK:BASELINE_LDL_CHOLESTEROL;PEOPLE;DISEASE:VASCULAR_DISEASES;CAUTION_DOSE_ADJUST
SUNITINIB;FGFR2;AA;rs2981582;EFFICACY;DECREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
SULFAMETHOXAZOLE / TRIMETHOPRIM;NAT2;A;rs1799931;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ADVERSE_REACTIONS;CHILDREN;DISEASE:PNEUMONIA;CAUTION_SIDE_EFFECT
SUNITINIB;FLT4;CC + CT;rs307826;EFFICACY;DECREASED;;DISEASE:OVERALL_SURVIVAL;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
HEROIN;OPRM1;AG + GG;rs1799971;TOXICITY;DECREASED;RISK;DISEASE:HEROIN_DEPENDENCE;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SUNITINIB;NR1I3;AA + AG;rs2307424;EFFICACY;DECREASED;;DISEASE:OVERALL_SURVIVAL;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
NAN;FADS1, FEN1, MIR611, TMEM258;T;rs174541;METABOLISM/PK;;;PK:BASELINE_LDL_CHOLESTEROL;PEOPLE;DISEASE:VASCULAR_DISEASES;CAUTION_DOSE_ADJUST
NAN;;C;rs258494;METABOLISM/PK;;;PK:BASELINE_LDL_CHOLESTEROL;PEOPLE;DISEASE:VASCULAR_DISEASES;CAUTION_DOSE_ADJUST
NAN;LDLR;T;rs6511720;OTHER;;;PK:BASELINE_LDL_CHOLESTEROL;PEOPLE;DISEASE:VASCULAR_DISEASES;CAUTION_DOSE_ADJUST
NAN;PNMT;T;rs2934965;OTHER;DECREASED;RISK;OTHER:SICKLE_CELL_PAIN_CRISIS;PEOPLE;OTHER:SICKLE_CELL_ANEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL, LEUCOVORIN, LEVAMISOLE, RADIOTHERAPY;GSTP1;GG;rs1695;EFFICACY;DECREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:RECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
DEXAMETHASONE, LENALIDOMIDE;ABCB1;CT;rs2229109;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:MULTIPLE_MYELOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
AZATHIOPRINE;DDRGK1, ITPA;AC;rs1127354;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:NON-RESPONSE;PEOPLE;DISEASE:INFLAMMATORY_BOWEL_DISEASES;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;PNMT;GG;rs2941523;OTHER;DECREASED;RISK;OTHER:SICKLE_CELL_PAIN_CRISIS;PEOPLE;OTHER:SICKLE_CELL_ANEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
MYCOPHENOLIC ACID;SLCO1B3;GT + TT;rs4149117;EFFICACY;INCREASED;RISK;OTHER:CHRONIC_LUNG_ALLOGRAFT_DYSFUNCTION;PEOPLE;OTHER:LUNG_TRANSPLANTATION;CAUTION_SIDE_EFFECT
NAN;PNMT;AA + AG;rs876493;OTHER;DECREASED;RISK;OTHER:SICKLE_CELL_PAIN_CRISIS;WOMEN;OTHER:SICKLE_CELL_ANEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATENOLOL, BISOPROLOL;ACY3;C;rs2514036;EFFICACY;DECREASED;SEVERITY;EFFICACY:ELEVATED_DIASTOLIC_BLOOD_PRESSURE, EFFICACY:ELEVATED_SYSTOLIC_BLOOD_PRESSURE;MEN;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
LOSARTAN;KIRREL2, NPHS1;T;rs3814995;EFFICACY;DECREASED;SEVERITY;EFFICACY:ELEVATED_DIASTOLIC_BLOOD_PRESSURE;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;ADORA1;TT;rs16851030;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ASPIRIN-INTOLERANT_ASTHMA;PEOPLE;DISEASE:ASTHMA;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC AGENTS;FPGS;TT;rs1544105;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
SUNITINIB;NR1I3;AA;rs4073054;EFFICACY;DECREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
SUNITINIB;FLT4;AA + AC;rs307821;EFFICACY;DECREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
ALPRAZOLAM;CYP3A4;AG;rs35599367;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ADVERSE_EVENTS;MEN;OTHER:ALCOHOL_ABUSE, OTHER:ANXIETY_DISORDERS;CAUTION_SIDE_EFFECT
MYCOPHENOLIC ACID;SLCO1B3;AG + GG;rs7311358;EFFICACY;INCREASED;RISK;OTHER:TRANSPLANT_REJECTION;PEOPLE;OTHER:LUNG_TRANSPLANTATION;CAUTION_SIDE_EFFECT
MYCOPHENOLIC ACID;SLCO1B3;AG + GG;rs7311358;EFFICACY;DECREASED;LIKELIHOOD;OTHER:OVERALL_SURVIVAL;PEOPLE;OTHER:LUNG_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
SUNITINIB;ABCB1;AG + GG;rs1128503;EFFICACY;INCREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
OLANZAPINE;CYP1A1;T;rs2472297;METABOLISM/PK;;;PK:25%_HIGHER_MEAN_4'-DESMETHYL_OLA/OLANZAPINE_(OLA)_RATIO;PEOPLE;DISEASE:PSYCHOTIC_DISORDER;CAUTION_DOSE_ADJUST
MYCOPHENOLIC ACID;SLCO1B3;GT + TT;rs4149117;EFFICACY;INCREASED;RISK;OTHER:TRANSPLANT_REJECTION;PEOPLE;OTHER:LUNG_TRANSPLANTATION;CAUTION_SIDE_EFFECT
BEVACIZUMAB, CAPECITABINE, CETUXIMAB, OXALIPLATIN;MGAT4A;G;rs885036;EFFICACY;INCREASED;;DISEASE:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;ADGRV1;C;rs2366929;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OPIOID-RELATED_DISORDERS;MEN;;CAUTION_SIDE_EFFECT
BEVACIZUMAB, CAPECITABINE, OXALIPLATIN;MGAT4A;G;rs885036;EFFICACY;DECREASED;;DISEASE:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;FMO3;AA;rs1736557;EFFICACY;DECREASED;RISK;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY;PEOPLE;EFFICACY:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
MYCOPHENOLIC ACID;SLCO1B3;GT + TT;rs4149117;EFFICACY;DECREASED;LIKELIHOOD;OTHER:OVERALL_SURVIVAL;PEOPLE;OTHER:LUNG_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
IRINOTECAN;UGT1A1;AA;rs10929302;TOXICITY;INCREASED;RISK;DISEASE:DIARRHEA;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
ASPIRIN, CLOPIDOGREL;PEAR1;G;rs2644592;EFFICACY;;;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY;;;CAUTION_DOSE_ADJUST
ASPIRIN, CLOPIDOGREL;PEAR1;C;rs11264580;EFFICACY;;;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY;;;CAUTION_DOSE_ADJUST
BUPROPION, NICOTINE;APOE;CC + CT;rs429358;OTHER;INCREASED;LIKELIHOOD;DISEASE:RECURRENCE;PEOPLE;DISEASE:TOBACCO_USE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN, CLOPIDOGREL;PEAR1;TT;rs57731889;EFFICACY;;;EFFICACY:LOW_ON-TREATMENT_PLATELET_REACTIVITY;;;CAUTION_DOSE_ADJUST
ALENDRONATE, IBANDRONATE, RISEDRONATE, ZOLEDRONATE;SIRT1;A;rs932658;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:OSTEONECROSIS_OF_THE_JAW;PEOPLE;OTHER:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
VALPROIC ACID;LEPR;AG + GG;rs1137101;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:WEIGHT_GAIN;PEOPLE;OTHER:EPILEPSY;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC AGENTS;GSTM5;C;rs3754446;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
ATORVASTATIN, BEZAFIBRATE;APOE;AT + TT;rs449647;EFFICACY;INCREASED;;EFFICACY:LIPID-LOWERING_EFFECT;PEOPLE;DISEASE:HYPERLIPIDEMIAS;LIKELIHOOD_THERAPEUTIC_SUCCESS
HALOPERIDOL;SLC6A5;AA;rs2298826;TOXICITY;;;SIDE_EFFECT:MOTOR_SIDE_EFFECTS;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_DOSE_ADJUST
OLANZAPINE;AHR;T;rs4410790;METABOLISM/PK;;;PK:29%_LOWER_MEAN_4'-DESMETHYL_OLA/OLANZAPINE_(OLA)_RATIO;PEOPLE;DISEASE:PSYCHOTIC_DISORDER;CAUTION_DOSE_ADJUST
CLOPIDOGREL;P2RY12;AA + AG;rs6785930;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ADVERSE_EVENTS;;;CAUTION_SIDE_EFFECT
ASPIRIN, CLOPIDOGREL;PEAR1;T;rs3737224;EFFICACY;;;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY;;;CAUTION_DOSE_ADJUST
ASPIRIN, CLOPIDOGREL;CYP4F2;T;rs3093135;EFFICACY;INCREASED;LIKELIHOOD;SIDE_EFFECT:EPISTAXIS, SIDE_EFFECT:GASTROINTESTINAL_HEMORRHAGE, SIDE_EFFECT:HEMATOMA, SIDE_EFFECT:HEMATURIA, SIDE_EFFECT:THROMBOTIC_DISEASE;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHANOL;OPRM1;G;rs1799971;TOXICITY;INCREASED;SEVERITY;DISEASE:ALCOHOL_ABUSE;;;CAUTION_SIDE_EFFECT
VENLAFAXINE;CYP2D6;del;rs5030655;METABOLISM/PK;;;PK:IMPAIRED_METABOLIC_ACTIVITY;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DOSE_ADJUST
ASPIRIN, TICAGRELOR;CYP4F2;T;rs3093135;EFFICACY;INCREASED;LIKELIHOOD;SIDE_EFFECT:EPISTAXIS, SIDE_EFFECT:GASTROINTESTINAL_HEMORRHAGE, SIDE_EFFECT:HEMATOMA, SIDE_EFFECT:HEMATURIA, SIDE_EFFECT:THROMBOTIC_DISEASE;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;P2RY12;AA + AC;rs6809699;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ADVERSE_EVENTS;;;CAUTION_SIDE_EFFECT
CISPLATIN, DOXORUBICIN;CASP3;C;rs2720376;EFFICACY;INCREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:OSTEOSARCOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACE INHIBITORS, PLAIN;XPNPEP2;A;rs3788853;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ANGIOEDEMA;MEN;;CAUTION_SIDE_EFFECT
HMG_COA_REDUCTASE_INHIBITORS;SLCO1B1;C;rs59502379;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:STATIN-RELATED_MYOPATHY;;;CAUTION_SIDE_EFFECT
CAPECITABINE;CES1;GG + GT;rs2244613;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;OTHER:NEOPLASMS;CAUTION_SIDE_EFFECT
NEVIRAPINE;CCHCR1;C;rs1265112;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEVIRAPINE-INDUCED_RASH;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
CISPLATIN, DOXORUBICIN;CYP3A4;A;rs4646437;EFFICACY;INCREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:OSTEOSARCOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;GLI1;CC;rs2228226;EFFICACY;DECREASED;;EFFICACY:RECURRENCE_FREE_SURVIVAL;PEOPLE;DISEASE:COLONIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
NICOTINE;ANKK1, DRD2;AA + AG;rs1800497;TOXICITY;INCREASED;SEVERITY;DISEASE:TOBACCO_USE_DISORDER;;;CAUTION_SIDE_EFFECT
VALPROIC ACID;UGT1A6;AG + GG;rs2070959;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:TREMOR;PEOPLE;OTHER:EPILEPSY;CAUTION_SIDE_EFFECT
ESCITALOPRAM;CYP1A2;T;rs4646425;TOXICITY;INCREASED;;DISEASE:FATIGUE;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_SIDE_EFFECT
CLOZAPINE;ACKR1;CC;rs2814778;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA;PEOPLE;OTHER:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
ESCITALOPRAM;;A;rs2069521;TOXICITY;INCREASED;;DISEASE:FATIGUE;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_SIDE_EFFECT
ASPIRIN, CLOPIDOGREL;PEAR1;T;rs41273215;EFFICACY;;;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY;;;CAUTION_DOSE_ADJUST
ESCITALOPRAM;CYP1A2;C;rs4646427;TOXICITY;INCREASED;;DISEASE:FATIGUE;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_SIDE_EFFECT
ESCITALOPRAM;;A;rs2069521;TOXICITY;INCREASED;;SIDE_EFFECT:NAUSEA/VOMITING;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_SIDE_EFFECT
ESCITALOPRAM;CYP1A2;T;rs4646425;TOXICITY;INCREASED;;SIDE_EFFECT:NAUSEA/VOMITING;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_SIDE_EFFECT
ESCITALOPRAM;CYP1A2;C;rs4646427;TOXICITY;INCREASED;;SIDE_EFFECT:NAUSEA/VOMITING;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_SIDE_EFFECT
ALLOPURINOL;CYCSP5;AA + AC;rs3099844;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP1A2;AA + AC;rs762551;EFFICACY, METABOLISM/PK;DECREASED;;EFFICACY:ON-TREATMENT_PLATELET_REACTIVITY;PEOPLE;OTHER:CIGARETTE_SMOKERS;LIKELIHOOD_THERAPEUTIC_FAILURE
ETHANOL;OPRK1;CC + CT;rs6473797;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:ALCOHOL_ABUSE;MEN;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE, DOXORUBICIN;NQO1;A;rs1800566;EFFICACY;;;EFFICACY:WORSE_OUTCOME_(OVERALL_SURVIVAL_AND_PROGRESSION-FREE_SURVIVAL);PEOPLE;DISEASE:BREAST_NEOPLASMS;CAUTION_DOSE_ADJUST
HEROIN;GRM3;T;rs274618;OTHER;INCREASED;RISK;DISEASE:HEROIN_DEPENDENCE;;;CAUTION_SIDE_EFFECT
THIAZOLIDINEDIONES;AQP2;T;rs296766;TOXICITY;INCREASED;RISK;DISEASE:EDEMA;PEOPLE;DISEASE:DIABETES_MELLITUS_T2;CAUTION_SIDE_EFFECT
ETHANOL;CHRNA3;G;rs578776;TOXICITY, OTHER;DECREASED;LIKELIHOOD;DISEASE:ALCOHOL_ABUSE;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN, DOXORUBICIN;ABCC5;G;rs939338;EFFICACY;DECREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:OSTEOSARCOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
CISPLATIN, DOXORUBICIN;FASLG;T;rs763110;EFFICACY;DECREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:OSTEOSARCOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
CISPLATIN, DOXORUBICIN;MSH2;C;rs4638843;EFFICACY;DECREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:OSTEOSARCOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;SLC1A1;C;rs3087879;EFFICACY;INCREASED;SEVERITY;EFFICACY:PHARMACOLOGICAL_RESISTANCE;PEOPLE;DISEASE:OBSESSIVE_COMPULSIVE_DISORDER;CAUTION_SIDE_EFFECT
COCAINE;CHRNA5;G;rs684513;OTHER;INCREASED;LIKELIHOOD;DISEASE:COCAINE_DEPENDENCE;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACE INHIBITORS, PLAIN;XPNPEP2;A;rs3788853;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ANGIOEDEMA;;;CAUTION_SIDE_EFFECT
ALLOPURINOL;;AG + GG;rs2734583;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;;;CAUTION_SIDE_EFFECT
METHOTREXATE;ABCC2;CT + TT;rs717620;TOXICITY;INCREASED;RISK;SIDE_EFFECT:LEUKOPENIA;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
ALLOPURINOL;PSORS1C1;AA + AG;rs9263726;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;;;CAUTION_SIDE_EFFECT
FEXOFENADINE;SLCO2B1;T;rs2306168;METABOLISM/PK;DECREASED;;PK:_AREA_UNDER_THE_PLASMA_CONCENTRATION-TIME_CURVE;HEALTHY;;CAUTION_DOSE_ADJUST
ANTINEOPLASTIC AGENTS;SLC28A3;AA;rs17343066;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;TT;rs3745274;METABOLISM/PK;INCREASED;;PK:PLASMA_CONCENTRATION_(P<0.001);PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DOSE_ADJUST
CLOZAPINE;TRAT1;C;rs116982346;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA;PEOPLE;OTHER:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;NUDT15;CT;rs116855232;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ANEMIA, SIDE_EFFECT:NEUTROPENIA, SIDE_EFFECT:PANCYTOPENIA, SIDE_EFFECT:THROMBOCYTOPENIA;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
EFAVIRENZ;CYP2A6;AC + CC;rs8192726;METABOLISM/PK;INCREASED;;PK:PLASMA_CONCENTRATION_(P=0.028);PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DOSE_ADJUST
CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;CYP3A4;CC;rs2740574;EFFICACY;DECREASED;;EFFICACY:DISEASE_FREE_SURVIVAL;PEOPLE;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;CYP3A4;CT;rs2740574;EFFICACY;DECREASED;;EFFICACY:DISEASE_FREE_SURVIVAL;PEOPLE;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
NAN;ADH1B;A;rs1789891;OTHER;INCREASED;;DISEASE:ALCOHOL_ABUSE;;;CAUTION_DOSE_ADJUST
ANTINEOPLASTIC AGENTS;DCTD;AA;rs12067645;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
EFAVIRENZ;UGT2B7;CC + CT;rs7439366;METABOLISM/PK;INCREASED;;PK:PLASMA_CONCENTRATION;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DOSE_ADJUST
MERCAPTOPURINE;SLC19A1;TT;rs1051266;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ANEMIA, SIDE_EFFECT:NEUTROPENIA, SIDE_EFFECT:PANCYTOPENIA, SIDE_EFFECT:THROMBOCYTOPENIA;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;ERCC2;G;rs13181;TOXICITY;INCREASED;RISK;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
CLOZAPINE;TRAC;A;rs377360;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA;PEOPLE;OTHER:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
NEVIRAPINE;CCHCR1;G;rs746647;TOXICITY;INCREASED;RISK;SIDE_EFFECT:EXANTHEMA;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
NAN;FGFBP1;CC;rs2245964;OTHER;INCREASED;;OTHER:BONE_MINERAL_DENSITY;;;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;VKORC1;CT + TT;rs9923231;EFFICACY;INCREASED;RISK;SIDE_EFFECT:DEATH, DISEASE:GASTROINTESTINAL_HEMORRHAGE;PEOPLE;DISEASE:CARDIOVASCULAR_DISEASE;CAUTION_SIDE_EFFECT
NAN;FGFBP1;TT;rs16892645;OTHER;INCREASED;;OTHER:BONE_MINERAL_DENSITY;;;CAUTION_DOSE_ADJUST
ATORVASTATIN;SLCO1B1;GG;rs2306283;EFFICACY;INCREASED;;EFFICACY:REDUCTION_IN_LDL;PEOPLE;DISEASE:HYPERCHOLESTEROLEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;;G;rs2824292;OTHER;INCREASED;RISK;DISEASE:VENTRICULAR_FIBRILLATION;PEOPLE;DISEASE:MYOCARDIAL_INFARCTION;CAUTION_SIDE_EFFECT
NEVIRAPINE;;G;rs6545803;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEVIRAPINE-INDUCED_RASH;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
NICOTINE;FMO1;C;rs10912675;OTHER;INCREASED;SEVERITY;OTHER:TOBACCO_USE_DISORDER;;;CAUTION_SIDE_EFFECT
NEVIRAPINE;POLR3G;T;rs2562519;TOXICITY;INCREASED;RISK;SIDE_EFFECT:EXANTHEMA;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
NICOTINE;FMO1;T;rs7877;OTHER;INCREASED;SEVERITY;OTHER:TOBACCO_USE_DISORDER;;;CAUTION_SIDE_EFFECT
ASPARAGINASE;GRIA1;T;rs4958381;TOXICITY;INCREASED;RISK;;PEOPLE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
PACLITAXEL;CYP17A1;AG + GG;rs743572;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;WOMEN;OTHER:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
ACENOCOUMAROL;CYP2C9;C;rs1057910;EFFICACY;INCREASED;RISK;SIDE_EFFECT:DEATH, DISEASE:GASTROINTESTINAL_HEMORRHAGE;PEOPLE;DISEASE:CARDIOVASCULAR_DISEASE;CAUTION_SIDE_EFFECT
CISPLATIN, FLUOROURACIL;ERCC1;AA + AC;rs3212986;EFFICACY;INCREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:NEOPLASM_OF_ESOPHAGUS;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOXORUBICIN;CYP2C19;AA + AG;rs4244285;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:NAUSEA, SIDE_EFFECT:VOMITING;WOMEN;OTHER:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
ANASTROZOLE, LETROZOLE;TNFRSF11B;CC;rs2073618;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:METABOLIC_BONE_DISORDER, DISEASE:OSTEOPOROSIS;WOMEN;OTHER:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
CARBOPLATIN, DOCETAXEL, PACLITAXEL;SOX10;CG;rs139887;TOXICITY;INCREASED;RISK;DISEASE:NEUROTOXICITY_SYNDROMES;WOMEN;DISEASE:OVARIAN_NEOPLASMS;CAUTION_SIDE_EFFECT
ANASTROZOLE, LETROZOLE;TNFRSF11B;CC;rs2073618;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:MUSCULOSKELETAL_PAIN, SIDE_EFFECT:ARTHRITIS, SIDE_EFFECT:PAIN;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
ANASTROZOLE, LETROZOLE;TNFSF11;CC;rs7984870;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:METABOLIC_BONE_DISORDER, DISEASE:OSTEOPOROSIS;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC AGENTS;CTPS1;A;rs12067645;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
DOXORUBICIN;CYP2C19;AA + AG;rs4244285;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;WOMEN;OTHER:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC AGENTS;CTPS1;A;rs12067645;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:MYELOSUPPRESSION;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
CAPECITABINE;CES2;CG + GG;rs11075646;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME;PEOPLE;OTHER:NEOPLASMS;CAUTION_SIDE_EFFECT
WARFARIN;VKORC1;T;rs9923231;EFFICACY;;;EFFICACY:TIME_TO_THERAPEUTIC_INR;PEOPLE;DISEASE:ATRIAL_FIBRILLATION;CAUTION_DOSE_ADJUST
ANASTROZOLE, LETROZOLE;TNFSF11;CC;rs7984870;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:MUSCULOSKELETAL_PAIN, SIDE_EFFECT:ARTHRITIS, SIDE_EFFECT:PAIN;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
DRUGS FOR TREATMENT OF TUBERCULOSIS;SOD2;AG + GG;rs4880;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE;;;CAUTION_SIDE_EFFECT
"""ANALGESICS AND ANESTHETICS"", ""ANTIBIOTICS"", ""ANTIEPILEPTICS"", ""ANTIFUNGALS FOR SYSTEMIC USE"", ""ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS"", ""ANTIMYCOBACTERIALS"", ""ANTITHYROID PREPARATIONS""";SOD2;AG + GG;rs4880;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;;;CAUTION_SIDE_EFFECT
DOXORUBICIN;CYP2C19;AA + AG;rs4244285;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:ANEMIA, SIDE_EFFECT:THROMBOCYTOPENIA, SIDE_EFFECT:NEUTROPENIA;WOMEN;OTHER:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
METFORMIN;PPARG;G;rs1801282;OTHER;INCREASED;LIKELIHOOD;OTHER:SHORT_AND_LONG-TERM_WEIGHT_LOSS;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
MITOTANE;CYP2B6;GT + TT;rs3745274;METABOLISM/PK;;;PK:BEING_A_PREDICTOR_OF_MITOTANE_PLASMA_CONCENTRATIONS_OF_AT_LEAST_14_ΜG/ML_AFTER_3_MONTHS_OF_TREATMENT;PEOPLE;DISEASE:ADRENOCORTICAL_CARCINOMA;CAUTION_DOSE_ADJUST
BORTEZOMIB, MELPHALAN, PREDNISONE;CTLA4;GG;rs4553808;TOXICITY;;;SIDE_EFFECT:EARLIER_ONSET_OF_BORTEZOMIB-INDUCED_PERIPHERAL_NEUROPATHY;PEOPLE;DISEASE:MULTIPLE_MYELOMA;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2B6;GT + TT;rs3745274;METABOLISM/PK;INCREASED;;PK:PBMC-ASSOCIATED_DRUG_CONCENTRATIONS;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DOSE_ADJUST
NAN;CRHR1;TT;rs1876828;METABOLISM/PK;DECREASED;;PK:BASELINE_CORTISOL_LEVELS;CHILDREN;DISEASE:ASTHMA;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2B6;TT;rs3745274;TOXICITY, METABOLISM/PK;INCREASED;;PK:INTRACELLULAR_PBMC_EXPOSURE;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
VALPROIC ACID;SOD2;AG + GG;rs4880;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:ALOPECIA;PEOPLE;OTHER:EPILEPSY;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;ABCB1;AA;rs1045642;OTHER;INCREASED;LIKELIHOOD;OTHER:HELICOBACTER_PYLORI_INFECTION;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
VALPROIC ACID;LEPR;AG + GG;rs1137101;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ALOPECIA;PEOPLE;OTHER:EPILEPSY;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;INCREASED;;OTHER:ADP-STIMULATED_PLATELET_AGGREGATION;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE;CDA;AG + GG;rs10916825;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:HAND-FOOT_SYNDROME;PEOPLE;OTHER:NEOPLASMS;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC AGENTS;ABCB1;CC + CT;rs4148737;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:MYELOSUPPRESSION;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
HMG_COA_REDUCTASE_INHIBITORS;SLCO1B1;C;rs4149056;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:STATIN-RELATED_MYOPATHY;;;CAUTION_SIDE_EFFECT
CLOPIDOGREL, TICAGRELOR;CYP4F2;TT;rs3093135;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:MYOCARDIAL_INFARCTION, EFFICACY:RECURRENCE;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;CT;rs28399499;METABOLISM/PK;INCREASED;;PK:MINIMUM_PLASMA_CONCENTRATIONS;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DOSE_ADJUST
DEFERASIROX;UGT1A3;CC;rs3806596;EFFICACY;DECREASED;RISK;EFFICACY:IRON_OVERLOAD;CHILDREN;OTHER:BETA-THALASSEMIA_AND_RELATED_DISEASES;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE, CISPLATIN, DOCETAXEL, EPIRUBICIN, GEMCITABINE;ERCC2;GG;rs13181;EFFICACY;DECREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:PANCREATIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
DEFERASIROX;UGT1A1;TT;rs887829;EFFICACY;DECREASED;RISK;DISEASE:IRON_OVERLOAD;CHILDREN;OTHER:BETA-THALASSEMIA_AND_RELATED_DISEASES;LIKELIHOOD_THERAPEUTIC_SUCCESS
METFORMIN;SLC47A2;AA + AG;rs12943590;METABOLISM/PK;INCREASED;;PK:RENAL_AND_SECRETORY_CLEARANCE_OF_METFORMIN;HEALTHY;;CAUTION_DOSE_ADJUST
METFORMIN;SLC47A2;AA;rs12943590;EFFICACY;DECREASED;;EFFICACY:RESPONSE_TO_METFORMIN;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
CAPECITABINE;CES1;GG + GT;rs2244613;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:HAND-FOOT_SYNDROME;PEOPLE;OTHER:NEOPLASMS;CAUTION_SIDE_EFFECT
ATORVASTATIN;SLCO1B1;CC + CT;rs4149056;METABOLISM/PK;DECREASED;;PK:ORAL_CLEARANCE_OF_ATORVASTATIN;PEOPLE;DISEASE:OBESITY;CAUTION_DOSE_ADJUST
CAPECITABINE;CES1;GG + GT;rs2244613;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DIARRHEA;PEOPLE;OTHER:NEOPLASMS;CAUTION_SIDE_EFFECT
DEFERASIROX;CYP1A2;AA;rs762551;EFFICACY;DECREASED;RISK;EFFICACY:IRON_OVERLOAD;CHILDREN;OTHER:BETA-THALASSEMIA_AND_RELATED_DISEASES;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTINEOPLASTIC AGENTS;CYP3A5;T;rs776746;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:MYELOSUPPRESSION;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
CAPECITABINE, CISPLATIN, DOCETAXEL, EPIRUBICIN, GEMCITABINE;ERCC2;GG;rs13181;EFFICACY;DECREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:PANCREATIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
DEFERASIROX;CYP1A1;CC;rs2606345;EFFICACY;DECREASED;RISK;EFFICACY:IRON_OVERLOAD;CHILDREN;OTHER:BETA-THALASSEMIA_AND_RELATED_DISEASES;LIKELIHOOD_THERAPEUTIC_SUCCESS
HEROIN;GRM3;C;rs274622;OTHER;INCREASED;RISK;DISEASE:HEROIN_DEPENDENCE;;;CAUTION_SIDE_EFFECT
EFAVIRENZ;ABCB1;CC + CT;rs3842;METABOLISM/PK;INCREASED;;PK:ACCUMULATION_OF_DRUG_IN_PBMCS;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DOSE_ADJUST
ETHANOL;CHRNA4;G;rs1044394;TOXICITY;DECREASED;RISK;OTHER:ALCOHOL_ABUSE;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;F2;AG;rs1799963;TOXICITY;INCREASED;RISK;DISEASE:VENOUS_THROMBOSIS;WOMEN;;CAUTION_SIDE_EFFECT
OPIOIDS;ENPP2;AA;rs2249015;EFFICACY;INCREASED;SEVERITY;EFFICACY:PAIN;PEOPLE;OTHER:NEOPLASMS;CAUTION_SIDE_EFFECT
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;F5;CT;rs6025;TOXICITY;INCREASED;RISK;DISEASE:VENOUS_THROMBOSIS;WOMEN;;CAUTION_SIDE_EFFECT
CAPECITABINE, CISPLATIN, DOCETAXEL, EPIRUBICIN, GEMCITABINE;XRCC1;CT + TT;rs25487;EFFICACY;DECREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:PANCREATIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
ASPIRIN;ADORA1;GG + GT;rs2228079;TOXICITY;DECREASED;RISK;SIDE_EFFECT:ASPIRIN-INTOLERANT_ASTHMA;PEOPLE;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
LOVASTATIN;SLCO1B1;CC;rs4149056;TOXICITY;INCREASED;RISK;SIDE_EFFECT:STATIN-RELATED_MYOPATHY;;;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;GG + GT;rs1801131;TOXICITY;DECREASED;RISK;SIDE_EFFECT:SKIN_DISORDER;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;FASTKD3, MTRR;AG + GG;rs1801394;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:MUCOSITIS;PEOPLE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;T;rs56038477;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;AA + AG;rs1801133;TOXICITY;INCREASED;RISK;SIDE_EFFECT:THROMBOCYTOPENIA;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
PROPRANOLOL;CYP2D6;AA;rs1065852;METABOLISM/PK;INCREASED;;PK:AREA_UNDER_PLASMA_CONCENTRATION_OF_PROPRANOLOL;HEALTHY;;CAUTION_DOSE_ADJUST
CAPECITABINE, FLUOROURACIL;DPYD;T;rs6668296;TOXICITY;INCREASED;SEVERITY;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
CLOZAPINE;HLA-DQB1;G;rs113332494;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:AGRANULOCYTOSIS;PEOPLE;OTHER:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
CAPECITABINE, CISPLATIN, DOCETAXEL, EPIRUBICIN, GEMCITABINE;ERCC2;CC;rs1799793;EFFICACY;INCREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:PANCREATIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;APOE;CT + TT;rs7412;OTHER;INCREASED;;OTHER:HYPERURICEMIA;PEOPLE;OTHER:CORONARY_DISEASE, OTHER:HYPERTENSION;CAUTION_DOSE_ADJUST
CAPECITABINE, FLUOROURACIL;DPYD;C;rs115349832;TOXICITY;INCREASED;SEVERITY;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
METFORMIN;PPARG;G;rs1801282;OTHER;INCREASED;LIKELIHOOD;OTHER:WEIGHT_REGAIN_AFTER_INTENTIONAL_WEIGHT_LOSS;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;APOE;CC + CT;rs429358;OTHER;INCREASED;;OTHER:HYPERTRIGLYCERIDEMIA;PEOPLE;OTHER:CORONARY_DISEASE, OTHER:HYPERTENSION;CAUTION_DOSE_ADJUST
CLOZAPINE;HLA-DQB1;G;rs113332494;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA;PEOPLE;OTHER:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
SIMVASTATIN;APOE;C;rs429358;EFFICACY;INCREASED;RISK;OTHER:MORTALITY_AFTER_MYOCARDIAL_INFARCTION, HOWEVER_THIS_CAN_BE_ELIMINATED;;;CAUTION_SIDE_EFFECT
CLOZAPINE, HALOPERIDOL, OLANZAPINE, RISPERIDONE;HTR2C;G;rs518147;OTHER;INCREASED;LIKELIHOOD;DISEASE:WEIGHT_GAIN;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
AMISULPRIDE, CLOZAPINE, HALOPERIDOL, ILOPERIDONE, OLANZAPINE, QUETIAPINE, RISPERIDONE, ZIPRASIDONE;HTR2C;C;rs3813929;OTHER;INCREASED;RISK;DISEASE:WEIGHT_GAIN;;;CAUTION_SIDE_EFFECT
HEROIN;SOD2;TT;rs5746136;TOXICITY;INCREASED;RISK;DISEASE:HEROIN_DEPENDENCE;;;CAUTION_SIDE_EFFECT
OPIOIDS;ENPP2;A;rs7832704;EFFICACY;INCREASED;SEVERITY;EFFICACY:PAIN;PEOPLE;OTHER:NEOPLASMS;CAUTION_SIDE_EFFECT
CARBOPLATIN, DOCETAXEL, PACLITAXEL;BCL2;TT;rs2849380;TOXICITY;INCREASED;RISK;DISEASE:NEUROTOXICITY_SYNDROMES;WOMEN;DISEASE:OVARIAN_NEOPLASMS;CAUTION_SIDE_EFFECT
CARBOPLATIN, DOCETAXEL, PACLITAXEL;OPRM1;TT;rs544093;TOXICITY;INCREASED;RISK;DISEASE:NEUROTOXICITY_SYNDROMES;WOMEN;DISEASE:OVARIAN_NEOPLASMS;CAUTION_SIDE_EFFECT
CARBOPLATIN, DOCETAXEL, PACLITAXEL;;AG;rs879207;TOXICITY;INCREASED;RISK;DISEASE:NEUROTOXICITY_SYNDROMES;WOMEN;DISEASE:OVARIAN_NEOPLASMS;CAUTION_SIDE_EFFECT
TOLCAPONE;;GG;rs4680;EFFICACY;INCREASED;;EFFICACY:REACTION_TIME;;OTHER:ABSTINENT_SMOKERS;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOLASETRON, GRANISETRON;NOS1AP;GT + TT;rs10494366;TOXICITY;INCREASED;RISK;SIDE_EFFECT:QTC_PROLONGATION;PEOPLE;OTHER:SURGERY_AS_PART_OF_ANESTHETIC_MANAGEMENT;CAUTION_SIDE_EFFECT
SUNITINIB;ABCB1;A;rs2032582;TOXICITY;DECREASED;RISK;SIDE_EFFECT:NEUTROPENIA;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE, FLUOROURACIL;DPYD;T;rs56276561;TOXICITY;INCREASED;SEVERITY;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
CLOZAPINE;ELAVL2;A;rs73482673;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA;PEOPLE;OTHER:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
EFAVIRENZ;CYP2B6;TT;rs3745274;METABOLISM/PK;INCREASED;;PK:MID-DOSE_PLASMA_CONCENTRATIONS;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DOSE_ADJUST
FLUOROURACIL;DPYD;CC + CT;rs2297595;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA;WOMEN;DISEASE:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOCETAXEL;SLCO1B3;G;rs4149118;OTHER, METABOLISM/PK;INCREASED;;PK:AUC;PEOPLE;DISEASE:NASOPHARYNGEAL_NEOPLASMS;CAUTION_DOSE_ADJUST
NEVIRAPINE;CYP2B6;TT;rs3745274;METABOLISM/PK;INCREASED;;PK:PLASMA_EXPOSURE;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DOSE_ADJUST
TOLCAPONE;COMT;AG;rs4680;EFFICACY;DECREASED;;EFFICACY:REACTION_TIME;;OTHER:ABSTINENT_SMOKERS;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;TT;rs3745274;METABOLISM/PK;INCREASED;;PK:PLASMA_EXPOSURE;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DOSE_ADJUST
HEROIN;SOD2;AC + CC;rs2758339;TOXICITY;DECREASED;RISK;DISEASE:HEROIN_DEPENDENCE;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOCETAXEL;SLCO1B3;G;rs11045585;OTHER, METABOLISM/PK;INCREASED;;PK:AUC;PEOPLE;DISEASE:NASOPHARYNGEAL_NEOPLASMS;CAUTION_DOSE_ADJUST
DOCETAXEL;SLCO1B3;A;rs7311358;OTHER, METABOLISM/PK;INCREASED;;PK:AUC;PEOPLE;DISEASE:NASOPHARYNGEAL_NEOPLASMS;CAUTION_DOSE_ADJUST
IRINOTECAN;TOP1;GG;rs6072262;TOXICITY;DECREASED;SEVERITY;DISEASE:NEUTROPENIA;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;APOB;G;rs679899;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HEMORRHAGE;PEOPLE;OTHER:HEART_VALVE_REPLACEMENT;CAUTION_SIDE_EFFECT
ERLOTINIB;EGFR;GG;rs712829;TOXICITY;INCREASED;SEVERITY;DISEASE:DIARRHEA;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
ERLOTINIB;ABCG2;CC;rs2622604;OTHER, METABOLISM/PK;DECREASED;;PK:MEAN_AUC;;;CAUTION_DOSE_ADJUST
WARFARIN;APOB;G;rs1367117;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HEMORRHAGE;PEOPLE;OTHER:HEART_VALVE_REPLACEMENT;CAUTION_SIDE_EFFECT
CAPECITABINE, FLUOROURACIL;DPYD;T;rs56038477;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
MORPHINE;OPRM1;AA;rs1799971;EFFICACY;INCREASED;;EFFICACY:REDUCTION_IN_PAIN;PEOPLE;DISEASE:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
MORPHINE;ABCB1;AA;rs1045642;EFFICACY;INCREASED;;EFFICACY:REDUCTION_IN_PAIN;PEOPLE;DISEASE:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
PHENYTOIN;ABCB1;G;rs1045642;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:DRUG_RESISTANCE;PEOPLE;DISEASE:EPILEPSY;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATORVASTATIN, FLUVASTATIN, HMG COA REDUCTASE INHIBITORS, PRAVASTATIN, ROSUVASTATIN, SIMVASTATIN;SLCO1B1;C;rs4149056;TOXICITY;;;SIDE_EFFECT:ALL_STATIN-INDUCED_MYOPATHY_AND_SEVERE_MYOPATHY;;;CAUTION_DOSE_ADJUST
ASPIRIN, CLOPIDOGREL;B4GALT2;CT + TT;rs1061781;EFFICACY;DECREASED;;EFFICACY:PLATELET_REACTIVITY;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
LEFLUNOMIDE;CYB5A;AA + AG;rs1790834;EFFICACY;DECREASED;;EFFICACY:DISEASE_ACTIVITY_SCORE_28_IN_RHEUMATOID_ARTHRITIS;WOMEN;OTHER:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;F5;CT;rs6025;TOXICITY;INCREASED;RISK;DISEASE:STROKE;WOMEN;;CAUTION_SIDE_EFFECT
NEVIRAPINE;CYP2B6;CT;rs28399499;METABOLISM/PK;INCREASED;;PK:PLASMA_CONCENTRATION;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DOSE_ADJUST
NEVIRAPINE;CYP2B6;T;rs3745274;METABOLISM/PK;INCREASED;;PK:PLASMA_CONCENTRATION;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DOSE_ADJUST
CETUXIMAB, PANITUMUMAB;KRAS;C;rs61764370;EFFICACY;;;EFFICACY:NONRESPONSE_TO_ANTI-EGFR-BASED_TREATMENT;PEOPLE;DISEASE:ADENOCARCINOMA;CAUTION_DOSE_ADJUST
EDOXABAN;SLCO1B1;CC + CT;rs4149056;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE;;;CAUTION_SIDE_EFFECT
CYCLOSPORINE;ABCB1;GG;rs1045642;EFFICACY, METABOLISM/PK;DECREASED;;PK:INTRACELLULAR_AND_BLOOD_CONCENTRATION;PEOPLE;DISEASE:TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
BLEOMYCIN;BLMH;CC;rs1050565;EFFICACY;DECREASED;;EFFICACY:SURVIVAL;MEN;DISEASE:TESTICULAR_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
CISPLATIN;GSTP1;AA + AG;rs1695;TOXICITY;INCREASED;RISK;SIDE_EFFECT:SEVERE_HEARING_IMPAIRMENT;MEN;DISEASE:TESTICULAR_NEOPLASMS;CAUTION_SIDE_EFFECT
CITALOPRAM;FKBP5;A;rs4713916;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:REMISSION;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;TH;AA + AG;rs10770141;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OPIOID-RELATED_DISORDERS;;;CAUTION_SIDE_EFFECT
DISULFIRAM;DBH;CC;rs1611115;EFFICACY;DECREASED;SEVERITY;EFFICACY:COCAINE_DEPENDENCE;PEOPLE;OTHER:COCAINE_DEPENDENCE, OTHER:SUBSTANCE-RELATED_DISORDERS;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;COMT;AA;rs4680;TOXICITY;DECREASED;RISK;OTHER:DEATH;PEOPLE;OTHER:OPIOID-RELATED_DISORDERS;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;VEGFA;CC + CG;rs2010963;EFFICACY;INCREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
SOFOSBUVIR, VELPATASVIR, VOXILAPREVIR;IFNL3, IFNL4;CT + TT;rs12979860;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:RECURRENCE;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;TH;CT + TT;rs10770140;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OPIOID-RELATED_DISORDERS;;;CAUTION_SIDE_EFFECT
PHENYTOIN;ABCB1;A;rs1128503;OTHER, METABOLISM/PK;INCREASED;;PK:PLASMA_DRUG_LEVELS;PEOPLE;OTHER:NO_DISEASE;CAUTION_DOSE_ADJUST
PHENYTOIN;ABCB1;A;rs1045642;OTHER, METABOLISM/PK;INCREASED;;PK:PLASMA_DRUG_LEVELS;PEOPLE;OTHER:NO_DISEASE;CAUTION_DOSE_ADJUST
ANTHRACYCLINES AND RELATED SUBSTANCES;CBR3;GG;rs1056892;TOXICITY;INCREASED;RISK;DISEASE:CARDIOMYOPATHIES;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
DEXMEDETOMIDINE;PRKCB;T;rs9922316;OTHER;INCREASED;;OTHER:DEXMEDETOMIDINE_ED50_VALUES_FOR_DRUG-INDUCED_DORSAL_HAND_VEIN_(DHV)_CONSTRICTION;HEALTHY;;CAUTION_DOSE_ADJUST
PRASUGREL;CYP2C19;T;rs12248560;EFFICACY;DECREASED;;EFFICACY:PLATELET_REACTIVITY_INDEX_(PRI)_VASODILATOR-STIMULATED_PHOSPHOPROTEIN_(VASP)_AT_1_MONTH_OF_TREATMENT;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOSPORINE;ABCB1;CC;rs2229109;EFFICACY, METABOLISM/PK;INCREASED;;PK:INTRACELLULAR_AND_BLOOD_CONCENTRATION;PEOPLE;DISEASE:TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
PRASUGREL;CYP2C19;T;rs12248560;EFFICACY;DECREASED;;EFFICACY:_RATE_OF_HIGH_ON-TREATMENT_PLATELET_REACTIVITY_(HTPR)_AT_1_MONTH_OF_TREATMENT;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;LIKELIHOOD_THERAPEUTIC_FAILURE
HMG_COA_REDUCTASE_INHIBITORS;LPA;G;rs10455872;TOXICITY;INCREASED;RISK;SIDE_EFFECT:CORONARY_DISEASE;;;CAUTION_SIDE_EFFECT
EFAVIRENZ;CYP2B6;C;rs28399499;TOXICITY, METABOLISM/PK;INCREASED;;PK:PLASMA_CONCENTRATION;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
PRASUGREL;CYP2C19;T;rs12248560;TOXICITY;INCREASED;RISK;SIDE_EFFECT:BLEEDING_COMPLICATIONS;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;CAUTION_SIDE_EFFECT
NICOTINE;DRD1;A;rs686;EFFICACY, TOXICITY, OTHER;INCREASED;RISK;DISEASE:TOBACCO_USE_DISORDER;;OTHER:SMOKERS;CAUTION_SIDE_EFFECT
PRASUGREL;CYP2C19;T;rs12248560;EFFICACY;INCREASED;;EFFICACY:_RATE_OF_HYPER-RESPONSE_AT_1_MONTH_OF_TREATMENT;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIPSYCHOTICS;DRD2;del;rs1799732;TOXICITY;INCREASED;RISK;DISEASE:WEIGHT_GAIN;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
MITOTANE;CYP2B6;GT + TT;rs3745274;METABOLISM/PK;INCREASED;;PK:MITOTANE_PLASMA_CONCENTRATIONS;PEOPLE;DISEASE:ADRENOCORTICAL_CARCINOMA;CAUTION_DOSE_ADJUST
NICOTINE;DRD1;T;rs4532;EFFICACY, TOXICITY, OTHER;INCREASED;RISK;DISEASE:TOBACCO_USE_DISORDER;;OTHER:SMOKERS;CAUTION_SIDE_EFFECT
REPAGLINIDE;SLC30A8;AG;rs16889462;EFFICACY;INCREASED;;EFFICACY:EFFICACY;PEOPLE;DISEASE:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATAZANAVIR, RITONAVIR;UGT1A7;AA;rs17863778;TOXICITY, OTHER;INCREASED;LIKELIHOOD;SIDE_EFFECT:HYPERBILIRUBINEMIA;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
BEVACIZUMAB;EDN1;TT;rs5370;EFFICACY;DECREASED;;EFFICACY:OVERALL_SURVIVAL;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
NAN;G6PD, IKBKG;A;rs5030868;NAN;;;OTHER:PROTECTION_FROM_PLASMODIUM_VIVAX_MALARIA_INFECTION;;;CAUTION_DOSE_ADJUST
MYCOPHENOLATE MOFETIL;IMPDH1;T;rs2278294;EFFICACY;DECREASED;RISK;DISEASE:TRANSPLANT_REJECTION;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATAZANAVIR, RITONAVIR;UGT1A3;CC;rs3806596;TOXICITY, OTHER;INCREASED;LIKELIHOOD;SIDE_EFFECT:HYPERBILIRUBINEMIA;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
GEFITINIB;ABCB1;AA;rs1128503;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DIARRHEA, SIDE_EFFECT:EXANTHEMA;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
MYCOPHENOLATE MOFETIL;IMPDH1;T;rs2278294;TOXICITY;INCREASED;RISK;DISEASE:LEUKOPENIA;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
ATAZANAVIR, RITONAVIR;UGT1A7;GG;rs7586110;TOXICITY, OTHER;INCREASED;LIKELIHOOD;SIDE_EFFECT:HYPERBILIRUBINEMIA;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
OXALIPLATIN;ERCC2, KLC3;GG + GT;rs13181;EFFICACY;DECREASED;;EFFICACY:OVERALL_SURVIVAL, EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
APREPITANT, OLANZAPINE;HTR3C;CC;rs6766410;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:NAUSEA, EFFICACY:VOMITING;PEOPLE;OTHER:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATAZANAVIR, RITONAVIR;UGT1A7;GG;rs17868323;TOXICITY, OTHER;INCREASED;LIKELIHOOD;SIDE_EFFECT:HYPERBILIRUBINEMIA;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
BEVACIZUMAB;VEGFA;TT;rs3025039;EFFICACY;DECREASED;;EFFICACY:OVERALL_SURVIVAL;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
APREPITANT, OLANZAPINE;MTHFR;TT;rs1801131;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:NAUSEA, EFFICACY:VOMITING;PEOPLE;OTHER:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
APREPITANT, OLANZAPINE;HTR3B;GG;rs7943062;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:NAUSEA, EFFICACY:VOMITING;PEOPLE;OTHER:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
TAFENOQUINE;;A;rs62103056;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:RECURRENCE;PEOPLE;OTHER:MALARIA_VIVAX;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;GGH;CC;rs719235;EFFICACY, TOXICITY;INCREASED;RISK;SIDE_EFFECT:BONE_MARROW_TOXICITY;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
TIMOLOL;ADRB1;AA;rs1801252;OTHER;INCREASED;;OTHER:SYSTOLIC_(SAP)_AND_DIASTOLIC_(DAP)_ARTERIAL_PRESSURE_RESPONSES_TO_TIMOLOL;HEALTHY;;CAUTION_DOSE_ADJUST
CISPLATIN;LRP2;G;rs2228171;TOXICITY;INCREASED;RISK;DISEASE:OTOTOXICITY;CHILDREN;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
DISULFIRAM;DBH;CT + TT;rs1611115;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS;PEOPLE;OTHER:ALCOHOL_ABUSE;CAUTION_SIDE_EFFECT
FENTANYL, PROPOFOL, REMIFENTANIL, SEVOFLURANE;ADRB2;AA;rs1042718;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:HYPOTENSIVE_DISORDER;;;CAUTION_SIDE_EFFECT
ROSUVASTATIN;ABCG2;T;rs2231142;EFFICACY;;SEVERITY;EFFICACY:HYPERCHOLESTEROLEMIA;;;CAUTION_DOSE_ADJUST
NAN;SLC30A8;C;rs13266634;OTHER;INCREASED;RISK;DISEASE:DIABETES_MELLITUS, TYPE_2;;;CAUTION_SIDE_EFFECT
THIAZIDES, PLAIN;SLCO2A1;T;rs34550074;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HYPONATREMIA;PEOPLE;DISEASE:HYPERTENSION;CAUTION_SIDE_EFFECT
ROSUVASTATIN;FMO3;A;rs1736557;EFFICACY;;SEVERITY;EFFICACY:HYPERCHOLESTEROLEMIA;;;CAUTION_DOSE_ADJUST
WARFARIN;GGCX;C;rs699664;EFFICACY;INCREASED;;EFFICACY:INTERNATIONAL_NORMALIZED_RATIO_VARIABILITY_(INR-VAR);;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN;GSTP1;AG + GG;rs1695;TOXICITY;INCREASED;RISK;DISEASE:OTOTOXICITY;CHILDREN;DISEASE:MEDULLOBLASTOMA;CAUTION_SIDE_EFFECT
WARFARIN;GGCX;G;rs11676382;EFFICACY;DECREASED;;EFFICACY:TIME_IN_THERAPEUTIC_RANGE;;;LIKELIHOOD_THERAPEUTIC_FAILURE
METHYLPHENIDATE;COMT;A;rs4680;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS;CHILDREN;OTHER:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY, OTHER:FETAL_ALCOHOL_SYNDROME;CAUTION_SIDE_EFFECT
ANTIEPILEPTICS;SCN2A;A;rs2304016;EFFICACY;;;EFFICACY:DRUG_RESISTANCE;PEOPLE;DISEASE:EPILEPSY;CAUTION_DOSE_ADJUST
WARFARIN;GGCX;G;rs11676382;EFFICACY;INCREASED;;EFFICACY:INTERNATIONAL_NORMALIZED_RATIO_VARIABILITY_(INR-VAR);;;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;NQO1;AA + AG;rs1800566;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HEMORRHAGE;;;CAUTION_SIDE_EFFECT
NAN;G6PD;T;rs1050828;NAN;INCREASED;;OTHER:PROTECTION_AGAINST_SEVERE_(P=0.006)_AND_MILD_MALARIA_(P=0.027);;;CAUTION_DOSE_ADJUST
ANTITHYROID PREPARATIONS, METHIMAZOLE, PROPYLTHIOURACIL;KLRC4;C;rs2734565;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:AGRANULOCYTOSIS;PEOPLE;OTHER:GRAVES_DISEASE;CAUTION_SIDE_EFFECT
OXALIPLATIN;ERCC1;AA;rs11615;EFFICACY;DECREASED;;EFFICACY:OVERALL_SURVIVAL, EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL;MTHFR;AA + AG;rs1801133;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DIARRHEA, SIDE_EFFECT:MUCOSITIS, SIDE_EFFECT:NEUTROPENIA;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
ACE INHIBITORS, PLAIN;;CC + CT;rs4267385;OTHER;;;OTHER:SAME_PROTECTIVE_PROPERTIES_AGAINST_ANGIOTENSIN-CONVERTING_ENZYME_INHIBITORS-INDUCED_COUGH;PEOPLE;OTHER:HOMOZYGOUS_GG_GENOTYPE_FOR_RS4343;CAUTION_DOSE_ADJUST
ACE INHIBITORS, PLAIN;;AA + AT;rs4459610;OTHER;;;OTHER:SAME_PROTECTIVE_PROPERTIES_AGAINST_ANGIOTENSIN-CONVERTING_ENZYME_INHIBITORS-INDUCED_COUGH;PEOPLE;OTHER:HOMOZYGOUS_GG_GENOTYPE_FOR_RS4343;CAUTION_DOSE_ADJUST
NAN;G6PD;T;rs1050828;NAN;INCREASED;;OTHER:PROTECTION_AGAINST_DEVELOPING_SEVERE_MALARIA;PEOPLE;DISEASE:MALARIA;CAUTION_DOSE_ADJUST
METHOTREXATE;MTHFR;AG;rs1801133;TOXICITY;INCREASED;RISK;DISEASE:ALOPECIA;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
ACE INHIBITORS, PLAIN;BDKRB2;AG;rs8016905;TOXICITY;;;DISEASE:COUGH;;;CAUTION_DOSE_ADJUST
NAN;F5;C;rs6025;OTHER;INCREASED;LIKELIHOOD;OTHER:RECURRENT_PREGCY_LOSS;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBOPLATIN, PACLITAXEL;TRIM5;C;rs7950311;EFFICACY;DECREASED;;EFFICACY:OVERALL_SURVIVAL;WOMEN;DISEASE:OVARIAN_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
NAN;MTHFR;G;rs1801131;OTHER;INCREASED;LIKELIHOOD;OTHER:RECURRENT_PREGCY_LOSS;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTINEOPLASTIC AGENTS;;G;rs6674079;EFFICACY;DECREASED;;EFFICACY:OVERALL_SURVIVAL;WOMEN;DISEASE:OVARIAN_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
NAN;MTHFR;G;rs1801133;OTHER;INCREASED;LIKELIHOOD;OTHER:RECURRENT_PREGCY_LOSS;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBOPLATIN, PACLITAXEL;;C;rs2549714;EFFICACY;DECREASED;;EFFICACY:OVERALL_SURVIVAL;WOMEN;DISEASE:OVARIAN_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
NAN;SERPINE1;A;rs2227631;OTHER;INCREASED;LIKELIHOOD;OTHER:RECURRENT_PREGCY_LOSS;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTINEOPLASTIC AGENTS;;G;rs4910232;EFFICACY;DECREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL;WOMEN;DISEASE:OVARIAN_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP4F2;CT + TT;rs2108622;EFFICACY;DECREASED;;EFFICACY:INTERNATIONAL_NORMALIZED_RATIO_VARIABILITY_(INR-VAR);;;LIKELIHOOD_THERAPEUTIC_FAILURE
ASPIRIN;PPARG;TT;rs3856806;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ASPIRIN_HYPERSENSITIVITY;PEOPLE;DISEASE:ASTHMA;CAUTION_SIDE_EFFECT
CYCLOSPORINE;ABCB1;AA;rs1045642;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEPHROTOXICITY;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC AGENTS;ZNF100;C;rs3795247;EFFICACY;DECREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL;WOMEN;DISEASE:OVARIAN_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;VKORC1;T;rs9923231;EFFICACY;INCREASED;;EFFICACY:MEAN_INR_DURING_3-MONTH_DAILY_OBSERVATION_PERIOD_IN_PATIENTS_WITH_MECHANICAL_HEART_VALVE_REPLACEMENT;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;PTGIR;AG + GG;rs1126510;OTHER;DECREASED;RISK;OTHER:ASPIRIN-INTOLERANT_ASTHMA;PEOPLE;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;CT + TT;rs9923231;EFFICACY;INCREASED;;EFFICACY:NUMBER_OF_EXAMINATIONS_ABOVE_THE_THERAPEUTIC_RANGE_DURING_3-MONTH_DAILY_OBSERVATION_PERIOD_IN_PATIENTS_WITH_MECHANICAL_HEART_VALVE_REPLACEMENT;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;TBXA2R;GG;rs1131882;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ASPIRIN-INTOLERANT_ASTHMA;PEOPLE;DISEASE:ASTHMA;CAUTION_SIDE_EFFECT
ASPIRIN;PTGER3;A;rs7551789;OTHER;INCREASED;RISK;OTHER:ASPIRIN-INTOLERANT_ASTHMA;PEOPLE;DISEASE:ASTHMA;CAUTION_SIDE_EFFECT
WARFARIN;VKORC1;CT + TT;rs9923231;EFFICACY;DECREASED;;EFFICACY:TIME_TO_THERAPEUTIC_INR>=2;;;LIKELIHOOD_THERAPEUTIC_FAILURE
ASPIRIN;PTGER2;GG;rs1353411;OTHER;INCREASED;RISK;OTHER:ASPIRIN-INTOLERANT_ASTHMA;PEOPLE;DISEASE:ASTHMA;CAUTION_SIDE_EFFECT
ASPIRIN;PTGER2;G;rs2075797;OTHER;DECREASED;RISK;OTHER:ASPIRIN-INTOLERANT_ASTHMA;PEOPLE;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOCETAXEL, PACLITAXEL;CYP3A4;CC;rs2740574;TOXICITY;INCREASED;RISK;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
DOXORUBICIN;ABCB1;AA + AG;rs1045642;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:NAUSEA, SIDE_EFFECT:VOMITING;WOMEN;OTHER:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED;;OTHER:STABLE_WARFARIN_DOSE;;;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;AG + GG;rs4244285;EFFICACY;INCREASED;;EFFICACY:_VASP_INDEX;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;PPARG;TT;rs3856806;TOXICITY;INCREASED;;SIDE_EFFECT:DECLINE_IN_FEV_1_AFTER_ASPIRIN_PROVOCATION;PEOPLE;DISEASE:ASTHMA;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;AG + GG;rs4986893;EFFICACY;;;EFFICACY:HIGH_POST-CLOPIDOGREL_PLATELET_REACTIVITY;;OTHER:UNDERGOING_SCHEDULED_PERCUTANEOUS_CORONARY_INTERVENTION;CAUTION_DOSE_ADJUST
ASPIRIN, CLOPIDOGREL;NECAB1;G;rs74569896;EFFICACY;INCREASED;RISK;EFFICACY:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE);PEOPLE;OTHER:ACUTE_CORONARY_SYNDROME;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;AG + GG;rs4244285;EFFICACY;;;EFFICACY:HIGH_POST-CLOPIDOGREL_PLATELET_REACTIVITY;;OTHER:UNDERGOING_SCHEDULED_PERCUTANEOUS_CORONARY_INTERVENTION;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;T;rs9923231;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ATHEROTHROMBOTIC_EVENTS_DURING_THE_6-YEAR_FOLLOW_UP_IN_PATIENTS_WITH_MECHANICAL_HEART_VALVE_REPLACEMENT;;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;T;rs1799853;EFFICACY, TOXICITY;INCREASED;;SIDE_EFFECT:BLOOD_COAGULATION_DISORDERS;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN, CLOPIDOGREL;EFR3A;G;rs4736529;EFFICACY;INCREASED;RISK;EFFICACY:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE);PEOPLE;OTHER:ACUTE_CORONARY_SYNDROME;CAUTION_SIDE_EFFECT
DOCETAXEL, PACLITAXEL;ABCB1;AA;rs1045642;TOXICITY;INCREASED;RISK;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
GEMCITABINE;SLC28A1;GG;rs2242046;TOXICITY;DECREASED;RISK;SIDE_EFFECT:HEMATOLOGIC_TOXICITY;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED;;OTHER:WARFARIN_DOSE_DURING_3-MONTH_DAILY_OBSERVATION_PERIOD_IN_PATIENTS_WITH_MECHANICAL_HEART_VALVE_REPLACEMENT;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;C;rs1057910;EFFICACY, TOXICITY;INCREASED;;SIDE_EFFECT:BLOOD_COAGULATION_DISORDERS;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEMCITABINE;CDA;CC + CT;rs1048977;OTHER, METABOLISM/PK;INCREASED;;PK:ELIMINATION_CLEARANCE_OF_DFDU_AND_FORMATION_CLEARANCE_OF_DFDCTP;PEOPLE;DISEASE:NEOPLASMS;CAUTION_DOSE_ADJUST
PACLITAXEL;ABCB1;AA + AG;rs1045642;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;WOMEN;OTHER:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
HMG_COA_REDUCTASE_INHIBITORS;LPA;AG + GG;rs10455872;TOXICITY;INCREASED;RISK;DISEASE:CORONARY_ARTERY_DISEASE;;;CAUTION_SIDE_EFFECT
HMG_COA_REDUCTASE_INHIBITORS;LPA;AG + GG;rs10455872;TOXICITY;INCREASED;RISK;DISEASE:CORONARY_ARTERY_DISEASE;;;CAUTION_SIDE_EFFECT
CYTARABINE;ABCB1;GG;rs1128503;EFFICACY;DECREASED;;EFFICACY:SURVIVAL;PEOPLE;DISEASE:ACUTE_MYELOID_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
HMG_COA_REDUCTASE_INHIBITORS;LPA;AG + GG;rs10455872;EFFICACY;;;EFFICACY:POORER_REDUCTION_IN_LOW-DENSITY_LIPOPROTEIN_CHOLESTEROL_(LDLC);;;CAUTION_DOSE_ADJUST
ETHAMBUTOL, ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;AA;rs1799930;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;PEOPLE;OTHER:TUBERCULOSIS;CAUTION_SIDE_EFFECT
HMG_COA_REDUCTASE_INHIBITORS;LPA;AG + GG;rs10455872;EFFICACY;;;EFFICACY:POORER_REDUCTION_IN_LOW-DENSITY_LIPOPROTEIN_CHOLESTEROL_(LDLC);;;CAUTION_DOSE_ADJUST
PRAVASTATIN;ABCB1;CC;rs2032582;EFFICACY;INCREASED;;EFFICACY:PERCENT_REDUCTION_IN_LDL-CHOLESTEROL;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEMCITABINE;CMPK1;CC;rs1044457;OTHER, METABOLISM/PK;DECREASED;;PK:FORMATION_CLEARANCE_OF_DFDCTP;PEOPLE;DISEASE:NEOPLASMS;CAUTION_DOSE_ADJUST
ASPIRIN, CLOPIDOGREL;WDR24;G;rs11640115;EFFICACY;INCREASED;RISK;EFFICACY:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE);PEOPLE;OTHER:ACUTE_CORONARY_SYNDROME;CAUTION_SIDE_EFFECT
GEMCITABINE;CDA;CC;rs4655226;OTHER, METABOLISM/PK;INCREASED;;PK:ELIMINATION_CLEARANCE_OF_DFDU;PEOPLE;DISEASE:NEOPLASMS;CAUTION_DOSE_ADJUST
CARBOPLATIN, PACLITAXEL;MAD1L1;CT + TT;rs1801368;OTHER;DECREASED;;OTHER:BIOCHEMICAL_RESPONSE, OPTIMAL_CYTOREDUCTION, AND_SENSITIVITY_TO_THE_INDUCTION_CHEMOTHERAPY_TREATMENT;PEOPLE;DISEASE:OVARIAN_NEOPLASMS;CAUTION_DOSE_ADJUST
VARENICLINE;ICAM5;T;rs901886;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:SLEEP_DISORDERS;PEOPLE;OTHER:TOBACCO_USE_DISORDER, OTHER:SMOKING_CESSATION;CAUTION_SIDE_EFFECT
METHOTREXATE;ABCC1;AG;rs2238476;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS;PEOPLE;OTHER:PSORIASIS;CAUTION_SIDE_EFFECT
MITOXANTRONE;ABCB1;AA;rs1128503;OTHER;INCREASED;;OTHER:SENSITIVITY_IN_VITRO;;;CAUTION_DOSE_ADJUST
MERCAPTOPURINE, METHOTREXATE;FOLH1;A;rs61886492;TOXICITY;INCREASED;RISK;DISEASE:DRUG_TOXICITY;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
CYTARABINE;ABCB1;CC;rs2032582;EFFICACY;DECREASED;;EFFICACY:SURVIVAL;PEOPLE;DISEASE:ACUTE_MYELOID_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
ETHAMBUTOL, ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;TT;rs1041983;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;PEOPLE;OTHER:TUBERCULOSIS;CAUTION_SIDE_EFFECT
NEVIRAPINE;CYP2B6;C;rs28399499;TOXICITY;INCREASED;RISK;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME/EPIDERMAL_NECROLYSIS, TOXIC;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
NAN;PPARA;AA + AG;rs135561;OTHER;DECREASED;RISK;OTHER:ALL-CAUSE_MORTALITY;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOZAPINE;ABCB1;AA;rs1045642;TOXICITY;INCREASED;RISK;SIDE_EFFECT:AGRANULOCYTOSIS, SIDE_EFFECT:NEUTROPENIA;;;CAUTION_SIDE_EFFECT
DRUGS FOR TREATMENT OF TUBERCULOSIS, ISONIAZID;;AA;rs1495741;TOXICITY;DECREASED;;SIDE_EFFECT:MEAN_CUMULATIVE_DOSES_OF_ISONIAZID_BEFORE_THE_DEVELOPMENT_OF_ABNORMAL_LIVER-FUNCTION_TESTS_(ALFTS);PEOPLE;DISEASE:TUBERCULOSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;ATIC;C;rs4673993;EFFICACY;DECREASED;RISK;EFFICACY:DISEASE_ACTIVITY;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
DRUGS FOR TREATMENT OF TUBERCULOSIS, ISONIAZID;;AA;rs1495741;TOXICITY;DECREASED;;SIDE_EFFECT:MEAN_CUMULATIVE_DOSES_OF_ISONIAZID_BEFORE_THE_DEVELOPMENT_OF_ANTITUBERCULOSIS_DRUG-INDUCED_HEPATOTOXICITY_(ATDIH);PEOPLE;DISEASE:TUBERCULOSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIVIRALS FOR TREATMENT OF HIV INFECTIONS, COMBINATIONS;APOC3;CG + GG;rs5128;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HYPERLIPIDEMIAS;PEOPLE;OTHER:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
FLUTICASONE PROPIONATE;CYP3A4;AA + AG;rs35599367;EFFICACY;;;EFFICACY:IMPROVED_ASTHMA_CONTROL_(AS_MEASURED_BY_DECREASE_IN_AVERAGE_ASTHMA_CONTROL_SCORE);CHILDREN;DISEASE:ASTHMA;CAUTION_DOSE_ADJUST
ALLOPURINOL;CCHCR1;A;rs9263745;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;;;CAUTION_SIDE_EFFECT
LETROZOLE;;C;rs74418677;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:MUSCULOSKELETAL_PAIN, SIDE_EFFECT:ARTHRITIS, OTHER:DISCONTINUATION;WOMEN;OTHER:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
ACE INHIBITORS, PLAIN;AGTR1;C;rs5186;TOXICITY;INCREASED;;SIDE_EFFECT:MAJOR_CARDIOVASCULAR_EVENTS_(MACE)_RATE;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;CAUTION_SIDE_EFFECT
CYTARABINE, DAUNORUBICIN, ETOPOSIDE, MITOXANTRONE;SLCO1B1;CT + TT;rs2291075;EFFICACY;INCREASED;;EFFICACY:EVENT-FREE_SURVIVAL, EFFICACY:OVERALL_SURVIVAL;CHILDREN;DISEASE:ACUTE_MYELOID_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;;PK:TROUGH_BLOOD_CONCENTRATION_NORMALIZED_FOR_THE_DAILY_DOSE_(C)_PER_KILOGRAM_BODY_WEIGHT_(D)_(C/D, NG/ML/MG/KG/DAY)_RATIO_DURING_THE_FIRST_MONTH_AFTER_TRANSPLANTATION;;;CAUTION_DOSE_ADJUST
CYCLOSPORINE;CYP3A4;AA + AG;rs35599367;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DELAYED_GRAFT_FUNCTION;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
ALLOPURINOL;CYCSP5;A;rs3099844;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;;;CAUTION_SIDE_EFFECT
METHOTREXATE;FOXP3;GT;rs3761548;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS;PEOPLE;OTHER:PSORIASIS;CAUTION_SIDE_EFFECT
NAN;CHAT;G;rs1880676;OTHER;INCREASED;RISK;DISEASE:SCHIZOPHRENIA;;;CAUTION_SIDE_EFFECT
ANTIVIRALS FOR TREATMENT OF HIV INFECTIONS, COMBINATIONS;SIK3;AA + AG;rs139961185;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HYPERLIPIDEMIAS;PEOPLE;OTHER:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
OXALIPLATIN;XRCC1;TT;rs25487;EFFICACY;DECREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOSPORINE;CYP3A4;AA + AG;rs35599367;TOXICITY;DECREASED;;SIDE_EFFECT:RENAL_FUNCTION_(LOWER_CREATININE_CLEARANCE)_AT_3_MONTHS_OF_FOLLOW-UP;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
METFORMIN;SLC22A1;AA;rs622342;METABOLISM/PK;DECREASED;;PK:CL_RENAL_REFERENCE_AND_LOWER_AND_CL_SEC_REFERENCE;HEALTHY;;CAUTION_DOSE_ADJUST
ALLOPURINOL;PSORS1C2;T;rs9263733;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;;;CAUTION_SIDE_EFFECT
CYCLOSPORINE;ABCB1;AA + AG;rs1045642;TOXICITY;DECREASED;RISK;SIDE_EFFECT:DELAYED_GRAFT_FUNCTION;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;ABCG2;CT + TT;rs13120400;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;OTHER:PSORIASIS;CAUTION_SIDE_EFFECT
ALLOPURINOL;PSORS1C1, PSORS1C2;A;rs9263726;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;;;CAUTION_SIDE_EFFECT
DRUGS FOR TREATMENT OF TUBERCULOSIS;;AA;rs1495741;TOXICITY;INCREASED;RISK;DISEASE:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
EXEMESTANE, LETROZOLE;;G;rs912571;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:MUSCULOSKELETAL_PAIN, SIDE_EFFECT:ARTHRITIS, OTHER:DISCONTINUATION;WOMEN;OTHER:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIVIRALS FOR TREATMENT OF HIV INFECTIONS, COMBINATIONS;APOA5;CG + GG;rs964184;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HYPERLIPIDEMIAS;PEOPLE;OTHER:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
VALPROIC ACID;POLG;C;rs2307441;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE;;;CAUTION_SIDE_EFFECT
CISPLATIN, CYCLOPHOSPHAMIDE;ADH1C;CT;rs698;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:COMPLETE_RESPONSE;WOMEN;DISEASE:OVARIAN_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
EXEMESTANE, LETROZOLE;CCDC148;T;rs79048288;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:MUSCULOSKELETAL_PAIN, SIDE_EFFECT:ARTHRITIS, OTHER:DISCONTINUATION;WOMEN;OTHER:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
OXALIPLATIN;GSTP1;GG;rs1695;EFFICACY;INCREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;DRD2;G;rs6277;NAN;INCREASED;RISK;DISEASE:ALCOHOL_ABUSE;;;CAUTION_SIDE_EFFECT
ATORVASTATIN, LOVASTATIN, SIMVASTATIN;CYP3A4;AA + AG;rs35599367;DOSAGE, METABOLISM/PK;DECREASED;;OTHER:STATIN_DOSES_FOR_OPTIMAL_LIPID_CONTROL;;;CAUTION_DOSE_ADJUST
NAN;DRD2;G;rs1799732;NAN;INCREASED;RISK;DISEASE:ALCOHOL_ABUSE;;;CAUTION_SIDE_EFFECT
VALPROIC ACID;POLG;A;rs3087374;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE;;;CAUTION_SIDE_EFFECT
EDOXABAN;SLCO1B1;GG;rs2306283;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
EDOXABAN;ABCB1;CC;rs3842;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE;;;CAUTION_SIDE_EFFECT
HYDROCHLOROTHIAZIDE;ADD1;TT;rs4961;OTHER;INCREASED;;OTHER:HYDROCHLOROTHIAZIDE_INDUCED_CALCIUM_RETENTION;MEN;DISEASE:HYPERTENSION;CAUTION_DOSE_ADJUST
EDOXABAN;SLCO1B1;AA + AC;rs999278;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE;;;CAUTION_SIDE_EFFECT
LEVODOPA;DRD3;TT;rs6280;TOXICITY;INCREASED;RISK;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY;PEOPLE;DISEASE:PARKINSON_DISEASE;CAUTION_SIDE_EFFECT
LEVODOPA;DRD2;GG;rs1799732;TOXICITY;INCREASED;RISK;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY;PEOPLE;SIDE_EFFECT:PARKINSON_DISEASE;CAUTION_SIDE_EFFECT
BUSULFAN, CYCLOPHOSPHAMIDE;CTH;TT;rs1021737;TOXICITY;INCREASED;RISK;DISEASE:HEPATIC_VENO-OCCLUSIVE_DISEASE;CHILDREN;OTHER:HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION;CAUTION_SIDE_EFFECT
FUROSEMIDE, SPIRONOLACTONE;CYP11B2;AA + AG;rs1799998;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:DIURETIC_UNRESPONSIVENESS;PEOPLE;DISEASE:LIVER_CIRRHOSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
EDOXABAN;SLCO1B1;CC + CT;rs4149057;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE;;;CAUTION_SIDE_EFFECT
SIMVASTATIN;ABCB1;AA;rs2032582;EFFICACY;INCREASED;;EFFICACY:REDUCTION_IN_TOTAL_CHOLESTEROL;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SIMVASTATIN;ABCB1;AC;rs2032582;EFFICACY;INCREASED;;EFFICACY:REDUCTION_IN_TOTAL_CHOLESTEROL;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FUROSEMIDE, SPIRONOLACTONE;ACE;CG + GG;rs4341;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:DIURETIC_UNRESPONSIVENESS;PEOPLE;DISEASE:LIVER_CIRRHOSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
SIMVASTATIN;ABCB1;AA;rs1045642;EFFICACY;INCREASED;;EFFICACY:REDUCTION_IN_TOTAL_CHOLESTEROL;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATORVASTATIN;NOS3;CC;rs2070744;EFFICACY;INCREASED;;EFFICACY:ANTI-INFLAMMATORY_EFFECTS;HEALTHY;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATORVASTATIN;NOS3;CC;rs2070744;OTHER;INCREASED;;OTHER:WHOLE_BLOOD_NITRITE;HEALTHY;;CAUTION_DOSE_ADJUST
PAROXETINE;CYP1A2;A;rs2472304;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:REMISSION;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
FUROSEMIDE, SPIRONOLACTONE;ADD1;GT + TT;rs4961;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:DIURETIC_UNRESPONSIVENESS;PEOPLE;DISEASE:LIVER_CIRRHOSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
PAROXETINE;CYP1A2;T;rs4646425;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:REMISSION;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
ATORVASTATIN;ABCB1;AA;rs2032582;OTHER, METABOLISM/PK;INCREASED;;PK:AUC;HEALTHY;;CAUTION_DOSE_ADJUST
CISPLATIN, DOXORUBICIN;ERCC1;AA;rs11615;TOXICITY;DECREASED;RISK;SIDE_EFFECT:MUCOSITIS;PEOPLE;OTHER:OSTEOSARCOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHAMPHETAMINE;ARRB2;C;rs4790694;OTHER;INCREASED;LIKELIHOOD;DISEASE:SUBSTANCE-RELATED_DISORDERS;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;ABCG2;GT;rs2231142;TOXICITY;DECREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;OTHER:OSTEOSARCOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
PAROXETINE;CYP1A2;T;rs2470890;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:REMISSION;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2A, RIBAVIRIN;SCARB1;GG;rs10846744;EFFICACY;DECREASED;;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_FAILURE
PLATINUM COMPOUNDS, RADIOTHERAPY;;AA;rs1829346;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DERMATITIS;PEOPLE;DISEASE:NASOPHARYNGEAL_NEOPLASMS;CAUTION_SIDE_EFFECT
CISPLATIN, DOXORUBICIN;CYBA;AA + AG;rs4673;TOXICITY;DECREASED;RISK;SIDE_EFFECT:ANEMIA, SIDE_EFFECT:MUCOSITIS;PEOPLE;OTHER:OSTEOSARCOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATORVASTATIN;ABCB1;AA;rs1128503;OTHER, METABOLISM/PK;INCREASED;;PK:AUC;HEALTHY;;CAUTION_DOSE_ADJUST
CLOZAPINE;CYP2C19;AA;rs4244285;OTHER, METABOLISM/PK;INCREASED;;PK:PLASMA_CONCENTRATIONS;;;CAUTION_DOSE_ADJUST
ATORVASTATIN;ABCB1;AA;rs1045642;OTHER, METABOLISM/PK;INCREASED;;PK:AUC;HEALTHY;;CAUTION_DOSE_ADJUST
PRASUGREL;CYP2C19;A;rs4244285;EFFICACY;INCREASED;RISK;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;CAUTION_SIDE_EFFECT
IRINOTECAN;SLCO1B1;GG;rs2306283;TOXICITY;INCREASED;RISK;DISEASE:NEUTROPENIA;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
PLATINUM COMPOUNDS, RADIOTHERAPY;;AG + GG;rs2027701;TOXICITY;DECREASED;RISK;SIDE_EFFECT:NEUTROPENIA;PEOPLE;DISEASE:NASOPHARYNGEAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
SIMVASTATIN;ABCB1;AA;rs1128503;OTHER, METABOLISM/PK;INCREASED;;PK:AUC_SIMVASTATIN_ACID;HEALTHY;;CAUTION_DOSE_ADJUST
PRASUGREL;CYP2C19;A;rs4244285;EFFICACY;;;EFFICACY:HIGHER_PLATELET_REACTIVITY_INDEX_(PRI)_VASODILATOR-STIMULATED_PHOSPHOPROTEIN_(VASP)_AT_1_MONTH_OF_TREATMENT;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;CAUTION_DOSE_ADJUST
ANTIPSYCHOTICS;SLC18A2;TT;rs363341;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:PSYCHOTIC_DISORDER;CAUTION_SIDE_EFFECT
PLATINUM COMPOUNDS, RADIOTHERAPY;;CC;rs1059698;TOXICITY;DECREASED;RISK;SIDE_EFFECT:MYELOSUPPRESSION;PEOPLE;DISEASE:NASOPHARYNGEAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIPSYCHOTICS;GRIK3;CT;rs1334802;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:PSYCHOTIC_DISORDER;CAUTION_SIDE_EFFECT
PLATINUM COMPOUNDS, RADIOTHERAPY;;AA + AG;rs73594404;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ANEMIA, SIDE_EFFECT:NEUTROPENIA;PEOPLE;DISEASE:NASOPHARYNGEAL_NEOPLASMS;CAUTION_SIDE_EFFECT
PAROXETINE;CYP1A2;TT;rs4646427;EFFICACY;;;EFFICACY:SLOWER_RESPONSE_TIME;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DOSE_ADJUST
METHOTREXATE;SHMT1;AG + GG;rs1979277;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ABDOMINAL_PAIN;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
PAROXETINE;CYP1A2;A;rs762551;TOXICITY;INCREASED;RISK;DISEASE:FATIGUE;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;HTR2A;AG + GG;rs9567733;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:PSYCHOTIC_DISORDER;CAUTION_SIDE_EFFECT
PLATINUM COMPOUNDS, RADIOTHERAPY;;CC;rs36080650;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DERMATITIS;PEOPLE;DISEASE:NASOPHARYNGEAL_NEOPLASMS;CAUTION_SIDE_EFFECT
METHOTREXATE;ABCB1;AG + GG;rs1045642;TOXICITY;INCREASED;RISK;SIDE_EFFECT:MUCOSITIS;PEOPLE;OTHER:OSTEOSARCOMA;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;DRD2;AA + AG;rs1124491;TOXICITY;DECREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:PSYCHOTIC_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM COMPOUNDS, RADIOTHERAPY;MEG3;CC;rs10132552;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ANEMIA;PEOPLE;DISEASE:NASOPHARYNGEAL_NEOPLASMS;CAUTION_SIDE_EFFECT
WARFARIN;CYP4F2;CT + TT;rs2108622;METABOLISM/PK;INCREASED;;PK:_SERUM_R_-WARFARIN_CONCENTRATION;;;CAUTION_DOSE_ADJUST
MYCOPHENOLATE MOFETIL;UGT1A9;C;rs72551330;TOXICITY;;;SIDE_EFFECT:DIMINISHED_ESTIMATED_GLOMERULAR_FILTRATION_RATE_(EGFR)_DURING_THE_FIRST_YEAR_AFTER_ENGRAFTMENT;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
METHOTREXATE;ABCC2;AT + TT;rs17222723;TOXICITY;INCREASED;RISK;SIDE_EFFECT:LEUKOPENIA;PEOPLE;OTHER:OSTEOSARCOMA;CAUTION_SIDE_EFFECT
METHAMPHETAMINE;SLC6A9;T;rs2486001;TOXICITY, OTHER;INCREASED;RISK;DISEASE:SUBSTANCE-RELATED_DISORDERS;;;CAUTION_SIDE_EFFECT
MYCOPHENOLATE MOFETIL;UGT1A9;C;rs72551330;TOXICITY;INCREASED;RISK;DISEASE:PROTEINURIA;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS, CLOZAPINE, OLANZAPINE, RISPERIDONE;HTR2C;C;rs1414334;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:METABOLIC_SYNDROME;PEOPLE;DISEASE:SCHIZOAFFECTIVE_DISORDER, DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
NAN;KCNH2;T;rs1805123;OTHER;INCREASED;LIKELIHOOD;DISEASE:ATRIAL_FIBRILLATION;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3, IFNL4;TT;rs8099917;EFFICACY;INCREASED;;EFFICACY:RAPID_VIROLOGICAL_RESPONSE_(RVR), EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHAMPHETAMINE;ARRB2;A;rs2036657;OTHER;INCREASED;LIKELIHOOD;DISEASE:SUBSTANCE-RELATED_DISORDERS;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;MTHFR;AA + AG;rs1801133;EFFICACY;DECREASED;;EFFICACY:SURVIVAL;CHILDREN;DISEASE:NON-HODGKIN_LYMPHOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
ASPIRIN;P2RY1;CT;rs1065776;EFFICACY;INCREASED;RISK;EFFICACY:_ASPIRIN-RESISTANT_PHENOTYPE;;;CAUTION_SIDE_EFFECT
ROSUVASTATIN;SLCO1B1;C;rs4149056;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:STATIN-RELATED_MYOPATHY;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;CAUTION_SIDE_EFFECT
NAN;CRHR1;AA;rs110402;OTHER;INCREASED;RISK;DISEASE:MAJOR_DEPRESSIVE_DISORDER;;;CAUTION_SIDE_EFFECT
NICOTINE;ARRB2;A;rs4790694;OTHER;INCREASED;RISK;DISEASE:TOBACCO_USE_DISORDER;;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;A;rs7900194;DOSAGE;DECREASED;;EFFICACY:MEDIAN_WEEKLY_WARFARIN_DOSE_REQUIREMENTS;;;CAUTION_DOSE_ADJUST
METHOTREXATE;MTHFR;AA + AG;rs1801133;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HEMATOLOGICAL_TOXICITY;CHILDREN;DISEASE:NON-HODGKIN_LYMPHOMA;CAUTION_SIDE_EFFECT
ATORVASTATIN;ABCB1;A;rs1045642;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:MYALGIA;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;CAUTION_SIDE_EFFECT
CAPECITABINE;MTHFR;GG;rs1801133;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:TREATMENT_INTERRUPTION;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
CARVEDILOL;ADRB2;C;rs1042714;EFFICACY;INCREASED;;EFFICACY:REDUCTION_IN_RESTING_BLOOD_PRESSURE;HEALTHY;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;PON1;CC + CT;rs662;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY;CHILDREN;OTHER:MUCOCUTANEOUS_LYMPH_NODE_SYNDROME;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIDEPRESSANTS;NTRK2;G;rs1439050;TOXICITY;INCREASED;RISK;DISEASE:SUICIDE;PEOPLE;DISEASE:DEPRESSIVE_DISORDER;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;AA;rs10929302;TOXICITY;INCREASED;RISK;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:COLONIC_NEOPLASMS;CAUTION_SIDE_EFFECT
BEVACIZUMAB;;CT + TT;rs1478947;TOXICITY;INCREASED;RISK;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY;PEOPLE;OTHER:PROSTATIC_NEOPLASMS;CAUTION_SIDE_EFFECT
ASPIRIN;TBXA2R;AA;rs4523;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ASPIRIN_RESISTANCE;HEALTHY;;CAUTION_SIDE_EFFECT
METHAMPHETAMINE;ARRB2;T;rs1045280;OTHER;INCREASED;LIKELIHOOD;DISEASE:SUBSTANCE-RELATED_DISORDERS;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;GP1BA;CC;rs6065;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ASPIRIN_RESISTANCE;HEALTHY;;CAUTION_SIDE_EFFECT
OLANZAPINE;PMCH;G;rs7973796;OTHER;INCREASED;LIKELIHOOD;SIDE_EFFECT:OBESITY;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN;UGT1A1;AA;rs10929302;TOXICITY;INCREASED;;DISEASE:NEUTROPENIA;PEOPLE;DISEASE:COLONIC_NEOPLASMS;CAUTION_SIDE_EFFECT
WARFARIN;VKORC1;AA;rs9934438;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OVER-ANTICOAGULATION;;;CAUTION_SIDE_EFFECT
ASPIRIN;TGFB1;AA + AG;rs1800469;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ASPIRIN-INTOLERANT_CHRONIC_URTICARIA;;;CAUTION_SIDE_EFFECT
WARFARIN;F7;AA;rs6046;EFFICACY;INCREASED;;EFFICACY:SEN_SITIVITY_TO_WARFARIN_DURING_INDUCTION;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;F7;AA;rs6046;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OVER-ANTICOAGULATION;;;CAUTION_SIDE_EFFECT
CARBOPLATIN, CISPLATIN, DOCETAXEL, GEMCITABINE, PACLITAXEL, VINORELBINE;MTHFR;AA;rs1801133;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:RESPONSE_TO_CHEMOTHERAPY;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN, CLOPIDOGREL;KRTAP10-4, TSPEAR;A;rs201441480;EFFICACY;INCREASED;RISK;EFFICACY:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE);PEOPLE;OTHER:ACUTE_CORONARY_SYNDROME;CAUTION_SIDE_EFFECT
CAPECITABINE, FLUOROURACIL;DPYD;CT;rs3918290;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY, SIDE_EFFECT:TREATMENT_MODIFICATION;PEOPLE;OTHER:NEOPLASMS;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFD1;AA + AG;rs2236225;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ANEMIA;PEOPLE;OTHER:OSTEOSARCOMA;CAUTION_SIDE_EFFECT
PACLITAXEL;ABCB1;AA;rs1128503;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;WOMEN;OTHER:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;GT + TT;rs1801131;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ANEMIA, SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;OTHER:OSTEOSARCOMA;CAUTION_SIDE_EFFECT
ATORVASTATIN;NOS3;CC;rs2070744;OTHER;DECREASED;;OTHER:ERYTHROCYTE_PLASMA_MEMBRANE_FLUIDITY;HEALTHY;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;A;rs7900194;METABOLISM/PK;DECREASED;;PK:S-WARFARIN_CLEARANCE;;;CAUTION_DOSE_ADJUST
ASPIRIN, CLOPIDOGREL;ECHS1;T;rs140410716;EFFICACY;INCREASED;RISK;EFFICACY:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE);PEOPLE;OTHER:ACUTE_CORONARY_SYNDROME;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;PIGB;G;rs12050587;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA, SIDE_EFFECT:NEUTROPENIA;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
ATORVASTATIN, FLUVASTATIN, LOVASTATIN, PITAVASTATIN, SIMVASTATIN;SLCO1B1;CT + TT;rs4149035;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE;;;CAUTION_SIDE_EFFECT
ASPIRIN, CLOPIDOGREL;AGAP3;A;rs75750968;EFFICACY;INCREASED;RISK;EFFICACY:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE);PEOPLE;OTHER:ACUTE_CORONARY_SYNDROME;CAUTION_SIDE_EFFECT
ATORVASTATIN, FLUVASTATIN, LOVASTATIN, PITAVASTATIN, SIMVASTATIN;SLCO1B1;AA + AG;rs11045818;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE;;;CAUTION_SIDE_EFFECT
GEMCITABINE;SLC28A2;CC;rs11854484;TOXICITY;DECREASED;RISK;SIDE_EFFECT:HEMATOLOGIC_TOXICITY;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
SIMVASTATIN;SLCO1B1;CC;rs4149056;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DISCONTINUATION;;;CAUTION_SIDE_EFFECT
ACETAMINOPHEN;TLR4;AA + AG;rs1927911;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ASTHMA;CHILDREN;;CAUTION_SIDE_EFFECT
TIMOLOL;;AA + AG;rs16947;TOXICITY;INCREASED;RISK;DISEASE:BRADYCARDIA;PEOPLE;DISEASE:OPEN-ANGLE_GLAUCOMA;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;;C;rs11636687;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA, SIDE_EFFECT:NEUTROPENIA;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
GEMCITABINE;SLC28A2;CC;rs1060896;TOXICITY;DECREASED;RISK;SIDE_EFFECT:HEMATOLOGIC_TOXICITY;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATORVASTATIN, FLUVASTATIN, LOVASTATIN, PITAVASTATIN, SIMVASTATIN;ABCG2;TT;rs2622629;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE;;;CAUTION_SIDE_EFFECT
PRAVASTATIN;SLCO1B1;CC + CT;rs4149056;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DISCONTINUATION;;;CAUTION_SIDE_EFFECT
ASPIRIN, CLOPIDOGREL;ZDHHC3;A;rs3749187;EFFICACY;INCREASED;RISK;EFFICACY:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE);PEOPLE;OTHER:ACUTE_CORONARY_SYNDROME;CAUTION_SIDE_EFFECT
VENLAFAXINE;CYP2D6;CT + TT;rs3892097;METABOLISM/PK;INCREASED;;PK:VENLAFAXINE_CONCENTRATION_PER_UNIT_DOSE;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DOSE_ADJUST
NAN;ADORA2A;AC + CC;rs5996696;OTHER;DECREASED;RISK;DISEASE:PARKINSON_DISEASE;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;ADORA2A;CT;rs71651683;OTHER;DECREASED;RISK;DISEASE:PARKINSON_DISEASE;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;IFITM3;GG;rs12252;OTHER;INCREASED;SEVERITY;OTHER:COVID-19;PEOPLE;OTHER:COVID-19;CAUTION_SIDE_EFFECT
METHOTREXATE;ABCB1;AG + GG;rs1128503;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;PEOPLE;OTHER:PRECURSOR_T-CELL_LYMPHOBLASTIC_LEUKEMIA-LYMPHOMA, OTHER:OSTEOSARCOMA,OTHER:NON-HODGKIN_LYMPHOMA;CAUTION_SIDE_EFFECT
CAFFEINE;CYP1A2;CC;rs762551;OTHER;DECREASED;RISK;DISEASE:PARKINSON_DISEASE;PEOPLE;OTHER:COFFEE_CONSUMPTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAFFEINE;CYP1A2;CC;rs2470890;OTHER;DECREASED;RISK;DISEASE:PARKINSON_DISEASE;PEOPLE;OTHER:COFFEE_CONSUMPTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOZAPINE;ABCB1;AA;rs1045642;METABOLISM/PK;INCREASED;;PK:PLASMA_CONCENTRATIONS;;;CAUTION_DOSE_ADJUST
HMG_COA_REDUCTASE_INHIBITORS;SLCO1B1;CC;rs4149056;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:STATIN-RELATED_MYOPATHY;;;CAUTION_SIDE_EFFECT
WARFARIN;VKORC1;AA;rs9934438;EFFICACY;INCREASED;;EFFICACY:MEAN_AUC_(AREA_UNDER_CURVE)_PROTHROMBIN_TIME;MEN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;ITPA;CC;rs1127354;EFFICACY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ANEMIA;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;KCNJ11;TT;rs5219;NAN;INCREASED;LIKELIHOOD;DISEASE:DIABETES_MELLITUS, TYPE_2;;;CAUTION_DOSE_ADJUST
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;TT;rs8099917;EFFICACY;INCREASED;;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATORVASTATIN, SIMVASTATIN;SLCO1B1;A;rs374113543;EFFICACY;INCREASED;SEVERITY;EFFICACY:HYPERCHOLESTEROLEMIA;;;CAUTION_SIDE_EFFECT
ATORVASTATIN, SIMVASTATIN;SLCO1B1;A;rs373327528;EFFICACY;INCREASED;SEVERITY;EFFICACY:HYPERCHOLESTEROLEMIA;;;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;DNAAF9;AA;rs6051702;EFFICACY;DECREASED;LIKELIHOOD;SIDE_EFFECT:THROMBOCYTOPENIA;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_FAILURE
DEXAMETHASONE;SERPINE1;AA + AG;rs6092;TOXICITY;INCREASED;RISK;DISEASE:OSTEONECROSIS;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
GEMCITABINE;CDA;AA + AC;rs2072671;TOXICITY;INCREASED;SEVERITY;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:PANCREATIC_NEOPLASMS;CAUTION_SIDE_EFFECT
NICOTINE;CHRNB2;GG;rs2072661;EFFICACY, TOXICITY, OTHER;INCREASED;;OTHER:ABSTINENCE;;OTHER:SMOKERS;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:HEPATITIS_D_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTHRACYCLINES AND RELATED SUBSTANCES;SLC28A3;A;rs7853758;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:CARDIOTOXICITY;CHILDREN;DISEASE:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;DPYD;CT;rs3918290;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN, SIMEPREVIR;IFNL3, IFNL4;TT;rs8099917;EFFICACY;INCREASED;;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOZAPINE;CYP1A2;A;rs2069514;OTHER;INCREASED;LIKELIHOOD;SIDE_EFFECT:ELEVATED_INSULIN_LEVELS;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN, DOXORUBICIN, METHOTREXATE;MTHFR;AA + AG;rs1801133;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEPHROTOXICITY;PEOPLE;OTHER:OSTEOSARCOMA;CAUTION_SIDE_EFFECT
CISPLATIN, DOXORUBICIN, METHOTREXATE;GSTP1;AG + GG;rs1695;TOXICITY;INCREASED;RISK;SIDE_EFFECT:CARDIOTOXICITY;PEOPLE;OTHER:OSTEOSARCOMA;CAUTION_SIDE_EFFECT
EVEROLIMUS;MTOR;C;rs2024627;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;OTHER:BREAST_NEOPLASMS, OTHER:KIDNEY_NEOPLASMS,OTHER:NEUROENDOCRINE_TUMORS;LIKELIHOOD_THERAPEUTIC_FAILURE
CAPECITABINE;DPYD;CT;rs3918290;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
CISPLATIN, DOXORUBICIN, METHOTREXATE;ERCC2;GG + GT;rs13181;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEPHROTOXICITY;PEOPLE;OTHER:OSTEOSARCOMA;CAUTION_SIDE_EFFECT
NICOTINE;CHRM2;T;rs324650;TOXICITY, OTHER;INCREASED;RISK;DISEASE:TOBACCO_USE_DISORDER;;;CAUTION_SIDE_EFFECT
CETUXIMAB, PANITUMUMAB;EGFR;GT + TT;rs712829;EFFICACY;INCREASED;;EFFICACY:SURVIVAL;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;VDR;C;rs1544410;NAN;INCREASED;RISK;DISEASE:ASTHMA;;;CAUTION_SIDE_EFFECT
CLOZAPINE;CYP1A2;del;rs35694136;OTHER;INCREASED;LIKELIHOOD;SIDE_EFFECT:ELEVATED_INSULIN_LEVELS;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
CETUXIMAB, PANITUMUMAB;AREG;AA + AG;rs9996584;EFFICACY;INCREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
BEVACIZUMAB, IRINOTECAN;VEGFA;GG;rs1570360;EFFICACY;DECREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;PON1;CT + TT;rs662;OTHER;INCREASED;;OTHER:SMALL-DENSE_LDL_LEVELS;;;CAUTION_DOSE_ADJUST
PROTON PUMP INHIBITORS;TRPM6;T;rs3750425;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HYPOMAGNESEMIA_PRIMARY;;;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;CT;rs3918290;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:COLONIC_NEOPLASMS;CAUTION_SIDE_EFFECT
NAN;FKBP5;CC + CT;rs1360780;EFFICACY;INCREASED;LIKELIHOOD;;PEOPLE;DISEASE:DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOZAPINE, OLANZAPINE, QUETIAPINE, RISPERIDONE;HTR2C, MIR1264, MIR1912;GG;rs12836771;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:METABOLIC_SYNDROME;PEOPLE;DISEASE:PSYCHOTIC_DISORDER, DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
METHOTREXATE;GGH;AA;rs3758149;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
HALOTHANE, SUCCINYLCHOLINE;RYR1;T;rs193922803;OTHER;INCREASED;RISK;DISEASE:MALIGT_HYPERTHERMIA;;;CAUTION_SIDE_EFFECT
CETUXIMAB, PANITUMUMAB;AREG;AA;rs11942466;EFFICACY;DECREASED;;EFFICACY:SURVIVAL;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
SIMVASTATIN;ABCB1;AA;rs1045642;OTHER, METABOLISM/PK;INCREASED;;PK:AUC_SIMVASTATIN_ACID;HEALTHY;;CAUTION_DOSE_ADJUST
PROTON PUMP INHIBITORS;TRPM6;C;rs2274924;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HYPOMAGNESEMIA_PRIMARY;;;CAUTION_SIDE_EFFECT
DOXORUBICIN;GSTP1;AG + GG;rs1695;TOXICITY;INCREASED;RISK;SIDE_EFFECT:LEUKOPENIA;PEOPLE;OTHER:OSTEOSARCOMA;CAUTION_SIDE_EFFECT
DOXORUBICIN;ERCC1;AA + AC;rs3212986;TOXICITY;DECREASED;RISK;SIDE_EFFECT:INFECTIOUS_DISEASE, SIDE_EFFECT:LEUKOPENIA;PEOPLE;OTHER:OSTEOSARCOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOZAPINE, OLANZAPINE, QUETIAPINE, RISPERIDONE;HTR2C;CC;rs518147;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:METABOLIC_SYNDROME;PEOPLE;DISEASE:PSYCHOTIC_DISORDER, DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
SIMVASTATIN;ABCB1;AA;rs2032582;OTHER, METABOLISM/PK;INCREASED;;PK:AUC_SIMVASTATIN_ACID;HEALTHY;;CAUTION_DOSE_ADJUST
DESFLURANE, ENFLURANE, HALOTHANE, ISOFLURANE, SEVOFLURANE, SUCCINYLCHOLINE;RYR1;T;rs118192172;OTHER;INCREASED;RISK;DISEASE:MALIGT_HYPERTHERMIA;;;CAUTION_SIDE_EFFECT
NEVIRAPINE;CYP2B6;C;rs2054675;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
ASUNAPREVIR, DACLATASVIR, DIRECT ACTING ANTIVIRALS, LEDIPASVIR / SOFOSBUVIR, OMBITASVIR / PARITAPREVIR / RITONAVIR;IFNL3, IFNL4;GG + GT;rs8099917;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HYPERCHOLESTEROLEMIA;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;CAUTION_SIDE_EFFECT
DESFLURANE, ENFLURANE, HALOTHANE, ISOFLURANE, SEVOFLURANE, SUCCINYLCHOLINE;RYR1;A;rs118192176;OTHER;INCREASED;RISK;DISEASE:MALIGT_HYPERTHERMIA;;;CAUTION_SIDE_EFFECT
DESFLURANE, ENFLURANE, HALOTHANE, ISOFLURANE, SEVOFLURANE, SUCCINYLCHOLINE;RYR1;T;rs118192177;OTHER;INCREASED;RISK;DISEASE:MALIGT_HYPERTHERMIA;;;CAUTION_SIDE_EFFECT
DESFLURANE, ENFLURANE, HALOTHANE, ISOFLURANE, SEVOFLURANE, SUCCINYLCHOLINE;RYR1;A;rs121918593;OTHER;INCREASED;RISK;DISEASE:MALIGT_HYPERTHERMIA;;;CAUTION_SIDE_EFFECT
NEVIRAPINE;CYP2B6;C;rs3786547;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
CAPECITABINE;DPYD;CC + CT;rs1801160;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:TREATMENT_INTERRUPTION;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
DESFLURANE, ENFLURANE, HALOTHANE, ISOFLURANE, SEVOFLURANE, SUCCINYLCHOLINE;RYR1;A;rs121918592;OTHER;INCREASED;RISK;DISEASE:MALIGT_HYPERTHERMIA;;;CAUTION_SIDE_EFFECT
CAPECITABINE;DPYD;C;rs1801159;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DIARRHEA;WOMEN;OTHER:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
METHYLPHENIDATE;DRD3;CT + TT;rs6280;TOXICITY;INCREASED;;SIDE_EFFECT:INTOLERABILITY;CHILDREN;DISEASE:AUTISM_SPECTRUM_DISORDER;CAUTION_SIDE_EFFECT
CISPLATIN;ACYP2;AA + AG;rs1872328;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OTOTOXICITY;CHILDREN;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
CLOPIDOGREL;PON1;CT + TT;rs662;TOXICITY;INCREASED;RISK;SIDE_EFFECT:CARDIOVASCULAR_EVENTS_(COMPOSITE_OF_CARDIAC_DEATH, MI, STENT_THROMBOSIS)_IN_KOREAN_PATIENTS_AFTER_PCI;;;CAUTION_SIDE_EFFECT
DOXORUBICIN;XPC;GG + GT;rs2228001;TOXICITY;DECREASED;RISK;SIDE_EFFECT:INFECTIOUS_DISEASE;PEOPLE;OTHER:OSTEOSARCOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIR;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
HEROIN;OPRM1;GG;rs9479757;TOXICITY;INCREASED;SEVERITY;OTHER:HEROIN_DEPENDENCE;;;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;TT;rs8099917;EFFICACY;INCREASED;;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
NALTREXONE;OPRM1;AG + GG;rs1799971;EFFICACY;INCREASED;;EFFICACY:BLUNTING_OF_ALCOHOL_CRAVING;HEALTHY;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIR;IFNL3;TT;rs8099917;EFFICACY;;;EFFICACY:HIGHER_RATE_OF_SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;CAUTION_DOSE_ADJUST
PD-1/PDL-1 (PROGRAMMED CELL DEATH PROTEIN 1/DEATH LIGAND 1) INHIBITORS;FTO;CC;rs1125338;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:OVERALL_SURVIVAL;PEOPLE;OTHER:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
BETA-LACTAM ANTIBACTERIALS, PENICILLINS;;T;rs71542416;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_HYPERSENSITIVITY;;;CAUTION_SIDE_EFFECT
IRINOTECAN;ABCG1;GG;rs425215;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
XELOX;ABCA2;AA;rs2271862;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA;PEOPLE;OTHER:COLORECTAL_NEOPLASMS, OTHER:METASTATIC_NEOPLASM;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN;ABCC5;CC;rs562;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
OPIOIDS;TACR1;AG + GG;rs6715729;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:OVERDOSE;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;DRD2;CT + TT;rs4436578;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:OVERDOSE;;;CAUTION_SIDE_EFFECT
OPIOIDS;CYP3A5;CC + CT;rs776746;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:OVERDOSE;;;CAUTION_SIDE_EFFECT
IRINOTECAN;SLCO1B1;AG;rs2306283;TOXICITY;DECREASED;LIKELIHOOD;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
TRAMADOL;ABCB1;AA;rs1045642;TOXICITY;DECREASED;RISK;OTHER:OPIOID-RELATED_DISORDERS;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;ABCB1;CC + TT;rs2032582;EFFICACY;DECREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL;;;LIKELIHOOD_THERAPEUTIC_FAILURE
CARBOPLATIN, PACLITAXEL;SLCO1B3;AA;rs7311358;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ANEMIA;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
METHOTREXATE;FPGS;CC + CT;rs10106;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
AZATHIOPRINE, MERCAPTOPURINE;NUDT15;T;rs116855232;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ALOPECIA, SIDE_EFFECT:LEUKOPENIA;PEOPLE;DISEASE:INFLAMMATORY_BOWEL_DISEASES;CAUTION_SIDE_EFFECT
NAN;HIF1A;AG;rs11549467;EFFICACY;DECREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL;;;LIKELIHOOD_THERAPEUTIC_FAILURE
PD-1/PDL-1 (PROGRAMMED CELL DEATH PROTEIN 1/DEATH LIGAND 1) INHIBITORS;FTO;GG;rs12596638;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:PROGRESSION-FREE_SURVIVAL, EFFICACY:OVERALL_SURVIVAL;PEOPLE;OTHER:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
COUMARIN, NICOTINE;CYP2A6;C;rs28399433;OTHER, METABOLISM/PK;DECREASED;;OTHER:EXPRESSION_OF_ENZYME_CONTRIBUTING_TO_THE_METABOLISM;;;CAUTION_DOSE_ADJUST
SUNITINIB;ABCG2;TT;rs2231142;TOXICITY;INCREASED;RISK;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;CAUTION_SIDE_EFFECT
NAN;PEMT;T;rs7946;NAN;INCREASED;RISK;DISEASE:FATTY_LIVER_DISEASE;;;CAUTION_SIDE_EFFECT
ANTIBIOTICS;LGALS3;AT + TT;rs11125;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HYPERSENSITIVITY;PEOPLE;DISEASE:INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
SUNITINIB;ABCG2;TT;rs2231142;TOXICITY;INCREASED;RISK;DISEASE:THROMBOCYTOPENIA;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;CAUTION_SIDE_EFFECT
PD-1/PDL-1 (PROGRAMMED CELL DEATH PROTEIN 1/DEATH LIGAND 1) INHIBITORS;;CG + GG;rs12600192;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS;PEOPLE;OTHER:NEOPLASMS;CAUTION_SIDE_EFFECT
SUNITINIB;ABCG2;TT;rs2231142;TOXICITY;INCREASED;RISK;DISEASE:NEUTROPENIA;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;CAUTION_SIDE_EFFECT
NAN;VKORC1;AA + AG;rs9934438;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OVER-ANTICOAGULATION;;;CAUTION_SIDE_EFFECT
SUNITINIB;ABCG2;TT;rs2231142;TOXICITY;INCREASED;RISK;DISEASE:HAND-FOOT_SYNDROME;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;CAUTION_SIDE_EFFECT
METHOTREXATE;DHFR;T;rs1650723;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:MUCOSITIS;PEOPLE;DISEASE:OSTEOSARCOMA;CAUTION_SIDE_EFFECT
PD-1/PDL-1 (PROGRAMMED CELL DEATH PROTEIN 1/DEATH LIGAND 1) INHIBITORS;;CC;rs12600192;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:PROGRESSION-FREE_SURVIVAL, EFFICACY:OVERALL_SURVIVAL;PEOPLE;OTHER:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;ABCG2;AG;rs2231135;TOXICITY;INCREASED;RISK;SIDE_EFFECT:MUCOSITIS;PEOPLE;DISEASE:OSTEOSARCOMA;CAUTION_SIDE_EFFECT
NICOTINE;HINT1;CC;rs3852209;OTHER;INCREASED;LIKELIHOOD;OTHER:SMOKING_CESSATION;MEN;OTHER:TOBACCO_USE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;SLC19A1;TT;rs1051266;EFFICACY;INCREASED;RISK;EFFICACY:METASTATIC_NEOPLASM;PEOPLE;DISEASE:OSTEOSARCOMA;CAUTION_SIDE_EFFECT
NAN;VDR;CC;rs1544410;OTHER;DECREASED;LIKELIHOOD;OTHER:PRE-ECLAMPSIA;WOMEN;OTHER:PREGNANCY;LIKELIHOOD_THERAPEUTIC_FAILURE
ETHAMBUTOL, ISONIAZID / PYRAZINAMIDE / RIFAMPIN;ALAS1;AA + AG;rs352139;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;PEOPLE;OTHER:TUBERCULOSIS;CAUTION_SIDE_EFFECT
RISPERIDONE;SLC6A4;AA;rs3813034;OTHER;INCREASED;LIKELIHOOD;SIDE_EFFECT:WEIGHT_GAIN;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ISONIAZID, RIFAMPIN;GSTP1;AA;rs1695;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE, DOXORUBICIN;ALDH1A1;A;rs3764435;TOXICITY;INCREASED;RISK;DISEASE:DRUG_TOXICITY;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE, DOXORUBICIN;ALDH1A1;A;rs168351;TOXICITY;INCREASED;RISK;DISEASE:DRUG_TOXICITY;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;A;rs1801133;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
CARBOPLATIN, PACLITAXEL;SLCO1B3;GG;rs4149117;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ANEMIA;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;AA + AG;rs117648444;EFFICACY;INCREASED;;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHANOL, NALTREXONE;OPRM1;AG + GG;rs1799971;EFFICACY;INCREASED;SEVERITY;EFFICACY:INTOXICATION;HEALTHY;;CAUTION_SIDE_EFFECT
ISONIAZID, RIFAMPIN;NAT2;TT;rs1799929;TOXICITY, METABOLISM/PK;INCREASED;LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
OPIOIDS;COMT;AG;rs4680;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HYPERALGESIA;PEOPLE;OTHER:PAIN;CAUTION_SIDE_EFFECT
ISONIAZID, RIFAMPIN;NAT2;AA;rs1799930;TOXICITY, METABOLISM/PK;INCREASED;LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
METHOTREXATE;SLC19A1;CC;rs1051266;EFFICACY;INCREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:OSTEOSARCOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;DHFR;CC;rs1053129;TOXICITY;INCREASED;RISK;EFFICACY:METASTATIC_NEOPLASM;PEOPLE;DISEASE:OSTEOSARCOMA;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;GG;rs1801133;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:OSTEOSARCOMA;CAUTION_SIDE_EFFECT
TAMOXIFEN;HS6ST3;A;rs118042719;EFFICACY;DECREASED;RISK;EFFICACY:RECURRENCE_FREE_SURVIVAL;WOMEN;OTHER:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
PHENYTOIN;ABCB1;A;rs2229107;OTHER, METABOLISM/PK;INCREASED;;PK:PLASMA_DRUG_LEVELS;PEOPLE;OTHER:NO_DISEASE;CAUTION_DOSE_ADJUST
"""3,4-METHYLENEDIOXYMETHAMPHETAMINE"", ""COCAINE"", ""ETHANOL"", ""OPIOIDS""";OPRM1;AG;rs1799971;TOXICITY;INCREASED;RISK;OTHER:SUBSTANCE-RELATED_DISORDERS;;;CAUTION_SIDE_EFFECT
TRASTUZUMAB;FCGR3A;CC;rs396991;EFFICACY;INCREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
MYCOPHENOLIC ACID, TACROLIMUS;ABCC2;C;rs717620;EFFICACY;INCREASED;LIKELIHOOD;"""EFFICACY:PRIMARY_GRAFT_FAILURE"", ""EFFICACY:KIDNEY_TUBULAR_NECROSIS, ACUTE""";PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHADONE;CYP2B6;TT;rs1038376;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:POSTOPERATIVE_NAUSEA_AND_VOMITING;CHILDREN;OTHER:POSTOPERATIVE_PAIN, OTHER:SCOLIOSIS;CAUTION_SIDE_EFFECT
TRASTUZUMAB;FCGR2A;AA;rs1801274;EFFICACY;INCREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;SLC19A1;CC + CT;rs1051266;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
SUCCINYLCHOLINE;BCHE;C;rs1799807;METABOLISM/PK;;;SIDE_EFFECT:BUTYRYLCHOLINESTERASE_DEFICIENCY;;;CAUTION_DOSE_ADJUST
SUCCINYLCHOLINE;BCHE;T;rs1803274;METABOLISM/PK;;;SIDE_EFFECT:BUTYRYLCHOLINESTERASE_DEFICIENCY;;;CAUTION_DOSE_ADJUST
FLUOROURACIL;DPYD;CT;rs3918290;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:THROMBOCYTOPENIA;WOMEN;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C18;A;rs1042192;EFFICACY;INCREASED;;EFFICACY:PLATELET_REACTIVITY;PEOPLE;OTHER:CARDIOVASCULAR_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOZAPINE;HNMT;GG;rs2737385;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:SEDATION;PEOPLE;DISEASE:SCHIZOAFFECTIVE_DISORDER, DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;DPYD;CT;rs1801160;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;INCREASED;;EFFICACY:PLATELET_REACTIVITY;PEOPLE;OTHER:CARDIOVASCULAR_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHADONE;CYP2B6;AG + GG;rs2279343;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:POSTOPERATIVE_NAUSEA_AND_VOMITING;CHILDREN;OTHER:POSTOPERATIVE_PAIN, OTHER:SCOLIOSIS;CAUTION_SIDE_EFFECT
CLOPIDOGREL;NOC3L;A;rs12572897;EFFICACY;INCREASED;;EFFICACY:PLATELET_REACTIVITY;PEOPLE;OTHER:CARDIOVASCULAR_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TAMOXIFEN;LPP;A;rs6790761;EFFICACY;DECREASED;RISK;EFFICACY:RECURRENCE_FREE_SURVIVAL;WOMEN;OTHER:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHAMBUTOL, ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;T;rs1799929;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;OTHER:TUBERCULOSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
SUNITINIB;ABCB1;AA + AG;rs1128503;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA, DISEASE:GASTROINTESTINAL_STROMAL_TUMORS;CAUTION_SIDE_EFFECT
NICOTINE;CHRNA5;A;rs16969968;TOXICITY, OTHER;INCREASED;LIKELIHOOD;DISEASE:TOBACCO_USE_DISORDER;;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C8;A;rs1058932;EFFICACY;INCREASED;;EFFICACY:PLATELET_REACTIVITY;PEOPLE;OTHER:CARDIOVASCULAR_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
SUNITINIB;ABCB1;AA + AC;rs2032582;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA, DISEASE:GASTROINTESTINAL_STROMAL_TUMORS;CAUTION_SIDE_EFFECT
NICOTINE;CHRNA3;A;rs578776;TOXICITY, OTHER;DECREASED;LIKELIHOOD;DISEASE:TOBACCO_USE_DISORDER;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TAMOXIFEN;LPP;A;rs77693286;EFFICACY;DECREASED;RISK;EFFICACY:RECURRENCE_FREE_SURVIVAL;WOMEN;OTHER:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTHRACYCLINES AND RELATED SUBSTANCES;UGT1A6;T;rs17863783;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:CARDIOTOXICITY;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA_OTHER:SARCOMA,OTHER:NEUROBLASTOMA, OTHER:OSTEOSARCOMA, OTHER:LYMPHOMA;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;CT + TT;rs776746;EFFICACY;INCREASED;RISK;DISEASE:TRANSPLANT_REJECTION;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
RIFAMPIN;RIPOR2;C;rs10946739;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
ANTHRACYCLINES AND RELATED SUBSTANCES;RARG;A;rs2229774;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:CARDIOTOXICITY;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA_OTHER:SARCOMA,OTHER:NEUROBLASTOMA, OTHER:OSTEOSARCOMA, OTHER:LYMPHOMA;CAUTION_SIDE_EFFECT
NAN;EGFR;AA;rs763317;EFFICACY;INCREASED;RISK;EFFICACY:DEATH;PEOPLE;OTHER:LUNG_NEOPLASMS;CAUTION_SIDE_EFFECT
NAN;GAL;C;rs948854;OTHER;INCREASED;SEVERITY;DISEASE:ANXIETY_DISORDERS;WOMEN;DISEASE:ANXIETY_DISORDERS;CAUTION_SIDE_EFFECT
HMG_COA_REDUCTASE_INHIBITORS;SLCO1B1;CC + CT;rs4149056;TOXICITY;INCREASED;RISK;SIDE_EFFECT:STATIN-RELATED_MYOPATHY;;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;ZNRD1-AS1;AG + GG;rs3869066;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;;;CAUTION_SIDE_EFFECT
ATAZANAVIR;ABCB1;AA;rs2032582;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HYPERBILIRUBINEMIA;HEALTHY;;CAUTION_SIDE_EFFECT
HMG_COA_REDUCTASE_INHIBITORS;EYS;G;rs1337512;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:RHABDOMYOLYSIS;PEOPLE;DISEASE:CARDIOVASCULAR_DISEASE;CAUTION_SIDE_EFFECT
RIFAMPIN;AGBL4;A;rs393994;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
ATAZANAVIR;ABCB1;AA;rs1045642;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HYPERBILIRUBINEMIA;HEALTHY;;CAUTION_SIDE_EFFECT
PHENYTOIN;CYP2C9;T;rs1799853;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:EPILEPSY;CAUTION_SIDE_EFFECT
HMG_COA_REDUCTASE_INHIBITORS, OTHER COMBINATIONS;EYS;A;rs9342288;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:RHABDOMYOLYSIS;PEOPLE;DISEASE:CARDIOVASCULAR_DISEASE;CAUTION_SIDE_EFFECT
ASPIRIN;SLC30A9;A;rs1047626;TOXICITY, OTHER;DECREASED;RISK;SIDE_EFFECT:ASPIRIN-INDUCED_ASTHMA;PEOPLE;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESCITALOPRAM, NORTRIPTYLINE;BDNF;C;rs962369;EFFICACY, TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:SUICIDAL_IDEATION;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACE INHIBITORS, PLAIN;KCNMA1;G;rs2253201;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ANGIOEDEMA;;;CAUTION_SIDE_EFFECT
HMG_COA_REDUCTASE_INHIBITORS, OTHER COMBINATIONS;EYS;A;rs3857532;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:RHABDOMYOLYSIS;PEOPLE;DISEASE:CARDIOVASCULAR_DISEASE;CAUTION_SIDE_EFFECT
ASPIRIN;TSC1;C;rs7862221;TOXICITY, OTHER;INCREASED;RISK;SIDE_EFFECT:ASPIRIN-INDUCED_ASTHMA;PEOPLE;DISEASE:ASTHMA;CAUTION_SIDE_EFFECT
RIFAMPIN;AGBL4;G;rs320003;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
ASPIRIN;THRA;G;rs11819745;TOXICITY, OTHER;INCREASED;RISK;SIDE_EFFECT:ASPIRIN-INDUCED_ASTHMA;PEOPLE;DISEASE:ASTHMA;CAUTION_SIDE_EFFECT
RIFAMPIN;CUX2;G;rs7958375;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
ANTHRACYCLINES AND RELATED SUBSTANCES;SLC28A3;A;rs7853758;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:CARDIOTOXICITY;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA_OTHER:SARCOMA,OTHER:NEUROBLASTOMA, OTHER:OSTEOSARCOMA, OTHER:LYMPHOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
HMG_COA_REDUCTASE_INHIBITORS;GATM;A;rs9806699;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:STATIN-RELATED_MYOPATHY;PEOPLE;DISEASE:CARDIOVASCULAR_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
HMG_COA_REDUCTASE_INHIBITORS;SLCO1B1;CC + CT;rs4363657;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:STATIN-RELATED_MYOPATHY;PEOPLE;DISEASE:CARDIOVASCULAR_DISEASE;CAUTION_SIDE_EFFECT
ASPIRIN;CHIA;A;rs3818822;TOXICITY, OTHER;INCREASED;RISK;SIDE_EFFECT:ASPIRIN-INDUCED_ASTHMA;PEOPLE;DISEASE:ASTHMA;CAUTION_SIDE_EFFECT
ATAZANAVIR;ABCB1;AA;rs1128503;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HYPERBILIRUBINEMIA;HEALTHY;;CAUTION_SIDE_EFFECT
ASPIRIN;;C;rs1074373;TOXICITY, OTHER;DECREASED;RISK;SIDE_EFFECT:ASPIRIN-INDUCED_ASTHMA;PEOPLE;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
PHENYTOIN;CYP2C9;T;rs1799853;TOXICITY, METABOLISM/PK;INCREASED;;PK:PLASMA_FREE_PHENYTOIN_CONCENTRATION;PEOPLE;DISEASE:EPILEPSY;CAUTION_SIDE_EFFECT
PHENYTOIN;CYP2C9;C;rs1057910;TOXICITY, METABOLISM/PK;INCREASED;;PK:PLASMA_FREE_PHENYTOIN_CONCENTRATION;PEOPLE;DISEASE:EPILEPSY;CAUTION_SIDE_EFFECT
HEROIN;GRM3;A;rs1990040;OTHER;INCREASED;RISK;DISEASE:HEROIN_DEPENDENCE;;;CAUTION_SIDE_EFFECT
ASPIRIN;ZBTB22;C;rs3130100;TOXICITY, OTHER;INCREASED;RISK;SIDE_EFFECT:ASPIRIN-INDUCED_ASTHMA;PEOPLE;DISEASE:ASTHMA;CAUTION_SIDE_EFFECT
CYCLOSPORINE, SIROLIMUS, TACROLIMUS;TCF7L2;T;rs7903146;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:DIABETES_MELLITUS;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
HMG_COA_REDUCTASE_INHIBITORS;SLCO1B1;CC + CT;rs4149056;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:RHABDOMYOLYSIS;PEOPLE;DISEASE:CARDIOVASCULAR_DISEASE;CAUTION_SIDE_EFFECT
PHENYTOIN;CYP2C9;C;rs1057910;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:EPILEPSY;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;EFFICACY, TOXICITY;INCREASED;RISK;SIDE_EFFECT:STENT_THROMBOSIS;;OTHER:PATIENTS_UNDERGOING_PERCUTANEOUS_CORONARY_INTERVENTION;CAUTION_SIDE_EFFECT
ASPIRIN;HLA-DPB1;C;rs3097671;TOXICITY, OTHER;INCREASED;RISK;SIDE_EFFECT:ASPIRIN-INDUCED_ASTHMA;PEOPLE;DISEASE:ASTHMA;CAUTION_SIDE_EFFECT
ASPIRIN;HLA-DPB2;C;rs3129294;TOXICITY, OTHER;INCREASED;RISK;SIDE_EFFECT:ASPIRIN-INDUCED_ASTHMA;PEOPLE;DISEASE:ASTHMA;CAUTION_SIDE_EFFECT
ASPIRIN;HLA-DPB1;G;rs1042151;TOXICITY, OTHER;INCREASED;RISK;SIDE_EFFECT:ASPIRIN-INDUCED_ASTHMA;PEOPLE;DISEASE:ASTHMA;CAUTION_SIDE_EFFECT
ASPIRIN;HLA-DPB1;C;rs1042136;TOXICITY, OTHER;INCREASED;RISK;SIDE_EFFECT:ASPIRIN-INDUCED_ASTHMA;PEOPLE;DISEASE:ASTHMA;CAUTION_SIDE_EFFECT
ATORVASTATIN, SIMVASTATIN;SLCO1B1;CC + CT;rs4149056;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:STATIN-RELATED_MYOPATHY;;;CAUTION_SIDE_EFFECT
RIFAMPIN;RIPOR2;A;rs10946737;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
PREDNISOLONE;GATA3;AA;rs3824662;PD;INCREASED;RISK;SIDE_EFFECT:SEPSIS;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
RIFAMPIN;AGBL4;A;rs319952;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
NICOTINE;OPRM1;AA;rs10485057;TOXICITY;INCREASED;RISK;OTHER:TOBACCO_USE_DISORDER;;;CAUTION_SIDE_EFFECT
ETHANOL;DPP6;C;rs2533200;TOXICITY;DECREASED;RISK;SIDE_EFFECT:ALCOHOL_ABUSE;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN, CYCLOPHOSPHAMIDE;EPHX1;CT;rs1051740;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEPHROTOXICITY_GRADES_1-4;WOMEN;DISEASE:OVARIAN_NEOPLASMS;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;;G;rs192543598;TOXICITY;INCREASED;RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;;;CAUTION_SIDE_EFFECT
ETHANOL;;T;rs7900002;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ALCOHOL_ABUSE;;;CAUTION_SIDE_EFFECT
ETHANOL;;T;rs2582405;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ALCOHOL_ABUSE;;;CAUTION_SIDE_EFFECT
CISPLATIN, CYCLOPHOSPHAMIDE;NAT2;CT;rs1801280;TOXICITY;INCREASED;RISK;DISEASE:ANEMIA;WOMEN;DISEASE:OVARIAN_NEOPLASMS;CAUTION_SIDE_EFFECT
ETHANOL;;T;rs56722963;TOXICITY;DECREASED;RISK;SIDE_EFFECT:ALCOHOL_ABUSE;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN, CYCLOPHOSPHAMIDE;MUTYH;CT;rs3219484;TOXICITY;DECREASED;RISK;SIDE_EFFECT:NEUTROPENIA_GRADE_3-4;WOMEN;DISEASE:OVARIAN_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE;ALK;G;rs187926838;TOXICITY;INCREASED;RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;;;CAUTION_SIDE_EFFECT
ETHANOL;MED19, TMX2;A;rs576859;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ALCOHOL_ABUSE;;;CAUTION_SIDE_EFFECT
METHOTREXATE;ATIC;CC;rs7563206;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
ENZYMES;A2M;TT;rs669;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HEMORRHAGIC_TRANSFORMATION;PEOPLE;DISEASE:STROKE;CAUTION_SIDE_EFFECT
METHOTREXATE;ATIC;GT + TT;rs3821353;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
CHOP, RITUXIMAB;NCF4;AA;rs1883112;EFFICACY;DECREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL, EFFICACY:OVERALL_SURVIVAL;PEOPLE;OTHER:LYMPHOMA, LARGE_B-CELL*^DIFFUSE;LIKELIHOOD_THERAPEUTIC_FAILURE
ENZYMES;F12;GG;rs1801020;TOXICITY;INCREASED;RISK;DISEASE:DEATH;PEOPLE;DISEASE:STROKE;CAUTION_SIDE_EFFECT
SUNITINIB;ABCB1;A;rs1128503;EFFICACY;DECREASED;;EFFICACY:OVERALL_SURVIVAL, EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;ATIC;CG + GG;rs2372536;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
ETHANOL;;T;rs6589386;TOXICITY;DECREASED;RISK;SIDE_EFFECT:ALCOHOL_ABUSE;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHANOL;OPRM1;AG + GG;rs1799971;TOXICITY;INCREASED;RISK;OTHER:ALCOHOL_ABUSE;MEN;;CAUTION_SIDE_EFFECT
ETHANOL;ADH1C;A;rs13125415;TOXICITY;DECREASED;RISK;SIDE_EFFECT:ALCOHOL_ABUSE;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;ATIC;CC;rs12995526;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
CISPLATIN, CYCLOPHOSPHAMIDE;RAD52;AG;rs11226;TOXICITY;DECREASED;RISK;SIDE_EFFECT:NEUTROPENIA_GRADE_3-4;WOMEN;DISEASE:OVARIAN_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHANOL;SLC39A8;A;rs13135092;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ALCOHOL_ABUSE;;;CAUTION_SIDE_EFFECT
CISPLATIN, CYCLOPHOSPHAMIDE;LIG3;CC;rs1052536;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUTROPENIA_GRADE_3-4;WOMEN;DISEASE:OVARIAN_NEOPLASMS;CAUTION_SIDE_EFFECT
ABIRATERONE, PREDNISOLONE;TSPYL1;AA;rs3828743;EFFICACY;DECREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:PROSTATIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
OPIOIDS;COMT;AA + AG;rs4680;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:NAUSEA, SIDE_EFFECT:FATIGUE, SIDE_EFFECT:DEPRESSION;PEOPLE;OTHER:PAIN, OTHER:NEOPLASMS;CAUTION_SIDE_EFFECT
CISPLATIN, FLUOROURACIL, RADIOTHERAPY;XRCC1;AA + AG;rs1799782;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:OVERALL_SURVIVAL;MEN;OTHER:CARCINOMA, SQUAMOUS_CELL;LIKELIHOOD_THERAPEUTIC_SUCCESS
INDINAVIR;UGT1A1;AG;rs4148323;TOXICITY;INCREASED;RISK;DISEASE:HYPERBILIRUBINEMIA;PEOPLE;OTHER:HIV;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;;EFFICACY:RAPID_VIROLOGICAL_RESPONSE_(RVR), EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHANOL;ADH1B;T;rs1229984;TOXICITY;DECREASED;RISK;SIDE_EFFECT:ALCOHOL_ABUSE;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;FPGS;AA;rs10760502;EFFICACY, TOXICITY, OTHER;DECREASED;LIKELIHOOD;OTHER:DISCONTINUATION;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;FPGS;TT;rs10106;EFFICACY, TOXICITY, OTHER;DECREASED;LIKELIHOOD;OTHER:DISCONTINUATION;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
CAPECITABINE, FLUOROURACIL, TEGAFUR;DPYD;AC + CC;rs55886062;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
METHOTREXATE;FPGS;TT;rs10106;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
ETHANOL;;T;rs9679319;TOXICITY;DECREASED;RISK;SIDE_EFFECT:ALCOHOL_ABUSE;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHANOL;;A;rs1402398;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ALCOHOL_ABUSE;;;CAUTION_SIDE_EFFECT
ETHANOL;THSD7B;A;rs13382553;TOXICITY;DECREASED;RISK;SIDE_EFFECT:ALCOHOL_ABUSE;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2A, RIBAVIRIN;;GG;rs4273729;EFFICACY;INCREASED;;EFFICACY:RAPID_VIROLOGICAL_RESPONSE_(RVR), EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3;AA;rs12980275;EFFICACY;INCREASED;;EFFICACY:RAPID_VIROLOGICAL_RESPONSE_(RVR), EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;ABCB1;TT;rs868755;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
ETHANOL;;A;rs2673136;TOXICITY;DECREASED;RISK;SIDE_EFFECT:ALCOHOL_ABUSE;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHANOL;;A;rs13129401;TOXICITY;DECREASED;RISK;SIDE_EFFECT:ALCOHOL_ABUSE;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;ABCB1;TT;rs10280623;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
ETHANOL;CADM2;A;rs62250713;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ALCOHOL_ABUSE;;;CAUTION_SIDE_EFFECT
ETHANOL;ADH1B;T;rs75967634;TOXICITY;DECREASED;RISK;SIDE_EFFECT:ALCOHOL_ABUSE;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBOPLATIN, CYCLOPHOSPHAMIDE, ETOPOSIDE, LOMUSTINE, METHOTREXATE, VINCRISTINE;METTL3;AA + AG;rs1139130;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:FEVER, SIDE_EFFECT:MUCOSITIS;CHILDREN;OTHER:MEDULLOBLASTOMA, OTHER:GLIOBLASTOMA,OTHER:ASTROCYTOMA, OTHER:BRAIN_NEOPLASMS;CAUTION_SIDE_EFFECT
HEROIN;OPRM1;AG + GG;rs1799971;TOXICITY;INCREASED;SEVERITY;OTHER:HEROIN_DEPENDENCE;MEN;;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;;GG;rs4273729;EFFICACY;INCREASED;;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;CYP2A6;T;rs56113850;OTHER;DECREASED;LIKELIHOOD;OTHER:SMOKING_CESSATION;WOMEN;OTHER:TOBACCO_USE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
ETHANOL;PDE4B;A;rs6421482;TOXICITY;DECREASED;RISK;SIDE_EFFECT:ALCOHOL_ABUSE;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHANOL;;A;rs61767420;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ALCOHOL_ABUSE;;;CAUTION_SIDE_EFFECT
ETHANOL;GCKR;T;rs1260326;TOXICITY;DECREASED;RISK;SIDE_EFFECT:ALCOHOL_ABUSE;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHANOL;;T;rs494904;TOXICITY;DECREASED;RISK;SIDE_EFFECT:ALCOHOL_ABUSE;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;CHRNA5;AA + AT;rs503464;OTHER;INCREASED;LIKELIHOOD;OTHER:SMOKING_CESSATION;WOMEN;OTHER:TOBACCO_USE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;SPATA9;A;rs72783407;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ELEVATED_LIVER_ENZYMES;PEOPLE;OTHER:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
METHOTREXATE;BIRC5;GG;rs9904341;EFFICACY;INCREASED;;EFFICACY:DISEASE_ACTIVITY_SCORE_28_IN_RHEUMATOID_ARTHRITIS;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
PROTEIN KINASE INHIBITORS;STAT6;TT;rs324011;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:ADVERSE_EVENTS;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;TT;rs8099917;EFFICACY;INCREASED;;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;DPYD;CT + TT;rs3918290;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
CAPECITABINE, FLUOROURACIL, TEGAFUR;DPYD;CT + TT;rs3918290;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
OPIOIDS;ANKK1, DRD2;AA + AG;rs1800497;TOXICITY;INCREASED;RISK;OTHER:OPIOID-RELATED_DISORDERS;;;CAUTION_SIDE_EFFECT
TAMOXIFEN;C1QTNF6;C;rs114557570;EFFICACY;DECREASED;RISK;EFFICACY:RECURRENCE_FREE_SURVIVAL;WOMEN;OTHER:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;CHRNA5;AA + AT;rs637137;OTHER;INCREASED;LIKELIHOOD;OTHER:SMOKING_CESSATION;WOMEN;OTHER:TOBACCO_USE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOCETAXEL;VEGFA;CC;rs833061;EFFICACY;INCREASED;;EFFICACY:OVERALL_SURVIVAL;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOCETAXEL;VEGFA;GG;rs13207351;EFFICACY;DECREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
DOCETAXEL;VEGFA;GG;rs35864111;EFFICACY;INCREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPARAGINASE, CYCLOPHOSPHAMIDE, CYTARABINE, DAUNORUBICIN, DEXAMETHASONE, DOXORUBICIN, LEUCOVORIN, MERCAPTOPURINE, METHOTREXATE, PEGASPARGASE, PREDNISONE, THIOGUANINE, VINCRISTINE;GATA3;A;rs3824662;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:RELAPSE;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPARAGINASE, CYCLOPHOSPHAMIDE, CYTARABINE, DAUNORUBICIN, DEXAMETHASONE, DOXORUBICIN, LEUCOVORIN, MERCAPTOPURINE, METHOTREXATE, PEGASPARGASE, PREDNISONE, THIOGUANINE, VINCRISTINE;GATA3;A;rs3824662;EFFICACY;INCREASED;;EFFICACY:MINIMAL_RESIDUAL_DISEASE;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOCETAXEL;VEGFA;AA;rs699947;EFFICACY;INCREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
EXEMESTANE;;C;rs62293499;EFFICACY;DECREASED;RISK;EFFICACY:RECURRENCE;PEOPLE;OTHER:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN, CLOPIDOGREL;CYP4F2;CT;rs2108622;OTHER;INCREASED;;OTHER:PLATELET_AGGREGATION_WITH_EPINEPHRINE;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;CAUTION_DOSE_ADJUST
FLUOROURACIL;DPYD;AT + TT;rs4294451;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:OVERALL_SURVIVAL;;;LIKELIHOOD_THERAPEUTIC_FAILURE
CITALOPRAM;COL26A1;T;rs17135437;TOXICITY;INCREASED;;SIDE_EFFECT:HEARING_AND_VISION-RELATED_SIDE-EFFECTS;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_SIDE_EFFECT
CITALOPRAM;;A;rs16965962;TOXICITY;INCREASED;;SIDE_EFFECT:GENERAL_SIDE-EFFECT_BURDEN;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_SIDE_EFFECT
ALLOPURINOL;PSORS1C1, PSORS1C2;A;rs9263726;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;;;CAUTION_SIDE_EFFECT
ASPIRIN;ACE;CC + CT;rs4292;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ASPIRIN_INTOLERANCE;PEOPLE;DISEASE:ASTHMA;CAUTION_SIDE_EFFECT
CLOPIDOGREL;P2RY12;AA;rs6809699;EFFICACY;;;EFFICACY:STRONGER_AGGREAGTION;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;CAUTION_DOSE_ADJUST
ANTHRACYCLINES AND RELATED SUBSTANCES;SLC22A17;T;rs4982753;TOXICITY;DECREASED;RISK;SIDE_EFFECT:CARDIOTOXICITY;PEOPLE;OTHER:HODGKIN_DISEASE, OTHER:SARCOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;T;rs776746;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DIABETES_MELLITUS;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;AT + TT;rs4294451;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;ACE2;T;rs2074192;OTHER;INCREASED;SEVERITY;OTHER:COVID-19;PEOPLE;OTHER:COVID-19;CAUTION_SIDE_EFFECT
CLOPIDOGREL;P2RY12;AA;rs6809699;EFFICACY;INCREASED;RISK;EFFICACY:CLOPIDOGREL_RESISTANCE;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;CAUTION_SIDE_EFFECT
ASPIRIN, CLOPIDOGREL;F2R;T;rs168753;EFFICACY;DECREASED;;EFFICACY:PLATELET_REACTIVITY;PEOPLE;OTHER:TRANSIENT_ISCHEMIC_ATTACK, OTHER:STROKE;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;P2RY12;AA;rs6809699;EFFICACY;INCREASED;RISK;EFFICACY:NON-RESPONSE;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;CAUTION_SIDE_EFFECT
ASPIRIN;P2RY1;CT;rs1065776;EFFICACY;INCREASED;;EFFICACY:NET_DECREASE_IN_AA-INDUCED_PLATELET_AGGREGATION_AFTER_ASPIRIN_TREATMENT;HEALTHY;;LIKELIHOOD_THERAPEUTIC_SUCCESS
MERCAPTOPURINE;ITPA;AC;rs1127354;METABOLISM/PK;INCREASED;;PK:6-MMPN_LEVELS;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DOSE_ADJUST
NAN;FGFR2;G;rs1219648;TOXICITY, OTHER;INCREASED;RISK;DISEASE:BREAST_NEOPLASMS;WOMEN;DISEASE:HODGKIN_DISEASE;CAUTION_SIDE_EFFECT
ANASTROZOLE;;T;rs6735923;EFFICACY;INCREASED;RISK;EFFICACY:RECURRENCE;PEOPLE;OTHER:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
ACENOCOUMAROL;CYP2C9;CT + TT;rs1799853;TOXICITY;INCREASED;RISK;DISEASE:GASTROINTESTINAL_HEMORRHAGE;;;CAUTION_SIDE_EFFECT
ASPIRIN, CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;INCREASED;;EFFICACY:PLATELET_REACTIVITY;PEOPLE;OTHER:TRANSIENT_ISCHEMIC_ATTACK, OTHER:STROKE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTHRACYCLINES AND RELATED SUBSTANCES;SLC10A2;A;rs7319981;TOXICITY;INCREASED;RISK;SIDE_EFFECT:CARDIOTOXICITY;PEOPLE;OTHER:HODGKIN_DISEASE, OTHER:SARCOMA;CAUTION_SIDE_EFFECT
NAN;AGT;AG;rs699;OTHER;INCREASED;LIKELIHOOD;OTHER:COVID-19;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANASTROZOLE;;C;rs1877193;EFFICACY;INCREASED;RISK;EFFICACY:RECURRENCE;PEOPLE;OTHER:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
CAPECITABINE;DPYD;A;rs2786783;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:DRUG_TOXICITY;;;CAUTION_SIDE_EFFECT
NAN;COMT;CC + CG;rs4818;OTHER;INCREASED;SEVERITY;OTHER:PAIN;CHILDREN;OTHER:DENTAL_CARIES, OTHER:TOOTH_DISORDER,OTHER:TOOTHACHE;CAUTION_SIDE_EFFECT
DRUGS FOR TREATMENT OF TUBERCULOSIS;UGT2B7;G;rs7662029;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;;;CAUTION_SIDE_EFFECT
DRUGS FOR TREATMENT OF TUBERCULOSIS;UGT2B7;C;rs7439366;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;EFFICACY, TOXICITY;INCREASED;;SIDE_EFFECT:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE);PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;LIKELIHOOD_THERAPEUTIC_SUCCESS
CEFACLOR;LIMD1;C;rs62242178;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_HYPERSENSITIVITY;;;CAUTION_SIDE_EFFECT
WARFARIN;VKORC1;TT;rs9923231;DOSAGE;DECREASED;;OTHER:WARFARIN_DOSE;;;CAUTION_DOSE_ADJUST
CEFACLOR;LIMD1;G;rs62242177;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_HYPERSENSITIVITY;;;CAUTION_SIDE_EFFECT
REPAGLINIDE;SLCO1B1;CC;rs4149056;OTHER, METABOLISM/PK;INCREASED;;PK:MEAN_PLASMA_AUC;;;CAUTION_DOSE_ADJUST
DIHYDROPYRIDINE DERIVATIVES;ADRA1A;AG + GG;rs1048101;EFFICACY;DECREASED;RISK;EFFICACY:KIDNEY_DISORDER;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
THALIDOMIDE;XRCC5;AG;rs1051685;EFFICACY;INCREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:MULTIPLE_MYELOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
THALIDOMIDE;ERCC1;AC + CC;rs735482;EFFICACY;INCREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:MULTIPLE_MYELOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOZAPINE, OLANZAPINE;GCG;C;rs13429709;OTHER;INCREASED;;DISEASE:WEIGHT_GAIN;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_DOSE_ADJUST
CLOZAPINE, OLANZAPINE;GLP1R;T;rs2268639;OTHER;INCREASED;;DISEASE:WEIGHT_GAIN;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_DOSE_ADJUST
NICOTINE;OPRM1;AA + AG;rs1799971;DOSAGE;INCREASED;;OTHER:SMOKING;CHILDREN;;CAUTION_DOSE_ADJUST
NICOTINE;OPRM1;AG + GG;rs1799971;DOSAGE;INCREASED;;OTHER:SMOKING;CHILDREN;;CAUTION_DOSE_ADJUST
TOLCAPONE;COMT;AA;rs4680;EFFICACY;INCREASED;SEVERITY;EFFICACY:ALCOHOL_ABUSE;PEOPLE;OTHER:ALCOHOL-RELATED_DISORDERS;CAUTION_SIDE_EFFECT
NICOTINE;UGT2B10;AG + GG;rs112561475;METABOLISM/PK;INCREASED;;PK:GLUCURONIDATION_OF_NICOTINE;;;CAUTION_DOSE_ADJUST
NICOTINE;UGT2B10;T;rs61750900;METABOLISM/PK;DECREASED;;PK:NICOTINE_GLUCURONIDATION;;;CAUTION_DOSE_ADJUST
CLOZAPINE, OLANZAPINE;GCG;CC;rs13429709;OTHER;INCREASED;;DISEASE:WEIGHT_GAIN;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_DOSE_ADJUST
DIHYDROPYRIDINE DERIVATIVES;CYP3A5;TT;rs776746;EFFICACY;INCREASED;RISK;EFFICACY:KIDNEY_DISORDER;;;CAUTION_SIDE_EFFECT
METHAMPHETAMINE;HTR1A;A;rs878567;TOXICITY, OTHER;;;DISEASE:PSYCHOTIC_DISORDER;PEOPLE;DISEASE:SUBSTANCE-RELATED_DISORDERS;CAUTION_DOSE_ADJUST
METHOTREXATE;MTHFR;A;rs1801133;TOXICITY;INCREASED;RISK;SIDE_EFFECT:MUCOSITIS;CHILDREN;OTHER:LYMPHOMA, OTHER:OSTEOSARCOMA,OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
CISPLATIN, FLUOROURACIL, MITOXANTRONE;GALNT14;TT;rs9679162;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:OVERALL_SURVIVAL, EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:HEPATOCELLULAR_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPTOPRIL;ACE;AA;rs4291;EFFICACY;DECREASED;SEVERITY;DISEASE:KIDNEY_FAILURE;PEOPLE;DISEASE:ALZHEIMER_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIEPILEPTICS;;T;rs4471527;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;;;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;LEPR;G;rs1137101;OTHER;INCREASED;LIKELIHOOD;DISEASE:OBESITY;WOMEN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTHRACYCLINES AND RELATED SUBSTANCES;HAS3;A;rs2232228;TOXICITY;DECREASED;RISK;SIDE_EFFECT:CARDIOTOXICITY;PEOPLE;OTHER:HODGKIN_DISEASE, OTHER:SARCOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHANOL;OPRM1;AG + GG;rs1799971;TOXICITY;INCREASED;RISK;OTHER:ALCOHOL_ABUSE;CHILDREN;;CAUTION_SIDE_EFFECT
ANTIEPILEPTICS;;T;rs77542827;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;;;CAUTION_SIDE_EFFECT
STAVUDINE;SAMHD1;A;rs8124728;TOXICITY;DECREASED;RISK;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARVEDILOL;ADRB1;CC;rs1801253;EFFICACY;DECREASED;;EFFICACY:RESPONSE_(HEART-RATE_LOWERING);PEOPLE;DISEASE:HEART_FAILURE;LIKELIHOOD_THERAPEUTIC_FAILURE
IRINOTECAN;TGFB1;AG + GG;rs1800469;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DIARRHEA;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
ANTHRACYCLINES AND RELATED SUBSTANCES;RARG;A;rs2229774;TOXICITY;INCREASED;RISK;SIDE_EFFECT:CARDIOTOXICITY;PEOPLE;OTHER:HODGKIN_DISEASE, OTHER:SARCOMA;CAUTION_SIDE_EFFECT
CYTARABINE, DAUNORUBICIN, MITOXANTRONE;DCK;CT;rs4643786;EFFICACY;INCREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:ACUTE_MYELOID_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIEPILEPTICS;NIPAL2;A;rs199755581;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;;;CAUTION_SIDE_EFFECT
OXALIPLATIN, PACLITAXEL;ABCB1;AA + AG;rs1045642;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;PEOPLE;OTHER:BREAST_NEOPLASMS, OTHER:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
AMLODIPINE, CHLORTHALIDONE, LISINOPRIL;ACE;AA + AT;rs4291;OTHER;DECREASED;;SIDE_EFFECT:FASTING_GLUCOSE;PEOPLE;DISEASE:HYPERTENSION;CAUTION_DOSE_ADJUST
SORAFENIB;KDR;T;rs1870377;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HAND-FOOT_SYNDROME;;;CAUTION_SIDE_EFFECT
IRINOTECAN;TGFBR2;GG;rs3087465;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DIARRHEA;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
SORAFENIB;KDR;T;rs1870377;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HYPERTENSION;;;CAUTION_SIDE_EFFECT
SUNITINIB;FLT4;CT;rs307826;EFFICACY;;;EFFICACY:REDUCED_PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;CAUTION_DOSE_ADJUST
SUNITINIB;CYP3A5;TT;rs776746;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DOSE_REDUCTIONS_DUE_TO_TOXICITY;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;CAUTION_SIDE_EFFECT
RITODRINE;PDE4B;AA;rs17128809;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ADVERSE_EVENTS;;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE, DOCETAXEL, EPIRUBICIN;ABCC1;CC;rs246221;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;WOMEN;OTHER:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
SUNITINIB;FLT4;AC;rs307821;EFFICACY;DECREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
BETA BLOCKING AGENTS;ADRB2;AG + GG;rs1042713;EFFICACY;INCREASED;RISK;EFFICACY:HEART_TRANSPLANTATION, EFFICACY:DEATH;PEOPLE;OTHER:HEART_FAILURE;CAUTION_SIDE_EFFECT
SALBUTAMOL;;C;rs9552679;EFFICACY;DECREASED;;EFFICACY:BRONCHODILATOR_RESPONSE_(FEV1);;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_FAILURE
SALBUTAMOL;COL22A1;T;rs6988229;EFFICACY;INCREASED;;EFFICACY:BRONCHODILATOR_RESPONSE_(FEV1);;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
SALBUTAMOL;;T;rs17495520;EFFICACY;INCREASED;;EFFICACY:BRONCHODILATOR_RESPONSE_(FEV1);;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN, CLOPIDOGREL;CDH15;C;rs72819363;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:CORONARY_RESTENOSIS, EFFICACY:DISEASE_PROGRESSION;PEOPLE;OTHER:CORONARY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIEPILEPTICS;DDX12P;C;rs77491650;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SALBUTAMOL;;T;rs1663332;EFFICACY;INCREASED;;EFFICACY:BRONCHODILATOR_RESPONSE_(FEV1);;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
SALBUTAMOL;;G;rs1663330;EFFICACY;INCREASED;;EFFICACY:BRONCHODILATOR_RESPONSE_(FEV1);;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
SALBUTAMOL;;A;rs17701271;EFFICACY;INCREASED;;EFFICACY:BRONCHODILATOR_RESPONSE_(FEV1);;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
SALBUTAMOL;;T;rs518350;EFFICACY;INCREASED;;EFFICACY:BRONCHODILATOR_RESPONSE_(FEV1);;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
SALBUTAMOL;;G;rs10511905;EFFICACY;DECREASED;;EFFICACY:BRONCHODILATOR_RESPONSE_(FEV1);;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_FAILURE
SORAFENIB;ABCC2;CC;rs717620;TOXICITY;INCREASED;RISK;SIDE_EFFECT:EXANTHEMA;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;CAUTION_SIDE_EFFECT
SALBUTAMOL;CLOCK;A;rs1522113;EFFICACY;INCREASED;;EFFICACY:BRONCHODILATOR_RESPONSE_(FEV1);;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
SALBUTAMOL;;A;rs1423515;EFFICACY;INCREASED;;EFFICACY:BRONCHODILATOR_RESPONSE_(FEV1);;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
SALBUTAMOL;;T;rs1419555;EFFICACY;INCREASED;;EFFICACY:BRONCHODILATOR_RESPONSE_(FEV1);;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
SALBUTAMOL;;C;rs6002674;EFFICACY;DECREASED;;EFFICACY:BRONCHODILATOR_RESPONSE_(FEV1);;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_FAILURE
NAN;ACE2;A;rs2106809;OTHER;INCREASED;LIKELIHOOD;OTHER:COVID-19;MEN;OTHER:COVID-19;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOXORUBICIN;GSTP1;AG + GG;rs1695;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:MUCOSITIS;WOMEN;OTHER:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
METHOTREXATE;ABCB1;A;rs1045642;TOXICITY;INCREASED;RISK;SIDE_EFFECT:MUCOSITIS;CHILDREN;OTHER:LYMPHOMA, OTHER:OSTEOSARCOMA,OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
ASPIRIN, CLOPIDOGREL;CDH13;AA + AG;rs11859453;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:CORONARY_RESTENOSIS, EFFICACY:DISEASE_PROGRESSION;PEOPLE;OTHER:CORONARY_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
ALLOPURINOL;CYCSP5;A;rs3099844;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;;;CAUTION_SIDE_EFFECT
ALLOPURINOL;;T;rs1634776;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;;;CAUTION_SIDE_EFFECT
PACLITAXEL;ABCB1;AA + AG;rs1128503;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;PEOPLE;OTHER:BREAST_NEOPLASMS, OTHER:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
SALBUTAMOL;;A;rs11252394;EFFICACY;INCREASED;;EFFICACY:BRONCHODILATOR_RESPONSE_(FEV1);;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
SORAFENIB;SLCO1B1;CT + TT;rs4149056;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:THROMBOCYTOPENIA;;;CAUTION_SIDE_EFFECT
COCAINE;GABRA2;G;rs11503014;TOXICITY;INCREASED;SEVERITY;OTHER:COCAINE_DEPENDENCE;;;CAUTION_SIDE_EFFECT
COCAINE;OPRM1;C;rs2236256;TOXICITY;DECREASED;SEVERITY;OTHER:COCAINE_DEPENDENCE;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SORAFENIB;SLCO1B1;AG + GG;rs2306283;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HYPERBILIRUBINEMIA;;;CAUTION_SIDE_EFFECT
SORAFENIB;SLCO1B1;AG + GG;rs2306283;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:DIARRHEA;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;ABCB1;A;rs1128503;TOXICITY;INCREASED;RISK;SIDE_EFFECT:MUCOSITIS;CHILDREN;OTHER:LYMPHOMA, OTHER:OSTEOSARCOMA,OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
NAN;AGT;A;rs699;OTHER;DECREASED;SEVERITY;OTHER:COVID-19;PEOPLE;OTHER:COVID-19;LIKELIHOOD_THERAPEUTIC_SUCCESS
CANGRELOR;P2RY12;TT;rs9859552;OTHER;;;OTHER:20%_AND_17%_LESS_INHIBITION_OF_PLATELET_AGGREGATION_WITH_CRANGRELOR_(0.05_AND_0.25_MICROM)_IN-VITRO;;;CAUTION_DOSE_ADJUST
SORAFENIB;NOS3;TT;rs2070744;EFFICACY;DECREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:HEPATOCELLULAR_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
RADIOTHERAPY;TANC1;C;rs10497203;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXICITY;MEN;DISEASE:PROSTATIC_NEOPLASMS;CAUTION_SIDE_EFFECT
AZATHIOPRINE, MERCAPTOPURINE;NUDT15;T;rs116855232;TOXICITY;INCREASED;RISK;DISEASE:LEUKOPENIA;PEOPLE;DISEASE:INFLAMMATORY_BOWEL_DISEASES;CAUTION_SIDE_EFFECT
SORAFENIB;NOS3;GG;rs1799983;EFFICACY;DECREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:HEPATOCELLULAR_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
SORAFENIB;NOS3;GG;rs1799983;EFFICACY;DECREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:HEPATOCELLULAR_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
GLUCOCORTICOIDS;GLCCI1;GG;rs37973;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:POOR_RESPONSE;PEOPLE;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL, IRINOTECAN, LEUCOVORIN;ABCG2;A;rs7699188;EFFICACY;INCREASED;;EFFICACY:TUMOR_RESPONSE_RATE;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
SORAFENIB;NOS3;TT;rs2070744;EFFICACY;DECREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:HEPATOCELLULAR_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
AZATHIOPRINE;NUDT15;T;rs116855232;TOXICITY;DECREASED;;SIDE_EFFECT:INTERVAL_OF_THERAPY_TO_LEUKOPENIA_ONSET;PEOPLE;DISEASE:LEUKOPENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;CTLA4;AG + GG;rs3087243;TOXICITY;DECREASED;RISK;SIDE_EFFECT:PSORIASIS;PEOPLE;DISEASE:PSORIASIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;G;rs8050894;DOSAGE;DECREASED;;OTHER:WARFARIN_DOSE;;;CAUTION_DOSE_ADJUST
AZATHIOPRINE, MERCAPTOPURINE;NUDT15;T;rs116855232;TOXICITY;INCREASED;RISK;DISEASE:LEUKOPENIA;PEOPLE;DISEASE:CROHN_DISEASE;CAUTION_SIDE_EFFECT
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;FBXL19;GG;rs10782001;TOXICITY;INCREASED;RISK;SIDE_EFFECT:PSORIASIS;PEOPLE;DISEASE:PSORIASIS;CAUTION_SIDE_EFFECT
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL23R;AG;rs11209026;TOXICITY;INCREASED;RISK;SIDE_EFFECT:PSORIASIS;PEOPLE;DISEASE:PSORIASIS;CAUTION_SIDE_EFFECT
AZATHIOPRINE;NUDT15;TT;rs116855232;TOXICITY;INCREASED;SEVERITY;DISEASE:LEUKOPENIA;PEOPLE;DISEASE:CROHN_DISEASE;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;A;rs1801133;METABOLISM/PK;INCREASED;RISK;PK:PROLONGED_HIGH_CONCENTRATIONS;CHILDREN;DISEASE:LEUKEMIA;CAUTION_SIDE_EFFECT
WARFARIN;VKORC1;G;rs8050894;DOSAGE;DECREASED;;OTHER:WARFARIN_DOSE;;;CAUTION_DOSE_ADJUST
ETHANOL;OPRM1;G;rs1799971;TOXICITY;INCREASED;RISK;DISEASE:ALCOHOL_ABUSE;;;CAUTION_SIDE_EFFECT
MORPHINE;ABCB1;CC;rs2032582;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:NAUSEA, SIDE_EFFECT:VOMITING;PEOPLE;DISEASE:POSTOPERATIVE_PAIN;LIKELIHOOD_THERAPEUTIC_SUCCESS
COLISTIMETHATE;SLC15A2;T;rs2257212;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:NEPHROTOXICITY;PEOPLE;OTHER:BACTERIAL_INFECTIONS;CAUTION_SIDE_EFFECT
HEROIN;OPRM1;G;rs1799971;TOXICITY;INCREASED;RISK;DISEASE:HEROIN_DEPENDENCE;;;CAUTION_SIDE_EFFECT
ASPARAGINASE, DAUNORUBICIN, METHOTREXATE, PREDNISOLONE, VINCRISTINE;MTHFR;AA + AG;rs1801133;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:FOLIC_ACID_DEFICIENCY_ANEMIA;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
ASPARAGINASE, DAUNORUBICIN, METHOTREXATE, PREDNISOLONE, VINCRISTINE;MTHFR;GT + TT;rs1801131;TOXICITY;INCREASED;RISK;SIDE_EFFECT:MUCOSITIS;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
WARFARIN;GGCX;CT + TT;rs699664;DOSAGE;DECREASED;;OTHER:WARFARIN_DOSE;;;CAUTION_DOSE_ADJUST
CETUXIMAB;FCGR3A;A;rs396991;EFFICACY;INCREASED;;EFFICACY:OVERALL_SURVIVAL_AND_PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;CT;rs28371685;DOSAGE;DECREASED;;OTHER:WARFARIN_DOSE;;;CAUTION_DOSE_ADJUST
CETUXIMAB;CCND1;G;rs9344;EFFICACY;DECREASED;;EFFICACY:OVERALL_SURVIVAL_AND_PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;F7;GT + TT;rs510335;DOSAGE;DECREASED;;OTHER:WARFARIN_DOSE;;;CAUTION_DOSE_ADJUST
TACROLIMUS;IL10;AA;rs1800871;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:TRANSPLANT_REJECTION;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESCITALOPRAM;HTR1B;AC + CC;rs11568817;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ADVERSE_COGNITIVE_EFFECTS;PEOPLE;DISEASE:ANXIETY_DISORDERS;CAUTION_SIDE_EFFECT
CETUXIMAB;CCND1;AA;rs9344;EFFICACY;DECREASED;;EFFICACY:SURVIVAL;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;SLC19A1;TT;rs1051266;TOXICITY;DECREASED;RISK;SIDE_EFFECT:ADVERSE_EVENTS;PEOPLE;OTHER:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUVOXAMINE, MILNACIPRAN, PAROXETINE;MDGA2;A;rs1160351;TOXICITY;INCREASED;RISK;SIDE_EFFECT:SEXSUAL_DYSFUNCTION;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_SIDE_EFFECT
"""ANTIVIRALS FOR TREATMENT OF HIV INFECTIONS, COMBINATIONS"", ""RITONAVIR""";APOC1, APOE, TOMM40;CC + CT;rs429358;TOXICITY;INCREASED;;SIDE_EFFECT:NON-HDL_CHOLESTEROL;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
ESCITALOPRAM;HTR2A;CT + TT;rs6311;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ADVERSE_COGNITIVE_EFFECTS;PEOPLE;DISEASE:ANXIETY_DISORDERS;CAUTION_SIDE_EFFECT
TACROLIMUS;IL10;TT;rs1800872;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:TRANSPLANT_REJECTION;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;;G;rs17234657;NAN;INCREASED;RISK;DISEASE:CROHN_DISEASE;;;CAUTION_SIDE_EFFECT
WARFARIN;VKORC1;AG + GG;rs9934438;DOSAGE;INCREASED;;OTHER:WARFARIN_DOSE;;;CAUTION_DOSE_ADJUST
LEVODOPA;HOMER1;AG + GG;rs4704559;TOXICITY;DECREASED;RISK;DISEASE:DYSKINESIAS;PEOPLE;DISEASE:PARKINSON_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE, DOCETAXEL, EPIRUBICIN;SOD2;AG + GG;rs4880;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;WOMEN;OTHER:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
LEVODOPA;HOMER1;AG + GG;rs4704559;TOXICITY;DECREASED;RISK;DISEASE:HALLUCINATIONS;PEOPLE;DISEASE:PARKINSON_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;;T;rs2200733;NAN;INCREASED;RISK;DISEASE:ATRIAL_FIBRILLATION;;;CAUTION_SIDE_EFFECT
ESTRADIOL;NFE2L2;T;rs6721961;TOXICITY;INCREASED;RISK;DISEASE:VENOUS_THROMBOEMBOLISM;;;CAUTION_SIDE_EFFECT
HYDROCHLOROTHIAZIDE;YEATS4;CC;rs7297610;EFFICACY;INCREASED;;EFFICACY:REDUCTION_IN_BLOOD_PRESSURE;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE;DPYD;CT;rs3918290;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
WARFARIN;F2;CT + TT;rs5896;DOSAGE;DECREASED;;OTHER:WARFARIN_DOSE;;;CAUTION_DOSE_ADJUST
NAN;HLA-DRA;A;rs3135388;NAN;INCREASED;RISK;DISEASE:MULTIPLE_SCLEROSIS;;;CAUTION_SIDE_EFFECT
VINCRISTINE;CEP72;TT;rs924607;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;WOMEN;OTHER:NON-HODGKIN_LYMPHOMA;CAUTION_SIDE_EFFECT
NAN;NOD2;G;rs17221417;NAN;INCREASED;RISK;DISEASE:CROHN_DISEASE;;;CAUTION_SIDE_EFFECT
CISPLATIN, PACLITAXEL;TP53;CG + GG;rs1042522;EFFICACY;DECREASED;;EFFICACY:ONE_YEAR_PROGRESSION_FREE_SURVIVAL;PEOPLE;DISEASE:STOMACH_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
AZATHIOPRINE;ITPA;AC;rs1127354;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:FLU-LIKE_SYMPTOMS;PEOPLE;DISEASE:INFLAMMATORY_BOWEL_DISEASES;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CES1;CT;rs71647871;PD;INCREASED;LIKELIHOOD;EFFICACY:PLATELET_REACTIVITY;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;TCF7L2;T;rs12255372;NAN;INCREASED;RISK;DISEASE:DIABETES_MELLITUS, TYPE_2;;;CAUTION_SIDE_EFFECT
NAN;IL6;AG + GG;rs1800797;OTHER;INCREASED;SEVERITY;OTHER:PAIN;CHILDREN;OTHER:NEOPLASMS;CAUTION_SIDE_EFFECT
NAN;TCF7L2;C;rs12243326;NAN;INCREASED;RISK;DISEASE:DIABETES_MELLITUS, TYPE_2;;;CAUTION_SIDE_EFFECT
NAN;TCF7L2;T;rs4506565;NAN;INCREASED;RISK;DISEASE:DIABETES_MELLITUS, TYPE_2;;;CAUTION_SIDE_EFFECT
WARFARIN;VKORC1;A;rs9934438;DOSAGE;DECREASED;;OTHER:WARFARIN_DOSE;;;CAUTION_DOSE_ADJUST
ETHANOL;ADH1B;T;rs1229984;TOXICITY;DECREASED;RISK;SIDE_EFFECT:ALCOHOL_ABUSE;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;AG;rs9934438;DOSAGE;INCREASED;;OTHER:WARFARIN_DOSE;;;CAUTION_DOSE_ADJUST
NAN;CDKN2B-AS1;G;rs10965219;OTHER;INCREASED;;OTHER:PLATELET_REACTIVITY;;;CAUTION_DOSE_ADJUST
MORPHINE;COMT;AA;rs4680;EFFICACY;INCREASED;;EFFICACY:NUMERICAL_RATING_SCALE_(NRS)_SCORE_FOR_PAIN_DURING_PAINFUL_PROCEDURE;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHANOL;RABGAP1L;G;rs61826952;TOXICITY;DECREASED;RISK;SIDE_EFFECT:ALCOHOL_ABUSE;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
MORPHINE;COMT;AA;rs4680;EFFICACY;INCREASED;;EFFICACY:OVERALL_MEAN_NUMERICAL_RATING_SCALE_(NRS)_SCORE_FOR_PAIN;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;CDKN2B-AS1;G;rs10965219;OTHER;INCREASED;RISK;DISEASE:CORONARY_ARTERY_DISEASE;;;CAUTION_SIDE_EFFECT
TRAMADOL;CYP2D6;CC;rs1058172;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:OVERDOSE;PEOPLE;OTHER:DEATH;CAUTION_SIDE_EFFECT
CLOZAPINE;CYP2D6;GG;rs16947;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:LEUKOPENIA;PEOPLE;OTHER:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
TRAMADOL;CYP2B6;CC;rs4803419;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:OVERDOSE;PEOPLE;OTHER:DEATH;CAUTION_SIDE_EFFECT
NAN;ACE2;CC;rs4240157;OTHER;INCREASED;RISK;OTHER:DEATH;PEOPLE;OTHER:COVID-19;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;;PK:DOSE-ADJUSTED_TROUGH_CONCENTRATIONS;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;DECREASED;;PK:DOSE-ADJUSTED_TROUGH_CONCENTRATIONS;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
NAN;ACE2;C;rs4240157;OTHER;INCREASED;LIKELIHOOD;OTHER:COVID-19;PEOPLE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOZAPINE;CYP2D6;AA;rs1065852;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:ELEVATED_CIRCULATING_CREATINE_KINASE_CONCENTRATION, SIDE_EFFECT:ELEVATED_LIVER_ENZYMES;PEOPLE;OTHER:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
CLOZAPINE;CYP2D6;AA;rs1065852;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:LEUKOPENIA;PEOPLE;OTHER:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;;PK:CONCENTRATION-TO-ADJUSTED_DOSE_RATIO;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
METHOTREXATE;SLC19A1;TT;rs1051266;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:MUCOSITIS, SIDE_EFFECT:NEUTROPENIA, SIDE_EFFECT:PANCREATITIS, SIDE_EFFECT:VOMITING;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
CLOZAPINE;CYP2D6;GG;rs16947;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:ELEVATED_CIRCULATING_CREATINE_KINASE_CONCENTRATION, SIDE_EFFECT:ELEVATED_LIVER_ENZYMES;PEOPLE;OTHER:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
HMG_COA_REDUCTASE_INHIBITORS;COQ5;AA + AG;rs10849757;EFFICACY;INCREASED;LIKELIHOOD;SIDE_EFFECT:STATIN-RELATED_MYOPATHY;PEOPLE;OTHER:STROKE;LIKELIHOOD_THERAPEUTIC_SUCCESS
AZATHIOPRINE;ITPA;AC;rs1127354;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA;PEOPLE;OTHER:INFLAMMATORY_BOWEL_DISEASES;CAUTION_SIDE_EFFECT
ZOLEDRONATE;FDPS;TT;rs2297480;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:OSTEONECROSIS;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
HMG_COA_REDUCTASE_INHIBITORS;COQ3;TT;rs11548336;EFFICACY;INCREASED;LIKELIHOOD;SIDE_EFFECT:STATIN-RELATED_MYOPATHY;PEOPLE;OTHER:STROKE;LIKELIHOOD_THERAPEUTIC_SUCCESS
IMATINIB;CYP2B6;GG;rs3745274;TOXICITY;INCREASED;RISK;SIDE_EFFECT:SIDE_EFFECTS;PEOPLE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;CAUTION_SIDE_EFFECT
HMG_COA_REDUCTASE_INHIBITORS;COQ2;CG + GG;rs4693075;EFFICACY;INCREASED;LIKELIHOOD;SIDE_EFFECT:STATIN-RELATED_MYOPATHY;PEOPLE;OTHER:STROKE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE, DOXORUBICIN;ABCB1;CT + TT;rs2032582;EFFICACY;DECREASED;;EFFICACY:SURVIVAL;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOPHOSPHAMIDE, DOXORUBICIN;CYP2B6;T;rs3211371;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DOSE_DELAY;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
ATORVASTATIN, PRAVASTATIN, SIMVASTATIN;CLMN;A;rs8014194;EFFICACY;;;EFFICACY:CHANGE_IN_TOTAL_CHOLESTEROL;;;CAUTION_DOSE_ADJUST
CYCLOPHOSPHAMIDE, DOXORUBICIN;CYP2B6;AG;rs12721655;EFFICACY;DECREASED;;EFFICACY:SURVIVAL;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
NINTEDANIB;DSP;TT;rs2076295;EFFICACY;DECREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;OTHER:PULMONARY_FIBROSIS;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED;;OTHER:WARFARIN_DOSE;;;CAUTION_DOSE_ADJUST
CYCLOPHOSPHAMIDE, DOXORUBICIN;CYP2B6;CT;rs8192709;EFFICACY;DECREASED;;EFFICACY:TIME_TO_PROGRESSION;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL, LEUCOVORIN;MTHFR;GG;rs1801133;TOXICITY;DECREASED;SEVERITY;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;F2;CT + TT;rs5896;DOSAGE;DECREASED;;OTHER:WARFARIN_DOSE;;;CAUTION_DOSE_ADJUST
BUSULFAN;CYP2C19;CC;rs12248560;METABOLISM/PK;INCREASED;;PK:METABOLIC_RATIO;CHILDREN;DISEASE:HEMOPOIETIC_STEM_CELL_TRANSPLANT;CAUTION_DOSE_ADJUST
CAPECITABINE;MTHFR;TT;rs1801131;TOXICITY;DECREASED;;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;F7;GG;rs510317;DOSAGE;DECREASED;;OTHER:WARFARIN_DOSE;;;CAUTION_DOSE_ADJUST
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TAP1;CT;rs1135216;TOXICITY;DECREASED;RISK;SIDE_EFFECT:PSORIASIS;PEOPLE;DISEASE:PSORIASIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
OLANZAPINE, QUETIAPINE, RISPERIDONE;ANKK1;AA;rs1800497;TOXICITY;INCREASED;RISK;DISEASE:HEADACHE;HEALTHY;;CAUTION_SIDE_EFFECT
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;SLC12A8;AA;rs651630;TOXICITY;DECREASED;RISK;SIDE_EFFECT:PSORIASIS;PEOPLE;DISEASE:PSORIASIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
RADIOTHERAPY;TANC1;A;rs264588;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXICITY;MEN;DISEASE:PROSTATIC_NEOPLASMS;CAUTION_SIDE_EFFECT
EFAVIRENZ;CYP2B6;TT;rs3745274;TOXICITY, METABOLISM/PK;INCREASED;;PK:PLASMA_CONCENTRATION;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
RADIOTHERAPY;TANC1;G;rs264631;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXICITY;MEN;DISEASE:PROSTATIC_NEOPLASMS;CAUTION_SIDE_EFFECT
BUSULFAN;CYP2C9;CT + TT;rs1799853;METABOLISM/PK;INCREASED;;PK:METABOLIC_RATIO;CHILDREN;DISEASE:HEMOPOIETIC_STEM_CELL_TRANSPLANT;CAUTION_DOSE_ADJUST
CYCLOPHOSPHAMIDE, DOXORUBICIN;SLC22A16;C;rs714368;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:DOSE_DELAY;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
RADIOTHERAPY;TANC1;T;rs7582141;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXICITY;MEN;DISEASE:PROSTATIC_NEOPLASMS;CAUTION_SIDE_EFFECT
FLUOROURACIL, IRINOTECAN, LEUCOVORIN;ABCG2;A;rs7699188;TOXICITY;INCREASED;RISK;SIDE_EFFECT:GRADE_3-4_NONHEMATOLOGICAL_TOXICITY;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
RADIOTHERAPY;TANC1;T;rs6432512;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXICITY;MEN;DISEASE:PROSTATIC_NEOPLASMS;CAUTION_SIDE_EFFECT
RADIOTHERAPY;TANC1;T;rs264663;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXICITY;MEN;DISEASE:PROSTATIC_NEOPLASMS;CAUTION_SIDE_EFFECT
FLUOROURACIL, IRINOTECAN, LEUCOVORIN;ABCB1;CC;rs2032582;EFFICACY;;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_DOSE_ADJUST
RADIOTHERAPY;TANC1;G;rs264651;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXICITY;MEN;DISEASE:PROSTATIC_NEOPLASMS;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE, DOXORUBICIN;CYP2B6;T;rs3745274;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:DOSE_REDUCTION;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE, DOXORUBICIN;CYP2B6;T;rs8192709;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DOSE_DELAY;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
PLATINUM COMPOUNDS;XPC;AA + AG;rs2228000;TOXICITY;DECREASED;RISK;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY, SIDE_EFFECT:HEMATOLOGIC_DISORDER, SIDE_EFFECT:LEUKOPENIA;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
SECUKINUMAB;ERAP2;GG;rs2248374;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:TREATMENT_FAILURE;PEOPLE;OTHER:PSORIASIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE, DOXORUBICIN;SLC22A16;G;rs12210538;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:DRUG_TOXICITY;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE, DOXORUBICIN;SLC22A16;G;rs723685;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:DOSE_DELAY;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE, DOXORUBICIN;SLC22A16;G;rs6907567;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:DOSE_DELAY;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;LTC4S;C;rs730012;TOXICITY;INCREASED;RISK;SIDE_EFFECT:URTICARIA;;;CAUTION_SIDE_EFFECT
ATORVASTATIN, ROSUVASTATIN;COQ2;G;rs4693075;TOXICITY;INCREASED;RISK;DISEASE:MUSCULAR_DISEASES;PEOPLE;DISEASE:HYPERLIPOPROTEINEMIA_TYPE_II;CAUTION_SIDE_EFFECT
ATEZOLIZUMAB, AVELUMAB, DURVALUMAB, IPILIMUMAB, NIVOLUMAB, PEMBROLIZUMAB;SEMA5A;A;rs35719165;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;;;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFD1;AA + AG;rs2236225;TOXICITY;DECREASED;RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;CC;rs2884737;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OVER-ANTICOAGULATION;;;CAUTION_SIDE_EFFECT
EFAVIRENZ, NELFINAVIR;ABCB1;AA;rs1045642;EFFICACY, OTHER;INCREASED;;EFFICACY:RISE_IN_CD4-CELL_COUNT;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;ABCB1;AA;rs1045642;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:FAVORABLE_VIROLOGIC_RESPONSES;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATEZOLIZUMAB, AVELUMAB, DURVALUMAB, IPILIMUMAB, NIVOLUMAB, PEMBROLIZUMAB;EDIL3;T;rs1862167;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;;;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;;PK:TROUGH_CONCENTRATION;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;;PK:TROUGH_CONCENTRATIONS;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
DOXORUBICIN;ABCC2;A;rs17222723;TOXICITY, METABOLISM/PK;INCREASED;RISK;SIDE_EFFECT:CARDIOTOXICITY;PEOPLE;DISEASE:NON-HODGKIN_LYMPHOMA;CAUTION_SIDE_EFFECT
AMITRIPTYLINE, CITALOPRAM, PAROXETINE, VENLAFAXINE;ABCB1;AG + GG;rs2032583;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:REMISSION;PEOPLE;DISEASE:DEPRESSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
AZATHIOPRINE;XDH;AA + AG;rs2295475;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:MYELOSUPPRESSION;PEOPLE;OTHER:INFLAMMATORY_BOWEL_DISEASES, OTHER:SYSTEMIC_LUPUS_ERYTHEMATOSUS,OTHER:NEUROMYELITIS_OPTICA;CAUTION_SIDE_EFFECT
AZATHIOPRINE;NUDT15;CT + TT;rs116855232;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:MYELOSUPPRESSION;PEOPLE;OTHER:INFLAMMATORY_BOWEL_DISEASES, OTHER:SYSTEMIC_LUPUS_ERYTHEMATOSUS,OTHER:NEUROMYELITIS_OPTICA;CAUTION_SIDE_EFFECT
NAN;ATP8B3;G;rs10421558;TOXICITY;DECREASED;LIKELIHOOD;OTHER:ASPIRIN-INDUCED_ASTHMA;PEOPLE;OTHER:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;ABCB1;AA;rs1045642;OTHER;INCREASED;LIKELIHOOD;DISEASE:BREAST_NEOPLASMS;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;T;rs1799929;TOXICITY, METABOLISM/PK;INCREASED;RISK;DISEASE:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;A;rs1799930;TOXICITY, METABOLISM/PK;INCREASED;RISK;DISEASE:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
ANTHRACYCLINES AND RELATED SUBSTANCES, DOXORUBICIN, EPIRUBICIN;ABCB1;GG;rs1045642;EFFICACY;INCREASED;;EFFICACY:TIME_TO_PROGRESSION;PEOPLE;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
RITONAVIR;APOC3;T;rs2854117;TOXICITY;INCREASED;RISK;DISEASE:HYPERTRIGLYCERIDEMIA;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
NAN;AGTR1;CC;rs5186;OTHER;INCREASED;RISK;DISEASE:ISCHEMIA;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;CAUTION_SIDE_EFFECT
IMATINIB;ARID5B;TT;rs10821936;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:TREATMENT_FAILURE;PEOPLE;OTHER:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;T;rs1041983;TOXICITY, METABOLISM/PK;INCREASED;RISK;DISEASE:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;C;rs1801280;TOXICITY, METABOLISM/PK;INCREASED;RISK;DISEASE:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
FEXOFENADINE;ABCB1;AA;rs1045642;DOSAGE, METABOLISM/PK;DECREASED;;PK:PLASMA_CONCENTRATION;HEALTHY;;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2B6;C;rs28399499;METABOLISM/PK;INCREASED;;PK:PLASMA_CMIN_VALUES;;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2B6;T;rs4803419;METABOLISM/PK;INCREASED;;PK:PLASMA_CMIN_VALUES;;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DOSE_ADJUST
IMATINIB;ATIC;G;rs2372536;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:TREATMENT_FAILURE;PEOPLE;OTHER:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATORVASTATIN, SIMVASTATIN;CYP3A4;CC + CT;rs2740574;OTHER;DECREASED;RISK;OTHER:DOSE_DECREASE_OR_DRUG_SWITCHING;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FEXOFENADINE;ABCB1;AA;rs2032582;DOSAGE, METABOLISM/PK;DECREASED;;PK:PLASMA_CONCENTRATION;HEALTHY;;CAUTION_DOSE_ADJUST
RITODRINE;KCNMB2;GG;rs7625907;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;T;rs3745274;METABOLISM/PK;INCREASED;;PK:PLASMA_CMIN_VALUES;;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DOSE_ADJUST
DOXORUBICIN;ABCC1;T;rs45511401;TOXICITY, METABOLISM/PK;INCREASED;RISK;SIDE_EFFECT:CARDIOTOXICITY;PEOPLE;DISEASE:NON-HODGKIN_LYMPHOMA;CAUTION_SIDE_EFFECT
DOXORUBICIN;ABCC2;A;rs8187710;TOXICITY, METABOLISM/PK;INCREASED;RISK;SIDE_EFFECT:CARDIOTOXICITY;PEOPLE;DISEASE:NON-HODGKIN_LYMPHOMA;CAUTION_SIDE_EFFECT
CAPECITABINE, FOLFOX, TEGAFUR;SMAD7;CC;rs4939827;EFFICACY;DECREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;OTHER:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
DOXORUBICIN;NCF4;AA;rs1883112;TOXICITY;INCREASED;RISK;SIDE_EFFECT:CARDIOTOXICITY;PEOPLE;DISEASE:NON-HODGKIN_LYMPHOMA;CAUTION_SIDE_EFFECT
NAN;ATP8B3;A;rs10403288;TOXICITY;DECREASED;LIKELIHOOD;OTHER:ASPIRIN-INDUCED_ASTHMA;PEOPLE;OTHER:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
SIMVASTATIN;ABCB1;A;rs1128503;EFFICACY;DECREASED;RISK;SIDE_EFFECT:MYALGIA;PEOPLE;DISEASE:HYPERCHOLESTEROLEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;ACE2;T;rs2074192;OTHER;INCREASED;SEVERITY;OTHER:COVID-19;;;CAUTION_SIDE_EFFECT
DOXORUBICIN;CYBA;A;rs4673;TOXICITY;INCREASED;RISK;SIDE_EFFECT:CARDIOTOXICITY;PEOPLE;DISEASE:NON-HODGKIN_LYMPHOMA;CAUTION_SIDE_EFFECT
SIMVASTATIN;ABCB1;A;rs1045642;EFFICACY;DECREASED;RISK;SIDE_EFFECT:MYALGIA;PEOPLE;DISEASE:HYPERCHOLESTEROLEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOXORUBICIN;RAC2;T;rs13058338;TOXICITY;INCREASED;RISK;SIDE_EFFECT:CARDIOTOXICITY;PEOPLE;DISEASE:NON-HODGKIN_LYMPHOMA;CAUTION_SIDE_EFFECT
SIMVASTATIN;ABCB1;C;rs2032582;EFFICACY;INCREASED;RISK;SIDE_EFFECT:MYALGIA;PEOPLE;DISEASE:HYPERCHOLESTEROLEMIA;CAUTION_SIDE_EFFECT
NAN;ABO;T;rs8176746;NAN;INCREASED;;OTHER:ACE_ACTIVITY;PEOPLE;DISEASE:HYPERTENSION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;DECREASED;;PK:CONCENTRATION-TO-ADJUSTED_DOSE_RATIO;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;CAUTION_DOSE_ADJUST
ATORVASTATIN, SIMVASTATIN;PON1;AA + AG;rs705379;EFFICACY;;;EFFICACY:CHANGE_IN_HDL-CHOLESTEROL;PEOPLE;DISEASE:HYPERCHOLESTEROLEMIA;CAUTION_DOSE_ADJUST
ATORVASTATIN, SIMVASTATIN;PON1;CC + CT;rs662;EFFICACY;;;EFFICACY:CHANGE_IN_HDL-CHOLESTEROL;PEOPLE;DISEASE:HYPERCHOLESTEROLEMIA;CAUTION_DOSE_ADJUST
ATORVASTATIN;PON1;GG;rs705379;OTHER;DECREASED;;OTHER:OXIDATIVE_STRESS;PEOPLE;DISEASE:HYPERCHOLESTEROLEMIA;CAUTION_DOSE_ADJUST
CLOZAPINE;TACR1;C;rs58933792;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRY_MOUTH;;;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;CT + TT;rs776746;METABOLISM/PK;DECREASED;;PK:CONCENTRATION/DOSE_RATIO;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;CAUTION_DOSE_ADJUST
FLUCONAZOLE, TACROLIMUS;CYP3A5;CC;rs776746;DOSAGE;DECREASED;;PK:TIME_TO_REACH_STABLE_DOSE_OF_TACROLIMUS;CHILDREN;DISEASE:TRANSPLANTATION;CAUTION_DOSE_ADJUST
FLUCONAZOLE, TACROLIMUS;CYP3A5;CC;rs776746;DOSAGE;DECREASED;;PK:DOSE_OF_TACROLIMUS;CHILDREN;DISEASE:TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED;;PK:TIME_TO_REACH_STABLE_DOSE;CHILDREN;DISEASE:TRANSPLANTATION;CAUTION_DOSE_ADJUST
TAMOXIFEN;SLCO1A2;AG + GG;rs10841795;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:DIZZINESS;WOMEN;OTHER:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOZAPINE;ERBB4;C;rs3942465;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRY_MOUTH;;;CAUTION_SIDE_EFFECT
DIAZEPAM;CYP2C19;AA + AG;rs4244285;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:ADVERSE_EVENTS;MEN;OTHER:ALCOHOL_ABUSE;CAUTION_SIDE_EFFECT
"""ACE INHIBITORS, PLAIN"", ""ANGIOTENSIN II ANTAGONISTS"", ""BETA BLOCKING AGENTS"", ""DIGOXIN"", ""DIURETICS"", ""SPIRONOLACTONE""";ADRB2;GG;rs1042713;OTHER;INCREASED;RISK;OTHER:EMERGENCY_DEPARTMENT_AND_HOSPITAL_UTLIIZATION;PEOPLE;DISEASE:HEART_FAILURE;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2B, RIBAVIRIN;ITPA;AA + AC;rs1127354;EFFICACY;INCREASED;;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;OTHER:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
L-ASPARAGINE, PREDNISONE, VINCRISTINE;ASNS;AT;rs1049674;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:CUSHING_SYNDROME;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
"""ACE INHIBITORS, PLAIN"", ""ANGIOTENSIN II ANTAGONISTS"", ""BETA BLOCKING AGENTS"", ""DIGOXIN"", ""DIURETICS"", ""SPIRONOLACTONE""";NOS3;TT;rs1799983;OTHER;INCREASED;RISK;OTHER:EMERGENCY_DEPARTMENT_UTLIIZATION;PEOPLE;DISEASE:HEART_FAILURE;CAUTION_SIDE_EFFECT
EFAVIRENZ, LOPINAVIR, NUCLEOSIDE AND NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITORS, RITONAVIR;;G;rs2853826;TOXICITY;INCREASED;;SIDE_EFFECT:BASELINE_ADIPONECTIN_AND_WITH_GREATER_ADIPONECTIN_DECLINE;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
DIAZEPAM;CYP2C19;CT + TT;rs12248560;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:ADVERSE_EVENTS;MEN;OTHER:ALCOHOL_ABUSE;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""ACE INHIBITORS, PLAIN"", ""ANGIOTENSIN II ANTAGONISTS"", ""BETA BLOCKING AGENTS"", ""DIGOXIN"", ""DIURETICS"", ""SPIRONOLACTONE""";ADRB1;GG;rs1801253;OTHER;DECREASED;RISK;OTHER:EMERGENCIES;PEOPLE;DISEASE:HEART_FAILURE;LIKELIHOOD_THERAPEUTIC_SUCCESS
L-ASPARAGINE, PREDNISONE, VINCRISTINE;ABCB1;CT;rs9282564;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
OLANZAPINE;UGT1A4;GG + GT;rs2011425;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:AUTONOMIC_NERVOUS_SYSTEM_DISORDER;PEOPLE;OTHER:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
OLANZAPINE;CYP3A4;CC + CT;rs2740574;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:DRY_MOUTH;HEALTHY;;CAUTION_SIDE_EFFECT
CABAZITAXEL;ABCB1;T;rs17327624;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;OTHER:METASTATIC_NEOPLASM, OTHER:PROSTATIC_NEOPLASMS;CAUTION_SIDE_EFFECT
SIMVASTATIN;ABCB1;AA;rs1128503;EFFICACY;INCREASED;;EFFICACY:REDUCTION_IN_TOTAL_CHOLESTEROL;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OLANZAPINE;UGT1A4;GG + GT;rs2011425;METABOLISM/PK;INCREASED;;PK:GLUCURONIDATED_METABOLITES_OF_OLANZAPINE;;;CAUTION_DOSE_ADJUST
NAN;COL1A1;AA + AC;rs1800012;NAN;INCREASED;RISK;DISEASE:FRACTURES, BONE;;;CAUTION_SIDE_EFFECT
CYCLOSPORINE;ABCB1;AG;rs1045642;TOXICITY;INCREASED;SEVERITY;DISEASE:GINGIVAL_HYPERPLASIA;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;CT;rs776746;EFFICACY;INCREASED;RISK;EFFICACY:ACUTE_REJECTION;CHILDREN;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
CLOPIDOGREL;P2RY12;AA + AG;rs6785930;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:DRUG_RESISTANCE;PEOPLE;OTHER:CORONARY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CABAZITAXEL;ABCB1;T;rs2235040;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:ASTHENIA;PEOPLE;OTHER:METASTATIC_NEOPLASM, OTHER:PROSTATIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;NOD2;CC;rs2066844;OTHER;INCREASED;;OTHER:HOSPITAL_STAY;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;TT;rs776746;EFFICACY;INCREASED;RISK;OTHER:ACUTE_REJECTION;;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;CT;rs776746;EFFICACY;INCREASED;RISK;OTHER:ACUTE_REJECTION;;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
CYCLOSPORINE, TACROLIMUS;CYP3A4;CT;rs2740574;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:TRANSPLANT_REJECTION;PEOPLE;;CAUTION_SIDE_EFFECT
WARFARIN;VKORC1;AA + AG;rs2359612;EFFICACY;DECREASED;;EFFICACY:TIME_TO_THE_FIRST_INR_WITHIN_THE_THERAPEUTIC_RANGE;;;LIKELIHOOD_THERAPEUTIC_FAILURE
AZATHIOPRINE, MERCAPTOPURINE;FTO;CC;rs16952570;TOXICITY;DECREASED;RISK;SIDE_EFFECT:LEUKOPENIA, SIDE_EFFECT:NEUTROPENIA;PEOPLE;OTHER:ULCERATIVE_COLITIS, OTHER:CROHN_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
OSELTAMIVIR;CES1;CT + TT;rs121912777;METABOLISM/PK;;;PK:SIGNIFICANTLY_LARGER_MEAN_AUC_OF_OSELTAMIVIR, LOWER_CMAX_OF_OSELTAMIVIR_CARBOXYLATE, AND_A_SMALLER_OSELTAMIVIR_CARBOXYLATE-TO-OSELTAMIVIR_AUC_RATIO;HEALTHY;;CAUTION_DOSE_ADJUST
AZATHIOPRINE, MERCAPTOPURINE;FTO;CT;rs16952570;TOXICITY;INCREASED;RISK;SIDE_EFFECT:LEUKOPENIA, SIDE_EFFECT:NEUTROPENIA;PEOPLE;OTHER:ULCERATIVE_COLITIS, OTHER:CROHN_DISEASE;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;;PK:PBMC_CONCENTRATIONS;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
CABAZITAXEL;CYP2C8;T;rs11572093;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ASTHENIA;PEOPLE;OTHER:METASTATIC_NEOPLASM, OTHER:PROSTATIC_NEOPLASMS;CAUTION_SIDE_EFFECT
WARFARIN;VKORC1;CT + TT;rs9923231;EFFICACY;DECREASED;;EFFICACY:TIME_TO_THE_FIRST_INR_WITHIN_THE_THERAPEUTIC_RANGE;;;LIKELIHOOD_THERAPEUTIC_FAILURE
CITALOPRAM;CYP2C19;A;rs4244285;TOXICITY;INCREASED;;SIDE_EFFECT:INTOLERANCE;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_SIDE_EFFECT
WARFARIN;VKORC1;AA + AG;rs9934438;EFFICACY;DECREASED;;EFFICACY:TIME_TO_THE_FIRST_INR_WITHIN_THE_THERAPEUTIC_RANGE;;;LIKELIHOOD_THERAPEUTIC_FAILURE
NORTRIPTYLINE;GNB3;TT;rs5443;TOXICITY;;;DISEASE:WEIGHT_GAIN;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;CG + GG;rs8050894;EFFICACY;DECREASED;;EFFICACY:TIME_TO_THE_FIRST_INR_WITHIN_THE_THERAPEUTIC_RANGE;;;LIKELIHOOD_THERAPEUTIC_FAILURE
NORTRIPTYLINE;GNB3;TT;rs5443;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:SLEEP_INITIATION_AND_MAINTECE_DISORDERS;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;AC + CC;rs2884737;EFFICACY;DECREASED;;EFFICACY:TIME_TO_THE_FIRST_INR_WITHIN_THE_THERAPEUTIC_RANGE;;;LIKELIHOOD_THERAPEUTIC_FAILURE
NORTRIPTYLINE;GNB3;TT;rs5443;EFFICACY;;;EFFICACY:IMPROVEMENTS_IN_NEUROVEGETATIVE_SYMPTOMS;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DOSE_ADJUST
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;;PK:TROUGH_CONCENTRATION;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;A;rs9934438;EFFICACY;DECREASED;;EFFICACY:TIME_TO_THERAPEUTIC_INR;;;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CC;rs776746;METABOLISM/PK;INCREASED;;PK:TROUGH_CONCENTRATION;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
NAN;SLC19A1;C;rs1051266;OTHER;INCREASED;LIKELIHOOD;OTHER:DOWN_SYNDROME;WOMEN;OTHER:PREGNANCY;LIKELIHOOD_THERAPEUTIC_SUCCESS
DIGOXIN;ABCB1;AA;rs1045642;METABOLISM/PK;DECREASED;;PK:DUODENAL_ABSORPTION_OF_DIGOXIN_AFTER_DIRECT_DELIVERY_TO_THE_SURFACE_OF_THE_DUODENUM_BY_ENDOSCOPE;;;CAUTION_DOSE_ADJUST
OLANZAPINE;HTR2A;AA;rs7997012;TOXICITY;INCREASED;RISK;SIDE_EFFECT:SIDE_EFFECTS;PEOPLE;OTHER:PSYCHIATRIC_DISORDERS;CAUTION_SIDE_EFFECT
CAPECITABINE, FLUOROURACIL, TEGAFUR;DPYD;T;rs3918290;TOXICITY;INCREASED;RISK;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
CAPECITABINE, FLUOROURACIL, TEGAFUR;DPYD;A;rs67376798;TOXICITY;INCREASED;RISK;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
OLANZAPINE;ABCB1;A;rs1045642;EFFICACY;;;EFFICACY:POSITIVE_RELATIONSHIP_BETWEEN_OLANZAPINE_PLASMA_LEVELS_AND_POSITIVE_SYMPTOM_REDUCTION_COMPARED_TO_SUBJECTS_WITH_THE_GG_GENOTYPE;;;CAUTION_DOSE_ADJUST
OLANZAPINE;CYP1A2;AA;rs762551;METABOLISM/PK;DECREASED;;PK:PLASMA_CONCENTRATIONS;PEOPLE;OTHER:PSYCHIATRIC_DISORDERS;CAUTION_DOSE_ADJUST
NICOTINE;OPRM1;AA;rs1799971;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:SMOKING_CESSATION;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OLANZAPINE;DRD2;A;rs6275;OTHER, METABOLISM/PK;INCREASED;;OTHER:PROLACTIN;WOMEN;;CAUTION_DOSE_ADJUST
ANTHRACYCLINES AND RELATED SUBSTANCES;CBR1;GG;rs9024;TOXICITY;INCREASED;RISK;DISEASE:CARDIOMYOPATHIES;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
OLANZAPINE;DRD2;G;rs6279;OTHER, METABOLISM/PK;INCREASED;;OTHER:PROLACTIN;WOMEN;;CAUTION_DOSE_ADJUST
CEPHALEXIN;;T;rs34545984;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ADVERSE_EVENTS;;;CAUTION_SIDE_EFFECT
OLANZAPINE;DRD2;T;rs1124493;OTHER, METABOLISM/PK;INCREASED;;OTHER:PROLACTIN;WOMEN;;CAUTION_DOSE_ADJUST
OLANZAPINE;DRD2;A;rs2734841;OTHER, METABOLISM/PK;INCREASED;;OTHER:PROLACTIN;WOMEN;;CAUTION_DOSE_ADJUST
ASPIRIN;;A;rs115346678;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ADVERSE_EVENTS;;;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFD1;A;rs2236225;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:EVENT_FREE_SURVIVAL;PEOPLE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
SIMVASTATIN;PPARA;AA;rs4253728;EFFICACY;INCREASED;;EFFICACY:REDUCTION_IN_TOTAL_CHOLESTEROL_AND_LDL-CHOLESTEROL;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;MTHFR;A;rs1801133;EFFICACY;INCREASED;RISK;EFFICACY:RECURRENCE;PEOPLE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
CODEINE;WBP2NL;G;rs9620007;TOXICITY;DECREASED;RISK;SIDE_EFFECT:ADVERSE_EVENTS;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;A;rs9934438;DOSAGE;DECREASED;;OTHER:WARFARIN_DOSE_IN_KOREAN_PATIENTS_WITH_MECHANICAL_HEART_VALVE_REPLACEMENT_SINCE_DAY_7_OF_WARFARIN_THERAPY;;;CAUTION_DOSE_ADJUST
CODEINE, HYDROCODONE, OXYCODONE, TRAMADOL;OPRM1;T;rs62436463;TOXICITY;DECREASED;RISK;SIDE_EFFECT:ADVERSE_EVENTS;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METFORMIN;SLC22A2;CC;rs316009;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;OTHER:DIABETES_MELLITUS_T2;CAUTION_SIDE_EFFECT
METFORMIN;SLC22A2;CC;rs316019;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;OTHER:DIABETES_MELLITUS_T2;CAUTION_SIDE_EFFECT
SIMVASTATIN;PPARA;GG;rs4823613;EFFICACY;INCREASED;;EFFICACY:REDUCTION_IN_TOTAL_CHOLESTEROL_AND_LDL-CHOLESTEROL;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;ANKK1;GG;rs1800497;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:SMOKING_CESSATION;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;COMT;GG;rs4680;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:RELAPSE;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESCITALOPRAM;HTR2A;CT + TT;rs6311;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:SUICIDAL_IDEATION, SIDE_EFFECT:ADVERSE_EVENTS, SIDE_EFFECT:DELIBERATE_SELF-HARM;CHILDREN;OTHER:DEPRESSION, OTHER:ANXIETY_DISORDERS;CAUTION_SIDE_EFFECT
NICOTINE;ANKK1;AA + AG;rs1800497;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:SMOKING_CESSATION;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
AMIODARONE, ANTIBIOTICS, ANTIPSYCHOTICS, DIURETICS, QUINIDINE, SOTALOL;KCNE1;T;rs1805128;TOXICITY;INCREASED;RISK;DISEASE:TORSADES_DE_POINTES;;;CAUTION_SIDE_EFFECT
NICOTINE;OPRM1;GG;rs1799971;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:SMOKING_CESSATION;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;OPRM1;AG;rs1799971;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:SMOKING_CESSATION;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUPROPION;ANKK1;GG;rs1800497;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:SMOKING_CESSATION;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OLANZAPINE;DRD2;G;rs2734842;OTHER, METABOLISM/PK;INCREASED;;OTHER:PROLACTIN;WOMEN;;CAUTION_DOSE_ADJUST
METHOTREXATE;MTHFR;A;rs1801133;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
PYRIMIDINE ANALOGUES;DPYD;CT + TT;rs1801160;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;;;CAUTION_SIDE_EFFECT
ROSUVASTATIN;ABCG2;GG;rs2231142;EFFICACY;DECREASED;;EFFICACY:PERCENTAGE_CHANGE_IN_LDL-CHOLESTEROL_LEVELS;PEOPLE;DISEASE:HYPERCHOLESTEROLEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
AMITRIPTYLINE;CYP2C19;AA;rs4244285;OTHER, METABOLISM/PK;INCREASED;;PK:LOG_METABOLIC_RATIO_OF_AMITRIPTYLINE/NORTRIPTYLINE;;;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;INCREASED;RISK;EFFICACY:CARDIOVASCULAR_DEATH, MYOCARDIAL_INFARCTION, OR_STROKE;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;CAUTION_SIDE_EFFECT
ROSUVASTATIN;SLCO1B1;TT;rs4149056;METABOLISM/PK;DECREASED;;PK:PLASMA_CONCENTRATIONS_OF_ROSUVASTATIN;PEOPLE;DISEASE:HYPERCHOLESTEROLEMIA;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;A;rs4986893;EFFICACY;INCREASED;RISK;EFFICACY:CARDIOVASCULAR_DEATH, MYOCARDIAL_INFARCTION, OR_STROKE;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;CAUTION_SIDE_EFFECT
ROSUVASTATIN;ABCG2;TT;rs2231142;METABOLISM/PK;INCREASED;;PK:PLASMA_CONCENTRATIONS_OF_ROSUVASTATIN;PEOPLE;DISEASE:HYPERCHOLESTEROLEMIA;CAUTION_DOSE_ADJUST
CLOPIDOGREL;ABCB1;AA;rs1045642;EFFICACY;INCREASED;RISK;EFFICACY:CARDIOVASCULAR_DEATH, MYOCARDIAL_INFARCTION, OR_STROKE;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;CAUTION_SIDE_EFFECT
CLOPIDOGREL;ABCB1;AA;rs1045642;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:CORONARY_RESTENOSIS;PEOPLE;DISEASE:PERIPHERAL_VASCULAR_DISEASES;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN, DOCETAXEL, FLUOROURACIL;CCL2;GG;rs1024611;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:ANEMIA;PEOPLE;OTHER:CARCINOMA, SQUAMOUS_CELL,OTHER:ADENOCARCINOMA, OTHER:ADENOSQUAMOUS_CARCINOMA, OTHER:NEOPLASM_OF_ESOPHAGUS;CAUTION_SIDE_EFFECT
NAN;SERPINE1;T;rs7242;OTHER;INCREASED;LIKELIHOOD;DISEASE:MAJOR_DEPRESSIVE_DISORDER;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;SERPINE1;G;rs2227684;OTHER;INCREASED;LIKELIHOOD;DISEASE:MAJOR_DEPRESSIVE_DISORDER;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;MTHFR;G;rs1801131;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:CLINICAL_RESPONSE;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEMCITABINE;CDA;A;rs60369023;TOXICITY, METABOLISM/PK;INCREASED;SEVERITY;DISEASE:NEUTROPENIA;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
METHOTREXATE;GGH;AA;rs3758149;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ANEMIA;PEOPLE;OTHER:NON-HODGKIN_LYMPHOMA, OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
BISPHOSPHONATES;IL1B;GG;rs16944;EFFICACY;INCREASED;LIKELIHOOD;PK:RESISTANCE;PEOPLE;DISEASE:OSTEITIS_DEFORMANS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLODRONATE;VDR;C;rs1544410;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:RESISTANCE;PEOPLE;DISEASE:OSTEITIS_DEFORMANS;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;CT + TT;rs9923231;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:OVER_ANTI-COAGULATION;;;CAUTION_SIDE_EFFECT
CLODRONATE;VDR;A;rs731236;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:RESISTANCE;PEOPLE;DISEASE:OSTEITIS_DEFORMANS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYTARABINE, IDARUBICIN;NT5C3A;GG;rs3750117;EFFICACY;INCREASED;RISK;EFFICACY:INDUCTION_FAILURE;PEOPLE;DISEASE:ACUTE_MYELOID_LEUKEMIA;CAUTION_SIDE_EFFECT
ATORVASTATIN, LOVASTATIN, SIMVASTATIN;APOA5;AG + GG;rs662799;EFFICACY;DECREASED;;EFFICACY:REDUCTION_IN_LDLC;PEOPLE;DISEASE:HYPERLIPIDEMIAS;LIKELIHOOD_THERAPEUTIC_FAILURE
CITALOPRAM, SERTRALINE;HTR2A;T;rs6311;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:PHYSIOLOGICAL_SEXUAL_DISORDER;PEOPLE;OTHER:MAJOR_DEPRESSIVE_DISORDER;CAUTION_SIDE_EFFECT
CISPLATIN, DOCETAXEL, FLUOROURACIL;IL6;CC;rs1800796;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:THROMBOCYTOPENIA;PEOPLE;OTHER:CARCINOMA, SQUAMOUS_CELL,OTHER:ADENOCARCINOMA, OTHER:ADENOSQUAMOUS_CARCINOMA, OTHER:NEOPLASM_OF_ESOPHAGUS;CAUTION_SIDE_EFFECT
CITALOPRAM;HTR2A;AA;rs6313;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:PHYSIOLOGICAL_SEXUAL_DISORDER;PEOPLE;OTHER:MAJOR_DEPRESSIVE_DISORDER;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;AA;rs1801133;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA, SIDE_EFFECT:THROMBOCYTOPENIA, SIDE_EFFECT:ANEMIA;PEOPLE;OTHER:NON-HODGKIN_LYMPHOMA, OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
BUPRENORPHINE / NALOXONE;OPRM1;AG + GG;rs648893;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:DEPRESSION;PEOPLE;OTHER:OPIOID-RELATED_DISORDERS;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;ADORA2A;T;rs2267076;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ADVERSE_EVENTS;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
METHOTREXATE;ADORA2A;T;rs2236624;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ADVERSE_EVENTS;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
METHOTREXATE;ADORA2A;T;rs2298383;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ADVERSE_EVENTS;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;CT + TT;rs776746;OTHER;INCREASED;;PK:BLOOD_PRESSURE;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
METHOTREXATE;ADORA2A;T;rs3761422;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ADVERSE_EVENTS;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
CISPLATIN, DOCETAXEL, FLUOROURACIL;TNF;CC + CT;rs1799964;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:THROMBOCYTOPENIA;PEOPLE;OTHER:CARCINOMA, SQUAMOUS_CELL,OTHER:ADENOCARCINOMA, OTHER:ADENOSQUAMOUS_CARCINOMA, OTHER:NEOPLASM_OF_ESOPHAGUS;CAUTION_SIDE_EFFECT
CLOPIDOGREL;ABCB1;AA;rs1045642;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:DRUG_RESISTANCE;PEOPLE;OTHER:STROKE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN, CLOPIDOGREL;PEAR1;AA + AG;rs12041331;EFFICACY;DECREASED;;EFFICACY:PLATELET_AGGREGATION;;;LIKELIHOOD_THERAPEUTIC_FAILURE
CISPLATIN, DOCETAXEL, FLUOROURACIL;ABCC2;CT + TT;rs717620;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:NEUTROPENIA;PEOPLE;OTHER:CARCINOMA, SQUAMOUS_CELL,OTHER:ADENOCARCINOMA, OTHER:ADENOSQUAMOUS_CARCINOMA, OTHER:NEOPLASM_OF_ESOPHAGUS;CAUTION_SIDE_EFFECT
HYDROCHLOROTHIAZIDE;NELL1;C;rs12279250;METABOLISM/PK;INCREASED;;SIDE_EFFECT:PLASMA_TRIGLYCERIDES;PEOPLE;DISEASE:HYPERTENSION;CAUTION_DOSE_ADJUST
BUPRENORPHINE / NALOXONE;OPRD1;TT;rs678849;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:ANXIETY_DISORDERS;PEOPLE;OTHER:OPIOID-RELATED_DISORDERS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ARIPIPRAZOLE;DAOA;A;rs2391191;EFFICACY;DECREASED;;EFFICACY:BRIEF_PSYCHIATRIC_RATING_SCALE_SCORES;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_FAILURE
BUPRENORPHINE / NALOXONE;OPRD1;A;rs569356;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:CRAVING;PEOPLE;OTHER:OPIOID-RELATED_DISORDERS;LIKELIHOOD_THERAPEUTIC_FAILURE
OLANZAPINE;HTR2C;C;rs6318;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:WEIGHT_GAIN;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;T;rs776746;TOXICITY;INCREASED;RISK;OTHER:TACROLIMUS_NEPHROTOXICITY;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;CC;rs776746;EFFICACY, TOXICITY;INCREASED;RISK;OTHER:SUBCLINICAL_ALLOGRAFT_NEPHROPATHY;;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
SIMVASTATIN;CYBA;AA + AG;rs4673;EFFICACY;INCREASED;;EFFICACY:REDUCTION_IN_DNA_DAMAGE;PEOPLE;DISEASE:HYPERCHOLESTEROLEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUPROPION;CYP2B6;CT;rs3211371;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:SMOKING_CESSATION;PEOPLE;OTHER:FEMALE_GENDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;ABCB1;AG + GG;rs1045642;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:DRUG_RESISTANCE;PEOPLE;OTHER:STROKE;LIKELIHOOD_THERAPEUTIC_SUCCESS
OLANZAPINE;DRD3;CC;rs6280;EFFICACY;;;EFFICACY:GREATER_POSITIVE_SYMPTOM_IMPROVEMENT_AND_POSITIVE_SYMPTOM_REMISSION;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_DOSE_ADJUST
AZATHIOPRINE, MERCAPTOPURINE;NUDT15;CT + TT;rs116855232;TOXICITY;INCREASED;RISK;SIDE_EFFECT:LEUKOPENIA, SIDE_EFFECT:NEUTROPENIA;PEOPLE;DISEASE:CROHN_DISEASE;CAUTION_SIDE_EFFECT
OLANZAPINE;RGS4;CT;rs951439;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:RESPONSE;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CABAZITAXEL;TUBB1;G;rs151352;EFFICACY;INCREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;OTHER:METASTATIC_NEOPLASM, OTHER:PROSTATIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
RISPERIDONE;RGS4;TT;rs951439;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:RESPONSE;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
OLANZAPINE, PERPHENAZINE;RGS4;CC;rs951439;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:POSITIVE_RESPONSE;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CABAZITAXEL;CYP2C8;C;rs1341164;EFFICACY;INCREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;OTHER:METASTATIC_NEOPLASM, OTHER:PROSTATIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
OLANZAPINE;LEP;GG;rs4731426;TOXICITY;INCREASED;RISK;DISEASE:WEIGHT_GAIN;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
HEROIN;GRM3;T;rs13242038;OTHER;INCREASED;RISK;DISEASE:HEROIN_DEPENDENCE;;;CAUTION_SIDE_EFFECT
AMITRIPTYLINE, CITALOPRAM, PAROXETINE, VENLAFAXINE;ABCB1;A;rs2235015;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:REMISSION;PEOPLE;DISEASE:DEPRESSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;ACE;G;rs4343;METABOLISM/PK;INCREASED;;OTHER:ACE_ACTIVITY;PEOPLE;DISEASE:HYPERTENSION;CAUTION_DOSE_ADJUST
ANTIDEPRESSANTS;HTR1A;GG;rs6295;EFFICACY;DECREASED;;EFFICACY:TREATMENT_RESPONSE;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
OPIOIDS;ABCB1;CC + CT;rs9282564;TOXICITY;DECREASED;RISK;OTHER:DEATH;PEOPLE;OTHER:OPIOID-RELATED_DISORDERS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTHRACYCLINES AND RELATED SUBSTANCES, TAXANES;ABCB1;AA;rs1045642;EFFICACY, METABOLISM/PK;INCREASED;LIKELIHOOD;EFFICACY:COMPLETE_RESPONSE;PEOPLE;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;TT;rs8099917;EFFICACY;INCREASED;;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
PAROXETINE, SERTRALINE;HTR1A;CC;rs6295;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:NON-RESPONSE;PEOPLE;DISEASE:PANIC_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;KCNJ6;TT;rs2070995;EFFICACY;INCREASED;;EFFICACY:FREQUENCY_OF_RESCUE_ANALGESIC_ADMINISTRATION;PEOPLE;DISEASE:PAIN;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;G;rs8050894;DOSAGE, EFFICACY;;;EFFICACY:DECREASED_WARFARIN_DOSE_AND_INCREASED_RISK_OF_OVER-ANTICOAGULATION;;;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;T;rs9923231;DOSAGE, EFFICACY;;;EFFICACY:DECREASED_WARFARIN_DOSE_AND_INCREASED_RISK_OF_OVER-ANTICOAGULATION;;;CAUTION_DOSE_ADJUST
NEVIRAPINE;CYP2B6;CT;rs28399499;OTHER;INCREASED;LIKELIHOOD;SIDE_EFFECT:ELEVATED_LIVER_ENZYMES;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
NEVIRAPINE;CYP3A5;CC + CT;rs776746;OTHER;INCREASED;LIKELIHOOD;SIDE_EFFECT:ELEVATED_LIVER_ENZYMES;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;C9orf72;T;rs3849942;EFFICACY;INCREASED;RISK;EFFICACY:NON-RESPONSE;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
METHAMPHETAMINE;DTNBP1;C;rs3213207;TOXICITY;INCREASED;RISK;SIDE_EFFECT:PSYCHOTIC_DISORDER;;;CAUTION_SIDE_EFFECT
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;MOB3B;T;rs2814707;EFFICACY;INCREASED;RISK;EFFICACY:NON-RESPONSE;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
METHAMPHETAMINE;PICK1;T;rs2076369;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:RELAPSE_OF_PSYCHOSIS;;;CAUTION_SIDE_EFFECT
NEVIRAPINE;CYP2B6;CT + TT;rs12721646;OTHER;INCREASED;LIKELIHOOD;SIDE_EFFECT:ELEVATED_LIVER_ENZYMES;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;GBP6;A;rs928655;EFFICACY;INCREASED;RISK;EFFICACY:NON-RESPONSE;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;AG + GG;rs1801265;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:OVERALL_GASTROINTESTINAL_TOXICITY;PEOPLE;DISEASE:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;C9orf72;C;rs774359;EFFICACY;INCREASED;RISK;EFFICACY:NON-RESPONSE;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;CSRP3;T;rs983332;EFFICACY;INCREASED;RISK;EFFICACY:NON-RESPONSE;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;MOB3B;A;rs868856;EFFICACY;INCREASED;RISK;EFFICACY:NON-RESPONSE;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;G;rs1801131;TOXICITY;INCREASED;RISK;SIDE_EFFECT:SIDE_EFFECTS;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;TT;rs1801131;EFFICACY;INCREASED;;EFFICACY:RESPONSE_BASE_ON_DISEASE_ACTIVITY_SCORE_IN_44_JOINTS_IMPROVEMENT_AT_6_MONTHS_OF_TREATMENT;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;SLC19A1;TT;rs1051266;EFFICACY;DECREASED;;EFFICACY:_DISEASE_ACTIVITY_AS_ASSESSED_BY_THE_PHYSICIAN, LESS_PATIENT-ASSESSED_DIFFICULTY_WITH_PHYSICAL_TASKS, AND_FEWER_SWOLLEN_JOINTS;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
GEFITINIB;EGFR;GT + TT;rs712829;EFFICACY;INCREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL_(PFS)_TIME;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIANDROGENS;AKR1C3;CC;rs12529;EFFICACY;INCREASED;RISK;EFFICACY:PROSTATE_CANCER-SPECIFIC_MORTALITY;MEN;DISEASE:PROSTATIC_NEOPLASMS;CAUTION_SIDE_EFFECT
WARFARIN;VKORC1;AA + AG;rs9934438;DOSAGE;DECREASED;;OTHER:MAINTECE_DOSE_OF_WARFARIN;;;CAUTION_DOSE_ADJUST
CISPLATIN, CYCLOPHOSPHAMIDE;ERCC1;AG;rs11615;TOXICITY;INCREASED;RISK;DISEASE:NEPHROTOXICITY;PEOPLE;DISEASE:OVARIAN_NEOPLASMS;CAUTION_SIDE_EFFECT
CISPLATIN, CYCLOPHOSPHAMIDE;TP53;GG;rs1042522;TOXICITY;INCREASED;SEVERITY;DISEASE:NEUTROPENIA;PEOPLE;DISEASE:OVARIAN_NEOPLASMS;CAUTION_SIDE_EFFECT
PACLITAXEL;CYP2C8;TT;rs11572080;TOXICITY;INCREASED;RISK;DISEASE:NEUROTOXICITY_SYNDROMES;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
METHOTREXATE;ABCC1;GG;rs2238476;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXICITY;PEOPLE;DISEASE:PSORIASIS;CAUTION_SIDE_EFFECT
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;MAFB;T;rs6028945;EFFICACY;INCREASED;RISK;EFFICACY:NON-RESPONSE;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
OLANZAPINE;HTR2C;T;rs3813929;TOXICITY;DECREASED;RISK;SIDE_EFFECT:WEIGHT_GAIN;PEOPLE;DISEASE:DEPRESSIVE_DISORDER, DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;MAFB;C;rs6071980;EFFICACY;INCREASED;RISK;EFFICACY:NON-RESPONSE;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;CT;rs3918290;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:MUCOSITIS;WOMEN;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
OLANZAPINE;HTR2C;T;rs3813929;TOXICITY;DECREASED;RISK;SIDE_EFFECT:WEIGHT_GAIN;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;CST5;T;rs6138150;EFFICACY;INCREASED;RISK;EFFICACY:NON-RESPONSE;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
OLANZAPINE;HTR2C;T;rs3813929;TOXICITY;DECREASED;RISK;SIDE_EFFECT:WEIGHT_GAIN;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN, CYCLOPHOSPHAMIDE;GSTP1;AA;rs1695;EFFICACY, METABOLISM/PK;INCREASED;;EFFICACY:PROGRESSION_FREE_SURVIVAL;PEOPLE;DISEASE:OVARIAN_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIPSYCHOTICS;CLCN6, MTHFR;A;rs1801133;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:METABOLIC_SYNDROME;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;PON1;A;rs854548;EFFICACY;INCREASED;RISK;EFFICACY:NON-RESPONSE;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;PON1;A;rs854555;EFFICACY;INCREASED;RISK;EFFICACY:NON-RESPONSE;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;MOB3B;A;rs7046653;EFFICACY;INCREASED;RISK;EFFICACY:NON-RESPONSE;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
BUPRENORPHINE;CYP3A4;CC + CT;rs2740574;EFFICACY;INCREASED;RISK;OTHER:SUBSTANCE_WITHDRAWAL_SYNDROME;PEOPLE;OTHER:OPIOID-RELATED_DISORDERS;CAUTION_SIDE_EFFECT
WARFARIN;VKORC1;AG;rs9934438;EFFICACY;DECREASED;;EFFICACY:TIME_IN_THERAPEUTIC_RANGE_OF_INR_(TTR);;;LIKELIHOOD_THERAPEUTIC_FAILURE
DOCETAXEL;;CT;rs11185648;TOXICITY;INCREASED;SEVERITY;DISEASE:ANEMIA;PEOPLE;DISEASE:NASOPHARYNGEAL_NEOPLASMS;CAUTION_SIDE_EFFECT
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED;;OTHER:WARFARIN_DOSE_IN_JAPANESE_PATIENTS;;;CAUTION_DOSE_ADJUST
DOCETAXEL;RXRA;AG;rs11185647;TOXICITY;INCREASED;SEVERITY;DISEASE:ANEMIA, DISEASE:NEUTROPENIA;PEOPLE;DISEASE:NASOPHARYNGEAL_NEOPLASMS;CAUTION_SIDE_EFFECT
CISPLATIN;TPMT;T;rs12201199;TOXICITY;INCREASED;RISK;DISEASE:OTOTOXICITY;CHILDREN;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
DOCETAXEL;RXRA;AG;rs2234753;TOXICITY;INCREASED;SEVERITY;DISEASE:ANEMIA;PEOPLE;DISEASE:NASOPHARYNGEAL_NEOPLASMS;CAUTION_SIDE_EFFECT
DOCETAXEL;RXRA;GT;rs6413517;TOXICITY;INCREASED;SEVERITY;DISEASE:ANEMIA;PEOPLE;DISEASE:NASOPHARYNGEAL_NEOPLASMS;CAUTION_SIDE_EFFECT
DOCETAXEL;RXRA;GG;rs62576288;TOXICITY;INCREASED;SEVERITY;DISEASE:ANEMIA;PEOPLE;DISEASE:NASOPHARYNGEAL_NEOPLASMS;CAUTION_SIDE_EFFECT
NAN;DRD2;GG;rs1799732;NAN;INCREASED;LIKELIHOOD;DISEASE:SCHIZOPHRENIA;;;CAUTION_DOSE_ADJUST
NAN;SCN1A;CT;rs2298771;OTHER;INCREASED;LIKELIHOOD;DISEASE:EPILEPSY;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;;G;rs9345389;TOXICITY;;;SIDE_EFFECT:END-OF-INDUCTION_MINIMAL_RISIDUAL_DISEASE_(MRD)_IN_CHILDHOOD_ACUTE_LYMPHOBLASTIC_LEUKEMIA_(ALL)_AND_IS_ALSO_ASSOCIATED_WITH_GREATER_METHOTREXATE_CLEARANCE.;;;CAUTION_DOSE_ADJUST
DOCETAXEL;HNF4A;TT;rs6130615;TOXICITY;INCREASED;SEVERITY;DISEASE:ANEMIA;PEOPLE;DISEASE:NASOPHARYNGEAL_NEOPLASMS;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;HTR2A;GG;rs7997012;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:DRUG_RESISTANCE;PEOPLE;OTHER:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
SIMVASTATIN;;A;rs76103438;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ADVERSE_EVENTS;;;CAUTION_SIDE_EFFECT
DIAZEPAM;CYP3A4;GG;rs35599367;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:ADVERSE_EVENTS;MEN;OTHER:ALCOHOL_ABUSE;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;HTR2A;AG;rs6314;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:DRUG_RESISTANCE;PEOPLE;OTHER:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOCETAXEL;HNF4A;CT;rs2273618;TOXICITY;INCREASED;SEVERITY;DISEASE:ANEMIA;PEOPLE;DISEASE:NASOPHARYNGEAL_NEOPLASMS;CAUTION_SIDE_EFFECT
DOCETAXEL;HNF4A;CT;rs3746574;TOXICITY;INCREASED;SEVERITY;DISEASE:ANEMIA;PEOPLE;DISEASE:NASOPHARYNGEAL_NEOPLASMS;CAUTION_SIDE_EFFECT
WARFARIN;VKORC1;A;rs9934438;DOSAGE, EFFICACY;;;OTHER:A_MORE_RAPID_ATTAINMENT_OF_TARGET_INR_AND_HIGHER_FREQUENCY_OF_DOSE_ADJUSTMENTS;;;CAUTION_DOSE_ADJUST
DOCETAXEL;NR1I2;TT;rs3732360;TOXICITY;INCREASED;SEVERITY;DISEASE:ANEMIA;PEOPLE;DISEASE:NASOPHARYNGEAL_NEOPLASMS;CAUTION_SIDE_EFFECT
NAN;NRXN1;C;rs985919;OTHER;INCREASED;LIKELIHOOD;DISEASE:TOBACCO_USE_DISORDER;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""BETA BLOCKING AGENTS, SELECTIVE"", ""DIURETICS""";NEDD4L;AG + GG;rs4149601;EFFICACY;DECREASED;RISK;OTHER:CARDIOVASCULAR_EVENTS;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
MEPERIDINE;SERINC5;C;rs185462714;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ADVERSE_EVENTS;;;CAUTION_SIDE_EFFECT
CISPLATIN, CYCLOPHOSPHAMIDE;GSTA1;AA;rs3957357;EFFICACY;INCREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:OVARIAN_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOCETAXEL;NR1I2;AA;rs3732359;TOXICITY;INCREASED;SEVERITY;DISEASE:ANEMIA;PEOPLE;DISEASE:NASOPHARYNGEAL_NEOPLASMS;CAUTION_SIDE_EFFECT
NAN;CHRNA5;C;rs17408276;OTHER;INCREASED;LIKELIHOOD;DISEASE:TOBACCO_USE_DISORDER;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
BETA BLOCKING AGENTS;;T;rs139945292;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ADVERSE_CARDIOVASCULAR_EVENTS;PEOPLE;OTHER:HYPERTENSION;CAUTION_SIDE_EFFECT
NICOTINE;COMT;AA;rs4680;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:SMOKING_CESSATION;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SIMVASTATIN;SLCO1B1;CC + CT;rs4149056;TOXICITY;INCREASED;RISK;DISEASE:MUSCULAR_DISEASES;;;CAUTION_SIDE_EFFECT
PENICILLIN G, PENICILLIN V;;A;rs115200108;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ADVERSE_EVENTS;;;CAUTION_SIDE_EFFECT
NICOTINE;COMT;AG;rs4680;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:RELAPSE;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;A;rs9934438;DOSAGE;DECREASED;;OTHER:WARFARIN_DOSE;;;CAUTION_DOSE_ADJUST
DOCETAXEL;NR1I2;CC + TT;rs3814058;TOXICITY;INCREASED;SEVERITY;DISEASE:ANEMIA;PEOPLE;DISEASE:NASOPHARYNGEAL_NEOPLASMS;CAUTION_SIDE_EFFECT
NAN;CHRNA5;A;rs16969968;OTHER;INCREASED;LIKELIHOOD;DISEASE:TOBACCO_USE_DISORDER;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;NRXN1;C;rs1882296;OTHER;INCREASED;LIKELIHOOD;DISEASE:TOBACCO_USE_DISORDER;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOCETAXEL;NR1I3;TT;rs10538494;TOXICITY;INCREASED;SEVERITY;DISEASE:NEUTROPENIA;PEOPLE;DISEASE:NASOPHARYNGEAL_NEOPLASMS;CAUTION_SIDE_EFFECT
CODEINE, HYDROCODONE, OXYCODONE, TRAMADOL;SEPTIN3, WBP2NL;A;rs739296;TOXICITY;DECREASED;RISK;SIDE_EFFECT:ADVERSE_EVENTS;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
MEPERIDINE;FIP1L1;G;rs113100019;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ADVERSE_EVENTS;;;CAUTION_SIDE_EFFECT
DOCETAXEL;NR1I3;AG;rs75114882;TOXICITY;INCREASED;SEVERITY;DISEASE:NEUTROPENIA;PEOPLE;DISEASE:NASOPHARYNGEAL_NEOPLASMS;CAUTION_SIDE_EFFECT
NAN;NRXN1;C;rs10865246;OTHER;INCREASED;SEVERITY;DISEASE:TOBACCO_USE_DISORDER;;;CAUTION_SIDE_EFFECT
CISPLATIN;COMT;T;rs9332377;TOXICITY;INCREASED;RISK;DISEASE:OTOTOXICITY;CHILDREN;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
DOCETAXEL;NR1I3;CC;rs2501873;TOXICITY;DECREASED;SEVERITY;DISEASE:ANEMIA;PEOPLE;DISEASE:NASOPHARYNGEAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN, CYCLOPHOSPHAMIDE;ERCC2;CT;rs1799793;TOXICITY;INCREASED;SEVERITY;DISEASE:NEUTROPENIA;PEOPLE;DISEASE:OVARIAN_NEOPLASMS;CAUTION_SIDE_EFFECT
CISPLATIN, CYCLOPHOSPHAMIDE;ERCC1;AC;rs3212986;TOXICITY;INCREASED;RISK;DISEASE:NEPHROTOXICITY;PEOPLE;DISEASE:OVARIAN_NEOPLASMS;CAUTION_SIDE_EFFECT
CISPLATIN, CYCLOPHOSPHAMIDE;XRCC1;CC;rs25487;TOXICITY;INCREASED;SEVERITY;DISEASE:NEUTROPENIA;PEOPLE;DISEASE:OVARIAN_NEOPLASMS;CAUTION_SIDE_EFFECT
MEPERIDINE;;A;rs11049274;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ADVERSE_EVENTS;;;CAUTION_SIDE_EFFECT
DOCETAXEL;RXRA;AG;rs1536475;TOXICITY;INCREASED;SEVERITY;DISEASE:ANEMIA;PEOPLE;DISEASE:NASOPHARYNGEAL_NEOPLASMS;CAUTION_SIDE_EFFECT
CISPLATIN;XPC;G;rs2228001;TOXICITY;INCREASED;RISK;DISEASE:OTOTOXICITY;PEOPLE;DISEASE:OSTEOSARCOMA;CAUTION_SIDE_EFFECT
DOCETAXEL;NR1I3;GG;rs2502815;TOXICITY;INCREASED;SEVERITY;DISEASE:ANEMIA;PEOPLE;DISEASE:NASOPHARYNGEAL_NEOPLASMS;CAUTION_SIDE_EFFECT
DOCETAXEL;NR1I3;AA;rs9725457;TOXICITY;INCREASED;SEVERITY;DISEASE:ANEMIA;PEOPLE;DISEASE:NASOPHARYNGEAL_NEOPLASMS;CAUTION_SIDE_EFFECT
CISPLATIN;ERCC2, KLC3;G;rs13181;EFFICACY;DECREASED;;EFFICACY:EVENT_FREE_SURVIVAL;PEOPLE;DISEASE:OSTEOSARCOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
ETHANOL;ACSS2;T;rs6088638;TOXICITY;INCREASED;RISK;OTHER:ALCOHOL_ABUSE;;;CAUTION_SIDE_EFFECT
CAPECITABINE, FLUOROURACIL;DPYD;AG;rs17376848;TOXICITY;INCREASED;RISK;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
ETHANOL;OPRM1;G;rs1799971;TOXICITY;INCREASED;RISK;DISEASE:ALCOHOL_ABUSE;;;CAUTION_SIDE_EFFECT
ANGIOTENSIN II ANTAGONISTS;CYP2D6;C;rs1058164;EFFICACY;DECREASED;SEVERITY;EFFICACY:ELEVATED_DIASTOLIC_BLOOD_PRESSURE;PEOPLE;OTHER:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN;ERCC1;G;rs11615;EFFICACY;INCREASED;;EFFICACY:OVERALL_SURVIVAL_AND_PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:NEOPLASM_OF_ESOPHAGUS;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;APOE;CC;rs429358;OTHER;INCREASED;SEVERITY;OTHER:COVID-19;;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;A;rs4986893;EFFICACY, TOXICITY;INCREASED;RISK;SIDE_EFFECT:CARDIOVASCULAR_EVENTS;PEOPLE;DISEASE:MYOCARDIAL_INFARCTION;CAUTION_SIDE_EFFECT
ANGIOTENSIN II ANTAGONISTS;CYP2D6;T;rs1985842;EFFICACY;DECREASED;SEVERITY;EFFICACY:ELEVATED_DIASTOLIC_BLOOD_PRESSURE;PEOPLE;OTHER:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;NAT2;T;rs1801280;OTHER;INCREASED;SEVERITY;DISEASE:INSULIN_RESISTANCE;;;CAUTION_SIDE_EFFECT
ANGIOTENSIN II ANTAGONISTS;CYP2D6;G;rs1135840;EFFICACY;DECREASED;SEVERITY;EFFICACY:ELEVATED_DIASTOLIC_BLOOD_PRESSURE;PEOPLE;OTHER:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;G;rs28399504;EFFICACY, TOXICITY;INCREASED;RISK;SIDE_EFFECT:CARDIOVASCULAR_EVENTS;PEOPLE;DISEASE:MYOCARDIAL_INFARCTION;CAUTION_SIDE_EFFECT
ANGIOTENSIN II ANTAGONISTS;CYP2D6;G;rs28371713;EFFICACY;DECREASED;SEVERITY;EFFICACY:ELEVATED_DIASTOLIC_BLOOD_PRESSURE;PEOPLE;OTHER:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;NAT2;A;rs1208;OTHER;INCREASED;SEVERITY;DISEASE:INSULIN_RESISTANCE;;;CAUTION_SIDE_EFFECT
AMOXICILLIN, CLAVULANATE, FLUCLOXACILLIN;;C;rs72631546;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;;;CAUTION_SIDE_EFFECT
GEFITINIB;ABCG2;GT;rs2231142;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DIARRHEA;PEOPLE;DISEASE:LUNG_NEOPLASMS;CAUTION_SIDE_EFFECT
ANGIOTENSIN II ANTAGONISTS;CYP2D6;G;rs112568578;EFFICACY;DECREASED;SEVERITY;EFFICACY:ELEVATED_DIASTOLIC_BLOOD_PRESSURE;PEOPLE;OTHER:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE, FLUOROURACIL;MIR23A, MIR24-2, MIR27A;C;rs895819;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA;PEOPLE;OTHER:NEOPLASMS;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;CT;rs3918290;TOXICITY;;;DISEASE:NEUTROPENIA;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_DOSE_ADJUST
AMOXICILLIN, CLAVULANATE;PTPN22;A;rs2476601;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;;;CAUTION_SIDE_EFFECT
MORPHINE;OPRM1;AA;rs1799971;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:SLEEP_APNEA_SYNDROMES;MEN;;CAUTION_SIDE_EFFECT
COCAINE;CNR1;GT + TT;rs6454674;OTHER;INCREASED;RISK;DISEASE:COCAINE_DEPENDENCE;;;CAUTION_SIDE_EFFECT
NAN;PTGS2;G;rs20417;NAN;INCREASED;RISK;DISEASE:STROKE;;;CAUTION_SIDE_EFFECT
ATENOLOL, BETA BLOCKING AGENTS, CARVEDILOL, METOPROLOL;PPARA;GG;rs4253778;EFFICACY;DECREASED;;OTHER:CARDIAC_REHOSPITALIZATION;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;LIKELIHOOD_THERAPEUTIC_FAILURE
DOXORUBICIN;RARG;AG;rs2229774;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:CARDIOTOXICITY;;;CAUTION_SIDE_EFFECT
FLUVASTATIN;ABCG2;GT + TT;rs2231142;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
ASPIRIN;TMEM196;T;rs9886152;TOXICITY;DECREASED;RISK;SIDE_EFFECT:ASPIRIN-INDUCED_ASTHMA;PEOPLE;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
PAZOPANIB;HIF1A;AG;rs11549467;EFFICACY;DECREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
NAN;CLOCK;AA + AG;rs1801260;OTHER;INCREASED;LIKELIHOOD;OTHER:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY;CHILDREN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
MERCAPTOPURINE, METHOTREXATE;ITPA;CC;rs7270101;TOXICITY;INCREASED;RISK;SIDE_EFFECT:LEUKOPENIA, SIDE_EFFECT:NEUTROPENIA;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
COCAINE;CNR1;GT + TT;rs6454674;OTHER;INCREASED;RISK;DISEASE:COCAINE_DEPENDENCE;;;CAUTION_SIDE_EFFECT
RITUXIMAB;FCGR3A;C;rs396991;EFFICACY;INCREASED;;EFFICACY:COMPLETE_RESPONSE_RATE;PEOPLE;DISEASE:LYMPHOMA, LARGE_B-CELL*^DIFFUSE;LIKELIHOOD_THERAPEUTIC_SUCCESS
MERCAPTOPURINE, METHOTREXATE;IMPDH1;CT;rs2278293;TOXICITY;INCREASED;RISK;SIDE_EFFECT:LEUKOPENIA;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
RITUXIMAB;FCGR3A;AA;rs396991;NAN;DECREASED;;OTHER:LEVELS_OF_IGG;PEOPLE;OTHER:NON-HODGKIN'S_LYMPHOMA_AND_STEM_CELL_TRANSPLANTATION;CAUTION_DOSE_ADJUST
COCAINE;CNR1;C;rs806368;OTHER;DECREASED;RISK;DISEASE:COCAINE_DEPENDENCE;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
MERCAPTOPURINE, METHOTREXATE;ITPA;CC;rs1127354;TOXICITY;INCREASED;RISK;SIDE_EFFECT:LEUKOPENIA;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
ALENDRONATE, RALOXIFENE;VDR;CC;rs1544410;EFFICACY;INCREASED;;EFFICACY:IMPROVEMENT_IN_BONE_MINERAL_DENSITY;PEOPLE;DISEASE:OSTEOPOROSIS, POSTMENOPAUSAL;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPARAGINASE, DEXAMETHASONE, METHOTREXATE;PYGL;CC + CT;rs7142143;DOSAGE;INCREASED;RISK;EFFICACY:RELAPSE;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DOSE_ADJUST
INTERFERONS;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
PAZOPANIB;CXCL8;AA;rs4073;EFFICACY;DECREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
ERLOTINIB;EGFR;T;rs121434569;EFFICACY;DECREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL_(PFS)_TIME;PEOPLE;OTHER:EGFR_MUTATION_POSITIVE_NON-SMALL-CELL_LUNG_CANCER;LIKELIHOOD_THERAPEUTIC_FAILURE
ERLOTINIB, GEFITINIB;EGFR;T;rs121434569;EFFICACY;DECREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL_(PFS)_TIME;PEOPLE;OTHER:EGFR_MUTATION_POSITIVE_NON-SMALL-CELL_LUNG_CANCER;LIKELIHOOD_THERAPEUTIC_FAILURE
INTERFERONS;IFNL3;TT;rs8099917;EFFICACY;INCREASED;;EFFICACY:RESPONSE_(SVR)_TO_INTERFERON_MONOTHERAPY_IN_HCV_GENOTYPE_1_PATIENTS;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE, IRINOTECAN, OXALIPLATIN;DPYD;AG;rs17376848;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
METHOTREXATE;;G;rs4888024;TOXICITY;;;SIDE_EFFECT:END-OF-INDUCTION_MINIMAL_RISIDUAL_DISEASE_(MRD)_IN_CHILDHOOD_ACUTE_LYMPHOBLASTIC_LEUKEMIA_(ALL)_AND_IS_ALSO_ASSOCIATED_WITH_GREATER_METHOTREXATE_CLEARANCE;;;CAUTION_DOSE_ADJUST
TACROLIMUS;ABCB1;AG;rs1128503;METABOLISM/PK;INCREASED;;PK:TROUGH_CONCENTRATIONS;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
TACROLIMUS;ABCB1;AC + CT;rs2032582;METABOLISM/PK;INCREASED;;PK:TROUGH_CONCENTRATIONS;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
METHOTREXATE;ABCC1;AA;rs3784862;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:TOXICITY;PEOPLE;DISEASE:PSORIASIS;CAUTION_SIDE_EFFECT
ETHANOL;OPRM1;A;rs1799971;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ALCOHOL_ABUSE;MEN;;CAUTION_SIDE_EFFECT
CAPECITABINE;DPYD;CT;rs2297595;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
CLOPIDOGREL;ABCB1;A;rs1045642;TOXICITY;INCREASED;RISK;SIDE_EFFECT:CARDIOVASCULAR_EVENTS;;;CAUTION_SIDE_EFFECT
EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) TYROSINE KINASE INHIBITORS;CTBP2;A;rs945665113;EFFICACY;INCREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;OTHER:LUNG_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;EFFICACY;INCREASED;;EFFICACY:PLATELET_REACTIVITY;;OTHER:PCI-SCHEDULED_PATIENTS;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED;;EFFICACY:RESPONSE_(SVR)_IN_HCV_GENOTYPE_1_PATIENTS;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE, FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;MTHFR;AG;rs1801133;TOXICITY;INCREASED;RISK;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
ANTIDEPRESSANTS;HTR2A;AA + AG;rs6313;TOXICITY;DECREASED;RISK;SIDE_EFFECT:ADVERSE_EVENTS;PEOPLE;OTHER:BIPOLAR_DISORDER, OTHER:DEPRESSION,OTHER:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
SUNITINIB;SLC22A5;C;rs2631367;EFFICACY;DECREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:GASTROINTESTINAL_STROMAL_TUMORS;LIKELIHOOD_THERAPEUTIC_FAILURE
ERLOTINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;;EFFICACY:OVERALL_SURVIVAL_(OS)_TIME;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;AA;rs4244285;EFFICACY, TOXICITY;INCREASED;RISK;SIDE_EFFECT:PRIMARY_CLINICAL_ENDPOINT_OF_DEATH_DUE_TO_CARDIOVASCULAR_CAUSES, NON-FATAL_MI_OR_STENT_THROMBOSIS;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;CAUTION_SIDE_EFFECT
ERLOTINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;;EFFICACY:RESPONSE_RATE;PEOPLE;DISEASE:ADENOCARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ERLOTINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;;EFFICACY:RESPONSE_RATE;PEOPLE;DISEASE:ADENOCARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
SUNITINIB;SLC22A5;C;rs2631370;EFFICACY;DECREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:GASTROINTESTINAL_STROMAL_TUMORS;LIKELIHOOD_THERAPEUTIC_FAILURE
NAN;PTGS2;CG + GG;rs20417;NAN;DECREASED;RISK;DISEASE:STROKE;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) TYROSINE KINASE INHIBITORS;CTBP2;G;rs376695472;EFFICACY;INCREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;OTHER:LUNG_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIDEPRESSANTS;HTR2A;CC;rs6311;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ADVERSE_EVENTS;PEOPLE;OTHER:BIPOLAR_DISORDER, OTHER:DEPRESSION,OTHER:MAJOR_DEPRESSIVE_DISORDER;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;A;rs4244285;TOXICITY;INCREASED;RISK;SIDE_EFFECT:CARDIOVASCULAR_EVENTS;;;CAUTION_SIDE_EFFECT
BETA BLOCKING AGENTS;ADRB2;GG;rs1042713;EFFICACY;DECREASED;RISK;EFFICACY:DEATH;PEOPLE;OTHER:ACUTE_CORONARY_SYNDROME;LIKELIHOOD_THERAPEUTIC_SUCCESS
HMG_COA_REDUCTASE_INHIBITORS;SLCO1B1;CC;rs4149056;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DISCONTINUATION;PEOPLE;OTHER:ACUTE_CORONARY_SYNDROME, OTHER:MYOCARDIAL_INFARCTION;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYS;G;rs2959023;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
SUNITINIB;IL4R;C;rs1805015;EFFICACY;DECREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:GASTROINTESTINAL_STROMAL_TUMORS;LIKELIHOOD_THERAPEUTIC_FAILURE
OMEGA-3 POLYUNSATURATED FATTY ACIDS;PTGS2;CG + GG;rs20417;OTHER;INCREASED;RISK;DISEASE:COLONIC_NEOPLASMS;;;CAUTION_SIDE_EFFECT
NAN;PTGS2;CG + GG;rs20417;OTHER;DECREASED;RISK;DISEASE:MYOCARDIAL_INFARCTION;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;DPYS;G;rs2669429;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;CLCN6, MTHFR;AG;rs1801133;TOXICITY;INCREASED;RISK;SIDE_EFFECT:MYELOSUPPRESSION;PEOPLE;OTHER:PRIMARY_CENTRAL_NERVOUS_SYSTEM_LYMPHOMA;CAUTION_SIDE_EFFECT
CAPECITABINE, FLUOROURACIL;DPYD;CT;rs3918290;TOXICITY;INCREASED;RISK;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
SUNITINIB;SLC22A5;C;rs2631372;EFFICACY;DECREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:GASTROINTESTINAL_STROMAL_TUMORS;LIKELIHOOD_THERAPEUTIC_FAILURE
CAPECITABINE, FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;MTHFR;GG;rs1801131;TOXICITY;INCREASED;RISK;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
ERLOTINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL_(PFS)_TIME;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
SUNITINIB;IL4R;G;rs1801275;EFFICACY;DECREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:GASTROINTESTINAL_STROMAL_TUMORS;LIKELIHOOD_THERAPEUTIC_FAILURE
HEROIN;BDNF;TT;rs16917234;TOXICITY;DECREASED;AGE_AT_ONSET;SIDE_EFFECT:HEROIN_DEPENDENCE;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
AMINOGLYCOSIDE ANTIBACTERIALS;MT-RNR1;T;rs267606619;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OTOTOXICITY;;;CAUTION_SIDE_EFFECT
TENOFOVIR;ABCC4;CC + CT;rs1751034;METABOLISM/PK;INCREASED;;PK:INTRACELLULAR_TENOFOVIR_DIPHOSPHATE_(TFV-DP)_CONCENTRATIONS;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DOSE_ADJUST
AZITHROMYCIN, ERYTHROMYCIN;ABCB1;AA + AG;rs1045642;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:PAIN, SIDE_EFFECT:DIARRHEA;PEOPLE;OTHER:BACTERIAL_INFECTIONS, OTHER:INFLUENZA;CAUTION_SIDE_EFFECT
CORTICOSTEROIDS;DTNBP1;T;rs35514893;EFFICACY;DECREASED;SEVERITY;DISEASE:ASTHMA;CHILDREN;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;CYP1B1;CC + CG;rs1056836;OTHER;INCREASED;RISK;DISEASE:BREAST_NEOPLASMS;WOMEN;DISEASE:TOBACCO_USE_DISORDER;CAUTION_SIDE_EFFECT
THIOTEPA;GSTP1;T;rs1138272;OTHER;INCREASED;;PK:NON-INDUCIBLE_THIOTEPA_CLEARANCE_AND_DECREASED_TEPA_CLEARANCE;;;CAUTION_DOSE_ADJUST
TENOFOVIR;ABCC4;TT;rs1751034;OTHER;INCREASED;;PK:TENOFOVIR_RENAL_CLEARANCE, AND_LOWER_AUC;;;CAUTION_DOSE_ADJUST
FLUOROURACIL;DPYD;A;rs2786783;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;OTHER:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
NAN;G6PD;T;rs72554664;OTHER;INCREASED;LIKELIHOOD;OTHER:DIABETES_MELLITUS, TYPE_2;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;;T;rs12442183;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:OPIOID-RELATED_DISORDERS;;;CAUTION_SIDE_EFFECT
CORTICOSTEROIDS;KL;G;rs450789;EFFICACY;DECREASED;SEVERITY;DISEASE:ASTHMA;CHILDREN;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
INTERFERON BETA-1A, INTERFERON BETA-1B;IRF6;G;rs2205986;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;PEOPLE;DISEASE:MULTIPLE_SCLEROSIS;CAUTION_SIDE_EFFECT
METHOTREXATE;NR1I2;C;rs3814058;TOXICITY;DECREASED;RISK;DISEASE:TOXIC_LIVER_DISEASE;CHILDREN;DISEASE:OSTEOSARCOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;ABCC2;A;rs2273697;TOXICITY;INCREASED;RISK;SIDE_EFFECT:BONE_MARROW_DISORDER;CHILDREN;DISEASE:OSTEOSARCOMA;CAUTION_SIDE_EFFECT
FLUOROURACIL;WNT5B;CC;rs2010851;EFFICACY;DECREASED;;OTHER:TIME_TO_TUMOR_RECURRENCE_(TTR);PEOPLE;DISEASE:COLONIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
CORTICOSTEROIDS;ME3;A;rs2125362;EFFICACY;INCREASED;SEVERITY;DISEASE:ASTHMA;CHILDREN;DISEASE:ASTHMA;CAUTION_SIDE_EFFECT
HEROIN;OPRD1;GG;rs508448;TOXICITY;DECREASED;AGE_AT_ONSET;SIDE_EFFECT:HEROIN_DEPENDENCE;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;NR1I2;G;rs6785049;TOXICITY;DECREASED;RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE;CHILDREN;DISEASE:OSTEOSARCOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CORTICOSTEROIDS;LHX2;A;rs7851998;EFFICACY;DECREASED;SEVERITY;DISEASE:ASTHMA;CHILDREN;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;DPYD;C;rs2811178;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;OTHER:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
CORTICOSTEROIDS;LHFPL3;G;rs61585310;EFFICACY;DECREASED;SEVERITY;DISEASE:ASTHMA;CHILDREN;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPARAGINASE, CORTICOSTEROIDS, CYCLOPHOSPHAMIDE, CYTARABINE, MERCAPTOPURINE, METHOTREXATE, VINCRISTINE;IL10;CC;rs1800896;EFFICACY;INCREASED;;EFFICACY:OVERALL_SURVIVAL;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;GSK3B;A;rs3732361;METABOLISM/PK;DECREASED;RISK;SIDE_EFFECT:BONE_MARROW_DISORDER, SIDE_EFFECT:TOXIC_LIVER_DISEASE;CHILDREN;DISEASE:OSTEOSARCOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
HEROIN;BDNF;TT;rs6265;TOXICITY;DECREASED;AGE_AT_ONSET;SIDE_EFFECT:HEROIN_DEPENDENCE;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
MORPHINE;SLC22A1;T;rs12208357;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:POSTOPERATIVE_NAUSEA_AND_VOMITING;CHILDREN;;CAUTION_SIDE_EFFECT
CORTICOSTEROIDS;TRDN;T;rs4897302;EFFICACY;INCREASED;SEVERITY;DISEASE:ASTHMA;CHILDREN;DISEASE:ASTHMA;CAUTION_SIDE_EFFECT
NICOTINE;CHRNA5;G;rs55781567;TOXICITY;INCREASED;;DISEASE:TOBACCO_USE_DISORDER;;;CAUTION_SIDE_EFFECT
HEROIN;OPRD1;AA;rs4654327;TOXICITY;DECREASED;RISK;SIDE_EFFECT:HEROIN_DEPENDENCE;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OLANZAPINE;GIPR;AA + AT;rs10423928;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:WEIGHT_GAIN;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
NICOTINE;CHRNA5;A;rs16969968;TOXICITY;INCREASED;;DISEASE:TOBACCO_USE_DISORDER;;;CAUTION_SIDE_EFFECT
NICOTINE;CHRNA5;A;rs503464;TOXICITY;INCREASED;;DISEASE:TOBACCO_USE_DISORDER;;;CAUTION_SIDE_EFFECT
ALLOPURINOL;CYCSP5;C;rs9469003;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;;;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;G;rs1801265;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;OTHER:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
DAUNORUBICIN, DOXORUBICIN;SLC22A17;T;rs4982753;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:CARDIOTOXICITY;CHILDREN;DISEASE:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;TT;rs9923231;EFFICACY;INCREASED;;EFFICACY:TIME_IN_THERAPEUTIC_RANGE;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ALLOPURINOL, CARBAMAZEPINE, PHENYTOIN;CYCSP5;C;rs9469003;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;;;CAUTION_SIDE_EFFECT
NICOTINE;CHRNA5;G;rs55853698;TOXICITY;INCREASED;;DISEASE:TOBACCO_USE_DISORDER;;;CAUTION_SIDE_EFFECT
AMANTADINE, ANTICHOLINERGICS, DOPAMINE AGONISTS, LEVODOPA, SELEGILINE;SLC22A1;C;rs622342;DOSAGE, EFFICACY, TOXICITY;INCREASED;RISK;DISEASE:DEATH;PEOPLE;DISEASE:PARKINSON_DISEASE;CAUTION_DOSE_ADJUST
MELPHALAN;POLR1G;A;rs967591;EFFICACY, TOXICITY;INCREASED;;EFFICACY:OVERALL_SURVIVAL_AND_TIME-TO-TREAT_FAILURE;PEOPLE;DISEASE:MULTIPLE_MYELOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CORTICOSTEROIDS;ACOT7;G;rs11121611;EFFICACY;DECREASED;SEVERITY;DISEASE:ASTHMA;CHILDREN;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIR;ITPA;CC;rs1127354;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ANEMIA;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;CAUTION_SIDE_EFFECT
MORPHINE;TLR2;CC + CT;rs3804100;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:NAUSEA, SIDE_EFFECT:FATIGUE, SIDE_EFFECT:COGNITIVE_DISORDER, SIDE_EFFECT:CONSTIPATION, SIDE_EFFECT:ADVERSE_EVENTS;PEOPLE;OTHER:PAIN, OTHER:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
DAUNORUBICIN, DOXORUBICIN;SLC22A7;G;rs4149178;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:CARDIOTOXICITY;CHILDREN;DISEASE:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ROSUVASTATIN;SCAP;CC + CT;rs12487736;EFFICACY;DECREASED;SEVERITY;EFFICACY:HYPERLIPIDEMIAS;PEOPLE;DISEASE:METABOLIC_SYNDROME;LIKELIHOOD_THERAPEUTIC_SUCCESS
ALLOPURINOL;PSORS1C3;A;rs3094188;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;;;CAUTION_SIDE_EFFECT
CORTICOSTEROIDS;APOBEC3B;A;rs5995653;EFFICACY;DECREASED;SEVERITY;DISEASE:ASTHMA;CHILDREN;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ALLOPURINOL, CARBAMAZEPINE, PHENYTOIN;PSORS1C3;A;rs3094188;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;;;CAUTION_SIDE_EFFECT
MORPHINE;COMT;AA + AG;rs4680;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:NAUSEA, SIDE_EFFECT:FATIGUE, SIDE_EFFECT:DEPRESSION;PEOPLE;OTHER:PAIN, OTHER:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEMCITABINE, PACLITAXEL;CDA;CC;rs2072671;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NAUSEA;PEOPLE;OTHER:PANCREATIC_NEOPLASMS;CAUTION_SIDE_EFFECT
MONTELUKAST;ABCC1;CT;rs119774;EFFICACY;INCREASED;;EFFICACY:CHANGES_IN_FEV1;PEOPLE;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
TRIAMCINOLONE;HCG22;T;rs2523864;TOXICITY;INCREASED;;SIDE_EFFECT:OCULAR_HYPERTENSION;PEOPLE;DISEASE:RETINAL_DISEASES;CAUTION_SIDE_EFFECT
ANTIDEPRESSANTS;CREB1, METTL21A;GG;rs7569963;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:REMISSION;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
MORPHINE;IL6;CC;rs10499563;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:NAUSEA, SIDE_EFFECT:FATIGUE, SIDE_EFFECT:DEPRESSION;PEOPLE;OTHER:PAIN, OTHER:NEOPLASMS;CAUTION_SIDE_EFFECT
ALLOPURINOL;POU5F1;G;rs3130501;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;;;CAUTION_SIDE_EFFECT
ALLOPURINOL, CARBAMAZEPINE, PHENYTOIN;POU5F1;G;rs3130501;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;;;CAUTION_SIDE_EFFECT
EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) TYROSINE KINASE INHIBITORS;HLA-DRB5;A;rs184278615;EFFICACY;DECREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;OTHER:LUNG_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
CITALOPRAM;;T;rs4675690;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:TREATMENT-EMERGENT_SUICIDALITY;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_SIDE_EFFECT
CITALOPRAM;CREB1, METTL21A;A;rs7569963;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:TREATMENT-EMERGENT_SUICIDALITY;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) TYROSINE KINASE INHIBITORS;HLA-DRB5;T;rs201469165;EFFICACY;DECREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;OTHER:LUNG_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
"""ANTIVIRALS FOR TREATMENT OF HIV INFECTIONS, COMBINATIONS"", ""RITONAVIR""";APOE;T;rs7412;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HYPERTRIGLYCERIDEMIA;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
ALLOPURINOL;POU5F1;C;rs3130931;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;;;CAUTION_SIDE_EFFECT
TRIAMCINOLONE;HCG22;G;rs3873352;TOXICITY;INCREASED;;SIDE_EFFECT:OCULAR_HYPERTENSION;PEOPLE;DISEASE:RETINAL_DISEASES;CAUTION_SIDE_EFFECT
ALLOPURINOL, CARBAMAZEPINE, PHENYTOIN;PSORS1C1;A;rs3815087;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;;;CAUTION_SIDE_EFFECT
MORPHINE;IL6R;AC + CC;rs2228145;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:NAUSEA, SIDE_EFFECT:FATIGUE, SIDE_EFFECT:DEPRESSION;PEOPLE;OTHER:PAIN, OTHER:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ALLOPURINOL, CARBAMAZEPINE, PHENYTOIN;POU5F1;C;rs3130931;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;;;CAUTION_SIDE_EFFECT
MORPHINE;BDNF;TT;rs6265;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:NAUSEA, SIDE_EFFECT:FATIGUE, SIDE_EFFECT:DEPRESSION;PEOPLE;OTHER:PAIN, OTHER:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ALLOPURINOL;PSORS1C1;A;rs3815087;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;;;CAUTION_SIDE_EFFECT
MORPHINE;IL2;AC + CC;rs2069762;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:NAUSEA, SIDE_EFFECT:FATIGUE, SIDE_EFFECT:DEPRESSION;PEOPLE;OTHER:PAIN, OTHER:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) TYROSINE KINASE INHIBITORS;HLA-DRB5;C;rs1071748;EFFICACY;DECREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;OTHER:LUNG_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
ASPIRIN, CLOPIDOGREL;B4GALT2;CT + TT;rs1061781;EFFICACY;DECREASED;;EFFICACY:PLATELET_AGGREGATION;;;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;ABCB1;AA + AG;rs1128503;TOXICITY;INCREASED;RISK;DISEASE:DRUG_TOXICITY;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
ALLOPURINOL;;C;rs2844665;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE, METHOTREXATE;SLC28A2;AA;rs2413775;TOXICITY;INCREASED;RISK;SIDE_EFFECT:LEUKOPENIA;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
CHLORTHALIDONE;NPPA;G;rs5065;EFFICACY;DECREASED;;EFFICACY:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE);PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;ABCB1;AA + AG;rs1045642;TOXICITY;INCREASED;RISK;DISEASE:DRUG_TOXICITY;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
MERCAPTOPURINE, METHOTREXATE;SLC28A2;AT;rs2413775;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUTROPENIA;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;SOD2;G;rs4880;EFFICACY;DECREASED;;EFFICACY:SURVIVAL;PEOPLE;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOPHOSPHAMIDE;CYP3A4;C;rs2740574;TOXICITY;DECREASED;RISK;SIDE_EFFECT:PRIMARY_OVARIAN_FAILURE;PEOPLE;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOXORUBICIN;SLC22A16;CC;rs714368;TOXICITY, METABOLISM/PK;INCREASED;;PK:DOXORUBICINOL_AUC;PEOPLE;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
MERCAPTOPURINE, METHOTREXATE;SLC29A1;CC;rs747199;TOXICITY;DECREASED;RISK;SIDE_EFFECT:AGRANULOCYTOSIS, SIDE_EFFECT:LEUKOPENIA;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ALLOPURINOL, CARBAMAZEPINE, PHENYTOIN;;C;rs2844665;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;CYP2B6;AG + GG;rs2279343;TOXICITY, METABOLISM/PK;INCREASED;RISK;SIDE_EFFECT:ORAL_MUCOSITIS;PEOPLE;OTHER:RECIPIENTS_OF_HLA-IDENTICAL_HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;CYP2B6;CT + TT;rs8192709;TOXICITY, METABOLISM/PK;INCREASED;RISK;SIDE_EFFECT:HEMORRHAGIC_CYSTITIS;PEOPLE;OTHER:RECIPIENTS_OF_HLA-IDENTICAL_HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION;CAUTION_SIDE_EFFECT
EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) TYROSINE KINASE INHIBITORS;KIR3DL2;G;rs973541788;EFFICACY;DECREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;OTHER:LUNG_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
AMOXICILLIN, CLAVULANATE, FLUCLOXACILLIN;HLA-DRA;T;rs3129880;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;;;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;AA + AG;rs1801133;TOXICITY;INCREASED;RISK;DISEASE:DRUG_TOXICITY;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;CYP2B6;GT + TT;rs3745274;TOXICITY, METABOLISM/PK;DECREASED;RISK;SIDE_EFFECT:VENOOCCLUSIVE_DISEASE_OF_THE_LIVER;PEOPLE;OTHER:HLA-IDENTICAL_HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANGIOTENSIN II ANTAGONISTS;CYP2D6;C;rs28371725;EFFICACY;DECREASED;SEVERITY;EFFICACY:ELEVATED_DIASTOLIC_BLOOD_PRESSURE;PEOPLE;OTHER:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;OPRM1;GG;rs1799971;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:SLEEP_DISORDERS;PEOPLE;OTHER:PAIN;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;EFFICACY;INCREASED;;EFFICACY:PLATELET_AGGREGATION;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOSPORINE, METHOTREXATE;MTHFR;A;rs1801133;OTHER;;;SIDE_EFFECT:GRAFT_VS_HOST_DISEASE;PEOPLE;OTHER:RECIPIENTS_OF_HLA-IDENTICAL_HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION;CAUTION_DOSE_ADJUST
CARBOPLATIN, CISPLATIN, GEMCITABINE;GSTP1;AG + GG;rs1695;EFFICACY;INCREASED;RISK;EFFICACY:DEATH;PEOPLE;OTHER:GALLBLADDER_NEOPLASMS;CAUTION_SIDE_EFFECT
ANGIOTENSIN II ANTAGONISTS;CYP2D6;T;rs2004511;EFFICACY;DECREASED;SEVERITY;EFFICACY:ELEVATED_DIASTOLIC_BLOOD_PRESSURE;PEOPLE;OTHER:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
MERCAPTOPURINE, METHOTREXATE;ABCC4;CC;rs2274407;TOXICITY;INCREASED;RISK;SIDE_EFFECT:LEUKOPENIA, SIDE_EFFECT:NEUTROPENIA;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
DOXORUBICIN;CBR3;G;rs8133052;EFFICACY;DECREASED;;EFFICACY:TUMOR_RESPONSE;PEOPLE;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
DOXORUBICIN;CBR3;G;rs8133052;TOXICITY, METABOLISM/PK;DECREASED;SEVERITY;DISEASE:NEUTROPENIA;PEOPLE;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOXORUBICIN;CBR3;A;rs1056892;DOSAGE, METABOLISM/PK;INCREASED;;PK:DOXORUBICINOL_AUC;PEOPLE;DISEASE:BREAST_NEOPLASMS;CAUTION_DOSE_ADJUST
ANTIHYPERTENSIVES;ATP2B1;AA + AG;rs1401982;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:RESISTANT_HYPERTENSION;PEOPLE;OTHER:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANGIOTENSIN II ANTAGONISTS;CYP2D6;A;rs28371702;EFFICACY;DECREASED;SEVERITY;EFFICACY:ELEVATED_DIASTOLIC_BLOOD_PRESSURE;PEOPLE;OTHER:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
MORPHINE;OPRM1;AA;rs1799971;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:PRURITUS;WOMEN;OTHER:POSTOPERATIVE_PAIN;CAUTION_SIDE_EFFECT
MERCAPTOPURINE, METHOTREXATE;SLC28A3;CC + CT;rs10868138;TOXICITY;INCREASED;RISK;SIDE_EFFECT:LEUKOPENIA;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
HEROIN;GRM3;A;rs724226;OTHER;INCREASED;RISK;DISEASE:HEROIN_DEPENDENCE;;;CAUTION_SIDE_EFFECT
ACENOCOUMAROL;VKORC1;T;rs7294;OTHER;DECREASED;LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE;PEOPLE;DISEASE:ATRIAL_FIBRILLATION, DISEASE:ATRIAL_FLUTTER,DISEASE:VENOUS_THROMBOSIS;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;EFFICACY;INCREASED;;EFFICACY:RESIDUAL_PLATELET_REACTIVITY;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED;;OTHER:WARFARIN_DOSE;;;CAUTION_DOSE_ADJUST
CORTICOSTEROIDS;CRHR1;AA;rs242941;EFFICACY;INCREASED;;EFFICACY:PERCENT_CHANGE_IN_FEV;PEOPLE;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;CLCN6, MTHFR;AA;rs1801133;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:RECURRENCE;CHILDREN;DISEASE:OSTEOSARCOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CORTICOSTEROIDS;FKBP5;AA + AG;rs4713916;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:GLUCOCORTICOID_RESPONSIVENESS;PEOPLE;DISEASE:CROHN_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUDESONIDE, FLUTICASONE PROPIONATE;CRHR1;AA;rs242941;EFFICACY;;;PK:DELAYED_CORTISOL_RESPONSE_TO_STRESS;CHILDREN;DISEASE:ASTHMA;CAUTION_DOSE_ADJUST
OPIOIDS;ABCB1;G;rs1045642;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:NAUSEA;PEOPLE;OTHER:LOW_BACK_PAIN;CAUTION_SIDE_EFFECT
CORTICOSTEROIDS;CRHR1;TT;rs1876828;EFFICACY;INCREASED;;EFFICACY:PERCENT_CHANGE_IN_FEV;PEOPLE;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEMCITABINE;;C;rs1155463;TOXICITY;INCREASED;RISK;DISEASE:NEUTROPENIA;;;CAUTION_SIDE_EFFECT
EFAVIRENZ;CYP2B6;GT + TT;rs3745274;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:CENTRAL_NERVOUS_SYSTEM_DISORDER;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC1;AA + AT;rs212090;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:NEUTROPENIA, SIDE_EFFECT:LEUKOPENIA, SIDE_EFFECT:THROMBOCYTOPENIA, SIDE_EFFECT:ANEMIA;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUDESONIDE, FLUTICASONE PROPIONATE;CRHR1;TT;rs1876828;EFFICACY;;;PK:DELAYED_CORTISOL_RESPONSE_TO_STRESS;CHILDREN;DISEASE:ASTHMA;CAUTION_DOSE_ADJUST
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;SLC22A6;CC + CT;rs4149171;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:NEUTROPENIA, SIDE_EFFECT:LEUKOPENIA, SIDE_EFFECT:THROMBOCYTOPENIA, SIDE_EFFECT:ANEMIA;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;;AA + AG;rs955434;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:NEUTROPENIA, SIDE_EFFECT:LEUKOPENIA, SIDE_EFFECT:THROMBOCYTOPENIA, SIDE_EFFECT:ANEMIA;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE;;A;rs61824877;EFFICACY, TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:HYPERGLYCEMIA;PEOPLE;DISEASE:HYPERTENSION;CAUTION_SIDE_EFFECT
WARFARIN;VKORC1;CT + TT;rs9923231;EFFICACY;DECREASED;;EFFICACY:TIME_TO_THERAPEUTIC_INR;;;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;SLC22A6;CT + TT;rs4149170;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:NEUTROPENIA, SIDE_EFFECT:LEUKOPENIA, SIDE_EFFECT:THROMBOCYTOPENIA, SIDE_EFFECT:ANEMIA;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
TRAMADOL;OPRM1;GG;rs1799971;TOXICITY;DECREASED;LIKELIHOOD;DISEASE:NAUSEA;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE;HMGCS2;G;rs9943291;EFFICACY, TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:HYPERGLYCEMIA;PEOPLE;DISEASE:HYPERTENSION;CAUTION_SIDE_EFFECT
METHOTREXATE;CLCN6, MTHFR;AG;rs1801133;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
METHADONE;DAO;TT;rs55944529;EFFICACY;INCREASED;SEVERITY;EFFICACY:SUBSTANCE_WITHDRAWAL_SYNDROME;PEOPLE;OTHER:HEROIN_DEPENDENCE;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC5;CC;rs4148579;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:NEUTROPENIA, SIDE_EFFECT:LEUKOPENIA, SIDE_EFFECT:THROMBOCYTOPENIA, SIDE_EFFECT:ANEMIA;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
NAN;KCNIP1, KCNMB1;CT + TT;rs11739136;OTHER;DECREASED;RISK;DISEASE:HYPERTENSION;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
INFLIXIMAB;IL1B;GG;rs1143634;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:TREATMENT_FAILURE;PEOPLE;OTHER:CROHN_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
IRINOTECAN;UGT1A1;AA;rs10929302;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUTROPENIA, SIDE_EFFECT:VOMITING;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
ATAZANAVIR;ABCB1;AT;rs2032582;TOXICITY;INCREASED;RISK;DISEASE:HYPERBILIRUBINEMIA;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
DABIGATRAN;ABCB1;CC + CT;rs4148738;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE;PEOPLE;OTHER:STROKE;CAUTION_SIDE_EFFECT
NICOTINE;CHRNA5;A;rs16969968;OTHER;INCREASED;RISK;DISEASE:TOBACCO_USE_DISORDER;;;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC1;AA + AG;rs212087;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:NEUTROPENIA, SIDE_EFFECT:LEUKOPENIA, SIDE_EFFECT:THROMBOCYTOPENIA, SIDE_EFFECT:ANEMIA;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
INFLIXIMAB;IL23R;TT;rs10489629;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:TREATMENT_FAILURE;PEOPLE;OTHER:CROHN_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
IRINOTECAN;UGT1A1;AA;rs10929302;TOXICITY;INCREASED;RISK;DISEASE:NEUTROPENIA;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC5;CC;rs4148580;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:NEUTROPENIA, SIDE_EFFECT:LEUKOPENIA, SIDE_EFFECT:THROMBOCYTOPENIA, SIDE_EFFECT:ANEMIA;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
INFLIXIMAB;SLCO1C1;GG;rs3794271;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:TREATMENT_FAILURE;PEOPLE;OTHER:CROHN_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
NICOTINE;CHRNA3;A;rs578776;OTHER;DECREASED;RISK;DISEASE:TOBACCO_USE_DISORDER;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARVEDILOL;ADRB1;CC;rs1801253;EFFICACY;INCREASED;;EFFICACY:IMPROVEMENT_IN_LEFT_VENTRICULAR_FUNCTION_(LVEF);PEOPLE;DISEASE:HEART_FAILURE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2A;ABCB1;AA + AG;rs1045642;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:CRYOGLOBULINEMIA;PEOPLE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PD-1/PDL-1 (PROGRAMMED CELL DEATH PROTEIN 1/DEATH LIGAND 1) INHIBITORS;IL7;A;rs16906115;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS;PEOPLE;OTHER:NEOPLASMS;CAUTION_SIDE_EFFECT
IRINOTECAN;ABCC1;CT + TT;rs3743527;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:NEUTROPENIA;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;CHRNA3;A;rs1051730;OTHER;INCREASED;RISK;DISEASE:TOBACCO_USE_DISORDER;;;CAUTION_SIDE_EFFECT
IRINOTECAN;ABCB1;AC + CC;rs12720066;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:NEUTROPENIA;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
NICOTINE;CHRNA3;C;rs3743078;OTHER;DECREASED;RISK;DISEASE:TOBACCO_USE_DISORDER;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC5;GG;rs4148575;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:NEUTROPENIA, SIDE_EFFECT:LEUKOPENIA, SIDE_EFFECT:THROMBOCYTOPENIA, SIDE_EFFECT:ANEMIA;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
NICOTINE;CHRNB4;G;rs3813567;OTHER;DECREASED;RISK;DISEASE:TOBACCO_USE_DISORDER;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN;ABCC1;AG + GG;rs17501331;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:NEUTROPENIA;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARVEDILOL;ADRB1;CC;rs1801253;EFFICACY;;;EFFICACY:SIGNIFICANTLY_GREATER_IMPROVEMENT_IN_LEFT_VENTRICULAR_EJECTION_FRACTION_(LVEF);PEOPLE;DISEASE:HEART_FAILURE;CAUTION_DOSE_ADJUST
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:CRYOGLOBULINEMIA;PEOPLE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2A;IFNL4;TT;rs8099917;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:CRYOGLOBULINEMIA;PEOPLE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;UGT1A1;AA;rs4148323;EFFICACY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS, SIDE_EFFECT:CEREBRAL_PALSY, SIDE_EFFECT:HEARING_LOSS;CHILDREN;OTHER:NEONATAL_HYPERBILIRUBINEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2A;NT5C2;CT;rs10883841;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:CRYOGLOBULINEMIA;PEOPLE;;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;VKORC1;TT;rs9923231;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OVER-ANTICOAGULATION;;;CAUTION_SIDE_EFFECT
INFLIXIMAB;ADAM17;TT;rs10929587;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:TREATMENT_FAILURE;PEOPLE;OTHER:CROHN_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;MED12L, P2RY12;AG;rs10935838;EFFICACY;DECREASED;;EFFICACY:PLATELET_AGGREGATION;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
NAN;AGO2;AA + AC;rs4961280;OTHER;DECREASED;;OTHER:PROGRESSION-FREE_SURVIVAL;PEOPLE;OTHER:RENAL_CELL_CARCINOMA;CAUTION_DOSE_ADJUST
STAVUDINE;TNF;C;rs1799964;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:NEUROPATHY;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
CLOPIDOGREL;MED12L, P2RY12;AG;rs2046934;EFFICACY;DECREASED;;EFFICACY:PLATELET_AGGREGATION;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;MED12L, P2RY12;AC;rs6809699;EFFICACY;DECREASED;;EFFICACY:PLATELET_AGGREGATION;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC5;AA;rs3749442;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:NEUTROPENIA, SIDE_EFFECT:LEUKOPENIA, SIDE_EFFECT:THROMBOCYTOPENIA, SIDE_EFFECT:ANEMIA;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
NICOTINE;CHRNA5;G;rs684513;OTHER;DECREASED;RISK;DISEASE:TOBACCO_USE_DISORDER;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
AMINOGLYCOSIDE ANTIBACTERIALS;MT-RNR1;C;rs267606618;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OTOTOXICITY;;;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC5;GG;rs1132776;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:NEUTROPENIA, SIDE_EFFECT:LEUKOPENIA, SIDE_EFFECT:THROMBOCYTOPENIA, SIDE_EFFECT:ANEMIA;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
NICOTINE;CHRNA5;A;rs637137;OTHER;DECREASED;RISK;DISEASE:TOBACCO_USE_DISORDER;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;IL1A;A;rs1800587;OTHER;INCREASED;SEVERITY;DISEASE:PAIN;PEOPLE;DISEASE:SICKLE_CELL_ANEMIA;CAUTION_SIDE_EFFECT
FLUTICASONE / SALMETEROL;CRHR1;CC;rs242941;EFFICACY;INCREASED;;EFFICACY:MEAN_CHANGE_IN_FEV;PEOPLE;DISEASE:CHRONIC_OBSTRUCTIVE_PULMONARY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PROPRANOLOL;COMT;G;rs4680;EFFICACY;INCREASED;SEVERITY;EFFICACY:PAIN;WOMEN;EFFICACY:PAIN, DISEASE:TEMPOROMANDIBULAR_JOINT_DISORDER;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC5;AA;rs939338;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:NEUTROPENIA, SIDE_EFFECT:LEUKOPENIA, SIDE_EFFECT:THROMBOCYTOPENIA, SIDE_EFFECT:ANEMIA;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2A;CYP27B1, METTL1;GT + TT;rs10877012;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:HEPATITIS_B_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_FAILURE
PROPRANOLOL;COMT;G;rs4818;EFFICACY;INCREASED;SEVERITY;EFFICACY:PAIN;WOMEN;EFFICACY:PAIN, DISEASE:TEMPOROMANDIBULAR_JOINT_DISORDER;CAUTION_SIDE_EFFECT
CORTICOSTEROIDS;APOBEC3B;T;rs6001366;EFFICACY;DECREASED;SEVERITY;DISEASE:ASTHMA;CHILDREN;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2A;IFNL3;TT;rs12979860;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:HEPATITIS_B_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
CORTICOSTEROIDS;KCNN1;C;rs2278992;EFFICACY;DECREASED;SEVERITY;DISEASE:ASTHMA;CHILDREN;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2A;VDR;AA;rs7975232;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:HEPATITIS_B_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_FAILURE
CORTICOSTEROIDS;ANKRD30B;A;rs12959468;EFFICACY;DECREASED;SEVERITY;DISEASE:ASTHMA;CHILDREN;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ROSUVASTATIN;CRP;CT + TT;rs1205;EFFICACY, OTHER, METABOLISM/PK;DECREASED;;OTHER:PLASMA_LEVEL_OF_HIGH-SENSITIVITY_C-REACTIVE_PROTEIN;PEOPLE;DISEASE:CORONARY_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
PROPRANOLOL;COMT;G;rs6269;EFFICACY;INCREASED;SEVERITY;EFFICACY:PAIN;WOMEN;EFFICACY:PAIN, DISEASE:TEMPOROMANDIBULAR_JOINT_DISORDER;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC1;CC + CG;rs129081;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:NEUTROPENIA, SIDE_EFFECT:LEUKOPENIA, SIDE_EFFECT:THROMBOCYTOPENIA, SIDE_EFFECT:ANEMIA;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
RISPERIDONE;HTR2A;TT;rs6311;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS;CHILDREN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
HEROIN;GRM3;T;rs2189814;OTHER;INCREASED;RISK;DISEASE:HEROIN_DEPENDENCE;;;CAUTION_SIDE_EFFECT
ROSUVASTATIN;;CC + CT;rs2808630;EFFICACY, OTHER, METABOLISM/PK;DECREASED;;OTHER:PLASMA_LEVEL_OF_HIGH-SENSITIVITY_C-REACTIVE_PROTEIN;PEOPLE;DISEASE:CORONARY_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
METHADONE;OPRD1;AT + TT;rs204076;EFFICACY;INCREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;OTHER:OPIOID-RELATED_DISORDERS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ROSUVASTATIN;HNF1A;AC + CC;rs1169288;EFFICACY, OTHER, METABOLISM/PK;DECREASED;;OTHER:PLASMA_LEVEL_OF_HIGH-SENSITIVITY_C-REACTIVE_PROTEIN;PEOPLE;DISEASE:CORONARY_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
METOPROLOL;ADRB1;CC;rs1801253;EFFICACY;INCREASED;;EFFICACY:IMPROVEMENT_IN_LEFT_VENTRICULAR(LV)_REMODELING_AND_GREATER_INCREASE_IN_LVEF_(LEFT_VENTRICULAR_EJECTION_FRACTION);PEOPLE;DISEASE:HEART_FAILURE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PROPRANOLOL;COMT;C;rs4633;EFFICACY;INCREASED;SEVERITY;EFFICACY:PAIN;WOMEN;EFFICACY:PAIN, DISEASE:TEMPOROMANDIBULAR_JOINT_DISORDER;CAUTION_SIDE_EFFECT
BUCINDOLOL;ADRB1;CC;rs1801253;EFFICACY;INCREASED;;EFFICACY:RESPONSE;PEOPLE;DISEASE:HEART_FAILURE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ERYTHROMYCIN;CYP3A4;AA + AG;rs35599367;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;OTHER:BACTERIAL_INFECTIONS, OTHER:INFLUENZA;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;INCREASED;RISK;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;CAUTION_SIDE_EFFECT
ASPIRIN;PEAR1;AA + AG;rs12041331;TOXICITY;INCREASED;RISK;DISEASE:MYOCARDIAL_INFARCTION;;;CAUTION_SIDE_EFFECT
NAN;KCNIP1, KCNMB1;CT + TT;rs11739136;OTHER;DECREASED;;OTHER:BLOOD_PRESSURE;MEN;;CAUTION_DOSE_ADJUST
TACROLIMUS;ABCB1;A;rs2032582;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:TRANSPLANT_REJECTION;CHILDREN;OTHER:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAFFEINE, ISOFLURANE;RYR1;AC;rs118192162;TOXICITY;;;DISEASE:MALIGT_HYPERTHERMIA;;;CAUTION_DOSE_ADJUST
RISPERIDONE;NR1I2;GG;rs7643645;METABOLISM/PK;DECREASED;;PK:9-HYDROXY-RISPERIDONE_LEVELS;PEOPLE;DISEASE:PSYCHOTIC_DISORDER;CAUTION_DOSE_ADJUST
REPAGLINIDE;SLCO1B1;GG;rs2306283;OTHER, METABOLISM/PK;DECREASED;;PK:REPAGLINIDE_PLASMA_CONCENTRATION_(AUC)_AND_CMAX;HEALTHY;;CAUTION_DOSE_ADJUST
HALOTHANE;RYR1;CT;rs118192161;TOXICITY;;;DISEASE:MALIGT_HYPERTHERMIA;;;CAUTION_DOSE_ADJUST
RISPERIDONE;NR1I2;GG;rs7643645;METABOLISM/PK;DECREASED;;PK:ACTIVE_MOIETY_LEVELS;PEOPLE;DISEASE:PSYCHOTIC_DISORDER;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY, TOXICITY;INCREASED;RISK;SIDE_EFFECT:STENT_THROMBOSIS;PEOPLE;DISEASE:MYOCARDIAL_INFARCTION;CAUTION_SIDE_EFFECT
TACROLIMUS;ABCB1;G;rs1045642;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:TRANSPLANT_REJECTION;CHILDREN;OTHER:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEFITINIB;CYP2D6;AA + AG;rs1065852;EFFICACY;DECREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
DALCETRAPIB;ADCY9;AA;rs1967309;EFFICACY;DECREASED;RISK;EFFICACY:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE);PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;LIKELIHOOD_THERAPEUTIC_SUCCESS
EGFR INHIBITORS;PIK3CA;C;rs6443624;TOXICITY;DECREASED;LIKELIHOOD;DISEASE:EXANTHEMA;PEOPLE;DISEASE:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
EGFR INHIBITORS;PIK3CA;T;rs2677760;TOXICITY;DECREASED;LIKELIHOOD;DISEASE:EXANTHEMA;PEOPLE;DISEASE:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
MISOPROSTOL;SLCO1B1;GG;rs4149087;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:FEVER;WOMEN;DISEASE:POST-PARTUM_HEMORRHAGE;CAUTION_SIDE_EFFECT
MISOPROSTOL;ABCC4;AA;rs11568658;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:FEVER;WOMEN;DISEASE:POST-PARTUM_HEMORRHAGE, DISEASE:THERAPEUTIC_ABORTION;CAUTION_SIDE_EFFECT
ASPIRIN, CLOPIDOGREL;PEAR1;A;rs12041331;EFFICACY;DECREASED;;EFFICACY:COLLAGEN_INDUCED_PLATELET_AGGREGATION_AFTER_ASPIRIN_OR_DUAL_ANTIPLATELET_THERAPY_(DAPT)_ADMINISTRATION;;;LIKELIHOOD_THERAPEUTIC_FAILURE
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;CYP2E1;TT;rs2031920;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
CARBOPLATIN, CISPLATIN, DOCETAXEL, GEMCITABINE, PACLITAXEL;RAF1;AG;rs11710163;EFFICACY;INCREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;T;rs12248560;TOXICITY;DECREASED;RISK;DISEASE:MYOCARDIAL_INFARCTION;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN, CLOPIDOGREL;PEAR1;AA + AG;rs12041331;TOXICITY;INCREASED;;SIDE_EFFECT:CARDIOVASCULAR_EVENTS_IN_PATIENTS_UNDERGOING_PCI;;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;NUDT15;CT + TT;rs116855232;TOXICITY;INCREASED;RISK;SIDE_EFFECT:LEUKOPENIA;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
OLANZAPINE;GSTP1;AG + GG;rs1695;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:ELEVATED_LIVER_ENZYMES;PEOPLE;OTHER:SCHIZOPHRENIA, OTHER:SCHIZOAFFECTIVE_DISORDER;CAUTION_SIDE_EFFECT
ASPIRIN, CLOPIDOGREL;PEAR1;AA + AG;rs12041331;TOXICITY;INCREASED;;SIDE_EFFECT:CARDIOVASCULAR_EVENTS_IN_PATIENTS_UNDERGOING_PCI;;;CAUTION_SIDE_EFFECT
ANTIINFLAMMATORY AGENTS, NON-STEROIDS;ALOX15;C;rs3892408;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ASPIRIN-INDUCED_ASTHMA;PEOPLE;DISEASE:ASTHMA;CAUTION_SIDE_EFFECT
METHADONE;CCL11;A;rs1129844;TOXICITY;INCREASED;;SIDE_EFFECT:INSOMNIA;PEOPLE;DISEASE:OPIOID-RELATED_DISORDERS;CAUTION_SIDE_EFFECT
EGFR INHIBITORS;PIK3CA;C;rs2699905;TOXICITY;DECREASED;LIKELIHOOD;DISEASE:EXANTHEMA;PEOPLE;DISEASE:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOXETINE;;GG;rs2433320;EFFICACY;DECREASED;;EFFICACY:HAMD_SCORES;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIPSYCHOTICS;MTHFR;G;rs1801133;TOXICITY;INCREASED;;SIDE_EFFECT:WEIGHT_GAIN;PEOPLE;DISEASE:SCHIZOAFFECTIVE_DISORDER, DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
ASPARAGINASE, CYCLOPHOSPHAMIDE, CYTARABINE, DAUNORUBICIN, MERCAPTOPURINE, PREDNISOLONE, VINCRISTINE;PNPLA3;CG + GG;rs738409;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
ANTIINFLAMMATORY AGENTS, NON-STEROIDS;PTGS1;C;rs5789;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:ASPIRIN-INDUCED_ASTHMA;PEOPLE;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOZAPINE, OLANZAPINE;MTHFR;GG;rs1801131;TOXICITY;INCREASED;;SIDE_EFFECT:WEIGHT_GAIN;PEOPLE;DISEASE:SCHIZOAFFECTIVE_DISORDER, DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;CT;rs1799929;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE, CYTARABINE, DAUNORUBICIN, DOXORUBICIN, MERCAPTOPURINE, METHOTREXATE, PEGASPARGASE, THIOGUANINE, VINCRISTINE;PNPLA3;G;rs738409;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ELEVATED_LIVER_ENZYMES;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
LEUCOVORIN, TEGAFUR;UMPS;CC;rs1801019;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:DIARRHEA, SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;OTHER:RECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL_(PFS)_TIME;PEOPLE;OTHER:EGFR_MUTATION_POSITIVE_NON-SMALL-CELL_LUNG_CANCER;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEFITINIB;EGFR;T;rs121434568;EFFICACY;DECREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL_(PFS)_TIME;PEOPLE;OTHER:EGFR_MUTATION_NEGATIVE_NON-SMALL-CELL_LUNG_CANCER;LIKELIHOOD_THERAPEUTIC_FAILURE
CARBOPLATIN, CISPLATIN, DOCETAXEL, PACLITAXEL;MAP3K1;AA + AG;rs726501;EFFICACY;DECREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;CYP2C9;CT + TT;rs9332096;TOXICITY;DECREASED;LIKELIHOOD;DISEASE:MACULOPAPULAR_EXANTHEMA;PEOPLE;DISEASE:TUBERCULOSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTHRACYCLINES AND RELATED SUBSTANCES, CYCLOPHOSPHAMIDE, FLUOROURACIL, TAXANES;CYP4X1;AA;rs17102977;EFFICACY;INCREASED;;EFFICACY:EVENT-FREE_SURVIVAL;WOMEN;OTHER:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE, CYTARABINE, DAUNORUBICIN, DOXORUBICIN, MERCAPTOPURINE, METHOTREXATE, PEGASPARGASE, THIOGUANINE, VINCRISTINE;TPMT;C;rs1142345;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:ELEVATED_LIVER_ENZYMES;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;CYP2C19;AA + AG;rs4986893;TOXICITY;DECREASED;LIKELIHOOD;DISEASE:MACULOPAPULAR_EXANTHEMA;PEOPLE;DISEASE:TUBERCULOSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
SIMVASTATIN;SLCO1B1;CC;rs4149056;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DOSE_DECREASE_OR_SWITCH_TO_ANOTHER_CHOLESTEROL-LOWERING_DRUG;;;CAUTION_SIDE_EFFECT
ANTIINFLAMMATORY AGENTS, NON-STEROIDS;PTGS1;A;rs10306135;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ASPIRIN-INDUCED_ASTHMA;PEOPLE;DISEASE:ASTHMA;CAUTION_SIDE_EFFECT
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL_(PFS)_TIME;PEOPLE;OTHER:EGFR_MUTATION_POSITIVE_NON-SMALL-CELL_LUNG_CANCER;LIKELIHOOD_THERAPEUTIC_SUCCESS
IMATINIB;SLC22A1;CG + GG;rs683369;EFFICACY;DECREASED;;DISEASE:EVENT-FREE_SURVIVAL;PEOPLE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIPSYCHOTICS;GABRG3;A;rs2061051;TOXICITY;INCREASED;SEVERITY;DISEASE:TARDIVE_DYSKINESIA;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
GEMCITABINE;;CT + TT;rs642990;TOXICITY;DECREASED;RISK;DISEASE:NEUTROPENIA;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;;EFFICACY:LONGER_MEDIAN_PROGRESSION-FREE_SURVIVAL_TIME;PEOPLE;OTHER:EGFR_MUTATION_POSITIVE_NON-SMALL-CELL_LUNG_CANCER;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;;EFFICACY:RESPONSE_RATE;PEOPLE;OTHER:EGFR_MUTATION_POSITIVE_NON-SMALL-CELL_LUNG_CANCER;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBOPLATIN, CISPLATIN, DOCETAXEL, PACLITAXEL;MAP3K1;CC + CT;rs16886403;EFFICACY;DECREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
GEMCITABINE;RRM1;A;rs1042858;DOSAGE;DECREASED;RISK;SIDE_EFFECT:NEUTROPENIA;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_DOSE_ADJUST
CARBOPLATIN, CISPLATIN, DOCETAXEL, PACLITAXEL;;AG + GG;rs17661089;EFFICACY;DECREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
CARBOPLATIN, CISPLATIN, DOCETAXEL, GEMCITABINE, PACLITAXEL;ACSS2;AT;rs17309872;EFFICACY;DECREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;ABCC1;AG + GG;rs246240;TOXICITY;DECREASED;RISK;SIDE_EFFECT:ONSET_OF_TOXICITY;PEOPLE;DISEASE:PSORIASIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUPROPION, NICOTINE;EPB41;AA;rs6702335;EFFICACY;INCREASED;;EFFICACY:ABSTINENCE;MEN;DISEASE:TOBACCO_USE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL_(PFS)_TIME;PEOPLE;OTHER:EGFR_MUTATION_POSITIVE_NON-SMALL-CELL_LUNG_CANCER;LIKELIHOOD_THERAPEUTIC_SUCCESS
DRUGS FOR TREATMENT OF TUBERCULOSIS;METTL14;G;rs62328061;TOXICITY;DECREASED;RISK;SIDE_EFFECT:LEUKOPENIA;PEOPLE;OTHER:TUBERCULOSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;IL17F;CC;rs763780;OTHER;INCREASED;LIKELIHOOD;OTHER:RECURRENT_PREGCY_LOSS;WOMEN;OTHER:PREGNANCY;LIKELIHOOD_THERAPEUTIC_SUCCESS
DAUNORUBICIN;NOS3;GG;rs1799983;EFFICACY;INCREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:ACUTE_MYELOID_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;IL17A;AA;rs2275913;OTHER;INCREASED;LIKELIHOOD;OTHER:RECURRENT_PREGCY_LOSS;WOMEN;OTHER:PREGNANCY;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACE INHIBITORS, PLAIN;KCNIP4;A;rs145489027;OTHER;INCREASED;LIKELIHOOD;SIDE_EFFECT:COUGH;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEMETREXED;ATIC;C;rs12995526;EFFICACY;INCREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;PDYN;A;rs910080;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OPIOID-RELATED_DISORDERS;;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;AA + AG;rs4148323;TOXICITY;INCREASED;RISK;DISEASE:NEUTROPENIA;PEOPLE;DISEASE:BILIARY_TRACT_NEOPLASM, DISEASE:PANCREATIC_NEOPLASMS;CAUTION_SIDE_EFFECT
ACE INHIBITORS, PLAIN;KCNIP4;C;rs1495509;OTHER;INCREASED;LIKELIHOOD;SIDE_EFFECT:COUGH;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FOLFIRI, FOLFOX, XELOX;MTHFR;GG;rs1801131;EFFICACY;DECREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;OTHER:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
GEMCITABINE;ALG10;AA + AG;rs1705772;TOXICITY;DECREASED;RISK;SIDE_EFFECT:TOXICITY;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
MERCAPTOPURINE;NUDT15;CT + TT;rs116855232;TOXICITY;INCREASED;RISK;SIDE_EFFECT:MYELOSUPPRESSION;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL_(PFS)_TIME;PEOPLE;OTHER:EGFR_MUTATION_POSITIVE_NON-SMALL-CELL_LUNG_CANCER;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE, CYTARABINE, DAUNORUBICIN, DOXORUBICIN, MERCAPTOPURINE, METHOTREXATE, PEGASPARGASE, THIOGUANINE, VINCRISTINE;UGT1A1;T;rs887829;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HYPERBILIRUBINEMIA;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
RITONAVIR;APOC3;C;rs2854116;OTHER;INCREASED;RISK;DISEASE:HYPERTRIGLYCERIDEMIA;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
PEMETREXED;GGH;CT + TT;rs16930092;EFFICACY;INCREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANASTROZOLE;UGT1A4;GG;rs3732218;METABOLISM/PK;INCREASED;;PK:GLUCURONIDATION;;OTHER:HUMAN_LIVER_MICROSOMES;CAUTION_DOSE_ADJUST
HALOPERIDOL;CYP2D6;CT;rs3892097;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS;MEN;OTHER:ALCOHOL_WITHDRAWAL_DELIRIUM;CAUTION_SIDE_EFFECT
FOLFIRI, FOLFOX, XELOX;ABCB1;GG;rs1045642;EFFICACY;DECREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;OTHER:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
ACE INHIBITORS, PLAIN;KCNIP4;A;rs7675300;OTHER;INCREASED;LIKELIHOOD;SIDE_EFFECT:COUGH;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE;VEGFA;CC;rs2010963;EFFICACY;DECREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:PROSTATIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
NICOTINE;CHRNA3;A;rs1051730;OTHER;INCREASED;LIKELIHOOD;OTHER:SMOKING;WOMEN;OTHER:SMOKERS_WHO_ARE_PREGNANT;LIKELIHOOD_THERAPEUTIC_SUCCESS
NEVIRAPINE;TRAF3IP2;C;rs76228616;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
GEMCITABINE;ALOX5AP;AG + GG;rs4769060;METABOLISM/PK;DECREASED;;PK:CMAX_AND_A_LOWER_MEAN_AUC;;;CAUTION_DOSE_ADJUST
ERLOTINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL_(PFS)_TIME;PEOPLE;OTHER:EGFR_MUTATION_POSITIVE_NON-SMALL-CELL_LUNG_CANCER;LIKELIHOOD_THERAPEUTIC_SUCCESS
SUFENTANIL;OPRM1;AG;rs1799971;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS;PEOPLE;OTHER:POSTOPERATIVE_PAIN;CAUTION_SIDE_EFFECT
IPILIMUMAB, NIVOLUMAB, PEMBROLIZUMAB;IL7;AA + AG;rs16906115;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS;;;CAUTION_SIDE_EFFECT
GEMTUZUMAB OZOGAMICIN;CD33;CC + CG;rs1803254;TOXICITY;INCREASED;;SIDE_EFFECT:DEATH;CHILDREN;DISEASE:ACUTE_MYELOID_LEUKEMIA;CAUTION_SIDE_EFFECT
FOLFIRI, FOLFOX, XELOX;BRAF;T;rs113488022;EFFICACY;DECREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;OTHER:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;CLCN6, MTHFR;AG + GG;rs1801133;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:LEUKOPENIA;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
OPIOIDS;TH;G;rs2070762;TOXICITY;INCREASED;RISK;DISEASE:OPIOID-RELATED_DISORDERS;;;CAUTION_SIDE_EFFECT
GEMTUZUMAB OZOGAMICIN;CD33;GG;rs35112940;EFFICACY;INCREASED;;EFFICACY:OVERALL_SURVIVAL;CHILDREN;DISEASE:ACUTE_MYELOID_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ISONIAZID, RIFAMPIN;CYP2E1, DUX1;AT;rs6413432;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
CISPLATIN;SLC22A2;A;rs316019;TOXICITY;DECREASED;RISK;SIDE_EFFECT:OTOTOXICITY;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTINEOPLASTIC AGENTS, FLUOROURACIL, LEUCOVORIN;SPARC;AG + GG;rs1059829;EFFICACY;INCREASED;;EFFICACY:TIME_TO_TUMOR_RECURRENCE;PEOPLE;DISEASE:STOMACH_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;DBH;G;rs1611131;TOXICITY;DECREASED;RISK;DISEASE:OPIOID-RELATED_DISORDERS;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIPSYCHOTICS;HSPG2;C;rs2445142;TOXICITY;INCREASED;SEVERITY;DISEASE:TARDIVE_DYSKINESIA;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
FOLFIRI, FOLFOX, XELOX;DPYD;AG + GG;rs1801265;EFFICACY;DECREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;OTHER:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIPSYCHOTICS;HSPG2;T;rs878949;TOXICITY;INCREASED;RISK;DISEASE:TARDIVE_DYSKINESIA;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
QUETIAPINE;RIMS1;CC + CT;rs502046;EFFICACY, TOXICITY;DECREASED;LIKELIHOOD;EFFICACY:DISCONTINUATION;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_FAILURE
ETHANOL;TAS2R16;C;rs846664;OTHER;INCREASED;RISK;DISEASE:ALCOHOL_ABUSE;;;CAUTION_SIDE_EFFECT
DRUGS FOR TREATMENT OF TUBERCULOSIS;METTL3;G;rs1139130;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;PEOPLE;OTHER:TUBERCULOSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;C1orf167, CLCN6, MTHFR;GG + GT;rs1801131;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:NEUTROPENIA;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
ERLOTINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL_(PFS)_TIME;PEOPLE;OTHER:EGFR_MUTATION_POSITIVE_NON-SMALL-CELL_LUNG_CANCER;LIKELIHOOD_THERAPEUTIC_SUCCESS
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;F5;T;rs6025;TOXICITY;INCREASED;RISK;SIDE_EFFECT:VENOUS_THROMBOSIS;WOMEN;;CAUTION_SIDE_EFFECT
SORAFENIB;KDR;CT + TT;rs2239702;EFFICACY;DECREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL;SCN1A;CC;rs3812718;OTHER;DECREASED;;OTHER:TIME_TO_TUMOR_RECURRENCE_(TTR);;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2B6;GT + TT;rs3745274;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:DISCONTINUATION;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""ACETAMINOPHEN"", ""ANTIEPILEPTICS"", ""ANTIINFLAMMATORY AGENTS, NON-STEROIDS"", ""OPIOIDS""";OPRM1;CT + TT;rs510769;EFFICACY;DECREASED;SEVERITY;EFFICACY:PAIN;PEOPLE;OTHER:COLORECTAL_NEOPLASMS, OTHER:METASTATIC_NEOPLASM;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;A;rs9934438;EFFICACY;DECREASED;;EFFICACY:TIME_IN_THERAPEUTIC_RANGE;;;LIKELIHOOD_THERAPEUTIC_FAILURE
OPIOIDS;DRD2;A;rs1076560;TOXICITY;INCREASED;RISK;DISEASE:OPIOID-RELATED_DISORDERS;;;CAUTION_SIDE_EFFECT
EFAVIRENZ;NR1I2;TT;rs2472677;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:DISCONTINUATION;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;TT;rs3745274;EFFICACY;INCREASED;;EFFICACY:VIROLOGICAL_RESPONSE;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CETUXIMAB;KRAS;T;rs112445441;EFFICACY;INCREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN, CYCLOPHOSPHAMIDE, DACTINOMYCIN, DOXORUBICIN, METHOTREXATE, VINCRISTINE;MTHFR;AA;rs1801133;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:DRUG_TOXICITY;CHILDREN;DISEASE:OSTEOSARCOMA;CAUTION_SIDE_EFFECT
SORAFENIB;VEGFA;CG + GG;rs2010963;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HAND-FOOT_SYNDROME;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;CAUTION_SIDE_EFFECT
CISPLATIN, CYCLOPHOSPHAMIDE, DACTINOMYCIN, DOXORUBICIN, METHOTREXATE, VINCRISTINE;MTR;GG;rs1805087;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:OSTEOSARCOMA;CAUTION_SIDE_EFFECT
SORAFENIB;ABCB1;AA + AG;rs1045642;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HYPERTENSION;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;CAUTION_SIDE_EFFECT
SORAFENIB;VEGFA;AA + AG;rs1570360;EFFICACY;DECREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
ATORVASTATIN;ABCG2;GT + TT;rs2231142;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY, SIDE_EFFECT:MUSCULAR_DISEASES, SIDE_EFFECT:RHABDOMYOLYSIS, SIDE_EFFECT:TOXIC_LIVER_DISEASE;;;CAUTION_SIDE_EFFECT
COCAINE, HEROIN;OPRM1;T;rs62638690;TOXICITY;DECREASED;LIKELIHOOD;DISEASE:COCAINE_DEPENDENCE, DISEASE:HEROIN_DEPENDENCE;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SORAFENIB;KDR;CT + TT;rs2239702;EFFICACY;DECREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;ABCB1;AA;rs1045642;TOXICITY;INCREASED;RISK;SIDE_EFFECT:CENTRAL_NERVOUS_SYSTEM_DISORDER;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
CETUXIMAB, PANITUMUMAB;KRAS;A;rs112445441;EFFICACY;INCREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;CYP2C9;T;rs1799853;TOXICITY;INCREASED;RISK;SIDE_EFFECT:VENOUS_THROMBOSIS;WOMEN;;CAUTION_SIDE_EFFECT
NAN;MTR;GG;rs1805087;OTHER;INCREASED;LIKELIHOOD;DISEASE:RHEUMATOID_ARTHRITIS;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;MTR;GG;rs1805087;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:METHOTREXATE-INDUCED_NODULOSIS;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
"""ACETAMINOPHEN"", ""ANTIEPILEPTICS"", ""ANTIINFLAMMATORY AGENTS, NON-STEROIDS"", ""OPIOIDS""";OPRD1;AG + GG;rs2236861;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;OTHER:COLORECTAL_NEOPLASMS, OTHER:METASTATIC_NEOPLASM;CAUTION_SIDE_EFFECT
PRAVASTATIN;SLCO1B1;CT;rs4149056;METABOLISM/PK;INCREASED;;PK:AUC0-12;HEALTHY;;CAUTION_DOSE_ADJUST
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;F2;A;rs1799963;TOXICITY;INCREASED;RISK;SIDE_EFFECT:VENOUS_THROMBOSIS;WOMEN;;CAUTION_SIDE_EFFECT
EFAVIRENZ;CYP2B6;TT;rs3745274;EFFICACY;INCREASED;RISK;EFFICACY:DISCONTINUATION;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
FLUOROURACIL;SCN1A;TT;rs3812718;OTHER;DECREASED;;OTHER:TIME_TO_TUMOR_RECURRENCE_(TTR);;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_DOSE_ADJUST
ATAZANAVIR;UGT1A1;T;rs887829;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HYPERBILIRUBINEMIA;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
SIMVASTATIN;SLCO1B1;CC;rs4363657;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:MUSCULAR_DISEASES;PEOPLE;DISEASE:MYOCARDIAL_INFARCTION;CAUTION_SIDE_EFFECT
EFAVIRENZ;CYP2B6;CC + CT;rs28399499;TOXICITY;DECREASED;RISK;SIDE_EFFECT:CENTRAL_NERVOUS_SYSTEM_DISORDER;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;TT;rs9923231;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OVER-ANTICOAGULATION;;;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;CT;rs776746;TOXICITY;INCREASED;RISK;DISEASE:NEPHROTOXICITY;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
SIMVASTATIN;SLCO1B1;CC;rs4149056;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:MUSCULAR_DISEASES;PEOPLE;DISEASE:MYOCARDIAL_INFARCTION;CAUTION_SIDE_EFFECT
EFAVIRENZ;CYP2B6;CT + TT;rs4803419;TOXICITY;INCREASED;RISK;SIDE_EFFECT:CENTRAL_NERVOUS_SYSTEM_DISORDER;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
WARFARIN;VKORC1;TT;rs9923231;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HEMORRHAGE;;;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;CT;rs1801160;METABOLISM/PK;DECREASED;;PK:DPD_ACTIVITY;HEALTHY;;CAUTION_DOSE_ADJUST
ALLOPURINOL;PSORS1C1;AG + GG;rs3131003;TOXICITY;INCREASED;RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;;;CAUTION_SIDE_EFFECT
FLUOROURACIL;MTHFR;GG;rs1801133;EFFICACY;INCREASED;;DISEASE:EVENT-FREE_SURVIVAL, DISEASE:OVERALL_SURVIVAL;PEOPLE;DISEASE:RECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;PDYN;CT + TT;rs1997794;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:OPIOID-RELATED_DISORDERS;;;CAUTION_SIDE_EFFECT
ONDANSETRON;ABCB1;GG;rs1045642;EFFICACY;INCREASED;LIKELIHOOD;SIDE_EFFECT:VOMITING;PEOPLE;DISEASE:ACUTE_MYELOID_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
DEXMEDETOMIDINE;CYP2A6;GG;rs8192733;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:BRADYCARDIA, SIDE_EFFECT:HYPOTENSIVE_DISORDER;CHILDREN;OTHER:SURGERY;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;;EFFICACY:RAPID_VIROLOGICAL_RESPONSE_(RVR);PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""ACETAMINOPHEN"", ""ANTIEPILEPTICS"", ""ANTIINFLAMMATORY AGENTS, NON-STEROIDS"", ""OPIOIDS""";OPRM1;AA;rs1799971;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:PAIN;PEOPLE;OTHER:COLORECTAL_NEOPLASMS, OTHER:METASTATIC_NEOPLASM;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;PDYN;CC;rs1022563;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:OPIOID-RELATED_DISORDERS;;;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;;;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;CAUTION_DOSE_ADJUST
RISPERIDONE;LEP;GG;rs7799039;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:OBESITY;CHILDREN;DISEASE:ATYPICAL_BEHAVIOR, DISEASE:MENTAL_DISORDERS;CAUTION_SIDE_EFFECT
PERINDOPRIL;AGTR1;TT;rs5182;EFFICACY;DECREASED;RISK;EFFICACY:CARDIAC_EVENTS;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;;;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)_AND_CHANGES_IN_VIRAL_LOAD_AFTER_4_WEEKS_OF_TREATMENT;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;CAUTION_DOSE_ADJUST
GEMCITABINE;CDA;AC + CC;rs2072671;TOXICITY;INCREASED;RISK;SIDE_EFFECT:SEVERE_NEUTROPENIA;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
CYTARABINE;CDA;GG;rs602950;EFFICACY, METABOLISM/PK;INCREASED;;EFFICACY:CYTOTOXICITY;PEOPLE;DISEASE:MYELOID_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
HALOPERIDOL;CYP2D6;CC;rs3892097;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS;MEN;DISEASE:ALCOHOLIC_PSYCHOSIS, DISEASE:ALCOHOL_ABUSE,DISEASE:ALCOHOL-RELATED_DISORDERS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYTARABINE;CDA;TT;rs532545;EFFICACY, METABOLISM/PK;INCREASED;;EFFICACY:CYTOTOXICITY;PEOPLE;DISEASE:MYELOID_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ALLOPURINOL;CYCSP5;AA + AC;rs3099844;TOXICITY;INCREASED;RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;;;CAUTION_SIDE_EFFECT
BISPHOSPHONATES;RBMS3;A;rs17024608;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:OSTEONECROSIS;;;CAUTION_SIDE_EFFECT
NAN;NEDD4L;AG;rs4149601;OTHER;INCREASED;RISK;DISEASE:CARDIOVASCULAR_DISEASE;PEOPLE;DISEASE:HYPERTENSION;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;AC;rs55886062;METABOLISM/PK;DECREASED;;PK:DPD_ACTIVITY;HEALTHY;;CAUTION_DOSE_ADJUST
ANTIPSYCHOTICS;INSIG2;C;rs17587100;OTHER;INCREASED;SEVERITY;SIDE_EFFECT:WEIGHT_GAIN;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
ONDANSETRON;ABCB1;CC;rs2032582;EFFICACY;INCREASED;LIKELIHOOD;SIDE_EFFECT:VOMITING;PEOPLE;DISEASE:ACUTE_MYELOID_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;CTLA4;A;rs3087243;OTHER;DECREASED;RISK;DISEASE:RHEUMATOID_ARTHRITIS;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
EPIRUBICIN, FLUOROURACIL, OXALIPLATIN;GCKR;CC + CT;rs780094;EFFICACY;INCREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:STOMACH_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;DPYD;CT;rs115232898;METABOLISM/PK;DECREASED;;PK:DPD_ACTIVITY;HEALTHY;;CAUTION_DOSE_ADJUST
RIBAVIRIN, SOFOSBUVIR;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION, DISEASE:LIVER_CIRRHOSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
TENOFOVIR;ABCC4;G;rs1059751;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:KIDNEY_DISORDER;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
EPIRUBICIN, FLUOROURACIL, OXALIPLATIN;IGF2BP2;C;rs6769511;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:DISEASE_PROGRESSION;PEOPLE;DISEASE:STOMACH_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;A;rs9934438;EFFICACY;DECREASED;;EFFICACY:TIME_TO_THERAPEUTIC_INR;;;LIKELIHOOD_THERAPEUTIC_FAILURE
CYTARABINE;CDA;CC;rs2072671;EFFICACY, METABOLISM/PK;INCREASED;;EFFICACY:CYTOTOXICITY;PEOPLE;DISEASE:MYELOID_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;A;rs9934438;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OVER-ANTICOAGULATION;;;CAUTION_SIDE_EFFECT
ALLOPURINOL;NOTCH4;AA + AG;rs367398;TOXICITY;DECREASED;RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
EPIRUBICIN, FLUOROURACIL, OXALIPLATIN;KCNQ1;CC + GG;rs163182;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:DISEASE_PROGRESSION;PEOPLE;DISEASE:STOMACH_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
NAN;NQO1;AA;rs1800566;OTHER;DECREASED;LIKELIHOOD;OTHER:SURVIVAL;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;;;EFFICACY:RAPID_VIRAL_RESPONSE_(RVR)_TO_PEG-IFN/RIBAVIRIN_THERAPY_AT_4_WEEKS_IN_HCV_GENOTYPE_3_PATIENTS;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;CAUTION_DOSE_ADJUST
EPIRUBICIN, FLUOROURACIL, OXALIPLATIN;IGF2BP2;G;rs4402960;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:DISEASE_PROGRESSION;PEOPLE;DISEASE:STOMACH_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;;;EFFICACY:RAPID_VIROLOGICAL_RESPONSE_(RVR);PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;CAUTION_DOSE_ADJUST
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;;EFFICACY:RESPONSE_RATE;;EFFICACY:CHEMOREFRACTORY_ADVANCED_NON-SMALL-CELL_LUNG_CANCER_PATIENTS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ERLOTINIB, GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;;EFFICACY:RESPONSE_RATE;;EFFICACY:NON-SMALL-CELL_LUNG_CANCER_PATIENTS;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;GG;rs3745274;EFFICACY;INCREASED;RISK;EFFICACY:IMMUNOLOGICAL_FAILURE;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
AZATHIOPRINE, MERCAPTOPURINE;NUDT15;CT + TT;rs116855232;TOXICITY;INCREASED;RISK;SIDE_EFFECT:LEUKOPENIA;PEOPLE;DISEASE:INFLAMMATORY_BOWEL_DISEASES;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;NQO1;AA;rs1800566;TOXICITY;DECREASED;LIKELIHOOD;OTHER:SURVIVAL;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;SLCO1B1;AG + GG;rs2306283;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY, SIDE_EFFECT:GASTROINTESTINAL_TOXICITY, SIDE_EFFECT:TOXIC_LIVER_DISEASE;CHILDREN;OTHER:JUVENILE_RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
EFAVIRENZ;CYP2B6;GT;rs3745274;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:SLEEP_DISORDERS;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
SUNITINIB;ABCB1;AA;rs1045642;TOXICITY;DECREASED;RISK;SIDE_EFFECT:NEUTROPENIA;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
VERAPAMIL;CACNA1C;AA;rs1051375;EFFICACY;DECREASED;RISK;OTHER:PRIMARY_OUTCOME;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;;EFFICACY:MEDIAN_SURVIVAL_TIME_(MST);;EFFICACY:ADVANCED_NON-SMALL-CELL_LUNG_CANCER_PATIENTS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN, IRINOTECAN;UGT1A1;AA + AG;rs4148323;TOXICITY;INCREASED;SEVERITY;DISEASE:THROMBOCYTOPENIA;WOMEN;DISEASE:FEMALE_REPRODUCTIVE_SYSTEM_NEOPLASM;CAUTION_SIDE_EFFECT
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;;EFFICACY:OVERALL_SURVIVAL_(OS)_TIME;;EFFICACY:NON-SMALL-CELL_LUNG_CANCER_PATIENTS;LIKELIHOOD_THERAPEUTIC_SUCCESS
SUNITINIB;ABCB1;AA + AG;rs1045642;TOXICITY;DECREASED;RISK;SIDE_EFFECT:DIARRHEA;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL_(PFS)_TIME;;EFFICACY:NON-SMALL-CELL_LUNG_CANCER_PATIENTS;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;;EFFICACY:RESPONSE_RATE;;EFFICACY:NON-SMALL-CELL_LUNG_CANCER_PATIENTS;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;GT;rs3745274;METABOLISM/PK;INCREASED;;PK:PLASMA_LEVEL;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DOSE_ADJUST
CISPLATIN, IRINOTECAN;UGT1A1;AA + AG;rs4148323;TOXICITY;INCREASED;SEVERITY;DISEASE:DIARRHEA;WOMEN;DISEASE:FEMALE_REPRODUCTIVE_SYSTEM_NEOPLASM;CAUTION_SIDE_EFFECT
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;;EFFICACY:OVERALL_SURVIVAL_(OS)_TIME;;EFFICACY:NON-SMALL-CELL_LUNG_CANCER_PATIENTS;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2A6;AC + CC;rs28399433;METABOLISM/PK;INCREASED;;PK:PLASMA_CONCENTRATION;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DOSE_ADJUST
NAN;DRD2;AA + AG;rs1800497;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:DEATH;PEOPLE;DISEASE:ALCOHOL_ABUSE;CAUTION_SIDE_EFFECT
EFAVIRENZ;CYP2B6;CC + CT;rs28399499;METABOLISM/PK;INCREASED;;PK:PLASMA_CONCENTRATION;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2B6;TT;rs3745274;METABOLISM/PK;INCREASED;;PK:PLASMA_CONCENTRATION;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DOSE_ADJUST
VERAPAMIL;CACNA1C;GG;rs1051375;EFFICACY;INCREASED;RISK;EFFICACY:PRIMARY_OUTCOME;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;CAUTION_SIDE_EFFECT
EPIRUBICIN, FLUOROURACIL, OXALIPLATIN;GCKR;CC + CT;rs780093;EFFICACY;INCREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:STOMACH_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;;EFFICACY:RESPONSE_RATE;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
SIMVASTATIN;SLCO1B1;CC;rs4149056;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DOSE_DECREASE_OR_SWITCH_TO_ANOTHER_CHOLESTEROL-LOWERING_DRUG;;;CAUTION_SIDE_EFFECT
ATORVASTATIN;SLCO1B1;CC + CT;rs4149056;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DOSE_DECREASE_OR_SWITCH_TO_ANOTHER_CHOLESTEROL-LOWERING_DRUG_IN_USERS_WITH_A_STARTING_DOSE_OF_MORE_THAN_20_MG;;;CAUTION_SIDE_EFFECT
CARBOPLATIN, CISPLATIN, GEMCITABINE;;AG;rs12118636;EFFICACY;DECREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
AZATHIOPRINE, MERCAPTOPURINE;NUDT15;T;rs116855232;TOXICITY;INCREASED;RISK;SIDE_EFFECT:LEUKOPENIA;PEOPLE;DISEASE:INFLAMMATORY_BOWEL_DISEASES;CAUTION_SIDE_EFFECT
CISPLATIN, IRINOTECAN;UGT1A1;AA + AG;rs4148323;TOXICITY;INCREASED;SEVERITY;DISEASE:NEUTROPENIA;WOMEN;DISEASE:FEMALE_REPRODUCTIVE_SYSTEM_NEOPLASM;CAUTION_SIDE_EFFECT
AZATHIOPRINE, MERCAPTOPURINE;NUDT15;TT;rs116855232;TOXICITY;;;SIDE_EFFECT:ALOPECIA;PEOPLE;DISEASE:INFLAMMATORY_BOWEL_DISEASES;CAUTION_DOSE_ADJUST
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;;EFFICACY:RESPONSE_RATE;;EFFICACY:ADVANCED_NON-SMALL-CELL_LUNG_CANCER_PATIENTS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTINEOPLASTIC AGENTS;ABCB1;AG;rs1045642;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:NAUSEA;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;;EFFICACY:MEDIAN_SURVIAL_TIME;;EFFICACY:NON-SMALL-CELL_LUNG_CANCER_PATIENTS;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL_(PFS)_TIME;;EFFICACY:NON-SMALL-CELL_LUNG_CANCER_PATIENTS;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;;EFFICACY:OVERALL_SURVIVAL_(OS)_TIME;;EFFICACY:NON-SMALL-CELL_LUNG_CANCER_PATIENTS;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;;EFFICACY:RESPONSE_RATE;;EFFICACY:NON-SMALL-CELL_LUNG_CANCER_PATIENTS;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;;EFFICACY:RESPONSE_RATE;PEOPLE;EFFICACY:NON-SMALL-CELL_LUNG_CANCER;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBOPLATIN, CISPLATIN, GEMCITABINE;NRAS;CT;rs1065634;EFFICACY;DECREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL_(PFS)_TIME;PEOPLE;EFFICACY:NON-SMALL-CELL_LUNG_CANCER;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;;EFFICACY:RESPONSE_RATE;;EFFICACY:NON-SMALL-CELL_LUNG_CANCER_PATIENTS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBOPLATIN, CISPLATIN, GEMCITABINE;GPX5;AG + GG;rs451774;EFFICACY;INCREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
VINCRISTINE;ACTG1;A;rs1135989;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
ACENOCOUMAROL, WARFARIN;VKORC1;T;rs9923231;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE;PEOPLE;DISEASE:VENOUS_THROMBOEMBOLISM;CAUTION_SIDE_EFFECT
METHADONE;CYP2B6;GG;rs3745274;TOXICITY;INCREASED;SEVERITY;OTHER:NEONATAL_ABSTINENCE_SYNDROME;INFANTS;;CAUTION_SIDE_EFFECT
CARBOPLATIN, TAXANES;ATP7B;AA;rs1801249;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY;WOMEN;DISEASE:OVARIAN_NEOPLASMS;CAUTION_SIDE_EFFECT
VINCRISTINE;CAPG;T;rs3770102;TOXICITY;DECREASED;RISK;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
VALPROIC ACID;COL1A1;AA + AC;rs1800012;TOXICITY;DECREASED;;SIDE_EFFECT:BONE_DENSITY;PEOPLE;DISEASE:EPILEPSY;LIKELIHOOD_THERAPEUTIC_SUCCESS
VINCRISTINE;ABCB1;A;rs4728709;TOXICITY;DECREASED;RISK;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOXORUBICIN;AKR1C3;GG;rs1937840;OTHER;DECREASED;;OTHER:ABSOLUTE_LEUCOCYTE_AND_NEUTROPHIL_COUNTS_ON_DAY_15;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_DOSE_ADJUST
METHADONE;CYP2B6;AA;rs2279343;TOXICITY;INCREASED;SEVERITY;OTHER:NEONATAL_ABSTINENCE_SYNDROME;INFANTS;;CAUTION_SIDE_EFFECT
KETOPROFEN;CYP2C9;CC;rs1799853;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:DYSPEPSIA;PEOPLE;OTHER:POSTOPERATIVE_PAIN;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACENOCOUMAROL, WARFARIN;VKORC1;T;rs9923231;EFFICACY;INCREASED;;OTHER:TIME_TO_THERAPEUTIC_INR;PEOPLE;DISEASE:VENOUS_THROMBOEMBOLISM;LIKELIHOOD_THERAPEUTIC_SUCCESS
MYCOPHENOLATE MOFETIL;SLCO1B3;GG;rs4149117;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
REMIFENTANIL;OPRM1;GG;rs1799971;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:POSTOPERATIVE_NAUSEA_AND_VOMITING;WOMEN;DISEASE:POSTOPERATIVE_PAIN;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;AA + AG;rs9934438;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OVER-ANTICOAGULATION;;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;ITPA;AA + AC;rs1127354;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:MYELOSUPPRESSION;PEOPLE;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA_OTHER:LEUKEMIA;CAUTION_SIDE_EFFECT
CARBOPLATIN, TAXANES;GSR;CC;rs3594;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY;WOMEN;DISEASE:OVARIAN_NEOPLASMS;CAUTION_SIDE_EFFECT
ACENOCOUMAROL, WARFARIN;APOE;C;rs429358;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE;PEOPLE;DISEASE:VENOUS_THROMBOEMBOLISM;CAUTION_SIDE_EFFECT
ETHANOL;SLC6A4;T;rs4251417;TOXICITY;DECREASED;RISK;SIDE_EFFECT:ALCOHOL_ABUSE;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBOPLATIN, TAXANES;VEGFA;TT;rs6900017;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY;WOMEN;DISEASE:OVARIAN_NEOPLASMS;CAUTION_SIDE_EFFECT
ACENOCOUMAROL, WARFARIN;CYP2C9;C;rs1057910;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE;PEOPLE;DISEASE:VENOUS_THROMBOEMBOLISM;CAUTION_SIDE_EFFECT
METHYLPHENIDATE;COMT;AA + AG;rs4680;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS;CHILDREN;OTHER:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY;LIKELIHOOD_THERAPEUTIC_SUCCESS
NALOXONE;OPRM1;G;rs1799971;EFFICACY;INCREASED;;EFFICACY:CORTISOL_RESPONSE;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHANOL;SLC6A4;C;rs25531;TOXICITY;DECREASED;RISK;SIDE_EFFECT:ALCOHOL_ABUSE;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
INTERFERONS, RIBAVIRIN;VDR;AG + GG;rs2228570;TOXICITY;DECREASED;RISK;SIDE_EFFECT:CRYOGLOBULINEMIA;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED;;OTHER:WARFARIN_DOSE;;;CAUTION_DOSE_ADJUST
EGFR INHIBITORS;PIK3CA;C;rs2677760;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:DIARRHEA;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
CETUXIMAB;EGFR;AA + AG;rs2227983;EFFICACY;DECREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:HEAD_AND_NECK_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
EGFR INHIBITORS;PIK3CA;T;rs2459693;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:DIARRHEA;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
IRINOTECAN;CES1;CC;rs7187684;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:THROMBOCYTOPENIA;PEOPLE;OTHER:NEOPLASMS, OTHER:PANCREATIC_NEOPLASMS,OTHER:COLORECTAL_NEOPLASMS, OTHER:OVARIAN_NEOPLASMS, OTHER:STOMACH_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;ATIC;GG;rs2372536;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
ETHANOL;SLC6A4;A;rs2066713;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ALCOHOL_ABUSE;;;CAUTION_SIDE_EFFECT
CORTICOSTEROIDS, SALMETEROL;ADRB2;AA;rs1042713;EFFICACY;INCREASED;RISK;EFFICACY:EXACERBATIONS;CHILDREN;DISEASE:ASTHMA;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;IL1B;AA + AG;rs4849127;TOXICITY;INCREASED;;SIDE_EFFECT:WEIGHT_GAIN;PEOPLE;DISEASE:SCHIZOAFFECTIVE_DISORDER, DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
BETA BLOCKING AGENTS;CYP2D6;GG;rs1065852;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:BRADYCARDIA;PEOPLE;OTHER:ACUTE_CORONARY_SYNDROME;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;GG;rs1801265;METABOLISM/PK;INCREASED;;PK:DPD_ACTIVITY;HEALTHY;OTHER:WITHOUT_THE_RS115232898_A>G_VARIANT_(DPYD_Y186C);CAUTION_DOSE_ADJUST
EGFR INHIBITORS;PIK3CA;C;rs6443624;EFFICACY;DECREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIPSYCHOTICS;IL1B;AG;rs16944;TOXICITY;INCREASED;;SIDE_EFFECT:WEIGHT_GAIN;PEOPLE;DISEASE:SCHIZOAFFECTIVE_DISORDER, DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
DAUNORUBICIN, DOXORUBICIN;SLC28A3;A;rs885004;TOXICITY;DECREASED;LIKELIHOOD;DISEASE:CARDIOTOXICITY;CHILDREN;DISEASE:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOSPORINE;ABCB1;AA;rs1045642;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:GINGIVAL_OVERGROWTH;PEOPLE;DISEASE:HEART_TRANSPLANTATION, DISEASE:KIDNEY_TRANSPLANTATION,DISEASE:LIVER_TRANSPLANTATION, DISEASE:TRANSPLANTATION;CAUTION_SIDE_EFFECT
EGFR INHIBITORS;PIK3CA;T;rs2677760;EFFICACY;DECREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
CORTICOSTEROIDS;ADRB2;AA;rs1042713;EFFICACY;INCREASED;RISK;EFFICACY:UNCONTROLLED_ASTHMA;CHILDREN;DISEASE:ASTHMA;CAUTION_SIDE_EFFECT
IRINOTECAN;CES1;AA + AG;rs2244614;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:THROMBOCYTOPENIA;PEOPLE;OTHER:NEOPLASMS, OTHER:PANCREATIC_NEOPLASMS,OTHER:COLORECTAL_NEOPLASMS, OTHER:OVARIAN_NEOPLASMS, OTHER:STOMACH_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
EXEMESTANE, LETROZOLE;CYP19A1;AA;rs6493497;TOXICITY;DECREASED;;SIDE_EFFECT:BONE_DENSITY;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIPSYCHOTICS;IL1B;AA;rs1143634;TOXICITY;DECREASED;;SIDE_EFFECT:WEIGHT_GAIN;PEOPLE;DISEASE:SCHIZOAFFECTIVE_DISORDER, DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIPSYCHOTICS;BDNF;CT + TT;rs6265;TOXICITY;DECREASED;;SIDE_EFFECT:WEIGHT_GAIN;PEOPLE;DISEASE:SCHIZOAFFECTIVE_DISORDER, DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHYLPHENIDATE;ADGRL3;CG + GG;rs2345039;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS;CHILDREN;OTHER:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY;CAUTION_SIDE_EFFECT
DAUNORUBICIN, DOXORUBICIN;SLC28A3;A;rs7853758;TOXICITY;DECREASED;LIKELIHOOD;DISEASE:CARDIOTOXICITY;CHILDREN;DISEASE:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
MERCAPTOPURINE;NUDT15;CT;rs116855232;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:MYELOSUPPRESSION;PEOPLE;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA_OTHER:LEUKEMIA;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;T;rs1799853;EFFICACY;;;EFFICACY:TIME_TO_THERAPEUTIC_INR;;;CAUTION_DOSE_ADJUST
CARBOPLATIN, TAXANES;ATP7B;TT;rs1061472;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY;WOMEN;DISEASE:OVARIAN_NEOPLASMS;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A1;AG;rs4148323;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUTROPENIA;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
HMG_COA_REDUCTASE_INHIBITORS;SLCO1B1;C;rs4149056;TOXICITY;INCREASED;RISK;SIDE_EFFECT:MUSCULAR_DISEASES;;;CAUTION_SIDE_EFFECT
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;SUGCT;T;rs4379368;TOXICITY;INCREASED;RISK;SIDE_EFFECT:VENOUS_THROMBOSIS;WOMEN;;CAUTION_SIDE_EFFECT
NAN;FMO3;AG + GG;rs2266780;OTHER;DECREASED;SEVERITY;DISEASE:TOBACCO_USE_DISORDER;PEOPLE;DISEASE:TOBACCO_USE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;KNG1;C;rs710446;TOXICITY;INCREASED;RISK;SIDE_EFFECT:VENOUS_THROMBOSIS;WOMEN;;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;AA;rs1801265;EFFICACY;INCREASED;;EFFICACY:EVENT-FREE_SURVIVAL;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN;ABCG2;GT + TT;rs2231142;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;OTHER:NEOPLASMS, OTHER:PANCREATIC_NEOPLASMS,OTHER:COLORECTAL_NEOPLASMS, OTHER:OVARIAN_NEOPLASMS, OTHER:STOMACH_NEOPLASMS;CAUTION_SIDE_EFFECT
ASPIRIN;LPA;CT;rs3798220;EFFICACY;DECREASED;RISK;DISEASE:MYOCARDIAL_INFARCTION;WOMEN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;SLC19A1;TT;rs1051266;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
BOCEPREVIR, PEGINTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIR;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C19;T;rs3814637;TOXICITY;;RISK;SIDE_EFFECT:OVER-ANTICOAGULATION;;;CAUTION_DOSE_ADJUST
FLUOROURACIL;DPYD;CT;rs72728438;METABOLISM/PK;DECREASED;;PK:DPD_ACTIVITY;HEALTHY;;CAUTION_DOSE_ADJUST
FLUOROURACIL;ABCC11;GG + GT;rs7194667;TOXICITY;INCREASED;RISK;SIDE_EFFECT:LEUKOPENIA;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
EGFR INHIBITORS;PIK3CA;C;rs2699905;EFFICACY;DECREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL;DPYD;CT;rs115632870;METABOLISM/PK;DECREASED;;PK:DPD_ACTIVITY;HEALTHY;;CAUTION_DOSE_ADJUST
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;ABO;del;rs56392308;TOXICITY;DECREASED;RISK;SIDE_EFFECT:VENOUS_THROMBOSIS;WOMEN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;DPYD;CT;rs3918290;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
ETHANOL;SLC6A3;AG;rs6350;TOXICITY;INCREASED;RISK;DISEASE:ALCOHOL_ABUSE;;;CAUTION_SIDE_EFFECT
CAPECITABINE, FLUOROURACIL;DPYD;AT;rs67376798;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;ABO;C;rs8176719;TOXICITY;INCREASED;RISK;SIDE_EFFECT:VENOUS_THROMBOSIS;WOMEN;;CAUTION_SIDE_EFFECT
METHOTREXATE;SLCO1B1;TT;rs4149056;TOXICITY;DECREASED;RISK;SIDE_EFFECT:NEPHROTOXICITY;PEOPLE;DISEASE:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;PROCR;G;rs9574;TOXICITY;INCREASED;RISK;SIDE_EFFECT:VENOUS_THROMBOSIS;WOMEN;;CAUTION_SIDE_EFFECT
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;F11;T;rs2289252;TOXICITY;INCREASED;RISK;SIDE_EFFECT:VENOUS_THROMBOSIS;WOMEN;;CAUTION_SIDE_EFFECT
METHOTREXATE;SLCO1B1;AG + GG;rs2306283;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEPHROTOXICITY;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;CT;rs3918290;TOXICITY;INCREASED;;SIDE_EFFECT:INFECTIOUS_DISEASE, SIDE_EFFECT:TOXIC_LIVER_DISEASE;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
DEXMEDETOMIDINE;NR1I2;CC;rs3814057;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:BRADYCARDIA, SIDE_EFFECT:HYPOTENSIVE_DISORDER;CHILDREN;OTHER:SURGERY;CAUTION_SIDE_EFFECT
NAN;MAOA;TT;rs1137070;TOXICITY;DECREASED;RISK;SIDE_EFFECT:TOBACCO_USE_DISORDER;WOMEN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;MAOB;CC;rs1799836;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOBACCO_USE_DISORDER;WOMEN;;CAUTION_SIDE_EFFECT
CAPECITABINE;;C;rs9936750;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXICITY;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;AG + GG;rs1801265;TOXICITY;INCREASED;;SIDE_EFFECT:INFECTIOUS_DISEASE, SIDE_EFFECT:NEPHROTOXICITY, SIDE_EFFECT:TOXIC_LIVER_DISEASE;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
DOXORUBICIN;ABCB1;A;rs1045642;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:CARDIOTOXICITY;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOXORUBICIN;CBR3;A;rs1056892;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:CARDIOTOXICITY;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
CAPECITABINE;DPYD;T;rs3918290;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
FOLFIRI;UGT1A1;GG;rs4124874;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:MYELOSUPPRESSION;;;CAUTION_SIDE_EFFECT
CAPECITABINE;DPYD;A;rs67376798;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
CETUXIMAB;EGF;GG;rs4444903;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:COMPLETE_PATHOLOGIC_RESPONSE;PEOPLE;DISEASE:RECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
AFATINIB, ERLOTINIB, GEFITINIB;UHRF1;TT;rs2261988;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:OVERALL_SURVIVAL, EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;OTHER:LUNG_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
NAN;HAVCR2;AA + AC;rs10515746;EFFICACY;DECREASED;LIKELIHOOD;SIDE_EFFECT:GRAFT_VS_HOST_DISEASE;PEOPLE;OTHER:HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
NAN;HAVCR2;AC + CC;rs1036199;EFFICACY;DECREASED;LIKELIHOOD;SIDE_EFFECT:GRAFT_VS_HOST_DISEASE;PEOPLE;OTHER:HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
AFATINIB, ERLOTINIB, GEFITINIB;DVL2;AA;rs2074216;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:OVERALL_SURVIVAL, EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;OTHER:LUNG_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
GLATIRAMER ACETATE;;T;rs12459996;TOXICITY;INCREASED;RISK;DISEASE:CORONARY_ARTERY_DISEASE;PEOPLE;DISEASE:MULTIPLE_SCLEROSIS;CAUTION_SIDE_EFFECT
WARFARIN;VKORC1;T;rs9923231;EFFICACY;DECREASED;;EFFICACY:TIME_TO_THERAPEUTIC_INR;;;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;VKORC1;T;rs9923231;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OVER-ANTICOAGULATION;;;CAUTION_SIDE_EFFECT
FLUOROURACIL;OR10AE3P, PSMB3P;A;rs10876844;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:DIARRHEA;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;AA;rs1801133;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXICITY;;;CAUTION_SIDE_EFFECT
HEROIN;BDNF;TT;rs6265;OTHER;INCREASED;RISK;OTHER:ADDICTION;;;CAUTION_SIDE_EFFECT
METHAMPHETAMINE;BDNF;T;rs6265;OTHER;INCREASED;RISK;OTHER:ADDICTION;;;CAUTION_SIDE_EFFECT
DOXORUBICIN, PACLITAXEL, TRASTUZUMAB;ABCB1;C;rs2235047;TOXICITY;INCREASED;RISK;SIDE_EFFECT:CARDIOTOXICITY;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
DOXORUBICIN, PACLITAXEL, TRASTUZUMAB;CBR3;A;rs1056892;TOXICITY;INCREASED;RISK;SIDE_EFFECT:CARDIOTOXICITY;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
FENTANYL;OPRM1;T;rs540825;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:VOMITING;WOMEN;DISEASE:POSTOPERATIVE_PAIN;CAUTION_SIDE_EFFECT
ASPIRIN, TICAGRELOR;CYP4F2;AA;rs3093135;EFFICACY;DECREASED;;EFFICACY:PLATELET_AGGREGATION;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME, DISEASE:MYOCARDIAL_INFARCTION;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;ABCB1;T;rs2032582;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HEMORRHAGE;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;CAUTION_SIDE_EFFECT
AFATINIB, ERLOTINIB, GEFITINIB;NUP62;CC;rs9523;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:OVERALL_SURVIVAL, EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;OTHER:LUNG_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
NAN;;GG;rs2207418;OTHER;INCREASED;RISK;DISEASE:DEATH;PEOPLE;DISEASE:HEART_FAILURE;CAUTION_SIDE_EFFECT
ALFENTANIL;OPRM1;GG;rs1799971;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:RESPIRATORY_INSUFFICIENCY;HEALTHY;;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;C;rs9332197;EFFICACY;;;EFFICACY:TIME_TO_ACHIEVE_STABLE_DOSE;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C9;C;rs1057910;TOXICITY;;RISK;SIDE_EFFECT:OVER-ANTICOAGULATION;;;CAUTION_DOSE_ADJUST
WARFARIN;CYP2C18;AG + GG;rs2901783;EFFICACY;INCREASED;;EFFICACY:TIME_TO_THERAPEUTIC_INR;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;F5;G;rs6018;TOXICITY;;RISK;SIDE_EFFECT:HEMORRHAGE;;;CAUTION_DOSE_ADJUST
WARFARIN;PROS1;AA;rs8178607;EFFICACY;DECREASED;;EFFICACY:TIME_TO_ACHIEVE_STABLE_DOSE;;;LIKELIHOOD_THERAPEUTIC_FAILURE
NAN;CHRM3;GG;rs2165870;TOXICITY;INCREASED;RISK;DISEASE:POSTOPERATIVE_NAUSEA_AND_VOMITING;;;CAUTION_SIDE_EFFECT
WARFARIN;VKORC1;CT + TT;rs9923231;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HEMORRHAGE;;;CAUTION_SIDE_EFFECT
CISPLATIN, GEMCITABINE;CDA;AA;rs2072671;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXICITY;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
CAPECITABINE;DPYD;G;rs1801265;TOXICITY;DECREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOXORUBICIN;GSTP1;GG;rs1695;TOXICITY;INCREASED;;SIDE_EFFECT:MICRONUCLEATED_BINUCLEATED_CELLS;;;CAUTION_SIDE_EFFECT
WARFARIN;VKORC1;CT + TT;rs9923231;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OVER-ANTICOAGULATION;;;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;TT;rs1801131;EFFICACY;INCREASED;;EFFICACY:EVENT_FREE_SURVIVAL;PEOPLE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;MTHFR;GG;rs1801133;EFFICACY;INCREASED;;EFFICACY:EVENT-FREE_SURVIVAL;PEOPLE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;FCGR2A;AG;rs1801274;EFFICACY;DECREASED;;EFFICACY:DISEASE_ACTIVITY_SCORE_28_IN_RHEUMATOID_ARTHRITIS;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_FAILURE
NAN;SCN5A;GT + TT;rs7626962;OTHER;INCREASED;LIKELIHOOD;DISEASE:CARDIAC_RHYTHM_DISEASE;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBOPLATIN, TAXANES;VEGFA;GG;rs879825;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY;WOMEN;DISEASE:OVARIAN_NEOPLASMS;CAUTION_SIDE_EFFECT
EXEMESTANE, LETROZOLE;ESR1;CT + TT;rs4870061;TOXICITY;DECREASED;;SIDE_EFFECT:BONE_DENSITY;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;MTRR;AG + GG;rs1801394;METABOLISM/PK;DECREASED;LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE;PEOPLE;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DOSE_ADJUST
CARBOPLATIN, TAXANES;SCN10A;TT;rs9825762;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY;WOMEN;DISEASE:OVARIAN_NEOPLASMS;CAUTION_SIDE_EFFECT
CARBOPLATIN, TAXANES;VEGFA;CC;rs9369421;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY;WOMEN;DISEASE:OVARIAN_NEOPLASMS;CAUTION_SIDE_EFFECT
LETROZOLE;ESR1;TT;rs4870061;TOXICITY;DECREASED;;SIDE_EFFECT:BONE_DENSITY;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;CC;rs1057910;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HEMORRHAGE;MEN;;CAUTION_SIDE_EFFECT
METHOTREXATE;ABCC2;AA + AG;rs2273697;METABOLISM/PK;INCREASED;LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE;PEOPLE;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DOSE_ADJUST
EXEMESTANE, LETROZOLE;ESR1;TT;rs9322335;TOXICITY;DECREASED;;SIDE_EFFECT:BONE_DENSITY;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
LETROZOLE;ESR1;TT;rs9322335;TOXICITY;DECREASED;;SIDE_EFFECT:BONE_DENSITY;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN, ETOPOSIDE;NQO1;AA;rs1800566;OTHER;DECREASED;;OTHER:OVERALL_SURVIVAL;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_DOSE_ADJUST
CISPLATIN;SLC22A2;AC;rs316019;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:NEPHROTOXICITY;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
LETROZOLE;ESR2;CC;rs10140457;TOXICITY;DECREASED;;SIDE_EFFECT:BONE_DENSITY;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
EXEMESTANE;ESR1;AA;rs2813543;TOXICITY;DECREASED;;SIDE_EFFECT:BONE_DENSITY;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
EXEMESTANE;CYP19A1;AA;rs6493497;TOXICITY;DECREASED;;SIDE_EFFECT:BONE_DENSITY;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;SLCO1B1;CC + CT;rs4149056;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:MUCOSITIS;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
METHOTREXATE;SLCO1B1;CC + CT;rs4149056;METABOLISM/PK;INCREASED;LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA;PEOPLE;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DOSE_ADJUST
BISPHOSPHONATES;;C;rs2736308;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OSTEONECROSIS_OF_THE_JAW;PEOPLE;OTHER:NEOPLASMS;CAUTION_SIDE_EFFECT
METHOTREXATE;SLCO1B1;CC + CT;rs4149056;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:THROMBOCYTOPENIA;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
BISPHOSPHONATES;;C;rs2736308;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OSTEONECROSIS_OF_THE_JAW;PEOPLE;OTHER:OSTEOPOROSIS;CAUTION_SIDE_EFFECT
ANTIINFLAMMATORY AGENTS, NON-STEROIDS;PTGS1;TT;rs10306135;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:ACUTE_CORONARY_SYNDROME;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;CAUTION_SIDE_EFFECT
BEVACIZUMAB, CAPECITABINE, CISPLATIN, DOCETAXEL, EPIRUBICIN, OXALIPLATIN, TRASTUZUMAB;DPYD;AT;rs67376798;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HAND-FOOT_SYNDROME;PEOPLE;DISEASE:STOMACH_NEOPLASMS;CAUTION_SIDE_EFFECT
CARBOPLATIN, GEMCITABINE;TNF;A;rs1800629;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
SORAFENIB;KDR;CC;rs2305948;EFFICACY;INCREASED;;EFFICACY:OVERALL_SURVIVAL, EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:HEPATOCELLULAR_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;COMT;AG + GG;rs4680;OTHER;DECREASED;;OTHER:LENGTH_OF_HOSPITAL_STAY;INFANTS;DISEASE:NEONATAL_ABSTINENCE_SYNDROME;CAUTION_DOSE_ADJUST
CARBOPLATIN, GEMCITABINE;PRRC2A;G;rs11229;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
CARBOPLATIN, GEMCITABINE;PRRC2A;T;rs10885;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
METHADONE, MORPHINE;COMT;AG + GG;rs4680;OTHER;DECREASED;LIKELIHOOD;OTHER:TREATMENT;INFANTS;OTHER:NEONATAL_ABSTINENCE_SYNDROME;LIKELIHOOD_THERAPEUTIC_FAILURE
SORAFENIB;FLT1;TT;rs664393;EFFICACY;DECREASED;;EFFICACY:OVERALL_SURVIVAL, EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:HEPATOCELLULAR_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
SORAFENIB;KDR;AA;rs2071559;EFFICACY;DECREASED;;EFFICACY:OVERALL_SURVIVAL, EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:HEPATOCELLULAR_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
CARBOPLATIN, GEMCITABINE;MSH5;T;rs3115672;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE, DOXORUBICIN, FEC100, FLUOROURACIL;ALDH1A1;AA + AG;rs13959;EFFICACY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ANEMIA;PEOPLE;OTHER:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
HMG_COA_REDUCTASE_INHIBITORS;ATP2B1;T;rs17381194;TOXICITY;INCREASED;RISK;DISEASE:MYALGIA;PEOPLE;DISEASE:HYPERLIPIDEMIAS;CAUTION_SIDE_EFFECT
CARBOPLATIN, GEMCITABINE;DOCK8;A;rs10491684;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
HMG_COA_REDUCTASE_INHIBITORS;;C;rs4693570;TOXICITY;INCREASED;RISK;DISEASE:MYALGIA;PEOPLE;DISEASE:HYPERLIPIDEMIAS;CAUTION_SIDE_EFFECT
NAN;EPO;A;rs1617640;OTHER;INCREASED;;OTHER:ENDOGENOUS_LEVELS_OF_EPO;HEALTHY;;CAUTION_DOSE_ADJUST
HMG_COA_REDUCTASE_INHIBITORS;DMPK;G;rs672348;TOXICITY;INCREASED;RISK;DISEASE:MYALGIA;PEOPLE;DISEASE:HYPERLIPIDEMIAS;CAUTION_SIDE_EFFECT
ASPIRIN;EYA1;T;rs12678747;TOXICITY;INCREASED;RISK;SIDE_EFFECT:PEPTIC_ULCER_DISEASE;;;CAUTION_SIDE_EFFECT
CARBOPLATIN, GEMCITABINE;CYP2C8;A;rs1058932;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBOPLATIN, GEMCITABINE;CYP2C8;A;rs11572078;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
AZITHROMYCIN, CHLORPROMAZINE, CILOSTAZOL, CIPROFLOXACIN, CITALOPRAM, CLARITHROMYCIN, DOFETILIDE, DONEPEZIL, DRONEDARONE, ERYTHROMYCIN, ESCITALOPRAM, FLECAINIDE, FLUCONAZOLE, HALOPERIDOL, HYDROXYCHLOROQUINE, LEVOFLOXACIN, METHADONE, MOXIFLOXACIN, ONDANSETRON, OXALIPLATIN, PAPAVERINE, PENTAMIDINE, PROCAINAMIDE, PROPOFOL, QUINIDINE, SOTALOL;KCNE1;T;rs1805128;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ACQUIRED_LONG_QT_SYNDROME_(ALQTS);;;CAUTION_SIDE_EFFECT
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;;EFFICACY:RESPONSE_RATE;;EFFICACY:NON-SMALL-CELL_LUNG_CANCER_PATIENTS;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL_(PFS)_TIME;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;;EFFICACY:RESPONSE_RATE;;EFFICACY:NON-SMALL-CELL_LUNG_CANCER_PATIENTS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBOPLATIN, GEMCITABINE;C6orf15;A;rs2233980;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
CARBOPLATIN, GEMCITABINE;CDSN;T;rs3130985;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
ETOPOSIDE, PLATINUM COMPOUNDS;DYNC2H1;AG + GG;rs716274;EFFICACY;INCREASED;RISK;DISEASE:DEATH;PEOPLE;DISEASE:SMALL_CELL_CARCINOMA;CAUTION_SIDE_EFFECT
ERLOTINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;;EFFICACY:RESPONSE_RATE;;EFFICACY:BRONCHIOLOALVEOLAR_CARCINOMA_AND_ADENOCARCINOMA_PATIENTS;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHADONE, MORPHINE;OPRM1;AG + GG;rs1799971;OTHER;DECREASED;LIKELIHOOD;OTHER:TREATMENT;INFANTS;DISEASE:NEONATAL_ABSTINENCE_SYNDROME;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOPHOSPHAMIDE, DOXORUBICIN, FEC100, FLUOROURACIL;NQO1;AA + AG;rs1800566;EFFICACY;DECREASED;LIKELIHOOD;SIDE_EFFECT:ANEMIA, SIDE_EFFECT:NEUTROPENIA, SIDE_EFFECT:GASTROINTESTINAL_TOXICITY;PEOPLE;OTHER:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
ETOPOSIDE, PLATINUM COMPOUNDS;YAP1;GT + TT;rs10895256;EFFICACY;INCREASED;RISK;DISEASE:DEATH;PEOPLE;DISEASE:SMALL_CELL_CARCINOMA;CAUTION_SIDE_EFFECT
HMG_COA_REDUCTASE_INHIBITORS;COQ2;A;rs6535454;TOXICITY;INCREASED;RISK;SIDE_EFFECT:STATIN_INTOLERANCE, DEFINED_PRIMARILY_THROUGH_MUSCLE_SYMPTOMATOLOGY;;;CAUTION_SIDE_EFFECT
HMG_COA_REDUCTASE_INHIBITORS;COQ2;G;rs4693075;TOXICITY;INCREASED;RISK;SIDE_EFFECT:STATIN_INTOLERANCE, DEFINED_PRIMARILY_THROUGH_MUSCLE_SYMPTOMATOLOGY;;;CAUTION_SIDE_EFFECT
CARBOPLATIN, GEMCITABINE;HLA-C;C;rs1049709;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
ERLOTINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL_(PFS)_TIME;;EFFICACY:BRONCHIOLOALVEOLAR_CARCINOMA_AND_ADENOCARCINOMA_PATIENTS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBOPLATIN, GEMCITABINE;HCP5;G;rs3130907;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
LENALIDOMIDE;CTNNB1;AA;rs4135385;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUTROPENIA;PEOPLE;DISEASE:MULTIPLE_MYELOMA;CAUTION_SIDE_EFFECT
CARBOPLATIN, ERLOTINIB, PACLITAXEL;EGFR;G;rs121434568;EFFICACY;INCREASED;;EFFICACY:OVERALL_SURVIVAL, EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBOPLATIN, GEMCITABINE;SERPINC1;C;rs5877;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
IBRUTINIB;KCNQ1;AA;rs2237895;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:CARDIAC_RHYTHM_DISEASE, SIDE_EFFECT:CARDIOTOXICITY;PEOPLE;OTHER:CHRONIC_B-CELL_LYMPHOCITIC_LEUKEMIA_OTHER:WALDENSTROM_MACROGLOBULINEMIA;CAUTION_SIDE_EFFECT
TAMOXIFEN;SLCO1B1;CC + CT;rs4149056;EFFICACY;DECREASED;;EFFICACY:OVERALL_SURVIVAL;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;SLC19A1;CC;rs1051266;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:MUCOSITIS;PEOPLE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
NAN;SCN5A;GG;rs7626962;OTHER;INCREASED;LIKELIHOOD;DISEASE:SUDDEN_INFANT_DEATH;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
LENALIDOMIDE;CTNNB1;AA;rs4533622;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUTROPENIA;PEOPLE;DISEASE:MULTIPLE_MYELOMA;CAUTION_SIDE_EFFECT
CARBOPLATIN, GEMCITABINE;;C;rs886423;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
CARBOPLATIN, GEMCITABINE;;T;rs886424;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
BETA BLOCKING AGENTS;ADRB1;AG + GG;rs1801252;EFFICACY;INCREASED;RISK;SIDE_EFFECT:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE);;;CAUTION_SIDE_EFFECT
CARBOPLATIN, GEMCITABINE;ATAT1;C;rs9262132;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
SORAFENIB;VEGFA;GG;rs2010963;EFFICACY;DECREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:HEPATOCELLULAR_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
SORAFENIB;VEGFA;GG;rs2010963;EFFICACY;DECREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:HEPATOCELLULAR_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;;EFFICACY:RESPONSE_RATE;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;ABO;GG;rs495828;METABOLISM/PK;INCREASED;;OTHER:ACE_ACTIVITY;PEOPLE;DISEASE:HYPERTENSION;CAUTION_DOSE_ADJUST
CARBOPLATIN, GEMCITABINE;PPP1R18;T;rs9262143;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
NAN;OPRM1;AG + GG;rs1799971;OTHER;DECREASED;;OTHER:LENGTH_OF_HOSPITAL_STAY;INFANTS;DISEASE:NEONATAL_ABSTINENCE_SYNDROME;CAUTION_DOSE_ADJUST
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;;EFFICACY:RESPONSE_RATE;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
SORAFENIB;;CC;rs4604006;EFFICACY;DECREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:HEPATOCELLULAR_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
IBRUTINIB;KCNQ1;GG;rs163182;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:CARDIAC_RHYTHM_DISEASE, SIDE_EFFECT:CARDIOTOXICITY;PEOPLE;OTHER:CHRONIC_B-CELL_LYMPHOCITIC_LEUKEMIA_OTHER:WALDENSTROM_MACROGLOBULINEMIA;CAUTION_SIDE_EFFECT
CARBOPLATIN, GEMCITABINE;MUCL3;A;rs3094086;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
OLANZAPINE;GIPR;AA;rs10423928;TOXICITY;INCREASED;;SIDE_EFFECT:PLASMA_INSULIN_LEVELS;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
SORAFENIB;;CC;rs4604006;EFFICACY;DECREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:HEPATOCELLULAR_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
SORAFENIB;VEGFA;CC;rs25648;EFFICACY;INCREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:HEPATOCELLULAR_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTHRACYCLINES AND RELATED SUBSTANCES;;A;rs28714259;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:CARDIOTOXICITY;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
CYCLOSPORINE;CTLA4;A;rs231775;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:GINGIVAL_OVERGROWTH;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
SORAFENIB;VEGFA;CC;rs833061;EFFICACY;DECREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:HEPATOCELLULAR_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
SORAFENIB;VEGFA;CC;rs699947;EFFICACY;INCREASED;;EFFICACY:OVERALL_SURVIVAL, EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:HEPATOCELLULAR_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
SORAFENIB;VEGFA;CC;rs25648;EFFICACY;INCREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:HEPATOCELLULAR_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
FENTANYL;OPRM1;AG;rs9397685;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:NAUSEA, SIDE_EFFECT:VOMITING;PEOPLE;DISEASE:POSTOPERATIVE_PAIN;LIKELIHOOD_THERAPEUTIC_SUCCESS
SORAFENIB;VEGFA;CC;rs833061;EFFICACY;DECREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:HEPATOCELLULAR_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;CT + TT;rs776746;EFFICACY;;;EFFICACY:DECREASED_GLOMERULAR_FILTRATION_RATE;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
NAN;ABCC4;AA + AC;rs2274407;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:EVENT-FREE_SURVIVAL;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL_(PFS)_TIME;PEOPLE;OTHER:EGFR_MUTATION_POSITIVE_NON-SMALL-CELL_LUNG_CANCER;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;;EFFICACY:PHYSICAL_AND_LIFE_WELL-BEING_QUALITY_OF_LIFE_(QOL)_SCALES;;OTHER:PEOPLE_WITH_EGFR_MUTATION_POSITIVE_ADVANCED_NON-SMALL-CELL_LUNG_CANCER;LIKELIHOOD_THERAPEUTIC_SUCCESS
ERLOTINIB, GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL_(PFS)_TIME;;OTHER:EGFR_MUTATION_POSITIVE_NON-SMALL-CELL_LUNG_CANCER_PATIENTS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ERLOTINIB, GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;;EFFICACY:OVERALL_SURVIVAL_(OS)_TIME;;OTHER:EGFR_MUTATION_POSITIVE_NON-SMALL-CELL_LUNG_CANCER_PATIENTS;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;TT;rs9923231;DOSAGE, EFFICACY, TOXICITY;INCREASED;RISK;EFFICACY:OVER-ANTICOAGULATION;;;CAUTION_DOSE_ADJUST
PAZOPANIB;HFE;TT;rs2858996;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;CAUTION_SIDE_EFFECT
PACLITAXEL;ABCB1;AA;rs1128503;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;AA + AG;rs1801133;TOXICITY;INCREASED;RISK;SIDE_EFFECT:LEUKOPENIA, SIDE_EFFECT:NEUTROPENIA;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
NAN;;GG;rs2207418;OTHER;INCREASED;RISK;DISEASE:HEART_FAILURE;;;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;CT + TT;rs776746;EFFICACY, METABOLISM/PK;DECREASED;;PK:TROUGH_CONCENTRATIONS;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
GLATIRAMER ACETATE;;A;rs75041078;TOXICITY;INCREASED;RISK;DISEASE:CORONARY_ARTERY_DISEASE;PEOPLE;DISEASE:MULTIPLE_SCLEROSIS;CAUTION_SIDE_EFFECT
GLATIRAMER ACETATE;;A;rs1056854;TOXICITY;INCREASED;RISK;DISEASE:CORONARY_ARTERY_DISEASE;PEOPLE;DISEASE:MULTIPLE_SCLEROSIS;CAUTION_SIDE_EFFECT
METHAMPHETAMINE;GAD2;AG + GG;rs2236418;OTHER;INCREASED;LIKELIHOOD;DISEASE:METHAMPHETAMINE_DEPENDENCE, DISEASE:PSYCHOTIC_DISORDER, DISEASE:SUBSTANCE-RELATED_DISORDERS;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
GLICLAZIDE, GLYBURIDE;ABCC8, KCNJ11;CC;rs757110;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:TREATMENT_FAILURE;PEOPLE;OTHER:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
ERLOTINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL_(PFS)_TIME;PEOPLE;EFFICACY:ADVANCED_NON-SMALL-CELL_LUNG_CANCER;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;AA + AC;rs4803217;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:RECURRENCE;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;ABCB1;CT + TT;rs2229109;EFFICACY;INCREASED;RISK;EFFICACY:RENAL_TRANSPLANT_FAILURE;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;CC;rs4803217;EFFICACY;INCREASED;;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CT + TT;rs776746;EFFICACY;INCREASED;LIKELIHOOD;SIDE_EFFECT:TRANSPLANT_REJECTION;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
FENTANYL;ABCB1;AA;rs1045642;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HYPOVENTILATION;PEOPLE;DISEASE:POSTOPERATIVE_PAIN;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;CT + TT;rs776746;EFFICACY, METABOLISM/PK;DECREASED;;PK:TROUGH_LEVELS;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
AFATINIB, ERLOTINIB, GEFITINIB;ARF1;GT + TT;rs11541557;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:OVERALL_SURVIVAL, EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;OTHER:LUNG_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
DRUGS FOR TREATMENT OF TUBERCULOSIS;CYP2E1;CT + TT;rs2031920;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
OSELTAMIVIR;ABCB1;AG + GG;rs1045642;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DEPRESSION, SIDE_EFFECT:GASTRITIS, SIDE_EFFECT:HYPERSENSITIVITY;PEOPLE;OTHER:ACUTE_RESPIRATORY_DISEASES, OTHER:SUSPECTED_INFLUENZA_A/H1N1_INFECTION;CAUTION_SIDE_EFFECT
METHOTREXATE;ABCC3;AA + AT;rs9895420;TOXICITY, METABOLISM/PK;INCREASED;;SIDE_EFFECT:PLASMA_LEVELS;PEOPLE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
METHOTREXATE;ABCC3;AA + AT;rs9895420;EFFICACY;DECREASED;;EFFICACY:EVENT_FREE_SURVIVAL;PEOPLE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
COCAINE;OPRD1;T;rs678849;TOXICITY;DECREASED;RISK;OTHER:COCAINE_DEPENDENCE;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CERIVASTATIN;RYR2;AA;rs2819742;TOXICITY;DECREASED;RISK;DISEASE:RHABDOMYOLYSIS;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE, CYTARABINE, DAUNORUBICIN, DEXAMETHASONE, DOXORUBICIN, METHOTREXATE, PEGASPARGASE, PREDNISONE, THIOGUANINE, VINCRISTINE;;A;rs1891059;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OSTEONECROSIS;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
ANTIEPILEPTICS;ABCC2;A;rs2273697;EFFICACY;INCREASED;;EFFICACY:PROBABILITY_OF_ANTIEPILEPTIC_DRUG_RESPONSE;CHILDREN;DISEASE:EPILEPSY;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;ABCC3;AA + AT;rs9895420;EFFICACY;INCREASED;RISK;EFFICACY:RELAPSE_IN_THE_CENTRAL_NERVOUS_SYSTEM;PEOPLE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
NAN;CYP1A2;T;rs35694136;OTHER;INCREASED;LIKELIHOOD;DISEASE:CHRONIC_OBSTRUCTIVE_PULMONARY_DISEASE;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTITHYMOCYTE GLOBULIN;FCGR3A;AC + CC;rs396991;OTHER;INCREASED;;OTHER:SENSITIVE_TO_ANTILYMPHOCYTE_SERUM;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
CYCLOPHOSPHAMIDE, CYTARABINE, DAUNORUBICIN, DEXAMETHASONE, DOXORUBICIN, METHOTREXATE, PEGASPARGASE, PREDNISONE, THIOGUANINE, VINCRISTINE;LINC00251;G;rs141059755;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OSTEONECROSIS;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE, CYTARABINE, DAUNORUBICIN, DEXAMETHASONE, DOXORUBICIN, METHOTREXATE, PEGASPARGASE, PREDNISONE, THIOGUANINE, VINCRISTINE;;C;rs17021408;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OSTEONECROSIS;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
PEGASPARGASE;ARHGAP28;T;rs9958628;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HYPERSENSITIVITY;;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE, CYTARABINE, DAUNORUBICIN, DEXAMETHASONE, DOXORUBICIN, METHOTREXATE, PEGASPARGASE, PREDNISONE, THIOGUANINE, VINCRISTINE;DOK5;A;rs117532069;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OSTEONECROSIS;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE, CYTARABINE, DAUNORUBICIN, DEXAMETHASONE, DOXORUBICIN, METHOTREXATE, PEGASPARGASE, PREDNISONE, THIOGUANINE, VINCRISTINE;;G;rs80223967;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OSTEONECROSIS;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
CARBOPLATIN, ETOPOSIDE, IFOSFAMIDE;ABCG2;CT + TT;rs3114020;EFFICACY;INCREASED;RISK;SIDE_EFFECT:DEATH;CHILDREN;OTHER:CENTRAL_NERVOUS_SYSTEM_CANCER;CAUTION_SIDE_EFFECT
THEOPHYLLINE;CYP1A2;T/del + TT;rs35694136;EFFICACY;INCREASED;SEVERITY;DISEASE:CHRONIC_OBSTRUCTIVE_PULMONARY_DISEASE;PEOPLE;DISEASE:CHRONIC_OBSTRUCTIVE_PULMONARY_DISEASE;CAUTION_SIDE_EFFECT
THEOPHYLLINE;CYP1A2;T;rs35694136;EFFICACY, METABOLISM/PK;DECREASED;;PK:PLASMA_DRUG_LEVELS;PEOPLE;DISEASE:CHRONIC_OBSTRUCTIVE_PULMONARY_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
NAN;CYP1A2;C;rs762551;OTHER;INCREASED;LIKELIHOOD;DISEASE:CHRONIC_OBSTRUCTIVE_PULMONARY_DISEASE;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHAMBUTOL, ISONIAZID / PYRAZINAMIDE / RIFAMPIN;ATP7B;CC;rs1061472;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;PEOPLE;OTHER:TUBERCULOSIS;CAUTION_SIDE_EFFECT
VERAPAMIL;NR1H3;T;rs2279238;EFFICACY;INCREASED;RISK;EFFICACY:MYOCARDIAL_INFARCTION, EFFICACY:STROKE;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE, DISEASE:HYPERTENSION;CAUTION_SIDE_EFFECT
VERAPAMIL;NR1H3;A;rs12221497;EFFICACY;DECREASED;RISK;EFFICACY:MYOCARDIAL_INFARCTION, EFFICACY:STROKE;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE, DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;DDC;T;rs921451;NAN;;SEVERITY;DISEASE:TOBACCO_USE_DISORDER;;;CAUTION_DOSE_ADJUST
ATENOLOL, VERAPAMIL;NR1H3;G;rs11039149;EFFICACY;DECREASED;RISK;EFFICACY:MYOCARDIAL_INFARCTION, EFFICACY:STROKE;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE, DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;DDC;C;rs3735273;NAN;;SEVERITY;DISEASE:TOBACCO_USE_DISORDER;;;CAUTION_DOSE_ADJUST
SEVOFLURANE;KCNK2;CC + CG;rs6686529;EFFICACY;INCREASED;;EFFICACY:SEDATION;PEOPLE;OTHER:OTORHINOLARYNGOLOGY_SURGERY;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;DDC;T;rs1451371;NAN;;SEVERITY;DISEASE:TOBACCO_USE_DISORDER;;;CAUTION_DOSE_ADJUST
CHOP, RITUXIMAB;SLC35F4;CC;rs74832512;EFFICACY;INCREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;OTHER:LYMPHOMA, LARGE_B-CELL*^DIFFUSE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PROTEASE INHIBITORS;APOC3;CC + CT;rs2854116;EFFICACY;DECREASED;SEVERITY;SIDE_EFFECT:HYPERTRIGLYCERIDEMIA;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
VARENICLINE;CHRNB1, ZBTB4;C;rs2302764;TOXICITY;INCREASED;SEVERITY;DISEASE:NAUSEA;PEOPLE;DISEASE:TOBACCO_USE_DISORDER;CAUTION_SIDE_EFFECT
PROTEASE INHIBITORS;APOC3;CT + TT;rs2854117;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:HYPERTRIGLYCERIDEMIA;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
VARENICLINE;CHRNB2;A;rs2072661;TOXICITY;INCREASED;SEVERITY;DISEASE:NAUSEA;PEOPLE;DISEASE:TOBACCO_USE_DISORDER;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE, CYTARABINE, DAUNORUBICIN, DEXAMETHASONE, DOXORUBICIN, METHOTREXATE, PEGASPARGASE, PREDNISONE, THIOGUANINE, VINCRISTINE;BMP7;T;rs79085477;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OSTEONECROSIS;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
VARENICLINE;CHRNB2;T;rs4292956;TOXICITY;INCREASED;SEVERITY;DISEASE:NAUSEA;PEOPLE;DISEASE:TOBACCO_USE_DISORDER;CAUTION_SIDE_EFFECT
VARENICLINE;CHRNB2;C;rs2072660;TOXICITY;INCREASED;SEVERITY;DISEASE:NAUSEA;PEOPLE;DISEASE:TOBACCO_USE_DISORDER;CAUTION_SIDE_EFFECT
CARBOPLATIN, ETOPOSIDE, IFOSFAMIDE;ABCB1;AA + AG;rs1045642;EFFICACY;INCREASED;RISK;SIDE_EFFECT:DEATH;CHILDREN;OTHER:CENTRAL_NERVOUS_SYSTEM_CANCER;CAUTION_SIDE_EFFECT
AZATHIOPRINE;DDRGK1, ITPA;A;rs1127354;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA;PEOPLE;DISEASE:INFLAMMATORY_BOWEL_DISEASES;CAUTION_SIDE_EFFECT
MORPHINE;FAAH;AA;rs324420;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:RESPIRATORY_INSUFFICIENCY;CHILDREN;DISEASE:KYPHOSIS, DISEASE:SCOLIOSIS;CAUTION_SIDE_EFFECT
CHOP, RITUXIMAB;OXNAD1;TT;rs11721010;EFFICACY;INCREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;OTHER:LYMPHOMA, LARGE_B-CELL*^DIFFUSE;LIKELIHOOD_THERAPEUTIC_SUCCESS
MORPHINE;FAAH;TT;rs11576941;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:POSTOPERATIVE_NAUSEA_AND_VOMITING;CHILDREN;DISEASE:KYPHOSIS, DISEASE:SCOLIOSIS;CAUTION_SIDE_EFFECT
PROTEASE INHIBITORS;APOC3;CG + GG;rs5128;TOXICITY;DECREASED;;SIDE_EFFECT:HYPERTRIGLYCERIDEMIA;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SUNITINIB;ABCB1;AC;rs2032582;EFFICACY;INCREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOCETAXEL;SLCO1B3;G;rs11045585;TOXICITY;INCREASED;RISK;DISEASE:LEUKOPENIA;;;CAUTION_SIDE_EFFECT
APIXABAN;ABCB1;CT + TT;rs4148738;TOXICITY;DECREASED;RISK;SIDE_EFFECT:HEMORRHAGE;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOCETAXEL;ABCC2;G;rs12762549;TOXICITY;INCREASED;RISK;SIDE_EFFECT:LEUKOPENIA;;;CAUTION_SIDE_EFFECT
NAN;DTNBP1;T;rs3213207;NAN;DECREASED;RISK;DISEASE:BIPOLAR_DISORDER;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;ITGB3;CT;rs5918;OTHER;INCREASED;;OTHER:SENSITIVITY_TO_ASPIRIN;;;CAUTION_DOSE_ADJUST
CHOP, RITUXIMAB;CIDEA;TT;rs75614943;EFFICACY;INCREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;OTHER:LYMPHOMA, LARGE_B-CELL*^DIFFUSE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYTARABINE;CDA;C/del + del/del;rs3215400;TOXICITY;INCREASED;;DISEASE:DRUG_TOXICITY;;;CAUTION_SIDE_EFFECT
METHAMPHETAMINE;BDNF;CC;rs6265;OTHER;INCREASED;LIKELIHOOD;DISEASE:SUBSTANCE-RELATED_DISORDERS;MEN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CHOP, RITUXIMAB;NOS1;GG;rs77241831;EFFICACY;INCREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;OTHER:LYMPHOMA, LARGE_B-CELL*^DIFFUSE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHAMPHETAMINE;BDNF;CC;rs6265;OTHER;DECREASED;LIKELIHOOD;SIDE_EFFECT:PSYCHOTIC_DISORDER;MEN;DISEASE:SUBSTANCE-RELATED_DISORDERS;LIKELIHOOD_THERAPEUTIC_FAILURE
CYTARABINE;CDA;AC + CC;rs2072671;TOXICITY;INCREASED;;DISEASE:DRUG_TOXICITY;;;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;;GG + GT;rs9346455;TOXICITY;INCREASED;;SIDE_EFFECT:WEIGHT_GAIN;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
NAN;DTNBP1;T;rs3213207;NAN;DECREASED;SEVERITY;OTHER:MANIC_SYMPTOMS_IN_PSYCHOSIS;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SUFENTANIL;ABCB1;GG;rs1045642;EFFICACY;INCREASED;SEVERITY;EFFICACY:PAIN, POSTOPERATIVE;CHILDREN;OTHER:POSTOPERATIVE_PAIN;CAUTION_SIDE_EFFECT
NAN;DTNBP1;C;rs2619539;NAN;DECREASED;SEVERITY;OTHER:MANIC_SYMPTOMS_IN_PSYCHOSIS;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYTARABINE;CDA;AG + GG;rs602950;TOXICITY;INCREASED;;DISEASE:DRUG_TOXICITY;;;CAUTION_SIDE_EFFECT
HEROIN;OPRD1;C;rs2236857;TOXICITY;INCREASED;RISK;OTHER:HEROIN_DEPENDENCE;;;CAUTION_SIDE_EFFECT
CYTARABINE;CDA;CT + TT;rs532545;TOXICITY;INCREASED;;DISEASE:DRUG_TOXICITY;HEALTHY;;CAUTION_SIDE_EFFECT
HEROIN;OPRD1;A;rs2236855;TOXICITY;INCREASED;RISK;OTHER:HEROIN_DEPENDENCE;;;CAUTION_SIDE_EFFECT
SUNITINIB;ABCB1;AG;rs1128503;EFFICACY;INCREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIVAROXABAN;ABCB1;AA + AG;rs1045642;TOXICITY;DECREASED;RISK;SIDE_EFFECT:THROMBOEMBOLISM;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
HEROIN;OPRD1;C;rs3766951;TOXICITY;INCREASED;RISK;OTHER:HEROIN_DEPENDENCE;;;CAUTION_SIDE_EFFECT
NICOTINE;NRXN1;C;rs2193225;OTHER;;;OTHER:SMOKING_QUANTITY;;OTHER:SMOKERS;CAUTION_DOSE_ADJUST
HEROIN;OPRD1;C;rs2298897;TOXICITY;INCREASED;RISK;OTHER:HEROIN_DEPENDENCE;;;CAUTION_SIDE_EFFECT
NICOTINE;NRXN1;C;rs2193225;OTHER;;;OTHER:SMOKING_QUANTITY, HEAVINESS_OF_SMOKING_INDEX_AND_FAGERSTROM_TEST_FOR_NICOTINE_DEPENDENCE;;OTHER:SMOKERS;CAUTION_DOSE_ADJUST
NICOTINE;NRXN1;A;rs6721498;OTHER;;;OTHER:SMOKING_QUANTITY, HEAVINESS_OF_SMOKING_INDEX_AND_FAGERSTROM_TEST_FOR_NICOTINE_DEPENDENCE;;OTHER:SMOKERS;CAUTION_DOSE_ADJUST
SUNITINIB;ABCB1;AG;rs1045642;EFFICACY;INCREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CHOP, RITUXIMAB;;CC;rs1607795;EFFICACY;INCREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;OTHER:LYMPHOMA, LARGE_B-CELL*^DIFFUSE;LIKELIHOOD_THERAPEUTIC_SUCCESS
SUFENTANIL;COMT;AA;rs4680;EFFICACY;INCREASED;SEVERITY;EFFICACY:PAIN, POSTOPERATIVE;CHILDREN;OTHER:POSTOPERATIVE_PAIN;CAUTION_SIDE_EFFECT
NAN;DTNBP1;T;rs2619538;NAN;DECREASED;SEVERITY;OTHER:MANIC_SYMPTOMS_IN_PSYCHOSIS;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHANOL;FUT2;A;rs492602;TOXICITY;DECREASED;RISK;SIDE_EFFECT:ALCOHOL_ABUSE;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHANOL;FTO;A;rs9937709;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ALCOHOL_ABUSE;;;CAUTION_SIDE_EFFECT
PLATINUM;RICTOR;GG;rs6878291;TOXICITY;DECREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIDEPRESSANTS;NR3C1;G;rs852977;EFFICACY;INCREASED;;PK:ANTIDEPRESSANT_RESPONSE;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CERIVASTATIN;SLCO1B1;CC;rs4149056;TOXICITY;INCREASED;RISK;DISEASE:RHABDOMYOLYSIS;;;CAUTION_SIDE_EFFECT
PAROXETINE;HTR3B;AA;rs1176744;TOXICITY;INCREASED;RISK;DISEASE:NAUSEA;PEOPLE;DISEASE:MENTAL_DISORDERS;CAUTION_SIDE_EFFECT
ETHANOL;;A;rs1783835;TOXICITY;DECREASED;RISK;SIDE_EFFECT:ALCOHOL_ABUSE;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CHOP, RITUXIMAB;TNIP3;CC;rs116665727;EFFICACY;INCREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;OTHER:LYMPHOMA, LARGE_B-CELL*^DIFFUSE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN, FLUOROURACIL, RADIOTHERAPY;APEX1;GG;rs1760944;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:OVERALL_SURVIVAL;MEN;OTHER:CARCINOMA, SQUAMOUS_CELL;LIKELIHOOD_THERAPEUTIC_FAILURE
CHOP, RITUXIMAB;IL10;AG + GG;rs1800871;EFFICACY;INCREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL, EFFICACY:OVERALL_SURVIVAL;PEOPLE;OTHER:LYMPHOMA, LARGE_B-CELL*^DIFFUSE;LIKELIHOOD_THERAPEUTIC_SUCCESS
SUNITINIB;ABCB1;A;rs2032582;EFFICACY;DECREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
CISPLATIN, FLUOROURACIL, RADIOTHERAPY;MUTYH;CG + GG;rs3219489;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:PROGRESSION-FREE_SURVIVAL;MEN;OTHER:CARCINOMA, SQUAMOUS_CELL;LIKELIHOOD_THERAPEUTIC_FAILURE
ETHANOL;SLC4A8;C;rs12296477;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ALCOHOL_ABUSE;;;CAUTION_SIDE_EFFECT
ASPIRIN;ITGB3;CC + CT;rs5918;OTHER;;;OTHER:SHORTER_BLEEDING_TIME;HEALTHY;;CAUTION_DOSE_ADJUST
NAN;NR3C1;G;rs10482633;NAN;INCREASED;;EFFICACY:ANTIDEPRESSANT_RESPONSE;;;CAUTION_DOSE_ADJUST
ESCITALOPRAM;HTR2A;C;rs9316233;EFFICACY;INCREASED;;EFFICACY:ANTIDEPRESSANT_RESPONSE;PEOPLE;DISEASE:DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHANOL;ARID4A;T;rs61974485;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ALCOHOL_ABUSE;;;CAUTION_SIDE_EFFECT
ETHANOL;;T;rs8008020;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ALCOHOL_ABUSE;;;CAUTION_SIDE_EFFECT
NICOTINE;OPRM1;AG;rs1799971;TOXICITY;INCREASED;SEVERITY;OTHER:TOBACCO_USE_DISORDER;;;CAUTION_SIDE_EFFECT
ETHANOL;TNRC6A;A;rs72768626;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ALCOHOL_ABUSE;;;CAUTION_SIDE_EFFECT
GLIMEPIRIDE, GLIPIZIDE, GLYBURIDE;NOS1AP;T;rs10494366;TOXICITY;INCREASED;RISK;OTHER:HYPOGLYCEMIA;PEOPLE;OTHER:DIABETES_MELLITUS_T2;CAUTION_SIDE_EFFECT
KETOROLAC;;CC;rs2562456;EFFICACY;;;EFFICACY:SLOWER_ANALGESIC_ONSET_IN_EUROPEAN_AMERICANS_UNDERGOING_ORAL_SURGERY;;;CAUTION_DOSE_ADJUST
OPIOIDS;OPRM1;AG + GG;rs1799971;DOSAGE;DECREASED;LIKELIHOOD;SIDE_EFFECT:VOMITING;;;CAUTION_DOSE_ADJUST
AZATHIOPRINE;ABCC1;CC + CG;rs2074087;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:LYMPHOPENIA;CHILDREN;DISEASE:INFLAMMATORY_BOWEL_DISEASES;CAUTION_SIDE_EFFECT
FLUVASTATIN;SREBF1;CC;rs60282872;EFFICACY;INCREASED;;EFFICACY:APOLIPOPROTEIN_A1_AND_C3;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
BEVACIZUMAB, PEMETREXED;SLC19A1;G;rs1051298;EFFICACY;INCREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:LUNG_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN, RADIOTHERAPY;TP53;CG;rs1042522;EFFICACY;INCREASED;;EFFICACY:OVERALL_SURVIVAL;WOMEN;OTHER:UTERINE_CERVICAL_NEOPLASM;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;SLC30A8;C;rs13266634;OTHER, METABOLISM/PK;INCREASED;;OTHER:BASELINE_PROINSULIN_LEVELS_AFTER_ADJUSTING_FOR_INSULIN_LEVELS;PEOPLE;OTHER:SUSPECTED_INCREASED_RISK_OF_DIABETES;CAUTION_DOSE_ADJUST
OPIOIDS;OPRM1;AG + GG;rs1799971;DOSAGE;DECREASED;LIKELIHOOD;SIDE_EFFECT:POSTOPERATIVE_NAUSEA_AND_VOMITING;PEOPLE;OTHER:POSTOPERATIVE_PAIN;CAUTION_DOSE_ADJUST
ANTIINFLAMMATORY AGENTS, NON-STEROIDS;AGT;GG;rs943580;TOXICITY;DECREASED;LIKELIHOOD;DISEASE:ACUTE_CORONARY_SYNDROME;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIINFLAMMATORY AGENTS, NON-STEROIDS;MMP1, MMP10;AG + GG;rs2071230;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:ACUTE_CORONARY_SYNDROME;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;CAUTION_SIDE_EFFECT
LEVONORGESTREL;ADAMTS10;CG;rs7255721;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS;WOMEN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIINFLAMMATORY AGENTS, NON-STEROIDS;MMP1, MMP10;CT + TT;rs7945189;TOXICITY;DECREASED;LIKELIHOOD;DISEASE:ACUTE_CORONARY_SYNDROME;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;LIKELIHOOD_THERAPEUTIC_SUCCESS
CITALOPRAM;HTR2A;AA;rs6313;TOXICITY;DECREASED;RISK;SIDE_EFFECT:HEART_PALPITATIONS;PEOPLE;DISEASE:DEPRESSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIINFLAMMATORY AGENTS, NON-STEROIDS;PTGS1;TT;rs12353214;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:ACUTE_CORONARY_SYNDROME;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;CAUTION_SIDE_EFFECT
ANTIINFLAMMATORY AGENTS, NON-STEROIDS;KL;CG + GG;rs211247;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:ACUTE_CORONARY_SYNDROME;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;CAUTION_SIDE_EFFECT
ANTIINFLAMMATORY AGENTS, NON-STEROIDS;CRP;CT + TT;rs1205;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:ACUTE_CORONARY_SYNDROME;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;CAUTION_SIDE_EFFECT
NICOTINE;CHRNA4;AG;rs1044396;OTHER;INCREASED;LIKELIHOOD;OTHER:SMOKING_INITIATION;MEN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIINFLAMMATORY AGENTS, NON-STEROIDS;CDKN2B-AS1;AA + AG;rs10757274;TOXICITY;DECREASED;LIKELIHOOD;DISEASE:ACUTE_CORONARY_SYNDROME;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;CHRNA4;GG;rs1044396;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:TOBACCO_USE_DISORDER;MEN;;CAUTION_SIDE_EFFECT
ANTIINFLAMMATORY AGENTS, NON-STEROIDS;AGT;GG;rs699;TOXICITY;DECREASED;LIKELIHOOD;DISEASE:ACUTE_CORONARY_SYNDROME;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;CHRNA4;CC;rs1044397;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:TOBACCO_USE_DISORDER;MEN;;CAUTION_SIDE_EFFECT
COXIBS;PTGS2;CG + GG;rs20417;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:ACUTE_CORONARY_SYNDROME;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;CAUTION_SIDE_EFFECT
COXIBS;PTGS2;AG + GG;rs4648276;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:ACUTE_CORONARY_SYNDROME;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;CAUTION_SIDE_EFFECT
SEVOFLURANE;FASTKD3, MTRR;CC + CT;rs3733784;EFFICACY;INCREASED;;EFFICACY:VOL%_END-TIDAL_SEVOFLURANE_CONCENTRATION;PEOPLE;OTHER:OTORHINOLARYNGOLOGY_SURGERY;LIKELIHOOD_THERAPEUTIC_SUCCESS
HEROIN;OPRM1;A;rs524731;TOXICITY;INCREASED;RISK;OTHER:HEROIN_DEPENDENCE;;;CAUTION_SIDE_EFFECT
HEROIN;OPRM1;T;rs511435;TOXICITY;INCREASED;RISK;OTHER:HEROIN_DEPENDENCE;;;CAUTION_SIDE_EFFECT
HEROIN;OPRM1;G;rs495491;TOXICITY;INCREASED;RISK;OTHER:HEROIN_DEPENDENCE;;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;ADK;TT;rs10824095;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA;CHILDREN;DISEASE:INFLAMMATORY_BOWEL_DISEASES;CAUTION_SIDE_EFFECT
HEROIN;OPRM1;T;rs510769;TOXICITY;INCREASED;RISK;OTHER:HEROIN_DEPENDENCE;;;CAUTION_SIDE_EFFECT
CISPLATIN;ACYP2;A;rs1872328;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OTOTOXICITY;CHILDREN;DISEASE:BRAIN_NEOPLASMS;CAUTION_SIDE_EFFECT
AZATHIOPRINE;SLC29A1;CG + GG;rs747199;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA;CHILDREN;DISEASE:INFLAMMATORY_BOWEL_DISEASES;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;EFFICACY;INCREASED;;EFFICACY:ON-TREATMENT_PLATELET_AGGREGATION;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
AZATHIOPRINE;IMPDH2;AG + GG;rs11706052;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:LYMPHOPENIA;CHILDREN;DISEASE:INFLAMMATORY_BOWEL_DISEASES;CAUTION_SIDE_EFFECT
HEROIN;OPRM1;C;rs3778151;TOXICITY;INCREASED;RISK;OTHER:HEROIN_DEPENDENCE;;;CAUTION_SIDE_EFFECT
AZATHIOPRINE;IMPDH1;CT + TT;rs2278294;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:LYMPHOPENIA;CHILDREN;DISEASE:INFLAMMATORY_BOWEL_DISEASES;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOZAPINE, OLANZAPINE, RISPERIDONE;SLC1A1;A;rs2228622;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OBSESSIVE_COMPULSIVE_SYMPTOMS;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
HEROIN;OPRM1;A;rs3823010;TOXICITY;INCREASED;RISK;OTHER:HEROIN_DEPENDENCE;;;CAUTION_SIDE_EFFECT
CLOZAPINE, OLANZAPINE, RISPERIDONE;SLC1A1;G;rs3780413;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OBSESSIVE_COMPULSIVE_SYMPTOMS;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
CLOZAPINE, OLANZAPINE, RISPERIDONE;SLC1A1;C;rs3780412;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OBSESSIVE_COMPULSIVE_SYMPTOMS;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
HEROIN;;A;rs9478495;TOXICITY;INCREASED;RISK;OTHER:HEROIN_DEPENDENCE;;;CAUTION_SIDE_EFFECT
NAN;;G;rs9424490;NAN;INCREASED;RISK;OTHER:CURRENT_SMOKING;;;CAUTION_SIDE_EFFECT
NAN;USH2A;C;rs12126638;NAN;INCREASED;RISK;OTHER:CURRENT_SMOKING;;;CAUTION_SIDE_EFFECT
NAN;AK4;C;rs1109374;NAN;INCREASED;RISK;OTHER:CURRENT_SMOKING;;;CAUTION_SIDE_EFFECT
ASPIRIN, CLOPIDOGREL;ITGA2;AA + AG;rs1062535;EFFICACY;INCREASED;RISK;EFFICACY:RESIDUAL_PLATELET_REACTIVITY;PEOPLE;DISEASE:MYOCARDIAL_INFARCTION;CAUTION_SIDE_EFFECT
NAN;ITGB1;AA;rs1187075;EFFICACY;INCREASED;RISK;EFFICACY:DEATH;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
HEROIN;OPRM1;C;rs562859;TOXICITY;INCREASED;RISK;OTHER:HEROIN_DEPENDENCE;;;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;T;rs3918290;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:DRUG_TOXICITY;;;CAUTION_SIDE_EFFECT
LETROZOLE;;A;rs1324052;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:MUSCULOSKELETAL_PAIN, SIDE_EFFECT:ARTHRITIS, OTHER:DISCONTINUATION;WOMEN;OTHER:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
PLATINUM, VINORELBINE;STMN1;AA;rs182455;EFFICACY;DECREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;;LIKELIHOOD_THERAPEUTIC_FAILURE
TEGAFUR;DPYD;TT;rs1801159;EFFICACY;DECREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:STOMACH_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
NAN;ITGB1;GG;rs2230395;EFFICACY;INCREASED;RISK;EFFICACY:DEATH;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
HEROIN;OPRM1;C;rs3778150;TOXICITY;INCREASED;RISK;OTHER:HEROIN_DEPENDENCE;;;CAUTION_SIDE_EFFECT
BEVACIZUMAB, PEMETREXED;GGH;G;rs3780126;EFFICACY;INCREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:LUNG_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;TPH2;TT;rs1843809;OTHER;DECREASED;LIKELIHOOD;SIDE_EFFECT:AGGRESSION, SIDE_EFFECT:DEPRESSION;PEOPLE;DISEASE:ALCOHOL_ABUSE;LIKELIHOOD_THERAPEUTIC_FAILURE
ASPIRIN, CLOPIDOGREL;ITGA2;CT + TT;rs1126643;EFFICACY;INCREASED;RISK;EFFICACY:RESIDUAL_PLATELET_REACTIVITY;PEOPLE;DISEASE:MYOCARDIAL_INFARCTION;CAUTION_SIDE_EFFECT
HEROIN;;C;rs9384169;TOXICITY;INCREASED;RISK;OTHER:HEROIN_DEPENDENCE;;;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;CYP1A2;AC + CC;rs762551;TOXICITY;INCREASED;;SIDE_EFFECT:QT_INTERVAL;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
PLATINUM COMPOUNDS;SLC22A2;AA + AC;rs316019;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
PLATINUM COMPOUNDS;SLC22A2;AA + AC;rs316019;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
ANTIDEPRESSANTS, ANTIPSYCHOTICS, BENZODIAZEPINE DERIVATIVES, OPIOIDS, SYMPATHOMIMETICS;OPRM1;G;rs1799971;TOXICITY;INCREASED;RISK;OTHER:CARDIAC_ARREST, OTHER:RESPIRATORY_INSUFFICIENCY;;OTHER:OVERDOSE;CAUTION_SIDE_EFFECT
BEVACIZUMAB, PEMETREXED;GGH;CT;rs11545077;EFFICACY;INCREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:LUNG_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
DIGOXIN;NOS1AP;GG;rs10494366;TOXICITY;INCREASED;;SIDE_EFFECT:SHORTENED_QT_INTERVAL;;;CAUTION_SIDE_EFFECT
SUNITINIB;ABCB1;CC;rs2032582;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS, SIDE_EFFECT:HAND-FOOT_SYNDROME, SIDE_EFFECT:HYPERTENSION;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;CAUTION_SIDE_EFFECT
ASPIRIN, CLOPIDOGREL;ITGA2;CT + TT;rs1126643;EFFICACY;INCREASED;;EFFICACY:PLATELET_AGGREGATION_AFTER_STIMULI_WITH_ADENOSINE_DIPHOSPHATE, COLLAGEN, AND_EPINEPHRINE;PEOPLE;DISEASE:CORONARY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
FENTANYL;OPRM1;GG;rs1799971;DOSAGE;;;EFFICACY:HIGHER_FENTANYL_DOSE_REQUIREMENT_TO_ACHIEVE_ADEQUATE_PAIN_RELIEF_IN_CHINESE_WOMEN_UNDERGOING_GYNECOLOGIC_SURGERY;;;CAUTION_DOSE_ADJUST
CANNABINOIDS, COCAINE, ETHANOL, NICOTINE, OPIOIDS;OPRM1;G;rs1799971;TOXICITY;DECREASED;RISK;OTHER:SUBSTANCE-RELATED_DISORDERS;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE, FLUOROURACIL;MIR27A;CT;rs895819;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;OTHER:NEOPLASMS;CAUTION_SIDE_EFFECT
SUNITINIB;FLT1;GG;rs7993418;EFFICACY;DECREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
CISPLATIN;NFE2L2;GG + GT;rs6721961;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:OTOTOXICITY;PEOPLE;OTHER:HEAD_AND_NECK_NEOPLASMS;CAUTION_SIDE_EFFECT
SUNITINIB;FLT1;CC;rs9582036;EFFICACY;DECREASED;;EFFICACY:OVERALL_SURVIVAL, EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
FENTANYL;OPRM1;AG + GG;rs1799971;DOSAGE, EFFICACY;;;EFFICACY:HIGHER_RESPONSIVENESS_TO_OPIOIDS_AND_REQUIRED_LESS_ANALGESIC_DRUGS_IN_LABORING_WOMEN;WOMEN;;CAUTION_DOSE_ADJUST
FLUVOXAMINE;HTR2A;CC + CT;rs6311;TOXICITY;INCREASED;RISK;SIDE_EFFECT:GASTROINTESTINAL_SIDE_EFFECTS;PEOPLE;DISEASE:DEPRESSIVE_DISORDER;CAUTION_SIDE_EFFECT
FENTANYL;OPRM1;AG + GG;rs1799971;EFFICACY;;;EFFICACY:LESS_PAIN_CONTROL_IN_JAPANESE_PATIENTS_UNDERGOING_PAINFUL_OROFACIAL_COSMETIC_SURGERY;;;CAUTION_DOSE_ADJUST
OLANZAPINE;FMO3;GG;rs2266780;METABOLISM/PK;DECREASED;;PK:DOSE-ADJUSTED_SERUM_OLANZAPINE_N-OXIDE_CONCENTRATIONS;;;CAUTION_DOSE_ADJUST
METOPROLOL;CYP2D6;T;rs3892097;EFFICACY, METABOLISM/PK;INCREASED;;PK:PLASMA_CONCENTRATIONS_OF_METOPROLOL_AND_GREATER_REDUCTIONS_IN_HEART_RATE, DIASTOLIC_BLOOD_PRESSURE, AND_MEAN_ARTERIAL_PRESSURE_IN_PMS_THAN_IN_NON-PMS.;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SUNITINIB;FLT1;AA;rs9554320;EFFICACY;DECREASED;;EFFICACY:OVERALL_SURVIVAL, EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;INCREASED;;EFFICACY:RESIDUAL_PLATELET_REACTIVITY;PEOPLE;DISEASE:CORONARY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM COMPOUNDS;CCN4;AA + AC;rs10956697;EFFICACY;DECREASED;RISK;EFFICACY:OVERALL_SURVIVAL, EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;OTHER:LUNG_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;ITGB3;CC + CT;rs5918;EFFICACY;INCREASED;RISK;EFFICACY:THE_LACK_OF_ASPIRIN_EFFECT;MEN;;CAUTION_SIDE_EFFECT
SUNITINIB;FLT1;AA;rs9554320;EFFICACY;DECREASED;;EFFICACY:OVERALL_SURVIVAL, EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
OLANZAPINE;FMO1;AA + AC;rs12720462;METABOLISM/PK;INCREASED;;PK:DOSE-ADJUSTED_SERUM_OLANZAPINE_CONCENTRATIONS;;;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY, TOXICITY;INCREASED;RISK;SIDE_EFFECT:CARDIOVASCULAR_EVENTS;PEOPLE;DISEASE:CORONARY_DISEASE;CAUTION_SIDE_EFFECT
PLATINUM COMPOUNDS;ERCC1;CC;rs3212986;EFFICACY;INCREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:OVARIAN_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ARIPIPRAZOLE;DRD2;CC;rs2514218;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:PSYCHOMOTOR_AGITATION;PEOPLE;OTHER:PSYCHOTIC_DISORDER, OTHER:SCHIZOAFFECTIVE_DISORDER,OTHER:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
PLATINUM COMPOUNDS, TAXANES;GSTP1;AA;rs1695;TOXICITY, METABOLISM/PK;INCREASED;RISK;SIDE_EFFECT:HEMATOLOGICAL_TOXICITY;PEOPLE;DISEASE:OVARIAN_NEOPLASMS;CAUTION_SIDE_EFFECT
PLATINUM, TAXANES;ABCB1;CC;rs2032582;TOXICITY, METABOLISM/PK;DECREASED;RISK;SIDE_EFFECT:GRADE_3_OR_4_GASTROINTESTINAL_TOXICITY;PEOPLE;DISEASE:OVARIAN_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;A;rs4986893;EFFICACY, TOXICITY;INCREASED;RISK;SIDE_EFFECT:CARDIOVASCULAR_EVENTS;PEOPLE;DISEASE:CORONARY_DISEASE;CAUTION_SIDE_EFFECT
SUNITINIB;FLT1;CC;rs9582036;EFFICACY;DECREASED;;EFFICACY:OVERALL_SURVIVAL, EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
OLANZAPINE;FMO1;CT + TT;rs7877;METABOLISM/PK;INCREASED;;PK:DOSE-ADJUSTED_SERUM_OLANZAPINE_CONCENTRATIONS;;;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;A;rs4986893;EFFICACY;INCREASED;;EFFICACY:RESIDUAL_PLATELET_REACTIVITY;PEOPLE;DISEASE:CORONARY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUMETANIDE, FUROSEMIDE, TORASEMIDE;SLC12A3;C;rs1529927;EFFICACY;INCREASED;;EFFICACY:24-H_EXCRETION_OF_CHLORIDE_AND_POTASSIUM;HEALTHY;;LIKELIHOOD_THERAPEUTIC_SUCCESS
AMPHETAMINE, CANNABINOIDS, COCAINE, OPIOIDS;KAT2B;C;rs9829896;TOXICITY;DECREASED;RISK;OTHER:SUBSTANCE-RELATED_DISORDERS;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PACLITAXEL;EPHA5;TT;rs7349683;TOXICITY;INCREASED;RISK;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;WOMEN;OTHER:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
IMATINIB;ABCG2;TT;rs2231142;EFFICACY;INCREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:GASTROINTESTINAL_STROMAL_TUMORS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;NAT2;C;rs4271002;TOXICITY;INCREASED;RISK;SIDE_EFFECT:INTOLERANCE;PEOPLE;DISEASE:ASTHMA;CAUTION_SIDE_EFFECT
OPIOIDS;OPRM1;AG + GG;rs1799971;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:NAUSEA;PEOPLE;OTHER:PAIN, OTHER:POSTOPERATIVE_PAIN;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHADONE;ARRB2;AA;rs3786047;EFFICACY;INCREASED;RISK;EFFICACY:NONRESPONSE_TO_METHADONE_MAINTECE_TREATMENT;PEOPLE;DISEASE:OPIOID-RELATED_DISORDERS;CAUTION_SIDE_EFFECT
BUMETANIDE, FUROSEMIDE, TORASEMIDE;SCNN1G;G;rs5723;EFFICACY;DECREASED;;EFFICACY:24-H_EXCRETION_OF_CALCIUM_AND_DECREASED_URINARY_VOLUME;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
PLATINUM COMPOUNDS;CCN4;GG + GT;rs2929973;EFFICACY;DECREASED;RISK;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;OTHER:LUNG_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ENALAPRIL;SLCO1B1;CC + CT;rs4149056;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:COUGH;PEOPLE;DISEASE:ESSENTIAL_HYPERTENSION;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;HTR2A;TT;rs6311;TOXICITY;INCREASED;RISK;DISEASE:TARDIVE_DYSKINESIA;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
METHADONE;ARRB2;CC;rs1045280;EFFICACY;INCREASED;RISK;EFFICACY:NONRESPONSE_TO_METHADONE_MAINTECE_TREATMENT;PEOPLE;DISEASE:OPIOID-RELATED_DISORDERS;CAUTION_SIDE_EFFECT
METHADONE;MYOCD;AA + AG;rs1714984;EFFICACY;;;EFFICACY:INCREASED_RISK_OF_BEING_NONRESPONDERS;;;CAUTION_DOSE_ADJUST
METHADONE;ARRB2;GG;rs2036657;EFFICACY;INCREASED;RISK;EFFICACY:NONRESPONSE_TO_METHADONE_MAINTECE_TREATMENT;PEOPLE;DISEASE:OPIOID-RELATED_DISORDERS;CAUTION_SIDE_EFFECT
BUMETANIDE, FUROSEMIDE, TORASEMIDE;SCNN1G;A;rs5729;EFFICACY;DECREASED;;EFFICACY:24-H_EXCRETION_OF_CALCIUM_AND_DECREASED_URINARY_VOLUME;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIPSYCHOTICS;CYP1A2;CC;rs762551;TOXICITY;INCREASED;RISK;DISEASE:TARDIVE_DYSKINESIA;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;CYP2D6;A;rs1065852;TOXICITY;INCREASED;RISK;DISEASE:TARDIVE_DYSKINESIA;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
OLANZAPINE;HTR2C;C;rs518147;TOXICITY;DECREASED;RISK;DISEASE:WEIGHT_GAIN;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
PRAVASTATIN;CETP;AG;rs708272;EFFICACY;DECREASED;SEVERITY;EFFICACY:CORONARY_ARTERY_DISEASE;MEN;OTHER:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATORVASTATIN;KIF6;AG + GG;rs20455;EFFICACY;INCREASED;;EFFICACY:BENEFIT;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;ITGB3;TT;rs5918;EFFICACY;;;EFFICACY:ASPIRIN-DEPRESSED_THROMBIN_GENERATION_AND_PROLONGED_BLEEDING_TIME_AFTER_ASPIRIN;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;CAUTION_DOSE_ADJUST
ASPIRIN;F13A1;AA + AC;rs5985;EFFICACY;INCREASED;;EFFICACY:INHIBITION_OF_FXIII_ACTIVATION_BY_ASPIRIN;MEN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
VERAPAMIL;ADRB1;CC + CG;rs1801253;EFFICACY;INCREASED;RISK;DISEASE:DEATH;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;CAUTION_SIDE_EFFECT
AZATHIOPRINE;ITPA;C;rs1127354;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:TRANSPLANT_REJECTION;PEOPLE;OTHER:LIVER_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
CHOP, RITUXIMAB;NCF4;GG;rs1883112;EFFICACY;DECREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;OTHER:LYMPHOMA, LARGE_B-CELL*^DIFFUSE;LIKELIHOOD_THERAPEUTIC_FAILURE
IVACAFTOR;CFTR;AA + AG;rs75527207;EFFICACY;DECREASED;SEVERITY;SIDE_EFFECT:BONE_DENSITY;PEOPLE;DISEASE:CYSTIC_FIBROSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CHOP, RITUXIMAB;ABCG2;CC;rs2231137;EFFICACY;DECREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;OTHER:LYMPHOMA, LARGE_B-CELL*^DIFFUSE;LIKELIHOOD_THERAPEUTIC_FAILURE
PRAVASTATIN;CETP;GG;rs708272;EFFICACY;DECREASED;;EFFICACY:REDUCTION_IN_LUMINAL_DIAMETER;MEN;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
AMIODARONE, DIURETICS, SOTALOL;NOS1AP;T;rs10800397;TOXICITY;;;SIDE_EFFECT:DRUG-INDUCED_VENTRICULAR_ARRHYTHMIA_AND_QT_PROLONGATION;;;CAUTION_DOSE_ADJUST
ANTIPSYCHOTICS;;CT + TT;rs6977820;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:TARDIVE_DYSKINESIA;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
AMIODARONE;NOS1AP;T;rs10800397;TOXICITY;;;SIDE_EFFECT:AMIODARONE-INDUCED_VENTRICULAR_ARRHYTHMIA_AND_QT_PROLONGATION;;;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;T;rs17880887;DOSAGE;;;EFFICACY:LOWER_LEVELS_OF_TRANSTHYRETIN_PRECUROR;;;CAUTION_DOSE_ADJUST
AMIODARONE;NOS1AP;T;rs10919035;TOXICITY;;;SIDE_EFFECT:AMIODARONE-INDUCED_VENTRICULAR_ARRHYTHMIA_AND_QT_PROLONGATION;;;CAUTION_DOSE_ADJUST
ASPIRIN;HNMT;G;rs1050891;TOXICITY;DECREASED;RISK;SIDE_EFFECT:ACETYLSALICYLIC_ACID-INTOLERANT_CHRONIC_URTICARIA;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
AMIODARONE;NOS1AP;T;rs10919035;TOXICITY;;;SIDE_EFFECT:AMIODARONE-INDUCED_VENTRICULAR_ARRHYTHMIA_AND_QT_PROLONGATION;;;CAUTION_DOSE_ADJUST
ASPIRIN;LTC4S;AC + CC;rs730012;TOXICITY;INCREASED;RISK;SIDE_EFFECT:SENSITIVITY_TO_ASPIRIN;;;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;SMYD3;T;rs2485914;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:TARDIVE_DYSKINESIA;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;TT;rs1799929;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HEPATOTOXICTY;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;CC;rs1799929;TOXICITY;DECREASED;RISK;SIDE_EFFECT:HEPATOTOXICTY;PEOPLE;DISEASE:TUBERCULOSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYTARABINE, IDARUBICIN;ABCB1;GG;rs1045642;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:COMPLETE_REMISSION;PEOPLE;DISEASE:ACUTE_MYELOID_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;CYP2C9;AC;rs1057910;DOSAGE;DECREASED;;OTHER:WARFARIN_DOSE_REQUIREMENTS_ON_DAY_14;;;CAUTION_DOSE_ADJUST
LEVONORGESTREL;TP53;CG;rs1042522;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS;WOMEN;;CAUTION_SIDE_EFFECT
ASPIRIN;GP6;AG;rs1613662;EFFICACY;INCREASED;RISK;EFFICACY:NON-RESPONSE_TO_ASPIRIN;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;CAUTION_SIDE_EFFECT
CISPLATIN, DOXORUBICIN, IFOSFAMIDE, METHOTREXATE;ERCC2;CT + TT;rs1799793;EFFICACY;INCREASED;;EFFICACY:EVENT_FREE_SURVIVAL;PEOPLE;DISEASE:OSTEOSARCOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYTARABINE, IDARUBICIN;ABCB1;GG;rs1045642;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:3-YEAR_EVENT_FREE_SURVIVAL;PEOPLE;DISEASE:ACUTE_MYELOID_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN, DOXORUBICIN, IFOSFAMIDE, METHOTREXATE;ERCC2, KLC3;GG;rs13181;EFFICACY;INCREASED;;EFFICACY:EVENT_FREE_SURVIVAL;PEOPLE;DISEASE:OSTEOSARCOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACENOCOUMAROL, PHENPROCOUMON, WARFARIN;CYP4F2;CT + TT;rs2108622;DOSAGE;;;EFFICACY:8.3%_HIGHER_MEAN_DAILY_COUMARIN_DOSE_TO_REACH_A_STABLE_INTERNATIONAL_NORMALIZED_RATIO_(INR);;;CAUTION_DOSE_ADJUST
ASPIRIN;ITGB3;CT;rs5918;TOXICITY;INCREASED;;SIDE_EFFECT:BLOOD_LOSS;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;AA + AG;rs1801133;TOXICITY;INCREASED;RISK;SIDE_EFFECT:LEUKOPENIA, SIDE_EFFECT:THROMBOCYTOPENIA;CHILDREN;OTHER:NON-HODGKIN_LYMPHOMA;CAUTION_SIDE_EFFECT
SUNITINIB;KDR;C;rs2305948;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA, DISEASE:GASTROINTESTINAL_STROMAL_TUMORS;CAUTION_SIDE_EFFECT
CAPECITABINE, EPIRUBICIN, PLATINUM;GSTP1;GG;rs1695;EFFICACY;INCREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;PON1;CT + TT;rs662;EFFICACY;INCREASED;;EFFICACY:ON-CLOPIDOGREL_PLATELET_REACTIVITY_(HPR);PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;ITGB3;CC + CT;rs5918;OTHER;;;OTHER:SHORTER_BLEEDING_TIME;HEALTHY;;CAUTION_DOSE_ADJUST
BETA BLOCKING AGENTS;GRK5;AA;rs2230345;OTHER;INCREASED;RISK;OTHER:DEATH;PEOPLE;OTHER:HEART_FAILURE;CAUTION_SIDE_EFFECT
FENTANYL, HYDROMORPHONE, OXYCODONE;OPRM1;AG + GG;rs1799971;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:PAIN;PEOPLE;OTHER:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;PON1;CT + TT;rs662;EFFICACY;INCREASED;;EFFICACY:ADP-INDUCED_PLATELET_AGGREGATION;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;LIKELIHOOD_THERAPEUTIC_SUCCESS
BEVACIZUMAB;CXCR4;AA + AG;rs2228014;EFFICACY;DECREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
BETA BLOCKING AGENTS;ADRB1;CC;rs1801253;OTHER;DECREASED;RISK;OTHER:DEATH;PEOPLE;OTHER:HEART_FAILURE;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOCETAXEL, FEC100, GEMCITABINE, TRASTUZUMAB, ZOLEDRONATE;PPCDC;G;rs147451859;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:AMENORRHEA;WOMEN;OTHER:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
SUNITINIB;FLT4;GG;rs6877011;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:DISEASE_PROGRESSION;PEOPLE;DISEASE:GASTROINTESTINAL_STROMAL_TUMORS;LIKELIHOOD_THERAPEUTIC_FAILURE
HALOPERIDOL;ABCB5;CT;rs17143212;TOXICITY;INCREASED;;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:PSYCHOTIC_DISORDER;CAUTION_SIDE_EFFECT
DOCETAXEL, FEC100, GEMCITABINE, TRASTUZUMAB, ZOLEDRONATE;;G;rs17587029;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:AMENORRHEA;WOMEN;OTHER:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
SUNITINIB;ABCG2;T;rs2231142;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;CAUTION_SIDE_EFFECT
OPIOIDS;CNIH3;A;rs10799590;TOXICITY;DECREASED;RISK;SIDE_EFFECT:OPIOID-RELATED_DISORDERS;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
AZATHIOPRINE, MERCAPTOPURINE;ITPA;AC + CC;rs7270101;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:THROMBOCYTOPENIA;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
SUNITINIB;VEGFA;CT + TT;rs3025039;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:GASTROINTESTINAL_STROMAL_TUMORS;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;CYP1A2;CC;rs762551;TOXICITY;INCREASED;SEVERITY;DISEASE:TARDIVE_DYSKINESIA;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;A;rs1801133;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:EVENT-FREE_SURVIVAL;PEOPLE;DISEASE:NON-HODGKIN_LYMPHOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
CISPLATIN;SLC22A2;A;rs316019;TOXICITY;DECREASED;RISK;SIDE_EFFECT:OTOTOXICITY;PEOPLE;DISEASE:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
SUNITINIB;CYP3A4;AA + AG;rs4646437;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HYPERTENSION;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;CAUTION_SIDE_EFFECT
ATORVASTATIN;ABCB1;C;rs2032582;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;;;CAUTION_SIDE_EFFECT
"""ACE INHIBITORS, PLAIN"", ""ANGIOTENSIN II ANTAGONISTS""";F5;CT + TT;rs6025;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ANGIOEDEMA;;;CAUTION_SIDE_EFFECT
CISPLATIN;NFE2L2;T;rs6721961;TOXICITY;DECREASED;RISK;SIDE_EFFECT:OTOTOXICITY;PEOPLE;DISEASE:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARVEDILOL;ADRB2;CC;rs1042714;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:IMPROVED_LEFT_VENTRICULAR_EJECTION_FRACTION;PEOPLE;DISEASE:HEART_FAILURE;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;FOXP3;GT + TT;rs3761548;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEPHROTOXICITY;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A4;CC + CT;rs2740574;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:DIABETES_MELLITUS;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;RAVER2;A;rs72675408;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ELEVATED_LIVER_ENZYMES;PEOPLE;OTHER:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
PHENYTOIN;CYP2C9;C;rs1057910;EFFICACY;INCREASED;RISK;SIDE_EFFECT:ATAXIA, SIDE_EFFECT:DIPLOPIA, SIDE_EFFECT:DIZZINESS, SIDE_EFFECT:DYSARTHRIA;PEOPLE;OTHER:EPILEPSY;CAUTION_SIDE_EFFECT
PHENYTOIN;CYP2C9;T;rs1799853;EFFICACY;INCREASED;RISK;SIDE_EFFECT:ATAXIA, SIDE_EFFECT:DIPLOPIA, SIDE_EFFECT:DIZZINESS, SIDE_EFFECT:DYSARTHRIA;PEOPLE;OTHER:EPILEPSY;CAUTION_SIDE_EFFECT
CAPECITABINE, FLUOROURACIL;PPARD;T;rs2016520;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;OTHER:NEOPLASMS;CAUTION_SIDE_EFFECT
EFAVIRENZ;CYP2B6;CT + TT;rs8192719;METABOLISM/PK;INCREASED;;PK:PLASMA_CONCENTRATION;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DOSE_ADJUST
NAN;SULT1A1, SULT1A2;CC + CT;rs1801030;OTHER;INCREASED;LIKELIHOOD;DISEASE:HOT_FLASHES;PEOPLE;OTHER:MENOPAUSE;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;MCOLN1;A;rs116181528;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:OVERDOSE;;;CAUTION_SIDE_EFFECT
CERIVASTATIN, HMG COA REDUCTASE INHIBITORS, ROSUVASTATIN, SIMVASTATIN;SLCO1B1;CC + CT;rs4149056;TOXICITY;INCREASED;RISK;SIDE_EFFECT:MUSCULAR_DISEASES;;;CAUTION_SIDE_EFFECT
NAN;AKT1;CC;rs2494732;OTHER;INCREASED;LIKELIHOOD;DISEASE:PSYCHOTIC_DISORDER;PEOPLE;DISEASE:MARIJUANA_ABUSE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE;MTHFR;GG;rs1801131;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HAND-FOOT_SYNDROME;PEOPLE;DISEASE:GASTROINTESTINAL_NEOPLASMS;CAUTION_SIDE_EFFECT
WARFARIN;VKORC1;G;rs8050894;DOSAGE;DECREASED;;OTHER:WARFARIN_DOSE_REQUIREMENTS_ON_DAY_14;;;CAUTION_DOSE_ADJUST
BEVACIZUMAB;KCNAB1;G;rs6770663;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HYPERTENSION;PEOPLE;OTHER:NEOPLASMS;CAUTION_SIDE_EFFECT
WARFARIN;VKORC1;A;rs9934438;DOSAGE;DECREASED;;OTHER:WARFARIN_DOSE_REQUIREMENTS_ON_DAY_14;;;CAUTION_DOSE_ADJUST
CYCLOPHOSPHAMIDE, EPIRUBICIN;GSTP1;AA + AG;rs1695;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:TOXICITY;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;CEP68;AA;rs7572857;TOXICITY;INCREASED;;SIDE_EFFECT:DECLINE_OF_FORCED_EXPIRATORY_VOLUME_IN_1S_(FEV(1))_BY_ASPIRIN_PROVOCATION;PEOPLE;DISEASE:ASTHMA;CAUTION_SIDE_EFFECT
OPIOIDS;MCOLN1;T;rs114077267;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:OVERDOSE;;;CAUTION_SIDE_EFFECT
ACENOCOUMAROL;VKORC1;TT;rs9923231;EFFICACY;DECREASED;;EFFICACY:TIME_TO_ACHIEVE_STABLE_DOSE;;;LIKELIHOOD_THERAPEUTIC_FAILURE
PLATINUM COMPOUNDS;MDM2;GT + TT;rs2279744;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
SUNITINIB;FLT3;AG + GG;rs1933437;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA, DISEASE:GASTROINTESTINAL_STROMAL_TUMORS;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;TT;rs3745274;METABOLISM/PK;INCREASED;;PK:PLASMA_CONCENTRATION;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DOSE_ADJUST
ASPIRIN;ITGB3;CT;rs5918;EFFICACY;DECREASED;;EFFICACY:PLATELET_INHIBITION_BY_ASPIRIN;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
NAN;SLC2A9;AG;rs62293298;OTHER;DECREASED;LIKELIHOOD;OTHER:HYPERURICEMIA;PEOPLE;OTHER:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
EFAVIRENZ;CYP2B6;GG;rs2279343;METABOLISM/PK;INCREASED;;PK:PLASMA_CONCENTRATION;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DOSE_ADJUST
ASPIRIN;TLR3;CT + TT;rs3775291;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ASPIRIN-EXACERBATED_RESPIRATORY_DISEASE;PEOPLE;DISEASE:ASTHMA;CAUTION_SIDE_EFFECT
EFAVIRENZ;CYP2B6;CC + CT;rs2279345;METABOLISM/PK;DECREASED;;PK:PLASMA_CONCENTRATION;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DOSE_ADJUST
OPIOIDS;MCOLN1;G;rs115208233;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:OVERDOSE;;;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A4;CC + CT;rs2740574;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:ACUTE_CELLULAR_REJECTION;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;DRD2;AA + AG;rs1800497;TOXICITY;INCREASED;;SIDE_EFFECT:CRAVING;CHILDREN;;CAUTION_SIDE_EFFECT
NICOTINE;DRD2;GG;rs1800497;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:CRAVING;CHILDREN;;CAUTION_SIDE_EFFECT
WARFARIN;VKORC1;CC;rs2884737;DOSAGE;DECREASED;;OTHER:WARFARIN_DOSE_REQUIREMENTS_ON_DAY_14;;;CAUTION_DOSE_ADJUST
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IL6;CC;rs1800795;EFFICACY;INCREASED;;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;ABCG2;GT + TT;rs2231142;OTHER;INCREASED;LIKELIHOOD;OTHER:HYPERURICEMIA;PEOPLE;OTHER:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACENOCOUMAROL, WARFARIN;CYP2C9;AG;rs72558189;EFFICACY;INCREASED;;EFFICACY:TIME_TO_ACHIEVE_STABLE_DOSE;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TELBIVUDINE;TK2;CC + CT;rs3826160;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ELEVATED_CIRCULATING_CREATINE_KINASE_CONCENTRATION;PEOPLE;OTHER:HEPATITIS_B, CHRONIC;CAUTION_SIDE_EFFECT
SUNITINIB;FLT1;CC;rs9582036;EFFICACY;DECREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED;;OTHER:WARFARIN_DOSE_REQUIREMENTS_ON_DAY_14;;;CAUTION_DOSE_ADJUST
NAN;SLC22A12;CT;rs3825017;OTHER;INCREASED;LIKELIHOOD;OTHER:HYPERURICEMIA;PEOPLE;OTHER:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACENOCOUMAROL, WARFARIN;CYP4F2;CT + TT;rs2108622;EFFICACY;INCREASED;;EFFICACY:TIME_TO_ACHIEVE_STABLE_DOSE;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SUNITINIB;CYP1A1;C;rs1048943;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA, SIDE_EFFECT:MUCOSITIS;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA, DISEASE:GASTROINTESTINAL_STROMAL_TUMORS;CAUTION_SIDE_EFFECT
OLANZAPINE;DRD2;T;rs2440390;TOXICITY;INCREASED;;DISEASE:WEIGHT_GAIN;PEOPLE;DISEASE:MENTAL_DISORDERS;CAUTION_SIDE_EFFECT
PRAVASTATIN;ADAMTS1;GG;rs428785;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:FATAL_CORONARY_DISEASE_OR_NONFATAL_MYOCARDIAL_INFARCTION;MEN;;LIKELIHOOD_THERAPEUTIC_FAILURE
OLANZAPINE;HTR2C;G;rs6318;TOXICITY;INCREASED;;DISEASE:WEIGHT_GAIN;WOMEN;DISEASE:MENTAL_DISORDERS;CAUTION_SIDE_EFFECT
CAFFEINE;CYP1A2;AA;rs762551;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:NEURAL_TUBE_DEFECTS;WOMEN;OTHER:WHO_ARE_PREGNANT;CAUTION_SIDE_EFFECT
OLANZAPINE;HTR2C;C;rs2497538;TOXICITY;INCREASED;;DISEASE:WEIGHT_GAIN;WOMEN;DISEASE:MENTAL_DISORDERS;CAUTION_SIDE_EFFECT
OLANZAPINE;HTR2C;G;rs1414334;TOXICITY;INCREASED;;DISEASE:WEIGHT_GAIN;WOMEN;DISEASE:MENTAL_DISORDERS;CAUTION_SIDE_EFFECT
VINCRISTINE;CEP72;TT;rs924607;TOXICITY;INCREASED;RISK;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
PIOGLITAZONE;LPL;CG + GG;rs328;EFFICACY;DECREASED;;EFFICACY:RESPONSE_RATE_AFTER_10_WEEKS_OF_PIOGLITAZONE_TREATMENT;PEOPLE;DISEASE:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_FAILURE
PACLITAXEL;EPHA5;CT + TT;rs7349683;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;;;CAUTION_SIDE_EFFECT
NAN;SCN1A;T;rs3812718;OTHER;INCREASED;RISK;DISEASE:SEIZURES, FEBRILE;PEOPLE;DISEASE:EPILEPSY;CAUTION_SIDE_EFFECT
NAN;UGT1A1;AA + AG;rs4148323;OTHER;INCREASED;SEVERITY;OTHER:NEONATAL_HYPERBILIRUBINEMIA, OTHER:HYPERBILIRUBINEMIA;CHILDREN;;CAUTION_SIDE_EFFECT
NAN;CHRNA5;A;rs16969968;OTHER;INCREASED;SEVERITY;OTHER:TOBACCO_USE_DISORDER;PEOPLE;OTHER:TOBACCO_USE_DISORDER;CAUTION_SIDE_EFFECT
PACLITAXEL;ABCB1;AG + GG;rs3213619;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
VERAPAMIL;NOS1AP;GG;rs10494366;TOXICITY;INCREASED;RISK;SIDE_EFFECT:QTC_PROLONGATION;;;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;PACSIN2;TT;rs2413739;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ADVERSE_EVENTS;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
NAN;;A;rs1051730;OTHER;INCREASED;SEVERITY;OTHER:TOBACCO_USE_DISORDER;PEOPLE;OTHER:TOBACCO_USE_DISORDER;CAUTION_SIDE_EFFECT
NAN;CYP2R1;A;rs12794714;OTHER;INCREASED;LIKELIHOOD;OTHER:VITAMIN_D_DEFICIENCY;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OLANZAPINE;ABCB1;AA;rs1045642;EFFICACY;INCREASED;;EFFICACY:SOCIAL_AND_CLINICAL_NEEDS;PEOPLE;DISEASE:PSYCHOTIC_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B, RIBAVIRIN, SIMEPREVIR;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHAMBUTOL, ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;A;rs1799930;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE;PEOPLE;OTHER:TUBERCULOSIS;CAUTION_SIDE_EFFECT
NAN;CYP2R1;A;rs10741657;OTHER;DECREASED;LIKELIHOOD;OTHER:VITAMIN_D_DEFICIENCY;;;LIKELIHOOD_THERAPEUTIC_FAILURE
ETHAMBUTOL, ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;T;rs1799929;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE;PEOPLE;OTHER:TUBERCULOSIS;CAUTION_SIDE_EFFECT
ATORVASTATIN;SLCO1B1;CC + CT;rs4149056;TOXICITY;INCREASED;RISK;SIDE_EFFECT:STATIN-RELATED_MYOPATHY;;;CAUTION_SIDE_EFFECT
PAROXETINE;HTR1A;GG;rs6295;EFFICACY;INCREASED;;EFFICACY:RESPONSE_AT_4_WEEKS_AFTER_THE_INITIATION_OF_TREATMENT;PEOPLE;DISEASE:PANIC_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
TAMOXIFEN;E2F7;CC;rs310786;TOXICITY;INCREASED;;SIDE_EFFECT:LUMBAR_BONE_LOSS;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
ALENDRONATE;DKK1;AA;rs2241529;EFFICACY;DECREASED;;EFFICACY:BONE_DENSITY;WOMEN;DISEASE:METABOLIC_BONE_DISORDER, DISEASE:OSTEOPOROSIS;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CES1;G;rs8192950;EFFICACY;DECREASED;RISK;EFFICACY:TRANSIENT_ISCHEMIC_ATTACK, EFFICACY:STROKE;PEOPLE;OTHER:CEREBROVASCULAR_DISORDERS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIPSYCHOTICS;DRD2;GG;rs1799732;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:SIDE_EFFECTS;;;CAUTION_SIDE_EFFECT
SUNITINIB;KDR;CC;rs2305948;EFFICACY;DECREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;CYP2C9;C;rs4918758;DOSAGE;DECREASED;;OTHER:WARFARIN_DOSE_REQUIREMENT_IN_MECHANICAL_HEART_VALVE_REPLACEMENT_PATIENTS;;;CAUTION_DOSE_ADJUST
SUNITINIB;VEGFA;CC;rs3025039;EFFICACY;DECREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
SIMVASTATIN;SLCO1B1;CC + CT;rs4149056;TOXICITY;INCREASED;RISK;SIDE_EFFECT:STATIN-RELATED_MYOPATHY;;;CAUTION_SIDE_EFFECT
OLANZAPINE;ANKK1;GG;rs1800497;OTHER;DECREASED;;PK:AREA_UNDER_THE_CURVE_FROM_BASELINE_TO_THE_LAST_MEASURED_CONCENTRATION;HEALTHY;;CAUTION_DOSE_ADJUST
EXEMESTANE;ESR1;CC;rs9322336;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:MUSCULOSKELETAL_TOXICITY;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;T;rs9332096;DOSAGE;DECREASED;;OTHER:WARFARIN_DOSE_REQUIREMENT_IN_MECHANICAL_HEART_VALVE_REPLACEMENT_PATIENTS;;;CAUTION_DOSE_ADJUST
OLANZAPINE;ANKK1;GG;rs1800497;OTHER;DECREASED;;OTHER:PEAK_PLASMA_CONCENTRATION_OF_INCREASED_PROLACTIN;HEALTHY;;CAUTION_DOSE_ADJUST
SUNITINIB;VEGFA;G;rs2010963;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HYPERTENSION;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;CAUTION_SIDE_EFFECT
SUNITINIB;FLT4;C;rs6877011;EFFICACY;INCREASED;;EFFICACY:OVERALL_SURVIVAL, EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
OLANZAPINE;GSTP1;AA;rs1695;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:SYNCOPE;HEALTHY;;CAUTION_SIDE_EFFECT
SUNITINIB;NR1I2;TT;rs2276707;EFFICACY;DECREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;VKORC1;AG + GG;rs9934438;DOSAGE;INCREASED;;OTHER:WARFARIN_DOSE;;;CAUTION_DOSE_ADJUST
ANTHRACYCLINES AND RELATED SUBSTANCES;HAS3;AA;rs2232228;TOXICITY;INCREASED;RISK;DISEASE:CARDIOMYOPATHIES;CHILDREN;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED;;OTHER:WARFARIN_DOSE;;;CAUTION_DOSE_ADJUST
SUNITINIB;FLT3;AG + GG;rs1933437;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:THROMBOCYTOPENIA;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA, DISEASE:GASTROINTESTINAL_STROMAL_TUMORS;LIKELIHOOD_THERAPEUTIC_SUCCESS
NORTRIPTYLINE;ABCB1;AA;rs1045642;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:ORTHOSTATIC_HYPOTENSION;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_SIDE_EFFECT
WARFARIN;VKORC1;A;rs2359612;DOSAGE;DECREASED;;OTHER:WARFARIN_DOSE;;;CAUTION_DOSE_ADJUST
MORPHINE, OXYCODONE;OPRM1;GG;rs1799971;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:SOMNOLENCE;PEOPLE;OTHER:LUNG_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
MORPHINE, OXYCODONE;COMT;GG;rs4680;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:SOMNOLENCE;PEOPLE;OTHER:LUNG_NEOPLASMS;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HNF4A;GG;rs2071197;EFFICACY;INCREASED;;PK:CONCENTRATION-TO-DOSE_RATIOS;PEOPLE;DISEASE:EPILEPSY;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;G;rs8050894;DOSAGE;DECREASED;;OTHER:WARFARIN_DOSE;;;CAUTION_DOSE_ADJUST
PRAVASTATIN;MTHFR;GG;rs1801133;EFFICACY;DECREASED;LIKELIHOOD;DISEASE:CORONARY_ARTERY_DISEASE, DISEASE:MYOCARDIAL_INFARCTION;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_FAILURE
SUNITINIB;ABCB1;AA;rs1128503;EFFICACY;DECREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
SUNITINIB;VEGFA;CC + CT;rs833061;EFFICACY;INCREASED;;EFFICACY:OVERALL_SURVIVAL, EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOSPORINE, MYCOPHENOLATE MOFETIL;IMPDH2;AG + GG;rs11706052;EFFICACY;INCREASED;RISK;DISEASE:TRANSPLANT_REJECTION;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
CYCLOSPORINE, MYCOPHENOLATE MOFETIL;TNF;AA + AG;rs1800629;EFFICACY;INCREASED;RISK;DISEASE:TRANSPLANT_REJECTION;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;GG;rs1801131;TOXICITY;INCREASED;RISK;SIDE_EFFECT:MUCOSITIS;PEOPLE;DISEASE:NON-HODGKIN_LYMPHOMA;CAUTION_SIDE_EFFECT
CYCLOSPORINE, MYCOPHENOLATE MOFETIL;IL10;TT;rs1800872;EFFICACY;INCREASED;RISK;EFFICACY:TRANSPLANT_REJECTION;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
SUNITINIB;ABCB1;AA + AT;rs2032582;EFFICACY;DECREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;A;rs4986893;EFFICACY;INCREASED;RISK;EFFICACY:TRANSIENT_ISCHEMIC_ATTACK, EFFICACY:STROKE;PEOPLE;OTHER:CEREBROVASCULAR_DISORDERS;CAUTION_SIDE_EFFECT
SUNITINIB;VEGFA;G;rs2010963;EFFICACY;INCREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;CHRNA5;A;rs16969968;OTHER;INCREASED;SEVERITY;OTHER:SMOKING;PEOPLE;OTHER:SCHIZOPHRENIA_WHO_ARE_SMOKERS;CAUTION_SIDE_EFFECT
NICOTINE;CHRNA5;A;rs16969968;OTHER;INCREASED;SEVERITY;OTHER:SMOKING;PEOPLE;OTHER:SMOKING;CAUTION_SIDE_EFFECT
NAN;CHRNA5;A;rs16969968;OTHER;INCREASED;LIKELIHOOD;DISEASE:SCHIZOPHRENIA;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;MTHFR;AA;rs1801133;TOXICITY;INCREASED;RISK;SIDE_EFFECT:MUCOSITIS;PEOPLE;DISEASE:NON-HODGKIN_LYMPHOMA;CAUTION_SIDE_EFFECT
CLOPIDOGREL;N6AMT1;GG;rs2254638;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY;PEOPLE;OTHER:ACUTE_CORONARY_SYNDROME;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;MTHFR;AA;rs1801133;EFFICACY;INCREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;MTHFR;AA;rs1801133;TOXICITY;INCREASED;RISK;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;AA;rs1801133;TOXICITY;INCREASED;RISK;SIDE_EFFECT:THROMBOCYTOPENIA, SIDE_EFFECT:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:NON-HODGKIN_LYMPHOMA;CAUTION_SIDE_EFFECT
NICOTINE;GALR1;CT + TT;rs2717162;OTHER;INCREASED;SEVERITY;OTHER:CRAVING;PEOPLE;DISEASE:TOBACCO_USE_DISORDER;CAUTION_SIDE_EFFECT
CAPECITABINE, FLUOROURACIL;DPYD;A;rs67376798;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
CAPECITABINE, FLUOROURACIL;DPYD;T;rs3918290;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
ERYTHROMYCIN;SLCO1B1;C;rs4149056;METABOLISM/PK;DECREASED;;PK:ERYTHROMYCIN_METABOLISM;PEOPLE;DISEASE:NEOPLASMS;CAUTION_DOSE_ADJUST
PAZOPANIB, SIMVASTATIN;ABCG2;GT + TT;rs2231142;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
GENTAMICIN;MT-RNR1;G;rs267606617;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OTOTOXICITY;INFANTS;;CAUTION_SIDE_EFFECT
CYCLOSPORINE, TACROLIMUS;LEP;A;rs2167270;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:DIABETES_MELLITUS;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
ERLOTINIB;ABCB1;AA;rs1045642;TOXICITY, METABOLISM/PK;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;NUDT15;GT;rs73189762;DOSAGE;INCREASED;LIKELIHOOD;SIDE_EFFECT:MYELOSUPPRESSION;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DOSE_ADJUST
ETHANOL;HTR3B;C;rs1176744;OTHER;INCREASED;LIKELIHOOD;DISEASE:ALCOHOL_ABUSE;MEN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;T;rs12248560;TOXICITY;DECREASED;;SIDE_EFFECT:CARDIOVASCULAR_EVENTS;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;MTHFR;AA;rs1801133;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:MUCOSITIS;PEOPLE;DISEASE:HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION;CAUTION_SIDE_EFFECT
METHOTREXATE;ADORA2A, SPECC1L;G;rs5760410;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ADVERSE_EVENTS;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
CALCIUM CHANNEL BLOCKERS, NITRENDIPINE;KCNH2;AA + AG;rs1137617;EFFICACY;INCREASED;;EFFICACY:REDUCTION_IN_BLOOD_PRESSURE;PEOPLE;DISEASE:ESSENTIAL_HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;KDR;CC;rs7667298;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:ANGINA_PECTORIS;PEOPLE;DISEASE:CORONARY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;MTHFR;G;rs1801131;EFFICACY;INCREASED;RISK;DISEASE:GRAFT_VS_HOST_DISEASE;PEOPLE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;AA;rs1801133;EFFICACY;DECREASED;RISK;DISEASE:GRAFT_VS_HOST_DISEASE;PEOPLE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;GALR1;CT + TT;rs2717162;OTHER;INCREASED;SEVERITY;OTHER:CRAVING;PEOPLE;DISEASE:TOBACCO_USE_DISORDER;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC AGENTS;CLCN6, MTHFR;GG;rs1801133;EFFICACY;INCREASED;;EFFICACY:PROGRESSION_FREE_SURVIVAL;PEOPLE;DISEASE:CHRONIC_B-CELL_LYMPHOCITIC_LEUKEMIA,;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN;UGT1A1;AG;rs4148323;TOXICITY;INCREASED;SEVERITY;DISEASE:NEUTROPENIA;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
NAN;MTHFR;G;rs1801131;EFFICACY;INCREASED;;EFFICACY:PROGRESSION_FREE_SURVIVAL;PEOPLE;DISEASE:CHRONIC_B-CELL_LYMPHOCITIC_LEUKEMIA,;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUSULFAN, CYCLOPHOSPHAMIDE, METHOTREXATE;MTHFR;AA;rs1801133;TOXICITY;INCREASED;RISK;SIDE_EFFECT:MUCOSITIS;;;CAUTION_SIDE_EFFECT
ERLOTINIB;ABCB1;AA;rs1128503;TOXICITY, METABOLISM/PK;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;GG;rs1801131;EFFICACY;DECREASED;RISK;EFFICACY:RELAPSE;PEOPLE;OTHER:ALLOGENEIC_HEMATOPOIETIC_CELL_TRANSPLANTATION_FOR_CHRONIC_MYELOGENOUS_LEUKEMIA.;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;KDR;TT;rs2305948;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ANGINA_PECTORIS, SIDE_EFFECT:MYOCARDIAL_INFARCTION;PEOPLE;DISEASE:CORONARY_DISEASE;CAUTION_SIDE_EFFECT
METHOTREXATE;ABCB1;GG;rs1128503;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:MUCOSITIS;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;AA;rs1801133;TOXICITY;INCREASED;RISK;SIDE_EFFECT:MUCOSITIS;PEOPLE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;GG;rs1801131;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:ORAL_MUCOSITIS;PEOPLE;OTHER:HEMATOPOIETIC-CELL-TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;MTHFR;AA;rs1801133;TOXICITY;INCREASED;RISK;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:LEUKEMIA;CAUTION_SIDE_EFFECT
WARFARIN;VKORC1;TT;rs9923231;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HEMORRHAGE;PEOPLE;DISEASE:ATRIAL_FIBRILLATION;CAUTION_SIDE_EFFECT
ERLOTINIB;ABCB1;AA;rs2032582;TOXICITY, METABOLISM/PK;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
WARFARIN;VKORC1;TT;rs9923231;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OVER-ANTICOAGULATION;PEOPLE;DISEASE:ATRIAL_FIBRILLATION;CAUTION_SIDE_EFFECT
PACLITAXEL;ARHGEF10;C;rs9657362;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;PEOPLE;DISEASE:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;FKBP5;CC + CT;rs1360780;NAN;INCREASED;RISK;OTHER:POST-TRAUMATIC_STRESS_DISORDER_(PTSD);PEOPLE;OTHER:HISTORY_OF_CHILD_ABUSE;CAUTION_SIDE_EFFECT
NAN;FKBP5;AA + AC;rs3800373;OTHER;INCREASED;RISK;DISEASE:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY;PEOPLE;OTHER:HISTORY_OF_CHILD_ABUSE;CAUTION_SIDE_EFFECT
PACLITAXEL;ARHGEF10;C;rs9657362;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;PEOPLE;DISEASE:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;TBX21;A;rs17244587;NAN;INCREASED;RISK;DISEASE:MAJOR_DEPRESSIVE_DISORDER;;;CAUTION_SIDE_EFFECT
NAN;PSMB4;T;rs2296840;OTHER;INCREASED;RISK;DISEASE:MAJOR_DEPRESSIVE_DISORDER;;;CAUTION_SIDE_EFFECT
METFORMIN;SLC22A1;A;rs34059508;DOSAGE, METABOLISM/PK;INCREASED;;PK:BIOAVAILABILITY;;;CAUTION_DOSE_ADJUST
METFORMIN;SLC22A1;C;rs12208357;DOSAGE, METABOLISM/PK;INCREASED;;PK:BIOAVAILABILITY_(AUC, CL_&_AUC/CL_RATIO);;;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;T;rs12248560;TOXICITY;INCREASED;RISK;SIDE_EFFECT:BLEEDING_EVENTS;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;A;rs4244285;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DEATH;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;CAUTION_SIDE_EFFECT
NAN;CHRNA5;C;rs680244;OTHER;INCREASED;RISK;DISEASE:TOBACCO_USE_DISORDER;;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;A;rs4244285;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ISCHAEMIC_EVENTS;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;A;rs4244285;TOXICITY;INCREASED;RISK;SIDE_EFFECT:CARDIOVASCULAR_EVENTS;PEOPLE;OTHER:PERCUTANEOUS_CORONARY_INTERVENTION;CAUTION_SIDE_EFFECT
METHOTREXATE;PTPN22;AA;rs2476601;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DISCONTINUATION;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
NAN;CHRNA3;G;rs1051730;NAN;INCREASED;RISK;DISEASE:TOBACCO_USE_DISORDER;;;CAUTION_SIDE_EFFECT
METHOTREXATE;TNFAIP3;A;rs6920220;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DISCONTINUATION;PEOPLE;DISEASE:ARTHRITIS;CAUTION_SIDE_EFFECT
NAN;CHRNA3, CHRNA5;G;rs578776;NAN;INCREASED;RISK;DISEASE:TOBACCO_USE_DISORDER;;;CAUTION_SIDE_EFFECT
SUNITINIB;ABCG2;TT;rs2231142;TOXICITY;DECREASED;RISK;SIDE_EFFECT:NEUTROPENIA;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;CHRNA5;A;rs16969968;NAN;INCREASED;RISK;DISEASE:TOBACCO_USE_DISORDER;;;CAUTION_SIDE_EFFECT
RISPERIDONE;ABCB1;AA;rs1045642;METABOLISM/PK;INCREASED;SEVERITY;SIDE_EFFECT:HYPERPROLACTINEMIA;WOMEN;DISEASE:BIPOLAR_DISORDER, DISEASE:SCHIZOAFFECTIVE_DISORDER,DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
NAN;CHRNA5;C;rs569207;NAN;INCREASED;RISK;DISEASE:TOBACCO_USE_DISORDER;;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE, PHENOBARBITAL, PHENYTOIN, VALPROIC ACID;CYP1A1;A;rs2606345;EFFICACY, METABOLISM/PK;INCREASED;RISK;DISEASE:SEIZURES;PEOPLE;DISEASE:EPILEPSY;CAUTION_SIDE_EFFECT
NAN;SLCO1B3;C;rs2417940;OTHER;INCREASED;SEVERITY;OTHER:NEONATAL_HYPERBILIRUBINEMIA, OTHER:HYPERBILIRUBINEMIA;CHILDREN;;CAUTION_SIDE_EFFECT
SERTRALINE;;G;rs13432159;TOXICITY;INCREASED;;SIDE_EFFECT:GENERAL_SIDE-EFFECTS;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_SIDE_EFFECT
HMG_COA_REDUCTASE_INHIBITORS;SLCO1B1;CC + CT;rs4149056;TOXICITY;INCREASED;RISK;SIDE_EFFECT:STATIN-RELATED_MYOPATHY;;;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;TT;rs3892097;EFFICACY;INCREASED;;EFFICACY:DISEASE_FREE_SURVIVAL;PEOPLE;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
SIMVASTATIN;SLCO1B1;CC + CT;rs4149056;TOXICITY;INCREASED;RISK;SIDE_EFFECT:STATIN-RELATED_MYOPATHY;;;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;TT;rs3892097;EFFICACY;DECREASED;;EFFICACY:DISEASE_FREE_SURVIVAL;PEOPLE;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;CYP2D6;TT;rs3892097;EFFICACY;DECREASED;;EFFICACY:RELAPSE_FREE_TIME;PEOPLE;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
NAN;KIF6;AG + GG;rs20455;OTHER;INCREASED;RISK;DISEASE:MYOCARDIAL_INFARCTION;;;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2B, RIBAVIRIN;ITPA;A;rs1127354;TOXICITY;DECREASED;;SIDE_EFFECT:ANEMIA;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ROSUVASTATIN;GATM;AA + AG;rs9806699;TOXICITY;DECREASED;RISK;SIDE_EFFECT:STATIN-RELATED_MYOPATHY;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TAMOXIFEN;CYP2D6;T;rs3892097;EFFICACY;DECREASED;;EFFICACY:EVENT-FREE_SURVIVAL;PEOPLE;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
HMG_COA_REDUCTASE_INHIBITORS;SLCO1B1;CC + CT;rs4363657;TOXICITY;DECREASED;RISK;SIDE_EFFECT:STATIN-RELATED_MYOPATHY;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B, RIBAVIRIN;ITPA;C;rs7270101;TOXICITY;DECREASED;;SIDE_EFFECT:ANEMIA;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN;UGT1A1;AA;rs4148323;TOXICITY;INCREASED;SEVERITY;DISEASE:NEUTROPENIA;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
FLUOROURACIL, IRINOTECAN, OXALIPLATIN;GSTP1;AA;rs1695;TOXICITY;INCREASED;RISK;DISEASE:NEUROTOXICITY_SYNDROMES, SIDE_EFFECT:NEUTROPENIA;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
PRAVASTATIN;IL1B;GG;rs16944;OTHER;INCREASED;;OTHER:CORONARY_FLOW_RESERVE;MEN;;CAUTION_DOSE_ADJUST
HMG_COA_REDUCTASE_INHIBITORS;;G;rs116561224;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;;;CAUTION_SIDE_EFFECT
NAN;KCNH2;T;rs3815459;OTHER;INCREASED;;OTHER:QT_INTERVAL;;;CAUTION_DOSE_ADJUST
FENOFIBRATE, SERTRALINE, TERBINAFINE, TICLOPIDINE;;C;rs114577328;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;;;CAUTION_SIDE_EFFECT
ANTIDEPRESSANTS;HTR2A;CC;rs17288723;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:REMISSION;PEOPLE;DISEASE:DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;KCNH2;CT + TT;rs3807375;OTHER;INCREASED;;OTHER:QT_INTERVAL;;;CAUTION_DOSE_ADJUST
CITALOPRAM;GRIK4;C;rs1954787;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:NON-RESPONSE;PEOPLE;DISEASE:DEPRESSION;LIKELIHOOD_THERAPEUTIC_FAILURE
NAN;KCNH2;GT + TT;rs1805123;OTHER;INCREASED;;OTHER:QT_INTERVAL;;;CAUTION_DOSE_ADJUST
CYCLOSPORINE;NR1I2;C;rs2276707;DOSAGE, METABOLISM/PK;DECREASED;;PK:BIOAVAILABILITY;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;CT + TT;rs1799929;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;;;CAUTION_SIDE_EFFECT
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;AA + AG;rs1799930;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;;;CAUTION_SIDE_EFFECT
PLATINUM COMPOUNDS;GSTP1;G;rs1695;TOXICITY, METABOLISM/PK;DECREASED;RISK;DISEASE:NEUTROPENIA;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOZAPINE;;T;rs149104283;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUTROPENIA;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;AA + AG;rs1799931;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;;;CAUTION_SIDE_EFFECT
NAN;KCNH2;G;rs1805123;OTHER;DECREASED;;OTHER:QT_INTERVAL;;;CAUTION_DOSE_ADJUST
ASPARAGINASE, CYCLOPHOSPHAMIDE, DAUNORUBICIN, PREDNISOLONE, VINCRISTINE;PNPLA3;CG + GG;rs738409;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
NAN;KCNH2;T;rs3807375;OTHER;INCREASED;;OTHER:QT_INTERVAL;;;CAUTION_DOSE_ADJUST
OXALIPLATIN;GSTP1;GG;rs1695;TOXICITY;INCREASED;SEVERITY;DISEASE:NEUROTOXICITY_SYNDROMES;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
NAN;KCNQ1;G;rs757092;OTHER;INCREASED;;OTHER:QT_INTERVAL;;;CAUTION_DOSE_ADJUST
NAN;KCNH2;T;rs3815459;OTHER;INCREASED;;OTHER:QT_INTERVAL;;;CAUTION_DOSE_ADJUST
PRAVASTATIN;IL1B;GG;rs16944;OTHER;INCREASED;;OTHER:ADENOSINE-STIMULATED_MYOCARDIAL_FLOW;MEN;;CAUTION_DOSE_ADJUST
NAN;VEGFA;CG + GG;rs2010963;OTHER;INCREASED;RISK;OTHER:PREMATURE_BIRTH;WOMEN;;CAUTION_SIDE_EFFECT
NAN;KCNH2;GG;rs1805123;OTHER;DECREASED;;OTHER:QT_INTERVAL;;;CAUTION_DOSE_ADJUST
NAN;KCNQ1;G;rs757092;OTHER;INCREASED;;OTHER:QT_INTERVAL;;;CAUTION_DOSE_ADJUST
OXALIPLATIN;GSTP1;AA;rs1695;TOXICITY, METABOLISM/PK;INCREASED;SEVERITY;DISEASE:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;PEOPLE;DISEASE:GASTROINTESTINAL_NEOPLASMS;CAUTION_SIDE_EFFECT
METHOTREXATE;SLCO1B1;TT;rs4149056;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:INFECTIOUS_DISEASE;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
CYCLOSPORINE;NR1I2;T;rs2276707;DOSAGE, METABOLISM/PK;INCREASED;;PK:BIOAVAILABILITY;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
RIFAMPIN;NR1I2;TT;rs3814055;OTHER;INCREASED;;PK:ERYTHROMYCIN_BREATH_TEST;;;CAUTION_DOSE_ADJUST
PLATINUM COMPOUNDS;CCN4;CC + CT;rs2977549;EFFICACY;DECREASED;RISK;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;OTHER:LUNG_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CITALOPRAM;HTR2A;AA;rs7997012;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:RESPONSE;PEOPLE;DISEASE:DEPRESSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A4;CC + TT;rs2740574;TOXICITY, METABOLISM/PK;INCREASED;RISK;SIDE_EFFECT:NEPHROTOXICITY;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
CITALOPRAM;HTR2A;A;rs7997012;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:RESPONSE;PEOPLE;DISEASE:DEPRESSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;T;rs776746;TOXICITY, METABOLISM/PK;INCREASED;RISK;SIDE_EFFECT:NEPHROTOXICITY;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
CYCLOSPORINE;NR1I2;C;rs3814055;DOSAGE, METABOLISM/PK;DECREASED;;PK:BIOAVAILABILTY;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
ASPIRIN, CLOPIDOGREL;MYOM2;CC + CT;rs17064642;EFFICACY;INCREASED;RISK;EFFICACY:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE);PEOPLE;OTHER:ACUTE_CORONARY_SYNDROME;CAUTION_SIDE_EFFECT
ANTIDEPRESSANTS;HTR2A;G;rs7997012;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:REMISSION;PEOPLE;DISEASE:DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
CITALOPRAM;HTR2A;A;rs7997012;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:RESPONSE;PEOPLE;DISEASE:DEPRESSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
SUFENTANIL;COMT;AA + AG;rs4680;DOSAGE;INCREASED;SEVERITY;EFFICACY:PAIN;PEOPLE;OTHER:PREGNANCY;CAUTION_DOSE_ADJUST
ANTIDEPRESSANTS;GRIK4;CC;rs1954787;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:REMISSION;PEOPLE;DISEASE:DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
SUFENTANIL;OPRM1;AG + GG;rs1799971;DOSAGE;DECREASED;SEVERITY;EFFICACY:PAIN;PEOPLE;OTHER:PREGNANCY;CAUTION_DOSE_ADJUST
ANTIDEPRESSANTS;GRIK4;GG;rs12800734;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:REMISSION;PEOPLE;DISEASE:DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
PRAVASTATIN;KIF6;AG + GG;rs20455;EFFICACY;DECREASED;RISK;DISEASE:MYOCARDIAL_INFARCTION;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;KIF6;AG + GG;rs20455;OTHER;INCREASED;RISK;DISEASE:CORONARY_DISEASE;;;CAUTION_SIDE_EFFECT
PRAVASTATIN;SLCO1B1;G;rs2306283;METABOLISM/PK;DECREASED;;PK:PLASMA_AUC;;;CAUTION_DOSE_ADJUST
PRAVASTATIN;SLCO1B1;AG;rs4149015;OTHER, METABOLISM/PK;INCREASED;;PK:AUC0-12;HEALTHY;;CAUTION_DOSE_ADJUST
MERCAPTOPURINE;NUDT15;CT + TT;rs116855232;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA;PEOPLE;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;NUDT15;CT + TT;rs116855232;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA;PEOPLE;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
PLATINUM COMPOUNDS;CCN4;CC + CT;rs2977551;EFFICACY;DECREASED;RISK;EFFICACY:OVERALL_SURVIVAL, EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;OTHER:LUNG_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;ABCB1;AA;rs1045642;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY;PEOPLE;OTHER:ACUTE_CORONARY_SYNDROME;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL;TP53;GG;rs1042522;EFFICACY;DECREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:STOMACH_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON ALFA-2A, RIBAVIRIN;ITPA;AC + CC;rs6051702;TOXICITY;DECREASED;RISK;SIDE_EFFECT:ANEMIA;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;CHRNA3, CHRNA5;GG;rs578776;TOXICITY;INCREASED;LIKELIHOOD;OTHER:SMOKING_CESSATION;PEOPLE;OTHER:LUNG_NEOPLASMS;CAUTION_SIDE_EFFECT
NICOTINE;CHRNA4;AA;rs1044396;TOXICITY;INCREASED;LIKELIHOOD;OTHER:SMOKING_CESSATION;PEOPLE;OTHER:LUNG_NEOPLASMS;CAUTION_SIDE_EFFECT
NICOTINE;CHRNA4;CC;rs2229959;TOXICITY;INCREASED;LIKELIHOOD;OTHER:SMOKING_CESSATION;PEOPLE;OTHER:LUNG_NEOPLASMS;CAUTION_SIDE_EFFECT
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;COMT, TXNRD2;T;rs13306278;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:REMISSION;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
PRAVASTATIN;TLR4;AG + GG;rs4986790;EFFICACY;DECREASED;RISK;EFFICACY:CARDIOVASCULAR_EVENTS;MEN;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PHENPROCOUMON;VKORC1;TT;rs9923231;EFFICACY;INCREASED;RISK;SIDE_EFFECT:OVER-ANTICOAGULATION;;;CAUTION_SIDE_EFFECT
AMINOGLYCOSIDE ANTIBACTERIALS;MT-RNR1;G;rs267606617;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OTOTOXICITY;;;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2A, RIBAVIRIN;VDR;TT;rs1544410;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ANEMIA;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;CAUTION_SIDE_EFFECT
PHENPROCOUMON;VKORC1;TT;rs9923231;TOXICITY;INCREASED;;SIDE_EFFECT:TIME_ABOVE_THERAPEUTIC_RANGE;;;CAUTION_SIDE_EFFECT
ACENOCOUMAROL;VKORC1;CT + TT;rs9923231;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:TIME_ABOVE_THERAPEUTIC_RANGE;;;CAUTION_SIDE_EFFECT
FLUOROURACIL;IGFBP3;CC;rs2854746;EFFICACY;;;OTHER:BETTER_SURVIVAL_OUTCOME;PEOPLE;DISEASE:STOMACH_NEOPLASMS;CAUTION_DOSE_ADJUST
PHENPROCOUMON;VKORC1;TT;rs9923231;EFFICACY;INCREASED;;EFFICACY:TIME_TO_ACHIEVE_STABLE_DOSE;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM COMPOUNDS;GSTP1;AA;rs1695;EFFICACY;INCREASED;RISK;EFFICACY:DYING;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
PLATINUM COMPOUNDS;ERCC2, KLC3;GG;rs13181;EFFICACY;INCREASED;RISK;EFFICACY:DYING;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
PHENPROCOUMON;EPHX1;CC;rs1051740;TOXICITY;INCREASED;;SIDE_EFFECT:TIME_ABOVE_THERAPEUTIC_RANGE;;;CAUTION_SIDE_EFFECT
PLATINUM COMPOUNDS;ERCC1;AA;rs11615;EFFICACY;INCREASED;RISK;EFFICACY:DYING;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
CLOPIDOGREL;ABCB1;AA;rs2032582;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY;PEOPLE;OTHER:ACUTE_CORONARY_SYNDROME;LIKELIHOOD_THERAPEUTIC_FAILURE
PLATINUM COMPOUNDS;GSTP1;AA;rs1695;EFFICACY;INCREASED;RISK;EFFICACY:DISEASE_PROGRESSION;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
CARBOPLATIN, PACLITAXEL;NR1I2;TT;rs1523130;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:THROMBOCYTOPENIA;PEOPLE;DISEASE:LUNG_NEOPLASMS, DISEASE:PERITONEUM_CANCER,DISEASE:NEOPLASMS, DISEASE:OVARIAN_NEOPLASMS, DISEASE:UTERINE_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
AZATHIOPRINE;NUDT15;T;rs116855232;TOXICITY;INCREASED;RISK;SIDE_EFFECT:LEUKOPENIA;PEOPLE;DISEASE:INFLAMMATORY_BOWEL_DISEASES, DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
CETUXIMAB;EGF;AA;rs4444903;EFFICACY;INCREASED;;EFFICACY:SURVIVAL;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBOPLATIN, PACLITAXEL;NR1I2;CC;rs1523127;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:THROMBOCYTOPENIA;PEOPLE;DISEASE:LUNG_NEOPLASMS, DISEASE:PERITONEUM_CANCER,DISEASE:NEOPLASMS, DISEASE:OVARIAN_NEOPLASMS, DISEASE:UTERINE_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN;UGT1A1;AA + AG;rs10929302;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:NEUTROPENIA;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
CARBOPLATIN, PACLITAXEL;SLCO1B3;GT + TT;rs4149117;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:THROMBOCYTOPENIA;PEOPLE;DISEASE:LUNG_NEOPLASMS, DISEASE:PERITONEUM_CANCER,DISEASE:NEOPLASMS, DISEASE:OVARIAN_NEOPLASMS, DISEASE:UTERINE_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;CHRNA4;G;rs1044396;OTHER;INCREASED;RISK;DISEASE:TOBACCO_USE_DISORDER;;;CAUTION_SIDE_EFFECT
CISPLATIN;LRP2;T;rs2075252;TOXICITY;INCREASED;RISK;DISEASE:OTOTOXICITY;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
CETUXIMAB;EGF;AA;rs4444903;EFFICACY;DECREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
CAPECITABINE;CDA;C/del + CC;rs3215400;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME;PEOPLE;DISEASE:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;POR;GG;rs2286823;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY;PEOPLE;OTHER:ACUTE_CORONARY_SYNDROME;LIKELIHOOD_THERAPEUTIC_FAILURE
SUNITINIB;POR;TT;rs1057868;EFFICACY;INCREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:GASTROINTESTINAL_STROMAL_TUMORS;LIKELIHOOD_THERAPEUTIC_SUCCESS
SUNITINIB;SLCO1B3;GG;rs4149117;EFFICACY;DECREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;EFFICACY:GASTROINTESTINAL_STROMAL_TUMORS;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;SLC19A1;CC + CT;rs1051266;TOXICITY;INCREASED;RISK;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
PHENPROCOUMON;VKORC1;TT;rs9923231;TOXICITY;INCREASED;;SIDE_EFFECT:TIME_ABOVE_THERAPEUTIC_RANGE;;;CAUTION_SIDE_EFFECT
CAPECITABINE;CDA;T;rs532545;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:HAND-FOOT_SYNDROME;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CES1P1;AC + CC;rs3785161;EFFICACY;INCREASED;;EFFICACY:ON-TREATMENT_PLATELET_ACTIVITY;PEOPLE;DISEASE:CORONARY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;CT + TT;rs9923231;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HEMORRHAGE;;;CAUTION_SIDE_EFFECT
METHOTREXATE;ATIC;G;rs2372536;NAN;;SEVERITY;DISEASE:RHEUMATOID_ARTHRITIS;;;CAUTION_DOSE_ADJUST
LEUCOVORIN, TEGAFUR;FASTKD3, MTRR;GG;rs1801394;TOXICITY;INCREASED;SEVERITY;DISEASE:STOMATITIS;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
CAPECITABINE;DPYD;A;rs67376798;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
LEUCOVORIN, TEGAFUR;UMPS;CC;rs1801019;TOXICITY;INCREASED;SEVERITY;DISEASE:DIARRHEA;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
LEUCOVORIN, TEGAFUR;UMPS;CC;rs1801019;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ANY_GRADE_3_ADVERSE_EVENT;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
ASPIRIN, CLOPIDOGREL;F13A1;AA + AC;rs5985;EFFICACY;INCREASED;RISK;DISEASE:DEATH;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;CAUTION_SIDE_EFFECT
PAZOPANIB;CXCL8;TT;rs1126647;EFFICACY;DECREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;VKORC1;CT + TT;rs9923231;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OVER-ANTICOAGULATION;;;CAUTION_SIDE_EFFECT
NICOTINE;CHRNA4;G;rs2236196;OTHER;INCREASED;RISK;DISEASE:TOBACCO_USE_DISORDER;;;CAUTION_SIDE_EFFECT
ANGIOTENSIN II ANTAGONISTS;CYP2D6;CT;rs111564371;EFFICACY;DECREASED;SEVERITY;EFFICACY:ELEVATED_DIASTOLIC_BLOOD_PRESSURE, EFFICACY:ELEVATED_SYSTOLIC_BLOOD_PRESSURE;PEOPLE;OTHER:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;SLC19A1;CT + TT;rs1051266;TOXICITY;DECREASED;RISK;SIDE_EFFECT:MUCOSITIS;CHILDREN;OTHER:OSTEOSARCOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;CHRNA3;AA + AG;rs1051730;TOXICITY;DECREASED;;SIDE_EFFECT:LUNG_FUNCTION;PEOPLE;DISEASE:TOBACCO_USE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE, FLUOROURACIL;MTHFR;A;rs1801133;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
LEDIPASVIR, SOFOSBUVIR;IFNL3, IFNL4;TT;rs12979860;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:RECURRENCE;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE;HSPA1A;T;rs1043620;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:HYPERSENSITIVITY;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN, CLOPIDOGREL;F13A1;AA + AC;rs5985;EFFICACY;INCREASED;RISK;DISEASE:MYOCARDIAL_INFARCTION;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;CAUTION_SIDE_EFFECT
LEDIPASVIR, SOFOSBUVIR;IFNL3, IFNL4;TT;rs8099917;EFFICACY;INCREASED;;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE;HSPA1A;G;rs506770;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:HYPERSENSITIVITY;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN, CLOPIDOGREL;F13A1;AA;rs5985;EFFICACY;DECREASED;;EFFICACY:FIBRIN_CLOT_FORMATION_TIME;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOPHOSPHAMIDE, FLUOROURACIL;TP53;G;rs1042522;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;HSPA1L;G;rs2227956;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:HYPERSENSITIVITY;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;P2RY12;AG + GG;rs6787801;EFFICACY;;;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY_IN_CYP2C19*1/*1_CARRIERS;;OTHER:PATIENTS_UNDERGOING_PERCUTANEOUS_CORONARY_INTERVENTION;CAUTION_DOSE_ADJUST
CLOZAPINE;ABCB1;AG + GG;rs1045642;TOXICITY;INCREASED;;SIDE_EFFECT:HYPERTENSION;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
RIBAVIRIN;ITPA;CC;rs1127354;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DOSE_REDUCTION, SIDE_EFFECT:TREATMENT_INTERRUPTION;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;CAUTION_SIDE_EFFECT
EFAVIRENZ;CYP2B6;TT;rs3745274;METABOLISM/PK;INCREASED;;PK:EXPOSURE;WOMEN;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DOSE_ADJUST
CLOZAPINE;ABCC1;AT + TT;rs212090;TOXICITY;INCREASED;;SIDE_EFFECT:HYPERTENSION;MEN;DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;MLN;A;rs2894342;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HYPERSENSITIVITY_SYNDROME;;;CAUTION_SIDE_EFFECT
EFAVIRENZ;CYP2B6;CC + CT;rs28399499;METABOLISM/PK;INCREASED;;PK:EXPOSURE;WOMEN;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DOSE_ADJUST
CLOZAPINE;ABCB1;AG + GG;rs1045642;TOXICITY;INCREASED;;SIDE_EFFECT:WEIGHT_GAIN;MEN;DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
CLOZAPINE;ABCC1;AT + TT;rs212090;TOXICITY;INCREASED;;SIDE_EFFECT:WEIGHT_GAIN;MEN;;CAUTION_SIDE_EFFECT
CAFFEINE;ADORA2A;TT;rs5751876;TOXICITY;INCREASED;;SIDE_EFFECT:ANXIETY;PEOPLE;OTHER:NO_DISEASE;CAUTION_SIDE_EFFECT
CAFFEINE;ADORA2A;CC;rs2298383;TOXICITY;INCREASED;;SIDE_EFFECT:ANXIETY;PEOPLE;OTHER:NO_DISEASE;CAUTION_SIDE_EFFECT
CAFFEINE;;CC;rs4822492;TOXICITY;INCREASED;;SIDE_EFFECT:ANXIETY;PEOPLE;OTHER:NO_DISEASE;CAUTION_SIDE_EFFECT
NAN;MT-RNR1;G;rs267606617;OTHER;INCREASED;LIKELIHOOD;OTHER:HEARING_LOSS, SENSORINEURAL;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBAMAZEPINE;;T;rs3130690;TOXICITY;INCREASED;RISK;DISEASE:STEVENS-JOHNSON_SYNDROME;;;CAUTION_SIDE_EFFECT
CAFFEINE;ADORA2A;CC;rs5751876;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:BEING_SENSITIVE_TO_CAFFEINE;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAFFEINE;ADORA2A;CC;rs5751876;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:INSOMNIA;;;CAUTION_SIDE_EFFECT
ETHANOL, HEROIN, METHAMPHETAMINE;ANKS1B;T;rs2133896;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ALCOHOL_ABUSE, SIDE_EFFECT:HEROIN_DEPENDENCE, SIDE_EFFECT:METHAMPHETAMINE_DEPENDENCE;;;CAUTION_SIDE_EFFECT
CARBAMAZEPINE;MICA;C;rs2848716;TOXICITY;INCREASED;RISK;DISEASE:STEVENS-JOHNSON_SYNDROME;;;CAUTION_SIDE_EFFECT
"""ANTIINFLAMMATORY AGENTS, NON-STEROIDS"", ""ASPIRIN""";;TT;rs2965667;OTHER;DECREASED;RISK;DISEASE:COLORECTAL_NEOPLASMS;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAFFEINE;ADORA2A;TT;rs5751876;DOSAGE;DECREASED;;OTHER:HABITUAL_CONSUMPTION;;;CAUTION_DOSE_ADJUST
CARBAMAZEPINE;BAG6, PRRC2A;C;rs750332;TOXICITY;INCREASED;RISK;DISEASE:STEVENS-JOHNSON_SYNDROME;;;CAUTION_SIDE_EFFECT
"""ANTIINFLAMMATORY AGENTS, NON-STEROIDS"", ""ASPIRIN""";;AA;rs16973225;OTHER;DECREASED;LIKELIHOOD;DISEASE:COLORECTAL_NEOPLASMS;;;LIKELIHOOD_THERAPEUTIC_FAILURE
NAN;CHRNA5;T;rs588765;EFFICACY;;;EFFICACY:DECREASED_CHANCE_OF_ACHIEVING_6_MONTH_ABSTINENCE_IN_THE_PLACEBO_GROUP;;;CAUTION_DOSE_ADJUST
WARFARIN;VKORC1;AG + GG;rs9934438;DOSAGE;INCREASED;;OTHER:WARFARIN_DOSE;;;CAUTION_DOSE_ADJUST
RIBAVIRIN;ITPA;AA;rs7270101;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HEMOLYTIC_ANEMIA;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;CAUTION_SIDE_EFFECT
SIMVASTATIN;LEPR;GG;rs1137101;EFFICACY;INCREASED;;EFFICACY:PERCENTAGE_CHANGE_IN_HDL-C_LEVELS;PEOPLE;DISEASE:CORONARY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ALENDRONATE;SOST;CC;rs1234612;EFFICACY;INCREASED;;EFFICACY:BONE_DENSITY;WOMEN;DISEASE:METABOLIC_BONE_DISORDER, DISEASE:OSTEOPOROSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYTARABINE, DAUNORUBICIN;ABCB1;GG;rs1128503;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:CARDIOTOXICITY;CHILDREN;OTHER:ACUTE_MYELOID_LEUKEMIA;CAUTION_SIDE_EFFECT
CYTARABINE, DAUNORUBICIN;CDA;CC;rs532545;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:COLITIS;CHILDREN;OTHER:ACUTE_MYELOID_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYTARABINE, DAUNORUBICIN;ABCB1;GG;rs1045642;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ELEVATED_LIVER_ENZYMES;CHILDREN;OTHER:ACUTE_MYELOID_LEUKEMIA;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;;;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY;;OTHER:PATIENTS_UNDERGOING_PERCUTANEOUS_CORONARY_INTERVENTION;CAUTION_DOSE_ADJUST
ALENDRONATE;SOST;GG;rs865429;EFFICACY;DECREASED;;EFFICACY:BONE_DENSITY;WOMEN;DISEASE:METABOLIC_BONE_DISORDER, DISEASE:OSTEOPOROSIS;LIKELIHOOD_THERAPEUTIC_FAILURE
RIBAVIRIN;ITPA;CC;rs1127354;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HEMOLYTIC_ANEMIA;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;CAUTION_SIDE_EFFECT
CYTARABINE;ABCB1;AA + AG;rs1128503;EFFICACY;INCREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:ACUTE_MYELOID_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;MED12L, P2RY12;T;rs6801273;EFFICACY;DECREASED;;EFFICACY:RESIDUAL_ON-CLOPIDOGREL_PLATELET_REACTIVITY;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
CYTARABINE;ABCB1;AA + AC;rs2032582;EFFICACY;INCREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:ACUTE_MYELOID_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;MED12L;G;rs6798347;EFFICACY;DECREASED;;EFFICACY:RESIDUAL_ON-CLOPIDOGREL_PLATELET_REACTIVITY;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
ERLOTINIB, GEFITINIB;EGFR;T;rs121434569;EFFICACY;DECREASED;;EFFICACY:PROGRESSION_FREE_SURVIVAL_(PFS)_TIME;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
CYTARABINE;ABCB1;AA + AG;rs1045642;EFFICACY;INCREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:ACUTE_MYELOID_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
SEVOFLURANE;ABCB1;GG;rs1128503;OTHER;DECREASED;LIKELIHOOD;OTHER:ADVERSE_EVENTS;CHILDREN;OTHER:TONSILLECTOMY;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;KCNJ11;CT + TT;rs5219;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DIABETES_MELLITUS, TYPE_2;PEOPLE;DISEASE:HEART_TRANSPLANTATION, DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
ACE INHIBITORS, PLAIN;ETV6;GG;rs2724635;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ANGIOEDEMA;;;CAUTION_SIDE_EFFECT
ERLOTINIB, GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL_(PFS)_TIME;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
SUNITINIB;ABCB1;AA;rs1128503;TOXICITY;DECREASED;RISK;SIDE_EFFECT:NEUTROPENIA;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;TAPBP;CC + CG;rs2071888;TOXICITY;INCREASED;;SIDE_EFFECT:FEV1_DECREASE_AFTER_ASPIRIN_CHALLENGE;PEOPLE;DISEASE:ASTHMA;CAUTION_SIDE_EFFECT
DRUGS FOR TREATMENT OF TUBERCULOSIS;ABCC2;AG + GG;rs3740065;TOXICITY;DECREASED;RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE;PEOPLE;OTHER:TUBERCULOSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESCITALOPRAM;HTR2A;CT + TT;rs6311;TOXICITY;INCREASED;RISK;SIDE_EFFECT:PHYSIOLOGICAL_SEXUAL_DISORDER;PEOPLE;OTHER:ANXIETY_DISORDERS;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;AA;rs4244285;TOXICITY;INCREASED;RISK;SIDE_EFFECT:COMPOSITE_OUTCOME_OF_NON-FATAL_MI, ALL_CAUSE_DEATH_AND_STENT_THROMBOSIS;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;CAUTION_SIDE_EFFECT
HYDROCHLOROTHIAZIDE;KCNJ1;C;rs12795437;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:DIABETES_MELLITUS;PEOPLE;DISEASE:HYPERTENSION;CAUTION_SIDE_EFFECT
PHENPROCOUMON;VKORC1;AA + AG;rs9934438;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE;;;CAUTION_SIDE_EFFECT
VALPROIC ACID;LEPR;AA + AG;rs1137101;TOXICITY;INCREASED;;SIDE_EFFECT:WEIGHT_GAIN;PEOPLE;DISEASE:EPILEPSY;CAUTION_SIDE_EFFECT
PHENYTOIN;CFHR4;G;rs78239784;TOXICITY;INCREASED;RISK;DISEASE:MACULOPAPULAR_EXANTHEMA;;;CAUTION_SIDE_EFFECT
HYDROCHLOROTHIAZIDE;KCNJ1;A;rs11600347;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:DIABETES_MELLITUS;PEOPLE;DISEASE:HYPERTENSION;CAUTION_SIDE_EFFECT
CABAZITAXEL;ABCB1;A;rs2032582;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY;PEOPLE;DISEASE:TRANSITIONAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
VALPROIC ACID;ANKK1;AG + GG;rs1800497;TOXICITY;INCREASED;;SIDE_EFFECT:WEIGHT_GAIN;PEOPLE;DISEASE:EPILEPSY;CAUTION_SIDE_EFFECT
HYDROCHLOROTHIAZIDE;KCNJ1;A;rs658903;TOXICITY;DECREASED;LIKELIHOOD;DISEASE:DIABETES_MELLITUS;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
CABAZITAXEL;ABCB1;A;rs1045642;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY;PEOPLE;DISEASE:TRANSITIONAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;P2RY12;G;rs6787801;EFFICACY;DECREASED;;EFFICACY:RESIDUAL_ON-CLOPIDOGREL_PLATELET_REACTIVITY;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
CABAZITAXEL;CYP3A5;T;rs776746;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY;PEOPLE;DISEASE:TRANSITIONAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACE INHIBITORS, PLAIN;PRKCQ;CT + TT;rs500766;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:ANGIOEDEMA;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
HYDROCHLOROTHIAZIDE;KCNJ1;A;rs675388;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:DIABETES_MELLITUS;PEOPLE;DISEASE:HYPERTENSION;CAUTION_SIDE_EFFECT
DOXORUBICIN;GSTP1;GG;rs1695;EFFICACY;DECREASED;RISK;EFFICACY:CHEMORESISTANCE;PEOPLE;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CABAZITAXEL;ABCB1;A;rs1128503;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:TRANSITIONAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
PROPOFOL;DRD2;AA + AC;rs2283265;OTHER;DECREASED;;OTHER:HEART_RATE;;;CAUTION_DOSE_ADJUST
NICOTINE;CHRNA4;A;rs2236196;OTHER;INCREASED;LIKELIHOOD;OTHER:NICOTINE_DEPENDENCE;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACETAMINOPHEN;UGT1A;CG + GG;rs1042640;TOXICITY;DECREASED;RISK;DISEASE:LIVER_FAILURE, ACUTE;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;ABCB1;AA;rs1045642;TOXICITY;DECREASED;;SIDE_EFFECT:BLEEDING_EVENTS;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACETAMINOPHEN;UGT1A;CG + GG;rs8330;TOXICITY;DECREASED;RISK;DISEASE:LIVER_FAILURE, ACUTE;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEFITINIB;EGFR;T;rs121434569;EFFICACY;DECREASED;;EFFICACY:RESPONSE_RATE_(RR);;EFFICACY:NON-SMALL-CELL_LUNG_CANCER_PATIENTS;LIKELIHOOD_THERAPEUTIC_FAILURE
HYDROCHLOROTHIAZIDE;KCNJ1;AG;rs59172778;TOXICITY;INCREASED;;SIDE_EFFECT:SERUM_POTASSIUM;PEOPLE;DISEASE:HYPERTENSION;CAUTION_SIDE_EFFECT
ETHANOL;CACNA1C;TT;rs1034936;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ALCOHOL_ABUSE;PEOPLE;OTHER:BIPOLAR_DISORDER;CAUTION_SIDE_EFFECT
DOXORUBICIN, METHOTREXATE, PREDNISOLONE, VINCRISTINE;ABCB1;AA;rs1045642;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ANEMIA, SIDE_EFFECT:THROMBOCYTOPENIA;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;AA;rs4244285;TOXICITY;INCREASED;RISK;DISEASE:MYOCARDIAL_INFARCTION;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;CAUTION_SIDE_EFFECT
WARFARIN;EPHA7;A;rs114504854;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HEMORRHAGE;;;CAUTION_SIDE_EFFECT
ACETAMINOPHEN;UGT1A;CT + TT;rs10929303;TOXICITY;DECREASED;RISK;DISEASE:LIVER_FAILURE, ACUTE;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACE INHIBITORS, PLAIN;XPNPEP2;T;rs2050011;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ANGIOEDEMA;;;CAUTION_SIDE_EFFECT
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;TNF;AA + AG;rs1800629;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
NICOTINE;ADGRL3;AG;rs2271339;TOXICITY;INCREASED;RISK;OTHER:TOBACCO_USE_DISORDER;PEOPLE;OTHER:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY;CAUTION_SIDE_EFFECT
NICOTINE;ADGRL3;AT;rs1456862;TOXICITY;INCREASED;RISK;OTHER:TOBACCO_USE_DISORDER;PEOPLE;OTHER:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY;CAUTION_SIDE_EFFECT
GEFITINIB;EGFR;CC;rs2293347;EFFICACY;INCREASED;;EFFICACY:RESPONSE_RATE_(RR);;EFFICACY:ADVANCED_NON-SMALL-CELL_LUNG_CANCER_PATIENTS;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEFITINIB;EGFR;CC;rs2293347;EFFICACY;INCREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL_(PFS)_TIME;;EFFICACY:ADVANCED_NON-SMALL-CELL_LUNG_CANCER_PATIENTS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHANOL;MAP2K4;CT;rs2159140;TOXICITY;INCREASED;RISK;OTHER:ALCOHOL_ABUSE;PEOPLE;OTHER:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY;CAUTION_SIDE_EFFECT
SUNITINIB;ABCB1;GG;rs1045642;TOXICITY;INCREASED;RISK;SIDE_EFFECT:EXANTHEMA, SIDE_EFFECT:MUCOSITIS;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;CAUTION_SIDE_EFFECT
SORAFENIB;UGT1A9;T;rs17868320;TOXICITY;INCREASED;RISK;DISEASE:DIARRHEA;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL_(PFS)_TIME;;EFFICACY:ADVANCED_NON-SMALL-CELL_LUNG_CANCER_PATIENTS;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;;EFFICACY:OVERALL_SURVIVAL_(OS)_TIME;;EFFICACY:ADVANCED_NON-SMALL-CELL_LUNG_CANCER_PATIENTS;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEFITINIB;EGFR;GT + TT;rs712829;EFFICACY;INCREASED;;EFFICACY:RESPONSE_RATE_(RR);PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACENOCOUMAROL;VKORC1;AA + AG;rs9934438;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:OVER-ANTICOAGULATION;;;CAUTION_SIDE_EFFECT
MORPHINE;OPRM1;AA;rs1799971;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HYPOVENTILATION;CHILDREN;;CAUTION_SIDE_EFFECT
ACE INHIBITORS, PLAIN;XPNPEP2;A;rs3788853;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ANGIOEDEMA;;;CAUTION_SIDE_EFFECT
VINCRISTINE;CEP72;TT;rs924607;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
CLOPIDOGREL;ABCB1;AA + AG;rs1045642;TOXICITY;INCREASED;RISK;SIDE_EFFECT:MAJOR_ADVERSE_CARDIOVASCULAR_EVENTS_(MACE)_(MORE_THAN_ONE_YEAR)_WHEN_RECEIVING_A_LOADING_DOSE_OF_300_MG;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;CAUTION_SIDE_EFFECT
DOCETAXEL;ABCC10;CT;rs2125739;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:NEUTROPENIA;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;ARNT;CG + GG;rs2228099;OTHER;DECREASED;LIKELIHOOD;DISEASE:COLORECTAL_NEOPLASMS;;;LIKELIHOOD_THERAPEUTIC_FAILURE
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;CYP2E1;GG;rs3813867;TOXICITY;INCREASED;SEVERITY;DISEASE:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:TOXIC_LIVER_DISEASE;CAUTION_SIDE_EFFECT
CLOPIDOGREL;ABCB1;AA + AG;rs1045642;TOXICITY;INCREASED;RISK;SIDE_EFFECT:EARLY_MAJOR_ADVERSE_CARDIOVASCULAR_EVENTS_(MACE);PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;CAUTION_SIDE_EFFECT
NAN;DEPTOR;AA + AG;rs4871827;OTHER;INCREASED;;OTHER:HDL_CHOLESTEROL;PEOPLE;OTHER:DIABETES_MELLITUS_T2;CAUTION_DOSE_ADJUST
CISPLATIN, IRINOTECAN;SYNE3;CC;rs8020368;EFFICACY;DECREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:SMALL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
NAN;DEPTOR;AG;rs4871827;OTHER;DECREASED;LIKELIHOOD;OTHER:BRAIN_ISCHEMIA, OTHER:MYOCARDIAL_INFARCTION, OTHER:PERIPHERAL_VASCULAR_DISEASES;PEOPLE;OTHER:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_FAILURE
"""ANTIVIRALS FOR TREATMENT OF HIV INFECTIONS, COMBINATIONS"", ""DRUGS FOR TREATMENT OF TUBERCULOSIS""";CYP2B6;TT;rs3745274;TOXICITY;INCREASED;RISK;DISEASE:DRUG-INDUCED_LIVER_INJURY;PEOPLE;OTHER:HIV_AND_TUBERCULOSIS_CO-INFECTION;CAUTION_SIDE_EFFECT
NAN;DEPTOR;AG;rs4871827;OTHER;DECREASED;LIKELIHOOD;OTHER:DIABETIC_RETINOPATHY, OTHER:CHRONIC_KIDNEY_FAILURE;PEOPLE;OTHER:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_FAILURE
LOSARTAN;STK39;GG + GT;rs6749447;EFFICACY;DECREASED;;EFFICACY:REDUCTION_IN_AMBULATORY_BLOOD_PRESSURE;MEN;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;ABCB1;AA;rs1045642;TOXICITY;INCREASED;RISK;SIDE_EFFECT:EARLY_MAJOR_ADVERSE_CARDIOVASCULAR_EVENTS_(MACE);PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;CAUTION_SIDE_EFFECT
NAN;AHR;AA + AG;rs2066853;OTHER;INCREASED;RISK;OTHER:ADENOMATOUS_AND_HYPERPLASTIC_POLYPS;PEOPLE;OTHER:A_NAT1_RAPID_ACETYLATOR_GENOTYPE_AND_HIGH_MEAT_CONSUMPTION;CAUTION_SIDE_EFFECT
RISPERIDONE;HTR6;CC + CT;rs9659997;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:HYPERPROLACTINEMIA;CHILDREN;DISEASE:AUTISM;CAUTION_SIDE_EFFECT
CISPLATIN, IRINOTECAN;DCBLD1;AG;rs17574269;EFFICACY;DECREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:SMALL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
CISPLATIN, IRINOTECAN;;AG + GG;rs7186128;EFFICACY;DECREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:SMALL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;TYMS;A;rs3786362;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HYPERPROLACTINEMIA;CHILDREN;DISEASE:AUTISM_SPECTRUM_DISORDER;CAUTION_SIDE_EFFECT
NAN;TNF;C;rs1800630;EFFICACY;INCREASED;SEVERITY;EFFICACY:LEUKOCYTOSIS;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
CISPLATIN, IRINOTECAN;;TT;rs2166219;EFFICACY;DECREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:SMALL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;HTR2A;CC;rs6311;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:HYPERPROLACTINEMIA;CHILDREN;DISEASE:AUTISM;CAUTION_SIDE_EFFECT
CISPLATIN, IRINOTECAN;;CC;rs4655567;EFFICACY;DECREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:SMALL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTINEOPLASTIC AGENTS, CORTICOSTEROIDS;ITPA;AA + AC;rs1127354;TOXICITY;INCREASED;RISK;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY, SIDE_EFFECT:NEUROTOXICITY_SYNDROMES;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
CISPLATIN, IRINOTECAN;;TT;rs2018683;EFFICACY;DECREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:SMALL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;BDNF;CT + TT;rs6265;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:HYPERPROLACTINEMIA;CHILDREN;DISEASE:AUTISM;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC AGENTS, CORTICOSTEROIDS;ADORA2A;CC;rs2236624;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
LEUCOVORIN, METHOTREXATE;ABCC2;CT + TT;rs717620;METABOLISM/PK;INCREASED;;PK:DISTRIBUTION_VOLUME;PEOPLE;DISEASE:LYMPHOMA;CAUTION_DOSE_ADJUST
CISPLATIN, IRINOTECAN;;TT;rs2018683;EFFICACY;INCREASED;RISK;EFFICACY:RESISTANT_RELAPSE;PEOPLE;DISEASE:SMALL_CELL_CARCINOMA;CAUTION_SIDE_EFFECT
NAN;OPRM1;G;rs1799971;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:HEROIN_DEPENDENCE;;;CAUTION_SIDE_EFFECT
CISPLATIN, IRINOTECAN;SYNE3;CC;rs8020368;EFFICACY;INCREASED;RISK;EFFICACY:RESISTANT_RELAPSE;PEOPLE;DISEASE:SMALL_CELL_CARCINOMA;CAUTION_SIDE_EFFECT
CISPLATIN, IRINOTECAN;;CC;rs4655567;EFFICACY;INCREASED;RISK;EFFICACY:RESISTANT_RELAPSE;PEOPLE;DISEASE:SMALL_CELL_CARCINOMA;CAUTION_SIDE_EFFECT
METHOTREXATE;ABCC4;AA;rs7317112;TOXICITY;INCREASED;RISK;SIDE_EFFECT:MUCOSITIS;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
RISPERIDONE;UGT1A1;AG;rs1976391;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HYPERPROLACTINEMIA;CHILDREN;DISEASE:AUTISM_SPECTRUM_DISORDER;CAUTION_SIDE_EFFECT
RISPERIDONE;HTR2C;C;rs6318;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:HYPERPROLACTINEMIA;CHILDREN;DISEASE:AUTISM;CAUTION_SIDE_EFFECT
CYCLOSPORINE;;GG;rs2275913;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:TRANSPLANT_REJECTION;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
LENALIDOMIDE;ABCB1;AA;rs2032582;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:MYELOSUPPRESSION;PEOPLE;OTHER:MANTLE_CELL_LYMPHOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
HEROIN;DBH;TT;rs1611114;TOXICITY;DECREASED;RISK;SIDE_EFFECT:MEMORY_IMPAIRMENT;PEOPLE;OTHER:HEROIN_DEPENDENCE;LIKELIHOOD_THERAPEUTIC_SUCCESS
DILTIAZEM;PLCD3;T;rs12946454;EFFICACY;INCREASED;;EFFICACY:REDUCTION_IN_BLOOD_PRESSURE;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE, FLUOROURACIL, OXALIPLATIN;MTHFR;GG;rs1801131;EFFICACY;DECREASED;;EFFICACY:EVENT-FREE_SURVIVAL, EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON ALFA-2B, RIBAVIRIN;ITPA;AC;rs1127354;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:ANEMIA;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOCETAXEL;ABCB1;AA;rs1045642;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA;;;CAUTION_SIDE_EFFECT
"""BETA BLOCKING AGENTS"", ""THIAZIDES, PLAIN""";;C;rs11191548;EFFICACY;INCREASED;;EFFICACY:REDUCTION_IN_DIASTOLIC_BLOOD_PRESSURE;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;COMT;GG;rs4680;OTHER;INCREASED;SEVERITY;SIDE_EFFECT:WITHDRAWAL;WOMEN;DISEASE:TOBACCO_USE_DISORDER;CAUTION_SIDE_EFFECT
EFAVIRENZ;CYP2B6;TT;rs3745274;METABOLISM/PK;INCREASED;;PK:MINIMUM_PLASMA_CONCENTRATIONS;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DOSE_ADJUST
MORPHINE;ABCB1;CC + CT;rs9282564;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HYPOVENTILATION;CHILDREN;;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC AGENTS, CORTICOSTEROIDS;ABCC1;GG;rs246240;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
LENALIDOMIDE;NCF4;AA + AG;rs1883112;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:MYELOSUPPRESSION;PEOPLE;OTHER:MANTLE_CELL_LYMPHOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;COMT;GG;rs4680;OTHER;INCREASED;;OTHER:BLOOD_PRESSURE;PEOPLE;DISEASE:TOBACCO_USE_DISORDER;CAUTION_DOSE_ADJUST
LENALIDOMIDE;GSTP1;GG;rs1695;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:MYELOSUPPRESSION;PEOPLE;OTHER:MANTLE_CELL_LYMPHOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN, IRINOTECAN;ABCC4;CT;rs16950650;EFFICACY;DECREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:SMALL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
ASPIRIN, CLOPIDOGREL;ITGA2;CT + TT;rs1126643;OTHER;INCREASED;;OTHER:COLLAGEN-INDUCED_PLATELET_AGGREGATION;;OTHER:PATIENTS_UNDERGOING_CORONARY_STENTING;CAUTION_DOSE_ADJUST
MYCOPHENOLATE MOFETIL;SLCO1B3;TT;rs4149117;TOXICITY;INCREASED;RISK;DISEASE:DIARRHEA;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
EFAVIRENZ, LAMIVUDINE, TENOFOVIR;ABCB1;GG;rs1045642;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:EXANTHEMA;PEOPLE;OTHER:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEMCITABINE;SLC29A3;CT + TT;rs780668;EFFICACY;INCREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B, RIBAVIRIN;ITPA;A;rs1127354;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:ANEMIA;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
MYCOPHENOLATE MOFETIL;SLCO1B3;TT;rs4149117;TOXICITY;INCREASED;RISK;DISEASE:DIARRHEA;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
ATORVASTATIN;SLCO1B1;C;rs4149056;TOXICITY;INCREASED;RISK;SIDE_EFFECT:MUSCULAR_DISEASES;;;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2B, RIBAVIRIN;ITPA;C;rs7270101;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:ANEMIA;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAFFEINE;CYP1A2;AC + CC;rs762551;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ALBUMINURIA, SIDE_EFFECT:HYPERTENSION;;;CAUTION_SIDE_EFFECT
GEMCITABINE;ABCG2;GT + TT;rs2231142;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
PLATINUM COMPOUNDS;ERCC1;AA;rs11615;EFFICACY;INCREASED;RISK;DISEASE:DEATH;WOMEN;DISEASE:OVARIAN_NEOPLASMS;CAUTION_SIDE_EFFECT
CAPECITABINE;CDA;CT + TT;rs1048977;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DISCONTINUATION;PEOPLE;OTHER:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C9;CT + TT;rs1799853;METABOLISM/PK;DECREASED;;PK:EXPOSURE_TO_CLOPIDOGREL_ACTIVE_METABOLITE;HEALTHY;;CAUTION_DOSE_ADJUST
ATORVASTATIN;SLCO1B1;CC + CT;rs4149056;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY, SIDE_EFFECT:MUSCULAR_DISEASES, SIDE_EFFECT:RHABDOMYOLYSIS, SIDE_EFFECT:TOXIC_LIVER_DISEASE;;;CAUTION_SIDE_EFFECT
ALLOPURINOL;CFLAR;A;rs1594;TOXICITY;;;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;;;CAUTION_DOSE_ADJUST
OXYCODONE;ABCB1;AA + AG;rs1045642;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS;PEOPLE;OTHER:PAIN, OTHER:NEOPLASMS;CAUTION_SIDE_EFFECT
CAPECITABINE;CES2;CG + GG;rs11075646;EFFICACY;INCREASED;;EFFICACY:TIME_TO_PROGRESSION;PEOPLE;DISEASE:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM COMPOUNDS;ERCC1;AA;rs11615;EFFICACY;INCREASED;RISK;EFFICACY:RECURRENCE_OF_DISEASE;WOMEN;DISEASE:OVARIAN_NEOPLASMS;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C9;CT + TT;rs1799853;EFFICACY;DECREASED;;EFFICACY:INHIBITION_OF_PLATELET_AGGREGATION_AND_POOR-RESPONDER_STATUS;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
PLATINUM COMPOUNDS;HSPA5;TT;rs430397;EFFICACY;DECREASED;;OTHER:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;DECREASED;;EFFICACY:INHIBITION_OF_PLATELET_AGGREGATION_AND_POOR-RESPONDER_STATUS;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
ASPIRIN;AGT;GG;rs5050;TOXICITY;INCREASED;RISK;DISEASE:PEPTIC_ULCER_HEMORRHAGE;;;CAUTION_SIDE_EFFECT
SUNITINIB;NR1I2;A;rs6785049;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HYPERTENSION;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
BUPROPION;SACM1L;C;rs2251954;TOXICITY;DECREASED;;SIDE_EFFECT:SEXUAL_SIDE-EFFECTS;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
ROSUVASTATIN;GATM;AA;rs9806699;TOXICITY;DECREASED;RISK;SIDE_EFFECT:MUSCULAR_DISEASES;PEOPLE;OTHER:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;A;rs4244285;METABOLISM/PK;DECREASED;;PK:EXPOSURE_TO_CLOPIDOGREL_ACTIVE_METABOLITE;HEALTHY;;CAUTION_DOSE_ADJUST
BUPROPION;SACM1L;G;rs2742421;TOXICITY;DECREASED;;SIDE_EFFECT:SEXUAL_SIDE-EFFECTS;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHAMBUTOL, ISONIAZID / PYRAZINAMIDE / RIFAMPIN;CYP3A4;AG;rs28371759;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;PEOPLE;OTHER:TUBERCULOSIS;CAUTION_SIDE_EFFECT
ROSUVASTATIN;SLCO1B1;AG;rs4149081;EFFICACY;INCREASED;;EFFICACY:LDL-C_REDUCTION;PEOPLE;DISEASE:CORONARY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUPROPION;SACM1L;G;rs2742423;TOXICITY;DECREASED;;SIDE_EFFECT:SEXUAL_SIDE-EFFECTS;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;TT;rs3745274;TOXICITY;;;SIDE_EFFECT:EARLY_(<_3_MONTHS)_TERMINATION_OF_EFAVIRENZ_THERAPY;;;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C9;AC + CC;rs1057910;METABOLISM/PK;DECREASED;;PK:EXPOSURE_TO_CLOPIDOGREL_ACTIVE_METABOLITE;HEALTHY;;CAUTION_DOSE_ADJUST
BUPROPION;SACM1L;T;rs1969624;TOXICITY;DECREASED;;SIDE_EFFECT:SEXUAL_SIDE-EFFECTS;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;NR1I3;GG;rs2307424;TOXICITY;;;SIDE_EFFECT:EARLY_(<_3_MONTHS)_TERMINATION_OF_EFAVIRENZ_THERAPY;;;CAUTION_DOSE_ADJUST
BUPROPION;SACM1L;C;rs2245705;TOXICITY;DECREASED;;SIDE_EFFECT:SEXUAL_SIDE-EFFECTS;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUPROPION;SACM1L;G;rs2742435;TOXICITY;DECREASED;;SIDE_EFFECT:SEXUAL_SIDE-EFFECTS;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C9;AC + CC;rs1057910;EFFICACY;DECREASED;;EFFICACY:INHIBITION_OF_PLATELET_AGGREGATION_AND_POOR-RESPONDER_STATUS;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
BUPROPION;SACM1L;A;rs2742390;TOXICITY;DECREASED;;SIDE_EFFECT:SEXUAL_SIDE-EFFECTS;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
SIMVASTATIN;SLCO1B1;AG;rs4149081;EFFICACY;INCREASED;;EFFICACY:LDL-C_REDUCTION;PEOPLE;DISEASE:CORONARY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM COMPOUNDS;HSPA5;TT;rs430397;EFFICACY;INCREASED;LIKELIHOOD;OTHER:EARLY_RELAPSE;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
SIMVASTATIN;SLCO1B1;AA;rs4149081;EFFICACY;INCREASED;;EFFICACY:LDL-C_REDUCTION;PEOPLE;DISEASE:CORONARY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEMETREXED;DHFR;GG;rs442767;TOXICITY;INCREASED;RISK;DISEASE:FATIGUE;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
FLUOROURACIL;MTHFR;GG;rs1801131;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
BUPROPION;SACM1L;T;rs2742417;TOXICITY;DECREASED;;SIDE_EFFECT:SEXUAL_SIDE-EFFECTS;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
TEMSIROLIMUS;NR1I2;T;rs3814055;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS;PEOPLE;DISEASE:URINARY_BLADDER_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
PHENPROCOUMON;VKORC1;CT + TT;rs9923231;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OVER-ANTICOAGULATION;;;CAUTION_SIDE_EFFECT
SUNITINIB;FLT3;AA;rs1933437;TOXICITY;INCREASED;RISK;SIDE_EFFECT:LEUKOPENIA, SIDE_EFFECT:NEUTROPENIA;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;CAUTION_SIDE_EFFECT
CAPECITABINE;CES1;CT + TT;rs71647871;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:HAND-FOOT_SYNDROME, SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;OTHER:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
ROSUVASTATIN;SLCO1B1;CC + CT;rs4149056;TOXICITY;INCREASED;RISK;SIDE_EFFECT:MUSCULAR_DISEASES;PEOPLE;OTHER:CORONARY_ARTERY_DISEASE;CAUTION_SIDE_EFFECT
GEMCITABINE;ABCG2;GT + TT;rs2231142;EFFICACY;INCREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM COMPOUNDS;HSPA5;TT;rs430397;EFFICACY;INCREASED;RISK;DISEASE:DEATH;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
ROSUVASTATIN;SLCO1B1;AA;rs4149081;EFFICACY;INCREASED;;EFFICACY:LDL-C_REDUCTION;PEOPLE;DISEASE:CORONARY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
NALTREXONE;OPRD1;A;rs4654327;EFFICACY;INCREASED;;EFFICACY:NALTREXONE-INDUCED_BLUNTING_OF_ALCOHOL_STIMULATION_AND_ALCOHOL_CRAVING;PEOPLE;DISEASE:ALCOHOL_ABUSE;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN;UGT1A;AG + GG;rs11563250;TOXICITY;DECREASED;RISK;SIDE_EFFECT:NEUTROPENIA;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATORVASTATIN, SIMVASTATIN;RYR2;A;rs2819742;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:MUSCULAR_DISEASES, DISEASE:MYALGIA;PEOPLE;DISEASE:CARDIOVASCULAR_DISEASE;CAUTION_SIDE_EFFECT
CAPECITABINE, FLUOROURACIL, GEMCITABINE;SPARC;GG;rs2347128;EFFICACY;INCREASED;;OTHER:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:PANCREATIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;MET;AG + GG;rs40239;OTHER;INCREASED;;OTHER:OVERALL_SURVIVAL;MEN;DISEASE:STOMACH_NEOPLASMS;CAUTION_DOSE_ADJUST
AZATHIOPRINE;ITPA;AC + CC;rs7270101;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:MYELOSUPPRESSION, SIDE_EFFECT:DRUG_TOXICITY, SIDE_EFFECT:ADVERSE_EVENTS;PEOPLE;OTHER:CROHN_DISEASE;CAUTION_SIDE_EFFECT
CAPECITABINE, FLUOROURACIL, GEMCITABINE;SPARC;TT;rs17718347;EFFICACY;INCREASED;;OTHER:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:PANCREATIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;MET;AG + GG;rs40239;OTHER;INCREASED;;OTHER:OVERALL_SURVIVAL;PEOPLE;DISEASE:STOMACH_NEOPLASMS;CAUTION_DOSE_ADJUST
"""ANTIVIRALS FOR TREATMENT OF HIV INFECTIONS, COMBINATIONS"", ""DRUGS FOR TREATMENT OF TUBERCULOSIS""";ABCB1;AA;rs1045642;TOXICITY, METABOLISM/PK;INCREASED;RISK;DISEASE:DRUG-INDUCED_LIVER_INJURY;PEOPLE;OTHER:HIV_AND_TUBERCULOSIS_CO-INFECTION;CAUTION_SIDE_EFFECT
EFAVIRENZ;CYP2B6;T;rs3745274;OTHER, METABOLISM/PK;INCREASED;;PK:PLASMA_EFAVIRENZ_EXPOSURE_(AUC)_DURING_THE_FIRST_24_WEEKS_OF_ANTIRETROVIRAL_THERAPY;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2B6;T;rs3745274;TOXICITY;INCREASED;RISK;DISEASE:CENTRAL_NERVOUS_SYSTEM_DISORDER;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;CT;rs3918290;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
DESFLURANE, ENFLURANE, HALOTHANE, ISOFLURANE, SEVOFLURANE, SUCCINYLCHOLINE;RYR1;A;rs112563513;OTHER;INCREASED;RISK;DISEASE:MALIGT_HYPERTHERMIA;;;CAUTION_SIDE_EFFECT
EFAVIRENZ;CYP3A4;C;rs2740574;OTHER, METABOLISM/PK;INCREASED;;PK:PLASMA_EFAVIRENZ_EXPOSURE;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DOSE_ADJUST
FLUOROURACIL;DPYD;AT;rs67376798;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;AA + AG;rs1801133;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DISCONTINUATION;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
EFAVIRENZ;CYP3A5;C;rs776746;METABOLISM/PK;DECREASED;;PK:PLASMA_EFAVIRENZ_EXPOSURE;PEOPLE;PK:HIV;CAUTION_DOSE_ADJUST
CLOPIDOGREL;ABCB1;GG;rs1045642;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ISCHAEMIC_EVENTS;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;AA;rs4244285;TOXICITY;INCREASED;RISK;SIDE_EFFECT:_CARDIOVASCULAR_EVENTS;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;A;rs4986893;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ISCHAEMIC_EVENTS;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;CAUTION_SIDE_EFFECT
ACE INHIBITORS, PLAIN;MME;CT + TT;rs989692;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ANGIOEDEMA;;;CAUTION_SIDE_EFFECT
HMG_COA_REDUCTASE_INHIBITORS;LILRB5;TT;rs12975366;DOSAGE, TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS;;;CAUTION_DOSE_ADJUST
ESCITALOPRAM, FLUOXETINE, PAROXETINE, SERTRALINE, VENLAFAXINE;HTR2A;TT;rs6311;TOXICITY;INCREASED;LIKELIHOOD;OTHER:PHYSIOLOGICAL_SEXUAL_DISORDER;MEN;OTHER:MAJOR_DEPRESSIVE_DISORDER;CAUTION_SIDE_EFFECT
CABAZITAXEL;CYP3A5;CT;rs776746;EFFICACY;DECREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:TRANSITIONAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;AA;rs4986893;EFFICACY;INCREASED;RISK;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;CAUTION_SIDE_EFFECT
CITALOPRAM, ESCITALOPRAM, FLUOXETINE, PAROXETINE, SERTRALINE;HTR2A;CC;rs6311;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:PHYSIOLOGICAL_SEXUAL_DISORDER;PEOPLE;OTHER:DEPRESSION;CAUTION_SIDE_EFFECT
CABAZITAXEL;TUBB1;AC;rs463312;EFFICACY;DECREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:TRANSITIONAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;G;rs28399504;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ISCHAEMIC_EVENTS;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;AA;rs1801133;TOXICITY;INCREASED;RISK;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;AA;rs4986893;TOXICITY;INCREASED;RISK;SIDE_EFFECT:CARDIOVASCULAR_EVENTS;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;CAUTION_SIDE_EFFECT
NEVIRAPINE;CYP2B6;C;rs28399499;METABOLISM/PK;INCREASED;;OTHER:PLASMA_LEVEL;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DOSE_ADJUST
NAN;SLC2A9;T;rs16890979;METABOLISM/PK;DECREASED;;PK:SERUM_URIC_ACID;HEALTHY;;CAUTION_DOSE_ADJUST
CYCLOPHOSPHAMIDE;IKZF3;CC;rs9908694;EFFICACY;INCREASED;;DISEASE:EVENT-FREE_SURVIVAL;CHILDREN;DISEASE:NEUROBLASTOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;ABCB1;AG;rs1045642;TOXICITY;DECREASED;RISK;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
DESFLURANE, ENFLURANE, HALOTHANE, ISOFLURANE, SEVOFLURANE, SUCCINYLCHOLINE;RYR1;A;rs118192122;OTHER;INCREASED;RISK;DISEASE:MALIGT_HYPERTHERMIA;;;CAUTION_SIDE_EFFECT
DESFLURANE, ENFLURANE, HALOTHANE, ISOFLURANE, SEVOFLURANE, SUCCINYLCHOLINE;RYR1;T;rs193922816;OTHER;INCREASED;RISK;DISEASE:MALIGT_HYPERTHERMIA;;;CAUTION_SIDE_EFFECT
METHAMPHETAMINE;DRD4;CC + CT;rs1800955;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_PSYCHOSIS;PEOPLE;OTHER:METHAMPHETAMINE_DEPENDENCE;LIKELIHOOD_THERAPEUTIC_SUCCESS
BEVACIZUMAB;GC;TT;rs4588;EFFICACY;DECREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS, DISEASE:METASTATIC_NEOPLASM;LIKELIHOOD_THERAPEUTIC_FAILURE
CETUXIMAB;GC;TT;rs4588;EFFICACY;INCREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS, DISEASE:METASTATIC_NEOPLASM;LIKELIHOOD_THERAPEUTIC_SUCCESS
DESFLURANE, ENFLURANE, HALOTHANE, ISOFLURANE, SEVOFLURANE, SUCCINYLCHOLINE;RYR1;T;rs28933397;OTHER;INCREASED;RISK;DISEASE:MALIGT_HYPERTHERMIA;;;CAUTION_SIDE_EFFECT
ASPIRIN;TAPBP;AG + GG;rs1059288;TOXICITY;INCREASED;;SIDE_EFFECT:FEV1_DECREASE_AFTER_ASPIRIN_CHALLENGE;PEOPLE;DISEASE:ASTHMA;CAUTION_SIDE_EFFECT
"""ACE INHIBITORS, PLAIN"", ""ANGIOTENSIN II ANTAGONISTS""";F5;CT;rs140530655;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ANGIOEDEMA;;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;AG;rs4244285;EFFICACY;INCREASED;RISK;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;CAUTION_SIDE_EFFECT
GEFITINIB;IKBKB;CC;rs2272733;TOXICITY;DECREASED;RISK;SIDE_EFFECT:EXANTHEMA;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""METFORMIN"", ""SULFONAMIDES, UREA DERIVATIVES""";SLC22A1;AA + AG;rs628031;EFFICACY;INCREASED;LIKELIHOOD;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY;PEOPLE;OTHER:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;AA;rs4244285;EFFICACY;INCREASED;RISK;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;CAUTION_SIDE_EFFECT
DESFLURANE, ENFLURANE, HALOTHANE, ISOFLURANE, SEVOFLURANE, SUCCINYLCHOLINE;RYR1;T;rs193922772;OTHER;INCREASED;RISK;DISEASE:MALIGT_HYPERTHERMIA;;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;AG;rs4986893;EFFICACY;INCREASED;RISK;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;CAUTION_SIDE_EFFECT
FENOTEROL;SLC22A1;T;rs12208357;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS;HEALTHY;;CAUTION_SIDE_EFFECT
FENOTEROL;SLC22A1;A;rs34130495;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS;HEALTHY;;CAUTION_SIDE_EFFECT
ACE INHIBITORS, PLAIN;AGT;GG;rs699;EFFICACY;DECREASED;RISK;DISEASE:STROKE;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;P2RY12;G;rs2046934;OTHER;INCREASED;RISK;DISEASE:PERIPHERAL_VASCULAR_DISEASES;;;CAUTION_SIDE_EFFECT
GEFITINIB;RELA;CC;rs11227247;TOXICITY;DECREASED;RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
FENOTEROL;SLC22A1;C;rs55918055;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS;HEALTHY;;CAUTION_SIDE_EFFECT
IRINOTECAN;KCNQ5;C;rs9351963;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DIARRHEA;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
FENOTEROL;SLC22A1;A;rs34059508;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS;HEALTHY;;CAUTION_SIDE_EFFECT
NAN;P2RY12;G;rs2046934;OTHER;INCREASED;;EFFICACY:PLATELET_AGGREGATION;;;CAUTION_DOSE_ADJUST
GEFITINIB;IKBKE;AG + GG;rs2151222;TOXICITY;DECREASED;RISK;SIDE_EFFECT:DIARRHEA;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ISONIAZID, PHENYTOIN;NAT2;C;rs1801280;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:CENTRAL_NERVOUS_SYSTEM_TUBERCULOSIS, DISEASE:MENINGEAL_TUBERCULOSIS;CAUTION_SIDE_EFFECT
ISONIAZID, PHENYTOIN;NAT2;A;rs1799931;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:CENTRAL_NERVOUS_SYSTEM_TUBERCULOSIS, DISEASE:MENINGEAL_TUBERCULOSIS;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;T;rs28371725;EFFICACY;INCREASED;RISK;EFFICACY:RECURRENCE;PEOPLE;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;C;rs3892097;EFFICACY;INCREASED;RISK;EFFICACY:RECURRENCE;PEOPLE;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP2D6;A;rs1065852;EFFICACY;INCREASED;RISK;EFFICACY:RECURRENCE;PEOPLE;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
PAROXETINE;HTR2A;AG;rs6314;EFFICACY;;;EFFICACY:IMPROVED_RESPONSE;PEOPLE;DISEASE:DEPRESSION;CAUTION_DOSE_ADJUST
GABAPENTIN, PREGABALIN;SLC7A5;AG;rs4240803;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ADVERSE_EVENTS;PEOPLE;OTHER:NEUROPATHIC_PAIN;CAUTION_SIDE_EFFECT
BEVACIZUMAB, CYCLOPHOSPHAMIDE;CXCR2;TT;rs2230054;EFFICACY;DECREASED;;EFFICACY:PROGRESSION_FREE_SURVIVAL;WOMEN;DISEASE:OVARIAN_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
PAROXETINE;HTR2A;AG;rs6314;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:REMISSION;PEOPLE;DISEASE:DEPRESSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
TAMOXIFEN;CYP2C19;T;rs12248560;EFFICACY;DECREASED;RISK;EFFICACY:RECURRENCE;PEOPLE;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEMCITABINE;SLCO1B1;AG + GG;rs4149086;EFFICACY;DECREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:PANCREATIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
PAROXETINE;HTR2A;GG;rs6313;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ADVERSE_DRUG_REACTION;PEOPLE;DISEASE:DEPRESSION;CAUTION_SIDE_EFFECT
HYDROCHLOROTHIAZIDE;CDCA3, GNB3, USP5;TT;rs5443;EFFICACY;INCREASED;;EFFICACY:REDUCTION_IN_BLOOD_PRESSURE;PEOPLE;DISEASE:ESSENTIAL_HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
BETA BLOCKING AGENTS;GRK5;AT + TT;rs2230345;OTHER;DECREASED;RISK;DISEASE:DEATH;PEOPLE;DISEASE:HEART_FAILURE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACENOCOUMAROL, WARFARIN;VKORC1;CT + TT;rs9923231;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OVER-ANTICOAGULATION;;;CAUTION_SIDE_EFFECT
NAN;CHRNA3;A;rs1051730;OTHER;INCREASED;RISK;DISEASE:LUNG_NEOPLASMS;PEOPLE;OTHER:WHO_HAVE_EVER_BEEN_SMOKERS;CAUTION_SIDE_EFFECT
CITALOPRAM;GRIK2;CC;rs2518224;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TREATMENT-EMERGENT_SUICIDAL_IDEATION;PEOPLE;DISEASE:DEPRESSION;CAUTION_SIDE_EFFECT
ACENOCOUMAROL, WARFARIN;VKORC1;AA + AG;rs9934438;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OVER-ANTICOAGULATION;;;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A9;G;rs7586110;TOXICITY;INCREASED;RISK;DISEASE:ANEMIA;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
ACENOCOUMAROL, WARFARIN;CYP4F2;CT + TT;rs2108622;TOXICITY;DECREASED;RISK;SIDE_EFFECT:OVER-ANTICOAGULATION;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;HYKK;C;rs8034191;OTHER;INCREASED;RISK;DISEASE:LUNG_NEOPLASMS;PEOPLE;OTHER:WHO_HAVE_EVER_BEEN_SMOKERS;CAUTION_SIDE_EFFECT
ISONIAZID, PHENYTOIN;NAT2;T;rs1041983;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:CENTRAL_NERVOUS_SYSTEM_TUBERCULOSIS, DISEASE:MENINGEAL_TUBERCULOSIS;CAUTION_SIDE_EFFECT
TACROLIMUS;TCF7L2;CC + CT;rs290487;TOXICITY;INCREASED;RISK;DISEASE:DIABETES_MELLITUS;PEOPLE;DISEASE:LIVER_TRANSPLANTATION;CAUTION_SIDE_EFFECT
ACE INHIBITORS, PLAIN;AGT;GG;rs699;EFFICACY;DECREASED;RISK;DISEASE:STROKE;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEMCITABINE;POLR2A;CC;rs2228130;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
VALPROIC ACID;CYP2C9;AC;rs1057910;OTHER, METABOLISM/PK;INCREASED;;PK:MEAN_PLASMA_DRUG_CONCENTRATIONS;PEOPLE;DISEASE:EPILEPSY;CAUTION_DOSE_ADJUST
CITALOPRAM;GRIA3;G;rs4825476;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TREATMENT-EMERGENT_SUICIDAL_IDEATION;PEOPLE;DISEASE:DEPRESSION;CAUTION_SIDE_EFFECT
IMATINIB;SLC22A5;AA + AG;rs274558;TOXICITY;DECREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY, SIDE_EFFECT:EYE_DISEASES;PEOPLE;DISEASE:GASTROINTESTINAL_STROMAL_TUMORS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ISONIAZID, PHENYTOIN;NAT2;G;rs1208;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:CENTRAL_NERVOUS_SYSTEM_TUBERCULOSIS, DISEASE:MENINGEAL_TUBERCULOSIS;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;COMT;CC + CG;rs4818;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:TARDIVE_DYSKINESIA;PEOPLE;OTHER:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
NAN;CHRNA3;A;rs1051730;OTHER;INCREASED;LIKELIHOOD;DISEASE:PERIPHERAL_VASCULAR_DISEASES;PEOPLE;DISEASE:TOBACCO_USE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;CHRNA3;A;rs1051730;OTHER;INCREASED;LIKELIHOOD;DISEASE:LUNG_NEOPLASMS;PEOPLE;DISEASE:TOBACCO_USE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
DACARBAZINE, PROCARBAZINE;EPM2AIP1;AA + AG;rs1800734;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:BREAST_NEOPLASMS;PEOPLE;DISEASE:HODGKIN_DISEASE;CAUTION_SIDE_EFFECT
ISONIAZID, PHENYTOIN;NAT2;A;rs1799930;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:CENTRAL_NERVOUS_SYSTEM_TUBERCULOSIS, DISEASE:MENINGEAL_TUBERCULOSIS;CAUTION_SIDE_EFFECT
NAN;CHRNA3;A;rs1051730;OTHER;INCREASED;;OTHER:NUMBER_OF_CIGARETTES_SMOKED_PER_DAY;PEOPLE;DISEASE:TOBACCO_USE_DISORDER;CAUTION_DOSE_ADJUST
ISONIAZID, PHENYTOIN;NAT2;T;rs1799929;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:CENTRAL_NERVOUS_SYSTEM_TUBERCULOSIS, DISEASE:MENINGEAL_TUBERCULOSIS;CAUTION_SIDE_EFFECT
IMATINIB;ABCB1;CT;rs2235040;TOXICITY;DECREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY, SIDE_EFFECT:EYE_DISEASES;PEOPLE;DISEASE:GASTROINTESTINAL_STROMAL_TUMORS;LIKELIHOOD_THERAPEUTIC_SUCCESS
DEXAMETHASONE, DOXORUBICIN, VINCRISTINE;ABCB1;AA + AC;rs2032582;EFFICACY;INCREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:MULTIPLE_MYELOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
DACARBAZINE, PROCARBAZINE;EPM2AIP1;AA + AG;rs1800734;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:THERAPY-RELATED_ACUTE_MYELOID_LEUKEMIA_(T-AML);PEOPLE;DISEASE:HODGKIN_DISEASE;CAUTION_SIDE_EFFECT
IMATINIB;EGFR;CT + TT;rs10258429;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY, SIDE_EFFECT:EYE_DISEASES;PEOPLE;DISEASE:GASTROINTESTINAL_STROMAL_TUMORS;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;COMT;AG;rs165599;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:TARDIVE_DYSKINESIA;MEN;OTHER:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
IMATINIB;SLC22A1;CG + GG;rs683369;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY, SIDE_EFFECT:EYE_DISEASES;PEOPLE;DISEASE:GASTROINTESTINAL_STROMAL_TUMORS;CAUTION_SIDE_EFFECT
RISPERIDONE;CYP2D6;AA;rs1065852;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:OBESITY;CHILDREN;DISEASE:ATYPICAL_BEHAVIOR, DISEASE:MENTAL_DISORDERS;CAUTION_SIDE_EFFECT
DACLATASVIR, SOFOSBUVIR;IFNL3, IFNL4;TT;rs8099917;EFFICACY;INCREASED;;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""ANALGESICS"", ""ANTIINFLAMMATORY AGENTS, NON-STEROIDS"", ""ERGOT ALKALOIDS"", ""OPIOIDS"", ""SUMATRIPTAN""";HTR2A;A;rs6305;OTHER;INCREASED;LIKELIHOOD;DISEASE:HEADACHE_DISORDERS, DISEASE:SUBSTANCE_WITHDRAWAL_SYNDROME;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;TBXA2R;AA;rs4523;EFFICACY;INCREASED;RISK;OTHER:HIGH_ON-ASPIRIN_RESIDUAL_PLATELET_REACTIVITY;PEOPLE;OTHER:OFF-PUMP_CORONARY_ARTERY_BYPASS_GRAFTING;CAUTION_SIDE_EFFECT
"""ANALGESICS"", ""ANTIINFLAMMATORY AGENTS, NON-STEROIDS"", ""ERGOT ALKALOIDS"", ""OPIOIDS"", ""SUMATRIPTAN""";DBH;T;rs1611115;OTHER;DECREASED;LIKELIHOOD;DISEASE:HEADACHE_DISORDERS, DISEASE:SUBSTANCE_WITHDRAWAL_SYNDROME;;;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;DRD2;CT;rs1799978;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:INSULIN_RESISTANCE;CHILDREN;DISEASE:ATYPICAL_BEHAVIOR, DISEASE:MENTAL_DISORDERS;CAUTION_SIDE_EFFECT
PACLITAXEL;ABCB1;AA;rs2032582;TOXICITY;INCREASED;RISK;DISEASE:NEUTROPENIA;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
PACLITAXEL;ABCB1;AA;rs1045642;TOXICITY;INCREASED;RISK;DISEASE:NEUTROPENIA;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
"""ANALGESICS"", ""ANTIINFLAMMATORY AGENTS, NON-STEROIDS"", ""ERGOT ALKALOIDS"", ""OPIOIDS"", ""SUMATRIPTAN""";OPRM1;G;rs1799971;OTHER;INCREASED;LIKELIHOOD;DISEASE:HEADACHE_DISORDERS, DISEASE:SUBSTANCE_WITHDRAWAL_SYNDROME;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;OTHER:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""ANALGESICS"", ""ANTIINFLAMMATORY AGENTS, NON-STEROIDS"", ""ERGOT ALKALOIDS"", ""OPIOIDS"", ""SUMATRIPTAN""";BDNF;T;rs6265;OTHER;DECREASED;LIKELIHOOD;DISEASE:HEADACHE_DISORDERS, DISEASE:SUBSTANCE_WITHDRAWAL_SYNDROME;;;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIPSYCHOTICS;COMT;AA;rs4680;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:TARDIVE_DYSKINESIA;PEOPLE;OTHER:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;TT;rs8099917;EFFICACY;INCREASED;;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;OTHER:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""ANALGESICS"", ""ANTIINFLAMMATORY AGENTS, NON-STEROIDS"", ""ERGOT ALKALOIDS"", ""OPIOIDS"", ""SUMATRIPTAN""";COMT;AA;rs4680;OTHER;DECREASED;LIKELIHOOD;DISEASE:HEADACHE_DISORDERS, DISEASE:SUBSTANCE_WITHDRAWAL_SYNDROME;;;LIKELIHOOD_THERAPEUTIC_FAILURE
RISPERIDONE;CYP2D6;AA;rs1065852;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HYPERTENSION;CHILDREN;DISEASE:ATYPICAL_BEHAVIOR, DISEASE:MENTAL_DISORDERS;CAUTION_SIDE_EFFECT
TACROLIMUS;CAPN10;CT;rs5030952;TOXICITY;INCREASED;RISK;DISEASE:DIABETES_MELLITUS;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C18;G;rs2901783;DOSAGE;;;OTHER:OUTCOME_TIME_TO_STABLE_DOSE;;;CAUTION_DOSE_ADJUST
IDARUBICIN;RAC2;AA;rs13058338;TOXICITY;DECREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:ACUTE_MYELOID_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""ANALGESICS"", ""ANTIINFLAMMATORY AGENTS, NON-STEROIDS"", ""ERGOT ALKALOIDS"", ""OPIOIDS"", ""SUMATRIPTAN""";DRD2;AA;rs6275;OTHER;DECREASED;LIKELIHOOD;DISEASE:HEADACHE_DISORDERS, DISEASE:SUBSTANCE_WITHDRAWAL_SYNDROME;;;LIKELIHOOD_THERAPEUTIC_FAILURE
IDARUBICIN;NCF4;AA;rs1883112;TOXICITY;INCREASED;RISK;SIDE_EFFECT:CARDIOTOXICITY;PEOPLE;DISEASE:ACUTE_MYELOID_LEUKEMIA;CAUTION_SIDE_EFFECT
OPIOIDS;OPRM1;AG;rs9479757;OTHER;DECREASED;RISK;DISEASE:OPIOID-RELATED_DISORDERS;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CC;rs776746;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE;PEOPLE;OTHER:LIVER_TRANSPLANTATION;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2B, PROTEASE INHIBITORS, RIBAVIRIN;ITPA;AA + AC;rs1127354;TOXICITY;DECREASED;RISK;SIDE_EFFECT:ANEMIA;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;GAL;CC;rs948854;OTHER;INCREASED;RISK;DISEASE:OPIOID-RELATED_DISORDERS;;;CAUTION_SIDE_EFFECT
OPIOIDS;ABCB1;GG;rs1045642;OTHER;DECREASED;RISK;DISEASE:OPIOID-RELATED_DISORDERS;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;OPRD1;A;rs2236861;OTHER;DECREASED;RISK;DISEASE:OPIOID-RELATED_DISORDERS;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IDARUBICIN;CYBA;AG + GG;rs4673;EFFICACY;INCREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:ACUTE_MYELOID_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
HYDROCHLOROTHIAZIDE;NOS3;GG;rs1799983;EFFICACY;INCREASED;;EFFICACY:REDUCTION_IN_DIASTOLIC_BLOOD_PRESSURE;PEOPLE;DISEASE:ESSENTIAL_HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
IDARUBICIN;CYBA;AA + AG;rs4673;TOXICITY;DECREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:ACUTE_MYELOID_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
PRAVASTATIN;CETP;A;rs708272;EFFICACY;INCREASED;RISK;DISEASE:DEATH;MEN;DISEASE:CORONARY_ARTERY_DISEASE;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2B, PROTEASE INHIBITORS, RIBAVIRIN;SLC28A2;TT;rs11854484;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ANEMIA;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;CAUTION_SIDE_EFFECT
DACLATASVIR, SOFOSBUVIR;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
DIURETICS;PDE4D;TT;rs702553;EFFICACY;DECREASED;;EFFICACY:BASELINE_MEAN_ARTERIAL_BLOOD_PRESSURE;PEOPLE;DISEASE:NEPHROSCLEROSIS;LIKELIHOOD_THERAPEUTIC_FAILURE
CITALOPRAM, FLUVOXAMINE, PAROXETINE, SERTRALINE, VENLAFAXINE;ABCB1;T;rs2235040;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ADVERSE_EFFECTS;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_SIDE_EFFECT
ESCITALOPRAM;KCNE1;C;rs1805127;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ACQUIRED_LONG_QT_SYNDROME_(ALQTS);;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;DECREASED;;EFFICACY:PLATELET_INHIBITION;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
ESCITALOPRAM;KCNE1;TT;rs4817668;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ACQUIRED_LONG_QT_SYNDROME_(ALQTS);;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;INCREASED;RISK;OTHER:HIGH_PLATELET_REACTIVITY;PEOPLE;OTHER:CORONARY_ARTERY_DISEASE_UNDERGOING_STENT_IMPLANTATION;CAUTION_SIDE_EFFECT
DRUGS USED IN NICOTINE DEPENDENCE;CHRNA5;T;rs588765;EFFICACY;;;EFFICACY:INCREASED_CHANCE_OF_ACHIEVING_6_MONTH_ABSTINENCE_IF_PRESCRIBED_NRT_(NICOTIENE_REPLACEMENT_THERAPY);;;CAUTION_DOSE_ADJUST
NAN;CHRNA3;A;rs1051730;EFFICACY;;;EFFICACY:DECREASED_CHANCE_OF_ACHIEVING_6_MONTH_ABSTINENCE_IN_THE_PLACEBO_GROUP;;;CAUTION_DOSE_ADJUST
AZATHIOPRINE, MERCAPTOPURINE;NUDT15;T;rs116855232;TOXICITY;INCREASED;RISK;SIDE_EFFECT:PANCYTOPENIA, SIDE_EFFECT:THROMBOCYTOPENIA;PEOPLE;OTHER:AUTOIMMUNE_DISEASES, OTHER:INFLAMMATORY_BOWEL_DISEASES;CAUTION_SIDE_EFFECT
DRUGS USED IN NICOTINE DEPENDENCE;CHRNA3;A;rs1051730;EFFICACY;;;EFFICACY:INCREASED_CHANCE_OF_ACHIEVING_6_MONTH_ABSTINENCE_IF_PRESCRIBED_NRT_(NICOTIENE_REPLACEMENT_THERAPY);;;CAUTION_DOSE_ADJUST
CITALOPRAM, FLUVOXAMINE, PAROXETINE, SERTRALINE, VENLAFAXINE;ABCB1;G;rs2032583;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ADVERSE_EFFECTS;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;CC;rs1801159;TOXICITY, METABOLISM/PK;INCREASED;LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;CC;rs1801159;TOXICITY, METABOLISM/PK;INCREASED;LIKELIHOOD;SIDE_EFFECT:NAUSEA, SIDE_EFFECT:VOMITING;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
CISPLATIN, CYCLOPHOSPHAMIDE, DOXORUBICIN, METHOTREXATE, VINCRISTINE;ABCB1;C;rs4148737;EFFICACY;INCREASED;RISK;EFFICACY:DEATH;PEOPLE;DISEASE:OSTEOSARCOMA;CAUTION_SIDE_EFFECT
CISPLATIN, CYCLOPHOSPHAMIDE, DOXORUBICIN, METHOTREXATE, VINCRISTINE;ABCC3;T;rs4148416;EFFICACY;INCREASED;RISK;EFFICACY:DEATH;PEOPLE;DISEASE:OSTEOSARCOMA;CAUTION_SIDE_EFFECT
NAN;FOXO3;TT;rs4946936;EFFICACY;DECREASED;;EFFICACY:OVERALL_SURVIVAL;CHILDREN;OTHER:RHABDOMYOSARCOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
NEVIRAPINE;ABCB1;A;rs1045642;TOXICITY;DECREASED;RISK;DISEASE:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;FOXO3;GG;rs17069665;EFFICACY;DECREASED;;EFFICACY:OVERALL_SURVIVAL;CHILDREN;OTHER:RHABDOMYOSARCOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
NAN;ARNT;T/del + del/del;rs3215133;OTHER;DECREASED;LIKELIHOOD;DISEASE:COLORECTAL_NEOPLASMS;;;LIKELIHOOD_THERAPEUTIC_FAILURE
METHADONE;ARRB2;GG;rs2036657;EFFICACY;INCREASED;SEVERITY;EFFICACY:PAIN;PEOPLE;OTHER:NEOPLASMS;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE, EPIRUBICIN, PACLITAXEL;ABCB1;A;rs2032582;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
ETHANOL;GHSR;AG;rs2232165;OTHER;;;OTHER:HEAVY_CONSUMPTION;;;CAUTION_DOSE_ADJUST
CYCLOPHOSPHAMIDE, EPIRUBICIN, PACLITAXEL;ABCB1;G;rs1045642;TOXICITY;DECREASED;LIKELIHOOD;DISEASE:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN, CYCLOPHOSPHAMIDE, DOXORUBICIN, METHOTREXATE, VINCRISTINE;ABCB1;C;rs10276036;EFFICACY;INCREASED;RISK;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:OSTEOSARCOMA;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;NEFM;G;rs1379357;EFFICACY;;;EFFICACY:RESPONSE_TIME;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_DOSE_ADJUST
CISPLATIN, CYCLOPHOSPHAMIDE, DOXORUBICIN, METHOTREXATE, VINCRISTINE;ABCB1;G;rs1128503;EFFICACY;INCREASED;RISK;EFFICACY:DEATH;PEOPLE;DISEASE:OSTEOSARCOMA;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;NEFM;G;rs1457266;EFFICACY;;;EFFICACY:RESPONSE_TIME;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_DOSE_ADJUST
NAN;ARNT;AA + AG;rs12410394;OTHER;DECREASED;LIKELIHOOD;DISEASE:COLORECTAL_NEOPLASMS;;;LIKELIHOOD_THERAPEUTIC_FAILURE
CELECOXIB;IL23R;A;rs7518660;TOXICITY;INCREASED;RISK;DISEASE:ADENOMA;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
CELECOXIB;ALOX12;A;rs11078659;TOXICITY;INCREASED;RISK;DISEASE:ADENOMA;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
NAN;CYP1A2;CT + TT;rs2470890;OTHER;DECREASED;LIKELIHOOD;DISEASE:COLORECTAL_NEOPLASMS;;;LIKELIHOOD_THERAPEUTIC_FAILURE
NAN;;CT + TT;rs11072508;OTHER;DECREASED;LIKELIHOOD;DISEASE:COLORECTAL_NEOPLASMS;;;LIKELIHOOD_THERAPEUTIC_FAILURE
CELECOXIB;PTGES;C;rs2302821;TOXICITY;INCREASED;RISK;SIDE_EFFECT:CARDIOVASCULAR_TOXICITY_AND_SYMPTOMS;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
NAN;CSK;CG + GG;rs4886410;OTHER;DECREASED;LIKELIHOOD;DISEASE:COLORECTAL_NEOPLASMS;;;LIKELIHOOD_THERAPEUTIC_FAILURE
CELECOXIB;PTGER4;T;rs4133101;TOXICITY;INCREASED;RISK;SIDE_EFFECT:GASTROINTESTINAL_TOXICITIES;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
CARBOPLATIN, CYCLOPHOSPHAMIDE, THIOTEPA;ALDH3A1;CC + CG;rs2228100;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:CYSTITIS;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
TAMOXIFEN;ABCC2;AA;rs3740065;EFFICACY, METABOLISM/PK;INCREASED;RISK;EFFICACY:RECURRENCE_OF_BREAST_CANCER;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
CAFFEINE;CYP1A2;AA;rs762551;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:INSOMNIA;;;CAUTION_SIDE_EFFECT
DEXAMETHASONE, DOXORUBICIN, VINCRISTINE;ABCB1;GG;rs1045642;EFFICACY;DECREASED;;EFFICACY:SURVIVAL;PEOPLE;DISEASE:MULTIPLE_MYELOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
FARGLITAZAR, INSULINS AND ANALOGUES;SCNN1B;A;rs34241435;TOXICITY;;;SIDE_EFFECT:OEDEMA;PEOPLE;DISEASE:DIABETES_MELLITUS_T2;CAUTION_DOSE_ADJUST
HYDROCHLOROTHIAZIDE;SCNN1G;CC;rs5723;EFFICACY;DECREASED;;EFFICACY:REDUCTION_IN_OFFICE_DIASTOLIC_BLOOD_PRESSURE;PEOPLE;DISEASE:ESSENTIAL_HYPERTENSION;LIKELIHOOD_THERAPEUTIC_FAILURE
FARGLITAZAR, GLYBURIDE;SCNN1B;A;rs889299;TOXICITY;;;SIDE_EFFECT:OEDEMA;PEOPLE;DISEASE:DIABETES_MELLITUS_T2;CAUTION_DOSE_ADJUST
HYDROCHLOROTHIAZIDE;SCNN1G;TT;rs5729;EFFICACY;DECREASED;;EFFICACY:REDUCTION_IN_OFFICE_DIASTOLIC_BLOOD_PRESSURE;PEOPLE;DISEASE:ESSENTIAL_HYPERTENSION;LIKELIHOOD_THERAPEUTIC_FAILURE
GEFITINIB;IKBKE;CC;rs12142086;TOXICITY;INCREASED;RISK;SIDE_EFFECT:EXANTHEMA;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
NICOTINE;CHRNA5;C;rs680244;OTHER;DECREASED;LIKELIHOOD;OTHER:ABSTINENCE;PEOPLE;DISEASE:TOBACCO_USE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;MTHFR;AA + AG;rs1801133;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:MUCOSITIS, SIDE_EFFECT:ORAL_ULCER;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
METHADONE;ARRB2;CC;rs1045280;EFFICACY;INCREASED;SEVERITY;EFFICACY:PAIN;PEOPLE;OTHER:NEOPLASMS;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;CT;rs776746;EFFICACY;DECREASED;;EFFICACY:DOSE-ADJUSTED_TACROLIMUS_BLOOD_CONCENTRATION;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
LORAZEPAM;UGT2B15;AA;rs1902023;METABOLISM/PK;INCREASED;;PK:AREA_UNDER_THE_VISUAL_ANALOG_SCALE-TIME_CURVE_DURING_THE_INDUCED_STATE;;;CAUTION_DOSE_ADJUST
CYCLOPHOSPHAMIDE, EPIRUBICIN, PACLITAXEL;ABCB1;G;rs3213619;TOXICITY;DECREASED;LIKELIHOOD;DISEASE:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE, EPIRUBICIN, PACLITAXEL;TUBB2A;C;rs9501929;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
NALOXONE, OXYCODONE;COMT;GG;rs4680;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ERYTHEMA;PEOPLE;OTHER:PAIN;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A4;CT;rs2740574;METABOLISM/PK;DECREASED;;PK:DOSE-ADJUSTED_TACROLIMUS_BLOOD_CONCENTRATIONS;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
NICOTINE;CHRNA5;A;rs16969968;OTHER;DECREASED;LIKELIHOOD;OTHER:ABSTINENCE;PEOPLE;DISEASE:TOBACCO_USE_DISORDER;LIKELIHOOD_THERAPEUTIC_FAILURE
METHADONE;ARRB2;AA;rs3786047;EFFICACY;INCREASED;SEVERITY;EFFICACY:PAIN;PEOPLE;OTHER:NEOPLASMS;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;AA + AG;rs1801133;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ELEVATED_LIVER_ENZYMES;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
BISOPROLOL;CYP3A5;TT;rs776746;EFFICACY;INCREASED;SEVERITY;EFFICACY:ELEVATED_SYSTOLIC_BLOOD_PRESSURE, EFFICACY:ELEVATED_DIASTOLIC_BLOOD_PRESSURE;PEOPLE;OTHER:ACUTE_CORONARY_SYNDROME;CAUTION_SIDE_EFFECT
NALOXONE, OXYCODONE;OPRM1;AA;rs1799971;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ERYTHEMA;PEOPLE;OTHER:PAIN;CAUTION_SIDE_EFFECT
PAZOPANIB;VEGFA;CC;rs2010963;EFFICACY;INCREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
HYDROCHLOROTHIAZIDE;WNK1;GG;rs1159744;EFFICACY;INCREASED;;EFFICACY:REDUCTION_IN_WHOLE_DAY_AMBULATORY_BLOOD_PRESSURE;PEOPLE;DISEASE:ESSENTIAL_HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
TAMOXIFEN;CYP2C19;T;rs12248560;EFFICACY;INCREASED;;EFFICACY:EVENT-FREE_SURVIVAL;PEOPLE;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE;CYP2B6;TT;rs3745274;TOXICITY;DECREASED;RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE;PEOPLE;OTHER:LUPUS_NEPHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;SLC22A3;TT;rs2504938;EFFICACY;DECREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:PANCREATIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
NALOXONE, OXYCODONE;COMT;AA;rs4680;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:VOMITING;PEOPLE;OTHER:PAIN;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;CYP2B6;GT;rs3745274;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DIARRHEA;PEOPLE;OTHER:LUPUS_NEPHRITIS;CAUTION_SIDE_EFFECT
FLUOROURACIL, LEUCOVORIN;UMPS;CC + CG;rs1801019;TOXICITY, METABOLISM/PK;;;DISEASE:DIARRHEA;PEOPLE;DISEASE:ADENOCARCINOMA;CAUTION_DOSE_ADJUST
FLUOROURACIL, LEUCOVORIN;UMPS;CC;rs1801019;TOXICITY, METABOLISM/PK;INCREASED;LIKELIHOOD;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:ADENOCARCINOMA;CAUTION_SIDE_EFFECT
BUPRENORPHINE, METHADONE;COMT;AG + GG;rs4680;EFFICACY;DECREASED;SEVERITY;EFFICACY:PAIN;PEOPLE;OTHER:OPIOID-RELATED_DISORDERS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE, FLUOROURACIL;DPYD;T;rs56038477;TOXICITY;INCREASED;SEVERITY;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
NAN;SLC22A3;AA;rs512077;EFFICACY;INCREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:PANCREATIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUPRENORPHINE, METHADONE;OPRM1;AG + GG;rs1799971;EFFICACY;DECREASED;SEVERITY;EFFICACY:PAIN;PEOPLE;OTHER:OPIOID-RELATED_DISORDERS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE, FLUOROURACIL;DPYD;CC + CT;rs2297595;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:BREAST_NEOPLASMS, DISEASE:GASTROESOPHAGEAL_CANCER;CAUTION_SIDE_EFFECT
GLUCARPIDASE;ABCC4;AG + GG;rs7317112;TOXICITY;INCREASED;RISK;OTHER:NEPHROTOXICITY;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
HYDROCHLOROTHIAZIDE;ADRB2;AA + AG;rs2400707;EFFICACY;INCREASED;;EFFICACY:REDUCTION_IN_WHOLE_DAY_AMBULATORY_BLOOD_PRESSURE;PEOPLE;DISEASE:ESSENTIAL_HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE;CYP2B6;TT;rs3745274;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;OTHER:LUPUS_NEPHRITIS;CAUTION_SIDE_EFFECT
NICOTINE;CHRNA5;GG;rs16969968;OTHER;INCREASED;;OTHER:FUNCTIONAL_MRI_REACTIVITY_TO_SMOKING_IMAGES;WOMEN;OTHER:NICOTINE_DEPENDENCE;CAUTION_DOSE_ADJUST
HYDROCHLOROTHIAZIDE;WNK1;CC;rs1159744;OTHER;INCREASED;;SIDE_EFFECT:URINARY_POTASSIUM_EXCRETION;PEOPLE;DISEASE:ESSENTIAL_HYPERTENSION;CAUTION_DOSE_ADJUST
HEROIN;DRD2;A;rs1076560;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:HEROIN_DEPENDENCE;;;CAUTION_SIDE_EFFECT
SUFENTANIL;ABCB1;GG;rs1128503;EFFICACY;DECREASED;SEVERITY;EFFICACY:PAIN, POSTOPERATIVE;PEOPLE;OTHER:SURGERY, OTHER:FRACTURES*^BONE;LIKELIHOOD_THERAPEUTIC_SUCCESS
HYDROCHLOROTHIAZIDE;WNK1;CC + CT;rs2107614;EFFICACY;INCREASED;;EFFICACY:REDUCTION_IN_WHOLE_DAY_AMBULATORY_BLOOD_PRESSURE;PEOPLE;DISEASE:ESSENTIAL_HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
HYDROCHLOROTHIAZIDE;RAD52, WNK1;CC;rs2277869;EFFICACY;INCREASED;;EFFICACY:REDUCTION_IN_WHOLE_DAY_AMBULATORY_BLOOD_PRESSURE;PEOPLE;DISEASE:ESSENTIAL_HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPARAGINASE, CYCLOPHOSPHAMIDE, CYTARABINE, DOXORUBICIN, MERCAPTOPURINE, PREDNISONE, VINCRISTINE;XRCC1;AA + AG;rs1799782;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:MYELOSUPPRESSION;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
METFORMIN;SLC47A2;T;rs34399035;METABOLISM/PK;DECREASED;;PK:METFORMIN_UPTAKE_IN_HEK-293_CELLS_AND_REDUCTION_IN_PROTEIN_EXPRESSION_LEVELS;;;CAUTION_DOSE_ADJUST
OXALIPLATIN;ABCB1;AA;rs1128503;EFFICACY;INCREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANLOTINIB, APATINIB, AXITINIB, BEVACIZUMAB, SORAFENIB, SUNITINIB;KDR;A;rs1870377;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HYPERTENSION, SIDE_EFFECT:HAND-FOOT_SYNDROME;PEOPLE;OTHER:COLORECTAL_NEOPLASMS, OTHER:BREAST_NEOPLASMS,OTHER:OVARIAN_NEOPLASMS, OTHER:HEPATOCELLULAR_CARCINOMA, OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
CYTARABINE, IDARUBICIN;CBR3;GG;rs8133052;TOXICITY;DECREASED;RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE;PEOPLE;OTHER:ACUTE_MYELOID_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;;T;rs16871327;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HEMORRHAGE;;;CAUTION_SIDE_EFFECT
WARFARIN;EPHA7;C;rs78132896;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HEMORRHAGE;;;CAUTION_SIDE_EFFECT
FENOFIBRATE;FABP1;CC + CT;rs2241883;TOXICITY;INCREASED;RISK;DISEASE:HYPERTRIGLYCERIDEMIA;PEOPLE;DISEASE:HYPERTRIGLYCERIDEMIA;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;SNAP25;TT;rs1051312;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:WEIGHT_GAIN;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEFITINIB;TAB2;CT + TT;rs577001;TOXICITY;DECREASED;RISK;SIDE_EFFECT:DIARRHEA;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFIT1;TT;rs304478;EFFICACY;INCREASED;;EFFICACY:SVR_(SUSTAINED_VIROLOGICAL_RESPONSE);PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B, RIBAVIRIN;OASL;T;rs12819210;EFFICACY;INCREASED;;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
OXALIPLATIN;ABCB1;AG;rs1045642;EFFICACY;INCREASED;;EFFICACY:RECURRENCE-FREE_SURVIVAL;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
PAZOPANIB;VEGFA;TT;rs833061;EFFICACY;INCREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
COCAINE;SLC6A3;TT;rs6347;TOXICITY;INCREASED;RISK;DISEASE:DEATH;PEOPLE;DISEASE:COCAINE_DEPENDENCE;CAUTION_SIDE_EFFECT
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;;EFFICACY:RESPONSE_RATE_(RR);PEOPLE;DISEASE:ADENOCARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATORVASTATIN;ABCB1;AA;rs1045642;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:STATIN-RELATED_MYOPATHY;;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE, EPIRUBICIN, PACLITAXEL;ABCC2;A;rs8187710;TOXICITY;DECREASED;LIKELIHOOD;DISEASE:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL_(PFS)_TIME;PEOPLE;DISEASE:ADENOCARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
COCAINE;DRD2;A;rs1076560;TOXICITY;INCREASED;RISK;DISEASE:DEATH;PEOPLE;DISEASE:COCAINE_DEPENDENCE;CAUTION_SIDE_EFFECT
ANTIINFLAMMATORY AGENTS, NON-STEROIDS;VKORC1;CT + TT;rs9923231;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:GASTROINTESTINAL_HEMORRHAGE;;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE, EPIRUBICIN, PACLITAXEL;ABCC2;A;rs17222723;TOXICITY;DECREASED;LIKELIHOOD;DISEASE:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE, EPIRUBICIN, PACLITAXEL;CYP1B1;C;rs1056836;TOXICITY;DECREASED;LIKELIHOOD;DISEASE:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANLOTINIB, APATINIB, AXITINIB, BEVACIZUMAB, SORAFENIB, SUNITINIB;KDR;A;rs1870377;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;OTHER:COLORECTAL_NEOPLASMS, OTHER:BREAST_NEOPLASMS,OTHER:OVARIAN_NEOPLASMS, OTHER:HEPATOCELLULAR_CARCINOMA, OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED;;EFFICACY:RESPONSE_RATE_(RR);PEOPLE;DISEASE:ADENOCARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEFITINIB;NFKBIA;AA + AT;rs2233407;TOXICITY;DECREASED;RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE, EPIRUBICIN, PACLITAXEL;SPIDR;G;rs6473187;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
GEFITINIB;NR1H2;CT + TT;rs2695121;TOXICITY;DECREASED;RISK;SIDE_EFFECT:DIARRHEA;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE, EPIRUBICIN, PACLITAXEL;SLCO1B1;T;rs3829306;TOXICITY;DECREASED;LIKELIHOOD;DISEASE:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
SUNITINIB;VEGFA;CG + GG;rs2010963;EFFICACY;INCREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE, EPIRUBICIN, PACLITAXEL;EPHA6;G;rs301927;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
WARFARIN;;G;rs115112393;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HEMORRHAGE;;;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;HTR2C;GG;rs6318;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:WEIGHT_GAIN;;;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;HTR2C;CC;rs3813929;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:WEIGHT_GAIN;;;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;HTR2C;GG;rs518147;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:WEIGHT_GAIN;;;CAUTION_SIDE_EFFECT
ATORVASTATIN;ABCB1;AA;rs2032582;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:STATIN-RELATED_MYOPATHY;;;CAUTION_SIDE_EFFECT
COCAINE;DRD2;A;rs2283265;TOXICITY;INCREASED;RISK;DISEASE:DEATH;PEOPLE;DISEASE:COCAINE_DEPENDENCE;CAUTION_SIDE_EFFECT
ANLOTINIB, APATINIB, AXITINIB, BEVACIZUMAB, SORAFENIB, SUNITINIB;KDR;CT + TT;rs2305948;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:OVERALL_SURVIVAL;PEOPLE;OTHER:COLORECTAL_NEOPLASMS, OTHER:BREAST_NEOPLASMS,OTHER:OVARIAN_NEOPLASMS, OTHER:HEPATOCELLULAR_CARCINOMA, OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIPSYCHOTICS;DRD2;A;rs6275;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:WEIGHT_GAIN;;;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;DRD2;CC;rs7131056;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:WEIGHT_GAIN;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIPSYCHOTICS;INSIG2;C;rs17047764;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:WEIGHT_GAIN;;;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;GNB3;TT;rs5443;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:WEIGHT_GAIN;;;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;MC4R;AA;rs489693;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:WEIGHT_GAIN;;;CAUTION_SIDE_EFFECT
TIANEPTINE;OPRM1;AA;rs1799971;TOXICITY;INCREASED;RISK;OTHER:SUICIDAL_IDEATION;PEOPLE;OTHER:MAJOR_DEPRESSIVE_DISORDER;CAUTION_SIDE_EFFECT
ATORVASTATIN;ABCB1;A;rs1128503;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:STATIN-RELATED_MYOPATHY;;;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;BDNF, BDNF-AS;CC;rs6265;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:WEIGHT_GAIN;;;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;ADRA2A;G;rs1800544;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:WEIGHT_GAIN;;;CAUTION_SIDE_EFFECT
ANLOTINIB, APATINIB, AXITINIB, BEVACIZUMAB, SORAFENIB, SUNITINIB;KDR;G;rs2071559;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;OTHER:COLORECTAL_NEOPLASMS, OTHER:BREAST_NEOPLASMS,OTHER:OVARIAN_NEOPLASMS, OTHER:HEPATOCELLULAR_CARCINOMA, OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
THEOPHYLLINE;CYP1A2;GG;rs2069514;METABOLISM/PK;INCREASED;;PK:RATIO_OF_1,3_DMU/THEOPHYLLINE;PEOPLE;DISEASE:ASTHMA;CAUTION_DOSE_ADJUST
ANTIPSYCHOTICS;DRD2;del;rs1799732;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:WEIGHT_GAIN;;;CAUTION_SIDE_EFFECT
GEFITINIB;NFKBIA;AG + GG;rs2233409;TOXICITY;DECREASED;RISK;SIDE_EFFECT:DIARRHEA;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
GEFITINIB;NFKBIA;AG + GG;rs8904;TOXICITY;INCREASED;RISK;SIDE_EFFECT:EXANTHEMA;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;A;rs4986893;EFFICACY;INCREASED;RISK;EFFICACY:CLOPIDOGREL_RESISTANCE;;OTHER:PATIENTS_WHO_UNDERWENT_SUCCESSFUL_PERCUTANEOUS_CORONARY_INTERVENTION;CAUTION_SIDE_EFFECT
GEFITINIB;NFKBIB;CC;rs2053071;TOXICITY;DECREASED;RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
LEVODOPA;DRD3;CT + TT;rs6280;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HALLUCINATIONS;PEOPLE;OTHER:PARKINSON_DISEASE;CAUTION_SIDE_EFFECT
GEFITINIB;NFKBIA;AG + GG;rs2233406;TOXICITY;DECREASED;RISK;SIDE_EFFECT:DIARRHEA;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;ITGB3;C;rs5918;EFFICACY;;;EFFICACY:LESS_DECREASE_IN_THE_PLATELET_REACTIVITY_AFTER_600_MG_OF_CLOPIDOGREL;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;CAUTION_DOSE_ADJUST
CLOPIDOGREL;ITGB3;CT;rs5918;EFFICACY;DECREASED;;EFFICACY:ANTIPLATELET_EFFECT_TO_A_300_MG_CLOPIDOGREL_LOADING-DOSE_UP_TO_24_H_FOLLOWING_INTERVENTION;;OTHER:PATIENTS_UNDERGOING_CORONARY_STENT_IMPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
CYTARABINE, FLUDARABINE, GEMTUZUMAB OZOGAMICIN, IDARUBICIN;CYP2E1;A;rs2070673;TOXICITY;DECREASED;LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:ACUTE_MYELOID_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYTARABINE, FLUDARABINE, GEMTUZUMAB OZOGAMICIN, IDARUBICIN;CYP2E1;T;rs2515641;TOXICITY;DECREASED;LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:ACUTE_MYELOID_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYTARABINE, FLUDARABINE, GEMTUZUMAB OZOGAMICIN, IDARUBICIN;SLCO1B1;C;rs4149056;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:ACUTE_MYELOID_LEUKEMIA;CAUTION_SIDE_EFFECT
PERINDOPRIL;AGTR1;TT;rs275651;EFFICACY;DECREASED;RISK;EFFICACY:CARDIAC_EVENTS;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYTARABINE, FLUDARABINE, GEMTUZUMAB OZOGAMICIN, IDARUBICIN;SULT2B1;T;rs2302948;TOXICITY;DECREASED;LIKELIHOOD;DISEASE:FEVER;PEOPLE;DISEASE:ACUTE_MYELOID_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ESCITALOPRAM;KCNH2;AA;rs3807372;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ACQUIRED_LONG_QT_SYNDROME_(ALQTS);;;CAUTION_SIDE_EFFECT
HEROIN;OPRM1;AA + AG;rs1799971;OTHER;DECREASED;LIKELIHOOD;OTHER:ADDICTION;;;LIKELIHOOD_THERAPEUTIC_FAILURE
GEFITINIB;IKBKB;AA;rs9694958;TOXICITY;INCREASED;RISK;SIDE_EFFECT:EXANTHEMA;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
CYTARABINE, FLUDARABINE, GEMTUZUMAB OZOGAMICIN, IDARUBICIN;SLC22A12;TT;rs11231825;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:FEVER;PEOPLE;DISEASE:ACUTE_MYELOID_LEUKEMIA;CAUTION_SIDE_EFFECT
GEFITINIB;IKBKE;CC + CT;rs3748022;TOXICITY;INCREASED;RISK;SIDE_EFFECT:EXANTHEMA;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
ASPIRIN;FSIP1;G;rs7179742;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ASPIRIN-INTOLERANT_ASTHMA;PEOPLE;DISEASE:ASTHMA;CAUTION_SIDE_EFFECT
ASPIRIN;PTGS1;G;rs10306114;EFFICACY;INCREASED;RISK;EFFICACY:NON-RESPONSE_TO_ASPIRIN;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;CAUTION_SIDE_EFFECT
DRUGS FOR TREATMENT OF TUBERCULOSIS;XPO1;AA;rs4430924;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;OTHER:TUBERCULOSIS;CAUTION_SIDE_EFFECT
ASPIRIN;CEP68;AA + AG;rs7572857;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ASPIRIN-INTOLERANT_ASTHMA;PEOPLE;DISEASE:ASTHMA;CAUTION_SIDE_EFFECT
CYCLOSPORINE, MYCOPHENOLATE MOFETIL;ABCB1;A;rs2032582;EFFICACY;INCREASED;RISK;DISEASE:TRANSPLANT_REJECTION;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
PAROXETINE;HTR2A;CC;rs6311;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:NAUSEA;PEOPLE;OTHER:MAJOR_DEPRESSIVE_DISORDER;CAUTION_SIDE_EFFECT
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;;G;rs10945919;EFFICACY;INCREASED;RISK;EFFICACY:NON-RESPONSE;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
AMISULPRIDE, CLOZAPINE, HALOPERIDOL, OLANZAPINE, QUETIAPINE, RISPERIDONE, ZIPRASIDONE, ZUCLOPENTHIXOL;CYP2D6;A/DELA;rs5030655;TOXICITY;INCREASED;RISK;SIDE_EFFECT:EXTRAPYRAMIDAL_SYMPTOMS;PEOPLE;OTHER:SCHIZOPHRENIA, OTHER:BIPOLAR_DISORDER,OTHER:PERSONALITY_DISORDER, OTHER:PSYCHOTIC_DISORDER, OTHER:OBSESSIVE_COMPULSIVE_DISORDER;CAUTION_SIDE_EFFECT
DAUNORUBICIN, DOXORUBICIN, EPIRUBICIN;SLC28A3;AA + AG;rs7853758;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:LEFT_VENTRICULAR_DYSFUNCTION;CHILDREN;OTHER:NEOPLASMS;CAUTION_SIDE_EFFECT
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;AA;rs1799930;TOXICITY;INCREASED;RISK;DISEASE:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;AG;rs1799931;TOXICITY;INCREASED;RISK;DISEASE:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
CETUXIMAB, PANITUMUMAB;KRAS;AC + CC;rs61764370;EFFICACY;INCREASED;;DISEASE:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;TT;rs1041983;TOXICITY;INCREASED;RISK;DISEASE:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE, FLUOROURACIL, METHOTREXATE;FGFR4;GG;rs351855;EFFICACY;INCREASED;LIKELIHOOD;OTHER:DISEASE_FREE_SURVIVAL;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;CERS6;A;rs13393173;EFFICACY;INCREASED;RISK;EFFICACY:NON-RESPONSE;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CES1;CT;rs71647871;METABOLISM/PK;INCREASED;;PK:LEVELS_OF_CLOPIDOGREL_ACTIVE_METABOLITE;HEALTHY;;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CES1;CT;rs71647871;EFFICACY;DECREASED;;EFFICACY:_ON-TREATMENT_ADP-INDUCED_PLATELET_AGGREGATION;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CES1;CT;rs71647871;EFFICACY;DECREASED;;EFFICACY:ON-TREATMENT_ADP-INDUCED_PLATELET_AGGREGATION;PEOPLE;DISEASE:CORONARY_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;A;rs4986893;EFFICACY;DECREASED;;PK:CMAX_OF_THE_ACTIVE_METABOLITE;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;DECREASED;;PK:CMAX_OF_THE_ACTIVE_METABOLITE;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
CARBOPLATIN, PEMETREXED;MTHFR;AA;rs1801133;EFFICACY;INCREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
VEMURAFENIB;ABCB1;AA;rs1045642;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;OTHER:MELANOMA;CAUTION_SIDE_EFFECT
VEMURAFENIB;CYP3A4;AA + AG;rs35599367;TOXICITY;INCREASED;LIKELIHOOD;"""SIDE_EFFECT:CARCINOMA, SQUAMOUS_CELL"", ""SIDE_EFFECT:HYPERBILIRUBINEMIA"", ""SIDE_EFFECT:NAUSEA""";PEOPLE;OTHER:MELANOMA;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;INCREASED;;EFFICACY:PLATELET_REACTIVITY_INDEX_(PRI)_AT_4_H_AFTER_THE_DOSING;HEALTHY;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CITALOPRAM, ESCITALOPRAM, FLUOXETINE, PAROXETINE, SERTRALINE;HTR2A;AA;rs7997012;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;A;rs4986893;EFFICACY;INCREASED;;EFFICACY:PLATELET_REACTIVITY_INDEX_(PRI)_AT_4_H_AFTER_THE_DOSING;HEALTHY;;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;TT;rs9923231;EFFICACY;DECREASED;;EFFICACY:TIME_TO_THERAPEUTIC_INR;;;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL, IRINOTECAN, LEUCOVORIN;KLC1, XRCC3;GG;rs861539;EFFICACY;DECREASED;;EFFICACY:PROGRESSION_FREE_SURVIVAL;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP3A5;TT;rs776746;DOSAGE, METABOLISM/PK;;;PK:RISK_OF_BEING_UNDERDOSED;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
OPIOIDS;SLC18A2;A;rs363332;OTHER;INCREASED;LIKELIHOOD;SIDE_EFFECT:OPIOID-RELATED_DISORDERS;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;SLC18A2;G;rs363334;OTHER;INCREASED;LIKELIHOOD;SIDE_EFFECT:OPIOID-RELATED_DISORDERS;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;SLC18A2;C;rs363338;OTHER;INCREASED;LIKELIHOOD;SIDE_EFFECT:OPIOID-RELATED_DISORDERS;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE, EPIRUBICIN, PACLITAXEL;MISP;G;rs8110536;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;AA + AG;rs4986893;EFFICACY;;;EFFICACY:HIGHER_P2Y12_REACTION_UNITS_(PRU)_AND_LOWER_PERCENT_INHIBITION;PEOPLE;DISEASE:CEREBROVASCULAR_DISORDERS;CAUTION_DOSE_ADJUST
PACLITAXEL;EPHA5;TT;rs7349683;TOXICITY;INCREASED;RISK;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;WOMEN;DISEASE:BREAST_NEOPLASMS, DISEASE:OVARIAN_NEOPLASMS;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;INCREASED;RISK;EFFICACY:NON-RESPONSE_TO_CLOPIDOGREL;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;CAUTION_SIDE_EFFECT
SUNITINIB;VEGFA;AA + AC;rs699947;EFFICACY;INCREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
PAZOPANIB;VEGFA;CC;rs699947;EFFICACY;INCREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYTARABINE, IDARUBICIN;NQO2;CC;rs1143684;TOXICITY;INCREASED;RISK;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY;PEOPLE;OTHER:ACUTE_MYELOID_LEUKEMIA;CAUTION_SIDE_EFFECT
PACLITAXEL;EPHA6;G;rs301927;TOXICITY;INCREASED;RISK;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;WOMEN;DISEASE:BREAST_NEOPLASMS, DISEASE:OVARIAN_NEOPLASMS;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;CC;rs776746;TOXICITY;INCREASED;RISK;DISEASE:HYPERLIPIDEMIAS;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;A;rs4986893;EFFICACY;INCREASED;RISK;EFFICACY:NON-RESPONSE_TO_CLOPIDOGREL;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;CAUTION_SIDE_EFFECT
WARFARIN;VEGFA;CC;rs35410204;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE;PEOPLE;OTHER:HEART_VALVE_REPLACEMENT;CAUTION_SIDE_EFFECT
PACLITAXEL;EPHA8;G;rs209709;TOXICITY;INCREASED;RISK;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;WOMEN;DISEASE:BREAST_NEOPLASMS, DISEASE:OVARIAN_NEOPLASMS;CAUTION_SIDE_EFFECT
URSODEOXYCHOLIC ACID;MGAT5;TT;rs661899;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS;PEOPLE;OTHER:CHOLANGITIS;CAUTION_SIDE_EFFECT
GLUCOCORTICOIDS, METHOTREXATE, RADIOTHERAPY;CDH2;AT + TT;rs1944294;TOXICITY;DECREASED;;SIDE_EFFECT:BONE_DENSITY;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;INCREASED;;EFFICACY:PLATELET_REACTIVITY;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
MYCOPHENOLATE MOFETIL;IMPDH2;AG;rs11706052;TOXICITY;DECREASED;RISK;DISEASE:LYMPHOPENIA;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
PACLITAXEL;EPHA5;TT;rs7349683;TOXICITY;DECREASED;RISK;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;EFFICACY;;;EFFICACY:HIGHER_P2Y12_REACTION_UNITS_(PRU)_AND_LOWER_PERCENT_INHIBITION;PEOPLE;DISEASE:CEREBROVASCULAR_DISORDERS;CAUTION_DOSE_ADJUST
CYTARABINE, IDARUBICIN;NQO1;AA;rs1800566;TOXICITY;INCREASED;RISK;SIDE_EFFECT:MUCOSITIS;PEOPLE;OTHER:ACUTE_MYELOID_LEUKEMIA;CAUTION_SIDE_EFFECT
WARFARIN;VEGFA;AA;rs866236;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE;PEOPLE;OTHER:HEART_VALVE_REPLACEMENT;CAUTION_SIDE_EFFECT
PACLITAXEL;ABCG1;AA;rs492338;TOXICITY;INCREASED;RISK;DISEASE:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
CISPLATIN;AQP1;CC + CG;rs1049305;TOXICITY;INCREASED;RISK;SIDE_EFFECT:LEUKOPENIA;PEOPLE;OTHER:MESOTHELIOMA;CAUTION_SIDE_EFFECT
OXALIPLATIN;ABCB1;AG;rs1128503;EFFICACY;INCREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
PACLITAXEL;EPHA6;AA;rs301927;TOXICITY;DECREASED;RISK;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;SULT1A1;T;rs1042028;OTHER;INCREASED;LIKELIHOOD;DISEASE:BREAST_NEOPLASMS;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;SULT1A1;T;rs1042028;OTHER;INCREASED;LIKELIHOOD;DISEASE:LUNG_NEOPLASMS;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;SULT1A1;T;rs1042028;OTHER;INCREASED;LIKELIHOOD;OTHER:LYMPH_NODE_METASTASIS;PEOPLE;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;AG;rs4244285;EFFICACY;DECREASED;;EFFICACY:PLATELET_RESPONSIVENESS_TO_CLOPIDOGREL;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
AMITRIPTYLINE, CLOMIPRAMINE, DOXEPIN, IMIPRAMINE, MAPROTILINE, NORTRIPTYLINE, OPIPRAMOL;CYP2D6;TT;rs3892097;TOXICITY;INCREASED;RISK;SIDE_EFFECT:SIDE_EFFECTS;PEOPLE;DISEASE:DEPRESSION;CAUTION_SIDE_EFFECT
CALCIUM;VDR;G;rs731236;EFFICACY;INCREASED;RISK;DISEASE:FRACTURES, BONE;;;CAUTION_SIDE_EFFECT
NAN;SULT1A1;T;rs1042028;OTHER;DECREASED;LIKELIHOOD;DISEASE:UROLOGIC_NEOPLASMS;;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;AG;rs4244285;EFFICACY;DECREASED;;EFFICACY:PLATELET_RESPONSIVENESS_TO_CLOPIDOGREL;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
NAN;SULT1A1;T;rs1042028;OTHER;INCREASED;LIKELIHOOD;DISEASE:BREAST_NEOPLASMS;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
AMITRIPTYLINE, CITALOPRAM, PAROXETINE, VENLAFAXINE;ABCB1;T;rs2235040;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:REMISSION;PEOPLE;DISEASE:DEPRESSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
AMITRIPTYLINE, CITALOPRAM, PAROXETINE, VENLAFAXINE;ABCB1;T;rs12720067;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:REMISSION;PEOPLE;DISEASE:DEPRESSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN, CLOPIDOGREL;IRS1;AG + GG;rs13431554;EFFICACY;INCREASED;;EFFICACY:PLATELET_REACTIVITY;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE, DISEASE:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOCETAXEL;VAC14;T;rs875858;TOXICITY;INCREASED;RISK;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;MEN;DISEASE:PROSTATIC_NEOPLASMS;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP3A4;CT + TT;rs2242480;EFFICACY;;;EFFICACY:REDUCED_GP_IIB/IIIA_ACTIVATION_AND_LOWER_PLATELET_ACTIVATION;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;CAUTION_DOSE_ADJUST
AMITRIPTYLINE, CITALOPRAM, PAROXETINE, VENLAFAXINE;ABCB1;C;rs10280101;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:REMISSION;PEOPLE;DISEASE:DEPRESSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
DIRECT FACTOR XA INHIBITORS, DIRECT THROMBIN INHIBITORS;FGG;CC;rs1800792;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE;;;CAUTION_SIDE_EFFECT
AMITRIPTYLINE, CITALOPRAM, PAROXETINE, VENLAFAXINE;ABCB1;A;rs7787082;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:REMISSION;PEOPLE;DISEASE:DEPRESSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;COMT;AG + GG;rs6269;OTHER;INCREASED;LIKELIHOOD;OTHER:REQUIRING_POSTOPERATIVE_INTERVENTION;CHILDREN;OTHER:ADENOTONSILLECTOMY;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUINDIONE;VKORC1;AA;rs9934438;EFFICACY;DECREASED;;EFFICACY:THE_TIME_TO_ACHIEVE_A_FIRST_INR_WITHIN_THE_THERAPEUTIC_RANGE;PEOPLE;DISEASE:VENOUS_THROMBOEMBOLISM;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUINDIONE;VKORC1;AA;rs9934438;EFFICACY;DECREASED;;EFFICACY:THE_TIME_TO_ACHIEVE_A_FIRST_INR_WITHIN_THE_THERAPEUTIC_RANGE;PEOPLE;DISEASE:VENOUS_THROMBOEMBOLISM;LIKELIHOOD_THERAPEUTIC_FAILURE
OSIMERTINIB;EGFR;T;rs121434569;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:PROGRESSION-FREE_SURVIVAL, EFFICACY:OVERALL_SURVIVAL;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
AMITRIPTYLINE, CITALOPRAM, PAROXETINE, VENLAFAXINE;ABCB1;C;rs4148739;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:REMISSION;PEOPLE;DISEASE:DEPRESSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUINDIONE;VKORC1;AA;rs9934438;EFFICACY;;;EFFICACY:SHORTER_TIME_TO_HAVE_OVER-ANTICOAGULATION_(INR_>4)_RISK;PEOPLE;DISEASE:VENOUS_THROMBOEMBOLISM;CAUTION_DOSE_ADJUST
OPIOIDS;COMT;AG + GG;rs4680;OTHER;INCREASED;LIKELIHOOD;OTHER:REQUIRING_POSTOPERATIVE_INTERVENTION;CHILDREN;OTHER:ADENOTONSILLECTOMY;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHANOL;ADH1B;TT;rs1229984;METABOLISM/PK;INCREASED;;PK:VMAX;HEALTHY;;CAUTION_DOSE_ADJUST
AMITRIPTYLINE, CITALOPRAM, PAROXETINE, VENLAFAXINE;ABCB1;C;rs11983225;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:REMISSION;PEOPLE;DISEASE:DEPRESSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUINDIONE;VKORC1;AA;rs9934438;EFFICACY;;;EFFICACY:SHORTER_TIME_TO_HAVE_OVER-ANTICOAGULATION_(INR_>4)_RISK;PEOPLE;DISEASE:VENOUS_THROMBOEMBOLISM;CAUTION_DOSE_ADJUST
OPIOIDS;COMT;CG + GG;rs4818;OTHER;INCREASED;LIKELIHOOD;OTHER:REQUIRING_POSTOPERATIVE_INTERVENTION;CHILDREN;OTHER:ADENOTONSILLECTOMY;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUINDIONE;VKORC1;AA;rs9934438;EFFICACY;DECREASED;;EFFICACY:AVERAGE_DAILY_DOSE_DURING_THE_FIRST_PERIOD_OF_STABILITY;PEOPLE;DISEASE:VENOUS_THROMBOEMBOLISM;LIKELIHOOD_THERAPEUTIC_FAILURE
OPIOIDS;COMT;CC + CT;rs4633;OTHER;INCREASED;LIKELIHOOD;OTHER:REQUIRING_POSTOPERATIVE_INTERVENTION;CHILDREN;OTHER:ADENOTONSILLECTOMY;LIKELIHOOD_THERAPEUTIC_SUCCESS
AMITRIPTYLINE, CITALOPRAM, PAROXETINE, VENLAFAXINE;ABCB1;G;rs10248420;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:REMISSION;PEOPLE;DISEASE:DEPRESSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;A;rs1799931;TOXICITY, METABOLISM/PK;INCREASED;RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC AGENTS;UGT1A;TT;rs6744284;EFFICACY;INCREASED;;EFFICACY:EVENT-FREE_SURVIVAL;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA_SIDE_EFFECT:HYPERBILIRUBINEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
DIRECT FACTOR XA INHIBITORS, DIRECT THROMBIN INHIBITORS;F2;TT;rs5896;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE;;;CAUTION_SIDE_EFFECT
BORTEZOMIB;PKNOX1;A;rs2839629;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;PEOPLE;OTHER:MULTIPLE_MYELOMA;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC AGENTS;UGT1A;T;rs6744284;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HYPERBILIRUBINEMIA;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
SUNITINIB;VEGFA;A;rs699947;TOXICITY;INCREASED;;SIDE_EFFECT:SYSTOLIC_BLOOD_PRESSURE_AND_INCREASED_RISK_OF_DEVELOPING_GRADE_3_HYPERTENSION;;;CAUTION_SIDE_EFFECT
AMITRIPTYLINE, CITALOPRAM, PAROXETINE, VENLAFAXINE;ABCB1;T;rs2235067;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:REMISSION;PEOPLE;DISEASE:DEPRESSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATENOLOL;FTO;G;rs9940629;OTHER;;;DISEASE:HYPERCHOLESTEROLEMIA;PEOPLE;DISEASE:HYPERTENSION;CAUTION_DOSE_ADJUST
SUNITINIB;VEGFA;C;rs833061;TOXICITY;INCREASED;;SIDE_EFFECT:SYSTOLIC_BLOOD_PRESSURE_AND_INCREASED_RISK_OF_DEVELOPING_GRADE_3_HYPERTENSION;;;CAUTION_SIDE_EFFECT
ALFENTANIL, FENTANYL;OPRM1;AG + GG;rs1799971;EFFICACY;INCREASED;SEVERITY;EFFICACY:PAIN, POSTOPERATIVE;CHILDREN;OTHER:TONSILLECTOMY;CAUTION_SIDE_EFFECT
SUNITINIB;VEGFA;G;rs2010963;TOXICITY;INCREASED;;SIDE_EFFECT:SYSTOLIC_BLOOD_PRESSURE_AND_INCREASED_RISK_OF_DEVELOPING_GRADE_3_HYPERTENSION;;;CAUTION_SIDE_EFFECT
AMITRIPTYLINE, CITALOPRAM, PAROXETINE, VENLAFAXINE;ABCB1;G;rs4148740;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:REMISSION;PEOPLE;DISEASE:DEPRESSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATENOLOL;ABCB1;G;rs10267099;OTHER;INCREASED;RISK;DISEASE:HYPERCHOLESTEROLEMIA;PEOPLE;DISEASE:HYPERTENSION;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;OTHER;DECREASED;;OTHER:PLATELET_FUNCTION;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;CAUTION_DOSE_ADJUST
ATENOLOL;ABCB1;G;rs3213619;OTHER;INCREASED;RISK;DISEASE:HYPERCHOLESTEROLEMIA;PEOPLE;DISEASE:HYPERTENSION;CAUTION_SIDE_EFFECT
CORTICOSTEROIDS;DCAF4;CC;rs7160796;EFFICACY;INCREASED;;EFFICACY:CHANGE_IN_FORCED_EXPIRATORY_VOLUME_IN_1_S_(FEV1);PEOPLE;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
SUNITINIB;NOS3;CC + CT;rs2070744;TOXICITY;INCREASED;RISK;SIDE_EFFECT:GRADE_3_HYPERTENSION;;;CAUTION_SIDE_EFFECT
ATENOLOL;PRKCB;GT + TT;rs11649514;TOXICITY, OTHER;INCREASED;LIKELIHOOD;SIDE_EFFECT:HYPERGLYCEMIA;PEOPLE;DISEASE:ESSENTIAL_HYPERTENSION;CAUTION_SIDE_EFFECT
ATENOLOL;FTO;AA;rs12595985;OTHER;INCREASED;RISK;DISEASE:HYPERCHOLESTEROLEMIA;PEOPLE;DISEASE:HYPERTENSION;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;ALDH1A1;CT + TT;rs8187996;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY, SIDE_EFFECT:TREATMENT_MODIFICATION;PEOPLE;OTHER:BREAST_NEOPLASMS, OTHER:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;P2RY12;AG + GG;rs2046934;OTHER;DECREASED;;OTHER:PLATELET_FUNCTION;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;CAUTION_DOSE_ADJUST
ATENOLOL;GALNT2;T;rs2144297;OTHER;;;DISEASE:HYPERCHOLESTEROLEMIA;PEOPLE;DISEASE:HYPERTENSION;CAUTION_DOSE_ADJUST
ATENOLOL;GALNT2;C;rs2144300;OTHER;;;DISEASE:HYPERCHOLESTEROLEMIA;PEOPLE;DISEASE:HYPERTENSION;CAUTION_DOSE_ADJUST
ETHANOL;ANKK1, DRD2;A;rs1800497;TOXICITY;INCREASED;RISK;DISEASE:ALCOHOL_ABUSE;;;CAUTION_SIDE_EFFECT
WARFARIN;CYP2C9;AC;rs1057910;DOSAGE, METABOLISM/PK;DECREASED;;PK:IN_VIVO_METABOLISM_OF_(S)-WARFARIN_BUT_NOT_(R)-WARFARIN;;;CAUTION_DOSE_ADJUST
ATENOLOL;PLA2G4A;C;rs10157410;OTHER;INCREASED;RISK;DISEASE:HYPERCHOLESTEROLEMIA;PEOPLE;DISEASE:HYPERTENSION;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;EFFICACY;INCREASED;;EFFICACY:PLATELET_AGGREGATION_VALUES;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATENOLOL;PTGS2;G;rs4648287;OTHER;INCREASED;LIKELIHOOD;DISEASE:HYPERCHOLESTEROLEMIA;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ISONIAZID, RIFAMPIN;NOS2;CC;rs11080344;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
ENALAPRIL;SLCO1B1;AA;rs2306283;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:COUGH;PEOPLE;OTHER:HYPERTENSION;CAUTION_SIDE_EFFECT
ISONIAZID, RIFAMPIN;BACH1;GG;rs2070401;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;CT + TT;rs12248560;EFFICACY;DECREASED;;EFFICACY:PLATELET_AGGREGATION_VALUES;PEOPLE;EFFICACY:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
ISONIAZID, RIFAMPIN;MAFK;AA + AG;rs4720833;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
ISONIAZID, RIFAMPIN;XPO1;AC + CC;rs11125883;TOXICITY;DECREASED;LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:TUBERCULOSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;CC;rs12248560;EFFICACY;;;EFFICACY:GREATER_PLATELET_INHIBITION_2_H_AFTER_A_600-MG_DOSE;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;CAUTION_DOSE_ADJUST
ISONIAZID;NAT2;T;rs1041983;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
ISONIAZID;NAT2;G;rs1495741;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C9;C;rs1057910;EFFICACY;DECREASED;;EFFICACY:PLATELET_INHIBITION_7H_AFTER_A_CLOPIDOGREL_600-MG_LOADING_DOSE;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
CAPECITABINE, FLUOROURACIL;DPYD;CT + TT;rs1801158;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;OTHER:NEOPLASMS;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:PLATELET_AGGREGATION_INHIBITION;PEOPLE;DISEASE:CORONARY_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;ITPA;AA;rs7270101;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ANEMIA;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;CAUTION_SIDE_EFFECT
ANASTROZOLE, LETROZOLE;ESR1;A;rs9340799;OTHER;INCREASED;RISK;DISEASE:MUSCULOSKELETAL_PAIN;WOMEN;OTHER:WITH_EARLY_BREAST_CANCER;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP3A5;CT + TT;rs776746;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:PLATELET_AGGREGATION_INHIBITION;PEOPLE;DISEASE:CORONARY_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
ANASTROZOLE, LETROZOLE;ESR1;C;rs2234693;OTHER;INCREASED;RISK;DISEASE:MUSCULOSKELETAL_PAIN;WOMEN;OTHER:WITH_EARLY_BREAST_CANCER;CAUTION_SIDE_EFFECT
CLOPIDOGREL;P2RY12;AG + GG;rs2046934;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:PLATELET_AGGREGATION_INHIBITION;PEOPLE;DISEASE:CORONARY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;CYP3A4;CC;rs2740574;OTHER;INCREASED;LIKELIHOOD;OTHER:ELEVATED_CIRCULATING_CREATINE_KINASE_CONCENTRATION;PEOPLE;OTHER:CARDIOVASCULAR_DISEASE, OTHER:HYPERLIPIDEMIAS;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;OPRM1;AA + AG;rs1799971;OTHER;DECREASED;LIKELIHOOD;OTHER:ADDICTION;;;LIKELIHOOD_THERAPEUTIC_FAILURE
CAPECITABINE, FLUOROURACIL;DPYD;C;rs75017182;DOSAGE, TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:NEOPLASMS;CAUTION_DOSE_ADJUST
REPAGLINIDE;NEUROD1;CT + TT;rs1801262;EFFICACY;DECREASED;;EFFICACY:DIFFERENCE_IN_POSTPRANDIAL_PLASMA_GLUCOSE_(BEFORE_AND_AFTER_DRUG_TREATMENT);PEOPLE;DISEASE:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_FAILURE
REPAGLINIDE;PAX4;AA + AG;rs114202595;EFFICACY;DECREASED;;EFFICACY:DIFFERENCE_IN_POSTPRANDIAL_PLASMA_GLUCOSE_(BEFORE_AND_AFTER_DRUG_TREATMENT);PEOPLE;DISEASE:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_FAILURE
NAN;CYP3A4;CT;rs2740574;OTHER;INCREASED;RISK;DISEASE:ENDOMETRIAL_NEOPLASMS;;;CAUTION_SIDE_EFFECT
VINCRISTINE;COCH;CG + GG;rs1045644;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CETUXIMAB, IRINOTECAN, LEUCOVORIN, TEGAFUR;EGFR;CC;rs712830;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
TAMOXIFEN;CYP3A4;CT;rs2740574;OTHER;INCREASED;RISK;DISEASE:ENDOMETRIAL_NEOPLASMS;PEOPLE;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
VINCRISTINE;;C;rs7963521;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
REPAGLINIDE;NEUROD1;CT + TT;rs1801262;EFFICACY;DECREASED;;EFFICACY:DIFFERENCE_IN_FASTING_PLASMA_GLUCOSE_(BEFORE_AND_AFTER_DRUG_TREATMENT);PEOPLE;DISEASE:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_FAILURE
NAN;VDR;G;rs3782905;OTHER;INCREASED;RISK;DISEASE:ASTHMA;;;CAUTION_SIDE_EFFECT
OPIOIDS;OPRL1;C;rs6090043;TOXICITY;INCREASED;RISK;DISEASE:OPIOID-RELATED_DISORDERS;;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;EFFICACY;INCREASED;RISK;EFFICACY:HIGH-ON_CLOPIDOGREL_PLATELET_REACTIVITY;;OTHER:PATIENTS_UNDERGOING_ELECTIVE_CORONARY_STENT_PLACEMENT;CAUTION_SIDE_EFFECT
CLOPIDOGREL;P2RY12;A;rs6785930;EFFICACY;INCREASED;RISK;SIDE_EFFECT:NEUROLOGICAL_EVENTS;PEOPLE;DISEASE:PERIPHERAL_VASCULAR_DISEASES;CAUTION_SIDE_EFFECT
OPIOIDS;COMT;AA + AG;rs165599;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:SOMNOLENCE;PEOPLE;OTHER:PAIN, OTHER:NEOPLASMS;CAUTION_SIDE_EFFECT
DOCETAXEL, PACLITAXEL;ABCB1;A;rs2032582;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA;PEOPLE;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;VDR;G;rs2239185;NAN;INCREASED;RISK;DISEASE:ASTHMA;;;CAUTION_SIDE_EFFECT
NAN;VDR;T;rs1540339;NAN;INCREASED;RISK;DISEASE:ASTHMA;;;CAUTION_SIDE_EFFECT
CISPLATIN;AQP1;CC + CG;rs1049305;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ALOPECIA;PEOPLE;OTHER:MESOTHELIOMA;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;AA + AG;rs4986893;EFFICACY;DECREASED;;EFFICACY:ANTIPLATELET_EFFECT;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
CALCITRIOL;VDR;A;rs2228570;EFFICACY;INCREASED;RISK;DISEASE:FRACTURES, BONE;;;CAUTION_SIDE_EFFECT
CISPLATIN;AQP1;CC + CG;rs1049305;TOXICITY;DECREASED;RISK;SIDE_EFFECT:ANEMIA;PEOPLE;OTHER:MESOTHELIOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;INCREASED;RISK;EFFICACY:HIGH_POST-TREATMENT_PLATELET_REACTIVITY;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;CAUTION_SIDE_EFFECT
PERINDOPRIL;BDKRB1;AA;rs12050217;EFFICACY;DECREASED;RISK;EFFICACY:CARDIAC_EVENTS;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN;AQP1;CC;rs1049305;TOXICITY;INCREASED;RISK;SIDE_EFFECT:THROMBOCYTOPENIA;PEOPLE;OTHER:MESOTHELIOMA;CAUTION_SIDE_EFFECT
ATENOLOL, VERAPAMIL;GRK4;TT;rs1801058;EFFICACY, TOXICITY, OTHER;INCREASED;RISK;SIDE_EFFECT:ADVERSE_CARDIOVASCULAR_OUTCOMES;PEOPLE;OTHER:HYPERTENSION_AND_CORONORY_ARTERY_DISEASE;CAUTION_SIDE_EFFECT
CLOZAPINE;CYP1A2;AA;rs762551;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:METABOLIC_SYNDROME;PEOPLE;DISEASE:SCHIZOPHRENIA, DISEASE:TOBACCO_USE_DISORDER;CAUTION_SIDE_EFFECT
MYCOPHENOLATE MOFETIL;IMPDH1;CT + TT;rs2278294;TOXICITY;DECREASED;RISK;SIDE_EFFECT:BIOPSY-PROVEN_ACUTE_REJECTION;PEOPLE;OTHER:KIDNEY_TRANSPLANT;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM COMPOUNDS;HLA-DOB;CT + TT;rs2071554;EFFICACY;INCREASED;RISK;DISEASE:DEATH;PEOPLE;DISEASE:LUNG_NEOPLASMS;CAUTION_SIDE_EFFECT
PLATINUM COMPOUNDS;;AA + AG;rs2900420;EFFICACY;DECREASED;RISK;DISEASE:DEATH;PEOPLE;DISEASE:LUNG_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOZAPINE;CYP1A2;AA;rs762551;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:METABOLIC_SYNDROME;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE, CYTARABINE, DAUNORUBICIN, MERCAPTOPURINE, METHOTREXATE, PREDNISONE, VINCRISTINE;DROSHA;T;rs639174;TOXICITY;INCREASED;RISK;DISEASE:DRUG_TOXICITY;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
OPIOIDS;DRD2;AG + GG;rs6275;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:SOMNOLENCE;PEOPLE;OTHER:PAIN, OTHER:NEOPLASMS;CAUTION_SIDE_EFFECT
CISPLATIN;TPMT;T;rs12201199;TOXICITY;INCREASED;RISK;DISEASE:OTOTOXICITY;CHILDREN;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
ISONIAZID, PYRAZINAMIDE, RIFAMPIN;CYP2E1;A;rs6413432;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE;CHILDREN;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
CISPLATIN;;AG + GG;rs3746444;EFFICACY;DECREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:LUNG_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
ACENOCOUMAROL, WARFARIN;CYP2C9;CC;rs1057910;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE, SIDE_EFFECT:ADVERSE_EVENTS;PEOPLE;OTHER:HEART_VALVE_REPLACEMENT;CAUTION_SIDE_EFFECT
ASPIRIN;PTGS2;G;rs20417;OTHER;DECREASED;RISK;DISEASE:CORONARY_DISEASE;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN;AQP1;AG;rs28362731;TOXICITY;INCREASED;RISK;SIDE_EFFECT:THROMBOCYTOPENIA;PEOPLE;OTHER:MESOTHELIOMA;CAUTION_SIDE_EFFECT
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;CYP2E1;CC;rs2031920;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
ASPIRIN;PTGS2;G;rs20417;OTHER;INCREASED;RISK;DISEASE:CORONARY_DISEASE;;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;A;rs4986893;EFFICACY;DECREASED;;EFFICACY:CLOPIDOGREL_INHIBITION_OF_ADP-INDUCED_PLATELET_AGGREGATION;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
FOLFIRI;ABCC1;AA + AG;rs17501011;EFFICACY;DECREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;OTHER:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
OPIOIDS;OPRL1;G;rs6090041;TOXICITY;INCREASED;RISK;DISEASE:OPIOID-RELATED_DISORDERS;;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;EFFICACY;DECREASED;;EFFICACY:ANTIPLATELET_EFFECT;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIDEPRESSANTS;CUX1;G;rs365836;EFFICACY;;LIKELIHOOD;EFFICACY:NON-RESPONSE;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DOSE_ADJUST
NAN;SULT1A1;CC + CT;rs1042028;NAN;INCREASED;RISK;DISEASE:PROSTATIC_NEOPLASMS;;;CAUTION_SIDE_EFFECT
NAN;SULT1A1;CT + TT;rs1042028;OTHER;INCREASED;RISK;DISEASE:BREAST_NEOPLASMS;WOMEN;DISEASE:TOBACCO_USE_DISORDER;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;DECREASED;;EFFICACY:CLOPIDOGREL_INHIBITION_OF_ADP-INDUCED_PLATELET_AGGREGATION;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
NAN;SULT1A1;CT + TT;rs1042028;OTHER;DECREASED;LIKELIHOOD;DISEASE:BREAST_NEOPLASMS;PEOPLE;OTHER:AT_LEAST_THREE_PREGNANCIES_AND_PREMENOPAUSAL;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOZAPINE;LEPR;AG + GG;rs1137101;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:METABOLIC_SYNDROME;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
ACENOCOUMAROL, WARFARIN;VKORC1;TT;rs9923231;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE, SIDE_EFFECT:ADVERSE_EVENTS;PEOPLE;OTHER:HEART_VALVE_REPLACEMENT;CAUTION_SIDE_EFFECT
ANTIDEPRESSANTS;CUX1;A;rs201522;EFFICACY;;LIKELIHOOD;EFFICACY:NON-RESPONSE;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DOSE_ADJUST
BORTEZOMIB;PKNOX1;AA;rs2839629;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES, SIDE_EFFECT:PAIN, SIDE_EFFECT:NEUROPATHIC_PAIN;PEOPLE;OTHER:MULTIPLE_MYELOMA;CAUTION_SIDE_EFFECT
CISPLATIN;COMT;T;rs9332377;TOXICITY;INCREASED;RISK;DISEASE:OTOTOXICITY;CHILDREN;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
WARFARIN;VKORC1;CT + TT;rs9923231;EFFICACY;DECREASED;;EFFICACY:TIME_TO_THERAPEUTIC_INR;;;LIKELIHOOD_THERAPEUTIC_FAILURE
CISPLATIN;COMT;C;rs4646316;TOXICITY;INCREASED;RISK;DISEASE:OTOTOXICITY;CHILDREN;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
CAPECITABINE;ENOSF1;T;rs2741171;TOXICITY;INCREASED;RISK;DISEASE:HAND-FOOT_SYNDROME;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
CAPECITABINE;ENOSF1;C;rs2612091;TOXICITY;INCREASED;RISK;DISEASE:HAND-FOOT_SYNDROME;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;AA + AG;rs1801133;TOXICITY;INCREASED;;DISEASE:DRUG_TOXICITY;CHILDREN;;CAUTION_SIDE_EFFECT
CISPLATIN;ABCC3;G;rs1051640;TOXICITY;INCREASED;RISK;DISEASE:OTOTOXICITY;CHILDREN;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
CAPECITABINE;DPYD;T;rs12022243;TOXICITY;INCREASED;SEVERITY;DISEASE:DIARRHEA;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
FOLFIRI;CES1;CC;rs9921399;EFFICACY;INCREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;OTHER:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
DEXTROAMPHETAMINE, METHYLPHENIDATE;DRD1;CC;rs4532;TOXICITY;INCREASED;SEVERITY;OTHER:SOCIAL_WITHDRAWAL;CHILDREN;DISEASE:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY;CAUTION_SIDE_EFFECT
CISPLATIN;TPMT;C;rs1142345;TOXICITY;INCREASED;RISK;DISEASE:OTOTOXICITY;CHILDREN;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
METHAMPHETAMINE;GRIN1;GG;rs1126442;TOXICITY;INCREASED;RISK;DISEASE:PSYCHOTIC_DISORDER;MEN;DISEASE:METHAMPHETAMINE_DEPENDENCE;CAUTION_SIDE_EFFECT
FOLFIRI;UGT1A10, UGT1A8;AA;rs1113193;EFFICACY;DECREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;OTHER:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
CISPLATIN;TPMT;T;rs1800460;TOXICITY;INCREASED;RISK;DISEASE:OTOTOXICITY;CHILDREN;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
CAPECITABINE;ENOSF1;T;rs2741171;TOXICITY;INCREASED;RISK;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
CAPECITABINE;ENOSF1;C;rs2612091;TOXICITY;INCREASED;RISK;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
CAPECITABINE;DPYD;T;rs12022243;TOXICITY;INCREASED;SEVERITY;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;;EFFICACY:RESPONSE_RATE_TO_PEGIFN-ALPHA/RBV_TREATMENT_AT_WEEK_20/24;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
IODINE (131I) COMPOUNDS, RADIOTHERAPY;TGFB1;AA;rs1800469;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:SIALOADENITIS;PEOPLE;OTHER:THYROID_TUMOR;CAUTION_SIDE_EFFECT
NICOTINE;CHRNA5;CT + TT;rs588765;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:SMOKING_CESSATION;;OTHER:SMOKERS;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;GG + GT;rs8099917;EFFICACY;INCREASED;RISK;EFFICACY:TREATMENT_FAILURE;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;CAUTION_SIDE_EFFECT
CAPECITABINE;DPYD;A;rs76387818;TOXICITY;INCREASED;SEVERITY;DISEASE:HAND-FOOT_SYNDROME;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
CAPECITABINE;DPYD;A;rs12132152;TOXICITY;INCREASED;SEVERITY;DISEASE:HAND-FOOT_SYNDROME;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
CAPECITABINE;DPYD;A;rs76387818;TOXICITY;INCREASED;SEVERITY;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
ATENOLOL;DPYS;AG + GG;rs2669429;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:HYPERGLYCEMIA;PEOPLE;DISEASE:HYPERTENSION;CAUTION_SIDE_EFFECT
LENALIDOMIDE;ABCB1;AA + AG;rs1045642;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:ADVERSE_EVENTS;PEOPLE;OTHER:MULTIPLE_MYELOMA, OTHER:LYMPHOMA,OTHER:MYELODYSPLASTIC_SYNDROMES;CAUTION_SIDE_EFFECT
CAPECITABINE;DPYD;A;rs12132152;TOXICITY;INCREASED;SEVERITY;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
NAN;IFNL3, IFNL4;CC;rs12979860;OTHER;INCREASED;;OTHER:SPONTANEOUS_HCV_CLEARANCE;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;CAUTION_DOSE_ADJUST
RISPERIDONE;LEP;G;rs7799039;OTHER;INCREASED;RISK;SIDE_EFFECT:WEIGHT_GAIN;CHILDREN;DISEASE:AUTISM_SPECTRUM_DISORDER;CAUTION_SIDE_EFFECT
WARFARIN;VKORC1;T;rs9923231;EFFICACY, TOXICITY;INCREASED;;SIDE_EFFECT:BLOOD_COAGULATION_DISORDERS;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
IODINE (131I) COMPOUNDS, RADIOTHERAPY;ATG10;CC;rs10514231;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:FATIGUE;PEOPLE;OTHER:THYROID_TUMOR;CAUTION_SIDE_EFFECT
VINCRISTINE;CEP72;TT;rs924607;TOXICITY;INCREASED;RISK;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;PEOPLE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
CARBOPLATIN, PACLITAXEL;EIF4E2, TIGD1;CC;rs1656402;EFFICACY;DECREASED;;EFFICACY:SURVIVAL;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
IODINE (131I) COMPOUNDS, RADIOTHERAPY;ATM;AG;rs11212570;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:FATIGUE;PEOPLE;OTHER:THYROID_TUMOR;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;;CT + TT;rs2056527;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:SMOKING_CESSATION;;OTHER:SMOKERS;LIKELIHOOD_THERAPEUTIC_FAILURE
NICOTINE;;CT + TT;rs2056527;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:SMOKING_CESSATION;;OTHER:SMOKERS;LIKELIHOOD_THERAPEUTIC_FAILURE
CAPECITABINE, FLUOROURACIL;DPYD;AA + AT;rs67376798;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DIARRHEA;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
PIRFENIDONE;TOLLIP;CC + CT;rs5743890;EFFICACY;INCREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;OTHER:PULMONARY_FIBROSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE, FLUOROURACIL;DPYD;CT + TT;rs1801160;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
WARFARIN;VKORC1;T;rs9923231;EFFICACY;DECREASED;;EFFICACY:TIME_TO_THERAPEUTIC_INR;;;LIKELIHOOD_THERAPEUTIC_FAILURE
IMATINIB;ABCB1;GG;rs1045642;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM COMPOUNDS;XBP1;GG;rs2269577;TOXICITY;INCREASED;RISK;DISEASE:NAUSEA;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
IMATINIB;SLC22A1;CC;rs683369;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_BCR-ABL1_POSITIVE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CARBOPLATIN, PACLITAXEL;DSCAM;TT;rs9981861;EFFICACY;DECREASED;;EFFICACY:SURVIVAL;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
CARBOPLATIN, PACLITAXEL;ETS2;CT + TT;rs1209950;EFFICACY;DECREASED;;EFFICACY:SURVIVAL;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
IODINE (131I) COMPOUNDS, RADIOTHERAPY;ATG10;CC;rs10514231;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DIZZINESS, SIDE_EFFECT:HEADACHE;PEOPLE;OTHER:THYROID_TUMOR;CAUTION_SIDE_EFFECT
IODINE (131I) COMPOUNDS, RADIOTHERAPY;TGFB1;AA;rs1800469;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DIZZINESS, SIDE_EFFECT:HEADACHE;PEOPLE;OTHER:THYROID_TUMOR;CAUTION_SIDE_EFFECT
WARFARIN;VKORC1;T;rs9923231;EFFICACY;INCREASED;RISK;SIDE_EFFECT:OVER-ANTICOAGULATION;;;CAUTION_SIDE_EFFECT
IODINE (131I) COMPOUNDS, RADIOTHERAPY;ATG10;TT;rs1864183;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY;PEOPLE;OTHER:THYROID_TUMOR;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;NUDT15;A;rs186364861;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
AMISULPRIDE, CLOZAPINE, OLANZAPINE, PALIPERIDONE, QUETIAPINE, RISPERIDONE;MC4R;CC;rs17782313;OTHER;INCREASED;RISK;SIDE_EFFECT:WEIGHT_GAIN;;;CAUTION_SIDE_EFFECT
AMISULPRIDE, ARIPIPRAZOLE, CLOZAPINE, HALOPERIDOL, QUETIAPINE, RISPERIDONE, ZIPRASIDONE;MC4R;A;rs489693;OTHER;INCREASED;RISK;SIDE_EFFECT:WEIGHT_GAIN;PEOPLE;DISEASE:SCHIZOAFFECTIVE_DISORDER, DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;NUDT15;T;rs116855232;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
AMISULPRIDE, ARIPIPRAZOLE, CLOZAPINE, HALOPERIDOL, QUETIAPINE, RISPERIDONE, ZIPRASIDONE;MC4R;AA;rs489693;OTHER;INCREASED;LIKELIHOOD;DISEASE:HYPERTRIGLYCERIDEMIA, SIDE_EFFECT:WEIGHT_GAIN;PEOPLE;DISEASE:SCHIZOAFFECTIVE_DISORDER, DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATENOLOL, VERAPAMIL;PLEKHH2;G;rs11124945;TOXICITY;DECREASED;RISK;DISEASE:DIABETES_MELLITUS;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;AG;rs4244285;EFFICACY;INCREASED;;DISEASE:PLATELET_AGGREGATION;PEOPLE;DISEASE:ANGINA_PECTORIS, DISEASE:MYOCARDIAL_INFARCTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
REGADENOSON;AMPD1;AA + AG;rs17602729;EFFICACY;INCREASED;SEVERITY;SIDE_EFFECT:ELEVATED_SYSTOLIC_BLOOD_PRESSURE;;;CAUTION_SIDE_EFFECT
EFAVIRENZ;CYP2B6;T;rs3745274;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:SOMNOLENCE;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;AA;rs4244285;EFFICACY;INCREASED;;OTHER:PLATELET_REACTIVITY;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE, FLUOROURACIL;DPYD;CT + TT;rs3918290;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
NAN;;CC;rs2952768;EFFICACY;DECREASED;SEVERITY;OTHER:SUBSTANCE-RELATED_DISORDERS;PEOPLE;OTHER:METHAMPHETAMINE_DEPENDENCE, OTHER:ALCOHOL_ABUSE,OTHER:EATING_DISORDERS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN, CYCLOPHOSPHAMIDE;ERCC2;CT;rs1799793;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:OVERALL_SURVIVAL;WOMEN;DISEASE:OVARIAN_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACENOCOUMAROL, WARFARIN;VKORC1;CT + TT;rs9923231;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HEMORRHAGE, SIDE_EFFECT:STROKE;PEOPLE;DISEASE:ATRIAL_FIBRILLATION, DISEASE:VENOUS_THROMBOEMBOLISM;CAUTION_SIDE_EFFECT
NICOTINE;DBH;CC;rs1541333;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:END_OF_TREATMENT_ABSTINENCE;;OTHER:SMOKERS_WITH_LOW_DEPENDENCY;LIKELIHOOD_THERAPEUTIC_FAILURE
REGADENOSON;AMPD1;AA + AG;rs17602729;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;;;CAUTION_SIDE_EFFECT
RISPERIDONE;CNR1;T;rs806378;OTHER;INCREASED;RISK;SIDE_EFFECT:WEIGHT_GAIN;CHILDREN;DISEASE:AUTISM_SPECTRUM_DISORDER;CAUTION_SIDE_EFFECT
RISPERIDONE;CNR1;C;rs1049353;OTHER;INCREASED;RISK;SIDE_EFFECT:WEIGHT_GAIN;CHILDREN;DISEASE:AUTISM_SPECTRUM_DISORDER;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;ABCC4;T;rs3765534;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
ASPARAGINASE;NFATC2;T;rs6021191;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HYPERSENSITIVITY;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
ASPARAGINASE;HLA-DRB1;T;rs17885382;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HYPERSENSITIVITY;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE, EPIRUBICIN;GSTP1;AA;rs1695;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUTROPENIA;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
IVACAFTOR;CFTR;A;rs75527207;EFFICACY;DECREASED;LIKELIHOOD;DISEASE:CYSTIC_FIBROSIS_PULMONARY_EXACERBATION;PEOPLE;DISEASE:CYSTIC_FIBROSIS;LIKELIHOOD_THERAPEUTIC_FAILURE
VANCOMYCIN;;A;rs2789047;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ELEVATED_CIRCULATING_CREATINE_KINASE_CONCENTRATION;;;CAUTION_SIDE_EFFECT
LISINOPRIL;MMP3;AA;rs35068180;EFFICACY;INCREASED;RISK;SIDE_EFFECT:STROKE;PEOPLE;DISEASE:HYPERTENSION;CAUTION_SIDE_EFFECT
CARBOPLATIN, GEMCITABINE;SERPINA5;C;rs6113;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;;;EFFICACY:SUBOPTIMAL_REPERFUSION_(POST-PCI_TIMI_FLOW_<3);PEOPLE;DISEASE:MYOCARDIAL_INFARCTION;CAUTION_DOSE_ADJUST
CARBOPLATIN, GEMCITABINE;SERPINA5;T;rs6118;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
CARBOPLATIN, GEMCITABINE;XYLT2;G;rs6504649;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
CARBOPLATIN, GEMCITABINE;SERPINA5;G;rs6119;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
ETHANOL;CAT;T;rs1001179;OTHER;INCREASED;RISK;DISEASE:ALCOHOL_ABUSE;;;CAUTION_SIDE_EFFECT
CARBOPLATIN, GEMCITABINE;ETS2;A;rs73450548;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
BEVACIZUMAB, PEGAPTANIB, RANIBIZUMAB;VEGFA;CC;rs2010963;EFFICACY;INCREASED;;EFFICACY:ANTI-VEGF_INJECTIONS;PEOPLE;DISEASE:CHOROIDAL_NEOVASCULARIZATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;ABCB1;AA;rs1045642;EFFICACY;INCREASED;;OTHER:PLATELET_REACTIVITY;PEOPLE;DISEASE:MYOCARDIAL_INFARCTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;MTHFR;AA;rs1801133;EFFICACY;INCREASED;LIKELIHOOD;DISEASE:RECURRENCE;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOXORUBICIN;GSTA1;AA;rs3957357;EFFICACY;INCREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:SARCOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
AMISULPRIDE, CLOZAPINE, OLANZAPINE, PALIPERIDONE, QUETIAPINE, RISPERIDONE;MC4R;AA;rs489693;OTHER;INCREASED;RISK;SIDE_EFFECT:WEIGHT_GAIN;;;CAUTION_SIDE_EFFECT
ETHANOL;CAT;T;rs1001179;OTHER;INCREASED;SEVERITY;DISEASE:ALCOHOL_ABUSE;PEOPLE;DISEASE:ALCOHOL_ABUSE;CAUTION_SIDE_EFFECT
NAN;ERCC1;AC;rs3212986;OTHER;DECREASED;;OTHER:DISEASE-FREE_SURVIVAL_AND_OVERALL_SURVIVAL;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_DOSE_ADJUST
DEXMEDETOMIDINE;GABRA2;GG;rs279847;TOXICITY;DECREASED;;SIDE_EFFECT:HEART_RATE;WOMEN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TAMOXIFEN;ESR1;AG + GG;rs9340799;TOXICITY;INCREASED;RISK;SIDE_EFFECT:VENOUS_THROMBOEMBOLISM;PEOPLE;OTHER:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
"""ACE INHIBITORS, PLAIN"", ""ANGIOTENSIN II ANTAGONISTS""";F5;AG;rs149389480;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ANGIOEDEMA;;;CAUTION_SIDE_EFFECT
MORPHINE;FAAH;AA + AG;rs3766246;TOXICITY;INCREASED;RISK;SIDE_EFFECT:POSTOPERATIVE_NAUSEA_AND_VOMITING;CHILDREN;;CAUTION_SIDE_EFFECT
CLOZAPINE, OLANZAPINE;TBC1D1;CC;rs9852;TOXICITY;INCREASED;;DISEASE:WEIGHT_GAIN;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;AT;rs67376798;EFFICACY;DECREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;OTHER:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
MORPHINE;FAAH;CT + TT;rs4141964;TOXICITY;INCREASED;RISK;SIDE_EFFECT:POSTOPERATIVE_NAUSEA_AND_VOMITING;CHILDREN;;CAUTION_SIDE_EFFECT
NAN;ABCB11;GG;rs2287622;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HEPATOCELLULAR_INJURY;;;CAUTION_SIDE_EFFECT
HYDROCODONE;OPRM1;AG + GG;rs1799971;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HYPOVENTILATION;WOMEN;DISEASE:PREGNANCY;CAUTION_SIDE_EFFECT
HYDROCODONE;OPRM1;AG + GG;rs1799971;TOXICITY;INCREASED;RISK;SIDE_EFFECT:SIDE_EFFECTS;WOMEN;DISEASE:PREGNANCY;CAUTION_SIDE_EFFECT
NAN;DRD2;AA + AG;rs1800497;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:ALCOHOL_ABUSE, DISEASE:SUBSTANCE-RELATED_DISORDERS;;;CAUTION_SIDE_EFFECT
OPIOIDS;GNB3;CT + TT;rs5443;TOXICITY, OTHER;INCREASED;LIKELIHOOD;SIDE_EFFECT:INCREASED_PULSE_RATE;PEOPLE;SIDE_EFFECT:WITHDRAWAL_FROM_OPIOID_ADDICTION;CAUTION_SIDE_EFFECT
ARIPIPRAZOLE, CLOZAPINE, HALOPERIDOL, OLANZAPINE, QUETIAPINE, RISPERIDONE;FAAH;A;rs324420;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:WEIGHT_GAIN;PEOPLE;DISEASE:PSYCHOTIC_DISORDER;CAUTION_SIDE_EFFECT
MORPHINE;FAAH;GT + TT;rs2295632;TOXICITY;INCREASED;RISK;SIDE_EFFECT:POSTOPERATIVE_NAUSEA_AND_VOMITING;CHILDREN;;CAUTION_SIDE_EFFECT
CAFFEINE;CYP1A2;AC + CC;rs762551;OTHER;DECREASED;RISK;DISEASE:BREAST_NEOPLASMS;PEOPLE;OTHER:BRCA1_MUTATIONS;LIKELIHOOD_THERAPEUTIC_SUCCESS
MORPHINE;FAAH;AA + AC;rs324420;TOXICITY;INCREASED;RISK;SIDE_EFFECT:POSTOPERATIVE_NAUSEA_AND_VOMITING;CHILDREN;;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2B, RIBAVIRIN;VDR;AA + AG;rs2228570;EFFICACY;INCREASED;;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;ABCB11;GG;rs2287622;TOXICITY;INCREASED;RISK;DISEASE:DRUG-INDUCED_LIVER_INJURY;;;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2B, RIBAVIRIN, SIMEPREVIR;ITPA;CC;rs1127354;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ANEMIA;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;CAUTION_SIDE_EFFECT
DOCETAXEL;NR1I3;AA;rs3003593;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:NEUTROPENIA;PEOPLE;DISEASE:NASOPHARYNGEAL_NEOPLASMS;CAUTION_SIDE_EFFECT
ANTITHYROID PREPARATIONS;EHMT2;G;rs652888;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:AGRANULOCYTOSIS;;;CAUTION_SIDE_EFFECT
IODINE (131I) COMPOUNDS, RADIOTHERAPY;TNF;AG;rs1800629;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:PAIN;PEOPLE;DISEASE:THYROID_TUMOR;CAUTION_SIDE_EFFECT
HYDROCODONE;OPRM1;AG + GG;rs1799971;TOXICITY;INCREASED;RISK;DISEASE:CONSTIPATION;WOMEN;DISEASE:PREGNANCY;CAUTION_SIDE_EFFECT
HMG_COA_REDUCTASE_INHIBITORS;HLA-G;G;rs1063320;OTHER;DECREASED;LIKELIHOOD;DISEASE:ASTHMA;PEOPLE;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_FAILURE
HYDROCODONE;OPRM1;AG + GG;rs1799971;TOXICITY;INCREASED;RISK;DISEASE:DRY_MOUTH;WOMEN;DISEASE:PREGNANCY;CAUTION_SIDE_EFFECT
DEXMEDETOMIDINE;CYP2A6;C;rs28399433;EFFICACY;INCREASED;;EFFICACY:SEDATION;WOMEN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DEFERIPRONE;UGT1A6;GG;rs6759892;TOXICITY;INCREASED;RISK;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:BETA-THALASSEMIA_AND_RELATED_DISEASES;CAUTION_SIDE_EFFECT
DEFERIPRONE;UGT1A6;GG;rs6759892;TOXICITY;INCREASED;RISK;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:BETA-THALASSEMIA_AND_RELATED_DISEASES;CAUTION_SIDE_EFFECT
ANTITHYROID PREPARATIONS;;del;rs111618861;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:AGRANULOCYTOSIS;;;CAUTION_SIDE_EFFECT
ANTITHYROID PREPARATIONS;HLA-B;C;rs1071816;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:AGRANULOCYTOSIS;;;CAUTION_SIDE_EFFECT
IODINE (131I) COMPOUNDS, RADIOTHERAPY;ATM;AA + AG;rs11212570;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:PAIN;PEOPLE;DISEASE:THYROID_TUMOR;CAUTION_SIDE_EFFECT
EFAVIRENZ;IL10;TT;rs1800896;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_HYPERSENSITIVITY;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
ETHANOL;ANKK1, DRD2;A;rs1800497;OTHER;INCREASED;RISK;DISEASE:ALCOHOL_ABUSE;;;CAUTION_SIDE_EFFECT
IODINE (131I) COMPOUNDS, RADIOTHERAPY;NFKB1;AT;rs230493;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:PAIN;PEOPLE;DISEASE:THYROID_TUMOR;LIKELIHOOD_THERAPEUTIC_SUCCESS
OPIOIDS;OPRM1;G;rs1799971;TOXICITY;DECREASED;RISK;OTHER:OPIOID-RELATED_DISORDERS;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHANOL;DRD2;A;rs1800497;OTHER;INCREASED;RISK;DISEASE:ALCOHOL_ABUSE;;;CAUTION_SIDE_EFFECT
IODINE (131I) COMPOUNDS, RADIOTHERAPY;TGFB1;TT;rs2241716;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:PAIN;PEOPLE;DISEASE:THYROID_TUMOR;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;NUDT15;CT + TT;rs116855232;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
IODINE (131I) COMPOUNDS, RADIOTHERAPY;TGFB1;GG;rs1800469;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:PAIN;PEOPLE;DISEASE:THYROID_TUMOR;CAUTION_SIDE_EFFECT
ANTITHYROID PREPARATIONS;FOXF2;del;rs199564443;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:AGRANULOCYTOSIS;;;CAUTION_SIDE_EFFECT
CAPECITABINE;CES1P1;T;rs7187684;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
ASPARAGINASE, CYCLOPHOSPHAMIDE, CYTARABINE, DAUNORUBICIN, HYDROCORTISONE, METHOTREXATE, PREDNISONE, VINCRISTINE;;GG;rs6977967;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:MUCOSITIS;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
CAPECITABINE;CES1P1;G;rs11861118;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
PLATINUM;XRCC1;TT;rs25487;EFFICACY;;;OTHER:WORSE_OVERALL_SURVIVAL_OUTCOME;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_DOSE_ADJUST
PLATINUM;ERCC1;AG + GG;rs11615;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:RESPONSE;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE;CES1;G;rs2244613;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
PLATINUM;ERCC1;AA + AC;rs3212986;EFFICACY;INCREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOZAPINE, ETHANOL;CYP1A2;GG;rs2069514;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS;PEOPLE;OTHER:PSYCHOTIC_DISORDER;CAUTION_SIDE_EFFECT
MERCAPTOPURINE, METHOTREXATE;PACSIN2;CT + TT;rs2413739;EFFICACY;INCREASED;RISK;EFFICACY:RECURRENCE;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
ASPARAGINASE, CYCLOPHOSPHAMIDE, CYTARABINE, DAUNORUBICIN, HYDROCORTISONE, METHOTREXATE, PREDNISONE, VINCRISTINE;MIR4268;CC + CT;rs4674470;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:MUCOSITIS;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE;CES1;G;rs2244614;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;CT + TT;rs12979860;EFFICACY;DECREASED;;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_FAILURE
CITALOPRAM;CYP2C19;AG;rs4244285;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS;MEN;OTHER:ALCOHOL_ABUSE, OTHER:MAJOR_DEPRESSIVE_DISORDER;CAUTION_SIDE_EFFECT
IODINE (131I) COMPOUNDS, RADIOTHERAPY;ATM;TT;rs620815;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY;PEOPLE;DISEASE:THYROID_TUMOR;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;TT;rs12979860;EFFICACY;INCREASED;RISK;EFFICACY:TREATMENT_FAILURE_TO_PEGYLATED_INTERFERON-ALPHA/RIBAVIRIN_THERAPY_IN_HCV/HIV-1_COINFECTED_PATIENTS;;;CAUTION_SIDE_EFFECT
TENOFOVIR;ABCC2;A;rs17222723;TOXICITY;DECREASED;RISK;SIDE_EFFECT:RENAL_PROXIMAL_TUBULOPATHY;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
TENOFOVIR;ABCC2;A;rs2273697;TOXICITY;INCREASED;RISK;SIDE_EFFECT:RENAL_PROXIMAL_TUBULOPATHY;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;CT;rs1801160;EFFICACY;DECREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;OTHER:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
CYTARABINE, IDARUBICIN;;AA + AG;rs12036333;EFFICACY;DECREASED;;EFFICACY:EVENT-FREE_SURVIVAL;PEOPLE;DISEASE:ACUTE_MYELOID_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
ASPARAGINASE, CYCLOPHOSPHAMIDE, CYTARABINE, DAUNORUBICIN, HYDROCORTISONE, METHOTREXATE, PREDNISONE, VINCRISTINE;ATF5;AA + AG;rs8667;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DIARRHEA;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
NEVIRAPINE;CYP2B6;CC + CT;rs28399499;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2B, RIBAVIRIN;CYP2R1;AA + AG;rs10741657;EFFICACY;INCREASED;;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPARAGINASE, CYCLOPHOSPHAMIDE, CYTARABINE, DAUNORUBICIN, HYDROCORTISONE, METHOTREXATE, PREDNISONE, VINCRISTINE;MIR3117;AA + AG;rs12402181;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:VOMITING;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
NEVIRAPINE;CYP2B6;T;rs3745274;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;WOMEN;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
TENOFOVIR DISOPROXIL FUMARATE;CYP24A1;TT;rs2248359;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:NEPHROTOXICITY;PEOPLE;OTHER:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;AA + AG;rs1801133;TOXICITY;INCREASED;RISK;DISEASE:TOXIC_LIVER_DISEASE;CHILDREN;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;CYP2C19;GG;rs4244285;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXICITY;WOMEN;DISEASE:SYSTEMIC_LUPUS_ERYTHEMATOSUS;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIR;IFNL3;TT;rs8099917;EFFICACY;INCREASED;;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
TENOFOVIR DISOPROXIL FUMARATE;CYP27B1;GG;rs4646536;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:NEPHROTOXICITY;PEOPLE;OTHER:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;DDC;C;rs2060761;OTHER;INCREASED;RISK;DISEASE:TOBACCO_USE_DISORDER;;OTHER:SMOKERS;CAUTION_SIDE_EFFECT
DRUGS FOR TREATMENT OF TUBERCULOSIS;RIPOR2;AA + AG;rs10946737;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;PEOPLE;DISEASE:TUBERCULOSIS;CAUTION_SIDE_EFFECT
NICOTINE;DDC;A;rs12718541;OTHER;INCREASED;RISK;DISEASE:TOBACCO_USE_DISORDER;;OTHER:SMOKERS;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;;EFFICACY:RESPONSE_(RAPID_AND_SUSTAINED_VIROLOGICAL_RESPONSE)_FOR_PATIENTS_WITH_HEPATITIS_C_VIRUS_GENOTYPE_1;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
IMIPRAMINE;CYP2C19;CT + TT;rs12248560;METABOLISM/PK;DECREASED;;PK:DOSE-CORRECTED_PLASMA_CONCENTRATIONS;PEOPLE;DISEASE:DEPRESSIVE_DISORDER;CAUTION_DOSE_ADJUST
IMIPRAMINE;CYP2C19;CT + TT;rs11188072;METABOLISM/PK;DECREASED;;PK:DOSE-CORRECTED_PLASMA_CONCENTRATIONS;PEOPLE;DISEASE:DEPRESSIVE_DISORDER;CAUTION_DOSE_ADJUST
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;AA;rs12980275;EFFICACY;INCREASED;;EFFICACY:RAPID_VIROLOGICAL_RESPONSE_(RVR), EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;CXCL5;GG;rs352046;OTHER;INCREASED;RISK;DISEASE:DEATH;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;CAUTION_SIDE_EFFECT
NEVIRAPINE;CYP2B6;C;rs28399499;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;WOMEN;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED;;EFFICACY:RAPID_VIROLOGICAL_RESPONSE_(RVR), EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;VKORC1;AA + AG;rs9934438;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OVER-ANTICOAGULATION;;;CAUTION_SIDE_EFFECT
CAPECITABINE;CDA;G;rs602950;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DIARRHEA;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
CAPECITABINE;CDA;T;rs532545;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DIARRHEA;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
TENOFOVIR DISOPROXIL FUMARATE;ABCC2;TT;rs717620;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:NEPHROTOXICITY;PEOPLE;OTHER:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
CAPECITABINE;CDA;A;rs6690069;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HAND-FOOT_SYNDROME;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
TENOFOVIR;ABCC2;CC;rs717620;TOXICITY;INCREASED;RISK;SIDE_EFFECT:KIDNEY_TUBULAR_DYSFUNCTION;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
METHYLPHENIDATE;DRD1;CC;rs4532;TOXICITY;INCREASED;SEVERITY;OTHER:SOCIAL_WITHDRAWAL;CHILDREN;DISEASE:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY;CAUTION_SIDE_EFFECT
CAPECITABINE, FLUOROURACIL;DPYD;AA + AT;rs67376798;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;EFFICACY;INCREASED;RISK;EFFICACY:SUBCLINICAL_INTRA-STENT_THROMBUS;;OTHER:PATIENTS_UNDERGOING_DRUG-ELUTING_STENT_(DES)_IMPLANTATION;CAUTION_SIDE_EFFECT
CAPECITABINE;CES1;G;rs3217164;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
CAPECITABINE;CDA;A;rs10916825;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DIARRHEA;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
CAPECITABINE, FLUOROURACIL;DPYD;CT + TT;rs1801160;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
TENOFOVIR DISOPROXIL FUMARATE;SLC28A2;CT + TT;rs11854484;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:NEPHROTOXICITY;PEOPLE;OTHER:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;HTR2A;CC;rs6311;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:DIZZINESS;PEOPLE;OTHER:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE;NSUN3;C;rs144470777;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME;PEOPLE;DISEASE:BREAST_NEOPLASMS, DISEASE:COLORECTAL_NEOPLASMS,DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
CAPECITABINE;PHC1;C;rs187805828;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME;PEOPLE;DISEASE:BREAST_NEOPLASMS, DISEASE:COLORECTAL_NEOPLASMS,DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
ALENDRONATE;VDR;CC;rs1544410;EFFICACY;DECREASED;;EFFICACY:SERUM_OSTEOCALCIN;PEOPLE;DISEASE:OSTEOPOROSIS;LIKELIHOOD_THERAPEUTIC_FAILURE
ASPIRIN;ITGB3;TT;rs5918;EFFICACY;INCREASED;RISK;EFFICACY:INADEQUATE_INHIBITION_OF_PLATELET_ACTIVITY;;;CAUTION_SIDE_EFFECT
CAPECITABINE;FAT1;T;rs116134453;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME;PEOPLE;DISEASE:BREAST_NEOPLASMS, DISEASE:COLORECTAL_NEOPLASMS,DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
CISPLATIN;XPC;GG + GT;rs2228001;TOXICITY;INCREASED;RISK;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:URINARY_BLADDER_NEOPLASMS;CAUTION_SIDE_EFFECT
CAPECITABINE;TENM4;C;rs141531882;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME;PEOPLE;DISEASE:BREAST_NEOPLASMS, DISEASE:COLORECTAL_NEOPLASMS,DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
TICAGRELOR;ABCB1;AA + AG;rs1045642;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DYSPNEA;PEOPLE;OTHER:ACUTE_CORONARY_SYNDROME;CAUTION_SIDE_EFFECT
WARFARIN;CYP4F2;T;rs2108622;DOSAGE;;;EFFICACY:A_22%_INCREASE_IN_THERAPEUTIC_WARFARIN_DOSE_REQUIREMENT_AFTER_ADJUSTMENT_FOR_CLINICAL_AND_GENETIC_COVARIATES_IN_HISPANIC-AMERICANS;;;CAUTION_DOSE_ADJUST
AMOXICILLIN, CLAVULANATE;HLA-DQB1;A;rs9274407;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_INDUCED_LIVER_INJURY;PEOPLE;DISEASE:DRUG_TOXICITY;CAUTION_SIDE_EFFECT
CAPECITABINE;CD96;C;rs77475703;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME;PEOPLE;DISEASE:BREAST_NEOPLASMS, DISEASE:COLORECTAL_NEOPLASMS,DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
METHOTREXATE;ABCB1;AA;rs1045642;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:BURKITT_LYMPHOMA, DISEASE:T-CELL_LYMPHOMA,DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE, DOCETAXEL, DOXORUBICIN, EPIRUBICIN, FLUOROURACIL, GOSERELIN;SLCO1B1;TT;rs4149056;TOXICITY;INCREASED;RISK;SIDE_EFFECT:AMENORRHEA;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
WARFARIN;NQO1;A;rs1800566;DOSAGE;;;EFFICACY:A_34%_INCREASE_IN_THERAPEUTIC_WARFARIN_DOSE_REQUIREMENT_WHILE_HOLDING_CLINICAL_AND_GENETIC_PREDICTORS_CONSTANT_IN_HISPANIC-AMERICANS;;;CAUTION_DOSE_ADJUST
CAPECITABINE;ZMIZ1;C;rs117484357;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME;PEOPLE;DISEASE:BREAST_NEOPLASMS, DISEASE:COLORECTAL_NEOPLASMS,DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
CAPECITABINE;VPS13D;G;rs138385713;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME;PEOPLE;DISEASE:BREAST_NEOPLASMS, DISEASE:COLORECTAL_NEOPLASMS,DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
CETUXIMAB;RASSF1;CC;rs2236947;EFFICACY;INCREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
PAROXETINE;CYP1A2;CC;rs4646425;EFFICACY;INCREASED;;EFFICACY:SLOWER_RESPONSE_TIME;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE;CCDC77;G;rs141213385;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME;PEOPLE;DISEASE:BREAST_NEOPLASMS, DISEASE:COLORECTAL_NEOPLASMS,DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;RGS2;C;rs4606;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:EXTRAPYRAMIDAL_SYMPTOMS, SIDE_EFFECT:PARKINSONIAN_DISORDER;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
PRAVASTATIN;SLCO1B1;C;rs4149056;METABOLISM/PK;INCREASED;;PK:PRAVASTATIN_PLASMA_CONCENTRATIONS_(AUC);HEALTHY;;CAUTION_DOSE_ADJUST
DEXMEDETOMIDINE;WBP2NL;AA;rs5758550;EFFICACY;INCREASED;SEVERITY;EFFICACY:SEDATION;PEOPLE;OTHER:SURGERY;CAUTION_SIDE_EFFECT
CAPECITABINE;ADGRG7;T;rs117308378;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME;PEOPLE;DISEASE:BREAST_NEOPLASMS, DISEASE:COLORECTAL_NEOPLASMS,DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
CARBOPLATIN, CISPLATIN;AKT1;AA + AC;rs1130214;EFFICACY;DECREASED;RISK;EFFICACY:DISEASE_PROGRESSION;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOSPORINE, MYCOPHENOLIC ACID, PREDNISONE;NFATC1;CC;rs2280055;EFFICACY;;;EFFICACY:DECREASED_GLOMERULAR_FILTRATION_RATE;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
ASPIRIN, CLOPIDOGREL;PEAR1;T;rs41273215;EFFICACY;INCREASED;RISK;EFFICACY:MYOCARDIAL_INFARCTION, EFFICACY:STROKE, EFFICACY:DEATH;PEOPLE;OTHER:ACUTE_CORONARY_SYNDROME;CAUTION_SIDE_EFFECT
CARBOPLATIN, CISPLATIN;;AA + AC;rs2498804;EFFICACY;DECREASED;RISK;EFFICACY:DISEASE_PROGRESSION;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOZAPINE, OLANZAPINE, RISPERIDONE;DRD2;CC;rs4436578;TOXICITY;INCREASED;RISK;SIDE_EFFECT:BODY_WEIGHT_GAIN;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIR;IFNL3, IFNL4;TT;rs8099917;EFFICACY;INCREASED;;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
VINCRISTINE;ABCC2;T;rs12826;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
EFAVIRENZ;CYP2B6;TT;rs3745274;METABOLISM/PK;INCREASED;;PK:PLASMA_EXPOSURE;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_DOSE_ADJUST
NICOTINE;GRIN3A;C;rs10121600;OTHER;INCREASED;RISK;DISEASE:TOBACCO_USE_DISORDER;;;CAUTION_SIDE_EFFECT
ASPIRIN, CLOPIDOGREL;CYP1A2;C;rs762551;EFFICACY;INCREASED;RISK;EFFICACY:MYOCARDIAL_INFARCTION, EFFICACY:STROKE, EFFICACY:DEATH;PEOPLE;OTHER:ACUTE_CORONARY_SYNDROME;CAUTION_SIDE_EFFECT
WARFARIN;VKORC1;TT;rs9923231;EFFICACY;INCREASED;;EFFICACY:MEAN_PEAK_INR_DURING_WEEK_1_OF_WARFARIN_THERAPY;CHILDREN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN, CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;INCREASED;RISK;EFFICACY:MYOCARDIAL_INFARCTION, EFFICACY:STROKE, EFFICACY:DEATH;PEOPLE;OTHER:ACUTE_CORONARY_SYNDROME;CAUTION_SIDE_EFFECT
CITALOPRAM;HTR1B;CC;rs6296;TOXICITY;INCREASED;RISK;SIDE_EFFECT:AGITATION;CHILDREN;DISEASE:ANXIETY_DISORDERS, DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_SIDE_EFFECT
PRAVASTATIN;ABCA1;TT;rs2230806;EFFICACY;INCREASED;;EFFICACY:HDL-CHOLESTEROL;PEOPLE;DISEASE:CORONARY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN, CLOPIDOGREL;PON1;T;rs662;EFFICACY;INCREASED;RISK;EFFICACY:MYOCARDIAL_INFARCTION, EFFICACY:STROKE, EFFICACY:DEATH;PEOPLE;OTHER:ACUTE_CORONARY_SYNDROME;CAUTION_SIDE_EFFECT
DEXMEDETOMIDINE;ABCG2;GG;rs2231142;EFFICACY;INCREASED;SEVERITY;EFFICACY:SEDATION;PEOPLE;OTHER:SURGERY;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2B, RIBAVIRIN, SIMEPREVIR;IFNL3, IFNL4;TT;rs8099917;EFFICACY;INCREASED;;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""ANTIINFLAMMATORY AGENTS, NON-STEROIDS"", ""CELECOXIB"", ""DICLOFENAC"", ""IBUPROFEN"", ""NAPROXEN"", ""PIROXICAM""";CYP2C9;C;rs1057910;TOXICITY;INCREASED;RISK;SIDE_EFFECT:GASTROINTESTINAL_BLEEDING;;;CAUTION_SIDE_EFFECT
CAPECITABINE;DPYD;A;rs75267292;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME;PEOPLE;DISEASE:BREAST_NEOPLASMS, DISEASE:COLORECTAL_NEOPLASMS,DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
NICOTINE;GRIN3A;G;rs11788456;OTHER;;RISK;DISEASE:TOBACCO_USE_DISORDER;;;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2B6;TT;rs3745274;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:FATIGUE;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
"""ANTIINFLAMMATORY AGENTS, NON-STEROIDS"", ""CELECOXIB"", ""DICLOFENAC""";CYP2C9;C;rs1057910;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ACUTE_GASTROINTESTINAL_BLEEDING;;;CAUTION_SIDE_EFFECT
EFAVIRENZ;CYP2B6;TT;rs3745274;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:SLEEP_DISORDERS;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
PRAVASTATIN;KIF6;AG + GG;rs20455;EFFICACY;DECREASED;RISK;DISEASE:CORONARY_DISEASE;PEOPLE;OTHER:PRIOR_VASCULAR_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;MTHFR;AA;rs1801133;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:BURKITT_LYMPHOMA, DISEASE:T-CELL_LYMPHOMA,DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
"""ACE INHIBITORS, PLAIN"", ""ANGIOTENSIN II ANTAGONISTS""";F5;AG;rs368967198;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ANGIOEDEMA;;;CAUTION_SIDE_EFFECT
CAPECITABINE;SSU72;C;rs146898897;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME;PEOPLE;DISEASE:BREAST_NEOPLASMS, DISEASE:COLORECTAL_NEOPLASMS,DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
ASPIRIN, CLOPIDOGREL;F2R;T;rs168753;EFFICACY;DECREASED;RISK;EFFICACY:MYOCARDIAL_INFARCTION, EFFICACY:STROKE, EFFICACY:DEATH;PEOPLE;OTHER:ACUTE_CORONARY_SYNDROME;LIKELIHOOD_THERAPEUTIC_SUCCESS
BETA BLOCKING AGENTS;GNB3;CT + TT;rs5443;OTHER;DECREASED;;OTHER:HEART_RATE;;;CAUTION_DOSE_ADJUST
CARBOPLATIN, CISPLATIN;PIK3CA;CC;rs2699887;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
BETA BLOCKING AGENTS;GNB3;CT + TT;rs5443;OTHER;DECREASED;;OTHER:HEART_RATE;;;CAUTION_DOSE_ADJUST
CARBOPLATIN, CISPLATIN;PTEN;AC + CC;rs2299939;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE;MAN1A1;A;rs185346775;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME;PEOPLE;DISEASE:BREAST_NEOPLASMS, DISEASE:COLORECTAL_NEOPLASMS,DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
CARBOPLATIN, CISPLATIN;AKT1;C;rs3803304;EFFICACY;;RISK;EFFICACY:DISEASE_PROGRESSION;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_DOSE_ADJUST
COCAINE;BCHE;TT;rs1803274;OTHER;;;DISEASE:COCAINE_DEPENDENCE;;;CAUTION_DOSE_ADJUST
PRAVASTATIN;SLCO1B1;CC;rs4149056;METABOLISM/PK;INCREASED;;PK:MEAN_PEAK_CONCENTRATION_IN_PLASMA_AND_AREA_UNDER_THE_PLASMA_CONCENTRATION;MEN;;CAUTION_DOSE_ADJUST
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;EGFR;AA;rs11506105;EFFICACY;INCREASED;;EFFICACY:RAPID_VIROLOGICAL_RESPONSE_(RVR), EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN, FLUOROURACIL;ABCB1;GG;rs1045642;EFFICACY;DECREASED;;EFFICACY:SURVIVAL_RATE;PEOPLE;DISEASE:NEOPLASM_OF_ESOPHAGUS;LIKELIHOOD_THERAPEUTIC_FAILURE
ASPIRIN, CLOPIDOGREL;P2RY12;AG + GG;rs2046934;EFFICACY;INCREASED;;EFFICACY:PLATELET_REACTIVITY;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
HMG_COA_REDUCTASE_INHIBITORS;STAT4;T;rs7574865;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;PEOPLE;DISEASE:DRUG-INDUCED_LIVER_INJURY;CAUTION_SIDE_EFFECT
CISPLATIN, FLUOROURACIL;ABCB1;AA + AG;rs1045642;EFFICACY;DECREASED;RISK;EFFICACY:LYMPH_NODE_METASTASES;PEOPLE;DISEASE:NEOPLASM_OF_ESOPHAGUS;LIKELIHOOD_THERAPEUTIC_SUCCESS
MERCAPTOPURINE;NUDT15;CT + TT;rs116855232;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
HEROIN;ALDH2;AA + AG;rs671;OTHER;INCREASED;;DISEASE:HEROIN_DEPENDENCE;;;CAUTION_DOSE_ADJUST
FENTANYL;CALCA;GG;rs145837941;DOSAGE;DECREASED;SEVERITY;SIDE_EFFECT:POSTOPERATIVE_NAUSEA_AND_VOMITING;WOMEN;OTHER:POSTOPERATIVE_PAIN, OTHER:CAESARIAN_SECTION;CAUTION_DOSE_ADJUST
"""METFORMIN"", ""SULFONAMIDES, UREA DERIVATIVES""";KCNJ11;T;rs5219;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:TREATMENT_FAILURE;PEOPLE;DISEASE:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIHYPERTENSIVES, BETA BLOCKING AGENTS, DIURETICS;ADRB1;CC;rs1801253;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:STROKE;PEOPLE;OTHER:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;GRIN3A;T;rs17189632;OTHER;;RISK;DISEASE:TOBACCO_USE_DISORDER;;;CAUTION_DOSE_ADJUST
FLUOROURACIL;DPYD;CT + TT;rs3918290;TOXICITY;INCREASED;RISK;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
HMG_COA_REDUCTASE_INHIBITORS;SLCO1A2;T;rs4149000;TOXICITY;INCREASED;RISK;SIDE_EFFECT:MUSCULAR_DISEASES;;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;EFFICACY;INCREASED;RISK;EFFICACY:POOR-RESPONSE_TO_CLOPIDOGREL;;OTHER:PATIENTS_UNDERGOING_PERCUTANEOUS_CORONARY_INTERVENTION_(PCI);CAUTION_SIDE_EFFECT
TRAMADOL;SLC22A1;del;rs35167514;METABOLISM/PK;INCREASED;;PK:PLASMA_CONCENTRATIONS_OF_O-DESMETHYLTRAMADOL;HEALTHY;;CAUTION_DOSE_ADJUST
EFAVIRENZ;CYP2B6;TT;rs3745274;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
SEVOFLURANE;FASTKD3, MTRR;AA + AG;rs2307116;EFFICACY;INCREASED;;EFFICACY:VOL%_END-TIDAL_SEVOFLURANE_CONCENTRATION;PEOPLE;OTHER:OTORHINOLARYNGOLOGY_SURGERY;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN, CLOPIDOGREL;P2RY12;AG + GG;rs2046934;TOXICITY;INCREASED;RISK;SIDE_EFFECT:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE);;;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;;EFFICACY:RAPID_VIROLOGICAL_RESPONSE_(RVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;ABCB1;AA;rs1045642;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA, SIDE_EFFECT:NEUTROPENIA, SIDE_EFFECT:MUCOSITIS;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
TRAMADOL;SLC22A1;A;rs34130495;METABOLISM/PK;INCREASED;;PK:PLASMA_CONCENTRATIONS_OF_O-DESMETHYLTRAMADOL;HEALTHY;;CAUTION_DOSE_ADJUST
TRAMADOL;SLC22A1;T;rs12208357;METABOLISM/PK;;;PK:HIGHER_PLASMA_CONCENTRATIONS_OF_O-DESMETHYLTRAMADOL;HEALTHY;;CAUTION_DOSE_ADJUST
METHADONE;KCNJ6;TT;rs2070995;TOXICITY;DECREASED;RISK;SIDE_EFFECT:WITHDRAWAL_EFFECTS;PEOPLE;DISEASE:HEROIN_DEPENDENCE;LIKELIHOOD_THERAPEUTIC_SUCCESS
IMATINIB;SLCO1A2;CC;rs3764043;METABOLISM/PK;DECREASED;;PK:IMATINIB_CLEARANCE;;;CAUTION_DOSE_ADJUST
IMATINIB;SLCO1A2;CC;rs4148978;METABOLISM/PK;INCREASED;;PK:IMATINIB_CLEARANCE;;;CAUTION_DOSE_ADJUST
VINCRISTINE;ABCC2;T;rs3740066;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
IMATINIB;SLCO1A2;CC;rs4148977;METABOLISM/PK;INCREASED;;PK:IMATINIB_CLEARANCE;;;CAUTION_DOSE_ADJUST
FLUOROURACIL;DPYD;AC;rs55886062;TOXICITY;INCREASED;RISK;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
FLUCLOXACILLIN;NR1I2;CC;rs3814055;TOXICITY;INCREASED;RISK;DISEASE:TOXIC_LIVER_DISEASE;;;CAUTION_SIDE_EFFECT
CYCLOSPORINE, MYCOPHENOLIC ACID, PREDNISONE;NFATC1;CC;rs3894049;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:TRANSPLANT_REJECTION;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED;;EFFICACY:RAPID_VIROLOGICAL_RESPONSE_(RVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
SEVOFLURANE;FASTKD3, MTRR;AG + GG;rs1801394;EFFICACY;INCREASED;;EFFICACY:VOL%_END-TIDAL_SEVOFLURANE_CONCENTRATION;PEOPLE;OTHER:OTORHINOLARYNGOLOGY_SURGERY;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;DPYD;AT;rs67376798;TOXICITY;INCREASED;RISK;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
EFAVIRENZ;CYP2B6;CC;rs28399499;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
"""ACE INHIBITORS, PLAIN"", ""ANGIOTENSIN II ANTAGONISTS""";F5;GT;rs143509841;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ANGIOEDEMA;;;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;G;rs8099917;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_FAILURE
"""ACE INHIBITORS, PLAIN"", ""ANGIOTENSIN II ANTAGONISTS""";F5;AG;rs200157005;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ANGIOEDEMA;;;CAUTION_SIDE_EFFECT
PAROXETINE;CYP1A2;TT;rs4646427;EFFICACY;;;EFFICACY:SLOWER_RESPONSE_TIME;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_DOSE_ADJUST
CARBAMAZEPINE;SCN1A;CC;rs3812718;OTHER;INCREASED;;OTHER:CORTICAL_SILENT_PERIOD_DURATION;HEALTHY;;CAUTION_DOSE_ADJUST
METHOTREXATE;MIR1206;GG;rs2114358;TOXICITY;INCREASED;RISK;SIDE_EFFECT:MUCOSITIS;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
PAROXETINE;CYP1A2;CC;rs4646425;EFFICACY;INCREASED;;EFFICACY:SLOWER_RESPONSE_TIME;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATORVASTATIN;SLCO1B1;G;rs2306283;METABOLISM/PK;DECREASED;;PK:PLASMA_CONCENTRATIONS;;;CAUTION_DOSE_ADJUST
ATORVASTATIN;SLCO1B1;C;rs4149056;METABOLISM/PK;INCREASED;;PK:PLASMA_CONCENTRATIONS;;;CAUTION_DOSE_ADJUST
FOLIC ACID, METHOTREXATE;ABCB1;A;rs1045642;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ADVERSE_DRUG_EVENT;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
CYTARABINE, IDARUBICIN;BRD10;AA + AG;rs10758713;EFFICACY;DECREASED;;EFFICACY:EVENT-FREE_SURVIVAL;PEOPLE;DISEASE:ACUTE_MYELOID_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
HMG_COA_REDUCTASE_INHIBITORS;SLCO1B1;C;rs4149056;TOXICITY;INCREASED;RISK;SIDE_EFFECT:MUSCULAR_DISEASES;;;CAUTION_SIDE_EFFECT
SORAFENIB;KDR;A;rs4864950;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;OTHER:NEOPLASMS;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;T;rs12979860;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_FAILURE
SORAFENIB;PIK3R5;T;rs444904;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HYPERTENSION;PEOPLE;OTHER:RENAL_CELL_CARCINOMA;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A10, UGT1A6, UGT1A7, UGT1A8, UGT1A9;G;rs17868323;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DIARRHEA_WITHIN_24_HOURS_AND_THROMBOCYTOPENIA;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
CYTARABINE, IDARUBICIN;;AG;rs2897047;EFFICACY;INCREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:ACUTE_MYELOID_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;ABCC2;AA;rs2273697;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
CYTARABINE, IDARUBICIN;;GG;rs6550826;EFFICACY;INCREASED;RISK;EFFICACY:EVENT-FREE_SURVIVAL;PEOPLE;DISEASE:ACUTE_MYELOID_LEUKEMIA;CAUTION_SIDE_EFFECT
METHOTREXATE;ABCB1;AG;rs1128503;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
AZATHIOPRINE, MERCAPTOPURINE;ABCC4;CT + TT;rs3765534;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:LEUKOPENIA;PEOPLE;DISEASE:INFLAMMATORY_BOWEL_DISEASES;CAUTION_SIDE_EFFECT
METHOTREXATE;ABCC2;CC + CT;rs4148396;TOXICITY;INCREASED;;SIDE_EFFECT:TIME_TO_DISCONTINUATION_OR_DOSE_REDUCTION;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
METHOTREXATE;ABCC2;CC;rs4148396;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:ALOPECIA;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
CYTARABINE, IDARUBICIN;;CC;rs9883101;EFFICACY;INCREASED;RISK;EFFICACY:EVENT-FREE_SURVIVAL;PEOPLE;DISEASE:ACUTE_MYELOID_LEUKEMIA;CAUTION_SIDE_EFFECT
FOLIC ACID, METHOTREXATE;TLR4;G;rs4986790;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ADVERSE_DRUG_EVENTS;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
ROSUVASTATIN;ABCG2;T;rs2231142;METABOLISM/PK;INCREASED;;PK:PLASMA_CONCENTRATIONS;;;CAUTION_DOSE_ADJUST
ROSUVASTATIN;SLCO1B1;C;rs4149056;METABOLISM/PK;INCREASED;;PK:PLASMA_CONCENTRATIONS;;;CAUTION_DOSE_ADJUST
FLUOROURACIL, LEUCOVORIN;DPYD;AT;rs67376798;TOXICITY;INCREASED;SEVERITY;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
PRAVASTATIN;SLCO1B1;C;rs4149056;METABOLISM/PK;INCREASED;;PK:PRAVASTATIN_PLASMA_CONCENTRATIONS_(AUC)_AND_CMAX;;;CAUTION_DOSE_ADJUST
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;AA;rs12980275;EFFICACY;INCREASED;;EFFICACY:RAPID_VIROLOGICAL_RESPONSE_(RVR), EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;;EFFICACY:RAPID_VIROLOGICAL_RESPONSE_(RVR), EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;DPYD;CT;rs3918290;TOXICITY;INCREASED;SEVERITY;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
HYDROCHLOROTHIAZIDE;;G;rs10792367;EFFICACY;DECREASED;;EFFICACY:BLOOD_PRESSURE_(BP)_REDUCTION;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_FAILURE
IRINOTECAN;UGT1A10, UGT1A6, UGT1A7, UGT1A8, UGT1A9;G;rs17868323;DOSAGE;INCREASED;LIKELIHOOD;SIDE_EFFECT:NECESSITY_TO_REDUCE_IRINOTECAN_DOSAGE;PEOPLE;DISEASE:NEOPLASMS;CAUTION_DOSE_ADJUST
NAN;HMGCR;AT + TT;rs12654264;OTHER;INCREASED;;OTHER:SERUM_TOTAL_CHOLESTEROL;;;CAUTION_DOSE_ADJUST
DOXORUBICIN;SLC28A3;AA + AG;rs7853758;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:CARDIOTOXICITY;CHILDREN;OTHER:NEOPLASMS, OTHER:WILMS_TUMOR,OTHER:SARCOMA_ EWING'S, OTHER:HODGKIN_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
HMG_COA_REDUCTASE_INHIBITORS;ABCB1;AA;rs1045642;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ELEVATED_CIRCULATING_CREATINE_KINASE_CONCENTRATION;;;CAUTION_SIDE_EFFECT
NICOTINE;CHRNA3;T;rs3743075;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:TOBACCO_USE_DISORDER;MEN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NICOTINE;CHRNB4;G;rs7178270;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:TOBACCO_USE_DISORDER;MEN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
VINCRISTINE;NDRG1;G;rs2272653;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA_OTHER:HODGKIN_DISEASE,OTHER:RHABDOMYOSARCOMA, OTHER:MEDULLOBLASTOMA, OTHER:GLIOMA;CAUTION_SIDE_EFFECT
NICOTINE;CHRNB4;A;rs1948;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:TOBACCO_USE_DISORDER;MEN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM COMPOUNDS;ERCC2;AA + AG;rs1052555;EFFICACY;DECREASED;;EFFICACY:OVERALL_SURVIVAL, EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
HMG_COA_REDUCTASE_INHIBITORS, SIMVASTATIN;;T;rs1719247;TOXICITY;DECREASED;LIKELIHOOD;DISEASE:MUSCULAR_DISEASES;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
HMG_COA_REDUCTASE_INHIBITORS;SLCO1B1;AA;rs2306283;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ELEVATED_CIRCULATING_CREATINE_KINASE_CONCENTRATION;;;CAUTION_SIDE_EFFECT
HMG_COA_REDUCTASE_INHIBITORS;SLCO1B1;CC;rs4149056;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ELEVATED_CIRCULATING_CREATINE_KINASE_CONCENTRATION;;;CAUTION_SIDE_EFFECT
HMG_COA_REDUCTASE_INHIBITORS, SIMVASTATIN;;C;rs1346268;TOXICITY;DECREASED;LIKELIHOOD;DISEASE:MUSCULAR_DISEASES;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PRAVASTATIN;SLCO1B1;CT;rs4149056;METABOLISM/PK;INCREASED;;PK:PRAVASTATIN_PLASMA_CONCENTRATIONS_(AUC)_AND_CMAX;HEALTHY;;CAUTION_DOSE_ADJUST
CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;ABCC2;CT + TT;rs3740066;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NAUSEA;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
IMATINIB;UGT2A1;CC;rs11249454;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:GASTROINTESTINAL_STROMAL_TUMORS;CAUTION_SIDE_EFFECT
ANTHRACYCLINES AND RELATED SUBSTANCES;ECT2L;A;rs11155012;EFFICACY;INCREASED;RISK;DISEASE:DEATH;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
HMG_COA_REDUCTASE_INHIBITORS;ABCB1;AA;rs1128503;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ELEVATED_CIRCULATING_CREATINE_KINASE_CONCENTRATION;;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;ATM;AA;rs1801516;TOXICITY;INCREASED;RISK;SIDE_EFFECT:VOMITING;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
GEMCITABINE;SLC28A1;AA;rs3825876;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUTROPENIA;PEOPLE;DISEASE:PANCREATIC_NEOPLASMS;CAUTION_SIDE_EFFECT
ATORVASTATIN;SLCO1B1;CC;rs4149056;METABOLISM/PK;INCREASED;;PK:AUC;HEALTHY;;CAUTION_DOSE_ADJUST
GEMCITABINE;CDA;AC + CC;rs2072671;TOXICITY;DECREASED;RISK;SIDE_EFFECT:NEUTROPENIA;PEOPLE;DISEASE:PANCREATIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
RISPERIDONE;ABCB1;AA + AG;rs1045642;TOXICITY;INCREASED;;SIDE_EFFECT:PROLONGED_QTC_INTERVAL;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
PITAVASTATIN;SLCO1B1;AG + GG;rs2306283;METABOLISM/PK;INCREASED;;PK:PITAVASTATIN_PLASMA_CONCENTRATIONS_(AUC)_AND_CMAX;HEALTHY;;CAUTION_DOSE_ADJUST
SORAFENIB;EGFR;C;rs2330951;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HYPERTENSION;PEOPLE;OTHER:RENAL_CELL_CARCINOMA;CAUTION_SIDE_EFFECT
ROSUVASTATIN;SLCO1B1;CC;rs4149056;METABOLISM/PK;INCREASED;;PK:AUC_(P=0.002)_AND_CMAX_(P=0.003);HEALTHY;;CAUTION_DOSE_ADJUST
HMG_COA_REDUCTASE_INHIBITORS;GATM;A;rs9806699;TOXICITY;DECREASED;LIKELIHOOD;DISEASE:MUSCULAR_DISEASES;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;INCREASED;RISK;SIDE_EFFECT:STENT_THROMBOSIS;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;INCREASED;RISK;OTHER:MAJOR_ADVERSE_CARDIOVASCULAR_EVENTS;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;CAUTION_SIDE_EFFECT
EVEROLIMUS;ABCB1;A;rs2032582;TOXICITY, OTHER;INCREASED;LIKELIHOOD;SIDE_EFFECT:LYMPHOPENIA;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;CYP1B1;CC;rs1056836;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NAUSEA;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
AZATHIOPRINE, MERCAPTOPURINE;;C;rs2647087;TOXICITY;INCREASED;RISK;SIDE_EFFECT:PANCREATITIS;PEOPLE;DISEASE:INFLAMMATORY_BOWEL_DISEASES;CAUTION_SIDE_EFFECT
EVEROLIMUS;RPTOR;T;rs9906827;TOXICITY, OTHER;DECREASED;LIKELIHOOD;SIDE_EFFECT:PNEUMONITIS;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
RADIOTHERAPY;XPC;G;rs2228001;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:EXANTHEMA;PEOPLE;OTHER:HEAD_AND_NECK_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
EVEROLIMUS;ABCB1;A;rs1045642;TOXICITY, OTHER;INCREASED;LIKELIHOOD;SIDE_EFFECT:MUCOSITIS;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;ATM;AA + AG;rs1801516;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NAUSEA;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
AZATHIOPRINE, MERCAPTOPURINE;NUDT15;C;rs116855232;TOXICITY;INCREASED;RISK;SIDE_EFFECT:LEUKOPENIA;PEOPLE;DISEASE:IRRITABLE_BOWEL_SYNDROME;CAUTION_SIDE_EFFECT
PLATELET AGGREGATION INHIBITORS EXCL. HEPARIN;PEAR1;AA + AG;rs12041331;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:MYOCARDIAL_INFARCTION, EFFICACY:MYOCARDIAL_ISCHEMIA, EFFICACY:STROKE;PEOPLE;OTHER:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
SUNITINIB;VEGFA;CC + CT;rs833061;EFFICACY;INCREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
AZACITIDINE;MTHFR;AA;rs1801133;EFFICACY;DECREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:MYELODYSPLASTIC_SYNDROMES;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;AA + AG;rs4986893;EFFICACY;INCREASED;RISK;EFFICACY:HIGH_POST-TREATMENT_PLATELET_REACTIVITY;;OTHER:PATIENTS_TREATED_WITH_PERCUTANEOUS_CORONARY_INTERVENTION_(PCI);CAUTION_SIDE_EFFECT
PLATELET AGGREGATION INHIBITORS EXCL. HEPARIN;PEAR1;AA;rs2768759;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:MYOCARDIAL_INFARCTION, EFFICACY:MYOCARDIAL_ISCHEMIA, EFFICACY:STROKE;PEOPLE;OTHER:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;ERCC1;AA;rs3212986;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUTROPENIA;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
IMATINIB;SLC22A1;GG;rs628031;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:GASTROINTESTINAL_STROMAL_TUMORS;CAUTION_SIDE_EFFECT
ACETAMINOPHEN, IBUPROFEN, LOXOPROFEN, SALICYLAMIDE;;CT + TT;rs6500265;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;;;CAUTION_SIDE_EFFECT
IMATINIB;SLC19A1;TT;rs1051266;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:GASTROINTESTINAL_STROMAL_TUMORS;CAUTION_SIDE_EFFECT
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;GRIA1;CC;rs1994862;OTHER;DECREASED;RISK;SIDE_EFFECT:AROUSAL_DYSFUNCTION;PEOPLE;DISEASE:DEPRESSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
EVEROLIMUS;RPTOR;CT + TT;rs9906827;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:PROGRESSION-FREE_SURVIVAL;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
IMATINIB;CHST1;AA + AG;rs9787901;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:GASTROINTESTINAL_STROMAL_TUMORS;CAUTION_SIDE_EFFECT
IMATINIB;CYP2F1;AA;rs305968;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:GASTROINTESTINAL_STROMAL_TUMORS;CAUTION_SIDE_EFFECT
ACETAMINOPHEN, IBUPROFEN, LOXOPROFEN, SALICYLAMIDE;;GT + TT;rs9933632;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS, SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME;;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;CBR1;TT;rs20572;TOXICITY;INCREASED;RISK;SIDE_EFFECT:VOMITING;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;TP53;GG;rs1042522;TOXICITY;INCREASED;RISK;SIDE_EFFECT:VOMITING;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
SORAFENIB;PRKCE;G;rs11125039;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HYPERTENSION;PEOPLE;OTHER:RENAL_CELL_CARCINOMA;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;SLC22A16;CC + CT;rs714368;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NAUSEA;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
ANTIINFLAMMATORY AGENTS, NON-STEROIDS;IL10;C;rs1800896;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_HYPERSENSITIVITY;;;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;XRCC1;CT + TT;rs25487;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NAUSEA;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
ANTIINFLAMMATORY AGENTS, NON-STEROIDS;CTLA4;G;rs231775;TOXICITY;DECREASED;RISK;SIDE_EFFECT:DRUG_HYPERSENSITIVITY;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;ADH7;CT + TT;rs971074;OTHER;INCREASED;SEVERITY;OTHER:PAIN;PEOPLE;OTHER:SICKLE_CELL_ANEMIA;CAUTION_SIDE_EFFECT
SORAFENIB;ADAMTS18;A;rs1346563;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HYPERTENSION;PEOPLE;OTHER:RENAL_CELL_CARCINOMA;CAUTION_SIDE_EFFECT
PLATINUM COMPOUNDS;XRCC1;CT + TT;rs25487;EFFICACY;INCREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;GSTP1;AA + AG;rs1695;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NAUSEA;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
CISPLATIN;SLC31A1;GG + GT;rs10981694;TOXICITY;INCREASED;SEVERITY;DISEASE:OTOTOXICITY;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;CYP2C19;CC;rs12248560;TOXICITY;INCREASED;RISK;SIDE_EFFECT:LEUKOPENIA;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;ABCC2;TT;rs3740066;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUTROPENIA;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
DEXMEDETOMIDINE;ABCC9;AA;rs11046209;EFFICACY;INCREASED;SEVERITY;EFFICACY:SEDATION;PEOPLE;OTHER:SURGERY;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;ABCB1;GG;rs1045642;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ANEMIA;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
VINCRISTINE;CEP72;A;rs12522955;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;PEOPLE;OTHER:MEDULLOBLASTOMA, OTHER:GLIOMA,OTHER:BRAIN_NEOPLASMS;CAUTION_SIDE_EFFECT
CAPECITABINE;;T;rs72765700;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME;PEOPLE;DISEASE:BREAST_NEOPLASMS, DISEASE:COLORECTAL_NEOPLASMS,DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;ABCG2;GT;rs2231142;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ANEMIA;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC AGENTS, MERCAPTOPURINE, METHOTREXATE;ABCC4;AC;rs2274407;TOXICITY;INCREASED;SEVERITY;DISEASE:THROMBOCYTOPENIA;PEOPLE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
AZATHIOPRINE, MERCAPTOPURINE;FTO;A;rs79206939;TOXICITY;INCREASED;RISK;SIDE_EFFECT:LEUKOPENIA;PEOPLE;DISEASE:IRRITABLE_BOWEL_SYNDROME;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;ALDH3A1;CG + GG;rs2228100;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ANEMIA, SIDE_EFFECT:LEUKOPENIA;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
ANTINEOPLASTIC AGENTS, MERCAPTOPURINE, METHOTREXATE;ABCC4;AC;rs2274407;EFFICACY;DECREASED;;EFFICACY:EVENT_FREE_SURVIVAL;PEOPLE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
PRAVASTATIN;HMGCR;GT;rs17238540;EFFICACY;DECREASED;;EFFICACY:REDUCTION_IN_TOTAL_CHOLESTEROL;;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;EFFICACY;INCREASED;RISK;EFFICACY:HIGH_POST-TREATMENT_PLATELET_REACTIVITY;;OTHER:PATIENTS_TREATED_WITH_PERCUTANEOUS_CORONARY_INTERVENTION_(PCI);CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;ABCC2;GG;rs2273697;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ANEMIA;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;SLC22A16;AA;rs6907567;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUTROPENIA;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
EVEROLIMUS;FGFR4;A;rs351855;TOXICITY, OTHER;DECREASED;LIKELIHOOD;OTHER:DISCONTINUATION;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
VINCRISTINE;CEP72;TT;rs924607;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;PEOPLE;OTHER:MEDULLOBLASTOMA, OTHER:GLIOMA,OTHER:BRAIN_NEOPLASMS, OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA, OTHER:LYMPHOMA;CAUTION_SIDE_EFFECT
AZATHIOPRINE, MERCAPTOPURINE;;T;rs2834826;TOXICITY;INCREASED;RISK;SIDE_EFFECT:LEUKOPENIA;PEOPLE;DISEASE:IRRITABLE_BOWEL_SYNDROME;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;CYP2C19;AA + AG;rs4244285;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUTROPENIA;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
IMATINIB;SLC19A1;AG + GG;rs12659;TOXICITY;DECREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:GASTROINTESTINAL_STROMAL_TUMORS;LIKELIHOOD_THERAPEUTIC_SUCCESS
AZATHIOPRINE, MERCAPTOPURINE;FTO;C;rs16952570;TOXICITY;INCREASED;RISK;SIDE_EFFECT:LEUKOPENIA;PEOPLE;DISEASE:IRRITABLE_BOWEL_SYNDROME;CAUTION_SIDE_EFFECT
AZACITIDINE;XRCC1;CC;rs25487;EFFICACY;DECREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:MYELODYSPLASTIC_SYNDROMES;LIKELIHOOD_THERAPEUTIC_FAILURE
IMATINIB;NQO1;GG;rs10517;EFFICACY;DECREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:GASTROINTESTINAL_STROMAL_TUMORS;LIKELIHOOD_THERAPEUTIC_FAILURE
EVEROLIMUS;PIK3R1;G;rs10515074;TOXICITY, OTHER;DECREASED;LIKELIHOOD;SIDE_EFFECT:HYPERGLYCEMIA;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
DESLORATADINE;HRH1;CC;rs901865;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:SEDATION;PEOPLE;OTHER:URTICARIA;CAUTION_SIDE_EFFECT
IMATINIB;ABCC2;GG;rs2273697;EFFICACY;DECREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:GASTROINTESTINAL_STROMAL_TUMORS;LIKELIHOOD_THERAPEUTIC_FAILURE
CYTARABINE, DOXORUBICIN, LEUCOVORIN, METHOTREXATE, PREDNISONE, VINCRISTINE;NOS3;TT;rs1799983;TOXICITY;DECREASED;;SIDE_EFFECT:IQ;PEOPLE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
IMATINIB;ABCB4;AA + AG;rs1202283;EFFICACY;INCREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:GASTROINTESTINAL_STROMAL_TUMORS;LIKELIHOOD_THERAPEUTIC_SUCCESS
EVEROLIMUS;PIK3R1;G;rs10515074;TOXICITY, OTHER;INCREASED;LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
CAPECITABINE;MIR2054;A;rs10024471;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME;PEOPLE;DISEASE:BREAST_NEOPLASMS, DISEASE:COLORECTAL_NEOPLASMS,DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
AZATHIOPRINE;NUDT15;CT + TT;rs116855232;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA;PEOPLE;DISEASE:AUTOIMMUNE_DISEASES, DISEASE:SYSTEMIC_LUPUS_ERYTHEMATOSUS,DISEASE:SJOGREN'S_SYNDROME;CAUTION_SIDE_EFFECT
METHOTREXATE;DHFR;CT + TT;rs1105525;EFFICACY;DECREASED;;EFFICACY:EVENT_FREE_SURVIVAL;PEOPLE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
ANTIPSYCHOTICS, CLOZAPINE, OLANZAPINE;PRKAB2;TT;rs3766522;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:WEIGHT_GAIN;PEOPLE;DISEASE:SCHIZOAFFECTIVE_DISORDER, DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHADONE;NECTIN4;AA;rs11265549;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:PRURITUS;PEOPLE;OTHER:OPIOID-RELATED_DISORDERS;CAUTION_SIDE_EFFECT
CAPECITABINE;SPRY2;A;rs117876855;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME;PEOPLE;DISEASE:BREAST_NEOPLASMS, DISEASE:COLORECTAL_NEOPLASMS,DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
AZATHIOPRINE;NUDT15;T;rs116855232;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA;PEOPLE;DISEASE:AUTOIMMUNE_DISEASES, DISEASE:SYSTEMIC_LUPUS_ERYTHEMATOSUS,DISEASE:SJOGREN'S_SYNDROME;CAUTION_SIDE_EFFECT
CAPECITABINE;SPRY2;A;rs139544515;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME;PEOPLE;DISEASE:BREAST_NEOPLASMS, DISEASE:COLORECTAL_NEOPLASMS,DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
HMG_COA_REDUCTASE_INHIBITORS;HMGCR;AA;rs12654264;EFFICACY;DECREASED;RISK;DISEASE:COLONIC_NEOPLASMS;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIVAROXABAN;CYP3A4;AA;rs2246709;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE;PEOPLE;OTHER:ATRIAL_FIBRILLATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;GGH;A;rs11545078;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:THROMBOCYTOPENIA;PEOPLE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
CAPECITABINE;NCOA7;T;rs185217050;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME;PEOPLE;DISEASE:BREAST_NEOPLASMS, DISEASE:COLORECTAL_NEOPLASMS,DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
CAPECITABINE;CCDC70;A;rs139368788;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME;PEOPLE;DISEASE:BREAST_NEOPLASMS, DISEASE:COLORECTAL_NEOPLASMS,DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;AA + AG;rs1801133;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;CHILDREN;OTHER:JUVENILE_RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
NAN;HMGCR;AT + TT;rs12654264;OTHER;INCREASED;;OTHER:SERUM_LDL;;;CAUTION_DOSE_ADJUST
CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;ERCC1;AG + GG;rs11615;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ANEMIA, SIDE_EFFECT:NEPHROTOXICITY;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
CAPECITABINE;TMEM131L;G;rs117412990;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME;PEOPLE;DISEASE:BREAST_NEOPLASMS, DISEASE:COLORECTAL_NEOPLASMS,DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
PRAVASTATIN;HMGCR;AT;rs17244841;EFFICACY;DECREASED;;EFFICACY:REDUCTION_IN_TOTAL_CHOLESTEROL;;;LIKELIHOOD_THERAPEUTIC_FAILURE
HMG_COA_REDUCTASE_INHIBITORS;HMGCR;TT;rs12654264;EFFICACY;DECREASED;RISK;DISEASE:COLONIC_NEOPLASMS;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE;SIRPA;G;rs191934521;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME;PEOPLE;DISEASE:BREAST_NEOPLASMS, DISEASE:COLORECTAL_NEOPLASMS,DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS, CLOZAPINE, OLANZAPINE;PRKAA2;AA;rs10789038;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:WEIGHT_GAIN;PEOPLE;DISEASE:SCHIZOAFFECTIVE_DISORDER, DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIVAROXABAN;CYP3A4;TT;rs3735451;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE;PEOPLE;OTHER:ATRIAL_FIBRILLATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
CAPECITABINE;LMNTD1;T;rs146644707;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME;PEOPLE;DISEASE:BREAST_NEOPLASMS, DISEASE:COLORECTAL_NEOPLASMS,DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;GG;rs1801133;TOXICITY;DECREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;CHILDREN;DISEASE:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTINEOPLASTIC AGENTS;RBFOX1;G;rs6500843;EFFICACY;INCREASED;RISK;DISEASE:DEATH;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
HMG_COA_REDUCTASE_INHIBITORS;HMGCR;AA;rs12654264;EFFICACY;DECREASED;RISK;DISEASE:COLONIC_NEOPLASMS;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM;XRCC5;G;rs1051685;TOXICITY;DECREASED;SEVERITY;DISEASE:ANEMIA, DISEASE:LEUKOPENIA, DISEASE:NEUTROPENIA, DISEASE:THROMBOCYTOPENIA;PEOPLE;DISEASE:LUNG_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOZAPINE, OLANZAPINE, RISPERIDONE;LEP;AG + GG;rs7799039;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:METABOLIC_SYNDROME;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
IRINOTECAN;ABCC1;A;rs17287570;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:SEVERE_MYELOSUPPRESSION;PEOPLE;DISEASE:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
SORAFENIB;EPAS1;C;rs1868089;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DERMATOLOGIC_TOXICITY;PEOPLE;OTHER:RENAL_CELL_CARCINOMA;CAUTION_SIDE_EFFECT
PLATINUM;XRCC5;A;rs6941;TOXICITY;INCREASED;SEVERITY;DISEASE:ANEMIA, DISEASE:LEUKOPENIA, DISEASE:NEUTROPENIA, DISEASE:THROMBOCYTOPENIA;PEOPLE;DISEASE:LUNG_NEOPLASMS;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;CYP2A6;A;rs143731390;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DEATH;PEOPLE;OTHER:HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION;CAUTION_SIDE_EFFECT
IRINOTECAN;ABCG2;T;rs2622604;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:SEVERE_MYELOSUPPRESSION;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
FOLIC ACID;MTHFD1;AA;rs2236225;OTHER;DECREASED;LIKELIHOOD;OTHER:DIABETES, GESTATIONAL;WOMEN;OTHER:PREGNANCY;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;DHFR;GG;rs442767;EFFICACY;DECREASED;;EFFICACY:EVENT-FREE_SURVIVAL;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
IRINOTECAN;UGT1A10, UGT1A6, UGT1A7, UGT1A8, UGT1A9;CT + TT;rs11692021;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:SEVERE_MYELOSUPPRESSION;PEOPLE;DISEASE:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM;AQP2;T;rs10875989;TOXICITY;INCREASED;SEVERITY;DISEASE:ANEMIA, DISEASE:LEUKOPENIA, DISEASE:NEUTROPENIA, DISEASE:THROMBOCYTOPENIA;PEOPLE;DISEASE:LUNG_NEOPLASMS;CAUTION_SIDE_EFFECT
APIXABAN, RIVAROXABAN;ABCG2;AA + AC;rs3114018;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HEMORRHAGE;PEOPLE;OTHER:ATRIAL_FIBRILLATION;CAUTION_SIDE_EFFECT
IRINOTECAN;SLCO1B3;G;rs7977213;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:SEVERE_MYELOSUPPRESSION;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
METHOTREXATE;DHFR;TT;rs408626;EFFICACY;DECREASED;;EFFICACY:EVENT-FREE_SURVIVAL;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOPHOSPHAMIDE;CYP2B6;T;rs3745274;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:GRAFT_VS_HOST_DISEASE;PEOPLE;OTHER:HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM;AQP2;AA + AC;rs3759125;TOXICITY;INCREASED;SEVERITY;DISEASE:ANEMIA, DISEASE:LEUKOPENIA, DISEASE:NEUTROPENIA, DISEASE:THROMBOCYTOPENIA;PEOPLE;DISEASE:LUNG_NEOPLASMS;CAUTION_SIDE_EFFECT
IRINOTECAN;SLCO1B3;T;rs10841661;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:SEVERE_MYELOSUPPRESSION;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
METHOTREXATE;DHFR;AA;rs1650697;EFFICACY;DECREASED;;EFFICACY:EVENT-FREE_SURVIVAL;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
APIXABAN, RIVAROXABAN;ABCG2;CT + TT;rs2622604;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HEMORRHAGE;PEOPLE;OTHER:ATRIAL_FIBRILLATION;CAUTION_SIDE_EFFECT
PLATINUM;AQP2;A;rs461872;TOXICITY;DECREASED;SEVERITY;DISEASE:DIARRHEA, DISEASE:NAUSEA, DISEASE:VOMITING;PEOPLE;DISEASE:LUNG_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM;AQP2;CC + CT;rs7305534;TOXICITY;INCREASED;SEVERITY;DISEASE:DIARRHEA, DISEASE:NAUSEA, DISEASE:VOMITING;PEOPLE;DISEASE:LUNG_NEOPLASMS;CAUTION_SIDE_EFFECT
MEPHENYTOIN, TOLBUTAMIDE;CYP2C19;C;rs41291556;METABOLISM/PK;;;PK:DRAMATIC_(APPROXIMATELY_90%_AND_70%)_REDUCTION_IN_THE_METABOLISM_OF_S-MEPHENYTOIN_AND_TOLBUTAMIDE;;;CAUTION_DOSE_ADJUST
PLATINUM;CD74;A;rs2748249;TOXICITY;INCREASED;SEVERITY;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
ASPIRIN;TBXAS1;AA;rs6962291;OTHER;DECREASED;RISK;SIDE_EFFECT:INTOLERANCE;PEOPLE;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM;CD74;C;rs1560661;TOXICITY;DECREASED;SEVERITY;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYTARABINE;CDA;AA;rs2072671;TOXICITY, METABOLISM/PK;DECREASED;RISK;SIDE_EFFECT:GRADE_III/IV_LIVER_TOXICITY;PEOPLE;DISEASE:ACUTE_MYELOID_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
WARFARIN;;A;rs12777823;DOSAGE;;;EFFICACY:REDUCED_WARFARIN_DOSE_IN_AFRICAN_AMERICANS, INDEPENDENT_OF_CYP2C9*2_AND_CYP2C9*3.;;;CAUTION_DOSE_ADJUST
WARFARIN;;A;rs12777823;DOSAGE;;;EFFICACY:REDUCED_WARFARIN_DOSE_IN_AFRICAN_AMERICANS, INDEPENDENT_OF_CYP2C9*2_AND_CYP2C9*3.;;;CAUTION_DOSE_ADJUST
NAN;ALDH1A2;A;rs12915901;OTHER;INCREASED;LIKELIHOOD;OTHER:OSTEOARTHRITIS;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
RALOXIFENE, TAMOXIFEN;;G;rs10030044;EFFICACY;INCREASED;RISK;EFFICACY:OCCURRENCE_OF_BREAST_CANCER_DURING_SERM_(SELECTIVE_ESTROGEN_RECEPTOR_MODULATORS)_THERAPY;PEOPLE;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
CAPECITABINE, FLUOROURACIL;DPYD;CT + TT;rs2297595;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME, SIDE_EFFECT:MUCOSITIS, SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
NAN;SLC2A1;CG + GG;rs841844;TOXICITY;INCREASED;SEVERITY;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:LUNG_NEOPLASMS;CAUTION_SIDE_EFFECT
CAPECITABINE, FLUOROURACIL;DPYD;TT;rs2297595;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:DIARRHEA;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;EFFICACY;INCREASED;RISK;EFFICACY:INSUFFICIENT_ANTIPLATELET_RESPONSE_TO_CLOPIDOGREL;;OTHER:PATIENTS_UNDERGOING_ELECTIVE_CORONARY_STENT_IMPLANTATION;CAUTION_SIDE_EFFECT
DASATINIB;ABL1;CT;rs121913459;OTHER, METABOLISM/PK;DECREASED;;PK:AUC_0-4_HOURS;PEOPLE;DISEASE:LEUKEMIA;CAUTION_DOSE_ADJUST
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;DECREASED;SEVERITY;DISEASE:HEPATITIS_C_VIRUS_INFECTION;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
HYDROCHLOROTHIAZIDE;AGT;T;rs5051;EFFICACY;INCREASED;;EFFICACY:REDUCTION_IN_BLOOD_PRESSURE;WOMEN;DISEASE:ESSENTIAL_HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
HYDROCHLOROTHIAZIDE;AGTR1;A;rs5186;EFFICACY;INCREASED;;EFFICACY:REDUCTION_IN_BLOOD_PRESSURE;WOMEN;DISEASE:ESSENTIAL_HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
TAMOXIFEN;ESR2;CC;rs4986938;OTHER;INCREASED;;SIDE_EFFECT:TRIGLYCERIDES_IN_POSTMENOPAUSAL_WOMAN;;;CAUTION_DOSE_ADJUST
AZATHIOPRINE, MERCAPTOPURINE;NUDT15;T;rs116855232;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:LEUKOPENIA, SIDE_EFFECT:NEUTROPENIA;PEOPLE;DISEASE:INFLAMMATORY_BOWEL_DISEASES;CAUTION_SIDE_EFFECT
ONDANSETRON;ABCB1;AA;rs1045642;EFFICACY;DECREASED;LIKELIHOOD;DISEASE:POSTOPERATIVE_NAUSEA_AND_VOMITING;;;LIKELIHOOD_THERAPEUTIC_FAILURE
TAMOXIFEN;ESR1;GG;rs9340799;OTHER;DECREASED;;SIDE_EFFECT:IN_TOTAL_CHOLESTEROL_IN_POSTMENOPAUSAL_WOMAN_AND_INCREASE_IN_TRIGLYCERIDES_AND_DECREASE_IN_HIGH_DENSITY_LIPOPROTEIN_IN_PREMENOPAUSAL_WOMEN;;;CAUTION_DOSE_ADJUST
TALINOLOL;ABCC2;A;rs2273697;OTHER;INCREASED;;PK:RESIDUAL_CLEARANCE_OF_INTRAVENOUS_TALINOLOL_AND_LOWER_BIOAVAILABLILTY_OF_ORALLY_ADMINISTERED_TALINOLOL;;;CAUTION_DOSE_ADJUST
CLOZAPINE, OLANZAPINE, RISPERIDONE;HTR2C;C;rs1414334;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:METABOLIC_SYNDROME;PEOPLE;DISEASE:SCHIZOAFFECTIVE_DISORDER, DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
DOXORUBICIN;CBR3;G;rs8133052;TOXICITY, METABOLISM/PK;INCREASED;;PK:DOXORUBICINOL_AUC;PEOPLE;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
ONDANSETRON;ABCB1;AA;rs2032582;EFFICACY;DECREASED;LIKELIHOOD;DISEASE:POSTOPERATIVE_NAUSEA_AND_VOMITING;;;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOZAPINE, OLANZAPINE, RISPERIDONE;HTR2C;C;rs518147;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:METABOLIC_SYNDROME;PEOPLE;DISEASE:SCHIZOAFFECTIVE_DISORDER, DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
BEVACIZUMAB, CYANOCOBALAMIN, FOLIC ACID, PEMETREXED;MTHFR;GG + GT;rs1801131;EFFICACY;INCREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:HEAD_AND_NECK_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ARTESUNATE, PRIMAQUINE, PYRIMETHAMINE, SULFADOXINE;G6PD, IKBKG;CT;rs1050828;TOXICITY;INCREASED;RISK;SIDE_EFFECT:MODERATE_ANEMIA;CHILDREN;;CAUTION_SIDE_EFFECT
RALOXIFENE, TAMOXIFEN;ZNF423;A;rs8060157;EFFICACY;DECREASED;RISK;EFFICACY:OCCURRENCE_OF_BREAST_CANCER_DURING_SERM_(SELECTIVE_ESTROGEN_RECEPTOR_MODULATORS)_THERAPY;PEOPLE;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;ABCB1;AA + AG;rs1045642;EFFICACY;;;EFFICACY:DECREASED_GLOMERULAR_FILTRATION_RATE;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_DOSE_ADJUST
CARBAMAZEPINE;ABCC2;AA + AG;rs2273697;TOXICITY, METABOLISM/PK;INCREASED;RISK;SIDE_EFFECT:NEUROLOGICAL_ADR;PEOPLE;DISEASE:EPILEPSY;CAUTION_SIDE_EFFECT
ARTESUNATE, PRIMAQUINE, PYRIMETHAMINE, SULFADOXINE;G6PD, IKBKG;TT;rs1050828;OTHER;INCREASED;RISK;SIDE_EFFECT:MODERATE_ANEMIA;CHILDREN;;CAUTION_SIDE_EFFECT
SORAFENIB;VEGFB;T;rs12366035;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DERMATOLOGIC_TOXICITY;PEOPLE;OTHER:RENAL_CELL_CARCINOMA;CAUTION_SIDE_EFFECT
CYTARABINE;CDA;TT;rs532545;EFFICACY;DECREASED;;EFFICACY:5_YEAR_SURVIVAL;PEOPLE;DISEASE:ACUTE_MYELOID_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
CYTARABINE;CDA;TT;rs532545;EFFICACY;INCREASED;RISK;DISEASE:DEATH;PEOPLE;DISEASE:ACUTE_MYELOID_LEUKEMIA;CAUTION_SIDE_EFFECT
VINCRISTINE;CEP72;C;rs71585289;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA_OTHER:HODGKIN_DISEASE,OTHER:RHABDOMYOSARCOMA, OTHER:MEDULLOBLASTOMA, OTHER:GLIOMA;CAUTION_SIDE_EFFECT
CYCLOSPORINE, TACROLIMUS;ABCB1;AA + AG;rs1128503;EFFICACY;INCREASED;RISK;DISEASE:INFECTIOUS_DISEASE;PEOPLE;DISEASE:HEART_TRANSPLANTATION;CAUTION_SIDE_EFFECT
CLOPIDOGREL;P2RY12;GG;rs2046934;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ACUTE_CORONARY_SYNDROME;;;CAUTION_SIDE_EFFECT
VINCRISTINE;MIR6076;CC + CG;rs35650931;TOXICITY;DECREASED;RISK;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
SORAFENIB;WWOX;A;rs9927200;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DIARRHEA;PEOPLE;OTHER:RENAL_CELL_CARCINOMA;CAUTION_SIDE_EFFECT
DOXEPIN;CYP2C19;AA;rs4244285;METABOLISM/PK;DECREASED;;PK:MEDIAN_ORAL_CLEARANCE_OF_DOXEPIN;HEALTHY;;CAUTION_DOSE_ADJUST
ANTHRACYCLINES AND RELATED SUBSTANCES;RARG;A;rs2229774;TOXICITY;INCREASED;RISK;DISEASE:CARDIOTOXICITY;CHILDREN;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
VINCRISTINE;MIR4481;G;rs7896283;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
CLOMIPRAMINE;CYP2C19;AG;rs4244285;METABOLISM/PK;INCREASED;;PK:MEAN_CLOMIPRAMINE_CONCENTRATIONS_CORRECTED_FOR_DOSE_AND_WEIGHT_AND_HIGHER_METABOLIC_RATIO_OF_CLOMIPRAMINE/DESMETHYLCLOMIPRAMINE;PEOPLE;DISEASE:MENTAL_DISORDERS;CAUTION_DOSE_ADJUST
CAPECITABINE, FLUOROURACIL;DPYD;CC;rs2297595;EFFICACY;DECREASED;;EFFICACY:EVENT-FREE_SURVIVAL;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;SLC19A1;CT;rs1051266;EFFICACY;INCREASED;RISK;OTHER:TOXIC_LIVER_DISEASE;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
CORTICOSTEROIDS;ACP1;TT;rs11553746;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:OSTEONECROSIS;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
SORAFENIB;MAP2K6;C;rs11651488;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DIARRHEA;PEOPLE;OTHER:RENAL_CELL_CARCINOMA;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;GT;rs1801131;EFFICACY;DECREASED;RISK;OTHER:TOXIC_LIVER_DISEASE;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
SORAFENIB;CDH13;C;rs17682789;TOXICITY;DECREASED;RISK;SIDE_EFFECT:DIARRHEA;PEOPLE;OTHER:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CC;rs776746;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:RECURRENCE;CHILDREN;OTHER:NEPHROTIC_SYNDROME;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOMIPRAMINE;CYP2C19;AA;rs4244285;METABOLISM/PK;INCREASED;;PK:MEAN_CLOMIPRAMINE_CONCENTRATIONS_CORRECTED_FOR_DOSE_AND_WEIGHT_AND_HIGHER_METABOLIC_RATIO_OF_CLOMIPRAMINE/DESMETHYLCLOMIPRAMINE;PEOPLE;DISEASE:MENTAL_DISORDERS;CAUTION_DOSE_ADJUST
PAROXETINE;FKBP5;T;rs1360780;OTHER;INCREASED;RISK;SIDE_EFFECT:SUICIDAL_IDEATION;PEOPLE;DISEASE:DEPRESSION;CAUTION_SIDE_EFFECT
CLOMIPRAMINE, LIOTHYRONINE, LITHIUM, NEFAZODONE, PAROXETINE, VENLAFAXINE;FKBP5;T;rs1360780;OTHER;INCREASED;RISK;SIDE_EFFECT:SUICIDAL_IDEATION;PEOPLE;DISEASE:DEPRESSION;CAUTION_SIDE_EFFECT
ILOPERIDONE;CYP2D6;GG;rs1065852;OTHER;INCREASED;;SIDE_EFFECT:QTC_INTERVAL;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_DOSE_ADJUST
GEMCITABINE;SLC28A1;A;rs12148896;TOXICITY;DECREASED;RISK;SIDE_EFFECT:NEUTROPENIA;PEOPLE;DISEASE:PANCREATIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;MTHFR;AA;rs1801133;EFFICACY;INCREASED;RISK;SIDE_EFFECT:MYELOSUPPRESSION;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
CLOMIPRAMINE, LIOTHYRONINE, LITHIUM, NEFAZODONE, VENLAFAXINE;HTR1B;A;rs130058;EFFICACY;DECREASED;RISK;SIDE_EFFECT:SUICIDAL_IDEATION;PEOPLE;DISEASE:DEPRESSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
PAROXETINE;HTR1B;A;rs130058;OTHER;INCREASED;RISK;SIDE_EFFECT:SUICIDAL_IDEATION;PEOPLE;DISEASE:DEPRESSION;CAUTION_SIDE_EFFECT
GEMCITABINE;CDA;A;rs471760;TOXICITY;DECREASED;RISK;SIDE_EFFECT:NEUTROPENIA;PEOPLE;DISEASE:PANCREATIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CANNABIDIOL;ABCC5;AA + AG;rs3749442;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:SEDATION;PEOPLE;OTHER:EPILEPSY;CAUTION_SIDE_EFFECT
CISPLATIN;ACYP2;AG;rs1872328;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OTOTOXICITY;PEOPLE;DISEASE:OSTEOSARCOMA;CAUTION_SIDE_EFFECT
CLOMIPRAMINE, LIOTHYRONINE, LITHIUM, NEFAZODONE, PAROXETINE, VENLAFAXINE;ABCB1;A;rs2032582;OTHER;INCREASED;RISK;SIDE_EFFECT:SUICIDAL_IDEATION;PEOPLE;DISEASE:DEPRESSION;CAUTION_SIDE_EFFECT
MELPHALAN;SLC7A5;AA + AG;rs4240803;TOXICITY;DECREASED;RISK;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY;PEOPLE;DISEASE:MULTIPLE_MYELOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ANTIPSYCHOTICS;MC4R;CC + CT;rs17782313;OTHER;INCREASED;RISK;DISEASE:WEIGHT_GAIN;;;CAUTION_SIDE_EFFECT
PLATINUM;SLC2A1;T;rs3738514;TOXICITY;DECREASED;SEVERITY;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:LUNG_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOXORUBICIN;RARG;AA;rs2229774;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:CARDIOTOXICITY;CHILDREN;OTHER:NEOPLASMS, OTHER:WILMS_TUMOR,OTHER:SARCOMA_ EWING'S, OTHER:HODGKIN_DISEASE;CAUTION_SIDE_EFFECT
VINCRISTINE;GARS1;G;rs1049402;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA_OTHER:HODGKIN_DISEASE,OTHER:RHABDOMYOSARCOMA, OTHER:MEDULLOBLASTOMA, OTHER:GLIOMA;CAUTION_SIDE_EFFECT
SORAFENIB;EGFR;A;rs917881;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DIARRHEA;PEOPLE;OTHER:RENAL_CELL_CARCINOMA;CAUTION_SIDE_EFFECT
VINCRISTINE;FGD4;A;rs12823621;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA_OTHER:HODGKIN_DISEASE,OTHER:RHABDOMYOSARCOMA, OTHER:MEDULLOBLASTOMA, OTHER:GLIOMA;CAUTION_SIDE_EFFECT
CARBOPLATIN, CISPLATIN;SLC31A1;AA;rs7851395;EFFICACY;INCREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
VINCRISTINE;MIR3117;AA + AG;rs12402181;TOXICITY;DECREASED;RISK;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL, OXALIPLATIN;ERCC2, KLC3;GT;rs13181;EFFICACY;INCREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM;SLC2A1;CC;rs4658;TOXICITY;DECREASED;SEVERITY;DISEASE:DRUG_TOXICITY;PEOPLE;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIR;ITPA;CC;rs1127354;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:ANEMIA;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;CAUTION_SIDE_EFFECT
FLUOROURACIL, OXALIPLATIN;GSTP1;AG + GG;rs1695;EFFICACY;INCREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;ADD1;GT + TT;rs4961;OTHER;INCREASED;;OTHER:AMBULATORY_BLOOD_PRESSURE;PEOPLE;DISEASE:HYPERTENSION;CAUTION_DOSE_ADJUST
BLEOMYCIN, CISPLATIN, ETOPOSIDE;ERCC2;GT + TT;rs238406;TOXICITY;INCREASED;RISK;SIDE_EFFECT:LEUKOPENIA;MEN;DISEASE:TESTICULAR_NEOPLASMS;CAUTION_SIDE_EFFECT
ATORVASTATIN;SLCO1B1;CC + CT;rs4149056;TOXICITY;INCREASED;RISK;SIDE_EFFECT:STATIN-RELATED_MYOPATHY;;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP3A5;CC + CT;rs776746;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS;PEOPLE;DISEASE:STROKE;CAUTION_SIDE_EFFECT
HMG_COA_REDUCTASE_INHIBITORS;SLCO1B1;CC + CT;rs4149056;TOXICITY;INCREASED;RISK;SIDE_EFFECT:STATIN-RELATED_MYOPATHY;;;CAUTION_SIDE_EFFECT
NAN;RAD52, WNK1;CC;rs2277869;OTHER;INCREASED;;OTHER:AMBULATORY_BLOOD_PRESSURE;PEOPLE;DISEASE:HYPERTENSION;CAUTION_DOSE_ADJUST
FENTANYL, MORPHINE, OPIOIDS, OXYCODONE;;C;rs13422094;EFFICACY;;;EFFICACY:OPIOIDS_RESPONSE;PEOPLE;DISEASE:NEOPLASMS;CAUTION_DOSE_ADJUST
SUNITINIB;IL13;TT;rs1800925;OTHER;INCREASED;SEVERITY;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;CAUTION_SIDE_EFFECT
FENTANYL, MORPHINE, OPIOIDS, OXYCODONE;;G;rs12211463;EFFICACY;;;EFFICACY:OPIOIDS_RESPONSE;PEOPLE;DISEASE:NEOPLASMS;CAUTION_DOSE_ADJUST
FENTANYL, MORPHINE, OPIOIDS, OXYCODONE;;A;rs7757130;EFFICACY;;;EFFICACY:OPIOIDS_RESPONSE;PEOPLE;DISEASE:NEOPLASMS;CAUTION_DOSE_ADJUST
FENTANYL;OPRM1;AG + GG;rs1799971;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:SOMNOLENCE;HEALTHY;;CAUTION_SIDE_EFFECT
FENTANYL, MORPHINE, OPIOIDS, OXYCODONE;;G;rs2473967;EFFICACY;;;EFFICACY:OPIOIDS_RESPONSE;PEOPLE;DISEASE:NEOPLASMS;CAUTION_DOSE_ADJUST
THIAZIDES, PLAIN;ADD1;GG;rs4961;EFFICACY;DECREASED;RISK;DISEASE:MYOCARDIAL_INFARCTION;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
BLEOMYCIN, CISPLATIN, ETOPOSIDE;ERCC2;TT;rs1799793;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ANEMIA;MEN;DISEASE:TESTICULAR_NEOPLASMS;CAUTION_SIDE_EFFECT
SUNITINIB;IL13;TT;rs1800925;OTHER;INCREASED;RISK;SIDE_EFFECT:LEUKOPENIA;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;CAUTION_SIDE_EFFECT
FENTANYL;COMT;AG;rs4680;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:SOMNOLENCE;HEALTHY;;CAUTION_SIDE_EFFECT
SIMVASTATIN;SLCO1B1;CC + CT;rs4149056;TOXICITY;INCREASED;RISK;SIDE_EFFECT:STATIN-RELATED_MYOPATHY;;;CAUTION_SIDE_EFFECT
FENTANYL, MORPHINE, OPIOIDS, OXYCODONE;RHBDF2;AA + AG;rs12948783;EFFICACY;DECREASED;;EFFICACY:EFFICACT_AS_MEASURED_BY_LOWER_PAIN_RELIEF_TO_OPIOIDS;PEOPLE;DISEASE:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
ACE INHIBITORS, PLAIN;SH2B1;T;rs192613545;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DISCONTINUATION;;;CAUTION_SIDE_EFFECT
RADIOTHERAPY;OSMR;T;rs1239344;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ESOPHAGITIS;;;CAUTION_SIDE_EFFECT
BLEOMYCIN, CISPLATIN, ETOPOSIDE;BLMH;CC;rs1050565;TOXICITY;INCREASED;RISK;SIDE_EFFECT:PAIN;MEN;DISEASE:TESTICULAR_NEOPLASMS;CAUTION_SIDE_EFFECT
RADIOTHERAPY;CDK1;G;rs10711;TOXICITY;INCREASED;RISK;SIDE_EFFECT:PNEUMONITIS;;;CAUTION_SIDE_EFFECT
BLEOMYCIN, CISPLATIN, ETOPOSIDE;BLMH;CC;rs1050565;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ALOPECIA;MEN;DISEASE:TESTICULAR_NEOPLASMS;CAUTION_SIDE_EFFECT
CELECOXIB;CYP2C9;CT;rs1799853;METABOLISM/PK;;;PK:HIGHER_PLASMA_CONCENTRATIONS_OF_CELECOXIB;HEALTHY;;CAUTION_DOSE_ADJUST
HYDROCHLOROTHIAZIDE;REN;GG;rs11240688;EFFICACY;INCREASED;;EFFICACY:REDUCTION_IN_SBP;PEOPLE;DISEASE:ESSENTIAL_HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
HYDROCHLOROTHIAZIDE;YEATS4;C;rs7297610;EFFICACY;INCREASED;;EFFICACY:REDUCTION_IN_BLOOD_PRESSURE;PEOPLE;DISEASE:ESSENTIAL_HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACE INHIBITORS, PLAIN;RBFOX3;C;rs62063838;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DISCONTINUATION;;;CAUTION_SIDE_EFFECT
HYDROCHLOROTHIAZIDE;ADD1;GT + TT;rs4961;EFFICACY;INCREASED;;EFFICACY:REDUCTION_IN_BLOOD_PRESSURE;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
RADIOTHERAPY;PRKCE;G;rs940052;TOXICITY;DECREASED;RISK;SIDE_EFFECT:ESOPHAGITIS;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACE INHIBITORS, PLAIN;MBOAT1;T;rs10946364;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DISCONTINUATION;;;CAUTION_SIDE_EFFECT
RADIOTHERAPY;PRKCE;T;rs11125035;TOXICITY;DECREASED;RISK;SIDE_EFFECT:ESOPHAGITIS;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ROFECOXIB;PTGS1;T;rs3842787;EFFICACY;;;EFFICACY:REDUCTION_IN_COX-1_INHIBITION_AND_DEPRESSION_OF_THE_URINARY_THROMBOXANE_METABOLITE;HEALTHY;;CAUTION_DOSE_ADJUST
BLEOMYCIN, CISPLATIN, ETOPOSIDE;ERCC1;AA;rs11615;TOXICITY;INCREASED;RISK;SIDE_EFFECT:FEBRILE_NEUTROPENIA;MEN;DISEASE:TESTICULAR_NEOPLASMS;CAUTION_SIDE_EFFECT
RADIOTHERAPY;RIGI;C;rs11795343;TOXICITY;INCREASED;RISK;SIDE_EFFECT:PNEUMONITIS;;;CAUTION_SIDE_EFFECT
CISPLATIN;TPMT;T;rs12201199;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OTOTOXICITY;CHILDREN;OTHER:NEOPLASMS;CAUTION_SIDE_EFFECT
DRUGS FOR TREATMENT OF TUBERCULOSIS;;AA;rs1495741;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE;;;CAUTION_SIDE_EFFECT
ACE INHIBITORS, PLAIN;RBFOX3;G;rs56044629;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DISCONTINUATION;;;CAUTION_SIDE_EFFECT
HYDROCHLOROTHIAZIDE;WNK1;TT;rs880054;EFFICACY;DECREASED;;EFFICACY:REDUCTION_IN_SBP;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_FAILURE
RADIOTHERAPY;;C;rs7259857;TOXICITY;DECREASED;RISK;SIDE_EFFECT:ESOPHAGITIS;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CELECOXIB;PTGS1;T;rs3842787;EFFICACY;;;EFFICACY:REDUCTION_IN_COX-1_INHIBITION;HEALTHY;;CAUTION_DOSE_ADJUST
NAN;COL1A1;AA + AC;rs1800012;NAN;INCREASED;RISK;DISEASE:FRACTURES, BONE;;;CAUTION_SIDE_EFFECT
HYDROCHLOROTHIAZIDE;ADD1;T;rs4961;EFFICACY;DECREASED;;EFFICACY:ABSOLUTE_MEAN_BLOOD_PRESSURE;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_FAILURE
ACE INHIBITORS, PLAIN;GABRG2;G;rs77370934;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DISCONTINUATION;;;CAUTION_SIDE_EFFECT
NAN;COL1A1;AA + AC;rs1800012;NAN;DECREASED;;OTHER:BONE_MINERAL_DENSITY_(BMD);;;CAUTION_DOSE_ADJUST
VINCRISTINE;BAHD1;AA + AC;rs3803357;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACE INHIBITORS, PLAIN;RBFOX3;G;rs56209714;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DISCONTINUATION;;;CAUTION_SIDE_EFFECT
CAPECITABINE, FLUOROURACIL;DPYD;CT + TT;rs1801160;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:COLONIC_NEOPLASMS;CAUTION_SIDE_EFFECT
METHYLPREDNISOLONE, PREDNISOLONE;ABCB1;AA;rs1045642;TOXICITY;DECREASED;RISK;SIDE_EFFECT:OSTEONECROSIS;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
BLEOMYCIN, CISPLATIN, ETOPOSIDE;GSTP1;GG;rs1695;TOXICITY;INCREASED;RISK;SIDE_EFFECT:INFECTIOUS_DISEASE;MEN;DISEASE:TESTICULAR_NEOPLASMS;CAUTION_SIDE_EFFECT
ANASTROZOLE, LETROZOLE, TAMOXIFEN;ZNF613;C;rs8113308;EFFICACY;DECREASED;;EFFICACY:OVERALL_SURVIVAL;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
PIRFENIDONE;CYP1A2;AA;rs762551;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS;PEOPLE;OTHER:PULMONARY_FIBROSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
BLEOMYCIN, CISPLATIN, ETOPOSIDE;ERCC2;GG + GT;rs13181;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ALOPECIA;MEN;DISEASE:TESTICULAR_NEOPLASMS;CAUTION_SIDE_EFFECT
CISPLATIN;OTOS;CC + CT;rs2291767;TOXICITY;DECREASED;RISK;SIDE_EFFECT:OTOTOXICITY;PEOPLE;DISEASE:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACE INHIBITORS, PLAIN;RBFOX3;G;rs2061538;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DISCONTINUATION;;;CAUTION_SIDE_EFFECT
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;HTR2A;CC;rs6311;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DIMINISHED_ABILITY_TO_CONCENTRATE;PEOPLE;OTHER:MAJOR_DEPRESSIVE_DISORDER;CAUTION_SIDE_EFFECT
CITALOPRAM;HTR2A;CC;rs6311;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:NAUSEA, SIDE_EFFECT:VOMITING;PEOPLE;OTHER:MAJOR_DEPRESSIVE_DISORDER;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A5;CT + TT;rs776746;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEPHROTOXICITY;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
MERCAPTOPURINE, METHOTREXATE;MTHFR;GG;rs1801131;TOXICITY;DECREASED;RISK;DISEASE:MYELOSUPPRESSION;PEOPLE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
SUNITINIB;CXCL8;TT;rs1126647;OTHER;INCREASED;LIKELIHOOD;SIDE_EFFECT:HYPERTENSION;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
BEVACIZUMAB, FLUOROURACIL, IRINOTECAN, LEUCOVORIN;PDGFRB;AA + AG;rs2302273;EFFICACY;INCREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHANOL;PNPLA3;GG;rs738409;TOXICITY;INCREASED;RISK;OTHER:ALCOHOL_ABUSE;MEN;;CAUTION_SIDE_EFFECT
BEVACIZUMAB, FLUOROURACIL, IRINOTECAN, LEUCOVORIN;RGS5;CC + CG;rs2661280;EFFICACY;INCREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
SORAFENIB;EPAS1;T;rs9973653;TOXICITY;DECREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;OTHER:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;WT1;CC + CT;rs16754;OTHER;INCREASED;LIKELIHOOD;DISEASE:EVENT-FREE_SURVIVAL;CHILDREN;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;CYP3A5;CT + TT;rs776746;EFFICACY;INCREASED;RISK;EFFICACY:TRANSPLANT_REJECTION;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;ITPA;A;rs1127354;TOXICITY;INCREASED;RISK;DISEASE:NEUTROPENIA;PEOPLE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
CANNABINOIDS;FAAH;AA;rs324420;TOXICITY;DECREASED;RISK;DISEASE:SUBSTANCE-RELATED_DISORDERS;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
SORAFENIB;;C;rs315498;TOXICITY;DECREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;OTHER:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE;GSTA1;A;rs3957357;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DEATH;PEOPLE;OTHER:HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION;CAUTION_SIDE_EFFECT
VINCRISTINE;MRPL47;CT + TT;rs10513762;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;AT;rs67376798;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:COLONIC_NEOPLASMS;CAUTION_SIDE_EFFECT
VINCRISTINE;SYNE2;A;rs2781377;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
SORAFENIB;EPAS1;A;rs4035887;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;OTHER:RENAL_CELL_CARCINOMA;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;COMT;AA + AG;rs4680;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ELEVATED_DIASTOLIC_BLOOD_PRESSURE, SIDE_EFFECT:ELEVATED_SYSTOLIC_BLOOD_PRESSURE;CHILDREN;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;INCREASED;;EFFICACY:ON-TREATMENT_PLATELET_REACTIVITY;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;MTHFR;AA;rs1801133;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS;PEOPLE;DISEASE:JUVENILE_RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
METHOTREXATE;DHFR;CC;rs408626;EFFICACY;DECREASED;;OTHER:EVENT-FREE_SURVIVAL, OTHER:OVERALL_SURVIVAL;PEOPLE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;MTHFR;G;rs1801131;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ELEVATED_TRANSAMINASES;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;GSTA1;C;rs1051775;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DEATH;PEOPLE;OTHER:HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION;CAUTION_SIDE_EFFECT
EFAVIRENZ;ABCB1;A;rs1045642;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:TOXICITY-RELATED_TREATMENT_FAILURE;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;CAUTION_SIDE_EFFECT
DOXORUBICIN;GALNT14;TT;rs9679162;EFFICACY;INCREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:HEPATOCELLULAR_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;CYP2D6;CC;rs28360521;TOXICITY, OTHER;INCREASED;RISK;SIDE_EFFECT:GASTROINTESTINAL_HEMORRHAGE;;;CAUTION_SIDE_EFFECT
DESFLURANE, PROPOFOL;ATP8B3;CT + TT;rs45574836;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:POSTOPERATIVE_NAUSEA_AND_VOMITING, SIDE_EFFECT:VOMITING;PEOPLE;OTHER:SURGERY;CAUTION_SIDE_EFFECT
LOSARTAN;CAMK1D;AG + GG;rs10752271;EFFICACY;DECREASED;SEVERITY;EFFICACY:ELEVATED_SYSTOLIC_BLOOD_PRESSURE;PEOPLE;DISEASE:ESSENTIAL_HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;MTHFR;AA;rs1801133;TOXICITY;INCREASED;RISK;DISEASE:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:PSORIATIC_ARTHRITIS;CAUTION_SIDE_EFFECT
METHOTREXATE;DHFR;TT;rs408626;TOXICITY;INCREASED;RISK;SIDE_EFFECT:LEUKOPENIA;PEOPLE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
LOSARTAN;CAMK1D;AG + GG;rs10737062;EFFICACY;DECREASED;SEVERITY;EFFICACY:ELEVATED_SYSTOLIC_BLOOD_PRESSURE;PEOPLE;DISEASE:ESSENTIAL_HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOPHOSPHAMIDE;GSTA1;C;rs1051775;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:GRAFT_VS_HOST_DISEASE;PEOPLE;OTHER:HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;MTHFR;T;rs1801131;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
METHOTREXATE;DHFR;GT;rs442767;TOXICITY;INCREASED;RISK;SIDE_EFFECT:LEUKOPENIA;PEOPLE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
CELECOXIB;CYP2C9;C;rs1057910;EFFICACY;DECREASED;RISK;DISEASE:ADENOMA;PEOPLE;DISEASE:ADENOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
MERCAPTOPURINE;SLC19A1;CT + TT;rs1051266;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:TREATMENT_INTERRUPTIONS;PEOPLE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
BLEOMYCIN, CISPLATIN, ETOPOSIDE;CYP3A4;CT;rs2740574;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ALOPECIA;MEN;DISEASE:TESTICULAR_NEOPLASMS;CAUTION_SIDE_EFFECT
MERCAPTOPURINE;MTHFR;AA + AG;rs1801133;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:TREATMENT_INTERRUPTION;PEOPLE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;AA + AG;rs1801133;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:TREATMENT_INTERRUPTION;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
EFAVIRENZ;ABCB1;A;rs1045642;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:EMERGING_VIRAL_DRUG_RESISTANCE;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
BEVACIZUMAB, FLUOROURACIL, IRINOTECAN, LEUCOVORIN;CSPG4;AG;rs1127648;EFFICACY;DECREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
SORAFENIB;;G;rs10958704;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DERMATOLOGIC_TOXICITY;PEOPLE;OTHER:RENAL_CELL_CARCINOMA;CAUTION_SIDE_EFFECT
METHOTREXATE;SHMT1;AG;rs1979277;TOXICITY;DECREASED;LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;FASTKD3, MTRR;AG;rs1801394;TOXICITY;INCREASED;;SIDE_EFFECT:SPEED_OF_PLATELET_RECOVERY;PEOPLE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
SORAFENIB;EPAS1;G;rs7557402;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DERMATOLOGIC_TOXICITY;PEOPLE;OTHER:RENAL_CELL_CARCINOMA;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;TT;rs1801131;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:RED_BLOOD_CELL_TRANSFUSIONS;PEOPLE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;CYP2B6;T;rs3211371;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:GRAFT_VS_HOST_DISEASE;PEOPLE;OTHER:HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION;CAUTION_SIDE_EFFECT
APIXABAN, RIVAROXABAN;ABCB1;AA;rs1045642;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HEMORRHAGE;PEOPLE;OTHER:ATRIAL_FIBRILLATION;CAUTION_SIDE_EFFECT
EFAVIRENZ;ABCB1;A;rs2032582;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:EMERGING_VIRAL_DRUG_RESISTANCE;PEOPLE;DISEASE:HIV_INFECTIOUS_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
CYCLOPHOSPHAMIDE, DOCETAXEL;VEGFA;AA;rs1570360;EFFICACY;DECREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:PROSTATIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
CARBOPLATIN, GEMCITABINE;OR4D6;CC;rs1453542;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:NEUTROPENIA;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
SORAFENIB;MAP2K6;G;rs12948059;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DERMATOLOGIC_TOXICITY;PEOPLE;OTHER:RENAL_CELL_CARCINOMA;CAUTION_SIDE_EFFECT
CARBOPLATIN, GEMCITABINE;DDX53;T;rs5925720;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;MTHFD1;AA;rs2236225;OTHER;INCREASED;;PK:RED_BLOOD_CELL_FOLATE;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_DOSE_ADJUST
METHOTREXATE;FASTKD3, MTRR;AA;rs1801394;OTHER;INCREASED;;PK:RED_BLOOD_CELL_FOLATE;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_DOSE_ADJUST
IRINOTECAN;SEMA3C;T;rs11979430;TOXICITY;INCREASED;SEVERITY;DISEASE:NEUTROPENIA;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;DRD2;A;rs1800497;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;TOXICITY;INCREASED;RISK;SIDE_EFFECT:CARDIOVASCULAR_EVENTS;;;CAUTION_SIDE_EFFECT
ANTIPSYCHOTICS;COMT;AA + AG;rs4680;TOXICITY;DECREASED;RISK;DISEASE:TARDIVE_DYSKINESIA;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN;SEMA3C;C;rs7779029;TOXICITY;INCREASED;SEVERITY;DISEASE:NEUTROPENIA;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
ANTIEPILEPTICS;ABCB1;C;rs2032582;EFFICACY;;;EFFICACY:PROTECTION_FROM_DRUG_RESISTANCE;PEOPLE;DISEASE:EPILEPSY;CAUTION_DOSE_ADJUST
ANTIPSYCHOTICS;DRD2;G;rs1800497;TOXICITY;INCREASED;RISK;DISEASE:TARDIVE_DYSKINESIA;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
ANTIEPILEPTICS;ABCB1;C;rs2032582;EFFICACY;;;EFFICACY:PROTECTION_FROM_DRUG_RESISTANCE;MEN;DISEASE:EPILEPSY;CAUTION_DOSE_ADJUST
ANTIPSYCHOTICS;DRD2;G;rs1800497;TOXICITY;INCREASED;RISK;DISEASE:TARDIVE_DYSKINESIA;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
IRINOTECAN;;G;rs1661167;TOXICITY;INCREASED;SEVERITY;DISEASE:DIARRHEA;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
ANTIEPILEPTICS;ABCB1;C;rs2032582;EFFICACY;;;EFFICACY:PROTECTION_FROM_DRUG_RESISTANCE;PEOPLE;DISEASE:EPILEPSY;CAUTION_DOSE_ADJUST
AMISULPRIDE, CLOZAPINE, OLANZAPINE, QUETIAPINE, RISPERIDONE;HTR2C;AA;rs498207;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:WEIGHT_GAIN;PEOPLE;DISEASE:SCHIZOAFFECTIVE_DISORDER, DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
CISPLATIN, CYCLOPHOSPHAMIDE;CYP2E1;TT;rs6413432;EFFICACY;INCREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL;WOMEN;DISEASE:OVARIAN_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUDESONIDE;FCER2;G;rs28364072;OTHER;;;OTHER:SEVERE_EXACERBATIONS_WITH_ASTHMA;PEOPLE;DISEASE:ASTHMA;CAUTION_DOSE_ADJUST
CYCLOPHOSPHAMIDE;NOS3;TT;rs1799983;EFFICACY;INCREASED;;EFFICACY:DISEASE_FREE_SURVIVAL;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
AMISULPRIDE, CLOZAPINE, OLANZAPINE, QUETIAPINE, RISPERIDONE;HTR2C;GG;rs3813928;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:WEIGHT_GAIN;PEOPLE;DISEASE:SCHIZOAFFECTIVE_DISORDER, DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
MYCOPHENOLATE MOFETIL;IL12A;A;rs568408;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TIME_TO_ANEMIA_IN_PATIENTS_UNDERGOING_LIVING_OR_DECEASED_DONOR_KIDNEY_TRANSPLANT;;;CAUTION_SIDE_EFFECT
IRINOTECAN;PLCB1;C;rs2745761;TOXICITY;INCREASED;SEVERITY;DISEASE:DIARRHEA;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE;NOS3;CC;rs2070744;EFFICACY;INCREASED;;EFFICACY:DISEASE_FREE_SURVIVAL;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
AMISULPRIDE, CLOZAPINE, OLANZAPINE, QUETIAPINE, RISPERIDONE;HTR2C;CC;rs3813929;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:WEIGHT_GAIN;PEOPLE;DISEASE:SCHIZOAFFECTIVE_DISORDER, DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL, METHOTREXATE;NOS3;GG + GT;rs1799983;EFFICACY;INCREASED;;EFFICACY:DISEASE_FREE_SURVIVAL;PEOPLE;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN;PDZRN3;C;rs11128347;TOXICITY;INCREASED;SEVERITY;DISEASE:NEUTROPENIA;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
METHADONE;UGT2B7;TT;rs4554144;EFFICACY, METABOLISM/PK;INCREASED;SEVERITY;OTHER:OPIATE_WITHDRAWAL_SYMPTOMS;PEOPLE;DISEASE:OPIOID-RELATED_DISORDERS;CAUTION_SIDE_EFFECT
DAPSONE;HLA-DRB1;A;rs201929247;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_HYPERSENSITIVITY;;;CAUTION_SIDE_EFFECT
OLANZAPINE;PPARG;CG;rs1801282;OTHER;INCREASED;;DISEASE:WEIGHT_GAIN;PEOPLE;DISEASE:SCHIZOPHRENIA;CAUTION_DOSE_ADJUST
METHADONE;UGT2B7;CC;rs11940316;EFFICACY, METABOLISM/PK;INCREASED;SEVERITY;OTHER:OPIATE_WITHDRAWAL_SYMPTOMS;PEOPLE;DISEASE:OPIOID-RELATED_DISORDERS;CAUTION_SIDE_EFFECT
CORTICOSTEROIDS;BCL2L11;AA;rs2241843;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OSTEONECROSIS;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
METHADONE;UGT2B7;AA;rs7438135;EFFICACY, METABOLISM/PK;INCREASED;SEVERITY;OTHER:OPIATE_WITHDRAWAL_SYMPTOMS;PEOPLE;DISEASE:OPIOID-RELATED_DISORDERS;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHADONE;UGT2B7;GG;rs7662029;EFFICACY, METABOLISM/PK;INCREASED;SEVERITY;OTHER:OPIATE_WITHDRAWAL_SYMPTOMS;PEOPLE;DISEASE:OPIOID-RELATED_DISORDERS;CAUTION_SIDE_EFFECT
CISPLATIN, CYCLOPHOSPHAMIDE;GSTA1;AA + AG;rs3957357;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:ANEMIA;WOMEN;DISEASE:OVARIAN_NEOPLASMS;CAUTION_SIDE_EFFECT
OXALIPLATIN;PIN1;CC + CG;rs2233678;EFFICACY;DECREASED;;EFFICACY:OVERALL_SURVIVAL, EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
METHADONE;UGT2B7;CC;rs7668258;EFFICACY, METABOLISM/PK;INCREASED;SEVERITY;OTHER:OPIATE_WITHDRAWAL_SYMPTOMS;PEOPLE;DISEASE:OPIOID-RELATED_DISORDERS;CAUTION_SIDE_EFFECT
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;CYP2C9;CT + TT;rs9332096;TOXICITY;DECREASED;RISK;SIDE_EFFECT:MACULOPAPULAR_EXANTHEMA;PEOPLE;OTHER:TUBERCULOSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;ABCG2;TT;rs2231142;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;AMPD1;AG;rs17602729;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:CNS_ADVERSE_EVENTS;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
ANTIEPILEPTICS;ABCB1;A;rs1045642;EFFICACY;INCREASED;RISK;EFFICACY:DRUG_RESISTANCE;MEN;DISEASE:EPILEPSY;CAUTION_SIDE_EFFECT
METHADONE;UGT2B7;CC;rs7439366;EFFICACY, METABOLISM/PK;INCREASED;SEVERITY;OTHER:OPIATE_WITHDRAWAL_SYMPTOMS;PEOPLE;DISEASE:OPIOID-RELATED_DISORDERS;CAUTION_SIDE_EFFECT
ANTIEPILEPTICS;ABCB1;A;rs1128503;EFFICACY;INCREASED;RISK;EFFICACY:DRUG_RESISTANCE;PEOPLE;DISEASE:EPILEPSY;CAUTION_SIDE_EFFECT
ANTIEPILEPTICS;ABCB1;G;rs3789243;EFFICACY;INCREASED;RISK;EFFICACY:DRUG_RESISTANCE;MEN;DISEASE:EPILEPSY;CAUTION_SIDE_EFFECT
METHADONE;UGT2B7;GG;rs4292394;EFFICACY, METABOLISM/PK;INCREASED;SEVERITY;OTHER:OPIATE_WITHDRAWAL_SYMPTOMS;PEOPLE;DISEASE:OPIOID-RELATED_DISORDERS;CAUTION_SIDE_EFFECT
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;CYP2C19;AA + AG;rs4986893;TOXICITY;DECREASED;RISK;SIDE_EFFECT:MACULOPAPULAR_EXANTHEMA;PEOPLE;OTHER:TUBERCULOSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN, CYCLOPHOSPHAMIDE;CYP2E1;CG;rs2070676;TOXICITY;INCREASED;RISK;SIDE_EFFECT:SEVERE_EMESIS;WOMEN;DISEASE:OVARIAN_NEOPLASMS;CAUTION_SIDE_EFFECT
ANTIEPILEPTICS;ABCB1;G;rs3789243;EFFICACY;INCREASED;RISK;EFFICACY:DRUG_RESISTANCE;PEOPLE;DISEASE:EPILEPSY;CAUTION_SIDE_EFFECT
FLUOROURACIL;DPYD;CT;rs3918290;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY, SIDE_EFFECT:LEUKOPENIA, SIDE_EFFECT:MUCOSITIS;PEOPLE;DISEASE:NEOPLASMS;CAUTION_SIDE_EFFECT
THIAZIDES, PLAIN;GNB3;CC;rs5443;TOXICITY;INCREASED;RISK;DISEASE:DIABETES_MELLITUS;;;CAUTION_SIDE_EFFECT
AMLODIPINE;RYR3;TT;rs877087;EFFICACY;INCREASED;RISK;DISEASE:HEART_FAILURE;PEOPLE;DISEASE:HYPERTENSION;CAUTION_SIDE_EFFECT
FLUOROURACIL;GSTP1;GG;rs1695;TOXICITY;DECREASED;RISK;SIDE_EFFECT:HAEMATOLOGICAL_TOXICITY;PEOPLE;DISEASE:RECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;COL1A1;AA;rs1800012;NAN;DECREASED;;OTHER:BONE_MINERAL_DENSITY_AT_FEMORAL_NECK_AND_LUMBAR_SPINE;;;CAUTION_DOSE_ADJUST
METHADONE;UGT2B7;GG;rs6600879;EFFICACY, METABOLISM/PK;INCREASED;SEVERITY;OTHER:OPIATE_WITHDRAWAL_SYMPTOMS;PEOPLE;DISEASE:OPIOID-RELATED_DISORDERS;CAUTION_SIDE_EFFECT
NAN;COL1A1;AA + AC;rs1800012;NAN;DECREASED;;OTHER:BMD_VALUES_AT_THE_LUMBAR_SPINE_AND_FEMORAL_NECK;;;CAUTION_DOSE_ADJUST
METHADONE;UGT2B7;AA;rs6600880;EFFICACY, METABOLISM/PK;INCREASED;SEVERITY;OTHER:OPIATE_WITHDRAWAL_SYMPTOMS;PEOPLE;DISEASE:OPIOID-RELATED_DISORDERS;CAUTION_SIDE_EFFECT
PLATINUM COMPOUNDS;EIF3A;A;rs10510050;TOXICITY;INCREASED;RISK;SIDE_EFFECT:THROMBOCYTOPENIA, SIDE_EFFECT:TOXIC_LIVER_DISEASE, SIDE_EFFECT:VOMITING;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
CAPECITABINE;DPYD;AT;rs67376798;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
THIAZIDES, PLAIN;AGTR1;AA + AC;rs5186;TOXICITY;INCREASED;RISK;DISEASE:DIABETES_MELLITUS;;;CAUTION_SIDE_EFFECT
THIAZIDES, PLAIN;ACE;GG;rs4341;TOXICITY;INCREASED;RISK;DISEASE:DIABETES_MELLITUS;;;CAUTION_SIDE_EFFECT
ATORVASTATIN, RIFAMPIN;SLCO1B1;TT;rs4149056;METABOLISM/PK;;;PK:A_NEARLY_TRIPLED_INCREASED_PERCENTAGE_OF_ATORVASTATIN_AUC(0_-_48)_VALUES_AFTER_A_SINGLE_ORAL_DOSE_OF_RIFAMPICIN;;;CAUTION_DOSE_ADJUST
CAPECITABINE, FLUOROURACIL;MIR27A;C;rs895819;TOXICITY;;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:NEOPLASMS;CAUTION_DOSE_ADJUST
ATORVASTATIN;FDPS;TT;rs2297480;TOXICITY;INCREASED;;SIDE_EFFECT:BONE_DENSITY;PEOPLE;DISEASE:CORONARY_DISEASE;CAUTION_SIDE_EFFECT
ETHANOL;OPRM1;G;rs1799971;NAN;INCREASED;;OTHER:SUBJECTIVE_FEELINGS_OF_INTOXICATION, STIMULATION, SEDATION, AND_HAPPINESS;;;CAUTION_DOSE_ADJUST
NAN;ABCC2;C;rs3740066;METABOLISM/PK;;;OTHER:ALLELIC_IMBALENCE;;;CAUTION_DOSE_ADJUST
CISPLATIN;GSTM4;CC;rs560018;EFFICACY, TOXICITY;INCREASED;;EFFICACY:IC-50;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATORVASTATIN;FDPS;AA;rs11264359;TOXICITY;INCREASED;;SIDE_EFFECT:BONE_DENSITY;PEOPLE;DISEASE:CORONARY_DISEASE;CAUTION_SIDE_EFFECT
IRINOTECAN;C8orf34;C;rs1517114;TOXICITY;INCREASED;SEVERITY;DISEASE:DIARRHEA;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
DICLOXACILLIN, PROBENECID;ABCB1;GG;rs1045642;OTHER, METABOLISM/PK;INCREASED;;PK:CLEARANCE_OF_DICLOXACILLIN;;;CAUTION_DOSE_ADJUST
ANTIPSYCHOTICS, CLOZAPINE, OLANZAPINE, RISPERIDONE;HTR2C;C;rs1414334;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:OBESITY;PEOPLE;DISEASE:SCHIZOAFFECTIVE_DISORDER, DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
ETHANOL;OPRM1;G;rs1799971;OTHER;;RISK;DISEASE:ALCOHOL_ABUSE;;;CAUTION_DOSE_ADJUST
CYCLOSPORINE, DICLOXACILLIN;ABCB1;CC;rs2032582;OTHER, METABOLISM/PK;INCREASED;;PK:CLEARANCE_OF_DICLOXACILLIN;;;CAUTION_DOSE_ADJUST
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;CYP2E1;CT + TT;rs2031920;TOXICITY;DECREASED;RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE;PEOPLE;OTHER:TUBERCULOSIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATORVASTATIN, FLUVASTATIN, PRAVASTATIN, ROSUVASTATIN, SIMVASTATIN;SLCO1B1;CC;rs4149056;NAN;INCREASED;;OTHER:CHOLESTEROL_SYNTHESIS_RATE;;;CAUTION_DOSE_ADJUST
PLATINUM COMPOUNDS;MDM2;CC;rs1690924;EFFICACY;DECREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;SLC19A1;TT;rs1051266;METABOLISM/PK;INCREASED;;PK:PLASMA_DRUG_LEVELS;PEOPLE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;DECREASED;;EFFICACY:PLATELET_INHIBITION_AFTER_A_CLOPIDOGREL_600-MG_LOADING_DOSE;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
SEVOFLURANE;GRIN2B;AA + AG;rs1806201;OTHER;INCREASED;;OTHER:MEAN_ARTERIAL_PRESSURE;PEOPLE;OTHER:OTORHINOLARYNGOLOGY_SURGERY;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;G;rs28399504;EFFICACY;DECREASED;;EFFICACY:PLATELET_INHIBITION_AFTER_A_CLOPIDOGREL_600-MG_LOADING_DOSE;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES;ADRB2;GG;rs1042714;EFFICACY;INCREASED;;OTHER:STATUS_ASTHMATICUS;CHILDREN;DISEASE:ASTHMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;CCND1;AA;rs9344;TOXICITY;DECREASED;SEVERITY;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
RISPERIDONE;ABCB1;A;rs1045642;TOXICITY;INCREASED;;SIDE_EFFECT:WEIGHT_GAIN;WOMEN;DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
METHOTREXATE;MTHFR;AA + AG;rs1801133;TOXICITY;DECREASED;SEVERITY;DISEASE:LEUKOPENIA;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
PACLITAXEL;SOD2;AA;rs4880;TOXICITY;INCREASED;RISK;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
MERCAPTOPURINE, METHOTREXATE;SLC19A1;CT + TT;rs1051266;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
METHYLPHENIDATE;ABCB1;AA;rs2032582;TOXICITY;INCREASED;;SIDE_EFFECT:ADVERSE_EVENTS;CHILDREN;DISEASE:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY;CAUTION_SIDE_EFFECT
DOCETAXEL;ERCC2;TT;rs13181;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NEUTROPENIA;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
CYCLOSPORINE, TACROLIMUS;CRTC2;AA;rs8450;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HYPERLIPIDEMIAS;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
DOCETAXEL;ERCC1;AA;rs11615;TOXICITY;INCREASED;RISK;SIDE_EFFECT:MUCOSITIS;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;T;rs12248560;EFFICACY;DECREASED;;EFFICACY:RATES_OF_TARGET_LESION_REVASCULARIZATION_AND_MAJOR_ADVERSE_CARDIOVASCULAR_EVENTS;PEOPLE;DISEASE:MYOCARDIAL_INFARCTION;LIKELIHOOD_THERAPEUTIC_FAILURE
METFORMIN;SP1;C;rs2683511;METABOLISM/PK;DECREASED;;PK:METFORMIN_SECRETORY_CLEARANCE;HEALTHY;;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;VKORC1;CT + TT;rs9923231;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:OVER-ANTICOAGULATION;;;CAUTION_SIDE_EFFECT
NICOTINE;CHRNA3, CHRNA5;A;rs16969968;TOXICITY;INCREASED;RISK;DISEASE:TOBACCO_USE_DISORDER;;;CAUTION_SIDE_EFFECT
METFORMIN;;G;rs10747673;EFFICACY;DECREASED;;EFFICACY:POST-HBA1C_LEVELS;PEOPLE;DISEASE:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_FAILURE
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:TO_BE_CLASSIFIED_AS_CLOPIDOGREL_POOR_RESPONDERS;PEOPLE;DISEASE:CARDIOVASCULAR_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
METFORMIN;;G;rs10747673;METABOLISM/PK;DECREASED;;PK:METFORMIN_SECRETORY_CLEARANCE;HEALTHY;;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;VKORC1;CT + TT;rs9923231;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE;;;CAUTION_SIDE_EFFECT
METHOTREXATE;SLC19A1;TT;rs1051266;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
CLOPIDOGREL;ATP10A;AA + AG;rs12913988;EFFICACY;INCREASED;LIKELIHOOD;SIDE_EFFECT:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE);PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM COMPOUNDS;EIF3A;A;rs4752220;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ANEMIA, SIDE_EFFECT:LEUKOPENIA, SIDE_EFFECT:THROMBOCYTOPENIA, SIDE_EFFECT:TOXIC_LIVER_DISEASE, SIDE_EFFECT:VOMITING;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
CHOP, RITUXIMAB;NCF4;AG + GG;rs1883112;TOXICITY;DECREASED;RISK;SIDE_EFFECT:TOXICITY;PEOPLE;DISEASE:LYMPHOMA, LARGE_B-CELL*^DIFFUSE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C9;AC + CC;rs1057910;EFFICACY;INCREASED;RISK;EFFICACY:CLOPIDOGREL_POOR_RESPONSE;PEOPLE;DISEASE:CARDIOVASCULAR_DISEASE;CAUTION_SIDE_EFFECT
PLATINUM COMPOUNDS;EIF3A;A;rs1409314;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ANEMIA, SIDE_EFFECT:LEUKOPENIA, SIDE_EFFECT:THROMBOCYTOPENIA, SIDE_EFFECT:TOXIC_LIVER_DISEASE, SIDE_EFFECT:VOMITING;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
PLATINUM COMPOUNDS;EIF3A;C;rs4752219;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ANEMIA, SIDE_EFFECT:LEUKOPENIA, SIDE_EFFECT:THROMBOCYTOPENIA, SIDE_EFFECT:TOXIC_LIVER_DISEASE, SIDE_EFFECT:VOMITING;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C9;AC + CC;rs1057910;EFFICACY;INCREASED;RISK;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY;PEOPLE;DISEASE:CARDIOVASCULAR_DISEASE;CAUTION_SIDE_EFFECT
MERCAPTOPURINE, METHOTREXATE;GSTP1;GG;rs1695;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
CLOZAPINE;HTR2C;T;rs3813929;TOXICITY;DECREASED;RISK;SIDE_EFFECT:WEIGHT_GAIN;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACENOCOUMAROL;ABCB1;GG + GT;rs1045642;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:OVER-ANTICOAGULATION;;;CAUTION_SIDE_EFFECT
RISPERIDONE;ABCB1;A;rs2032582;TOXICITY;INCREASED;;SIDE_EFFECT:WEIGHT_GAIN;WOMEN;DISEASE:SCHIZOPHRENIA;CAUTION_SIDE_EFFECT
METHOTREXATE;SLC19A1;TT;rs1051266;METABOLISM/PK;INCREASED;;PK:PLASMA_DRUG_LEVELS;PEOPLE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_DOSE_ADJUST
SEVOFLURANE;KCNK3;CT + TT;rs1275988;OTHER;INCREASED;;OTHER:MEAN_ARTERIAL_PRESSURE;PEOPLE;OTHER:OTORHINOLARYNGOLOGY_SURGERY;CAUTION_DOSE_ADJUST
LEUCOVORIN, MERCAPTOPURINE, METHOTREXATE;SLC19A1;CC;rs1051266;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
LEUCOVORIN, MERCAPTOPURINE, METHOTREXATE;SLC19A1;TT;rs1051266;TOXICITY;INCREASED;LIKELIHOOD;DISEASE:MYELOSUPPRESSION;PEOPLE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
DOCETAXEL;CYP3A4;CC + CT;rs2740574;TOXICITY;INCREASED;RISK;SIDE_EFFECT:INFUSION_RELATED_REACTION;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
METFORMIN;SP1;G;rs784888;EFFICACY;DECREASED;SEVERITY;DISEASE:HYPERGLYCEMIA;PEOPLE;DISEASE:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM COMPOUNDS;MTR;AA + AG;rs1805087;EFFICACY;DECREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
SEVOFLURANE;GABRA2;CC + CT;rs279858;OTHER;DECREASED;;OTHER:MEAN_ARTERIAL_PRESSURE;PEOPLE;OTHER:OTORHINOLARYNGOLOGY_SURGERY;CAUTION_DOSE_ADJUST
LEUCOVORIN, MERCAPTOPURINE, METHOTREXATE;SLC19A1;TT;rs1051266;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:STAYING_IN_REMISSION;PEOPLE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACENOCOUMAROL;VKORC1;CT + TT;rs9923231;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:OVER-ANTICOAGULATION;;;CAUTION_SIDE_EFFECT
PLATINUM COMPOUNDS;EIF3A;T;rs7091672;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ANEMIA, SIDE_EFFECT:LEUKOPENIA, SIDE_EFFECT:THROMBOCYTOPENIA, SIDE_EFFECT:TOXIC_LIVER_DISEASE, SIDE_EFFECT:VOMITING;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;CAUTION_SIDE_EFFECT
PACLITAXEL;CYP2C8;CG + GG;rs1113129;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ANEMIA;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
METFORMIN;PPARA;T;rs149711321;EFFICACY;DECREASED;;EFFICACY:POST-HBA1C_LEVELS;PEOPLE;DISEASE:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_FAILURE
NAN;COL1A1;AA;rs1800012;NAN;INCREASED;RISK;DISEASE:FRACTURES, BONE;;;CAUTION_SIDE_EFFECT
ACENOCOUMAROL;CYP4F2;CT + TT;rs2108622;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:OVER-ANTICOAGULATION;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PLATINUM COMPOUNDS;SLC19A1;TT;rs1051266;EFFICACY;DECREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
PACLITAXEL;CYP2C8;CT + TT;rs1934951;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ANEMIA;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
LENALIDOMIDE;VEGFA;AA;rs699947;EFFICACY;DECREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;OTHER:MANTLE_CELL_LYMPHOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
METFORMIN;SP1;C;rs2683511;EFFICACY;DECREASED;;EFFICACY:POST-HBA1C_LEVELS;PEOPLE;DISEASE:DIABETES_MELLITUS_T2;LIKELIHOOD_THERAPEUTIC_FAILURE
SEVOFLURANE;FASTKD3, MTRR;AG + GG;rs1801394;OTHER;DECREASED;;OTHER:MEAN_ARTERIAL_PRESSURE;PEOPLE;OTHER:OTORHINOLARYNGOLOGY_SURGERY;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;G;rs28399504;TOXICITY;INCREASED;RISK;DISEASE:DEATH;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;CAUTION_SIDE_EFFECT
BUPROPION, NICOTINE;DRD1;A;rs2168631;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:SMOKING_ABSTINENCE_WITHIN_SLOW_NICOTINE_METABOLIZERS;PEOPLE;DISEASE:TOBACCO_USE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
SIMVASTATIN;HMGCR;TT;rs17238540;EFFICACY;INCREASED;;EFFICACY:REDUCTION_OF_LDL_CHOLESTEROL;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;NR3C1;C;rs9324918;OTHER;INCREASED;;DISEASE:SICKLE_CELL_PAIN_CRISIS;PEOPLE;DISEASE:SICKLE_CELL_ANEMIA;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;A;rs4986893;TOXICITY;INCREASED;RISK;DISEASE:DEATH;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;CAUTION_SIDE_EFFECT
SEVOFLURANE;FASTKD3, MTRR;AA + AG;rs2307116;OTHER;DECREASED;;OTHER:MEAN_ARTERIAL_PRESSURE;PEOPLE;OTHER:OTORHINOLARYNGOLOGY_SURGERY;CAUTION_DOSE_ADJUST
PACLITAXEL;ERCC1;AA + AC;rs3212986;TOXICITY;INCREASED;RISK;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
MORPHINE;ABCC3;C;rs1978153;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:HYPOVENTILATION;CHILDREN;DISEASE:SLEEP_APNEA_SYNDROMES, DISEASE:TONSILLECTOMY;CAUTION_SIDE_EFFECT
NAN;P2RY12;G;rs2046934;NAN;INCREASED;RISK;SIDE_EFFECT:CORONARY_ARTERY_DISEASE;;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;T;rs12248560;TOXICITY;INCREASED;RISK;SIDE_EFFECT:BLEEDING;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;CAUTION_SIDE_EFFECT
BUPROPION, NICOTINE;DRD1;T;rs11749035;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:SMOKING_ABSTINENCE_WITHIN_SLOW_NICOTINE_METABOLIZERS;PEOPLE;DISEASE:TOBACCO_USE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;T;rs12248560;EFFICACY;DECREASED;;EFFICACY:ADP-INDUCED_PLATELET_AGGREGATION;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_FAILURE
PAZOPANIB, SUNITINIB;CXCL8;T;rs1126647;EFFICACY;DECREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
NAN;NR3C1;G;rs2963155;OTHER;INCREASED;;DISEASE:SICKLE_CELL_PAIN_CRISIS;PEOPLE;DISEASE:SICKLE_CELL_ANEMIA;CAUTION_DOSE_ADJUST
MORPHINE;ABCC3;G;rs733392;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:HYPOVENTILATION;CHILDREN;DISEASE:SLEEP_APNEA_SYNDROMES, DISEASE:TONSILLECTOMY;CAUTION_SIDE_EFFECT
METHADONE;UGT2B7;CC;rs6600893;EFFICACY, METABOLISM/PK;INCREASED;SEVERITY;OTHER:OPIATE_WITHDRAWAL_SYMPTOMS;PEOPLE;DISEASE:OPIOID-RELATED_DISORDERS;CAUTION_SIDE_EFFECT
FENTANYL;MYD88;G;rs6853;TOXICITY;DECREASED;RISK;SIDE_EFFECT:COGNITIVE_DISORDER;PEOPLE;DISEASE:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE, PREDNISONE;SLC19A1;TT;rs1051266;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:REMISSION;PEOPLE;DISEASE:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUPROPION, NICOTINE;DRD1;G;rs11746641;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:SMOKING_ABSTINENCE_WITHIN_SLOW_NICOTINE_METABOLIZERS;PEOPLE;DISEASE:TOBACCO_USE_DISORDER;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;NR3C1;T;rs33389;OTHER;INCREASED;;DISEASE:SICKLE_CELL_PAIN_CRISIS;PEOPLE;DISEASE:SICKLE_CELL_ANEMIA;CAUTION_DOSE_ADJUST
SPIRONOLACTONE;ACE;AA + AG;rs4343;EFFICACY;;;EFFICACY:IMPROVEMENT_IN_LEFT_VENTRICULAR_EJECTION_FRACTION, END-SYSTOLIC_AND_END-DIASTOLIC_VOLUME;PEOPLE;OTHER:CHRONIC_HEART_FAILURE;CAUTION_DOSE_ADJUST
SIMVASTATIN;HMGCR;AA;rs17244841;EFFICACY;INCREASED;;EFFICACY:REDUCTION_OF_LDL_CHOLESTEROL;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DOCETAXEL;ERCC1;CC;rs3212986;TOXICITY;INCREASED;RISK;SIDE_EFFECT:MUCOSITIS;WOMEN;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
SEVOFLURANE;CYP2E1;CC + CG;rs3813867;OTHER;DECREASED;;OTHER:MEAN_ARTERIAL_PRESSURE;PEOPLE;OTHER:OTORHINOLARYNGOLOGY_SURGERY;CAUTION_DOSE_ADJUST
CYCLOPHOSPHAMIDE, DOXORUBICIN, PREDNISONE, RITUXIMAB, VINCRISTINE;GSTA1;AA + AG;rs3957357;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:EVENT-FREE_SURVIVAL;PEOPLE;DISEASE:LYMPHOMA, LARGE_B-CELL*^DIFFUSE;LIKELIHOOD_THERAPEUTIC_SUCCESS
SEVOFLURANE;CYP2E1, DUX1;CT + TT;rs2031920;OTHER;DECREASED;;OTHER:MEAN_ARTERIAL_PRESSURE;PEOPLE;OTHER:OTORHINOLARYNGOLOGY_SURGERY;CAUTION_DOSE_ADJUST
ANTIHYPERTENSIVES, DIURETICS;NOS3;CC;rs2070744;EFFICACY;INCREASED;RISK;EFFICACY:RESISTANT_HYPERTENSION;PEOPLE;DISEASE:HYPERTENSION;CAUTION_SIDE_EFFECT
CYCLOPHOSPHAMIDE, DOXORUBICIN, PREDNISONE, RITUXIMAB, VINCRISTINE;CYBA;AA;rs4673;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:EVENT-FREE_SURVIVAL;PEOPLE;DISEASE:LYMPHOMA, LARGE_B-CELL*^DIFFUSE;LIKELIHOOD_THERAPEUTIC_FAILURE
IBUPROFEN;PTGS2;CG + GG;rs20417;EFFICACY;INCREASED;;EFFICACY:PAIN_RELIEF;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DIFLOMOTECAN;ABCG2;T;rs2231142;METABOLISM/PK;INCREASED;;PK:PLASMA_CONCENTRATIONS_OF_DIFLOMOTECAN;;;CAUTION_DOSE_ADJUST
CYCLOSPORINE;ABCB1;AA;rs2032582;EFFICACY;INCREASED;RISK;EFFICACY:RESISTANCE;PEOPLE;DISEASE:ULCERATIVE_COLITIS;CAUTION_SIDE_EFFECT
CYCLOSPORINE, TACROLIMUS;CRTC2;AA;rs8450;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DIABETES_MELLITUS;PEOPLE;DISEASE:TRANSPLANTATION;CAUTION_SIDE_EFFECT
ROFECOXIB;PTGS2;CC;rs20417;EFFICACY;INCREASED;;EFFICACY:PAIN_RELIEF;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FENTANYL, MORPHINE, OPIOIDS, OXYCODONE;;G;rs2884129;EFFICACY;;;EFFICACY:OPIOIDS_RESPONSE;PEOPLE;DISEASE:NEOPLASMS;CAUTION_DOSE_ADJUST
HMG_COA_REDUCTASE_INHIBITORS;;C;rs13210472;TOXICITY;INCREASED;RISK;OTHER:NEOPLASMS;WOMEN;;CAUTION_SIDE_EFFECT
FENTANYL, MORPHINE, OPIOIDS, OXYCODONE;;T;rs7104613;EFFICACY;;;EFFICACY:OPIOIDS_RESPONSE;PEOPLE;DISEASE:NEOPLASMS;CAUTION_DOSE_ADJUST
PAZOPANIB, SUNITINIB;CXCL8;A;rs4073;EFFICACY;DECREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:RENAL_CELL_CARCINOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
BLEOMYCIN, CISPLATIN, ETOPOSIDE;GSTP1;GG;rs1695;TOXICITY;INCREASED;RISK;SIDE_EFFECT:NAUSEA;MEN;DISEASE:TESTICULAR_NEOPLASMS;CAUTION_SIDE_EFFECT
FENTANYL, MORPHINE, OPIOIDS, OXYCODONE;;T;rs10413396;EFFICACY;;;EFFICACY:OPIOIDS_RESPONSE;PEOPLE;DISEASE:NEOPLASMS;CAUTION_DOSE_ADJUST
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;DECREASED;;EFFICACY:PHARMACODYNAMIC_RESPONSE;HEALTHY;;LIKELIHOOD_THERAPEUTIC_FAILURE
METHOTREXATE;CCND1;AA;rs9344;EFFICACY;DECREASED;;EFFICACY:EVENT_FREE_SURVIVAL;PEOPLE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
BLEOMYCIN, CISPLATIN, ETOPOSIDE;ERCC1;AC + CC;rs3212986;TOXICITY;DECREASED;RISK;SIDE_EFFECT:VOMITING;MEN;DISEASE:TESTICULAR_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
ASPIRIN;PTGS1;AA + AG;rs10306114;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:RECURRENCE;PEOPLE;OTHER:CEREBRAL_INFARCTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;DPYD;A;rs67376798;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:COLONIC_NEOPLASMS;CAUTION_SIDE_EFFECT
ANTHRACYCLINES AND RELATED SUBSTANCES;ABCB1;CC;rs2032582;EFFICACY;INCREASED;RISK;EFFICACY:RESISTANCE;PEOPLE;DISEASE:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
CYCLOSPORINE, TACROLIMUS;CRTC2;AA + AG;rs8450;TOXICITY;INCREASED;;SIDE_EFFECT:WEIGHT_GAIN;PEOPLE;DISEASE:TRANSPLANTATION;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;A;rs4244285;METABOLISM/PK;DECREASED;;PK:PLASMA_EXPOSURE_TO_THE_ACTIVE_METABOLITE_OF_CLOPIDOGREL;HEALTHY;;CAUTION_DOSE_ADJUST
ACENOCOUMAROL;VKORC1;TT;rs9923231;DOSAGE;DECREASED;;EFFICACY:ACENOCOUMAROL_DOSE;PEOPLE;DISEASE:ATRIAL_FIBRILLATION;CAUTION_DOSE_ADJUST
FLUOROURACIL;DPYD;T;rs1801160;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:COLONIC_NEOPLASMS, DISEASE:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;A;rs4244285;TOXICITY;INCREASED;RISK;SIDE_EFFECT:STENT_THROMBOSIS;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;CAUTION_SIDE_EFFECT
MORPHINE;ABCC3;G;rs886493;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:HYPOVENTILATION;CHILDREN;DISEASE:SLEEP_APNEA_SYNDROMES, DISEASE:TONSILLECTOMY;CAUTION_SIDE_EFFECT
BLEOMYCIN, CISPLATIN, ETOPOSIDE;ABCB1;AA;rs1045642;TOXICITY;INCREASED;RISK;SIDE_EFFECT:VOMITING;MEN;DISEASE:TESTICULAR_NEOPLASMS;CAUTION_SIDE_EFFECT
MORPHINE;ABCC3;T;rs7216383;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:HYPOVENTILATION;CHILDREN;DISEASE:SLEEP_APNEA_SYNDROMES, DISEASE:TONSILLECTOMY;CAUTION_SIDE_EFFECT
METHOTREXATE;ABCB1;A;rs1045642;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
ETHANOL;;A;rs10516440;TOXICITY;DECREASED;RISK;OTHER:ALCOHOL_ABUSE;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
TRAMADOL;ABCB1;A;rs1045642;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:A_DECREASE_IN_VISUAL_ANALOG_SCALE_>30MM_WITHIN_6_HOURS;PEOPLE;DISEASE:FRACTURES, BONE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CITALOPRAM;CYP2C19;TT;rs12248560;METABOLISM/PK;DECREASED;;PK:METABOLIC_RATIO_CIT/DCIT_VALUES;;;CAUTION_DOSE_ADJUST
TRAMADOL;ABCB1;A;rs2032582;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:A_DECREASE_IN_VISUAL_ANALOG_SCALE_>30MM_WITHIN_6_HOURS;PEOPLE;DISEASE:FRACTURES, BONE;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2B, RIBAVIRIN;ITPA;A;rs1127354;TOXICITY;DECREASED;SEVERITY;SIDE_EFFECT:ANEMIA;PEOPLE;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY, TOXICITY;INCREASED;RISK;SIDE_EFFECT:CARDIOVASCULAR_EVENTS;PEOPLE;DISEASE:MYOCARDIAL_INFARCTION;CAUTION_SIDE_EFFECT
METHOTREXATE;ABCC2;A;rs17222723;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
RISPERIDONE;UGT1A1;CT;rs887829;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HYPERPROLACTINEMIA;CHILDREN;DISEASE:AUTISM_SPECTRUM_DISORDER;CAUTION_SIDE_EFFECT
FLUOXETINE;CRHR1;CC;rs242941;EFFICACY;INCREASED;;EFFICACY:RESPONSE;PEOPLE;OTHER:MAJOR_DEPRESSION_AND_HIGH_ANXIETY;LIKELIHOOD_THERAPEUTIC_SUCCESS
RISPERIDONE;UGT1A1;AG;rs10929302;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HYPERPROLACTINEMIA;CHILDREN;DISEASE:AUTISM_SPECTRUM_DISORDER;CAUTION_SIDE_EFFECT
SARILUMAB;IL6R;CC;rs11265618;EFFICACY;INCREASED;LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE;PEOPLE;OTHER:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN;ERCC2;CT + TT;rs1799793;EFFICACY;INCREASED;;EFFICACY:EVENT-FREE_SURVIVAL;PEOPLE;DISEASE:OSTEOSARCOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
CISPLATIN;GSTP1;CT + TT;rs1138272;EFFICACY;DECREASED;;EFFICACY:EVENT-FREE_SURVIVAL, EFFICACY:OVERALL_SURVIVAL;PEOPLE;DISEASE:OSTEOSARCOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
SARILUMAB;IL6R;TT;rs4845625;EFFICACY;INCREASED;LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE;PEOPLE;OTHER:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
VITAMIN K ANTAGONISTS;CYP4F2;TT;rs2108622;EFFICACY;INCREASED;RISK;EFFICACY:STROKE;PEOPLE;DISEASE:ATRIAL_FIBRILLATION;CAUTION_SIDE_EFFECT
RISPERIDONE;HTR2C;GG;rs6318;TOXICITY;INCREASED;SEVERITY;SIDE_EFFECT:WEIGHT_GAIN;CHILDREN;DISEASE:AUTISM;CAUTION_SIDE_EFFECT
WARFARIN;CRP;CT + TT;rs1205;TOXICITY;INCREASED;RISK;SIDE_EFFECT:HEMORRHAGE;;;CAUTION_SIDE_EFFECT
HYDROCHLOROTHIAZIDE;TCF7L2;A;rs4132670;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DIABETES;PEOPLE;DISEASE:HYPERTENSION;CAUTION_SIDE_EFFECT
HYDROCHLOROTHIAZIDE;TCF7L2;T;rs7917983;TOXICITY;INCREASED;RISK;DISEASE:DIABETES_MELLITUS;PEOPLE;DISEASE:HYPERTENSION;CAUTION_SIDE_EFFECT
ATORVASTATIN, CERIVASTATIN, FLUVASTATIN, PRAVASTATIN, ROSUVASTATIN, SIMVASTATIN;HMGCR;GT;rs17238540;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:REACHING_TARGET_CHOLESTEROL_LEVELS;PEOPLE;DISEASE:DIABETES_MELLITUS;LIKELIHOOD_THERAPEUTIC_FAILURE
HYDROCHLOROTHIAZIDE;TCF7L2;T;rs4506565;TOXICITY;INCREASED;RISK;DISEASE:DIABETES_MELLITUS;PEOPLE;DISEASE:HYPERTENSION;CAUTION_SIDE_EFFECT
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:RECURRENCE;PEOPLE;OTHER:STROKE;LIKELIHOOD_THERAPEUTIC_SUCCESS
CITALOPRAM;CYP2C19;AA;rs4244285;METABOLISM/PK;INCREASED;;PK:METABOLIC_RATIO_CIT/DCIT_VALUES_AND_MEAN_CITALOPRAM_DOSE;;;CAUTION_DOSE_ADJUST
LENALIDOMIDE;ABCB1;CC;rs2032582;EFFICACY;DECREASED;;EFFICACY:OVERALL_SURVIVAL;PEOPLE;OTHER:MANTLE_CELL_LYMPHOMA;LIKELIHOOD_THERAPEUTIC_FAILURE
FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;XRCC1;CC;rs25487;OTHER;;;OTHER:LATER_ONSET_OF_SENSORY_NEUROPATHY;PEOPLE;DISEASE:COLONIC_NEOPLASMS;CAUTION_DOSE_ADJUST
DOCETAXEL, THALIDOMIDE;CHST3;A;rs4148950;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXICITY;PEOPLE;DISEASE:PROSTATIC_NEOPLASMS;CAUTION_SIDE_EFFECT
IRINOTECAN;UGT1A9;T/del + del/del;rs3832043;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA;PEOPLE;OTHER:STOMACH_NEOPLASMS;CAUTION_SIDE_EFFECT
BUPRENORPHINE, FENTANYL, TRAMADOL;COMT;AA;rs4680;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:VOMITING;PEOPLE;OTHER:OPIOID-RELATED_DISORDERS;CAUTION_SIDE_EFFECT
SARILUMAB;IL6R;CC;rs4537545;EFFICACY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DYSLIPIDAEMIA;PEOPLE;OTHER:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CALCIUM, ETIDRONIC ACID;VDR;TT;rs1544410;EFFICACY;INCREASED;;EFFICACY:MEAN_SPINAL_BONE_MINERAL_DENSITY_CHANGES;PEOPLE;DISEASE:OSTEOPOROSIS, POSTMENOPAUSAL;LIKELIHOOD_THERAPEUTIC_SUCCESS
SARILUMAB;IL6R;AA;rs2228145;EFFICACY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DYSLIPIDAEMIA;PEOPLE;OTHER:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUPRENORPHINE, FENTANYL, TRAMADOL;OPRD1;CT;rs2234918;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:PHYSIOLOGICAL_SEXUAL_DISORDER;PEOPLE;OTHER:OPIOID-RELATED_DISORDERS;LIKELIHOOD_THERAPEUTIC_SUCCESS
VALPROIC ACID;SOD2;AA + AG;rs4880;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:EPILEPSY;LIKELIHOOD_THERAPEUTIC_SUCCESS
SARILUMAB;IL6R;TT;rs4329505;EFFICACY;INCREASED;LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE;PEOPLE;OTHER:RHEUMATOID_ARTHRITIS;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;;EFFICACY:COMPLETE_EARLY_VIROLOGICAL_RESPONSE;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUPRENORPHINE, FENTANYL, TRAMADOL;ARRB2;TT;rs1045280;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS;PEOPLE;OTHER:OPIOID-RELATED_DISORDERS;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2A, RIBAVIRIN;;GG;rs4273729;EFFICACY;INCREASED;;EFFICACY:COMPLETE_EARLY_VIROLOGICAL_RESPONSE;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
BISPHOSPHONATES;CYP2C8;TT;rs1934951;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OSTEONECROSIS_OF_THE_JAW;PEOPLE;DISEASE:MULTIPLE_MYELOMA;CAUTION_SIDE_EFFECT
BUPRENORPHINE, FENTANYL, TRAMADOL;OPRM1;AG + GG;rs1799971;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:NAUSEA;PEOPLE;OTHER:OPIOID-RELATED_DISORDERS;CAUTION_SIDE_EFFECT
BUPRENORPHINE, FENTANYL, TRAMADOL;COMT;AG;rs4680;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:EXANTHEMA;PEOPLE;OTHER:OPIOID-RELATED_DISORDERS;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3;AA;rs12980275;EFFICACY;INCREASED;;EFFICACY:RAPID_VIROLOGICAL_RESPONSE_(RVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUPRENORPHINE, FENTANYL, TRAMADOL;OPRM1;AA;rs1799971;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS;PEOPLE;OTHER:OPIOID-RELATED_DISORDERS;CAUTION_SIDE_EFFECT
BUPRENORPHINE, FENTANYL, TRAMADOL;COMT;AA + GG;rs4680;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS, SIDE_EFFECT:PHYSIOLOGICAL_SEXUAL_DISORDER;PEOPLE;OTHER:OPIOID-RELATED_DISORDERS;CAUTION_SIDE_EFFECT
NAN;IFNL3, IFNL4;CC;rs12979860;OTHER;INCREASED;LIKELIHOOD;DISEASE:JAUNDICE;WOMEN;DISEASE:HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
BUPRENORPHINE, FENTANYL, TRAMADOL;OPRM1;AA;rs1799971;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:NAUSEA;PEOPLE;OTHER:OPIOID-RELATED_DISORDERS;CAUTION_SIDE_EFFECT
FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;ABCC2;CC;rs717620;TOXICITY;INCREASED;RISK;DISEASE:DRUG_TOXICITY;PEOPLE;DISEASE:COLONIC_NEOPLASMS;CAUTION_SIDE_EFFECT
BUPRENORPHINE, FENTANYL, TRAMADOL;OPRM1;AA + AG;rs1799971;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY;PEOPLE;OTHER:OPIOID-RELATED_DISORDERS;CAUTION_SIDE_EFFECT
LENALIDOMIDE;CRBN;CC;rs1705814;DOSAGE, TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DOSE_REDUCTION, SIDE_EFFECT:DISCONTINUATION;PEOPLE;OTHER:MANTLE_CELL_LYMPHOMA;CAUTION_DOSE_ADJUST
BUPRENORPHINE, FENTANYL, TRAMADOL;COMT;AG;rs4680;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:EXANTHEMA;PEOPLE;OTHER:OPIOID-RELATED_DISORDERS;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;ERCC1;AA;rs11615;TOXICITY;INCREASED;RISK;DISEASE:NEUTROPENIA;PEOPLE;DISEASE:COLONIC_NEOPLASMS;CAUTION_SIDE_EFFECT
FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;XRCC1;CC;rs25487;TOXICITY;DECREASED;RISK;DISEASE:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;PEOPLE;DISEASE:COLONIC_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
RIFAMPIN;NR1I2;T;rs2472677;OTHER, METABOLISM/PK;DECREASED;;PK:CYP3A4_ACITVITY;;;CAUTION_DOSE_ADJUST
CARBAMAZEPINE, LAMOTRIGINE, OXCARBAZEPINE, PHENYTOIN, TOPIRAMATE;SCN2A;A;rs2304016;EFFICACY;;;EFFICACY:DRUG_RESISTANCE;PEOPLE;DISEASE:EPILEPSY;CAUTION_DOSE_ADJUST
CAPECITABINE, OXALIPLATIN;PTGS2;AA;rs5275;EFFICACY;INCREASED;;OTHER:PROGRESSION-FREE_SURVIVAL_AND_OVERALL_SURVIVAL;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;CETP;A;rs708272;NAN;;;OTHER:VARIANCE_IN_LDL, HDL_AND_LDL/HDL;;;CAUTION_DOSE_ADJUST
HMG_COA_REDUCTASE_INHIBITORS;CETP;A;rs708272;EFFICACY;DECREASED;RISK;EFFICACY:CARDIOVASCULAR_EVENTS;PEOPLE;DISEASE:CORONARY_ARTERY_DISEASE;LIKELIHOOD_THERAPEUTIC_SUCCESS
DIURETICS;ADD1;GT + TT;rs4961;EFFICACY;DECREASED;LIKELIHOOD;DISEASE:MYOCARDIAL_INFARCTION;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_FAILURE
WARFARIN;VKORC1;CT + TT;rs9923231;DOSAGE;;;EFFICACY:LOWER_WARFARIN_DOSE_REQUIREMENT;;;CAUTION_DOSE_ADJUST
ETHANOL;DRD2;A;rs1076560;OTHER;INCREASED;RISK;DISEASE:ALCOHOL_ABUSE;;;CAUTION_SIDE_EFFECT
CLOPIDOGREL;P2RY12;AG + GG;rs2046934;EFFICACY;INCREASED;;EFFICACY:PLATELET_ACTIVATION_RESPONSE_TO_ADP;PEOPLE;DISEASE:ACUTE_CORONARY_SYNDROME;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHOTREXATE;ABCC2;CT + TT;rs717620;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
HYDROCHLOROTHIAZIDE;ADD1;GT + TT;rs4961;EFFICACY;INCREASED;;EFFICACY:REDUCTION_IN_MEAN_BLOOD_PRESSURE;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;MTHFR;AA;rs1801133;TOXICITY;INCREASED;RISK;DISEASE:NEUTROPENIA;PEOPLE;DISEASE:COLONIC_NEOPLASMS;CAUTION_SIDE_EFFECT
BROMPERIDOL, NEMONAPRIDE;DRD2;GG;rs1799732;EFFICACY;INCREASED;;EFFICACY:IMPROVEMENT_IN_ANXIETY-DEPRESSION_SYMPTOMS;PEOPLE;DISEASE:SCHIZOPHRENIA;LIKELIHOOD_THERAPEUTIC_SUCCESS
THIAZIDES, PLAIN;SLC12A3;CC;rs13306673;EFFICACY;INCREASED;;EFFICACY:REDUCTION_IN_MEAN_BLOOD_PRESSURE;PEOPLE;DISEASE:ESSENTIAL_HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
VALPROIC ACID;ABCB1;GG;rs3789243;EFFICACY;DECREASED;LIKELIHOOD;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY;CHILDREN;OTHER:EPILEPSY;LIKELIHOOD_THERAPEUTIC_FAILURE
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3, IFNL4;CC;rs12979860;EFFICACY;INCREASED;;EFFICACY:RAPID_VIROLOGICAL_RESPONSE_(RVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
AZATHIOPRINE;ITPA;AC;rs1127354;TOXICITY;INCREASED;RISK;DISEASE:LEUKOPENIA;PEOPLE;DISEASE:INFLAMMATORY_BOWEL_DISEASES;CAUTION_SIDE_EFFECT
VALPROIC ACID;ABCB1;GG;rs3789243;EFFICACY;INCREASED;LIKELIHOOD;SIDE_EFFECT:EXANTHEMA, SIDE_EFFECT:ALOPECIA, SIDE_EFFECT:HYPERSENSITIVITY;CHILDREN;OTHER:EPILEPSY;LIKELIHOOD_THERAPEUTIC_SUCCESS
ATORVASTATIN, ROSUVASTATIN;CYP3A5;CC;rs776746;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:MUSCULAR_DISEASES;PEOPLE;DISEASE:DIABETES_MELLITUS, DISEASE:HYPERLIPIDEMIAS,DISEASE:HYPERTENSION, DISEASE:OBESITY;CAUTION_SIDE_EFFECT
METHOTREXATE;SLCO1B1;CC + CT;rs4149056;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:RECURRENCE;CHILDREN;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
THIAZIDES, PLAIN;ADRB3;AA;rs4994;EFFICACY;INCREASED;;EFFICACY:REDUCTION_IN_MEAN_BLOOD_PRESSURE;PEOPLE;DISEASE:ESSENTIAL_HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
TRASTUZUMAB;FCGR2A;AA;rs1801274;EFFICACY;INCREASED;;EFFICACY:PROGRESSION_FREE_SURVIVAL;WOMEN;DISEASE:BREAST_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
IRINOTECAN;UGT1A9;T/del + del/del;rs3832043;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DIARRHEA;PEOPLE;OTHER:STOMACH_NEOPLASMS;CAUTION_SIDE_EFFECT
ASPARAGINASE;CPA2;T;rs199695765;TOXICITY;INCREASED;RISK;SIDE_EFFECT:PANCREATITIS;PEOPLE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3;AA;rs12980275;EFFICACY;INCREASED;;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3;AA;rs12980275;EFFICACY;INCREASED;;EFFICACY:COMPLETE_EARLY_VIROLOGICAL_RESPONSE;PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
DAPSONE;HLA-DRB1;T;rs701829;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_HYPERSENSITIVITY;;;CAUTION_SIDE_EFFECT
TACROLIMUS;POR;CT + TT;rs1057868;TOXICITY;INCREASED;RISK;DISEASE:DIABETES_MELLITUS;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
WARFARIN;THBD;CC + CT;rs1042580;TOXICITY;DECREASED;RISK;SIDE_EFFECT:HEMORRHAGE;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3, IFNL4;TT;rs8099917;EFFICACY;INCREASED;;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
METHYLPHENIDATE;CES1;AC + CC;rs3815583;TOXICITY;INCREASED;RISK;SIDE_EFFECT:APPETITE_SUPPRESSION;CHILDREN;DISEASE:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY;CAUTION_SIDE_EFFECT
ACE INHIBITORS, PLAIN;BDKRB2;C;rs8012552;TOXICITY;INCREASED;RISK;DISEASE:COUGH;PEOPLE;DISEASE:HYPERTENSION;CAUTION_SIDE_EFFECT
CORTICOSTEROIDS;BCL2L11;CC;rs724710;TOXICITY;INCREASED;RISK;SIDE_EFFECT:OSTEONECROSIS;CHILDREN;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
ACE INHIBITORS, PLAIN;MME;A;rs2016848;TOXICITY;INCREASED;RISK;DISEASE:COUGH;PEOPLE;DISEASE:HYPERTENSION;CAUTION_SIDE_EFFECT
IRINOTECAN;PIN1;CC + CG;rs2233678;EFFICACY;INCREASED;;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;DISEASE:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
PEGINTERFERON ALFA-2A, RIBAVIRIN;;GG;rs4273729;EFFICACY;INCREASED;;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR);PEOPLE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION;LIKELIHOOD_THERAPEUTIC_SUCCESS
HYDROCHLOROTHIAZIDE;ADD1;GT;rs4961;EFFICACY;INCREASED;;EFFICACY:REDUCTION_IN_MEAN_ARTERIAL_PRESSURE;PEOPLE;DISEASE:ESSENTIAL_HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
ACENOCOUMAROL;VKORC1;AA + AG;rs9934438;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:OVER-ANTICOAGULATION;;;CAUTION_SIDE_EFFECT
ASPIRIN;ACE;AT + TT;rs4291;TOXICITY;INCREASED;RISK;SIDE_EFFECT:ASPIRIN_INTOLERANCE;PEOPLE;DISEASE:ASTHMA;CAUTION_SIDE_EFFECT
MYCOPHENOLATE MOFETIL;CYP2C8;A;rs11572103;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TIME_TO_ANEMIA_IN_PATIENTS_UNDERGOING_LIVING_OR_DECEASED_DONOR_KIDNEY_TRANSPLANT;;;CAUTION_SIDE_EFFECT
HYDROCHLOROTHIAZIDE;ADD1;GT + TT;rs4961;EFFICACY;INCREASED;;EFFICACY:REDUCTION_IN_MEAN_BLOOD_PRESSURE;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
MYCOPHENOLATE MOFETIL;CYP2C8;T;rs11572076;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TIME_TO_ANEMIA_IN_PATIENTS_UNDERGOING_LIVING_OR_DECEASED_DONOR_KIDNEY_TRANSPLANT;;;CAUTION_SIDE_EFFECT
ACE INHIBITORS, PLAIN;PTGER3;C;rs11209716;TOXICITY;DECREASED;RISK;DISEASE:COUGH;PEOPLE;DISEASE:HYPERTENSION;LIKELIHOOD_THERAPEUTIC_SUCCESS
MYCOPHENOLATE MOFETIL;HUS1;T;rs1056663;TOXICITY;DECREASED;RISK;SIDE_EFFECT:TIME_TO_ANEMIA_IN_PATIENTS_UNDERGOING_LIVING_OR_DECEASED_DONOR_KIDNEY_TRANSPLANT;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
DAPSONE;HLA-DRB1;A;rs17211071;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_HYPERSENSITIVITY;;;CAUTION_SIDE_EFFECT
TACROLIMUS;PPARA;AA + AG;rs4253728;TOXICITY;INCREASED;RISK;DISEASE:DIABETES_MELLITUS;PEOPLE;DISEASE:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
MYCOPHENOLATE MOFETIL;HUS1;A;rs2037483;TOXICITY;DECREASED;RISK;SIDE_EFFECT:TIME_TO_ANEMIA_IN_PATIENTS_UNDERGOING_LIVING_OR_DECEASED_DONOR_KIDNEY_TRANSPLANT;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
NAN;ADD1;GT + TT;rs4961;OTHER;INCREASED;LIKELIHOOD;DISEASE:HYPERTENSION;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;ABCB1;C;rs2032582;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:EXANTHEMA;PEOPLE;OTHER:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
FLUOROURACIL;SLCO1B1;A;rs2306283;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;PEOPLE;OTHER:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
NAN;ARG1;TT;rs2781666;OTHER;INCREASED;SEVERITY;OTHER:ASTHMA;;;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP3A4;TT;rs2740574;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:TRANSPLANT_REJECTION;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
EPIRUBICIN;ABCC1;CT;rs246221;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:LEFT_VENTRICULAR_DYSFUNCTION;PEOPLE;OTHER:BREAST_NEOPLASMS;CAUTION_SIDE_EFFECT
LEVODOPA;COMT;AA;rs4680;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DYSKINESIA, DRUG-INDUCED;PEOPLE;OTHER:PARKINSON_DISEASE;CAUTION_SIDE_EFFECT
METHOTREXATE;SLC19A1;TT;rs1051266;TOXICITY;INCREASED;RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE;PEOPLE;DISEASE:BURKITT_LYMPHOMA, DISEASE:T-CELL_LYMPHOMA,DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA;CAUTION_SIDE_EFFECT
DAUNORUBICIN, DOXORUBICIN;ABCC2;A;rs8187710;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:CARDIOTOXICITY;CHILDREN;OTHER:NEOPLASMS;CAUTION_SIDE_EFFECT
FOLFOX;DPYD;c.1129-5923C>G, c.1236G>A (HapB3);DPYD C.1129-5923C>G, C.1236G>A (HAPB3);EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:RECURRENCE_FREE_SURVIVAL;PEOPLE;OTHER:RECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_FAILURE
DAUNORUBICIN, DOXORUBICIN;HFE;G;rs1799945;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:CARDIOTOXICITY;CHILDREN;OTHER:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
DAUNORUBICIN, DOXORUBICIN;GPR35;T;rs12468485;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:CARDIOTOXICITY;CHILDREN;OTHER:NEOPLASMS;CAUTION_SIDE_EFFECT
DAUNORUBICIN, DOXORUBICIN;UGT1A6;T;rs17863783;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:CARDIOTOXICITY;CHILDREN;OTHER:NEOPLASMS;CAUTION_SIDE_EFFECT
DAUNORUBICIN, DOXORUBICIN;GSTA2;G;rs2180314;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:CARDIOTOXICITY;CHILDREN;OTHER:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
DAUNORUBICIN, DOXORUBICIN;ETFB;A;rs79338777;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:CARDIOTOXICITY;CHILDREN;OTHER:NEOPLASMS;CAUTION_SIDE_EFFECT
DAUNORUBICIN, DOXORUBICIN;HNMT;A;rs17583889;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:CARDIOTOXICITY;CHILDREN;OTHER:NEOPLASMS;CAUTION_SIDE_EFFECT
DAUNORUBICIN, DOXORUBICIN;ABCC5;AA + AT;rs7627754;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:CARDIOTOXICITY;CHILDREN;OTHER:NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
CEFAZOLIN, CEFDINIR, CEFTRIAXONE, CEFUROXIME, CEPHALEXIN;HLA-A;*02:01;HLA-A*02:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY;;;CAUTION_SIDE_EFFECT
TACROLIMUS;CYP2B6;GT;rs3745274;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:TRANSPLANT_REJECTION;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
CORTICOSTEROIDS;WNT7B;A;rs73175102;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:OSTEONECROSIS;CHILDREN;OTHER:LEUKEMIA_OTHER:LYMPHOMA;CAUTION_SIDE_EFFECT
CORTICOSTEROIDS;POGK;A;rs115587273;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:OSTEONECROSIS;CHILDREN;OTHER:LEUKEMIA_OTHER:LYMPHOMA;CAUTION_SIDE_EFFECT
CORTICOSTEROIDS;FAM240C;A;rs78233573;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:OSTEONECROSIS;CHILDREN;OTHER:LEUKEMIA_OTHER:LYMPHOMA;CAUTION_SIDE_EFFECT
CORTICOSTEROIDS;ZNF37A;A;rs376867011;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:OSTEONECROSIS;CHILDREN;OTHER:LEUKEMIA_OTHER:LYMPHOMA;CAUTION_SIDE_EFFECT
CODEINE, HYDROCODONE, TRAMADOL;CYP2D6;;CYP2D6 INTERMEDIATE_METABOLIZER;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:EMERGENCIES, EFFICACY:PAIN;PEOPLE;OTHER:PAIN;LIKELIHOOD_THERAPEUTIC_SUCCESS
GANCICLOVIR, VALGANCICLOVIR;NUDT15;*2 + *3 + *4;NUDT15*1, NUDT15*2, NUDT15*3, NUDT15*4;NAN;INCREASED;LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA;CHILDREN;OTHER:LIVER_TRANSPLANTATION, OTHER:CYTOMEGALOVIRUS_INFECTION;CAUTION_DOSE_ADJUST
VALPROIC ACID;ACOT1;T;rs758109;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE;PEOPLE;OTHER:EPILEPSY;CAUTION_SIDE_EFFECT
TACROLIMUS;SLCO1B1;AA + AG;rs2306283;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:NEPHROTOXICITY;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
AZATHIOPRINE;MOCOS;GT;rs73430958;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA;PEOPLE;OTHER:INFLAMMATORY_BOWEL_DISEASES;CAUTION_SIDE_EFFECT
VALPROIC ACID;GABPA;CC;rs59288687;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE;PEOPLE;OTHER:EPILEPSY;LIKELIHOOD_THERAPEUTIC_SUCCESS
VALPROIC ACID;NQO1;GG;rs10517;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE;PEOPLE;OTHER:EPILEPSY;LIKELIHOOD_THERAPEUTIC_SUCCESS
VALPROIC ACID;PPARA;G;rs881740;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE;PEOPLE;OTHER:EPILEPSY;CAUTION_SIDE_EFFECT
METHOTREXATE;SLCO1B3;AA;rs7311358;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ANEMIA;PEOPLE;OTHER:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
METHOTREXATE;SLCO1B3;GG;rs4149117;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ANEMIA;PEOPLE;OTHER:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
METHOTREXATE;SLCO1B1;AA + AG;rs2306283;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ANEMIA;PEOPLE;OTHER:RHEUMATOID_ARTHRITIS;CAUTION_SIDE_EFFECT
APIXABAN;APOE;C;rs7412;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:INTRACRANIAL_HEMORRHAGES;PEOPLE;OTHER:ATRIAL_FIBRILLATION;CAUTION_SIDE_EFFECT
APIXABAN;APOE;C;rs429358;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:INTRACRANIAL_HEMORRHAGES;PEOPLE;OTHER:ATRIAL_FIBRILLATION;CAUTION_SIDE_EFFECT
PD-1/PDL-1 (PROGRAMMED CELL DEATH PROTEIN 1/DEATH LIGAND 1) INHIBITORS;IFNL3;GG;rs8099917;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:PNEUMONITIS;PEOPLE;OTHER:LUNG_NEOPLASMS, OTHER:TOBACCO_USE_DISORDER;CAUTION_SIDE_EFFECT
PD-1/PDL-1 (PROGRAMMED CELL DEATH PROTEIN 1/DEATH LIGAND 1) INHIBITORS;IFNL3;GG;rs12980275;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:PNEUMONITIS;PEOPLE;OTHER:LUNG_NEOPLASMS;CAUTION_SIDE_EFFECT
PD-1/PDL-1 (PROGRAMMED CELL DEATH PROTEIN 1/DEATH LIGAND 1) INHIBITORS;IFNL3;TT;rs12979860;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:PNEUMONITIS;PEOPLE;OTHER:LUNG_NEOPLASMS, OTHER:TOBACCO_USE_DISORDER;CAUTION_SIDE_EFFECT
TACROLIMUS;ABCB1;TT;rs9282564;EFFICACY;DECREASED;RISK;EFFICACY:DEATH;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;ABCC2;GG;rs2273697;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:OVERALL_SURVIVAL;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_SUCCESS
TACROLIMUS;SLCO1B1;TT;rs4149056;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:TRANSPLANT_REJECTION;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;LIKELIHOOD_THERAPEUTIC_FAILURE
TACROLIMUS;CYP2C19;AA;rs4244285;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:NEPHROTOXICITY;PEOPLE;OTHER:KIDNEY_TRANSPLANTATION;CAUTION_SIDE_EFFECT
AZATHIOPRINE;NUDT15;CT;rs116855232;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA;PEOPLE;OTHER:INFLAMMATORY_BOWEL_DISEASES;CAUTION_SIDE_EFFECT
AZATHIOPRINE;RRM1;AG + GG;rs1735053;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA;PEOPLE;OTHER:INFLAMMATORY_BOWEL_DISEASES;CAUTION_SIDE_EFFECT
AZATHIOPRINE;TPMT;GT + TT;rs9465102;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA;PEOPLE;OTHER:INFLAMMATORY_BOWEL_DISEASES;CAUTION_SIDE_EFFECT
CISPLATIN;TRPA1;TT;rs920829;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:NEPHROTOXICITY;PEOPLE;OTHER:CARCINOMA, SQUAMOUS_CELL,OTHER:CARCINOMA, OTHER:ADENOCARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
FOLFOX, XELOX;DPYD;AG + GG;rs1801265;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES;PEOPLE;OTHER:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
FLUOXETINE;CYP2D6;;CYP2D6 ULTRARAPID_METABOLIZER;EFFICACY, TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:TREATMENT_MODIFICATION;;;LIKELIHOOD_THERAPEUTIC_SUCCESS
CYCLOSPORINE;SLC29A1;AA;rs693955;EFFICACY;DECREASED;LIKELIHOOD;EFFICACY:OVERALL_SURVIVAL, EFFICACY:RECURRENCE_FREE_SURVIVAL;CHILDREN;OTHER:HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION, OTHER:LEUKEMIA;LIKELIHOOD_THERAPEUTIC_FAILURE
AFATINIB, ERLOTINIB, GEFITINIB;AKT1;CC;rs2494750;EFFICACY;INCREASED;LIKELIHOOD;EFFICACY:PROGRESSION-FREE_SURVIVAL;PEOPLE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA;LIKELIHOOD_THERAPEUTIC_SUCCESS
SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-B;*44:03;HLA-B*44:03;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;;;CAUTION_SIDE_EFFECT
SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-B;*38:01;HLA-B*38:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;;;CAUTION_SIDE_EFFECT
SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-C;*04:01;HLA-C*04:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS;;;CAUTION_SIDE_EFFECT
FOLFOX, XELOX;GSTP1;GG;rs1695;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES, SIDE_EFFECT:MYELOSUPPRESSION;PEOPLE;OTHER:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
FOLFOX, XELOX;TYMS;TTA/TTA + TTA/TTAAAGTTA;rs11280056;TOXICITY;DECREASED;LIKELIHOOD;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES, SIDE_EFFECT:MYELOSUPPRESSION;PEOPLE;OTHER:COLORECTAL_NEOPLASMS;LIKELIHOOD_THERAPEUTIC_SUCCESS
FOLFOX, XELOX;TYMS;(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3/(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3;rs45445694;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME, SIDE_EFFECT:EXANTHEMA, SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;OTHER:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
FOLFOX, XELOX;GSTP1;GG;rs1695;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:MUCOSITIS;PEOPLE;OTHER:COLORECTAL_NEOPLASMS;CAUTION_SIDE_EFFECT
AZATHIOPRINE;HLA-DQA1;*02:01;HLA-DQA1*02:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:PANCREATITIS;PEOPLE;OTHER:INFLAMMATORY_BOWEL_DISEASES;CAUTION_SIDE_EFFECT
AZATHIOPRINE;HLA-DRB1;*07:01;HLA-DRB1*07:01;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:PANCREATITIS;PEOPLE;OTHER:INFLAMMATORY_BOWEL_DISEASES;CAUTION_SIDE_EFFECT
HMG_COA_REDUCTASE_INHIBITORS;ABCG2;T;rs2231142;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY, SIDE_EFFECT:TOXIC_LIVER_DISEASE;;;CAUTION_SIDE_EFFECT
AMITRIPTYLINE;CYP2D6;*1/*4 + *2/*4 + *2/*5 + *4/*41 + *4/*10;CYP2D6*1, CYP2D6*1XN, CYP2D6*2, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*41;TOXICITY;INCREASED;RISK;SIDE_EFFECT:DRUG_TOXICITY;PEOPLE;DISEASE:MAJOR_DEPRESSIVE_DISORDER;CAUTION_SIDE_EFFECT
AZATHIOPRINE, MERCAPTOPURINE;TPMT;*3A + *3B + *3C;TPMT*1, TPMT*3A, TPMT*3B, TPMT*3C;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA;PEOPLE;OTHER:INFLAMMATORY_BOWEL_DISEASES;CAUTION_SIDE_EFFECT
RISPERIDONE;CYP2D6;*4/*4 + *3/*4 + *3/*5 + *4/*4xN + *4/*6 + *5/*41 + *4/*29 + *4/*17 + *5/*10 + *3/*41 + *4/*9 + *4/*41 + *4/*10 + *5/*17;CYP2D6*1, CYP2D6*1XN, CYP2D6*2, CYP2D6*2XN, CYP2D6*3, CYP2D6*4, CYP2D6*4XN, CYP2D6*5, CYP2D6*6, CYP2D6*9, CYP2D6*10, CYP2D6*17, CYP2D6*29, CYP2D6*35, CYP2D6*41;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS;CHILDREN;;CAUTION_SIDE_EFFECT
CODEINE, MORPHINE, OXYCODONE;OPRM1;AA;rs1799971;TOXICITY;INCREASED;LIKELIHOOD;SIDE_EFFECT:URINARY_RETENTION, SIDE_EFFECT:CONSTIPATION, SIDE_EFFECT:NAUSEA, SIDE_EFFECT:VOMITING, SIDE_EFFECT:ABDOMINAL_PAIN, SIDE_EFFECT:EXANTHEMA, SIDE_EFFECT:WHEEZING, SIDE_EFFECT:ADVERSE_EVENTS;PEOPLE;OTHER:NEOPLASMS, OTHER:PAIN;CAUTION_SIDE_EFFECT
